,Unnamed: 0,Unnamed: 0.1,cord_uid,sha,source_x,title,doi,pmcid,pubmed_id,license,abstract,publish_time,authors,journal,mag_id,who_covidence_id,arxiv_id,pdf_json_files,pmc_json_files,url,s2_id,cluster
143,143,148,xv0esvos,5227121ac5523e669cc04c9a8f2660080d995a34,PMC,A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses,10.1186/1479-0556-3-7,PMC1249587,16115319.0,cc-by,several study shown cellmediated immune response play crucial role controlling viral replication candidate sars vaccine elicit broad cd tcell immune response several group mouse immunized alone combination sarsnucleocapsid immunogen high level specific sarscd tcell response demonstrated mouse received dna encoding sarsnucleocapsid protein xiap adjuvant also observed coadministration plasmid expressing nucleocapsid recombinant protein montanidecpg induces high antibody titer immunized mouse moreover vaccine approach merit investigation potential candidate vaccine sars,2005-08-22,"Azizi, Ali; Aucoin, Susan; Tadesse, Helina; Frost, Rita; Ghorbani, Masoud; Soare, Catalina; Naas, Turaya; Diaz-Mitoma, Francisco",Genet Vaccines Ther,,,,document_parses/pdf_json/5227121ac5523e669cc04c9a8f2660080d995a34.json,document_parses/pmc_json/PMC1249587.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1249587/,,3
148,148,153,bb27z7h0,e6d533faf65d64332697077b71aa71dfc78fc06a,PMC,The effects of injection of bovine vaccine into a human digit: a case report,10.1186/1476-069x-4-21,PMC1262740,16219096.0,cc-by,background incidence needlestick injury farmer veterinary surgeon significant consequence injection serious case presentation report accidental injection bovine vaccine base little finger resulted increased pressure flexor sheath causing sign symptom ischemia amputation digit required despite repeated surgical debridement decompression conclusion previous report injection oilbased vaccine human hand resulting granulomatous inflammation sterile abscess causing morbidity tissue loss selfinjection veterinary vaccine occupational hazard farmer veterinary surgeon injection vaccine closed compartment human finger serious sequela including loss injected digit injury underestimated early debridement irrigation injected area decompression likely give best outcome frequent review necessary first procedure repeat operation may required,2005-10-11,"O'Neill, Jennifer K; Richards, Simon W; Ricketts, David M; Patterson, Marc H",Environ Health,,,,document_parses/pdf_json/e6d533faf65d64332697077b71aa71dfc78fc06a.json,document_parses/pmc_json/PMC1262740.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1262740/,,3
194,194,201,krzhxu1p,acb6848d159dbf4970d1f76474a634110b3558e7,PMC,Heterologous expression of Brucella abortus GroEL heat-shock protein in Lactococcus lactis,10.1186/1475-2859-5-14,PMC1444932,16556312.0,cc-by,background brucella abortus facultative intracellular pathogen mainly infects cattle human current vaccine rely live attenuated strain b abortus revert pathogenic status thus totally safe use human therefore development mucosal live vaccine using foodgrade lactic acid bacterium lactococcus lactis antigen delivery vector attractive alternative safer vaccination strategy b abortus report construction l lactis strain genetically modified produce b abortus groel heatshock protein candidate antigen two cellular location intracellular secreted result secreted form groel stably produced l lactis suggesting detrimental effect groel protein intracellularly produced bacterium trace amount mature groel detected supernatant fraction induced lactococcal culture groel precursor remained stacked cell fraction attempt raise secretion yield made even groel fused synthetic propeptide secretion antigen improved conclusion found l lactis able produce secrete stable form groel extracellular medium despite low secretion efficiency groel suggest antigen interacts cell envelope l lactis secretion seems best way achieve production protein yield regardless cellular location l lactis strain secreting groel potential vivo immunization,2006-03-23,"Miyoshi, Anderson; Bermúdez-Humarán, Luis G; Ribeiro, Luciana A; Le Loir, Yves; Oliveira, Sérgio C; Langella, Philippe; Azevedo, Vasco",Microb Cell Fact,,,,document_parses/pdf_json/acb6848d159dbf4970d1f76474a634110b3558e7.json,document_parses/pmc_json/PMC1444932.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1444932/,,3
201,201,208,na7z92i8,f38f3b112e4b702b60ba56be806d418bbb2b83c3,PMC,Immune Protection of Nonhuman Primates against Ebola Virus with Single Low-Dose Adenovirus Vectors Encoding Modified GPs,10.1371/journal.pmed.0030177,PMC1459482,16683867.0,cc0,background ebola virus cause hemorrhagic fever syndrome associated high mortality human absence effective therapy ebola virus infection development vaccine becomes important strategy contain outbreak immunization dna andor replicationdefective adenoviral vector rad encoding ebola glycoprotein gp nucleoprotein np previously shown confer specific protective immunity nonhuman primate gp exert cytopathic effect transfected cell vitro multiple gp form identified nature raising question would optimal human vaccine method finding address question explored efficacy mutant gps multiple ebola virus strain reduced vitro cytopathicity analyzed protective effect primate challenge model without np deletion gp transmembrane domain eliminated vitro cytopathicity reduced protective efficacy least one order magnitude contrast point mutation identified abolished cytopathicity retained immunogenicity conferred immune protection absence np minimal effective rad dose established particle two log lower used previously conclusion expression specific gps alone vectored rad sufficient confer protection lethal challenge relevant nonhuman primate model elimination np vaccine dose reduction rad particle diminish protection simplify vaccine providing basis selection human vaccine candidate,2006-05-16,"Sullivan, Nancy J; Geisbert, Thomas W; Geisbert, Joan B; Shedlock, Devon J; Xu, Ling; Lamoreaux, Laurie; Custers, Jerome H. H. V; Popernack, Paul M; Yang, Zhi-Yong; Pau, Maria G; Roederer, Mario; Koup, Richard A; Goudsmit, Jaap; Jahrling, Peter B; Nabel, Gary J",PLoS Med,,,,document_parses/pdf_json/f38f3b112e4b702b60ba56be806d418bbb2b83c3.json,document_parses/pmc_json/PMC1459482.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1459482/,,3
233,233,246,exm1rv1w,67727dc7bb076ef6ddeb55c754af98e672ee60e0,PMC,Live bacterial vaccines – a review and identification of potential hazards,10.1186/1475-2859-5-23,PMC1538998,16796731.0,cc-by,use live bacteria induce immune response carried vaccine component attractive vaccine strategy advantage live bacterial vaccine include mimicry natural infection intrinsic adjuvant property possibility administered orally derivative pathogenic nonpathogenic food related bacteria currently evaluated live vaccine however pathogenic bacteria demand attenuation weaken virulence use bacteria vaccine delivery vehicle implies construction recombinant strain contain gene cassette encoding antigen increased knowledge mucosal immunity availability genetic tool heterologous gene expression concept live vaccine vehicle gain renewed interest however administration live bacterial vaccine pose risk addition vaccination using recombinant bacteria result release live recombinant organism nature place vaccine debate application genetically modified organism review give overview live bacterial vaccine market describe development new live vaccine focus attenuated bacteria foodrelated lactic acid bacteria furthermore outline safety concern identify hazard associated live bacterial vaccine try give suggestion consider development,2006-06-23,"Detmer, Ann; Glenting, Jacob",Microb Cell Fact,,,,document_parses/pdf_json/67727dc7bb076ef6ddeb55c754af98e672ee60e0.json,document_parses/pmc_json/PMC1538998.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1538998/,,3
248,248,262,j3p1u80n,4c84dbfd01f7b2009ebed54376da8afcbcf1ec64,PMC,Model-Based Design of Growth-Attenuated Viruses,10.1371/journal.pcbi.0020116,PMC1557587,16948530.0,cc-by,livevirus vaccine activate humoral cellmediated immunity require single boosting generally provide longer immune protection killed subunit vaccine however growth livevirus vaccine must attenuated minimize potential pathogenic effect mechanism attenuation conventional serialtransfer viral adaptation wellunderstood new method attenuation based rational engineering viral genome may offer potentially greater control one link defined genetic modification change virus growth begin establish link genotype growth phenotype developed computer model intracellular growth vesicular stomatitis virus vsv wellstudied nonsegmented negativestranded rna virus model incorporated established regulatory mechanism vsv integrating key wildtype infection step hijacking host resource transcription translation replication followed assembly release progeny vsv particle generalization wildtype model allow genome rearrangement matched experimentally observed attenuation ranking recombinant vsv strain altered genome position nucleocapsid gene finally simulation captured previously reported experimental result showing altering position vsv gene potential attenuate vsv growth overexpressing immunogenic vsv surface glycoprotein model facilitate engineering new livevirus vaccine linking genomic manipulation controlled change virus geneexpression growth,2006-09-01,"Lim, Kwang-il; Lang, Tobias; Lam, Vy; Yin, John",PLoS Comput Biol,,,,document_parses/pdf_json/4c84dbfd01f7b2009ebed54376da8afcbcf1ec64.json,document_parses/pmc_json/PMC1557587.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1557587/,,3
286,286,303,5hryh1ft,0491da5ae5c2fa38824350bde5462ed82ebc24e7,PMC,Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters,10.1186/1471-2172-7-25,PMC1636068,17076905.0,cc-by,background one major obstacle design effective vaccine hiv hypervariability hiv envelope glycoprotein hiv vaccine candidate utilized envelope glycoprotein single virus isolate date none elicited broadly reactive humoral immunity herein hypothesised cocktail hiv gp protein containing multiple epitope may increase breadth immune response hiv compared evaluated immunogenicity hiv vaccine containing either gp protein alone combination four fourteen gps different primary hiv isolates immunized hamster result amplified characterized different gps primary subtype b isolates syncytium nonsyncytium inducing property expressed protein chinese hamster ovary cho cell line purified protein used either alone combination four fourteen different gps vaccinate golden hamster polyvalent vaccine showed higher antibody titer hiv subtype b isolates mn sf compared group received one four gp protein however polyvalent vaccine able show higher neutralizing antibody response hiv primary isolates interestingly polyvalent vaccine group highest proliferative immune response showed substantial proportion crosssubtype cd reactivity hiv subtypes b c ae conclusion although polyvalent approach achieved modest increase breadth humoral cellular immunity qualitative change vaccine v gp resulted quantitative improvement vaccineinduced immunity,2006-10-31,"Azizi, Ali; Anderson, David E; Ghorbani, Masoud; Gee, Katrina; Diaz-Mitoma, Francisco",BMC Immunol,,,,document_parses/pdf_json/0491da5ae5c2fa38824350bde5462ed82ebc24e7.json,document_parses/pmc_json/PMC1636068.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1636068/,,3
297,297,314,bs3j3nss,29b6131c0d572d383cbc6774b12e4471aa612b07,PMC,Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike Variants,10.1371/journal.pmed.0030525,PMC1716185,17194199.0,cc-by,background severe acute respiratory syndrome coronavirus sarscov identified etiological agent severe acute respiratory syndrome disease characterized severe pneumonia sometimes result death sarscov zoonotic virus crossed specie barrier likely originating bat specie including civet raccoon dog domestic cat swine rodent sarscov vaccine confer longterm protection especially vulnerable senescent population epidemic strain zoonotic strain may yet emerge animal reservoir report comprehensive investigation sars vaccine efficacy young senescent mouse following homologous heterologous challenge method finding using venezuelan equine encephalitis virus replicon particle vrp expressing epidemic urbani sarscov strain spike glycoprotein vrps nucleocapsid n protein strain vrpn demonstrate vrps vrpn vaccine provide complete short longterm protection homologous strain challenge young senescent mouse test vrp vaccine efficacy heterologous sarscov used phylogenetic analysis synthetic biology reverse genetics construct chimeric virus icgdos encoding synthetic glycoprotein gene genetically divergent human strain gdo cluster among zoonotic sarscov icgds replicated efficiently human airway epithelial cell lung young senescent mouse highly resistant neutralization antiserum directed urbani strain although vrps vaccine provided complete shortterm protection heterologous icgds challenge young mouse limited protection seen vaccinated senescent animal vrpn vaccine failed protect homologous heterologous challenge resulted enhanced immunopathology eosinophilic infiltrates within lung sarscov–challenged mouse vrpn–induced pathology presented day peaked around day persisted day likely mediated cellular immune response conclusion study identifies gap challenge vaccine design controlling future sarscov zoonosis especially vulnerable elderly population availability sarscov virus bearing heterologous glycoprotein provides robust challenge inoculum evaluating vaccine efficacy zoonotic strain likely source future outbreak,2006-12-26,"Deming, Damon; Sheahan, Timothy; Heise, Mark; Yount, Boyd; Davis, Nancy; Sims, Amy; Suthar, Mehul; Harkema, Jack; Whitmore, Alan; Pickles, Raymond; West, Ande; Donaldson, Eric; Curtis, Kristopher; Johnston, Robert; Baric, Ralph",PLoS Med,,,,document_parses/pdf_json/29b6131c0d572d383cbc6774b12e4471aa612b07.json,document_parses/pmc_json/PMC1716185.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1716185/,,3
305,305,322,5qwtvm9x,57d2a2f022fc3ec32d1b92bb0a234c9f4ac8e1d6,PMC,DNA Encoding an HIV-1 Gag/Human Lysosome-Associated Membrane Protein-1 Chimera Elicits a Broad Cellular and Humoral Immune Response in Rhesus Macaques,10.1371/journal.pone.0000135,PMC1762437,17205139.0,cc-by,previous study hiv pgag immunization mouse demonstrated usefulness targeting antigen cellular compartment containing major histocompatibility complex type ii mhc ii complex molecule use dna antigen formulation encoding gag chimera mouse lysosomeassociated membrane protein mlampgag present study analyzed magnitude breadth gagspecific tlymphocyte antibody response elicited rhesus macaque immunization dna encoding human lampgag hlampgag chimera elispot analysis indicated average gagspecific ifnγ response elicited hlampgag chimera detectable two three naked dna immunization five immunized macaque reached average spotforming cell sfc pbmcs high ifnγ elispot response detected cddepleted cell indicating cd tcells play major role response tcell response four macaque also tested use elispot overlapping amino acid aa peptide pool containing ten peptide encompassing complete gag protein sequence two mamu immunized macaque responded eight twelve pool mamu b six macaque five pool indicating hlampgag dna antigen formulation elicits broad tcell response gag additionally strong hivspecific igg response igg antibody titer increased dna injection indicating strong amnestic bcell response highly elevated macaque three immunization moreover serum macaque recognized peptide aa peptide library covering complete gag amino acid sequence addition hivspecific iga antibody present plasma external secretion including nasal wash data support finding increased immunogenicity genetic vaccine encoded lamp chimera including response dna vaccine nonhuman primate,2006-12-27,"Chikhlikar, Priya; de Arruda, Luciana Barros; Maciel, Milton; Silvera, Peter; Lewis, Mark G.; August, J. Thomas; Marques, Ernesto T.A.",PLoS One,,,,document_parses/pdf_json/57d2a2f022fc3ec32d1b92bb0a234c9f4ac8e1d6.json,document_parses/pmc_json/PMC1762437.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1762437/,,3
396,396,416,n9sih438,4994fa72322bbf19120592304d92629226948d8e,PMC,Rapid Identification of Malaria Vaccine Candidates Based on α-Helical Coiled Coil Protein Motif,10.1371/journal.pone.0000645,PMC1920550,17653272.0,cc-by,identify malaria antigen vaccine development selected αhelical coiled coil domain protein predicted present parasite erythrocytic stage corresponding synthetic peptide expected mimic structurally “ native ” epitope indeed chemically synthesized peptide specifically recognized human immune serum though various prevalence peptide specific antibody obtained affinitypurification malaria immune serum immunization mouse antibody show significant cross reaction ie specific original peptide reacted native parasite protein infected erythrocyte several active inhibiting vitro parasite growth circular dichroism study indicated selected peptide assumed partial high αhelical content thus demonstrate bioinformaticschemical synthesis approach described lead rapid identification molecule target biologically active antibody thus identifying suitable vaccine candidate strategy principle extended vaccine discovery wide range pathogen,2007-07-25,"Villard, Viviane; Agak, George W.; Frank, Géraldine; Jafarshad, Ali; Servis, Catherine; Nébié, Issa; Sirima, Sodiomon B.; Felger, Ingrid; Arevalo-Herrera, Myriam; Herrera, Socrates; Heitz, Frederic; Bäcker, Volker; Druilhe, Pierre; Kajava, Andrey V.; Corradin, Giampietro",PLoS One,,,,document_parses/pdf_json/4994fa72322bbf19120592304d92629226948d8e.json,document_parses/pmc_json/PMC1920550.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1920550/,,3
406,406,426,1n69h3i3,bada3cc0577a226694617d77f95ac443c6431969,PMC,DNA Vaccines against Protozoan Parasites: Advances and Challenges,10.1155/2007/90520,PMC1940056,17710244.0,no-cc,past year dna vaccine gone scientific curiosity one dynamic research field may offer new alternative control parasitic disease leishmaniasis chaga disease review advance challenge development dna vaccine disease many study validated concept using dna vaccine protection therapy protozoan parasite variety mouse model challenge translate achieved model veterinary human vaccine comparable efficacy also genomemining new antigen discovery strategy may provide new tool rational search novel vaccine candidate,2007-06-24,"Dumonteil, Eric",J Biomed Biotechnol,,,,document_parses/pdf_json/bada3cc0577a226694617d77f95ac443c6431969.json,document_parses/pmc_json/PMC1940056.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1940056/,,3
435,435,456,z2u5frvq,9992ffbec7c8256d057b05a858cde82d36d64ae3,PMC,Antibody-Based HIV-1 Vaccines: Recent Developments and Future Directions: A summary report from a Global HIV Vaccine Enterprise Working Group,10.1371/journal.pmed.0040348,PMC2100141,18052607.0,cc-by,author discus humoral immune response hiv approach designing vaccine induce viral neutralizing potentially protective antibody,2007-12-01,"Montefiori, David; Sattentau, Quentin; Flores, Jorge; Esparza, José; Mascola, John",PLoS Med,,,,document_parses/pdf_json/9992ffbec7c8256d057b05a858cde82d36d64ae3.json,document_parses/pmc_json/PMC2100141.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2100141/,,3
437,437,458,88g7iqg3,0e046152bb9c537c62ed4c4616a0b627ccfc992a,PMC,Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant,10.1186/1476-8518-5-11,PMC2104530,17953756.0,cc-by,background clear need vaccine therapeutic potential biological weapon mass destruction emerging disease anthrax caused bacterium bacillus anthracis used biological warfare agent bioterrorist weapon previously although antibiotic therapy effective early stage anthrax infection effect exposed individual become symptomatic due b anthracis exotoxin accumulation bipartite exotoxin major contributing factor morbidity mortality observed acute anthrax infection method using recombinant b anthracis protective antigen pa covalently coupled novel nontoxic muramyl dipeptide ntmdp derivative hyperimmunized goat three time course week goat plasmapheresed igg fraction affinity purified fab derivative characterized vitro vivo protection lethal toxin mediated intoxication result antipa igg conferred protection μg cell toxin neutralization assay mouse exposed ld bacillus anthracis ames spore intranares inoculation demonstrated survival postinfection administered single bolus dose mgkg body weight antipa igg h post spore challenge antipa fab fragment retained similar neutralization protection level vitro vivo conclusion protection afforded gmpgrade caprine immunotherapeutics postexposure pilot murine model suggests could used effectively treat postexposure symptomatic human anthrax patient following bioterrorism event result also indicate recombinant pa coupled ntmdp potent inducer neutralizing antibody suggest would promising vaccine candidate anthrax ease production ease covalent attachment immunostimulatory activity ntmdp indicate would superior adjuvant alum traditional adjuvant vaccine formulation,2007-10-22,"Kelly, Cassandra D; O'Loughlin, Chris; Gelder, Frank B; Peterson, Johnny W; Sower, Laurie E; Cirino, Nick M",J Immune Based Ther Vaccines,,,,document_parses/pdf_json/0e046152bb9c537c62ed4c4616a0b627ccfc992a.json,document_parses/pmc_json/PMC2104530.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2104530/,,3
472,472,493,3t4vv50z,7d7dbaff8c306dacea117552f6c97cb0b2b79ce3,PMC,Leptospirosis vaccines,10.1186/1475-2859-6-39,PMC2231387,18072968.0,cc-by,leptospirosis serious infection disease caused pathogenic strain leptospira spirochete affect human also animal long expected find effective vaccine prevent leptospirosis immunization high risk human animal although leptospirosis vaccine obtained vaccination relatively unsuccessful clinical application despite decade research million dollar spent review recent advancement recombinant outer membrane protein omp vaccine lipopolysaccharide lp vaccine inactivated vaccine attenuated vaccine dna vaccine leptospirosis reviewed comparison vaccine may lead development new potential method combat leptospirosis facilitate leptospirosis vaccine research moreover vaccine ontology database built scientist working leptospirosis vaccine starting tool,2007-12-11,"Wang, Zhijun; Jin, Li; Węgrzyn, Alicja",Microb Cell Fact,,,,document_parses/pdf_json/7d7dbaff8c306dacea117552f6c97cb0b2b79ce3.json,document_parses/pmc_json/PMC2231387.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2231387/,,3
494,494,516,eflxldnr,050e73f86cfa4ab3f3fc84b0cb55ac779fb9abc2,PMC,"La Crosse virus infectivity, pathogenesis, and immunogenicity in mice and monkeys",10.1186/1743-422x-5-25,PMC2276200,18267012.0,cc-by,background la crosse virus lacv family bunyaviridae first identified human pathogen isolation yearold girl fatal encephalitis la crosse wisconsin lacv major cause pediatric encephalitis north america infects person year – result severe disease central nervous system cns initial step establishment useful animal model support vaccine development examined lacv infectivity pathogenesis immunogenicity weanling mouse rhesus monkey result following intraperitoneal inoculation mouse lacv replicated various organ reaching cns replicates high titer causing death neurological disease peripheral site lacv replicates highest titer nasal turbinate presumably lacv enter cns via olfactory neuron nasal olfactory epithelium mouse infectious dose lethal dose similar lacv administered either intranasally intraperitoneally lacv highly infectious rhesus monkey infected animal pfu however infection asymptomatic monkey developed strong neutralizing antibody response conclusion mouse lacv likely gain access cns via blood stream via olfactory neuron ability efficiently infect mouse intranasally raise possibility lacv might use route infect natural host rhesus monkey susceptible lacv infection develop strong neutralizing antibody response inoculation little pfu mouse rhesus monkey useful animal model lacv vaccine immunologic testing although rhesus monkey model optimal,2008-02-11,"Bennett, Richard S; Cress, Christina M; Ward, Jerrold M; Firestone, Cai-Yen; Murphy, Brian R; Whitehead, Stephen S",Virol J,,,,document_parses/pdf_json/050e73f86cfa4ab3f3fc84b0cb55ac779fb9abc2.json,document_parses/pmc_json/PMC2276200.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276200/,,3
511,511,533,0pt6dxb3,20b56df135b91b5798e9394b8a730a7c10b01eed,PMC,"Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene Inserts",10.1093/toxsci/kfj169,PMC2377020,16569729.0,bronze-oa,vaccine research center developed number vaccine candidate different diseasesinfectious agent hiv severe acute respiratory syndrome virus west nile virus ebola virus plus plasmid cytokine adjuvant—ilig based dna plasmid vaccine platform support clinical development vaccine candidate preclinical study performed mouse rabbit determine body plasmid vaccine would biodistribute rapidly would clear course study observed regardless gene insert expressing vaccine immunogen cytokine adjuvant regardless promoter used drive expression gene insert plasmid backbone plasmid vaccine biodistribute widely remain essentially site injection muscle overlying subcutis even though ∼ molecule inoculated study rabbit day ∼ week postinoculation already order − molecule per microgram dna extracted tissue cleared injection site course month plasmid clear site injection small percentage animal generally − retaining small number copy generally around copy muscle injection site pattern biodistribution confined injection site clearance within month consistent regardless difference promoter plasmid backbone difference gene insert expressed plasmid vaccine addition integration observed plasmid vaccine candidate inoculated im biojector needle syringe data build repeateddose toxicology study performed see companion article sheet et al demonstrate safety suitability investigational human use dna plasmid vaccine candidate variety infectious disease prevention indication,2006-03-28,"Sheets, Rebecca L.; Stein, Judith; Manetz, T. Scott; Duffy, Chris; Nason, Martha; Andrews, Charla; Kong, Wing-Pui; Nabel, Gary J.; Gomez, Phillip L.",Toxicological Sciences,,,,document_parses/pdf_json/20b56df135b91b5798e9394b8a730a7c10b01eed.json,document_parses/pmc_json/PMC2377020.xml.json,https://academic.oup.com/toxsci/article-pdf/91/2/610/10977044/kfj169.pdf,,3
512,512,534,8rrkf78o,235855da90347b259f4d6b244821f3c1c264c04e,PMC,Expression of Foot-and-Mouth Disease Virus Capsid Proteins in Silkworm-Baculovirus Expression System and Its Utilization as a Subunit Vaccine,10.1371/journal.pone.0002273,PMC2386233,18509464.0,cc-by,background footandmouth disease fmd highly contagious disease livestock cause severe economic loss susceptible clovenhoofed animal although traditional inactivated vaccine proved effective may lead new outbreak fmd either incomplete inactivation fmdv escape live virus vaccine production workshop thus urgent develop novel fmdv vaccine safer effective economical traditional vaccine methodology principal finding recombinant silkworm baculovirus bmpac contained intact pa c protease coding region fmdv asia hnkcha developed indirect immunofluorescence test sandwichelisa used verify bmpac could express target cassette expression product silkworm diluted fold used antigen immunize cattle specific antibody induced vaccinated animal challenge virulent homologous virus four five animal completely protected clinical symptom alleviated delayed remaining one furthermore pd bovine protective dose test performed ass bovine potency subunit vaccine result showed subunit vaccine could achieve pd per dose conclusion result suggest strategy might used develop new subunit fmdv vaccine,2008-05-28,"Li, Zhiyong; Yi, Yongzhu; Yin, Xiangping; Zhang, Zhifang; Liu, Jixing",PLoS One,,,,document_parses/pdf_json/235855da90347b259f4d6b244821f3c1c264c04e.json,document_parses/pmc_json/PMC2386233.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2386233/,,3
555,555,577,pr9i9swk,dad72c9c3422ef1c9b9149e8dd567de494d46a8a,PMC,Nasal Delivery of an Adenovirus-Based Vaccine Bypasses Pre-Existing Immunity to the Vaccine Carrier and Improves the Immune Response in Mice,10.1371/journal.pone.0003548,PMC2569416,18958172.0,cc-by,preexisting immunity human adenovirus serotype ad common general population bypassing preexisting immunity could maximize ad vaccine efficacy vaccination intramuscular im nasal oral po route ad expressing ebola zaire glycoprotein adzgp fully protected naïve mouse lethal challenge ebola presence preexisting immunity mouse vaccinated survived frequency ifnγ cd cell reduced animal vaccinated im po route respectively neutralizing antibody could detected serum either treatment group preexisting immunity compromise frequency ifnγ cd cell ± naïve v ± preexisting immunity pei antiebola neutralizing antibody nab ± reciprocal dilution group number infγ cd cell detected bronchioalveolar lavage fluid bal immunization compromised preexisting immunity ad ± naïve v ± sfcmillion mncs pei however preexisting immunity reduced nab level bal ∼ group improve immune response oral vaccination adbased vaccine pegylated mouse given modified vaccine survive challenge reduced level ifnγ cd cell day administration ± peg v ± unmodified pegylation increase nab level fold result provide insight degree b cell mediated immunity necessary protection ebola virus suggest modification virus capsid influence type immune response elicited adbased vaccine,2008-10-29,"Croyle, Maria A.; Patel, Ami; Tran, Kaylie N.; Gray, Michael; Zhang, Yi; Strong, James E.; Feldmann, Heinz; Kobinger, Gary P.",PLoS One,,,,document_parses/pdf_json/dad72c9c3422ef1c9b9149e8dd567de494d46a8a.json,document_parses/pmc_json/PMC2569416.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2569416/,,3
590,590,615,tfcerilc,ef872b80cf38917f64c42bfa52a57beb4399897a,PMC,Multivalent HA DNA Vaccination Protects against Highly Pathogenic H5N1 Avian Influenza Infection in Chickens and Mice,10.1371/journal.pone.0002432,PMC2657001,19293944.0,cc0,background sustained outbreak highly pathogenic avian influenza hpai hn avian specie increase risk reassortment adaptation human ability contain spread chicken would reduce threat help maintain capacity eggbased vaccine production vaccine offer potential control avian disease major concern current vaccine potency inability protect evolving avian influenza virus methodology principal finding ability dna vaccine encoding hemagglutinin ha protein different hpai hn serotypes evaluated ability elicit neutralizing antibody protect homologous heterologous hpai hn strain challenge mouse chicken dna immunization needle syringe pressure injection device vaccine elicited antibody neutralized multiple strain hpai hn given combination containing response dosedependent breadth determined choice influenza virus ha vaccine monovalent trivalent ha vaccine tested first mouse conferred protection lethal hn avietnam challenge week vaccination chicken protection observed heterologous strain hpai hn vaccination trivalent h serotype dna vaccine dos low µg dna given twice either intramuscular needle injection needlefree device conclusionssignificance dna vaccine offer generic approach influenza virus immunization applicable multiple animal specie addition ability substitute plasmid encoding different strain enables rapid adaptation vaccine newly evolving field isolates,2008-06-18,"Rao, Srinivas; Kong, Wing-Pui; Wei, Chih-Jen; Yang, Zhi-Yong; Nason, Martha; Styles, Darrel; DeTolla, Louis J.; Sorrell, Erin M.; Song, Haichen; Wan, Hongquan; Ramirez-Nieto, Gloria C.; Perez, Daniel; Nabel, Gary J.",PLoS One,,,,document_parses/pdf_json/ef872b80cf38917f64c42bfa52a57beb4399897a.json,document_parses/pmc_json/PMC2657001.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2657001/,,3
727,727,766,5l48fvx2,4df45b8404d9de0b376a8ae3c282a517df36fe51,PMC,Two novel HLA-A*0201 T-cell epitopes in avian H5N1 viral nucleoprotein induced specific immune responses in HHD mice,10.1051/vetres/2009071,PMC2820229,19941812.0,no-cc,influenza nucleoprotein np attractive target avian flu vaccine development high conversancy evolutionary chain virus identified two novel hlaa restricted np epitope named hn np amdsntlel np np fqgrgvfel np using computational bioinformatic analysis np peptide showed high binding affinity hlaa cell able induce activation cytotoxic cell human peripheral blood mononuclear cell examined potential using np np peptide sequence supplemented singlechain trimer potential dna vaccine candidate hhd transgenic mouse model gene gun delivery system used administrating vaccine candidate animal result cytotoxicity elispot assay indicated significant amount ifnγ secreted cell vaccinated mouse cell able eliminate corresponding peptideloaded cell discovery novel immunogenic np peptide provides valuable information avian flu vaccine design construction,2009-11-27,"Cheung, Ying-Kit; Cheng, Samuel Chak-Sum; Ke, Yan; Xie, Yong",Vet Res,,,,document_parses/pdf_json/4df45b8404d9de0b376a8ae3c282a517df36fe51.json,document_parses/pmc_json/PMC2820229.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2820229/,,3
753,753,792,epkw6222,1e77d7c7edc8692bbe4056e0ea0bb52ffabafa96,PMC,DNA Vaccines: Developing New Strategies against Cancer,10.1155/2010/174378,PMC2846346,20368780.0,no-cc,due rapid widespread development dna vaccine entered variety human clinical trial vaccine various disease including cancer evidence dna vaccine well tolerated excellent safety profile proved advantage many clinical trial combine first phase second saving time money clear result obtained clinical trial dna vaccine require much improvement antigen expression delivery method make sufficiently effective clinic similarly clear additional strategy required activate effective immunity poorly immunogenic tumor antigen engineering vaccine design manipulating antigen presentation processing pathway one important aspect easily handled dna vaccine technology several approach investigated including dna vaccine engineering codelivery immunomodulatory molecule safe route administration primeboost regimen strategy break immunosuppressive network mechanism adopted malignant cell prevent immune cell function combined single strategy enhance efficacy immunogenicity dna vaccine applied completed ongoing clinical trial safety tolerability dna platform substantiated review dna vaccine salient aspect topic going basic research clinic evaluated representative dna cancer vaccine study also discussed,2010-03-28,"Fioretti, Daniela; Iurescia, Sandra; Fazio, Vito Michele; Rinaldi, Monica",J Biomed Biotechnol,,,,document_parses/pdf_json/1e77d7c7edc8692bbe4056e0ea0bb52ffabafa96.json,document_parses/pmc_json/PMC2846346.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846346/,,3
756,756,795,cwzpb8fu,56e040a2052581a7133f24e50dc7261b579fe22f,PMC,Confronting Potential Influenza A (H5N1) Pandemic with Better Vaccines,10.3201/eid1310.061262,PMC2851514,18258000.0,no-cc,influenza hn virus strong candidate causing next influenza pandemic acquire ability efficient humantohuman transmission major public health goal make efficacious vaccine virus using novel approach including cellculture system reverse genetics adjuvant development important consideration strategy includes preparation vaccine currently circulating strain induce broadspectrum immunity toward newly emerged human h strain strategy would good solution early pandemic antigenically matched approved vaccine produced concept therapeutic vaccine eg antidisease vaccine directed diminishing cytokine storm frequently seen subtype hn–infected person underscored better understanding host–virus interaction essential identify tool produce effective vaccine influenza hn,2007-10-26,"Haque, Azizul; Hober, Didier; Kasper, Lloyd H.",Emerg Infect Dis,,,,document_parses/pdf_json/56e040a2052581a7133f24e50dc7261b579fe22f.json,document_parses/pmc_json/PMC2851514.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851514/,,3
804,804,846,m4sp9sjn,fac2afdb0450de6c766a24baf26e3ce6e03e09e2,PMC,HIV Antigen Incorporation within Adenovirus Hexon Hypervariable 2 for a Novel HIV Vaccine Approach,10.1371/journal.pone.0011815,PMC2910733,20676400.0,cc-by,adenoviral ad vector used variety vaccine application including cancer infectious disease traditionally adbased vaccine designed express antigen transgene expression given antigen however case conventional adbased vaccine suboptimal clinical result suboptimal result attributed part preexisting ad serotype ad immunity order circumvent need antigen expression via transgene incorporation “ antigen capsidincorporation ” strategy developed used adbased vaccine development context disease strategy embodies incorporation antigenic peptide within capsid structure viral vector major capsid protein hexon utilized capsid incorporation strategy due hexons natural role generation antiad immune response numerical representation within ad virion using strategy developed mean incorporate heterologous peptide epitope specifically within major surfaceexposed domain ad capsid protein hexon study herein focus generation multivalent vaccine vector presenting hiv antigen within ad capsid protein hexon well expressing hiv antigen transgene novel vector utilize hvr incorporation site twentyfour amino acid region hiv membrane proximal ectodomain region mper derived hiv glycoprotein gp gp study herein illustrates multivalent antihiv vector elicit cellular antihiv response furthermore vaccination vector present hiv antigen hvr elicit hiv epitopespecific humoral immune response,2010-07-27,"Matthews, Qiana L.; Fatima, Aiman; Tang, Yizhe; Perry, Brian A.; Tsuruta, Yuko; Komarova, Svetlana; Timares, Laura; Zhao, Chunxia; Makarova, Natalia; Borovjagin, Anton V.; Stewart, Phoebe L.; Wu, Hongju; Blackwell, Jerry L.; Curiel, David T.",PLoS One,,,,document_parses/pdf_json/fac2afdb0450de6c766a24baf26e3ce6e03e09e2.json,document_parses/pmc_json/PMC2910733.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910733/,,3
860,860,903,yci0a6bt,e8e766af194b641ae3a9636379a18515c053ae65,PMC,Human monoclonal IgG selection of Plasmodium falciparum for the expression of placental malaria-specific variant surface antigens,10.1111/j.1365-3024.2009.01097.x,PMC3001033,19493213.0,cc-by,pregnancyassociatedplasmodium falciparum malaria pam major cause morbidity mortality african woman offspring pam characterized accumulation infected erythrocyte y adhere chondroitin sulphate csa placental intervillous space show human monoclonal igg antibody specificity variant surface antigen vsa specifically expressed csaadhering y vsapam used vitro select parasite nonpregnant donor express vsapam selection vsapam expression result preferential transcription varcsa result corroborate current effort develop pamspecific vaccine based varcsa,2009-06-26,"SOERLI, J; BARFOD, L; LAVSTSEN, T; BERNASCONI, N L; LANZAVECCHIA, A; HVIID, L",Parasite Immunol,,,,document_parses/pdf_json/e8e766af194b641ae3a9636379a18515c053ae65.json,document_parses/pmc_json/PMC3001033.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3001033/,,3
866,866,909,l3ej1hdk,f46d2803581226a9a94026693e95db88e7c70641,PMC,A Porcine Adenovirus with Low Human Seroprevalence Is a Promising Alternative Vaccine Vector to Human Adenovirus 5 in an H5N1 Virus Disease Model,10.1371/journal.pone.0015301,PMC3002947,21179494.0,cc-by,human adenovirus adhu vector robust vaccine platform however presence naturallyacquired neutralizing antibody may reduce vector efficacy potential readministration study evaluates immune response protection following vaccination replicationincompetent porcine adenovirus pav vector alternative vaccine adhu using avian influenza hn disease model vaccine efficacy evaluated balbc mouse following vaccination different dos pav vector expressing optimized ahanoi hn hemagglutinin antigen pavha compared adhuha control pavha rapidly generated antibody response significant neutralizing antibody titer day stronger cellular immune response detected day compared adhuha pavha vaccine administered day challenge demonstrated improved survival lower virus load evaluation longterm vaccine efficacy month postvaccination showed better protection pavha adhuha vaccine importantly opposed adhu pav vector significantly neutralized human antibody pooled individual overall pavbased vector capable mediating swift strong immune response offer promising alternative adhu,2010-12-16,"Patel, Ami; Tikoo, Suresh; Kobinger, Gary",PLoS One,,,,document_parses/pdf_json/f46d2803581226a9a94026693e95db88e7c70641.json,document_parses/pmc_json/PMC3002947.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002947/,,3
868,868,911,cgx90xnt,d3f7afa8b4d0f21b23ccb1135dec12356375f5cc,PMC,Therapeutic Vaccination in Chronic Hepatitis B: Preclinical Studies in the Woodchuck,10.1155/2010/817580,PMC3003998,21188201.0,cc-by,recommended treatment chronic hepatitis b interferonα andor nucleostide analogue lead satisfactory result induction hbvspecific cell therapeutic vaccination immunotherapy may innovative strategy overcome virus persistence vaccination commercially available hbv vaccine patient result effective control hbv infection suggesting new formulation therapeutic vaccine needed woodchuck marmota monax useful preclinical model developing new therapeutic approach chronic hepadnaviral infection several innovative approach combining antiviral treatment nucleostide analogue dna vaccine protein vaccine tested woodchuck model paper summarize available data concerning therapeutic immunization gene therapy using recombinant viral vector approach woodchuck show encouraging result addition present potential innovation immunomodulatory strategy evaluated animal model,2010-09-07,"Kosinska, Anna D.; Zhang, Ejuan; Lu, Mengji; Roggendorf, Michael",Hepat Res Treat,,,,document_parses/pdf_json/d3f7afa8b4d0f21b23ccb1135dec12356375f5cc.json,document_parses/pmc_json/PMC3003998.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3003998/,,3
903,903,954,ussnj6ux,7b9e45133c8a6f6c48ec8c5f1f0c01ad0cd1d3ae,PMC,Avipoxviruses: infection biology and their use as vaccine vectors,10.1186/1743-422x-8-49,PMC3042955,21291547.0,cc-by,avipoxviruses apvs belong chordopoxvirinae subfamily poxviridae family apvs distributed worldwide cause disease domestic pet wild bird many specie apvs transmitted aerosol biting insect particularly mosquito arthropod usually named bird specie originally isolated virus specie fowlpox virus fwpv cause disease poultry associated mortality usually low flock stress disease high production mortality reach apvs also major player viral vaccine vector development disease human veterinary medicine abortive infection mammalian cell production progeny virus ability accommodate multiple gene insert characteristic make apvs promising vaccine vector although abortive infection mammalian cell conceivably represents major vaccine biosafety advantage molecular mechanism restricting apvs certain host yet fully understood review summarizes current knowledge relating apvs including classification morphogenesis hostvirus interaction diagnostics disease also highlight use apvs recombinant vaccine vector,2011-02-03,"Weli, Simon C; Tryland, Morten",Virol J,,,,document_parses/pdf_json/7b9e45133c8a6f6c48ec8c5f1f0c01ad0cd1d3ae.json,document_parses/pmc_json/PMC3042955.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042955/,,3
914,914,965,57es391o,9791652bce8752738f1bfb75305fd5faa6e30374,PMC,Factors Affecting Intention to Receive and Self-Reported Receipt of 2009 Pandemic (H1N1) Vaccine in Hong Kong: A Longitudinal Study,10.1371/journal.pone.0017713,PMC3055876,21412418.0,cc-by,background vaccination core component mitigating influenza pandemic phn however vaccination program efficacy largely depends population compliance examined general population decisionmaking phn vaccination using modified theory planned behaviour tbp methodology conducted longitudinal study collecting data introduction phn vaccine hong kong structural equation modeling sem tested modified tpb explanatory utility vaccine uptake among adult principal finding among subject completed baseline followup survey reported “ likelyvery likelycertain ” vaccinated intent two month later reported received phn vaccination perception low risk phn concern regarding adverse effect vaccine primary justification avoiding phn vaccination greater perceived vaccine benefit β le concern regarding vaccine sideeffects β − greater adherence social norm vaccination β anticipated higher regret vaccinated β perceived higher selfefficacy vaccination β history seasonal influenza vaccination β associated higher intention receive phn vaccine turn predicted selfreported vaccination uptake β social norm β anticipated regret β vaccination intention β positively associated accounted variance vaccination planning turn subsequently predicted selfreported vaccination uptake β accounting variance reported vaccination behaviour conclusionssignificance perceived low risk phn perceived high risk phn vaccine inhibited phn vaccine uptake tpb additional component contributed intended vaccination uptake social norm anticipated regret predominantly associated vaccination intention planning vaccination planning significant proximal determinant uptake phn vaccine intention intention alone unreliable predictor future vaccine uptake,2011-03-11,"Liao, Qiuyan; Cowling, Benjamin J.; Lam, Wendy Wing Tak; Fielding, Richard",PLoS One,,,,document_parses/pdf_json/9791652bce8752738f1bfb75305fd5faa6e30374.json,document_parses/pmc_json/PMC3055876.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3055876/,,3
974,974,1029,f9cgt2z3,4481ddf0d81e186b0be8ab48c20e8b206ec2879c,PMC,Non-Apical Membrane Antigen 1 (AMA1) IgGs from Malian Children Interfere with Functional Activity of AMA1 IgGs as Judged by Growth Inhibition Assay,10.1371/journal.pone.0020947,PMC3113848,21695140.0,cc0,background apical membrane antigen ama one beststudied bloodstage malaria vaccine candidate ama vaccine tested malaria naïve population induced functionally active antibody judged growth inhibition assay gia however vaccine failed induce higher growthinhibitory activity adult living malaria endemic area vaccination induce functionally active antibody malariaexposed child le inhibition gia baseline child level baseline inhibition method total igg purified plasma collected pediatric trial immunization pool total igg made another set total igg purified u adult immunized ama ustotal igg total igg amaspecific nonama igg affinity purified functional activity igg evaluated gia competition elisa performed ustotal igg nonama igg malariaexposed child result amaspecific igg malariaexposed child u vaccinee showed similar growthinhibitory activity concentration mixed ustotal igg nonama igg child showed interference effect gia interestingly interference effect higher nonama igg higher titer pool nonama igg compete antiama antibody ustotal igg competition elisa conclusion child living malaria endemic area fraction igg interferes biological activity antiama antibody judged gia mechanism interference resolved study result suggest caused direct competition nonama igg ama protein study indicates antimalaria igg induced natural exposure may interfere biological effect antibody induced amabased vaccine target population,2011-06-13,"Miura, Kazutoyo; Perera, Suwani; Brockley, Sarah; Zhou, Hong; Aebig, Joan A.; Moretz, Samuel E.; Miller, Louis H.; Doumbo, Ogobara K.; Sagara, Issaka; Dicko, Alassane; Ellis, Ruth D.; Long, Carole A.",PLoS One,,,,document_parses/pdf_json/4481ddf0d81e186b0be8ab48c20e8b206ec2879c.json,document_parses/pmc_json/PMC3113848.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3113848/,,3
991,991,1046,2eq24jth,b470eec84fd5bb0a9a7079506df05c3cdf398832,PMC,Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins,10.3390/v2020547,PMC3133461,21755021.0,cc-by,elicitation antibody potent broad neutralizing activity hiv immunization remains challenge several monoclonal antibody mabs isolated human hiv infection exhibit activity vaccine immunogen based structure containing epitope successful elicitation known broadly neutralizing mabs bnmabs immunoglobulin ig g igg highly somatically hypermutated could impede elicitation ig m igm average significantly le divergent germline antibody relevant development vaccine immunogen underexplored compared igg describe identification characterization several human igmderived mabs hiv selected large phagedisplayed naive human antibody library constructed blood lymph node spleen healthy donor antibody bound high affinity recombinant envelope glycoprotein gps envs hiv isolates different clade enhanced neutralize infection hiv primary isolates using ccr coreceptor neutralized cxcr isolates tested although weakly one antibody relatively low degree somatic hypermutation extensively characterized bound highly conserved region partially overlapping coreceptor binding site close overlapping cd binding site result suggest existence conserved structure could direct immune response nonneutralizing even enhancing antibody may represent strategy used virus escape neutralizing immune response study show whether strategy play role hiv infection human important role could mechanism infection enhancement newly identified mabs could used reagent characterize conserved nonneutralizing weakly neutralizing enhancing epitope modify remove candidate vaccine immunogen,2010-02-04,"Chen, Weizao; Zhu, Zhongyu; Liao, Huaxin; Quinnan, Gerald V.; Broder, Christopher C.; Haynes, Barton F.; Dimitrov, Dimiter S.",Viruses,,,,document_parses/pdf_json/b470eec84fd5bb0a9a7079506df05c3cdf398832.json,document_parses/pmc_json/PMC3133461.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3133461/,,3
1012,1012,1067,9ka3jdbf,98948855a76926474a0ca576cf984b00053fcac3,PMC,B Cell Repertoire Analysis Identifies New Antigenic Domains on Glycoprotein B of Human Cytomegalovirus which Are Target of Neutralizing Antibodies,10.1371/journal.ppat.1002172,PMC3154849,21852946.0,cc-by,human cytomegalovirus hcmv herpesvirus ubiquitously distributed pathogen cause severe disease immunosuppressed patient infected newborn effort underway prepare effective subunit vaccine therapy including antiviral antibody however current vaccine effort hampered lack information protective immune response hcmv characterizing bcell response healthy infected individual could aid design optimal vaccine therapeutic antibody address problem determined first time bcell repertoire glycoprotein b gb hcmv different healthy hcmv seropositive individual unbiased fashion hcmv gb represents dominant viral antigenic determinant induction neutralizing antibody infection also component several experimental hcmv vaccine currently tested human finding revealed vast majority gbspecific antibody secreted bcell clone virus neutralizing activity neutralizing antibody found bind epitope located within previously characterized antigenic domain ad gb map target structure neutralizing antibody generated model hcmv gb used identify surface exposed protein domain two protein domain found targeted majority neutralizing antibody domain located amino acid aa – gb domain ii discontinuous domain built residue – – analysis larger panel human serum hcmv seropositive individual revealed positivity rate domain domain ii respectively accordance previous nomenclature domain designated ad dom ii ad dom respectively collectively data contribute optimal vaccine design development antibody effective passive immunization,2011-08-11,"Pötzsch, Sonja; Spindler, Nadja; Wiegers, Anna-Katharina; Fisch, Tanja; Rücker, Pia; Sticht, Heinrich; Grieb, Nina; Baroti, Tina; Weisel, Florian; Stamminger, Thomas; Martin-Parras, Luis; Mach, Michael; Winkler, Thomas H.",PLoS Pathog,,,,document_parses/pdf_json/98948855a76926474a0ca576cf984b00053fcac3.json,document_parses/pmc_json/PMC3154849.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154849/,,3
1017,1017,1072,k1hwh640,b27597f4106492dc77eb8e3e6ae832cc5a8262be,PMC,Antigen-expressing immunostimulatory liposomes as a genetically programmable synthetic vaccine,10.1007/s11693-010-9066-z,PMC3159695,21949673.0,no-cc,liposome versatile submicronsized membrane vesicle used variety application including drug delivery vivo imaging also represent excellent model artificial membrane cell several study demonstrated vitro transcription translation take place inside liposome obtain compartmentalized production functional protein within liposome kita et al chembiochem – moritani et alin feb j kuruma et al method mol biol – murtas et al biochem biophys re commun – sunami et al anal biochem – ishikawa et al feb lett – oberholzer et al biochem biophys re commun – minimal artificial cellbased model ideal synthetic biology based application study propose use liposome artificial microbe vaccination artificial microbe genetically programmed produce specific antigen show proofofconcept artificial cellbased platform bacterial vitro transcription translation system together gene construct encoding model antigen βgalactosidase entrapped inside multilamellar liposome vaccination study mouse showed antigenexpressing immunostimulatory liposome anexils elicited higher specific humoral immune response produced antigen βgalactosidase control vaccine ie anexils without genetic input liposomal βgalactosidase pdna encoding βgalactosidase conclusion anexils present new platform dnabased vaccine combine antigen production adjuvanticity delivery one system offer several advantage existing vaccine formulation,2010-10-26,"Amidi, Maryam; de Raad, Markus; Crommelin, Daan J. A.; Hennink, Wim E.; Mastrobattista, Enrico",Syst Synth Biol,,,,document_parses/pdf_json/b27597f4106492dc77eb8e3e6ae832cc5a8262be.json,document_parses/pmc_json/PMC3159695.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159695/,,3
1032,1032,1088,1gd006zy,d36f86b21b3eb024c83ffa1d68b49663258d896f,PMC,Delivery Systems for Intradermal Vaccination,10.1007/82_2011_123,PMC3173582,21472533.0,no-cc,intradermal id vaccination offer improved immunity simpler logistics delivery use medicine limited need simple reliable method id delivery id injection mantoux technique requires special training may reliably target skin nonetheless used currently bcg rabies vaccination scarification using bifurcated needle extensively used smallpox eradication provides variable inefficient delivery skin recently id vaccination simplified introduction simpletouse hollow microneedle approved id injection influenza vaccine europe various design hollow microneedles studied preclinically human vaccine also injected skin using needlefree device jet injection receiving renewed clinical attention id vaccination projectile delivery using powder gold particle ie gene gun also used clinically id vaccination building scarification approach number preclinical study examined solid microneedle patch use vaccine coated onto metal microneedles encapsulated within dissolving microneedles added topically skin microneedle pretreatment well adapting tattoo gun id vaccination finally technology designed increase skin permeability combination vaccine patch studied use skin abrasion ultrasound electroporation chemical enhancer thermal ablation prospect bringing id vaccination widespread clinical practice encouraging given large number technology id delivery development,2011-04-07,"Kim, Y. C.; Jarrahian, C.; Zehrung, D.; Mitragotri, S.; Prausnitz, M. R.",Intradermal Immunization,,,,document_parses/pdf_json/d36f86b21b3eb024c83ffa1d68b49663258d896f.json,document_parses/pmc_json/PMC3173582.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3173582/,,3
1070,1070,1126,rckp1kc7,3d91cc711f18ce05f6d63c11760e3ff4fd88928a,PMC,Evaluation of Approaches to Identify the Targets of Cellular Immunity on a Proteome-Wide Scale,10.1371/journal.pone.0027666,PMC3214079,22096610.0,cc-by,background vaccine development malaria complex disease remains challenge scientific community recent elucidation genome proteome transcriptome many complex pathogen provides basis rational vaccine design identifying proteomewide scale novel target antigen recognized cell antibody exposed individual however currently algorithm effectively identify important target antigen genome sequence data especially challenging cell target furthermore pathogen plasmodium protein expression using conventional platform problematic cellfree vitro transcription translation ivtt strategy recently proved successful herein report novel approach proteomewide scale identification antigenic target cell response using ivtt product principal finding conducted series vitro vivo experiment using ivtt protein either unpurified absorbed carboxylated polybeads affinity purified nickel resin magnetic bead vitro study human using cmv ebv influenza virus protein showed antigenspecific cytokine production elispot cytometric bead array assay cell stimulated purified unpurified ivtt antigen vitro vivo study mouse immunized plasmodium yoelii circumsporozoite dna vaccine without ivtt protein boost showed antigenspecific cytokine production using purified ivtt antigen overall nickel resin method ivtt antigen purification proved optimal human murine system conclusion work provides proof concept potential highthroughput approach identify cell target complex parasitic viral bacterial pathogen genomic sequence data rational vaccine development emerging reemerging disease pose threat public health,2011-11-11,"Cardoso, Fernanda C.; Roddick, Joanne S.; Groves, Penny; Doolan, Denise L.",PLoS One,,,,document_parses/pdf_json/3d91cc711f18ce05f6d63c11760e3ff4fd88928a.json,document_parses/pmc_json/PMC3214079.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214079/,,3
1242,1242,1315,kf1fs1ka,51a9f0de2c657fd582c5ff023027833d48e4876b,PMC,A Human PrM Antibody That Recognizes a Novel Cryptic Epitope on Dengue E Glycoprotein,10.1371/journal.pone.0033451,PMC3317930,22509258.0,cc-by,dengue virus denv major mosquitoborne pathogen infecting million people year far effective treatment vaccine available recently highly crossreactive infectionenhancing premembrane prmspecific antibody found dominate antidenv immune response human raising concern vaccine candidate contain native dengue prm sequence study isolated broadly crossreactive prmspecific antibody screen nonimmunized human fabphage library four serotypes denv antibody capable restoring infectivity virtually noninfectious immature denv imdenv fcγrbearing k cell remarkably also crossreacted cryptic epitope envelope e protein located didii junction evidenced sitedirected mutagenesis cryptic epitope inaccessible antibody binding native virus particle may become exposed e properly folded finding suggest generation antiprm antibody enhance denv infection may completely avoided even immunization strategy employing e protein alone subunit e protein,2012-04-03,"Chan, Annie Hoi Yi; Tan, Hwee Cheng; Chow, Angelia Yee; Lim, Angeline Pei Chiew; Lok, Shee Mei; Moreland, Nicole J.; Vasudevan, Subhash G.; MacAry, Paul A.; Ooi, Eng Eong; Hanson, Brendon J.",PLoS One,,,,document_parses/pdf_json/51a9f0de2c657fd582c5ff023027833d48e4876b.json,document_parses/pmc_json/PMC3317930.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3317930/,,3
1348,1348,1456,dby5aksb,da5f78374b6b0b58d01188a2029fe9d74336e473,PMC,Baculovirus-based Vaccine Displaying Respiratory Syncytial Virus Glycoprotein Induces Protective Immunity against RSV Infection without Vaccine-Enhanced Disease,10.4110/in.2012.12.1.8,PMC3329602,22536165.0,cc-by-nc,background respiratory syncytial virus rsv major cause severe lower respiratory tract disease infancy early childhood despite importance pathogen licensed vaccine rsv yet attachment glycoprotein g rsv potentially important target protective antiviral immune response recombinant baculovirus recently emerged new vaccine vector since intrinsic immunostimulatory property good biosafety profile method constructed recombinant baculovirusbased rsv vaccine bacrsvg displaying g glycoprotein evaluated immunogenicity protective efficacy intranasal immunization balbc mouse bacrsvg result bacrsvg efficiently provides protective immunity rsv challenge strong serum igg mucosal iga response induced intranasal immunization bacrsvg addition humoral immunity gspecific th well thtype tcell response detected lung bacrsvgimmune mouse upon rsv challenge neither lung eosinophilia vaccineinduced weight loss observed upon bacrsvg immunization subsequent rsv infection conclusion data demonstrate intranasal administration baculovirusbased bacrsvg vaccine efficient induction protection rsv represents promising prophylactic vaccination regimen,2012-02-29,"Kim, Sol; Chang, Jun",Immune Netw,,,,document_parses/pdf_json/da5f78374b6b0b58d01188a2029fe9d74336e473.json,document_parses/pmc_json/PMC3329602.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3329602/,,3
1350,1350,1458,wbj0w365,d17d9c2e082583da2dba7cfc61995f5af37e6851,PMC,Protective Immunity to Listeria Monocytogenes Infection Mediated by Recombinant Listeria innocua Harboring the VGC Locus,10.1371/journal.pone.0035503,PMC3334901,22536395.0,cc-by,study propose novel bacterial vaccine strategy nonpathogenic bacteria complemented trait desirable induction protective immunity illustrate proof principle novel vaccination strategy use model organism intracellular immunity listeria introduced low copy number bacplasmid harbouring virulence gene cluster vgc l monocytogenes lm nonpathogenic l innocua linn strain examined ability induce protective cellular immunity resulting strain linnvgc attenuated virulence vivo showed strongly reduced host detrimental inflammatory response compared lm like lm linnvgc induced production type interferon protection mediated listeriaspecific cd cell rational vaccine design whereby avirulent strain equipped capability induce protection lack detrimental inflammatory effect offer great promise towards future study using nonpathogenic bacteria vector vaccination,2012-04-19,"Mohamed, Walid; Sethi, Shneh; Tchatalbachev, Svetlin; Darji, Ayub; Chakraborty, Trinad",PLoS One,,,,document_parses/pdf_json/d17d9c2e082583da2dba7cfc61995f5af37e6851.json,document_parses/pmc_json/PMC3334901.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3334901/,,3
1384,1384,1494,3bdey2mz,86431a5391ad8d12589fe686d0486cf2a0e912f0,PMC,The Sigma Class Glutathione Transferase from the Liver Fluke Fasciola hepatica,10.1371/journal.pntd.0001666,PMC3362645,22666515.0,cc-by,background liver fluke infection livestock cause economic loss u billion worldwide per annum disease increasing livestock worldwide reemerging human disease currently commercial vaccine one drug significant efficacy adult worm juvenile liver fluke vaccine deemed essential shortlived chemotherapy prone resistance unsustainable option developed developing country protein superfamily provided number leading liver fluke vaccine candidate new form glutathione transferase gst family sigma class gst closely related leading schistosome vaccine candidate sm previously revealed proteomics liver fluke functionally characterised methodologyprincipal finding manuscript show purified recombinant form f hepatica sigma class gst posse prostaglandin synthase activity influence activity host immune cell immunocytochemistry western blotting shown protein present near surface fluke expressed egg newly excysted juvenile present excretorysecretory fraction adult assessed potential use f hepatica sigma class gst vaccine goatbased vaccine trial significant reduction worm burden found show significant reduction pathology normally associated liver fluke infection conclusionssignificance shown f hepatica sigma class gst likely multifunctional role hostparasite interaction general detoxification bile acid sequestration pgd synthase activity,2012-05-29,"LaCourse, E. James; Perally, Samirah; Morphew, Russell M.; Moxon, Joseph V.; Prescott, Mark; Dowling, David J.; O'Neill, Sandra M.; Kipar, Anja; Hetzel, Udo; Hoey, Elizabeth; Zafra, Rafael; Buffoni, Leandro; Pérez Arévalo, José; Brophy, Peter M.",PLoS Negl Trop Dis,,,,document_parses/pdf_json/86431a5391ad8d12589fe686d0486cf2a0e912f0.json,document_parses/pmc_json/PMC3362645.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362645/,,3
1403,1403,1513,uup16bhm,e30c94f17bd7f1fb5ffa651457bc3625c8311223,PMC,Adventitious Agents and Smallpox Vaccine in Strategic National Stockpile,10.3201/eid1107.050277,PMC3371778,16022785.0,no-cc,keeping current standard urge old smallpox vaccine made animal skin still key part strategic national stockpile tested adventitious infectious agent advisory especially applies virus potential zoonotic transmission human vaccine recipient,2005-07-26,"Murphy, Frederick A.; Osburn, Bennie I.",Emerg Infect Dis,,,,document_parses/pdf_json/e30c94f17bd7f1fb5ffa651457bc3625c8311223.json,document_parses/pmc_json/PMC3371778.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3371778/,,3
1490,1490,1610,4yfohp9w,c66d7cf6243be684d42751e19f4f9c27ca8a1f3b,PMC,A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection,10.1155/2011/126794,PMC3447297,23074652.0,cc-by,using peptide nanoparticle technology designed two novel vaccine construct representing monomeric monome tetrameric tetrame form group specific pathogen free spf chicken immunized intramuscularly monome tetrame without adjuvant two week second boost chicken challenged eid hn low pathogenicity avian influenza lpai virus mespecific antibody response vaccine construct tested elisa vaccinated chicken exhibited increased mespecific igg response construct compared nonvaccinated group however vaccine construct tetrame elicited significantly higher antibody response used adjuvant hand virus neutralization assay indicated immune protection way neutralizing antibody level protection evaluated using quantitative real time pcr day postchallenge hn lpai measuring virus shedding trachea cloaca tetrame adjuvant offered statistically significant p protection subtype hn lpai reduction ai virus shedding result suggest selfassembling polypeptide nanoparticle show promise potential platform development vaccine ai,2012-01-12,"Babapoor, Sankhiros; Neef, Tobias; Mittelholzer, Christian; Girshick, Theodore; Garmendia, Antonio; Shang, Hongwei; Khan, Mazhar I.; Burkhard, Peter",Influenza Res Treat,,,,document_parses/pdf_json/c66d7cf6243be684d42751e19f4f9c27ca8a1f3b.json,document_parses/pmc_json/PMC3447297.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447297/,,3
1493,1493,1613,3m3ytwwv,85f3c300e460e62364ef4a74fb1289334a5c2317,PMC,Protection conferred by a recombinant Marek’s disease virus that expresses the spike protein from infectious bronchitis virus in specific pathogen-free chicken,10.1186/1743-422x-9-85,PMC3447679,22559869.0,cc-by,background many country predominant field isolates infectious bronchitis virus ibv classified qxlike strain since however commercial vaccine specific type ibv currently available therefore urgent need develop novel vaccine prevent qxlike ibv infection result recombinant marek ’ disease virus mdv rmdvs express subunit spike protein qxlike infectious bronchitis virus ibv constructed inserting ibv gene genome cvirispens strain mdv specific pathogenfree spf chicken vaccinated rmdvs protected challenged qxlike ibv observed mild clinical sign disease short virusshedding period low mortality additionally rmdvs conferred full protection chicken virulent mdv cvirispens strain conclusion result demonstrate rmdvs effective promising recombinant vaccine prevention qxlike ibv infection,2012-05-04,"Zhang, Xiaorong; Wu, Yantao; Huang, Yezhen; Liu, Xiufan",Virol J,,,,document_parses/pdf_json/85f3c300e460e62364ef4a74fb1289334a5c2317.json,document_parses/pmc_json/PMC3447679.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447679/,,3
1495,1495,1615,okh6i4l1,891adb48f822d8e7f4749448ea5e2b4828c9aae5,PMC,"Protective efficacy of a broadly cross-reactive swine influenza DNA vaccine encoding M2e, cytotoxic T lymphocyte epitope and consensus H3 hemagglutinin",10.1186/1743-422x-9-127,PMC3447699,22738661.0,cc-by,background pig implicated mixing reservoir generation new pandemic influenza strain control swine influenza veterinary public health significance unlike human influenza vaccine strain used commercially available swine influenza vaccine regularly replaced making vaccine provide limited protection antigenically diverse virus therefore necessary develop broadly protective swine influenza vaccine efficacious homologous heterologous virus infection study two form dna vaccine constructed one made fusing consensus hha mha represents majority ha sequence hn swine influenza virus another made fusing conserved ctl epitope np consensus hha mnha protective efficacy homologous heterologous challenge tested result balbc mouse immunized twice particlemediated epidermal delivery gene gun two dna vaccine shown two vaccine elicited substantial antibody response mnha induced significant cellmediated immune response mha two hn strain representative different evolutional antigenic cluster used challenge vaccineimmunized mouse homosubtypic challenge result indicated dna vaccine prevented homosubtypic virus infection completely vaccine ’ heterologous protective efficacy tested challenging hn swine influenza virus reassortant pandemic strain found mnha reduced lung viral titer significantly challenge group histopathological observation showed obvious reduction lung pathogenesis compared mha control group conclusion combined utility consensus ha conserved ctl epitope confer complete partial protection homologous heterologous challenge respectively mouse model may provide basis development universal swine influenza vaccine,2012-06-27,"Wang, Bin; Yu, Hai; Yang, Fu-Ru; Huang, Meng; Ma, Ji-Hong; Tong, Guang-Zhi",Virol J,,,,document_parses/pdf_json/891adb48f822d8e7f4749448ea5e2b4828c9aae5.json,document_parses/pmc_json/PMC3447699.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447699/,,3
1515,1515,1635,wfrmvlhi,6135c4bb442a034b18ef4e9b3fc5701507225f0d,PMC,Acute Reactogenicity after Intramuscular Immunization with Recombinant Vesicular Stomatitis Virus Is Linked to Production of IL-1β,10.1371/journal.pone.0046516,PMC3466325,23056330.0,cc-by,vaccine based live virus attractive immunogenic costeffective delivered multiple route however live virus vaccine also cause reactogenic side effect fever myalgia injection site pain reduced acceptance clinic several recent study linked vaccineinduced reactogenic side effect production proinflammatory cytokine interleukinβ ilβ human objective therefore determine whether ilβ contributed pathology immunization recombinant vesicular stomatitis virus rvsv vaccine vector identify strategy ilβ mediated pathology might reduced without compromising immunogenicity found rvsv vaccine induced local systemic production ilβ vivo accumulation ilβ correlated acute pathology rvsv immunization rvsvinduced pathology reduced mouse deficient il receptor type ilr−− mouse fully protected lethal rechallenge high dose vsv result demonstrated il contributed reactogenicity rvsv dispensable induction protective immunity amount ilβ detected mouse deficient either caspase inflammasome adaptor molecule asc rvsv immunization significantly different produced wild type animal caspase−− asc−− mouse partially protected rvsvinduced pathology data support idea ilβ expressed vivo response vsv may activated caspase ascindependent mechanism together result suggest rvsv vector engineered suppress induction ilβ signaling ilr would le reactogenic vivo would retain immunogenicity protective capacity rvsv would highly desirable either vaccine vector oncolytic therapy would likely better tolerated human vaccinee,2012-10-08,"Athearn, Kathleen; Sample, Christopher J.; Barefoot, Brice E.; Williams, Kristi L.; Ramsburg, Elizabeth A.",PLoS One,,,,document_parses/pdf_json/6135c4bb442a034b18ef4e9b3fc5701507225f0d.json,document_parses/pmc_json/PMC3466325.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3466325/,,3
1522,1522,1642,ofpcgxce,75396899537915606b74f2b600478ad066f9d594,PMC,Hepatitis C VLPs Delivered to Dendritic Cells by a TLR2 Targeting Lipopeptide Results in Enhanced Antibody and Cell-Mediated Responses,10.1371/journal.pone.0047492,PMC3472981,23091628.0,cc-by,although many study provide strong evidence supporting development hcv viruslike particle vlpbased vaccine fact heterologous viral vector andor multiple dosing regime required induce protective immunity indicates necessary improve immunogenicity study evaluated use anionic selfadjuvanting lipopeptide containing tlr agonist pamcys epamcys enhance immunogenicity vlps containing hcv structural protein core e e genotype coformulation lipopeptide vlps resulted marginal improvement dendritic cell dc uptake ability concomitantly induce dc maturation small dos feature observed using vlps alone presence aluminium hydroxidebased adjuvant alum dramatically improved vlp especific antibody response observed vlpepamcys vaccinated mouse dos nonadjuvanted traditionally alumadjuvanted vlps required match antibody titre obtained single dose vlps formulated lipopeptide result also correlated significantly higher number specific antibody secreting cell detected spleen vlpepamcys vaccinated mouse greater ability serum mouse neutralise binding uptake vlps huh cell moreover vaccination hlaa transgenic mouse formulation also induced better vlpspecific ifnγmediated response compared nonadjuvanted vlps comparable level achieved coadministered complete freund ’ adjuvant result suggest overall immunogenicity hcv vlps significantly improved addition novel adjuvant targeting delivery dc could therefore constitute viable vaccine strategy treatment hcv,2012-10-16,"Chua, Brendon Y.; Johnson, Douglas; Tan, Amabel; Earnest-Silveira, Linda; Sekiya, Toshiki; Chin, Ruth; Torresi, Joseph; Jackson, David C.",PLoS One,,,,document_parses/pdf_json/75396899537915606b74f2b600478ad066f9d594.json,document_parses/pmc_json/PMC3472981.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472981/,,3
1538,1538,1659,i8zikevn,5deba58c72c66f2c3f47ec82569c9b2527f6f21d,PMC,"Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques",10.1007/s00210-012-0793-4,PMC3495096,22983013.0,no-cc,new human immunodeficiency virus type hiv vaccine approach liveattenuated measles virus mv schwarz vaccine strain genetically engineered express f antigen mvf f fusion protein comprising hiv antigen p p reverse transcriptase nef study assessed toxicity biodistribution shedding profile mvf cynomolgus macaque intramuscularly immunized one three time highest dose mvf intended clinical use reference schwarz measles vaccine saline monitored clinically day toxicological parameter included local systemic clinical sign organ weight haematology clinical gross pathology histopathology vaccine well tolerated morbidity clinical sign gross pathological finding observed mean spleen weight increased three dos either vaccine corresponded increased number andor size germinal center likely result immune response vaccine either vaccine virus replicated preferentially secondary lymphoid organ lesser extent epitheliumrich tissue eg intestine urinary bladder trachea liver expected peak viremia viral rna detected biological fluid sample animal immunized either vaccine none sample contained infectious virus conclusion shedding infectious viral particle identified cynomolgus monkey injection mvf schwarz measles vaccine furthermore toxic effect relation mv vaccination found vaccine study,2012-09-16,"Lorin, Clarisse; Segal, Lawrence; Mols, Johann; Morelle, Danielle; Bourguignon, Patricia; Rovira, Olga; Mettens, Pascal; Silvano, Jérémy; Dumey, Nicolas; Le Goff, Frédérick; Koutsoukos, Marguerite; Voss, Gerald; Tangy, Frédéric",Naunyn Schmiedebergs Arch Pharmacol,,,,document_parses/pdf_json/5deba58c72c66f2c3f47ec82569c9b2527f6f21d.json,document_parses/pmc_json/PMC3495096.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495096/,,3
1574,1574,1695,4mhh29l0,b0889b0058183e21ed81e8b41414fd4cc450ce84,PMC,"Adjuvant Activity of Sargassum pallidum Polysaccharides against Combined Newcastle Disease, Infectious Bronchitis and Avian Influenza Inactivated Vaccines",10.3390/md10122648,PMC3528116,23342387.0,cc-by,study evaluates effect sargassum pallidum polysaccharide spp immune response chicken model adjuvanticity sargassum pallidum polysaccharide newcastle disease nd infectious bronchitis ib avian influenza ai investigated examining antibody titer lymphocyte proliferation following immunization chicken chicken administrated combined nd ib ai inactivated vaccine containing spp mgml using oil adjuvant vaccine control nd ib ai antibody titer lymphocyte proliferation enhanced mgml spp conclusion appropriate dose spp may safe efficacious immune stimulator candidate suitable vaccine produce early persistent prophylaxis,2012-11-22,"Li, Li-Jie; Li, Ming-Yi; Li, Yan-Tuan; Feng, Jing-Jing; Hao, Feng-Qiang; Zhang, Lun",Mar Drugs,,,,document_parses/pdf_json/b0889b0058183e21ed81e8b41414fd4cc450ce84.json,document_parses/pmc_json/PMC3528116.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3528116/,,3
1646,1646,1770,e278thvo,bf134be7dfc56c7d9a66f0cfe6afc7d3df112b9e,PMC,Epidemiological Determinants of Successful Vaccine Development,10.7150/ijms.5689,PMC3590596,23471119.0,cc-by-nc-nd,epidemiological determinant successful vaccine development explored using measurable biological variable including antigenic stability requirement tcell immunity employing logistic regression model demonstrate high affinity blood immune cell pathogen interaction eg interference would risk factor failure vaccine development,2013-02-21,"Nishiura, Hiroshi; Mizumoto, Kenji",Int J Med Sci,,,,document_parses/pdf_json/bf134be7dfc56c7d9a66f0cfe6afc7d3df112b9e.json,document_parses/pmc_json/PMC3590596.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3590596/,,3
1650,1650,1774,6l6c7jpq,532e417a66dbe4822a3f8f9b496c105ccc7dd412,PMC,"Vaccination to Conserved Influenza Antigens in Mice Using a Novel Simian Adenovirus Vector, PanAd3, Derived from the Bonobo Pan paniscus",10.1371/journal.pone.0055435,PMC3594242,23536756.0,cc0,among approximately adenovirus chimpanzee bonobo studied recently pan adenovirus type panad isolated bonobo pan paniscus one best profile vaccine vector combining potent transgene immunogenicity minimal preexisting immunity human population study inserted replication defective panad transgene expressing fusion protein conserved influenza antigen nucleoprotein np matrix studied antibody cell response well protection challenge infection mouse model single intranasal administration panadnpm vaccine induced strong antibody cell response protected high dose lethal influenza virus challenge thus panad promising candidate vector vaccine including universal influenza vaccine,2013-03-11,"Vitelli, Alessandra; Quirion, Mary R.; Lo, Chia-Yun; Misplon, Julia A.; Grabowska, Agnieszka K.; Pierantoni, Angiolo; Ammendola, Virginia; Price, Graeme E.; Soboleski, Mark R.; Cortese, Riccardo; Colloca, Stefano; Nicosia, Alfredo; Epstein, Suzanne L.",PLoS One,,,,document_parses/pdf_json/532e417a66dbe4822a3f8f9b496c105ccc7dd412.json,document_parses/pmc_json/PMC3594242.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3594242/,,3
1661,1661,1785,gg4qi4tj,00951716e01c8e0cc341770389fc38d1b5455210,PMC,"Knowledge of, attitudes toward, and preventive practices relating to cholera and oral cholera vaccine among urban high-risk groups: findings of a cross-sectional study in Dhaka, Bangladesh",10.1186/1471-2458-13-242,PMC3608226,23509860.0,cc-by,background endemic country bangladesh consequence cholera place enormous financial social burden patient family cholera vaccine provide health benefit susceptible population also effect earning capability financial stability family communitybased research evaluation necessary understand perception practice community relating cholera oral cholera vaccine may help identify way vaccine may successfully introduced preventive measure implemented present study assessed knowledge attitude toward preventive practice relating cholera oral cholera vaccine among urban population residing high choleraprone setting dhaka bangladesh method crosssectional study conducted area high cholera prevalence randomlyselected cluster mirpur dhaka city study team collected data survey indepth interview december –february result family included final analysis could recognize cholera acute watery diarrhea ever heard oral cholera vaccine respondent poor knowledge cholerarelated issue positive attitude toward cholera oral cholera vaccine onethird showed poor practice relating prevention cholera finding showed significant p association respondent ’ knowledge sex education occupation monthly overall household expenditure attitude practice adjusted model male sex lower monthly overall household expenditure le positive attitude toward cholera significant predictor poor knowledge conclusion finding suggest strengthening health education activity improve knowledge cholera prevention treatment information cholera vaccination among highrisk population data also underscore potential mass cholera vaccination prevent control cholera,2013-03-19,"Wahed, Tasnuva; Kaukab, Sheikh Shah Tanvir; Saha, Nirod Chandra; Khan, Iqbal Ansary; Khanam, Farhana; Chowdhury, Fahima; Saha, Amit; Khan, Ashraful Islam; Siddik, Ashraf Uddin; Cravioto, Alejandro; Qadri, Firdausi; Uddin, Jasim",BMC Public Health,,,,document_parses/pdf_json/00951716e01c8e0cc341770389fc38d1b5455210.json,document_parses/pmc_json/PMC3608226.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3608226/,,3
1667,1667,1793,ir0rbr0i,4278a9b763f17829897dde88a49fcab6ab86b8c7,PMC,Alginic Acid-Coated Chitosan Nanoparticles Loaded with Legumain DNA Vaccine: Effect against Breast Cancer in Mice,10.1371/journal.pone.0060190,PMC3618226,23577091.0,cc-by,legumainbased dna vaccine potential protect breast cancer however lack safe efficient oral delivery system restricts clinical application constructed alginic acidcoated chitosan nanoparticles acnps oral delivery carrier legumain dna vaccine first tested characteristic acidic environment vitro dna agarose electrophoresis data show acnps protected dna better degradation acidic solution ph chitosan nanoparticles cnps furthermore size distribution analysis showed acnps tended aggregate form micrometer scale complex ph dispersing nanoparticles increase ph mouse intragastrically administrated acnps carrying egfp plasmid egfp expression detected intestinal peyer ’ patch fulllength legumain plasmid loaded different delivery carrier including cnps attenuated salmonella typhimurium acnps acnps loaded empty plasmid served control oral vaccination performed murine orthotopic breast cancer model data indicate tumor volume significantly smaller group using acnps attenuated salmonella typhimurium carrier furthermore splenocytes cocultured cell prestimulated cocl influenced translocation legumain cytoplasm plasma membrane showed fold increase active cytotoxic lymphocyte cdcdcd treated acnps carrier compared pb cnps study suggests cnps coated alginic acid may safe efficient tool oral delivery dna vaccine moreover legumain dna vaccine delivered orally acnps effectively improve autoimmune response protect breast cancer mouse,2013-04-05,"Liu, Ze; Lv, Dan; Liu, Shu; Gong, Junbo; Wang, Da; Xiong, Min; Chen, Xiaoniao; Xiang, Rong; Tan, Xiaoyue",PLoS One,,,,document_parses/pdf_json/4278a9b763f17829897dde88a49fcab6ab86b8c7.json,document_parses/pmc_json/PMC3618226.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3618226/,,3
1678,1678,1804,msmq91d2,7d9f6bae2b7ced5834b4e92e7ef805d85fdea405,PMC,Characterization of Rift Valley Fever Virus MP-12 Strain Encoding NSs of Punta Toro Virus or Sandfly Fever Sicilian Virus,10.1371/journal.pntd.0002181,PMC3630143,23638202.0,cc-by,rift valley fever virus rvfv genus phlebovirus family bunyaviridae mosquitoborne zoonotic pathogen cause hemorrhagic fever neurological disorder blindness human high rate abortion ruminant mp strain liveattenuated candidate vaccine attenuated lsegments ssegment retains virulent phenotype mp manufactured investigational new drug vaccine using mrc cell encodes functional n gene major virulence factor rvfv induces shutoff host transcription inhibits interferon ifnβ promoter activation promotes degradation dsrnadependent protein kinase pkr mp lack marker differentiation infected vaccinated animal diva although mp lacking n work diva replicate efficiently typei ifncompetent mrc cell use typei ifnincompetent cell may negatively affect genetic stability generate modified mp vaccine candidate encoding diva marker still replicating efficiently mrc cell generated recombinant mp encoding punta toro virus adames strain n rmpptnss sandfly fever sicilian virus n rmpsfsnss place mp n demonstrated recombinant mp virus inhibit ifnβ mrna synthesis yet promote degradation pkr rmpptnss rmpsfsnss replicated efficiently recombinant mp lacking n mrc cell mouse vaccinated rmpptnss rmpsfsnss induced neutralizing antibody level equivalent vaccinated mp efficiently protected wildtype rvfv challenge rmpptnss rmpsfsnss induce antibody crossreactive antirvfv n antibody therefore applicable diva thus rmpptnss highly efficacious replicates efficiently mrc cell encodes diva marker important vaccine development rift valley fever,2013-04-18,"Lihoradova, Olga A.; Indran, Sabarish V.; Kalveram, Birte; Lokugamage, Nandadeva; Head, Jennifer A.; Gong, Bin; Tigabu, Bersabeh; Juelich, Terry L.; Freiberg, Alexander N.; Ikegami, Tetsuro",PLoS Negl Trop Dis,,,,document_parses/pdf_json/7d9f6bae2b7ced5834b4e92e7ef805d85fdea405.json,document_parses/pmc_json/PMC3630143.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3630143/,,3
1705,1705,1833,dh9pr82o,6fcc000ecf39dd1da69d94d8cd764790ce96aaba,PMC,Recombinant Vaccines against T. gondii: Comparison between Homologous and Heterologous Vaccination Protocols Using Two Viral Vectors Expressing SAG1,10.1371/journal.pone.0063201,PMC3654925,23690999.0,cc-by,use recombinant viral vector expressing gondii antigen safe efficient approach induce immune response parasite valuable tool vaccine development previously protected mouse toxoplasmosis immunizing animal adenovirus expressing protein sag adsag gondii looking way improve vaccination strategy enhance protection one limitation homologous vaccination sequential dos vector induction antivector immune response block cell transduction restricts transgene expression consequently compromise overall outcome vaccination one way avert effect antivector response use different virus prime boost heterologous vaccination bearing mind generated modified vaccinia virus ankara encoding sag mvasag tested boost agent prime adsag although minor difference observed magnitude antisag immune response induced vaccination protocol heterologous immunization adsag followed mvasag resulted improved capacity control brain cyst formation model chronic toxoplasmosis cbl mouse,2013-05-15,"Mendes, Érica Araújo; Fonseca, Flavio G.; Casério, Bárbara M.; Colina, Janaína P.; Gazzinelli, Ricardo Tostes; Caetano, Braulia C.",PLoS One,,,,document_parses/pdf_json/6fcc000ecf39dd1da69d94d8cd764790ce96aaba.json,document_parses/pmc_json/PMC3654925.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654925/,,3
1739,1739,1870,wi7qdbc7,91ac78d2a3c677d322fc8b14bc23e6b4244b5bdc,PMC,Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses,10.1371/journal.pone.0067123,PMC3694142,23840600.0,cc-by,study analyzed heterologous primeboost vaccine approach hiv using three different antigenically unrelated negativestranded virus nsv expressing hiv gag vaccine vector rabies virus rabv vesicular stomatitis virus vsv newcastle disease virus ndv hypothesized approach would result robust cellular immune response achieved use vaccine alone homologous primeboost regimen end primed balbc mouse nsvbased vector primed mouse rested thirtyfive day administered second immunization heterologous nsvgag virus magnitude quality gagspecific cd cell response vector post boost measured addition performed challenge experiment using vaccinia virus expressing hiv gag vvgag thirtythree day boost inoculation result showed choice vaccine used priming important detected gagspecific cd cell recall response post boost ndvgag appeared result robust recall cd cell response independent prime vaccine used however different primeboost strategy distinct parameter studied challenge experiment using vvgag indicate benefit compared single immunization taken together data show nsv vector individually stimulate hivgag specific cd cell effectively recalled nsv vector heterologous primeboost approach result provide evidence rabv vsv ndv used combination develop vaccine needing primeboost regimen stimulate effective immune response,2013-06-26,"Lawrence, Tessa M.; Wanjalla, Celestine N.; Gomme, Emily A.; Wirblich, Christoph; Gatt, Anthony; Carnero, Elena; García-Sastre, Adolfo; Lyles, Douglas S.; McGettigan, James P.; Schnell, Matthias J.",PLoS One,,,,document_parses/pdf_json/91ac78d2a3c677d322fc8b14bc23e6b4244b5bdc.json,document_parses/pmc_json/PMC3694142.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3694142/,,3
1749,1749,1881,gyetna96,53114f0f5e6fdc237988a366cd9af65372e959c9,PMC,Chronic psychosocial stress: does it modulate immunity to the influenza vaccine in Hong Kong Chinese elderly caregivers?,10.1007/s11357-012-9449-z,PMC3705094,22772580.0,green-oa,previous study evaluated effect psychosocial stress influenza vaccine response however methodological limitation study aim determine whether chronic stress associated poorer influenzaspecific immune response influenza vaccine hong kong chinese elderly people prospective study week followup subject recruited government general outpatient clinic nongovernment organization public housing estate hong kong participant include caregiver spouse chronic condition impaired activity daily living age sexmatched noncaregivers singledose trivalent influenza vaccine given subject intramuscular ingestion blood sample collected vaccination week week vaccination influenza vaccine strainspecific antibody titer measured hemagglutination inhibition method lymphocyte subset analyzed ratio absolute count cytokine concentration measured flow cytometry validated scale used ass psychological depressive symptom perceived stress caregiver strain social multidimensional social support scale lifestyle factor physical exercise cigarette smoking alcohol consumption baseline prior vaccination demographic socioeconomic variable also collected albumin level measured indicator nutritional status subject caregiver statistically significant p lower cellmediated immune response influenza vaccination week compared control difference humoral immune response vaccination observed caregiver control hong kong chinese elderly experience chronic stress significantly lower cellmediated immune response influenza vaccination compared noncaregivers,2012-07-08,"Wong, Samuel Yeung Shan; Wong, Chun Kwok; Chan, Frank Wan Kin; Chan, Paul K. S.; Ngai, Karry; Mercer, Stewart; Woo, Jean",AGE,,,,document_parses/pdf_json/53114f0f5e6fdc237988a366cd9af65372e959c9.json,document_parses/pmc_json/PMC3705094.xml.json,http://europepmc.org/articles/pmc3705094?pdf=render,,3
1758,1758,1890,jpo9oomb,5076cec908e9bc3ba685507e00ac19deab50b02e,PMC,Peptide-Based Vaccinology: Experimental and Computational Approaches to Target Hypervariable Viruses through the Fine Characterization of Protective Epitopes Recognized by Monoclonal Antibodies and the Identification of T-Cell-Activating Peptides,10.1155/2013/521231,PMC3710646,23878584.0,cc-by,defining immunogenic domain viral protein capable eliciting protective immune response crucial development novel epitopebased prophylactic strategy particularly important selective targeting conserved region shared among hypervariable virus studying postinfection postimmunization serum well cloning characterization monoclonal antibody mabs still represents best approach identify protective epitope particular protective mab directed conserved region play key role immunogen design human therapy well experimental approach aiming characterize protective mab epitope identify tcellactivating peptide often burdened technical limitation require long time correctly addressed thus last decade many epitope predictive algorithm developed algorithm continually evolving use address empirical research widely increasing review several strategy based experimental technique alone addressed silico analysis frequently used predict immunogen included novel epitopebased vaccine approach list main strategy aiming design new vaccine preparation conferring protection neutralizing mab combined effective cellmediated response,2013-06-26,"Castelli, Matteo; Cappelletti, Francesca; Diotti, Roberta Antonia; Sautto, Giuseppe; Criscuolo, Elena; Dal Peraro, Matteo; Clementi, Nicola",Clin Dev Immunol,,,,document_parses/pdf_json/5076cec908e9bc3ba685507e00ac19deab50b02e.json,document_parses/pmc_json/PMC3710646.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710646/,,3
1769,1769,1902,or0czzdp,943491914a5f52c713070accbde7e0e868771e91,PMC,Evaluation of Mucosal and Systemic Immune Responses Elicited by GPI-0100- Adjuvanted Influenza Vaccine Delivered by Different Immunization Strategies,10.1371/journal.pone.0069649,PMC3729563,23936066.0,cc-by,vaccine protection respiratory infection optimally induce mucosal immune response respiratory tract addition systemic immune response however current parenteral immunization modality generally fail induce mucosal immunity mucosal vaccine delivery often result poor systemic immunity order find immunization strategy satisfies need induction mucosal systemic immunity compared local systemic immune response elicited two mucosal immunization given either intranasal intrapulmonary ipl route response elicited mucosal prime followed systemic boost immunization study conducted balbc mouse vaccine formulation influenza subunit vaccine supplemented gpi saponinderived adjuvant optimal mucosal antibody titer obtained two intrapulmonary vaccination optimal systemic antibody response achieved intranasal prime followed intramuscular boost latter strategy also resulted best cell response yet ineffective inducing nose lung iga successful induction secretory iga igg cell response achieved primeboost strategy involving intrapulmonary immunization optimal immunization given via intrapulmonary route result underline immunization via lung particularly effective priming well boosting local systemic immune response,2013-07-31,"Liu, Heng; Patil, Harshad P.; de Vries-Idema, Jacqueline; Wilschut, Jan; Huckriede, Anke",PLoS One,,,,document_parses/pdf_json/943491914a5f52c713070accbde7e0e868771e91.json,document_parses/pmc_json/PMC3729563.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3729563/,,3
1780,1780,1913,3t97ubzc,790506537d41f8336265c309548c3f95759c7370,PMC,Enhanced Nasal Mucosal Delivery and Immunogenicity of Anti-Caries DNA Vaccine through Incorporation of Anionic Liposomes in Chitosan/DNA Complexes,10.1371/journal.pone.0071953,PMC3748075,23977186.0,cc-by,design optimized nanoparticles offer promising strategy enable dna vaccine cross various physiological barrier eliciting specific protective mucosal immunity via intranasal administration reported new designed nanoparticle system incorporating anionic liposome al chitosandna csdna complex enhanced cellular uptake constructed alcsdna nanoparticles deliver anticaries dna vaccine pgjapvax nasal mucosa tem result showed alcsdna spherical structure high dna loading ability effective dna protection nuclease proved gel electrophoresis surface charge alcsdna depended strongly ph environment enabling intracellular release loaded dna via phmediated manner comparison traditional csdna system new design rendered higher transfection efficiency longer residence time alcsdna nasal mucosal surface outstanding feature enable alcsdna induce significantly p higher level secretory iga siga csdna animal study longerterm mucosal immunity hand alcsdna exhibited minimal cytotoxicity result suggest developed nanoparticles offer potential platform dna vaccine packaging delivery efficient elicitation mucosal immunity,2013-08-20,"Chen, Liulin; Zhu, Junming; Li, Yuhong; Lu, Jie; Gao, Li; Xu, Huibi; Fan, Mingwen; Yang, Xiangliang",PLoS One,,,,document_parses/pdf_json/790506537d41f8336265c309548c3f95759c7370.json,document_parses/pmc_json/PMC3748075.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3748075/,,3
1822,1822,1959,dugsh7mp,a462888bb4b9f31940fb166c07a8590406150575,PMC,Mucosal Vaccination with Recombinant Adenovirus Encoding Nucleoprotein Provides Potent Protection against Influenza Virus Infection,10.1371/journal.pone.0075460,PMC3783479,24086536.0,cc-by,influenza vaccine target highly variable surface glycoprotein hemagglutinin neuraminidase cause inconvenience vaccination every year reason development universal vaccine targeting conserved viral component needed study generated recombinant adenovirus rad vaccine encoding nucleoprotein np apr influenza virus designated radnp balbc mouse immunized intranasally sublingually radnp vaccine subsequently challenged lethal dos heterologous well homologous influenza virus found intranasal immunization radnp elicited strong mucosal iga response well stronger cd tcell response toward immunodominant kdrestricted np epitope sublingual immunization importantly single intranasal sublingual immunization radnp provides potent protection homologous heterologous influenza virus challenge result suggest recombinant radnp could universal vaccine candidate mucosal administration influenza virus,2013-09-25,"Kim, So-Hee; Kim, Joo Young; Choi, Youngjoo; Nguyen, Huan H.; Song, Man Ki; Chang, Jun",PLoS One,,,,document_parses/pdf_json/a462888bb4b9f31940fb166c07a8590406150575.json,document_parses/pmc_json/PMC3783479.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3783479/,,3
1847,1847,1984,1fgz2fyr,db055944a3acc538005fe7af772ec33c16b2fdd9,PMC,Vaccines for the future: learning from human immunology,10.1111/j.1751-7915.2011.00276.x,PMC3815775,21880117.0,no-cc,conventional vaccine extremely successful preventing infection pathogen expressing relatively conserved antigen antibody‐mediated effector mechanism thanks vaccination disease eradicated mortality due infectious disease significantly reduced however still many infection preventable vaccination represent major cause mortality worldwide infection caused pathogen high degree antigen variability controlled antibody require mix humoral cellular immune response novel technology antigen discovery expression formulation allow development vaccine better cope pathogen diversity trigger multifunctional immune response addition application new genomic assay system biology approach human immunology help better identify vaccine correlate protection availability novel vaccine technology together knowledge distinct human immune response required prevent different type infection help rationally design effective vaccine conventional approach failed,2012-02-20,"De Gregorio, Ennio; Rappuoli, Rino",Microb Biotechnol,,,,document_parses/pdf_json/db055944a3acc538005fe7af772ec33c16b2fdd9.json,document_parses/pmc_json/PMC3815775.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815775/,,3
1876,1876,2014,q2y7fewk,92dc5a63d0776632f789e874bb0217c4ac1d021b,PMC,Coping with genetic diversity: the contribution of pathogen and human genomics to modern vaccinology,10.1590/s0100-879x2011007500142,PMC3854287,22030866.0,cc-by-nc,vaccine development face major difficulty partly genetic variation infectious organism human cause antigenic variation infectious agent high interindividual variability human response vaccine exponential growth genome sequence information induced shift conventional culturebased genomebased vaccinology allows tackling challenge vaccine development due pathogen genetic variability additionally recent advance immunogenetics genomics help understanding influence genetic factor interindividual interpopulation variation immune response vaccine could useful developing new vaccine strategy accumulating result provide evidence existence number gene involved protective immune response induced either natural infection vaccine variation immune response could viewed result perturbation gene network help understanding particular polymorphism combination thereof could affect protective immune response present first genomebased vaccine served proof concept provided new critical insight vaccine development strategy ii overview genetic predisposition infectious disease genetic control response vaccine iii population genetic difference rationale behind grouptargeted vaccine iv outlook genetic control infectious disease special emphasis concept molecular network provide structure huge amount genomic data,2011-10-28,"Lemaire, D.; Barbosa, T.; Rihet, P.",Braz J Med Biol Res,,,,document_parses/pdf_json/92dc5a63d0776632f789e874bb0217c4ac1d021b.json,document_parses/pmc_json/PMC3854287.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3854287/,,3
1921,1921,2062,jkg7qkj6,d876d3d89d579f47df9ac251a4139ab1051561f5,PMC,Randomized Controlled Ferret Study to Assess the Direct Impact of 2008–09 Trivalent Inactivated Influenza Vaccine on A(H1N1)pdm09 Disease Risk,10.1371/journal.pone.0086555,PMC3903544,24475142.0,cc-by,springsummer several observational study canada showed increased risk medicallyattended laboratoryconfirmed ahnpdm illness among prior recipient – trivalent inactivated influenza vaccine tiv explanatory hypothesis included direct indirect vaccine effect randomized placebocontrolled ferret study tested whether prior receipt – tiv may directly influenced ahnpdm illness thirtytwo ferret group received ml intramuscular injection canadianmanufactured commerciallyavailable nonadjuvanted split – fluviral pb placebo day day animal challenged ch ahnpdm four ferret per group randomly selected sacrifice day postchallenge ch rest followed ch serum tested antibody vaccine antigen ahnpdm hemagglutination inhibition hi microneutralization mn nucleoproteinbased elisa habased microarray assay clinical characteristic nasal virus titer recorded prechallenge postchallenge sacrifice lung virus titer cytokine inflammatory score determined baseline characteristic similar two group influenzanaïve animal antibody rise vaccine antigen evident elisa habased microarray hi mn assay virus challenge raised antibody ahnpdm assay group beginning ch vaccinated animal experienced greater loss appetite weight placebo animal reaching greatest betweengroup difference weight loss relative baseline ch v p ch vaccinated animal higher lung virus titer logmean v pfuml respectively p lung inflammatory score v respectively p cytokine level p ch group recovered finding influenzanaïve systematicallyinfected ferret may replicate human experience considered conclusive explain human observation ferret finding consistent direct adverse effect prior – tiv receipt ahnpdm illness warrant indepth investigation search possible mechanistic explanation,2014-01-27,"Skowronski, Danuta M.; Hamelin, Marie-Eve; De Serres, Gaston; Janjua, Naveed Z.; Li, Guiyun; Sabaiduc, Suzana; Bouhy, Xavier; Couture, Christian; Leung, Anders; Kobasa, Darwyn; Embury-Hyatt, Carissa; de Bruin, Erwin; Balshaw, Robert; Lavigne, Sophie; Petric, Martin; Koopmans, Marion; Boivin, Guy",PLoS One,,,,document_parses/pdf_json/d876d3d89d579f47df9ac251a4139ab1051561f5.json,document_parses/pmc_json/PMC3903544.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3903544/,,3
1961,1961,2103,fh0mhqhv,832fab67c299fb2682948d33858e58a5db71e6f8,PMC,A Novel Vaccine against Crimean-Congo Haemorrhagic Fever Protects 100% of Animals against Lethal Challenge in a Mouse Model,10.1371/journal.pone.0091516,PMC3951450,24621656.0,cc-by,crimeancongo haemorrhagic fever cchf severe tickborne disease endemic many country africa middle east eastern europe asia – reported case fatal approved vaccine available preclinical protection vivo experimental vaccine demonstrated previously present study attenuated poxvirus vector modified vaccinia virus ankara used develop recombinant candidate vaccine expressing cchf virus glycoprotein cellular humoral immunogenicity confirmed two mouse strain including type interferon receptor knockout mouse susceptible cchf disease vaccine protected recipient animal lethal disease challenge model adapted represent infection via tick bite histopathology viral load analysis protected animal confirmed exposed challenge virus even though exhibit clinical sign first demonstration efficacy cchf vaccine,2014-03-12,"Buttigieg, Karen R.; Dowall, Stuart D.; Findlay-Wilson, Stephen; Miloszewska, Aleksandra; Rayner, Emma; Hewson, Roger; Carroll, Miles W.",PLoS One,,,,document_parses/pdf_json/832fab67c299fb2682948d33858e58a5db71e6f8.json,document_parses/pmc_json/PMC3951450.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951450/,,3
2001,2001,2143,6krujv2m,374834808ed55e895c9da2d0687b007b84972897,PMC,Injection Route and TLR9 Agonist Addition Significantly Impact Heroin Vaccine Efficacy,10.1021/mp400631w,PMC3993894,24517171.0,no-cc,image see text active immunization effective mean blocking pharmacodynamic effect drug hold promise treatment heroin addiction previously demonstrated efficacy firstgeneration vaccine blocking heroin selfadministration rat however many vaccine component modified improve performance herein examine effect varying heroin vaccine injection route adjuvant formulation mouse immunized via subcutaneous sc injection exhibited inferior antiheroin titer compared intraperitoneal ip scip coadministration injection route addition tlr agonist cytosineguanine oligodeoxynucleotide cpg odn original alum adjuvant elicited superior antibody titer opioid affinity compared alum alone thoroughly ass vaccine efficacy full dose–response curve generated heroininduced analgesia hot plate tail immersion test mouse treated cpg odn exhibited greatly shifted dose–response curve –fold v unvaccinated control noncpg odn vaccine group exhibit robust effect –fold shift ip combo –fold shift sc result suggest cpg odn highly potent adjuvant injection route considered development small molecule–protein conjugate vaccine lastly study established new standard assessing drug abuse vaccine wherein full dose–response curve performed appropriate behavioral task,2014-02-11,"Bremer, Paul T.; Schlosburg, Joel E.; Lively, Jenny M.; Janda, Kim D.",Mol Pharm,,,,document_parses/pdf_json/374834808ed55e895c9da2d0687b007b84972897.json,document_parses/pmc_json/PMC3993894.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3993894/,,3
2017,2017,2159,a9o2dvke,ecea1d9607209bfcf32da251f53136e7f5c12f3e,PMC,A Vaccine of L2 Epitope Repeats Fused with a Modified IgG1 Fc Induced Cross-Neutralizing Antibodies and Protective Immunity against Divergent Human Papillomavirus Types,10.1371/journal.pone.0095448,PMC4011685,24802101.0,cc-by,current human papillomavirus hpv major capsid protein l viruslike particle vlpsbased vaccine clinic induce strong hpv typespecific neutralizing antibody response develop panhpv vaccine show fusion protein er consisting three repeat hpv l aa – epitope e modified human igg fc scaffold r induces crossneutralizing antibody protective immunity divergent hpv type er expressed secreted protein baculovirus expression system could simply purified one step protein affinity chromatography purity vaccination er formulated freunds adjuvant induced crossneutralizing antibody hpv pseudovirus type mouse also protected mouse vaginal challenge hpv pseudovirus type least eleven month first immunization moreover vaccination er formulated fda approved adjuvant alum plus monophosphoryl lipid also induced crossneutralizing antibody hpv type rabbit thus result demonstrate delivery l antigen modified fcfusion protein may facilitate panhpv vaccine development,2014-05-06,"Chen, Xue; Liu, Hongyang; Zhang, Ting; Liu, Yanchun; Xie, Xixiu; Wang, Zhirong; Xu, Xuemei",PLoS One,,,,document_parses/pdf_json/ecea1d9607209bfcf32da251f53136e7f5c12f3e.json,document_parses/pmc_json/PMC4011685.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4011685/,,3
2041,2041,2186,2ax1e7zw,2ebf1526911eca26db1a7933e592260302caa3b7,PMC,A Novel Universal Neutralizing Monoclonal Antibody against Enterovirus 71 That Targets the Highly Conserved “Knob” Region of VP3 Protein,10.1371/journal.pntd.0002895,PMC4038473,24875055.0,cc-by,hand foot mouth disease caused enterovirus ev lead majority neurological complication death young child putative inactivated vaccine undergoing clinical trial specific treatment option exist yet ideally ev specific intravenous immunoglobulin could developed targeted treatment severe case date single universally neutralizing monoclonal antibody conserved linear epitope vp identified enterovirus shown posse major conformational neutralizing epitope vp vp capsid protein hence attempted isolate neutralizing antibody conformational epitope potential treatment infection well differential diagnosis vaccine optimization describe universal neutralizing monoclonal antibody recognizes conserved conformational epitope ev mapped using escape mutant eight escape mutant different subgenogroups b b c c rescued harbored three essential mutation either amino acid position vp protein situated “ knob ” region escape mutant phenotype could mimicked incorporating mutation reverse genetically engineered virus showing pl ad ap ed abolish monoclonal antibody binding neutralization activity first conformational neutralization epitope mapped vp ev,2014-05-29,"Kiener, Tanja K.; Jia, Qiang; Meng, Tao; Chow, Vincent Tak Kwong; Kwang, Jimmy",PLoS Negl Trop Dis,,,,document_parses/pdf_json/2ebf1526911eca26db1a7933e592260302caa3b7.json,document_parses/pmc_json/PMC4038473.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4038473/,,3
2084,2084,2230,q8gshba8,04f4cff6c1a32e0edb50bdb8daf00f82708a5142,PMC,Plasmodium vivax Antigen Discovery Based on Alpha-Helical Coiled Coil Protein Motif,10.1371/journal.pone.0100440,PMC4069070,24959747.0,cc-by,protein αhelical coiled coil structure elicit antibody response block critical function medically important microorganism represent mean vaccine development using bioinformatics algorithm total antigen αhelical coiled coil motif orthologous plasmodium falciparum identified p vivax genome peptide identified silico chemically synthesized circular dichroism study indicated partial high αhelical content antigenicity evaluated using human serum sample malariaendemic area colombia papua new guinea eight fragment selected used ass immunogenicity balbc mouse elisa assay indicated strong reactivity serum sample individual residing malariaendemic region serum immunized mouse αhelical coiled coil structure addition ex vivo production ifnγ murine mononuclear cell confirmed immunogenicity structure presence tcell epitope peptide sequence moreover serum mouse immunized four eight antigen recognized native protein bloodstage p vivax parasite antigenic crossreactivity three peptide observed reacted p falciparum orthologous fragment whole parasite result point αhelical coiled coil peptide possible p vivax malaria vaccine candidate observed p falciparum fragment selected warrant study human nonhuman primate model ass protective efficacy single component assembled hybrid linear epitope,2014-06-24,"Céspedes, Nora; Habel, Catherine; Lopez-Perez, Mary; Castellanos, Angélica; Kajava, Andrey V.; Servis, Catherine; Felger, Ingrid; Moret, Remy; Arévalo-Herrera, Myriam; Corradin, Giampietro; Herrera, Sócrates",PLoS One,,,,document_parses/pdf_json/04f4cff6c1a32e0edb50bdb8daf00f82708a5142.json,document_parses/pmc_json/PMC4069070.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4069070/,,3
2093,2093,2239,de5or4mc,ea08d7bb1c95436e9ed7af4ed5419cc8fc56e7b7,PMC,Immunogenicity and efficacy of a plasmid DNA rabies vaccine incorporating Myd88 as a genetic adjuvant,10.7774/cevr.2014.3.2.202,PMC4083073,25003094.0,cc-by-nc,purpose myeloid differentiation factor myd ubiquitous tolllike receptor adaptor molecule reported play important role b cell response infection vaccination present study evaluated effect genetic adjuvanting myd immune response plasmid dna rabies vaccine material method plasmid encoding rabies glycoprotein alone piresrgp fragment myd gene addition piresrgpmyd constructed administered intramuscularly intrademally swiss albino mouse day rabies virus neutralizing antibody rvna titre estimated mouse serum day rapid fluorescent focus inhibition test protective efficacy construct evaluated intracerebral challenge challenge virus standard virus day result coexpression myd increased rvna response piresrgp fold following intramuscular intradermal immunization respectively piresrgp protected mouse following intramuscular intradermal immunization piresrgpmyd afforded protection following similar administration conclusion genetic adjuvanting myd enhanced rvna response protective efficacy plasmid dna rabies vaccine strategy might useful rabies vaccination canine field need evaluation,2014-06-20,"Ullas, Padinjaremattathil Thankappan; Desai, Anita; Madhusudana, Shampur Narayan",Clin Exp Vaccine Res,,,,document_parses/pdf_json/ea08d7bb1c95436e9ed7af4ed5419cc8fc56e7b7.json,document_parses/pmc_json/PMC4083073.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4083073/,,3
2095,2095,2241,k785hl1r,41deae1169912161f5195d978626aa2ca1898994,PMC,Production and immunogenicity of chimeric virus-like particles containing the spike glycoprotein of infectious bronchitis virus,10.4142/jvs.2014.15.2.209,PMC4087222,24378590.0,cc-by-nc,infectious bronchitis virus ibv pose severe threat poultry industry cause heavy economic loss worldwide vaccination effective method preventing infection controlling spread ibv currently available inactivated attenuated virus vaccine disadvantage developed chimeric viruslike particle vlpbased candidate vaccine ibv protection chimeric vlp composed matrix protein avian influenza hn virus fusion protein neuraminidase naspike generated fusing ibv protein cytoplasmic transmembrane domain na protein avian influenza hn virus chimeric vlps elicited significantly higher sspecific antibody response intramuscularly immunized mouse chicken inactivated ibv virus furthermore chimeric vlps induced significantly higher neutralization antibody level inactivated h virus spf chicken finally chimeric vlps induced significantly higher il production mouse result demonstrate chimeric vlps potential use vaccine ibv infection,2014-06-16,"Lv, Lishan; Li, Xiaoming; Liu, Genmei; Li, Ran; Liu, Qiliang; Shen, Huifang; Wang, Wei; Xue, Chunyi; Cao, Yongchang",J Vet Sci,,,,document_parses/pdf_json/41deae1169912161f5195d978626aa2ca1898994.json,document_parses/pmc_json/PMC4087222.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4087222/,,3
2100,2100,2246,o55s1j25,220eb67c641822dd276f4d30683c692de58e5221,PMC,ICoVax 2013: The 3(rd )ISV Pre-conference Computational Vaccinology Workshop,10.1186/1471-2105-15-s4-i1,PMC4094997,25104130.0,cc-by,following last year computational vaccinology workshop shanghai china third isv preconference computational vaccinology workshop icovax held barcelona spain icovax provided international platform attendee showcase research discus problem solution development application computational vaccinology vaccine informatics tool first three fulllength paper presented icovax discussed discovery viral camouflage crossconservation tcell epitope using tool called janusmatrix important paper report virus may camouflage presence human body incorporating sequence protein highly crossconserved tcell receptor surface human genome protein discovery wide ranging implication development vaccine virus use camouflage method paper described database storing experimentally verified data dna vaccine compared therapeutic target western drug chinese herbal medicine cardiovascular disease short poster presentation covered various us informatics tool processing dna microrna pathogen improve vaccine coverage efficacy development live online demonstration vaccine design toolkit ivax presented france terry epivax illustrated computational vaccinology could used design next generation vaccine,2014-03-19,"De Groot, Anne S; De Groot, Phoebe; He, Yongqun",BMC Bioinformatics,,,,document_parses/pdf_json/220eb67c641822dd276f4d30683c692de58e5221.json,document_parses/pmc_json/PMC4094997.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4094997/,,3
2110,2110,2257,6u80p5sj,3aa75376556fa96324ad4cacb0b862ad86b7a11e,PMC,A Novel MVA Vectored Chikungunya Virus Vaccine Elicits Protective Immunity in Mice,10.1371/journal.pntd.0002970,PMC4109897,25058320.0,cc-by,background chikungunya virus chikv reemerging arbovirus associated febrile illness often accompanied rash arthralgia may persist several year outbreak associated high morbidity create public health challenge country affected recent outbreak occurred europe america suggesting chikv may continue spread despite sustained threat virus approved vaccine antiviral therapy chikv therefore critical develop vaccine well tolerated highly protective methodologyprincipal finding study describe construction characterization modified vaccinia virus ankara mva virus expressing chikv e e protein mvachik protected several mouse model challenge chikv particular balbc mouse completely protected viremia upon challenge chikv two dos mvachik additionally mouse deficient ifnαβ protected viremia footpad swelling mortality high antivirus antibody elicited low undetectable level neutralizing antibody produced mouse model however passive transfer mvachik immune serum naïve mouse protect mortality suggesting antibody may main effector protection afforded mvachik furthermore depletion cd cd tcells vaccinated mouse resulted mortality implicating indispensable role cd tcells protection afforded mvachik conclusionssignificance result presented herein demonstrate potential mva effectively express chikv ee protein generate protective immune response finding challenge assumption neutralizing antibody effective providing protection chikv provides framework development novel effective vaccine strategy combat chikv,2014-07-24,"Weger-Lucarelli, James; Chu, Haiyan; Aliota, Matthew T.; Partidos, Charalambos D.; Osorio, Jorge E.",PLoS Negl Trop Dis,,,,document_parses/pdf_json/3aa75376556fa96324ad4cacb0b862ad86b7a11e.json,document_parses/pmc_json/PMC4109897.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4109897/,,3
2258,2258,2410,8o7oqb5d,2b36f467dee97f9675e187cabd4e4585e7ab17f2,PMC,Developing a vaccine for human rhinoviruses,10.14312/2053-1273.2014-3,PMC4291752,25593706.0,cc-by-nc,rhinovirus rv ’ common human pathogen respiratory tract frequent cause mild disease upper respiratory tract common cold importantly major initiator acute exacerbation chronic airway disease infection life threatening latter context however rv induced common cold associated economic cost loss productivity due absence work school appropriate antiviral therapy available vaccine strategy failed large number viral serotypes lack crossserotype protection generated approach past present development vaccine widespread human pathogen highlighted,2014-10-01,"McLean, Gary R",J Vaccines Immun,,,,document_parses/pdf_json/2b36f467dee97f9675e187cabd4e4585e7ab17f2.json,document_parses/pmc_json/PMC4291752.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291752/,,3
2268,2268,2420,x11t9pbv,128fc4c67ef01890625e271452e1b9c7a4ac7984,PMC,Therapeutic vaccination and immunomodulation in the treatment of chronic hepatitis B: preclinical studies in the woodchuck,10.1007/s00430-014-0379-5,PMC4305085,25535101.0,no-cc,infection hepatitis b virus hbv may lead subclinical acute chronic hepatitis prevaccination era hbv infection endemic due frequent mother child transmission large region world however still estimated million chronic hbv carrier today ca patient die per year due hbvrelated liver disease recommended treatment chronic hepatitis b interferonα andor nucleostide analogue lead satisfactory result induction hbvspecific cell therapeutic vaccination immunomodulation may innovative strategy overcome virus persistence vaccination commercially available hbv vaccine patient without therapeutic reduction viral load result effective immune control hbv infection suggesting combination antiviral treatment new formulation therapeutic vaccine needed woodchuck marmota monax hbvlike woodchuck hepatitis virus useful preclinical animal model developing new therapeutic approach chronic hepadnaviral infection several innovative approach combining antiviral treatment using nucleostide analogue primeboost vaccination using dna vaccine new hepadnaviral antigen recombinant adenoviral vector tested woodchuck model review summarize encouraging result obtained therapeutic vaccine addition present potential innovation immunostimulatory strategy blocking interaction inhibitory programmed death receptor ligand animal model,2014-12-23,"Kosinska, Anna D.; Liu, Jia; Lu, Mengji; Roggendorf, Michael",Med Microbiol Immunol,,,,document_parses/pdf_json/128fc4c67ef01890625e271452e1b9c7a4ac7984.json,document_parses/pmc_json/PMC4305085.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4305085/,,3
2272,2272,2424,048eszf8,9d36c9a5c87380ec6bb1cee77ced91fd6265d343,PMC,Clinical vaccine development,10.7774/cevr.2015.4.1.46,PMC4313108,25648742.0,cc-by-nc,vaccination regarded one biggest triumph history medicine living successful period vaccine development accumulation multidisciplinary knowledge investment massive funding enabled development vaccine many infectious disease well disease including malignant tumor paradigm clinical vaccine evaluation licensure also modernized based scientific improvement historical experience however remain number hurdle overcome continuous effort focused increasing efficacy reducing risk related vaccine use cuttingedge knowledge immunology microbiology rapidly translated vaccine development thus physician others involved clinical development vaccine sufficient understanding recent developmental trend vaccination disease interest,2015-01-30,"Han, Seunghoon",Clin Exp Vaccine Res,,,,document_parses/pdf_json/9d36c9a5c87380ec6bb1cee77ced91fd6265d343.json,document_parses/pmc_json/PMC4313108.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4313108/,,3
2322,2322,2480,sctfgzdo,592c1efd20dcb1ff5644f5d20e76f2c28a2b8da0,PMC,Vaccination with Human Papillomavirus Pseudovirus-Encapsidated Plasmids Targeted to Skin Using Microneedles,10.1371/journal.pone.0120797,PMC4364728,25785935.0,cc0,human papilloma viruslike particle hpv vlp serve basis current licensed vaccine hpv previously shown encapsidation dna expressing model antigen mm respiratory syncytial virus rsv hpv pseudovirions psv immunogenic delivered intravaginally hpv capsid confer tropism basal epithelium represent attractive carrier vaccination targeted skin using microneedles study asked whether hpv vlp administered microneedles could induce protective immune response hpv whether hpv psvencapsidated plasmid delivered microneedles could elicit immune response hpv antigen delivered transgene mouse immunized hpv vlp coated microneedles generated robust neutralizing antibody response protected hpv challenge microneedle array coated hpvmm hpvf protein gene rsv tested dosedependent hpv fspecific antibody response detected postimmunization mmspecific tcell response detected post rsv challenge respectively hpv psvf immunized mouse fully protected challenge hpv psv reduced rsv viral load lung nose upon intranasal rsv challenge summary hpv psvencapsidated dna delivered microneedles induced neutralizing antibody response hpv primed antibody tcell response rsv antigen encoded encapsidated plasmid although immunogenicity dna component dose response threshold hpvspecific immunity robust taken together data suggest microneedle delivery lyophilized hpv psv could provide practical thermostable combined vaccine approach could developed clinical evaluation,2015-03-18,"Kines, Rhonda C.; Zarnitsyn, Vladimir; Johnson, Teresa R.; Pang, Yuk-Ying S.; Corbett, Kizzmekia S.; Nicewonger, John D.; Gangopadhyay, Anu; Chen, Man; Liu, Jie; Prausnitz, Mark R.; Schiller, John T.; Graham, Barney S.",PLoS One,,,,document_parses/pdf_json/592c1efd20dcb1ff5644f5d20e76f2c28a2b8da0.json,document_parses/pmc_json/PMC4364728.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364728/,,3
2352,2352,2511,3wt8z1gk,3521d912c060861a0bdeeb1607d2e262d62707fa,PMC,Establishment of MDCK Stable Cell Lines Expressing TMPRSS2 and MSPL and Their Applications in Propagating Influenza Vaccine Viruses in Absence of Exogenous Trypsin,10.1155/2015/402628,PMC4396729,25918647.0,cc-by,established two madindarby canine kidney mdck cell line stably expressing human airway transmembrane protease transmembrane protease serine tmprss mosaic serine protease large form mspl support multicycle growth two h highly pathogenic avian influenza virus hpaiv recombinant vaccine h avian influenza virus aiv recombinant vaccine absence trypsin data showed cell line stably expressed tmprss mspl serial passage mdcktmprss mdckmspl could proteolytically cleave ha supported hightiter growth vaccine without exogenous trypsin efficiently infected replicated within mdcktmprss mdckmspl cell viral titer comparable virus grown mdck cell tpcktrypsin thus result indicate potential application cell line cellbased influenza vaccine production may serve useful tool ha proteolytic cleavagerelated study,2015-03-30,"Wen, Zhiyuan; Wu, Chao; Chen, Weiye; Zeng, Xianying; Shi, Jianzhong; Ge, Jinying; Chen, Hualan; Bu, Zhigao",Biotechnol Res Int,,,,document_parses/pdf_json/3521d912c060861a0bdeeb1607d2e262d62707fa.json,document_parses/pmc_json/PMC4396729.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4396729/,,3
2355,2355,2514,irw9kyfn,27ada359a2b9536a180bd93585f47a13d5b82517; 95ab4b0ddc015a430ed865c9cdd105f1e50faf31,PMC,Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults,10.1371/journal.pone.0123969,PMC4401709,25884189.0,cc0,background novel swineorigin influenza hn virus detected worldwide april world health organization declared global pandemic june dna vaccine priming improves response inactivated influenza vaccine describe rapid production clinical evaluation dna vaccine encoding hemagglutinin protein pandemic acaliforniahn influenza virus accomplished nearly two month faster production acaliforniahn licensed monovalent inactivated vaccine miv method subject received three h dna vaccination mg intramuscularly biojector week interval eighteen subject received optional boost licensed hn miv became available interval third h dna injection miv boost – week vaccine safety assessed clinical observation laboratory parameter day solicited reactogenicity antibody response assessed elisa hai neutralization assay cell response elispot flow cytometry result vaccination safe welltolerated evaluated hai developed positive response week third dna injection week miv boost similar result detected neutralization assay cell response detected dna miv antibody response significantly amplified miv boost however boost increased cell response induced dna vaccine conclusion h dna vaccine produced quickly welltolerated modest immunogenicity single agent ha dna primemiv boost regimen utilizing one dna prime vaccination longer boost interval shown significant immunogenicity rapid largescale production ha dna vaccine potential contribute efficient response future influenza pandemic trial registration clinicaltrialsgov nct,2015-04-17,"Crank, Michelle C.; Gordon, Ingelise J.; Yamshchikov, Galina V.; Sitar, Sandra; Hu, Zonghui; Enama, Mary E.; Holman, LaSonji A.; Bailer, Robert T.; Pearce, Melissa B.; Koup, Richard A.; Mascola, John R.; Nabel, Gary J.; Tumpey, Terrence M.; Schwartz, Richard M.; Graham, Barney S.; Ledgerwood, Julie E.",PLoS One,,,,document_parses/pdf_json/27ada359a2b9536a180bd93585f47a13d5b82517.json; document_parses/pdf_json/95ab4b0ddc015a430ed865c9cdd105f1e50faf31.json,document_parses/pmc_json/PMC4401709.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401709/,,3
2362,2362,2524,zdb0xjic,79ffac5ab7acd3c43a3e0866ed150fea9a0ec1c8,PMC,"BAP31, a promising target for the immunotherapy of malignant melanomas",10.1186/s13046-015-0153-6,PMC4405826,25903101.0,cc-by,purpose malignant melanoma ’ mm incidence rising faster cancer u overall survival year le b cell associated protein bap overexpressed mm might promising target immunotherapy disease experimental design firstly investigated expression profile human bap hbap mouse bap mbap human mouse normal tissue respectively expression level hbap human mm mbap b melanoma cell also analyzed constructed novel mbap dna vaccine tested ability stimulate mbapspecific immune response antitumor immunity b melanomabearing mouse result first time found protein expression hbap dramatically upregulated human mm compared human normal tissue predominant protein expression mbap found mouse b melanoma cell mouse important organ mouse immunized mbap dna vaccine strong cellular response mbap observed vaccinated mouse ctls isolated immunized mouse could effectively kill mbappositive target mouse b melanoma tumor cell vitro vaccination mbap dna vaccine potent antitumor activity therapeutic model using b melanoma cell conclusion first data supporting vaccine targeting bap capable inducing effective immunity bapexpressing mm applicable human mm hbap dna vaccine warrant investigation human clinical trial electronic supplementary material online version article doi contains supplementary material available authorized user,2015-04-18,"Yu, Shaojuan; Wang, Fuli; Fan, Li; Wei, Yuying; Li, Haitao; Sun, Yuanjie; Yang, Angang; Jin, Boquan; Song, Chaojun; Yang, Kun",J Exp Clin Cancer Res,,,,document_parses/pdf_json/79ffac5ab7acd3c43a3e0866ed150fea9a0ec1c8.json,document_parses/pmc_json/PMC4405826.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405826/,,3
2394,2394,2557,navjkevd,a3a2b5d607691f30dd1b1baeca0e41817e2fde86,PMC,Designation of a Novel DKK1 Multiepitope DNA Vaccine and Inhibition of Bone Loss in Collagen-Induced Arthritic Mice,10.1155/2015/765490,PMC4436448,26075259.0,cc-by,dickkopf dkk secretory inhibitor canonical wnt signaling play critical role certain bone loss disease study shown serum level dkk significantly higher rheumatoid arthritis ra patient correlated severity disease indicates possibility bone erosion ra may inhibited neutralizing biological activity dkk study selected panel twelve peptide using software dnastar screened high affinity immunogenicity epitope vitro vivo assay furthermore optimized four b cell epitope design novel dkk multiepitope dna vaccine evaluated bone protective effect collageninduced arthritis cia mouse model ra high level expression designed vaccine measured supernatant co cell addition intramuscular immunization balbc mouse vaccine also highly expressed sufficient induce production longterm igg neutralized natural dkk vivo importantly vaccine significantly attenuated bone erosion cia mouse compared positive control mouse result provide evidence development dna vaccine targeted dkk attenuate bone erosion,2015-05-05,"Zhang, Xiaoqing; Liu, Sibo; Li, Shentao; Du, Yuxuan; Dou, Yunpeng; Li, Zhanguo; Yuan, Huihui; Zhao, Wenming",Biomed Res Int,,,,document_parses/pdf_json/a3a2b5d607691f30dd1b1baeca0e41817e2fde86.json,document_parses/pmc_json/PMC4436448.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4436448/,,3
2416,2416,2581,p6ikd8ns,30f5bfe5ca79c2e25e5dca95d8dfe473b780a51a,PMC,Exploration of New Sites in Adenovirus Hexon for Foreign Peptides Insertion,10.2174/1874357901509010001,PMC4460227,26069516.0,cc-by-nc,adenoviral vector explored vaccine carrier prevent infectious disease human animal two strategy aimed expression vaccine antigen adenoviral vector first includes insertion foreign gene expression cassette e region second strategy antigen incorporation viral capsid protein extend methodology searched new site human adenovirus serotype major capsid protein hexon vaccine antigen insertion end utilized site hexon hypervariable region hvr display mer peptide containing main neutralizing epitope porcine reproductive respiratory syndrome virus however could rescue virus insertion peptide hvr consistent virus unable tolerate insertion site contrast virus insertion peptide hvr viable growing well cell culture inserted peptide exposed virion surface,2015-05-29,"Hansra, Satyender; Pujhari, Sujit; Zakhartchouk, Alexander N",Open Virol J,,,,document_parses/pdf_json/30f5bfe5ca79c2e25e5dca95d8dfe473b780a51a.json,document_parses/pmc_json/PMC4460227.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460227/,,3
2472,2472,2638,4eyn7pjq,3cb43b6223f2860048cc7bce8cb0ed0e490ddbda,PMC,Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine,10.1038/gt.2015.35,PMC4530203,25871827.0,cc-by-nc-nd,leishmania complex vectorborne disease caused protozoan parasite genus leishmania leishdnavax multiantigen tcell epitopeenriched dna vaccine candidate human leishmaniasis vaccine candidate proven immunogenic showed prophylactic efficacy preclinical study describe safety testing leishdnavax naive mouse rat complemented demonstration tolerability leishmaniainfected mouse biodistribution persistence examined following single repeated intradermal id administration rat dna vector distributed systemically accumulate upon repeated injection although vector dna cleared tissue within day last injection persisted skin site injection draining lymph node evaluation singledose repeateddose toxicity vaccine candidate id administration naive noninfected mouse reveal safety concern leishdnavax also well tolerated leishmaniainfected mouse taken together result substantiate favorable safety profile leishdnavax naive infected animal thus support initiation clinical trial preventive therapeutic application vaccine,2015-04-30,"Riede, O; Seifert, K; Oswald, D; Endmann, A; Hock, C; Winkler, A; Salguero, F J; Schroff, M; Croft, S L; Juhls, C",Gene Ther,,,,document_parses/pdf_json/3cb43b6223f2860048cc7bce8cb0ed0e490ddbda.json,document_parses/pmc_json/PMC4530203.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4530203/,,3
2493,2493,2659,z1tt014r,8147b5b09a09887d1b4c4871d9d49746d8c4d418,PMC,A Multiple Antigenic Peptide Mimicking Peptidoglycan Induced T Cell Responses to Protect Mice from Systemic Infection with Staphylococcus aureus,10.1371/journal.pone.0136888,PMC4552945,26317210.0,cc-by,due enormous capacity staphylococcus aureus acquire antibiotic resistance becomes imperative develop vaccine decreasing risk lifethreatening infection peptidoglycan pgn conserved major component aureus cell wall however used vaccine candidate since thymusindependent antigen study synthesized multiple antigenic peptide named map comprised four copy peptide mimic epitope pgn immunization map five time boosting heatinactivated bacterium one time antimap serum bound directly aureus pgn immunization map decreased bacterial burden organ balbc mouse significantly prolonged survival time aureus lethalchallenge percentage ifnγcd cell ilcd cell spleen well level ifnγ ilaf ccl spleen lung significantly increased mapimmunized mouse infection moreover vitro incubation heatinactivated aureus splenocytes isolated mapimmunized mouse stimulated production ifnγ ilaf finding demonstrated map thymusdependent antigen efficient eliciting cellmediated response protect mouse aureus infection study shed light possible strategy design vaccine aureus,2015-08-28,"Wang, Xiang-Yu; Huang, Zhao-Xia; Chen, Yi-Guo; Lu, Xiao; Zhu, Ping; Wen, Kun; Fu, Ning; Liu, Bei-Yi",PLoS One,,,,document_parses/pdf_json/8147b5b09a09887d1b4c4871d9d49746d8c4d418.json,document_parses/pmc_json/PMC4552945.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4552945/,,3
2505,2505,2671,7wv4cb37,faf97643a11aab59f114bd0032ed61a2c11808a0,PMC,Vaccination With a Highly Attenuated Recombinant Vesicular Stomatitis Virus Vector Protects Against Challenge With a Lethal Dose of Ebola Virus,10.1093/infdis/jiv316,PMC4564554,26109675.0,green-oa,previously recombinant vesicular stomatitis virus rvsv pseudotypes expressing ebolavirus glycoprotein gps place vsv g protein demonstrated protection nonhuman primate lethal homologous ebolavirus challenge pseudotype vector contained additional attenuating mutation rvsv genome describe rvsv vector containing full complement vsv gene expressing ebola virus ebov gp additional transcription unit rvsv vector contain combination attenuating mutation used previously clinical development pathway rvsvhuman immunodeficiency virus type vaccine one rvsv vector nctebovgp express membraneanchored ebov gp first position genome gp elicited balanced cellular humoral gpspecific immune response mouse guinea pig immunized single dose vector protected sign disease following lethal ebov challenge control animal died – day subsequently nctebovgp demonstrated complete singledose protection macaque following lethal ebov challenge single shamvaccinated macaque died disease due ebov infection result demonstrate highly attenuated rvsv vector expressing ebov gp may provide safer alternative current ebov vaccine,2015-06-24,"Matassov, Demetrius; Marzi, Andrea; Latham, Terri; Xu, Rong; Ota-Setlik, Ayuko; Feldmann, Friederike; Geisbert, Joan B.; Mire, Chad E.; Hamm, Stefan; Nowak, Becky; Egan, Michael A.; Geisbert, Thomas W.; Eldridge, John H.; Feldmann, Heinz; Clarke, David K.",Journal of Infectious Diseases,,,,document_parses/pdf_json/faf97643a11aab59f114bd0032ed61a2c11808a0.json,document_parses/pmc_json/PMC4564554.xml.json,http://europepmc.org/articles/pmc4564554?pdf=render,,3
2507,2507,2674,8vljd5cv,dab074e75c2dae02b60e8094aa5a06e553122831,PMC,Protection conferred by live infectious bronchitis vaccine viruses against variant Middle East IS/885/00-like and IS/1494/06-like isolates in commercial broiler chicks,10.1136/vetreco-2014-000111,PMC4567785,26392909.0,cc-by-nc,ability infectious bronchitis h massachusetts strain cr b strain live attenuated vaccine virus protect two middle east infectious bronchitis virus isolates islike islike broiler chick investigated dayold chick separated three group vaccinated h dayold followed cr daysold ii vaccinated h cr simultaneously dayold cr daysold iii control unvaccinated daysold group challenged virulent protection evaluated based clinical sign tracheal kidney gross lesion tracheal ciliostasis result showed administering combined live h cr vaccine simultaneously dayold followed cr vaccine daysold gave per cent tracheal ciliary protection middle east isolates addition programme conferred per cent protection clinical sign tracheal kidney lesion vaccination programme h dayold followed cr daysold tracheal ciliary protection conferred per cent per cent islike islike respectively,2015-09-09,"Awad, Faez; Forrester, Anne; Baylis, Matthew; Lemiere, Stephane; Ganapathy, Kannan",Vet Rec Open,,,,document_parses/pdf_json/dab074e75c2dae02b60e8094aa5a06e553122831.json,document_parses/pmc_json/PMC4567785.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567785/,,3
2550,2550,2719,ov1qssnu,8b33d1cedd5e6f39a2609b233d7070e3ddf52831,PMC,Formalin Inactivation of Japanese Encephalitis Virus Vaccine Alters the Antigenicity and Immunogenicity of a Neutralization Epitope in Envelope Protein Domain III,10.1371/journal.pntd.0004167,PMC4619746,26495991.0,cc0,formalininactivated japanese encephalitis virus jev vaccine widely available effect formalin inactivation antigenic structure jev profile antibody elicited vaccination well understood used panel monoclonal antibody mabs map antigenic structure live jev virus untreated control virus ucv formalininactivated commercial vaccine ficv formalininactivated virus fiv binding activity mab nakayamaderived ficv several strain fiv significantly lower compared live virus ucv mab weakly neutralizing jev serocomplex antibody found inhibit jev infection postattachment step epitope mapped amino acid within domain iii ediii envelope e glycoprotein explored effect formalin inactivation immunogenicity jev found nakayamaderived ficv fiv ucv exhibited similar immunogenicity mouse model inducing antijev antiedii epitopespecific antibody however ediii epitopespecific igg antibody neutralizing antibody titer significantly lower ficvimmunized fivimmunized mouse serum ucvimmunized formalin inactivation seems alter antigenic structure e protein may reduce potency commercially available jev vaccine virus inactivation ho uv shortduration higher temperature formalin treatment able maintain antigenic structure jev e protein thus alternative inactivation method ho able maintain integrity e protein may essential improving potency inactivated jev vaccine,2015-10-23,"Fan, Yi-Chin; Chiu, Hsien-Chung; Chen, Li-Kuang; Chang, Gwong-Jen J.; Chiou, Shyan-Song",PLoS Negl Trop Dis,,,,document_parses/pdf_json/8b33d1cedd5e6f39a2609b233d7070e3ddf52831.json,document_parses/pmc_json/PMC4619746.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619746/,,3
2556,2556,2725,jrnm113q,a65b8907068dde79fb7cc6e885a745607ed1f371,PMC,Vaccination Method Affects Immune Response and Bacterial Growth but Not Protection in the Salmonella Typhimurium Animal Model of Typhoid,10.1371/journal.pone.0141356,PMC4625024,26509599.0,cc-by,understanding immune response elicited vaccine together immune response required protection fundamental designing effective vaccine immunisation program study examines effect route administration live attenuated vaccine interaction stimulation murine immune system well ability increase survival provide protection colonisation virulent challenge strain ass effect administration method using murine model typhoid animal infected typhimurium mouse vaccinated either intravenously orally live attenuated typhimurium strain data collected vaccine strain growth shedding stimulation antibody cytokine following vaccination mouse challenged virulent strain typhimurium protection conferred different vaccination route measured term challenge suppression animal survival main difference immune stimulation found study development secretory iga response orallyvaccinated mouse absent iv vaccinated mouse strain showed similar protection term challenge suppression systemic organ spleen liver well survival differed term challenge suppression virulent pathogen gutassociated organ difference gut colonisation present important question around ability vaccine prevent shedding transmission finding demonstrate protection conferred two vaccine appear mechanism controlling protection differ important implication infection dynamic within population,2015-10-28,"Kinnear, Clare L.; Strugnell, Richard A.",PLoS One,,,,document_parses/pdf_json/a65b8907068dde79fb7cc6e885a745607ed1f371.json,document_parses/pmc_json/PMC4625024.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4625024/,,3
2632,2632,2804,4hygz05o,277e85da79677586ae01bb02ea6e410ebc97fd29,PMC,Recent Progress towards Novel EV71 Anti-Therapeutics and Vaccines,10.3390/v7122949,PMC4690872,26670245.0,cc-by,enterovirus ev group virus belongs picornaviridae family also includes virus poliovirus ev together coxsackievirus widely known association hand foot mouth disease hfmd generally affect child age five besides hfmd ev also trigger severe lifethreatening neurological condition encephalitis considering lack vaccine antiviral drug ev together increasing spread virus development drug vaccine becomes top priority protecting younger generation article hence review recent progress formulation antitherapeutics vaccine generation ev covering inactivated vaccine ii baculovirusexpressed vaccine ev iii human intravenous immunoglobulin ivig treatment iv use monoclonal antibody therapy prevention treatment ev infection,2015-12-08,"Ng, Qingyong; He, Fang; Kwang, Jimmy",Viruses,,,,document_parses/pdf_json/277e85da79677586ae01bb02ea6e410ebc97fd29.json,document_parses/pmc_json/PMC4690872.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4690872/,,3
2650,2650,2822,hrfbygub,58a0105289bbee3214a3fe6494ba86fce867df3a,PMC,Heterologous Immunity between Adenoviruses and Hepatitis C Virus: A New Paradigm in HCV Immunity and Vaccines,10.1371/journal.pone.0146404,PMC4709057,26751211.0,cc-by,adenovirus ad commonly used vector gene therapy andor vaccine delivery recombinant ad vector tested vaccine many pathogen made surprising observation peptide derived various hepatitis c virus hcv antigen contain extensive region homology multiple adenovirus protein conclusively demonstrate adenovirus vector induce robust heterologous cellular humoral immune response multiple hcv antigen intriguingly induction crossreactive immunity lead significant reduction viral load recombinant vacciniahcv virus infected mouse model supporting role antiviral immunity hcv healthy human subject adspecific preexisting immunity demonstrated crossreactive cellular humoral immune response multiple hcv antigen finding reveal potential previously uncharacterized property natural human adenovirus infection dictate modulate andor alter course hcv infection upon exposure intrinsic property adenovirus vector crossprime hcv immunity also exploited develop prophylactic andor therapeutic vaccine hcv,2016-01-11,"Singh, Shakti; Vedi, Satish; Samrat, Subodh Kumar; Li, Wen; Kumar, Rakesh; Agrawal, Babita",PLoS One,,,,document_parses/pdf_json/58a0105289bbee3214a3fe6494ba86fce867df3a.json,document_parses/pmc_json/PMC4709057.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4709057/,,3
2658,2658,2830,b9dk07tk,abb5a68caf42d65dcb946056258028cccf87cd4a,PMC,A CRISPR/Cas9 and Cre/Lox system-based express vaccine development strategy against re-emerging Pseudorabies virus,10.1038/srep19176,PMC4726036,26777545.0,cc-by,virus evolves rapidly escape vaccineinduced immunity posing desperate demand efficient vaccine development biotechnology present express vaccine development strategy based crisprcas crelox system reemerging pseudorabies virus caused recent devastating swine pseudorabies outbreak china crisprcas system virulent gene newly isolated strain simultaneously substituted marker gene subsequently excised using crelox system vaccine safety concern notably single cell facs technology applied promote virus purification efficiency combination stateofart technology greatly accelerated vaccine development finally vaccination challenge experiment proved vaccine candidate ’ protective efficacy pig promise control current pseudorabies outbreak knowledge first successful vaccine development based gene edit technology demonstrating technology leap laboratory industry may pave way future express antiviral vaccine development,2016-01-18,"Liang, Xun; Sun, Leqiang; Yu, Teng; Pan, Yongfei; Wang, Dongdong; Hu, Xueying; Fu, Zhenfang; He, Qigai; Cao, Gang",Sci Rep,,,,document_parses/pdf_json/abb5a68caf42d65dcb946056258028cccf87cd4a.json,document_parses/pmc_json/PMC4726036.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4726036/,,3
2663,2663,2835,i99pgmd1,c23d0e5107a2764e299a147d41a8c76ce91c231d,PMC,Sequence-based approach for rapid identification of cross-clade CD8+ T-cell vaccine candidates from all high-risk HPV strains,10.1007/s13205-015-0352-z,PMC4729761,28330110.0,cc-by,human papilloma virus hpv primary etiological agent responsible cervical cancer woman although total highrisk hpv strain identified far currently available commercial vaccine designed targeting mainly hpv hpv viral strain common strain associated cervical cancer high level antigenic specificity hpv capsid antigen currently available vaccine suitable provide crossprotection highrisk hpv strain due increasing report cervical cancer case hpv highrisk strain hpv crucial design vaccine generate reasonable cd tcell response possibly highrisk strain aim developed computational workflow identify conserved crossclade cd tcell hpv vaccine candidate considering e e e e protein highrisk hpv strain identified set immunogenic conserved peptide fragment supposed provide protection infection highrisk hpv strain across globe electronic supplementary material online version article doisz contains supplementary material available authorized user,2016-01-27,"Singh, Krishna P.; Verma, Neeraj; Akhoon, Bashir A.; Bhatt, Vishal; Gupta, Shishir K.; Gupta, Shailendra K.; Smita, Suchi",3 Biotech,,,,document_parses/pdf_json/c23d0e5107a2764e299a147d41a8c76ce91c231d.json,document_parses/pmc_json/PMC4729761.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4729761/,,3
2700,2700,2873,2gt3fwpy,4a94f3fe57da5dad4c965d59faf0facc2039175a,PMC,Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines,10.1371/journal.pone.0149364,PMC4760941,26895072.0,cc0,robustness immune response antigen could dictated route vaccine inoculation traditional smallpox vaccine essentially vaccinia virus strain used eradication smallpox administered percutaneous inoculation skin scarification modified vaccinia virus ankara licensed smallpox vaccine europe canada currently undergoing clinical development united state mva also investigated vector delivery heterologous gene prophylactic therapeutic immunization since mva replicationdeficient mva mvavectored vaccine often inoculated intramuscular intradermal subcutaneous route vaccine inoculation via intramuscular intradermal subcutaneous route requires use injection needle estimated population united state needle phobia following observation laboratory replicationdeficient recombinant vaccinia virus derived new york city board health strain elicited protective immune response mouse model upon inoculation tail scarification investigated whether mva mva recombinant elicit protective response following percutaneous administration mouse model data suggest mva administered percutaneous inoculation elicited vacciniaspecific antibody response protected mouse lethal vaccinia virus challenge level comparable better subcutaneous intramuscular inoculation high titer specific neutralizing antibody elicited mouse inoculated recombinant mva expressing herpes simplex type glycoprotein scarification similarly recombinant mva expressing hemagglutinin attenuated influenza virus rgaviet nam hn elicited protective immune response administered low dos scarification taken together data suggest mva mvavectored vaccine inoculated scarification elicit protective immune response comparable subcutaneous vaccination may allow antigen sparing vaccine supply limited,2016-02-19,"Meseda, Clement A.; Atukorale, Vajini; Kuhn, Jordan; Schmeisser, Falko; Weir, Jerry P.",PLoS One,,,,document_parses/pdf_json/4a94f3fe57da5dad4c965d59faf0facc2039175a.json,document_parses/pmc_json/PMC4760941.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760941/,,3
2702,2702,2876,0ic7twhy,710127845c3bf0670bd685616f56b3d18e53ebce,PMC,Vaccination against type 1 angiotensin receptor prevents streptozotocin-induced diabetic nephropathy,10.1007/s00109-015-1343-6,PMC4762923,26407577.0,cc-by,recently group developed therapeutic hypertensive vaccine angiotensin ang ii type receptor atr named atrqβ explore potential effectiveness streptozotocininduced diabetic nephropathy male sprague dawley rat randomly divided two group control diabetic model week diabetic rat divided four subgroup rat week treatment saline olmesartan atrqβ qβ viruslike particle vlp respectively addition lower blood pressure atrqβ vaccination ameliorated biochemical parameter change renal dysfunction mesangial expansion fibrosis inhibiting oxidative stress macrophage infiltration proinflammatory factor expression furthermore atrqβ vaccination suppressed renal ang iiatr activation abrogated downregulation angiotensinconverting enzyme ang – similar olmesartan treatment obvious feedback activation circulating local reninangiotensin system ra observed vaccine group rat mesangial cell antiatr antibody inhibited high glucoseinduced transforming growth factorβ tgfβsmad signal pathway additionally significant immunemediated damage detected vaccinated animal conclusion atrqβ vaccine ameliorated streptozotocininduced diabetic renal injury via modulating two ra ax inhibiting tgfβsmad signal pathway providing novel safe promising method treat diabetic nephropathy key message overactivation ra play crucial role development dn aim verify effectiveness atrqβ vaccine stzinduced dn atrqβ modulated two ra ax inhibited tgfβsmad signal pathway vaccine therapy may provide novel safe promising method treat dn electronic supplementary material online version article doi contains supplementary material available authorized user,2015-09-26,"Ding, Dan; Du, Yimei; Qiu, Zhihua; Yan, Sen; Chen, Fen; Wang, Min; Yang, Shijun; Zhou, Yanzhao; Hu, Xiajun; Deng, Yihuan; Wang, Shijia; Wang, Liangping; Zhang, Hongrong; Wu, Hailang; Yu, Xian; Zhou, Zihua; Liao, Yuhua; Chen, Xiao",J Mol Med (Berl),,,,document_parses/pdf_json/710127845c3bf0670bd685616f56b3d18e53ebce.json,document_parses/pmc_json/PMC4762923.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4762923/,,3
2707,2707,2881,qe5lg8jn,7bbed13119c94625bd7b7b92a945ca65dc20afc7,PMC,Polymerase Mechanism-Based Method of Viral Attenuation,10.1007/978-1-4939-3008-1_6,PMC4772695,26458831.0,no-cc,vaccine remain effective way preventing infection spread infectious disease prophylactic used century still day three main design strategy exist live attenuated virus lav vaccine killed inactivated virus vaccine subunit vaccine three efficacious vaccine remain lav lav replicate relevant tissue elicit strong cellular humoral response often confer lifelong immunity vaccine strategy produced majority successful vaccine use today also important safety concern consider approach past development lav empirical blind passage virus various cell type result accumulation multiple attenuating mutation leaving molecular mechanism attenuation unknown also due high error rate rna virus selective pressure host environment lav derived virus potentially revert back wildtype virulence put vaccinee risk shed put unvaccinated risk well vaccine successful still remains need rational design strategy create additional lav one approach rational vaccine design involves increasing fidelity viral rdrp increased fidelity decrease viral mutational frequency thereby reducing genetic variation virus need order evade host imposed bottleneck infection polymerase mutant exist decrease viral mutation frequency mutation conserved region polymerase ’ lend toward using common mutant approach toward developing universal vaccine strategy rna virus identified conserved lysine residue active site pv rdrp act general acid nucleotide incorporation mutation lysine arginine result high fidelity polymerase replicates slowly thus creating attenuated virus genetically stable le likely revert wildtype phenotype chapter provides detailed method identify conserved lysine residue evaluating fidelity attenuation cell culture vitro pv transgenic murine model vivo,2015-06-01,"Lee, Cheri A.; August, Avery; Arnold, Jamie J.; Cameron, Craig E.",Vaccine Technologies for Veterinary Viral Diseases,,,,document_parses/pdf_json/7bbed13119c94625bd7b7b92a945ca65dc20afc7.json,document_parses/pmc_json/PMC4772695.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4772695/,,3
2711,2711,2885,xvjd0g60,d21eaa427bea34a60db8a4fec53ee3a5021a1eba,PMC,CpG Improves Influenza Vaccine Efficacy in Young Adult but Not Aged Mice,10.1371/journal.pone.0150425,PMC4774967,26934728.0,cc-by,several study shown reduced efficacy influenza vaccine elderly compared young adult study evaluated immunogenicity protective efficacy commercially available inactivated influenza vaccine fluzone® young adult aged mouse cbl mouse administered single double immunization fluzone® without cpg challenged intranasally hn acalifornia virus double immunization fluzone® adjuvanted cpg elicited highest level protection young adult mouse associated increase influenza specific igg elevated hai titre reduced viral titre lung inflammation contrast vaccine schedule provided fully protective immunity young adult mouse conferred limited protection aged mouse antigen presenting cell aged mouse found le responsive vitro stimulation fluzone cpg may partially explain result data supportive study shown limited effectiveness influenza vaccine elderly provide important information relevant design immunogenic vaccine age group,2016-03-02,"Ramirez, Alejandro; Co, Mary; Mathew, Anuja",PLoS One,,,,document_parses/pdf_json/d21eaa427bea34a60db8a4fec53ee3a5021a1eba.json,document_parses/pmc_json/PMC4774967.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4774967/,,3
2742,2742,2918,3xb3ibsq,398cbb196acb9f8ee91a22edcca3b32c044878b8,PMC,Evolutionary reversion of live viral vaccines: Can genetic engineering subdue it?,10.1093/ve/vev005,PMC4811365,27034780.0,cc-by,attenuated live viral vaccine extraordinarily successful protecting many disease main drawback development use reliance unpredictable method attenuation potential evolutionary reversion high virulence method genetic engineering provide many safer alternative live vaccine live vaccine compete alternative future must either superior immunogenicity must able overcome former disadvantage several live vaccine design historically inaccessible feasible advance genome synthesis method addressed emphasis whether enable predictable level attenuation whether stable evolutionary reversion new design overcome many former drawback position live vaccine competitive alternative new method appear retard evolutionary reversion enough prevent vaccinederived epidemic may even possible permanently attenuate live vaccine transmissible evolve higher virulence prolonged adaptation,2015-07-31,"Bull, J. J.",Virus Evol,,,,document_parses/pdf_json/398cbb196acb9f8ee91a22edcca3b32c044878b8.json,document_parses/pmc_json/PMC4811365.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4811365/,,3
2749,2749,2926,uyoerxvu,fbcdafa6bac2c69c1f5afafc5338f777f234d592,PMC,Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design,10.1084/jem.20151960,PMC4821650,27022144.0,cc-by-nc-sa,traditionally vaccine developed cultivating infectious agent isolating inactivated whole pathogen purified component year ago reverse vaccinology enabled vaccine discovery design based information deriving sequence microbial genome rather via growth pathogen today high throughput discovery protective human antibody sequencing b cell repertoire increasing structural characterization protective antigen epitope provide molecular mechanistic understanding drive discovery novel vaccine previously impossible entering “ reverse vaccinology ” era,2016-04-04,"Rappuoli, Rino; Bottomley, Matthew J.; D’Oro, Ugo; Finco, Oretta; De Gregorio, Ennio",J Exp Med,,,,document_parses/pdf_json/fbcdafa6bac2c69c1f5afafc5338f777f234d592.json,document_parses/pmc_json/PMC4821650.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4821650/,,3
2766,2766,2945,zy2yc8gs,0257e6797e12beb91a4a4fcd7130f90d84260718,PMC,Integrated sequence and immunology filovirus database at Los Alamos,10.1093/database/baw047,PMC4839628,27103629.0,cc-by,ebola outbreak – infected people claimed life previous filovirus outbreak combined governmental agency clinical team world scientific community pulled together multifaceted response ranging prevention disease control evaluating vaccine therapeutic human trial epidemic finally coming close refocusing longterm prevention strategy becomes paramount given real threat future filovirus outbreak inherent uncertainty next outbreak virus geographic location prudent consider extent implication known natural diversity advancing vaccine therapeutic approach facilitate consideration updated enhanced content filovirus portion los alamo hemorrhagic fever virus database integrated performed baseline analysis family filoviridae sequence deposited genbank associated immune response data metadata added new computational tool webinterfaces assist user analysis describe main feature updated database ii provide integrated view basic analysis summarizing evolutionary pattern relate geotemporal data captured database iii highlight conserved region proteome may useful cell vaccine strategy database url wwwhfvlanlgov,2016-04-21,"Yusim, Karina; Yoon, Hyejin; Foley, Brian; Feng, Shihai; Macke, Jennifer; Dimitrijevic, Mira; Abfalterer, Werner; Szinger, James; Fischer, Will; Kuiken, Carla; Korber, Bette",Database (Oxford),,,,document_parses/pdf_json/0257e6797e12beb91a4a4fcd7130f90d84260718.json,document_parses/pmc_json/PMC4839628.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839628/,,3
2778,2778,2958,l951nirf,5edd56f96660760a5f8ae69efd7d9e976a00c4ee; 106b81593063e1df0817b8ca2e0a90823003201d,PMC,Immunogenicity of Virus Like Particle Forming Baculoviral DNA Vaccine against Pandemic Influenza H1N1,10.1371/journal.pone.0154824,PMC4858234,27149064.0,cc-by,outbreak influenza hn representing first influenza pandemic st century transmitted million individual claimed life current status many country prepare influenza vaccine using cellbased eggbased killed vaccine however traditional influenza vaccine platform several limitation overcome limitation many researcher tried various approach develop alternative production platform one alternative approach reported efficacy influenza ha vaccination using baculoviral dna vaccine achervha however immune response elicited achervha vaccine target ha antigen lower commercial killed vaccine overcome limitation previous vaccine constructed human endogenous retrovirus herv envelopecoated baculovirusbased viruslikeparticle vlp–forming dna vaccine termed achervvlp pandemic influenza acalifornia phn balbc mouse immunized achervvlp × ffu achervvlp im compared mouse immunized killed vaccine mouse immunized achervha result achervvlp immunization produced greater humoral immune response exhibited neutralizing activity intrasubgroup h strain pr elicited neutralizing antibody production high level interferonγ secretion splenocytes diminished virus shedding lung challenge lethal dose influenza virus conclusion vlpforming baculovirus dna vaccine could potential vaccine candidate capable efficiently delivering dna vaccinee vlp forming dna eliciting stronger immunogenicity eggbased killed vaccine,2016-05-05,"Gwon, Yong-Dae; Kim, Sehyun; Cho, Yeondong; Heo, Yoonki; Cho, Hansam; Park, Kihoon; Lee, Hee-Jung; Choi, Jiwon; Poo, Haryoung; Kim, Young Bong",PLoS One,,,,document_parses/pdf_json/5edd56f96660760a5f8ae69efd7d9e976a00c4ee.json; document_parses/pdf_json/106b81593063e1df0817b8ca2e0a90823003201d.json,document_parses/pmc_json/PMC4858234.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858234/,,3
2821,2821,3005,z9molxg9,d38a164a0b254a96195ad1715929340f82cc110e,PMC,Association between Interferon Response and Protective Efficacy of NS1-Truncated Mutants as Influenza Vaccine Candidates in Chickens,10.1371/journal.pone.0156603,PMC4892592,27257989.0,cc-by,influenza virus mutant encode cterminally truncated n protein nstruncated mutant attractive candidate avian live attenuated influenza vaccine laiv development attenuated immunogenic chicken previously showed high protective efficacy nstruncated laiv chicken corresponds induction high level type interferon ifn response chicken embryonic fibroblast cell study investigated relationship induction ifn ifnstimulated gene response vivo immunogenicity protective efficacy nstruncated laiv data demonstrates accelerated antibody induction protective efficacy nstruncated laiv correlate well upregulation ifnstimulated gene oral administration recombinant chicken ifn alpha drinking water provide direct evidence type ifn promote rapid induction adaptive immune response protective efficacy influenza vaccine chicken,2016-06-03,"Jang, Hyesun; Ngunjiri, John M.; Lee, Chang-Won",PLoS One,,,,document_parses/pdf_json/d38a164a0b254a96195ad1715929340f82cc110e.json,document_parses/pmc_json/PMC4892592.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4892592/,,3
2830,2830,3014,e6e6omxt,f9476a333c17961ff4cc34b45f4b2da5ed29457f,PMC,Ad Hoc Influenza Vaccination During Years of Significant Antigenic Drift in a Tropical City With 2 Seasonal Peaks: A Cross-Sectional Survey Among Health Care Practitioners,10.1097/md.0000000000003359,PMC4902475,27175633.0,cc-by-nd,evaluated acceptability additional ad hoc influenza vaccination among health care professional following season significant antigenic drift selfadministered anonymous survey performed hard copy questionnaire public hospital online platform available healthcare professional april st may st total healthcare professional completed questionnaire including doctor nurse allied health professional working public private system participating respondent expressed intention receive additional vaccine despite majority agreed strongly agreed would bring benefit community save life reduce medical expense satisfy public expectation increase awareness vaccination however significant proportion expressed concern vaccine could disturb normal immunization schedule felt uncertain next vaccination round perceived summer peak might occur believed summer peak might virus furthermore respondent expected additional vaccination could weaken efficacy previous vaccination concerned side effect estimated would low uptake rate supply vaccine limited higher priority group considered include elderly aged ≥ year chronic medical condition elderly living residential care home longstay resident institution disabled strongest factor associated accepting additional vaccine included immunization influenza vaccine past year higher perceived risk contracting influenza higher perceived severity disease impact acceptability additional ad hoc influenza vaccination low among healthcare professional could negative impact additional vaccination campaign since healthcare professional key driver vaccine acceptance discordance perceived risk acceptance vaccination regarding self versus public deserves evaluation,2016-05-13,"Wong, Martin C.S.; Nelson, E. Anthony S.; Leung, Czarina; Lee, Nelson; Chan, Martin C.W.; Choi, Kin Wing; Rainer, Timothy H.; Cheng, Frankie W.T.; Wong, Samuel Y.S.; Lai, Christopher K.C.; Lam, Bosco; Cheung, Tak Hong; Leung, Ting Fan; Chan, Paul K.S.",Medicine (Baltimore),,,,document_parses/pdf_json/f9476a333c17961ff4cc34b45f4b2da5ed29457f.json,document_parses/pmc_json/PMC4902475.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902475/,,3
2843,2843,3028,8dye7e9m,68868e82c4747b8f7a06816c14d495117c9ffb79,PMC,"The swine flu vaccine, public attitudes, and researcher interpretations: a systematic review of qualitative research",10.1186/s12913-016-1466-7,PMC4919843,27338141.0,cc-by,background pandemic health authority may uncertain spread severity disease effectiveness safety available intervention case swine flu hn pandemic – government forced make decision despite uncertainty many country chose implement wide scale vaccination programme accomplished vaccination goal many research study aiming explore barrier facilitator vaccine uptake conducted aftermath pandemic including several qualitative study aim explore public attitude swine flu vaccine different country review qualitative primary study describe discus implication drawn primary study author method systematic review qualitative research study using broadly comparative cross casestudy approach study quality appraised using adaptation critical appraisal skill programme casp quality assessment tool result review indicates public varying opinion disease risk prevalence concern vaccine safety primary study author concluded participant uninformed information disease vaccine would led increase vaccine uptake find conclusion problematic suggest instead people ’ question concern legitimate given uncertainty situation time fact authority necessary information convince public quality assessment included study point lack reflexivity lack information study context suggest study weakness tied primary study author ’ lack acknowledgement uncertainty surrounding disease vaccine conclusion primary study author suggest authority could increase vaccine uptake increased information suggest instead health authority transparent information decisionmaking process future pandemic situation electronic supplementary material online version article doi contains supplementary material available authorized user,2016-06-24,"Carlsen, Benedicte; Glenton, Claire",BMC Health Serv Res,,,,document_parses/pdf_json/68868e82c4747b8f7a06816c14d495117c9ffb79.json,document_parses/pmc_json/PMC4919843.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4919843/,,3
2851,2851,3036,r52nev7v,8ad6fe3d0031f1dffb84dec640ac0bb7c5ba84fb,PMC,Alzheimer’s disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules,10.1038/srep28912,PMC4929459,27363809.0,cc-by,although βamyloid aβ may primary driver alzheimer ’ disease ad pathology accumulation pathological tau correlate dementia ad patient thus preventioninhibition ad may require vaccine targeting aβ tau simultaneously sequentially since high antibody titer required ad vaccine efficacy decided generate vaccine targeting aβ avr tau avr aβtau avr b cell epitope based immunogenic multitep platform evaluate immunogenicity vaccine formulated advaxcpg delta inulin alhydrogel® montanideisa montanideisa mplasm pharmaceutical grade adjuvant formulation avr advaxcpg induced highest cellular humoral immune response mouse dualepitope vaccine avr combination avr avr vaccine formulated advaxcpg induced robust antibody response various form aβ tau pathological molecule antiaβ antibody titer avr immunization similar mouse vaccinated avr avravr combination antitau titer significantly lower avr injection compared avr avravr silico dmodeling provided insight difference immunogenicity vaccine construct sum avr avr formulated advaxcpg adjuvant identified promising immunogenic vaccine ongoing preclinical assessment future human clinical trial,2016-07-01,"Davtyan, Hayk; Zagorski, Karen; Rajapaksha, Harinda; Hovakimyan, Armine; Davtyan, Arpine; Petrushina, Irina; Kazarian, Konstantin; Cribbs, David H.; Petrovsky, Nikolai; Agadjanyan, Michael G.; Ghochikyan, Anahit",Sci Rep,,,,document_parses/pdf_json/8ad6fe3d0031f1dffb84dec640ac0bb7c5ba84fb.json,document_parses/pmc_json/PMC4929459.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4929459/,,3
2869,2869,3054,b02owiak,31c0ee2b6dff1699d251316667c0b56c7b8f09a3,PMC,Host protective ASP-based vaccine against the parasitic nematode Ostertagia ostertagi triggers NK cell activation and mixed IgG1-IgG2 response,10.1038/srep29496,PMC4941725,27403891.0,cc-by,mucusdwelling parasite ostertagia ostertagi one important gastrointestinal nematode cattle group previously demonstrated protective capacity vaccine parasite based native activationassociated secreted protein asp nasp combination saponin adjuvant quila aim current study analyse effect antigen adjuvant cellular humoral vaccineinduced immune response comparing native asp recombinant version expressed pichia pastoris pasp replacing quila aloh immunization cattle protective naspquila vaccine associated antigeninduced proliferation natural killer nk cell combined ifnγ secretion induction mixed iggigg antibody response aspspecific activation proliferation nk cell also observed mouse following vaccination regime replacing quila aloh nasp pasp significantly decreased capacity vaccine trigger nk cell activation antibody response failed induce protection challenge infection reduction structurally anchoring disulphide bond nasp completely abolished ability induce nk cell activation antibody response highlighting importance protein conformation immunostimulatory activity,2016-07-11,"González-Hernández, Ana; Van Coppernolle, Stefanie; Borloo, Jimmy; Van Meulder, Frederik; Paerewijck, Oonagh; Peelaers, Iris; Leclercq, Georges; Claerebout, Edwin; Geldhof, Peter",Sci Rep,,,,document_parses/pdf_json/31c0ee2b6dff1699d251316667c0b56c7b8f09a3.json,document_parses/pmc_json/PMC4941725.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4941725/,,3
2891,2891,3076,e0zhq18g,c1cd72dfc8c71714d7751a0b9820f8f8e0ee3756,PMC,Efficient Qualitative and Quantitative Determination of Antigen-induced Immune Responses,10.1074/jbc.m116.736660,PMC4965583,27288409.0,cc-by,determine effectiveness immunization strategy used therapeutic antibody vaccine development critical ass quality immunizationinduced polyclonal antibody response developed workflow us sensitive method quantitatively qualitatively ass immune response foreign antigen regard antibody binding affinity epitope diversity application detailed assessment throughout immunization campaign significantly reduce resource required generate highly specific antibody workflow consists following two step use surface plasmon resonance quantify antigenspecific antibody evaluate apparent binding affinity recovery serum igg using automated small scale purification system followed determination epitope diversity using hydrogen deuterium exchange coupled mass spectrometry showed method sensitive enough detect antigenspecific igg nanogramμl range provided information differentiating antibody response various immunized animal could obtained conventional method also showed workflow guide selection animal produce high affinity antibody desired epitope coverage profile resulting generation potential therapeutic monoclonal antibody clone desirable functional profile postulate workflow important tool development effective vaccine combat highly sophisticated evasion mechanism pathogen,2016-07-29,"Yang, Danlin; Frego, Lee; Lasaro, Marcio; Truncali, Kristopher; Kroe-Barrett, Rachel; Singh, Sanjaya",J Biol Chem,,,,document_parses/pdf_json/c1cd72dfc8c71714d7751a0b9820f8f8e0ee3756.json,document_parses/pmc_json/PMC4965583.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965583/,,3
2895,2895,3082,t2qpisrn,d2b714f43fa6302301a1aa7d282de555f71024b2,PMC,Germinal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines,10.4049/jimmunol.1502472,PMC4974488,27412417.0,cc-by,great interest development abinducing subunit vaccine targeting infection including hiv malaria ebola previously reported adenovirus vectored vaccine potent priming ab response uncertainty remains regarding optimal approach induction humoral immune response study using ovum model ag assessed magnitude primary anamnestic ag–specific igg response mouse four clinically relevant vaccine formulation replicationdeficient adenovirus modified vaccinia ankara poxvirus protein alum protein squalene oilinwater adjuvant addavax used flow cytometric assay capable measuring total agspecific germinal center gc b cell follicular th cell response compare induction response different formulation report adenovirus vectored vaccine induce ag insert–specific gc b cell ab response magnitude comparable induced potent proteinsqualene oilinwater formulation whereas—despite robust overall gc response—the insertspecific gc b cell ab response induced modified vaccinia ankara extremely weak agspecific follicular th cell response adenovirus vectored vaccine exceeded induced platform day immunization found little evidence innate immune activation adenovirus may act adjuvant manner humoral response recombinant protein may enhanced coadministering adenovirus lacking transgene interest overall study provide support use replicationdeficient adenovirus induce humoral response,2016-08-15,"Wang, Chuan; Hart, Matthew; Chui, Cecilia; Ajuogu, Augustine; Brian, Iona J.; de Cassan, Simone C.; Borrow, Persephone; Draper, Simon J.; Douglas, Alexander D.",J Immunol,,,,document_parses/pdf_json/d2b714f43fa6302301a1aa7d282de555f71024b2.json,document_parses/pmc_json/PMC4974488.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974488/,,3
2907,2907,3094,nt1shjtl,d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba,PMC,Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge,10.1371/journal.pone.0161193,PMC4985159,27525409.0,cc-by,current hemagglutinin habased seasonal influenza vaccine induce vaccine strainspecific neutralizing antibody usually fail provide protection mismatched circulating virus inclusion vaccine highly conserved internal protein nucleoprotein np matrix protein shown previously increase vaccine efficacy eliciting crossreactive tcells however appropriate delivery system required efficient priming tcell response study demonstrated administration novel selfamplifying mrna sam® vector expressing influenza np samnp samm np sammnp delivered lipid nanoparticles lnp induced robust polyfunctional cd helper cell npcontaining sam also induced cytotoxic cd cell robust expansion central memory tcm effector memory tem cd cd cell also measured enhanced recruitment npspecific cytotoxic cd cell observed lung samnpimmunized mouse influenza infection paralleled reduced lung viral titer pathology increased survival homologous heterosubtypic influenza challenge finally demonstrated first time coadministration rna sammnp protein monovalent inactivated influenza vaccine miiv feasible induced simultaneously np haspecific cell haspecific neutralizing antibody enhanced miiv efficacy heterologous challenge conclusion systemic administration sam vector expressing conserved internal influenza antigen induced protective immune response mouse supporting sam® platform another promising strategy development broadspectrum universal influenza vaccine,2016-08-15,"Magini, Diletta; Giovani, Cinzia; Mangiavacchi, Simona; Maccari, Silvia; Cecchi, Raffaella; Ulmer, Jeffrey B.; De Gregorio, Ennio; Geall, Andrew J.; Brazzoli, Michela; Bertholet, Sylvie",PLoS One,,,,document_parses/pdf_json/d26fb6227fcc98e9e8f9fecbedfd47bc4c00e7ba.json,document_parses/pmc_json/PMC4985159.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985159/,,3
2919,2919,3106,a3nzj6yh,0dc8d11784da63b899dbb2b404be4efd330e4ac3,PMC,Adenoviral vector-based strategies against infectious disease and cancer,10.1080/21645515.2016.1165908,PMC4994731,27105067.0,cc-by-nc,adenoviral vector widely employed infectious disease cancer elicit specific antibody response cell response armed foreign gene vaccine carrier induce apoptosis cancer cell genetically modified cancer therapy review summarize biological characteristic adenovirus ad latest development ad vectorbased strategy prevention control emerging infectious disease cancer strategy circumvent preexisting neutralizing antibody dampen immunogenicity adbased vaccine also discussed,2016-04-22,"Zhang, Chao; Zhou, Dongming",Hum Vaccin Immunother,,,,document_parses/pdf_json/0dc8d11784da63b899dbb2b404be4efd330e4ac3.json,document_parses/pmc_json/PMC4994731.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4994731/,,3
2949,2949,3136,jppa2pbw,0cf083b09e13b9c6d8fe008590784d479f67f2f6,PMC,Low genetic diversity among historical and contemporary clinical isolates of felid herpesvirus 1,10.1186/s12864-016-3050-2,PMC5010698,27589862.0,cc-by,background felid herpesvirus fhv cause upper respiratory tract disease cat worldwide including nasal ocular discharge conjunctivitis oral ulceration nature severity disease vary clinical case genetic determinant virulence likely contribute difference vivo phenotype fhv isolates date limited study investigating fhv genetic diversity study used next generation sequencing compare genome contemporary australian clinical isolates fhv vaccine isolates historical clinical isolates including isolates predated introduction live attenuated vaccine australia analysis genome sequence aimed ass level genetic diversity identify potential genetic marker could influence vivo phenotype isolates examine sequence evidence recombination result full genome sequence isolates fhv determined including two vaccine isolates clinical isolates collected period approximately year analysis genome sequence revealed remarkably low level diversity – isolates potential genetic determinant virulence identified unique single nucleotide polymorphism snp ul ul gene detected vaccine isolates present clinical isolates evidence fhv recombination detected using multiple method recombination detection even though many isolates originated cat housed shelter environment high infective pressure likely exist evidence displacement dominant fhv isolates genetically distinct fhv isolates time observed amongst isolates obtained shelterhoused animal conclusion result show fhv genome highly conserved lack recombination detected fhv genome suggests risk attenuated vaccine recombining generate virulent field virus lower suggested herpesviruses snp detected vaccine isolates offer potential develop pcrbased method differentiating vaccine clinical isolates fhv order facilitate future epidemiological study electronic supplementary material online version article doi contains supplementary material available authorized user,2016-09-02,"Vaz, Paola K.; Job, Natalie; Horsington, Jacquelyn; Ficorilli, Nino; Studdert, Michael J.; Hartley, Carol A.; Gilkerson, James R.; Browning, Glenn F.; Devlin, Joanne M.",BMC Genomics,,,,document_parses/pdf_json/0cf083b09e13b9c6d8fe008590784d479f67f2f6.json,document_parses/pmc_json/PMC5010698.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010698/,,3
2961,2961,3149,af8ofuwo,d0d47cee33a4e690e05f6277dd513682b7d35bdb,PMC,Immunogenicity of RSV F DNA Vaccine in BALB/c Mice,10.1155/2016/7971847,PMC5027326,27688769.0,cc-by,respiratory syncytial virus rsv cause severe acute lower respiratory tract disease leading numerous hospitalization death among infant elderly population worldwide vaccine le effective drug available rsv infection natural rsv infection stimulates th immune response activates production neutralizing antibody earlier vaccine trial used uvinactivated rsv exacerbated disease due activation allergic th response focus th immunity developed dna vaccine containing native rsv fusion rsv f protein studied immune response balbc mouse high level rsv specific antibody induced subsequent immunization serum antibody able neutralize rsv vitro rsv inhibition serum also shown immunofluorescence analysis antibody response rsv f dna vaccine showed strong th response also serum rsv f immunized rsv infected mouse reduced rsv infection respectively data evidently showed rsv f dna vaccine activated th biased immune response led production neutralizing antibody desired immune response required protection rsv infection,2016-09-05,"Eroglu, Erdal; Singh, Ankur; Bawage, Swapnil; Tiwari, Pooja M.; Vig, Komal; Pillai, Shreekumar R.; Dennis, Vida A.; Singh, Shree R.",Adv Virol,,,,document_parses/pdf_json/d0d47cee33a4e690e05f6277dd513682b7d35bdb.json,document_parses/pmc_json/PMC5027326.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5027326/,,3
2968,2968,3156,vvge4nus,69d3400351b1b4dbce54ecdec3d4c897dc76b9a8,PMC,Tuberculosis Susceptibility and Vaccine Protection Are Independently Controlled by Host Genotype,10.1128/mbio.01516-16,PMC5030360,27651361.0,cc-by,outcome mycobacterium tuberculosis infection immunological response bacillus calmetteguerin bcg vaccine highly variable human deciphering relative importance host genetics environment vaccine preparation efficacy bcg proven difficult natural population developed model system capture breadth immunological response observed outbred individual mouse used understand contribution host genetics vaccine efficacy system employ panel highly diverse inbred mouse strain consisting founder recombinant progeny “ collaborative cross ” project unlike natural population structure panel allows serial evaluation genetically identical individual quantification genotypespecific effect intervention vaccination analyzed aggregate panel resembled natural population several important respect animal displayed broad range susceptibility tuberculosis differed immunological response infection durably protected bcg vaccination however analyzed genotype level found phenotypic difference heritable tuberculosis susceptibility varied line extreme sensitivity progressive tuberculosis clearance similarly minority genotype protected vaccination efficacy bcg genetically separable susceptibility tuberculosis lack efficacy aggregate analysis driven nonresponsive line mounted qualitatively distinct response infection observation support important role host genetic diversity determining bcg efficacy provide new resource rationally develop broadly efficacious vaccine,2016-09-20,"Smith, Clare M.; Proulx, Megan K.; Olive, Andrew J.; Laddy, Dominick; Mishra, Bibhuti B.; Moss, Caitlin; Gutierrez, Nuria Martinez; Bellerose, Michelle M.; Barreira-Silva, Palmira; Phuah, Jia Yao; Baker, Richard E.; Behar, Samuel M.; Kornfeld, Hardy; Evans, Thomas G.; Beamer, Gillian; Sassetti, Christopher M.",mBio,,,,document_parses/pdf_json/69d3400351b1b4dbce54ecdec3d4c897dc76b9a8.json,document_parses/pmc_json/PMC5030360.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5030360/,,3
2969,2969,3157,9a163ad7,b11cf879da2036d92fbdbbca07fd8cb7f0416e5f,PMC,A Rationally Designed TNF-α Epitope-Scaffold Immunogen Induces Sustained Antibody Response and Alleviates Collagen-Induced Arthritis in Mice,10.1371/journal.pone.0163080,PMC5033357,27658047.0,cc-by,tnfα biological inhibitor significantly improved clinical outcome many autoimmune disease particular rheumatoid arthritis however practical us limited due high cost risk antidrug antibody response attempt develop antitnfα vaccine generated encouraging data animal model however data clinical trial met expectation present study designed tnfα epitopescaffold immunogen dtnf using transmembrane domain diphtheria toxin named dtt scaffold molecular dynamic simulation show grafted tnfα epitope entirely surfaceexposed presented nativelike conformation rigid helical structure dtt minimally perturbed thereby rendering immunogen highly stable immunization mouse alum formulated dtnf induced humoral response native tnfα antibody titer sustained month support role universal cd cell epitope dtt breaking selfimmune tolerance mouse model rheumatoid arthritis dtnfalum vaccination markedly delayed onset collageninduced arthritis reduced incidence well clinical score dtt presumed safe epitope carrier catalytic inactive mutant diphtheria toxin crm good clinical safety record active vaccine component taken together show dttbased epitope vaccine promising strategy prevention treatment autoimmune disease,2016-09-22,"Zhang, Li; Wang, Jin; Xu, Aizhang; Zhong, Conghao; Lu, Wuguang; Deng, Li; Li, Rongxiu",PLoS One,,,,document_parses/pdf_json/b11cf879da2036d92fbdbbca07fd8cb7f0416e5f.json,document_parses/pmc_json/PMC5033357.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5033357/,,3
2977,2977,3165,s4xlrav8,04ed44ad0aed30771e1ba0f38e4aa00101d1b8c3; fc8c37b262255f1af7df6aa9bbbce30f5d5aa20a,PMC,A polyvalent inactivated rhinovirus vaccine is broadly immunogenic in rhesus macaques,10.1038/ncomms12838,PMC5036149,27653379.0,cc-by,predominant aetiological agent common cold human rhinovirus hrv leading cause human infectious disease early study showed monovalent formalininactivated hrv vaccine protective virusneutralizing antibody nab correlated protection however cocirculation many hrv type discouraged vaccine effort test hypothesis increasing virus input titre polyvalent inactivated hrv vaccine may result broad nab response show serum nab many rhinovirus type induced polyvalent inactivated hrvs plus alhydrogel alum adjuvant using formulation valent mouse valent rhesus macaque hrv vaccine immunogenicity related sufficient quantity input antigen valency major factor potency breadth response thus generated vaccine capable inducing nab response numerous diverse hrv type,2016-09-22,"Lee, Sujin; Nguyen, Minh Trang; Currier, Michael G.; Jenkins, Joe B.; Strobert, Elizabeth A.; Kajon, Adriana E.; Madan-Lala, Ranjna; Bochkov, Yury A.; Gern, James E.; Roy, Krishnendu; Lu, Xiaoyan; Erdman, Dean D.; Spearman, Paul; Moore, Martin L.",Nat Commun,,,,document_parses/pdf_json/04ed44ad0aed30771e1ba0f38e4aa00101d1b8c3.json; document_parses/pdf_json/fc8c37b262255f1af7df6aa9bbbce30f5d5aa20a.json,document_parses/pmc_json/PMC5036149.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5036149/,,3
2992,2992,3180,t90d19zq,35fd455662a4a9c03d3791ee3a390c163a53f242,PMC,Phage display as a promising approach for vaccine development,10.1186/s12929-016-0285-9,PMC5041315,27680328.0,cc-by,bacteriophage specific antagonist bacterial host viral entity attracted growing interest optimal vaccine delivery vehicle phage wellmatched vaccine design due highly stable harsh environmental condition simple inexpensive large scale production potent adjuvant capacity phage vaccine efficient immunostimulatory effect present high safety profile virus made constant relationship mammalian body longstanding evolutionary period birth phage display technology turning point development phagebased vaccine phage display vaccine made expressing multiple copy antigen surface immunogenic phage particle thereby eliciting powerful effective immune response also ability produce combinatorial peptide library highly diverse pool randomized ligand transformed phage display straightforward versatile high throughput screening methodology identification potential vaccine candidate different disease particular microbial infection library conveniently screened affinity selectionbased strategy called biopanning wide variety target selection mimotopes high antigenicity immunogenicity also panned antiserum convalescent individual recognize novel peptidomimetics pathogenrelated epitope phage display represented enormous promise finding new strategy vaccine discovery production current breakthrough promise brilliant future development different phagebased vaccine platform,2016-09-29,"Aghebati-Maleki, Leili; Bakhshinejad, Babak; Baradaran, Behzad; Motallebnezhad, Morteza; Aghebati-Maleki, Ali; Nickho, Hamid; Yousefi, Mehdi; Majidi, Jafar",J Biomed Sci,,,,document_parses/pdf_json/35fd455662a4a9c03d3791ee3a390c163a53f242.json,document_parses/pmc_json/PMC5041315.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5041315/,,3
3049,3049,3238,99bmn9oo,cbabbd687725e949c99a0a6f53f033128ea1aaca,PMC,Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses,10.1371/journal.pntd.0005071,PMC5072622,27764114.0,cc-by,dengue virus denv causative agent dengue fever dengue hemorrhagic fever virus endemic country causing million infection per year dengue vaccine development challenging need induce simultaneous protection four antigenically distinct denv serotypes evidence condition vaccination enhance disease due specific immunity virus several liveattenuated tetravalent dengue virus vaccine display partial efficacy challenging induce balanced protective immunity serotypes instead using wholevirus formulation exploring potential particulate subunit vaccine based denv eprotein displayed nanoparticles precisely molded using particle replication nonwetting template print technology describe immunization study denvnanoparticle vaccine candidate ectodomain denve protein expressed secreted recombinant protein srece purified adsorbed poly lacticcoglycolic acid plga nanoparticles different size shape show print nanoparticle adsorbed srece without adjuvant induces higher igg titer potent denvspecific neutralizing antibody response compared soluble srece protein alone antigen trafficking indicate print nanoparticle display srece prolongs bioavailability antigen draining lymph node creating antigen depot result demonstrate print nanoparticles promising platform delivering subunit vaccine flavivirus dengue zika,2016-10-20,"Metz, Stefan W.; Tian, Shaomin; Hoekstra, Gabriel; Yi, Xianwen; Stone, Michelle; Horvath, Katie; Miley, Michael J.; DeSimone, Joseph; Luft, Chris J.; de Silva, Aravinda M.",PLoS Negl Trop Dis,,,,document_parses/pdf_json/cbabbd687725e949c99a0a6f53f033128ea1aaca.json,document_parses/pmc_json/PMC5072622.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5072622/,,3
3078,3078,3267,ldfa616a,0660d9281c1607ca1ca9cb62dfa00b56f49ddee1,PMC,The Last Ten Years of Advancements in Plant-Derived Recombinant Vaccines against Hepatitis B,10.3390/ijms17101715,PMC5085746,27754367.0,cc-by,disease prevention vaccination considered greatest contribution public health past century every year million child vaccinated standard world health organization whorecommended vaccine including hepatitis b hepb hepb serious type liver infection caused hepatitis b virus hbv however prevented currently available recombinant vaccine excellent record safety effectiveness date recombinant vaccine produced many system bacteria yeast insect mammalian plant cell among platform use plant cell received considerable attention term intrinsic safety scalability appropriate modification target protein research group worldwide attempted develop efficacious plantderived vaccine disease frequently hepb influenza inspiring approximately plantmade antigen already tested clinical trial successful outcome study latest information last year plantderived antigen especially hepatitis b surface antigen approach reviewed breakthrough regarding weak point also discussed,2016-10-13,"Joung, Young Hee; Park, Se Hee; Moon, Ki-Beom; Jeon, Jae-Heung; Cho, Hye-Sun; Kim, Hyun-Soon",Int J Mol Sci,,,,document_parses/pdf_json/0660d9281c1607ca1ca9cb62dfa00b56f49ddee1.json,document_parses/pmc_json/PMC5085746.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5085746/,,3
3152,3152,3342,rie2fo14,4abc50cfc81265083d4cb2aed0a493bb704d0b5b,PMC,Rabies Control and Treatment: From Prophylaxis to Strategies with Curative Potential,10.3390/v8110279,PMC5127009,27801824.0,cc-by,rabies acute fatal neurological disease affect almost kind mammal vaccination using inactivated rabies vaccine combined administration rabies immune globulin approved effective method postexposure prophylaxis rabies human search novel rabies control treatment strategy liveattenuated virus recently emerged practical promising approach immunizing controlling rabies unlike conventional inactivated rabies vaccine liveattenuated virus genetically modified virus able replicate inoculated recipient without causing adverse effect still eliciting robust effective immune response rabies virus infection number virus intrinsic capacity could used putative candidate liveattenuated rabies vaccine intensively evaluated therapeutic purpose additional novel strategy monoclonal antibodybased approach nucleic acidbased vaccine small interfering rna sirnas interfering virus replication could add arena strategy combat rabies review highlight current advance rabies therapy discus role might future rabies treatment given pronounced complex impact rabies patient combination novel modality potential achieve maximal antirabies efficacy may even promising curative effect future however several hurdle regarding clinical safety consideration public awareness overcome approach ultimately become clinically relevant therapy,2016-10-28,"Zhu, Shimao; Guo, Caiping",Viruses,,,,document_parses/pdf_json/4abc50cfc81265083d4cb2aed0a493bb704d0b5b.json,document_parses/pmc_json/PMC5127009.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5127009/,,3
3223,3223,3419,8au24p7l,7314f2ac32ead26d507b36cd305ffd76736f1007,PMC,Deep sequencing reveals persistence of cell-associated mumps vaccine virus in chronic encephalitis,10.1007/s00401-016-1629-y,PMC5209397,27770235.0,cc-by,routine childhood vaccination measles mumps rubella virtually abolished virusrelated morbidity mortality notwithstanding describe devastating neurological complication associated detection liveattenuated mumps virus jeryl lynn muvjl brain child undergone successful allogeneic transplantation severe combined immunodeficiency scid first confirmed report muvjl associated chronic encephalitis highlight need exclude immunodeficient individual immunisation liveattenuated vaccine diagnosis possible deep sequencing brain biopsy sequence comparison vaccine batch muvjl isolated brain identified biased hypermutation particularly matrix gene similar found measles case sspe finding provide unique insight pathogenesis paramyxovirus brain infection electronic supplementary material online version article doisy contains supplementary material available authorized user,2016-10-21,"Morfopoulou, Sofia; Mee, Edward T.; Connaughton, Sarah M.; Brown, Julianne R.; Gilmour, Kimberly; Chong, WK ‘Kling’; Duprex, W. Paul; Ferguson, Deborah; Hubank, Mike; Hutchinson, Ciaran; Kaliakatsos, Marios; McQuaid, Stephen; Paine, Simon; Plagnol, Vincent; Ruis, Christopher; Virasami, Alex; Zhan, Hong; Jacques, Thomas S.; Schepelmann, Silke; Qasim, Waseem; Breuer, Judith",Acta Neuropathol,,,,document_parses/pdf_json/7314f2ac32ead26d507b36cd305ffd76736f1007.json,document_parses/pmc_json/PMC5209397.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5209397/,,3
3252,3252,3449,jzcyxjxt,ece140f2d510d370f594707b718066f7173a39e1,PMC,Preventative Vaccines for Zika Virus Outbreak: Preliminary Evaluation,10.1016/j.ebiom.2016.09.028,PMC5264651,27717627.0,cc-by-nc-nd,since emerged brazil may mosquitoborne zika virus zikv raised global concern due association significant rise number infant born microcephaly neurological disorder guillainbarré syndrome developed prototype subunit adenoviralbased zika vaccine encoding extracellular portion zikv envelope gene e fused fibritin foldon trimerization domain efl subunit vaccine delivered intradermally carboxymethyl cellulose microneedle array mna immunogenicity two vaccine named adzikvefl zikvrefl tested cbl mouse primeboost immunization regimen associated induction zikvspecific antibody response provided neutralizing immunity moreover protection evaluated sevendayold pup virulent zikv intraperitoneal challenge pup born mouse immunized adzikvefl protected lethal challenge infection without weight loss neurological sign pup born dam immunized mnazikvrefl partially protected protection seen pup born phosphate buffered salineimmunized mouse study illustrates preliminary efficacy e zikv antigen vaccination controlling zikv infectivity providing promising candidate vaccine antigen format prevention zika virus disease,2016-10-03,"Kim, Eun; Erdos, Geza; Huang, Shaohua; Kenniston, Thomas; Falo, Louis D.; Gambotto, Andrea",EBioMedicine,,,,document_parses/pdf_json/ece140f2d510d370f594707b718066f7173a39e1.json,document_parses/pmc_json/PMC5264651.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5264651/,,3
3262,3262,3459,2seqgjoy,3d8ad2b7cceac3f97d193df3beb627b05860c499,PMC,Assessment of the efficacy of two novel DNA vaccine formulations against highly pathogenic Porcine Reproductive and Respiratory Syndrome Virus,10.1038/srep41886,PMC5291100,28157199.0,cc-by,since may highly pathogenic porcine reproductive respiratory syndrome virus hpprrsv emerged prevailed mainland china affecting million pig commercial prrsv killed modified live vaccine provide complete protection hpprrsv due genetic variation development effective vaccine emerging hpprrsv urgently required previous study two formulation dna vaccine pcdnapoifnλsynorf bpeiplgasynorf based hpprrsv constructed shown induce enhanced humoral cellular immune response mouse objective study evaluate immune response induced novel formulation piglet pcdnapoifnλsynorf bpeiplgasynorf vaccine induced significantly enhanced gpspecific antibody prrsvspecific neutralizing antibody pig compared pcdnasynorf parental construct though ifnγ level lymphocyte proliferation response induced two dna vaccine formulation comparable induced pcdnasynorf construct novel formulation provided efficient protection challenge hpprrsv nonsevere clinical sign rectal temperature observed pig immunized bpeiplgasynorf compared group thus novel dna construct may represent promising candidate vaccine emerging hpprrsv,2017-02-03,"Du, Luping; Pang, Fengjiao; Yu, Zhengyu; Xu, Xiangwei; Fan, Baochao; Huang, Kehe; He, Kongwang; Li, Bin",Sci Rep,,,,document_parses/pdf_json/3d8ad2b7cceac3f97d193df3beb627b05860c499.json,document_parses/pmc_json/PMC5291100.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5291100/,,3
3263,3263,3460,f7gv18qq,6a246d3621609eba5e7fb36c483280aa9cacd166,PMC,Vesicular Stomatitis Virus-Vectored Multi-Antigen Tuberculosis Vaccine Limits Bacterial Proliferation in Mice following a Single Intranasal Dose,10.3389/fcimb.2017.00034,PMC5293745,28224119.0,cc-by,tuberculosis tb remains serious health problem worldwide urgent need exists improve replace available vaccine mycobacterium bovis bacillus calmetteguérin bcg vaccination protocol adapt two three dos induce longterm lasting immunity previous study showed naked dna encoding tripleantigen fusion tfp rvcmtbrvc induced robust cellular immune response accompanying four inoculation mycobacteria infection however number compliance issue exist area lacking appropriate medical infrastructure multiple administration study novel vesicular stomatitis virus expressing tfp vsv developed immune response elicited vsv evaluated observed intranasal delivery vsv induced potent antigenspecific cell response following single dose vsv efficiently controlled bacterial growth level fold lower observed mock group week postinfection bcginfected mouse importantly mouse immunized vsv provided longterm protection mycobacteria infection compared receiving p bcg immunization increased memory cell also observed spleen vsvvaccinated mouse could potential mechanism associated longterm protective immune response finding supported use vsv antigen delivery vector potential tb vaccine development,2017-02-07,"Zhang, Ming; Dong, Chunsheng; Xiong, Sidong",Front Cell Infect Microbiol,,,,document_parses/pdf_json/6a246d3621609eba5e7fb36c483280aa9cacd166.json,document_parses/pmc_json/PMC5293745.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5293745/,,3
3340,3340,3537,o12ts2ha,57bac09c0563474a03a233b1e7f60ed8c82a9642,PMC,"In silico CD4+, CD8+ T-cell and B-cell immunity associated immunogenic epitope prediction and HLA distribution analysis of Zika virus",10.17179/excli2016-719,PMC5379118,28435428.0,cc-by,zika virus zikv mosquitoborne flavivirus distributed africa south america asia infection virus may cause acute febrile sickness clinically resembles dengue fever yet vaccine satisfactory treatment mean evaluating risk disease prognosis infected people present study efficacy host immune response reducing risk infectious disease taken account carry immunoinformatics driven epitope screening strategy vaccine candidate zikv study hla distribution analysis done ensure coverage vast majority population systematic screening effective dominant immunogen done help immune epitope abcpred database outcome suggested predicted epitope may protective immunogen highly conserved sequence bear potential induce protective neutralizing antibody b cell response total cd cd peptide screened tcell mediated immunity predicted epitope tgldfsdlyyltmnnkhwlv selected highly immunogenic epitope humoral immunity peptide screened nontoxic immunogenic nonmutated residue envelop viral protein predicted epitope could work suitable candidate peptide based vaccine development experimental validation epitope warranted ensure potential b tcells stimulation efficient use vaccine candidate diagnostic agent zikv,2017-01-13,"Janahi, Essam Mohammed; Dhasmana, Anupam; Srivastava, Vandana; Sarangi, Aditya Narayan; Raza, Sana; Arif, Jamal M.; Bhatt, Madan Lal Bramha; Lohani, Mohtashim; Areeshi, Mohammed Yahya; Saxena, Anand Murari; Haque, Shafiul",EXCLI J,,,,document_parses/pdf_json/57bac09c0563474a03a233b1e7f60ed8c82a9642.json,document_parses/pmc_json/PMC5379118.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5379118/,,3
3364,3364,3562,9p2n8tjx,2f464f69ee34fff67b35b41170660a4e3dac0654,PMC,A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?,10.1098/rstb.2016.0295,PMC5394635,28396468.0,cc-by,sporadic outbreak ebola virus infection documented since midseventies viral exposure lead lethal haemorrhagic fever case fatality high comprehensive body data ongoing completed clinical trial assessing various vaccine strategy rapidly advanced clinical trial response – ebola virus disease evd public health emergency careful consideration immunogenicity post vaccination essential somewhat stifled wide array immunological assay output used numerous clinical trial discus different aspect immune assay currently used phase clinical trial ebola virus vaccine draw comparison across immune output possible various trial examined cellular humoral immunity european african cohort assessment safety data immunological output ease field deployment various vaccine modality help scientific community policymakers prioritize potentially license vaccine candidate achieved next outbreak ebola virus emerging pathogen readily contained widespread devastating consequence article part themed issue ‘ – west african ebola epidemic data decisionmaking disease control ’,2017-05-26,"Lambe, Teresa; Bowyer, Georgina; Ewer, Katie J",Philos Trans R Soc Lond B Biol Sci,,,,document_parses/pdf_json/2f464f69ee34fff67b35b41170660a4e3dac0654.json,document_parses/pmc_json/PMC5394635.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394635/,,3
3414,3414,3614,mpu1ico3,678116d4f14c2470ef9dbde987d11b2e9b679865,PMC,Antigen-Sparing and Enhanced Efficacy of Multivalent Vaccines Adjuvanted with Immunopotentiators in Chickens,10.3389/fmicb.2017.00927,PMC5445108,28603519.0,cc-by,previously described immunopotentiators cvcva increased efficacy h h subtype avian influenza vaccine chicken duck goose study investigated effect cvcva improving efficacy univalent multivalent inactivated vaccine immune response administrated halfdose monovalent vaccine plus cvcva higher one dose monovalent vaccine without immunopotentiators measured level antibody serum tear bronchoalveolar lavage fluid cytokine ifnγ il serum vaccine included univalent vaccine newcastle disease virus nd egg drop syndrome virus ed infectious bronchitis virus ib infectious bursal disease virus ibd cvcva also improved immune response nd ibd vaccine le dosage sterile protective immunity monitored one halfdose adjuvanted nd vaccine one dose adjuvanted ibd vaccine respectively improved immune efficacy observed halfdose adjuvanted bivalent vaccine compared one dose vaccine without cvcva measured antibody level including bivalent vaccine ndh ndib ndibd cvcva also boosted immune efficacy tetravalent vaccine ndibedsh halfdose adjuvanted commercial vaccine antigensparing adjuvanted vaccine elicited similar antibody level one dose nonadjuvanted commercial vaccine cvcva improved effect booster vaccination measured antibody level h h virus antigen chicken primed adjuvanted ndib vaccine given booster h–h bivalent vaccine without cvcva using day interval inflammatory response may contribute additional effect increasing level ifnγ il injection adjuvanted ndib vaccine result indicated cvcva improved serum mucosal antibody level cytokine level chicken given univalent vaccine also improved serum antibody titer bivalent tetravalent vaccine potential improve vaccine,2017-05-26,"Wu, Peipei; Lu, Jihu; Feng, Lei; Wu, Hongzhuan; Zhang, Xuehua; Mei, Mei; Hou, Jibo; Liu, Xiufan; Tang, Yinghua",Front Microbiol,,,,document_parses/pdf_json/678116d4f14c2470ef9dbde987d11b2e9b679865.json,document_parses/pmc_json/PMC5445108.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5445108/,,3
3434,3434,3634,wr2sgixs,2b38999c47f55f18f27ce6dc678dc2b4df381043,PMC,DNA vaccination protects mice against Zika virus-induced damage to the testes,10.1038/ncomms15743,PMC5467228,28589934.0,cc-by,zika virus zikv emerging pathogen causally associated serious sequela fetus inducing fetal microcephaly neurodevelopment defect zikv primarily transmitted mosquito persist human semen sperm sexual transmission documented moreover exposure typei interferon knockout mouse zikv result severe damage testis epididymis sperm candidate zikv vaccine shown protective efficacy preclinical study carried animal model several vaccine entered clinical trial report administration synthetic dna vaccine encoding zikv premembrane envelope prme completely protects mouse zikvassociated damage testis sperm prevents viral persistence testis following challenge contemporary strain zikv data suggest dna vaccination merit investigation potential mean reduce zikv persistence male reproductive tract,2017-06-07,"Griffin, Bryan D.; Muthumani, Kar; Warner, Bryce M.; Majer, Anna; Hagan, Mable; Audet, Jonathan; Stein, Derek R.; Ranadheera, Charlene; Racine, Trina; De La Vega, Marc-Antoine; Piret, Jocelyne; Kucas, Stephanie; Tran, Kaylie N.; Frost, Kathy L.; De Graff, Christine; Soule, Geoff; Scharikow, Leanne; Scott, Jennifer; McTavish, Gordon; Smid, Valerie; Park, Young K.; Maslow, Joel N.; Sardesai, Niranjan Y.; Kim, J. Joseph; Yao, Xiao-jian; Bello, Alexander; Lindsay, Robbin; Boivin, Guy; Booth, Stephanie A.; Kobasa, Darwyn; Embury-Hyatt, Carissa; Safronetz, David; Weiner, David B.; Kobinger, Gary P.",Nat Commun,,,,document_parses/pdf_json/2b38999c47f55f18f27ce6dc678dc2b4df381043.json,document_parses/pmc_json/PMC5467228.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5467228/,,3
3443,3443,3644,sz6fso2y,8fe6e12ec1f61c111c3ca33189fcc0ec90c03803,PMC,Vaccinations against respiratory infections in Arabian Gulf countries: Barriers and motivators,10.12998/wjcc.v5.i6.212,PMC5480069,28685134.0,cc-by-nc,aim study uptake barrier motivator influenza pneumococcal meningococcal pertussis vaccine among member public arabian gulf country method crosssectional survey among gulf cooperation council gcc country ’ resident data collected electronically smartphone app survey variable aimed investigate respondent ’ awareness vaccine influenza pneumococcal meningococcal pertussis infection collected data concerning respondent ’ sociodemographic characteristic perception toward vaccine uptake factor motivate demotivate taking influenza vaccine data analysed statistically using spss v difference characteristic user different country quantified bivariate analysis important variable controlling factor studied using logistic regression result total respondent participated study mean age year male ≥ chronic disease overall uptake influenza vaccine among “ risk ” people ranged saudi arabia qatar doctor ’ advice perception low body immunity main cited reason vaccinated whereas unawareness vaccine main barrier overall uptake pneumococcal vaccine preceding three year among “ risk ” individual ranged bahrain kuwait overall uptake pertussis vaccine among “ vulnerable ” people ranged saudi arabia oman overall uptake meningococcal vaccine among “ risk ” people ranged oman bahrain conclusion vaccination uptake across gcc country suboptimal varies widely across country research needed unearth reason formulate action plan,2017-06-16,"Alqahtani, Amani S; Bondagji, Daniah M; Alshehari, Abdullah A; Basyouni, Mada H; Alhawassi, Tariq M; BinDhim, Nasser F; Rashid, Harunor",World J Clin Cases,,,,document_parses/pdf_json/8fe6e12ec1f61c111c3ca33189fcc0ec90c03803.json,document_parses/pmc_json/PMC5480069.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5480069/,,3
3502,3502,3704,bylmvtiz,fce74c6d77b50d5f596c327529665bf89087097c,PMC,Polyethylenimine-based micro/nanoparticles as vaccine adjuvants,10.2147/ijn.s137980,PMC5546778,28814862.0,cc-by-nc,vaccine shown great success treating preventing tumor infection adjuvant always demanded ensure potent immune response polyethylenimine pei one wellstudied cationic polymer used transfection reagent decade however increasing evidence shown peibased particle also capable acting adjuvant paper briefly review physicochemical property broad application pei different field elaborate intracellular process peibased vaccine addition sum proof vivo clinical application also highlight mechanism proposed intrinsic immunoactivation function pei followed challenge future perspective application pei vaccine well strategy elicit desirable immune response,2017-07-31,"Shen, Chen; Li, Jun; Zhang, Yi; Li, Yuce; Shen, Guanxin; Zhu, Jintao; Tao, Juan",Int J Nanomedicine,,,,document_parses/pdf_json/fce74c6d77b50d5f596c327529665bf89087097c.json,document_parses/pmc_json/PMC5546778.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5546778/,,3
3516,3516,3718,wzjdm4q2,9eb3ea6224aabe868a10af37dc829b9636be5856,PMC,"Modified Vaccinia Virus Ankara Preferentially Targets Antigen Presenting Cells In Vitro, Ex Vivo and In Vivo",10.1038/s41598-017-08719-y,PMC5561217,28819261.0,cc-by,modified vaccinia virus ankara mva promising vaccine vector excellent safety profile however despite extensive preclinical clinical testing surprisingly little known cellular tropism mva especially relevant animal specie performed vitro ex vivo vivo experiment recombinant mva expressing green fluorescent protein rmvagfp human peripheral blood mononuclear cell mouse lung explants rmvagfp predominantly infected antigen presenting cell subsequent vivo experiment performed mouse ferret nonhuman primate indicated preferential targeting dendritic cell alveolar macrophage observed respiratory administration although subtle difference observed respective animal specie following intramuscular injection rmvagfp detected interdigitating cell myocytes also myocytes data important advancing understanding basis immunogenicity mvabased vaccine aid rational vaccine design delivery strategy,2017-08-17,"Altenburg, Arwen F.; van de Sandt, Carolien E.; Li, Bobby W. S.; MacLoughlin, Ronan J.; Fouchier, Ron A. M.; van Amerongen, Geert; Volz, Asisa; Hendriks, Rudi W.; de Swart, Rik L.; Sutter, Gerd; Rimmelzwaan, Guus F.; de Vries, Rory D.",Sci Rep,,,,document_parses/pdf_json/9eb3ea6224aabe868a10af37dc829b9636be5856.json,document_parses/pmc_json/PMC5561217.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5561217/,,3
3534,3534,3738,z8db3qi6,df753ddb66629cfd0795d0ffa319caa0440de284,PMC,The use of a P. falciparum specific coiled-coil domain to construct a self-assembling protein nanoparticle vaccine to prevent malaria,10.1186/s12951-017-0295-0,PMC5588597,28877692.0,cc-by,background parasitic disease malaria remains major global public health concern truly effective vaccine exists one approach development malaria vaccine target asexual blood stage result clinical symptom attempt failed new antigen pa p emerged potential new vaccine candidate multiple study demonstrated antigen immunogenic better correlated protection presented particulate delivery system one particulate delivery system selfassembling protein nanoparticle sapn relies coiledcoil domain protein form stable nanoparticles past used de novo designed amino acid domain drive formation coiledcoil scaffold present antigenic epitope particle surface result use naturally occurring domain found tex protein form coiledcoil scaffolding nanoparticle thus engineering pa new extended form coiledcoil domain p onto n c terminus sapn protein monomer developed particulate delivery system effectively display antigen single particle us malaria tex sequence form nanoparticle scaffold particle immunogenic murine model induce immune response similar one observed seropositive individual malaria endemic region conclusion demonstrate ppasapns induce immune response akin one seropositive individual burkina faso since p highly conserved among different plasmodium specie novel sapns may even provide crossprotection plasmodium falciparum plasmodium vivax two major human malaria pathogen sapns also easy manufacture store delivered population need without complication thus providing low cost malaria vaccine,2017-09-06,"Karch, Christopher P.; Doll, Tais A. P. F.; Paulillo, Sara M.; Nebie, Issa; Lanar, David E.; Corradin, Giampietro; Burkhard, Peter",J Nanobiotechnology,,,,document_parses/pdf_json/df753ddb66629cfd0795d0ffa319caa0440de284.json,document_parses/pmc_json/PMC5588597.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5588597/,,3
3559,3559,3767,t0pv7xz0,7d59b9187e7e96661594c50c8a8c9eab6b1ba177; 59b6229ca07d737a197ae0708282a1f6ed4fa435,PMC,An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial,10.1038/s41541-017-0016-6,PMC5627236,29263871.0,cc-by,novel avian influenza subtype ahn emerged represents public health threat pandemic potential previously shown dna vaccine priming increase magnitude quality antibody response hn monovalent inactivated boost report safety immunogenicity h dnahn monovalent inactivated vaccine primeboost regimen phase open label randomized clinical trial evaluated three hn vaccination regimen healthy adult primeboost interval week group received h dna vaccine prime hn monovalent inactivated vaccine boost group received h dna hn monovalent inactivated vaccine prime hn monovalent inactivated vaccine boost group received hn monovalent inactivated vaccine homologous primeboost regimen overall individual year old enrolled completed vaccination injection well tolerated serious adverse event week postboost group group achieved hai titer ≥ compared group also least fourfold increase neutralizing antibody response seen group group group subject peak neutralizing antibody geometric mean titer significantly greater group gmt p group gmt p compared group gmt novel h dna vaccine safe welltolerated immunogenic boosted hn monovalent inactivated vaccine priming higher hai neutralizing antibody titer hn monovalent inactivated vaccine alone,2017-06-01,"DeZure, Adam D.; Coates, Emily E.; Hu, Zonghui; Yamshchikov, Galina V.; Zephir, Kathryn L.; Enama, Mary E.; Plummer, Sarah H.; Gordon, Ingelise J.; Kaltovich, Florence; Andrews, Sarah; McDermott, Adrian; Crank, Michelle C.; Koup, Richard A; Schwartz, Richard M.; Bailer, Robert T.; Sun, Xiangjie; Mascola, John R.; Tumpey, Terrence M.; Graham, Barney S.; Ledgerwood, Julie E.",NPJ Vaccines,,,,document_parses/pdf_json/7d59b9187e7e96661594c50c8a8c9eab6b1ba177.json; document_parses/pdf_json/59b6229ca07d737a197ae0708282a1f6ed4fa435.json,document_parses/pmc_json/PMC5627236.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5627236/,,3
3566,3566,3775,e8im13go,1cfa24297a36bcd526ad00635440d59bce705a17,PMC,Induction of PrP(Sc)-specific systemic and mucosal immune responses in white-tailed deer with an oral vaccine for chronic wasting disease,10.1080/19336896.2017.1367083,PMC5639826,28968152.0,cc-by-nc-nd,ongoing epidemic chronic wasting disease cwd within cervid population indicates need novel approach disease management vaccine either reduces susceptibility infection reduces shedding prion infected animal combination could benefit disease control development vaccine challenged unique nature prion disease requirement formulation delivery oral format application wildlife setting address unique nature prion group target epitope termed disease specific epitope ds whose exposure antibody binding depends diseaseassociated misfolding prpc prpsc dse corresponding rigid loop rl region immunogenic following parenteral vaccination translated oral vaccine vaccine consists replicationincompetent human adenovirus expressing truncated rabies glycoprotein g recombinant fusion rl epitope hadtggrl oral immunization whitetailed deer hadtggrl induced prpscspecific systemic mucosal antibody response encouraging safety profile term adverse health effect prolonged vector shedding building upon proven strategy formulation wildlife vaccine effort generate particular prpscspecific oral vaccine cwd well providing versatile platform term carrier protein biological vector generation oral peptidebased cwd vaccine,2017-10-02,"Taschuk, Ryan; Scruten, Erin; Woodbury, Murray; Cashman, Neil; Potter, Andrew; Griebel, Philip; Tikoo, Suresh K.; Napper, Scott",Prion,,,,document_parses/pdf_json/1cfa24297a36bcd526ad00635440d59bce705a17.json,document_parses/pmc_json/PMC5639826.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5639826/,,3
3586,3586,3796,3pnuzxqv,0a05a7b95ce42f0b53c86a24842ecc9845a7d023,PMC,Adjuvants and the vaccine response to the DS-Cav1-stabilized fusion glycoprotein of respiratory syncytial virus,10.1371/journal.pone.0186854,PMC5658087,29073183.0,cc0,appropriate adjuvant selection may essential optimize potency tailor immune response subunit vaccine induce protective response respiratory syncytial virus rsv—a highly prevalent childhood pathogen without licensed vaccine—we previously engineered prefusionstabilized trimeric rsv f pref “ dscav ” immunogen induced high titer rsvneutralizing antibody mouse nonhuman primate formulated adjuvant poly ic poly iclc respectively ass impact different adjuvant formulated rsv f dscav multiple adjuvant assessed immune response high rsvneutralizing antibody response ec observed naïve mouse immunized dos dscav adjuvanted sigma adjuvant system sa oilinwater adjuvant plus carbopol high response – observed dscav adjuvanted alum sa alone adjuplex poly ic poly iclc moderate response – observed dscav adjuvanted tlr agonist mpla alum plus mpla addavax contrast dscav without adjuvant induced lowlevel response balanced igg igga thth immune response elicited high high response group alum adjuplex also tested immune response induced dscav elderly mouse preexisting dscav immunity observed dscav adjuvanted sa plus carbopol boosted response fold whereas dscav adjuvanted alum boosted response fold finally tested whether mixture isa vg carbopol would enhanced antibody response dscav immunized calf prefstabilized bovine rsv f induced high titer mouse adjuvanted sa plus carbopol addition carbopol isa vg enhance immune response calf vaccine response prefstabilized rsv f augmented adjuvant degree adjuvantinduced enhancement appears contextdependent speciesspecific,2017-10-26,"Sastry, Mallika; Zhang, Baoshan; Chen, Man; Joyce, M. Gordon; Kong, Wing-Pui; Chuang, Gwo-Yu; Ko, Kiyoon; Kumar, Azad; Silacci, Chiara; Thom, Michelle; Salazar, Andres M.; Corti, Davide; Lanzavecchia, Antonio; Taylor, Geraldine; Mascola, John R.; Graham, Barney S.; Kwong, Peter D.",PLoS One,,,,document_parses/pdf_json/0a05a7b95ce42f0b53c86a24842ecc9845a7d023.json,document_parses/pmc_json/PMC5658087.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5658087/,,3
3624,3624,3835,oti9btqp,3cff423d90d10aed4310a7d726a6a873d37b2693,PMC,In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine,10.1038/npjvaccines.2016.21,PMC5707885,29263859.0,cc-by,significant concern raised owing rapid global spread infection disease caused mosquitoborne zika virus zikv recent study suggest zikv also transmitted sexually increasing exposure risk virus associated spread dramatic increase case microcephaly additional congenital abnormality infant zikvinfected mother well rise occurrence guillain barre ’ syndrome infected adult importantly licensed therapy vaccine zikv infection study generate evaluate vivo efficacy novel synthetic dna vaccine targeting premembraneenvelope protein prme zikv following initial vitro development evaluation study plasmid construct mouse nonhuman primate immunised prme dnabased immunogen electroporationmediated enhanced dna delivery vaccinated animal found generate antigenspecific cellular humoral immunity neutralisation activity mouse lacking receptor interferon ifnαβ designated ifnar−− immunisation dna vaccine induced following vivo viral challenge protection infectionassociated weight loss death addition preventing viral pathology brain tissue addition passive transfer nonhuman primate antizikv immune serum protected ifnar−− mouse subsequent viral challenge study nhp pathogenic mouse model support importance immune response targeting prme zikv infection suggests additional research vaccine approach may relevance zikv control disease prevention human,2016-11-10,"Muthumani, Karuppiah; Griffin, Bryan D; Agarwal, Sangya; Kudchodkar, Sagar B; Reuschel, Emma L; Choi, Hyeree; Kraynyak, Kimberly A; Duperret, Elizabeth K; Keaton, Amelia Anne; Chung, Christopher; Kim, Yinho K; Booth, Stephanie A; Racine, Trina; Yan, Jian; Morrow, Matthew P; Jiang, Jingjing; Lee, Brian; Ramos, Stephanie; Broderick, Kate E; Reed, Charles C; Khan, Amir S; Humeau, Laurent; Ugen, Kenneth E; Park, Young K; Maslow, Joel N; Sardesai, Niranjan Y; Joseph Kim, J; Kobinger, Gary P; Weiner, David B",NPJ Vaccines,,,,document_parses/pdf_json/3cff423d90d10aed4310a7d726a6a873d37b2693.json,document_parses/pmc_json/PMC5707885.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707885/,,3
3632,3632,3844,hw96we95,7f59def3fa1e3dc7992025e057949df92b7f6f0c,PMC,"Intention to vaccinate universally against varicella, rotavirus gastroenteritis, meningococcal B disease and seasonal influenza among parents in the Netherlands: an internet survey",10.1186/s13104-017-3004-z,PMC5716237,29202798.0,cc-by,objective decisionmaking process regarding introduction new vaccine national immunisation programme nip advance insight potential acceptance among population relevant studied intention parent child vaccinated four disease currently covered nip netherlands result varicella published article add result vaccination rotavirus gastroenteritis meningococcal b disease seasonal influenza result invited random sample national immunisation register parent internet survey completed parent response intention vaccinate highest meningococcal b disease positive intention followed rotavirus gastroenteritis lowest varicella seasonal influenza prediction analysis performed determine seven questionnaire statement informative predicting intention vaccinate main driver intention perceived importance vaccination particular disease perception whether disease severe enough justify vaccination result study informative decisionmaking process whether introduce new vaccine nip electronic supplementary material online version article sz contains supplementary material available authorized user,2017-12-04,"van Lier, Alies; Ferreira, José A.; Mollema, Liesbeth; Sanders, Elisabeth A. M.; de Melker, Hester E.",BMC Res Notes,,,,document_parses/pdf_json/7f59def3fa1e3dc7992025e057949df92b7f6f0c.json,document_parses/pmc_json/PMC5716237.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716237/,,3
3637,3637,3850,dvw4ajtv,03dce266594748330a10d2d11dbe611bf42aa42d,PMC,"Rhinovirus Biology, Antigenic Diversity, and Advancements in the Design of a Human Rhinovirus Vaccine",10.3389/fmicb.2017.02412,PMC5723287,29259600.0,cc-by,human rhinovirus hrv remains leading cause several human disease including common cold despite considerable research last year development effective vaccine hrv viewed many unfeasible due part antigenic diversity circulating hrvs nature antigenically distinct type hrv currently known span three specie hrv hrv b hrv c early attempt develop rhinovirus vaccine shown inactivated hrv capable serving strong immunogen inducing neutralizing antibody yet limitation virus preparation recovery continued identification antigenic variant hrv logistical challenge pertaining preparing polyvalent preparation magnitude required true efficacy circulating rhinovirus continue prove daunting challenge review describe hrv biology antigenic diversity past present advance hrv vaccine design,2017-12-05,"Stobart, Christopher C.; Nosek, Jenna M.; Moore, Martin L.",Front Microbiol,,,,document_parses/pdf_json/03dce266594748330a10d2d11dbe611bf42aa42d.json,document_parses/pmc_json/PMC5723287.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723287/,,3
3638,3638,3851,auum3tn7,e2fbe8d2a00bf0e7041a1b7c9e08c80ef87cb5cb,PMC,Preclinical Development and Production of Virus-Like Particles As Vaccine Candidates for Hepatitis C,10.3389/fmicb.2017.02413,PMC5723323,29259601.0,cc-by,hepatitis c virus hcv infects world ’ population leading cause liver disease liver transplantation pose serious growing worldwide public health problem partially addressed introduction new antiviral therapy however treatment prevent reinfection particularly high risk population introduction hcv vaccine predicted using simulation model high risk population significant effect reducing incidence hcv vaccine efficacy targeted highrisk intravenous drug user could dramatically reduce hcv incidence population virus like particle vlps composed viral structural protein selfassemble noninfectious particle lack genetic material resemble native virus thus vlps represent safe highly immunogenic vaccine delivery platform able induce potent adaptive immune response currently many vlpbased vaccine entered clinical trial licensed vlp vaccine hepatitis b virus hbv human papilloma virus hpv use many year hcv core e e protein selfassemble immunogenic vlps inclusion hcv antigen heterogenous chimeric vlps also promising approach vlps produced using different expression system bacterial yeast mammalian plant insect cell paper review hcv vlpbased vaccine immunogenicity animal model well different expression system used production,2017-12-05,"Masavuli, Makutiro Ghislain; Wijesundara, Danushka K.; Torresi, Joseph; Gowans, Eric J.; Grubor-Bauk, Branka",Front Microbiol,,,,document_parses/pdf_json/e2fbe8d2a00bf0e7041a1b7c9e08c80ef87cb5cb.json,document_parses/pmc_json/PMC5723323.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723323/,,3
3693,3693,3909,4evbeijx,d05db9cdccfa196d13b8eb58b09208937911d70e,PMC,Novel Immunoinformatics Approaches to Design Multi-epitope Subunit Vaccine for Malaria by Investigating Anopheles Salivary Protein,10.1038/s41598-018-19456-1,PMC5773588,29348555.0,cc-by,malaria fever pervasive quite tropical developing region causing high morbidity mortality causal organism protozoan parasite genus plasmodium spread human host bite hitherto infected female anopheles mosquito course biting salivary protein anopheles help blood feeding behavior ability elicit host immune response study represents series immunoinformatics approach design multiepitope subunit vaccine using anopheles mosquito salivary protein designed subunit vaccine evaluated immunogenicity allergenicity physiochemical parameter enhance stability vaccine protein disulfide engineering performed region high mobility codon adaptation silico cloning also performed ensure higher expression designed subunit vaccine e coli k expression system finally molecular docking simulation study performed vaccine protein tlr receptor determine binding free energy complex stability moreover designed subunit vaccine found induce antisalivary immunity may ability prevent entry plasmodium sporozoite human host,2018-01-18,"Pandey, Rajan Kumar; Bhatt, Tarun Kumar; Prajapati, Vijay Kumar",Sci Rep,,,,document_parses/pdf_json/d05db9cdccfa196d13b8eb58b09208937911d70e.json,document_parses/pmc_json/PMC5773588.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773588/,,3
3722,3722,3938,evy1neal,a0c63dfdc2dba0ccca7f0026b0bedc145649d27d; ff7bf5c8a285587c9e39f4acacd57aee0aa77981,PMC,Non-specific Effect of Vaccines: Immediate Protection against Respiratory Syncytial Virus Infection by a Live Attenuated Influenza Vaccine,10.3389/fmicb.2018.00083,PMC5797773,29445364.0,cc-by,nonspecific effect n vaccine discussed potential longterm beneficial effect beyond direct protection specific pathogen coldadapted live attenuated influenza vaccine caiv induces local innate immune response provide broad range antiviral immunity herein examined whether xca donor virus caivs provides nonspecific crossprotection respiratory syncytial virus rsv degree rsv replication significantly reduced xca administered rsv infection without rsvspecific antibody response vaccination induced immediate release cytokine infiltration leukocyte respiratory tract moderating immune perturbation caused rsv infection potency protection rsv challenge significantly reduced tlr tlr mouse confirming tlr signaling pathway necessary observed immediate shortterm protection result suggest caivs provide shortterm nonspecific protection genetically unrelated respiratory pathogen additional benefit caivs mitigating acute respiratory infection vaccine yet available need assessed future study,2018-01-31,"Lee, Young J.; Lee, Jeong Y.; Jang, Yo H.; Seo, Sang-Uk; Chang, Jun; Seong, Baik L.",Front Microbiol,,,,document_parses/pdf_json/a0c63dfdc2dba0ccca7f0026b0bedc145649d27d.json; document_parses/pdf_json/ff7bf5c8a285587c9e39f4acacd57aee0aa77981.json,document_parses/pmc_json/PMC5797773.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5797773/,,3
3756,3756,3973,bdi8v79t,64b4ec9158c8f378000f3d15492f317f19baeafb,PMC,Lipid-Based Particles: Versatile Delivery Systems for Mucosal Vaccination against Infection,10.3389/fimmu.2018.00431,PMC5845866,29563912.0,cc-by,vaccination process administering immunogenic formulation order induce harness antigen agspecific antibody cell response order protect infection important success obtained protecting individual many deleterious pathological situation parenteral vaccination however one major limitation current vaccination strategy administration route may optimal induction immunity site pathogen entry ie mucosal surface well documented immune response along genital respiratory gastrointestinal tract elicited locally ensure efficient trafficking effector memory b cell mucosal tissue moreover needlefree mucosal delivery vaccine advantageous term safety compliance ease administration however quest mucosal vaccine challenging due fact ag sampling performed across epithelium relatively limited number portal entry deleterious acidic proteolytic environment mucosa affect stability integrity retention time applied ag tolerogenic environment mucosa requires addition adjuvant elicit efficient effector immune response mucosally applicable vaccine formulation developed successfully tested animal model clinical trial use lipidic structure liposome virosomes immune stimulating complex gasfilled microbubbles emulsion proven efficient mucosal delivery associated ag induction local systemic immune reponses particle suitable mucosal delivery protect associated payload degradation deliver concentrated amount ag via specialized sampling cell microfold cell within mucosal epithelium underlying antigenpresenting cell review aim summarizing recent development field mucosal vaccination using lipidbased particle modularity ensured tailoring lipidic design content particle known safety already established human make continuing appraisal vaccine candidate promising development field targeted mucosal vaccination,2018-03-07,"Corthésy, Blaise; Bioley, Gilles",Front Immunol,,,,document_parses/pdf_json/64b4ec9158c8f378000f3d15492f317f19baeafb.json,document_parses/pmc_json/PMC5845866.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5845866/,,3
3761,3761,3978,5yn52cuh,552ee0cc0a8266b6c22dbc287bd080513a3374fb,PMC,Prolonging herd immunity to cholera via vaccination: Accounting for human mobility and waning vaccine effects,10.1371/journal.pntd.0006257,PMC5847240,29489815.0,cc-by,background oral cholera vaccination approach preventing outbreak atrisk setting controlling cholera endemic setting however vaccinederived herd immunity may shortlived due interaction human mobility imperfect waning vaccine efficacy supply utilization oral cholera vaccine grows critical question related herd immunity emerging including targeted revaccination performed cholera outbreak occurred recently vaccinated population method finding use mathematical model simulate routine mass oral cholera vaccination population varying degree migration transmission intensity vaccine coverage show migration waning vaccine efficacy strongly influence duration herd immunity birth death rate relatively minimal impact compared either periodic mass vaccination routine vaccination alone community could protected longer blended “ mass maintain ” strategy show vaccination may best targeted population intermediate degree mobility compared community high low population turnover using case study internally displaced person camp south sudan underwent highcoverage mass vaccination show waning vaccine direct effect high population turnover rendered camp susceptible time cholera outbreak beginning october conclusion oral cholera vaccine powerful tool quickly protecting population period time depends critically vaccine coverage vaccine efficacy time rate population turnover human mobility due waning herd immunity epidemic vaccinated community possible become le likely complementary intervention datadriven revaccination strategy,2018-02-28,"Peak, Corey M.; Reilly, Amanda L.; Azman, Andrew S.; Buckee, Caroline O.",PLoS Negl Trop Dis,,,,document_parses/pdf_json/552ee0cc0a8266b6c22dbc287bd080513a3374fb.json,document_parses/pmc_json/PMC5847240.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847240/,,3
3787,3787,4004,mnvievju,c0b11b19a87de55ec7803cad2e855942ce498d6b,PMC,Oral Immunization against PEDV with Recombinant Lactobacillus casei Expressing Dendritic Cell-Targeting Peptide Fusing COE Protein of PEDV in Piglets,10.3390/v10030106,PMC5869499,29494530.0,cc-by,porcine epidemic diarrhea ped highly contagious disease newborn piglet previous study genetically engineered lactobacillus casei oral vaccine ppgcoedcpepl expressing dendritic cell dctargeting peptide fused porcine epidemic diarrhea virus pedv coe antigen developed vaccine induced significant level antipedv specific igg iga antibody response mouse indicating potential strategy pedv infection study ppgcoedcpepl used oral vaccination newborn piglet pedv assessed immune response protection efficacy ppgcoedcpepl indirect enzymelinked immunosorbent assay elisa showed recombinant lactobacillus vaccine elicits specific systemic mucosal immune response thelper cell mediated ppgcoedcpepl pedv infection display th phenotype histopathological result showed ppgcoedcpepl promotes lymphocyte proliferation effectively protects piglet pedv infection transforming growth factorβ level indicated recombinant lactobacillus vaccine play role antiinflammatory response mesenteric lymph node pedv infection result show ppgcoedcpepl potential vaccine pedv infection,2018-03-01,"Hou, Xingyu; Jiang, Xinpeng; Jiang, Yanping; Tang, Lijie; Xu, Yigang; Qiao, Xinyuan; Liu, Min; Cui, Wen; Ma, Guangpeng; Li, Yijing",Viruses,,,,document_parses/pdf_json/c0b11b19a87de55ec7803cad2e855942ce498d6b.json,document_parses/pmc_json/PMC5869499.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5869499/,,3
3807,3807,4024,upuy8wvc,ec29bbff5e2e2eeb4bdc6651a3fbb49441ab2fa0,PMC,Efficacy and synergy of live-attenuated and inactivated influenza vaccines in young chickens,10.1371/journal.pone.0195285,PMC5889186,29624615.0,cc-by,outbreak novel highly pathogenic avian influenza virus reported poultry specie united state since outbreak proven limitation biosecurity control program new tool needed reinforce current avian influenza control arsenal enzootic country implemented inactivated influenza vaccine iiv control program serious concern longterm use iiv without eradication may result selection novel antigenically divergent strain broadly protective vaccine needed liveattenuated influenza vaccine laiv showed previous study pclaiv variant encodes cterminally truncated n protein provide significant protection heterologous challenge virus chicken vaccinated – week age upregulation innate adaptive immune response current study conducted compare performance pclaiv iiv young chicken vaccinated day age single dose pclaiv able induce stronger innate mucosal iga response protect young immunologically immature chicken better single dose iiv importantly dayold chicken intranasally primed pclaiv subcutaneously boosted iiv three week later showed rapid robust highly crossreactive serum antibody response high level mucosal iga antibody response vaccination regimen warrant optimization increase range protection,2018-04-06,"Jang, Hyesun; Elaish, Mohamed; KC, Mahesh; Abundo, Michael C.; Ghorbani, Amir; Ngunjiri, John M.; Lee, Chang-Won",PLoS One,,,,document_parses/pdf_json/ec29bbff5e2e2eeb4bdc6651a3fbb49441ab2fa0.json,document_parses/pmc_json/PMC5889186.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5889186/,,3
3809,3809,4026,akri8qdk,426eeb6c4a3047760cd5402f4f4771a317026f95,PMC,Assessment of the ability of V920 recombinant vesicular stomatitis-Zaire ebolavirus vaccine to replicate in relevant arthropod cell cultures and vector species,10.1080/21645515.2017.1412898,PMC5893201,29206076.0,cc-by-nc-nd,v rvsvδgzebovgp recombinant vesicular stomatitiszaire ebolavirus vaccine shown acceptable safety profile provides protective immune response ebola virus disease evd induced zaire ebolavirus human purpose study determine whether v vaccine capable replicating arthropod cell culture relevant vector specie replicating live mosquito v vaccine replicated well vero cell replication observed anopheles aedes mosquito culicoides biting midge lutzomyia sand fly cell live culex aedes mosquito following exposure intrathoracic inoculation feeding hightiter infectious blood meal insect taxon selected use study represent actual potential epidemic vector vsv v vaccine inoculated cx quinquefasciatus ae aegypti mosquito demonstrated persistence replicationcompetent virus following inoculation consistent recognized biological stability vaccine evidence active virus replication live mosquito observed following administration infectious blood meal ae aegypti cx quinquefasciatus mosquito titer several log pfu concentrated would observed vaccinated individual infection dissemination v observed either mosquito specie vitro vivo data gathered study support minimal risk vectorborne potential v vaccine,2018-01-03,"Bergren, Nicholas A.; Miller, Megan R.; Monath, Thomas P.; Kading, Rebekah C.",Hum Vaccin Immunother,,,,document_parses/pdf_json/426eeb6c4a3047760cd5402f4f4771a317026f95.json,document_parses/pmc_json/PMC5893201.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5893201/,,3
3851,3851,4070,ynm7x502,89a3e7a6691f7cc1f79dc465fca8968f1a1739f8,PMC,Exploring Leptospiral proteomes to identify potential candidates for vaccine design against Leptospirosis using an immunoinformatics approach,10.1038/s41598-018-25281-3,PMC5932004,29720698.0,cc-by,leptospirosis widespread zoonotic disease estimated cause severe infection one million people year particularly developing country tropical area several factor variable nonspecific clinical manifestation existence large number serovars asymptomatic host spreading infection poor sanitation lack effective vaccine make prophylaxis difficult consequently urgent need develop effective vaccine halt spread world study immunoinformatics approach employed identify vital effective immunogenic protein proteome leptospira interrogans serovar copenhageni strain l may suitable stimulate significant immune response aiding development peptide vaccine leptospirosis bcell tcell helper tlymphocyte htl cytotoxic lymphocyte ctl epitope predicted conserved immunogenic outer membrane lipoprotein binding interaction ctl epitope major histocompatibility complex class mhci evaluated using docking technique molecular dynamic simulation study also performed evaluate stability resulting epitopemhci complex overall study provides novel vaccine candidate may prompt development vaccine leptospirosis,2018-05-02,"Lata, Kumari Snehkant; Kumar, Swapnil; Vaghasia, Vibhisha; Sharma, Priyanka; Bhairappanvar, Shivarudrappa B.; Soni, Subhash; Das, Jayashankar",Sci Rep,,,,document_parses/pdf_json/89a3e7a6691f7cc1f79dc465fca8968f1a1739f8.json,document_parses/pmc_json/PMC5932004.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932004/,,3
3873,3873,4092,1wl7i7ch,bd71b1a62a406002b599f93967b26d84f1d3f8fc,PMC,"Therapeutics and Immunoprophylaxis Against Noroviruses and Rotaviruses: The Past, Present, and Future",10.2174/1389200218666170912161449,PMC5971199,28901254.0,cc-by-nc,background noroviruses rotavirus important viral etiology severe gastroenteritis noroviruses primary cause nonbacterial diarrheal outbreak human whilst rotavirus major cause childhood diarrhea although enteric pathogen substantially impact human health economy approved drug noroviruses rotavirus far hand whilst currently licensed rotavirus vaccine successfully implemented country advanced norovirus vaccine recently completed phasei ii trial method performed structured search bibliographic database peerreviewed research literature advance field norovirus rotavirus therapeutic immunoprophylaxis result technological advance coupled proper understanding viral morphology replication past decade facilitated pioneering research therapeutic immunoprophylaxis noroviruses rotavirus promising outcome human clinical trial drug vaccine review focus various development field norovirus rotavirus therapeutic immunoprophylaxis potential antiviral drug molecule passive immunotherapy oral human immunoglobulin egg yolk bovine colostral antibody llamaderived nanobodies antibody expressed probiotic plant rice grain insect larva immune system modulators probiotic phytochemical biological substance bovine milk protein therapeutic nanoparticles hydrogel viscogens conventional viral vaccine live inactivated whole virus vaccine genetically engineered viral vaccine reassortant viral particle viruslike particle vlps subunit recombinant vaccine including multivalent viral vaccine edible plant vaccine encapsulated viral particle conclusion review provides important insight various approach therapeutic immunoprophylaxis noroviruses rotavirus,2018-03-26,"Ghosh, Souvik; Malik, Yashpal Singh; Kobayashi, Nobumichi",Curr Drug Metab,,,,document_parses/pdf_json/bd71b1a62a406002b599f93967b26d84f1d3f8fc.json,document_parses/pmc_json/PMC5971199.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5971199/,,3
3911,3911,4134,j2edc3sz,53a126d28e3dee03d1bcda8154f4070e26212770,PMC,Chemical Modification of Chitosan for Efficient Vaccine Delivery,10.3390/molecules23020229,PMC6017229,29370100.0,cc-by,chitosan exhibit good biocompatibility safety microbial degradation excellent performance found application walk life field medicine usage chitosan delivery vaccine favored wide range researcher however due natural limitation application constrained beginning study order improve applicability vaccine delivery researcher carried various chemical modification chitosan review summarizes variety modification method application chitosan derivative field vaccine delivery,2018-01-25,"Xing, Lei; Fan, Ya-Tong; Zhou, Tian-Jiao; Gong, Jia-Hui; Cui, Lian-Hua; Cho, Ki-Hyun; Choi, Yun-Jaie; Jiang, Hu-Lin; Cho, Chong-Su",Molecules,,,,document_parses/pdf_json/53a126d28e3dee03d1bcda8154f4070e26212770.json,document_parses/pmc_json/PMC6017229.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6017229/,,3
3925,3925,4148,lyp24gh5,85d80ad717017002446bd0be2d5f369096c31517,PMC,Live Bacterial Vectors—A Promising DNA Vaccine Delivery System,10.3390/medsci6020027,PMC6024733,29570602.0,cc-by,vaccination one successful immunology application considerably improved human health dna vaccine new vaccine developed since early although dna vaccine promising human dna vaccine approved date main problem facing dna vaccine efficacy lack dna vaccine delivery system several study explored limitation one best dna vaccine delivery system us live bacterial vector carrier live bacterial vector induces robust immune response due natural characteristic recognized immune system moreover route administration used live bacterial vector mucosal route beneficially induces mucosal systemic immune response mucosal route invasive making vaccine easy administer increasing patient ’ acceptance lactic acid bacterium one promising bacteria used live bacterial vector however attenuated pathogenic bacteria salmonella spp shigella spp used dna vaccine carrier numerous study showed live bacterial vector promising candidate deliver dna vaccine,2018-03-23,"Yurina, Valentina",Med Sci (Basel),,,,document_parses/pdf_json/85d80ad717017002446bd0be2d5f369096c31517.json,document_parses/pmc_json/PMC6024733.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024733/,,3
3950,3950,4174,gnbpngef,2daa7e4d82eecdff82b6ea2bf5f1986b9a9fa8ef,PMC,An Immunopharmacoinformatics Approach in Development of Vaccine and Drug Candidates for West Nile Virus,10.3389/fchem.2018.00246,PMC6043868,30035107.0,cc-by,outbreak west nile virus wnv like recent ebola epidemic fatal public health throughout world wnv posse utmost threat vaccine drug currently available treatment except mosquito control current study applied combined approach immunoinformatics pharmacoinformatics design potential epitopebased vaccine drug candidate wnv analyzing whole proteome protein wnv envelope glycoprotein selected therapeutic target based highest antigenicity proper assessment “ ksflvhrew ” “ itpsapsyt ” found potential bcell epitope respectively besides designed validated four novel drug known wnv inhibitor ap adopting computational approach toxicity assessment drug score confirmed effectiveness drug candidate silico research might greatly facilitate wet lab experiment develop vaccine drug wnv,2018-07-06,"Hossain, Mohammad Uzzal; Keya, Chaman Ara; Das, Keshob Chandra; Hashem, Abu; Omar, Taimur Md.; Khan, Md. Arif; Rakib-Uz-Zaman, S. M.; Salimullah, Md.",Front Chem,,,,document_parses/pdf_json/2daa7e4d82eecdff82b6ea2bf5f1986b9a9fa8ef.json,document_parses/pmc_json/PMC6043868.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6043868/,,3
3961,3961,4185,8l44fnq6,936e6e20342454e2646bd840d70148c893262146,PMC,Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge,10.1371/journal.pntd.0006628,PMC6062107,30011277.0,cc0,crimeancongo hemorrhagic fever cchf acute often fatal viral disease characterized rapid onset febrile symptom followed hemorrhagic manifestation etiologic agent cchf orthonairovirus cchfv infect several mammal nature seems cause clinical disease human past two decade increase total number cchf case report including imported cchf patient expansion cchf endemic area despite increased public health burden currently licensed vaccine treatment prevent cchf report development assessment protective efficacy adenovirus adbased vaccine expressing nucleocapsid protein n cchfv adn lethal immunocompromised mouse model cchf result show adn protect mouse cchf mortality platform considered future cchfv vaccine strategy,2018-07-16,"Zivcec, Marko; Safronetz, David; Scott, Dana P.; Robertson, Shelly; Feldmann, Heinz",PLoS Negl Trop Dis,,,,document_parses/pdf_json/936e6e20342454e2646bd840d70148c893262146.json,document_parses/pmc_json/PMC6062107.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062107/,,3
3989,3989,4213,o7y3wygc,1579fbff7af9b156c6f49fee0526e48f852ea460,PMC,A Recombinant Newcastle Disease Virus (NDV) Expressing S Protein of Infectious Bronchitis Virus (IBV) Protects Chickens against IBV and NDV,10.1038/s41598-018-30356-2,PMC6086832,30097608.0,cc-by,infectious bronchitis virus ibv cause highly contagious respiratory reproductive urogenital tract disease chicken worldwide resulting substantial economic loss poultry industry currently liveattenuated ibv vaccine used control disease however safety attenuation immunization outcome current vaccine guaranteed several study indicate attenuated ibv vaccine strain contribute emergence variant virus field due mutation recombination therefore need develop stable safe ibv vaccine create variant virus study generated recombinant newcastle disease virus rndvs expressing protein ibv using reverse genetics technology result showed rndv expressing protein ibv provided better protection rndv expressing protein ibv indicating protein best protective antigen ibv immunization weekold spf chicken rndv expressing protein elicited ibvspecific neutralizing antibody provided complete protection virulent ibv virulent ndv challenge result suggest rndv expressing protein ibv safe effective bivalent vaccine candidate ibv ndv,2018-08-10,"Shirvani, Edris; Paldurai, Anandan; Manoharan, Vinoth K.; Varghese, Berin P.; Samal, Siba K.",Sci Rep,,,,document_parses/pdf_json/1579fbff7af9b156c6f49fee0526e48f852ea460.json,document_parses/pmc_json/PMC6086832.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6086832/,,3
3996,3996,4220,bjg20xnk,b39ba8e55292f9b4774c688f21d8271219c3c226,PMC,"Advances in Designing and Developing Vaccines, Drugs, and Therapies to Counter Ebola Virus",10.3389/fimmu.2018.01803,PMC6095993,30147687.0,cc-by,ebola virus ebov member family filoviridae responsible causing ebola virus disease evd formerly named ebola hemorrhagic fever severe often fatal illness mortality rate varying human although virus associated disease recognized since recent outbreak ebov – highlighted danger global impact virus necessitating need coming effective vaccine drug counter pandemic threat albeit commercial vaccine available far ebov vaccine candidate evaluation clinical trial ass prophylactic efficacy include recombinant viral vector recombinant vesicular stomatitis virus vector chimpanzee adenovirus type vector modified vaccinia ankara virus ebola viruslike particle viruslike replicon particle dna plantbased vaccine due improvement field genomics proteomics epitopetargeted vaccine gained top priority correspondingly several therapy also developed including immunoglobulin specific viral structure small cellpenetrating antibody fragment target intracellular ebov protein small interfering rna oligomermediated inhibition also verified evd treatment treatment option include viral entry inhibitor transfusion convalescent bloodserum neutralizing antibody gene expression inhibitor repurposed drug proven safety profile adapted highthroughput screening efficacy potency evd treatment herbal natural product also explored evd treatment study better understand pathogenesis antigenic structure virus help developing effective vaccine identifying appropriate antiviral target review present recent advance designing developing vaccine drug therapy counter ebov threat,2018-08-10,"Dhama, Kuldeep; Karthik, Kumaragurubaran; Khandia, Rekha; Chakraborty, Sandip; Munjal, Ashok; Latheef, Shyma K.; Kumar, Deepak; Ramakrishnan, Muthannan Andavar; Malik, Yashpal Singh; Singh, Rajendra; Malik, Satya Veer Singh; Singh, Raj Kumar; Chaicumpa, Wanpen",Front Immunol,,,,document_parses/pdf_json/b39ba8e55292f9b4774c688f21d8271219c3c226.json,document_parses/pmc_json/PMC6095993.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6095993/,,3
4088,4088,4316,g72rpssy,4ebae5a999522c721177ba353fbd95a72439e060,PMC,Nanoparticle Vaccines Against Infectious Diseases,10.3389/fimmu.2018.02224,PMC6180194,30337923.0,cc-by,due emergence new variant pathogenic microorganism treatment immunization infectious disease become great challenge past year context vaccine development remarkable effort made develop new vaccine also improve efficacy existing vaccine specific disease date vaccine developed protein subunit killed pathogen whilst several vaccine based liveattenuated organism carry risk regaining pathogenicity certain immunocompromised condition avoid development riskfree effective vaccine conjunction adequate delivery system considered imperative need obtain desired humoral cellmediated immunity infectious disease last several year use nanoparticlebased vaccine received great attention improve vaccine efficacy immunization strategy targeted delivery achieve desired immune response cellular level improve vaccine efficacy nanocarriers protect antigen premature proteolytic degradation facilitate antigen uptake processing antigen presenting cell control release safe human use nanocarriers composed lipid protein metal polymer already used attain attribute context several physicochemical property nanoparticles play important role determination vaccine efficacy review article focus application nanocarrierbased vaccine formulation strategy used functionalization nanoparticles accomplish efficient delivery vaccine order induce desired host immunity infectious disease,2018-10-04,"Pati, Rashmirekha; Shevtsov, Maxim; Sonawane, Avinash",Front Immunol,,,,document_parses/pdf_json/4ebae5a999522c721177ba353fbd95a72439e060.json,document_parses/pmc_json/PMC6180194.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180194/,,3
4131,4131,4361,h6vm2nb0,9ae96559416973a6d3bb6ddd5d446bfb4aaf40a0,PMC,The effects of in ovo administration of encapsulated Toll-like receptor 21 ligand as an adjuvant with Marek’s disease vaccine,10.1038/s41598-018-34760-6,PMC6219601,30401976.0,cc-by,marek ’ disease virus mdv causative agent lymphoproliferative disease marek ’ disease md chicken md controlled mass vaccination however immunity induced md vaccine unable prevent mdv replication transmission herpesvirus turkey hvt vaccine one widely used md vaccine poultry industry vaccine adjuvanted tolllike receptor ligand tlrls enhance efficacy study examined whether combining tlrls hvt boost host immunity md improve efficacy result demonstrated hvt alone hvt combined encapsulated cpgodn partially protected chicken tumor incidence reduced virus replication compared control group however encapsulated cpgodn moderately significantly improved hvt efficacy reduced tumor incidence investigation cytokine gene profile spleen bursa fabricius revealed inverse association interleukin il il expression protection conferred different treatment addition result study raise possibility interferon ifnβ ifnγ induced treatment may exert antiviral response mdv replication bursa fabricius early stage mdv infection chicken,2018-11-06,"Bavananthasivam, Jegarubee; Read, Leah; Astill, Jake; Yitbarek, Alexander; Alkie, Tamiru N.; Abdul-Careem, Mohamed Faizal; Wootton, Sarah K.; Behboudi, Shahriar; Sharif, Shayan",Sci Rep,,,,document_parses/pdf_json/9ae96559416973a6d3bb6ddd5d446bfb4aaf40a0.json,document_parses/pmc_json/PMC6219601.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219601/,,3
4132,4132,4362,vjddw6yw,c54a28ed68b1d30d44a3bce4033fa3e74103a33b,PMC,The Fourth International Neonatal and Maternal Immunization Symposium (INMIS 2017): Toward Integrating Maternal and Infant Immunization Programs,10.1128/msphere.00221-18,PMC6222055,30404933.0,cc-by,prevention serious infection pregnant mother newborn young infant immunization pregnancy early life potential reduce maternal neonatal morbidity mortality worldwide past decade research field advanced substantially understanding biology immunology pregnancy early life active development several candidate vaccine challenge opportunity global implementation consideration expert academia industry regulatory funding agency public health international organization met brussels belgium september th international neonatal maternal immunization symposium inmis review relevant advance maternal neonatal immunization overarching focus conference identify path forward achieve integration maternal early life immunization strategy successful implementation vaccine antenatal care pediatric program reduction maternal infant mortality worldwide importance report provides overview proceeding th international maternal neonatal immunization symposium presentation focused stateoftheart research development implementation vaccine given pregnancy protection mother infant,2018-11-07,"Munoz, Flor M.; Van Damme, Pierre; Dinleyici, Ener; Clarke, Ed; Kampmann, Beate; Heath, Paul T.; Levy, Ofer; Leuridan, Elke; Cutland, Clare; Sobanjo-ter Meulen, Ajoke; Marchant, Arnaud",mSphere,,,,document_parses/pdf_json/c54a28ed68b1d30d44a3bce4033fa3e74103a33b.json,document_parses/pmc_json/PMC6222055.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6222055/,,3
4166,4166,4398,76uk9tj5,2a3e6aaf35057f4222ef436b616e9d05106e076e,PMC,Immunogenicity of Pigeon Circovirus Recombinant Capsid Protein in Pigeons,10.3390/v10110596,PMC6265742,30384424.0,cc-by,pigeon circovirus picv frequently diagnosed virus pigeon thought one causative factor complex disease called young pigeon disease syndrome ypds development vaccine virus could strategy ypds control since laboratory culture picv impossible recombinant capsid protein rcp considered potential antigen candidate subunit vaccine aim basic research evaluate immune response pigeon picv rcp sixty sixweekold carrier pigeon divided two group experimental immunized picv rcp mixed adjuvant control immunized adjuvant immunized twice day interval day immunization two day post first immunization dpv sample blood spleen bursa fabricius collected six bird group examine antipicv rcp igy antipicv rcp igysecreting b cell sbc ifnγ gene expression percentage cd cd cd b igm lymphocyte result indicated correct immune response picv rcp humoral cellmediated immunity manifested seroconversion since dpv significantly higher antipicv rcp igysbc number two dpv significantly higher ifnγ gene expression since two dpv significant difference trend noted particular b lymphocyte subpopulation conclude picv rcp may deemed immunogenic could considered antigen candidate subunit vaccine picv infection pigeon,2018-10-31,"Stenzel, Tomasz; Dziewulska, Daria; Tykałowski, Bartłomiej; Śmiałek, Marcin; Kowalczyk, Joanna; Koncicki, Andrzej",Viruses,,,,document_parses/pdf_json/2a3e6aaf35057f4222ef436b616e9d05106e076e.json,document_parses/pmc_json/PMC6265742.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6265742/,,3
4187,4187,4419,zhjp3bd2,e08398305bb975e1eeb01ab0f93335347005297f,PMC,DNA Vaccines—How Far From Clinical Use?,10.3390/ijms19113605,PMC6274812,30445702.0,cc-by,two decade ago successful transfection antigen presenting cell apc vivo demonstrated resulted induction primary adaptive immune response due good biocompatibility plasmid dna costefficient production long shelf life many researcher aimed develop dna vaccinebased immunotherapeutic strategy treatment infection cancer also autoimmune disease allergy review aim summarize current knowledge course action dna vaccine factor responsible poor immunogenicity human far important optimization step improve dna transfection efficiency comprise introduction dnacomplexing nanocarriers aimed prevent extracellular dna degradation enabling apc targeting enhanced endolysosomal escape dna attachment virusderived nuclear localization sequence facilitates nuclear entry dna improvement dna vaccine design include use apcspecific promotors transcriptional targeting arrangement multiple antigen sequence codelivery molecular adjuvant prevent tolerance induction strategy circumvent potential inhibitory effect vector backbone successful clinical use dna vaccine may require combined employment parameter combination treatment additional drug,2018-11-15,"Hobernik, Dominika; Bros, Matthias",Int J Mol Sci,,,,document_parses/pdf_json/e08398305bb975e1eeb01ab0f93335347005297f.json,document_parses/pmc_json/PMC6274812.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6274812/,,3
4203,4203,4437,f8f2utzx,d7101f63979fbbfbce1f7b9b1e6bd51f50adfd02,PMC,A Functionally Different Immune Phenotype in Cattle Is Associated With Higher Mastitis Incidence,10.3389/fimmu.2018.02884,PMC6291514,30574152.0,cc-by,novel vaccine bovine viral diarrhea bvd induced pathogenic antibody production – bvdvaccinated cow transfer antibody via colostrum caused bovine neonatal pancytopenia bnp calf lethality rate exact immunological mechanism behind onset bnp fully understood date gain insight mechanism analyzed immune proteome alloreactive antibody producer bnp cow nonresponders vitro stimulation peripheral blood derived lymphocyte pbl detected distinctly deviant expression level several master regulator immune response bnp cell pointing changed immune phenotype severe dysregulation immune response bnp cow interestingly also found response pattern nonbvdvaccinated cow indicating genetic predisposition immune deviant id phenotype cattle additionally analyzed functional correlation id phenotype health parameter disease retrospective study month significantly increased prevalence mastitis among id cow emphasizes clinical relevance deviant immune response potential impact ability fight infection,2018-12-06,"Lutterberg, Karina; Kleinwort, Kristina J. H.; Hobmaier, Bernhard F.; Hauck, Stefanie M.; Nüske, Stefan; Scholz, Armin M.; Deeg, Cornelia A.",Front Immunol,,,,document_parses/pdf_json/d7101f63979fbbfbce1f7b9b1e6bd51f50adfd02.json,document_parses/pmc_json/PMC6291514.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291514/,,3
4225,4225,4461,1jzqzc7r,8b3f1411a204bf1cd829342b87e5fa88bb9f12ed,PMC,"Mandatory meningococcal vaccine, and other recommended immunisations: Uptake, barriers, and facilitators among health care workers and trainees at Hajj",10.12998/wjcc.v6.i16.1128,PMC6306626,30613671.0,cc-by-nc,aim evaluate uptake mandatory meningococcal highly recommended influenza optional pneumococcal vaccine explore key factor affecting vaccination rate among health care worker hcws hajj method anonymous crosssectional online survey distributed among hcws trainee worked volunteered hajj line manager visiting hospital healthcare centre makkah mina overseas hcws accompanied pilgrim work foreign hajj medical mission excluded pearson ’ χ test used compare categorical variable odds ratio calculated “ risk estimate ” statistic along confidence interval ci result total respondent aged median year male female ratio participated survey participant reported receiving three vaccine receive vaccine received meningococcal influenza pneumococcal vaccine female likely receive vaccine male ci p willingness follow health authority ’ recommendation main reason receipt vaccine believing uptodate vaccination prime reason nonreceipt conclusion hcws hajj miss compulsory highly recommended vaccine lack awareness key barrier authority ’ advice important motivator health education followed stringent measure may required improve vaccination rate,2018-12-26,"Badahdah, Al-Mamoon; Alfelali, Mohammad; Alqahtani, Amani S; Alsharif, Saeed; Barasheed, Osamah; Rashid, Harunor",World J Clin Cases,,,,document_parses/pdf_json/8b3f1411a204bf1cd829342b87e5fa88bb9f12ed.json,document_parses/pmc_json/PMC6306626.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6306626/,,3
4237,4237,4473,ypefqm71,88b18a2771249ead085fdebfab0aea7839176e05,PMC,Assay Challenges for Emerging Infectious Diseases: The Zika Experience,10.3390/vaccines6040070,PMC6313918,30279372.0,cc-by,perspective vaccine development imperative accurately diagnose target infection order exclude subject prior exposure evaluation vaccine effectiveness track incident infection course clinical trial differentiate immune reaction due natural infection response vaccine related vaccine development accelerated rapid pace response emerging infectious disease threat challenge develop diagnostic tool even greater observed recent expansion zika virus infection western hemisphere – initial zika vaccine clinical trial designed launched response outbreak standardized set viral immunological assay approved diagnostic test zika virus infection diagnosis zika virus infection still area active research development many front review emerging infectious disease vaccine clinical assay development trial execution special focus state zika virus clinical assay diagnostics,2018-10-02,"Roberts, Christine C.; Maslow, Joel N.",Vaccines (Basel),,,,document_parses/pdf_json/88b18a2771249ead085fdebfab0aea7839176e05.json,document_parses/pmc_json/PMC6313918.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313918/,,3
4239,4239,4475,es1xllm0,b28a8c489742fd2227e6e4049d777febfd4051cc,PMC,Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8(+) T Cell Responses,10.3389/fimmu.2018.02968,PMC6315164,30631324.0,cc-by,gynecological cancer leading cause mortality woman cd cell immunity largely correlate enhanced survival whereas inflammation associated poor prognosis previous study shown polystyrene nanoparticles psnps biocompatible induce inflammation used vaccine carrier model peptide induce cd cell response herein test immunogenicity different peptide three leading vaccine target protein gynecological cancer e protein human papilloma virus hpv wilms tumor antigen wt survivin sv psnp conjugate vaccine relevance vaccine development finding minimal cd cell peptide epitope hpv able induce hlaa specific cd cell response transgenic humanized mouse using conventional adjuvant cpg nevertheless able generate strong immunity delivered part specific longer peptide conjugated psnps vaccine conversely case minimal cd cell epitope able induce immune response wt sv super agonist cpg also induced response conjugated psnps case extending sequence around cd cell epitope using natural protein context engineering linker sequence proposed enhance antigen processing minimal effect enhancing changing crossreactivity pattern induced super agonist nanoparticle approach psnps therefore may offer alternative vaccination strategy conventional adjuvant unable elicit desired cd cell specificity finding herein also offer sequence specific insight peptide vaccine design nanoparticlebased vaccine carrier,2018-12-21,"Xiang, Sue D.; Wilson, Kirsty L.; Goubier, Anne; Heyerick, Arne; Plebanski, Magdalena",Front Immunol,,,,document_parses/pdf_json/b28a8c489742fd2227e6e4049d777febfd4051cc.json,document_parses/pmc_json/PMC6315164.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6315164/,,3
4324,4324,4563,rodqdtfj,856b6b5e0e5baedd6eef6801c3f59305438c47eb,PMC,Key Gaps in the Knowledge of the Porcine Respiratory Reproductive Syndrome Virus (PRRSV),10.3389/fvets.2019.00038,PMC6391865,30842948.0,cc-by,porcine reproductive respiratory syndrome virus prrsv one important swine disease world causing enormous economic burden due reproductive failure sow complex respiratory syndrome pig age mortality varying extreme case emergent highly pathogenic strain prrsv display complex interaction immune system high mutation rate making development implementation control strategy major challenge review biology virus addressed focusing newly discovered function nonstructural protein novel dissemination mechanism secondly role different cell type viral protein reviewed natural vaccineinduced immune response together role different immune evasion mechanism focusing gap knowledge critical generate efficacious vaccine finally novel strategy antigen discovery vaccine development discussed particular use exosomes extracellular vesicle endocytic origin nanocarriers lipid protein nucleic acid exosomes potential effect cell activation modulation immune response antigen presentation thus representing novel vaccination approach devastating disease,2019-02-20,"Montaner-Tarbes, Sergio; del Portillo, Hernando A.; Montoya, María; Fraile, Lorenzo",Front Vet Sci,,,,document_parses/pdf_json/856b6b5e0e5baedd6eef6801c3f59305438c47eb.json,document_parses/pmc_json/PMC6391865.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391865/,,3
4377,4377,4618,yoog0kft,b1cb9713cb3f669a5f4b63e04395fb4669312d5b,PMC,A DNA Vaccine Encoding the VAA Gene of Vibrio anguillarum Induces a Protective Immune Response in Flounder,10.3389/fimmu.2019.00499,PMC6435001,30941134.0,cc-by,vibrio anguillarum pathogenic bacterium infects flounder resulting significant loss aquaculture industry vaa protein previously identified flounder associated role immune protection within fish present study recombinant dna plasmid encoding vaa gene v anguillarum constructed potential dna vaccine prevent infection v anguillarum flounder fish investigated verified expression vaa protein vitro cell line vivo flounder fish protective effect pcdnavaa pvaa analyzed determination percentage sigm cd cd cdβ lymphocyte production vaaspecific antibody flounder following immunization dna vaccine histopathological change immune related tissue bacterial load relative percentage survival rate flounder postchallenge v anguillarum investigated ass efficacy pvaa dna vaccine candidate fish intramuscularly immunized pvaa showed significant increase cd cd cdβ lymphocyte day postvaccination reaching peak tcell level day postimmunization percentage sigm lymphocyte reached peak level week – postimmunization specific antiv anguillarum antirvaa antibody induced inoculated fish day – postimmunization liver vaccinated flounder exhibited slight histopathological change compared significant pathology observed control immunized fish additionally lower bacterial burden liver spleen kidney observed pvaa protected fish response bacterial challenge compared pcdna vector control injected fish moreover pvaa vaccine confers relative percentage survival following v anguillarum infection summary first study indicating initial induction lymphocyte response followed b lymphocyte induction specific antibody result dna immunization flounder signifies important potential pvaa dna vaccine candidate control v anguillarum infection,2019-03-19,"Xing, Jing; Xu, Hongsen; Tang, Xiaoqian; Sheng, Xiuzhen; Zhan, Wenbin",Front Immunol,,,,document_parses/pdf_json/b1cb9713cb3f669a5f4b63e04395fb4669312d5b.json,document_parses/pmc_json/PMC6435001.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6435001/,,3
4396,4396,4639,ekxq4l9a,766f315970750baecd98b7fcc1a0ba8d7368d1cc,PMC,Protection against homo and hetero-subtypic inﬂuenza A virus by optimized M2e DNA vaccine,10.1080/22221751.2018.1558962,PMC6455129,30866759.0,cc-by,current influenza vaccine provide hemagglutinin strainspecific protection rarely provide crossprotection divergent strain therefore particularly important develop universal vaccine conserved protein conserved region virus study used nterminal extracellular region influenza virus protein target antigen constructed two optimized dna vaccine ptpapme ppme increased antigenic epitope density enhanced antigen secretion vaccine induced high mespecific humoral cellular immune response vaccinated mouse two vaccine also conferred protection lethal infection homosubtypic hn virus ptpapme effective addition ptpapme also showed crossprotection different subtypes influenza virus hn hn hn varying rate respectively passive immunization dna vaccineinduced antibody serum provided complete protection homologous virus challenge analysis mechanism underlying immunizationmediated protection indicates mespecific igg tcell immune response may play critical role prevention infection viral clearance taken together result indicate optimized dna vaccine promising candidate development universal broadspectrum influenza virus vaccine,2019-01-16,"Yao, Yanfeng; Wang, Huadong; Chen, Jianjun; Shao, Zhiyong; He, Bin; Chen, Jie; Lan, Jiaming; Chen, Quanjiao; Chen, Ze",Emerg Microbes Infect,,,,document_parses/pdf_json/766f315970750baecd98b7fcc1a0ba8d7368d1cc.json,document_parses/pmc_json/PMC6455129.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6455129/,,3
4404,4404,4647,ovoli9dr,02753048c4dc699d155288935b9dc6517a79f279,PMC,Rabies-based vaccine induces potent immune responses against Nipah virus,10.1038/s41541-019-0109-5,PMC6465360,31016033.0,cc-by,nipah virus niv reemerging zoonotic pathogen genus henipavirus paramyxoviridae family virus niv endemic bangladesh malaysia highly fatal livestock human human case fatality rate currently approved vaccine niv market goal study use recombinant rabv vector expressing niv glycoprotein niv g develop bivalent candidate vaccine niv disease rabies virus rabv disease also significant health burden region niv endemic rabies vector wellestablished vaccine strain lack neurovirulence stably express foreign antigen immunogenic various animal model mouse inoculated intranasally live recombinant rabvniv vaccine niparab showed sign disease test immunogenicity vaccine candidate group cbl mouse immunized intramuscularly single dose live vaccine particle two dos chemically inactivated viral particle vaccination group showed niv gspecific seroconversion inactivated inac vaccine group yielded higher titer niv gspecific antibody furthermore crossreactivity niv gspecific immune serum hendra virus hev confirmed immunofluorescence indirect elisa soluble recombinant hev glycoprotein hev g live killed vaccine induced neutralizing antibody result indicate niparab may used killed virus vaccine protect human niv rabv possibly preventative measure hev well,2019-04-15,"Keshwara, Rohan; Shiels, Thomas; Postnikova, Elena; Kurup, Drishya; Wirblich, Christoph; Johnson, Reed F.; Schnell, Matthias J.",NPJ Vaccines,,,,document_parses/pdf_json/02753048c4dc699d155288935b9dc6517a79f279.json,document_parses/pmc_json/PMC6465360.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465360/,,3
4469,4469,4716,kjkuet78,40bf10143cbee94371fb682e9bf1dbfe05884433,PMC,Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus,10.3390/v11040322,PMC6521086,30987160.0,cc-by,chikungunya virus chikv caused extensive outbreak several country within america asia oceanicpacific island europe human chikv infection cause debilitating disease acute febrile illness longterm polyarthralgia acute chronic symptom impose major economic burden health system contribute poverty affected country efficacious vaccine would important step towards decreasing disease burden caused chikv infection despite licensed vaccine yet available chikv strong evidence effective asymptomatic viral clearance due neutralising antibody viral structural protein designed viralvectored vaccine express structural protein chikv using replicationdeficient chimpanzee adenoviral platform chadox expression chikv antigen result formation chikungunya viruslike particle vaccine induce high frequency antichikungunya specific tcell response well high titre antichikv e antibody high capacity vitro neutralisation result indicate potential clinical development chadox vaccine platform chikv vaccinology,2019-04-03,"López-Camacho, César; Chan Kim, Young; Blight, Joshua; Lazaro Moreli, Marcos; Montoya-Diaz, Eduardo; T Huiskonen, Juha; Mareike Kümmerer, Beate; Reyes-Sandoval, Arturo",Viruses,,,,document_parses/pdf_json/40bf10143cbee94371fb682e9bf1dbfe05884433.json,document_parses/pmc_json/PMC6521086.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6521086/,,3
4478,4478,4725,g6hs3ud5,e09ca57e55d73869520543f456019ee081d88a00,PMC,Vaccination With a Single Consensus Envelope Protein Ectodomain Sequence Administered in a Heterologous Regimen Induces Tetravalent Immune Responses and Protection Against Dengue Viruses in Mice,10.3389/fmicb.2019.01113,PMC6524413,31134046.0,cc-by,development safe effective tetravalent dengue vaccine elicits protection dengue virus denv serotypes urgently needed consensus sequence ectodomain envelope e protein denv ce examined immunogen previously current study ce dna vaccine constructed evaluated conjunction ce protein p vaccine examine whether vaccine used together improve immune response ce dna vaccine administrated using either homologous dna alone ddd heterologous dna primeprotein boost ddp dpp regimen evaluated immunogenicity protective efficacy mouse among three dnabased immunization regimen tested ddp immunization optimal immunization regimen elicited greatest systemic immune response conferred protection four denv serotypes work provides innovative idea development consensus ebased dengue vaccine testing optimal immunization regimen,2019-05-10,"Wang, Ran; Zheng, Xiaoyan; Sun, Jin; Feng, Kaihao; Gao, Na; Fan, Dongying; Chen, Hui; Jin, Xia; An, Jing",Front Microbiol,,,,document_parses/pdf_json/e09ca57e55d73869520543f456019ee081d88a00.json,document_parses/pmc_json/PMC6524413.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6524413/,,3
4480,4480,4727,7mzsaz7a,62e4e3bb07c0d49b928f9cfb46d2efedc04991dd,PMC,DNA Vaccines Against Mycoplasma Elicit Humoral Immune Responses in Ostriches,10.3389/fimmu.2019.01061,PMC6527592,31139188.0,cc-by,ostrich population density resulting intensive rearing increase susceptibility pathogen mycoplasma addition good management practice vaccination offer attractive alternative controlling mycoplasma infection food animal instead using antibiotic often leave unacceptable residue use live attenuated vaccine however carry concern reversion virulence genetic recombination field strain currently commercially available vaccine ostrichinfecting mycoplasma study therefore set develop evaluate use dna vaccine mycoplasma infection ostrich using oppa protein antigen end oppa gene “ mycoplasma nasistruthionis sp nov ” str m cloned two dna vaccine expression vector codon correction sitedirected mutagenesis threemonthsold ostrich vaccinated intramuscularly different dos followed booster vaccination week ability dna vaccine elicit antioppa antibody response evaluated elisa using recombinant oppa protein m coating antigen statistically significant antioppa antibody response could detected administration booster vaccination indicating oppa protein successfully immunogenic response also dose vector dependent conclusion dna vaccine able elicit immune response ostrich therefore viewed option development vaccine mycoplasma infection,2019-05-14,"Wium, Martha; Jonker, Hester Isabella; Olivier, Adriaan Jacobus; Bellstedt, Dirk Uwe; Botes, Annelise",Front Immunol,,,,document_parses/pdf_json/62e4e3bb07c0d49b928f9cfb46d2efedc04991dd.json,document_parses/pmc_json/PMC6527592.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6527592/,,3
4492,4492,4739,u1xa44nw,d8e134d93a4666285518b7916316a97dcc258788,PMC,Vesicular Stomatitis Virus-Based Vaccine Protects Mice against Crimean-Congo Hemorrhagic Fever,10.1038/s41598-019-44210-6,PMC6533279,31123310.0,cc-by,crimeancongo hemorrhagic fever virus cchfv tickborne bunyavirus cause lifethreatening hemorrhagic syndrome human animal host virus widely distributed throughout southeastern europe middle east africa asia disease management proven difficult broadly licensed vaccine therapeutic recombinant vesicular stomatitis virus rvsv expressing foreign glycoprotein gp shown promise experimental vaccine several viral hemorrhagic fever developed assessed replication competent rvsv vector expressing cchfv glycoprotein precursor gpc encodes cchfv structural glycoprotein construct drive strong expression cchfvgp vitro using vector vaccinated stat knockout mouse animal model cchfv vector tolerated efficacious challenge clinical strain cchfv anticchfvgp igg neutralizing antibody titer observed surviving animal study demonstrates rvsv expressing cchfvgp potential serve replication competent vaccine platform cchf infection,2019-05-23,"Rodriguez, Sergio E.; Cross, Robert W.; Fenton, Karla A.; Bente, Dennis A.; Mire, Chad E.; Geisbert, Thomas W.",Sci Rep,,,,document_parses/pdf_json/d8e134d93a4666285518b7916316a97dcc258788.json,document_parses/pmc_json/PMC6533279.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533279/,,3
4546,4546,4794,jvxv7y1b,92663b93c60bb3ddfa270dc105dbf28ec853eae5,PMC,Protective effects of the Francisella tularensis ΔpdpC mutant against its virulent parental strain SCHU P9 in Cynomolgus macaques,10.1038/s41598-019-45412-8,PMC6591246,31235714.0,cc-by,tularemia severe infectious zoonotic disease caused francisella tularensis although f tularensis considered potential biological weapon due high infectivity mortality rate vaccine currently licensed recently reported f tularensis schu p derived δpdpc strain lacking pathogenicity determinant protein c gene conferred stable good protection mouse lethal model study protective effect δpdpc evaluated using monkey lethal model two cynomolgus macaque macaca fascicularis intratracheally challenged virulent strain schu p euthanized day postchallenge development severe clinical sign bacterial replication alveolar macrophage type ii epithelial cell lung would cause severe pneumonia accompanied necrosis conversely two animal subcutaneously immunized δpdpc survived week schu p challenge though one two animal developed mild symptom tularemia bacterial replication limited respiratory organ may due high level humoral cellular immune response f tularensis result suggest δpdpc mutant would safe promising candidate live attenuated tularemia vaccine,2019-06-24,"Tian, Deyu; Uda, Akihiko; Ami, Yasushi; Hotta, Akitoyo; Park, Eun-sil; Nagata, Noriyo; Iwata-Yoshikawa, Naoko; Yamada, Akio; Hirayama, Kazuhiro; Miura, Kozue; Koyama, Yuki; Azaki, Mika; Morikawa, Shigeru",Sci Rep,,,,document_parses/pdf_json/92663b93c60bb3ddfa270dc105dbf28ec853eae5.json,document_parses/pmc_json/PMC6591246.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6591246/,,3
4585,4585,4836,dgeisr8h,7531c4305658b8cf4fa576ae050d7162043fe535,PMC,Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine,10.3390/vaccines7020040,PMC6630572,31096710.0,cc-by,adenovirus vectored vaccine highly effective strategy induce cellular immune response particularly effective intracellular pathogen recombinant simian adenovirus vector developed circumvent limitation imposed use human adenovirus due widespread seroprevalence neutralising antibody constructed replication deficient simian adenovirusvectored vaccine chadox expressing gene mycobacterium avium subspecies paratuberculosis ahpc gsd p mpa safety tcell immunogenicity result first clinical use chadox vector presented trial conducted using ‘ threeplusthree ’ dose escalation study design demonstrate vaccine safe well tolerated immunogenic,2019-05-15,"Folegatti, Pedro M.; Bellamy, Duncan; Roberts, Rachel; Powlson, Jonathan; Edwards, Nick J.; Mair, Catherine F.; Bowyer, Georgina; Poulton, Ian; Mitton, Celia H.; Green, Nicky; Berrie, Eleanor; Lawrie, Alison M.; Hill, Adrian V.S.; Ewer, Katie J.; Hermon-Taylor, John; Gilbert, Sarah C.",Vaccines (Basel),,,,document_parses/pdf_json/7531c4305658b8cf4fa576ae050d7162043fe535.json,document_parses/pmc_json/PMC6630572.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630572/,,3
4587,4587,4838,141u6ax7,2cbcfb658251f2d2873e1ec118deea4167283c0a,PMC,Cytolytic Perforin as an Adjuvant to Enhance the Immunogenicity of DNA Vaccines,10.3390/vaccines7020038,PMC6630607,31052178.0,cc-by,dna vaccine present one costeffective platform develop global vaccine tested nearly three decade preclinical clinical setting success clinic however one major challenge development dna vaccine poor immunogenicity human led refinement dna delivery dosage primeboost regimen inclusion adjuvant enhance immunogenicity review focus adjuvant enhance immunogenicity dna encoded antigen highlight development novel cytolytic dna platform encoding truncated mouse perforin application innovative dna technology considerable potential development effective vaccine,2019-04-30,"Shrestha, Ashish C.; Wijesundara, Danushka K.; Masavuli, Makutiro G.; Mekonnen, Zelalem A.; Gowans, Eric J.; Grubor-Bauk, Branka",Vaccines (Basel),,,,document_parses/pdf_json/2cbcfb658251f2d2873e1ec118deea4167283c0a.json,document_parses/pmc_json/PMC6630607.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630607/,,3
4589,4589,4840,pp8kmpz7,75af9aa0e63889abde2eedaf0e41738b8ab082df,PMC,Current and Novel Approaches in Influenza Management,10.3390/vaccines7020053,PMC6630949,31216759.0,cc-by,influenza disease pose significant health burden worldwide vaccination best way prevent influenza virus infection however conventional vaccine effective short period time due propensity influenza virus undergo antigenic drift antigenic shift efficacy vaccine uncertain yeartoyear due potential mismatch circulating virus vaccine strain mutation arising due egg adaptation subsequently inability store vaccine longterm vaccine shortage challenge need overcome conventional vaccine also variable efficacy certain population including young old immunocompromised warrant diverse efficacious vaccine developmental approach involving active passive immunization opposed active immunization platform requiring use whole portion pathogen vaccine rapidly developing passive immunization involves administration either pathogenspecific broadly acting antibody kind class pathogen treatment corresponding acute infection several antibody broadly acting capacity discovered may serve mean suppress influenza viral infection allow process natural immunity engage opsonized pathogen whilst boosting immune system antibodydependent mechanism bridge innate adaptive arm passive immunotherapeutics approach assumes robust tool could aid control influenza virus review comment improvement influenza management promising vaccine development platform emphasis protective capacity passive immunotherapeutics especially coupled use antiviral management influenza infection,2019-06-18,"Kotey, Erasmus; Lukosaityte, Deimante; Quaye, Osbourne; Ampofo, William; Awandare, Gordon; Iqbal, Munir",Vaccines (Basel),,,,document_parses/pdf_json/75af9aa0e63889abde2eedaf0e41738b8ab082df.json,document_parses/pmc_json/PMC6630949.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630949/,,3
4591,4591,4842,61cl4k8k,9ee05def9e9c177e9c22bf4ef9bfcca045572916,PMC,Computational Approaches and Challenges to Developing Universal Influenza Vaccines,10.3390/vaccines7020045,PMC6631137,31141933.0,cc-by,traditional design effective vaccine rapidlyevolving pathogen influenza virus failed provide broad spectrum longlasting protection low cost whole genome sequencing technology powerful computing capability novel computational approach demonstrated potential facilitate design universal influenza vaccine however study integrated computational optimization design discovery new vaccine understanding potential computational vaccine design necessary approach implemented broad scale review summarizes promising computational approach current development including computationally optimized broadly reactive antigen consensus sequence phylogenetic modelbased ancestral sequence reconstruction immunomics compute conserved crossreactive tcell epitope interaction virushostenvironment determine evolvability influenza population propose development novel technology allow integration data source protein structural modeling host antibody repertoire analysis advanced phylodynamic modeling computational approach crucial development longlasting universal influenza vaccine taken together computational approach powerful promising tool development universal influenza vaccine durable broad protection,2019-05-28,"Qiu, Xueting; Duvvuri, Venkata R.; Bahl, Justin",Vaccines (Basel),,,,document_parses/pdf_json/9ee05def9e9c177e9c22bf4ef9bfcca045572916.json,document_parses/pmc_json/PMC6631137.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631137/,,3
4593,4593,4844,0fx1b7ph,a16aeee3d8878ab6dd536c418742d58b946b4699,PMC,A Comparison of Plasmid DNA and mRNA as Vaccine Technologies,10.3390/vaccines7020037,PMC6631684,31022829.0,cc-by,review provides comparison theoretical issue experimental finding plasmid dna mrna vaccine technology development since recent year significant excitement turned mrna despite licensure several veterinary dna vaccine required effort increase potency either via manipulating plasmid dna mrna directly addition adjuvant immunomodulators well delivery system formulation greater inherent inflammatory nature mrna vaccine discussed potential immunological utility vaccine potential toxicity status clinical trial mrna vaccine described along comparison dna vaccine specifically immunogenicity licensed veterinary dna vaccine select dna vaccine candidate human clinical trial,2019-04-24,"Liu, Margaret A.",Vaccines (Basel),,,,document_parses/pdf_json/a16aeee3d8878ab6dd536c418742d58b946b4699.json,document_parses/pmc_json/PMC6631684.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631684/,,3
4599,4599,4850,6fisbx49,c04c85e7d1935bf71b5ccca3b9cb3fe3b68131d6,PMC,Novel Synthetic DNA Immunogens Targeting Latent Expressed Antigens of Epstein–Barr Virus Elicit Potent Cellular Responses and Inhibit Tumor Growth,10.3390/vaccines7020044,PMC6631996,31137606.0,cc-by,infectious disease linked – cancer worldwide among epstein–barr virus ebv oncogenic herpesvirus chronically infects adult population case cancer cancerrelated death attributed yearly acute ebv infection present infectious mononucleosis lead future onset multiple cancer including burkitt lymphoma hodgkin lymphoma nasopharyngeal carcinoma gastric carcinoma many cancer express latent viral gene including epstein–barr virus nuclear antigen ebna latent membrane protein lmp lmp previous attempt create potent immunogen ebv reported generated mixed success designed novel synthetic consensus syncon dna vaccine ebna lmp lmp improve immune potency targeting important antigen expressed latently infected cell ebv tumor antigen hypothesized useful target potential immunotherapy ebvdriven cancer optimized genetic sequence three antigen studied expression examined immune profile vivo observed immunogen generated unique profile based antigen delivered vaccine target ebnavax lmpavax generated robust cell immunity interestingly lmpvax weak immunogen generating low level cd cell immunity standalone vaccine part trivalent vaccine cocktail lmpavax able drive immunity impacted ebvantigenpositive tumor growth study suggest engineered ebv latent protein vaccine deserve additional study potential agent immunotherapy ebvdriven cancer,2019-05-24,"Wojtak, Krzysztof; Perales-Puchalt, Alfredo; Weiner, David B.",Vaccines (Basel),,,,document_parses/pdf_json/c04c85e7d1935bf71b5ccca3b9cb3fe3b68131d6.json,document_parses/pmc_json/PMC6631996.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631996/,,3
4624,4624,4875,rbjps3oe,79641a9857d5320c10a6619c351f113b1940ce6f,PMC,"Molecular detection and genetic characterization of Mycoplasma gallisepticum, Mycoplama synoviae, and infectious bronchitis virus in poultry in Myanmar",10.1186/s12917-019-2018-2,PMC6659308,31345206.0,cc-by,background southeast asian country including myanmar poultry farming major industry order manage maintain stable productivity important establish policy biosecurity infectious respiratory disease major threat poultry farming avian influenza newcastle disease reported myanmar scientific information available respiratory pathogen mycoplasma infectious bronchitis virus ibv identifying genotype serotypes ibvs especially important inform vaccination program study detected mycoplasma gallisepticum mg synoviae m ibv several poultry farm myanmar result sample collected farm three major poultry farming area myanmar mg m ibv detected two four eight farm respectively polymerase chain reaction phylogenetic analysis revealed observed mg m isolates identical vaccine strain three different genotype ibv detected none unknown variant conclusion mycoplasma ibv detected poultry farm myanmar periodic surveillance required establish distribution pathogen institute better vaccine protocol,2019-07-25,"Fujisawa, Sotaro; Murata, Shiro; Takehara, Masaki; Katakura, Ken; Hmoon, Myint Myint; Win, Shwe Yee; Ohashi, Kazuhiko",BMC Vet Res,,,,document_parses/pdf_json/79641a9857d5320c10a6619c351f113b1940ce6f.json,document_parses/pmc_json/PMC6659308.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6659308/,,3
4630,4630,4881,ctass7hz,c1aff1d1cda60a3215266ed6d56288d5b3630c50,PMC,Recombinant vector vaccine evolution,10.1371/journal.pcbi.1006857,PMC6668849,31323032.0,cc-by,replicating recombinant vector vaccine consist fully competent viral vector backbone engineered express antigen foreign transgene perspective viral replication transgene dispensable may even detrimental thus vaccine revertants delete inactivate transgene may evolve dominate vaccine virus population process manufacture vaccine well course host infection particular concern vaccine evolution could reduce antigenicity—the immunity elicited transgene use mathematical computational model study vaccine evolution immunity model include evolution arising process manufacture dynamic vaccine revertant growth plus innate adaptive immunity elicited course infection although selective basis vaccine evolution easy comprehend immunological consequence one complication opportunity vaccine evolution limited short period withinhost growth viral population cleared even le obvious revertant growth may weakly interfere vaccine growth host thus limited effect immunity vaccine overall find withinhost vaccine evolution sometimes compromise vaccine immunity extent evolution vaccine manufacture severe evolution easily avoided mitigated,2019-07-19,"Bull, James J.; Nuismer, Scott L.; Antia, Rustom",PLoS Comput Biol,,,,document_parses/pdf_json/c1aff1d1cda60a3215266ed6d56288d5b3630c50.json,document_parses/pmc_json/PMC6668849.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6668849/,,3
4653,4653,4904,bhfghcby,ac03f138574464ac7c9bfbeee803ebcf3db5e26c,PMC,Vaccination in Multiple Sclerosis: Friend or Foe?,10.3389/fimmu.2019.01883,PMC6693409,31440255.0,cc-by,multiple sclerosis m debilitating disease central nervous system cns diseasemodifying treatment including immunosuppressive treatment shown positive effect disease course associated systemic consequence immune system may increase risk infection alter vaccine efficiency therefore vaccination m patient major interest last year vaccine hesitancy steadily grown especially western country partly due fear sequela arising vaccination especially neurological disorder interaction vaccination m discussed decade review highlight immunology vaccination provide review literature discus clinical consideration m vaccination immunosuppression conclusion consensus m caused vaccine neither inactivated live vaccine however particular attention paid two aspect first immunocompromised patient live vaccine may lead stronger immune reaction sign disease patient vaccinated albeit weakened form second protection provided vaccination controlled patient vaccinated receiving immunomodulatory immunosuppressive treatment conclusion evidence systemic infection worsen m thus vaccination lower risk relapse reducing risk infection therefore vaccination general recommended m patient,2019-08-07,"Zrzavy, Tobias; Kollaritsch, Herwig; Rommer, Paulus S.; Boxberger, Nina; Loebermann, Micha; Wimmer, Isabella; Winkelmann, Alexander; Zettl, Uwe K.",Front Immunol,,,,document_parses/pdf_json/ac03f138574464ac7c9bfbeee803ebcf3db5e26c.json,document_parses/pmc_json/PMC6693409.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6693409/,,3
4660,4660,4912,d4rq1du1,7a920d6b53c292f53323cb6c5109732a9575e33c,PMC,Epitope-based vaccine as a universal vaccination strategy against Toxoplasma gondii infection: A mini-review,10.5455/javar.2019.f329,PMC6702889,31453188.0,cc-by-nc,despite significant progress recent effort toward developing effective vaccine toxoplasmosis search new protective vaccination strategy still remains challenge elusive goal becomes appropriate way prevent disease various experimental approach past year showed developing potential vaccine disease achievable combination multiepitopes expressing different stage parasite life cycle become optimal strategy acquiring potent safe effective vaccine epitopebased vaccine gained attention alternative vaccine candidate due ability inducing protective immune response minireview highlight current status prospect toxoplasma gondii vaccine development along application epitopebased vaccine future parasite immunization novel development evaluation strategy,2019-03-24,"Hajissa, Khalid; Zakaria, Robaiza; Suppian, Rapeah; Mohamed, Zeehaida",J Adv Vet Anim Res,,,,document_parses/pdf_json/7a920d6b53c292f53323cb6c5109732a9575e33c.json,document_parses/pmc_json/PMC6702889.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6702889/,,3
4668,4668,4920,zs8urh6c,bafab6b3dd88dcdefe111698d02f81998c9accdb,PMC,Evolution and containment of transmissible recombinant vector vaccines,10.1111/eva.12806,PMC6708430,31462917.0,cc-by,transmissible vaccine offer revolutionary approach controlling infectious disease may provide one feasible method eliminating pathogen inaccessible wildlife population current effort develop transmissible vaccine use recombinant vector technology whereby pathogen antigen engineered expressed innocuous infectious viral vector resulting vaccine transmit host host amplifying number vaccine‐protected individual beyond initially vaccinated directly parenteral inoculation one main engineering challenge potential natural selection favor vaccine mutant eliminate reduce expression antigenic insert resulting immunogenic decay vaccine time study mathematical model vector mutation whereby continuous elimination antigenic insert result reversion vaccine back insert‐free vector use model quantify maximum allowable rate reversion tolerated transmissible vaccine maintain critical threshold level immunogenicity target pathogen result demonstrate even transmissible vaccine reversion frequent performance often substantially exceed conventional directly administered vaccine result demonstrate feasibility designing transmissible vaccine yield desired level immunogenicity yet degrade rate sufficient persistence recombinant vaccine within environment minimized,2019-06-12,"Nuismer, Scott L.; Basinski, Andrew; Bull, James J.",Evol Appl,,,,document_parses/pdf_json/bafab6b3dd88dcdefe111698d02f81998c9accdb.json,document_parses/pmc_json/PMC6708430.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708430/,,3
4733,4733,4994,ss8vdpox,2835b0f9f06e3e829cfa7d3f1e3805af94249d65,PMC,Oral Immunization of Chickens With Recombinant Lactobacillus plantarum Vaccine Against Early ALV-J Infection,10.3389/fimmu.2019.02299,PMC6783503,31632395.0,cc-by,study novel oral vaccine recombinant lactobacillus plantarum l plantarum containing gp protein explored effect vaccine prevention subgroup j avian leukosis virus alvj infection assessed current study gp protein alvj expressed surface l plantarum surfacedisplay motif pgsa constructing shuttle vector pmgepgsagp surface localization fusion protein verified western blotting flow cytometry subsequently specific pathogen free hyline brown layer chicken orally vaccinated recombinant l plantarum presented high level serum immunoglobulin g igg secretory immunoglobulin siga titer bile duodenalmucosal fluid challenged alvj × tissue culture infective dose tcid serum sample chicken collected viremia analyzed result showed compared l plantarum pb control group recombinant l plantarum group showed significant rise antibody level inoculation provide improved protection alvj according viremia detection result indicate oral immunization recombinant l plantarum provided effective mean eliciting protective immune response early alvj infection,2019-10-02,"Wang, Shenghua; Geng, Na; Zhou, Dong; Qu, Yi; Shi, Mengke; Xu, Yuliang; Liu, Kangping; Liu, Yongxia; Liu, Jianzhu",Front Immunol,,,,document_parses/pdf_json/2835b0f9f06e3e829cfa7d3f1e3805af94249d65.json,document_parses/pmc_json/PMC6783503.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6783503/,,3
4745,4745,5006,ycdaw2vh,7a8f035845b43c4e3b01a3034bff85a7ae9b8dfc,PMC,Zika Vaccine Development—Current Progress and Challenges for the Future,10.3390/tropicalmed4030104,PMC6789600,31337115.0,cc-by,zika virus emergent pathogen gained significant importance epidemic south central america unusual alarming complication infection recognized although initially considered selflimited benign infection panoply neurologic complication recognized including guillain–barrélike syndrome inutero fetal infection causing microcephaly blindness congenital neurologic complication numerous zika virus vaccine developed nine different vaccine representing five different platform entered clinical trial one progressing phase ii review current landscape challenge confronting zika virus vaccine development,2019-07-14,"Maslow, Joel N.",Trop Med Infect Dis,,,,document_parses/pdf_json/7a8f035845b43c4e3b01a3034bff85a7ae9b8dfc.json,document_parses/pmc_json/PMC6789600.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789600/,,3
4755,4755,5017,3lyaza89,5148320311832c95cb1c8b4fa32569e5a7945ff9,PMC,Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats,10.1038/s41541-019-0138-0,PMC6802222,31646004.0,cc-by,rift valley fever virus rvfv zoonotic mosquitoborne virus first discovered kenya since spread become endemic much africa arabian peninsula rift valley fever rvf cause recurrent outbreak febrile illness associated high level mortality poor outcome pregnancy—including foetal malformation spontaneous abortion stillbirths—in livestock associated miscarriage human vaccine available human use licensed veterinary use potential drawback including residual virulence may contraindicate use pregnancy address gap previously developed simian adenovirus vectored vaccine chadox rvf encodes rvfv envelope glycoprotein chadox rvf fully protective rvf nonpregnant livestock also development human use demonstrate administered pregnant sheep goat chadox rvf safe elicits high titre rvfv neutralizing antibody provides protection viraemia foetal loss although protection robust goat addition provide description rvfv challenge pregnant goat contrast pathology observed pregnant sheep together data support ongoing development chadox rvf vaccine use livestock human,2019-10-18,"Stedman, Anna; Wright, Daniel; Wichgers Schreur, Paul J.; Clark, Madeleine H. A.; Hill, Adrian V. S.; Gilbert, Sarah C.; Francis, Michael J.; van Keulen, Lucien; Kortekaas, Jeroen; Charleston, Bryan; Warimwe, George M.",NPJ Vaccines,,,,document_parses/pdf_json/5148320311832c95cb1c8b4fa32569e5a7945ff9.json,document_parses/pmc_json/PMC6802222.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802222/,,3
4828,4828,5094,q4p77ukw,595ec9383d19b691e17362abb472fa1103074014,PMC,"Enhancement of antigen-specific humoral immune responses and protein solubility through conjugation of bacterial flagellin, Vibrio vulnificus FlaB, to the N-terminus of porcine epidemic diarrhea virus surface protein antigen S0",10.4142/jvs.2019.20.e70,PMC6883195,31775197.0,cc-by-nc,porcine epidemic diarrhea ped highly contagious enteric swine disease large economic impact ped swine industry worldwide made development effective ped vaccine necessity truncated region porcine epidemic diarrhea virus pedv spike protein suggested candidate antigen ped subunit vaccine however poor solubility problem protein expressed escherichia coli inherent problem subunit vaccine low immunogenicity remain flagellin widely used fusion partner enhance immunogenicity solubility many difficulttoexpress protein however conjugation effect flagellin varies depending target antigen position fusion placement conjugated flagellin vibrio vulnificus flab n ctermini evaluated ability fusion enhance solubility immunogenicity flagellin conjugation presence trigger factor chaperone tig greatly improved solubility fusion protein regardless conjugation position importance flagellin conjugated nterminus significantly enhanced sspecific humoral immune response compared recombinant antigen balbc mouse mechanism phenomenon investigated vitro vivo study finding provide important information development novel ped vaccine flagellinbased immunotherapeutics,2019-11-05,"Oh, Seo-ho; Kim Cho, Young-Saeng; Lee, Ho-Bin; Lee, Sang-Mok; Kim, Whee-Soo; Hong, Liang; Cho, Chong-Su; Choi, Yun-Jaie; Kang, Sang-Kee",J Vet Sci,,,,document_parses/pdf_json/595ec9383d19b691e17362abb472fa1103074014.json,document_parses/pmc_json/PMC6883195.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883195/,,3
4894,4894,5162,d1pd09zj,1cee4a0d0e823379ec34a462a04561bf4cd736a2,PMC,Synthetic carbohydrate-based vaccines: challenges and opportunities,10.1186/s12929-019-0591-0,PMC6941340,31900143.0,cc-by,glycoconjugate vaccine based bacterial capsular polysaccharide cps extremely successful preventing bacterial infection glycan antigen preparation cps based glycoconjugate vaccine mainly obtained bacterial fermentation quality length glycans always inconsistent kind situation make cmc glycoconjugate vaccine difficult well control thanks advantage synthetic method carbohydrate synthesis well controlled glycan antigen easily obtain conjugated carrier protein socall homogeneous fully synthetic glycoconjugate vaccine several fully glycoconjugate vaccine different phase clinical trial bacteria cancer review introduce recent development fully synthetic glycoconjugate vaccine,2020-01-03,"Mettu, Ravinder; Chen, Chiang-Yun; Wu, Chung-Yi",J Biomed Sci,,,,document_parses/pdf_json/1cee4a0d0e823379ec34a462a04561bf4cd736a2.json,document_parses/pmc_json/PMC6941340.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941340/,,3
4896,4896,5164,44ip3jda,2caf288d2b6723ea0d82657ab1ecb1199a5b3b6b,PMC,Identification of antigens presented by MHC for vaccines against tuberculosis,10.1038/s41541-019-0148-y,PMC6941960,31908851.0,cc-by,mycobacterium tuberculosis mtb responsible death globally pathogen available vaccine bacillus calmetteguérin bcg variable efficacy throughout world effective vaccine urgently needed immune response tuberculosis relies least part cd cell protective vaccine require induction antigenspecific cd cell via mycobacterial peptide presented mhc classii infected macrophage order identify mycobacterial antigen bound mhc immunoprecipitated mhc classi classii complex thp macrophage infected bcg purified mhc classi mhc classii peptide analysed liquid chromatography tandem mass spectrometry successfully identified mycobacterial peptide presented mhcii presented mhci antigen respectively antigen found highly expressed infected macrophage gene ontology analysis suggests antigen associated membrane involved lipid biosynthesis transport sequence selected peptide confirmed spectral match validation immunogenicity evaluated ifngamma elispot peripheral blood mononuclear cell volunteer vaccinated bcg mtb latently infected subject patient tuberculosis disease three antigen expressed viral vector evaluated vaccine candidate alone combination murine aerosol mtb challenge model delivered combination three candidate vaccine conferred significant protection lung spleen compared bcg alone demonstrating proofofconcept unbiased approach identifying new candidate antigen,2020-01-03,"Bettencourt, Paulo; Müller, Julius; Nicastri, Annalisa; Cantillon, Daire; Madhavan, Meera; Charles, Philip D.; Fotso, Carine B.; Wittenberg, Rachel; Bull, Naomi; Pinpathomrat, Nawamin; Waddell, Simon J.; Stylianou, Elena; Hill, Adrian V. S.; Ternette, Nicola; McShane, Helen",NPJ Vaccines,,,,document_parses/pdf_json/2caf288d2b6723ea0d82657ab1ecb1199a5b3b6b.json,document_parses/pmc_json/PMC6941960.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6941960/,,3
4910,4910,5178,7bpeszm5,b0af9d20cbdfd0114cf1fb10ad2b8ae46848dcec,PMC,"Genetic polymorphisms in malaria vaccine candidate Plasmodium falciparum reticulocyte-binding protein homologue-5 among populations in Lagos, Nigeria",10.1186/s12936-019-3096-0,PMC6945540,31906953.0,cc-by,background vaccine reliable alternative elicit sterile immunity malaria development hindered polymorphism strainspecificity previously studied antigen new vaccine candidate therefore urgently needed highly conserved plasmodium falciparum reticulocytebinding protein homologue pfrh identified potential candidate antidisease vaccine development pfrh essential erythrocyte invasion merozoite crucial parasite survival however paucity data extent genetic variation pfrh field isolates plasmodium falciparum study described genetic polymorphism high affinity binding polypeptide habps pfrh nigerian isolates p falciparum study tested hypothesis specific conserved b cell epitope pfrh habps crucial vaccine development method one hundred ninetyfive microscopically confirmed p falciparum sample collected prospective crosssectional study three different population lagos nigeria genetic diversity haplotype construct pfrh gene determined using bidirectional sequencing approach tajima ’ ratio nonsynonymous v synonymous mutation utilized estimate extent balancing directional selection pfrh gene result sequence analysis revealed three haplotype pfrh negative tajima ’ dnds value − ± respectively single nucleotide polymorphism snp g → position observed resulted change amino acid cysteine position tyrosine haplotype nucleotide diversity ± ± interpopulation genetic differentiation ranged five polypeptide variant identified frequent ktkyh frequency one bcell epitope major histocompatibility complex mhc class ii tcell epitope four intrinsically unstructured region iurs six mhc class tcell epitope observed study phylogenetic analysis sequence showed clustering evidence evolutionary relationship pa fcb rh sequence conclusion study revealed low level genetic polymorphism pfrh antigen b tcell epitope intrinsically unstructured region along pfrh gene lagos nigeria broader investigation however required part country support possible inclusion pfrh crossprotective multicomponent vaccine,2020-01-06,"Ajibaye, Olusola; Osuntoki, Akinniyi A.; Balogun, Emmanuel O.; Olukosi, Yetunde A.; Iwalokun, Bamidele A.; Oyebola, Kolapo M.; Hikosaka, Kenji; Watanabe, Yoh-ichi; Ebiloma, Godwin U.; Kita, Kiyoshi; Amambua-Ngwa, Alfred",Malar J,,,,document_parses/pdf_json/b0af9d20cbdfd0114cf1fb10ad2b8ae46848dcec.json,document_parses/pmc_json/PMC6945540.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6945540/,,3
4948,4948,5216,i5xjp1m2,3e6bc3e91e6d1982c44b0382d40a78947e326580,PMC,Cell culture propagation of foot-and-mouth disease virus: adaptive amino acid substitutions in structural proteins and their functional implications,10.1007/s11262-019-01714-7,PMC6957568,31776851.0,cc-by,footandmouth disease endemic livestock large part africa asia important driver food insecurity major obstacle agricultural development international trade animal product virtually commercially available vaccine inactivated wholevirus vaccine produced cell culture adaptation field isolate virus growth culture laborious timeconsuming particular concern development vaccine newly emerging virus lineage long lead time virus isolate vaccine delay implementation effective control program high antigen yield production cell also necessary make vaccine affordable le developed country endemic area therefore rational approach cell culture adaptation combine prior knowledge common adaptive mutation reverse genetics technique urgently required review provides overview amino acid exchange viral capsid protein context adaptation cell culture electronic supplementary material online version article contains supplementary material available authorized user,2019-11-27,"Dill, Veronika; Eschbaumer, Michael",Virus Genes,,,,document_parses/pdf_json/3e6bc3e91e6d1982c44b0382d40a78947e326580.json,document_parses/pmc_json/PMC6957568.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6957568/,,3
4955,4955,5223,mqjwnp98,2c7260dadc28671d3ba4e14120b63a5232765805,PMC,"Meningococcal Vaccine for Hajj Pilgrims: Compliance, Predictors, and Barriers",10.3390/tropicalmed4040127,PMC6958484,31618945.0,cc-by,background major intercontinental outbreak invasive meningococcal disease associated hajj occurred mandatory meningococcal vaccination pilgrim serogroups c subsequently c w controlled epidemic overseas pilgrim show excellent adherence policy however vaccine uptake among domestic pilgrim suboptimal survey aimed evaluate meningococcal vaccine uptake among hajj pilgrim identify key factor affecting method anonymous crosssectional survey conducted among pilgrim greater makkah hajj – data sociodemographic characteristic vaccination status cost vaccination reason behind nonreceipt vaccine collected result total respondent aged median year participated survey male domestic pilgrim confirmed meningococcal vaccination status individual domestic pilgrim receive vaccine unsure among overseas pilgrim certainly received vaccine unsure compared domestic pilgrim p employed tertiary qualification significant predictor vaccination adherence odds ratio confidence interval ci – p ci – p respectively obtained prehajj health advice three time likely vaccinated ci – p lack awareness lack time common reason reported nonreceipt vaccine conclusion many domestic pilgrim missed compulsory meningococcal vaccine regard lack awareness key barrier overseas pilgrim living distance makkah receipt prehajj health advice employment predictor greater compliance vaccination policy opportunity remain reduce policy–practice gap among domestic pilgrim,2019-10-15,"Badahdah, Al-Mamoon; Alghabban, Fatimah; Falemban, Wajd; Albishri, Abdullah; Rani Banik, Gouri; Alhawassi, Tariq; Abuelizz, Hatem; Bakarman, Marwan A.; Khatami, Ameneh; Booy, Robert; Rashid, Harunor",Trop Med Infect Dis,,,,document_parses/pdf_json/2c7260dadc28671d3ba4e14120b63a5232765805.json,document_parses/pmc_json/PMC6958484.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958484/,,3
4966,4966,5234,8e7dndfq,445b086554f3fe551acecca32b722b05579446e0,PMC,Intranasal vaccination with Listeria ivanovii as vector of Mycobacterium tuberculosis antigens promotes specific lung-localized cellular and humoral immune responses,10.1038/s41598-019-57245-6,PMC6962167,31942003.0,cc-by,previously demonstrated recombinant listeria ivanovii li strain expressing esat agc protein mycobacterium tuberculosis mtb tuberculosis tb vaccine candidate induced antigenspecific cellular immune response intravenous immunization mouse however whether recombinant strain could induce desired immune response lung tb infection occurs clear paper cbl j mouse intranasally vaccinated attenuated liδactaplcbrv δ refers gene deletion bacterial genome liδactaplcbrvc two vaccine candidate utilize li antigen delivery vector bacterial load target organ histological change infected organ percentage specific cytokinesecreting cell lung spleen igg level serum secretory iga siga levles bronchoalveolar lavage bal fluid determined specific day post inoculation dpi result showed strain mainly confined lung eliminated dpi histological damage caused infection lung slight recovered day intranasal vaccination mouse twice interval week notably elicited tb antigenspecific cd cd cell response lung siga secretion pulmonary mucosa significantly enhanced percentage doublefunctional cd cell ifnγ tnfα cd knowledge first report regarding used li vector vaccine induce promising lunglocalized cellular humoral immune response intranasal vaccination data suggest li could novel promising live vector construct intranasal vaccine respiratory disease,2020-01-15,"Jiang, Ming-juan; Liu, Si-jing; Su, Lin; Zhang, Xiang; Li, Yong-yu; Tang, Tian; Wang, Chuan",Sci Rep,,,,document_parses/pdf_json/445b086554f3fe551acecca32b722b05579446e0.json,document_parses/pmc_json/PMC6962167.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962167/,,3
4971,4971,5239,rkdvds4t,29ffe6751373335a54c9d02cec1af4cfdf049ea8,PMC,A Single and Un-Adjuvanted Dose of a Chimpanzee Adenovirus-Vectored Vaccine against Chikungunya Virus Fully Protects Mice from Lethal Disease,10.3390/pathogens8040231,PMC6963200,31718104.0,cc-by,mosquitoborne chikungunya virus chikv become major global health problem upon infection chikungunya fever chikf result longterm joint pain arthritis despite intense research licensed vaccine chikv available developed two recombinant chimpanzee adenovirusvectored vaccine chadox induce swift robust antichikv immune response single dose without need adjuvant booster vaccine report vaccine ’ protective efficacy chikv infection lethal mouse model result indicate single unadjuvanted chadox chik chadox chik δcap dose provided complete protection lethal virus challenge prevented chikvassociated severe inflammation candidate vaccine supported survival equal attenuated chikv reference vaccine without vaccinerelated side effect weight loss vaccination either chadox chik chadox chik δcap resulted high titer neutralizing antibody associated protection indicating presence capsid within vaccine construct may essential afford protection condition tested conclude replicationdeficient chadox chik vaccine safe even used mouse afford complete protection lethal challenge,2019-11-12,"Campos, Rafael Kroon; Preciado-Llanes, Lorena; Azar, Sasha R.; Lopez-Camacho, Cesar; Reyes-Sandoval, Arturo; Rossi, Shannan L.",Pathogens,,,,document_parses/pdf_json/29ffe6751373335a54c9d02cec1af4cfdf049ea8.json,document_parses/pmc_json/PMC6963200.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963200/,,3
4972,4972,5240,1apf9w7j,0899b0f8df5f20c6a46ba1dc7675c85858b59a68,PMC,Recombinant Lactobacillus casei Expressing Capsid Protein VP60 can Serve as Vaccine Against Rabbit Hemorrhagic Disease Virus in Rabbits,10.3390/vaccines7040172,PMC6963290,31684059.0,cc-by,rabbit hemorrhagic disease virus rhdv causative agent rabbit hemorrhagic disease rhd rhd characterized hemorrhaging liver necrosis high morbidity mortality rabbit hare cause severe economic loss rabbit industry worldwide due lack efficient invitro propagation system rhdv current vaccine produced via chemical inactivation crude rhdv preparation derived liver infected rabbit inactivated vaccine effective controlling rhd potential problem biosafety animal welfare negative effect application inactivated vaccine study oral lactobacillus casei l casei vaccine used antigen delivery system express rhdv capsid protein vpvpegfp fusion protein expression recombinant protein confirmed via western blotting immunofluorescence ifa result indicate oral administration probiotic vaccine stimulate secretory immunoglobulin sigabased mucosal iggbased humoral immune response rabbit immunized rabbit completely protected challenge rhdv finding indicate l casei expression system new strategy development safe efficient vaccine rhdv,2019-11-02,"Wang, Li; Xia, Tian; Guo, Tiantian; Ru, Yi; Jiang, Yanping; Cui, Wen; Zhou, Han; Qiao, Xinyuan; Tang, Lijie; Xu, Yigang; Li, Yijing",Vaccines (Basel),,,,document_parses/pdf_json/0899b0f8df5f20c6a46ba1dc7675c85858b59a68.json,document_parses/pmc_json/PMC6963290.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963290/,,3
4974,4974,5242,bv9mngl3,d213253353b62aa454d0bb02a7651a0ef7c0d34f,PMC,Vaccination against Paediatric Respiratory Pathogens,10.3390/vaccines7040168,PMC6963365,31683882.0,cc-by,acute respiratory infection aris extremely common child especially year old lead complication superinfection respiratory failure even compromised respiratory function adulthood responsible pathogen vaccine available review report current issue vaccine main respiratory pathogen highlight available strategy reduce burden paediatric respiratory disease optimal use influenza pneumococcal pertussis measles vaccine required order reduce ari burden vaccination coverage rate must improved achieve full benefit vaccine recently advance knowledge respiratory syncytial virus structural biology immunology well development new technique generate vaccine candidate increased number promising vaccine even harmful pathogen,2019-11-01,"Bianchini, Sonia; Argentiero, Alberto; Camilloni, Barbara; Silvestri, Ettore; Alunno, Anna; Esposito, Susanna",Vaccines (Basel),,,,document_parses/pdf_json/d213253353b62aa454d0bb02a7651a0ef7c0d34f.json,document_parses/pmc_json/PMC6963365.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963365/,,3
4976,4976,5244,tm7krxxw,0ae65070d7cbfa7b5454181af026a8ea7391d5d2,PMC,Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers,10.3390/pathogens8040216,PMC6963679,31684117.0,cc-by,zika virus zikv emerging mosquitoborne flavivirus spread country worldwide since despite active research currently licensed vaccine therapeutic previously reported development various adenoviral vectored vaccine candidate chadox zikv ability stimulate effective immunity mouse provide protection upon zikv challenge model using nonadjuvanted single vaccination approach study constructed various modified vaccinia ankara mva virus express zikv envelope e modification precursor membrane prm cterminus envelope transmembrane domain tm similar chadox vaccine candidate mvazikv vaccine candidate evaluated nonadjuvanted single vaccination regimen zikv brazilian isolate using viraemia correlate protection report induction modest level antizikv e antibody mva vectored vaccine suboptimal efficacy zikv challenge model result indicate requirement additional strategy using mvazikv vaccine afford sterile protection upon nonadjuvanted single vaccination regime,2019-11-02,"López-Camacho, César; Kim, Young Chan; Abbink, Peter; Larocca, Rafael A.; Huiskonen, Juha T.; Barouch, Dan H.; Reyes-Sandoval, Arturo",Pathogens,,,,document_parses/pdf_json/0ae65070d7cbfa7b5454181af026a8ea7391d5d2.json,document_parses/pmc_json/PMC6963679.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6963679/,,3
4991,4991,5259,exbs3tz7,2efc8c38dea01325883ef30efc21f128515c3e33,PMC,Novel Chimeric Multiepitope Vaccine for Streptococcosis Disease in Nile Tilapia (Oreochromis niloticus Linn.),10.1038/s41598-019-57283-0,PMC6969146,31953479.0,cc-by,streptococcus agalactiae causative agent streptococcosis disease various fish specie including nile tilapia oreochromis niloticus linn vaccination effective disease prevention control method limitation remain protecting catastrophic mortality fish infected different strain streptococci immunoproteomics analysis agalactiae used identify antigenic protein construct chimeric multiepitope vaccine epitope five antigenic protein shuffled five helix flavodoxin backbone silico analysis predicted suitable rna protein structure protein expression f e identified best candidate chimeric multiepitope vaccine recombinant plasmid constructed produce recombinant protein vaccine dna vaccine system overexpressed protein determined kda kda e coli tk system respectively efficacy chimeric multiepitope construct recombinant protein vaccine dna vaccine evaluated nile tilapia followed agalactiae challenge × cfuml relative percentage survival rps cumulative mortality recorded approximately – – respectively chimeric multiepitope vaccine applied streptococcosis disease control developed multivalent vaccine control multiple disease,2020-01-17,"Pumchan, Ansaya; Krobthong, Sucheewin; Roytrakul, Sittiruk; Sawatdichaikul, Orathai; Kondo, Hidehiro; Hirono, Ikuo; Areechon, Nontawith; Unajak, Sasimanas",Sci Rep,,,,document_parses/pdf_json/2efc8c38dea01325883ef30efc21f128515c3e33.json,document_parses/pmc_json/PMC6969146.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6969146/,,3
4994,4994,5262,fpygaht5,e1f2c0859f44eaf3e7a2110a5ca98ac0104815bc,PMC,A self-aggregating peptide: implications for the development of thermostable vaccine candidates,10.1186/s12896-019-0592-9,PMC6971912,31959159.0,cc-by,background use biomaterials expanded improve characteristic vaccine recently identified peptide ph– polyhedrin selfaggregates incorporates foreign protein form particle proposed peptide used antigen carrying system vaccine however immune response generated antigen fused peptide fully characterized addition adjuvant effect thermostability particle evaluated result present study demonstrate use system developed generate nano microparticles carrying fusion protein peptide protein interest used vaccine particle purified easily centrifugation immunization animal particle absence adjuvant result robust longlasting immune response protein contained inside particle maintained year ambient temperature preserving immunological property conclusion rapid efficient production particle addition robust immune response generate position system excellent method rapid response emerging disease thermostability conferred particle system facilitates distribution vaccine developing country area electricity,2020-01-21,"Cruz-Reséndiz, Adolfo; Zepeda-Cervantes, Jesús; Sampieri, Alicia; Bastián-Eugenio, Carlos; Acero, Gonzalo; Sánchez-Betancourt, J. Iván; Gevorkian, Goar; Vaca, Luis",BMC Biotechnol,,,,document_parses/pdf_json/e1f2c0859f44eaf3e7a2110a5ca98ac0104815bc.json,document_parses/pmc_json/PMC6971912.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971912/,,3
5002,5002,5270,mnkj3q0t,f567c400f12b7ba351fe17327978cfff0dc11803,PMC,Canadian Newspaper Coverage of the A/H1N1 Vaccine Program,10.1007/bf03404896,PMC6973664,21714319.0,no-cc,objective ahn mass vaccination program canada garnered considerable attention medium including extensive newspaper coverage medium report shown influence public ’ health care decision including vaccination choice analyzed canadian newspaper ’ portrayal ahn vaccine including mention risk benefit vaccine whether article supported questioned neutral vaccine method compiled data set canadian newspaper article n conducted frequency content analysis examine discussion andor mention evidence concerning vaccination risk ahn virus vaccine tone article regard vaccination program canada result reason getting vaccinated appeared article whereas provided reason getting vaccinated discussion evidence support claim getting vaccinated appeared article respectively risk associated contracting ahn virus discussed article risk ahn vaccine discussed article conclusion newspaper coverage canada largely supportive ahn mass vaccination program however serious risk associated contracting ahn virus also frequently discussed print medium news article rarely presented direct evidence support statement vaccine safe effective properly tested known risk potential allergic reaction flulike side effect vaccine rarely reported relationship medium portrayal vaccine uptake warrant research,2011-05-01,"Rachul, Christen M.; Ries, Nola M.; Caulfield, Timothy",Can J Public Health,,,,document_parses/pdf_json/f567c400f12b7ba351fe17327978cfff0dc11803.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6973664/,,3
5023,5023,5298,aqv7xhng,f473743ab5512de8b4e42b5480fd76ea2facad0d,PMC,Schistosomiasis vaccine development: update on human clinical trials,10.1186/s12929-020-0621-y,PMC6977295,31969170.0,cc-by,schistosomiasis cause significant level morbidity mortality many geographical region world disease caused infection parasitic blood fluke known schistosome control schistosomiasis last several decade centered mass drug administration mda praziquantel pzq drug currently available treatment despite concerted effort mda program prevalence transmission schistosomiasis remained largely unchecked due fact pzq ineffective juvenile schistosome prevent reinfection emergence pzqresistant parasite addition measure water sanitation hygiene program snail intermediate host control little impact drawback indicate current control strategy severely inadequate interrupting transmission therefore implementation control strategy required ideally efficient vaccine needed long term protection thereby eliminating current effort repeated mass drug administration however general consensus field integration viable vaccine mda control measure offer best chance achieving goal schistosomiasis elimination review focus present status schistosomiasis vaccine candidate different phase human clinical trial provide insight future vaccine discovery design,2020-01-22,"Molehin, Adebayo J.",J Biomed Sci,,,,document_parses/pdf_json/f473743ab5512de8b4e42b5480fd76ea2facad0d.json,document_parses/pmc_json/PMC6977295.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6977295/,,3
5026,5026,5301,j6txbpz4,e9274240a87ddf8bdec1664fbe0e03fe422a6e4a; baa71ccc36f31d41824181ca7df1bba588b35a8f,PMC,Flagellin adjuvanted F1/V subunit plague vaccine induces T cell and functional antibody responses with unique gene signatures,10.1038/s41541-020-0156-y,PMC6978331,31993217.0,cc-by,yersinia pestis cause plague could weaponized unfortunately development new vaccine limited lack correlate protection used pre postvaccination serum peripheral blood mononuclear cell flagellin adjuvanted fv vaccine trial evaluate protective marker report first time human inverse caspase level measure protective antibody significantly increased day postsecond vaccination respectively addition significant increase tcell response day postsecond vaccination strongest positive negative correlation protective antibody level gene expression signature identified ifng ensg gene respectively flagellinfv subunit vaccine induced macrophageprotective antibody significant cd tcell response several gene associated response identified could serve potential correlate protection,2020-01-23,"Hamzabegovic, Fahreta; Goll, Johannes B.; Hooper, William F.; Frey, Sharon; Gelber, Casey E.; Abate, Getahun",NPJ Vaccines,,,,document_parses/pdf_json/e9274240a87ddf8bdec1664fbe0e03fe422a6e4a.json; document_parses/pdf_json/baa71ccc36f31d41824181ca7df1bba588b35a8f.json,document_parses/pmc_json/PMC6978331.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978331/,,3
5028,5028,5303,u8d7zmkz,7d30e1f934d199ac2fba5488bb758bf92a9f4e75,PMC,In silico Design of a Multivalent Vaccine Against Candida albicans,10.1038/s41598-020-57906-x,PMC6978452,31974431.0,cc-by,invasive candidiasis ic common nosocomial infection leading cause mycosesrelated death highsystemic toxicity emergence antifungalresistant specie warrant development newer preventive approach ic adopted immunotherapeutic peptide vaccinebased approach enhance body ’ immune response invasive candida infection using computational tool screened entire candida proteome protein identified immunodominant hla class hla class ii b cell epitope immunoinformatic analysis enhanced vaccine efficacy selected promising epitope joined together using molecular linkers create multivalent recombinant protein candida albicans mvpc increase mvpc ’ immunogenicity added synthetic adjuvant r mvpc design selected mvpc epitope homologous currently available annotated reference sequence c albicans strain thus offering higher coverage greater protective response major advantage current vaccine approach mvpc ’ multivalent nature recognizing multipleepitopes likely provide enhanced protection complex candida antigen describe computational analysis leading mvpc design,2020-01-23,"Tarang, Shikha; Kesherwani, Varun; LaTendresse, Blake; Lindgren, Laramie; Rocha-Sanchez, Sonia M.; Weston, Michael D.",Sci Rep,,,,document_parses/pdf_json/7d30e1f934d199ac2fba5488bb758bf92a9f4e75.json,document_parses/pmc_json/PMC6978452.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978452/,,3
5062,5062,5343,xb9ko0c3,7abdca8783f18240fde2423af2f7c957cd7c4470,PMC,Vaccination with virosomally formulated recombinant CyRPA elicits protective antibodies against Plasmodium falciparum parasites in preclinical in vitro and in vivo models,10.1038/s41541-020-0158-9,PMC6994490,32025340.0,cc-by,plasmodium falciparum pf cysteinerich protective antigen pfcyrpa emerged promising bloodstage candidate antigen inclusion broadly crossreactive malaria vaccine highly conserved protein among various geographical strain play key role red blood cell invasion process p falciparum merozoite antibody pfcyrpa efficiently prevent entry malaria parasite red blood cell aim present study develop humancompatible formulation pfcyrpa vaccine candidate confirming activity preclinical study recombinant pfcyrpa expressed hek cell chemically coupled phosphoethanolamine incorporated membrane unadjuvanted influenza virosomes approved antigen delivery system human laboratory animal immunised virosomebased pfcyrpa vaccine determine immunogenic property particular capacity elicit parasite binding growthinhibitory antibody vaccine elicited mouse rabbit high titer pfcyrpaspecific antibody bound bloodstage parasite concentration mgml purified total serum igg immunised rabbit inhibited parasite growth vitro furthermore p falciparum infection mouse model passive transfer mg purified total igg pfcyrpa vaccinated rabbit reduced vivo parasite load influenza virosomes thus represent suitable antigen delivery system induction protective antibody recombinant pfcyrpa designating highly suitable component inclusion multivalent multistage virosomal malaria vaccine,2020-01-31,"Tamborrini, Marco; Hauser, Julia; Schäfer, Anja; Amacker, Mario; Favuzza, Paola; Kyungtak, Kwak; Fleury, Sylvain; Pluschke, Gerd",NPJ Vaccines,,,,document_parses/pdf_json/7abdca8783f18240fde2423af2f7c957cd7c4470.json,document_parses/pmc_json/PMC6994490.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6994490/,,3
5076,5076,5357,d6domrgx,acae9ff2aa45fe67cf994e18c4e7e8d95353b0c2,PMC,Plasmodium falciparum pre-erythrocytic stage vaccine development,10.1186/s12936-020-3141-z,PMC6998842,32013956.0,cc-by,worldwide strategy aimed controlling malarial parasite mainly plasmodium falciparum led reduction regarding disease incidence rate many biologicallyderived antimalarial vaccine candidate developed date involved using many experimental animal immense amount work investment million dollar review provides overview current state main result clinical trial sporozoitetargeting vaccine ie parasite stage infecting liver carried research group area variable malaria transmission rate however none led promising result regarding effective control disease thereby making necessary complement effort findingintroducing new vaccine candidate adopting multiepitope multistage approach based minimal subunit main sporozoite protein involved invasion liver,2020-02-03,"Molina-Franky, Jessica; Cuy-Chaparro, Laura; Camargo, Anny; Reyes, César; Gómez, Marcela; Salamanca, David Ricardo; Patarroyo, Manuel Alfonso; Patarroyo, Manuel Elkin",Malar J,,,,document_parses/pdf_json/acae9ff2aa45fe67cf994e18c4e7e8d95353b0c2.json,document_parses/pmc_json/PMC6998842.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6998842/,,3
5079,5079,5360,cot05vx7,e4cbe910a0124531782e337a897f90b4f3107cad,PMC,The promise of mRNA vaccines: a biotech and industrial perspective,10.1038/s41541-020-0159-8,PMC7000814,32047656.0,cc-by,mrna technology potential transform area medicine including prophylaxis infectious disease advantage vaccine range acceleration immunogen discovery rapid response multiple disease target manufacturing greater understanding quality attribute dictate translation efficiency well comprehensive appreciation importance mrna delivery influencing new era investment development activity application translational science growing earlyphase clinical experience continue inform candidate vaccine selection review state art prevention infectious disease using mrna pertinent topic biotechnology pharmaceutical industry,2020-02-04,"Jackson, Nicholas A. C.; Kester, Kent E.; Casimiro, Danilo; Gurunathan, Sanjay; DeRosa, Frank",NPJ Vaccines,,,,document_parses/pdf_json/e4cbe910a0124531782e337a897f90b4f3107cad.json,document_parses/pmc_json/PMC7000814.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7000814/,,3
5085,5085,5366,m6wid9v5,ce0425b48e9b111a10f612fc562a2cd316633c15,PMC,Vaccines and Therapeutics Against Hantaviruses,10.3389/fmicb.2019.02989,PMC7002362,32082263.0,cc-by,hantaviruses hvs rodenttransmitted virus cause hantavirus cardiopulmonary syndrome hcps america hemorrhagic fever renal syndrome hfrs eurasia together virus annually caused approximately human infection worldwide recent year case fatality rate – hfrs hcps currently effective treatment available either hfrs hcps whole virus inactivated vaccine htnv seov licensed use republic korea china protective efficacy vaccine uncertain large extent immune correlate protection hantavirus known review summarized epidemiology virology pathogenesis four hfrscausing virus htnv seov puuv dobv two hcpscausing virus andv snv discussed existing knowledge vaccine therapeutic disease think information shed light rational development new vaccine treatment,2020-01-30,"Liu, Rongrong; Ma, Hongwei; Shu, Jiayi; Zhang, Qiang; Han, Mingwei; Liu, Ziyu; Jin, Xia; Zhang, Fanglin; Wu, Xingan",Front Microbiol,,,,document_parses/pdf_json/ce0425b48e9b111a10f612fc562a2cd316633c15.json,document_parses/pmc_json/PMC7002362.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002362/,,3
5121,5121,5404,z9jnljrt,b78ea091f284f606d682156812dd9c9df29427e7; 5c4deb927835b9957db2a64b4abc21b5f59afdcf,PMC,Genome-wide screening of lipoproteins in Actinobacillus pleuropneumoniae identifies three antigens that confer protection against virulent challenge,10.1038/s41598-020-58968-7,PMC7012816,32047221.0,cc-by,actinobacillus pleuropneumoniae important veterinary pathogen cause porcine pleuropneumonia lipoprotein bacterial pathogen play pleiotropic role infection process addition many bacterial lipoprotein antigenic immunoprotective therefore characterization lipoprotein promising strategy identification novel vaccine candidate diagnostic marker cloned lipoprotein pleuropneumoniae jl serovar expressed escherichia coli five protein strong positive signal western blotting analysis used immunize mouse protein elicited significant antibody response three apjl apjl apjl generated efficient immunoprotection mouse lethal heterologous challenge pleuropneumoniae serovar active passive immunization assay immunogenicity three lipoprotein apjl apjl apjl tested pig result showed protein elicited considerable humoral immune response effective protective immunity virulent pleuropneumoniae challenge finding suggest three novel lipoprotein could potential subunit vaccine candidate,2020-02-11,"Cao, Yurou; Gao, Lulu; Zhang, Li; Zhou, Lixiang; Yang, Jihong; Deng, Lingfu; Zhao, Jin; Qi, Chao; Liu, Jinlin",Sci Rep,,,,document_parses/pdf_json/b78ea091f284f606d682156812dd9c9df29427e7.json; document_parses/pdf_json/5c4deb927835b9957db2a64b4abc21b5f59afdcf.json,document_parses/pmc_json/PMC7012816.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7012816/,,3
5142,5142,5425,co9s26x1,8c0abed8df23dfeab773f970d2d1a29e7d50bc44,PMC,A single dose polyanhydride-based nanovaccine against paratuberculosis infection,10.1038/s41541-020-0164-y,PMC7021715,32128256.0,cc-by,mycobacterium avium subsp paratuberculosis paratuberculosis cause johne ’ disease ruminant characterized chronic gastroenteritis leading heavy economic loss dairy industry worldwide currently available vaccine inactivated bacterin oil base effective preventing pathogen shedding rarely used control johne ’ disease dairy herd develop better vaccine prevent spread johne ’ disease utilized polyanhydride nanoparticles pan encapsulate mycobacterial antigen composed whole cell lysate panlysate culture filtrate pancf paratuberculosis nanoparticlebased vaccine ie nanovaccines well tolerated mouse causing inflammatory lesion site injection immunological assay demonstrated substantial increase level antigenspecific cell response postvaccination pancf vaccinated group indicated high percentage triple cytokine ifnγ il tnfα producing cd cell following challenge animal vaccinated pancf continued produce significant level double ifnγ tnfα single cytokine ifnγ secreting cd cell compared animal vaccinated inactivated vaccine significant reduction bacterial load observed multiple organ animal vaccinated pancf clear indication protection overall use polyanhydride nanovaccines resulted development protective sustained immunity johne ’ disease approach could applied counter intracellular pathogen,2020-02-14,"Thukral, Akanksha; Ross, Kathleen; Hansen, Chungyi; Phanse, Yashdeep; Narasimhan, Balaji; Steinberg, Howard; Talaat, Adel M.",NPJ Vaccines,,,,document_parses/pdf_json/8c0abed8df23dfeab773f970d2d1a29e7d50bc44.json,document_parses/pmc_json/PMC7021715.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7021715/,,3
5149,5149,5432,4jdn4kw6,2bb358128470d15075f9881415660126f8812b26,PMC,Better influenza vaccines: an industry perspective,10.1186/s12929-020-0626-6,PMC7023813,32059697.0,cc-by,vaccination effective measure preventing influenza virus infection however current seasonal influenza vaccine protective closely matched circulating strain even extensive monitoring annual reformulation effort remain one step behind rapidly evolving virus often resulting mismatch low vaccine effectiveness fortunately many nextgeneration influenza vaccine currently development utilizing array innovative technique shorten production time increase breadth protection review summarizes production method current vaccine recent advance made influenza vaccine research highlight potential challenge yet overcome special emphasis put potential role glycoengineering influenza vaccine development advantage removing glycan shield influenza surface antigen increase vaccine immunogenicity potential future development novel influenza vaccine candidate discussed industry perspective,2020-02-14,"Chen, Juine-Ruey; Liu, Yo-Min; Tseng, Yung-Chieh; Ma, Che",J Biomed Sci,,,,document_parses/pdf_json/2bb358128470d15075f9881415660126f8812b26.json,document_parses/pmc_json/PMC7023813.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023813/,,3
5160,5160,5445,zctxbhqf,8258250cfa2702747fae2f183d320e4e264bf6fe,PMC,"Identification, molecular characterization and expression of aminopeptidase N-1 (APN-1) from Anopheles stephensi in SF9 cell line as a candidate molecule for developing a vaccine that interrupt malaria transmission",10.1186/s12936-020-03154-3,PMC7029531,32075635.0,cc-by,background according world health organization report billion people around world risk malaria disease important consider preventive strategy protecting people living high risk area one main reason disease survival diversity vector parasite different malaria region specific feature behaviour biology therefore specific regional strategy necessary successful control malaria one tool need developed elimination prevention reintroduction malaria vaccine interrupt malaria transmission vimts vimt broad concept adjusted biological characteristic disease region one type vimt vectorbased vaccine affect sexual stage plasmodium life cycle according recent study aminopeptidase n anopheles gambiae agapn potent vectorbased vimt considerable inhibition activity sexual stage plasmodium parasite method system rapid amplification cdna end ʹrace genome walking method used sequence determination apn gene anopheles stephensi distinct bioinformatics software used structural analysis asapn expressed spodoptera frugiperda sf insect cell line using baculovirus expression system recombinant asapn purified hybrid condition biological activity assayed result asapn gene coded protein stephensi characterized first time study subsequently structural feature immunological property coded protein evaluated silico approach enzymatic activity recombinant asapn expressed sf insect cell line equal unitμl conclusion result study revealed asapn similar counterpart gambiae silico evaluation fundamental data necessary evaluation vimtbased vaccine next step acquired study could useful research group study malaria vaccine country stephensi main malaria vector,2020-02-19,"Dadgar Pakdel, Javad; Zakeri, Sedigheh; Raz, Abbasali; Dinparast Djadid, Navid",Malar J,,,,document_parses/pdf_json/8258250cfa2702747fae2f183d320e4e264bf6fe.json,document_parses/pmc_json/PMC7029531.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029531/,,3
5166,5166,5451,qnk4srcd,90d0cc333194af9af5edc789a871e1d4a159001f; c4a7a6342be471e0059f017b0eaa850718bbeae4,PMC,Immune checkpoint modulation enhances HIV-1 antibody induction,10.1038/s41467-020-14670-w,PMC7031230,32075963.0,cc-by,eliciting protective titer hiv broadly neutralizing antibody bnabs goal hiv vaccine development current vaccine strategy yet induce bnabs human many bnabs isolated hivinfected individual encoded immunoglobulin gene rearrangments infrequent naive b cell precursor unusual genetic feature may subject host regulatory control administer antibody targeting immune cell regulatory receptor ctla pd ox along hiv envelope env vaccine rhesus macaque bnab immunoglobulin knockin ki mouse expressing diverse precursor cd binding site hiv bnabs ctla blockade augments hiv env antibody response macaque bnabprecursor mouse model ctla blocking ox agonist antibody increase germinal center b follicular helper cell plasma neutralizing antibody thus modulation ctla ox immune checkpoint vaccination promote germinal center activity enhance hiv env antibody response,2020-02-19,"Bradley, Todd; Kuraoka, Masayuki; Yeh, Chen-Hao; Tian, Ming; Chen, Huan; Cain, Derek W.; Chen, Xuejun; Cheng, Cheng; Ellebedy, Ali H.; Parks, Robert; Barr, Maggie; Sutherland, Laura L.; Scearce, Richard M.; Bowman, Cindy M.; Bouton-Verville, Hilary; Santra, Sampa; Wiehe, Kevin; Lewis, Mark G.; Ogbe, Ane; Borrow, Persephone; Montefiori, David; Bonsignori, Mattia; Anthony Moody, M.; Verkoczy, Laurent; Saunders, Kevin O.; Ahmed, Rafi; Mascola, John R.; Kelsoe, Garnett; Alt, Frederick W.; Haynes, Barton F.",Nat Commun,,,,document_parses/pdf_json/90d0cc333194af9af5edc789a871e1d4a159001f.json; document_parses/pdf_json/c4a7a6342be471e0059f017b0eaa850718bbeae4.json,document_parses/pmc_json/PMC7031230.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031230/,,3
5167,5167,5452,fx1ykk5z,4768acf46246f0f81d3234ab21eb5c147a7932bb,PMC,Responsiveness of various reservoir species to oral rabies vaccination correlates with differences in vaccine uptake of mucosa associated lymphoid tissues,10.1038/s41598-020-59719-4,PMC7031338,32076025.0,cc-by,oral rabies vaccination orv highly effective fox raccoon dog whereas unknown reason efficacy orv reservoir specie le pronounced investigate possible variation speciesspecific cell tropism local replication vaccine virus different reservoir specie including fox raccoon dog raccoon mongoose dog skunk orally immunised highly attenuated hightitred gfpexpressing rabies virus rabv immunofluorescence rtqpcr screening revealed clear difference among specie suggesting host specific limitation orv responsive specie palatine tonsil tonsilla palatina identified main site virus replication le virus dissemination observed tonsil rather refractory specie comparison vaccine virus tropism emphasizes important role tonsilla palatina play eliciting immune response orv data also indicate lymphoid tissue may important role originally anticipated overall data support model susceptibility oral live rabv vaccine infection lymphatic tissue major determinant vaccination efficacy present result may help direct future research improving vaccine uptake efficacy oral rabies vaccine field condition,2020-02-19,"te Kamp, Verena; Freuling, Conrad M.; Vos, Ad; Schuster, Peter; Kaiser, Christian; Ortmann, Steffen; Kretzschmar, Antje; Nemitz, Sabine; Eggerbauer, Elisa; Ulrich, Reiner; Schinköthe, Jan; Nolden, Tobias; Müller, Thomas; Finke, Stefan",Sci Rep,,,,document_parses/pdf_json/4768acf46246f0f81d3234ab21eb5c147a7932bb.json,document_parses/pmc_json/PMC7031338.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031338/,,3
5180,5180,5465,96rrh93f,096387227e48d4927ed4914abfc0f60f3a6f2214,PMC,Preclinical Development of a Fusion Peptide Conjugate as an HIV Vaccine Immunogen,10.1038/s41598-020-59711-y,PMC7033230,32080235.0,cc-by,vaccine elicitation broadly neutralizing antibody hiv longsought goal previously reported aminoterminal eight residue hivfusion peptide fp – conjugated carrier protein keyhole limpet hemocyanin klh – capable inducing broadly neutralizing response hiv animal model however klh multisubunit particle derived natural source manufacture clinical product remains challenge report preclinical development recombinant tetanus toxoid heavy chain fragment rtthc linked fp fprtthc suitable fpconjugate vaccine immunogen assessed conjugate made coupling prevalent fp sequence carrier protein aforementioned klh rtthc h influenzae protein hid crossreactive material diphtheria toxin crm fpcarrier conjugate could elicit hivneutralizing response rtthc conjugate induced higher fpdirected response overall sulfosiab linker yielded superior result smpeg linker combination carrier conjugation ratio peptide carrier choice adjuvant adjuplex alum significantly impact elicited fpdirected neutralizing response mouse overall siablinked fprtthc appears promising vaccine candidate advancing clinical assessment,2020-02-20,"Ou, Li; Kong, Wing-Pui; Chuang, Gwo-Yu; Ghosh, Mridul; Gulla, Krishana; O’Dell, Sijy; Varriale, Joseph; Barefoot, Nathan; Changela, Anita; Chao, Cara W.; Cheng, Cheng; Druz, Aliaksandr; Kong, Rui; McKee, Krisha; Rawi, Reda; Sarfo, Edward K.; Schön, Arne; Shaddeau, Andrew; Tsybovsky, Yaroslav; Verardi, Raffaello; Wang, Shuishu; Wanninger, Timothy G.; Xu, Kai; Yang, Gengcheng J.; Zhang, Baoshan; Zhang, Yaqiu; Zhou, Tongqing; Arnold, Frank J.; Doria-Rose, Nicole A.; Lei, Q. Paula; Ryan, Edward T.; Vann, Willie F.; Mascola, John R.; Kwong, Peter D.",Sci Rep,,,,document_parses/pdf_json/096387227e48d4927ed4914abfc0f60f3a6f2214.json,document_parses/pmc_json/PMC7033230.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033230/,,3
5196,5196,5481,rh6dhtxj,5d3a621f6939e479c4996331dbd24e39841c7b46,PMC,Adaption of the ex vivo mycobacterial growth inhibition assay for use with murine lung cells,10.1038/s41598-020-60223-y,PMC7039920,32094451.0,cc-by,absence correlate protection human tuberculosis validated animal model disease tool facilitate vaccine development must identified present optimised ex vivo mycobacterial growth inhibition assay mgia ass ability host cell within lung inhibit mycobacterial growth including bacille calmette–guérin bcg mycobacterium tuberculosis mtb erdman growth bcg reduced log cfu following subcutaneous sc bcg intranasal bcg bcg sc mucosal boost respectively versus naïve mouse comparatively sc sc mucosal boost log reduction mtb cfu found bcg growth inhibitor thiophenecarboxylic acid hydrazide tch used prevent quantification residual bcg immunisation allow accurate mtb quantification using tch log reduction mtb cfu revealed group combination existing method ex vivo lung mgia may represent important tool analysis vaccine efficacy immune mechanism associated vaccination organ primarily affected mtb disease,2020-02-24,"Painter, Hannah; Prabowo, Satria A.; Cia, Felipe; Stockdale, Lisa; Tanner, Rachel; Willcocks, Samuel; Reljic, Rajko; Fletcher, Helen A.; Zelmer, Andrea",Sci Rep,,,,document_parses/pdf_json/5d3a621f6939e479c4996331dbd24e39841c7b46.json,document_parses/pmc_json/PMC7039920.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7039920/,,3
5211,5211,5497,08dljap3,95d7c21ff4b6cb33bda814d13a6e6eaba5d7d68b,PMC,Complete Protection in Macaques Conferred by Purified Inactivated Zika Vaccine: Defining a Correlate of Protection,10.1038/s41598-020-60415-6,PMC7044319,32103097.0,cc-by,critical global health need exists zika vaccine capable mitigating effect future zika epidemic study evaluated antibody response efficacy aluminum hydroxide adjuvanted purified inactivated zika vaccine pizv challenge zika virus zikv strain prvabc indian rhesus macaque received two dos pizv varying concentration ranging µg − µg subsequently challenged zikv six week one year following second immunization pizv induced dosedependent immune response boosted second immunization complete protection zikv infection achieved higher pizv dos µg µg µg week ug pizv year following vaccination partial protection achieved lower pizv dos µg µg based data neutralizing antibody response log ec determined correlate protection macaque pizv elicited dosedependent neutralizing antibody response protective least year following vaccination,2020-02-26,"Young, Ginger; Bohning, Kelly J.; Zahralban-Steele, Melissa; Hather, Greg; Tadepalli, Sambasivarao; Mickey, Kristen; Godin, C. Steven; Sanisetty, Srisowmya; Sonnberg, Stephanie; Patel, Hetal K.; Dean, Hansi J.",Sci Rep,,,,document_parses/pdf_json/95d7c21ff4b6cb33bda814d13a6e6eaba5d7d68b.json,document_parses/pmc_json/PMC7044319.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044319/,,3
5227,5227,5513,l66ost6q,8dad92c1030a6547f112250184572c50dae43c8d,PMC,Immunoinformatics and Vaccine Development: An Overview,10.2147/itt.s241064,PMC7049754,32161726.0,cc-by-nc,use vaccine resulted remarkable improvement global health saved several life reduced treatment cost raised quality animal human life current traditional vaccine came empirically either vague completely knowledge modulate immune system even face potential vaccine design advance immunerelated concern seen specific vulnerable population case emergingreemerging infectious disease pathogen complex lifecycle antigenic variability need personalized vaccination concern vaccine immunological safety specifically vaccine likelihood trigger nonantigenspecific response may cause autoimmunity vaccine allergy raised concern driven immunologist toward research better approach vaccine design consider challenge currently immunoinformatics paved way better understanding infectious disease pathogenesis diagnosis immune system response computational vaccinology importance immunoinformatics study infectious disease diverse term computational approach used united common quality related host–pathogen relationship bioinformatics method also used assign function uncharacterized gene targeted candidate vaccine design better approach toward inclusion woman pregnant vaccine trial program essence review give insight need focus novel computational experimental computationdriven experimental approach studying host–pathogen interaction thus making case use vaccine development,2020-02-26,"Oli, Angus Nnamdi; Obialor, Wilson Okechukwu; Ifeanyichukwu, Martins Ositadimma; Odimegwu, Damian Chukwu; Okoyeh, Jude Nnaemeka; Emechebe, George Ogonna; Adejumo, Samson Adedeji; Ibeanu, Gordon C",Immunotargets Ther,,,,document_parses/pdf_json/8dad92c1030a6547f112250184572c50dae43c8d.json,document_parses/pmc_json/PMC7049754.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049754/,,3
5231,5231,5517,0xj6zk31,09202b5dcb04f88711ac3757998c296603a65ae9,PMC,Microarray analyses reveal strain-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 variants following natural infection and vaccination,10.1038/s41598-020-60551-z,PMC7054363,32127565.0,cc-by,vaccine based plasmodium falciparum apical membrane antigen ama failed due extensive polymorphism ama ass strainspecificity antibody response malaria infection ama vaccination designed protein peptide microarrays representing hundred unique ama variant following clinical malaria episode child shortlived sequenceindependent increase average wholeprotein seroreactivity well strainspecific response peptide representing diverse epitope vaccination resulted dramatically increased seroreactivity ama wholeprotein variant highdensity peptide analysis revealed vaccinated child increase seroreactivity four distinct epitope exceeded response natural infection single amino acid change critical seroreactivity peptide region ama associated strainspecific vaccine efficacy antibody measurement using whole antigen may biased towards conserved immunodominant epitope peptide microarrays may help identify immunogenic epitope define correlate vaccine protection measure strainspecific vaccineinduced antibody,2020-03-03,"Bailey, Jason A.; Berry, Andrea A.; Travassos, Mark A.; Ouattara, Amed; Boudova, Sarah; Dotsey, Emmanuel Y.; Pike, Andrew; Jacob, Christopher G.; Adams, Matthew; Tan, John C.; Bannen, Ryan M.; Patel, Jigar J.; Pablo, Jozelyn; Nakajima, Rie; Jasinskas, Algis; Dutta, Sheetij; Takala-Harrison, Shannon; Lyke, Kirsten E.; Laurens, Matthew B.; Niangaly, Amadou; Coulibaly, Drissa; Kouriba, Bourema; Doumbo, Ogobara K.; Thera, Mahamadou A.; Felgner, Philip L.; Plowe, Christopher V.",Sci Rep,,,,document_parses/pdf_json/09202b5dcb04f88711ac3757998c296603a65ae9.json,document_parses/pmc_json/PMC7054363.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054363/,,3
5257,5257,5547,m2fwefuy,c95bc52314489ac00018c205dd17e5250f361d2b,PMC,Vaccine-Induced Th1-Type Response Protects against Invasive Group A Streptococcus Infection in the Absence of Opsonizing Antibodies,10.1128/mbio.00122-20,PMC7064752,32156809.0,cc-by,recent global advocacy effort highlighted importance development vaccine group streptococcus gas combo nonm proteinbased vaccine provides protection gas skin infection mouse reduces severity pharyngitis nonhuman primate however combo addition aluminum hydroxide alum adjuvant failed protect invasive gas infection mouse show formulation combo adjuvant containing saponin q significantly improves protective efficacy even though adjuvant tested generated high antigenspecific igg antibody titer including alum detailed characterization combo formulated smq adjuvant squaleneinwater emulsion containing tlr agonist q showed significant difference result obtained alum igg subclass generated following immunization absence gas opsonizing antibody smq alum generated strong interleukin il gamma interferon ifnγ tumor necrosis alpha tnfα response work highlight importance adjuvant selection nonm proteinbased gas vaccine optimize immune response protective efficacy,2020-03-10,"Rivera-Hernandez, Tania; Rhyme, Mira Syahira; Cork, Amanda J.; Jones, Scott; Segui-Perez, Celia; Brunner, Livia; Richter, Johanna; Petrovsky, Nikolai; Lawrenz, Maria; Goldblatt, David; Collin, Nicolas; Walker, Mark J.",mBio,,,,document_parses/pdf_json/c95bc52314489ac00018c205dd17e5250f361d2b.json,document_parses/pmc_json/PMC7064752.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064752/,,3
5282,5282,5574,gs9pii1d,9f890263add8ebfefec469c4a61ae25f3b6327dd,PMC,Economic evaluation of meningococcal vaccines: considerations for the future,10.1007/s10198-019-01129-z,PMC7072054,31754924.0,cc-by,panel health economics meningococcal disease expert convened review methodology framework decisionmaking process economic evaluation vaccine focus evaluation vaccine targeting invasive meningococcal disease imd panel discussed vaccine evaluation method across country imd prevention benefit well quantified using current method well quantified missing current costeffectiveness methodology development recommendation future evaluation method consensus reached number point consideration deemed necessary topic expert agreed unpredictability imd complicates accurate evaluation meningococcal vaccine benefit vaccine costeffectiveness evaluation encompass indirect benefit meningococcal vaccine vaccine general addition panel agreed transparency vaccine decisionmaking process beneficial implemented possible discussion required ascertain enhancing consistency framework evaluating outcome vaccine introduction improved review existing tool used capture quality life indirect cost considered within model whether weighting qualityadjusted lifeyears qaly application qaly adjustment factor use altered costeffectiveness threshold used economic evaluation vaccine,2019-11-21,"Christensen, Hannah; Al-Janabi, Hareth; Levy, Pierre; Postma, Maarten J.; Bloom, David E.; Landa, Paolo; Damm, Oliver; Salisbury, David M.; Diez-Domingo, Javier; Towse, Adrian K.; Lorgelly, Paula K.; Shah, Koonal K.; Hernandez-Villafuerte, Karla; Smith, Vinny; Glennie, Linda; Wright, Claire; York, Laura; Farkouh, Raymond",Eur J Health Econ,,,,document_parses/pdf_json/9f890263add8ebfefec469c4a61ae25f3b6327dd.json,document_parses/pmc_json/PMC7072054.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7072054/,,3
5302,5302,5597,jd1wxobz,d6961703fbc4b3305ec67e5458cfb9ff76a885ba,PMC,DNA vaccines: are they still just a powerful tool for the future?,10.1007/s00005-007-0044-4,PMC7079751,18060369.0,no-cc,vaccination historically one successful strategy prevention infectious disease safety reason modern vaccinology tends toward usage inactivated attenuated microorganism us predominantly subunit vaccine antigen need clearly defined pure stable appropriately composed properly presented immune system host differing ratio various proportion specific cd cd cell response essential conferring required protection case individual vaccine stimulate cd cd cell antigen must processed presented antigenpresentation pathway mhc mhc ii protein antigen delivered vaccination processed extracellular antigen however extracellularly delivered antigen directed towards intracellular presentation pathway conjugation molecule involved antigen crosspresentation eg heat shock protein genomicdna vaccination overview current knowledge host immune response dna vaccine summarized introduction subsequent section discus technique enhancing dna vaccine efficacy dna delivery specific tissue delivery dna cell cytoplasm nucleus enhancement immune response using molecular adjuvant finally prospect dna vaccination ongoing clinical trial various dna vaccine discussed,2007-12-03,"Běláková, Jana; Horynová, Milada; Křupka, Michal; Weigl, Evžen; Raška, Milan",Arch Immunol Ther Exp (Warsz),,,,document_parses/pdf_json/d6961703fbc4b3305ec67e5458cfb9ff76a885ba.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079751/,,3
5352,5352,5657,2sg1tlrg,44232419011da5172b4e950153f8fe563563e7e2,PMC,Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector,10.1007/s00281-006-0042-3,PMC7079905,16977404.0,no-cc,recombinant vesicular stomatitis virus rvsv currently evaluation human immunodeficiency virus hiv vaccine vector compelling reason develop rvsv vaccine vector include low seroprevalence human ability infect robustly express foreign antigen broad range cell vigorous growth continuous cell line used vaccine manufacture numerous preclinical study rvsv vector expressing antigen variety human pathogen demonstrated versatility flexibility potential efficacy rvsv vaccine platform administered nonhuman primate nhps rvsv vector expressing hiv gag env elicited robust hivspecific cellular humoral immune response animal immunized rvsv vector expressing simian immunodeficiency virus siv gag hiv env protected aid challenge pathogenic sivhiv recombinant however result exploratory neurovirulence study nhps indicated prototypic rvsv vector might adequately attenuated widespread use human population address safety concern variety different attenuation strategy designed produce range attenuated rvsv vector currently investigation additional modification attenuated rvsv vector upregulate expression hiv antigen coexpress molecular adjuvant also developed effort balance immunogenicity attenuation,2006-09-15,"Clarke, David K.; Cooper, David; Egan, Michael A.; Hendry, R. Michael; Parks, Christopher L.; Udem, Stephen A.",Springer Semin Immunopathol,,,,document_parses/pdf_json/44232419011da5172b4e950153f8fe563563e7e2.json,document_parses/pmc_json/PMC7079905.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079905/,,3
5368,5368,5679,zciyvo29,7e46ae0414399709f36d00a9bff2ec3b362784bf,PMC,Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus,10.1007/s00253-007-1073-y,PMC7079952,17581748.0,no-cc,severe acute respiratory syndrome sars caused novel coronavirus cov sarscov previous study showed sarscov spike glycoproteinbased modified vaccinia ankara mvas vaccine could induce strong neutralizing antibody nab response might played critical role protecting chinese rhesus monkey pathogenic viral challenge date however remains unknown minimal level nab required achieve sterile immunity human therefore important explore technique maximize level nab response vivo evaluate various vaccination regimen using combination dna mvas adenovirus type ad vaccine show vaccinated mouse rabbit heterologous mvas prime ad boost regimen induces highest persistent level nab response compared combination interestingly initial level nab prime necessarily predict magnitude secondary response boost thus data provides promising optimal regimen vaccine development human sarscov infection,2007-06-21,"Ba, Lei; Yi, Christopher E.; Zhang, Linqi; Ho, David D.; Chen, Zhiwei",Appl Microbiol Biotechnol,,,,document_parses/pdf_json/7e46ae0414399709f36d00a9bff2ec3b362784bf.json,document_parses/pmc_json/PMC7079952.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079952/,,3
5399,5399,5720,wd12nhq5,f85045999d4040e8ec330b861f676b07c817122f,PMC,Recent advances and safety issues of transgenic plant-derived vaccines,10.1007/s00253-012-4566-2,PMC7080054,23447052.0,no-cc,transgenic plantderived vaccine comprise new type bioreactor combine plant genetic engineering technology organism immunological response combination considered bioreactor produced introducing foreign gene plant elicit special immunogenicity introduced animal human being comparison traditional vaccine plant vaccine significant advantage low cost greater safety greater effectiveness number recent study antigenspecific protein successfully expressed various plant tissue even tested animal human being therefore edible vaccine transgenic plant bright future review begin discussion immune mechanism expression system transgenic plant vaccine current advance different transgenic plant vaccine analyzed including vaccine pathogenic virus bacteria eukaryotic parasite view low expression level antigen plant highlevel expression strategy foreign protein transgenic plant recommended finally existing safety problem transgenic plant vaccine put forward discussed along number appropriate solution hopefully lead future clinical application edible plant vaccine,2013-03-01,"Guan, Zheng-jun; Guo, Bin; Huo, Yan-lin; Guan, Zheng-ping; Dai, Jia-kun; Wei, Ya-hui",Appl Microbiol Biotechnol,,,,document_parses/pdf_json/f85045999d4040e8ec330b861f676b07c817122f.json,document_parses/pmc_json/PMC7080054.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080054/,,3
5414,5414,5740,mksutjae,ed39eb0ca4b70bb930451b74bf8dd59110757f90,PMC,Prävention von Infektionskrankheiten in Industrieländern,10.1007/s00108-007-1996-5,PMC7080110,18210025.0,no-cc,prevention infectious disease targeted individual specific risk group community vaccine one costeffective medical intervention protect individual community vaccine preventable disease immunization program aim control eliminate eradicate infectious pathogen industrialized country several vaccine preventable disease almost eliminated strict implementation recommendation influenza pneumococcal immunization crucial reduce morbidity mortality hence uptake recommended immunization among adult elderly people often low internal specialist demanded improve vaccine coverage age group,2008-01-10,"Abu Sin, M.; Suttorp, N.",Internist (Berl),,,,document_parses/pdf_json/ed39eb0ca4b70bb930451b74bf8dd59110757f90.json,document_parses/pmc_json/PMC7080110.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7080110/,,3
5512,5512,5855,18js044m,6b1fbf43bb3e6169fd35ac120f7fe1609f324e8a,PMC,Attenuated Respiratory Syncytial Virus Vaccines in Asthmatic Children,10.1203/00006450-197407000-00001,PMC7086601,4601222.0,no-cc,extract two live “ attenuated ” respiratory syncytial virus rsv vaccine administered intranasally aerosol placebocontrolled trial among asthmatic child hospitalized national jewish hospital research center njh first vaccine ° adapted rsv vaccine given child placebo control given twentyone vaccinee “ take ” judged virus shedding andor rise serum antibody andor rise nasal secretion neutralizing activity excess wheezing attributable vaccine administration although high background level acute respiratory symptom vaccinee control subject outbreak natural rsv infection occurred month vaccine given evidence received vaccine le month exposure wild virus protected reinfection protection evident interval greater month second vaccine temperaturesensitive mutant strain t administered child placebo thirteen child “ take ” vaccinee year age “ take ” excess wheezing seen vaccinee compared control subject although evidence upper respiratory symptom frequent younger vaccinee four vaccinee shed virus temperaturesensitive characteristic somewhat different vaccine strain vaccine virus demonstrated spread uninoculated placebo control child natural rsv challenge occur period study speculation one two live “ attenuated ” rsv vaccine may produced brief period protection natural infection finding offer hope live vaccine might prevent disease selected child critical time period infant st year life allergic asthmatic child period epidemic prevalence asthmatic child appear develop symptom wheezing attenuated rsv infection finding suggests mechanism wheezing asthmatic child rsv infection may dependent among factor virulence virus strain perhaps capacity replicate possibly invade lower respiratory tract rather allergic response antigen introduced limited upper airway view spread t vaccine apparent loss temperature sensitivity vaccinee vaccine may potential reversion virulence hence initiation epidemic disease characteristic undesirable live respiratory virus vaccine possible avoided development future vaccine,1974,"Mcintosh, Kenneth; Arbeter, Allan M; Stahl, Marlene K; Orr, Inara A; Hodes, David S; Ellis, Elliot F",Pediatr Res,,,,document_parses/pdf_json/6b1fbf43bb3e6169fd35ac120f7fe1609f324e8a.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086601/,,3
5611,5611,5962,qcmsmfad,1c044167282ced278033dd4904a154a1ce0ce956,PMC,Contamination of live attenuated vaccines with an infectious feline endogenous retrovirus (RD-114 virus),10.1007/s00705-013-1809-1,PMC7086779,24068581.0,no-cc,retrovirus classified exogenous endogenous retrovirus according mode transmission endogenous retrovirus ervs retrovirus integrated germline cell inherited parent offspring ervs inactivated deletion mutation however certain ervs maintain infectivity infect host new host exogenous retrovirus domestic cat infectious ervs termed rd virus several canine feline attenuated vaccine manufactured using rd virusproducing cell line crandellrees feline kidney cell therefore possible infectious rd virus contaminates live attenuated vaccine recently japanese uk research group found several feline canine vaccine indeed contaminated infectious rd virus first incidence contamination ‘ infectious ’ ervs live attenuated vaccine rd virus replicates efficiently canine cell line primary cell therefore possible rd virus infects dog following inoculation contaminated vaccine induces proliferative disease immune suppression adapts grow efficiently dog review summarize incidence contamination rd virus live attenuated vaccine potential risk infection rd virus dog electronic supplementary material online version article doi contains supplementary material available authorized user,2013-09-26,"Yoshikawa, Rokusuke; Shimode, Sayumi; Sakaguchi, Shoichi; Miyazawa, Takayuki",Arch Virol,,,,document_parses/pdf_json/1c044167282ced278033dd4904a154a1ce0ce956.json,document_parses/pmc_json/PMC7086779.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086779/,,3
5860,5860,6230,iery2rbq,2b8ae6e6566252b0c6292ffa2c79c66fd924d346,PMC,Distribution of infectious bronchitis virus strains in different organs and evidence of vertical transmission in natural infection,10.1007/s00705-016-3030-5,PMC7087270,27586414.0,no-cc,basis partial sequencing infectious bronchitis virus ibv gene study investigated molecular diversity virus two life period batch breeding hen field level chick vaccinated ibv second day life vaccine age day exhibited clinical sign macroscopic lesion compatible avian infectious bronchitis ib clinical disease stage vaccine strain detected trachea lung small intestine chick ibv variant detected bursa fabricius kidney subsequently new sample collected batch end production cycle phase vaccine strain detected kidney small intestine oviduct hen however previously unidentified ibv variant found cecal tonsil additionally fragment viral rna completely identical corresponding region vaccine detected allantoic fluid viable embryo hen study day incubation finding suggest addition vaccine strain ibv variant coexist seeming establish chronic infection chicken potentially transmitted vertically result may assist immunoprophylaxis control program ibv electronic supplementary material online version article doi contains supplementary material available authorized user,2016-09-01,"Pereira, Claiton Gonçalves; Saraiva, Giuliana Loreto; Vidigal, Pedro Marcus Pereira; Fietto, Juliana Lopes Rangel; Bressan, Gustavo Costa; Moreira, Maria Aparecida Scatamburlo; de Almeida, Márcia Rogéria; Júnior, Abelardo Silva",Arch Virol,,,,document_parses/pdf_json/2b8ae6e6566252b0c6292ffa2c79c66fd924d346.json,document_parses/pmc_json/PMC7087270.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087270/,,3
6184,6184,6628,6xkx9a56,9d2643272ef6fb8325b194e981041cabf01852a8,PMC,Immunizations in the elderly: do they live up to their promise?,10.1007/s10354-006-0267-8,PMC7088340,16823527.0,no-cc,st century public health challenged newly emerging reemerging infectious disease also demographic development taking place many country importantly infection elderly frequent severe distinct feature respect clinical presentation treatment due decline function immune system referred immunosenescence important agerelated change affect cell system although derogates protective effect vaccine vaccination still considered costeffective medical procedure preventing morbidity mortality caused infectious disease present article aim outlining impact infectious disease elderly summarizing progress made field vaccination elderly agerelated change within immune system contribute decreased efficacy vaccine,2006,"Herndler-Brandstetter, Dietmar; Cioca, Daniel P.; Grubeck-Loebenstein, Beatrix",Wien Med Wochenschr,,,,document_parses/pdf_json/9d2643272ef6fb8325b194e981041cabf01852a8.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088340/,,3
6250,6250,6705,1l87fdmi,f984581b313ab9c4de4d6974efe3d9da5bb1f6e0,PMC,Neutralizing immunogenicity of transgenic carrot (Daucus carota L.)-derived measles virus hemagglutinin,10.1023/a:1022354322226,PMC7088612,12650613.0,no-cc,although edible vaccine seem feasible antigen human pathogen mostly expressed plant attractive human consumption potato unless cooked boiling may reduce immunogenicity many antigen recently technology transform fruit vegetable plant become perfected transformed carrot plant agrobacterium tumefaciens generate plant eaten raw transgenic immunodominant antigen measles virus major pathogen man hemagglutinin h glycoprotein principle target neutralizing protective antibody measles copy number h transgene verified southern blot specific transcription confirmed rtpcr h protein detected western blot membrane fraction transformed carrot plant recombinant protein seemed lower molecular weight viral protein although suggests different glycosylation pattern proper folding transgenic protein confirmed conformationaldependent monoclonal antibody immunization mouse leaf root extract induced high titre igg igga antibody crossreacted strongly measles virus neutralized virus vitro result demonstrate transgenic carrot plant used efficient expression system produce highly immunogenic viral antigen study may pave way towards edible vaccine measles could complementary current liveattenuated vaccine,2003,"Marquet-Blouin, E.; Bouche, F.B.; Steinmetz, A.; Muller, C.P.",Plant Mol Biol,,,,document_parses/pdf_json/f984581b313ab9c4de4d6974efe3d9da5bb1f6e0.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088612/,,3
6272,6272,6728,eg6ong1j,b7e1256e7e210aa650837d8426fcfb9c1855f8cf,PMC,Antiparasitic DNA vaccines in 21(st) century,10.1515/ap-2015-0026,PMC7088677,26203983.0,no-cc,demand effective vaccine control parasitic disease human livestock recently exacerbated development resistance pathogenic parasite antiparasitic drug novel genomic proteomic technology provided opportunity discovery improvement dna vaccine relatively easy well cheap fabricate stable room temperature however main limitation rather poor immunogenicity make necessary couple antigen adjuvant molecule paper review recent advance development dna vaccine pathogenic protozoa helminth numerous study conducted past year st century employing various administration technique adjuvant new immunogenic antigen increase efficacy dna vaccine unfortunately result rewarding research necessary using extensive combination antigen alternate delivery system efficient adjuvant based knowledge immunomodulatory capacity parasitic protozoa helminth,2015-04-01,"Wedrychowicz, Halina",Acta Parasitol,,,,document_parses/pdf_json/b7e1256e7e210aa650837d8426fcfb9c1855f8cf.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088677/,,3
6310,6310,6773,9u25qe3n,904982897704e4f7da459f4f57f2ae2d189fc198,PMC,Novel Approaches to Vaccine Delivery,10.1023/b:pham.0000041443.17935.33,PMC7088827,15497674.0,no-cc,although currently available vaccine represent outstanding success story modern medicine dramatic effect morbidity mortality worldwide clear improvement required current vaccine delivery technology improvement required enable successful development vaccine infectious disease far proven difficult control conventional approach improvement may include addition novel injectable adjuvant use novel route delivery including mucosal immunization mucosal delivery may required provide protection pathogen infect mucosal site including sexually transmitted disease alternatively novel approach delivery including mucosal administration may used improve compliance existing vaccine particular interest safer mass immunization campaign needlefree delivery device would avoid problem due needle reuse many part world would avoid needlestick injury,2004,"O'Hagan, Derek T.; Rappuoli, Rino",Pharm Res,,,,document_parses/pdf_json/904982897704e4f7da459f4f57f2ae2d189fc198.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088827/,,3
6364,6364,6842,8621p7da,c6a6b9ec0fd7d950caed1312c84c34fd92a3f951,PMC,Vaccine prevention of acute otitis media,10.1007/s11882-001-0049-8,PMC7089114,11892059.0,no-cc,incidence acute otitis medium aom infant young child increased dramatically recent year united state aom often follows upper respiratory tract infection due pathogen respiratory syncytial virus rsv influenza virus parainfluenza virus piv virus cause eustachian tube dysfunction critical pathogenesis aom vaccine virus would likely reduce incidence aom three previous study influenza virus vaccine reduced incidence aom vaccine prevent infection rsv piv type undergoing clinical testing time streptococcus pneumoniae nontypeable haemophilus influenzae nthi moraxella catarrhalis three common aom pathogen heptavalent pneumococcal conjugate vaccine effective preventing invasive disease aom caused serotypes contained vaccine vaccine candidate nthi catarrhalis development,2001,"Greenberg, David P.; Hoberman, Alejandro",Curr Allergy Asthma Rep,,,,document_parses/pdf_json/c6a6b9ec0fd7d950caed1312c84c34fd92a3f951.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089114/,,3
6426,6426,6906,1zokmlnd,3956833ecb4d48c68fabd845cb0ba44b5ae3bdd5,PMC,Production of vaccines and therapeutic antibodies for veterinary applications in transgenic plants: an overview,10.1007/s11248-007-9095-x,PMC7089296,17436059.0,no-cc,past two decade antibody antibody derivative vaccine developed therapeutic diagnostic application human veterinary medicine numerous specie dicot monocot plant genetically modified produce antibody vaccine number diverse transformation method strategy enhance accumulation pharmaceutical protein available veterinary application specific focus article particular pathogenic virus bacteria eukaryotic parasite focus advantage remaining challenge plantbased therapeutic protein veterinary application emphasis expression platform technology economic consideration,2007-04-14,"Floss, Doreen Manuela; Falkenburg, Dieter; Conrad, Udo",Transgenic Res,,,,document_parses/pdf_json/3956833ecb4d48c68fabd845cb0ba44b5ae3bdd5.json,document_parses/pmc_json/PMC7089296.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089296/,,3
6496,6496,6985,hbu25wlt,73c8ca3e77bb63ef59e98f5eccae841fd802aee4,PMC,Immune predictors of oral poliovirus vaccine immunogenicity among infants in South India,10.1038/s41541-020-0178-5,PMC7089977,32218999.0,cc-by,identification cause poor oral vaccine immunogenicity lowincome country might lead effective vaccine measured mucosal systemic immune parameter time vaccination oral poliovirus vaccine opv indian infant aged – month including plasma cytokine leukocyte count fecal biomarkers environmental enteropathy peripheral blood tcell phenotype focused guthoming regulatory cd population find distinct immune phenotype associated opv immunogenicity although viral pathogen prevalent stool time immunization among infant failed seroconvert v p using machinelearning approach could predict seroconversion priori using immune parameter infection status median accuracy crossvalidation iqr – compared expected chance better identification immune predictor opv immunogenicity likely require sampling mucosal tissue improved oral poliovirus infection model,2020-03-23,"Babji, Sudhir; Manickavasagam, Punithavathy; Chen, Yin-Huai; Jeyavelu, Nithya; Jose, Nisha Vincy; Praharaj, Ira; Syed, Chanduni; Kaliappan, Saravanakumar Puthupalayam; John, Jacob; Giri, Sidhartha; Venugopal, Srinivasan; Kampmann, Beate; Parker, Edward P. K.; Iturriza-Gómara, Miren; Kang, Gagandeep; Grassly, Nicholas C.; Uhlig, Holm H.",NPJ Vaccines,,,,document_parses/pdf_json/73c8ca3e77bb63ef59e98f5eccae841fd802aee4.json,document_parses/pmc_json/PMC7089977.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089977/,,3
6514,6514,7012,4h02bb70,a2936d9ddb597cf96d2c76f45b1554efb43fdc06,PMC,Exploiting virus-like particles as innovative vaccines against emerging viral infections,10.1007/s12275-017-7058-3,PMC7090582,28243941.0,no-cc,emerging virus pose major threat human livestock global public health economic burden vaccination remains effective tool reduce threat yet conventional cell culture often fails produce sufficient vaccine dose alternative cellculture based vaccine viruslike particle vlps considered highpriority vaccine strategy emerging virus vlps represent highly ordered repetitive structure via macromolecular assembly viral protein particulate nature allows efficient uptake antigen presenting cell stimulating innate adaptive immune response towards enhanced vaccine efficacy increasing research activity translation opportunity necessitate advance design vlps new bioprocessing modality efficient costeffective production herein describe major achievement challenge endeavor respect designing strategy harnessing immunogenic potential production platform downstream process exemplary case developing vlpbased vaccine,2017-02-28,"Jeong, Hotcherl; Seong, Baik Lin",J Microbiol,,,,document_parses/pdf_json/a2936d9ddb597cf96d2c76f45b1554efb43fdc06.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7090582/,,3
6572,6572,7082,vejbxne9,3e88e718b057ba3e73b9e1e811f39bf3c2a7afd2,PMC,Moloney leukemia virus-induced cell surface antigen mimicry by monoclonal antibodies,10.1007/bf02935626,PMC7091151,8722045.0,no-cc,investigated antigenindependent modulation immune response monoclonal antibody directed viral nonviral antigen balbc mouse immunized monoclonal igm ie ab specific either moloney murine leukemia virusinduced cell surface antigen mcsa hapten dinitrophenyl dnp injection either ab activated functional idiotypic id network evidenced production antiid ab antibody antiantiid ab antibody subset induced ab designated ab exhibited specificity antigen virus dnp mouse immunized antiid antibody ab production ab ab′ also observed mcsa system antibodyinduced ab′ response effective protecting mouse tumor development upon subsequent challenge live virus furthermore antigenindependent modulation immunity viral nonviral antigen found thymusdependent similar finding viral system suggest antibodyinduced activation id network may prove viable alternative vaccine strategy elicit antigenspecific response case protection apparent absence exposure antigen,1995,"Baskin, Julie G.; Powell, Thomas J.; Srinivas, R. V.; Elliott, Meenal; Lamon, Eddie W.",Immunol Res,,,,document_parses/pdf_json/3e88e718b057ba3e73b9e1e811f39bf3c2a7afd2.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091151/,,3
6610,6610,7124,50lmj4op,c2a29c04b0e28e374c5b2386030ff42fff388eaf,PMC,Overview of vaccines and vaccination,10.1385/mb:29:3:255,PMC7091467,15767703.0,no-cc,plus known infectious agent pathogenic human vaccine mainly viral bacterial infection greatly minimize subsequent disease prevent death exposure agent article describes nature vaccine live attenuated agent subunit efficacy safety kind immune response generated vaccine effective date licensed vaccine generate especially specific antibody attach infectious agent therefore largely prevent infection vaccine effective developed country preventing mortality subsequent infection attempt made develop vaccine many remaining infectious agent many latter difficult manipulate cause persisting infection show great antigenic variation range new approach improve selected immune response immunization dna chimeric live vector viral bacterial intense scrutiny well genomic analysis agent,2005,"Ada, Gordon",Mol Biotechnol,,,,document_parses/pdf_json/c2a29c04b0e28e374c5b2386030ff42fff388eaf.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091467/,,3
6619,6619,7136,wphc23nf,e14427577e7e07ddce1b218bcaf48f1ac5cc6d40,PMC,Evolutionary implications of Avian Infectious Bronchitis Virus (AIBV) analysis,10.1038/sj.cr.7310041,PMC7091586,16541132.0,no-cc,developing efficient vaccine essential identify amino acid change important survival virus investigate amino acid substitution feature avian infectious bronchitis virus aibv antigenic domain vaccine serotype de virulent viral strain ga better understand adaptive evolution aibv addition sars coronavirus sarscov also analyzed way interesting find extreme comparability exists aibv sars amino acid substitution pattern suggests amino acid change result overall shift residue charge polarity paid special attention development vaccine,2006-03-16,"Shi, Peng; Yu, Li; Fu, Yun-xin; Huang, Jing-Fei; Zhang, Ke-Qin; Zhang, Ya-ping",Cell Res,,,,document_parses/pdf_json/e14427577e7e07ddce1b218bcaf48f1ac5cc6d40.json,document_parses/pmc_json/PMC7091586.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091586/,,3
6641,6641,7159,n3fs7533,a7136066a42782369e2180e54010553e5fd7bbe4,PMC,Use of adenoviral vectors as veterinary vaccines,10.1038/sj.gt.3302618,PMC7091679,16231058.0,no-cc,vaccine effective inexpensive prophylactic tool veterinary medicine ideally vaccine induce lifelong protective immunity target pathogen causing clinical pathological sign disease vaccinated animal however ideal vaccine rare veterinary field many vaccine either limited effectiveness harmful side effect addition still severe disease effective vaccine important criterion ideal vaccine veterinary medicine low cost especially important developing country even poultry vaccination vaccine must sell cent dose traditional approach include inactivated vaccine attenuated live vaccine subunit vaccine recently genetic engineering applied design new improved vaccine adenovirus vector highly efficient gene transfer broad spectrum cell type specie moreover adenovirus often induce humoral mucosal cellular immune response antigen encoded inserted foreign gene thus adenovirus become vector choice delivery expression foreign protein vaccination consequently market requirement adenovirus vaccine increasing creating need production methodology concentrated vector warranted purity efficacy review summarizes recent development approach adenovirus production purification application vector including success failure clinical application date,2005-10-18,"Ferreira, T B; Alves, P M; Aunins, J G; Carrondo, M J T",Gene Ther,,,,document_parses/pdf_json/a7136066a42782369e2180e54010553e5fd7bbe4.json,document_parses/pmc_json/PMC7091679.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091679/,,3
6694,6694,7230,j9qucb0k,7d67e7ef4b8a49008ae8d88816b68811da0b1881,PMC,T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates,10.1038/gt.2016.55,PMC7091906,27416077.0,no-cc,immune response multiple epitope required prevention hepatitis c virus hcv infection progression phase trial candidate may guided comparative immunogenicity study nonhuman primate four vector dna sfv human serotype adenovirus huad modified vaccinia ankara mva poxvirus expressing hepatitis c virus core e e n combined three primeboost regimen ability elicit immune response hcv antigen rhesus macaque explored compared combination induced specific tcell immune response including high ifnγ production group immunized sfvmva regimen elicited higher especific response compared two modality animal receiving huad injection elicited lower il response compared receiving mva ifnγ response n remarkably similar group adenovirus induced envelopespecific antibody response failed show neutralizing activity therefore two novel regimen failed induce superior response compared already existing hcv vaccine candidate difference found response envelope protein relevance remain uncertain given surprisingly poor correlation immunogenicity data chimpanzee underlining difficulty predict efficacy immunology study supplementary information online version article doigt contains supplementary material available authorized user,2016-07-14,"Rollier, C S; Verschoor, E J; Verstrepen, B E; Drexhage, J A R; Paranhos-Baccala, G; Liljeström, P; Sutter, G; Arribillaga, L; Lasarte, J J; Bartosch, B; Cosset, F-L; Inchauspe, G; Heeney, J L",Gene Ther,,,,document_parses/pdf_json/7d67e7ef4b8a49008ae8d88816b68811da0b1881.json,document_parses/pmc_json/PMC7091906.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091906/,,3
6732,6732,7281,0tk38fs4,bca052bc8803da1be4388a5f7466b0005dff7893,PMC,In-depth characterization of a novel live-attenuated Mayaro virus vaccine candidate using an immunocompetent mouse model of Mayaro disease,10.1038/s41598-020-62084-x,PMC7093544,32210270.0,cc-by,mayaro virus mayv endemic south american country responsible sporadic outbreak acute febrile illness hallmark mayv infection highly debilitating chronic arthralgia although mayv emergence potential threat specific therapy licensed vaccine study developed murine model mayv infection emulates many relevant clinical feature infection human tested liveattenuated mayv vaccine candidate mayvires intraplantar inoculation wt strain mayv immunocompetent mouse induced persistent hypernociception transient viral replication target organ systemic production inflammatory cytokine chemokines specific humoral igm igg response inoculation mayvires balbc mouse induced strong specific cellular humoral response moreover mayvires vaccination immunocompetent interferon receptordefective mouse resulted protection disease induced virulent wt mayv strain thus study describes novel model mayv infection immunocompetent mouse highlight potential role liveattenuated mayv vaccine candidate host ’ protection disease induced virulent mayv strain,2020-03-24,"Mota, Mânlio Tasso de Oliveira; Costa, Vivian Vasconcelos; Sugimoto, Michelle Amantéa; Guimarães, Georgia de Freitas; Queiroz-Junior, Celso Martins; Moreira, Thaiane Pinto; de Sousa, Carla Daiane; Santos, Franciele Martins; Queiroz, Victoria Fulgêncio; Passos, Ingredy; Hubner, Josy; Souza, Danielle Gloria; Weaver, Scott C.; Teixeira, Mauro Martins; Nogueira, Maurício Lacerda",Sci Rep,,,,document_parses/pdf_json/bca052bc8803da1be4388a5f7466b0005dff7893.json,document_parses/pmc_json/PMC7093544.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7093544/,,3
6765,6765,7328,brb8gpgm,7db7b0550faee19a2b3ab0b3a707410cc99eb56d,PMC,Peptide-Based Vaccines: Current Progress and Future Challenges,10.1021/acs.chemrev.9b00472,PMC7094793,31804810.0,no-cc,image see text vaccine profound impact management prevention infectious disease addition development vaccine chronic disease attracted considerable interest approach prevent rather treat condition cancer alzheimer ’ disease others subunit vaccine consist nongenetic component infectious agent diseaserelated epitope review discus peptidebased vaccine potential three therapeutic area infectious disease alzheimer ’ disease cancer discus factor contribute vaccine efficacy parameter may potentially modulated design examine clinically tested vaccine well nascent approach explore current challenge potential remedy peptide vaccine hold substantial promise prevention human disease many obstacle remain hampered clinical use thus continued research effort address challenge warranted,2019-12-05,"Malonis, Ryan J.; Lai, Jonathan R.; Vergnolle, Olivia",Chem Rev,,,,document_parses/pdf_json/7db7b0550faee19a2b3ab0b3a707410cc99eb56d.json,document_parses/pmc_json/PMC7094793.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094793/,,3
6867,6867,7472,vvu2e80i,,PMC,Flu researchers slam US agency for hoarding data,10.1038/437458a,PMC7095131,16177749.0,no-cc,better sharing information would help vaccine design,2005-09-21,"Butler, Declan",Nature,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095131/,,3
6916,6916,7546,n96u270i,,PMC,Controlling avian flu at the source,10.1038/435415a,PMC7095291,15917777.0,no-cc,global agricultural authority harmonize publichealth sector ensure exchange flu virus sample establish single international standard vaccine say robert webster diane hulse,2005-05-25,"Webster, Robert; Hulse, Diane",Nature,,,,,document_parses/pmc_json/PMC7095291.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095291/,,3
6934,6934,7577,sg77zqs7,,PMC,Engineering immune evasion,10.1038/441161a,PMC7095343,16688158.0,no-cc,one obstacle realizing promise viral vector vaccine delivery preexisting immunity vector adroit application structurebased design point way around problem,2006-05-10,"Mascola, John R.",Nature,,,,,document_parses/pmc_json/PMC7095343.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095343/,,3
6948,6948,7599,7k088cqv,2e250b653aa35e89a16320df2e6495105f012fce,PMC,A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice,10.1038/nature02463,PMC7095382,15024391.0,no-cc,public health measure successfully identified contained outbreak severe acute respiratory syndrome sars coronavirus sarscov concern remain possibility future recurrence finding vaccine virus therefore remains high priority show dna vaccine encoding spike glycoprotein sarscov induces cell neutralizing antibody response well protective immunity mouse model alternative form analysed dna immunization expression vector induced robust immune response mediated cd cd cell well significant antibody titre measured enzymelinked immunosorbent assay moreover antibody response mouse vaccinated expression vector encoding form includes transmembrane domain elicited neutralizing antibody viral replication reduced six order magnitude lung mouse vaccinated plasmid dna expression vector protection mediated humoral tcelldependent immune mechanism genebased vaccination sarscov elicits effective immune response generate protective immunity animal model supplementary information online version article doinature contains supplementary material available authorized user,2004,"Yang, Zhi-yong; Kong, Wing-pui; Huang, Yue; Roberts, Anjeanette; Murphy, Brian R.; Subbarao, Kanta; Nabel, Gary J.",Nature,,,,document_parses/pdf_json/2e250b653aa35e89a16320df2e6495105f012fce.json,document_parses/pmc_json/PMC7095382.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095382/,,3
6991,6991,7662,sjqbfern,47767df09341f332e27ae641b932a9a7a32cb128,PMC,Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates,10.1038/nature01876,PMC7095492,12904795.0,no-cc,containment highly lethal ebola virus outbreak pose serious public health challenge although experimental vaccine successfully protected nonhuman primate disease six month required complete immunization making impractical limit acute epidemic report development accelerated vaccination ebola virus nonhuman primate antibody response immunization adenoviral adv vector encoding ebola glycoprotein gp induced rapidly dna priming adv boosting lower magnitude determine whether earlier immune response could nonetheless protect disease cynomolgus macaque challenged ebola virus vaccination adv–gp nucleoprotein np vector protection highly effective correlated generation ebolaspecific cd tcell antibody response even animal immunized adv–gpnp challenged day later remained resistant challenge either low high dos virus accelerated vaccine provides intervention may help limit epidemic spread ebola applicable virus supplementary information online version article doinature contains supplementary material available authorized user,2003,"Sullivan, Nancy J.; Geisbert, Thomas W.; Geisbert, Joan B.; Xu, Ling; Yang, Zhi-yong; Roederer, Mario; Koup, Richard A.; Jahrling, Peter B.; Nabel, Gary J.",Nature,,,,document_parses/pdf_json/47767df09341f332e27ae641b932a9a7a32cb128.json,document_parses/pmc_json/PMC7095492.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095492/,,3
7065,7065,7764,k5u9nt8b,dad14bd46be6e73e5cde5401fc7c63d15babf7c9,PMC,"Vaccines: past, present and future",10.1038/nm1209,PMC7095920,15812490.0,no-cc,vaccine developed first two hundred year since jenner lifetime accomplished striking reduction infection disease wherever applied pasteur early approach vaccine development attenuation inactivation even two pole vaccine technology today purification microbial element genetic engineering improved knowledge immune protection allow direct creation attenuated mutant expression vaccine protein live vector purification even synthesis microbial antigen induction variety immune response manipulation dna rna protein polysaccharide noninfectious infectious disease within realm vaccinology profusion new vaccine enables new population targeted vaccination requires development route administration additional injection come new problem production regulation distribution vaccine,2005-04-05,"Plotkin, Stanley A",Nat Med,,,,document_parses/pdf_json/dad14bd46be6e73e5cde5401fc7c63d15babf7c9.json,document_parses/pmc_json/PMC7095920.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095920/,,3
7071,7071,7770,opo4fyu7,61774eea46b17a9ba870dc0ecb715288dac66dfb,PMC,Rekombinante Hepatitis-B-Impfstoffe und Verdachtsfälle unerwünschter Reaktionen Eine Bewertung der Spontanerfassungsdaten des Paul-Ehrlich-Instituts 1995 bis 2000: Eine Bewertung der Spontanerfassungsdaten des Paul-Ehrlich-Instituts 1995 bis 2000,10.1007/s00103-002-0388-1,PMC7095933,24676980.0,no-cc,october realising strategy immunising individual high risk hepatitis b infection influence incidence stiko permanent committee vaccination robert kochinstitute recommended general immunisation infant child number paediatric dos recombinant vaccine sold show hbv vaccination widely accepted paediatrician case suspected adverse reaction reported german spontaneous pharmacovigilance system summarised discussed,2014-03-17,"Hartmann, K.; Keller-Stanislawski, B.",Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz,,,,document_parses/pdf_json/61774eea46b17a9ba870dc0ecb715288dac66dfb.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095933/,,3
7175,7175,7918,zetj7mxz,aebeef556f63f5d942766066873d47671fa12ad8,PMC,Identifying epitopes of HIV-1 that induce protective antibodies,10.1038/nri1307,PMC7097025,15039757.0,no-cc,past year pendulum opinion hiv vaccine field swung two extreme initially favouring induction antibody subsequently favouring induction cellmediated immune response present consensus seems induction humoral cellular immunity hiv vaccine required achieve maximum protection one obstacle development effective hiv vaccine difficulty inducing broadly reactive potent antibody protective function defining epitope designing immunogen induce antibody one main challenge confronts hiv vaccine field,2004,"Zolla-Pazner, Susan",Nat Rev Immunol,,,,document_parses/pdf_json/aebeef556f63f5d942766066873d47671fa12ad8.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097025/,,3
7187,7187,7932,63x3poxw,,PMC,DNA vaccines—back in the saddle again?,10.1038/nbt0704-799,PMC7097118,15229530.0,no-cc,promising new horse vaccine may reignite enthusiasm dna vaccine technology designing prophylactic infectious disease kendall powell report,2004,"Powell, Kendall",Nat Biotechnol,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097118/,,3
7199,7199,7946,s6x0igia,eefab7c5bd399448ff8055aec40929f833b3e286,PMC,Making prevention pay,10.1038/nbt0404-387,PMC7097210,15060549.0,no-cc,funding biodefense spurring new vaccine antiinfective program several biotech company,2004,"Dove, Alan",Nat Biotechnol,,,,document_parses/pdf_json/eefab7c5bd399448ff8055aec40929f833b3e286.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097210/,,3
7207,7207,7958,p0np6fvn,12fbecd4737a9af7b8fab5267094fdfa754f25fa,PMC,Recent advances in the discovery and delivery of vaccine adjuvants,10.1038/nrd1176,PMC7097252,12951579.0,no-cc,adjuvant design historically touch alchemy heart due reliance complex biology innate immune activation however new mechanistic understanding innate immunity combined new adjuvant delivery platform exploiting knowledge led significant advance recently although many challenge remain field moving rapidly proper tool methodology place use traditional drug discovery engine guiding development vaccine adjuvant review outline current trend immune potentiator delivery system adjuvant design shape vaccine future,2003,"O'Hagan, Derek T.; Valiante, Nicholas M.",Nat Rev Drug Discov,,,,document_parses/pdf_json/12fbecd4737a9af7b8fab5267094fdfa754f25fa.json,document_parses/pmc_json/PMC7097252.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097252/,,3
7227,7227,7986,6y0xvp37,e170e05180b033dacdad6cc5568bd2e0c4981499,PMC,"Pathogenic epitopes, heterologous immunity and vaccine design",10.1038/nrmicro1709,PMC7097378,17558423.0,no-cc,substantial research directed towards development new generation vaccine based inclusion immunogenic epitope recombinant vector examine evidence certain condition immunogenic epitope harm good might therefore considered pathogenic suggest specific removal pathogenic epitope vaccine might increase prophylactic potential minimizing risk sideeffects vaccine use,2007,"Welsh, Raymond M.; Fujinami, Robert S.",Nat Rev Microbiol,,,,document_parses/pdf_json/e170e05180b033dacdad6cc5568bd2e0c4981499.json,document_parses/pmc_json/PMC7097378.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097378/,,3
7234,7234,7995,cdzgfsik,482c393dcc2f220850b05598e4d2cae7f8121636,PMC,Rapid-response vaccines—does DNA offer a solution?,10.1038/nbt0905-1059,PMC7097425,16151391.0,no-cc,responding future influenza pandemic infectious agent plasmid dna overcomes many limitation conventional vaccine production approach,2005,"Forde, Gareth M",Nat Biotechnol,,,,document_parses/pdf_json/482c393dcc2f220850b05598e4d2cae7f8121636.json,document_parses/pmc_json/PMC7097425.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097425/,,3
7242,7242,8004,yuo6rv55,90cf4919218a03596a628fb3a4f1cd97d2be56d5,PMC,The business of making vaccines,10.1038/nbt1105-1359,PMC7097449,16273061.0,no-cc,growing need better plentiful vaccine traditional vaccine company responding increasing manufacturing capacity biotech industry innovative product surely needed,2005,"Sheridan, Cormac",Nat Biotechnol,,,,document_parses/pdf_json/90cf4919218a03596a628fb3a4f1cd97d2be56d5.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097449/,,3
7253,7253,8019,verg5dhn,03a061bbd85ef6aca2b2087a80ff2581eb24a8fc; b0093e82dc12e7e8f1b9afcdf07ed62c6d048b6b,PMC,Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity,10.1038/nmicrobiol.2016.164,PMC7097525,27642668.0,no-cc,vaccination achieved remarkable success control childhood viral disease control emerging infection however vaccine need delivered older individual unlike infant probably prior infection vaccination related virus thus crossreactive antibody vaccine whether crossreactive antibody impact live attenuated vaccination efficacy unclear using openlabel randomized trial design show subject specific range crossreactive antibody titre prior inactivated japanese encephalitis vaccination enhanced yellow fever yf immunogenicity upon yf vaccination enhancing titre crossreactive antibody prolonged yf vaccine viraemia provoked greater proinflammatory response induced adhesion molecule intrinsic activating fcreceptor signalling pathway namely immune semaphorins facilitating immune cell interaction trafficking finding clinically demonstrate antibodyenhanced infection suggest vaccine efficacy could improved exploiting crossreactive antibody supplementary information online version article doinmicrobiol contains supplementary material available authorized user,2016-09-19,"Chan, Kuan Rong; Wang, Xiaohui; Saron, Wilfried A. A.; Gan, Esther Shuyi; Tan, Hwee Cheng; Mok, Darren Z. L.; Zhang, Summer Li-Xin; Lee, Yie Hou; Liang, Cui; Wijaya, Limin; Ghosh, Sujoy; Cheung, Yin Bun; Tannenbaum, Steven R.; Abraham, Soman N.; St John, Ashley L.; Low, Jenny G. H.; Ooi, Eng Eong",Nat Microbiol,,,,document_parses/pdf_json/03a061bbd85ef6aca2b2087a80ff2581eb24a8fc.json; document_parses/pdf_json/b0093e82dc12e7e8f1b9afcdf07ed62c6d048b6b.json,document_parses/pmc_json/PMC7097525.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097525/,,3
7318,7318,8097,5spifbr2,44e119aaf38d30ac4f62bc1e57487def75658583,PMC,Preparing for Pandemic Vaccination: An International Policy Agenda for Vaccine Development,10.1057/palgrave.jphp.3200008,PMC7099264,15906873.0,no-cc,international use influenza vaccine growing especially developing country since avian hn influenza southeast asia caused several human infection high mortality expert warn next influenza pandemic imminent could severe prevention control depend rapid production worldwide distribution specific pandemic vaccine vaccine supply sufficient meet global demand issue related intellectual property right reverse genetics technology essential vaccine production must resolved addition candidate “ pandemiclike ” vaccine must developed tested clinical trial determine antigen sparing formulation best vaccination schedule study must involve vaccine company require international coordination public funding whether international policy agenda pandemic vaccine development succeed uncertain provide good indication whether “ good governance ” global public health achieved,2005-04-25,"Fedson, David S",J Public Health Policy,,,,document_parses/pdf_json/44e119aaf38d30ac4f62bc1e57487def75658583.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7099264/,,3
7403,7403,8205,cv4fhkq8,f1053f7e45b5bd7b63304aa0e13b064809875be2,PMC,Epitope Mapping: The First Step in Developing Epitope-Based Vaccines,10.2165/00063030-200721030-00002,PMC7100438,17516710.0,no-cc,antibody effective line defense preventing infectious disease highly potent neutralizing antibody intercept virus attache target cell thus inactivate ability based antibody ’ specific recognition epitope site antigen antibody bind thus understanding antibodyepitope interaction provides basis rational design preventive vaccine assumed immunization precise epitope corresponding effective neutralizing antibody would elicit generation similarly potent antibody vaccinee vaccine would ‘ bcell epitopebased vaccine ’ implementation requires ability backtrack desired antibody corresponding epitope article discus range method enable epitope discovery based specific antibody reversed immunological approach first step rational design epitopebased vaccine undoubtedly gold standard epitope definition xray analysis crystal antigen antibody complex method provides atomic resolution epitope however readily applicable many antigen antibody requires high degree sophistication expertise method rely ability monitor binding antibody antigen fragment mutated variation mutagenesis antigen loss binding due point modification amino acid residue often considered indication epitope component addition computational combinatorial method epitope mapping also useful method rely ability antibody interest affinity isolate specific short peptide combinatorial phage display peptide library peptide regarded lead definition epitope corresponding antibody used screen peptide library epitope mapping computational algorithm developed mapitope recently found effective mapping conformational discontinuous epitope pro con various approach towards epitope mapping also discussed,2012-08-15,"Gershoni, Jonathan M.; Roitburd-Berman, Anna; Siman-Tov, Dror D.; Freund, Natalia Tarnovitski; Weiss, Yael",BioDrugs,,,,document_parses/pdf_json/f1053f7e45b5bd7b63304aa0e13b064809875be2.json,document_parses/pmc_json/PMC7100438.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7100438/,,3
7449,7449,8279,dj3p41nr,b3b8f977bbb48c268211654b69f9c82c6416dc02,PMC,A bivalent vaccine confers immunogenicity and protection against Shigella flexneri and enterotoxigenic Escherichia coli infections in mice,10.1038/s41541-020-0180-y,PMC7101394,32257392.0,cc-by,vaccine study shigella flexneri enterotoxigenic escherichia coli impaired lack optimal animal model used two murine model show flexneri bivalent vaccine cvd expressing enterotoxigenic escherichia coli colonization factor antigeni cfai binding subunit b heat labileenterotoxin ltb immunogenic protects weight loss diarrhea finding document immunogenicity preclinical efficacy effect cvd vaccine suggest work help elucidate relevant immune response ultimately clinical efficacy human,2020-03-27,"Medeiros, Pedro Henrique Q. S.; Bolick, David T.; Ledwaba, Solanka E.; Kolling, Glynis L.; Costa, Deiziane V. S.; Oriá, Reinaldo B.; Lima, Aldo Ângelo M.; Barry, Eileen M.; Guerrant, Richard L.",NPJ Vaccines,,,,document_parses/pdf_json/b3b8f977bbb48c268211654b69f9c82c6416dc02.json,document_parses/pmc_json/PMC7101394.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101394/,,3
7459,7459,8289,gzl4zvhy,883a415af79d526c4d84610a7ea3b22a9bfcf9b6,PMC,Novel Ethanol-in-Fluorocarbon Microemulsions for Topical Genetic Immunization,10.1023/a:1022234305600,PMC7101539,12608531.0,no-cc,purpose traditionally vaccine administered needle injection topical immunization intact skin either protein dnabased vaccine attracted much attention recently sought enhance immune response induced dnabased vaccine topical application developing novel ethanolinfluorocarbon ef microemulsion system aid delivery plasmid dna pdna method ten different fluorosurfactants selected synthesized screened pseudophasediagram construction ability form ef microemulsions plasmid dna successfully incorporated ef microemulsions using several different fluorosurfactants perfluorooctyl bromide continuous fluorocarbon phase several reason zonyl® fsn ethoxylated nonionic fluorosurfactant selected study vivo study performed mouse ass pdna expression skin immunologic response topical application system using luciferaseencoding plasmid cmvluciferase cmvβgalactosidaseencoding plasmid respectively result plasmid dna incorporated ef microemulsion using fsn surfactant found stable topical application ef microemulsion system significant enhancement luciferase expression antibody thelper type biased immune response observed relative “ naked ” pdna saline ethanol example ef microemulsion system specific serum igg iga titer increased fold fold respectively conclusion novel fluorocarbonbased microemulsion system potential dna vaccine delivery developed,2003,"Cui, Zhengrong; Fountain, William; Clark, Michael; Jay, Michael; Mumper, Russell J.",Pharm Res,,,,document_parses/pdf_json/883a415af79d526c4d84610a7ea3b22a9bfcf9b6.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101539/,,3
7638,7638,8491,8k3wl971,60ee0e6f4ff94dce64daa2bea069b1f163562380,PMC,Prepubertal vaccination of mice against experimental infection of the genital tract with type 2 herpes simplex virus,10.1007/bf01320618,PMC7101888,6249243.0,no-cc,prepubertal immunisation mouse formalininactivated type herpes simplex virus vaccine conferred level lifelong protection primary type genital infection protection level better type vaccine strikingly influenced vaccine dosage onehundredfold reduction standard vaccine dosage diminished protection insignificant level vaccine efficacy significantly affected method virus inactivation number immunisation age mouse immunisation vaccination conferred better protection previous type genital infection may consequence higher antigenic dose acceptable antigenic presentation perversion immune response latently infected animal homologous virus challenge,1980,"Skinner, G. R. B.; Williams, D. R.; Moles, A. W.; Sargent, A.",Arch Virol,,,,document_parses/pdf_json/60ee0e6f4ff94dce64daa2bea069b1f163562380.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101888/,,3
7664,7664,8521,kruy0eex,ad08af3e8eae3b8a539fa223f7d0ab65c49161bf,PMC,Diagnosis and prevention of rabies,10.1007/s12019-001-0009-1,PMC7101946,11280857.0,no-cc,million american bitten animal every year since rabies vaccine uniformly effective disease uniformly fatal vaccine given management decision must made promptly,2001,"Weiner, H. Richard",Compr Ther,,,,document_parses/pdf_json/ad08af3e8eae3b8a539fa223f7d0ab65c49161bf.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101946/,,3
7800,7800,8671,91bxtc14,15ef34ad932a4296ae92534d079de54eeb6ed887,PMC,"Immunity following intranasal administration of an inactivated, freeze-dried A/England/42/72 vaccine",10.1007/bf01317429,PMC7102198,1200844.0,no-cc,group student volunteer inoculated intranasally iu inactivated freezedried aengland vaccine one volunteer showed fourfold rise serum hi antibody following immunization mean increase serum hi antibody gmt volunteer increase twofold thirteen volunteer developed detectable level nasal wash neutralizing antibody immunization local antibody commonly found volunteer also produced detectable le fourfold rise serum antibody titre produced nasal washing relatively high concentration protein secretory iga four week immunization vaccinee matched group control subject inoculated attenuated aengland mrc virus evidence infection found per cent control subject seven per cent immunized volunteer result showed significant protection p challenge virus infection volunteer given intranasal vaccine,1975,"Potter, C. W.; Jennings, R.; McLaren, C.; Clarke, A.",Arch Virol,,,,document_parses/pdf_json/15ef34ad932a4296ae92534d079de54eeb6ed887.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102198/,,3
7945,7945,8905,n2ncamqh,7d48736264c2e53be3288d79bd404eb3285cd6a5,PMC,Virus-like particle vaccines: immunology and formulation for clinical translation,10.1080/14760584.2018.1516552,PMC7103734,30173619.0,no-cc,introduction viruslike particle vlp vaccine face significant challenge translation laboratory model routine clinical administration vlp vaccine thrive readily adopted vaccination schedule others restrained regulatory obstacle proprietary limitation finding niche amongst crowded vaccine market often necessity supplant existing vaccination regimen posse immediate obstacle development vlp vaccine despite preclinical advantage identified competition novelty adaptability formulation compatibility may prove invaluable helping place vlp vaccine forefront vaccination technology area covered purpose review outline diversity vlp vaccine vlpspecific immune response explore modern formulation delivery technique enhance clinical relevance overall success vlp vaccine expert commentary role formation science emphasis diversity immune response induced vlp underrepresented amongst clinical trial vlp vaccine harnessing diversity particularly use combination select excipients adjuvant paramount development vlp vaccine,2018-09-19,"Donaldson, Braeden; Lateef, Zabeen; Walker, Greg F.; Young, Sarah L.; Ward, Vernon K.",Expert Rev Vaccines,,,,document_parses/pdf_json/7d48736264c2e53be3288d79bd404eb3285cd6a5.json,document_parses/pmc_json/PMC7103734.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7103734/,,3
7989,7989,8991,cdfhy4zk,b22e00b5e7ad7a07213948ca532c3eb950602c32,PMC,Developing vaccines to counter bioterrorist threats,10.1586/14760584.4.3.275,PMC7105752,16026243.0,no-cc,large innovative research program underway define immune parameter vaccine wide array pathogen considered represent potential bioterrorist threat however development utilization vaccine present number predicament previously addressed field vaccinology,2014-01-09,"Altmann, Daniel M",Expert Rev Vaccines,,,,document_parses/pdf_json/b22e00b5e7ad7a07213948ca532c3eb950602c32.json,document_parses/pmc_json/PMC7105752.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105752/,,3
7991,7991,8993,33vouyzo,e92fec9d5c4eace861fa53b19fcedc71ed6085f0,PMC,The role of reverse genetics in the development of vaccines against respiratory viruses,10.1517/14712598.5.3.369,PMC7105756,15833074.0,no-cc,despite significance available vaccine respiratory virus prevention influenza attempt made produce vaccine respiratory virus using traditional technique met little success reverse genetics although still relatively new tool manipulation negativestrand rna virus great potential preparation vaccine many common respiratory virus preparation live vaccine reverse genetics system allow direct modification specific region genome negativestranded rna virus concerned attenuation ultimate goal introduction sitespecific mutation cdna intermediate order develop strain requisite attenuation antigenic growth property needed vaccine technique also used disarm potentially highly pathogenic virus emerging hn avian influenza virus order facilitate largescale preparation virus use inactivated vaccine condition manufacturing safety vaccine become available residual issue concerned intellectual property right technology application need resolved,2005-04-20,"Marsh, GA; Tannock, GA",Expert Opin Biol Ther,,,,document_parses/pdf_json/e92fec9d5c4eace861fa53b19fcedc71ed6085f0.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105756/,,3
7999,7999,9005,c7ipqm45,e787f350feb2b86d0273a5c7c1e2dfc7adfbb70b,PMC,Immunization with virus-like particles conjugated to CIDRα1 domain of Plasmodium falciparum erythrocyte membrane protein 1 induces inhibitory antibodies,10.1186/s12936-020-03201-z,PMC7106694,32228596.0,cc-by,background erythrocytic cycle plasmodium falciparum malaria parasite express p falciparum erythrocyte membrane protein pfemp anchor infected erythrocyte ie vascular lining host cidrα domain pfemp responsible binding host endothelial protein c receptor epcr increasing evidence support interaction trigger severe malaria accounting majority malariarelated death high transmission region child develop immunity severe malaria first infection immunity believed mediated antibody targeting inhibiting pfemp causing infected erythrocyte circulate cleared spleen development immunity malaria coincides acquisition broad antibody reactivity across cidrα protein family altogether identifies cidrα important vaccine target however antigenic diversity cidrα domain family challenge vaccine development method immune response mouse vaccinated viruslike particle vlp presenting cidrα antigen investigated antibody reactivity tested panel recombinant cidrα domain antibody ability inhibit epcr binding recombinant cidrα domain tested luminexbased multiplex assay result vlppresented cidrα antigen induced rapid strong igg response capable inhibiting epcrbinding multiple cidrα domain mainly within group cidrα– subgroup conclusion study observation mirror previous cidrα vaccine study using vaccine construct platform suggests broad cidrα antibody reactivity may achieved vaccination limited number cidrα variant addition study suggest may achieved vaccination human compatible vlp vaccine platform,2020-03-30,"Harmsen, Charlotte; Turner, Louise; Thrane, Susan; Sander, Adam F.; Theander, Thor G.; Lavstsen, Thomas",Malar J,,,,document_parses/pdf_json/e787f350feb2b86d0273a5c7c1e2dfc7adfbb70b.json,document_parses/pmc_json/PMC7106694.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106694/,,3
8011,8011,9018,zgyocp07,6d4432caa5cf97afa0126e52aa5dbf2e2fddd2be,PMC,Evaluation of a coccidia vaccine using spray and gel applications,10.3382/ps/pey011,PMC7107172,29462420.0,no-cc,coccidiosis economically significant disease poultry caused specie eimeria parasitic protozoan disease result poor feed conversion reduced weight gain lead development necrotic enteritis prevention coccidiosis poultry commonly vaccinated live sporulated oocysts mass applied vaccination cabinet hatchery traditionally coccidia vaccine applied coarse spray water based diluent however new technology using gel diluent entered u market gel diluent variable viscosity “ dropped ” onto chick applicator bar thought gel droplet remain intact bird longer water based droplet allowing time preening ingestion oocysts experiment efficacy commercial coccidia vaccine applied water based diluent viscous gel diluent le viscous gel diluent compared fecal sample collected multiple time point postvaccination quantify vaccine oocyst shedding shedding first cycle day postvaccination related number oocysts received application method group receiving higher dos shed oocysts however decrease shedding seen viscous gel group second cycle day postvaccination chicken challenged eimeria maximum oocysts day postchallenge body weight gain gross microscopic lesion recorded evaluate protection level different vaccine application vaccinated group appeared protected based body weight gain lesion scoring result project indicate vaccine application effective protecting eimeria maximum challenge using proper dose vaccine allows repeated oocyst cycling litter postvaccination,2018-02-15,"Albanese, Grace A; Tensa, Laura R; Aston, Emily J; Hilt, Deborah A; Jordan, Brian J",Poult Sci,,,,document_parses/pdf_json/6d4432caa5cf97afa0126e52aa5dbf2e2fddd2be.json,document_parses/pmc_json/PMC7107172.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7107172/,,3
8019,8019,9026,iq1gtb5w,12869a83edbd31730ecc771671dc9f6ada677df1,PMC,Combined adjuvant effect of ginseng stem-leaf saponins and selenium on immune responses to a live bivalent vaccine of Newcastle disease virus and infectious bronchitis virus in chickens,10.3382/ps/pez207,PMC7107245,31220864.0,no-cc,vaccination live bivalent vaccine newcastle disease virus ndv infectious bronchitis virus ibv routine practice poultry industry china study designed evaluate ginseng stemleaf saponin gsls combination selenium se adjuvant effect immune response vaccination ndv ibv chicken live bivalent vaccine ndv ibv diluted saline solution containing gsls se used immunize chicken via intraocularandintranasal route result showed gsls promoted significantly higher ndv ibvspecific antibody response highest antibody response detected gslsse group increased antibody capable neutralizing ndv ibv addition gslsse enhanced lymphocyte proliferation production ifnγ il importantly gslsse found promote early production prolong duration antibody response order improve efficacy vaccination chicken flock diluent containing gslsse deserves study evaluate effect chicken vaccine,2019-04-25,"Ma, X; Bi, S; Wang, Y; Chi, X; Hu, S",Poult Sci,,,,document_parses/pdf_json/12869a83edbd31730ecc771671dc9f6ada677df1.json,document_parses/pmc_json/PMC7107245.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7107245/,,3
8032,8032,9042,u1xbkaq0,06feefc13f34b0d6ca007bf080b5e4f42f11a692,PMC,Protection Against Henipavirus Infection by Use of Recombinant Adeno-Associated Virus–Vector Vaccines,10.1093/infdis/jis699,PMC7107322,23175762.0,no-cc,nipah virus niv hendra virus hev closely related recently emerged paramyxovirus capable causing considerable morbidity mortality several mammalian specie including human henipavirusspecific vaccine still commercially unavailable development novel antiviral strategy prevent lethal infection due henipaviruses highly desirable describe development adenoassociated virus aav vaccine expressing niv g protein characterization vaccine mouse demonstrated single intramuscular aav injection sufficient induce potent longlasting antibody response translational study hamster demonstrated vaccinated animal protected lethal challenge niv addition vaccine induced crossprotective immune response able protect animal challenge hev study present new efficient vaccination strategy henipaviruses open novel perspective use aav vector vaccine emergent disease,2013-02-01,"Ploquin, Aurélie; Szécsi, Judit; Mathieu, Cyrille; Guillaume, Vanessa; Barateau, Véronique; Ong, Kien Chai; Wong, Kum Thong; Cosset, François-Loïc; Horvat, Branka; Salvetti, Anna",J Infect Dis,,,,document_parses/pdf_json/06feefc13f34b0d6ca007bf080b5e4f42f11a692.json,document_parses/pmc_json/PMC7107322.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7107322/,,3
8033,8033,9043,sp87qdkr,dd062ef8daf0aa69e08699b210d5a4c0fbe28202,PMC,Chikungunya Virus Vaccines: Viral Vector–Based Approaches,10.1093/infdis/jiw369,PMC7107338,27920181.0,no-cc,major chikungunya virus chikv epidemic reached america past year million people infected light current epidemic million people north south america risk effort rapidly develop effective vaccine increased focus chikv vaccine use viralvector technology group vaccine candidate share ability potently induce humoral cellular immune response use highly attenuated safe vaccine backbone far welldescribed vector modified vaccinia virus ankara complex adenovirus vesicular stomatitis virus alphavirusbased chimera measles vaccine schwarz strain mvschw described potential vaccine summarize recent data experimental vaccine focus preclinical clinical activity mvschwbased candidate first chikvvectored vaccine completed clinical trial,2016-12-15,"Ramsauer, Katrin; Tangy, Frédéric",J Infect Dis,,,,document_parses/pdf_json/dd062ef8daf0aa69e08699b210d5a4c0fbe28202.json,document_parses/pmc_json/PMC7107338.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7107338/,,3
8071,8071,9088,k4oc7i86,b8da6d649137c9ecc0da40e73ce884ed114815ce,PMC,Potential of Influenza Vaccine and Amantadine to Prevent Influenza A Illness in Canadian Forces Personnel 1980–1983,10.1093/milmed/151.9.459,PMC7107555,3095698.0,no-cc,randomized placebocontrolled singleblind trial designed compare efficacy sideeffects standard influenza vaccine amantadine chemoprophylaxis prevent influenza virus illness canadian force base cfb personnel manitoba three winter season volunteer allocated vaccine v saline injection vaccine placebo vp amantadine mgday al mgday placebo ap capsule group median v recipient hai titre week immunization indicating protection illness due vaccine strain myalgia commonest side effect clinically important influenza community outbreak due vaccine strain antigenically related one occurred – – chemoprophylaxis continued consecutive day respectively period well tolerated however al recipient noncompliant evidenced lack drug urine plasma incidence laboratoryconfirmed illness per two year low enable u ass efficacy preventative measure subclinical influenza occurred unimmunized subject data suggested strategy preventing influenza cfb personnel potential protective minimal adverse effect however data permit u recommend one preference,1986-09-26,"Aoki, Fred Y.; Sitar, Daniel S.; Milley, E. V.; Hughes, H. E.; Sekla, L.; Sheppard, T.; Stiver, H. Grant; Hammond, Gregory W.; Vermeersch, C.; Cooper, T.; Lamontage, M.; Callow, K.",Mil Med,,,,document_parses/pdf_json/b8da6d649137c9ecc0da40e73ce884ed114815ce.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7107555/,,3
8104,8104,9134,t0chpsuh,f7cea121c3cbcab38befdd89c4aa096529f61b32,PMC,Carbohydrate Moieties as Vaccine Candidates,10.1086/432582,PMC7107877,16080094.0,no-cc,carbohydrate epitope glycotopes structurally diverse occur variety chemical context present surface cell body surface pathogen various structure mode presentation affect perceived processed body dictate outcome immune response directed review focus mechanism carbohydrate immunity emphasis carbohydrate vaccine developed protection encapsulated bacterial pathogen discus cellular basis carbohydrate immunity newly identified glycotope processing pathway recognition capability synthetic microarray technology developed permit new experimental approach carbohydrate vaccine development exploration interaction immune system self nonself glycans,2005-09-01,"Lucas, Alexander H.; Apicella, Michael A.; Taylor, Christopher E.",Clin Infect Dis,,,,document_parses/pdf_json/f7cea121c3cbcab38befdd89c4aa096529f61b32.json,document_parses/pmc_json/PMC7107877.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7107877/,,3
8218,8218,9286,6c1rnou3,32156051a995fe12c19e2f60c851ae3a5ff5b708,PMC,Demand for Nonhuman Primate Resources in the Age of Biodefense,10.1093/ilar.46.1.15,PMC7108618,15644560.0,no-cc,demand nonhuman primate undoubtedly increase meet biomedical need current age biodefense availability funding increased research select agent created requirement validate result relevant primate model review provides description current potential biological threat likely require nonhuman primate development vaccine therapeutic primate invaluable resource dissection viral disease pathogenesis well testing vaccine efficacy dna vaccine approach studied successfully ebola lassa anthrax nonhuman primate model nonhuman primate research monkeypox provided insight role cytokine limiting disease severity biodefense research focused select agent bacterial origin also benefited nonhuman primate study rhesus macaque traditionally model choice anthrax research yielded successful finding vaccine development plague research african green monkey contributed vaccine development however disadvantage current vaccine undoubtedly require generation new vaccine thus increasing need nonhuman primate research unfortunately current biosafety level bsl bsl facility equipped perform research limited may ultimately impede progress era biodefense,2005-01-01,"Patterson, Jean L.; Carrion, Ricardo",ILAR J,,,,document_parses/pdf_json/32156051a995fe12c19e2f60c851ae3a5ff5b708.json,document_parses/pmc_json/PMC7108618.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108618/,,3
8324,8324,9410,65iwx5nv,fac2859eaaea814ddabb2999b344ba9a470c186c,PMC,DNA Vaccine of SARS-Cov S Gene Induces Antibody Response in Mice,10.1093/abbs/36.1.37,PMC7109828,14732873.0,no-cc,spike protein main surface antigen sarscoronavirus sarscov one important antigen candidate vaccine design present study three fragment truncated protein expressed e coli analyzed pooled serum convalescence phase sars patient full length gene dna vaccine constructed used immunize balbc mouse mouse serum igg antibody sarscov measured elisa e coli expressed truncated protein sarscov lysate diagnostic antigen result showed three fragment protein expressed e coli able react serum sars patient gene dna candidate vaccine could induce production specific igg antibody sarscov efficiently mouse seroconversion ratio time immunization finding lay foundation understanding immunology sarscov developing sars vaccine,2004-01-26,"Zhao, Ping; Ke, Jin-Shan; Qin, Zhao-Lin; Ren, Hao; Zhao, Lan-Juan; Yu, Jian-Guo; Gao, Jun; Zhu, Shi-Ying; Qi, Zhong-Tian",Acta Biochim Biophys Sin (Shanghai),,,,document_parses/pdf_json/fac2859eaaea814ddabb2999b344ba9a470c186c.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109828/,,3
8365,8365,9456,dpoljl78,b82a7e289836a97e6d2bc4edd7850bdbfa339160,PMC,Protective Immunity against Respiratory Tract Challenge with Yersinia pestis in Mice Immunized with an Adenovirus-Based Vaccine Vector Expressing V Antigen,10.1086/507644,PMC7109909,17041851.0,no-cc,aerosol form bacterium yersinia pestis cause pneumonic plague rapidly fatal disease present plague vaccine available use united state one candidate development subunit vaccine pestis virulence v antigen protein mediates function yersinia outer protein virulence factor suppresses inflammatory response host basis knowledge adenovirus ad genetransfer vector act adjuvant eliciting host immunity transgene carry tested hypothesis single administration replicationdefective ad genetransfer vector encoding pestis v antigen adsecv could stimulate strong protective immune response without requirement repeat administration adsecv elicited specific cell response high igg titer serum within week single intramuscular immunization importantly mouse protected lethal intranasal challenge pestis co week month immunization single intramuscular dose adsecv observation suggest ad genetransfer vector expressing v antigen candidate development effective antiplague vaccine,2006-11-01,"Chiuchiolo, Maria J.; Boyer, Julie L.; Krause, Anja; Senina, Svetlana; Hackett, Neil R.; Crystal, Ronald G.",J Infect Dis,,,,document_parses/pdf_json/b82a7e289836a97e6d2bc4edd7850bdbfa339160.json,document_parses/pmc_json/PMC7109909.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109909/,,3
8397,8397,9492,15m5m44x,934f60b96370d6ad3032b757dff3ed84dcebbd06,PMC,A Genetically Inactivated Herpes Simplex Virus Type 2 (HSV-2) Vaccine Provides Effective Protection against Primary and Recurrent HSV-2 Disease,10.1093/infdis/175.1.16,PMC7109964,8985191.0,no-cc,glycoprotein h ghdeleted herpes simplex virus type hsv evaluated vaccine prevention hsvinduced disease virus term disc disabled infectious single cycle virus complete one replication cycle normal cell thus safe yet still able stimulate broad humoral cellmediated antiviral immune response ghdeleted hsv virus tested vaccine guinea pig model recurrent hsv infection constructed animal vaccinated disc hsv showed complete protection primary hsv–induced disease even challenged month vaccination addition animal almost completely protected recurrent disease even low vaccination dos high degree protection primary disease reduction recurrent disease symptom also observed following therapeutic vaccination animal already infected wild type hsv,1997-01-26,"Boursnell, M. E. G.; Entwisle, C.; Blakeley, D.; Roberts, C.; Duncan, I. A.; Chisholm, S. E.; Martin, G. M.; Jennings, R.; Ní Challanaín, D.; Sobek, I.; Inglis, S. C.; McLean, C. S.",J Infect Dis,,,,document_parses/pdf_json/934f60b96370d6ad3032b757dff3ed84dcebbd06.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109964/,,3
8422,8422,9525,v5wxkdbk,5c03f7971e51a825be6a88d675b1cd05d1c3b527,PMC,Delivery technologies for human vaccines,10.1093/bmb/62.1.29,PMC7110014,12176848.0,no-cc,currently intense research activity aimed development new delivery system vaccine goal identify optimal method presenting target antigen immune system manner elicit immune response appropriate protection treatment specific disease several different approach general goal developed empirical remain poorly understood others rational based example mimicking natural infection vivo targeting particular feature immune system article review three category delivery system adjuvant formulation ii antigen vector including live attenuated microorganism synthetic vector iii novel device vaccine administration review restricted late stage development field human vaccination,2002-07-26,"Moingeon, Philippe; de Taisne, Charles; Almond, Jeffrey",Br Med Bull,,,,document_parses/pdf_json/5c03f7971e51a825be6a88d675b1cd05d1c3b527.json,document_parses/pmc_json/PMC7110014.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110014/,,3
8447,8447,9556,o4sf2zf1,bfd497c96e22272fc755a982eaec0c6871b4feba,PMC,Protective Effect of WC3 Vaccine Against Rotavirus Diarrhea in Infants During a Predominantly Serotype 1 Rotavirus Season,10.1093/infdis/158.3.570,PMC7110070,2842405.0,no-cc,used doubleblind placebocontrolled trial study efficacy wc rotavirus vaccine administered infant age three month rotavirus season fortynine infant received vaccine received placebo rotavirus disease season predominantly caused serotype strain placebo recipient case rotavirus diarrhea attack rate moderate severe attack rate vaccinee experienced three case rotavirus disease attack rate mild case whether associated rotavirus clinically significant diarrhea csd evaluated wc vaccine provided statistically significant p protection total number episode csd reduced number day csdassociated diarrhea vomiting fever illness seventyone percent thewcvaccinated infant serum antibody response vaccine placebo recipient experienced natural disease predominantly antibody response serotype serum taken rotavirus season revealed nearly identical rate natural rotavirus infection vaccinated placebo group,1988-09-26,"Clark, H Fred; Horian, Frances E.; Bell, Louis M.; Modesto, Karen; Gouvea, Vera; Plotkin, Stanley A.",J Infect Dis,,,,document_parses/pdf_json/bfd497c96e22272fc755a982eaec0c6871b4feba.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110070/,,3
8467,8467,9581,2d9tjzn6,d11f6cc7d39b7af56d0dcb35fc84b1f523d63ad2,PMC,Severe Acute Respiratory Syndrome Coronavirus Infection in Vaccinated Ferrets,10.1086/522431,PMC7110120,17922397.0,no-cc,background development vaccine prevent severe acute respiratory syndrome sars limited lack wellcharacterized animal model previous vaccine report noted robust neutralizing antibody inflammatory response ferret resulting enhanced hepatitis method evaluated humoral immune response pathological end point ferret challenged urbani strain sarsassociated coronavirus sarscov received formalininactivated wholevirus vaccine mock vaccine result humoral response observed ferret received inactivated virus vaccine histopathological finding lung showed infection ferret produced residual lung lesion seen mock vaccinated ferret sarscov infection demonstrated bronchial bronchiolar hyperplasia perivascular cuffing ferret lung tissue seen previously infected mouse evidence enhanced disease observed ferret ferret cleared virus day week earlier vaccinated conclusion vaccine provided mild immune protection ferret challenge however evidence enhanced liver lung disease induced inactivated wholevirus vaccine ferret may provide another useful model evaluating sars vaccine safety efficacy,2007-11-01,"Darnell, Miriam E. R.; Plant, Ewan P.; Watanabe, Hisayoshi; Byrum, Russ; St. Claire, Marisa; Ward, Jerrold M.; Taylor, Deborah R.",J Infect Dis,,,,document_parses/pdf_json/d11f6cc7d39b7af56d0dcb35fc84b1f523d63ad2.json,document_parses/pmc_json/PMC7110120.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110120/,,3
8508,8508,9627,kb5w9er5,df12372da4192c09f9cd909ee694461fa8e23272,PMC,Host and Viral Factors Affecting the Decreased Immunogenicity of Sabin Type 3 Vaccine after Administration of Trivalent Oral Polio Vaccine to Rural Mayan Children,10.1093/infdis/175.3.545,PMC7110245,9041324.0,no-cc,factor affecting immunogenicity first dos oral poliovirus vaccine opv among unimmunized mayan infant prospectively evaluated relative impact multiple variable including mass routine vaccination concurrent enteric bacterial salmonella shigella campylobacter viral adenovirus astrovirus nonpolio enterovirus rotavirus infection interference among sabin vaccine virus preexisting poliovirus antibody studied serum available infant opv dos seroresponses sabin type sabin type sabin type vaccine mass versus routine vaccination preexisting poliovirus antibody affect immunogenicity multiple logistic regression analysis fecal shedding homologous sabin strain associated increased seroresponses sabin type especially sabin type decreased opv immunogenicity primarily attributable interference sabin type sabin type opv formulation higher dos sabin type could improve immunogenicity among infant developing country,1997-03-26,"Maldonado, Yvonne A.; Peña-Cruz, Victor; de la Luz Sanchez, Maria; Logan, Linda; Blandón, Stewart; Cantwell, Michael F.; Matsui, Suzanne M.; Millan-Velasco, Francisco; Valdespino, Jose Luis; Sepulveda, Jaime",J Infect Dis,,,,document_parses/pdf_json/df12372da4192c09f9cd909ee694461fa8e23272.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110245/,,3
8541,8541,9666,rdf7mbx9,9482e5881613ae262f54437bc845f8e5c75ef365,PMC,Oral vaccination of mice against Helicobacter pylori with recombinant Lactococcus lactis expressing urease subunit B,10.1111/j.1574-695x.2009.00566.x,PMC7110364,19453750.0,no-cc,determine whether protective immune response could elicited oral delivery recombinant live bacterial vaccine helicobacter pylorus urease subunit b ureb expressed extracellular expression foodgrade bacterium lactococcus lactis urebproducing strain administered orally mouse immune response ureb examined orally vaccinated mouse produced significant urebspecific serum immunoglobulin g igg response specific antiureb iga response could detected feces mouse immunized secreting lactococcal strain mouse vaccinated orally significantly protected gastric helicobacter infection following challenge h pylorus strain s conclusion mucosal vaccination l lactis expressing ureb produced serum igg urebspecific fecal iga prevented gastric infection h pylorus,2009-08-01,"Gu, Qing; Song, Dafeng; Zhu, Muyuan",FEMS Immunol Med Microbiol,,,,document_parses/pdf_json/9482e5881613ae262f54437bc845f8e5c75ef365.json,document_parses/pmc_json/PMC7110364.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110364/,,3
8543,8543,9668,fcpg6rij,816474872c9935a8716bf3bc5d0a00496a2dc216,PMC,Group A Rotavirus Veterinary Vaccines,10.1093/infdis/174.supplement_1.s98,PMC7110367,8752298.0,no-cc,group rotavirus cause diarrhea young livestock poultry consequently vaccination strategy focused induction active passive immunity gnotobiotic pig calf serve useful model evaluate induction active immunity candidate animal human rotavirus vaccine however live attenuated rotavirus vaccine lacked efficacy administered orally calf pig field presumably colostral antibody inhibited vaccine virus replication widespread occurrence rotavirus antibody colostrum led strategy maternal rotavirus vaccination boost lactogenic immunity transfer passive antibody neonate via colostrum milk variable success maternal rotavirus vaccine field influenced vaccine dose strain inactivating agent adjuvant route administration environmental rotavirus exposure level use genetically engineered rotaviruslike particle vaccine cow boost antibody mammary secretion show promise subunit vaccine posse potential advantage existing vaccine,1996-09-26,"Saif, Linda J.; Fernandez, Fernando M.",J Infect Dis,,,,document_parses/pdf_json/816474872c9935a8716bf3bc5d0a00496a2dc216.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110367/,,3
8550,8550,9675,v5k4piid,40faeb01baf7a997387a087eba8b699bd3f7847a; f980fc2a71e33077bf5ae9f67bef647595ea609f,PMC,Mice protected by oral immunization with Lactobacillus reuteri secreting fusion protein of Escherichia coli enterotoxin subunit protein,10.1111/j.1574-695x.2007.00255.x,PMC7110380,17651125.0,no-cc,green fluorescent protein gfp gene ligated lactobacillus reuterispecific nisininducible expressionsecretion vector pnies generating pniesgfp vector capable secreting cloned gene gfpfusion protein fluorescent activity develop system live vehicle carrying heatstable enterotoxin st heatlabile enterotoxin b ltb enterotoxigenic escherichia coli etec recombinant ′stltb′ dna fragment cloned pniesgfp resulting l reuteripniesgfpstltb system found posse capability adhering mouse gut secreting gfpstltb product pgcell− induced noninduced condition respectively analysis gfpstltb product confirmed gangliosidebinding ability ltb antigenicity relative freedom stassociated toxicity making suitable use oral vaccine mouse oral inoculation l reuteripniesgfpstltb culture mouse elicited significant p serum igg mucosal iga antibody stltb antigen immunized mouse subsequently challenged etec showed full protection fluid influx response gut first report using l reuteri vaccine carrier induce complete immunologic protection etec,2007-08-01,"Wu, Chi-Ming; Chung, Tung-Ching",FEMS Immunol Med Microbiol,,,,document_parses/pdf_json/40faeb01baf7a997387a087eba8b699bd3f7847a.json; document_parses/pdf_json/f980fc2a71e33077bf5ae9f67bef647595ea609f.json,document_parses/pmc_json/PMC7110380.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110380/,,3
8598,8598,9744,5yb3dxse,909d950f950ddc4254a53b73ad1c5ada5a41c057,PMC,Vaccination with single plasmid DNA encoding IL-12 and antigens of severe fever with thrombocytopenia syndrome virus elicits complete protection in IFNAR knockout mice,10.1371/journal.pntd.0007813,PMC7112229,32196487.0,cc-by,severe fever thrombocytopenia syndrome sfts emerging tickborne disease caused sfts virus sftsv infection despite gradual increase sfts case high mortality endemic region specific viral therapy vaccine available developed single recombinant plasmid dna encoding sftsv gene gn gc together npns fusion antigen vaccine candidate viral antigen fused fmslike tyrosine kinase ligand fltl il gene incorporated plasmid enhance cellmediated immunity vaccination dna provides complete protection ifnar ko mouse upon lethal sftsv challenge whereas immunization plasmid without il gene resulted partial protection since failed detect antibody surface glycoprotein gn gc immunized mouse antigenspecific cellular immunity confirmed enhanced antigenspecific cell response might play major role protection finally evaluated degree protective immunity provided protein immunization individual glycoprotein gn gc although protein antigen induced significant level neutralizing activity sftsv gn vaccination resulted relatively higher neutralizing activity better protection gc vaccination however antigen failed provide complete protection given dna vaccine failed induce sufficient immunogenicity human trial compared protein vaccine optimal combination dna protein element proper selection target antigen incorporation efficient adjuvant need investigated sftsv vaccine development,2020-03-20,"Kang, Jun-Gu; Jeon, Kyeongseok; Choi, Hooncheol; Kim, Yuri; Kim, Hong-Il; Ro, Hyo-Jin; Seo, Yong Bok; Shin, Jua; Chung, Junho; Jeon, Yoon Kyung; Kim, Yang Soo; Lee, Keun Hwa; Cho, Nam-Hyuk",PLoS Negl Trop Dis,,,,document_parses/pdf_json/909d950f950ddc4254a53b73ad1c5ada5a41c057.json,document_parses/pmc_json/PMC7112229.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7112229/,,3
8635,8635,9787,y9i4hsy8,8883b4cdc15d7cc2d2d680305963aee56f4dc4e4,PMC,Combination therapy using human papillomavirus L1/E6/E7 genes and archaeosome: a nanovaccine confer immuneadjuvanting effects to fight cervical cancer,10.1038/s41598-020-62448-3,PMC7113280,32238821.0,cc-by,cancer leading cause death worldwide cervical cancer caused human papillomavirus hpv major health problem woman dna vaccine perfect approach immunization potency clinical trial insufficient generating effective immunity may related degradation dna via nuclease poor delivery antigenpresenting cell apc insufficient uptake dna plasmid cell upon injection archaeosome nanodelivery system based liposome immunological role developed gene delivery study human papillomavirus type gene containing truncated l e e simultaneously used combination therapy archaeosome assessed vivo finding supported archaeosomes promotes immune response dna vaccine longterm ctl response generated low antigen dose combination therapy archaeosomelee vaccine exhibited strong cytolytic activity tumor cell induced prophylactic therapeutic effect development tumor animal model,2020-04-01,"Karimi, Hesam; Soleimanjahi, Hoorieh; Abdoli, Asghar; Banijamali, Razieh Sadat",Sci Rep,,,,document_parses/pdf_json/8883b4cdc15d7cc2d2d680305963aee56f4dc4e4.json,document_parses/pmc_json/PMC7113280.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7113280/,,3
8641,8641,9796,alxeicf7,,PMC,Adverse Reactions to Vaccination: From Anaphylaxis to Autoimmunity,10.1016/j.cvsm.2017.10.005,PMC7114576,29195924.0,no-cc,vaccine important providing protection infectious disease vaccination initiate process stimulates development robust longlived immune response disease agent vaccine side effect sometimes associated vaccination vary development acute hypersensitivity response vaccine component local tissue reaction annoying significantly detrimental patient pathogenesis response consequent clinical outcome discussed overstimulation immune response potential relationship autoimmunity evaluated relation genetic predisposition,2017-11-29,"Gershwin, Laurel J.",Vet Clin North Am Small Anim Pract,,,,,document_parses/pmc_json/PMC7114576.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114576/,,3
8649,8649,9805,5hifn0cf,445051ed892d0bd3be6382253b55237fc1c8c075,PMC,Population implications of the deployment of novel universal vaccines against epidemic and pandemic influenza,10.1098/rsif.2019.0879,PMC7115234,32126190.0,cc-by,increasing interest development new ‘ universal ’ influenza vaccine uivs that––unlike current vaccines––are effective broad range seasonal influenza strain well novel pandemic virus existing literature discus potential epidemiological benefit uivs also important anticipate potential unintended population consequence using mathematical modelling illustrate two type adverse consequence first reducing amount infectioninduced immunity population without fully replacing seasonal uiv programme may permit larger pandemic absence vaccination second successful future uiv programme reducing transmission seasonal influenza vulnerable population could become emergence vaccine escape variant risk could mitigated optimal deployment future uiv vaccine namely use combined vaccine formulation incorporating conventional well multiple universal antigenic target achieving sufficient population coverage compensate reduction infectioninduced immunity absence largescale trial uivs diseasedynamic model provide helpful early insight potential impact future data continuing vaccine development invaluable developing robustly predictive modelling approach,2020-03-04,"Arinaminpathy, N.; Riley, S.; Barclay, W. S.; Saad-Roy, C.; Grenfell, B.",J R Soc Interface,,,,document_parses/pdf_json/445051ed892d0bd3be6382253b55237fc1c8c075.json,document_parses/pmc_json/PMC7115234.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7115234/,,3
8670,8670,9830,jyi5z10h,,PMC,Effect of dual-subtype vaccine against feline immunodeficiency virus infection,10.1016/s0378-1135(97)00164-8,PMC7117228,9453127.0,no-cc,dualsubtype feline immunodeficiency virus fiv vaccine consisting inaactivated cell infected subtypes petaluma strain shizuoka strain developed tested vaccine efficacy fiv infection specific pathogen free spf cat animal monitored proviral dna fivspecific pcr fivspecific antibody profile elisa virusneutralization assay addition blood challenged cat inoculated naive spf cat confirm viral status vaccinated cat cat immunized petaluma vaccine alone protected homologous petaluma challenge one four cat protected heterologous shizuoka challenge importantly cat immunized dualsubtype vaccine protected petaluma shizuoka challenge result suggest multisubtype vaccine approach may provide broadspectrum immunity necessary vaccine protection strain different subtypes,1998-02-13,"Hohdatsu, Tsutomu; Okada, Susumu; Motokawa, Kenji; Aizawa, Chikara; Yamamoto, Janet K.; Koyama, Hiroyuki",Vet Microbiol,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117228/,,3
8882,8882,10109,g26pi13c,8b3aff7c998808cdc61bde66e811eae51291ea2e,PMC,Measles Control and the Prospect of Eradication,10.1007/978-3-540-70617-5_9,PMC7120973,19203110.0,no-cc,remarkable progress made reducing measles incidence mortality consequence implementing measles mortality reduction strategy world health organization united nation childrens fund unicef revised global measles mortality reduction goal set forth whounicef global immunization vision strategy – reduce measles death compared estimated death possibility measles eradication discussed almost year measles meet many criterion eradication global measles eradication face number challenge achieving sustaining high level vaccine coverage population immunity including population growth demographic change conflict political instability public perception vaccine safety achieve measles mortality reduction goal continued progress need made delivering measles vaccine world child,2009,"Moss, W. J.",Measles,,,,document_parses/pdf_json/8b3aff7c998808cdc61bde66e811eae51291ea2e.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120973/,,3
8886,8886,10113,0u5ot5h4,4ed6867d8d50072e23cd598fda76e44cac963332,PMC,Challenges and Opportunities for Respiratory Syncytial Virus Vaccines,10.1007/978-3-642-38919-1_20,PMC7121045,24362701.0,no-cc,respiratory syncytial virus rsv cause significant proportion global burden respiratory disease summarize conclusion series chapter written investigator describing interpreting known virology clinical manifestation immunity pathogenesis epidemiology rsv relevant vaccine development several technological conceptual advance recently occurred make rsv vaccine development feasible collected knowledge intended help inform organize future contribution funding agency scientist regulatory agency policy maker needed achieve goal safe effective accessible vaccine prevent rsvassociated disease,2013-05-24,"Graham, Barney S.; Anderson, Larry J.",Challenges and Opportunities for Respiratory Syncytial Virus Vaccines,,,,document_parses/pdf_json/4ed6867d8d50072e23cd598fda76e44cac963332.json,document_parses/pmc_json/PMC7121045.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121045/,,3
8895,8895,10123,3ypv9k9p,aac375959196030a2b676555d1d940213aec3b3c,PMC,Classification of Human Leukocyte Antigen (HLA) Supertypes,10.1007/978-1-4939-1115-8_17,PMC7121184,25048132.0,no-cc,identification new antigenic peptide derived infectious agent cancer cell bind human leukocyte antigen hla class ii molecule importance development new effective vaccine capable activating cellular arm immune response however barrier development peptidebased vaccine maximum population coverage restricting hla gene extremely polymorphic resulting vast diversity peptidebinding hla specificity low population coverage given peptide–hla specificity one way reduce complexity group thousand different hla molecule several socalled hla supertypes classification refers group hla allele largely overlapping peptide binding specificity chapter focus stateoftheart classification hla supertypes including hlai supertypes hlaii supertypes application development peptidebased vaccine,2014-05-06,"Wang, Mingjun; Claesson, Mogens H.",Immunoinformatics,,,,document_parses/pdf_json/aac375959196030a2b676555d1d940213aec3b3c.json,document_parses/pmc_json/PMC7121184.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121184/,,3
8913,8913,10141,zh8e76w7,e3ae087ba8a12f5c3e751ec04cdda610c19b00d2,PMC,Pandemic Influenza Vaccines,10.1007/978-3-540-92165-3_15,PMC7121491,19768412.0,no-cc,since composition remain uncertain universal pandemic vaccine yet created would aim protect globally pandemic influenza virus yet evolved thus differ seasonal vaccine influenza virus updated annually spring incorporate latest circulating virus produced delivered peak influenza season start late fall winter efficacy seasonal vaccine linked ability induce virusneutralizing antibody provide subtypespecific protection influenza virus pandemic vaccine designed resemble current vaccine term composition mode action would developed tested massproduced onset pandemic causative virus identified logistic problem generating pandemic vaccine scratch conducting preclinical testing producing billion dos within month global distribution enormous may well insurmountable alternatively scientific community could step effort generate universal vaccine influenza virus provides broadly crossreactive protection induction antibody cell conserved region virus,2009-06-15,"DiMenna, Lauren J.; Ertl, Hildegund C. J.",Vaccines for Pandemic Influenza,,,,document_parses/pdf_json/e3ae087ba8a12f5c3e751ec04cdda610c19b00d2.json,document_parses/pmc_json/PMC7121491.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121491/,,3
8914,8914,10142,2o6nb2yj,dba6ea69d6b15ac9e6879e210ae2acaca5549a73,PMC,Plant-Based Oral Vaccines: Results of Human Trials,10.1007/978-3-540-70868-1_6,PMC7121496,19401823.0,no-cc,vaccine consisting transgenic plantderived antigen offer new strategy development safe inexpensive vaccine vaccine antigen eaten edible part plant purified plant material phase clinical study prototype potato cornbased vaccine vaccine safe immunogenic without need buffer vehicle plant cell transgenic plant technology attractive vaccine development vaccine needleless stable easy administer chapter examines early human study oral transgenic plantderived vaccine enterotoxigenic escherichia coli infection norovirus hepatitis b,2009,"Tacket, C. O.",Plant-produced Microbial Vaccines,,,,document_parses/pdf_json/dba6ea69d6b15ac9e6879e210ae2acaca5549a73.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121496/,,3
8963,8963,10191,7750z41g,9b3127228bf970ff5f47be7ee2e9ce78b9ded52a,PMC,Display of Peptides on the Surface of Tobacco Mosaic Virus Particles,10.1007/978-3-540-70868-1_2,PMC7122513,19401819.0,no-cc,review focus potential tobacco mosaic virus tmv carrier immunogenic epitope factor must considered order bring product based platform market large scale biology corporation developed facile scaleable method manufacture candidate peptide display vaccine based tmv describe rational design peptide vaccine improve manufacturability particular tmv product also discus downstream processing purification vaccine product particular attention metric product must attain order meet criterion regulatory approval injectable biologics,2009,"Smith, M. L.; Fitzmaurice, W. P.; Turpen, T. H.; Palmer, K. E.",Plant-produced Microbial Vaccines,,,,document_parses/pdf_json/9b3127228bf970ff5f47be7ee2e9ce78b9ded52a.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122513/,,3
9011,9011,10321,b4krhwfj,02009c1d1701053f52ae7ab91f9f01aebb10a79a,PMC,Vaccine Containing Natural TLR Ligands Protects from Salmonella typhimurium Infection in Mice and Acute Respiratory Infections in Children,10.1007/978-0-387-72005-0_40,PMC7123936,17713026.0,no-cc,shown single parenteral administration vaccine containing bacterial ligand tlr tlr tlr tlr tlr mouse induced rapid h administration effective shortterm h protection lethal challenge salmonella typhimurium repeated mucosal application vaccine stimulated longterm month protection acute respiratory infection child preschool age,2007,"Semenov, Boris; Zverev, Vitaly",Immune-Mediated Diseases,,,,document_parses/pdf_json/02009c1d1701053f52ae7ab91f9f01aebb10a79a.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123936/,,3
9016,9016,10348,xwbcfh6p,efb26217d5a2446e9b9853144d3c65fb40020cc8,PMC,Virus-Like Particles as a Vaccine Delivery System: Myths and Facts,10.1007/978-1-4419-1132-2_11,PMC7124136,20047040.0,no-cc,vaccine viral disease traditionally relied attenuated virus strain inactivation infectious virus subunit vaccine based viral protein expressed heterologous system effective pathogen often suffered poor immunogenicity due incorrect protein folding modification chapter focus specific class viral subunit vaccine mimic overall structure virus particle thus preserve native antigenic conformation immunogenic protein viruslike particle vlps produced wide range taxonomically structurally distinct virus unique advantage term safety immunogenicity previous approach new vlp vaccine papillomavirus beginning reach market place argue technology ‘ comeofage ’ must considered viable vaccine strategy,2009-12-30,"Roy, Polly; Noad, Rob",Pharmaceutical Biotechnology,,,,document_parses/pdf_json/efb26217d5a2446e9b9853144d3c65fb40020cc8.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7124136/,,3
9027,9027,10384,qqid9ntg,,PMC,Possible immunoenhancement of persistent viremia by feline leukemia virus envelope glycoprotein vaccines in challenge-exposure situations where whole inactivated virus vaccines were protective,10.1016/0165-2427(86)90093-0,PMC7125533,3008409.0,no-cc,kitten immunized purified native felvgp gp envelope protein developed elisa virus neutralizing antibody serum whole felv felvgp kitten vaccinated envelope protein infected feline sarcoma virus fesv developed smaller tumor nonvaccinates greater incidence persistent retroviremia similarly felvgp gp vaccinated kitten apt become persistently retroviremic following virulent felv challenge exposure nonvaccinates kitten vaccinated inactivated whole felv developed smaller tumor fesv inoculation lower incidence persistent retroviremia nonvaccinates protective effect inactivated whole felv vaccine persistent retroviremia also seen felv challengeexposed cat protection afforded inactivated whole felv vaccine associated virus neutralizing antibody although elisa antibody whole felv felvgp induced vaccination,2002-11-12,"Pedersen, N.C.; Johnson, L.; Birch, D.; Theilen, G.H.",Vet Immunol Immunopathol,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7125533/,,3
9078,9078,10482,rcf6rlzo,,PMC,Plant-based vaccines: unique advantages,10.1016/s0264-410x(00)00512-0,PMC7127671,11257418.0,no-cc,numerous study shown viral epitope subunit bacterial toxin expressed correctly processed transgenic plant recombinant protein induce immune response several benefit current vaccine technology including increased safety economy stability versatility efficacy antigen expressed corn particularly advantageous since seed produced vast quantity shipped long distance ambient temperature potentially allowing global vaccination expressed bsubunit escherichia coli heatlabile enterotoxin spike protein swine transmissible gastroenteritis virus high level corn demonstrate antigen delivered seed elicit protective immune response,2001-03-21,"Streatfield, Stephen J.; Jilka, Joseph M.; Hood, Elizabeth E.; Turner, Debra D.; Bailey, Michele R.; Mayor, Jocelyne M.; Woodard, Susan L.; Beifuss, Katherine K.; Horn, Michael E.; Delaney, Donna E.; Tizard, Ian R.; Howard, John A.",Vaccine,,,,,document_parses/pmc_json/PMC7127671.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127671/,,3
9081,9081,10489,7csjvrv4,d0e0877a44d56ff546ea45fa3319996b85401c80,PMC,Rotaviral Diarrhea,10.1016/s0749-0739(17)30398-x,PMC7127803,8358646.0,no-cc,rotavirus identified common cause foal diarrhea outbreak major breeding area worldwide article review latest information practical diagnosis prevention control rotavirus horse farm effective vaccine developed certain farm management method disinfection technique proved effective containing rotavirus outbreak research involving electropherotyping technique furthering knowledge different rotavirus serotypes aid epidemiologic study vaccine development,2017-05-19,"Dwyer, Roberta M.",Vet Clin North Am Equine Pract,,,,document_parses/pdf_json/d0e0877a44d56ff546ea45fa3319996b85401c80.json,document_parses/pmc_json/PMC7127803.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7127803/,,3
9110,9110,10623,fhs5wlw4,,PMC,Virus-like particles: Passport to immune recognition,10.1016/j.ymeth.2006.07.018,PMC7128828,16997714.0,no-cc,viruslike particle vlps formed selfassembly envelope andor capsid protein many virus many case vlps structural characteristic antigenicity similar parental virus already proven successful vaccine cognate virus infection structural component vlps also proven amenable insertion fusion foreign antigenic sequence allowing production chimeric vlps exposing foreign antigen surface vlps used carrier foreign antigen including nonprotein antigen via chemical conjugation review outline advantage disadvantage technical consideration use wide range vlp system vaccine development,2006-09-22,"Grgacic, Elizabeth V.L.; Anderson, David A.",Methods,,,,,document_parses/pmc_json/PMC7128828.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128828/,,3
9113,9113,10630,ocs3yr6n,,PMC,Veterinary Vaccines and Their Importance to Animal Health and Public Health,10.1016/j.provac.2011.10.009,PMC7128871,32288915.0,no-cc,veterinary vaccine continue major role protecting animal health public health reducing animal suffering enabling efficient production food animal feed burgeoning human population greatly reducing need antibiotic treat food companion animal prominent example include rabies vaccine rinderpest vaccine rabies vaccine domestic animal wildlife nearly eliminated human rabies developed country thanks global rinderpest eradication program involves vaccination trade restriction surveillance rinderpest may soon become second disease smallpox globally eradicated successful example new technology animal vaccine licensed use include genedeleted marker vaccine viruslikeparticle vaccine recombinant modified live virus vaccine chimeric vaccine dna vaccine animal vaccine also use wide variety novel adjuvant yet approved use human vaccine animal vaccine developed licensed much quickly human vaccine west nile virus discovered united state august august equine vaccine west nile virus conditionally licensed animal vaccine effectively protect animal public health must widely used mean must affordable regulatory process must meet need assuring safety efficacy without increasing cost licensing production point affordable end user,2011-12-23,"Roth, James A",Procedia Vaccinol,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128871/,,3
9118,9118,10653,52qwsv01,,PMC,Fimbriae assisted bacterial surface display of heterologous peptides,10.1016/s1438-4221(00)80118-6,PMC7129006,10959723.0,no-cc,display peptide segment surface bacteria offer many new exciting application biotechnology medical research fimbriaassisted display heterologous sequence paradigm chimeric organelle display bacteria fimbria particularly attractive candidate epitope display several reason present extremely high number cell surface strong immunogen posse inherent adhesive property easily purified majority work dealing fimbriaassisted peptide display focused development recombinant vaccine number different fimbrial type used display immunerelevant sector various foreign protein chimeric fimbrial vaccine used context purified protein however potential also exists exploit technology development live recombinant vaccine work also performed demonstrating amenability fimbria towards powerful technology random peptide display review summarises current state research field,2011-11-01,"Klemm, Per; Schembri, Mark A.",Int J Med Microbiol,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129006/,,3
9199,9199,10919,1l67qsfc,,PMC,DNA immunization and central nervous system viral infection,10.1016/s0065-3527(01)56030-3,PMC7130639,11450302.0,no-cc,chapter discus virus infection central nervous system cns dna vaccine mild central nervous system cns symptom headache drowsiness result systemically elevated cytokine level therefore common many virus infection even absence infection cns cns infection quite unusual initiated either result viremia rarely result neural spread poliovirus infects anterior horn motor neuron spinal cord causing poliomyelitis disease virus named dna vaccination relatively new entrant vaccine sweepstakes viewed optimism number reason dna vaccine encoding nucleoprotein lymphocytic choriomeningitis virus confer protection normally lethal intracranial challenge rabies mouse model immunization plasmid encoding rabies glycoprotein conferred complete protection subsequent viral challenge several virusinduced cns disease may explained triggering autoimmunity experimental autoimmune encephalomyelitis wellcharacterized cns disease induced administration certain cns protein,2004-01-07,"Lindsay Whitton, J.; Fujinami, Robert S.",Adv Virus Res,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7130639/,,3
9222,9222,10960,nf9wbo25,,PMC,Vaccines for preventing enterotoxigenic Escherichia coli infections in farm animals,10.1016/0264-410x(93)90020-x,PMC7130883,8094931.0,no-cc,fimbrial vaccine routinely given parenterally pregnant cattle sheep swine protect suckling newborn calf lamb pig enterotoxigenic escherichia coli etec infection vaccine practical effective fatal etec infection farm animal occur early neonatal period antibody titre colostrum milk highest etec farm animal belong small family fimbrial antigen type fimbria consist good protein antigen bacterial surface readily accessible antibody fimbria required critical step adhesioncolonization early pathogenesis disease etec infection continue significant clinical problem farm animal spite extensive use fimbriaebased vaccine definitive data efficacy commercial vaccine field use available prevailing perception among animal health professional vaccine effective problem occurs chiefly among nonvaccinated animal herd vaccination move peak prevalence disease first second third week birth mortality lower suggested extensive use vaccine rapidly select emergence novel previously low prevalence fimbrial antigen type evidence happened decade routine vaccine use united state however active direct surveillance emergence contrast rational development vaccine provide passive lacteal protection etec suckling neonate comparatively little progress made providing knowledge required development vaccine protect postweaning etec infection swine,2002-11-13,"Moon, Harley W.; Bunn, Thomas O.",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7130883/,,3
9251,9251,11000,8dkj6ps3,,PMC,Viral vectors for malaria vaccine development,10.1016/j.vaccine.2006.07.035,PMC7131149,16914237.0,no-cc,workshop viral vector malaria vaccine development organized path malaria vaccine initiative held bethesda md october recent advancement viralvectored malaria vaccine development emerging vector technology presented discussed classic viral vector poxvirus adenovirus alphavirus vector successfully used deliver malaria antigen vaccine candidate demonstrated potential inducing malariaspecific immunity animal model human trial addition emerging viralvector technology measles virus mv vesicular stomatitis virus vsv yellow fever yf virus may also useful malaria vaccine development study animal model suggest viral vector unique ability induce humoral andor cellular immune response study also revealed optimization plasmodium gene mammalian expression important aspect vaccine design codonoptimization surfacetrafficking deglycosylation removal toxic domain lead improved immunogenicity understanding vector ability induce immune response expression malaria antigen mammalian cell critical designing next generation viralvectored malaria vaccine,2007-03-30,"Li, Shengqiang; Locke, Emily; Bruder, Joseph; Clarke, David; Doolan, Denise L.; Havenga, Menzo J.E.; Hill, Adrian V.S.; Liljestrom, Peter; Monath, Thomas P.; Naim, Hussein Y.; Ockenhouse, Christian; Tang, De-chu C.; Van Kampen, Kent R.; Viret, Jean-Francois; Zavala, Fidel; Dubovsky, Filip",Vaccine,,,,,document_parses/pmc_json/PMC7131149.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131149/,,3
9254,9254,11003,u2g30x1j,,PMC,Isotype-specific antibody responses to rotavirus and virus proteins in cows inoculated with subunit vaccines composed of recombinant SA11 rotavirus core-like particles (CLP) or virus-like particles (VLP),10.1016/s0264-410x(96)00065-5,PMC7131174,9004438.0,no-cc,isotype antibody response bovine ind p g simian sa p g rotavirus sa rotavirus protein vp vp vp serum colostrum milk analysed elisa three group vaccinated cow nonvaccinated control pregnant cow vaccinated intramuscularly intramammarily recombinant baculovirusexpressed sa rotavirus vlp triplelayered viruslike particle containing rotavirus vp vp vp vp clp doublelayered corelike particle containing rotavirus vp vp inactivated sa rotavirus respectively rotavirus antigen titer highest –fold elisa vlp vaccine compared inactivated sa vaccine igg igg igm geometric mean antibody titer gmt rotavirus titer bovine rotavirus v sa rotavirus differ significantly isotype group igg gmt vp serum calving vaccinated group significantly p higher control group colostrum igg iga rotavirus antibody titer significantly elevated vlp igg gmt iga gmt clp igg gmt iga gmt sa igg gmt iga gmt vaccinated cow compared control cow igg gmt iga gmt igg iga gmt rotavirus significantly elevated –fold milk vlp clp vaccinated cow compared sa vaccinated control cow isotype antibody response vp serum colostrum milk paralleled response rotavirus titer ∼–fold lower cow vaccinated vlp significantly enhanced serum colostral milk antibody titer rotavirus vp vp result demonstrate rotavirus antibody titer serum colostrum milk significantly enhanced use noninfectious vlp clp inactivated sa rotavirus vaccine vlp clp vaccine induced highest antibody response corresponding higher rotavirus antigen titer measured elisa,1999-03-19,"Fernandez, F.M.; Conner, M.E.; Parwani, A.V.; Todhunter, D.; Smith, K.L.; Crawford, S.E.; Estes, M.K.; Saif, L.J.",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131174/,,3
9257,9257,11007,i0o25spx,,PMC,Efficacy of infectious bronchitis virus vaccines against heterologous challenge,10.1016/s0034-5288(18)30889-0,PMC7131188,2851866.0,no-cc,twentyfourweekold white leghorn layer inoculated subcutaneously killed newcastle diseaseinfectious bronchitis massachusetts type virus mibv vaccine twentyeight week vaccination bird challenged intraocularly arkansas strain infectious bronchitis virus aibv determine effect heterologous virus exposure egg production egg quality serum antibody response bird challenged hen laid significantly p· fewer egg unchallenged layer egg laid unchallenged group weighed significantly p· laid challenged group internal quality haugh unit shell quality egg laid aibvchallenged hen significantly p· inferior unchallenged hen addition aibvchallenged hen laid softshell misshapen small egg unchallenged hen arkansas serum haemagglutination inhibition aibvhi titre aibv challenged bird increased four week challenge corresponding mibv haemagglutinationinhibition mibvhi titre decreased period study indicates killed mibv vaccine offered protection bird exposed heterologous aibv,2018-08-23,"MUNEER, M.A.; NEWMAN, J.A.; HALVORSON, D.A.; SIVANANDAN, V.; NAGARAJA, K.V.; COON, C.N.",Res Vet Sci,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131188/,,3
9262,9262,11018,iaj8nc4z,,PMC,Proposed Calfhood Immunization Program for the Commercial Dairy Herd,10.3168/jds.s0022-0302(77)83868-x,PMC7131246,190280.0,no-cc,immunization program never usurp central role sound management practice good nutrition disease prevention program commercial dairy operation however certain immunization disease brucellosis leptospirosis clostridial infection routine disease infectious bovine rhinotracheitis bovine virus diarrhea parainfluenza colibacillosis pasteurellosis considered determined herd infected chronically present knowledge disease condition vaccine effectiveness safety make use vaccine disease questionable value,2010-04-26,"Smith, Paul C.",J Dairy Sci,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131246/,,3
9297,9297,11077,010w5ais,,PMC,Molecular Biology of Rubella Virus,10.1016/s0065-3527(08)60328-0,PMC7131582,7817880.0,no-cc,chapter summarizes present medical significance rubella virus rubella virus infection systemic nature accompanying symptom generally benign pronounced mild rash short duration common complication rubella virus infection transient joint involvement polyarthralgia arthritis primary health impact rubella virus teratogenic agent vaccination strategy aimed elimination rubella includes universal vaccination infant month age trivalent measles mumps rubella mmr vaccine specific targeting rubella vaccine seronegative woman planning pregnancy seronegative adult could come contact woman childbearing age although recommended individual age month without evidence natural infection vaccination vaccinated medically current challenge posed rubella virus achieve complete vaccination coverage prevent resurgence,2008-03-02,"Frey, Teryl K.",Adv Virus Res,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7131582/,,3
9427,9427,11302,mzsoh16g,,PMC,Chapter 4 Picornavirus infections,10.1016/s0168-7069(08)70012-0,PMC7134062,32287579.0,no-cc,oldest member picornavirus group polio virus recognized early clinician characteristic paralytic disease chapter examines polio virus regard virology disease prevention vaccine chemoprophylaxis polio well controlled developed country using live inactivated vaccine research work intensified using genetic engineering technique produce live attenuated virus defined stable mutation prevent reversion virulence also produce immunogenic oligopeptides protein new generation inactivated polio vaccine chemotherapy therefore required polio infection contrast neither vaccine developed rhinovirus infection vaccine thought use unless broadly reacting antigenic determinant located several interesting weakly effective antiviral compound selected rhinovirus major research area present study continue also interferon toxicity problem look le interesting present sequence biochemical data available several additional enterovirus strain could open new possibility antiviral vaccine example synthetic peptide near future,2008-05-29,,Perspect Med Virol,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134062/,,3
9437,9437,11315,l1gitdmz,,PMC,"Evolution des anticorps anti rota dans le lait de vaches traitees en fin de gestation soit par le vaccin anti rota complet, soit par l'adjuvant seul",10.1016/0147-9571(81)90015-1,PMC7134145,6277557.0,no-cc,author describe evolution secretion antirotavirus antibody vaccine given three week repeated moment parturition rota virus antibody detected high level three month test period indirect immunofluorescence test seroneutralisation test immunofluorescence test four untreated animal excreted rotaantibodies till day post partum seroneutralising antibody detected milk vaccinated animal level – colostral level till day aspecific stimulation excretion antirotavirus antibody milk inoculation adjuvant fraction vaccine confirmed excretion level however significantly lower rotavirus vaccination,2002-11-13,"Van Opdenbosch, E; Wellemans, G; Strobbe, R; De Brabander, D.L; Boucqué, Ch.V",Comp Immunol Microbiol Infect Dis,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134145/,,3
9455,9455,11343,qigdebgv,,PMC,Canine Vaccination,10.1016/s0195-5616(01)50603-8,PMC7134419,11446099.0,no-cc,new technology vaccine development infectious disease diagnosis likely introduced near future new technology come opportunity vaccinate companion animal even infectious agent currently practiced united state look forward becomes particularly important review current vaccination standard applied dog respect current knowledge duration immunity awareness incidence likelihood injurious even fatal adverse event associated vaccination individual risk factor dictate vaccine appropriate stage life,2015-01-13,"Greene, Craig E.; Schultz, Ronald D.; Ford, Richard B.",Vet Clin North Am Small Anim Pract,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134419/,,3
9471,9471,11379,1v5xisvl,,PMC,Vaccines and Principles of Immunization,10.1016/s0195-5616(86)50138-8,PMC7134508,3538634.0,no-cc,article discus production various class vaccine compare advantage disadvantage adjuvant combination vaccine heterologous viral vaccine vaccination failure discussed briefly reported adverse reaction vaccination described length essential vaccination several exotic specie given,2015-01-20,"Pearson, Renée C.; Dhein, Cheryl R.; Gorham, John R.",Vet Clin North Am Small Anim Pract,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134508/,,3
9485,9485,11434,579ronfq,,PMC,MULTISITE INTRADERMAL ANTIRABIES VACCINATION: Immune Responses in Man and Protection of Rabbits Against Death from Street Virus by Postexposure Administration of Human Diploid-Cell-Strain Rabies Vaccine,10.1016/s0140-6736(81)91402-1,PMC7134747,6117693.0,no-cc,lymphocyte transformation production neutralising antibody development antirabies igg antibody studied ten healthy volunteer response · ml human diploidcell strain hdcs rabies vaccine administered one occasion divided dos intradermal id site ten volunteer rapidly developed substantial titre rabies antibody eight ten lymphocyte immunologically stimulated hdcs rabiesvirus antigen postexposure treatment · ml hdcs vaccine given id site completely protected fourteen rabbit death street virus result suggest developing country patient could protected small volume potent tissueculture vaccine administered intradermally shortly exposure,1981-10-24,"Nicholson, KarlG; Prestage, Howard; Cole, PeterJ; Turner, GeorgeS; Bauer, SallyP",Lancet,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7134747/,,3
9604,9604,11865,rp9z4izp,482ecdcf3908002081cf457379ec4cac3978ffef; 921bb128c3acf9f6c41a40d5b18e00455fbdefec,PMC,Lipid moieties of Mycoplasma pneumoniae lipoproteins are the causative factor of vaccine-enhanced disease,10.1038/s41541-020-0181-x,PMC7142147,32284882.0,cc-by,vaccineenhanced disease ved occurs result vaccination followed infection virulent mycoplasma pneumoniae date ved prevented development efficacious vaccine significant human respiratory pathogen herein report vaccination balbc mouse pneumoniae lipidassociated membrane protein lamp induces lung lesion consistent exacerbated disease following challenge without reducing bacterial load removal lipid moiety lamp prior vaccination eliminates ved reduces bacterial load infection collectively data indicate lipid moiety lipoprotein causative factor pneumoniae ved,2020-04-08,"Mara, Arlind B.; Gavitt, Tyler D.; Tulman, Edan R.; Geary, Steven J.; Szczepanek, Steven M.",NPJ Vaccines,,,,document_parses/pdf_json/482ecdcf3908002081cf457379ec4cac3978ffef.json; document_parses/pdf_json/921bb128c3acf9f6c41a40d5b18e00455fbdefec.json,document_parses/pmc_json/PMC7142147.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7142147/,,3
9663,9663,12048,0vis4bwi,1f7c4b6fc91f3143baa4824a7f8050f16d9bcccd,PMC,Broad Protection of Pigs against Heterologous PRRSV Strains by a GP5-Mosaic DNA Vaccine Prime/GP5-Mosaic rVaccinia (VACV) Vaccine Boost,10.3390/vaccines8010106,PMC7157218,32121277.0,cc-by,background porcine reproductive respiratory syndrome prrs virus major cause disease economic loss pig worldwide high genetic diversity among prrsv strain problematic successful disease control vaccination mosaic dna vaccinia vacv vaccine developed order improve protection heterologous prrsv strain method piglet primed boosted gpmosaic dna vaccine recombinant gpmosaic vacv rgpmosaic vacv respectively pig vaccinated rgpwt vr dna rgpwt vacv empty vector dna empty vacv respectively served control virus challenge given separate group vaccinated pig vr mnc necropsy performed day challenge result vaccination gpmosaicbased vaccine resulted cellular reactivity higher level neutralizing antibody vr mnc prrsv strain contrast vaccination animal gpwt vaccine induced response vr furthermore vaccination gpmosaic based vaccine resulted protection challenge two heterologous virus strain demonstrated significantly lower viral load serum tissue porcine alveolar macrophage pams bronchoalveolar lavage bal fluid le severe lung lesion challenge either mnc vr identity contrast significant protection gpwt based vaccine achieved vr strain conclusion gpmosaic vaccine using dnaprimevacv boost regimen conferred protection pig heterologous virus,2020-02-28,"Cui, Junru; O’Connell, Caitlin M.; Hagen, Connor; Sawicki, Kim; Smyth, Joan A.; Verardi, Paulo H.; Van Kruiningen, Herbert J.; Garmendia, Antonio E.",Vaccines (Basel),,,,document_parses/pdf_json/1f7c4b6fc91f3143baa4824a7f8050f16d9bcccd.json,document_parses/pmc_json/PMC7157218.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157218/,,3
9664,9664,12049,63cci72h,e163fe50949e69946e890d637ce3be209fd61cc5,PMC,Intramuscular Immunization with Chemokine-Adjuvanted Inactive Porcine Epidemic Diarrhea Virus Induces Substantial Protection in Pigs,10.3390/vaccines8010102,PMC7157555,32102459.0,cc-by,intramuscular im immunization generally considered incapable generating protective mucosal immune response swine industry attempt develop safe protective vaccine controlling porcine epidemic diarrhea ped via im route administration unsuccessful present study porcine chemokine ligand protein ccl constructed stably expressed mammalian expression system im coadministration inactivated pedv ipedv particle different cc chemokines freund ’ adjuvant resulted recruiting ccr andor ccr inflammatory cell injection site thereby inducing superior systemic pedv specific igg fecal iga viral neutralizing antibody pig moreover pig immunized ipedv combination ccl ccl elicited substantial protection virulent pedv challenge show porcine cc chemokines could novel adjuvant developing im vaccine modulating mucosal immune response mucosal transmissible pathogen pig,2020-02-24,"Hsueh, Fu-Chun; Chang, Yen-Chen; Kao, Chi-Fei; Hsu, Chin-Wei; Chang, Hui-Wen",Vaccines (Basel),,,,document_parses/pdf_json/e163fe50949e69946e890d637ce3be209fd61cc5.json,document_parses/pmc_json/PMC7157555.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157555/,,3
9668,9668,12053,7br852ma,ffec12aa4a9fd44c1cef69a933194c5f19e75bf0,PMC,Humanized Mice for Live-Attenuated Vaccine Research: From Unmet Potential to New Promises,10.3390/vaccines8010036,PMC7157703,31973073.0,cc-by,liveattenuated vaccine lav represent one important medical innovation human history past three century lav saved hundred million life continue many decade come interestingly successful lav smallpox vaccine measles vaccine yellow fever vaccine isolated andor developed purely empirical manner without understanding immunological mechanism trigger today mechanism governing potent lav immunogenicity longterm induced protective immunity continue elusive therefore hamper rational design innovative vaccine strategy serious roadblock understanding lavinduced immunity lack suitable costeffective animal model accurately mimic human immune response last two decade humanimmune system mouse mouse ie mouse engrafted component human immune system instrumental investigating lifecycle immune response multiple humantropic pathogen however use lav research remained limited discus strong potential lav tool enhance understanding human immunity review past current future contribution mouse endeavor,2020-01-21,"O’Connell, Aoife K.; Douam, Florian",Vaccines (Basel),,,,document_parses/pdf_json/ffec12aa4a9fd44c1cef69a933194c5f19e75bf0.json,document_parses/pmc_json/PMC7157703.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157703/,,3
9669,9669,12054,n4ckuhtd,25308c7825d20d18494ba38ac49632ebbb14f256,PMC,Synthetic DNA Vaccines Adjuvanted with pIL-33 Drive Liver-Localized T Cells and Provide Protection from Plasmodium Challenge in a Mouse Model,10.3390/vaccines8010021,PMC7157753,31936739.0,cc-by,need malaria vaccine indisputable single vaccine plasmodium preerythrocytic stage targeting major sporozoite antigen circumsporozoite protein csp partial success additionally cd cell targeting liverstage l antigen induced live attenuated sporozoite vaccine associated protection human challenge experiment evaluate protection mediated l antigen focused exported preerythrocytic protein exported protein exp profilin pfn exported protein exp inhibitor cysteine protease icp transmembrane protein tmp upregulated infective sporozoite uis expressed plasmodium specie designed optimized synthetic dna syndna immunogen syndna antigen cocktail tested without molecular adjuvant plasmid il immunized animal developed robust cell response including induction antigenspecific liverlocalized cd cell enhanced codelivery plasmid il total mouse adjuvanted group – nonadjuvanted group protected bloodstage disease following plasmodium yoelii sporozoite challenge study support potential syndna l antigen vaccine component malaria parasite infection,2020-01-10,"Reeder, Sophia M.; Reuschel, Emma L.; Bah, Mamadou A.; Yun, Kun; Tursi, Nicholas J.; Kim, Kevin Y.; Chu, Jacqueline; Zaidi, Faraz I.; Yilmaz, Ilknur; Hart, Robert J.; Perrin, Benjamin; Xu, Ziyang; Humeau, Laurent; Weiner, David B.; Aly, Ahmed S. I.",Vaccines (Basel),,,,document_parses/pdf_json/25308c7825d20d18494ba38ac49632ebbb14f256.json,document_parses/pmc_json/PMC7157753.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157753/,,3
9682,9682,12069,mvapt627,4f0d6c0601ae25bed9ab0680ba5076776f8512c8,PMC,Recombinant lipidated Zika virus envelope protein domain III elicits durable neutralizing antibody responses against Zika virus in mice,10.1186/s12929-020-00646-x,PMC7158147,32290844.0,cc-by,background emergence zika virus zv tropical subtropical area world created urgent need vaccine zv however approved vaccine prevent zv infection available develop effective vaccine zv infection lipidated form zv envelope protein domain iii posse intrinsic adjuvant property rationally designed goal examine immunogenicity recombinant lipidated zv envelope protein domain iii rlze evaluate potential vaccine candidate zv method recombinant zv envelope protein domain iii rze rlze prepared escherichia colibased system dendritic cell surface marker expression cytokine production upon stimulation analyzed evaluate function rlze neutralizing antibody capacity evaluated using focus reduction neutralization test immunization investigate protective immunity immunized mouse serum sample collected immunized mouse adoptively transferred ag mouse viremia level survival time examined zv challenge result rlze alone rze alone efficiently activated dendritic cell vitro taken dendritic cell vivo immunization cbl mouse rlze alone without exogenous adjuvant could induce zvspecific neutralizing antibody response furthermore serum sample obtained rlzeimmunized mouse provided protection indicated reduction viremia level prolongation survival time zv challenge conclusion result indicate rlze excellent vaccine candidate great potential evaluated preclinical study,2020-04-14,"Chen, Mei-Yu; Chai, Kit Man; Chiang, Chen-Yi; Wu, Chiao-Chieh; Yu, Guann-Yi; Liu, Shih-Jen; Chen, Hsin-Wei",J Biomed Sci,,,,document_parses/pdf_json/4f0d6c0601ae25bed9ab0680ba5076776f8512c8.json,document_parses/pmc_json/PMC7158147.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158147/,,3
9686,9686,12075,3nsllrcj,cb787bfd60086917fe259007679482d24cbce175; 5d0fdef2585b41e7ca47640fafe1a7c11ab4b3f7,PMC,Nanoplasmid Vectors Co-expressing Innate Immune Agonists Enhance DNA Vaccines for Venezuelan Equine Encephalitis Virus and Ebola Virus,10.1016/j.omtm.2020.04.009,PMC7158766,32296729.0,no-cc,dna vaccine expressing codonoptimized venezuelan equine encephalitis virus veev ebola virus ebov glycoprotein gene provide protective immunity mouse nonhuman primate delivered intramuscular im electroporation ep achieve equivalent protective efficacy absence ep evaluated veev ebov dna vaccine constructed using minimalized nanoplasmid expression vector smaller conventional plasmid used dna vaccination vector may also designed coexpress type interferon inducing innate immune agonist gene adjuvant effect nanoplasmid vaccinated mouse increased antibody response compared receiving conventional pwrgbased vaccine delivered im injection response enhanced inclusion innate immune agonist gene nanoplasmid veev dna vaccine also significantly increased protection aerosol veev challenge compared pwrg veev dna vaccine although mouse receiving pwrg nanoplasmid ebov dna vaccine dose tested survived ebov challenge mouse receiving nanoplasmid ebov dna vaccine coexpresses innate immune agonist gene failed lose weight challenge result suggest nanoplasmid vector improve immunogenicity protective efficacy alphavirus filovirus dna vaccine,2020-06-12,"Suschak, John J.; Dupuy, Lesley C.; Shoemaker, Charles J.; Six, Carolyn; Kwilas, Steven A.; Spik, Kristin W.; Williams, James A.; Schmaljohn, Connie S.",Mol Ther Methods Clin Dev,,,,document_parses/pdf_json/cb787bfd60086917fe259007679482d24cbce175.json; document_parses/pdf_json/5d0fdef2585b41e7ca47640fafe1a7c11ab4b3f7.json,document_parses/pmc_json/PMC7158766.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7158766/,,3
9805,9805,12286,5idwra98,d955f0244387c396e1f683404384846ab520594d,PMC,An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes,10.1186/s13071-020-04064-8,PMC7160903,32295617.0,cc-by,background visceral leishmaniasis vl caused dimorphic leishmania specie parasitic disease high socioeconomic burden endemic area worldwide sustaining control vl term proper prevailing immunity development global necessity amid unavailability prophylactic vaccine screening experimental proteome human disease propagating form leishmania donovani amastigote pragmatic silico mining novel vaccine candidate method using immunoinformatic approach cd cd cellspecific epitope experimentally reported l donovani protein secretory potential increased abundance amastigotes screened chimera linked tolllike receptor tlr peptide adjuvant constructed evaluated physicochemical characteristic binding interaction tlr simulated physiological condition trend immune response following hypothetical immunization result selected epitope physiologically important l donovani protein found mostly conserved l infantum covering theoretically global population multiepitope chimeric vaccine predicted stable antigenic nonallergenic structural analysis vaccinetlr receptor docked complex molecular dynamic simulation suggest sufficiently stable binding interface along prospect noncanonical receptor activation simulation dynamic immune response following hypothetical immunization indicate active memory b well cd cell generation potential likely chance th polarized response conclusion methodological approach result study could facilitate informed screening selection candidate antigenic protein entry vaccine production pipeline future control human vl image see text,2020-04-15,"Khan, Md Anik Ashfaq; Ami, Jenifar Quaiyum; Faisal, Khaledul; Chowdhury, Rajashree; Ghosh, Prakash; Hossain, Faria; Abd El Wahed, Ahmed; Mondal, Dinesh",Parasit Vectors,,,,document_parses/pdf_json/d955f0244387c396e1f683404384846ab520594d.json,document_parses/pmc_json/PMC7160903.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160903/,,3
9853,9853,12343,08qoho81,fca4a578e65771f9b87e3ccb2004fb198d089285,PMC,Bioprocess Engineering Issues That Would Be Faced in Producing a DNA Vaccine at up to 100 m(3) Fermentation Scale for an Influenza Pandemic,10.1021/bp050190n,PMC7161863,16321039.0,no-cc,risk pandemic virulent form influenza acknowledged world health organization agency current vaccine production facility would unable meet global requirement vaccine possible supplement dna vaccine may appropriate bioprocess engineering factor bearing use existing biopharmaceutical antibiotic plant produce described approach address uncertainty timing pandemic precludes purpose‐built facility strength weakness alternative downstream processing route analyzed several gap public domain information addressed conclusion processing would challenging feasible,2008-09-05,"Hoare, Mike; Levy, M. Susana; Bracewell, Daniel G.; Doig, Steven D.; Kong, Simyee; Titchener‐Hooker, Nigel; Ward, John M.; Dunnill, Peter",Biotechnol Prog,,,,document_parses/pdf_json/fca4a578e65771f9b87e3ccb2004fb198d089285.json,document_parses/pmc_json/PMC7161863.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161863/,,3
9858,9858,12349,5kddituy,6b5630e02ea089f071b3242b6385a5b77717746e,PMC,Different applications of virus‐like particles in biology and medicine: Vaccination and delivery systems,10.1002/bip.22759,PMC7161881,26509554.0,no-cc,virus‐like particle vlps mimic whole construct virus particle devoid viral genome used subunit vaccine design vlps elicit efficient protective immunity direct immunogen compared soluble antigen co‐administered adjuvant several booster injection several prokaryotic eukaryotic system insect yeast plant e coli used express recombinant protein especially vlp production recent study also generating vlps plant using different transient expression vector edible vaccine vlps viral particle applied different function gene therapy vaccination nanotechnology diagnostics herein describe vlp production different system well application biology medicine © wiley periodical inc biopolymers –,2015-12-22,"Shirbaghaee, Zeinab; Bolhassani, Azam",Biopolymers,,,,document_parses/pdf_json/6b5630e02ea089f071b3242b6385a5b77717746e.json,document_parses/pmc_json/PMC7161881.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161881/,,3
10037,10037,12592,ka16lepv,e0aa7e544032d26f7eee624fcf0eaf22e72c861f,PMC,Cross‐typic specificity and immunotherapeutic potential of a human HPV16 E7‐specific CTL line,10.1002/ijc.20779,PMC7165518,15609329.0,no-cc,cervical cancer cacx strongly associated human papillomavirus hpv infection particularly hpv type constitutive expression hpv e e protein cacx make attractive target ctl based immunotherapy however cervical carcinoma may feature eg antigen processing defect limit effectiveness hpv specific ctl furthermore vaccine development concentrated hpv type clear whether vaccine could induce ctl able cross‐react related oncogenic hpv type eg hpv investigate potentially important parameter vitro used ctl specific hpv e– able kill variety hpv cacx cell line including suspected caski known antigen processing defect ca low hpv dna copy number siha also able cross react related peptide hpv e hpv e analysis suggested cross reactivity related peptide influenced tcr contact residue certain threshold peptide binding hpv cross‐reactivity confirmed whole protein level also able recognize endogenously processed form hpv e e result suggest hpv e– would useful epitope immunotherapy hpv tumour despite difficult generate ctl response vaccination emphasizing need definition novel epitope efficient vaccination strategy © wiley‐liss inc,2004-12-17,"Youde, Sarah J.; McCarthy, Corinna M.; Thomas, Karen J.; Smith, Kelly L.; Man, Stephen",Int J Cancer,,,,document_parses/pdf_json/e0aa7e544032d26f7eee624fcf0eaf22e72c861f.json,document_parses/pmc_json/PMC7165518.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165518/,,3
10109,10109,12673,d1pbys8x,108aefaa643124d184a5b899e5b4c9b07ef5ef89,PMC,Recombinant fowlpox virus vaccines for poultry,10.1038/icb.1993.45,PMC7165850,8270268.0,no-cc,intensive poultry industry rely heavily upon use vaccine disease control viral vector based vaccine offer new avenue development vaccine effective disease control poultry technique developed construction recombinant vaccinia virus readily adapted construction recombinant virus based fowlpox virus rfpv ability insert several gene large genome fowlpox may enable development multivalent vaccine vaccine incorporating immune response modifier lymphokine newcastle disease avian influenza infectious bursal disease mareks disease antigen expressed rfpv shown effective vaccine poultry none appear however provide substantial improvement vaccine efficacy recombinant fpv valuable adjunct conventional vaccine currently widespread use whether rfpv vector based vaccine circumvent problem vaccination presence high maternally derived antibody yet resolved observation avipoxvirus recombinant may suitable vaccination non‐avian specie provides added dimension vaccine based fpv avipoxviruses recombinant fpv find useful role poultry disease control used conjunction conventional vaccine,2017-12-22,"BOYLE, D. B.; HEINE, H. G.",Immunol Cell Biol,,,,document_parses/pdf_json/108aefaa643124d184a5b899e5b4c9b07ef5ef89.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165850/,,3
10123,10123,12690,rs1c1f50,c1f4e7386b0fe1d34b7c4b6ffa64810fdc7acf7b,PMC,Progress towards achieving new vaccine and vaccination goals,10.1046/j.1445-5994.2003.00365.x,PMC7165918,12823675.0,no-cc,viral bacterial vaccine especially childhood use one successful public health measure last two century good safety record however still many disease caused infectious agent vaccine available increasing ability manipulate immune system offer hope future least infection may prevented vaccin­ation surprising recent development use vaccine technology test whether range ­generally non‐communicable disease prevented least controlled way investigation disease still mainly experimental level however list includes different type cancer allergy drug addiction neurodegenerative disease intern med j −,2003-07-01,"Ada, G.",Intern Med J,,,,document_parses/pdf_json/c1f4e7386b0fe1d34b7c4b6ffa64810fdc7acf7b.json,document_parses/pmc_json/PMC7165918.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165918/,,3
10222,10222,12812,9f3lkhry,ad499c94d157b5cd65d65547361ef905fa8d7977,PMC,Comparative studies of the capsid precursor polypeptide P1 and the capsid protein VP1 cDNA vectors for DNA vaccination against foot‐and‐mouth disease virus,10.1002/jgm.723,PMC7166641,15693054.0,no-cc,background foot‐and‐mouth disease virus fmdv cause severe livestock disease virus interesting target virology vaccine study material method evaluated comparatively three different viral antigen‐encoding dna sequence delivered via two physical mean ie gene gun delivery skin electroporation delivery muscle naked dna‐mediated vaccination mouse system result method gave similar result demonstrating commonality observed dna vaccine effect immunization cdna vector expressing major viral antigen vp alone routinely failed induce production anti‐vp neutralizing antibody test mouse second approach plasmid l‐vp produce transgenic membrane‐anchored vp protein elicited strong antibody response test mouse failed fmdv challenge experiment contrast mouse immunized viral capsid precursor protein p cdna expression vector neutralizing antibody – protection test mouse detected conclusion strategy using whole capsid precursor protein p cdna vaccination intentionally without use virus‐specific protease encoding gene safety reason may thus employed relevant experimental system induction upgrading effective neutralizing antibody response convenient surrogate test system dna vaccination study fmdv presumably viral disease copyright © john wiley son ltd,2005-02-03,"Yang, Ning‐Sun; Wang, Jeng‐Hwan; Lin, Ku‐Feng; Wang, Chien‐Yu; Kim, Suk‐Am; Yang, Yu‐Ling; Jong, Ming‐Hwa; Kuo, Tsun‐Yung; Lai, Shiow‐Suey; Holland Cheng, R.; Chan, Ming‐Tsair; Liang, Shu‐Mei",J Gene Med,,,,document_parses/pdf_json/ad499c94d157b5cd65d65547361ef905fa8d7977.json,document_parses/pmc_json/PMC7166641.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166641/,,3
10508,10508,13179,asjxwlrn,f0a605eab92d373080b2bb921ef6d36a25ca9501,PMC,Retracted: Immunological properties reveal the monovalent and bivalent recombinant dengue virus‐like particles as candidate vaccine for dengue,10.1111/1348-0421.12179,PMC7168374,25040367.0,no-cc,retraction statement ‘ immunological property reveal monovalent bivalent recombinant dengue virus‐like particle candidate vaccine dengue ’ yan liu junmei zhou zhizhun yu danyun fang chunyun fu xun zhu zhenjian huijun yan wenquan liu yunxia tang mengfeng li lifang jiang article microbiology immunology ‐ published online july wiley online library httponlinelibrarywileycom retracted agreement author journal editors‐in‐chief akio nakane takaji wakita yasunobu yoshikai wiley publishing asia pty ltd retraction agreed article submitted dr liu without agreement co‐authors including two listed corresponding author,2015-03-03,,Microbiol Immunol,,,,document_parses/pdf_json/f0a605eab92d373080b2bb921ef6d36a25ca9501.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168374/,,3
10572,10572,13266,u1zxg17k,4296574f4db8e475c8e18d3654caebcd2bca68a0,PMC,Rotavirus typing methods and algorithms,10.1002/rmv.411,PMC7169166,15027000.0,no-cc,vaccination current strategy control prevention severe rotavirus infection major cause acute dehydrating diarrhoea young child worldwide public health intervention aimed improving water food sanitation unlikely adequately control disease development vaccine severe rotavirus diarrhoea based upon homotypic heterotypic protection provided either single common g serotype monovalent vaccine multiple serotypes multivalent vaccine rotavirus strain surveillance high priority disease control programme worldwide continued identification common g p serotypes inclusion vaccine important priority subsequent introduction vaccine candidate monitoring circulating strain recommended also surveillance potential reassortment animal rotavirus gene vaccine human rotavirus strain critical conventional method used characterisation rotavirus strain enzyme immunoassay serotyping reverse‐transcription pcr‐based genotyping often fail identify uncommon newly appearing strain application newer molecular approach including sequencing oligonucleotide microarray hybridisation may required characterise strain present paper present brief overview variety standard method available followed suggestion systematic approach routine rotavirus strain surveillance well characterisation incompletely typed rotavirus strain improved detection characterisation incompletely typed strain help develop comprehensive strain surveillance may required tailoring effective rotavirus vaccine published john wiley son ltd,2004-02-24,"Fischer, Thea K.; Gentsch, Jon R.",Rev Med Virol,,,,document_parses/pdf_json/4296574f4db8e475c8e18d3654caebcd2bca68a0.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169166/,,3
10678,10678,13441,v1cvlnmk,401130bc78293650cba2008be1c3e5f1cac3ed43,PMC,Viral Enteritis,10.1016/s0031-3955(16)36401-x,PMC7172607,3277135.0,no-cc,viral enteritis rotavirus enteritis particular emerged major cause infant diarrhea throughout world new understanding cause mechanism viral diarrhea provided basis new approach active preventive therapy administration rational oral fluid early provision nutrient beneficial acute case work develop vaccine human rotavirus promising safe vaccine proven effectiveness yet available,2016-08-01,"Hamilton, J. Richard",Pediatr Clin North Am,,,,document_parses/pdf_json/401130bc78293650cba2008be1c3e5f1cac3ed43.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172607/,,3
10733,10733,13525,hpm1x0bi,,PMC,Veterinary vaccines,10.1016/0734-9750(94)90021-3,PMC7173300,14548468.0,no-cc,vaccination animal prevention infectious disease practised number year little change product composition recent advance molecular biology pathogenesis immunology laid groundwork development new generation veterinary vaccine based pure subunit well live vectored bacteria virus along novel method antigen preparation use new adjuvant delivery system permit targeting appropriate immune response well offering flexibility term vaccination protocol new technology also applied development vaccine enhance animal productivity control reproduction,2002-12-20,"Babiuk, L.A.; Potter, A.A.",Biotechnol Adv,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173300/,,3
10736,10736,13529,ytnv0map,,PMC,Inactivation of viral antigens for vaccine preparation with particular reference to the application of binary ethylenimine,10.1016/0264-410x(90)90083-x,PMC7173316,2204242.0,no-cc,viral antigen human veterinary vaccine still inactivated formaldehyde ideal inactivant problem formaldehyde inactivation vaccine discussed vaccine inactivated aziridines superior safety antigenicity aziridines inactivate virus firstorder reaction inactivation rate endpoint determined preparation application aziridine compound binary ethylenimine bei necessary condition control inactivation process described discussed computer program written assistance use bei controlled inactivation viral antigen,2002-11-12,"Bahnemann, Hans G.",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7173316/,,3
10743,10743,13547,8htwjxmw,a5c45e6d48d5488b4f78ce6bf6605878a3013e8c; 1714d3fbd1b8622c8c01ac242130d85b2e74dba9,PMC,In Vivo Assembly of Nanoparticles Achieved through Synergy of Structure‐Based Protein Engineering and Synthetic DNA Generates Enhanced Adaptive Immunity,10.1002/advs.201902802,PMC7175333,32328416.0,cc-by,nanotechnology considered growing importance vaccine field decoration immunogen multivalent nanoparticles designed nanovaccines elicit improved humoral immunity however significant practical monetary challenge large‐scale production nanovaccines impeded widespread clinical translation alternative approach illustrated integrating computational protein modeling adaptive electroporation‐mediated synthetic dna delivery thus enabling direct vivo production nanovaccines dna‐launched nanoparticles demonstrated displaying hiv immunogen spontaneously self‐assembled vivo dna‐launched nanovaccines induce stronger humoral response monomeric counterpart mouse guinea pig uniquely elicit cd effector t‐cell immunity compared recombinant protein nanovaccines improvement vaccine response recapitulate dna‐launched nanovaccines alternative scaffold decorated antigen designed evaluated finally evaluation functional immune response induced dlnanovaccines demonstrates comparison control mouse mouse immunized dna‐encoded hemagglutinin monomer mouse immunized dna‐launched hemagglutinin nanoparticle vaccine fully survive lethal influenza challenge substantially lower viral load weight loss influenza‐induced lung pathology additional study next‐generation vivo‐produced nanovaccines may offer advantage immunization multiple disease target,2020-02-27,"Xu, Ziyang; Wise, Megan C.; Chokkalingam, Neethu; Walker, Susanne; Tello‐Ruiz, Edgar; Elliott, Sarah T. C.; Perales‐Puchalt, Alfredo; Xiao, Peng; Zhu, Xizhou; Pumroy, Ruth A.; Fisher, Paul D.; Schultheis, Katherine; Schade, Eric; Menis, Sergey; Guzman, Stacy; Andersen, Hanne; Broderick, Kate E.; Humeau, Laurent M.; Muthumani, Kar; Moiseenkova‐Bell, Vera; Schief, William R.; Weiner, David B.; Kulp, Daniel W.",Adv Sci (Weinh),,,,document_parses/pdf_json/a5c45e6d48d5488b4f78ce6bf6605878a3013e8c.json; document_parses/pdf_json/1714d3fbd1b8622c8c01ac242130d85b2e74dba9.json,document_parses/pmc_json/PMC7175333.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7175333/,,3
10784,10784,13597,ojd11a7i,8a7750539981af35bced41e47799c28d648bf8fa,PMC,Immunization with a fusion protein vaccine candidate generated from truncated peptides of human enterovirus 71 protects mice from lethal enterovirus 71 infections,10.1186/s12985-020-01328-8,PMC7178760,32321526.0,cc-by,background prophylactic vaccine critical preventing hand foot mouth disease hfmd primarily caused human enterovirus ev infection child aged le year especially susceptible ev infection addition development vaccine containing inactivated virus containing viruslike particle vlps repeated antigen also constitute effective preventive strategy ev infection safety productivity advantage previously developed fusion protein composed truncated peptide ev capsid protein assembled spherical particle study aimed ass immunoprotective effect fusion protein vaccine candidate mouse model ev infection method evaluate protective effect fusion protein vaccine candidate neonatal mouse born immunized female mouse well normal neonatal mouse immunized twice infected ev virus whereafter survival rate clinical score viral load measured result high dosage booster immunization helped induce specific serum antibody high neutralization titer transferred neonatal mouse thereby facilitating effective resistance towards ev infection active immune response also observed neonatal mouse generated following immunization conclusion present result suggest fusion protein suitable vaccine candidate treating ev infection,2020-04-22,"Liu, Jiangning; Zhao, Binbin; Xue, Ling; Wu, Jing; Xu, Yanfeng; Liu, Yongdong; Qin, Chuan",Virol J,,,,document_parses/pdf_json/8a7750539981af35bced41e47799c28d648bf8fa.json,document_parses/pmc_json/PMC7178760.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178760/,,3
10789,10789,13606,bspa2fz8,92df84431c14b4d2e57d36ac437d52951b282156,PMC,Enhanced Induction of SARS-CoV Nucleocapsid Protein-Specific Immune Response Using DNA Vaccination followed by Adenovirus Boosting in BALB/c Mice,10.1159/000094247,PMC7179534,16809936.0,no-cc,objective investigate immunogenicity induction humoral cellular immune response genetic vaccine recombinant severe acute respiratory syndromeassociated coronavirus sarscovn gene expressing protein plasmid pcdnan replicationdefective adenoviral vector radn pcdnan primeradn boost regimen reverse sequence radn primepcdnan boost regimen method mouse immunized intramuscularly andor intraperitoneally pcdnan radn primetriple boost immunization humoral cellular immune response detected result detection different level antin humoral cellular response shown compared control humoral immune response induced effectively dna priming recombinant adenovirus boosting regimen reverse sequence heterogeneous combination significant difference heterogeneous homologous vaccination however cytotoxic lymphocyte ctl response significantly altered different primeboost immunization recombinant adenovirus pcdnan primeradn boost regimen alone lymphoproliferation interferonγ ifnγ secretion enhanced heterologous combination immunization compared homologous combination reverse sequence immunization regimen lymphoproliferation ifnγ ctl response significantly weaker compared pcdnan primeradn boost regimen conclusion taken together combination primetriple boost immunization pcdnanpcdnanpcdnanradn effectively induce sarscovnspecific strong humoral cellular immune response mouse present result suggest dna immunization followed recombinant adenovirus boosting could used potential sarscov vaccine induction enhanced humoral cellular immune response,2006-08-16,"Chunling, Ma; Kun, Yao; Jian, Xu; Jian, Qin; Hua, Sun; Minsheng, Zhu",Intervirology,,,,document_parses/pdf_json/92df84431c14b4d2e57d36ac437d52951b282156.json,document_parses/pmc_json/PMC7179534.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179534/,,3
10850,10850,13710,qgkwm9p8,58524a1db06419f1109cbe4768eb3f2c424ebf89,PMC,"The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route",10.1186/s12979-020-00179-9,PMC7187507,32355503.0,cc-by,background reduced response hepatitis b vaccine associated aging confounding comorbid condition well inadvertent subcutaneous sc inoculation hypothesized antibody cellmediated immune response tcmi elderly adult vaccine intended intramuscular im administration would attenuated deposited sc fat independent confounding condition result fiftytwo healthy community dwelling elderly adult – year seronegative hbv enrolled senieur protocol strictly healthy population senior randomized receive licensed alumadjuvanted recombinant hbv vaccine either sc im inoculum site verified imaging response rate defined hepatitis b surface antibody hbsab ≥ iul significantly lower elderly young adult group healthy –yearold volunteer moreover elderly participant received vaccine im significantly likely responder immunized sc versus p low seroconversion rate im group progressively declined increasing age responder significantly lower hbsab titer limited isotype response moreover tcmi proliferation cytokine production significantly reduced percentage responder intensity response th th subset elderly conclusion data demonstrate blunted immunogenicity sc inoculation measured peak titer response rate qualitative quantitative deficit b tcmi response primary alum adjuvanted protein antigen persisted even strictly healthy elderly population verified im placement compared younger population clinical trial registration clinicaltrialsgov nct registered november retrospectively registered,2020-04-28,"Edelman, Robert; Deming, Meagan E.; Toapanta, Franklin R.; Heuser, Mark D.; Chrisley, Lisa; Barnes, Robin S.; Wasserman, Steven S.; Blackwelder, William C.; Handwerger, Barry S.; Pasetti, Marcela; Siddiqui, Khan M.; Sztein, Marcelo B.",Immun Ageing,,,,document_parses/pdf_json/58524a1db06419f1109cbe4768eb3f2c424ebf89.json,document_parses/pmc_json/PMC7187507.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187507/,,3
10865,10865,13732,9o1r8bpt,,PMC,"Knowledge, awareness and practices towards seasonal influenza and its vaccine: implications for future vaccination campaigns in Jordan",10.1093/fampra/cmw086,PMC7188315,27567011.0,no-cc,background influenza underestimated contributor morbidity mortality population knowledge regarding influenza vaccination key role enhancing vaccination coverage objective study aimed identify gap knowledge among jordanian population towards influenza vaccine identify major determinant accepting seasonal influenza vaccine adult child jordan method crosssectional study enrolled randomly selected adult amman jordan foursection questionnaire used included question sociodemographic characteristic knowledge influenza factor affect seasonal influenza vaccine acceptance refusal result participant considered knowledgeable half participant correctly identified main influenza preventative measure lack knowledge important role seasonal influenza vaccine disease prevention observed low vaccination rate adult reported critical barrier vaccination adult child concern safety efficacy vaccine important predictor future vaccination adult child physician recommendation government role child inclusion vaccine within national immunization program important determinant vaccine acceptance conclusion formulating new strategy improve population ’ level knowledge assuring population safety efficacy vaccine inclusion vaccine within national immunization program essential factor enhance vaccination coverage jordan,2016-08-27,"Abu-rish, Eman Y; Elayeh, Eman R; Mousa, Lubabah A; Butanji, Yasser K; Albsoul-Younes, Abla M",Fam Pract,,,,,document_parses/pmc_json/PMC7188315.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188315/,,3
10969,10969,13886,1tn3a4qs,3431417c7db9dfad0645e3fedcf8d8857845d9d4,PMC,Gold nanoparticles for preparation of antibodies and vaccines against infectious diseases,10.1080/14760584.2020.1758070,PMC7196924,31903811.0,no-cc,introduction vaccination remains effective stimulating protective immune response infection important task antibody vaccine preparation choose optimal carrier ensure high immune response particularly promising regard nanoscale particle carrier antigen adsorbed encapsulated nanoparticles used adjuvant optimize immune response vaccination popular antigen carrier used immunization vaccination gold nanoparticles used make new vaccine viral bacterial parasitic infection area covered review summarizes currently known use gold nanoparticles antigen carrier adjuvant prepare antibody vivo design vaccine viral bacterial parasitic infection basic principle recent advance current problem use gold nanoparticles discussed expert opinion gold nanoparticles used adjuvant increase effectiveness vaccine stimulating antigenpresenting cell ensuring controlled antigen release studying characteristic immune response obtained use gold nanoparticles carrier adjuvant permit particle ’ potential vaccine design increased,2020-04-28,"Dykman, Lev A.",Expert Rev Vaccines,,,,document_parses/pdf_json/3431417c7db9dfad0645e3fedcf8d8857845d9d4.json,document_parses/pmc_json/PMC7196924.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7196924/,,3
11087,11087,14033,s1oqphvn,43d75c4463c98c19ac71f984c0cdba7804089971,PMC,In-silico identification of the vaccine candidate epitopes against the Lassa virus hemorrhagic fever,10.1038/s41598-020-63640-1,PMC7203123,32376973.0,cc-by,lassa virus lasv member arenaviridae ambisense rna virus cause severe hemorrhagic fever high fatality rate human west central africa currently fda approved drug vaccine available treatment lasv fever lasv glycoprotein complex gp promising target vaccine drug development situated virion envelope play key role lasv growth cell tropism host range pathogenicity effort discover new lasv vaccine employ several sequencebased computational prediction tool identify lasv gp major histocompatibility complex mhc class ii tcell epitope addition many sequence structurebased computational prediction tool used identify lasv gp bcell epitope predicted bcell epitope filtered based consensus approach resulted identification thirty new epitope previously tested experimentally epitopeallele complex obtained selected strongly binding allele mhci tcell epitope using molecular docking complex relaxed molecular dynamic simulation investigate interaction dynamic epitopeallele complex prediction provide guidance experimental investigation validation epitope potential stimulating tcell response bcell antibody lasv allow design development lasv vaccine,2020-05-06,"Baral, Prabin; Pavadai, Elumalai; Gerstman, Bernard S.; Chapagain, Prem P.",Sci Rep,,,,document_parses/pdf_json/43d75c4463c98c19ac71f984c0cdba7804089971.json,document_parses/pmc_json/PMC7203123.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203123/,,3
11096,11096,14043,txh19t3u,cc29327d0d6c287986ce95dace0072364860a858,PMC,Live-attenuated Salmonella enterica serotype Choleraesuis vaccine with regulated delayed fur mutation confer protection against Streptococcus suis in mice,10.1186/s12917-020-02340-4,PMC7203871,32381017.0,cc-by,background recombinant salmonella enterica serotype choleraesuis choleraesuis vaccine vector could used deliver heterologous antigen prevent control pig disease previously shown liveattenuated choleraesuis vaccine candidate strain rsc δpcrptt arac pbadcrp δpmi δrelaarac pbadlaci tt δasda δ deletion tt terminator delivering saoa conserved surface protein suis serotypes provided excellent protection suis challenge occasionally lead morbidity enteritidis vaccinated mouse approximately every mouse thus alternated attenuation method sought reduce reactogenicity strain rsc herein described another recombinant attenuated choleraesuis vector rsc δpfur tt arac pbadfur δpmi δrela arac pbadlaci tt δasda regulated delayed fur mutation avoid inducing disease symptom exhibiting high degree immunogenicity result strain rsc strain δpfurtt arac pbadfur mutation induced le production inflammatory cytokine strain rsc δpcrptt arac pbadcrp mutation mouse delivering pssaoa plasmid intraperitoneal ld rsc time higher rsc weekold balbc mouse rsc either pssaoa pya cleared spleen liver tissue day earlier rsc vector oral inoculation strain rsc synthesizing saoa induced high titer antisaoa antibody systemic igg serum mucosal iga vaginal wash site well increased level il facilitator thtype cell immune response mouse recombinant vaccine rscpssaoa conferred high percentage protection suis choleraesuis challenge balbc mouse conclusion liveattenuated salmonella enterica serotype choleraesuis vaccine rscpssaoa regulated delayed fur mutation provides foundation development safe effective vaccine choleraesuis suis,2020-05-07,"Li, Yu-an; Chen, Yunyun; Du, Yuan zhao; Guo, Weiwei; Chu, Dianfeng; Fan, Juan; Wang, Xiaobo; Bellefleur, Matthew; Wang, Shifeng; Shi, Huoying",BMC Vet Res,,,,document_parses/pdf_json/cc29327d0d6c287986ce95dace0072364860a858.json,document_parses/pmc_json/PMC7203871.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203871/,,3
11169,11169,14130,mc17142t,6d2bf33107800f134aa9fe74841c0b454df88d75,PMC,Interplay between cost and benefits triggers nontrivial vaccination uptake,10.1103/physreve.97.032308,PMC7217527,29776104.0,no-cc,containment epidemic spreading major challenge science vaccination whenever available best way prevent spreading eventually immunizes individual however vaccine perfect total immunization guaranteed imperfect immunization driven emergence antivaccine movement totally alter prediction epidemic incidence propose mathematically solvable meanfield vaccination model mimic spontaneous adoption vaccine influenzalike disease expected epidemic incidence result agreement extensive monte carlo simulation epidemic vaccination coevolutionary process interestingly result reveal nonmonotonic behavior vaccination coverage increase imperfection vaccine decrease apparent counterintuitive behavior analyzed understood stability principle proposed mathematical model,2018-03-19,"Steinegger, Benjamin; Cardillo, Alessio; Rios, Paolo De Los; Gómez-Gardeñes, Jesús; Arenas, Alex",,,,,document_parses/pdf_json/6d2bf33107800f134aa9fe74841c0b454df88d75.json,document_parses/pmc_json/PMC7217527.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7217527/,,3
11204,11204,14168,1pmkg37t,bf881abd5bdf473c548ac22834cab2ac9b3b375b,PMC,"Detection of Group A Beta Hemolytic Streptococci Species, emm, and Exotoxin Genes Isolated from Patients with Tonsillopharyngitis",10.1007/s00284-020-01994-5,PMC7222056,32367278.0,no-cc,group beta hemolytic streptococci gas critical human pathogen lead tonsillopharyngitis aim study identify gas isolates determine emm typing coverage rate available vaccine distribution superantigen gene profile gas isolates isolated throat culture patient tonsillopharyngitis admitted canakkale health application research hospital october may identification isolates performed conventional method rrna sequence analysis emm typing exotoxin profiling isolates performed polymerase chain reaction gas detected patient gas isolates identified pyogenes emm typing carried pyogenes isolates emm emm emm emm emm emm found six emm type coverage rate pyogenes strain valent vaccine valent vaccine common exotoxin speb followed spec spef ssa spea spem spej spel spei result determining emm type pyogenes specie canakkale concluded potential valent vaccine considered turkey development vaccine containing exotoxin type may beneficial,2020-05-04,"Altun, Mehzat; Mericli Yapıcı, Binnur",Curr Microbiol,,,,document_parses/pdf_json/bf881abd5bdf473c548ac22834cab2ac9b3b375b.json,document_parses/pmc_json/PMC7222056.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222056/,,3
11208,11208,14172,bgehvxo7,a35c33686eb1945378d9b89b8896880f03b896a8,PMC,Neue Impfstoffe gegen Tuberkulose,10.1007/s00103-019-03065-y,PMC7222064,31784764.0,cc-by,million active disease case million death tuberculosis tb remains one threatening infectious disease yet world health organization aim reduce morbidity mortality respectively although diagnostics therapeutic vaccine available beyond doubt better intervention measure needed accomplish ambitious goal vaccine bacille calmetteguérin bcg partially protects infant tb virtually ineffective pulmonary tb adolescent adult efficacy vaccine however yet fully exploited addition new vaccine candidate currently assessed clinical trial quarter people latently infected mycobacterium tuberculosis mtb new vaccine must applied prior infection preexposure vaccination also infection postexposure vaccination prevention infection prevention disease prevention recurrence currently assessed clinical endpoint protection tb primarily mediated lymphocyte tb vaccine development focus protective cell response protein adjuvant formulation viral vector killed live bacterial vaccine currently assessed clinical trial moreover therapeutic vaccination clinically tested notably adjunct canonical drug therapy multiresistant tb likely single vaccine accomplish various indication different vaccination strategy required,2019-11-29,"Kaufmann, Stefan H. E.",Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz,,,,document_parses/pdf_json/a35c33686eb1945378d9b89b8896880f03b896a8.json,document_parses/pmc_json/PMC7222064.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222064/,,3
11352,11352,14558,aea67d8f,6fe5a691baa3cfd4b79b1626918d3b50730dbcbc,PMC,Immunogenicity of a recombinant coronavirus spike glycoprotein expressed in transgenic plants,10.1007/s001030050020,PMC7082855,,no-cc,recently demonstrated plant offer possibility producing low cost subunit vaccine either parenterally orally administered review data obtained immunological response elicited two recombinant version glycoprotein swine transmissible gastroenteritis coronavirus tgev expressed transgenic plant arabidopsis potato plant genetically transformed cdna construct encoding nterminal domain aa residue – fulllength glycoprotein tgev responsible neutralizing antibody induction virus control cauliflower mosaic virus camv promoter genomic dna mrna analysis leave extract transformed plant demonstrated incorporation foreign cdna plant genome well transcription expression recombinant polypeptide observed transgenic plant elisa using specific antibody mouse immunized either parenterally leave extract transgenic arabidopsis plant interestingly fed potato tuber developed antibody specifically reacted tgev elisa immunoprecipitated glycoprotein case neutralized virus infectivity result conclude transgenic plant expressing glycoprotein polypeptide may potentially used source recombinant antigen vaccine production,2000,"Escribano, J.M.; Borca, M.V.",Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz,,,,document_parses/pdf_json/6fe5a691baa3cfd4b79b1626918d3b50730dbcbc.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082855/,,3
11378,11378,14640,j0qlwmkn,3ebf58978acf7f2ad80813af0943926f20766c15,PMC,Pandemic simulation of antivirals + school closures: buying time until strain-specific vaccine is available,10.1007/s10588-008-9027-1,PMC7087848,,no-cc,strainspecific vaccine unlikely available early phase potential hn avian influenza pandemic could month current production rate may provide timely protection population intervention strategy control spread infection necessary situation use u stockpile antiviral medication coupled month school closure agentbased simulation model episims used ass impact intervention strategy followed three different vaccine approach dose effective dose effective dose effective simulation show combination antiviral school closure strainspecific vaccine reduce morbidity mortality effect significant second infection wave occur current vaccine technology school closure relaxed though ideal vaccine able contain simulation worker absenteeism increase case mostly attributed household adult staying home child due school closure,2008-04-11,"Mniszewski, S. M.; Del Valle, S. Y.; Stroud, P. D.; Riese, J. M.; Sydoriak, S. J.",Comput Math Organ Theory,,,,document_parses/pdf_json/3ebf58978acf7f2ad80813af0943926f20766c15.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087848/,,3
11415,11415,14715,kac96l0a,f7e3f42d3f2f9b121f7803ef64cf379e27fb20b8,PMC,Targeting and expression of antigenic proteins in transgenic plants for production of edible oral vaccines,10.1079/ivp2002292,PMC7088994,,no-cc,exploiting plant biological bioreactors production delivery edible oral subunit vaccine promising application biotechnology effort enhance expression level transgene coding antigenic protein exploiting promoter targeting sequence enhancer element produced rather low quantity antigen plant tissue enough induce immune response feeding study review cover component various gene construct used developing plantbased vaccine myriad viral bacterial disease specifically focus sequence involved targeting antigen mucosal tissue intestinal tract thus enhancing immunogenicity plantbased vaccine well component result higher accumulation protein within plant,2002,"Korban, Schuyler S.",In Vitro Cell Dev Biol Plant,,,,document_parses/pdf_json/f7e3f42d3f2f9b121f7803ef64cf379e27fb20b8.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7088994/,,3
11419,11419,14719,m2cokcpz,75536ca0d04b455f83bf62f92cab4f3ecf763156,PMC,Transgenic plants for animal health: plant-made vaccine antigens for animal infectious disease control,10.1007/s11101-008-9088-2,PMC7089046,,no-cc,variety plant specie genetically modified accumulate vaccine antigen human animal health first vaccine candidate approaching market regulatory burden animal vaccine le human use attracted attention researcher company investment plantmade vaccine animal infectious disease control increasing dosage cost vaccine animal infectious disease must kept minimum especially nonlethal disease diminish animal welfare growth efficient economic production storage delivery critical commercialization become clear transgenic plant economic efficient alternative fermentation largescale production vaccine antigen oral delivery plantmade vaccine particularly attractive since expensive purification step avoided reducing cost per dose review cover current status plantproduced vaccine prevention disease animal focus barrier development product method overcome,2008-03-08,"Joensuu, J. J.; Niklander-Teeri, V.; Brandle, J. E.",Phytochem Rev,,,,document_parses/pdf_json/75536ca0d04b455f83bf62f92cab4f3ecf763156.json,document_parses/pmc_json/PMC7089046.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089046/,,3
11426,11426,14731,f6369ge9,,PMC,The effect of adjuvants on vaccine-induced antibody response against influenza in aged mice,10.1007/s11515-014-1301-7,PMC7089211,,no-cc,influenza remains major threat public health researcher continue search universal solution improving efficacy influenza vaccine even though influenza affect people different age extremely hazardous people year age older since population make high majority death toll caused influenzarelated disease elderly individual suffer effect immunosenescence age diminishing overall immune response immunosenescence occurs specifically affecting adaptive immune response control establishment immunity vaccination infection many study way trying find resolution problem influenza vaccine providing enough protection elderly population one possible strategy seek use optimal adjuvant immunological agent enhance immune response current vaccine formulation used murine model review effect adjuvant antibody response influenza vaccine aged mouse since adjuvant enhance production important inflammatory cytokine activation dendritic cell stimulation cell boosted increase effectiveness influenza vaccine aged mouse would hopefully translate elderly,2014-04-03,"Concannon, Mark A.; Jiang, Jiu",Front Biol (Beijing),,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089211/,,3
11449,11449,14763,d9szap94,97a4513a333a020295682ac5d16dc9ced94f093d,PMC,State of research in the field of the creation of plant vaccines for veterinary use,10.1134/s1021443715010100,PMC7089518,,no-cc,transgenic plant alternative costly system recombinant immunogenic protein expression source production cheap highly efficient biotherapeuticals new generation including plant vaccine present review possibility plant system application production recombinant protein veterinary use considered history “ edible vaccine ” concept briefly summarized advantage disadvantage various plant system expression recombinant immunogenic protein discussed list recombinant plant vaccine veterinary use different stage clinical trial presented,2015-01-04,"Permyakova, N. V.; Uvarova, E. A.; Deineko, E. V.",Russ J Plant Physiol,,,,document_parses/pdf_json/97a4513a333a020295682ac5d16dc9ced94f093d.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7089518/,,3
11495,11495,14860,eqauuo1x,,PMC,Fast vaccine offers hope in battle with Ebola,10.1038/news030804-9,PMC7094940,,no-cc,similar vaccine could form part future emergency strategy,2003-08-07,"Clarke, Tom",Nature,,,,,document_parses/pmc_json/PMC7094940.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094940/,,3
11499,11499,14866,cyj3sf8d,,PMC,Nasal solution joins SARS race,10.1038/news040621-10,PMC7094978,,no-cc,vaccine fatal virus work monkey,2004-06-28,"Nelson, Laura",Nature,,,,,document_parses/pmc_json/PMC7094978.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7094978/,,3
11501,11501,14868,gt6g5g2x,,PMC,SARS may be here to stay,10.1038/news030505-10,PMC7095005,,no-cc,vaccine tracking could benefit slow mutation killer virus genome,2003-05-12,"Pilcher, Helen R.",Nature,,,,,document_parses/pmc_json/PMC7095005.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095005/,,3
11795,11795,15787,cdv6qlwx,c12bb1742ad9b4e9397e661110e30675ef48b8dd,PMC,Fundamentals of Vaccine Delivery in Infectious Diseases,10.1007/978-1-4614-0881-9_16,PMC7119968,,no-cc,infectious disease continue major cause illness disability death moreover recent year new infectious agent disease identified disease previously considered control reemerged furthermore antimicrobial resistance grown rapidly variety hospital well community acquired infection thus humanity still face big challenge prevention control infectious disease vaccination generally considered effective method preventing infectious disease work presenting foreign antigen immune system evoke immune response administered antigen either live weakened form pathogen bacteria virus killed inactivated form pathogen purified material protein however vaccine completely safe therefore vaccine safety research monitoring necessary minimize vaccine related harm formulation point view goal continues improve quality global availability vaccine delivery system chapter provides introduction vaccine formulation describes delivery route utilized discus factor affect safety stability vaccine formulation,2011-07-06,"Şenel, Sevda",Fundamentals and Applications of Controlled Release Drug Delivery,,,,document_parses/pdf_json/c12bb1742ad9b4e9397e661110e30675ef48b8dd.json,document_parses/pmc_json/PMC7119968.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7119968/,,3
11820,11820,15817,2qiy1glv,5f99887429d6a03249c4934f300164ff1b177953,PMC,Immunosenescence Modulation by Vaccination,10.1007/978-1-4020-9063-9_71,PMC7120001,,no-cc,decline immune function hallmark aging lead complicated illness variety infectious disease cancer immunemediated disorder may limit ability appropriately respond vaccination vaccine might alter senescent immune response immune correlate protection addressed perspective stimulating previously primed response case vaccine seasonal influenza herpes zoster priming response novel antigen pandemic influenza virus vaccination bacterial pathogen pneumococcus altering immune response endogenous protein case vaccine alzheimer ’ disease spite often limited efficacy vaccine older adult influenza vaccination remains costsaving medical intervention population thus considerable opportunity exists improve current vaccine develop new vaccine preventive approach variety disease older adult strategy selecting appropriate immunologic target new vaccine development evaluating vaccine may alter senescent immune response term potential benefit risk preclinical clinical trial phase vaccine development discussed,2008-08-04,"McElhaney, Janet E.",Handbook on Immunosenescence,,,,document_parses/pdf_json/5f99887429d6a03249c4934f300164ff1b177953.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120001/,,3
11839,11839,15837,jybh0x84,91e5ea899411aef9fec0bd446286623ceef533ca,PMC,Immunology of Norovirus Infection,10.1007/978-1-4020-8412-6_9,PMC7120028,,no-cc,noroviruses leading cause epidemic nonbacterial gastroenteritis worldwide despite discovery three decade ago little known host immune response norovirus infection purpose chapter review field norovirus immunology discus contribution outbreak investigation human animal challenge study populationbased study chapter survey humoral cellular immunity well recent advance norovirus vaccine development,2008,"Leon, Juan S.; Souza, Menira; Wang, Qiuhong; Smith, Emily R.; Saif, Linda J.; Moe, Christine L.",Immunity Against Mucosal Pathogens,,,,document_parses/pdf_json/91e5ea899411aef9fec0bd446286623ceef533ca.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120028/,,3
11873,11873,15877,n7er94eb,3af3a6b72277616ac25d2a766b0ae6aee06edf47,PMC,Ebola in West Africa: Biosocial and Biomedical Reflections,10.1007/978-3-319-57669-5_13,PMC7120094,,no-cc,west africa ebola epidemic killed people fading urgency memory technical biomedical lessonslearned applied drug vaccine development example response zika biosocial issue arose may directly confronted sometimes even noticed despite overall importance eventual control ending epidemic,2017-04-03,"Cohen, Daniel B.",Encouraging Openness,,,,document_parses/pdf_json/3af3a6b72277616ac25d2a766b0ae6aee06edf47.json,document_parses/pmc_json/PMC7120094.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120094/,,3
11877,11877,15882,50r61l1x,0176ece806dfd2ccef736cd9095f02894049782d,PMC,Strategies for the Nonclinical Safety Assessment of Vaccines,10.1007/978-1-4614-5380-2_16,PMC7120100,,no-cc,past century vaccine made large impact public health prophylactic vaccine prevent disability disease saving million dollar potential healthcare spending since prophylactic vaccine administered healthy individual including infant child important demonstrate safety vaccine preclinically prior testing vaccine clinical study benefittorisk profile considered individual vaccine depends many factor including preclinical clinical toxicity observed frequency administration intended target population prophylactic vaccine particular concern potential risk often outweigh perception benefit therefore past decade increased focus nonclinical safety assessment vaccine including toxicity testing,2012-08-02,"Wolf, Jayanthi J.; Plitnick, Lisa M.; Herzyk, Danuta J.",Novel Immune Potentiators and Delivery Technologies for Next Generation Vaccines,,,,document_parses/pdf_json/0176ece806dfd2ccef736cd9095f02894049782d.json,document_parses/pmc_json/PMC7120100.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120100/,,3
12016,12016,16042,i7z0tdrk,f197af46dbe7cc4b8a2342039e5c88aa9d471694,PMC,Advanced In Silico Tools for Designing of Antigenic Epitope as Potential Vaccine Candidates Against Coronavirus,10.1007/978-981-13-1562-6_15,PMC7120312,,no-cc,vaccine economical potent substitute available medicine cure various bacterial viral disease earlier killed attenuated pathogen employed vaccine development present era peptide vaccine much trend favoured whole vaccine superiority conventional vaccine vaccine either based single protein synthetic peptide including several bcell tcell epitope however overall mechanism action remains work prompting immune system activate specific bcell tcellmediated response pathogen rino rappuoli others contributed field plotting design potent fully computational approach discovery potential vaccine candidate popular reverse vaccinology quite unambiguous advance vaccine evolution one begin genome information pathogen end list certain epitope application multiple bioinformatics tool book chapter effort bring approach reverse vaccinology notice reader using example coronavirus,2018-10-14,"Dangi, Mehak; Kumari, Rinku; Singh, Bharat; Chhillar, Anil Kumar","Bioinformatics: Sequences, Structures, Phylogeny",,,,document_parses/pdf_json/f197af46dbe7cc4b8a2342039e5c88aa9d471694.json,document_parses/pmc_json/PMC7120312.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120312/,,3
12047,12047,16074,61cyofjx,93a1731e7eb0079dbff0cb5a3baa8cd6ff459250,PMC,Functionalised Nanoliposomes for Construction of Recombinant Vaccines: Lyme Disease as an Example,10.1007/978-3-319-00978-0_10,PMC7120364,,no-cc,liposome phospholipid bilayer vesicle represent almost ideal carrier system preparation synthetic vaccine due biodegradability capacity protect transport molecule different physicochemical property including size hydrophilicity hydrophobicity charge liposomal carrier applied invasive eg im sc id well noninvasive transdermal mucosal route last year liposome vaccine technology matured several vaccine containing liposomebased adjuvant approved human veterinary use reached late stage clinical evaluation given intensifying interest liposomebased vaccine important understand precisely liposome interact immune system stimulate immunity become clear physicochemical property liposomal vaccine – method antigen attachment lipid composition bilayer fluidity particle charge property – exert strong effect resulting immune response chapter discus aspect liposomal vaccine including effect novel emerging immunomodulator incorporation application metallochelating nanoliposomes development recombinant vaccine lyme disease presented suitable example,2013-06-13,"Turánek, Jaroslav; Mašek, Josef; Křupka, Michal; Raška, Milan",Molecular Vaccines,,,,document_parses/pdf_json/93a1731e7eb0079dbff0cb5a3baa8cd6ff459250.json,document_parses/pmc_json/PMC7120364.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120364/,,3
12065,12065,16094,2ix6c0he,dca9cd240f0cba204f3a73fe9f07fcc577aad646,PMC,An Oral Vaccine for TGEV Immunization of Pigs,10.1007/978-3-662-43836-7_8,PMC7120389,,no-cc,transmissible gastroenteritis virus tgev commercially important pathogen hog farm cause contagious lethal diarrhea piglet orally parenterally administered vaccine made inactivated attenuated tgev commercially available require individual administration piglet time labor intensive run risk reversion pathogenicity also parenteral vaccine produce neutralizing serum antibody may le effective orally transmitted pathogen compared oral vaccine would induce production mucosal antibody effort produce subunit vaccine edible form plant convenient administration feed effort towards expression santigen tgev maize seed effectiveness inducing neutralizing antibody production colostrum gilt efficacy protecting piglet challenge virulent tgev summarized,2014-05-28,"Rajan, V.",Commercial Plant-Produced Recombinant Protein Products,,,,document_parses/pdf_json/dca9cd240f0cba204f3a73fe9f07fcc577aad646.json,document_parses/pmc_json/PMC7120389.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120389/,,3
12067,12067,16097,vxyrsy83,1692bdb87552d6240c2091803452d6b1d31a0d61,PMC,Non-vaccine-Preventable Infections,10.1007/978-981-13-7252-0_5,PMC7120392,,no-cc,many potentially serious infection may pose risk traveller vaccine available following discussion vaccine malaria prevention traveller ’ diarrhoea consultation travelmedicine practitioner identify infectious risk may apply traveller whether destination duration travel occupational activity individual susceptibility information provided infection relevance mode transmission method prevention traveller referred authoritative source information chapter advice given destination activityrelated infection risk distribution clinical feature method prevention number specific infection vaccine available outlined includes information emerging viral infection zika mers ebola chikungunya,2019-10-19,"Torresi, Joseph; McGuinness, Sarah; Leder, Karin; O’Brien, Daniel; Ruff, Tilman; Starr, Mike; Gibney, Katherine",Manual of Travel Medicine,,,,document_parses/pdf_json/1692bdb87552d6240c2091803452d6b1d31a0d61.json,document_parses/pmc_json/PMC7120392.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120392/,,3
12083,12083,16116,zfh20im0,b20dd72f8529a7ec649e4426acead6baea5b4279,PMC,Edible Vaccines,10.1007/978-81-322-1554-7_12,PMC7120417,,no-cc,recent year edible vaccine emerged new concept developed biotechnologists edible vaccine subunit vaccine selected gene introduced plant transgenic plant induced manufacture encoded protein food application include potato banana lettuce corn soybean rice legume easy administer easy store readily acceptable delivery system different age group patient yet cost effective edible vaccine present exciting possibility significantly reducing various disease measles hepatitis b cholera diarrhea etc mainly developing country however various technical regulatory challenge need overcome path emerging vaccine technology make edible vaccine efficient applicable chapter attempt discus key aspect edible vaccine like host plant production mechanism action advantage limitation application different regulatory issue concerned edible vaccine,2013-10-22,"Saxena, Jyoti; Rawat, Shweta",Advances in Biotechnology,,,,document_parses/pdf_json/b20dd72f8529a7ec649e4426acead6baea5b4279.json,document_parses/pmc_json/PMC7120417.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120417/,,3
12145,12145,16184,xcx1c0da,64c25194dc908c1e68a8e6b65f52c5af63a24fb7,PMC,Plant Edible Vaccines: A Revolution in Vaccination,10.1007/978-94-007-6603-7_10,PMC7120501,,no-cc,plant used source many pharmaceutical since long however utilization plant system production edible vaccine comparatively recent phenomenon several potential advantage plant derived vaccine conventional system vaccine production mammalian avian cell culture cost vaccine one factor preventing use vaccination leaving hundred thousand child susceptible preventable disease especially developing world novel technique proved boon low cost production convenient administration easy storage negligible chance infection whereas conventional system vaccine production limit applicability vaccine many part world vaccine prepared introducing selected desired gene plant inducing genetically modified plant manufacture encoded protein transgenic plant may provide ideal expression system transgenic plant material fed directly oral dose recombinant vaccine expression vaccine plant tissue eliminates risk contamination animal pathogen provides heat stable environment enables oral delivery thus eliminating infection related hazard identification transgenic material containment transgene control recombinant protein may potential problem large scale production vaccine plant factor like scaling production well distribution handling transgenic plant material must comprise future consideration field,2013-04-15,"Sahai, Aastha; Shahzad, Anwar; Shahid, Mohd.",Recent Trends in Biotechnology and Therapeutic Applications of Medicinal Plants,,,,document_parses/pdf_json/64c25194dc908c1e68a8e6b65f52c5af63a24fb7.json,document_parses/pmc_json/PMC7120501.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120501/,,3
12224,12224,16275,hcdnbdvl,5e300aa83a729075b7ee62608b647218e7404b52,PMC,The Human Antibody Response Against WNV,10.1007/978-0-387-79840-0_18,PMC7120614,,no-cc,experimental evidence shown antibody response west nile virus wnv critical protection wnvmediated disease antibody response also important immune correlate protection clinical evaluation wnv vaccine however little direct study carried characteristic human antibody response natural wnv infection preliminary evidence suggests important difference way human experimental animal mount humoral response wnv human igm remarkably persistent serum specific igg slow appear addition mapping igg response functionally relevant eprotein suggests directed away critical protective epitope towards weakly neutralizing immunodominant epitope finding important implication vaccine design testing,2009,"Throsby, Mark; Goudsmit, Jaap; Kruif, John de",West Nile Encephalitis Virus Infection,,,,document_parses/pdf_json/5e300aa83a729075b7ee62608b647218e7404b52.json,document_parses/pmc_json/PMC7120614.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120614/,,3
12234,12234,16287,zkawdcac,d5a4741fe5fb889487e0942fc6ccabfb6cfb73b1,PMC,Vaccines,10.1007/978-1-4614-9164-4_17,PMC7120629,,no-cc,vaccine continue offer key line protection range infectious disease however range vaccine currently available limited one key consideration development vaccine riskversusbenefit environment perceived low risk benefit vaccination may recognised address move towards use subunitbased vaccine offer low sideeffect profile generally weakly immunogenic compensated development effective adjuvant nanotechnology offer key attribute field ability nanoparticulates incorporate protect antigen rapid degradation combined potential effectively deliver antigen appropriate cell within immune system characteristic exploited development new adjuvant chapter outline application nanosystems vaccine formulation consider mechanism action behind range formulation,2013-10-17,"Perrie, Yvonne; Kaur, Randip; Henriksen-Lacey, Malou",Fundamentals of Pharmaceutical Nanoscience,,,,document_parses/pdf_json/d5a4741fe5fb889487e0942fc6ccabfb6cfb73b1.json,document_parses/pmc_json/PMC7120629.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120629/,,3
12356,12356,16424,39glgeft,960b822a06b4b620367ff9a139cdc8af3fda45e3,PMC,"Vaccines: Biotechnology Market, Coverage, and Regulatory Challenges for Achieving Sustainable Development Goals",10.1007/978-981-13-9431-7_14,PMC7120800,,no-cc,chapter provides overview bioeconomic global sustainability perspective main constraint current global vaccine innovation system achieving sustainable development goal – sdgs biotechnology market trend gap vaccine coverage emerging neglected disease patent protection regulation discussed structured longterm “ publicreturndriven ” innovation model overcome vaccine market failure proposed,2019-06-13,"Possas, Cristina; Antunes, Adelaide Maria de Souza; de Magalhães, Jorge Lima; Mendes, Flavia Maria Lins; Ramos, Mateus Pinheiro; De Simone Morais, Juliana; Homma, Akira",Bioeconomy for Sustainable Development,,,,document_parses/pdf_json/960b822a06b4b620367ff9a139cdc8af3fda45e3.json,document_parses/pmc_json/PMC7120800.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120800/,,3
12431,12431,16507,xvji54bo,b4ffcd0614eec614554ca322abf9d7bff6c622b1,PMC,Engineered Viruses as Vaccine Platforms,10.1007/978-94-007-4543-8_4,PMC7120934,,no-cc,many virus investigated development genetic vaccine ideal one must endowed many property quality quantity immunological response induced encoded antigen safety production large scale basis viral based vaccine must also deal potential problem preexisting antivector immunity several viral vaccine vector emerged date relative advantage limit depending proposed application recent success reflect diverse improvement development new adenovirus serotypes primeboost regime chapter describes feature four viral vector system based poxvirus adenovirus alphavirus lentiviruses recent result following use particular emphasis clinical research highlighting challenge success,2012-03-29,"Folgori, Antonella; Capone, Stefania",Innovation in Vaccinology,,,,document_parses/pdf_json/b4ffcd0614eec614554ca322abf9d7bff6c622b1.json,document_parses/pmc_json/PMC7120934.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120934/,,3
12433,12433,16510,lj0us1dq,e51cc6e0c3ae2c7c12d202bf4de965e40847b95d,PMC,Identification of Candidate Vaccine Antigens In Silico,10.1007/978-1-4614-5070-2_3,PMC7120937,,no-cc,identification immunogenic wholeprotein antigen fundamental successful discovery candidate subunit vaccine rapid effective efficient transformation clinically useful commercially successful vaccine formulation wider context experimental discovery vaccine antigen particular reference reverse vaccinology chapter adumbrates principal computational approach currently deployed hunt novel antigen genomelevel prediction antigen antigen identification use protein sequence alignmentbased approach antigen detection use subcellular location prediction use alignmentindependent approach antigen discovery reference also made recent emergence various expert system protein antigen identification,2012-09-28,"Flower, Darren R.; Davies, Matthew N.; Doytchinova, Irini A.",Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines,,,,document_parses/pdf_json/e51cc6e0c3ae2c7c12d202bf4de965e40847b95d.json,document_parses/pmc_json/PMC7120937.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120937/,,3
12469,12469,16551,bfi48hcn,3557dbbe870572872eade9f0fe7147743e1816c4,PMC,Virus-Like Particles-Based Mucosal Nanovaccines,10.1007/978-3-030-31668-6_10,PMC7120988,,no-cc,viruslike particle vlps protein complex resemble virus constitute highly immunogenic entity mimic pathogen important degree among nanovaccines based vlps successful thus far formulation already commercialized eg hepatitis b e virus human papillomavirus chapter highlight advantage vlpsbased vaccine describing approach design transmittance state art mucosal vlpsbased vaccine development several candidate produced insect cell plant e coli mammalian cell mainly evaluated oral immunization scheme vaccine influenza virus norwalk virus advanced application latter formulation clinical evaluation perspective field comprise expansion use lowcost platform plant bacteria development multiepitopicmultivalent vaccine computationally designed vlps mucosal vlpsbased vaccine stand major promising approach vaccinology initiation clinical trial envisaged short time,2019-11-08,"Rosales-Mendoza, Sergio; González-Ortega, Omar",Nanovaccines,,,,document_parses/pdf_json/3557dbbe870572872eade9f0fe7147743e1816c4.json,document_parses/pmc_json/PMC7120988.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120988/,,3
12472,12472,16554,app590vw,56b705cf0e5693d402fbc72215af26803f67444c,PMC,Porcine Epidemic Diarrhea Virus,10.1007/978-3-319-90137-4_12,PMC7120993,,no-cc,porcine epidemic diarrhea virus pedv cause disease mortality piglet worldwide vaccine used combat disease ineffective live attenuated virus vaccine research emerged showing spike membrane protein virus potential use subunit vaccine research largely undertaken using plant expression platform promising candidate emerged,2018-05-03,"Khamis, Zayn; Menassa, Rima",Prospects of Plant-Based Vaccines in Veterinary Medicine,,,,document_parses/pdf_json/56b705cf0e5693d402fbc72215af26803f67444c.json,document_parses/pmc_json/PMC7120993.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7120993/,,3
12506,12506,16592,tfwllrfz,a644eab794deb8394b074d26c4823b48024e8a7e,PMC,Development of Mucosal Vaccines Based on Lactic Acid Bacteria,10.1007/978-0-387-79058-9_29,PMC7121035,,no-cc,today sufficient data available support use lactic acid bacteria lab notably lactococci lactobacillus delivery vehicle development new mucosal vaccine nonpathogenic grampositive bacteria safely consumed human century fermented food thus constitute attractive alternative attenuated pathogen popular live vector actually studied could recover pathogenic potential thus totally safe use human chapter review current research advance use lab live delivery vector protein interest development new safe mucosal vaccine use lab dna vaccine vehicle deliver dna directly antigenpresenting cell immune system also discussed,2009,"Bermúdez-Humarán, Luis G.; Innocentin, Silvia; Lefèvre, Francois; Chatel, Jean-Marc; Langella, Philippe",Prebiotics and Probiotics Science and Technology,,,,document_parses/pdf_json/a644eab794deb8394b074d26c4823b48024e8a7e.json,document_parses/pmc_json/PMC7121035.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121035/,,3
12517,12517,16604,3xx4zm4i,9a9749aa92e401e6d673880c18e2c8871fb1e163,PMC,Immunosenescence Modulation by Vaccination,10.1007/978-3-319-99375-1_71,PMC7121048,,no-cc,decline immune function hallmark aging lead complicated illness variety infectious disease cancer immunemediated disorder may limit ability appropriately respond vaccination vaccine might alter senescent immune response immune correlate protection addressed perspective stimulating previously primed response case vaccine seasonal influenza herpes zoster priming response novel antigen pandemic influenza west nile virus vaccination bacterial pathogen pneumococcus pertussis vaccine bacterial toxin tetanus clostridium difficile vaccine approach mitigate effect cytomegalovirus immune senescence new improved vaccine developed recent year demonstrate considerable opportunity improve current vaccine develop new vaccine preventive approach variety disease older adult strategy selecting appropriate immunologic target new vaccine development evaluating vaccine may alter senescent immune response term potential benefit risk preclinical clinical trial phase vaccine development discussed,2019-04-11,"McElhaney, Janet E.",Handbook of Immunosenescence,,,,document_parses/pdf_json/9a9749aa92e401e6d673880c18e2c8871fb1e163.json,document_parses/pmc_json/PMC7121048.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121048/,,3
12580,12580,16675,steypygd,9b23fe567b22082db0a583bc74636fc92d04cbc8,PMC,Computational Vaccinology,10.1007/978-1-4419-0540-6_1,PMC7121138,,no-cc,chapter shall review recent development computational vaccinology highlighting work area epitope antigen identification discovery delivery vector adjuvant diverse activity potential reduce significantly laboratory resource needed efficient vaccine discovery discus computational analysis pathogenic genome epitope mapping reverse vaccinology provide viable vaccine target,2009-08-08,"Davies, Matthew N.; Flower, Darren R.",Bioinformatics for Immunomics,,,,document_parses/pdf_json/9b23fe567b22082db0a583bc74636fc92d04cbc8.json,document_parses/pmc_json/PMC7121138.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121138/,,3
12582,12582,16677,3zlr2rl3,972e837da72af023243c06a6bfb37ae3c94d1d6c,PMC,Immunosenescence and Respiratory Infections Among Nursing Home Residents,10.1007/978-3-319-99375-1_130,PMC7121141,,no-cc,resident nursing home high risk infectious complication due respiratory infection nursing home setting place resident high risk given frequent contact among resident staff along possibility continuous introduction respiratory virus community nursing home resident among frail member society multiple comorbidities increase risk infection immunosenescence play important role rendering senior susceptible infection particularly viral respiratory infection also interferes protection ability mount robust immune response influenza pneumococcal vaccine increase risk number cell deficit described population cd cell particular tregs cmvreactive cd cell shown predictive respiratory viral infection population although evidence exists cell subset may correlate better response vaccine protection antibody response influenza vaccine remains important correlate population largescale epidemiologic study needed establish better correlation biomarkers protection respiratory pathogen circulate nursing home,2019-04-11,"Loeb, Mark",Handbook of Immunosenescence,,,,document_parses/pdf_json/972e837da72af023243c06a6bfb37ae3c94d1d6c.json,document_parses/pmc_json/PMC7121141.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121141/,,3
12672,12672,16776,dou97hx3,d1d09aefc100f99586b3561c4debc8cb862f2f36,PMC,Diseases with Limited Research of Plant-Based Vaccines,10.1007/978-3-319-90137-4_16,PMC7121283,,no-cc,number disease important globally term effect livestock development recombinant plantproduced vaccine preliminary many disease bovine viral diarrhoea bvd bovine rotavirus brv bovine herpes boh transmissible gastroenteritis tge pig infectious bronchitis ib chicken bluetongue bt sheep rift valley fever rvf sheep coccidiosis chicken commercially available liveattenuated killed vaccine available although effective varying degree numerous issue manufacture potential reassortment vaccine strain disease bovine papillomavirus bpv infection crimeancongo haemorrhagic fever cchf commercially available vaccine limited study conducted development chapter discus research development plantproduced vaccine candidate potential development towards commercialisation,2018-05-03,"Meyers, Ann",Prospects of Plant-Based Vaccines in Veterinary Medicine,,,,document_parses/pdf_json/d1d09aefc100f99586b3561c4debc8cb862f2f36.json,document_parses/pmc_json/PMC7121283.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121283/,,3
12715,12715,16819,z2vqfq98,8d068a34263f2e0e6479960107bab9aab48d1024,PMC,The Efficacy of Vaccines to Prevent Infectious Diseases in the Elderly,10.1007/978-0-387-76842-7_10,PMC7121339,,no-cc,infectious disease still represent major challenge human progress survival especially elderly person frequently severely affected infectious disease display distinct feature respect clinical presentation treatment although vaccination considered vital medical procedure preventing morbidity mortality caused infectious disease protective effect vaccination abrogated elderly person due decline function immune system referred immunosenescence first part chapter therefore summarize status quo efficacy vaccine preventing morbidity mortality caused typical infectious disease elderly influenza pneumonia tuberculosis second part elucidate underlying agerelated mechanism may contribute decreased efficacy vaccine based complex mechanism involved immunosenescence strategy outlined may succesfful enhancing protective immune response following vaccination elderly person,2007,"Herndler-Brandstetter, Dietmar; Grubeck-Loebenstein, Beatrix",Immunosenescence,,,,document_parses/pdf_json/8d068a34263f2e0e6479960107bab9aab48d1024.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121339/,,3
12720,12720,16827,7eqpb7ge,e735e575e537ee76608d6f4950833a7ed2f07acc,PMC,Adenovirus-Based Vectors for the Development of Prophylactic and Therapeutic Vaccines,10.1007/978-3-7091-1818-4_8,PMC7121347,,no-cc,emerging reemerging infectious disease well cancer pose great global health impact society vaccine emerged effective treatment prevent reduce burden already developed disease achieved mean activating various component immune system generate systemic inflammatory reaction targeting infectious agent diseased cell controlelimination dna virusbased genetic vaccine gained significant attention past decade owing development dna manipulation technology allowed engineering recombinant viral vector encoding sequence foreign antigen immunogenic epitope well various immunomodulatory molecule despite tremendous progress past year many hurdle still remain achieving full clinical potential viralvectored vaccine chapter present evolution vaccine “ live ” “ attenuated ” firstgeneration agent recombinant dna viralvectored vaccine particular emphasis given human adenovirus ad development prophylactic therapeutic vaccine ad biological property related vaccine development highlighted along advantage potential hurdle overcome particular discus genetic modification ad capsid protein reduce intrinsic viral immunogenicity antigen capsid incorporation effective presentation foreign antigen immune system modification hexon fiber capsid protein ad liver detargeting selective retargeting cancer cell adbased vaccine carrying “ arming ” transgene immunostimulatory function immune adjuvant oncolytic ad vector new therapeutic approach cancer finally combination adenoviral vector nonadenoviral vector system primeboost strategy immunization clinical trial involving adbased vaccine perspective field development discussed,2014-07-16,"Borovjagin, Anton V.; Gomez-Gutierrez, Jorge G.; Shirwan, Haval; Matthews, Qiana L.",Novel Technologies for Vaccine Development,,,,document_parses/pdf_json/e735e575e537ee76608d6f4950833a7ed2f07acc.json,document_parses/pmc_json/PMC7121347.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121347/,,3
12721,12721,16828,vnx74hft,ad0e1655fb72944f4c39e0a527fe46a5e29cc368,PMC,Strategic Actionable Net-Centric Biological Defense System,10.1007/1-4020-3384-2_1,PMC7121348,,no-cc,technology required strategic actionable netcentric biological defense system consist multiplexed multiarray sensor threat agent signature host response infection novel vaccine restricted access antiviralsbacterials reduce emergence drug resistant strain pre postevent telemedicine capability deliver postevent care victim biological strike communication system intelligent software resource allocation redundant pathway survive catastrophic attack integrated system must detect threat agent minimal false positivenegative event seamless integrated broadband communication capability enables conversion data actionable information novel pre postevent treatment development multiplexed multiarray sensor appropriate vaccine antibiotic integrated communication capability critical sustaining normal health commerce international activity,2005,"Kornguth, S.",Defense against Bioterror,,,,document_parses/pdf_json/ad0e1655fb72944f4c39e0a527fe46a5e29cc368.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121348/,,3
12833,12833,16954,hwmwh9q2,312234477c50e74d95d9e063281f20921b1f086f,PMC,HIV/AIDS: Lessons from a New Disease Pandemic,10.1007/978-0-387-75722-3_8,PMC7121503,,no-cc,acquired immunodeficiency syndrome aid first recognized year ago gottlieb et al masur et al siegal et al best available evidence suggests hiv newly infected human specie – year ago korber et al originate asia apparently moved people subhuman primate africa keele et al kanki different clinical presentation different population people long incubation period difficult diagnose sars avian influenza new epidemic originated era modern medicine taught u many lesson difficulty new infectious disease present already claiming least – million victim aid seems destined continue pandemic foreseeable future drug control hiv replication reverse disease progression developed none eliminate virus body sexual transmission prevented abstinence condom measure prevent procreation provide limited value approach making vaccine using conventional technique failed expert believe effective vaccine made eventually least – year need learn immunobiology acute hiv infection potentially protective immunoepitopes conformational intermediate virus envelope vaccine available little chance hiv eliminated even drastically reduced prevalence aid presented scientist political leader health policy expert unprecedented challenge,2008,"Essex, M.; Lu, Yichen",Emerging Infections in Asia,,,,document_parses/pdf_json/312234477c50e74d95d9e063281f20921b1f086f.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121503/,,3
12878,12878,17006,czqzsppq,a065f219244a30fbfe0008ab3ca4ebb2a535a34d,PMC,"Virus-Like Particles, a Versatile Subunit Vaccine Platform",10.1007/978-1-4939-1417-3_9,PMC7121566,,no-cc,viruslike particle vlps spontaneously formed expression selfpolymerising viral capsid protein vlps structurally resemble native source virus maintaining immunological relevance retaining formation immunogenic motif natural conformation absence virus genome render vlps safe administration subunit vaccine vlps target arm immune response vlps initiating production specific antibody others activating cytotoxic cell vlps also exceptionally versatile conferring protection host virus acting scaffold antigenic molecule addition vlp support intraparticulate encapsulation immunomodulation gene delivery vlp vaccine developed prophylactic protection infectious organism therapeutic treatment condition alzheimer ’ disease hypertension cancer expanding list vaccine candidate vlp vaccine promising field wide range application,2014-08-28,"Donaldson, Braeden; Al-Barwani, Farah; Young, Vivienne; Scullion, Sarah; Ward, Vernon; Young, Sarah",Subunit Vaccine Delivery,,,,document_parses/pdf_json/a065f219244a30fbfe0008ab3ca4ebb2a535a34d.json,document_parses/pmc_json/PMC7121566.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121566/,,3
12910,12910,17040,0uumih5h,42e133d18d3b95d035ebcbe33f8121d8d18e9961,PMC,Fungal Vaccines and Vaccination: Problems and Perspectives,10.1007/1-4020-5492-0_21,PMC7121605,,no-cc,vaccine human pathogenic fungi rather neglected medical need year ago gaining step public health priority scale awareness rising medical threat represented opportunistic fungal infection among health careassociated infection advance knowledge fungal pathogenicity immune response extraordinary progress biotechnology generated enthusiasm critical new tool active passive antifungal vaccination discovery antibody play critical role protection fungal infection greatly contributed advancement field recognition almost useful vaccine viral bacterial pathogen owe protective efficacy neutralizing opsonizing otherwise effective antibody overall hope year ago chance generating approved regulatory authority one antifungal vaccine active passive use human next year particular possibility protecting multiple opportunistic mycoses immunodepressed subject single welldefined glucanconjugate vaccine eliciting directly antifungal antibody may important step achieve public health goal,2007,"Cassone, Antonio MD",Immunology of Fungal Infections,,,,document_parses/pdf_json/42e133d18d3b95d035ebcbe33f8121d8d18e9961.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121605/,,3
12946,12946,17079,59i8bq2p,215ac47883d6a069b6d1327dda66b337740c302a,PMC,FIV as a Model for AIDS Vaccine Studies,10.1007/0-387-25741-1_10,PMC7121656,,no-cc,many experimental strategy adopted experiment protect cat fiv infection vaccination successful interest developing vaccine arose fiv common cause morbidity mortality pet cat feline virus provides model counterpart man human immunodeficiency virus hiv effective vaccine urgently required halt current tragic pandemic acquired immunodeficiency syndrome aid shortly discovery fiv characterization lentivirus attempt made produce vaccine success soon achieved relatively simple inactivated virus inactivated virusinfected cell vaccine development approach led introduction first commercial vaccine fiv estimated prevalence infection population pet cat effective fiv vaccine could significant influence animal welfare addition success pose question whether similar strategy might produce effective vaccine hiv,2006,"Dunham, Stephen; Jarrett, Oswald",In vivo Models of HIV Disease and Control,,,,document_parses/pdf_json/215ac47883d6a069b6d1327dda66b337740c302a.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121656/,,3
12952,12952,17086,pdlwgg3y,a5f28465c8283e6489649a301d95527f7cc8948d,PMC,Vaccines,10.1007/978-1-4614-6486-0_22,PMC7121664,,no-cc,since vaccination documented edward jenner become successful mean preventing infectious disease saving million life every year however application vaccine currently limited prevention infectious disease vaccine pipeline include antidrug abuse vaccine nicotine cocaine vaccine allergy cancer alzheimer ’ disease,2013-08-27,"Jiskoot, Wim; Kersten, Gideon F. A.; Mastrobattista, Enrico",Pharmaceutical Biotechnology,,,,document_parses/pdf_json/a5f28465c8283e6489649a301d95527f7cc8948d.json,document_parses/pmc_json/PMC7121664.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121664/,,3
13150,13150,17304,seaa46hz,e729626c72be503f3591391c8e6f743a3130bd40,PMC,The Importance of Animal Models in the Development of Vaccines,10.1007/978-94-007-4543-8_11,PMC7121941,,no-cc,efficient translation basic vaccine research clinical therapy greatly depends upon availability appropriate animal model testing novel vaccine candidate animal model critical step development modern vaccine animal model used ass quality quantity immune response identify optimal route delivery formulation determine protection infection disease transmission evaluate safety toxicity vaccine formulation animal model help make translation basic research clinical application often allow prediction vaccine potential help predicting financial risk vaccine manufacturer choosing appropriate animal model become increasingly important field model advantage disadvantage review criterion selecting right animal model advantage disadvantage various animal model well future need animal model discussed,2012-03-29,"Kiros, Tadele G.; Levast, Benoît; Auray, Gaël; Strom, Stacy; van Kessel, Jill; Gerdts, Volker",Innovation in Vaccinology,,,,document_parses/pdf_json/e729626c72be503f3591391c8e6f743a3130bd40.json,document_parses/pmc_json/PMC7121941.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121941/,,3
13192,13192,17350,to54sbmp,d727c328f28787cdf5baeccc04fe00062c17869d,PMC,Short Peptide Vaccine Design and Development: Promises and Challenges,10.1007/978-1-4939-2410-3_1,PMC7121995,,no-cc,vaccine development viral disease challenge subunit vaccine often ineffective therefore need alternative solution crucial thus short peptide vaccine candidate promise effective answer circumstance short peptide vaccine candidate linear tcell epitope antigenic determinant recognized immune system specifically function binding human leukocyte antigen hla allele different ethnicity including black caucasian oriental hispanic pacific islander american indian australian aboriginal mixed ethnicity populationspecific allelelevel hla sequence data public imgthla database contains approximately nomenclature defined class class ii hla allele march present several ethnic population bottleneck short peptide vaccine design development hla polymorphism one hand viral diversity hand hence crucial step design development hla allelespecific binding short antigen peptide usually combinatorial computationally labor intensive mathematical model utilizing structuredefined pocket currently available class class ii hlapeptidebinding peptide framework developed design protocol identify feasible short peptide cocktail vaccine candidate superantigen property among known hla supertypes approach promising solution develop new viral vaccine given current advancement tcell immunoinformatics yet challenging term prediction efficiency protocol development,2015-05-12,"Kangueane, Pandjassarame; Sowmya, Gopichandran; Anupriya, Sadhasivam; Dangeti, Sandeep Raja; Mathura, Venkatrajan S.; Sakharkar, Meena K.",Global Virology I - Identifying and Investigating Viral Diseases,,,,document_parses/pdf_json/d727c328f28787cdf5baeccc04fe00062c17869d.json,document_parses/pmc_json/PMC7121995.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121995/,,3
13195,13195,17353,wviq4ora,,PMC,"Requirements for Empirical Immunogenicity Trials, Rather than Structure-Based Design, for Developing an Effective HIV Vaccine",10.1007/978-3-030-32459-9_14,PMC7122000,,no-cc,claim possible rationally design structurebased hiv vaccine based misconception regarding nature protein epitope immunological specificity attempt use reverse vaccinology generate hiv vaccine basis structure viral epitope bound monoclonal neutralizing antibody failed far possible extrapolate observed antigenic structure immunogenic structure required vaccine vaccine immunogenicity depends numerous extrinsic factor host immunoglobulin gene repertoire presence various cellular regulatory mechanism immunized host process antibody affinity maturation factor played role appearance neutralizing antibody used select epitope investigated potential vaccine immunogen expected present identical form host vaccinated possible rationally design optimize epitope fit one particular antibody molecule improve paratope binding efficacy monoclonal antibody intended passive immunotherapy possible rationally design hiv vaccine immunogen elicit protective polyclonal antibody response predetermined efficacy effective vaccine immunogen discovered investigating experimentally immunogenicity candidate molecule demonstrating ability induce protective immune response discovered determining epitope engineered antigen molecule recognized neutralizing monoclonal antibody mean empirical immunogenicity trial rather structural analysis antigen offer best hope discovering hiv vaccine,2019-09-28,"Van Regenmortel, Marc H V","HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design",,,,,document_parses/pmc_json/PMC7122000.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122000/,,3
13204,13204,17365,vysn9vnz,e6ae5c524106c00556b4dbca49b73b9b3c3f7798,PMC,Vaccines and Vaccination,10.1007/978-3-662-46789-3_3,PMC7122016,,no-cc,livestock vaccine aim increase livestock product improve health welfare livestock animal costefficient manner prevent disease transmission successful livestock vaccine generated pathogen including bacterial viral protozoan multicellular pathogen livestock vaccine significant effect animal health product human health growing safe food procurement preventing zoonotic disease successful production biotechnologicalbased animal vaccine licensed use include viruslike particle vaccine genedeleted marker vaccine subunit vaccine diva vaccine dna vaccine,2015-04-08,"Atmaca, Hasan Tarik",The Role of Biotechnology in Improvement of Livestock,,,,document_parses/pdf_json/e6ae5c524106c00556b4dbca49b73b9b3c3f7798.json,document_parses/pmc_json/PMC7122016.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122016/,,3
13347,13347,17523,kt5awf8i,82d639734905dfe9e2442b3df17e5e8ca00b9bc4,PMC,Virus Glycoproteins Tagged with the Human Fc Domain as Second Generation Vaccine Candidates,10.1007/978-94-007-4543-8_3,PMC7122206,,no-cc,traditional vaccine inactivated live attenuated vaccine gradually giving way biochemically defined vaccine often based recombinant antigen known posse neutralizing epitope vaccine offer improvement speed safety manufacturing process inevitable consequence high degree purification immunogenicity reduced lack innate triggering molecule present complex preparation targeting recombinant vaccine antigen presenting cell apc dendritic cell however improve immunogenicity ensuring antigen processing efficient possible immune complex one number route apc targeting mimicked recombinant approach crystallizable fragment fc fusion protein target immunogen linked directly antibody effector domain capable interaction receptor fcr apc cell surface number virus fc fusion protein expressed insect cell using baculovirus expression system shown efficiently produced purified use immunization next nonfc tagged equivalent show powerfully immunogenic absence added adjuvant immune stimulation result fcfcr interaction,2012-03-29,"Loureiro, Silvia; Robinson, Elena; Chen, Hongying; Phapugrangkul, Pongsathon; Colaco, Camilo; Jones, Ian M",Innovation in Vaccinology,,,,document_parses/pdf_json/82d639734905dfe9e2442b3df17e5e8ca00b9bc4.json,document_parses/pmc_json/PMC7122206.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122206/,,3
13368,13368,17545,fuv157f1,df7f406f7ac71bde114c6ed5c11592e2e2e559b1,PMC,Epitope-Based Immunome-Derived Vaccines: A Strategy for Improved Design and Safety,10.1007/978-0-387-79208-8_3,PMC7122239,,no-cc,vaccine science extended beyond genomics proteomics come also encompass ‘ immunomics ’ study universe pathogenderived neoplasmderived peptide interface b cell host immune system theorized effective vaccine developed using minimum essential subset cell b cell epitope comprise ‘ immunome ’ researcher therefore using bioinformatics sequence analysis tool epitopemapping tool microarrays highthroughput immunology assay discover minimal essential component immunome minimal component epitope packaged adjuvant appropriate delivery vehicle complete package comprises epitopebased immunomederived vaccine vaccine may significant advantage conventional vaccine careful selection component may diminish undesired side effect observed whole pathogen protein subunit vaccine chapter review preclinical anticipated clinical development computerdriven vaccine design validation epitopebased immunomederived vaccine animal model also include overview heterologous immunity emerging issue need addressed vaccine type future,2008-07-31,"De Groot, Anne S.; Moise, Leonard; McMurry, Julie A.; Martin, William",Clinical Applications of Immunomics,,,,document_parses/pdf_json/df7f406f7ac71bde114c6ed5c11592e2e2e559b1.json,document_parses/pmc_json/PMC7122239.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122239/,,3
13457,13457,17641,uzqnv7m8,8a290424b872b5e500f3c7785f1af79c04af222c,PMC,Virus-like Particle Vaccines for Norovirus Gastroenteritis,10.1007/978-3-7091-1419-3_8,PMC7122369,,no-cc,gastroenteritis ge associated diarrheal disease remain one top cause death world noroviruses nov group genetically diverse rna virus cause great majority nonbacterial gastroenteritis human however still vaccine licensed human use prevent nov ge lack tissue culture system small animal model hinders development nov vaccine viruslike particle vlps mimic antigenic architecture authentic virion however produced insect mammalian plant cell expression capsid protein particulate nature highdensity presentation viral structure protein surface render vlps premier vaccine platform superior safety immunogenicity manufacturability therefore chapter focus development effective nov vaccine based vlps capsid protein expression structure nov vlps especially vlps norwalk virus prototype nov extensively discussed ability nov vlps stimulating potent systemic mucosal antinov immunity oral intranasal delivery mouse presented advantage plant expression system novel production platform vlpbased nov vaccine discussed light costeffectiveness production speed scalability recent achievement first successful demonstration nov vlp production plant expression system current good manufacture practice cgmp regulation u food drug administration fda detailed moreover result human clinical trial demonstrating safety efficacy insect plantderived nov vlps also presented due diversity capsid protein among different nov strain rapid antigenic drift speculate vaccine development focus multivalent vlp vaccine derived capsid protein prevalent strain recent approval first plantmade biologics fda also speculate plantbased production system play important role manufacturing multivalent vlpbased nov vaccine,2013-06-10,"Chen, Qiang",Molecular Vaccines,,,,document_parses/pdf_json/8a290424b872b5e500f3c7785f1af79c04af222c.json,document_parses/pmc_json/PMC7122369.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122369/,,3
13470,13470,17654,tetqfycq,202aef03c7f1b5becefe22f2733028a3ed915d69,PMC,Antimicrobial Resistance Among Streptococcus pneumoniae,10.1007/978-3-319-78538-7_2,PMC7122384,,no-cc,antibiotic resistance streptococcus pneumoniae pneumococcus main pathogen responsible communityacquired pneumonia cap meningitis bacteremia otitis medium major concern clinician pathogen associated high rate morbidity mortality especially among child year old immunocompromised person elderly population major antipneumococcus agent βlactams macrolides fluoroquinolones ranking third emergence antibioticresistant pneumococcus due overuse antibiotic global concern discovery novel class antibiotic pneumococcus standstill significant progress reducing problem resistance associated antibacterial vaccine nevertheless world health organization recently considered drugresistant pneumoniae ranking among bacteria urgent need new treatment challenge slow evolution new strain resistant vaccine,2018-03-07,"Cillóniz, Catia; Garcia-Vidal, Carolina; Ceccato, Adrian; Torres, Antoni",Antimicrobial Resistance in the 21st Century,,,,document_parses/pdf_json/202aef03c7f1b5becefe22f2733028a3ed915d69.json,document_parses/pmc_json/PMC7122384.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122384/,,3
13561,13561,17754,fbotc479,f9ae601d80762953a9f04abd3f2c5a3c77fe1c9d,PMC,Electroporation-Mediated DNA Vaccination,10.1007/978-1-4419-8363-3_18,PMC7122510,,no-cc,many positive attribute dna vaccination make conceptually desirable platform clinical study however standard dna injection alone generally induces low level transgenespecific immunity compared vaccine approach order boost immunogenicity platform nextgeneration dna vaccine require additional technique administration electroporation new method involves generation brief electric field tissue around local injection site result transient poration permeabilization cellular membrane result antigenspecific immune response greatly enhanced likely due increased dna uptake antigen expression thus electroporationmediated dna vaccination represents promising new strategy elicitation strong immune response directed expressed antigen vector ongoing study currently underway optimize working parameter technique review us technology conjunction vaccination suggest future direction exploration,2010-12-15,"Fagone, Paolo; Shedlock, Devon J.; Kemmerer, Stephen; Rabussay, Dietmar; Weiner, David B.",Clinical Aspects of Electroporation,,,,document_parses/pdf_json/f9ae601d80762953a9f04abd3f2c5a3c77fe1c9d.json,document_parses/pmc_json/PMC7122510.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122510/,,3
13564,13564,17757,57rm046y,ec92bca9668b3287b1c1109ff82f9d90059f5288,PMC,"Immunomic Discovery of Adjuvants, Delivery Systems, and Candidate Subunit Vaccines: A Brief Introduction",10.1007/978-1-4614-5070-2_1,PMC7122516,,no-cc,mass vaccination coupled profound improvement general sanitation given rise remarkable transformation public health human history yet development vaccine remains largely trapped past hostage methodology pasteur infectious disease continues threaten humanity new renascent disease emerging continually last two decade seen breathtaking revival commercial market vaccine simultaneous emergence whole tranche new technology promise free vaccine development muddle empirical thinking short introduction set scene renaissance explore combination computational experimental technique promise much future development vaccine science vaccinology,2012-09-28,"Flower, Darren R.; Perrie, Yvonne",Immunomic Discovery of Adjuvants and Candidate Subunit Vaccines,,,,document_parses/pdf_json/ec92bca9668b3287b1c1109ff82f9d90059f5288.json,document_parses/pmc_json/PMC7122516.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122516/,,3
13724,13724,17934,2yyv8vuy,c3d89880544a9acb730e542ec5baf824a18f0ebc,PMC,History and Promise of Plant-Made Vaccines for Animals,10.1007/978-3-319-90137-4_1,PMC7122757,,no-cc,plantmade vaccine wellestablished welltested concept veterinary medicine—yet product far licenced never produced commercially puzzling given breadth exploration plantmade animal vaccine immunogenicity efficacy twenty year research range candidate vaccine tested laboratory animal model includes vaccine e coli salmonella yersinia pestis foot mouth disease virus rabbit haemorrhagic disease virus rabbit canine bovine papillomaviruses mink enteritis porcine circovirus lately also bluetongue virus among many others many proof efficacy vaccine regulatory pathway appear explored licencing review briefly explore history plantmade vaccine use animal discus unique advantage plantmade vaccine use veterinary medicine setting detail proposal relevance within “ one health ” paradigm,2018-07-04,"Rybicki, Ed",Prospects of Plant-Based Vaccines in Veterinary Medicine,,,,document_parses/pdf_json/c3d89880544a9acb730e542ec5baf824a18f0ebc.json,document_parses/pmc_json/PMC7122757.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122757/,,3
13744,13744,17956,k0h5ejjt,db2ea38243d85842db9631d8c8d3c95aa64c1eaf,PMC,Aspects of Microparticle Utilization for Potentiation of Novel Vaccines: Promises and Risks,10.1007/978-90-481-2523-4_26,PMC7122810,,no-cc,many recombinant vaccine novel hiv hcv everchanging influenza infectious agent require presence adjuvantsdelivery vehicle induce strong immune response necessity improvement led major effort towards development vaccine delivery system generally particulate eg nano microparticles comparable dimension pathogen virus bacteria mode action adjuvant fully understood implies stimulation innate antigenspecific immune response andor increase antigen uptake processing antigenpresenting cell apc moreover enhancement adjuvant activity use micro nanoparticulate delivery system often resulted synergistic effect producing immune response stronger elicited adjuvant delivery system alone among particulate adjuvant biodegradable micro nanoparticles polydllactidecoglycoside plga polydllactide pla reported enhance humoral cellular immune response encapsulated protein antigen cationic anionic polylactide coglycolide plg microparticles successfully used adsorb variety agent include plasmid dna recombinant protein adjuvant active oligonucleotides also currently tested several vaccine application another approach envisions specific targeting apc especially peripheral dc exploitation particulate system small enough lymphatic uptake polystyrene nanobeads micro nanoparticles offer possibility enhancement uptake appropriate cell manipulation surface property still question regarding toxicity molecular interaction micro nanoparticles immune cell tissue whole organism remain addressed risk possible side effect assessed detail especially massproduction massive administration preparation considered,2009,"Ilyinskii, P.",Silicon Versus Carbon,,,,document_parses/pdf_json/db2ea38243d85842db9631d8c8d3c95aa64c1eaf.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7122810/,,3
13875,13875,18102,s7klkqka,4836fbff373cb9e9a2ee0089c5e53e18af553205,PMC,Porcine Coronaviruses,10.1007/978-981-15-0402-0_4,PMC7123000,,no-cc,transmissible gastroenteritis virus tgev porcine epidemic diarrhoea virus pedv porcine deltacoronavirus pdcov enteropathogenic coronaviruses covs swine tgev appearance preceded identification pedv pdcov considered emerging covs spike deletion mutant tgev associated respiratory tract infection piglet appeared pig belgium designated porcine respiratory coronavirus prcv prcv considered nonpathogenic infection mild subclinical since prcv emergence rapid spread pig become immune prcv tgev significantly reduced clinical economic importance tgev contrast pdcov pedv currently expanding geographic distribution report circulation tgevpedv recombinant cause disease clinically indistinguishable associated parent virus tgev pedv pdcov cause acute gastroenteritis pig severe neonatal piglet match clinical sign pathogenesis necrosis infected intestinal epithelial cell cause villous atrophy malabsorptive diarrhoea profuse diarrhoea frequently combined vomiting result dehydration lead death piglet strong immune response following natural infection protect subsequent homologous challenge however virus display crossprotection adoption advance biosecurity measure effective vaccine control prevent occurrence disease due porcineassociated covs recombination reversion virulence risk associated generally highly effective attenuated vaccine necessitating research alternative vaccine ensure safe application field,2020-02-23,"Vlasova, A. N.; Wang, Q.; Jung, K.; Langel, S. N.; Malik, Yashpal Singh; Saif, L. J.",Emerging and Transboundary Animal Viruses,,,,document_parses/pdf_json/4836fbff373cb9e9a2ee0089c5e53e18af553205.json,document_parses/pmc_json/PMC7123000.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123000/,,3
13933,13933,18167,zznjqdx2,,PMC,Evaluating Protective Effects of Vaccination,10.1007/978-0-387-68636-3_6,PMC7123083,,no-cc,evaluating direct protective effect vaccine individual vaccinated focus vaccine study past century generally interest ability vaccination prevent ameliorate disease rather prevent infection clementsmann ascertainment case often done finding suspected case population study people exhibit set symptom suspected case tested biological confirmation infectious agent interest alternatively surveillance ascertain case reported central registry however ascertained vaccine clinical disease primary outcome interest ascertainment clinical case asymptomatic infection may go undetected different situation arises infection primary outcome ascertain infection asymptomatic people active followup method testing asymptomatic people needed chapter consider estimation inference direct protective effect vaccination f vesp study condition exposure infectionwe consider aspect design study several example randomized doubleblind doublemasked controlled vaccine trial illustrate standard approach design analysis study choice study present motivated largely use illustration section book randomized pivotal study vaccine based vesp f much written study meet approval regulatory agency design clinical trial generally goal consider f vesp relate measure vaccine effect within dependent happening context consider design consideration f vesp condition exposure infection assumption relative exposure opportunity vaccine control group important,2009-09-26,"Halloran, M. Elizabeth; Longini, Ira M.; Struchiner, Claudio J.",Design and Analysis of Vaccine Studies,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123083/,,3
13946,13946,18181,twp33bb6,a3541fda5120cf0c3346777d6077a5e2e73d78fd,PMC,Community-acquired pneumonia: paving the way towards new vaccination concepts,10.1007/978-3-7643-7563-8_10,PMC7123104,,no-cc,despite availability antimicrobial agent vaccine communityacquired pneumonia remains serious problem severe form tend occur young child among elderly since immune competence eroded immaturity immune senescence respectively main etiologic agent differ according patient age geographic area streptococcus pneumoniae haemophilus influenzae respiratory syncytial virus rsv parainfluenza virus type piv important pathogen child whereas influenza virus leading cause fatal pneumonia elderly effective vaccine available organism however still many agent vaccine available existent one suboptimal tackle problem empiric approach systematically replaced rational vaccine design facilitated growing knowledge field immunology microbial pathogenesis host response infection well availability sophisticated strategy antigen selection potent immune modulators efficient antigen delivery system thus new generation vaccine improved safety efficacy profile compared old new agent emerging chapter overview provided currently available new vaccination concept,2007,"Becker, Pablo D.; Guzmán, Carlos A.",Community-Acquired Pneumonia,,,,document_parses/pdf_json/a3541fda5120cf0c3346777d6077a5e2e73d78fd.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123104/,,3
14029,14029,18276,9a4jw0ze,3b97daece91268763e6995ace7c98d0ccc6a9a6b,PMC,Employing Live Microbes for Vaccine Delivery,10.1007/978-3-7091-0709-6_5,PMC7123214,,no-cc,employment live attenuated vaccine longstanding record human veterinary medicine vaccine current use empirically developed last century today due great advance field immunology bioengineering rational development live attenuated vaccine becomes increasingly feasible moreover live vaccine used carrier system heterologous antigen therapeutic factor case development recombinant live attenuated vaccine complex task property targeting specificity antigen synthesis antigen release safety aspect integrated range recombinant vaccine candidate successfully tested clinic approved far many case optimization vaccine necessary regard efficacy safety profile present chapter focus current strategy employed development new optimization first generation recombinant live vaccine based bacteria virus,2012-02-18,"Loessner, Holger; Schwantes, Astrid; Hamdorf, Matthias; Komor, Uliana; Leschner, Sara; Weiss, Siegfried",Development of Novel Vaccines,,,,document_parses/pdf_json/3b97daece91268763e6995ace7c98d0ccc6a9a6b.json,document_parses/pmc_json/PMC7123214.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123214/,,3
14147,14147,18412,kpb1gprx,b1797c0dcef4d1f3306c45e2abb239b148027ab4,PMC,Vaccinia and Pox-Virus,10.1007/978-1-59745-222-9_4,PMC7123383,,no-cc,vaccinia virus studied extensively since discovery smallpox vaccine use smallpox vaccine documented safety profile later found large size ability accept large fragment dna combined natural tumor affinity make attractive agent cancer therapy chapter discus history vaccinia various strain available biology virus well step creating recombinant various clinical safety consideration addressed also discus various method used treat cancer using vaccinia virus review recent clinical trial using vaccinia treatment cancer,2007,"Chalikonda, Sricharan; Bartlett, David L.",Gene Therapy for Cancer,,,,document_parses/pdf_json/b1797c0dcef4d1f3306c45e2abb239b148027ab4.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123383/,,3
14187,14187,18459,mmh6503o,b1c5cad454d9037a12afd8a1589c2d50730722a3,PMC,Recombinant poxvirus vaccines in biomedical research,10.1007/978-3-7643-7557-7_15,PMC7123444,,no-cc,biomedical research recombinant poxvirus investigated important candidate medicine derive advanced option prevention andor treatment infectious disease cancer genetically engineered virus readily synthesize biologically active heterologous protein serve determine relevant target cellmediated humoral immunity identify type immune response needed protection multitude different specific disease substantial progress vaccine development based availability exceptionally safe efficient carrier virus increasingly versatile vector technology feasibility large scale manufacturing moreover advance deciphering molecular pathway regulating poxvirushost interaction provide additional mean potently activate innate immune stimulation upon vaccination derive vector specifically targeted replicative capacity experimental tumor therapy,2007,"Schnierle, Barbara S.; Suezer, Yasemin; Sutter, Gerd",Poxviruses,,,,document_parses/pdf_json/b1c5cad454d9037a12afd8a1589c2d50730722a3.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123444/,,3
14268,14268,18549,1ksz6nmx,0ac431a9a48289831c825c2b30f48bdf7f548995,PMC,Recombinant Live Vaccines to Protect Against the Severe Acute Respiratory Syndrome Coronavirus,10.1007/978-3-0346-0277-8_4,PMC7123558,,no-cc,severe acute respiratory syndrome sars coronavirus cov identified etiological agent acute respiratory disease causing atypical pneumonia diarrhea high mortality different type sarscov vaccine including nonreplicative vectored vaccine developed administration vaccine animal model system shown promise generation efficacious safe vaccine nevertheless identification side effect preferentially elderly animal model indicates need develop novel vaccine tested improved animal model system live attenuated virus generally proven effective vaccine viral infection limited number sarscov attenuating modification described including mutation partial complete gene deletion affecting replicase like nonstructural protein nsp nsp structural gene drastic change sequence regulate expression viral subgenomic mrna promising vaccine candidate developed laboratory based deletion envelope e gene alone combination removal six additional gene nonessential virus replication virus lacking e protein attenuated grew lung provided homologous heterologous protection improvement vaccine candidate directed toward increasing virus titer using power virus mutator phenotype maintaining attenuated phenotype safety live sarscov vaccine increased insertion complementary modification gene nsp nsp gene scrambling prevent rescue virulent phenotype recombination remodeling vaccine genome based codon deoptimization using synthetic biology newly generated vaccine candidate promising need evaluated animal model system include young aged animal,2010-07-07,"Enjuanes, Luis; Nieto-Torres, Jose L.; Jimenez-Guardeño, Jose M.; DeDiego, Marta L.",Replicating Vaccines,,,,document_parses/pdf_json/0ac431a9a48289831c825c2b30f48bdf7f548995.json,document_parses/pmc_json/PMC7123558.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123558/,,3
14310,14310,18592,c8vwlbnh,69edb43430f6add241fe9ca2e7fe7c8fe6b933c5,PMC,Vaccines Against Viral Infections,10.1007/978-3-319-07758-1_19,PMC7123619,,no-cc,vaccine one miracle modern medicine without vaccine population—particularly children—would troubled multitudinous infectious disease diphtheria scarlet fever whooping cough measles name vaccine available viral bacterial infection saved million life continue world health organization hope vaccinated child year old infectious disease history public ’ acceptance vaccine stormy one antivaccination movement active since creation development smallpox vaccine eighteenth century governmentmandated vaccination present example fabricated information spread relationship measles vaccine autism successful polio vaccine developed thanks research three group led koprowski salk sabin although vaccine advantage disadvantage oral vaccine advantage ease administration herd effect polio vaccine worker become target extremist nigeria pakistan recently recombinant dna technology used develop new vaccine order avoid side effect since live virus involved future may see production vaccine edible plant allowing cheap production ease worldwide distribution,2014-07-22,"Taylor, Milton W.",Viruses and Man: A History of Interactions,,,,document_parses/pdf_json/69edb43430f6add241fe9ca2e7fe7c8fe6b933c5.json,document_parses/pmc_json/PMC7123619.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123619/,,3
14351,14351,18634,7ckledq6,567d2d7b5ac5f8a35c586c7a6f35261592b6999b,PMC,Major Advances in the Development of Synthetic Oligosaccharide-Based Vaccines,10.1007/978-3-319-16298-0_65,PMC7123674,,no-cc,involvement variety different biological process occurrence onto pathogen malignant cell surface carbohydrate identified ideal candidate vaccine formulation however free oligosaccharide poorly immunogenic induce immunological memory risk population infant young child elderly immunocompromised patient glycoconjugate vaccine containing carbohydrate antigen covalently linked immunogenic carrier protein gained prominent role accordingly number glycoconjugate vaccine mostly directed infection caused bacterial pathogen licensed currently available market however also glycoconjugate vaccine suffer significant drawback challenging procedure required isolation purification carbohydrate antigen natural source often lead poor homogeneity presence biological contaminant resulting batchtobatch variability moreover case overwhelming immunogenicity carrier protein may induce carbohydrate epitope suppression causing hyporesponsiveness development synthetic oligosaccharidebased vaccine candidate characterized presence pure welldefined synthetic oligosaccharide structure expected meet requirement homogeneous highly reproducible preparation present chapter report major advance development synthetic carbohydratebased vaccine first describe different strategy developed last year circumvent inherent difficulty classical oligosaccharide synthesis onepot glycosylation solidphase synthesis application preparation carbohydrate antigen apt conjugation protein carrier next discus representative methodology employed chemical ligation oligosaccharide structure protein finally last section report significant example fully synthetic vaccine exploiting multivalency effect construct based concept conjugation multiple copy synthetic oligosaccharide antigen multivalent scaffold dendrimers cyclopeptides gold nanoparticles calixarenes raise cooperative interaction carbohydrate immune receptor leading strong enhancement saccharide antigen immunogenicity,2015-06-01,"Cancogni, Damiano; Fusari, Matteo; Poggi, Niccolò; Lay, Luigi",Polysaccharides,,,,document_parses/pdf_json/567d2d7b5ac5f8a35c586c7a6f35261592b6999b.json,document_parses/pmc_json/PMC7123674.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123674/,,3
14370,14370,18653,1h84yi2i,1801513c69b235e2631913f915203bb67a1757e3,PMC,"Live-Attenuated Bacterial Vectors for Delivery of Mucosal Vaccines, DNA Vaccines, and Cancer Immunotherapy",10.1007/978-3-030-01881-8_2,PMC7123696,,no-cc,vaccine save million life year various lifethreatening infectious disease vaccine currently licensed human use worldwide moreover recent decade immunotherapy become mainstream therapy highlight tremendous potential immune response mediator including vaccine prevention treatment various form cancer however despite tremendous advance microbiology immunology several vaccine preventable disease still lack effective vaccine classically weakened form attenuated pathogenic microbe used vaccine although attenuated microbe induce effective immune response significant risk reversion pathogenic form remains twentyfirst century advent genetic engineering microbe tailored desired property review focused use genetically modified bacteria delivery vaccine antigen specifically liveattenuated bacteria derived pathogenic bacteria posse many feature make highly suitable vector delivery vaccine antigen bacteria theoretically express heterologous gene deliver mammalian expression vector harboring vaccine antigen dna vaccine property liveattenuated microbe harnessed make vaccine several infectious noninfectious disease regard described desired feature liveattenuated bacterial vector mechanism immune response manifested liveattenuated bacterial vector interestingly anaerobic bacteria naturally attracted tumor make suitable vehicle deliver tumorassociated antigen thus discussed important study investigating role bacterial vector immunotherapy finally provided important discussion novel approach improvement tailoring liveattenuated bacterial vector generation desired immune response,2019-01-10,"Kumar, Sudeep",Pharmaceuticals from Microbes,,,,document_parses/pdf_json/1801513c69b235e2631913f915203bb67a1757e3.json,document_parses/pmc_json/PMC7123696.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123696/,,3
14472,14472,18758,xjtz13ol,e639fc8b330785fb2a816c18807b8c2ddbfd78a7,PMC,Vaccines,10.1007/978-3-030-00710-2_14,PMC7123827,,no-cc,since introduction smallpox vaccination two century ago vaccine been—and still are—instrumental prevention infectious disease nowadays vaccine form heterogeneous group pharmaceutical product differ several aspect biopharmaceuticals chapter brief introduction first cover immunological principle important vaccine design next give overview different vaccine category current approach vaccine development illustrated representative example also describe current trend field vaccine noninfectious disease therapeutic vaccine cancer disease moreover route administration relevant vaccination pharmaceutical aspect vaccine briefly discussed,2019-04-14,"Jiskoot, Wim; Kersten, Gideon F. A.; Mastrobattista, Enrico; Slütter, Bram",Pharmaceutical Biotechnology,,,,document_parses/pdf_json/e639fc8b330785fb2a816c18807b8c2ddbfd78a7.json,document_parses/pmc_json/PMC7123827.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123827/,,3
14575,14575,18871,0faqel02,d78b87cc664a3641715e637834f2242370a69f58,PMC,Genus Avipoxvirus,10.1007/978-3-7643-7557-7_11,PMC7123973,,no-cc,poxvirus identified skin lesion domestic pet wild bird assigned largely default avipoxvirus genus within subfamily chordopoxvirinae family poxviridae avipoxviruses identified causative agent disease least specie order bird vaccine based upon attenuated avipoxvirus strain provide good disease control production poultry although large intensive production system suggestion real risk emergence strain current vaccine might ineffective sequence analysis whole genome revealed overall genome structure function resemblance chordopoxvirinae however avipoxvirus genome exhibit largescale genomic rearrangement extensive gene family novel host range gene comparison chordopoxvirinae phylogenetic analysis place avipoxviruses externally chorodopoxvirinae extent future might appropriate consider avipoxviruses separate subfamily within poxviridae unique relationship exists fowlpox virus fwpv reticuloendothelosis virus fwpv strain carry remnant long terminal repeat field strain carry near fulllength provirus integrated location fwpv genome development technique construct poxvirus expressing foreign vaccine antigen avipoxviruses gone neglected obscurity important vaccine vector past year seminal observation utility delivery vaccine antigen nonavian specie driven much interest group virus veterinary area several recombinant avipoxviruses commercially licensed vaccine successful expressing glycoprotein antigen enveloped virus eg avian influenza newcastle disease west nile virus several recombinant undergone extensive human clinical trial experimental vaccine hivaids malaria treatment regimen cancer patient safety profile avipoxvirus recombinant use veterinary human vaccine therapeutic well established,2007,"Boyle, David B.",Poxviruses,,,,document_parses/pdf_json/d78b87cc664a3641715e637834f2242370a69f58.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7123973/,,3
14604,14604,18905,9g806lry,e24d5f15e9c92e41f5b4a030626dd2e472fb1957,PMC,Immunization and Vaccination,10.1007/978-3-030-15346-5_13,PMC7124023,,no-cc,vaccine recognized one successful public health measure chapter provide historical overview immunization measure discus basic immunization vaccination context pandemic outbreak also discus vaccine hesitancy factor lead vaccine acceptance refusal determinant individual decisionmaking vaccination strategy approach individual community global level,2019-05-16,"Hussain, Saira",Psychiatry of Pandemics,,,,document_parses/pdf_json/e24d5f15e9c92e41f5b4a030626dd2e472fb1957.json,document_parses/pmc_json/PMC7124023.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7124023/,,3
14605,14605,18906,w5cv4buc,f144634ea8153a4d8068416d2709afabb813a844,PMC,Global control of infectious diseases by vaccination programs,10.1007/978-3-7643-8099-1_1,PMC7124024,,no-cc,industrialized developing country childhood immunization become one important costeffective public health intervention national immunization program prevented million death since initiated ‘ expanded program immunization ’ smallpox eradicated poliomyelitis verge eradication two third developing country eliminated neonatal tetanus global immunization coverage impact childhood morbidity mortality immunization program contributing reaching ‘ millennium development goal ’ — twothirds reduction underfive mortality however failure reach world ’ child existing vaccine responsible least million estimated million death child year mainly developing country death million could prevented vaccine currently recommended rapid progress understanding pathogenesis infectious disease immunology biotechnology increased number candidate vaccine antigen available pressure growing public health decision maker establish evidencebased way decide new vaccine introduced large scale national immunization program gap access new vaccine developing industrialized world still wide wealthy country still first introduce use new vaccine interest country partner agency vaccination one costeffective public health intervention continues strong also due rapid progress biotechnology vaccine development emergence global infectious disease threat including hivaids sars influenza establishment global alliance vaccine immunization focused global activity support vaccination program raising considerable fund assist especially poorer country improving expanding vaccination program global effort concentrate reducing gap access existing vaccine industrialized developing country,2007,"Tangermann, Rudolf H.; Nohynek, Hanna; Eggers, Rudolf",Pediatric Infectious Diseases Revisited,,,,document_parses/pdf_json/f144634ea8153a4d8068416d2709afabb813a844.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7124024/,,3
14720,14720,19266,yp4gscbk,914fb414691d6d7061d7cca07660685798fbb3a0,PMC,Promotion of seasonal influenza vaccination among staff in residential care homes for elderly in Hong Kong,10.1071/hi10023,PMC7129256,,no-cc,annual influenza epidemic continue cause worldwide morbidity mortality societal disruption especially among aged resident residential care home elderly rches vaccination remains effective measure prevent influenza associated complication seasonal influenza vaccine uptake rate among rche staff much lower among resident order increase uptake influenza vaccination among rche staff hong kong study developed evaluated amultimodal vaccine promotion program vpp based identified factor affecting vaccination acceptance refusal within hong kong chinese context vaccine acceptance found significantly associated belief vaccine efficacy duration service staff group providing direct care resident focus group study revealed rche staff belief efficacy safety vaccine played major role vaccine acceptance vpp effectiveness evaluated cluster randomised controlled trial among rches staff vaccination rate compared mean staff vaccination rate increased significantly intervention p control group p rche staff intervention group higher vaccination rate control group versus p program reinforces importance comprehensive culturally sensitive approach promote influenza vaccination rche staff,2016-03-17,"Chen, H.; Ng, Sammy; King, Mark E.; Fong, Carol; Ng, W.P.; Szeto, K.H.; Ho, Sara; Leung, Jane; Lam, C.K.; Chan, Shelley; Chan, W.M.; Wong, T.Y.",Healthc Infect,,,,document_parses/pdf_json/914fb414691d6d7061d7cca07660685798fbb3a0.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129256/,,3
14726,14726,19375,abtpvam1,c4492bbb0a4d59b5d61a3bb13952b5d2e2134b40,PMC,A Novel Therapeutic and Prophylactic Vaccine against Tuberculosis Using the Cynomolgus Monkey Model and Mouse Model,10.1016/j.provac.2011.07.007,PMC7129750,,no-cc,developed novel tuberculosis tb vaccine combination dna vaccine expressing mycobacterial heat shock protein hsp interleukin il delivered hemagglutinating virus japan hvjenvelope –liposome hsp ilhvj vaccine provided remarkable protective efficacy mouse model compared bcg vaccine also provided therapeutic efficacy multidrug resistant tb mdrtb extremely drug resistant tb xdrtb murine model furthermore extended study cynomolgus monkey model currently best animal model human tuberculosis novel vaccine provided higher level protective efficacy bcg based upon assessment mortality bcg prime hsp ilhvj vaccine boost primeboost method showed synergistic prophylactic effect monkey furthermore vaccine exerted therapeutic efficacy survival augmentation immune response tbinfected monkeyshvjenvelopehsp dna il dna vaccine increased body weight tbinfected monkey improved esr augmented immuneresponses proliferation pbl il production enhancement il production monkey treated vaccine correlated therapeutic efficacy vaccine data indicate novel dna vaccine might useful mycobacterium tuberculosis including xdrtb mdrtb human therapeutic clinical trial,2011-09-29,"Okada, M.; Kita, Y.; Nakajima, T.; Kanamaru, N.; Kaneda, Y.; Saunderson, P.; Tan, E.V.; McMurray, DN.",Procedia Vaccinol,,,,document_parses/pdf_json/c4492bbb0a4d59b5d61a3bb13952b5d2e2134b40.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129750/,,3
14940,14940,20663,kbihjy2b,,PMC,The Role of Self-Assembling Lipid Molecules in Vaccination,10.1016/bs.abl.2017.12.001,PMC7147077,,no-cc,advent vaccine represents one significant advance medical history protection provided vaccine greatly contributed reducing number case infection notably eradication small pox large number new technology approach vaccine development currently investigated goal providing basis next generation prophylactic everexpanding list emerging reemerging pathogen chapter focus role lipid lipid selfassembling vesicle new promising vaccination approach start describing lipid induce activation innate immune system focus lipidderived vaccine adjuvant next review current lipidbased selfassembling particle used vaccine platform specifically liposome viruslike particle viruslike particle facilitated research highly pathogenic virus ebola,2018-02-14,"Martinez-Gil, Luis; Goff, Peter H.; Tan, Gene S.",,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147077/,,3
15120,15120,20908,xa6km2ev,,PMC,Antigen Delivery System II: Development of Live Attenuated Bacterial Vectors,10.1016/b978-0-12-415847-4.00064-1,PMC7148735,,no-cc,chapter review paper mostly written since report result using live attenuated bacterial vector deliver administration mucosal surface protective antigen dna vaccine encoding protective antigen induce immune response andor protective immunity pathogen colonize invade mucosal surface paper report use vaccine vector system parenteral vaccination deal nonmucosal pathogen address induction mucosal antibody andor cellular immune response reviewed,2015-03-13,"Curtiss, Roy",Mucosal Immunology,,,,,document_parses/pmc_json/PMC7148735.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148735/,,3
15193,15193,21086,7ck0hbus,,PMC,Crystal structures of Middle East respiratory syndrome coronavirus (MERS-CoV) spike protein,10.1038/scibx.2013.806,PMC7149068,,no-cc,crystal structure merscov spike protein complex receptor could aid development therapeutic vaccine disease,2013,,,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149068/,,3
15225,15225,21165,lkpuieux,a76a091b0fd99a62052882dc3c00c2e5c8d47811,PMC,Analysis of an influenza A (H1N1) epidemic model with vaccination,10.1007/s40065-012-0013-6,PMC7149170,,cc-by,nonlinear mathematical model spread influenza hn infectious disease including role vaccination proposed analyzed assumed susceptibles become infected direct contact infectives exposed population take consideration susceptible person vaccinated vaccine efficient model analyzed using stability theory differential equation numerical simulation found threshold condition term vaccination reproduction number formula see text le one disease dy provided vaccine efficacy high enough otherwise infection maintained population also shown spread infectious disease increase infective rate increase,2012-04-19,"Zhou, Xueyong; Guo, Zhen",,,,,document_parses/pdf_json/a76a091b0fd99a62052882dc3c00c2e5c8d47811.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7149170/,,3
15302,15302,21485,o9zxl2o3,,PMC,Maurice Hilleman: Creator of Vaccines That Changed the World,10.1016/b978-0-12-804571-8.00003-2,PMC7150172,,no-cc,maurice ralph hilleman – one greatest microbiologistsvaccinologists time played key role developing vaccine asian flu hong kong flu six decade spent merck company leadership innovation blazed new trail virology epidemiology immunology cancer research vaccine development unmatched work resulted current vaccine used prevention measles mumps hepatitis b chickenpox meningitis pneumonia saved million life across globe need close cooperation public private agency including donor promote research vaccinology reemphasized recent global health crisis ebola zika virus well annual influenza virus threat eradication many disease feasible requires political support resource vaccine development harmonization vaccination policy achievable hilleman worked many collaborator academic center industrial management led research development team produce worldchanging achievement,2018-03-30,"Tulchinsky, Theodore H.",Case Studies in Public Health,,,,,document_parses/pmc_json/PMC7150172.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150172/,,3
15397,15397,22118,qautse9a,3a7eac49b7d92e651c347e1c3661c76ca0b40f51,PMC,Clinical Use of DNA Vaccines,10.1007/978-3-319-32886-7_106,PMC7153459,,no-cc,owing unique advantage simplicity safety scalability possibility repeated administration dna vaccine represent appealing competitive immunization approach wide array condition including limited infectious disease cancer immunotherapy despite exciting efficacy observed preclinical study dna vaccine faced challenge inducing strong immune response human unexpected poor immunogenicity severely hampered translation dna vaccine investigational medication licensed product overcome obstacle tremendous effort made improve antigen expression enhance immunogenicity among endeavor vivo dna electroporation ep proved breakthrough technology capable mediating efficient dna uptake resulting enhanced antigen expression vaccine immunogenicity epmediated dna delivery become one major platform used clinical trial evaluate dna vaccine human chapter addition ep delivery progress made dna vaccine development including plasmid optimization antigen design immunologic adjuvant also reviewed finally use dna vaccine context clinical trial infectious disease cancer immunotherapy summarized specifically strategy allow dna vaccine overcome antigenic diversity viral infection break immune tolerance cancer therapy explored based advantage dna vaccine immense progress led electroporationmediated vaccine delivery dna vaccine appear potential fundamentally transform vaccine field providing important benefit preventing curing disease,2017-07-25,"Liu, Li; Morrow, Matthew P.; Bagarazzi, Mark",Handbook of Electroporation,,,,document_parses/pdf_json/3a7eac49b7d92e651c347e1c3661c76ca0b40f51.json,document_parses/pmc_json/PMC7153459.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153459/,,3
15409,15409,22134,dqhs3o82,086dca40bcaab24842ddbc8c140c823782ef34a6,PMC,Development and use of the H strain of avian infectious bronchitis virus from the Netherlands as a vaccine: a review,10.1080/03079450400013154,PMC7154294,,no-cc,h strain infectious bronchitis ib one earliest live attenuated ib vaccine developed continued used part world almost year developed use nd h th h vaccine level ability provide heterologous crossprotection number ib virus different serotypes proved one enduring live attenuated ib vaccine fact h vaccine possibly widely used live attenuated ib vaccine globally day use h however declined introduction safe highly efficacious inactivated ib vaccine review document original study isolate attenuate h strain serial embryo passage describes early study demonstrate efficacy laboratory study field condition efficacy h vaccine providing crossprotection many ib variant reported worldwide also discussed possible future vaccination strategy ib considered,2010-10-19,"Bijlenga, Gosse; Cook, Jane K. A.; Gelb, Jack; de Wit, J. J.",Avian Pathol,,,,document_parses/pdf_json/086dca40bcaab24842ddbc8c140c823782ef34a6.json,document_parses/pmc_json/PMC7154294.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154294/,,3
15412,15412,22137,fdkwklzj,7f1d647d43af4ed96625ed113f8bf0ab737e2f0c,PMC,Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus,10.1080/03079450310001621198,PMC7154303,,no-cc,vaccine infectious bronchitis chicken gallus gallus domesticus arguably successful certainly widely used vaccine disease caused coronaviruses others bovine canine feline porcine coronaviruses infectious bronchitis virus ibv together genetically related coronaviruses turkey meleagris gallopavo ringnecked pheasant phasianus colchicus group coronavirus severe acute respiratory syndrome sars coronavirus tentatively group known mammalian coronaviruses group ibv replicates respiratory tissue including nose trachea lung airsacs causing respiratory disease also kidney associated minor major nephritis oviduct many part alimentary tract—the oesophagus proventriculus duodenum jejunum bursa fabricius caecal tonsil rectum cloaca usually without clinical effect virus persist reexcreted onset egg laying month age believed consequence stress coming lay genetic line chicken differ extent ibv cause mortality chick respect clearance virus acute phase live attenuated passage chicken embryonated egg ibv strain introduced vaccine followed couple decade later inactivated vaccine boosting protection egglaying bird live vaccine usually applied meattype chicken day age experimental situation result sterile immunity challenged virulent homologous virus although chicken may protected clinical sign loss ciliary activity trachea sometimes vaccinated chick may respond protective immune response protection short lived start decline apparent week vaccination vaccine based highly attenuated strain ibv exists score serotypes defined neutralization test crossprotection often poor consequently chicken may revaccinated another serotype two three week later single application inactivated virus generally led protection chicken two application led protection report remaining others practice field inactivated vaccine used laying bird previously primed two three live attenuated virus vaccination increase protection laying bird egg production loss induces sustained level serum antibody passed progeny large spike glycoprotein comprises carboxyterminal subunit approximately amino acid residue anchor virus envelope aminoterminal subunit approximately residue believed largely form distal bulbous part subunit purified ibv virus expressed using baculovirus expressed bird fowlpoxvirus vector induced virus neutralizing antibody although protective immune response induced multiple inoculation required percentage protected chicken low commercial application remarkably expression bird using nonpathogenic fowl adenovirus vector induced protection chicken two experiment difference little sequence result poor crossprotection difference amino acid change serotype suggesting small number epitope immunodominant respect neutralizing antibody initial study role ibv nucleocapsid protein n immunity suggested immunization bacterially expressed n inducing protection directly improved induction protection subsequent inoculation inactivated ibv another study two intramuscular immunization plasmid expressing n induced protective immunity basis immunity ibv well understood serum antibody level correlate protection although local antibody believed play role adoptive transfer ibvinfectioninduced αβ cell bearing cd antigen protected chick challenge infection conclusion live attenuated ibv vaccine induce good although shortlived protection homologous challenge although minority individual may respond poorly inactivated ibv vaccine insufficiently efficacious applied absence priming live vaccine two application inactivated ibv much efficacious although commercially viable proposition poultry industry however cost logistics multiple application sars inactivated vaccine would acceptable protection human population especially limited targeted group eg health care worker highrisk contact application sars vaccine perhaps best limited minimal number targeted individual monitored vaccinated person might infected sars coronavirus become asymptomatic excretors virus thereby posing risk nonvaccinated people looking future high efficacy fowl adenovirus vector expressing ibv subunit provides optimism live sars vaccine deemed necessary possibility including n protein gene,2010-07-12,"Cavanagh, Dave",Avian Pathol,,,,document_parses/pdf_json/7f1d647d43af4ed96625ed113f8bf0ab737e2f0c.json,document_parses/pmc_json/PMC7154303.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154303/,,3
15475,15475,22582,ss0g0er0,61715d77e4d17afc4879a61ee1bc5b8e940f133b,PMC,Mucosally Targeted Prime‐Boost Vaccination Approaches for Tuberculosis Based on the TLR2/4 Ligand OprI Adjuvant,10.1111/j.0300-9475.2004.01423q.x,PMC7159386,,no-cc,immunity tuberculosis tb caused mycobacterium tuberculosis depends largely activation maintenance strong cell‐mediated immune response involving cd cd cell ability respond th‐type cytokine particularly ifn‐γ recent study suggested bcg licensed vaccine tuberculosis may fail induce t‐cell response lung mucosa may therefore protect pulmonary tb decrease tb mortality may achieved enhancing immunity lung present study evaluated induction antigen‐specific immunity lung intranasal delivery lipoprotein opri pseudomonas aeruginosa opri shown toll‐like receptor agonist given subcutaneously induces type‐ immune response heterologous antigen fusion opri aga mtb opri‐aga used subunit vaccine homologous prime‐boost immunization addition opri‐aga combined aga‐encoding dna vaccine aga dna bcg heterologous prime‐boost vaccination intranasal parenteral delivery opri‐aga elicited comparable t‐cell response spleen addition delivery elicited specific t‐cell response lung lymph node llns intramuscular delivery aga dna induced significant systemic th immune response intranasal boosting opri‐aga enhanced response addition induced antigen‐specific ifn‐γ response lln opri may therefore efficient adjuvant mucosal boosting continue evaluate protection induced opri‐based prime‐boost vaccination pulmonary tb result immunogenicity protection intravenous mtb hrv infection presented,2008-06-28,"Gartner, T.; Baeten, M.; De Baetselier, P.; Huygen, K.; Revets, H.",Scand J Immunol,,,,document_parses/pdf_json/61715d77e4d17afc4879a61ee1bc5b8e940f133b.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159386/,,3
15506,15506,22683,ea91fnmz,b1e1acdc533c94bfc231cff34162c0bebbf2113e,PMC,Preclinical Toxicology of Vaccines,10.1016/b978-0-12-803620-4.00027-x,PMC7161388,,no-cc,immunity targeted infectious disease may conferred enhanced vaccine manufactured recombinant form well inactivated attenuated organism vaccine meet requirement safety quality efficacy addition antigenic component various adjuvant may included vaccine evoke effective immune response ensure safety new vaccine preclinical toxicology study conducted prior initiation concurrently clinical study five different type preclinical toxicology study evaluation vaccine safety single andor repeat dose reproductive developmental mutagenicity carcinogenicity safety pharmacology adverse effect observed course study fully evaluated final safety decision made accordingly successful preclinical toxicology study depend multiple factor including using appropriate study design using right animal model evoking effective immune response additional vivo vitro assay establish identity purity safety potency vaccine play significant role assessing critical characteristic vaccine safety,2016-11-11,"Green, M.D.; Al-Humadi, N.H.",A Comprehensive Guide to Toxicology in Nonclinical Drug Development,,,,document_parses/pdf_json/b1e1acdc533c94bfc231cff34162c0bebbf2113e.json,document_parses/pmc_json/PMC7161388.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161388/,,3
15570,15570,22865,5m7q92fu,8be199a8d9cc8cd64d97d5d4298336094fefe16e,PMC,Omics‐Based Systems Vaccinology for Vaccine Target Identification,10.1002/ddr.21049,PMC7163697,,no-cc,table see text omics technology include genomics transcriptomics proteomics metabolomics immunomics technology used vaccine research summarized using term “ vaccinomics ” omics technology combined advanced bioinformatics analysis form core “ system vaccinology ” omics technology provide powerful method vaccine target identification genomics‐based reverse vaccinology start predicting vaccine protein candidate silico bioinformatics analysis genome sequence violin vaxign vaccine design program httpwwwviolinetorgvaxign first web‐based vaccine target prediction software based reverse vaccinology strategy systematic transcriptomics proteomics analysis facilitate rational vaccine target identification detesting genome‐wide gene expression profile immunomics study set antigen recognized host immune system also used efficient vaccine target prediction large amount omics data available necessary integrate various vaccine data using ontology including gene ontology go vaccine ontology vo efficient vaccine target prediction assessment omics technology combined advanced bioinformatics analysis method system biology‐based vaccine target prediction strategy article review various omics technology used vaccine target identification,2012-10-18,"He, Yongqun",Drug Dev Res,,,,document_parses/pdf_json/8be199a8d9cc8cd64d97d5d4298336094fefe16e.json,document_parses/pmc_json/PMC7163697.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7163697/,,3
15576,15576,22889,2ug1zdcc,d0eed4509faf6b54de87a76f754333bce7fd8012,PMC,The control of necrotic enteritis in sucking piglets by means of a Clostridium perfringens toxoid vaccine,10.1111/j.1574-695x.1999.tb01302.x,PMC7164034,,no-cc,necrotic enteritis sucking piglet constitutes serious problem piglet rearing unit high morbidity mortality associated disease primary causal agent clostridium perfringens type c β‐toxin play decisive role pathogenesis disease toxoid vaccine use sow developed studied field trial european pharmacopoeia monograph vaccine use animal lay method efficacy testing based immunization rabbit collection pooled serum subsequent assay anti‐toxin antibody mouse using appropriate test toxin vaccine regarded effective induces minimum iu β‐anti‐toxin per ml rabbit serum established range – iu β‐anti‐toxin per ml rabbit serum induced sample c perfringens toxoid vaccine vaccine used field condition different rearing unit time mostly form emergency vaccination following outbreak disease outcome vaccination evaluated recording total number piglet born alive piglet loss use vaccine coupled measure resulted approximately reduction number loss,2006-01-17,"Springer, S; Selbitz, H.‐J",FEMS Immunol Med Microbiol,,,,document_parses/pdf_json/d0eed4509faf6b54de87a76f754333bce7fd8012.json,document_parses/pmc_json/PMC7164034.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164034/,,3
15643,15643,23032,1soba0dw,89723e97179160f218fd1b7c79a39b4c91177b97,PMC,Vaccination of the young kitten,10.1111/j.1748-5827.1989.tb01491.x,PMC7166716,,no-cc,paper draw together disease cat vaccination either practised uk overseas currently considered uk vaccination routinely carried feline panleucopenia feline viral rhino‐tracheitis fvr feline calicivirus infection quarantine cat also vaccinated rabies usa country vaccination also carried feline leukaemia virus infection feline chlamydia psit‐taci infection routinely rabies attempt also made develop vaccine feline infectious peritonitis fip although number problem associated development successful fip vaccine referred later factor important prevention control three disease feline panleucopenia fvr feline calicivirus infection vaccination uk commonly practised discussed disease background information virus epizootiology disease given hoped lead greater understanding principle involved prevention control point made vaccination disease vaccine developed carried country,2008-04-10,"Gaskell, R. M.",J Small Anim Pract,,,,document_parses/pdf_json/89723e97179160f218fd1b7c79a39b4c91177b97.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7166716/,,3
15674,15674,23144,0iqhf2o5,ca77332f8de0b0262fac838affdccb3c2541296c,PMC,Disordered epitopes as peptide vaccines,10.1002/pep2.24067,PMC7167742,,no-cc,development clinically useful peptide‐based vaccine remains long‐standing goal review highlight intrinsically disordered protein antigen lack ordered three‐dimensional structure represent excellent starting point development vaccine disordered protein represent important class antigen wide range human pathogen contrary widespread belief frequently target protective antibody response importantly disordered epitope appear invariably linear epitope rendering ideally suited incorporation peptide vaccine nonetheless conformational property disordered antigen hence recognition antibody frequently depend interaction make context presented immune system effect must considered design effective vaccine discus issue propose design principle may facilitate development peptide vaccine targeting disordered antigen,2018-04-14,"MacRaild, Christopher A.; Seow, Jeffrey; Das, Sreedam C.; Norton, Raymond S.",Pept Sci (Hoboken),,,,document_parses/pdf_json/ca77332f8de0b0262fac838affdccb3c2541296c.json,document_parses/pmc_json/PMC7167742.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7167742/,,3
15686,15686,23187,ipb5qniu,235eeefb15c8ad94d6d9998cb892427f9ef82e38; 5bc6c031927d7866b49dd599d65f4e38e5d9a6d5,PMC,Dose‐Optimal Vaccine Allocation over Multiple Populations,10.1111/poms.12788,PMC7168135,,no-cc,vaccination effective way prevent epidemic result immunity vaccinated individual also reduces infection pressure unvaccinated people thus people may actually escape infection without vaccinated so‐called “ herd effect ” analytically study relation herd effect vaccination fraction seminal sir compartmental model consists set differential equation describing time course epidemic prove herd effect general convex‐concave vaccination fraction give precise condition epidemic convex part arise derive significant consequence structural insight allocating limited vaccine stockpile multiple non‐interacting population identify population unique vaccination fraction efficient per dose vaccine dose‐optimal coverage characterize solution vaccine allocation problem show crucial importance dose‐optimal coverage single dose vaccine may drop ocean multiple dos together save population benefit policy maker select subset population vaccine allocated focusing limited number population make significant difference whereas allocating equally population would substantially le effective,2017-10-19,"Duijzer, Lotty E.; van Jaarsveld, Willem L.; Wallinga, Jacco; Dekker, Rommert",Prod Oper Manag,,,,document_parses/pdf_json/235eeefb15c8ad94d6d9998cb892427f9ef82e38.json; document_parses/pdf_json/5bc6c031927d7866b49dd599d65f4e38e5d9a6d5.json,document_parses/pmc_json/PMC7168135.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168135/,,3
15791,15791,23506,yaxawqhj,75bdc9bf614eeefbad41fd687001b7773c7a4b9b,PMC,The Continuing Search for Antiviral Drugs,10.1016/s1054-3589(08)60460-3,PMC7172480,,no-cc,chapter discus continuing search antiviral drug many virus disease human animal successfully controlled vaccine success naturally led improvement spectrum duration protection offered vaccine present difficult see antiviral drug could compete vaccine control many virus disease one may cite smallpox yellow fever polio recently measles among human disease newcastle disease mareks disease infectious bronchitis among poultry diseases—an area veterinary disease control vaccine particularly important research treatment virus disease drug present directed toward three general area attempt stimulate defense mechanism host animal large screening program find drug directly block virusspecific process alleviation symptom disease treatment symptom rather cause disease mainstay medical practice time immemorial still case virus disease short incubation period many virus disease inevitably restrict therapeutic use antiviral drug case symptom already appeared,2008-04-10,"Bucknall, R.A.",Adv Pharmacol,,,,document_parses/pdf_json/75bdc9bf614eeefbad41fd687001b7773c7a4b9b.json,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172480/,,3
15880,15880,23783,y5g4ceq9,c938c9180275b7773233f99e38d432ff868ab26c,PMC,Global Immunization Challenge: Progress and Opportunities,10.1007/b106524_23,PMC7176199,,no-cc,reading chapter answering discussion question follow able outline important milestone emergence vaccine mean disease control prevention discus factor underpin disparity access vaccine rich poor country identify appraise innovative option financing vaccine development ensuring wider access new underused vaccine developing country evaluate strategy ensuring sustainability vaccine development management access outline priority future research policy practice regard vaccine development procurement access,2009-05-18,"Affolder, Rebecca; Zaffran, Michel; Lob-Levyt, Julian",Maternal and Child Health,,,,document_parses/pdf_json/c938c9180275b7773233f99e38d432ff868ab26c.json,document_parses/pmc_json/PMC7176199.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176199/,,3
15923,15923,23830,saz8w6r0,4d6adcb52402016390c63d7cb4a9fef94495be48,PMC,Structural Biology and the Design of Effective Vaccines for HIV-1 and Other Viruses,10.1007/978-1-60761-512-5_39,PMC7176257,,no-cc,structural biology provides wealth information threedimensional organization chemical makeup protein understanding atomiclevel structure offer enormous potential design rationally protein stimulate specific immune response yet current vaccine development effort make little use structural information vaccine research center major goal apply structural technique vaccine design challenging pathogen include human immunodeficiency virus type hiv enveloped virus influenza ebola respiratory syncytial virus threepart strategy involves definition functional viral spike atomic level achieving structural understanding neutralizing antibody recognize spike rational development protein elicit specific antibody response overall strategy aim incorporate information viral spikeantibody interaction assimilate immunogenic feedback leverage recent advance immunofocusing computational biology,2010-03-30,"Kwong, Peter D.; Nabel, Gary J.; Acharya, Priyamvada; Boyington, Jeffrey C.; Chen, Lei; Hood, Chantelle; Kim, Albert; Kong, Leopold; Kwon, Young Do; Majeed, Shahzad; McLellan, Jason; Ofek, Gilad; Pancera, Marie; Sastry, Mallika; Changela, Anita; Stuckey, Jonathan; Zhou, Tongqing","National Institute of Allergy and Infectious Diseases, NIH",,,,document_parses/pdf_json/4d6adcb52402016390c63d7cb4a9fef94495be48.json,document_parses/pmc_json/PMC7176257.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7176257/,,3
16060,16060,24096,vrf0ejy7,e817c3bf49cbb85bdacda362cb20296b66a70fca,PMC,Inactivated Viral Vaccines,10.1007/978-3-662-45024-6_2,PMC7189890,,no-cc,inactivated vaccine used century induce protection viral pathogen established approach vaccine production relatively straightforward achieve augmented safety profile compared live counterpart today six viral pathogen licensed inactivated vaccine available many development describe principle viral inactivation application principle vaccine development specifically emphasized manufacturing procedure accompanying assay assay used monitoring inactivation process preservation neutralizing epitope pivotal novel inactivated vaccine development hurdle face licensure also discussed well disadvantage inactivation vaccine production methodology,2014-11-28,"Sanders, Barbara; Koldijk, Martin; Schuitemaker, Hanneke","Vaccine Analysis: Strategies, Principles, and Control",,,,document_parses/pdf_json/e817c3bf49cbb85bdacda362cb20296b66a70fca.json,document_parses/pmc_json/PMC7189890.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7189890/,,3
16511,16511,24938,fcojxwgc,,Medline,Protection conferred by a vaccine derived from an inactivated Egyptian variant of infectious bronchitis virus: a challenge experiment.,10.1007/s11250-019-01898-y,,31020540.0,unk,current study investigated protective efficacy formalininactivated infectious bronchitis virus ibv vaccine derived field strain kp exhibit low spike protein sequence homology currently used vaccine strain egypt twoweekold specificpathogenfree chicken subcutaneously inoculated single dose vaccine containing embryo infective dose eid inactivated virus week age chicken challenged eid virus strain via oculonasal route comparison unvaccinated challenged group vaccinated chicken significantly higher ibvneutralizing antibody titer exhibited efficient protection challenge basis tracheal ciliary activity however challenge virus recovered kidney trachea chicken rate respectively finding suggest single application vaccine may provide sufficient clinical respiratory protection may ensure complete protection infection challenge virus,2019,"Al-Ebshahy, Emad; Abdel-Sabour, Mohammed; Abas, Osama; Yanai, Tokuma",Tropical animal health and production,,,,,,https://doi.org/10.1007/s11250-019-01898-y; https://www.ncbi.nlm.nih.gov/pubmed/31020540/,129946095.0,3
16690,16690,25141,8b8oax83,,Medline,"Bovine herpesvirus-1: Genetic diversity of field strains from cattle with respiratory disease, genital, fetal disease and systemic neonatal disease and their relationship to vaccine strains.",10.1016/j.virusres.2016.06.017,,27374060.0,unk,bovine herpesvirus bohv cause disease cattle varied clinical form u two bohv subtypes bohv bohvb control program north america incorporate modified live mlv killed kv viral vaccine however bohv strain continue isolated diseased animal fetus vaccination possible differentiate bohv wildtype mlv vaccine strain determining single nucleotide polymorphism snp pattern either wholegenome sequencing pcr sequencing genomic region containing vaccinedefining snp determine bohv subtype clinical isolates relationship mlv strain isolates varied clinical disease three different laboratory u sequenced phylogenetically analyzed five sample isolated within past year new york archived sample recovered year prior oklahoma louisiana based phylogenetic analysis four case appeared due mlv vaccine case aborted fetus one neonate systemic bohv disease one aborted fetus herd reported history mlv vaccination two year remaining four isolates group mlv vaccine two associated bovine respiratory disease one vulvovaginitis fourth determined bohvb respiratory isolate recovery bohv closely related mlv vaccine virus herd receiving vaccine extended period prior isolation suggests mlv virus may remain latent circulate within herd long period,2016,"Fulton, R W; d'Offay, J M; Dubovi, E J; Eberle, R",Virus research,,,,,,https://doi.org/10.1016/j.virusres.2016.06.017; https://www.ncbi.nlm.nih.gov/pubmed/27374060/,43518377.0,3
17115,17115,25634,g0mux5cb,,Medline,Exploitation of reverse vaccinology and immunoinformatics as promising platform for genome-wide screening of new effective vaccine candidates against Plasmodium falciparum.,10.1186/s12859-018-2482-x,,30717656.0,unk,background current scenario designing worldwide effective malaria vaccine plasmodium falciparum remain challenging despite significant progress made last decade conventional vaccinology isolate inactivate inject approach time consuming laborious expensive therefore use computational vaccinology tool imperative facilitate design new promising vaccine candidate result current investigation initially protein p falciparum genome carefully chosen incidence signal peptide anchor using signalp tool resulted surface linked protein slp slp predicted contain gpianchors using predgpi tool protein considered malarial antigenic adhesins maap vaxijen program respectively subsequent step cell epitope genome derived predicted antigenic adhesins gdpaa randomly selected known malarial adhesins rskma analysed employing mhc class ii tool iedb analysis resource finally vaxijen scored cell epitope antigen considered prediction population coverage ppc analysis worldwide population including malaria endemic region validation present silico strategy carried comparing ppc combined mhc class ii predicted epitope ensemble among gdpaa rskma experimentally known epitope eke p falciparum pertaining worldwide human population conclusion present study systematically screened potential protective antigen p falciparum genome using bioinformatics tool interestingly gdpaa rskma eke p falciparum epitope ensemble forecasted contain highly promiscuous cell epitope potentially effective worldwide human population malaria endemic region therefore epitope ensemble could considered near future novel significantly effective vaccine candidate malaria,2019,"Pritam, Manisha; Singh, Garima; Swaroop, Suchit; Singh, Akhilesh Kumar; Singh, Satarudra Prakash",BMC bioinformatics,,,,,,https://doi.org/10.1186/s12859-018-2482-x; https://www.ncbi.nlm.nih.gov/pubmed/30717656/,59603743.0,3
17118,17118,25637,wpf8cuj0,,Medline,The host immune dynamics of pneumococcal colonization: implications for novel vaccine development.,10.4161/21645515.2014.979631,,25668673.0,unk,human nasopharynx np microbiota complex diverse streptococcus pneumoniae pneumococcus frequent member first year life child experience maturation immune system thereby conferring homeostatic balance pneumococcus typically rendered harmless colonizer upper respiratory environment pneumococcal carriage decline many child acquire capsularspecific antibody suggesting capsule antibodyindependent mechanism natural protection pneumococcal carriage early childhood child immune system first year life thskewed avoid inflammationinduced immunopathology understanding thth th ontogeny early life adjuvant vaccine formulation shift balance helpercell differentiation may facilitate development new proteinbased pneumococcal vaccine article discus immune dynamic pneumococcal colonization infant discussion aim benefit design improvement protein subunitbased nextgeneration pneumococcal vaccine,2014,"Khan, M Nadeem; Pichichero, Michael E",Human vaccines & immunotherapeutics,,,,,,https://doi.org/10.4161/21645515.2014.979631; https://www.ncbi.nlm.nih.gov/pubmed/25668673/,207507133.0,3
17308,17308,25855,chgx70e2,,Medline,An attenuated Salmonella-vectored vaccine elicits protective immunity against Mycobacterium tuberculosis.,10.1016/j.vaccine.2009.08.096,,19733584.0,unk,need develop protective vaccine tuberculosis tb elicit full immune response including mucosal immunity live attenuated salmonellatyphimurium aroa sl vector tb vaccine namely sleb harboring mycobacterium tuberculosis tb hrv esatagb fusion gene developed experimental data demonstrated sleb vaccine combined bcg vaccination induced strongest tb agspecific mucosal humoral cellular immune response comprised increased proliferation cell ifngamma expression granzyme b production well greatest ifngamma production effectormemory tem effector cd cell response exerted high protective efficacy mouse virulent tb hrv challenge compared vaccinated group mouse immunized slagb dna vaccine bcg strategy may represent novel promising mucosal vaccine candidate prevention tb inexpensive produce efficacious able given orally rather injection,2009,"Wang, Qi-long; Pan, Qin; Ma, Yunfeng; Wang, Kun; Sun, Ping; Liu, Shengwu; Zhang, Xiao-Lian",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2009.08.096; https://www.ncbi.nlm.nih.gov/pubmed/19733584/,10137480.0,3
17321,17321,25873,qu7ddcw9,,Medline,Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains.,10.1007/s40121-020-00300-x,,32328978.0,unk,emergence strain coronavirus sarscov severe acute respiratory syndrome coronavirus impact global health made imperative development effective safe vaccine lethal strain sarscov add list coronavirus disease threatened global health along sars severe acute respiratory syndrome mers middle east respiratory syndrome coronaviruses emerged respectively april vaccine commercially available coronavirus strain nevertheless knowledge obtained vaccine development effort mers sars high value covid coronavirus disease review past ongoing vaccine development effort clinically relevant coronavirus strain intention information help development effective safe vaccine covid addition information naturally exposed individual animal model coronavirus strain described purpose helping development effective vaccine covid,2020-04-23,"Padron-Regalado, Eriko",Infectious diseases and therapy,,,,,,https://doi.org/10.1007/s40121-020-00300-x; https://www.ncbi.nlm.nih.gov/pubmed/32328978/,216109305.0,3
17991,17991,26658,62kyo1y6,,Medline,Mucosal vaccines to prevent porcine reproductive and respiratory syndrome: a new perspective.,10.1017/s1466252312000023,,22717576.0,unk,porcine reproductive respiratory syndrome prrs economically important infectious disease swine constant emergence variant strain prrs virus pprsv virusmediated immune evasion followed viral persistence result increased incidence recurrence prrs swine herd current live killed prrsv vaccine administered parenteral route ineffective inducing complete protection thus new approach design delivery prrsv vaccine needed reduce disease burden swine industry induction effective mucosal immunity several respiratory pathogen direct delivery vaccine mucosal site proven effective mouse model however challenge eliciting mucosal immunity prrs due limited understanding safe potent mucosal adjuvant could potentiate mucosal immune response prrsv purpose review discus method induction protective mucosal immune response respiratory tract pig manuscript also discus prrsv modulates innate adaptive immunoregulatory response mucosal systemic site infected andor vaccinated pig information may help design innovative mucosal vaccine elicit superior crossprotective immunity divergent field strain prrsv,2012,"Renukaradhya, Gourapura J; Dwivedi, Varun; Manickam, Cordelia; Binjawadagi, Basavaraj; Benfield, David",Animal health research reviews,,,,,,https://doi.org/10.1017/s1466252312000023; https://www.ncbi.nlm.nih.gov/pubmed/22717576/,206331502.0,3
18159,18159,26855,jwd96s79,,Medline,Combined infectious bronchitis virus Arkansas and Massachusetts serotype vaccination suppresses replication of Arkansas vaccine virus.,10.1080/03079457.2015.1077928,,26223977.0,unk,polyvalent infectious bronchitis virus vaccination common worldwide possibility vaccine interference simultaneous combined vaccination arkansas ark massachusetts masstype vaccine evaluated effort explain high prevalence arktype infectious bronchitis virus vaccinated chicken chicken ocularly vaccinated combination ark mass showed predominance mass vaccine virus day postvaccination dpv tear even mass ark vaccine inoculated separate eye mass vaccine virus able outcompete ark vaccine virus although mass vaccine virus apparently replication advantage ark vaccine ocular tissue ark vaccine virus appeared advantage spreading andor replicating trachea chicken vaccinated ark mass vaccine housed together mass vaccine virus able spread arkvaccinated chicken ark vaccine detected massvaccinated chicken mass vaccine detected tear sentinel bird introduced group receiving vaccine furthermore ark vaccine virus rna detectable dpv tear sample chicken vaccinated ark mass vaccine varying ark vaccine dos high concentration mass virus rna detectable dpv contrast ark vaccine virus replicated effectively early vaccination chicken vaccinated ark vaccine alone different replication dynamic ark mass virus chicken vaccinated combined vaccine result reduced protection ark challenge dpv study needed clarify viral interference detected determines difference protection challenge time point vaccination,2015,"Ndegwa, Eunice N; Bartlett, Samantha N; Toro, Haroldo; Joiner, Kellye S; van Santen, Vicky L",Avian pathology : journal of the W.V.P.A,,,,,,https://doi.org/10.1080/03079457.2015.1077928; https://www.ncbi.nlm.nih.gov/pubmed/26223977/,39027629.0,3
18215,18215,26921,t95hln83,,Medline,Efficacy of a modified live porcine reproductive and respiratory syndrome virus (PRRSV) vaccine in pigs naturally exposed to a heterologous European (Italian cluster) field strain: Clinical protection and cell-mediated immunity.,10.1016/j.vaccine.2009.03.028,,19442420.0,unk,purpose study ass clinical protection pig vaccinated commercially available attenuated porcine reproductive respiratory syndrome virus prrsv vaccine porcilis prrs naturally exposed field condition heterologous italian cluster strain virulent prrsv total weekold pig seronegative prrsv allocated group im id c group week age pig group im n pig id n pig vaccinated intramuscularly intradermally respectively modified live prrsv vaccine porcilis prrs pig group c n pig kept nonvaccinated control postvaccination pv day blood sample collected detection vaccine virus pcr antibody response elisa identification change lymphocyte subpopulation cytometry ifngamma prrsvspecific secreting cell sc elispot pv day pig b c group moved site conventional finishing herd history respiratory disease caused prrsv common bacteria exposed natural challenge prrsv field strain belonging italian cluster prrsv demonstrated identity vaccine virus dv strain orf sequencing exposure day day pv day postexposure pe blood sample collected detection titration prrsv antibody well lymphocyte ifngamma measurement described throughout postexposure period pig observed daily clinical sign overall clinical sign reduced respectively intramuscularly intradermally vaccinated pig compared control respiratory sign reduced respectively im id group clinical protection associated marked activation cellmediated immune response highest level specific ifngamma production day pe concomitant associated change natural killer nk cell gammadelta cytotoxic lymphocyte blood field study evidence eu attenuated vaccineinduced clinical protection natural exposure genetically diverse homology prrsv isolate italian cluster demonstrated statistically significant reduction clinical sign term incidence duration severity efficient cellmediated immune response vaccinated pig compared unvaccinated control,2009,"Martelli, Paolo; Gozio, Stefano; Ferrari, Luca; Rosina, Stefano; De Angelis, Elena; Quintavalla, Cecilia; Bottarelli, Ezio; Borghetti, Paolo",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2009.03.028; https://www.ncbi.nlm.nih.gov/pubmed/19442420/,5105568.0,3
18295,18295,27016,d4edwzcq,,Medline,Impact of systemic or mucosal immunity to adenovirus on Ad-based Ebola virus vaccine efficacy in guinea pigs.,10.1093/infdis/jir332,,21987739.0,unk,background approximately north american population estimated subsaharan african population antibody adenovirus serotype adhu capable neutralizing adhubased vaccine mouse intranasal delivery adhu expressing zaire ebolavirus glycoprotein human adenovirus serotype ad containing gene zaire ebolavirus glycoprotein zgp expressional control cytomegalovirus immediate early promoter cmv bypass systemic preexisting immunity resulting protection mouseadapted zaire ebolavirus mayinga method guinea pig administered adenovirusbased ebola virus vaccine either intramuscularly intranasally presence systemically mucosally induced adenovirus immunity challenged lethal dose guinea pigadapted zaire ebolavirus mayinga gazebov humoral immune response assayed determine effect vaccine delivery route preexisting immunity result intramuscular intranasal vaccination fully protected guinea pig lethal gazebov challenge however intramuscular vaccination animal systemically induced preexisting immunity resulted low survival following challenge interestingly intranasal vaccination protected guinea pig systemic preexisting immunity adhu mucosal adenoviral immunity induced intranasal administration adhu decreased protection following intranasal vaccination firstgeneration secondgeneration vaccine conclusion intranasal vaccination effective vaccine delivery route presence systemic lower extent mucosal preexisting immunity vaccine vector guinea pig,2011,"Richardson, Jason S; Abou, Max C; Tran, Kaylie N; Kumar, Anand; Sahai, Beni M; Kobinger, Gary P",The Journal of infectious diseases,,,,,,https://doi.org/10.1093/infdis/jir332; https://www.ncbi.nlm.nih.gov/pubmed/21987739/,8483110.0,3
18386,18386,27115,7zvnibrw,,Medline,Immunoprofiling of peripheral blood from infectious bronchitis virus vaccinated MHC-B chicken lines - Monocyte MHC-II expression as a potential correlate of protection.,10.1016/j.dci.2019.02.004,,30763593.0,unk,vaccination program implemented poultry farm limit outbreak spread infectious bronchitis virus ibv substantial economic burden poultry industry immune correlate used predict vaccine efficacy proved difficult find ibvvaccineinduced protection find correlate ibvvaccineinduced protection hence employed flow cytometric assay quantify peripheral leucocyte subset expression cell surface marker six different nonvaccinated vaccinated major histocompatibility complex mhc haplotype nonvaccinated vaccinated mhc haplotype presented differential leucocyte composition ibv viral load strong effect mhcb vaccination several leucocyte subset resulted positive correlation ibv viral load based mhc haplotype ranking addition strong effect mhcb vaccination monocyte mhcii expression showed animal highest monocyte mhcii expression weakest vaccineinduced protection conclusion found several interesting mhcb related immune correlate protection flow cytometric analysis employed study correlate ibvvaccineinduced protection,2019,"Larsen, Frederik T; Bed'Hom, Bertrand; Naghizadeh, Mohammad; Kjærup, Rikke B; Zohari, Siamak; Dalgaard, Tina S",Developmental and comparative immunology,,,,,,https://doi.org/10.1016/j.dci.2019.02.004; https://www.ncbi.nlm.nih.gov/pubmed/30763593/,73454492.0,3
18390,18390,27121,72cpq11s,,Medline,VHSV G glycoprotein major determinants implicated in triggering the host type I IFN antiviral response as DNA vaccine molecular adjuvants.,10.1016/j.vaccine.2014.07.111,,25203447.0,unk,recently identified two major determinant glycoprotein g viral hemorrhagic septicaemia rhabdovirus gpgvhsv peptide p p implicated triggering host type ifn antiviral response associated rhabdoviral antigen aim investigate property viral glycoprotein region dna molecular adjuvant corresponding cdna sequence cloned plasmid pmcv flanked signal peptide transmembrane sequence gpgvhsv addition plasmid construct encoding sequence p p pmcvpp also designed vitro transitory cell transfection assay showed vhsv gpg region able induce expression type ifn stimulated gene well confer resistance infection different fish rhabdovirus spring viremia carp virus svcv vivo zebrafish intramuscular injection μg construct pmcvpp conferred fish protection svcv lethal challenge day postimmunization moreover pmcvpp construct assayed molecular adjuvantcitys dna vaccine svcv based surface antigen virus paegsvcv result showed coinjection svcv dna vaccine molecular adjuvant allowed tenfold reduction dose paegsvcv without compromising efficacy ii increase duration protection iii increase survival rate knowledge first report specific ifninducing region viral gpg used design moreefficient costeffective viral vaccine well improve knowledge stimulate innate immune system,2014,"Martinez-Lopez, A; Garcia-Valtanen, P; Ortega-Villaizan, M; Chico, V; Gomez-Casado, E; Coll, J M; Estepa, A",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2014.07.111; https://www.ncbi.nlm.nih.gov/pubmed/25203447/,1925282.0,3
18411,18411,27143,ab87fp5k,,Medline,Continuous cell lines from the Muscovy duck as potential replacement for primary cells in the production of avian vaccines.,10.1080/03079457.2016.1138280,,26814192.0,unk,veterinary vaccine contribute food security interrupt zoonotic transmission help maintain overall health livestock although vaccine usually costeffective adoption depends multitude factor poultry vaccine usually given bird short life span low production cost per dose one important challenge hurdle ensure consistent reliable supply large number dos flexible production process accommodate range different pathogen dosage requirement poultry vaccine currently produced primary avian cell derived chicken waterfowl embryo production system associated high cost logistic complexity rigid interval harvest production supply limitation investigated whether continuous cell line cairina retina crpix may provide substrate independent primary cell culture embryonated egg virus examined replication cell line strain associated contained vaccine egg drop syndrome mareks disease newcastle disease avian influenza infectious bursal disease derzsys disease tested virus required development unique condition replication described used generate material vivo efficacy study accelerate transfer process larger production volume,2016,"Jordan, Ingo; John, Katrin; Höwing, Kristin; Lohr, Verena; Penzes, Zoltán; Gubucz-Sombor, Erzsébet; Fu, Yan; Gao, Peng; Harder, Timm; Zádori, Zoltán; Sandig, Volker",Avian pathology : journal of the W.V.P.A,,,,,,https://doi.org/10.1080/03079457.2016.1138280; https://www.ncbi.nlm.nih.gov/pubmed/26814192/,22648967.0,3
18575,18575,27334,ln2v50b7,,Medline,Built-in RNA-mediated Chaperone (Chaperna) for Antigen Folding Tailored to Immunized Hosts.,10.1002/bit.27355,,32297972.0,unk,highquality antibody ab production depends availability immunologically relevant antigen present potentially universal platform generating soluble antigen bacterial host tailored immunized animal ab production novel rnadependent chaperone target antigen genetically fused rnainteracting domain rid docking tag derived immunized host promotes solubility robust folding target antigen selected nterminal trnabinding domain lysyltrna synthetase lysrs rid fusion viral protein demonstrated expression rid fusion protein soluble native conformation immunization predominantly elicited ab response target antigen whereas self rid tag remained nonimmunogenic differential immunogenicity fusion protein greatly enriched simplified screening hybridoma clone monoclonal antibody mabs enabling specific sensitive serodiagnosis merscov infection moreover mabs consensus influenza hemagglutinin stalk domain enabled novel assay trivalent seasonal influenza vaccine fcmediated effector function demonstrated could harnessed design nextgeneration universal influenza vaccine nonimmunogenic builtin antigen folding module tailored repertoire immunized animal host drive immunochemical diagnostics therapeutic designer vaccine article protected copyright right reserved,2020-04-16,"Kim, Young-Seok; Lim, Jongkwan; Sung, Jemin; Cheong, Yucheol; Lee, Eun-Young; Kim, Jihoon; Oh, Hana; Kim, Yeon-Sook; Cho, Nam-Hyuk; Choi, Seongil; Kang, Sang-Moo; Nam, Jae-Hwan; Chae, Wonil; Seong, Baik L",Biotechnology and bioengineering,,,,,,https://doi.org/10.1002/bit.27355; https://www.ncbi.nlm.nih.gov/pubmed/32297972/,215794198.0,3
18617,18617,27382,h4f99inm,,Medline,Identifying Gaps in Respiratory Syncytial Virus Disease Epidemiology in the United States Prior to the Introduction of Vaccines.,10.1093/cid/cix432,,28903503.0,unk,respiratory syncytial virus rsv cause lower respiratory tract illness frequently effective antiviral vaccine rsv approved use united state however least vaccine monoclonal antibody product development targeting older adult pregnant woman protect young infant phase clinical trial unanswered question regarding rsv epidemiology need identified addressed prior rsv vaccine introduction guide measurement impact future recommendation center disease control prevention cdc convened technical consultation gather input external subject matter expert individual perspective regarding evidence gap current rsv epidemiology united state potential study surveillance platform needed fill gap prioritizing effort participant articulated individual view cdc staff synthesized individual input report,2017,"Kim, Lindsay; Rha, Brian; Abramson, Jon S; Anderson, Larry J; Byington, Carrie L; Chen, Grace L; DeVincenzo, John; Edwards, Kathryn M; Englund, Janet A; Falsey, Ann R; Griffin, Marie R; Karron, Ruth A; Martin, Karen G; Meissner, H Cody; Munoz, Flor M; Pavia, Andrew T; Piedra, Pedro A; Schaffner, William; Simões, Eric A F; Singleton, Rosalyn; Talbot, H Keipp; Walsh, Edward E; Zucker, Jane R; Gerber, Susan I",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,,,,,,https://doi.org/10.1093/cid/cix432; https://www.ncbi.nlm.nih.gov/pubmed/28903503/,206387866.0,3
18718,18718,27504,43f8q04n,,Medline,A flagellin-adjuvanted inactivated porcine epidemic diarrhea virus (PEDV) vaccine provides enhanced immune protection against PEDV challenge in piglets.,10.1007/s00705-020-04567-w,,32253616.0,unk,since late outbreak porcine epidemic diarrhea ped reported swine industry china variant pedv strain differs strain cv cause prevalent pedv infection commercial vaccine based cv provide complete protection study designed new vaccine based epidemic pedv strain ah adjuvanted flagellin mucosal adjuvant induces mucosal systemic production iga three group pregnant sow immunized twice day interval pedv adjuvanted flagellin pedv alone pb farrowing newborn piglet group selected challenged pedv immunization vaccine elicited high level igg iga neutralizing antibody serum colostrum sow newborn piglet protected pedv suckling study guide prevention control strategy pedv infection thereby reducing loss associated virus,2020-04-06,"Xu, Xiangwei; Du, Luping; Fan, Baochao; Sun, Bing; Zhou, Jinzhu; Guo, Rongli; Yu, Zhengyu; Shi, Danyi; He, Kongwang; Li, Bin",Archives of virology,,,,,,https://doi.org/10.1007/s00705-020-04567-w; https://www.ncbi.nlm.nih.gov/pubmed/32253616/,214810358.0,3
18926,18926,27741,d92grbqr,,Medline,Immunomodulatory biomaterials.,10.1016/j.ijpharm.2008.06.030,,18662761.0,unk,vaccination one successful medical intervention prevention disease twentieth century however development new le reactogenic vaccine antigen take advantage molecular recombinant technology come need effective adjuvant facilitate induction adaptive immune response context immunomodulatory biomaterials particularly one based biodegradable polymer show great promise article discus various class immunomodulatory biomaterials advocate crossdisciplinary approach brings together molecular concept various field rationally design vaccine adjuvant immunomodulatory property,2008,"Mallapragada, Surya K; Narasimhan, Balaji",International journal of pharmaceutics,,,,,,https://doi.org/10.1016/j.ijpharm.2008.06.030; https://www.ncbi.nlm.nih.gov/pubmed/18662761/,1735003.0,3
18980,18980,27803,l52dkwbx,,Medline,Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.,10.1128/iai.01722-07,,18285494.0,unk,generation protective humoral immune response receptorbinding domain domain iv protective antigen padiv bacillus anthracis represents plausible approach anthrax toxin current study developed naked dna vaccine encoding calreticulin crt linked padiv bacillus anthracis crtpadiv transfected human embryonic kidney cell line hek crtpadiv dna performed western blotting confocal microscopy analysis found linkage crt padiv target padiv endoplasmic reticulum resulting secretion chimeric crtpadiv protein evaluated ability crtpadiv dna generate padivspecific antibody response protective immunity lethal anthrax toxin pa plus lethal factor challenge found mouse immunized crtpadiv dna capable rapidly inducing significantly higher padivspecific antibody response mouse immunized padiv dna alone furthermore observed enhanced antibody response generated crtpadiv dna cd dependent since cd knockout mouse demonstrated significant reduction antibody response addition analysis titer avidity maturation induced paspecific antibody revealed vaccination crtpadiv dna vaccine accelerated avidity maturation antibody padiv compared vaccination padiv dna importantly enhanced antibody response correlated protective immunity lethal anthrax toxin challenge thus dna vaccine encoding crt linked padiv may dramatically enhance paspecific protective antibody response result significant clinical application biodefense anthrax toxin,2008,"Park, Yong Sung; Lee, Jin Hyup; Hung, Chien-Fu; Wu, T-C; Kim, Tae Woo",Infection and immunity,,,,,,https://doi.org/10.1128/iai.01722-07; https://www.ncbi.nlm.nih.gov/pubmed/18285494/,13290514.0,3
18986,18986,27811,pvl9oloa,,Medline,Antibody-mediated neutralization of African swine fever virus: myths and facts.,10.1016/j.virusres.2012.10.012,,23159730.0,unk,almost virus neutralized antibody however controversy antibodymediated neutralization african swine fever virus asfv serum convalescent pig protective relevance antibody experimentally vaccinated pig present vaccine available highly lethal economically relevant virus classical attempt generate vaccine unsuccessful failure attributed part many author describe absence neutralizing antibody finding study clearly contradict paradigm impossibility neutralize asfv mean monoclonal polyclonal antibody review discus scientific evidence type antibody convalescent experimentally immunized animal nature specificity neutralizationmediated mechanism demonstrated potential relevance antibody protection,2013,"Escribano, José M; Galindo, Inmaculada; Alonso, Covadonga",Virus research,,,,,,https://doi.org/10.1016/j.virusres.2012.10.012; https://www.ncbi.nlm.nih.gov/pubmed/23159730/,8922467.0,3
19277,19277,28146,wi5683yi,,Medline,Prioritising access to pandemic influenza vaccine: a review of the ethics literature.,10.1186/s12910-020-00477-3,,32408869.0,unk,background world threatened future pandemic vaccine play key role preventing harm inevitably shortage possibility advance stockpiling therefore need method prioritising access main text paper report critical interpretative review published literature discus ethical argument used justify could prioritise vaccine influenza pandemic found focus literature often proposing different group priority eg preexisting health condition young old health care worker etc different reason often suggested mean justifying priority grouping eg appeal best overall outcome fairness belonging vulnerable risk group etc suggest much literature wrongly assumes able plan priority group prior time particular pandemic development particular vaccine also point surprising absence various issue literature eg vaccine fit within overall pandemic planning lack specificity place issue global justice etc conclusion literature proposes wide range way prioritise vaccine focusing different group principle plan use pandemic vaccine must provide justification prioritisation focus review influenza pandemic vaccine lesson learnt future allocation coronavirus vaccine one becomes available,2020-05-14,"Williams, Jane H; Dawson, Angus",BMC medical ethics,,,,,,https://doi.org/10.1186/s12910-020-00477-3; https://www.ncbi.nlm.nih.gov/pubmed/32408869/,218640890.0,3
19580,19580,28508,w8d8xgzy,,Medline,Malaria vaccine based on self-assembling protein nanoparticles.,10.1586/14760584.2015.1096781,,26468608.0,unk,despite recent progress gsks rtss malaria vaccine remains desperate need efficient malaria vaccine used repetitive antigen display technology display malaria specific b cell cell epitope effort design vaccine plasmodium falciparum malaria protein sequence assembled nanoparticle induces strong longlived protective immune response infection parasite confident clinical trial developed vaccine candidate show good protection controlled human malaria infection trial,2015,"Burkhard, Peter; Lanar, David E",Expert review of vaccines,,,,,,https://doi.org/10.1586/14760584.2015.1096781; https://www.ncbi.nlm.nih.gov/pubmed/26468608/,39419726.0,3
20117,20117,29129,o6z1td66,,Medline,An intact signal peptide on dengue virus E protein enhances immunogenicity for CD8(+) T cells and antibody when expressed from modified vaccinia Ankara.,10.1016/j.vaccine.2014.03.093,,24726244.0,unk,dengue global public health concern aggravated lack vaccine antiviral therapy despite wellknown role cd cell immunopathogenesis dengue virus denv recent study highlighted importance arm immune response protection disease thus majority denv vaccine candidate designed achieve protective titer neutralizing antibody le regard cellular response used mouse model investigate cd cell humoral response set potential denv vaccine based recombinant modified vaccinia virus ankara rmva enable study identified two cd cell epitope denv e protein cbl mouse using found rmva vaccine elicited denvspecific cd cell cytotoxic vivo polyfunctional vitro moreover vaccine expressing e protein intact signal peptide sequence elicited denvspecific cd cell expressing e protein cytoplasm significantly ertargeted e protein vaccine elicited antibody response result support development rmva vaccine expressing denv e protein add tool available dengue vaccine development,2014,"Quinan, Bárbara R; Flesch, Inge E A; Pinho, Tânia M G; Coelho, Fabiana M; Tscharke, David C; da Fonseca, Flávio G",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2014.03.093; https://www.ncbi.nlm.nih.gov/pubmed/24726244/,24451229.0,3
20211,20211,29234,owhoj3y5,,Medline,PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice.,10.1172/jci64704,,23635778.0,unk,viral vectorbased vaccine induce protective cd cell immunity prevent control pathogenic siv infection issue preexisting immunity safety impeded implementation hiv report development believe novel antigentargeting dna vaccine strategy exploit binding programmed death pd ligand expressed dendritic cell dc fusing soluble pd hiv gag p antigen compared nondctargeting vaccine intramuscular immunization via electroporation ep fusion dna mouse elicited consistently high frequency gagspecific broadly reactive polyfunctional longlived cytotoxic cd cell robust antigag antibody titer vaccination conferred remarkable protection mucosal challenge vaccinia gag virus soluble pdbased vaccination potentiated cd cell response enhancing antigen binding uptake dc activation draining lymph node also increased ilproducing dc engaged antigen crosspresentation compared antidec antibodymediated dc targeting high frequency durable protective gagspecific cd cell immunity induced soluble pdbased vaccination suggests pdbased dna vaccine could potentially used hiv pathogen,2013,"Zhou, Jingying; Cheung, Allen K L; Tan, Zhiwu; Wang, Haibo; Yu, Wenbo; Du, Yanhua; Kang, Yuanxi; Lu, Xiaofan; Liu, Li; Yuen, Kwok-Yung; Chen, Zhiwei",The Journal of clinical investigation,,,,,,https://doi.org/10.1172/jci64704; https://www.ncbi.nlm.nih.gov/pubmed/23635778/,8950659.0,3
20228,20228,29253,t7dcn6kb,,Medline,"Vaccines, new opportunities for a new society.",10.1073/pnas.1402981111,,25136130.0,unk,vaccination effective medical intervention ever introduced together clean water sanitation eliminated large part infectious disease killed million people recent study concluded since united state alone vaccine prevented million case diphtheria million case measles total million case childhood disease report world health organization state today vaccine prevent million death per year every minute five life saved vaccine worldwide overall vaccine done continue excellent job eliminating reducing impact childhood disease furthermore thanks new technology vaccine potential make enormous contribution health modern society preventing treating communicable disease age also noncommunicable disease cancer neurodegenerative disorder achievement result requires development novel technology health economic model able capture mere costbenefit vaccination also value health per se,2014,"Rappuoli, Rino; Pizza, Mariagrazia; Del Giudice, Giuseppe; De Gregorio, Ennio",Proceedings of the National Academy of Sciences of the United States of America,,,,,,https://doi.org/10.1073/pnas.1402981111; https://www.ncbi.nlm.nih.gov/pubmed/25136130/,24018243.0,3
20539,20539,29615,tmd4e756,,Medline,"The ability of Hepatitis B surface antigen DNA vaccine to elicit cell-mediated immune responses, but not antibody responses, was affected by the deglysosylation of S antigen.",10.1016/j.vaccine.2008.03.072,,18462847.0,unk,hepatitis b virus hbv infection remains major worldwide infectious disease serious longterm morbidity mortality limited selection drug treatment able control progress disease people active persistent hbv infection immunotherapy control degree viral infection one possible alternative solution challenge hbv dna vaccine strong ability induce cellmediated immune response offer attractive option hbv surface protein important viral immunity reestablishing anti immunity chronic hbv infected patient bring significant benefit patient previous study shown hbv dna vaccine immunogenic number animal study current study investigated effect glycosylation expression immunogenicity dna vaccine result demonstrate deglycosylation two potential nlinked glycosylation site protein resulted significant decrease sspecific cellmediated immune response affect anti antibody response finding provides important direction development dna vaccine elicit optimal balanced antibody cellmediated immune response treat people hbv chronic infection,2008,"Xing, Yiping; Huang, Zuhu; Lin, Yan; Li, Jun; Chou, Te-Hui; Lu, Shan; Wang, Shixia",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2008.03.072; https://www.ncbi.nlm.nih.gov/pubmed/18462847/,25438710.0,3
20650,20650,29742,46lyg5wd,,Medline,Generation of plant-derived recombinant DTP subunit vaccine.,10.1016/j.vaccine.2009.03.084,,19464556.0,unk,current diphtheriatetanuspertussis dtp pediatric vaccine produced corresponding pathogenic bacteria corynebacterium diphtheriae clostridium tetani bordetella pertussis five injected dos dtap acellular vaccine required every child standard u vaccination schedule vaccine derived native live source adverse effect possible production complex costly address issue safety ease renewability expense used recombinant technology effort develop subunit dpt vaccine derived nonpathogenic plant expression system expression diphtheria toxin dt tetanus fragmentc tetc nontoxic subunit pertussis toxin ptx antigenic protein soluble form lowalkaloid tobacco plant carrot cell culture allowed efficient downstream purification level suitable intramuscular injection balbc mouse working concentration mug per dose preparation induced high level antigenspecific igg mouse serum result clearly support feasibility producing recombinant pediatric vaccine component plant,2009,"Brodzik, R; Spitsin, S; Pogrebnyak, N; Bandurska, K; Portocarrero, C; Andryszak, K; Koprowski, H; Golovkin, M",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2009.03.084; https://www.ncbi.nlm.nih.gov/pubmed/19464556/,205578878.0,3
20826,20826,29947,d684fn9n,,Medline,Virus-like particle vaccine containing hemagglutinin confers protection against 2009 H1N1 pandemic influenza.,10.1128/cvi.05206-11,,22030367.0,unk,immunization world population influenza pandemic hn virus spread globally possible current vaccine production platform new influenza vaccine technology viruslikeparticles vlps offer promising alternative tested immunogenicity protective efficacy vlp vaccine containing hemagglutinin ha pandemic hn influenza virus hnpdm ferret compared intramuscular im intranasal route immunization vaccination ferret vlps containing ha protein acalifornia hnpdm induced high antibody titer conferred significant protection virus challenge vlpvaccinated animal lost le weight shed le virus nasal wash markedly lower virus titer organ tested naïve control single dose vlps either im induced higher level antibody two dos commercial split vaccine ferret vaccinated split vaccine incompletely protected challenge animal lower virus titer olfactory bulb tonsil intestine lost weight shed virus nasal wash similar extent naïve control challenge heterologous abrisbane hn virus revealed vlps conferred minimal crossprotection heterologous infection revealed lack reduction nasal wash lung virus titer slightly higher weight loss relative control summary experiment demonstrate strong immunogenicity protective efficacy vlps compared split vaccine show vaccination vlps potential highly efficacious vaccination influenza,2011,"Hossain, M Jaber; Bourgeois, Melissa; Quan, Fu-Shi; Lipatov, Aleksandr S; Song, Jae-Min; Chen, Li-Mei; Compans, Richard W; York, Ian; Kang, Sang-Moo; Donis, Ruben O",Clinical and vaccine immunology : CVI,,,,,,https://doi.org/10.1128/cvi.05206-11; https://www.ncbi.nlm.nih.gov/pubmed/22030367/,206743308.0,3
20990,20990,30136,ll1ayjew,,Medline,Exploring the Prospects of Engineered Newcastle Disease Virus in Modern Vaccinology.,10.3390/v12040451,,32316317.0,unk,many traditional vaccine proven incapable controlling newly emerging infectious disease also achieved limited success fight variety human cancer thus innovative vaccine strategy highly needed overcome global burden disease advance molecular biology reverse genetics completely restructured concept vaccinology leading emergence stateoftheart technology vaccine design development delivery among modern vaccine technology recombinant viral vectored vaccine known incredible specificity antigen delivery well induction robust immune response vaccinated host although number virus used vaccine vector genetically engineered newcastle disease virus ndv posse useful attribute make preferable candidate vectoring vaccine antigen review molecular biology ndv discus reverse genetics approach used engineer virus efficient vaccine vector discus prospect engineered virus efficient vehicle vaccine cancer several infectious disease man animal,2020-04-16,"Bello, Muhammad Bashir; Yusoff, Khatijah; Ideris, Aini; Hair-Bejo, Mohd; Jibril, Abdurrahman Hassan; Peeters, Ben P H; Omar, Abdul Rahman",Viruses,,,,,,https://doi.org/10.3390/v12040451; https://www.ncbi.nlm.nih.gov/pubmed/32316317/,216072983.0,3
21062,21062,30226,9a1fckvh,,Medline,Development of Middle East Respiratory Syndrome Coronavirus vaccines - advances and challenges.,10.1080/21645515.2017.1389362,,29048984.0,unk,middle east respiratory syndrome coronavirus merscov emerging pathogen potential pose threat global public health sporadic case outbreak continue reported middle east case fatality rate remain high approximately globally specific preventive therapeutic countermeasure currently exist safe effective vaccine could play important role protecting threat merscov review discus human vaccine candidate currently development explores viral characteristic molecular epidemiology immunology relevant merscov vaccine development present dna vaccine candidate begun human clinical trial two vectorbased candidate soon begin human trial proteinbased vaccine still preclinical stage challenge successful development include incomplete understanding viral transmission pathogenesis immune response particular mucosal level optimal animal challenge model lack standardized immunological assay insufficient sustainable funding,2018,"Cho, Heeyoun; Excler, Jean-Louis; Kim, Jerome H; Yoon, In-Kyu",Human vaccines & immunotherapeutics,,,,,,https://doi.org/10.1080/21645515.2017.1389362; https://www.ncbi.nlm.nih.gov/pubmed/29048984/,23525271.0,3
21249,21249,30434,8hjbqxkg,,Medline,Predictors of influenza vaccination among emergency medical services personnel.,10.3109/10903127.2010.541982,,21226559.0,unk,background frequent patient interaction particularly patient longterm care facility emergency medical service em professional risk contracting spreading influenza however influenza vaccination rate among em professional poorly quantified objective sought document vaccination rate em professional identify predictor vaccination uptake method conducted crosssectional survey north carolina em professional influenza season survey assessed vaccination status well belief regarding influenza illness vaccine effectiveness similar construct health belief model prediction vaccine uptake modeled using logistic regression result total em professional completed survey among respondent reported receiving influenza vaccination vaccination rate varied among rural suburban urban respondent p significant difference found vaccinated unvaccinated group regarding employer vaccine recommendation odds ratio p employeroffered influenza training p employeroffered vaccination p belief vaccine safety p effectiveness p respondent believed higher risk influenza risk adverse reaction outweighed prevention disease vaccine safe effective vaccination protected patient however supported mandatory vaccination vaccinated cited reason belief personal health protector influenza concern vaccine effectiveness lack employer mandate predictor vaccination included previous influenza diagnosis perceived higher risk compared general population belief vaccine effectiveness belief favorable risk benefit ratio employer vaccine recommendation age conclusion multicenter evaluation em professional influenza vaccination rate unacceptably low previous influenza infection employer vaccine recommendation perception increased risk contracting illness favorable belief vaccine effectiveness predictive vaccination acceptance emergency medical service system focus effort combating misinformation employee educational campaign well develop policy regarding immunization requirement working ill,2011,"Hubble, Michael W; Zontek, Tracy L; Richards, Michael E",Prehospital emergency care : official journal of the National Association of EMS Physicians and the National Association of State EMS Directors,,,,,,https://doi.org/10.3109/10903127.2010.541982; https://www.ncbi.nlm.nih.gov/pubmed/21226559/,20827664.0,3
21694,21694,30957,1tmyzk9y,,Medline,Biosafety of DNA vaccines: New generation of DNA vectors and current knowledge on the fate of plasmids after injection.,10.1016/j.vaccine.2010.03.040,,20371391.0,unk,dna vaccination widely studied develop new alternative efficient safe vaccine human animal many effort made increase immunising potential vaccine three veterinary vaccine available market much work also dedicated develop effective dna vaccine human however new vaccination technique raise issue concerning biosafety due nature vector ie dna molecule contains sequence prokaryotic origin eg gene antibiotic resistance review describes development new generation dna vector partially completely devoid element prokaryotic origin outline result study fate plasmid injection vivo,2010,"Faurez, Florence; Dory, Daniel; Le Moigne, Vincent; Gravier, Rodolphe; Jestin, André",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2010.03.040; https://www.ncbi.nlm.nih.gov/pubmed/20371391/,8380731.0,3
21785,21785,31062,add1k62j,,Medline,"The contribution of vaccination to global health: past, present and future.",10.1098/rstb.2013.0433,,24821919.0,unk,vaccination made enormous contribution global health two major infection smallpox rinderpest eradicated global coverage vaccination many important infectious disease childhood enhanced dramatically since creation who expanded programme immunization global alliance vaccination immunization polio almost eradicated success controlling measles make infection another potential target eradication despite success approximately million child still die year half death caused infection including pneumonia diarrhoea could prevented vaccination enhanced deployment recently developed pneumococcal conjugate rotavirus vaccine therefore result decline childhood mortality development vaccine complex infection malaria tuberculosis hiv challenging achievement far modest final success infection may require combination vaccination component stimulating different arm immune system longer term vaccine likely used prevent modulate course noninfectious disease progress already made therapeutic cancer vaccine future potential target include addiction diabetes hypertension alzheimers disease,2014,"Greenwood, Brian","Philosophical transactions of the Royal Society of London. Series B, Biological sciences",,,,,,https://doi.org/10.1098/rstb.2013.0433; https://www.ncbi.nlm.nih.gov/pubmed/24821919/,14342863.0,3
21796,21796,31074,vumj43qh,,Medline,Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine - Preliminary Report.,10.1056/nejmoa1708120,,28976850.0,unk,background although zika virus zikv infection typically selflimiting associated complication congenital birth defect guillainbarré syndrome well described approved vaccine zikv infection method phase openlabel clinical trial evaluated safety immunogenicity synthetic consensus dna vaccine gls encoding zikv premembrane envelope protein two group participant participant received either mg mg vaccine intradermally injection followed electroporation use pulsed electric field introduce dna sequence cell baseline week week result median age participant year woman white black addition hispanic interim analysis week ie third dose vaccine serious adverse event reported local reaction vaccination site eg injectionsite pain redness swelling itching occurred approximately participant third dose vaccine binding antibody measured enzymelinked immunosorbent assay detected participant geometric mean titer recipient mg mg vaccine respectively neutralizing antibody developed sample verocell assay neuronalcell assay inhibition zikv infection serum sample inhibition sample intraperitoneal injection postvaccination serum protected ifnar knockout mouse bred deletion gene encoding interferonα interferonβ receptor challenged lethal dose zikvpr strain none mouse receiving baseline serum survived challenge survival independent neutralization titer conclusion phase openlabel clinical trial dna vaccine elicited antizikv immune response study needed better evaluate safety efficacy vaccine funded geneone life science others zika clinicaltrialsgov number nct,2017,"Tebas, Pablo; Roberts, Christine C; Muthumani, Kar; Reuschel, Emma L; Kudchodkar, Sagar B; Zaidi, Faraz I; White, Scott; Khan, Amir S; Racine, Trina; Choi, Hyeree; Boyer, Jean; Park, Young K; Trottier, Sylvie; Remigio, Celine; Krieger, Diane; Spruill, Susan E; Bagarazzi, Mark; Kobinger, Gary P; Weiner, David B; Maslow, Joel N",The New England journal of medicine,,,,,,https://doi.org/10.1056/nejmoa1708120; https://www.ncbi.nlm.nih.gov/pubmed/28976850/,8888258.0,3
21817,21817,31100,nt1hhmjj,,Medline,Maternal vaccination: moving the science forward.,10.1093/humupd/dmu041,,25015234.0,unk,background infection remain one leading cause morbidity pregnant woman newborn vaccinepreventable infection contributing significantly burden disease past decade maternal vaccination emerged promising public health strategy prevent combat maternal fetal neonatal infection despite number universally recommended maternal vaccine development evaluation safe effective maternal vaccine wide acceptance hampered lack thorough understanding efficacy safety pregnant woman offspring method outline synthesized based current status major gap knowledge maternal vaccination systematic literature search pubmed undertaken using key word section title outline retrieve article relevant pregnancy article cited selected based relevance quality basis reviewed information perspective future direction maternal vaccination research formulated result maternal vaccination generate active immune protection mother elicit systemic immunoglobulin g igg mucosal igg iga igm response confer neonatal protection maternal immune system undergoes significant modulation pregnancy influence responsiveness vaccine significant gap exist knowledge efficacy safety maternal vaccine maternal vaccine large number old emerging pathogen available public acceptance maternal vaccination low conclusion tackle scientific challenge maternal vaccination provide public informed vaccination choice scientist clinician different discipline must work closely mechanistic understanding systemic reproductive mammary mucosal immune response vaccine use animal model coupled human study iterative manner maternal vaccine experimentation evaluation optimization system biology approach adopted improve speed accuracy safety maternal vaccine targeting,2015,"Faucette, Azure N; Unger, Benjamin L; Gonik, Bernard; Chen, Kang",Human reproduction update,,,,,,https://doi.org/10.1093/humupd/dmu041; https://www.ncbi.nlm.nih.gov/pubmed/25015234/,10825640.0,3
21879,21879,31173,5u77let4,,Medline,Determinants of refusal of A/H1N1 pandemic vaccination in a high risk population: a qualitative approach.,10.1371/journal.pone.0034054,,22506011.0,unk,background study analysis main determinant refusal acceptance ahn vaccine patient cystic fibrosis highrisk population severe flu infection usually compliant seasonal flu vaccine methodologyprincipal finding conducted qualitative study based semistructured interview cystic fibrosis referral centre paris france study included patient cystic fibrosis refused vaccine vaccinated two group differed quite substantially perception vaccine diseaserelated risk refused vaccine motivated mainly fear aroused explicitly consider ahn flu potentially severe disease people vaccinated explained choice first foremost intended prevent flu potential consequence respiratory cystic fibrosis disease moreover considered vaccination indirect collective prevention tool patient refused vaccine mentioned multiple contradictory information source appear consider recommendation local health care provider predominant contrary vaccinated stated based decision solely clear unequivocal advice health care provider conclusionssignificance result survey led u formulate three main recommendation improving adhesion new pandemic vaccine appears necessary reinforce patient education disease specific risk also general population information community immunity essential disseminate clear effective message safety novel vaccine message conveyed local health care provider involved implementing immunization,2012,"d'Alessandro, Eugenie; Hubert, Dominique; Launay, Odile; Bassinet, Laurence; Lortholary, Olivier; Jaffre, Yannick; Sermet-Gaudelus, Isabelle",PloS one,,,,,,https://doi.org/10.1371/journal.pone.0034054; https://www.ncbi.nlm.nih.gov/pubmed/22506011/,12840287.0,3
22355,22355,31714,rcfzvf7r,,Medline,Avian Paramyxovirus: A Brief Review.,10.1111/tbed.12355,,25924108.0,unk,avian paramyxovirus apmvs reported wide variety avian specie around world avian paramyxovirus economically significant huge mortality morbidity associated twelve different serotypes apmv reported till date avian paramyxovirus belong family paramyxoviridae genus avulavirus newcastle disease virus apmv characterized member among apmv serotypes complete genome sequence twelve apmv serotypes published recently recent year apmv attracted virologist oncolytic activity use vaccine vector animal human recombinant apmvbased vaccine offer pertinent choice construction live attenuated vaccine due minimum recombination frequency modular nature transcription lack dna phase replication although insufficient data available regarding apmv serotypes understanding apmv biology expanding rapidly availability modern molecular biology tool highthroughput complete genome sequencing,2017,"Gogoi, P; Ganar, K; Kumar, S",Transboundary and emerging diseases,,,,,,https://doi.org/10.1111/tbed.12355; https://www.ncbi.nlm.nih.gov/pubmed/25924108/,21926959.0,3
22372,22372,31736,muo33sg4,,Medline,Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.,10.1126/scitranslmed.aac5745,,26268313.0,unk,respiratory syncytial virus rsv cause respiratory infection annual epidemic infant elderly particular risk developing severe disease death however despite importance vaccine exists chimpanzee adenovirus panadrsv modified vaccinia virus ankara mvarsv replicationdefective viral vector encoding rsv fusion f nucleocapsid n matrix protein induction humoral cellular response performed openlabel dose escalation phase clinical trial healthy adult four different combination primeboost vaccination investigated safety immunogenicity including intramuscular im intranasal administration adenovirusvectored vaccine vaccine safe well tolerated common reported adverse event mild injection site reaction vaccinerelated serious adverse event occurred rsv neutralizing antibody titer rose response im prime panadrsv im boost individual primed route circulating antif immunoglobulin g igg iga antibodysecreting cell ascs observed im prime im boost rsvspecific cell response increased im panadrsv prime efficiently boosted im mvarsv interferonγ ifnγ secretion boost cd cd cell without detectable helper cell th cytokine previously associated immune pathogenesis following exposure rsv formalininactivated rsv vaccine conclusion panadrsv mvarsv safe immunogenic healthy adult vaccine candidate warrant clinical evaluation efficacy ass potential reduce burden rsv disease,2015,"Green, Christopher A; Scarselli, Elisa; Sande, Charles J; Thompson, Amber J; de Lara, Catherine M; Taylor, Kathryn S; Haworth, Kathryn; Del Sorbo, Mariarosaria; Angus, Brian; Siani, Loredana; Di Marco, Stefania; Traboni, Cinzia; Folgori, Antonella; Colloca, Stefano; Capone, Stefania; Vitelli, Alessandra; Cortese, Riccardo; Klenerman, Paul; Nicosia, Alfredo; Pollard, Andrew J",Science translational medicine,,,,,,https://doi.org/10.1126/scitranslmed.aac5745; https://www.ncbi.nlm.nih.gov/pubmed/26268313/,13759291.0,3
22394,22394,31763,anjinz3v,,Medline,Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review.,10.1080/13543776.2017.1281248,,28121202.0,unk,introduction middle east respiratory syndrome coronavirus merscov emerged new pathogen causing severe complication high case fatality rate direct treatment available yet highlighting importance prevention suitable vaccination regime viral spike protein characterized key target antigen vaccine particular protein domain utilized produce high titer neutralizing antibody area covered since first report merscov infection limited number merscovspecific patent filed patent related merscov categorized three area treatment antibody vaccine receptorrelated review mainly focus type efficacy vaccine briefly covering treatment antibody virus merscov vaccine form delivery system together comparable development strategy sarscov additionally addressed expert opinion vaccine must combined delivery system administration route adjuvant maximize tcell response well neutralizing antibody production high immune response require study animal model human receptorexpressing mouse nonhuman primate camel consideration integrated action contribute rapid development vaccine merscov related coronaviruses,2017,"Choi, Jiwon; Kim, Mi-Gyeong; Oh, Yu-Kyoung; Kim, Young Bong",Expert opinion on therapeutic patents,,,,,,https://doi.org/10.1080/13543776.2017.1281248; https://www.ncbi.nlm.nih.gov/pubmed/28121202/,24069170.0,3
22412,22412,31782,3wrmkaol,,Medline,Development of Subunit Vaccines That Provide High-Level Protection and Sterilizing Immunity against Acute Inhalational Melioidosis.,10.1128/iai.00724-17,,29109172.0,unk,burkholderia pseudomallei etiologic agent melioidosis cause severe disease human animal diagnosis treatment melioidosis challenging licensed vaccine currently exist several study shown pathogen express variety structurally conserved protective antigen include cell surface polysaccharide cellassociated cellsecreted protein based finding antigen become important component subunit vaccine candidate currently developing present study deoxyheptan capsular polysaccharide cps b pseudomallei purified chemically activated covalently linked recombinant crm diphtheria toxin mutant crm produce cpscrm additionally tandem nickelcobalt affinity chromatography used prepare highly purified recombinant b pseudomallei hcp tssm protein immunization cbl mouse cpscrm produced hightiter igg opsonizing antibody response cps component glycoconjugate immunization hcp tssm produced hightiter igg robust gamma interferonsecreting cell response protein extending upon study found mouse vaccinated combination cpscrm hcp mouse survived lethal inhalational challenge b pseudomallei remarkably survivor culturable bacteria lung liver spleen indicating vaccine formulation generated sterilizing immune response collectively study help better establish surrogate antigeninduced immunity b pseudomallei well provide valuable insight toward development safe affordable effective melioidosis vaccine,2018,"Burtnick, Mary N; Shaffer, Teresa L; Ross, Brittany N; Muruato, Laura A; Sbrana, Elena; DeShazer, David; Torres, Alfredo G; Brett, Paul J",Infection and immunity,,,,,,https://doi.org/10.1128/iai.00724-17; https://www.ncbi.nlm.nih.gov/pubmed/29109172/,4546274.0,3
22478,22478,31855,c8dxuboi,,Medline,Evaluation of a modified vaccinia virus Ankara (MVA)-based candidate pandemic influenza A/H1N1 vaccine in the ferret model.,10.1099/vir.0.024885-0,,20719991.0,unk,zoonotic transmission highly pathogenic avian influenza virus hn subtype occurred since sparked development novel influenza vaccine advent reverse genetics technology cellculture production technique novel adjuvant improved vaccine strain preparation production process immunogenicity vaccine respectively accelerated availability pandemic influenza vaccine however still room improvement alternative vaccine preparation explored viral vector modified vaccinia virus ankara mva originally developed safe smallpox vaccine exploited viral vector many favourable property recently demonstrated mvabased vaccine could protect mouse macaque infection highly pathogenic influenza virus hn subtype present study recombinant mva expressing haemagglutinin ha gene pandemic influenza ahn virus evaluated ferret model single immunization induced modest antibody response afforded modest protection development severe disease upon infection hn strain contrast two immunization induced robust antibody response protected ferret developing severe disease confirming mva attractive influenza vaccine production platform,2010,"Kreijtz, Joost H C M; Süzer, Yasemin; Bodewes, Rogier; Schwantes, Astrid; van Amerongen, Geert; Verburgh, R Joyce; de Mutsert, Gerrie; van den Brand, Judith; van Trierum, Stella E; Kuiken, Thijs; Fouchier, Ron A M; Osterhaus, Albert D M E; Sutter, Gerd; Rimmelzwaan, Guus F",The Journal of general virology,,,,,,https://doi.org/10.1099/vir.0.024885-0; https://www.ncbi.nlm.nih.gov/pubmed/20719991/,22926557.0,3
22556,22556,31950,sv38ad6k,,Medline,Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A.,10.1128/jvi.02568-07,,18256155.0,unk,human adenovirus serotype adh vector vaccine elicit strong immune response encoded antigen used various disease model designed adh vector expressing antigen control human cytomegalovirus hcmv immediateearly promoter containing intron sequence transcriptional level antigen immune response antigen vector hcmv promoter intron sequence lp greater adh vector using hcmv promoter sequence without intron sp compared eedeleted adh adenoviral vector affords space insertion foreign sequence showed immunogenic edeleted adh vector neutralizing antibody adh limit efficacy vaccine based adh serotype simian adenoviral vector offer attractive option overcome problem constructed eedeleted human simian adenoviral vector encoding preerythrocyticstage malarial antigen plasmodium berghei circumsporozoite protein compared immunogenicity efficacy adc recombinant simian adenovirus serotype vector murine malaria model adh poxviral vector mva fp adc induced sterile protection single dose mouse contrast adh poxviral vector mva fp adenoviral vector maintained potent cd tcell response longer period immunization poxviral vector mainly induced effector memory phenotype cell significantly adc able maintain protection presence preexisting immunity adh,2008,"Sridhar, S; Reyes-Sandoval, A; Draper, S J; Moore, A C; Gilbert, S C; Gao, G P; Wilson, J M; Hill, A V S",Journal of virology,,,,,,https://doi.org/10.1128/jvi.02568-07; https://www.ncbi.nlm.nih.gov/pubmed/18256155/,19220868.0,3
22659,22659,32073,zs6bg8l0,,Medline,Perspectives on vaccination in adults.,10.1586/erv.13.44,,23750790.0,unk,second conference controversy vaccination adult leading vaccine expert among manufacturer physician microbiologist virologist immunologist public health specialist came together discus recent approach development strategy vaccination worldwide pressing epidemic endemic infectious disease pneumococcal staphylococcal influenza papillomavirusassociated tumor varicellazoster aid tuberculosis noninfectious epidemic atherosclerosis smoking outlining argument surrounding progress vaccine,2013,"Doerr, Hans W",Expert review of vaccines,,,,,,https://doi.org/10.1586/erv.13.44; https://www.ncbi.nlm.nih.gov/pubmed/23750790/,207225097.0,3
22723,22723,32147,vzhlmpvh,,Medline,Impacts of poultry vaccination on viruses of wild bird.,10.1016/j.coviro.2016.06.007,,27359320.0,unk,spillover virus farmed poultry wild bird relatively new area study livestockwildlife interface transmission event threaten health wild bird growing evidence transmission vaccine virus poultry wild bird including attenuated vaccine strain newcastle disease virus infectious bronchitis virus also spread virulent virus may evolved pressure vaccine use mareks disease virus viral contaminant poultry vaccine including reticuloendotheliosis virus may also transmitted wild bird result disease new vectored vaccine le likely directly spread wild bird risk may rise result recombination,2016,"Devlin, Joanne M; Vaz, Paola K; Coppo, Mauricio Jc; Browning, Glenn F",Current opinion in virology,,,,,,https://doi.org/10.1016/j.coviro.2016.06.007; https://www.ncbi.nlm.nih.gov/pubmed/27359320/,206992394.0,3
22800,22800,32231,d4efjxtu,,Medline,Spotlight on avian pathology: infectious bronchitis virus.,10.1080/03079457.2019.1617400,,31084356.0,unk,infectious bronchitis highly infectious disease domestic chicken age type affecting respiratory renal reproductive system secondary bacterial infection common serious economic welfare impact many genotypic serotypic variant infectious bronchitis virus ibv exist worldwide making diagnosis difficult challenging control strategy vaccination requiring use liveattenuated inactivated vaccine needed control ibv infection date attempt develop vectored vaccine effective traditional vaccine unsuccessful,2019,"Sjaak de Wit, J J; Cook, Jane K A",Avian pathology : journal of the W.V.P.A,,,,,,https://doi.org/10.1080/03079457.2019.1617400; https://www.ncbi.nlm.nih.gov/pubmed/31084356/,155086980.0,3
22964,22964,32424,1bwwp2lt,,Medline,Massively parallel sequencing for monitoring genetic consistency and quality control of live viral vaccines.,10.1073/pnas.1012537107,,21041640.0,unk,intrinsic genetic instability rna virus may lead accumulation revertants manufacture live viral vaccine requiring rigorous quality control ensure vaccine safety lot oral poliovirus vaccine opv tested neurovirulence animal also presence neurovirulent revertants mutant analysis pcr restriction enzyme cleavage maprec used measure frequency neurovirulent mutation untranslated region utr viral genome correlate level neurovirulence determined monkey neurovirulence test however maprec monitor mutation genomic locus miss mutation site could adversely affect vaccine quality propose use massively parallel sequencing mp sensitive detection quantification mutation entire genome attenuated virus analysis vaccine sample reference preparation demonstrated perfect agreement maprec result quantitative mp analysis validated reference preparation tested maprec produced identical result suggesting method could take advantage existing reference material used replacement maprec procedure lot release opv pattern mutation present low level vaccine preparation characteristic seed virus used manufacture could used identification individual batch approach may represent ultimate tool monitoring genetic consistency live viral vaccine,2010,"Neverov, Alexander; Chumakov, Konstantin",Proceedings of the National Academy of Sciences of the United States of America,,,,,,https://doi.org/10.1073/pnas.1012537107; https://www.ncbi.nlm.nih.gov/pubmed/21041640/,23853439.0,3
23117,23117,32596,mh8utmtj,,Medline,"Public preferences for vaccination programmes during pandemics caused by pathogens transmitted through respiratory droplets - a discrete choice experiment in four European countries, 2013.",10.2807/1560-7917.es.2016.21.22.30247,,27277581.0,unk,study aim quantify compare preference citizen different european country vaccination programme characteristic pandemic caused pathogen transmitted respiratory droplet internet panel member nationally representative based age sex educational level region four european union member state netherlands poland spain sweden n completed online discrete choice experiment country different geographical area europe chosen availability highquality internet panel cooperation member project entitled effective communication outbreak management development evidencebased tool europe ecom data analysed using panel latent class regression model case severe pandemic scenario vaccine effectiveness important characteristic determining vaccination preference country followed body advises vaccination sweden advice family andor friend advice physician strongly affected vaccine preference contrast poland spain advice international health authority decisive irrespective pandemic scenario vaccination programme characteristic predicted vaccination uptake lowest sweden highest poland increase vaccination uptake future pandemic responsible authority align important stakeholder country communicate coordinated manner,2016,"Determann, Domino; Korfage, Ida J; Fagerlin, Angela; Steyerberg, Ewout W; Bliemer, Michiel C; Voeten, Helene A; Richardus, Jan Hendrik; Lambooij, Mattijs S; de Bekker-Grob, Esther W",Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin,,,,,,https://doi.org/10.2807/1560-7917.es.2016.21.22.30247; https://www.ncbi.nlm.nih.gov/pubmed/27277581/,36840021.0,3
23123,23123,32605,nhspn7dx,,Medline,Nucleic acid vaccination strategies against infectious diseases.,10.1517/17425247.2015.1077559,,26365499.0,unk,introduction gene vaccine interesting emerging alternative prevention infectious disease well treatment pathology including cancer allergy autoimmune disease even drug dependency applied target organism vaccine induce expression encoded antigen elicit corresponding immune response potential ability able induce antibody helper cell cytotoxic cellmediated immune response area covered special attention paid variety adjuvant may coadministered enhance andor modulate immune response method delivery finally article review efficacy data gene vaccine infectious disease released current clinical trial expert opinion taken together approach major impact future strategy prevention infectious disease betterdesigned nucleic acid construct novel delivery technology well clarification mechanism antigen presentation improve potential application vaccination strategy microbial pathogen,2015,"Marć, Małgorzata Anna; Domínguez-Álvarez, Enrique; Gamazo, Carlos",Expert opinion on drug delivery,,,,,,https://doi.org/10.1517/17425247.2015.1077559; https://www.ncbi.nlm.nih.gov/pubmed/26365499/,207490227.0,3
23195,23195,32689,clbo4o16,,Medline,Protocols for Developing Novel Chikungunya Virus DNA Vaccines.,10.1007/978-1-4939-3618-2_28,,27233283.0,unk,date several million infection chikungunya virus chikv mosquitotransmitted emerging pathogen considered taxonomically old world rna virus although original chikv outbreak restricted india east asian country northern italy france recent sharp rise identified country territory caribbean central america south america north america total suspected laboratoryconfirmed chikv case reported area signal increasing risk u mainland unlike past epidemic usually associated ae aegypti transmission caribbean outbreak associated ae albopictus transmission principal mosquito vector addition substantial increase number death epidemic well incidence neurologic disease suggests chikv may become virulent currently licensed vaccine therapeutic available chikv associated disease pathology therefore development new vaccine therapy could confer immunity andor treat clinical symptom chikv greatly desired chapter describes use entirely cutting edge technologiesmethodologies developed group development evaluation novel dna vaccine chikv,2016,"Chung, Christopher; Ugen, Kenneth E; Sardesai, Niranjan Y; Weiner, David B; Muthumani, Kar",Methods in molecular biology,,,,,,https://doi.org/10.1007/978-1-4939-3618-2_28; https://www.ncbi.nlm.nih.gov/pubmed/27233283/,206661220.0,3
23255,23255,32753,ql9jctx0,,Medline,"A recombinant adenovirus expressing CFP10, ESAT6, Ag85A and Ag85B of Mycobacterium tuberculosis elicits strong antigen-specific immune responses in mice.",10.1016/j.molimm.2014.06.007,,24980867.0,unk,tuberculosis tb caused infection mycobacterium tuberculosis mtb remains enormous increasing health burden worldwide date mycobacterium bovis bacillus calmette guerin bcg licensed antitb vaccine worldwide provides important limited protection mtb infection development alternative antitb vaccine therefore urgently needed report generation adceab recombinant adenovirus expressing mtb antigen cfp esat aga agb protein form mixture order evaluate immunogenicity adceab mouse immunized adceab intranasal instillation three time week interval result demonstrated adceab elicited strong antigenspecific immune response particularly th immune response characterized increased ratio iggaigg secretion th type cytokine ifnγ tnfα il il addition adceab also showed ability enhance humoral response dramatically augmented antigenspecific serum igg furthermore elevated siga also found bronchoalveolar lavage fluid immunized mouse suggesting elicitation mucosal immune response data indicate adceab induce broad range antigenspecific immune response vivo provides promising novel route developing antitb vaccine warrant investigation,2014,"Li, Wu; Deng, Guangcun; Li, Min; Zeng, Jin; Zhao, Liping; Liu, Xiaoming; Wang, Yujiong",Molecular immunology,,,,,,https://doi.org/10.1016/j.molimm.2014.06.007; https://www.ncbi.nlm.nih.gov/pubmed/24980867/,2359531.0,3
23623,23623,33185,0u0yf10p,,Medline,Infectious bronchitis virus poly-epitope-based vaccine protects chickens from acute infection.,10.1016/j.vaccine.2016.09.022,,27665355.0,unk,infectious bronchitis virus ibv cause major loss poultry industry safe effective vaccine control ibv spread imperative present study developed ibv glycoprotein polyepitopebased dna vaccine pvsbst consisting sh holte strain bfrestricted cell epitope australian strain dominant b cell neutralization epitope specific pathogenfree chicken vaccinated pvsbst control plasmid twice elicit strong humoral cellular immune response indicated viral neutralization titer result cd cell proliferation assay lethal dose ibv sh strain used protection challenge experiment two week postbooster immunization following challenge protection virus shedding reverse transcription quantitative pcr assay indicated pvsbst protected ibv significantly reduced viral excretion result demonstrated ibv polyepitopebased vaccine effectively prevents infection represents potential ibv vaccine,2016,"Tan, Lei; Zhang, Yuqiang; Liu, Fang; Yuan, Yanmei; Zhan, Yuan; Sun, Yingjie; Qiu, Xusheng; Meng, Chunchun; Song, Cuiping; Ding, Chan",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2016.09.022; https://www.ncbi.nlm.nih.gov/pubmed/27665355/,205602543.0,3
23715,23715,33304,fo2et69u,,Medline,Immunization of mice with Lactobacillus casei expressing a beta-intimin fragment reduces intestinal colonization by Citrobacter rodentium.,10.1128/cvi.05262-11,,21900533.0,unk,enteropathogenic escherichia coli epec common cause diarrhea child developing country intimate adhesion bacteria intestinal cell occurs via binding adhesin intimin tir receptor exposed cell surface lactobacillus casei expressing fragment βintimin l caseiintcv tested mucosal vaccine mouse intestinal colonization murine pathogen citrobacter rodentium oral sublingual immunization cbl mouse l caseiintcv induced antiintcv iga feces igg serum conversely antiintcv igg induced serum mouse sublingual immunization purified intcv vaccine able decrease c rodentium recovery feces however reduction evident sustained time mouse immunized l caseiintcv sublingual route mouse also displayed increase interleukin il gamma interferon ifnγ secretion spleen cell day infection additionally oral sublingual immunization chhepas mouse highly susceptible c rodentium infection l caseiintcv induced antiintcv antibody significantly increased survival challenge immunohistological analysis colon section revealed c rodentium located deep fraction tissue chhepas mouse immunized l casei whereas superficial staining observed colon section mouse immunized l caseiintcv result indicate vaccine composed l casei expressing intimin may represent promising approach chhepas infection model c rodentium used evaluate potential vaccine epec,2011,"Ferreira, P C D; da Silva, J B; Piazza, R M F; Eckmann, L; Ho, P L; Oliveira, M L S",Clinical and vaccine immunology : CVI,,,,,,https://doi.org/10.1128/cvi.05262-11; https://www.ncbi.nlm.nih.gov/pubmed/21900533/,206743339.0,3
23724,23724,33313,sgt6ev7b,,Medline,High-throughput sequencing and vaccine design.,10.20506/rst.35.1.2417,,27217168.0,unk,nextgeneration sequencing ng technology reshaped genome research resulting increase sequencing depth resolution led unprecedented level genomic detail thus increasing awareness complexity animal human pathogen genome resulted new approach vaccine research one hand increase genome complexity challenge ability study understand pathogen biology pathogenhost interaction hand increase genomic data also provides key information developing designing improved vaccine pathogen previously extremely difficult deal rapidly mutating rna virus bacteria complex interaction host immune system review describes broad application ng technology genome research affecting vaccine research focus implication field viral genomics includes recent animal human study,2016,"Luciani, F",Revue scientifique et technique,,,,,,https://doi.org/10.20506/rst.35.1.2417; https://www.ncbi.nlm.nih.gov/pubmed/27217168/,34094848.0,3
23781,23781,33370,ozp3nwuu,,Medline,Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus.,10.1073/pnas.1114927109,,22492964.0,unk,hepatitis c virus hcv infects ∼ world population estimated new infection annually egypt country highest hcv prevalence effective vaccine would help control expanding global health burden hcv highly variable effective vaccine target conserved bcell epitope virus conserved bcell epitope overlapping cd receptorbinding site cdbs e viral envelope glycoprotein reported previously provide promising vaccine target study isolated human mabs recognizing five distinct antigenic region virus envelope glycoprotein complex ee hcvimmune phagedisplay antibody library using exhaustivepanning strategy many mabs broadly neutralizing particular mab ara recognizing discontinuous epitope outside cdbs ee complex exceptionally broad neutralizing activity toward diverse hcv genotype protects heterologous hcv challenge small animal model mab panel useful design development vaccine candidate elicit broadly neutralizing antibody hcv,2012,"Giang, Erick; Dorner, Marcus; Prentoe, Jannick C; Dreux, Marlène; Evans, Matthew J; Bukh, Jens; Rice, Charles M; Ploss, Alexander; Burton, Dennis R; Law, Mansun",Proceedings of the National Academy of Sciences of the United States of America,,,,,,https://doi.org/10.1073/pnas.1114927109; https://www.ncbi.nlm.nih.gov/pubmed/22492964/,1867162.0,3
23984,23984,33608,z0uk7xgp,,Medline,Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines.,10.1016/j.vaccine.2009.10.059,,20188257.0,unk,use dna immunization approach deliver protective antigen yersinia pestis pestis successful previously reported study current study gene design v f two wellstudied virulent factor serving main target vaccine development altered explore additional option hope improving protective immunity dna vaccine expressing two antigen compared wild type v gene dna vaccine use codon optimized v gene sequence effective improving antigen expression titer antiv antibody response survival mucosal lethal challenge f dna vaccine removal nterminal hydrophobic region able improve protective immunity however adding mammalian signal peptide sequence f actually led reduced protection despite inducing slightly higher antif antibody response f gene fused gene coding yscf newly confirmed partial protective antigen pestis produce dna vaccine express fused f yscf antigen one design particular yscf fused downstream sequence f produced better protection separate f yscf dna vaccine suggesting potential synergistic effect two antigen finding study indicated multiple approach optimize protective immunity plague dna vaccine importantly proper antigen engineering produce optimal antigen gene insert dna vaccine clearly play major role future design wide range dna vaccine,2010,"Wang, Shixia; Mboudjeka, Innocent; Goguen, Jon D; Lu, Shan",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2009.10.059; https://www.ncbi.nlm.nih.gov/pubmed/20188257/,21150993.0,3
24243,24243,33915,11hk4ny8,,Medline,Effectiveness of pneumococcal conjugate vaccines against invasive pneumococcal disease among children under five years of age in Africa: A systematic review.,10.1371/journal.pone.0212295,,30779801.0,unk,background despite widespread implementation pneumococcal conjugate vaccine streptococcus pneumoniae remains leading cause severe pneumonia associated mortality among child le year age worldwide highest mortality rate recorded africa asia however information effectiveness prevalence vaccine serotypes postroll remains scarce african country hence systematic review aimed describe known decline childhood invasive pneumococcal disease postintroduction pneumococcal conjugate vaccine africa method systematic review included article published implementation pneumococcal conjugate vaccine africa searched pubmed scopus african index medicus article english study implementation programme pneumococcal conjugate vaccine data different african country considered eligible review followed procedure published prospero id crd result total study identified electronic database research study eligible inclusion final analysis approximately half n study south africa overall decline invasive pneumococcal disease ranged invasive pneumococcal disease caused vaccine serotypes declined significantly decline ranged much higher decline found child month age vaccine serotypes relative proportion serotypes doubled following vaccine roll interpretation following introduction pneumococcal conjugate vaccine significant decline observed invasive pneumococcal disease caused vaccine serotypes however data effectiveness region remain scarce meriting continued surveillance ass effectiveness pneumococcal vaccination improve protection invasive pneumococcal disease,2019,"Ngocho, James Samwel; Magoma, Best; Olomi, Gaudencia Alois; Mahande, Michael Johnson; Msuya, Sia Emmanueli; de Jonge, Marien Isaäk; Mmbaga, Blandina Theophil",PloS one,,,,,,https://doi.org/10.1371/journal.pone.0212295; https://www.ncbi.nlm.nih.gov/pubmed/30779801/,67858143.0,3
24458,24458,34162,k23ltuvp,,Medline,Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses.,10.1128/jvi.00558-11,,21849459.0,unk,search safe efficacious vaccine ebola virus continues current vaccine candidate nearing licensure developed replicationcompetent ii replicationdeficient iii chemically inactivated rabies virus rabv vaccine expressing zaire ebola virus zebov glycoprotein gp reverse genetics system based sad b rabv wildlife vaccine zebov gp efficiently expressed vaccine candidate incorporated virion vaccine candidate avirulent inoculation adult mouse virus deletion rabv glycoprotein greatly reduced neurovirulence intracerebral inoculation suckling mouse immunization live inactivated rabv vaccine expressing zebov gp induced humoral immunity virus conferred protection lethal rabv ebov challenge mouse bivalent rabvzebov vaccine described several distinct advantage may speed development inactivated vaccine use human potentially live inactivated vaccine use nonhuman primate risk ebov infection endemic area,2011,"Blaney, Joseph E; Wirblich, Christoph; Papaneri, Amy B; Johnson, Reed F; Myers, Carey J; Juelich, Terry L; Holbrook, Michael R; Freiberg, Alexander N; Bernbaum, John G; Jahrling, Peter B; Paragas, Jason; Schnell, Matthias J",Journal of virology,,,,,,https://doi.org/10.1128/jvi.00558-11; https://www.ncbi.nlm.nih.gov/pubmed/21849459/,25449054.0,3
24481,24481,34187,hevvc71l,,Medline,Meeting report VLPNPV: Sessions 1 and 2: Plenary.,10.4161/21645515.2014.988552,,25485812.0,unk,following highly successful inaugural meeting second installment viruslike particle nanoparticle vaccine vlpnpv proved worthy followup outstanding conference series vlpnpv forum academic industry address one major area need biomedical science development novel prophylactic therapeutic vaccine conference opened professor marianne manchester university california san diego pointed significance site chosen conference salk institute founded jonas salk salk institute biological study nonprofit independent research institute focus molecular biology genetics neuroscience plant biology diversity research theme reflects wish institute founder saw value using interdisciplinary approach understanding basic principle life aimed generating new therapy treatment human disease likewise interdisciplinarity reflected main theme meeting also highlight potential advantage viruslike particle vlp nanoparticle vaccine including novel formulationsadjuvanting effect structurally accuratedesigned antigen production system capacity tailoring immune response theme covered plenary session opened conference described report,2014,"Sainsbury, Frank",Human vaccines & immunotherapeutics,,,,,,https://doi.org/10.4161/21645515.2014.988552; https://www.ncbi.nlm.nih.gov/pubmed/25485812/,207507210.0,3
24598,24598,34331,pgn1df4r,,Medline,An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus.,10.1017/s0950268808001696,,19171081.0,unk,rift valley fever virus rvfv mosquitotransmitted bunyavirus genus phlebovirus associated severe disease livestock fatal encephalitis haemorrhagic fever proportion infected human although live attenuated inactivated vaccine used livestock limited scale human need improved antirvfv vaccine towards goal sindbis virus replicon vector expressing rvfv gn gc glycoprotein well nonstructural nsm protein constructed evaluated ability induce protective immune response rvfv replicon vector shown produce rvfv glycoprotein high level vitro induce systemic antirvfv antibody response immunized mouse determined rvfvspecific elisa fluorescent antibody test demonstration neutralizing antibody response replicon vaccination also provided protection lethal rvfv challenge either intraperitoneal intranasal route furthermore preliminary result indicate replicon vector elicit rvfvspecific neutralizing antibody response vaccinated sheep result suggest alphavirusbased replicon vector induce protective immunity rvfv approach merit investigation potential utility rvfv vaccine,2009,"Heise, M T; Whitmore, A; Thompson, J; Parsons, M; Grobbelaar, A A; Kemp, A; Paweska, J T; Madric, K; White, L J; Swanepoel, R; Burt, F J",Epidemiology and infection,,,,,,https://doi.org/10.1017/s0950268808001696; https://www.ncbi.nlm.nih.gov/pubmed/19171081/,24125551.0,3
24667,24667,34409,vy62y25a,,Medline,Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection.,10.1080/21645515.2017.1296994,,28277821.0,unk,middle east respiratory syndrome mers continues raise worldwide concern due pandemic potential increased mers case licensed mers vaccine highlight need develop safe effective vaccine mers previously demonstrated receptorbinding domain rbd fragment containing residue merscoronavirus merscov spike protein critical neutralizing domain important vaccine target nevertheless optimal immunogen dosage immunization interval key factor humanused vaccine induce protective immunity never investigated study optimized criterion using recombinant merscov rbd protein fused fc sfc utilized optimal immunization schedule evaluate protective efficacy rbd merscov infection human dipeptidyl peptidase transgenic hdpptg mouse compared one dose dos week interval regimen dos protein separated interval week induced strongest antibody response neutralizing antibody merscov infection maintained high level detection period notably rbd protein optimal dosage interval protected hdpptg mouse lethal merscov challenge protection positively correlated serum neutralizing antibody taken together optimal immunogen dosage immunization interval identified study provide useful guideline development merscov rbdbased vaccine human use,2017,"Wang, Yufei; Tai, Wanbo; Yang, Jie; Zhao, Guangyu; Sun, Shihui; Tseng, Chien-Te K; Jiang, Shibo; Zhou, Yusen; Du, Lanying; Gao, Jimin",Human vaccines & immunotherapeutics,,,,,,https://doi.org/10.1080/21645515.2017.1296994; https://www.ncbi.nlm.nih.gov/pubmed/28277821/,3910907.0,3
24845,24845,34611,u1slcrux,,Medline,Parenteral vaccination of mammalian livestock with Newcastle disease virus-based vector vaccines offers optimal efficacy and safety.,10.4161/bbug.2.1.13349,,21636990.0,unk,newcastle disease virus ndv avian virus evaluated vaccine vector delivery foreign gene mammal use ndv vaccine vector specie offer two major advantage first ndv highly attenuated mammal rendering use inherently safe second mammal lack preexisting ndv immunity minimizes risk vaccination failure ndvvector vaccine generally administered mammal via respiratory route recently showed intramuscular vaccination ndvbased rift valley fever virus rvfv vaccine provides complete protection mouse induces neutralizing antibody sheep cattle main target specie rvfv discus use ndv vaccine vector application mammalian livestock emphasis vaccination route also report result novel experiment underscore notion vaccination via parenteral route effective immunization via respiratory route,2011,"Harmsen, Michiel M; Antonis, Adriaan F G; Moormann, Rob J M; Kortekaas, Jeroen",Bioengineered bugs,,,,,,https://doi.org/10.4161/bbug.2.1.13349; https://www.ncbi.nlm.nih.gov/pubmed/21636990/,18553081.0,3
24882,24882,34653,076qek8o,,Medline,Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein.,10.1128/jvi.00087-13,,23576515.0,unk,zoonotic coronaviruses including one caused severe acute respiratory syndrome sars cause significant morbidity mortality human specific therapy human coronavirus available making vaccine development critical protection virus previously showed recombinant sars coronavirus sarscov urbani strain based lacking envelope e protein expression ruδe provided good perfect protection young mouse challenge virulent mouseadapted sarscov improve vaccine efficacy developed second set edeleted vaccine candidate background rmaδe rmaδe safe causing disease week month monthold balbc mouse immunization virus completely protected mouse three age lethal disease effected morerapid virus clearance compared ruδe rmaδe immunization resulted significantly greater neutralizing antibody sarscovspecific cd cd cell response challenge inflammatory cell infiltration edema lung destruction decreased lung rmaδeimmunized mouse compared ruδeimmunized monthold mouse collectively result show immunization speciesadapted attenuated coronavirus lacking e protein expression safe provides optimal immunogenicity longterm protection challenge lethal virus approach generally useful development vaccine protective human coronaviruses well coronaviruses cause disease domestic companion animal,2013,"Fett, Craig; DeDiego, Marta L; Regla-Nava, Jose A; Enjuanes, Luis; Perlman, Stanley",Journal of virology,,,,,,https://doi.org/10.1128/jvi.00087-13; https://www.ncbi.nlm.nih.gov/pubmed/23576515/,8038375.0,3
24902,24902,34674,b9nbo8z4,,Medline,Vaccine testing for emerging infections: the case for individual randomisation.,10.1136/medethics-2015-103220,,28396558.0,unk,ebola outbreak guinea liberia sierra leone many opposed use individually randomised controlled trial test candidate ebola vaccine raging fatal disease explained unethical relegate study participant control arm zika future emerging infection similar opposition may hinder urgent vaccine research best address question article lay ethical case individually randomised control testing vaccine many emerging infection including lethal infection lowincome country even point trial control receive countermeasure tested individual randomisation feasibleand often beit tends save life alternative design would emerging infection individual randomisation also tends improve care access experimental vaccine prospect participant relative opportunity absent trial le alternative design would obtains even placebo control without equipoiserequiring would undermine individual randomisation alternative design opponent proffered argument expound four oftenneglected factor benefit nonparticipant benefit participant trial including posttrial access study intervention participant prospect randomisation arm nearinevitable disparity arm randomised controlled trial,2017,"Eyal, Nir; Lipsitch, Marc",Journal of medical ethics,,,,,,https://doi.org/10.1136/medethics-2015-103220; https://www.ncbi.nlm.nih.gov/pubmed/28396558/,21733066.0,3
24961,24961,34745,yvfyr4og,,Medline,Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department.,10.5811/westjem.2020.3.47328,,32302280.0,unk,march th total case total death sarscov united state number case expected rise supportive care sarscov specific treatment available patient discharged emergency department ed admitted hospital addition vaccine available protect atrisk healthcare worker national institute health conducting phase clinical trial evaluate potential vaccine recipient started receive investigational vaccine present brief overview potential prophylactic treatment agent investigation could initiated ed proven effective,2020-03-31,"Brown, Cortlyn; Noble, Jeanne; Coralic, Zlatan",The western journal of emergency medicine,,,,,,https://doi.org/10.5811/westjem.2020.3.47328; https://www.ncbi.nlm.nih.gov/pubmed/32302280/,215809415.0,3
25011,25011,34800,rb1r88oq,,Medline,DNA vaccines: ready for prime time?,10.1038/nrg2432,,18781156.0,unk,since discovery decade half ago genetically engineered dna delivered vaccine form elicit immune response much progress understanding basic biology platform large amount data generated preclinical model system sustained cellular response consistent antibody response observed clinic four dna vaccine product recently approved area veterinary medicine result suggest productive future technology optimized construct better trial design improved platform brought clinic,2008,"Kutzler, Michele A; Weiner, David B",Nature reviews. Genetics,,,,,,https://doi.org/10.1038/nrg2432; https://www.ncbi.nlm.nih.gov/pubmed/18781156/,22546925.0,3
25055,25055,34848,nhwhbtgg,,Medline,Evaluation of protective efficacy of the synthetic peptide vaccine containing the T-helper 1 epitope with CpG oligodeoxynucleotide against feline infectious peritonitis virus infection in cats.,10.3851/imp2735,,24458025.0,unk,background feline infectious peritonitis fip feline coronavirusinduced fatal disease domestic wild cat cellular immunity considered play important role prevention fip thus induction cellular immune response essential vaccine fip virus fipv infection method immunized cat peptide containing thelper th epitope derived nucleocapsid n protein type fipv ku strain np np feline cpgoligodeoxynucleotides fcpgodns vaccine adjuvant result prevention type ii fipv straininduced fip slightly better specific pathogenfree cat treated np np fcpgodns however immune tolerance suggested induced high dose frequency np np fcpgodns conclusion investigation combination concentration peptide fcpgodns dose frequency route administration needed,2014,"Takano, Tomomi; Tomizawa, Keisuke; Morioka, Hiroyuki; Doki, Tomoyoshi; Hohdatsu, Tsutomu",Antiviral therapy,,,,,,https://doi.org/10.3851/imp2735; https://www.ncbi.nlm.nih.gov/pubmed/24458025/,24994257.0,3
25140,25140,34943,l56gdz3w,,Medline,Modification of the avian coronavirus infectious bronchitis virus for vaccine development.,10.4161/bbug.18983,,22179147.0,unk,infectious bronchitis virus ibv cause infectious respiratory disease domestic fowl affect poultry age causing economic problem poultry industry worldwide although ibv controlled using live attenuated inactivated vaccine continues major problem due existence many serotypes determined surface spike protein resulting poor crossprotection loss immunogenicity associated vaccine production live attenuated ibv vaccine produced repeated passage embryonated egg resulting spontaneous mutation consequence attenuated virus mutation responsible loss virulence differ vaccine affecting virulence andor immunogenicity revert virulence new generation vaccine called one mean controlling ibv involves development new safer vaccine precisely modifying ibv genome using reverse genetics production rationally attenuated ibvs order obtain optimum balance loss virulence capacity induce immunity,2012,"Britton, Paul; Armesto, Maria; Cavanagh, David; Keep, Sarah",Bioengineered bugs,,,,,,https://doi.org/10.4161/bbug.18983; https://www.ncbi.nlm.nih.gov/pubmed/22179147/,32456845.0,3
25149,25149,34954,pm9ftxv3,,Medline,Combination Attenuation Offers Strategy for Live Attenuated Coronavirus Vaccines.,10.1128/jvi.00710-18,,29976657.0,unk,ongoing threat posed circulating zoonotic strain new strategy required prepare next emergent coronavirus cov previously group targeted conserved coronavirus protein strategy generate live attenuated vaccine strain current future covs mind explored whether manipulation cov nsp conserved methyltransferase mtase could provide broad attenuation platform future emergent strain using severe acute respiratory syndromecov mouse model nsp mutant vaccine evaluated protection heterologous challenge efficacy aging host potential reversion pathogenesis despite success concern virulence aged potential reversion make targeting nsp alone untenable approach however combining mtase mutation previously described cov fidelity mutant produced vaccine strain capable protection heterologous virus challenge efficacy aged mouse evidence reversion together result indicate targeting cov mtase parallel conserved attenuating mutation may provide platform strategy rapidly generating live attenuated coronavirus vaccinesimportance emergent coronaviruses remain significant threat global public health rapid response vaccine platform needed stem future outbreak however failure many previous cov vaccine formulation clearly highlighted need test efficacy different condition especially vulnerable population aged immunocompromised study illustrates despite success young model methyltransferase mutant carry much risk pathogenesis reversion vulnerable model used standalone vaccine strategy importantly methyltransferase mutation paired attenuating approach provide robust protection heterologous challenge vulnerable population coupled increased safety reduced pathogenesis study highlight potential methyltransferase attenuation major component future live attenuated coronavirus vaccine,2018,"Menachery, Vineet D; Gralinski, Lisa E; Mitchell, Hugh D; Dinnon, Kenneth H; Leist, Sarah R; Yount, Boyd L; McAnarney, Eileen T; Graham, Rachel L; Waters, Katrina M; Baric, Ralph S",Journal of virology,,,,,,https://doi.org/10.1128/jvi.00710-18; https://www.ncbi.nlm.nih.gov/pubmed/29976657/,49712695.0,3
25228,25228,35045,53y7ilzb,,Medline,Community-acquired pneumonia.,10.1097/mcp.0000000000000150,,25775050.0,unk,purpose review communityacquired pneumonia cap common infectious disease cause death summarize recent finding regarding epidemiology cap adult efficacy vaccine streptococcus pneumoniae diagnostics discus current controversy cap healthcareassociated pneumonia hcap recent finding emergence middle east respiratory syndrome coronavirus avian influenza strain hn concern still infrequent cause cap recent data indicate vaccinating child also protects adult cap generating significant herd immunity conjugated pneumococcal vaccine adult may offer efficacy preventing cap caused vaccine serotypes immunochromotagraphic urinary antigen test improved diagnostic yield aetiology cap initial data demonstrate novel multiplex urinary antigen test increase sensitivity detection pneumoniae significant concern relatively recently described pneumonia category hcap requires empirical treatment potentially multidrugresistant organism mdro however new evidence show least europe pneumonia caused mdro remains uncommon even hcap category patient summary cap remains major cause morbidity mortality advance vaccination diagnosis help reduce amount disease due pneumoniae commonest cause cap outside united state mdro relatively uncommon cause cap increased mortality hcap category patient seems related comorbidities age rather microbial aetiology,2015,"José, Ricardo J; Periselneris, Jimstan N; Brown, Jeremy S",Current opinion in pulmonary medicine,,,,,,https://doi.org/10.1097/mcp.0000000000000150; https://www.ncbi.nlm.nih.gov/pubmed/25775050/,25708429.0,3
25311,25311,35136,c9coq5u8,,Medline,Vaccination of dogs with canine parvovirus type 2b (CPV-2b) induces neutralising antibody responses to CPV-2a and CPV-2c.,10.1016/j.vaccine.2014.07.102,,25148778.0,unk,since identification canine parvovirus type three variant subsequently observed differing historical cpv amino acid result considerable research differential diagnostics researcher indicating need new vaccine containing different strain cpv study investigated whether vaccination cpvb containing vaccine would induce crossreactive antibody response cpv variant two study dog vaccinated multivalent vaccine subsequently challenged cpvb serum sample analysed presented six week old pup defined serological status vaccinated twice three week apart challenged either week mda override study one year vaccination duration immunity study serum sample collected vaccination period throughout study study antibody profile similar serological response cpva cpvb cpvc higher cpv nevertheless response cpv well level considered clinically protective study dog also showed rapid increase antibody titre following vaccination reached plateau following second vaccination slight decline challenge rapid anamnestic response seen evaluation serological response suggests vaccination cpvb would crossprotect cpva cpvc well cpv extinct field conclusion demonstrated vaccination minimum aged dog multivalent vaccine containing cpvb variant strain induce serological response crossreactive currently circulating field strain cpva cpvc extinct field strain cpv,2014,"Wilson, Stephen; Illambas, Joanna; Siedek, Elisabeth; Stirling, Catrina; Thomas, Anne; Plevová, Edita; Sture, Gordon; Salt, Jeremy",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2014.07.102; https://www.ncbi.nlm.nih.gov/pubmed/25148778/,28701161.0,3
25563,25563,35440,8sms6p19,,Medline,Increased level of protection of respiratory tract and kidney by combining different infectious bronchitis virus vaccines against challenge with nephropathogenic Brazilian genotype subcluster 4 strains.,10.1080/03079457.2015.1058916,,26181294.0,unk,genotyping seven infectious bronchitis virus ibv strain isolated brazil showed belonged common brazilian genotype strain closest subcluster strain ibvbrazilusp pathotyping four selected brazilian strain showed caused considerable level ciliostasis trachea somewhat lower level brazilian strain representing four different serotypes reported earlier contrast challenge strain brazilian isolates replicated kidney tissue high percentage nonvaccinated challenged bird clearly showing nephropathogenic tracheal protection result using massachusetts mass vaccination recent strain seemed show protection higher average strain reported earlier single twofold vaccination mass vaccine resulted mean tracheal protection level four challenge strain respectively whereas single twofold vaccination mass vaccine halved percentage infected kidney respectively p compared unvaccinated bird combination mass b vaccine provided average tracheal protection reduction percentage infected kidney mean significantly p higher protection achieved single twofold mass vaccination showing added value b vaccination following priming vaccine mass type,2015,"De Wit, J J; Brandao, P; Torres, C A; Koopman, R; Villarreal, L Y",Avian pathology : journal of the W.V.P.A,,,,,,https://doi.org/10.1080/03079457.2015.1058916; https://www.ncbi.nlm.nih.gov/pubmed/26181294/,40049726.0,3
25572,25572,35454,1pai697v,,Medline,Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus.,10.1128/jvi.01805-10,,20980507.0,unk,newly emerging virus often circulate heterogeneous swarm wild animal reservoir prior emergence human antigenic identity often unknown outbreak situation newly emerging severe acute respiratory syndrome coronavirus sarscov reemerging influenza virus cause disproportionate disease aged also notoriously difficult successfully vaccinate likely due immunosenescence protect future emerging strain vaccine platform induce broad crossreactive immunity sufficient protect homologous heterologous challenge age initial study hypothesized attenuated venezuelan equine encephalitis virus vee replicon particle vrp vaccine glycoprotein mediated vaccine failure aged compared efficacy vaccine bearing attenuated vrp wildtype vee glycoprotein vrp young aged mouse within novel model severe sarscov pathogenesis aged animal receiving vrpbased vaccine protected sarscov disease animal receiving vrpbased vaccine superior protection aged observed vrpbased vaccine confirmed lethal influenza virus challenge model vrp vaccine immune response aged sufficient protect lethal homologous heterologous challenge data suggest innate defect within vrp platform mediate vaccine failure exploration mechanism successful vaccination immunosenescent aid development successful vaccine strategy viral disease disproportionately affecting elderly like west nile virus influenza virus norovirus emerging virus future,2011,"Sheahan, Timothy; Whitmore, Alan; Long, Kristin; Ferris, Martin; Rockx, Barry; Funkhouser, William; Donaldson, Eric; Gralinski, Lisa; Collier, Martha; Heise, Mark; Davis, Nancy; Johnston, Robert; Baric, Ralph S",Journal of virology,,,,,,https://doi.org/10.1128/jvi.01805-10; https://www.ncbi.nlm.nih.gov/pubmed/20980507/,206807291.0,3
25621,25621,35515,0mp1qqhn,,Medline,Preclinical study and clinical trial of a novel therapeutic vaccine against multi-drug resistant tuberculosis.,10.1080/21645515.2017.1264781,,27960629.0,unk,purpose multidrug resistant mdr mycobacterium tuberculosis tb big problem world developed novel tb therapeutic vaccine hvjehsp dna il dna method result dna vaccine expressing tb heat shock protein il delivered hemagglutinating virus japan hvjenvelope vaccine provided remarkable protective efficacy strong therapeutic efficacy mdrtb xdrtb murine model furthermore vaccine provided therapeutic efficacy prolongation survival time tb infected monkey augmented immune response therefore preclinical test studied clinical trial injection μg vaccine mouse im three time two week induced significantly strong production ifnγ il μg μg dna vaccinemouse im augmented production cytokine compared μg dna vaccinemouse im ratio μg pdna au hvje enhanced production ifnγ il decrease number tuberculosis liver mouse observed vaccination μg pdna using condition safety pharmacology study toxicology test studied monkey administered gmp level dna vaccine toxicology test using monkey high dose gmp level vaccine monkey administrated safety pharmacological study repeated administration also investigated glp level furthermore planned clinical phase trial target human patient mdrtb safety tolerability vaccine evaluated conclusion recommendation data indicate novel vaccine might useful tuberculosis including xdrtb mdrtb human therapeutic clinical application,2017,"Okada, Masaji; Kita, Yoko; Hashimoto, Satomi; Nakatani, Hitoshi; Nishimastu, Shiho; Kioka, Yumiko; Takami, Yasuko",Human vaccines & immunotherapeutics,,,,,,https://doi.org/10.1080/21645515.2017.1264781; https://www.ncbi.nlm.nih.gov/pubmed/27960629/,205965255.0,3
25930,25930,35873,mvkb752g,,Medline,Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.,10.1586/erv.09.19,,19397417.0,unk,development cell culture system virus propagation led major advance virus vaccine development primary diploid cell culture system replaced use continuous cell line ccls substrate gaining increasing acceptance regulatory authority improved screening technology remove fear regarding potential oncogenic property vero cell line widely accepted ccl regulatory authority used year production polio rabies virus vaccine recent licensure vero cellderived live virus vaccine acam smallpox vaccine coincided explosion development range new viral vaccine ranging liveattenuated pediatric vaccine rotavirus infection inactivated wholevirus vaccine hn pandemic influenza development illustrated value cell culture platform rapid development vaccine range virus disease,2009,"Barrett, P Noel; Mundt, Wolfgang; Kistner, Otfried; Howard, M Keith",Expert review of vaccines,,,,,,https://doi.org/10.1586/erv.09.19; https://www.ncbi.nlm.nih.gov/pubmed/19397417/,207223617.0,3
26020,26020,35978,qk6pfsdy,,Medline,Intralymphatic immunotherapy and vaccination in mice.,10.3791/51031,,24513675.0,unk,vaccine typically injected subcutaneously intramuscularly stimulation immune response success requires efficient drainage vaccine lymph node antigen presenting cell interact lymphocyte generation wanted immune response strength type immune response induced also depend density frequency interaction well microenvironment especially content cytokine minute fraction peripherally injected vaccine reach lymph node vaccination mouse human performed direct injection vaccine inguinal lymph node ie intralymphatic injection man procedure guided ultrasound mouse small mm incision made inguinal region anesthetized animal lymph node localized immobilized forceps volume μl vaccine injected visual control incision closed single stitch using surgical suture mouse vaccinated plasmid dna rna peptide protein particle bacteria well adjuvant strong improvement immune response type vaccine observed intralymphatic method vaccination especially appropriate situation conventional vaccination produce insufficient immunity amount available vaccine limited,2014,"Johansen, Pål; Kündig, Thomas M",Journal of visualized experiments : JoVE,,,,,,https://doi.org/10.3791/51031; https://www.ncbi.nlm.nih.gov/pubmed/24513675/,46000651.0,3
26151,26151,36129,7ydblzuo,,Medline,Oral delivery of microparticles containing plasmid DNA encoding hepatitis-B surface antigen.,10.3109/1061186x.2012.662686,,22339323.0,unk,role albuminbased chitosan microparticles enhancing immune response plasmid dna pdna hepatitisb surface antigen hbsag vaccine oral administration investigated mouse pdna encoding hbsag entrapped albumin microparticles using onestep spray drying technique optimized laboratory encapsulated particle also characterized vitro shape size encapsulation efficiency content stability albumin microparticles could protect dna nuclease degradation confirmed agarose gel study immune modulating effect studied formulation measuring igg antibody serum well iga antibody fecal extract mouse immunized prime dose μg pdna microparticle formulation without interleukin biweekly week followed booster dose equivalent strength week compare response subcutaneous group oral immunization pdna hbsag microparticles gave significantly higher titer level siga igg week respectively oral vaccine interleukin group compared subcutaneous group thus observed augmentation humoral cellular immune response prolonged period immunization,2012,"Bhowmik, Tuhin; D'Souza, Bernadette; Uddin, Mohammad N; D'Souza, Martin J",Journal of drug targeting,,,,,,https://doi.org/10.3109/1061186x.2012.662686; https://www.ncbi.nlm.nih.gov/pubmed/22339323/,5134739.0,3
26336,26336,36337,ywofrosl,,Medline,Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies.,10.1128/jvi.01672-13,,23986586.0,unk,middle east respiratory syndrome coronavirus merscov recently emerged causative agent severe respiratory disease human constructed recombinant modified vaccinia virus ankara mva expressing fulllength merscov spike protein mvamerss genetic stability growth characteristic mvamerss make suitable candidate vaccine clinical testing vaccinated mouse produced high level serum antibody neutralizing merscov thus mvamerss may serve development emergency vaccine merscov,2013,"Song, Fei; Fux, Robert; Provacia, Lisette B; Volz, Asisa; Eickmann, Markus; Becker, Stephan; Osterhaus, Albert D M E; Haagmans, Bart L; Sutter, Gerd",Journal of virology,,,,,,https://doi.org/10.1128/jvi.01672-13; https://www.ncbi.nlm.nih.gov/pubmed/23986586/,10150603.0,3
26377,26377,36384,abxozmze,,Medline,Haemorrhagic enteritis of turkeys - current knowledge.,10.1080/01652176.2016.1277281,,28024457.0,unk,haemorrhagic enteritis virus hev adenovirus associated acute haemorrhagic gastrointestinal disease week old turkey predominantly hamper humoral cellular immunity affected bird prone secondary complication eg colibacillosis clostridiosis failure mount effective vaccineinduced immune response hev belongs new genus siadenovirus fecooral transmission main route entry virus mainly colonizes bursa intestine spleen naturally occurring virulent avirulent strain hevs serologically indistinguishable recent finding revealed orf e fib gene key factor affecting virulence adoption suitable diagnostic tool proper vaccination biosecurity measure restrained occurrence disease epidemic diagnostic purpose best source hev either intestinal content sample spleen rapid detection highly sensitive specific test quantitative realtime pcr based taq man probe designed avirulent strain hev msdv effectively used live vaccine novel vaccine include recombinant hexon proteinbased subunit vaccine recombinant virusvectored vaccine using fowl poxvirus fpv expressing native hexon hev notably subunit vaccine recombinant virus vectored vaccine altogether offer high protection challenge field virus herein converse comprehensive analysis hev genetics disease pathobiology advancement diagnosis vaccination along appropriate prevention control strategy,2017,"Dhama, Kuldeep; Gowthaman, Vasudevan; Karthik, Kumaragurubaran; Tiwari, Ruchi; Sachan, Swati; Kumar, M Asok; Palanivelu, M; Malik, Yashpal Singh; Singh, Raj Kumar; Munir, Muhammad",The Veterinary quarterly,,,,,,https://doi.org/10.1080/01652176.2016.1277281; https://www.ncbi.nlm.nih.gov/pubmed/28024457/,20383217.0,3
26486,26486,36512,n9fb5vxf,,Medline,Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus.,10.1016/j.virusres.2015.12.019,,26739425.0,unk,background current outbreak ebola virus disease west africa caused new variant ebola virus ebov named makona whose sequence differs isolates central africa mayinga ebov specificity kinetics neutralizing antibody response induced circulating makona ebov thoroughly studied method used lentiviral ebovglycoprotein gppseudotyped infection assay measure makonagp mayingagp specific neutralizing activity plasma three convalescent ebola virus disease patient current ebov outbreak month postinfection total antiebov gp igg measured commercial elisa assay finding convalescent ebola virus disease patient makonagpspecific neutralizing titer increased month mean ic month ic month ic month ic postinfection neutralizing activity plasma three convalescent ebola virus disease patient vigorous current makonagp pseudotyped ebov variant mayingagp pseudotyped ebov difference observed time point tested mayinga v makona mean ic fold month postinfection fold month postinfection month postinfection month postinfection difference p total level igg ebovgp evolve significantly follow discussion convalescent ebola virus disease patient ebovgp specific neutralizing activity increase time least month postinfection suggests active affinity maturation antibody take place long clinical recovery ebovgp specific neutralizing response significantly higher makona ebov circulating west africa variant included currently approved vaccine correlate protection ebov vaccine completely established relevance lower neutralizing activity convalescent plasma current outbreak one ebovgps contained vaccine term potential efficacy necessarily preclude efficacy however observation highlight concern regarding natural diversity ebov subsequent challenge diagnosis therapy vaccine design ebovgp neutralizing activity varies considerably time convalescent ebola virus disease patient titering convalescent blood product would desirable standardize evaluate potential therapeutic value,2016,"Luczkowiak, Joanna; Arribas, José R; Gómez, Sara; Jiménez-Yuste, Víctor; de la Calle, Fernando; Viejo, Aurora; Delgado, Rafael",Virus research,,,,,,https://doi.org/10.1016/j.virusres.2015.12.019; https://www.ncbi.nlm.nih.gov/pubmed/26739425/,25416048.0,3
26530,26530,36562,7cfs7yfd,,Medline,Prevalence and molecular characterization of avian infectious bronchitis virus in poultry flocks in Morocco from 2010 to 2014 and first detection of Italy 02 in Africa.,10.1080/03079457.2015.1044422,,25925561.0,unk,aim study investigate prevalence diversity infectious bronchitis virus ibv genotype poultry flock area morocco total chicken flock suspected infected ibv screened ibv n gene using realtime reverse transcriptasepolymerase chain reaction rtpcr flock classified four group according ibv vaccination programme group contained unvaccinated bird group received single application live h vaccine group bird received one two booster vaccination respectively mostly using h vaccine realtime rtpcr result showed flock positive ibv genome geographical disparity molecular characterization ibv performed rtpcr positive sample partially sequencing gene including hypervariable region nucleotide two predominant genotype detected massachusetts type dominating among sample identical h vaccine second common genotype present flock surprisingly italy revealing first detection genotype morocco also africa b predominant genotype late morocco detected one occasion identical vaccine strain study highlight high prevalence ibv poultry farm morocco confirms continuous dynamic change evolution,2015,"Fellahi, Siham; Ducatez, Mariette; El Harrak, Mehdi; Guérin, Jean-Luc; Touil, Nadia; Sebbar, Ghizlane; Bouaiti, El Arbi; Khataby, Khadija; Ennaji, My Mustapha; El-Houadfi, Mohammed",Avian pathology : journal of the W.V.P.A,,,,,,https://doi.org/10.1080/03079457.2015.1044422; https://www.ncbi.nlm.nih.gov/pubmed/25925561/,36698859.0,3
26612,26612,36659,ezccibg9,,Medline,"US Civilian Smallpox Preparedness and Response Program, 2003.",10.1086/524751,,18284355.0,unk,variola virus cause smallpox disease deemed possible bioterrorism agent since november federal state local public health partner implemented activity prepare possible smallpox outbreak center disease control prevention cdc produced delivered training educational material smallpox preparedness many format developed detailed smallpox vaccine information statement vaccine contraindication vaccination site care established mechanism monitor respond adverse event smallpox vaccination last included enhancement vaccine adverse event reporting system pregnancy registry inadvertently vaccinated pregnant woman clinician telephone information line collect report adverse event civilian responder vaccination program conducted rigorous safety procedure historically recognized adverse event observed however myocarditis andor pericarditis newly recognized adverse event caused new york city board health vaccinia vaccine strain smallpox preparedness program put place number measure advance united state readiness smallpox outbreak assisted preparedness threat,2008,"Strikas, Raymond A; Neff, Linda J; Rotz, Lisa; Cono, Joanne; Knutson, Donna; Henderson, Joseph; Orenstein, Walter A",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,,,,,,https://doi.org/10.1086/524751; https://www.ncbi.nlm.nih.gov/pubmed/18284355/,39647656.0,3
26784,26784,36856,1lpdxiqt,,Medline,"Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges.",10.1586/erv.12.38,,22873127.0,unk,aim review make researcher aware benefit efficient quality control system prediction developed vaccine efficacy two major goal addressed inactivating virus vaccine purpose first infectious virus inactivated completely order safe second viral epitope important induction protective immunity conserved inactivation order antigen high quality therefore problem associated virus inactivation process virus aggregate formation protein crosslinking protein denaturation degradation addressed testing inactivated vaccine vivo,2012,"Delrue, Iris; Verzele, Dieter; Madder, Annemieke; Nauwynck, Hans J",Expert review of vaccines,,,,,,https://doi.org/10.1586/erv.12.38; https://www.ncbi.nlm.nih.gov/pubmed/22873127/,5328363.0,3
27075,27075,37192,iu8miq8n,,Medline,Suggested guidelines for vaccination of cattle in Korea.,10.7774/cevr.2015.4.2.200,,26273580.0,unk,published vaccination guideline cattle even though vaccine company suggested program based product also veterinary vaccine multivalent therefore difficult standardize program suggesting general vaccine program based current situation cattle industry korea,2015,"Cho, Yong Il; Ryu, Il-Sun; Yoo, Han Sang",Clinical and experimental vaccine research,,,,,,https://doi.org/10.7774/cevr.2015.4.2.200; https://www.ncbi.nlm.nih.gov/pubmed/26273580/,30580689.0,3
27087,27087,37204,tfui9ikx,,Medline,Immunogenicity and Protective Effect of a Virus-Like Particle Containing the SAG1 Antigen of Toxoplasma gondii as a Potential Vaccine Candidate for Toxoplasmosis.,10.3390/biomedicines8040091,,32325746.0,unk,study carried evaluate vaccination effect viruslike particle vlp including surface antigen sag toxoplasma gondii potential vaccine toxoplasmosis sag viruslike particle sagvlps expressed sf cell expression confirmed cloning rtpcr analysis western blot method immunogenicity vaccine efficacy sagvlps assessed antibody response cytokine analysis neutralization activity splenocyte assay survival rate mouse model particular igg igg igga iga markedly increased immunization survival rate gondii strongly inhibited immunized serum furthermore immunization sagvlps effectively decreased production specific cytokine ilβ il tnfα ifnγ parasite infection particular immunized group showed strong activity viability compared nonimmunized infection group survival rate result demonstrate sagvlp immunogenicity block gondii infection effectively inducing generation specific antibody gondii also effective antigen delivery system preventing toxoplasmosis study indicates sagvlp effectively utilized promising vaccine candidate preventing inhibiting gondii infection,2020-04-18,"Choi, Won Hyung; Park, Ji Sun",Biomedicines,,,,,,https://doi.org/10.3390/biomedicines8040091; https://www.ncbi.nlm.nih.gov/pubmed/32325746/,216108195.0,3
27090,27090,37211,i9n95wgn,,Medline,"Advax4 delta inulin combination adjuvant together with ECMX, a fusion construct of four protective mTB antigens, induces a potent Th1 immune response and protects mice against Mycobacterium tuberculosis infection.",10.1080/21645515.2017.1368598,,28937879.0,unk,tuberculosis tb remains main public health concern million new case occurred around world bcg approved vaccine tb variable efficacy new vaccine needed developed two new mtb vaccine candidate based recombinant fusion protein rcmx recmx formulated advax new combination adjuvant combining delta inulin cpg oligonucleotide murabutide balbc mouse immunized three time intramuscularly vaccine formulation injection advax alone increased percentage lymphatic endothelial cell activated macrophage fcdb draining lymph node consistent chemotactic adjuvant effect advaxcmx advaxecmx induced highest level igg igga antibody rcmx recmx respectively immunized mouse challenged mycobacterium tuberculosis mtb increased vaccinespecific th response lung together reduced mtb associated alveolar damage although advaxecmx vaccine demonstrated significant reduction lung bacterial load study confirmed advaxecmx potential tb vaccine candidate potential optimization clinical development,2017,"de Paula Oliveira Santos, Bruno; Trentini, Monalisa Martins; Machado, Renato Beilner; Rúbia Nunes Celes, Mara; Kipnis, André; Petrovsky, Nikolai; Junqueira-Kipnis, Ana Paula",Human vaccines & immunotherapeutics,,,,,,https://doi.org/10.1080/21645515.2017.1368598; https://www.ncbi.nlm.nih.gov/pubmed/28937879/,205965876.0,3
27152,27152,37278,n8bvxzbb,,Medline,Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage.,10.1128/jvi.01722-17,,29298885.0,unk,recent outbreak zika virus zikv emerged global health concern zikv persist human semen transmitted sexual contact well mosquito seen classical arbovirus along others previously demonstrated zikv infection lead testis damage infertility mouse model far prophylactic therapeutic available therefore vaccine development urgently demanded recombinant chimpanzee adenovirus explored preferred vaccine vector many pathogen due low preexisting immunity vector among human population developed zikv vaccine based recombinant chimpanzee adenovirus type adc expressing zikv glycoprotein single vaccination adcme sufficient elicit potent neutralizing antibody protective immunity zikv immunocompetent immunodeficient mouse moreover vaccinated mouse rapidly developed neutralizing antibody high titer within week postvaccination elicited antiserum could crossneutralize heterologous zikv strain additionally zikv especific cell response robustly induced adcme moreover onedose inoculation adcme conferred mouse sterilizing immunity eliminate viremia viral burden tissue zikv challenge investigation showed vaccination adcme completely protected zikvinduced testicular damage data demonstrate adcme highly effective represents promising vaccine candidate zikv controlimportance zika virus zikv pathogenic flavivirus cause severe clinical consequence including congenital malformation fetus guillainbarré syndrome adult vaccine development high priority zikv control study avoid preexisting antivector immunity human rare serotype chimpanzee adenovirus adc expressing zikv glycoprotein used zikv vaccine development impressively adcme exhibited exceptional performance zikv vaccine follows protective efficacy single vaccination ii rapid development robust humoral response iii durable immune response iv robust cell response v sterilizing immunity achieved single vaccination advantage adcme strongly support potential application promising zikv vaccine clinic,2018,"Xu, Kun; Song, Yufeng; Dai, Lianpan; Zhang, Yongli; Lu, Xuancheng; Xie, Yijia; Zhang, Hangjie; Cheng, Tao; Wang, Qihui; Huang, Qingrui; Bi, Yuhai; Liu, William J; Liu, Wenjun; Li, Xiangdong; Qin, Chuan; Shi, Yi; Yan, Jinghua; Zhou, Dongming; Gao, George F",Journal of virology,,,,,,https://doi.org/10.1128/jvi.01722-17; https://www.ncbi.nlm.nih.gov/pubmed/29298885/,4819024.0,3
27194,27194,37331,yubsj4rx,,Medline,Political epidemiology: strengthening socio-political analysis for mass immunisation - lessons from the smallpox and polio programmes.,10.1080/17441690701727850,,19367477.0,unk,control reduction infectious disease key attaining millennium development goal important element work successful immunisation especially resourcepoor country mass immunisation intensively case eradication depends combination reliable demand eg public willingness comply vaccine protocol effective supply eg robust generally stateled vaccine delivery balance compliance enforceability quintessentially sociopolitical nature conditioned popular perception disease risk wider condition economic development poverty technical aspect vaccine delivery prevailing international norm regarding power relation state people past year three six disease eradication programme failed explanation failure focused biotechnical managerial financial issue le attention paid sociopolitical aspect yet sociopolitical explanation key eradication neither inherently prone failure necessarily doomed case polio however eradication similar mass immunisation initiative fail address social political reality intervention may comparison smallpox polio eradication programme illustrates importance diseasespecific sociopolitical analysis programme conceptualisation design management,2009,"Taylor, S",Global public health,,,,,,https://doi.org/10.1080/17441690701727850; https://www.ncbi.nlm.nih.gov/pubmed/19367477/,33803095.0,3
27525,27525,37728,s3t7prdj,,Medline,Coronavirus infection retards the development of the cortico-medullary capillary network in the bursa of Fabricius of chicken.,10.1556/004.2018.003,,29580080.0,unk,coronavirus infection delay development corticomedullary cm capillary network result retarded development bursal follicle smaller size medulla coronavirusinfected bird may lead lower number b lymphocyte bursal secretory dendritic cell negatively affect reactivity efficacy immune system contrary wildtype infectious bronchitis virus ibv strain infection induced h vaccine virus exerts moderate influence caveolin expression cm capillary web follicular development compared untreated control,2018,"Farsang, Attila; Bódi, Ildikó; Fölker, Orsolya; Minkó, Krisztina; Benyeda, Zsófia; Bálint, Ádám; Kiss, Anna L; Oláh, Imre",Acta veterinaria Hungarica,,,,,,https://doi.org/10.1556/004.2018.003; https://www.ncbi.nlm.nih.gov/pubmed/29580080/,4403615.0,3
27558,27558,37767,1zx7p757,,Medline,An immune competent mouse model for the characterization of recombinant measles vaccines.,10.4161/hv.34358,,25483519.0,unk,today immune compromised interferonαreceptor deficient mouse expressing hcd ifnarcdtg usually used measles virus mv based vaccine characterization however development mvbased recombinant vaccine candidate rmv immune competent mouse model desirable order induce evaluate meaningful immune response study humoral cellular immune response induced rmv immune competent mouse expressing human mv receptor cd hcdtg compared induced wildtype black ifnarcdtg mouse three strain developed humoral cellular response mv whereas hcdtg ifnarcdtg mouse developed humoral response transgene difference observed magnitude response ifnarcdtg mouse displayed strongest immune response followed hcdtg mouse black mouse interestingly hcdtg wt black mouse showed predominant cd tcell response mvn whereas ifnarcdtg mouse developed cd cd tcell response mvn analysis cytokine profile mvn specific cd tcells transgene sivgag specific cd tcells revealed qualitative difference tcell response noticeably significant reduction frequency cdil expressing cell ifnarcdtg mouse compared hcdtg wt black mouse show study significant quantitative qualitative difference immune response immune competent immunecompromised mouse result therefore highlight importance animal model support use hcdtg mouse mouse model characterization immunological profile induced recombinant measles virus vaccine candidate,2015,"Marty, René R; Knuchel, Marlyse C; Morin, Teldja Neige Azzouz; Naim, Hussein Y",Human vaccines & immunotherapeutics,,,,,,https://doi.org/10.4161/hv.34358; https://www.ncbi.nlm.nih.gov/pubmed/25483519/,32566556.0,3
27694,27694,37916,kfehlr2p,,Medline,A novel method for evaluating natural and vaccine induced serological responses to Bordetella pertussis antigens.,10.1016/j.vaccine.2013.05.073,,23742995.0,unk,studied time course serum igg antibody different pertussis vaccine antigen pt pertussis toxin fha filamentous hemagglutinin prn pertactin serum individual vaccinated four different pertussis vaccine year age n respectively compared response toafter natural infection bordetella pertussis n age year longitudinal data analyzed novel method using mathematical model describe observed response variation among subject allowed u estimate biologically meaningful characteristic serum antibody response like peak level decay rate compare among natural infection vaccine response compared natural infection response pt vaccination tested vaccine smaller magnitude tend decay slightly faster present vaccine fha prn tend produce high peak level higher naturally infected patient decay faster expected dutch whole cell vaccine produced lower antibody response acellular vaccine model allows better comparison kinetics vaccine induced antibody response natural infection long follow period,2013,"Berbers, G A M; van de Wetering, M S E; van Gageldonk, P G M; Schellekens, J F P; Versteegh, F G A; Teunis, P F M",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2013.05.073; https://www.ncbi.nlm.nih.gov/pubmed/23742995/,40876333.0,3
27698,27698,37920,14lc5swq,,Medline,Vaccines for the common cold.,10.1002/14651858.cd002190.pub4,,23757114.0,unk,background common cold spontaneously remitting infection upper respiratory tract characterised runny nose nasal congestion sneezing cough malaise sore throat fever usually ˚c widespread morbidity cause worldwide related ubiquitousness rather severity development vaccine common cold difficult antigenic variability common cold virus indistinguishable multiple virus even bacteria acting infective agent uncertainty regarding efficacy safety intervention preventing common cold healthy people objective ass clinical effectiveness safety vaccine preventing common cold healthy people search method searched central issue medline january week embase january cinahl january lilac january selection criterion randomised controlled trial rcts virus vaccine prevent common cold healthy people data collection analysis two review author independently evaluated methodological quality extracted trial data disagreement resolved discussion consulting third review author main result review included one rct healthy participant analysed trial compared effect adenovirus vaccine placebo statistically significant difference common cold incidence found event participant vaccine group event participant placebo group risk ratio rr confidence interval ci p adverse event related live vaccine reported author conclusion cochrane review found lack evidence effect vaccine common cold healthy people one rct found show difference comparison group also high risk bias conclusive data support use vaccine preventing common cold healthy people identified need welldesigned adequately powered rcts investigate vaccine common cold healthy people unless rcts provide evidence treatment effect tradeoff potential benefit harm established policymakers clinician academic recommend use vaccine preventing common cold healthy people future trial medical treatment preventing common cold ass variety virus vaccine condition outcome measure include common cold incidence vaccine safety mortality related vaccine,2013,"Simancas-Racines, Daniel; Guerra, Claudia V; Hidalgo, Ricardo",The Cochrane database of systematic reviews,,,,,,https://doi.org/10.1002/14651858.cd002190.pub4; https://www.ncbi.nlm.nih.gov/pubmed/23757114/,36634030.0,3
27852,27852,38093,33y3qf20,,Medline,Comparative evaluation of two hemagglutinating encephalomyelitis coronavirus vaccine candidates in mice.,10.1128/cvi.05716-12,,22518008.0,unk,porcine hemagglutinating encephalomyelitis phe caused coronavirus hemagglutinating encephalomyelitis virus phecov recent rapid spread phecov piglet many country emphasizes urgent need phecov vaccine use murine model evaluation induction humoral cellular immune response inactivated phecov dna vaccine order define immune correlate protection phecov inactivated vaccine composed purified phecov aluminum hydroxide gel alum chosen adjuvant long history safety human use phecov dna vaccine constructed subcloning gene phecov pvax vector create recombinant plasmid pvs result showed inactivated phecov vaccine ipv elicited high level humoral immunity resulting good protection efficacy phecov challenge ipv induced igg subclass serum antibody expression cytokine interleukin il suggesting ipv generated predominantly thtype immune response dna vaccine found mediate primarily cellular immune response high level igga cytokine il gamma interferon ifnγ however mouse vaccinated twice dna vaccine boosted ipv could mount sufficient neutralizing antibody response live phecov little variation igg igga level showed high level il il response may activate b cell mount specific humoral cellular immune response could turn elicit phagocytemediated defense phecov infection achieve viral clearance,2012,"Chen, Keyan; Zhao, Kui; He, Wenqi; Gao, Wei; Zhao, Chuanbo; Wang, Li; Pan, Wei; Song, Deguang; Wang, Chengli; Gao, Feng",Clinical and vaccine immunology : CVI,,,,,,https://doi.org/10.1128/cvi.05716-12; https://www.ncbi.nlm.nih.gov/pubmed/22518008/,36529799.0,3
27860,27860,38103,gojpfsgc,,Medline,Targeting mucosal dendritic cells with microbial antigens from probiotic lactic acid bacteria.,10.1586/14760584.7.2.163,,18324887.0,unk,use vaccine infectious microbe critical advancement medicine vaccine strategy combined without adjuvant established eradicate various bacterial viral pathogen new generation vaccine developed using specific strain grampositive lactic acid bacteria notably probiotic lactobacillus bacteria safely consumed human century fermented food thus orally administered well tolerated recipient could easily economically provided large population overview focus mucosal immunity cellular component particularly dendritic cell specifically targeted deliver immunogenic subunit protective antigen bacillus anthracis causative agent anthrax antigenspecific immune response elicited using specific strain lactobacillus acidophilus expressing protective antigen mucosal dendritic celltargeted approach increase bioavailability immunogen interest delivered orally l acidophilus provides efficiently elegant natural strategy serf dual function immunestimulating adjuvant vivo,2008,"Mohamadzadeh, Mansour; Duong, Tri; Hoover, Timothy; Klaenhammer, Todd R",Expert review of vaccines,,,,,,https://doi.org/10.1586/14760584.7.2.163; https://www.ncbi.nlm.nih.gov/pubmed/18324887/,16329395.0,3
27915,27915,38164,ompzd45v,,Medline,Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.,10.1016/j.vaccine.2016.06.071,,27395563.0,unk,brighton collaboration viral vector vaccine safety working group vswg formed evaluate safety live recombinant viral vaccine incorporating gene heterologous viral microbial pathogen genome socalled chimeric virus vaccine many viral vector vaccine various stage clinical evaluation introduce attenuated form recombinant vesicular stomatitis virus rvsv potential chimeric virus vaccine hiv implication use vaccine vector pathogen rvsvhiv vaccine vector attenuated combining two major genome modification modification acted synergistically greatly enhance vector attenuation resulting rvsv vector demonstrated safety sensitive mouse nonhuman primate neurovirulence model vector expressing hiv gag protein completed evaluation two phase clinical trial one trial rvsvhiv vector administered homologous twodose regimen second trial pdna heterologous prime boost regimen serious adverse event reported vector detected blood urine saliva post vaccination either trial gag specific immune response induced trial highest frequency cell response detected prime boost regimen rvsvhiv vector also demonstrated safety ongoing phase trial hiv positive participant additionally clinical trial material produced rvsv vector expressing hiv env phase clinical evaluation initiate beginning paper use standardized template describing key characteristic novel rvsv vaccine vector comparison wild type vsv template facilitates scientific discourse among key stakeholder increasing transparency comparability information brighton collaboration vswg template may also useful guide evaluation recombinant viral vector vaccine,2016,"Clarke, David K; Hendry, R Michael; Singh, Vidisha; Rose, John K; Seligman, Stephen J; Klug, Bettina; Kochhar, Sonali; Mac, Lisa Marie; Carbery, Baevin; Chen, Robert T",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2016.06.071; https://www.ncbi.nlm.nih.gov/pubmed/27395563/,4826304.0,3
28079,28079,38356,9ptflz1f,,Medline,Specificities of broadly neutralizing anti-HIV-1 sera.,10.1097/coh.0b013e32832e06fe,,20048699.0,unk,purpose review effective vaccineelicited immunity hiv infection likely require broadly neutralizing antibody interrupt fusionpromoting function viral envelope glycoprotein spike effort area however fraught challenge handful existing broadly neutralizing monoclonal antibody provided information virus site vulnerability fueling decade structureinformed vaccine design fact bnmabs recovered date illustrates poor immunogenicity epitope recognizing progress may require basic information notable shift field toward identifying new chink hiv armor effort based observation infected patient develop exceptionally broad serum neutralizing antibody response better understanding would valuable vaccine effort aimed eliciting similar specificity recent finding new mapping methodology providing appreciation incidence specificity similar existing known bnmabs well intriguing insight novel specificity summary new information emerging mapping effort help sharpen effort isolate new bnmabs moreover may provide crucial information rational design novel vaccine candidate,2009,"Binley, James",Current opinion in HIV and AIDS,,,,,,https://doi.org/10.1097/coh.0b013e32832e06fe; https://www.ncbi.nlm.nih.gov/pubmed/20048699/,205565018.0,3
28155,28155,38448,i6vfr6um,,Medline,Rinderpest eradication: appropriate technology and social innovations.,10.1126/science.1223805,,22984063.0,unk,rinderpest second infectious disease globally eradicated final stage eradication virus entrenched pastoral area greater horn africa region weak governance poor security little infrastructure presented profound challenge conventional control method although eradication process development activity rather scientific research success owed much several seminal research effort vaccine development epidemiology showed scientific decisionmaking management could accomplish limited resource key success development thermostable vaccine application participatory epidemiological technique allowed veterinary personnel interact grassroots level cattle herder effectively target control measure,2012,"Mariner, Jeffrey C; House, James A; Mebus, Charles A; Sollod, Albert E; Chibeu, Dickens; Jones, Bryony A; Roeder, Peter L; Admassu, Berhanu; van 't Klooster, Gijs G M",Science,,,,,,https://doi.org/10.1126/science.1223805; https://www.ncbi.nlm.nih.gov/pubmed/22984063/,2380187.0,3
28201,28201,38502,rctryi22,,Medline,Vaccines for the common cold.,10.1002/14651858.cd002190.pub5,,28516442.0,unk,background common cold spontaneously remitting infection upper respiratory tract characterised runny nose nasal congestion sneezing cough malaise sore throat fever usually º c widespread morbidity caused common cold worldwide related ubiquitousness rather severity development vaccine common cold difficult antigenic variability common cold virus indistinguishable multiple virus even bacteria acting infective agent uncertainty regarding efficacy safety intervention preventing common cold healthy people update cochrane review first published previously updated objective ass clinical effectiveness safety vaccine preventing common cold healthy people search method searched cochrane central register controlled trial central september medline september embase september cinahl september lilac september also searched three trial register ongoing study four website additional trial february included language date restriction selection criterion randomised controlled trial rcts virus vaccine compared placebo prevent common cold healthy people data collection analysis two review author independently evaluated methodological quality extracted trial data resolved disagreement discussion consulting third review author main result found additional rcts inclusion update review includes one rct dating overall high risk bias rct included healthy participant included analysis trial compared effect adenovirus vaccine placebo statistically significant difference common cold incidence found event participant vaccine group event participant placebo group risk ratio confidence interval p adverse event related live vaccine reported quality evidence low due limitation methodological quality wide confidence interval author conclusion cochrane review based one study lowquality evidence found conclusive result support use vaccine preventing common cold healthy people compared placebo identified need welldesigned adequately powered rcts investigate vaccine common cold healthy people future trial medical treatment preventing common cold ass variety virus vaccine condition outcome measure include common cold incidence vaccine safety mortality related vaccine,2017,"Simancas-Racines, Daniel; Franco, Juan Va; Guerra, Claudia V; Felix, Maria L; Hidalgo, Ricardo; Martinez-Zapata, Maria José",The Cochrane database of systematic reviews,,,,,,https://doi.org/10.1002/14651858.cd002190.pub5; https://www.ncbi.nlm.nih.gov/pubmed/28516442/,205166271.0,3
28313,28313,38638,sfgp6gnr,,Medline,Porcine GPX1 enhances GP5-based DNA vaccination against porcine reproductive and respiratory syndrome virus.,10.1016/j.vetimm.2016.12.001,,28063474.0,unk,porcine reproductive respiratory syndrome virus prrsv causing huge economic loss swine industry worldwide commercial prrsv vaccine including killed modified live one available however protective efficacy vaccine incomplete thus urgent need develop safer effective prrsv vaccine study constructed recombinant plasmid coexpressing porcine glutathione peroxidase gpx envelope glycoprotein gp encodinggene prrsv pcdnagpxlsynorf investigated immune response induced following inoculation mouse piglet significantly enhanced gpspecific antibody prrsvspecific neutralizing antibody ifnγ level well lymphocyte proliferation response induced mouse pig immunized dna construct encoding gpx gp compared inoculated construct encoding prrsv gp pcdnasynorf enhanced cellular immune response pig induced pcdnagpxlsynorf comparable induced attenuated virus vaccine jxar although humoral immune response induced plasmid much lower response induced jxar following challenge highly pathogenic prrsv lesssevere clinical sign rectal temperature observed pig immunized gpxgp construct compared control group however viraemia group immunized plasmid severe inoculated jxar likely could attributed poor humoral response induced gpxgp construct result demonstrated inclusion gpx prrsv dna vaccine lead adjuvant effect enhancing humoral cellular response following vaccination,2017,"Du, Luping; Li, Bin; Pang, Fengjiao; Yu, Zhengyu; Xu, Xiangwei; Fan, Baochao; Tan, Yeping; He, Kongwang; Huang, Kehe",Veterinary immunology and immunopathology,,,,,,https://doi.org/10.1016/j.vetimm.2016.12.001; https://www.ncbi.nlm.nih.gov/pubmed/28063474/,22807843.0,3
28459,28459,38804,s0zfa1jl,,Medline,Mucosal Lactobacillus vectored vaccines.,10.4161/hv.23302,,23322214.0,unk,traditional nongastrointestinal vaccine prevent effectively invasion pathogen however vaccine le effective mucosal infection sufficient immune response mucosa pathogen invade via mucosal pathway oral intranasal vaginal widely accepted lactobacillus specie play critical role commensal gastrointestinal gi tract ability survive digestive tract close association intestinal epithelium immunomodulatory property safety even consumed large amount make lactobacillus attractive candidate live vehicle delivery immunogen intestinal mucosa oral intranasal administration lactobacillusbased vaccine promising method control mucosal infection vaccine could induce strong humoral cellular immune response blood mucosal site,2013,"Yu, Qinghua; Zhu, Liqi; Kang, Haihong; Yang, Qian",Human vaccines & immunotherapeutics,,,,,,https://doi.org/10.4161/hv.23302; https://www.ncbi.nlm.nih.gov/pubmed/23322214/,5214150.0,3
28460,28460,38805,4dpgcyby,,Medline,Recombinant Newcastle disease virus-vectored vaccines against human and animal infectious diseases.,10.2217/fmb.15.59,,26234909.0,unk,recent advance recombinant genetic engineering technique brought forward leap designing new vaccine modern medicine one attractive strategy application reverse genetics technology make recombinant newcastle disease virus rndv deliver protective antigen pathogen recent year numerous study demonstrated rndvvectored vaccine induce quicker better humoral mucosal immune response conventional vaccine protective pathogen challenge deeper understanding ndv molecular biology feasible develop genemodified rndv vaccine accompanied good safety high efficacy low toxicity better immunogenicity review summarizes development reverse genetics technology using ndv promising vaccine vector design new vaccine human animal use,2015,"Duan, Zhiqiang; Xu, Houqiang; Ji, Xinqin; Zhao, Jiafu",Future microbiology,,,,,,https://doi.org/10.2217/fmb.15.59; https://www.ncbi.nlm.nih.gov/pubmed/26234909/,5514120.0,3
28572,28572,38936,eg4ukye8,,Medline,Genetic manipulation of porcine epidemic diarrhoea virus recovered from a full-length infectious cDNA clone.,10.1099/vir.0.000184,,25979733.0,unk,porcine epidemic diarrhoea virus pedv cause acute diarrhoea dehydration swine age significant mortality neonatal pig recent rise pedv outbreak asia north america warrant urgent search effective vaccine however pedv vaccine research hampered difficulty isolating propagating virus mammalian cell thereby complicating recovery infectious pedv using fulllength infectious clone engineered veroe cell stably express porcine aminopeptidase n papn used platform obtain highgrowth variant pedv termed pedvavct subsequently fulllength cdna clone constructed assembling contiguous cdna fragment encompassing complete genome pedvavct bacterial artificial chromosome infectious pedv could recovered rescued virus displayed phenotypic property identical parental virus interestingly found pedvavct contained cterminal deletion spike gene resulting disruption orf start codon functional orf gene restored recombinant virus could rescued suggesting orf could suppress pedv replication vitro addition highgrowth genetically stable recombinant pedv expressing foreign protein could rescued replacing orf gene mcherry gene together result study provide mean generate genetically defined pedv promising vaccine candidate,2015,"Jengarn, Juggragarn; Wongthida, Phonphimon; Wanasen, Nanchaya; Frantz, Phanramphoei Namprachan; Wanitchang, Asawin; Jongkaewwattana, Anan",The Journal of general virology,,,,,,https://doi.org/10.1099/vir.0.000184; https://www.ncbi.nlm.nih.gov/pubmed/25979733/,20770171.0,3
28580,28580,38946,w3c9u8fn,,Medline,Severe acute respiratory syndrome vaccine efficacy in ferrets: whole killed virus and adenovirus-vectored vaccines.,10.1099/vir.0.2008/001891-0,,18753223.0,unk,although severe acute respiratory syndrome sars outbreak controlled repeated transmission sars coronavirus cov several year make development sars vaccine desirable performed comparative evaluation two sars vaccine ability protect live sarscov intranasal challenge ferret whole killed sarscov vaccine without alum adenovirusbased vector encoding nucleocapsid n spike protein induced neutralizing antibody response reduced viral replication shedding upper respiratory tract progression virus lower respiratory tract vaccine also diminished haemorrhage thymus reduced severity extent pneumonia damage lung epithelium however despite high neutralizing antibody titre protection incomplete vaccine preparation administration route data suggest combination vaccine strategy may required effective protection pathogen ferret may good model sarscov infection model replicates fever seen human patient well replicating sars disease feature including infection respiratory route clinical sign viral replication upper lower respiratory tract lung damage,2008,"See, Raymond H; Petric, Martin; Lawrence, David J; Mok, Catherine P Y; Rowe, Thomas; Zitzow, Lois A; Karunakaran, Karuna P; Voss, Thomas G; Brunham, Robert C; Gauldie, Jack; Finlay, B Brett; Roper, Rachel L",The Journal of general virology,,,,,,https://doi.org/10.1099/vir.0.2008/001891-0; https://www.ncbi.nlm.nih.gov/pubmed/18753223/,7980238.0,3
28898,28898,39309,bwvtqgj7,,Medline,China's growing biomedical industry.,10.1016/j.biologicals.2009.02.010,,19427231.0,unk,biomedical industry china developing rapidly new biological drug increasing share pharmaceutical market based people need china largest producer user vaccine world existing production vaccine far enough meet need market entire market biological drug china still smaller traditional medicine chemical therefore biopharmaceutical industry potential rising star pharmaceutical market future,2009,"Han, Pei",Biologicals : journal of the International Association of Biological Standardization,,,,,,https://doi.org/10.1016/j.biologicals.2009.02.010; https://www.ncbi.nlm.nih.gov/pubmed/19427231/,3395851.0,3
28944,28944,39360,tninupmq,,Medline,Virus-mimetic polymer nanoparticles displaying hemagglutinin as an adjuvant-free influenza vaccine.,10.1016/j.biomaterials.2018.08.036,,30176403.0,unk,generation virusmimetic nanoparticles received much attention developing new vaccine overcoming limitation current vaccine thus method encompassing viral feature size hydrophobic domain antigen display would represent meaningful direction vaccine development present study polymertemplated protein nanoball direction oriented hemagglutinin surface hnb prepared new influenza vaccine exhibiting viral feature moreover concentration antigen particle surface controlled effect immunogenicity estimated vivo study finally hnb efficiently promoted hspecific immune activation crossprotective activity consequently prevented hn infection mouse,2018,"Lee, Chaeyeon; Jeong, Jonghwa; Lee, Taeheon; Zhang, Wei; Xu, Li; Choi, Ji Eun; Park, Ji Hyun; Song, Jae Kwang; Jang, Sinae; Eom, Chi-Yong; Shim, KyuHwan; Seong Soo, A An; Kang, Young-Sun; Kwak, Minseok; Jeon, Hyeong Jin; Go, Jeung Sang; Suh, Yung Doug; Jin, Jun-O; Paik, Hyun-Jong",Biomaterials,,,,,,https://doi.org/10.1016/j.biomaterials.2018.08.036; https://www.ncbi.nlm.nih.gov/pubmed/30176403/,52169762.0,3
28995,28995,39415,785zdhrr,,Medline,The role of antibodies in HIV vaccines.,10.1146/annurev-immunol-030409-101256,,20192810.0,unk,licensed vaccine viral disease generate antibody neutralize infecting virus protect infection disease similarly effective vaccine hiv likely need induce antibody prevent initial infection host cell limit early event viral dissemination antibody must target surface envelope glycoprotein hiv highly variable sequence structure first subunit vaccine enter clinical trail safe immunogenic unable elicit antibody neutralized circulating strain hiv however potent virus neutralizing antibody nabs develop course hiv infection type antibody response researcher seek generate vaccine thus current vaccine design effort focused detailed understanding broadly neutralizing antibody epitope inform design improved vaccine,2010,"Mascola, John R; Montefiori, David C",Annual review of immunology,,,,,,https://doi.org/10.1146/annurev-immunol-030409-101256; https://www.ncbi.nlm.nih.gov/pubmed/20192810/,7373030.0,3
29408,29408,39882,00zs3vp9,,Medline,"Assessing the functionality of viral entry-associated domains of porcine reproductive and respiratory syndrome virus during inactivation procedures, a potential tool to optimize inactivated vaccines.",10.1051/vetres/2009047,,19674538.0,unk,porcine reproductive respiratory syndrome virus prrsv cause severe economic loss pig industry worldwide currently vaccine based inactivated prrsv provide limited protection pig infection likely viral epitope associated induction neutralizing antibody poorly conserved inactivation analyze effect inactivation procedure interaction prrsv receptor involved virus entry new assay set study viral entryassociated domain likely important induction neutralizing antibody since neutralizing antibody block interaction prrsv cellular receptor investigate interaction prrsv cellular receptor upon different inactivation procedure attachment internalization inactivated prrsv macrophage monitored could inactivate prrsv completely therefore useful vaccine development prrsv inactivated ultraviolet light binary ethyleneimine gamma irradiation mainly effect genomic level showed difference compared control live virus level virus entry whereas prrsv treated formaldehyde glutaraldehyde ph change modifying effect protein able internalize macrophage anymore result suggest inactivation method main effect viral genome preserve prrsv entryassociated domain useful future development effective inactivated vaccine prrsv although prrsv incubation degree c completely inactivate prrsv preservation entryassociated domain method recommended vaccine development since mechanism yet unknown,2009,"Delrue, Iris; Delputte, Peter L; Nauwynck, Hans J",Veterinary research,,,,,,https://doi.org/10.1051/vetres/2009047; https://www.ncbi.nlm.nih.gov/pubmed/19674538/,14831985.0,3
29474,29474,39955,6iysezqa,,Medline,Kidney Cell-Adapted Infectious Bronchitis Virus Arkansas Delmarva Poultry Industry Vaccine Confers Effective Protection Against Challenge.,10.1637/11291-093015-reg,,27309281.0,unk,previously demonstrated adaptation embryoattenuated infectious bronchitis virus ibv arkansas delmarva poultry industry arkdpiderived vaccine chicken embryo kidney cek cell shifted virus population towards homogeneity spike nonstructural protein gene moreover typical ark vaccine subpopulation emerging chicken vaccinated commercial ark vaccine detected chicken vaccinated cekadapted virus study chicken vaccinated low dose × eidbird eid embryo infectious dose cekadapted ark vaccine day age showed significant reduction ibv rna lachrymal fluid decreased incidence ibv rna detection tracheal swab day challenge compared unvaccinated challenged chicken second experiment dayold chicken vaccinated eidchicken cekadapted ark vaccine protection compared chicken vaccinated eidchicken commercial arkdpiderived vaccine cekadapted virus originated vaccinated chicken group showed significant reduction respiratory sign viral load day ark virulent challenge compared unvaccinated challenged control viral subpopulation different challenge virus detected chicken vaccinated cekark challenge contrast ibv sequence differing predominant population challenge virus detected several chicken vaccinated commercial ark attenuated vaccine applied perspective cekadapted ibv arkdpiderived vaccine improved effective vaccine candidate protect chicken virulent arktype strain,2016,"Ghetas, A M; van Santen, V L; Joiner, K; Toro, H",Avian diseases,,,,,,https://doi.org/10.1637/11291-093015-reg; https://www.ncbi.nlm.nih.gov/pubmed/27309281/,37724848.0,3
29535,29535,40022,kowan19e,,Medline,Recombinant Ag85B vaccine by taking advantage of characteristics of human parainfluenza type 2 virus vector showed Mycobacteria-specific immune responses by intranasal immunization.,10.1016/j.vaccine.2013.11.108,,24486310.0,unk,viral vector promising vaccine candidate eliciting suitable agspecific immune response since mycobacterium tuberculosis mtb normally enters host via mucosal surface lung best defense mtb mucosal vaccine capable inducing systemic mucosal immunity although mycobacterium bovis bacille calmetteguérin licensed tuberculosis tb vaccine efficacy adult pulmonary form tb variable study assessed effectiveness novel mucosal tb vaccine using recombinant human parainfluenza type virus rhpiv vaccine vector balbc mouse replicationincompetent rhpiv geneeliminated expressing agb rhpivagb constructed reverse genetics technology intranasal administration rhpivagb induced mtbspecific immune response vaccinated mouse showed substantial reduction number cfu mtb lung spleen unlike viral vaccine vector immune response agb induced rhpivagb immunization advantage viral vector addition revealed rhpivagb adjuvant activity retinoic acidinducible gene receptor finding provide evidence possibility rhpivagb novel tb vaccine,2014,"Watanabe, Kenta; Matsubara, Akihiro; Kawano, Mitsuo; Mizuno, Satoru; Okamura, Tomotaka; Tsujimura, Yusuke; Inada, Hiroyasu; Nosaka, Tetsuya; Matsuo, Kazuhiro; Yasutomi, Yasuhiro",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2013.11.108; https://www.ncbi.nlm.nih.gov/pubmed/24486310/,31988453.0,3
29546,29546,40037,umnso91b,,Medline,Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein.,10.1128/jvi.00614-15,,26018172.0,unk,middle east respiratory syndrome coronavirus merscov cause severe respiratory disease human tested recombinant modified vaccinia virus ankara mva vaccine expressing fulllength merscov spike glycoprotein immunizing balbc mouse either intramuscular subcutaneous regimen case mvamerss induced merscovspecific cd cell virusneutralizing antibody vaccinated mouse protected merscov challenge infection transduction human dipeptidyl peptidase receptor merscov infection model demonstrates safety efficacy candidate vaccine,2015,"Volz, Asisa; Kupke, Alexandra; Song, Fei; Jany, Sylvia; Fux, Robert; Shams-Eldin, Hosam; Schmidt, Jörg; Becker, Christin; Eickmann, Markus; Becker, Stephan; Sutter, Gerd",Journal of virology,,,,,,https://doi.org/10.1128/jvi.00614-15; https://www.ncbi.nlm.nih.gov/pubmed/26018172/,39391349.0,3
29566,29566,40060,53gqe9i5,,Medline,Surface plasmon resonance for vaccine design and efficacy studies: recent applications and future trends.,10.1586/erv.10.52,,20518719.0,unk,lack clear correlation design protection continues present barrier progress vaccine research article outline surface plasmon resonance spr biosensors emerging tool help resolve key biophysical determinant protection thereby facilitate rational vaccine design campaign spr technology contributed significantly understanding complex biophysical determinant hiv neutralization offer platform preclinical evaluation vaccine candidate particular concept reverseengineering hiv vaccine target based known broadly neutralizing antibody modality explored extended include infectious disease malaria influenza disease cancer analytical capacity afforded spr includes serum screening monitor immune response highly efficient qualitycontrol surveillance measure discussed alongside key technological advance development sample throughput perspective predicting continued growth diversification role spr vaccine development proposed,2010,"Hearty, Stephen; Conroy, Paul J; Ayyar, B Vijayalakshmi; Byrne, Barry; O'Kennedy, Richard",Expert review of vaccines,,,,,,https://doi.org/10.1586/erv.10.52; https://www.ncbi.nlm.nih.gov/pubmed/20518719/,24747056.0,3
29708,29708,40225,hwl3da9m,,Medline,Isolation of an infectious endogenous retrovirus in a proportion of live attenuated vaccines for pets.,10.1128/jvi.02715-09,,20106919.0,unk,genome animal specie colonized endogenous retrovirus ervs although ervs accumulated defect render incapable replication fully infectious ervs identified various mammal study isolated feline infectious erv rd proportion live attenuated vaccine pet isolation rd made two independent laboratory using different detection strategy using vaccine cat dog commercially available japan united kingdom study show method currently employed screen veterinary vaccine retrovirus reevaluated,2010,"Miyazawa, Takayuki; Yoshikawa, Rokusuke; Golder, Matthew; Okada, Masaya; Stewart, Hazel; Palmarini, Massimo",Journal of virology,,,,,,https://doi.org/10.1128/jvi.02715-09; https://www.ncbi.nlm.nih.gov/pubmed/20106919/,6967926.0,3
29744,29744,40270,qs308pne,,Medline,Engineering attenuated virus vaccines by controlling replication fidelity.,10.1038/nm1726,,18246077.0,unk,longlasting protection viral infection best achieved vaccination attenuated virus obtaining stably attenuated vaccine strain traditionally empirical process greatly restricts number effective vaccine viral disease describe rational approach engineering stably attenuated virus serve safe effective vaccine approach exploit observation restricting viral population diversity increasing replication fidelity greatly reduces viral tissue tropism pathogenicity show poliovirus variant reduced genetic diversity elicit protective immune response animal model infection indeed novel vaccine candidate comparable efficacy currently available sabin type vaccine strain added advantage stable increased replication fidelity prevents reversion pathogenic wildtype phenotype propose restricting viral quasispecies diversity provides general approach rational design stable attenuated vaccine wide variety virus,2008,"Vignuzzi, Marco; Wendt, Emily; Andino, Raul",Nature medicine,,,,,,https://doi.org/10.1038/nm1726; https://www.ncbi.nlm.nih.gov/pubmed/18246077/,5519284.0,3
29934,29934,40497,tpk877r7,,Medline,Topical Administration Is a Promising Inoculating Route versus Intramuscular Inoculation for the Nanoparticle-Carried DNA Vaccine to Prevent Corneal Infections.,10.1159/000441898,,26650397.0,unk,purpose evaluate comparative effect topical versus intramuscular administration nanoparticlecarried dna vaccine preventing corneal herpes simplex virus type hsv infection method nanoparticle polyethylenimine peifeocarried dna vaccine peifeoprscgdil dna vaccine prscgdil alone topically versus intramuscularly inoculated one eye mouse day three week final immunization specific immune response clinical degree primary herpes simplex keratitis evaluated result topical inoculation nanoparticlecarried dna vaccine induced mouse generate similar level specific hsvneutralizing antibody ifnγ il serum specific killing cytotoxicity proliferative activity splenic lymphocyte significantly higher level secretory iga tear compared intramuscular inoculation importantly mouse inoculated topically showed significantly decreased herpes simplex keratitis severity mouse inoculated intramuscularly hsv challenge cornea mouse conclusion topical inoculation nanoparticlecarried dna vaccine elicits stronger specific local immune response effectively inhibits herpes simplex keratitis compared intramuscular inoculation hsv ocular challenge mouse model thus topical administration may promising inoculating route nanoparticlecarried dna vaccine prevent corneal infection,2015,"Hu, Kai; Malla, Tejsu; Zhai, Yujia; Dong, Lili; Tang, Ru",Ophthalmic research,,,,,,https://doi.org/10.1159/000441898; https://www.ncbi.nlm.nih.gov/pubmed/26650397/,22362450.0,3
30029,30029,40603,h95aelxy,,Medline,Bovine herpesvirus-1: evaluation of genetic diversity of subtypes derived from field strains of varied clinical syndromes and their relationship to vaccine strains.,10.1016/j.vaccine.2014.11.033,,25454086.0,unk,bovine herpesvirus bohv cause significant disease cattle control program north america incorporate vaccination modified live viral mlv killed kv vaccine bohv strain isolated diseased animal fetus vaccination marker differentiating mlv field strain using wholegenome sequencing analysis identifying single nucleotide polymorphism snp using multiple primer set sequencing product permit association bohv isolates vaccine determine association vaccine virus strain isolated clinical case following vaccination analyzed bohv isolates animal various clinical syndrome corresponded bohv respiratory group remaining three corresponded bohvb typically found genital tract cattle four bohv isolates identical vaccine strain three postvaccination abortion episode typical herpetic lesion whose dam received mlv vaccine pregnancy one heifer given related mlv vaccine sequence two respiratory isolates perfectly matched mutation characterizing rlb strain temperature sensitive mutant used intranasal parenteral vaccine last three respiratory strain clearly appeared related group mlv vaccine previously mlv vaccine grouped four group based snp pattern contrast abovementioned isolates closely matched snp pattern respective mlv vaccine virus strain lacked possessed number additional mutation compared group mlv vaccine viral genome finding bohvb respiratory case indicates focus given bohvb emerging virus virus recognized fully characterized brd,2015,"Fulton, R W; d'Offay, J M; Eberle, R; Moeller, R B; Campen, H Van; O'Toole, D; Chase, C; Miller, M M; Sprowls, R; Nydam, D V",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2014.11.033; https://www.ncbi.nlm.nih.gov/pubmed/25454086/,25569100.0,3
30228,30228,40825,laai8ohw,,Medline,"Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice.",10.1128/jvi.01570-14,,24920815.0,unk,unlabelled human norovirus infection common cause viral gastroenteritis worldwide development effective vaccine required reducing norovirus outbreak inability grow human norovirus cell culture hindered development liveattenuated vaccine overcome obstacle generated recombinant newcastle disease virus rndvvectored experimental norovirus vaccine expressing capsid protein vp norovirus strain va compared two different ndv vector conventional rndv vector modified rndv vector efficiency expressing vp protein result showed modified vector replicated higher titer expressed higher level vp protein df cell allantoic fluid embryonated chicken egg conventional vector demonstrated vp protein produced rndvs able selfassemble viruslike particle vlps morphologically similar baculovirusexpressed vlps evaluation immunogenicity mouse showed modified rndv vector induced higher level igg response induced conventional vector baculovirusexpressed vlps rndv vector predominantly induced igga subclass antibody th response specifically high level gamma interferon ifnγ tumor necrosis factor alpha tnfα interleukin il detected splenocytes addition modified rndv vector induced higher level fecal iga response mouse baculovirusexpressed vlps finding suggest rndv vector efficient system produce costeffective vlps embryonated chicken egg potential used liveattenuated vaccine human importance noroviruses major cause viral gastroenteritis worldwide currently effective vaccine norovirus infection available study evaluated newcastle disease virus ndv vaccine vector norovirus result suggest ndv used costeffective method largescale production noroviruslike particle vaccine also liveattenuated vectored vaccine,2014,"Kim, Shin-Hee; Chen, Shun; Jiang, Xi; Green, Kim Y; Samal, Siba K",Journal of virology,,,,,,https://doi.org/10.1128/jvi.01570-14; https://www.ncbi.nlm.nih.gov/pubmed/24920815/,2015396.0,3
30439,30439,41063,whyon8go,,Medline,Development of next-generation respiratory virus vaccines through targeted modifications to viral immunomodulatory genes.,10.1586/14760584.2015.1095096,,26434947.0,unk,vaccine represent one greatest contribution scientific community global health yet many pathogen remain either unchallenged inadequately hindered commercially available vaccine respiratory virus pose distinct difficult challenge due ability rapidly spread adapt modify host immune response considerable research directed understand role respiratory virus immunomodulatory protein influence host immune response review effort develop nextgeneration vaccine targeting key immunomodulatory gene influenza virus coronaviruses respiratory syncytial virus measles virus mumps virus,2015,"Stobart, Christopher C; Moore, Martin L",Expert review of vaccines,,,,,,https://doi.org/10.1586/14760584.2015.1095096; https://www.ncbi.nlm.nih.gov/pubmed/26434947/,207196090.0,3
30615,30615,41276,edrd55e1,,Medline,Effects of chicken anaemia virus and infectious bursal disease virus-induced immunodeficiency on infectious bronchitis virus replication and genotypic drift.,10.1080/03079457.2012.702889,,22897690.0,unk,followed change portion gene sequence dominant population infectious bronchitis virus ibv arkansas ark vaccine strain serial passage chicken infected immunosuppressive chicken anaemia virus cav andor infectious bursal disease virus ibdv well immunocompetent chicken ibvark vaccine applied ocularly tear collected infected chicken subsequent ocular inoculation later passage experiment performed twice experiment dominant genotype vaccine strain rapidly negatively selected chicken group cav ibdv cavibdv immunocompetent based genotype ibv subpopulation previously reported immunocompetent chicken named component c c emerged immunocompetent immunodeficient chicken first passage different subpopulation emerged followed establishment one two predominant population passage subpopulation designated c became established either cavinfected ibdvinfected chicken ibv maintained four passage result indicate selection cease immunodeficient chicken phenotype c may show distinct adaptation environment subpopulation c c initially became established immunocompetent bird became extinct succeeding passage similar result observed chicken coinfected cavibdv result suggest generation genetic diversity ibv constrained finding constitutes evidence phenotypic drift occurring mainly result selection,2012,"Gallardo, Rodrigo A; van Santen, Vicky L; Toro, Haroldo",Avian pathology : journal of the W.V.P.A,,,,,,https://doi.org/10.1080/03079457.2012.702889; https://www.ncbi.nlm.nih.gov/pubmed/22897690/,205547166.0,3
30692,30692,41361,jruddvbl,,Medline,Chloroplasts as expression platforms for plant-produced vaccines.,10.1586/erv.10.78,,20673012.0,unk,production recombinant subunit vaccine gene incorporated plastid genome advantageous attainable expression level due high transgene copy number absence gene silencing biocontainment consequence maternal inheritance plastid transgene presence pollen expression multiple transgene prokaryoticlike operon discus core technology plastid transformation chlamydomonas reinhardtii unicellular alga nicotiana tabacum tobacco flowering plant specie demonstrate utility technology production recombinant vaccine antigen,2010,"Cardi, Teodoro; Lenzi, Paolo; Maliga, Pal",Expert review of vaccines,,,,,,https://doi.org/10.1586/erv.10.78; https://www.ncbi.nlm.nih.gov/pubmed/20673012/,31127944.0,3
30784,30784,41473,3ghmyuq4,,Medline,Heat shock protein 70 enhances mucosal immunity against human norovirus when coexpressed from a vesicular stomatitis virus vector.,10.1128/jvi.00019-14,,24574391.0,unk,unlabelled human norovirus nov account nonbacterial gastroenteritis worldwide currently vaccine available combat human nov cultivable lack smallanimal model recently demonstrated recombinant vesicular stomatitis virus rvsv expressing human nov capsid protein rvsvvp induced strong immunity mouse j li j virol improve safety efficacy vaccine candidate heat shock protein hsp inserted rvsvvp backbone vector second construct generated firefly luciferase luc gene inserted place hsp control double insertion resultant recombinant virus rvsvhspvp rvsvlucvp significantly attenuated cell culture viral spread mouse rvsvvp inoculation dose × pfu rvsvhspvp triggered significantly higher vaginal iga rvsvvp significantly higher fecal vaginal iga response rvsvlucvp although serum igg cell response similar inoculation dose × pfu rvsvhspvp stimulated significantly higher cell fecal vaginal iga response rvsvvp fecal vaginal iga response also significantly increased combined vaccination rvsvvp rvsvhsp used collectively data indicate insertion additional gene hsp luc rvsvvp backbone attenuates vsvbased vaccine vitro vivo thus improving safety vaccine candidate ii hsp enhances human novspecific mucosal cell immunity triggered vsvbased human nov vaccine importance human norovirus nov responsible acute nonbacterial gastroenteritis worldwide currently vaccine virus development live attenuated vaccine human nov possible uncultivable thus live vectorbased vaccine may provide alternative vaccine strategy study developed vesicular stomatitis virus vsvbased human nov vaccine candidate constructed rvsvhspvp coexpressing heat shock protein hsp capsid vp gene human nov rvsvlucvp coexpressing firefly luciferase luc vp gene found vsvs double gene insertion significantly attenuated vsv single vp insertion rvsvvp furthermore found coexpression coadministration hsp vsv vector significantly enhanced human novspecific mucosal immunity collectively developed improved live vectored vaccine candidate human nov useful future clinical study,2014,"Ma, Yuanmei; Duan, Yue; Wei, Yongwei; Liang, Xueya; Niewiesk, Stefan; Oglesbee, Michael; Li, Jianrong",Journal of virology,,,,,,https://doi.org/10.1128/jvi.00019-14; https://www.ncbi.nlm.nih.gov/pubmed/24574391/,6144989.0,3
31119,31119,41853,f48cdufd,,Medline,Controlled viral glycoprotein expression as a safety feature in a bivalent rabies-ebola vaccine.,10.1016/j.virusres.2014.11.028,,25481284.0,unk,using recombinant rabies rabv vaccine platform developed several safe effective vaccine recently developed rabvbased ebolavirus ebov vaccine efficacious nonhuman primate one safety feature vaccine utilization live replicationdeficient rabv construct construct rabv glycoprotein g deleted genome requiring g trans complementation order new infectious virus released initial infected cell analyze safety feature bivalent rabvbased ebov vaccine comprised gdeleted rabv backbone expressing ebov glycoprotein gp found level rabv genome infected cell equivalent regardless g supplementation production infectious virus indeed restricted lack g importantly presence ebov gp substitute g finding support safety profile replicationdeficient rabvebov bivalent vaccine,2015,"Papaneri, Amy B; Bernbaum, John G; Blaney, Joseph E; Jahrling, Peter B; Schnell, Matthias J; Johnson, Reed F",Virus research,,,,,,https://doi.org/10.1016/j.virusres.2014.11.028; https://www.ncbi.nlm.nih.gov/pubmed/25481284/,205659888.0,3
31242,31242,41995,vduqpb1z,,Medline,Congenital cytomegalovirus infection.,10.1111/j.1749-6632.2010.05649.x,,20840266.0,unk,congenital cytomegalovirus cmv infection serious health problem obstacle limiting infection lack public awareness issue especially owing asymptomatic nature cmv infection inefficacy therapy unsuccessful vaccine trial date therefore important organize current data estimate result report development vaccine cmv must highest priority,2010,"Syggelou, Angeliki; Iacovidou, N; Kloudas, S; Christoni, Z; Papaevangelou, V",Annals of the New York Academy of Sciences,,,,,,https://doi.org/10.1111/j.1749-6632.2010.05649.x; https://www.ncbi.nlm.nih.gov/pubmed/20840266/,31029475.0,3
31290,31290,42053,n6gyy15f,,Medline,Cross-Protection by Infectious Bronchitis Viruses Under Controlled Experimental Conditions.,10.1637/11231-070615-reg.1,,26629628.0,unk,infectious bronchitis virus ibv crossprotection trial performed healthy chicken maintained controlled environmental condition chicken primed primed boosted massachusetts masstype attenuated vaccine subsequently challenged either ibv arkansas ark gatype virulent strain addition arkvaccinated chicken challenged ibv ga spike protein amino acid identity ibv vaccine challenge strain varied contrary expectation assessment clinical sign viral load histopathology indicated significant level crossprotection among antigenically distant ibv strain moreover prime booster vaccination mass protected ga improved protection ark compared mass single vaccination result emphasize need include single vaccination control group control group primed boosted single serotype testing efficacy ibv protectotypes andor novel ibv vaccine combination heterologous serotypes controlled experimental condition control distinct importance experiment supporting introduction attenuated ibv vaccine strain exotic region since exotic strain may provide new genetic material recombination emergence novel ibv strain,2015,"Toro, H; van Santen, V L; Ghetas, A M; Joiner, K S",Avian diseases,,,,,,https://doi.org/10.1637/11231-070615-reg.1; https://www.ncbi.nlm.nih.gov/pubmed/26629628/,22084916.0,3
31462,31462,42260,hivpamvs,,Medline,DNA vaccines for targeting bacterial infections.,10.1586/erv.10.57,,20624048.0,unk,dna vaccination great interest since discovery due ability elicit humoral cellular immune response dna vaccine consist dna plasmid containing transgene encodes sequence target protein pathogen control eukaryotic promoter revolutionary technology proven effective animal model four dna vaccine product recently approved veterinary use although dna vaccine bacterial infection tested result encouraging versatility safety simplicity wider range organism targeted vaccine show potential advantage public health article describes mechanism action dna vaccine potential use targeting bacterial infection addition provides updated summary method used enhance immunogenicity codon optimization adjuvant delivery technique including electroporation use nanoparticles,2010,"Ingolotti, Mariana; Kawalekar, Omkar; Shedlock, Devon J; Muthumani, Karuppiah; Weiner, David B",Expert review of vaccines,,,,,,https://doi.org/10.1586/erv.10.57; https://www.ncbi.nlm.nih.gov/pubmed/20624048/,37192194.0,3
31649,31649,42477,jpe8pk5k,,Medline,Human serum amyloid P functions as a negative regulator of the innate and adaptive immune responses to DNA vaccines.,10.4049/jimmunol.1003641,,21278351.0,unk,utility dna vaccine limited failure elicit sufficiently potent immune response many human application whereas dna vaccination mouse successful however underlying mechanism remain unknown hypothesize serum amyloid p component sap speciesspecific dnabinding ability contributes difference human mouse limit dna vaccine efficacy vivo study dna vaccineinduced adaptive immune response also significantly decreased human sap hsap transgenic mouse using human promonocytic cell line thpderived macrophage cell model found cell incubated hsapdna complex showed significant defect innate immune activation whereas mouse sap similar albeit weak activity hsap also significantly inhibited function two identified dna sentinel highmobility group b protein antimicrobial peptide redirected dna update fcrs leading endocytosis endosomal degradation also found chemical sap inhibitor strongly recovered suppressed innate immune response dna presence human serum enhanced immunogenicity dna vaccine vivo data indicated sap key negative regulator innate immune response dna may partly responsible insufficient immune response dna vaccination human sap suppression may novel strategy improving efficacy human dna vaccine requires clinical investigation,2011,"Wang, Yue; Guo, Yingjun; Wang, Xiaohui; Huang, Jinfeng; Shang, Jingli; Sun, Shuhan",Journal of immunology,,,,,,https://doi.org/10.4049/jimmunol.1003641; https://www.ncbi.nlm.nih.gov/pubmed/21278351/,1151558.0,3
31685,31685,42519,87tepjzs,,Medline,Prevention of Infectious Diseases due to Immunosuppression and Vaccinations in Asian Patients with Inflammatory Bowel Disease.,10.1159/000489643,,30505836.0,unk,background inflammatory bowel disease ibd patient immunocompromise high risk developing complication related viral infection western country first formulate vaccine guideline asian country developed national international vaccine guideline little later order reduce risk mortality viral infection however study date examined difference vaccination prevail among asian country summary review summarizes vaccination status schedule various asian country immunocompromised ibd patient vaccination rate regardless specific vaccine high japan south korea china low india philippine vaccine schedule differed country outbreak measles rubella seen due low vaccination rate southeast asia south asia live vaccine administered immunosuppressive treatment infection measles mumps varicella immunosuppressive therapy carry high risk mortality thus confirmation immunization status recommended soon ibd diagnosed possible live vaccine administered initiation immunosuppressive treatment patient seronegative hepatitis b administration hepatitis b vaccine also recommended key message physician considering severity outbreak understand difference vaccination status exist among various asian country region,2018,"Sagami, Shintaro; Kobayashi, Taku; Hibi, Toshifumi",Inflammatory intestinal diseases,,,,,,https://doi.org/10.1159/000489643; https://www.ncbi.nlm.nih.gov/pubmed/30505836/,54624998.0,3
31696,31696,42532,2cnwel07,,Medline,Putative suppressing effect of IgG Fc-conjugated haemagglutinin (HA) stalk of influenza virus H7N9 on the neutralizing immunogenicity of Fc-conjugated HA head: implication for rational design of HA-based influenza vaccines.,10.1099/jgv.0.000365,,26653217.0,unk,emergence influenza hn infection posed great threat public health globally poor immunogenicity hn haemagglutinin ha major obstacle development effective hn vaccine found vaccine containing hha head conjugated igg fc hdfc induced strong neutralizing antibody response protection hn infection whilst fcconjugated hha stalk stfcbased vaccine could induce neutralizing antibody although stfcimmunized mouse partially protected vaccine containing fulllength extracellular domain ha conjugated fc mixture hdfc plus stfc induced significantly lower neutralizing antibody haemagglutination inhibition titre hdfcbased vaccine result suggest stfc may inhibitory effect neutralizing immunogenicity hdfc therefore neutralizing domain receptorbinding domain ha head kept nonneutralizing domain ha stalk ability potentially suppress neutralizing immunogenicity ha head removed fcconjugated habased influenza vaccine increase neutralizing antibody response,2016,"He, B; Xia, S; Yu, F; Fu, Y; Li, W; Wang, Q; Lu, L; Jiang, S",The Journal of general virology,,,,,,https://doi.org/10.1099/jgv.0.000365; https://www.ncbi.nlm.nih.gov/pubmed/26653217/,43159176.0,3
31699,31699,42537,avdj4kqn,,Medline,Antibody-mediated protection against Ebola virus.,10.1038/s41590-018-0233-9,,30333617.0,unk,recent ebola virus disease epidemic highlighted need effective vaccine therapeutic prevent future outbreak antibody clearly critical control deadly disease however specific mechanism action protective antibody yet defined perspective discus antibody feature correlate vivo protection infection ebola virus based result systematic comprehensive study antibody directed virus although neutralization activity mediated fab domain antibody strongly correlated protection recruitment immune effector function fc domain also emerged complementary sometimes alternative route protection subset antibody fcmediated clearance killing infected cell seems main driver protection exposure mirror observation vaccination study continued analysis antibody achieve protection partially wholly fcmediated function precise function required intersection specificity importance function different animal model needed identify begin capitalize fcmediated protection vaccine therapeutic alike,2018,"Saphire, Erica Ollmann; Schendel, Sharon L; Gunn, Bronwyn M; Milligan, Jacob C; Alter, Galit",Nature immunology,,,,,,https://doi.org/10.1038/s41590-018-0233-9; https://www.ncbi.nlm.nih.gov/pubmed/30333617/,53011827.0,3
31933,31933,42814,dshatfok,,Medline,"One-Health: a Safe, Efficient, Dual-Use Vaccine for Humans and Animals against Middle East Respiratory Syndrome Coronavirus and Rabies Virus.",10.1128/jvi.02040-16,,27807241.0,unk,middle east respiratory syndrome coronavirus merscov emerged highly pathogenic respiratory virus treatment option merscov human animal largescale clinical trial therapy merscov address need developed inactivated rabies virus rabv contains merscov spike protein expressed surface initial recombinant vaccine bnsps express fulllength wildtype merscov protein however showed significantly reduced viral titer compared parental rabv strain lowlevel incorporation fulllength merscov rabv particle therefore developed rabvmers vector contained merscov domain merscov protein fused rabv g protein c terminus bnsps bnsps grew titer similar parental vaccine vector bnsp rabv gmerscov fusion protein efficiently expressed incorporated rabv particle vaccinated mouse chemically inactivated bnsps induced hightiter neutralizing antibody next challenged vaccinated mouse control mouse merscov adenovirus transduction human dipeptidyl peptidase hdpp receptor analyzed ability mouse control merscov infection result demonstrated vaccinated mouse fully protected merscov challenge indicated significantly lower merscov titer merscov mrna level challenged mouse unvaccinated control data establish inactivated rabvmers sbased vaccine may effective use animal human area merscov endemic importance rabies virusbased vector proven efficient dual vaccine rabies emergent infectious disease ebola virus show inactivated rabies virus particle containing merscov protein induce potent immune response merscov rabv novel vaccine easy produce may useful protect target animal camel well human deadly merscov rabv infection result indicate vaccine approach prevent disease rabvbased vaccine platform may valuable tool timely vaccine development emerging infectious disease,2017,"Wirblich, Christoph; Coleman, Christopher M; Kurup, Drishya; Abraham, Tara S; Bernbaum, John G; Jahrling, Peter B; Hensley, Lisa E; Johnson, Reed F; Frieman, Matthew B; Schnell, Matthias J",Journal of virology,,,,,,https://doi.org/10.1128/jvi.02040-16; https://www.ncbi.nlm.nih.gov/pubmed/27807241/,26457515.0,3
32014,32014,42904,zqafcwcu,,Medline,"Assuring the quality, safety, and efficacy of DNA vaccines.",10.1385/1-59259-688-6:499,,21374344.0,unk,scientist academia whose research aimed development novel vaccine approach vaccination may always fully aware regulatory process candidate vaccine becomes licensed product chapter provide overview regulatory process discus detail quality preclinical safety issue plasmid dna vaccine intended human use useful research scientist aware process development novel vaccine could problematic due starting material often developed research laboratory illdefined condition,2000,"Robertson, J S; Griffiths, E",Methods in molecular medicine,,,,,,https://doi.org/10.1385/1-59259-688-6:499; https://www.ncbi.nlm.nih.gov/pubmed/21374344/,22084923.0,3
32072,32072,42971,s95vzw47,,Medline,Innovative bioinformatic approaches for developing peptide-based vaccines against hypervariable viruses.,10.1038/icb.2010.65,,20458336.0,unk,application field pharmacogenomics pharmacogenetics vaccine design recently labeled vaccinomics newly named area vaccine research heavily intertwined bioinformatics seems leading charge developing novel vaccine currently unmet medical need hypervariable virus human immunodeficiency virus hiv hepatitis c emerging avian swine influenza recent bioinformatic approach area vaccine research include use epitope determination prediction algorithm exploring use peptide epitope vaccine immunogen paper briefly discus explores current us bioinformatics vaccine design toward pursuit peptide vaccine hypervariable virus various informatics vaccine design strategy attempted group toward hypervariable virus also briefly examined along strategy used group design synthesis peptide immunogen candidate hiv influenza vaccine,2011,"Sirskyj, Danylo; Diaz-Mitoma, Francisco; Golshani, Ashkan; Kumar, Ashok; Azizi, Ali",Immunology and cell biology,,,,,,https://doi.org/10.1038/icb.2010.65; https://www.ncbi.nlm.nih.gov/pubmed/20458336/,205150554.0,3
32202,32202,43120,iyak8jsj,,Medline,Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.,10.1128/cvi.05663-11,,22956656.0,unk,avian influenza virus cause outbreak domestic wild bird around world sporadic human infection reported dna vaccine encoding hemagglutinin ha protein aindonesia hn strain initially tested two randomized phase clinical study vaccine research center study vrc doubleblinded study subject randomized placebo mg vaccine mg vaccine treatment group n group intramuscular im biojector injection vrc openlabel study evaluate route subject randomized intradermal id injection mg needlesyringe biojector mg delivered two mg biojector injection deltoid mg deltoid n group injection administered week study antibody response h assessed hemagglutination inhibition hai assay enzymelinked immunosorbent assay elisa neutralization assay h cell response assessed enzymelinked immunospot intracellular cytokine staining assay vaccinerelated serious adverse event vaccine well tolerated group mg id vaccination compared im vaccination induced greater frequency magnitude response elisa significant difference frequency magnitude response id im route hai neutralization assay cell response common subject received mg dose im study demonstrated dna vaccine encoding h safe immunogenic served define proper dose route study id injection route offer significant advantage im route difference detected delivery one site versus splitting dose two site id vaccine administration mg dose im investigated primeboost regimen,2012,"Ledgerwood, J E; Hu, Z; Gordon, I J; Yamshchikov, G; Enama, M E; Plummer, S; Bailer, R; Pearce, M B; Tumpey, T M; Koup, R A; Mascola, J R; Nabel, G J; Graham, B S",Clinical and vaccine immunology : CVI,,,,,,https://doi.org/10.1128/cvi.05663-11; https://www.ncbi.nlm.nih.gov/pubmed/22956656/,206743730.0,3
32229,32229,43152,laj0vs53,,Medline,How well do vaccines for Bordetella bronchiseptica work in dogs? A critical review of the literature 1977-2014.,10.1016/j.tvjl.2015.02.006,,25747699.0,unk,bordetella bronchiseptica bb long causally associated respiratory disease dog parenteral intranasal vaccine pathogen common use since development late early recently commercial oral bb vaccine become available overall literature comprising experimental infection model field study document efficacy vaccine stimulating diseasesparing mucosal systemic immune response associated reduced growth bb vivo however many published study limited flaw experimental design notably failure consider biological statistical implication pen effect many question related longevity vaccine induced immunity bb impact natural exposure herd immunity remain unanswered,2015,"Ellis, John A",Veterinary journal,,,,,,https://doi.org/10.1016/j.tvjl.2015.02.006; https://www.ncbi.nlm.nih.gov/pubmed/25747699/,205516580.0,3
32331,32331,43268,9xh51cd1,,Medline,Optimizing Anti-Viral Vaccine Responses: Input from a Non-Specialist.,10.3390/antibiotics9050255,,32429032.0,unk,recently research community realworld look reason improving vaccine response emerging rna virus vaccine nonspecialist suggests might done propose two alternative option compare primary alternative option current practice basis comparison feasibility achieving need safe massproduced emerging virustargeted vaccine week notice primary option following start platform based live virus infect bacteria human bacteriophage phage isolate phage called pathogen homologs resemble provide antigenic context membranecovered pathogenic rna virus coronavirusphage homologs probably found search correctly done upon isolating viral pathogen evolve phage homolog bind antibody neutralizing viral pathogen vaccinate evolved phage homolog generating local nonhazardous infection phage host curing infection propagating phage artificially infecting bacterial host discus alternative option potential provide needed appropriate platform built,2020-05-15,"Serwer, Philip",Antibiotics,,,,,,https://doi.org/10.3390/antibiotics9050255; https://www.ncbi.nlm.nih.gov/pubmed/32429032/,218759802.0,3
32468,32468,43434,77mw0dws,,Medline,Defining Protective Epitopes for COVID-19 Vaccination Models.,10.1002/jmv.25876,,32285942.0,unk,recent paper journal provide tangible avenue covid vaccine production immunoreactive epitope brought forefront many emerging study development consistent predictable animal model covid infection evidently also welcome event preliminary antiviral vaccine assessment surely brings u another level progression article protected copyright right reserved,2020-04-14,"Cimolai, Nevio",Journal of medical virology,,,,,,https://doi.org/10.1002/jmv.25876; https://www.ncbi.nlm.nih.gov/pubmed/32285942/,215757377.0,3
32510,32510,43485,k9wyqnph,,Medline,A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in rhesus monkeys against all four serotypes of dengue virus.,10.1128/jvi.02724-07,,18480438.0,unk,nearly third human population risk infection four serotypes dengue virus estimated million infection occur year licensed vaccine dengue virus become global health priority major challenge developing dengue vaccine necessity produce fairly uniform protective immune response four dengue virus serotypes developed two bivalent dengue virus vaccine using complex adenovirus vector incorporating gene expressing premembrane prm envelope e protein dengue virus type dengue respectively cadvaxden dengue cadvaxden rhesus macaque vaccinated intramuscular inoculation tetravalent dengue vaccine formulated combining two bivalent vaccine construct vaccinated animal produced hightiter antibody neutralized four serotypes dengue virus vitro ability vaccine induce rapid well sustained protective immune response examined two separate livevirus challenge administered week final vaccination virus challenge study significant protection viremia demonstrated four dengue virus serotypes vaccinated animal viremia dengue dengue challenge completely blocked whereas viremia dengue dengue significantly reduced well delayed compared controlvaccinated animal result demonstrate tetravalent dengue vaccine formulation provides significant protection rhesus macaque challenge four dengue virus serotypes,2008,"Raviprakash, Kanakatte; Wang, Danher; Ewing, Dan; Holman, David H; Block, Karla; Woraratanadharm, Jan; Chen, Lan; Hayes, Curtis; Dong, John Y; Porter, Kevin",Journal of virology,,,,,,https://doi.org/10.1128/jvi.02724-07; https://www.ncbi.nlm.nih.gov/pubmed/18480438/,41824166.0,3
32533,32533,43511,i4e7z0hg,,Medline,Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies.,10.1073/pnas.1415310111,,25453106.0,unk,use neutralizing antibody identify effective antigen proposed strategy design vaccine capable eliciting protective bcell immunity study analyzed human antibody response cytomegalovirus human cytomegalovirus hcmv infection found antibody glycoprotein gb surface glycoprotein developed hcmv vaccine primarily nonneutralizing contrast antibody complex formed gh gl protein pul pul pul ghglpull pentamer neutralized hcmv infection high potency based analysis developed single polycistronic vector encoding five pentamer gene separated selfcleaving peptide generate stably transfected cho cell line constitutively secreting high level recombinant pentamer displayed functional antigenic site targeted human neutralizing antibody immunization mouse pentamer formulated different adjuvant elicited hcmv neutralizing antibody titer persisted high level time hundred thousandfold higher found individual recovered primary hcmv infection serum mouse immunized pentamer vaccine neutralized infection epithelial cell fibroblast prevented celltocell spread viral dissemination endothelial cell leukocyte neutralizing monoclonal antibody immunized mouse showed potency human antibody targeted well additional site pentamer result illustrate relevant example general practical approach analytic vaccinology development subunit vaccine complex pathogen,2014,"Kabanova, Anna; Perez, Laurent; Lilleri, Daniele; Marcandalli, Jessica; Agatic, Gloria; Becattini, Simone; Preite, Silvia; Fuschillo, Dario; Percivalle, Elena; Sallusto, Federica; Gerna, Giuseppe; Corti, Davide; Lanzavecchia, Antonio",Proceedings of the National Academy of Sciences of the United States of America,,,,,,https://doi.org/10.1073/pnas.1415310111; https://www.ncbi.nlm.nih.gov/pubmed/25453106/,20684765.0,3
32598,32598,43587,hf4hxf9u,,Medline,"Noscapine, a possible drug candidate for attenuation of cytokine release associated with SARS-CoV-2.",10.1002/ddr.21676,,32337769.0,unk,successful treatment viral infection proven huge challenge modern medicine effective approach prior vaccination problem vaccination time take develop effective vaccine validate safety manufacture large quantity facing severe acute respiratory syndrome coronavirus sarscov simply time develop vaccine thousand people die therefore treatment decrease severe symptom due lung damage may help attenuate mortality rate inactivation ace virus fusion host cell may one underlying reason intense immunological reaction seen lung tissue overreaction probably mediated bradykinin receptor activation noscapine medication used treatment cough shown inhibit bradykinin enhanced cough response man already marketed number country cough medicine even child suitable formulation required license available rapidly utilized preliminary trial,2020-04-26,"Ebrahimi, Soltan A",Drug development research,,,,,,https://doi.org/10.1002/ddr.21676; https://www.ncbi.nlm.nih.gov/pubmed/32337769/,216556995.0,3
32833,32833,43861,t250v8bq,,Medline,Current understanding of middle east respiratory syndrome coronavirus infection in human and animal models.,10.21037/jtd.2018.03.80,,30116605.0,unk,middle east respiratory syndrome mers highly lethal respiratory disease caused novel betacoronavirus mers coronavirus merscov since first emergence multiple transmission event merscov dromedary human human human reported indicating merscov potential cause widespread outbreak however epidemiology mers well immune response virus animal model patient still well understood hindering vaccine therapeutic development review summarize recent genetic epidemic finding merscov progress animal model development immune response study animal human last discussed breakthrough vaccine therapeutic development important potential future mers outbreak,2018,"Wang, Yanqun; Sun, Jing; Zhu, Airu; Zhao, Jingxian; Zhao, Jincun",Journal of thoracic disease,,,,,,https://doi.org/10.21037/jtd.2018.03.80; https://www.ncbi.nlm.nih.gov/pubmed/30116605/,52021028.0,3
32870,32870,43902,ipn5jl1f,,Medline,A Synthetic Porcine Reproductive and Respiratory Syndrome Virus Strain Confers Unprecedented Levels of Heterologous Protection.,10.1128/jvi.01657-15,,26401031.0,unk,unlabelled current vaccine provide sufficient level protection divergent porcine reproductive respiratory syndrome virus prrsv strain circulating field mainly due substantial variation viral genome describe novel approach generate prrsv vaccine candidate could confer unprecedented level heterologous protection divergent prrsv isolates using set nonredundant fullgenome sequence type prrsvs consensus genome designated prrsvcon generated aligning prrsv fullgenome sequence followed selecting common nucleotide found position alignment next synthetic prrsvcon strain generated use reverse genetics prrsvcon replicates efficiently prototype prrsv strain fl vitro vivo importantly inoculated pig prrsvcon confers significantly broader level heterologous protection wildtype prrsv collectively data demonstrate prrsvcon serve excellent candidate development broadly protective prrsv vaccine importance extraordinary genetic variation rna virus pose monumental challenge development broadly protective vaccine virus minimize genetic dissimilarity vaccine immunogen contemporary circulating virus computational strategy developed generation artificial immunogen sequence socalled centralized sequence equal genetic distance circulating virus thus far generation centralized vaccine immunogen carried level individual viral protein expand concept prrsv highly variable rna virus creating synthetic prrsv strain based centralized prrsv genome sequence study provides first example centralizing whole genome rna virus improve vaccine coverage concept may significant development vaccine genetically variable virus require active viral replication order achieve complete immune protection,2015,"Vu, Hiep L X; Ma, Fangrui; Laegreid, William W; Pattnaik, Asit K; Steffen, David; Doster, Alan R; Osorio, Fernando A",Journal of virology,,,,,,https://doi.org/10.1128/jvi.01657-15; https://www.ncbi.nlm.nih.gov/pubmed/26401031/,10455792.0,3
32875,32875,43909,x00107rk,,Medline,Kidney Cell-Adapted Infectious Bronchitis ArkDPI Vaccine is Stable and Protective.,10.1637/11537-111416-reg.1,,28665723.0,unk,previously demonstrated adaptation embryoattenuated infectious bronchitis virus ibv arkansas ark delmarva poultry industry dpiderived vaccine chicken embryo kidney cek cell cekp shifted virus population towards homogeneity spike nonstructural protein gene moreover typical ark vaccine subpopulation emerging chicken vaccinated commercial ark vaccine detected chicken vaccinated cekp indicating kidneycell adaptation drastically increased stability vaccine virus population chicken current study conventional nextgeneration sequencing result show change achieved cek adaptation remained five back passage embryonated chicken egg ece first protection study dayold chicken vaccinated embryo infectious dos eidchicken second ece back passage cekp cekpe demonstrated protection ark virulent eid challenge second protection trial protection cekpe compared protection conferred attenuated commercial arkdpiderived vaccine different cekadapted virus originated vaccinated chicken group showed significant reduction respiratory sign viral load ark virulent challenge compared unvaccinatedchallenged control cekpe vaccinated chicken viral subpopulation different challenge virus detected challenge marginal number chicken contrast ibv sequence differed predominant population challenge virus detected challenge large number chicken vaccinated commercial ark attenuated vaccine cekadapted ibv arkdpiderived vaccine stable effective vaccine drastically reduces emergence arklike virus vaccination challenge,2017,"Zegpi, R A; Breedlove, C; van Santen, V L; Rasmussen-Ivey, C R; Toro, H",Avian diseases,,,,,,https://doi.org/10.1637/11537-111416-reg.1; https://www.ncbi.nlm.nih.gov/pubmed/28665723/,207246414.0,3
33096,33096,44162,2gsy750k,,Medline,Immunogenicity and protective efficacy in mice and hamsters of a β-propiolactone inactivated whole virus SARS-CoV vaccine.,10.1089/vim.2010.0028,,20883165.0,unk,immunogenicity efficacy βpropiolactone bpl inactivated whole virion sarscov wisars vaccine evaluated balbc mouse golden syrian hamster vaccine preparation tested without adjuvant adjuvant system asb asa selected tested capacity elicit high humoral cellular immune response wisars vaccine evaluated effect vaccine dose adjuvant immunogenicity efficacy mouse effect vaccine dose without asb adjuvant immunogenicity efficacy hamster efficacy evaluated challenge wildtype virus early late time point wk postvaccination single dose vaccine without adjuvant poorly immunogenic mouse second dose resulted significant boost antibody level even absence adjuvant use adjuvant resulted higher antibody titer asbadjuvanted vaccine slightly immunogenic asaadjuvanted vaccine two dos wisars without adjuvant system highly efficacious mouse hamster two dos wisars without asb immunogenic two dos μg wisars without adjuvant provided complete protection early challenge although antibody titer declined group vaccinated hamster wk second dose vaccinated hamster still partially protected wildtype virus challenge vaccine adjuvant provided better protection nonadjuvanted wisars vaccine later time point enhanced disease observed lung liver hamster following sarscov challenge regardless level serum neutralizing antibody,2010,"Roberts, Anjeanette; Lamirande, Elaine W; Vogel, Leatrice; Baras, Benoît; Goossens, Geneviève; Knott, Isabelle; Chen, Jun; Ward, Jerrold M; Vassilev, Ventzislav; Subbarao, Kanta",Viral immunology,,,,,,https://doi.org/10.1089/vim.2010.0028; https://www.ncbi.nlm.nih.gov/pubmed/20883165/,30771641.0,3
33169,33169,44249,xhe9nuvt,,Medline,Efficacy of intradermally administrated E2 subunit vaccines in reducing horizontal transmission of classical swine fever virus.,10.1016/j.vaccine.2007.12.039,,18242794.0,unk,investigate intradermal id vaccination intramuscular im vaccination result comparable reduction horizontal transmission classical swine fever virus csfv two registered e subunit marker vaccine examined vaccine waterinoil emulsion containing e glycoprotein originating alforttübingen strain vaccine b wateroilwater emulsion containing e glycoprotein originating brescia strain eight group ten pig vaccinated either vaccine b intramuscularly im intradermally id two different vaccinationchallenge interval used vaccine furthermore one group vaccinated tenfold id dose vaccine one nonvaccinated group served control group five pig group challenged moderately virulent csfv strain paderborn remaining five pig served contact using vaccine full transmission contact pig id vaccinated group occurred virus transmission observed im vaccinated pig challenged day postvaccination dpv whereas one five contact pig became infected challenged dpv using vaccine b virus transmission observed pig id im vaccinated challenged dpv challenged dpv full transmission occurred id vaccinated group whereas four five contact pig became infected im vaccinated group result indicates id vaccination result better protection horizontal csfv transmission compared im vaccination vaccine studied,2008,"Dortmans, J C F M; Loeffen, W L A; Weerdmeester, K; van der Poel, W H M; de Bruin, M G M",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2007.12.039; https://www.ncbi.nlm.nih.gov/pubmed/18242794/,20408739.0,3
33209,33209,44291,k85v6nac,,Medline,Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine.,10.1016/j.vaccine.2014.02.038,,24631084.0,unk,despite intensive vaccine program influenza infection remain major health problem due virus ability change envelope glycoprotein hemagglutinin ha shift drift permitting influenza escape protection induced current vaccine natural immunity recently new variant hn emerged china causing global concern first laboratoryconfirmed human infection resulting alarmingly high death rate second genetic change found hn appear associated enabling avian influenza virus spread effectively mammal thus transmitting infection larger scale currently vaccine drug effectively able target hn report rapid development synthetic consensus dna vaccine phha elicit potent protective immunity hn virus show phha induces broad antibody response bind divergent multiple new member hn family antibody response result hightiter hai hn simultaneously vaccine induces potent polyfunctional effector cd cdt cell memory response animal vaccinated phha completely protected hn virus infection morbidity associated lethal challenge study establishes synthetic consensus dna vaccine represents new tool targeting emerging infection importantly design testing development seed stock vaccine production day pandemic setting significant implication rapid deployment vaccine protecting emerging infectious disease,2014,"Yan, Jian; Villarreal, Daniel O; Racine, Trina; Chu, Jaemi S; Walters, Jewell N; Morrow, Matthew P; Khan, Amir S; Sardesai, Niranjan Y; Kim, J Joseph; Kobinger, Gary P; Weiner, David B",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2014.02.038; https://www.ncbi.nlm.nih.gov/pubmed/24631084/,20653867.0,3
33311,33311,44417,xfo4tlz9,,Medline,Recombinant protein subunit vaccine synthesis in microbes: a role for yeast?,10.1111/jphp.12353,,25556638.0,unk,objective recombinant protein subunit vaccine formulated using protein antigen synthesized heterologous host cell several host cell available purpose ranging escherichia coli mammalian cell line article highlight benefit using yeast recombinant host key finding yeast specie saccharomyces cerevisiae pichia pastoris used optimize functional yield potential antigen development subunit vaccine wide range disease caused bacteria virus saccharomyces cerevisiae also used manufacture approved vaccine hepatitis b virus one human papillomavirus case recombinant protein form highly immunogenic viruslike particle summary advance understanding yeast cell responds metabolic load producing recombinant protein allow u identify host strain improved yield property enable synthesis challenging antigen produced system yeast therefore potential become important host organism production recombinant antigen used manufacture subunit vaccine new vaccine development,2015,"Bill, Roslyn M",The Journal of pharmacy and pharmacology,,,,,,https://doi.org/10.1111/jphp.12353; https://www.ncbi.nlm.nih.gov/pubmed/25556638/,22339760.0,3
33526,33526,44659,r1ip9pew,,Medline,Plant-derived virus-like particles as vaccines.,10.4161/hv.22218,,22995837.0,unk,viruslike particle vlps selfassembled structure derived viral antigen mimic native architecture virus lack viral genome vlps emerged premier vaccine platform due advantage safety immunogenicity manufacturing particulate nature highdensity presentation viral structure protein surface also render vlps attractive carrier displaying foreign epitope consequently several vlpbased vaccine licensed human use achieved significant clinical economical success major challenge however develop novel production platform deliver vlpbased vaccine significantly reducing production time cost therefore review focus essential role plant novel speedy economical production platform vlpbased vaccine advantage plant expression system discussed light distinctive posttranslational modification costeffectiveness production speed scalability recent achievement expression assembly vlps chimeric derivative plant system well immunogenicity animal model presented result human clinical trial demonstrating safety efficacy plantderived vlps also detailed moreover promising implication recent creation humanized glycosylation plant line well recent approval first plantmade biologics u food drug administration fda plant production commercialization vlpbased vaccine discussed speculated combined potential plant expression system vlp technology lead emergence successful vaccine novel application vlps near future,2013,"Chen, Qiang; Lai, Huafang",Human vaccines & immunotherapeutics,,,,,,https://doi.org/10.4161/hv.22218; https://www.ncbi.nlm.nih.gov/pubmed/22995837/,207516697.0,3
33661,33661,44812,4nrpcado,,Medline,[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].,10.3760/cma.j.cn112150-20200317-00366,,32234130.0,unk,outbreak novel coronavirus ncov infection pose serious threat global public health vaccination effective way prevent epidemic virus ncov along severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus merscov belong βgenus coronavirus family base previous experience technical platform developing sarscov merscov vaccine scientist world working hard quickly related field substantial progress field including characterizing ncov virus identification candidate antigen epitope establishment animal model characterizing immune response design vaccine development ncov vaccine cover type inactivated virus vaccine recombinant protein vaccine viral vectorbased vaccine mrna vaccine dna vaccine et al march two ncov vaccine entered phase clinical trial one named adncov developed chinese institute biotechnology academy military medical science tianjin cansino biotechnology inc adncov based replicationdefective adenovirus type vector express ncov spike protein another vaccine mrna developed national institute allergy infectious disease moderna inc rna mrna vaccine expressing ncov spike protein although rapid development ncov vaccine still face many challenge unknown knowledge including antigenic characteristic ncov influence antigenic variation protective immune response host protection elderly population downstream manufacturing process new vaccine safety efficacy vaccine first priority vaccine development carefully evaluated,2020-04-01,"Shi, Y; Wang, N; Zou, Q M",Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine],,,,,,https://doi.org/10.3760/cma.j.cn112150-20200317-00366; https://www.ncbi.nlm.nih.gov/pubmed/32234130/,214771730.0,3
33952,33952,45140,s8wnoee1,,Medline,Prospects for a MERS-CoV spike vaccine.,10.1080/14760584.2018.1506702,,30058403.0,unk,introduction six year passed since middle east respiratory syndrome mers coronavirus merscov newly emerging infectious virus first reported although merscov consistently high mortality rate human vaccine approved prevent merscov infection human merscov spike protein key target development mers vaccine area covered review illustrate structure function protein vaccine target describe available animal model evaluating mers vaccine summarize recent progress merscov sbased vaccine focusing ability elicit antibody andor cellular immune response neutralizing antibody protection merscov infection different model prospect future merscov sbased vaccine discussed expert commentary majority mers vaccine development based merscov protein including fulllength receptorbinding domain rbd essential evaluate safety fulllength sbased mers vaccine improvement efficacy rbdbased vaccine using novel strategy would necessary overall review provides informative guidance designing developing safe effective mers vaccine based viral protein,2018,"Zhou, Yusen; Jiang, Shibo; Du, Lanying",Expert review of vaccines,,,,,,https://doi.org/10.1080/14760584.2018.1506702; https://www.ncbi.nlm.nih.gov/pubmed/30058403/,51864086.0,3
34164,34164,45391,938z4x35,,Medline,Minimum Infectious Dose Determination of the Arkansas Delmarva Poultry Industry Infectious Bronchitis Virus Vaccine Delivered by Hatchery Spray Cabinet.,10.1637/11474-072216-resnote,,28301234.0,unk,arkansas delmarva poultry industry arkdpi infectious bronchitis virus ibv vaccine effective administered eye drop vaccine virus able infect replicate well bird able induce protection homologous challenge however accumulating evidence indicates arkdpi vaccine ineffective applied hatchery spray cabinet using manufacturerrecommended dose per bird study aimed determine minimum infectious dose sprayadministered arkdpi vaccine designate dose achieves level infection replication eye dropadministered arkdpi vaccine end used increasing dos commercial arkdpi vaccine vaccinate commercial broiler chick day hatch using commercial hatchery spray cabinet choanal cleft bird swabbed day postvaccination realtime reversetranscriptase pcr performed observed level infection replication spray vaccination match eye drop vaccination chick received time standard dose commercial arkdpi vaccine examined spike gene sequence subset reisolated arkdpi vaccine virus sample observed certain nucleotide change arise vaccine virus reisolated chick previously reported suggests arkdpi vaccine certain virus subpopulation successful infecting replicating chick represents minor virus subpopulation original vaccine thus minimum infectious dose arkdpi vaccine using hatchery spray cabinet appears dependent amount minor subpopulation reaching chick,2017,"Leyson, Christina M; Hilt, Deborah A; Jordan, Brian J; Jackwood, Mark W",Avian diseases,,,,,,https://doi.org/10.1637/11474-072216-resnote; https://www.ncbi.nlm.nih.gov/pubmed/28301234/,19425818.0,3
34167,34167,45394,x1l9lbnz,,Medline,"Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1.",10.1128/jvi.00411-17,,28701403.0,unk,rv hiv vaccine trial included recombinant hiv glycoprotein gp construct fused small portion herpes simplex virus hsv glycoprotein gd first amino acid gp replaced signal sequence first amino acid mature form gd region gd contains binding site hvem hsv receptor important virus infection epithelial cell lymphocyte rv induced antibody hiv partially protective infection well antibody hsv derived monoclonal antibody mabs peripheral blood b cell recipient rv hiv vaccine showed antibody neutralized hsv infection cell expressing hvem major virus receptor nectin mabs mediated antibodydependent cellular cytotoxicity adcc mouse received mabs challenged corneal inoculation hsv reduced eye disease shedding latent infection knowledge first description mabs derived human recipient vaccine specifically target hvem binding site gd summary found monoclonal antibody derived human vaccinated hvem binding domain hsv gd neutralized hsv infection cell receptorspecific manner ii mediated adcc iii reduced ocular disease virusinfected miceimportance herpes simplex virus hsv cause cold sore neonatal herpes leading cause blindness despite many trial hsv vaccine approved nectin hvem two major cellular receptor hsv receptor expressed different level various tissue role receptor hsv pathogenesis well understood derived human monoclonal antibody person received hiv rv vaccine contained hvem binding domain hsv gd fused hiv gp antibody able specifically neutralize hsv infection vitro via hvem furthermore showed first time hvemspecific hsv neutralizing antibody protect mouse hsv eye disease indicating critical role hvem hsv ocular infection,2017,"Wang, Kening; Tomaras, Georgia D; Jegaskanda, Sinthujan; Moody, M Anthony; Liao, Hua-Xin; Goodman, Kyle N; Berman, Phillip W; Rerks-Ngarm, Supachai; Pitisuttithum, Punnee; Nitayapan, Sorachai; Kaewkungwal, Jaranit; Haynes, Barton F; Cohen, Jeffrey I",Journal of virology,,,,,,https://doi.org/10.1128/jvi.00411-17; https://www.ncbi.nlm.nih.gov/pubmed/28701403/,4578818.0,3
34247,34247,45487,y4t84phi,,Medline,A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge.,10.1128/jvi.06048-11,,21937658.0,unk,severe acute respiratory syndrome coronavirus sarscov important emerging virus highly pathogenic aged population maintained great diversity zoonotic reservoir variety vaccine platform shown efficacy younganimal model homologous viral strain vaccine efficacy thoroughly evaluated using highly pathogenic variant replicate acute end stage lung disease phenotype seen human epidemic using adjuvanted unadjuvanted doubleinactivated sarscov div vaccine demonstrate eosinophilic immunopathology aged mouse comparable seen mouse immunized sars nucleocapsid protein poor protection nonlethal heterologous challenge young yearold animal demonstrate adjuvanted div vaccine provides protection lethal disease young animal following homologous heterologous challenge although enhanced immune pathology eosinophilia evident following heterologous challenge absence alum div vaccine performed poorly young animal challenged lethal homologous heterologous strain contrast div vaccine adjuvanted unadjuvanted performed poorly agedanimal model importantly aged animal displayed increased eosinophilic immune pathology lung protected significant virus replication data raise significant concern regarding div vaccine safety highlight need additional study molecular mechanism governing divinduced eosinophilia vaccine failure especially vulnerable agedanimal model human disease,2011,"Bolles, Meagan; Deming, Damon; Long, Kristin; Agnihothram, Sudhakar; Whitmore, Alan; Ferris, Martin; Funkhouser, William; Gralinski, Lisa; Totura, Allison; Heise, Mark; Baric, Ralph S",Journal of virology,,,,,,https://doi.org/10.1128/jvi.06048-11; https://www.ncbi.nlm.nih.gov/pubmed/21937658/,40217679.0,3
34363,34363,45625,s6yeljv0,,Medline,Fifteen-month duration of immunity for the serovar Grippotyphosa fraction of a tetravalent canine leptospirosis vaccine.,10.1136/vr.104694,,29459489.0,unk,fortyfour specific pathogenfree beagle median age day received two subcutaneous dos either commercially available fiveway combination vaccine vaccine combination tetravalent leptospira bacterin canicola grippotyphosa icterohaemorrhagiae pomona subsequently challenged pathogenic strain l kirschneri serovar grippotyphosa day following completion vaccination protocol titre agglutinating serum antibody determined various time point vaccination challenge along postchallenge reisolation challenge organism blood urine evaluation renal histopathology clinical sign generalised leptospirosis observed dog challenge order demonstrate efficacy leptospirosis defined least one positive urine sample positive renal histopathology score absence renal pathology multiple positive urine sample leptospiremia demonstrated vaccinated dog versus per cent control leptospiruria noted per cent vaccinates compared per cent control renal lesion observed per cent vaccinates per cent control using criterion vaccine able significantly prevent leptospirosis p vaccinated animal study establishes duration immunity least month prevention disease renal excretion leptospires leptospira serovar grippotyphosa fraction quadrivalent leptospira vaccine,2018,"Grosenbaugh, Deborah A; Pardo, Maria Camila",The Veterinary record,,,,,,https://doi.org/10.1136/vr.104694; https://www.ncbi.nlm.nih.gov/pubmed/29459489/,3413785.0,3
34600,34600,45903,3evun9jf,,Medline,Poxviral promoters for improving the immunogenicity of MVA delivered vaccines.,10.1080/21645515.2018.1513439,,30148692.0,unk,modified vaccinia virus ankara mva replicationdeficient poxvirus attenuated chick embryo fibroblast primary cell utilised viral vector develop many vaccine cancer infectious disease malaria hivaids influenza tuberculosis merscov ebola virus infection accumulating data many preclinical clinical study highlight excellent safety immunogenicity mva however due complex nature many pathogen pathogenicity mva vectored vaccine candidate need optimised improve immunogenicity one main approach improve mva immunogenicity focus optimising poxviral promoter drive recombinant vaccine antigen encoded within recombinant mva vector genome number promoter described optimised improve development mva based vaccine p pf mh promoter review focus poxviral promoter optimisation genetic stability clinical use,2019,"Alharbi, Naif Khalaf",Human vaccines & immunotherapeutics,,,,,,https://doi.org/10.1080/21645515.2018.1513439; https://www.ncbi.nlm.nih.gov/pubmed/30148692/,52095888.0,3
34603,34603,45907,7mi07qm9,,Medline,CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic.,10.1002/jgm.1648,,22228547.0,unk,ability dendritic cell dc orchestrate innate adaptive immune response exploited develop potent anticancer immunotherapy recent clinical trial exploring efficacy ex vivo modified autologous dcbased vaccine reported promising result however vitro generation autologous dc clinical administration loading tumor associated antigen taas activation laborious expensive result interindividual variability personalized vaccine remains poorly standardized attractive alternative approach load resident dc vivo targeted delivery taas using viral vector activating simultaneously end constructed geneticallymodified adenoviral ad vector bispecific adaptor molecule retarget ad vector encoding taas cd receptor dc preclinical human murine study conducted far clearly demonstrated suitability twocomponent ie ad adaptor molecule configuration targeted modification dc vivo cancer immunotherapy review summarizes recent progress development cdtargeted adbased cancer vaccine highlight preclinical issue clinical translation approach,2012,"Hangalapura, Basav N; Timares, Laura; Oosterhoff, Dinja; Scheper, Rik J; Curiel, David T; de Gruijl, Tanja D",The journal of gene medicine,,,,,,https://doi.org/10.1002/jgm.1648; https://www.ncbi.nlm.nih.gov/pubmed/22228547/,19639740.0,3
34668,34668,45977,crl8eyfv,,Medline,Bovine respiratory disease research (1983-2009).,10.1017/s146625230999017x,,20003649.0,unk,bovine respiratory disease brd research provided significant understanding disease past year modern research tool used include monoclonal antibody genomics polymerase chain reaction immunohistochemistry ihc dna vaccine viral vector coding immunogen emergingreemerging virus new antigenic strain virus bacteria identified method detection role cattle persistently infected bovine viral diarrhea virus bvdv identified viral subunit cellular component bacterial product characterized product advance included vaccine bovine respiratory syncytial virus mannheimia haemolytica pasteurella multocida addition bvdv existing vaccine new antibiotic role mycoplasma spp particularly mycoplasma bovis brd extensively studied bovine immunology research provided specific information immune response cell subset cytokine molecular genetic basis viralbacterial synergy brd described attempt made document prevention brd proper vaccination management prior exposure infectious agent minimize disease serve economic incentive certified health program,2009,"Fulton, Robert W",Animal health research reviews,,,,,,https://doi.org/10.1017/s146625230999017x; https://www.ncbi.nlm.nih.gov/pubmed/20003649/,9459547.0,3
34803,34803,46138,9ruxqfns,,Medline,Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: an accelerated approach toward epitope-driven vaccine development.,10.4161/hv.29177,,25424944.0,unk,million people chronically infected worldwide million infected annually hepatitis c continues pose burden global healthcare system standard therapy hepatitis c remains expensive severe associated side effect inconsistent cure rate vaccine development hepatitis c virus hampered practical biological challenge posed viral evasion mechanism despite challenge hcv vaccine research presented number candidate vaccine progressed phase ii trial however effort focused mainly hcv genotype vaccine target barely enough attention given genotype variant prevalent middle east central africa describe herein silico identification highly conserved immunogenic tcell epitope hcv genotype proteome using ivax immunoinformatics toolkit target epitopedriven vaccine also describe fast inexpensive approach result validation using empirical data immune epitope database iedb reference analysis identified hla class epitope found novel binding prediction retrospectively validated empirical data remaining epitope insufficient validate binding prediction analysis also identified hla class ii epitope binding prediction validated investigation required regarding efficacy identified epitope vaccine target population hcv genotype prevalent,2014,"Abdel-Hady, Karim M; Gutierrez, Andres H; Terry, Frances; Desrosiers, Joe; De Groot, Anne S; Azzazy, Hassan M E",Human vaccines & immunotherapeutics,,,,,,https://doi.org/10.4161/hv.29177; https://www.ncbi.nlm.nih.gov/pubmed/25424944/,32094254.0,3
35084,35084,46474,rhhafruq,,Medline,Severe acute respiratory syndrome-associated coronavirus vaccines formulated with delta inulin adjuvants provide enhanced protection while ameliorating lung eosinophilic immunopathology.,10.1128/jvi.02980-14,,25520500.0,unk,unlabelled although severe acute respiratory syndromeassociated coronavirus sarscov epidemic controlled nonvaccine measure coronaviruses remain major threat human health design optimal coronavirus vaccine therefore remains priority vaccine present major challenge coronavirus immunity often wane rapidly individual needing protected include elderly vaccine may exacerbate rather prevent coronavirus lung immunopathology address issue compared murine model range recombinant spike protein inactivated wholevirus vaccine candidate alone adjuvanted either alum cpg advax new delta inulinbased polysaccharide adjuvant vaccine protected lethal infection addition adjuvant significantly increased serum neutralizingantibody titer reduced lung virus titer day postchallenge whereas unadjuvanted alumformulated vaccine associated significantly increased lung eosinophilic immunopathology day postchallenge seen mouse immunized vaccine formulated delta inulin adjuvant protection eosinophilic immunopathology vaccine containing delta inulin adjuvant correlated better enhanced tcell gamma interferon ifnγ recall response rather reduced interleukin il response suggesting immunopathology predominantly reflects inadequate vaccineinduced th response study highlight critical importance development effective safe coronavirus vaccine selection adjuvant based ability induce durable ifnγ response importance coronaviruses sarscov middle east respiratory syndromeassociated coronavirus merscov cause high case fatality rate remain major human public health threat creating need effective vaccine coronavirus antigen induce protective neutralizing antibody identified coronavirus vaccine present unique problem immunized individual infected virus develop lung eosinophilic pathology problem exacerbated formulation sarscov vaccine alum adjuvant study show formulation sarscov spike protein inactivated wholevirus vaccine novel delta inulinbased polysaccharide adjuvant enhances neutralizingantibody titer protection clinical disease time also protects development lung eosinophilic immunopathology also show immunity achieved delta inulin adjuvant longlived thereby overcoming natural tendency rapidly waning coronavirus immunity thus delta inulin adjuvant may offer unique ability develop safer effective coronavirus vaccine,2015,"Honda-Okubo, Yoshikazu; Barnard, Dale; Ong, Chun Hao; Peng, Bi-Hung; Tseng, Chien-Te Kent; Petrovsky, Nikolai",Journal of virology,,,,,,https://doi.org/10.1128/jvi.02980-14; https://www.ncbi.nlm.nih.gov/pubmed/25520500/,31038908.0,3
35282,35282,46700,z8he6vp1,,Medline,"Construction of recombinant lactobacilli expressing the core neutralizing epitope (COE) of porcine epidemic diarrhea virus and a fusion protein consisting of COE and Escherichia coli heat-labile enterotoxin B, and comparison of the immune responses by orogastric immunization.",10.1139/w2012-098,,23145823.0,unk,core neutralizing epitope coe region porcine epidemic diarrhea virus pedv play important role development subunit vaccine pedv infection enhance vaccine immunogenicity escherichia coli heatlabile enterotoxin b ltb usually adopted molecular adjuvant study coe ltbcoe gene engineered lactobacillus escherichia coli shuttle vector psapg surfacedisplaying psapg secreting followed electrotransformation lactobacillus casei lc yield following recombinant strain lcpgltbcoe lcpgltbcoe lcpgcoe lcpgcoe result showed mouse immunized orogastrically l casei expressing coe ltbcoe produced secretory immunoglobulin immunoglobulin g ability neutralize pedv serum mucus moreover higher level interleukin gamma interferon also exhibited compared negative control data displayed tendency lcpgltbcoe lcpgltbcoe lcpgcoe lcpgcoe time point taken together ltbcoe suitable lactobacillus expressing system engineer mucosal vaccine pedv infection,2012,"Ge, Jun-Wei; Liu, Di-Qiu; Li, Yi-Jing",Canadian journal of microbiology,,,,,,https://doi.org/10.1139/w2012-098; https://www.ncbi.nlm.nih.gov/pubmed/23145823/,11354515.0,3
35423,35423,46864,dz3lbrx3,,Medline,Characterization of Epitope-Specific Anti-Respiratory Syncytial Virus (Anti-RSV) Antibody Responses after Natural Infection and after Vaccination with Formalin-Inactivated RSV.,10.1128/jvi.00235-16,,27099320.0,unk,unlabelled antibody fusion f protein respiratory syncytial virus rsv play important role protective immune response important respiratory virus little known however antibody level multiple fspecific epitope induced infection vaccination rsv important guide evaluation novel vaccine study analyzed antibody level rsv protein fspecific epitope human serum serum vaccinated experimentally infected cotton rat correlation thereof virus neutralization analysis human serum revealed substantial diversity antibody level f g attachment fspecific epitope individual highest correlation virus neutralization observed antibody recognizing prefusionspecific antigenic site ø nevertheless result indicate high level antibody targeting part f protein also mediate potent antiviral antibody response agreement serum experimentally infected cotton rat contained high neutralizing activity despite lacking antigenic site øspecific antibody strikingly vaccination formalininactivated rsv firsv exclusively resulted induction poorly neutralizing antibody postfusionspecific antigenic site although antigenic site ii iv efficiently displayed firsv apparent immunodominance antigenic site firsv likely explains low level neutralizing antibody upon vaccination challenge may play role vaccinationinduced enhancement disease observed preparation importance rsv importance cause hospitalization infant development vaccine rsv hampered disastrous result obtained firsv vaccine preparation resulted vaccinationinduced enhancement disease get better understanding antibody repertoire induced infection vaccination rsv investigated antibody level fusion f protein attachment g protein fspecific epitope human animal serum result indicate importance prefusionspecific antigenic site ø antibody well antibody targeting epitope virus neutralization however vaccination cotton rat firsv specifically resulted induction weakly neutralizing antigenic site ispecific antibody may play role enhancement disease observed vaccination preparation,2016,"Widjaja, Ivy; Wicht, Oliver; Luytjes, Willem; Leenhouts, Kees; Rottier, Peter J M; van Kuppeveld, Frank J M; Haijema, Bert Jan; de Haan, Cornelis A M",Journal of virology,,,,,,https://doi.org/10.1128/jvi.00235-16; https://www.ncbi.nlm.nih.gov/pubmed/27099320/,4767600.0,3
35670,35670,47159,y5k8f5mb,,Medline,Genetically modified live attenuated vaccine: a potential strategy to combat visceral leishmaniasis.,10.1111/pim.12732,,32418227.0,unk,visceral leishmaniasis vl caused protozoan parasite leishmania donovani mainly influencing population tropical subtropical region across globe arsenal drug available limited prolonged use drug make parasite become resistant therefore imperative develop safe costeffective inexpensive vaccine vl although recent year many strategy pursued researcher far vaccine candidate reached clinical trial half still pipeline broad consent among leishmania researcher perseverance parasite essential eliciting protective immune response may perhaps attained live attenuated parasite vaccination making live attenuated parasite essential ensure parasite deficient virulence study genetically modified parasite perceive mechanism pathogenesis believed near future complete understanding leishmania genome explore clear strategy discover novel vaccine review describes need genetically modified live attenuated vaccine vl obstacle associated development,2020-05-17,"Pandey, Satish Chandra; Kumar, Awanish; Samant, Mukesh",Parasite immunology,,,,,,https://doi.org/10.1111/pim.12732; https://www.ncbi.nlm.nih.gov/pubmed/32418227/,218680451.0,3
35681,35681,47171,t66r7aq6,,Medline,A brief report of toxicity end points of HER2 vaccines for the treatment of patients with HER2+ breast cancer.,10.2147/dddt.s188925,,30679903.0,unk,human epidermal growth factor receptor hertargeted vaccine development far demonstrated modest clinical efficacy additionally lack adequate safety assessment largescale prospective clinical trial therefore performed metaanalysis available clinical trial data summarize toxicity profile treatment literature search conducted february trial analyzed least one study arm consisting vaccine monotherapy heterogeneity across study analyzed using statistic data analyzed using randomeffects metaanalysis absolute risk ar eight trial patient included evidence heterogeneity study grade adverse event aes death ar treatmentrelated serious aes treatmentrelated death ar allgrade fatigue injection site reaction feverchillsrigors respectively asymptomatic drop left ventricle ejection fraction rare vaccine well tolerated increased ar fatigue injection site reaction feverchillsrigors,2019,"Costa, Ricardo; Zaman, Saif; Sharpe, Susan; Helenowski, Irene; Shaw, Colleen; Han, Hyo; Soliman, Hatem; Czerniecki, Brian","Drug design, development and therapy",,,,,,https://doi.org/10.2147/dddt.s188925; https://www.ncbi.nlm.nih.gov/pubmed/30679903/,59223974.0,3
35683,35683,47173,qk9wmdtn,,Medline,The establishment and characteristics of cell-adapted IBV strain H120.,10.1007/s00705-016-3008-3,,27558123.0,unk,avian infectious bronchitis virus important pathogen poultry worldwide vaccination effective way prevent control ibv infection h one safest vaccine strain used worldwide primary vaccine adapt passaged cell severely restricts quality vaccine based reverse genetics previous research work constructed recombinant rhbeaudetteps strain replacing complete spike gene h corresponding spike gene beaudette p strain biological characteristic including replication kinetics virulence immunological property rhbeaudetteps evaluated result showed biological characteristic rhbeaudetteps replication kinetics embryonated chicken egg eces embryo virulence similar h addition rhbeaudetteps could induce similar antibody titre provide immune protection chicken challenged strain result indicate rhbeaudetteps potential development celladapted vaccine,2016,"Zhou, Yingshun; Yang, Xin; Wang, Hongning; Zeng, Fanya; Zhang, Zhikun; Zhang, Anyun; Liu, Hui",Archives of virology,,,,,,https://doi.org/10.1007/s00705-016-3008-3; https://www.ncbi.nlm.nih.gov/pubmed/27558123/,30932561.0,3
36233,36233,47809,2xkeg0fm,,Medline,Two genotypes of infectious bronchitis virus are responsible for serological variation in KwaZulu-Natal poultry flocks prior to 2012.,10.4102/ojvr.v81i1.769,,25685887.0,unk,study describes isolation serotyping genotyping infectious bronchitis virus ibv case predominantly kwazulunatal compared several isolates south african province several historic isolates result indicate division isolates two different genotype ibv within province massachusetts masslike qxlike ibv masslike genotype prevalent detected full spike protein gene sequence variation detected within local masstype strain supporting hypothesis multiple ibv serotypes may cocirculate region simultaneously additionally conservation observed amongst mass serotypes versus qxlike serotypes implying vaccine use influence variability within ibv population deduced fact live vaccine registered use south africa time study mass origin qxlike vaccine available use study offer first published consolidation ibv isolates area south africa identifies variation within ibv population broiler flock within study area year period,2014,"Knoetze, Adrian D; Moodley, Niloshni; Abolnik, Celia",The Onderstepoort journal of veterinary research,,,,,,https://doi.org/10.4102/ojvr.v81i1.769; https://www.ncbi.nlm.nih.gov/pubmed/25685887/,5912645.0,3
36298,36298,47886,5gebzt8w,,Medline,Genetic mutations in live infectious bronchitis vaccine viruses following single or dual in vitro infection of tracheal organ cultures.,10.1099/jgv.0.000628,,27902312.0,unk,despite regular covaccination two different strain live infectious bronchitis vaccine virus little known possible mutation virus following vaccination alternative chick study used vitro infection model identify singlenucleotide polymorphism snp within part gene two live infectious bronchitis virus vaccine strain b massachusetts following single dual inoculation onto tracheal organ culture result indicate viral titre reduced duration study conversely amount detected infectious bronchitis virus genome increased result demonstrate greater number nonsynonymous snp vaccine strain coinoculated compared single inoculation influence increased snp hydrophobic property translated protein vaccine virus virulence unknown,2016,"Ball, Christopher; Bennett, Sarah; Forrester, Anne; Ganapathy, Kannan",The Journal of general virology,,,,,,https://doi.org/10.1099/jgv.0.000628; https://www.ncbi.nlm.nih.gov/pubmed/27902312/,39065391.0,3
36367,36367,47968,wvtjcwg9,,Medline,Additive preventive effect of influenza and pneumococcal vaccines in the elderly: results of a large cohort study.,10.4161/hv.22550,,23442587.0,unk,elderly people increased risk influenza pneumococcal disease influenza increase clinical pneumococcal disease incidence pneumococcal vaccination could therefore supplement influenza vaccination study evaluated allcause mortality antibiotic consumption according elderly people influenza pneumococcal vaccination status goal demonstrate vaccination influenza pneumococcal vaccine decrease allcause mortality antibiotic consumption mo elderly people ≥ lived gard department south france offered vaccination among subject followedup one year vaccination campaign vaccinated vaccine influenza vaccine alone pneumococcal vaccine alone subject unvaccinated mortality rate per inhabitantsyear adjusted gender age prior underlying chronic disease ci respectively elderly people underlying chronic disease received vaccine v unvaccinated elderly people decrease mortality rate subject received vaccine received influenza vaccine significant reduction mortality rate seen pneumococcal vaccine alone influenza andor pneumococcal vaccination decrease antibiotic consumption drastically increase winter period additive effect observed prevention allcause mortality influenza pneumococcal vaccine given together elderly people including underlying chronic disease,2013,"Mahamat, Aba; Daurès, Jean-Pierre; de Wzieres, Benoît",Human vaccines & immunotherapeutics,,,,,,https://doi.org/10.4161/hv.22550; https://www.ncbi.nlm.nih.gov/pubmed/23442587/,33289908.0,3
36463,36463,48075,qip0l9ss,,Medline,Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1).,10.2165/00063030-200923030-00001,,19627166.0,unk,infection hiv type hiv causative agent aid one catastrophic pandemic affect human healthcare latter th century best hope controlling pandemic development successful prophylactic vaccine however date goal proven exceptionally elusive recent failure experimental vaccine phase iib study named step trial intended solely elicit cellmediated immune response hiv highlighted need balanced immune response consisting cellular immunity also broad potent humoral antibody response prevent infection hiv article review effort made point elicit antibody response especially regard use dna primeprotein boost regimen proven highly effective platform induction neutralizing antibody animal earlyphase human study,2009,"Vaine, Michael; Lu, Shan; Wang, Shixia","BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy",,,,,,https://doi.org/10.2165/00063030-200923030-00001; https://www.ncbi.nlm.nih.gov/pubmed/19627166/,1769425.0,3
36756,36756,48414,7sl5m4q9,,Medline,Mucosal adenovirus-vectored vaccine for measles.,10.1016/j.vaccine.2010.09.055,,20887832.0,unk,several problem associated available antimeasles vaccine emphasize need single shot antimeasles vaccine efficacious mucosal route administration functional presence antimeasles neutralizing antibody achieve goal constructed two recombinant human adenovirus collectively designated adfh carrying gene measles virus mv fusion f haemagglutinin h protein single intranasal intramuscular vaccination mouse cotton rat adfh elicited high mvspecific serum neutralizingantibody titer furthermore bronchoalveolar lavage sample mouse vaccinated intranasally adfh showed fold increase mvspecific iga titer compared intramuscularly vaccinated mouse moreover adfh vaccine administered intranasally intramuscularly completely protected challenged cotton rat mv replication lung,2010,"Lobanova, Liubov M; Baig, Tayyba T; Tikoo, Suresh K; Zakhartchouk, Alexander N",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2010.09.055; https://www.ncbi.nlm.nih.gov/pubmed/20887832/,5364220.0,3
36832,36832,48502,a403rezg,,Medline,Self-replicating alphavirus RNA vaccines.,10.1586/14760584.2015.965690,,25269775.0,unk,recombinant nucleic acid considered promising nextgeneration vaccine vaccine express native antigen upon delivery tissue thus mimicking live attenuated vaccine without risk reversion pathogenicity also stimulate innate immune system thus potentiating response nucleic acid vaccine easy produce reasonable cost stable past year focus use plasmid dna vaccination mrna replicon vaccine come focus promising technology platform vaccine development review discus selfreplicating rna vaccine developed alphavirus expression vector replicon vaccine delivered rna dna recombinant virus particle three platform preclinically evaluated vaccine number infectious disease cancer result encouraging propelled first human clinical trial result promising,2015,"Ljungberg, Karl; Liljeström, Peter",Expert review of vaccines,,,,,,https://doi.org/10.1586/14760584.2015.965690; https://www.ncbi.nlm.nih.gov/pubmed/25269775/,207196157.0,3
36835,36835,48505,whhlcbv3,,Medline,"Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge.",10.1016/j.vaccine.2009.10.051,,19879223.0,unk,highly attenuated rabies virus rv vaccine vector evaluated ability protect highly pathogenic sivmac challenge mamua negative rhesus macaque immunized group four either rv expressing sivmacgagpol combination rv expressing sivmacenv rv expressing sivmacgagpol empty rv vector eight week later animal received booster immunization heterologous rv expressing antigen week postboost animal challenged intravenously tcid pathogenic sivmaccx immunized macaque vaccine group logfold decrease viral set point compared control animal gagpolenv immunized animal also significantly lower peak viral load compared control animal following challenge vaccinated macaque rapid induction sivmac neutralizing antibody cd cell response various siv epitope moreover vaccinated macaque better maintained peripheral memory cd cell able mount polyfunctional cd cell response mucosa finding indicate promise rvbased vector important implication development efficacious hiv vaccine,2009,"Faul, Elizabeth J; Aye, Pyone P; Papaneri, Amy B; Pahar, Bapi; McGettigan, James P; Schiro, Faith; Chervoneva, Inna; Montefiori, David C; Lackner, Andrew A; Schnell, Matthias J",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2009.10.051; https://www.ncbi.nlm.nih.gov/pubmed/19879223/,36552920.0,3
36992,36992,48685,od484ub1,,Medline,A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.,10.1128/jvi.01815-15,,26355094.0,unk,unlabelled first case infection middle east respiratory syndrome coronavirus merscov identified since case merscov infection confirmed infection typically associated considerable morbidity approximately case mortality currently protective vaccine available replicationcompetent recombinant measles virus mv expressing foreign antigen constitutes promising tool induce protective immunity corresponding pathogen therefore generated mv expressing spike glycoprotein merscov fulllength merss truncated soluble variant merss merssols gene encoding merss merssols cloned vaccine strain mvvac genome respective virus rescued mvvaccovs mvvaccovsols recombinant mv amplified characterized passage replication mvvaccovs vero cell turned comparable control virus mvvacgfp encoding green fluorescent protein titer mvvaccovsols impaired approximately fold genomic stability expression inserted antigen confirmed via sequencing viral cdna immunoblot analysis vivo immunization type interferon receptordeficient ifnarcdge mouse × tissue culture infective dos mvvaccovsh mvvaccovsolsh primeboost regimen induced robust level mv merscovneutralizing antibody additionally induction specific cell demonstrated cell proliferation antigenspecific cell cytotoxicity gamma interferon secretion stimulation splenocytes merscovs presented murine dendritic cell merscov challenge experiment indicated protective capacity immune response vaccinated mouse importance although merscov yet acquired extensive distribution mainly confined arabic korean peninsula could adapt spread readily among human thereby become pandemic therefore development vaccine mandatory integration antigencoding gene recombinant mv resulting coexpression mv foreign antigen efficiently achieved thus combination excellent safety profile mv vaccine recombinant mv seems constitute ideal vaccine platform present study show recombinant mv expressing merss genetically stable induces strong humoral cellular immunity merscov vaccinated mouse subsequent challenge experiment indicated protection vaccinated animal illustrating potential mv vaccine platform potential target emerging infection merscov,2015,"Malczyk, Anna H; Kupke, Alexandra; Prüfer, Steffen; Scheuplein, Vivian A; Hutzler, Stefan; Kreuz, Dorothea; Beissert, Tim; Bauer, Stefanie; Hubich-Rau, Stefanie; Tondera, Christiane; Eldin, Hosam Shams; Schmidt, Jörg; Vergara-Alert, Júlia; Süzer, Yasemin; Seifried, Janna; Hanschmann, Kay-Martin; Kalinke, Ulrich; Herold, Susanne; Sahin, Ugur; Cichutek, Klaus; Waibler, Zoe; Eickmann, Markus; Becker, Stephan; Mühlebach, Michael D",Journal of virology,,,,,,https://doi.org/10.1128/jvi.01815-15; https://www.ncbi.nlm.nih.gov/pubmed/26355094/,35992372.0,3
37876,37876,49705,v02ab670,,Medline,Oral administration of porcine epidemic diarrhea virus spike protein expressing in silkworm pupae failed to elicit immune responses in pigs.,10.1186/s13568-020-0952-9,,31993764.0,unk,silkworm bombyx mori pupa used decade nutritional additive applied production highquality recombinant protein via baculovirus expression vector bev system biocapsule fatrich body body component silkworm pupa deliver antigen passing harsh environment digestive tract reaching intestine used vehicle oral vaccine present study develop novel oral vaccine porcine epidemic diarrhea virus pedv pedv spike protein expressed silkworm pupa bmn cell using bev system three dos oral administration week interval pig neither pedv proteinspecific humoral mucosal immune response detected failure eliciting pedvspecific immune response suggested bev system using bmn cell silkworm pupa oral immunogenexpression vehicle able overcome immunological unresponsiveness possibly due gastrointestinal specific barrier oral tolerance better strategy enhance delivery immunogenicity oral vaccine investigated nevertheless pedv protein generated bmn cell silkworm pupa herein provides efficient tool produce recombinant antigen future application,2020-01-28,"Chang, Chia-Yu; Hsu, Wei-Ting; Tsai, Pei-Shiue; Chen, Chi-Min; Cheng, Ivan-Chen; Chao, Yu-Chan; Chang, Hui-Wen",AMB Express,,,,,,https://doi.org/10.1186/s13568-020-0952-9; https://www.ncbi.nlm.nih.gov/pubmed/31993764/,210926098.0,3
37998,37998,49852,3ew6tycv,,Medline,Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.,10.1093/infdis/jir349,,21987744.0,unk,filovirus marburg virus ebola virus cause severe hemorrhagic fever high mortality rate human nonhuman primate among mostpromising filovirus vaccine development system based recombinant vesicular stomatitis virus rvsv express single filovirus glycoprotein gp place vsv glycoprotein g importantly single injection blended rvsvbased filovirus vaccine shown completely protect nonhuman primate marburg virus different specie ebola virus rvsvbased vaccine also shown utility administered postexposure treatment filovirus infection rvsvbased ebola virus vaccine recently used treat potential laboratory exposure review history rvsvbased vaccine pivotal animal study showing utility combating ebola marburg virus infection,2011,"Geisbert, Thomas W; Feldmann, Heinz",The Journal of infectious diseases,,,,,,https://doi.org/10.1093/infdis/jir349; https://www.ncbi.nlm.nih.gov/pubmed/21987744/,5292423.0,3
38174,38174,50048,3mh63vjj,,Medline,Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo.,10.1126/scitranslmed.aaf1061,,26888429.0,unk,november laboratoryconfirmed human case middle east respiratory syndrome coronavirus merscov infection including death reported world health organization specific preventive therapeutic agent proven value merscov currently available public health england international severe acute respiratory emerging infection consortium identified passive immunotherapy neutralizing antibody treatment approach warrant priority study two experimental merscov vaccine used vaccinate two group transchromosomic tc bovine genetically modified produce large quantity fully human polyclonal immunoglobulin g igg antibody vaccination clade γirradiated whole killed virion vaccine jordan strain clade b spike protein nanoparticle vaccine alhasa strain resulted tc bovine serum high enzymelinked immunosorbent assay elisa neutralizing antibody titer vitro two purified tc bovine human igg immunoglobulin tc higg sab produced jordan strain vaccination sab produced alhasa strain vaccination also high elisa neutralizing antibody titer without antibodydependent enhancement vitro sab selected vivo preclinical study administration single dos sab hour hour merscov infection erasmus medical center strain adhdpp receptortransduced mouse rapidly resulted viral lung titer near limit detection tc bovine combined ability quickly produce tc higg develop vitro assay animal model potentially offer platform rapidly produce therapeutic prevent andor treat merscov infection andor emerging infectious disease,2016,"Luke, Thomas; Wu, Hua; Zhao, Jincun; Channappanavar, Rudragouda; Coleman, Christopher M; Jiao, Jin-An; Matsushita, Hiroaki; Liu, Ye; Postnikova, Elena N; Ork, Britini L; Glenn, Gregory; Flyer, David; Defang, Gabriel; Raviprakash, Kanakatte; Kochel, Tadeusz; Wang, Jonathan; Nie, Wensheng; Smith, Gale; Hensley, Lisa E; Olinger, Gene G; Kuhn, Jens H; Holbrook, Michael R; Johnson, Reed F; Perlman, Stanley; Sullivan, Eddie; Frieman, Matthew B",Science translational medicine,,,,,,https://doi.org/10.1126/scitranslmed.aaf1061; https://www.ncbi.nlm.nih.gov/pubmed/26888429/,206690464.0,3
38294,38294,50185,djpy8lhj,,Medline,Vesicular stomatitis virus as a novel cancer vaccine vector to prime antitumor immunity amenable to rapid boosting with adenovirus.,10.1038/mt.2009.154,,19603003.0,unk,vesicular stomatitis virus vsv proven effective vaccine vector immunization viral infection potential induce immune response selftumor antigen investigated constructed recombinant vsv expressing human dopachrome tautomerase hdct evaluated immunogenicity murine melanoma model intranasal delivery vsvhdct activated cd cd dctspecific tcell response magnitude response could significantly increased booster immunization recombinant adenovirus adhdct led enhanced efficacy bf melanoma prophylactic therapeutic setting notably interval vsvad heterologous vaccination could shortened day making potential regimen rapidly expand antigenspecific effector cell furthermore vsvhdct could increase dctspecific tcell response primed adhdct suggesting vsv efficient priming boosting immune response selftumor antigen,2009,"Bridle, Byram W; Boudreau, Jeanette E; Lichty, Brian D; Brunellière, Jérôme; Stephenson, Kyle; Koshy, Sandeep; Bramson, Jonathan L; Wan, Yonghong",Molecular therapy : the journal of the American Society of Gene Therapy,,,,,,https://doi.org/10.1038/mt.2009.154; https://www.ncbi.nlm.nih.gov/pubmed/19603003/,14751176.0,3
38314,38314,50210,nvqrtsor,,Medline,Immunogenicity and protective efficacy of a replication-defective infectious bronchitis virus vaccine using an adenovirus vector and administered in ovo.,10.1016/j.jviromet.2010.02.019,,20219540.0,unk,ovo vaccination remains attractive option cost effective uniform mass application vaccine commercial poultry however vaccine delivered safely method limited currently licensed embryosafe vaccine infectious bronchitis virus ibv study recombinant adenovirus expressing gene nephropathogenic ibv rad constructed immune response protective efficacy homologous challenge evaluated ovo vaccination result showed rad led dramatic augmentation humoral cellular response bird vaccinated ovo followed intramuscular inoculation ifngamma il chicken lymphocyte produced strategy following challenge ibv chicken vaccinated recombinant adenovirus showed fewer nephropathic lesion le severe clinical sign compared receiving wildtype adenovirus pb construction nonreplicating human adenovirus vector encoding gene ibv ovo delivery demonstrated potential alternative vaccination strategy ibv,2010,"Zeshan, Basit; Zhang, Lili; Bai, Juan; Wang, Xinglong; Xu, Jiarong; Jiang, Ping",Journal of virological methods,,,,,,https://doi.org/10.1016/j.jviromet.2010.02.019; https://www.ncbi.nlm.nih.gov/pubmed/20219540/,206665014.0,3
38400,38400,50314,ofv3aqmp,,Medline,Application of carbohydrate array technology to antigen discovery and vaccine development.,10.1586/14760584.6.6.957,,18377358.0,unk,carbohydrate array new technology developed highthroughput evaluation interaction carbohydrate protein cell virus carbohydrate array contain many different carbohydrate structure solid support format allows one probe hundred thousand potential receptorligand interaction using tiny amount material recently carbohydrate array applied vaccine development several way first carbohydrate array utilized discovery characterization carbohydrate antigen second used evaluate immune response vaccine candidate third carbohydrate array used identify characterize reagent necessary vaccine development although still early stage carbohydrate array technology tremendous potential accelerating vaccine development,2007,"Oyelaran, Oyindasola; Gildersleeve, Jeffrey C",Expert review of vaccines,,,,,,https://doi.org/10.1586/14760584.6.6.957; https://www.ncbi.nlm.nih.gov/pubmed/18377358/,6039625.0,3
38560,38560,50501,i466hq1e,,Medline,"Pathogenicity of a QX strain of infectious bronchitis virus in specific pathogen free and commercial broiler chickens, and evaluation of protection induced by a vaccination programme based on the Ma5 and 4/91 serotypes.",10.1080/03079450802356938,,18798022.0,unk,aim study firstly evaluate pathogenicity italian isolate qx strain infectious bronchitis ib virus using dayold female specific pathogen free chick layer type dayold female commercial broiler type chicken secondly ass level protection induced bird vaccination programme including ib massachusetts serotype live attenuated vaccine unvaccinated bird showed clinical sign varying severity predominantly affecting upper respiratory tract vaccinated bird appeared healthy exception mild conjunctivitis affecting limited number broiler vaccination fully protected specific pathogen free bird since histopathological lesion observed virus detected following challenge broiler replication challenge virus prevented significantly reduced study confirms vaccination day old day age using ib vaccine may instrumental reducing economic impact qx ib virus infection layer broiler farm,2008,"Terregino, Calogero; Toffan, Anna; Beato, Maria Serena; De Nardi, Roberta; Vascellari, Marta; Meini, Amelio; Ortali, Giovanni; Mancin, Marzia; Capua, Ilaria",Avian pathology : journal of the W.V.P.A,,,,,,https://doi.org/10.1080/03079450802356938; https://www.ncbi.nlm.nih.gov/pubmed/18798022/,26290934.0,3
38607,38607,50557,hcr5cz5t,,Medline,BacMam virus-based surface display of the infectious bronchitis virus (IBV) S1 glycoprotein confers strong protection against virulent IBV challenge in chickens.,10.1016/j.vaccine.2013.12.006,,24342247.0,unk,avian infectious bronchitis virus ibv associated production inefficiency domestic fowl cause massive economic loss poultry industry worldwide progress made designing novel efficient candidate vaccine control ibv infection bacmam virus modified baculovirus mediating transgene expression control mammalian promoter emerged versatile safe vector vaccine development previous work generated bacmam virus accmvs expressed glycoprotein ibvm showed accmvs induced excellent cellular immunity confer adequate protection chicken compared conventional inactivated vaccine current study generated improved bacmam virus bvduals virus displayed glycoprotein baculovirus envelope capable expressing mammalian cell bvduals elicited stronger humoral cellmediated immune response showed greater capacity induction cytotoxic lymphocyte response compared accmvs specific pathogenfree chicken significant difference observed protection rate chicken immunized bvduals inactivated vaccine following challenge virulent ibvm finding show protective efficacy bvduals could significantly enhanced baculovirus display technology bacmam virusbased surface display strategy could serve effective tool designing vaccine ib infectious disease,2014,"Zhang, Jie; Chen, Xiao-Wei; Tong, Tie-Zhu; Ye, Yu; Liao, Ming; Fan, Hui-Ying",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2013.12.006; https://www.ncbi.nlm.nih.gov/pubmed/24342247/,1861560.0,3
38739,38739,50705,w5b5yrbo,,Medline,Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.,10.1016/j.vaccine.2012.07.073,,22884661.0,unk,previously developed replicationcompetent b replicationdeficient c chemically inactivated rabies virus rabv vaccine expressing ebola virus ebov glycoprotein gp induce humoral immunity virus confer protection lethal rabv mouseadapted ebov challenge mouse expand investigation immunogenic property bivalent vaccine mouse live killed vaccine induced primary ebov gpspecific tcells robust recall response measured interferonγ elispot assay addition cellular immunity effective filovirus vaccine likely require multivalent humoral immune response multiple virus specie proofofprinciple experiment demonstrated inactivated rvgp could formulated another inactivated rabv vaccine expressing nontoxic fragment botulinum neurotoxin heavy chain hc without reduction immunity component finally demonstrated humoral immunity gp could induced immunization mouse inactivated rvgp presence preexisting immunity rabv ability novel vaccine induce strong humoral cellular immunity indicates evaluated additional animal model infection,2012,"Papaneri, Amy B; Wirblich, Christoph; Cooper, Kurt; Jahrling, Peter B; Schnell, Matthias J; Blaney, Joseph E",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2012.07.073; https://www.ncbi.nlm.nih.gov/pubmed/22884661/,13775521.0,3
38757,38757,50725,in0sel5u,,Medline,"Vaccinia virus vaccines: past, present and future.",10.1016/j.antiviral.2009.06.006,,19563829.0,unk,vaccinia virus vacv used extensively human immunization vaccine almost two century vacv employed provide crossprotection variola virus causative agent smallpox disease eradicated late since time continued research vacv produced number modified vaccine improved safety profile attenuation achieved several strategy including sequential passage alternative host deletion specific gene genetic engineering viral gene encoding immunomodulatory protein highly attenuated third fourthgeneration vacv vaccine considered stockpiling possible reintroduction smallpox bioterrorism researcher also taken advantage ability vacv genome accommodate additional genetic material produce novel vaccine wide variety infectious agent including recombinant vacv encoding rabies virus glycoprotein administered orally wild animal review provides indepth examination successive generation vacv vaccine focusing understanding poxviral replication viral gene function permit deliberate modification vacv immunogenicity virulence,2009,"Jacobs, Bertram L; Langland, Jeffrey O; Kibler, Karen V; Denzler, Karen L; White, Stacy D; Holechek, Susan A; Wong, Shukmei; Huynh, Trung; Baskin, Carole R",Antiviral research,,,,,,https://doi.org/10.1016/j.antiviral.2009.06.006; https://www.ncbi.nlm.nih.gov/pubmed/19563829/,24679582.0,3
38983,38983,50985,qzkqdo56,,Medline,Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs.,10.1128/jvi.05050-11,,21849467.0,unk,human immunodeficiency virus type hiv transmitted mainly mucosal site optimum strategy elicit systemic mucosal immunity critical development vaccine hiv therefore sought evaluate induction systemic mucosal immune response use newcastle disease virus ndv vaccine vector generated recombinant ndv designated rlasotagp expressing gp envelope env protein hiv added gene gp protein expressed rlasotagp virus detected infected cell surface incorporated ndv virion biochemical study showed gp present infected cell virion formed higherorder oligomer retained recognition conformationally sensitive monoclonal antibody expression gp increase virulence recombinant ndv rndv strain lasota guinea pig administered rlasotagp via intranasal intramuscular im route different primeboost combination systemic mucosal antibody response specific hiv envelope protein assessed serum vaginal wash respectively two three immunization via im route induced potent systemic mucosal immune response single immunization either route priming route immunogenic im route true boost furthermore immunization rlasotagp route combination route induced thtype response reflected induction stronger antigenspecific igga igg antibody response additionally immunization elicited stronger neutralizing serum antibody response laboratoryadapted hiv strain mn data illustrate feasible use ndv vaccine vector elicit potent humoral mucosal response hiv envelope protein,2011,"Khattar, Sunil K; Samal, Sweety; Devico, Anthony L; Collins, Peter L; Samal, Siba K",Journal of virology,,,,,,https://doi.org/10.1128/jvi.05050-11; https://www.ncbi.nlm.nih.gov/pubmed/21849467/,12310821.0,3
38984,38984,50986,884yuc7q,,Medline,Rapid COVID-19 vaccine development.,10.1126/science.abb8923,,32385100.0,unk,finding fastest pathway vaccine availability includes avoidance safety pitfall,2020-05-08,"Graham, Barney S",Science,,,,,,https://doi.org/10.1126/science.abb8923; https://www.ncbi.nlm.nih.gov/pubmed/32385100/,218563830.0,3
39297,39297,51344,mw5a6e7n,,Medline,"Evaluation of safety, humoral immune response and faecal shedding in horses inoculated with a modified-live bovine coronavirus vaccination.",10.1111/eve.13175,,32427191.0,unk,equine coronavirus ecov considered emerging enteric virus reported morbidity rate ranging fatality rate ranging adult horse vaccine ecov currently available study investigated safety humoral response viral shedding horse inoculated commercially available modifiedlive bovine coronavirus bcov vaccine twelve healthy adult horse vaccinated twice week apart either orally intranasally intrarectally two healthy unvaccinated horse served sentinel control following vaccine administration horse monitored daily physical abnormality whilst onset duration bcov shedding determined quantitative pcr qpcr nasal secretion faeces whole blood collected every week determine bcovspecific antibody response exception transient selflimiting change faecal character observed seven vaccinated one control horse additional abnormal clinical finding found study horse following first second vaccine administration two one horse respectively tested qpcrpositive bcov nasal secretion day post intranasal vaccination vaccinated horse tested qpcrpositive bcov faeces following vaccine administration one two horse shed bcov seroconverted bcov first vaccine administration additional two vaccinated horse oral intrarectal seroconverted bcov second vaccine administration conclusion result show modifiedlive bcov safe administer horse via various route cause minimal virus shedding result detectable antibody bcov vaccinates,2019-08-31,"Prutton, J S W; Barnum, S; Pusterla, N",Equine veterinary education,,,,,,https://doi.org/10.1111/eve.13175; https://www.ncbi.nlm.nih.gov/pubmed/32427191/,202833286.0,3
39426,39426,51494,enpuzt0y,,Medline,Development of subunit vaccines against severe acute respiratory syndrome.,10.1358/dot.2008.44.1.1131830,,18301805.0,unk,severe acute respiratory syndrome sars novel infectious disease caused sars coronavirus sarscov although sars appears successfully contained still risk reemergence due sporadic laboratory accident presence natural reservoir sarscovlike virus therefore development effective vaccine sarscov continues current focus sars research review first describe rationale developing safe effective sars vaccine followed elucidating viral antigen could used potential vaccine component comparing current vaccine category sars article demonstrate advantage subunit vaccine describe current situation developing subunit vaccine point possibility improvement subunit sars vaccine suggests recombinant proteinpeptidebased subunit vaccine containing spike protein especially receptorbind domain sarscov could developed safe effective sars vaccine,2008,"Du, Lanying; He, Yuxian; Jiang, Shibo; Zheng, Bo-Jian",Drugs of today,,,,,,https://doi.org/10.1358/dot.2008.44.1.1131830; https://www.ncbi.nlm.nih.gov/pubmed/18301805/,828338.0,3
39438,39438,51507,u1ky1mev,,Medline,Hand Awareness.,10.1177/1942602x14559421,,28071363.0,unk,concept hand awareness affect comprehensive respiratory infection prevention plan vaccine immunization alone respiratory infection vaccine solution additionally resurgence measles mumps pertussis vaccinated good reminder must improve approach respiratory infection prevention weak link exist vaccine production administration chain panacea hoped changing behavior difficult critical order greater impact reducing respiratory infection hand awareness defined integrated approach hand hygiene respiratory etiquette crosscontamination awareness practice lay term knowing hand time teaching strategy resource explored assist student understanding application desired behavior achieve greatest impact student staff productivity wellness,2015,"Sawyer, William P; White, Zandra",NASN school nurse,,,,,,https://doi.org/10.1177/1942602x14559421; https://www.ncbi.nlm.nih.gov/pubmed/28071363/,206812283.0,3
39647,39647,51751,c24q6gbo,,Medline,"Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: a randomized, placebo-controlled trial.",10.1016/j.vaccine.2011.07.128,,21835220.0,unk,background development influenza vaccine use embryonated egg substrate vaccine production high priority conducted study determine protective efficacy recombinant baculovirusexpressed seasonal trivalent influenza virus hemagglutinin rha vaccine flublok® method healthy adult subject center across u randomly assigned receive single injection saline placebo subject trivalent flublok containing mcg rha component subject serum sample assessment immune response hemagglutinationinhibition hai taken subset subject day immunization subject followed influenza season combined nasal throat swab virus isolation obtained subject reporting influenzalike illness result rate local systemic side effect low rate systemic side effect similar vaccine placebo group hai antibody response seen flublok recipient h h b component respectively flublok ci effective preventing cultureconfirmed influenza meeting cdc influenzalike illness case definition despite significant antigenic mismatch vaccine antigen circulating virus conclusion trivalent rha vaccine safe immunogenic effective prevention culture confirmed influenza illness including protection drift variant,2011,"Treanor, John J; El Sahly, Hana; King, James; Graham, Irene; Izikson, Ruvim; Kohberger, Robert; Patriarca, Peter; Cox, Manon",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2011.07.128; https://www.ncbi.nlm.nih.gov/pubmed/21835220/,19186201.0,3
39710,39710,51820,nub7i1nn,,Medline,An adenovirus vectored mucosal adjuvant augments protection of mice immunized intranasally with an adenovirus-vectored foot-and-mouth disease virus subunit vaccine.,10.1016/j.vaccine.2013.02.060,,23499593.0,unk,footandmouth disease virus fmdv highly contagious pathogen cause severe morbidity economic loss livestock industry many country oral respiratory mucosa main port entry fmdv stimulation local immunity tissue may help prevent initial infection viral spread e coli heatlabile enterotoxin lt described one molecule adjuvant activity mucosal surface objective study evaluate efficacy replicationdefective adenovirus ad vector encoding either two ltbased mucosal adjuvant ltb ltr vectored adjuvant delivered intranasally mouse concurrent adfmdv vaccine ada ass ability augment mucosal systemic humoral immune response ada protection fmdv mouse receiving ada plus adltr higher level mucosal systemic neutralizing antibody receiving ada alone ada plus adltb vaccine plus adltr group also demonstrated survival intradermal challenge lethal dose homologous fmdv serotype result suggest adltr could used important tool enhance mucosal systemic immunity fmdv potentially pathogen common route entry,2013,"Alejo, Diana M; Moraes, Mauro P; Liao, Xiaofen; Dias, Camila C; Tulman, Edan R; Diaz-San Segundo, Fayna; Rood, Debra; Grubman, Marvin J; Silbart, Lawrence K",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2013.02.060; https://www.ncbi.nlm.nih.gov/pubmed/23499593/,22271045.0,3
40161,40161,52330,yaf3crog,,Medline,Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines.,10.1016/j.vaccine.2008.07.028,,18675867.0,unk,alum adjuvant approved clinical application induce strong humoral th weak cellular th immune response necessary develop safe effective adjuvant capable inducing humoral cellular immune response previously showed activationassociated protein asp derived onchocerca volvulus potent adjuvant activity study evaluated adjuvanticity recombinant asp using panel recombinant protein synthetic peptidebased antigen including ovalbumin ovum synthetic hiv peptide hivp recombinant hiv gp rgp hbv hbsag well three commercially available inactivated vaccine haemorrhagic fever renal syndrome hfrs influenza rabies result indicate asp induced significantly higher igg thassociated igga thassociated response alum adjuvant ovum antigen hivp rgp consistently induced similar level igg response alum higher level igga ifngammaproducing cell response alum adjuvant hbsag asp improved igg igga response three commercial inactivated vaccine used separately combination conclusion recombinant asp unlike alum adjuvant able induce th thassociated humoral response th cellular response suggesting developed promising adjuvant subunitbased inactivated vaccine,2008,"Xiao, Wenjun; Du, Lanying; Liang, Chao; Guan, Jie; Jiang, Shibo; Lustigman, Sara; He, Yuxian; Zhou, Yusen",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2008.07.028; https://www.ncbi.nlm.nih.gov/pubmed/18675867/,205576656.0,3
40281,40281,52463,fla3qveh,,Medline,A gene deletion that up-regulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children.,10.1126/scitranslmed.aac8463,,26537255.0,unk,respiratory syncytial virus rsv leading viral cause severe pediatric respiratory illness safe effective vaccine use infancy early childhood needed previously showed deletion coding sequence viral protein δm downregulated viral rna replication upregulated gene transcription antigen synthesis raising possibility development attenuated vaccine enhanced immunogenicity rsv medi δm therefore evaluated live intranasal vaccine adult rsvseropositive child rsvseronegative child result rsvseronegative child compared achieved previous leading live attenuated rsv candidate vaccine vaccine virus shedding significantly restricted yet postvaccination rsvneutralizing serum antibody achieved geometric mean titer gmt significantly greater surveillance subsequent rsv season showed several seronegative rsv medi δm recipient substantial antibody rise without reported illness suggesting vaccine protective yet primed anamnestic response rsv rational design appears yielded candidate rsv vaccine intrinsically superior eliciting protective antibody rsvnaïve child highlight approach development live attenuated rsv vaccine,2015,"Karron, Ruth A; Luongo, Cindy; Thumar, Bhagvanji; Loehr, Karen M; Englund, Janet A; Collins, Peter L; Buchholz, Ursula J",Science translational medicine,,,,,,https://doi.org/10.1126/scitranslmed.aac8463; https://www.ncbi.nlm.nih.gov/pubmed/26537255/,13311038.0,3
40354,40354,52553,jyqlqz31,,Medline,Rapid selection in chickens of subpopulations within ArkDPI-derived infectious bronchitis virus vaccines.,10.1080/03079450802043783,,18568656.0,unk,examined spike gene sequence virus population four different commercial arkdpiderived infectious bronchitis coronavirus vaccine single passage specific pathogen free chicken found different degree genetic heterogeneity among four vaccine passage chicken ranging apparent heterogeneity heterogeneity position gene except one position nucleotide difference nonsynonymous majority amino acid difference subunit protein three four arkdpiderived vaccine single subpopulation gene sequence distinct vaccine majority consensus codon selected chicken within day ocular vaccination contrast obtained evidence selection specific subpopulation fourth arkdpiderived vaccine massachusetts de serotype vaccine virus subpopulation within vaccine selected chicken similar gene sequence distinct portion subunit gene three vaccine gene selected subpopulation similar virulent parental arkdpi isolate predominant vaccine population different proportion distinct subpopulation ark vaccine apparently fit replication respiratory tract chicken might cause different degree damage respiratory epithelium andor immune response vaccinated chicken sequence comparison provided evidence support arkdpilike field isolates derived directly hostselected vaccine virus subpopulation,2008,"van Santen, Vicky L; Toro, Haroldo",Avian pathology : journal of the W.V.P.A,,,,,,https://doi.org/10.1080/03079450802043783; https://www.ncbi.nlm.nih.gov/pubmed/18568656/,5768157.0,3
40525,40525,52764,a5ykxrw3,,Medline,U.S. medical countermeasure development since 2001: a long way yet to go.,10.1089/bsp.2012.0305,,22455680.0,unk,u government taken significant step toward developing acquiring vaccine drug medical countermeasure mcms protect treat population biological attack contrast procedure department health human service hhs develop license stockpile mcms civilian use another major accomplishment smallpox preparedness adequate supply vaccine every person u alternative vaccine meant immunocompromised people close contact spite accomplishment u government mcm effort criticized federal advisory committee national academy science report congressional commission outside analyst state effort lack central leadership accountability pace progress slow clear operational strategy using mcms would guide development acquisition also lacking article review key area progress made since develop acquire mcms summarize judge critical often mentioned area improvement needed,2012,"Russell, Philip K; Gronvall, Gigi Kwik","Biosecurity and bioterrorism : biodefense strategy, practice, and science",,,,,,https://doi.org/10.1089/bsp.2012.0305; https://www.ncbi.nlm.nih.gov/pubmed/22455680/,206145392.0,3
40813,40813,53111,awnwlvzc,,Medline,Media and public reactions toward vaccination during the 'hepatitis B vaccine crisis' in China.,10.1016/j.vaccine.2015.02.046,,25731787.0,unk,background public disputation affected vaccine confidence vaccine rate particularly adverse event occur vigorous development internet china provides opportunity observe public reaction sentiment toward vaccination kangtai hepatitis b vaccine crisis happened evolved widespread debate internet december january method study conducted internet surveillance examining three daily indicator including daily number relevant online news article sina weibo post baidu search index crisis also analyzed sentiment relevant original microblog post collected sina weibo platform crisis result total infant death reported associated hepatitis b vaccination three major wave high medium public attention detected daily indicator reached peak second wave relevant vaccine suspended authority december december daily online news report sina weibo post baidu search index significant correlation daily amount online news weibo post baidu search p content analysis suggested original weibo post expressed negative sentiment almost second wave conclusion study found kangtai vaccine crisis raised great public attention negative sentiment toward vaccination internet china policy change suspension suspected vaccine might trigger even greater reaction negative sentiment government provide way address emerging public concern policy change avoid misinformation misunderstanding vaccine crisis,2015,"Chen, Bin; Zhang, Jueman Mandy; Jiang, Zhenggang; Shao, Jian; Jiang, Tao; Wang, Zhengting; Liu, Kui; Tang, Siliang; Gu, Hua; Jiang, Jianmin",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2015.02.046; https://www.ncbi.nlm.nih.gov/pubmed/25731787/,24085724.0,3
40842,40842,53143,u7h279m6,,Medline,Receptor-binding domain as a target for developing SARS vaccines.,10.3978/j.issn.2072-1439.2013.06.06,,23977435.0,unk,decade ago severe acute respiratory syndrome sars coronavirus sarscov caused global pandemic mortality rate report recent outbreak sarslike disease caused middle east respiratory syndrome coronavirus merscov raised serious concern possible reemergence sarscov either laboratory escape presence natural reservoir therefore development effective safe sars vaccine still needed based previous study believe receptorbinding domain rbd subunit sarscov spike protein important target developing sars vaccine particular rbd protein contains critical neutralizing domain cnd able induce highly potent neutralizing antibody response crossprotection divergent sarscov strain furthermore rbdbased subunit vaccine expected safer vaccine may induce thtype immunopathology review discus key advance development rbdbased sars vaccine possibility using similar strategy develop vaccine merscov,2013,"Zhu, Xiaojie; Liu, Qi; Du, Lanying; Lu, Lu; Jiang, Shibo",Journal of thoracic disease,,,,,,https://doi.org/10.3978/j.issn.2072-1439.2013.06.06; https://www.ncbi.nlm.nih.gov/pubmed/23977435/,9448400.0,3
40955,40955,53276,x1m8zb4r,,Medline,Repertoire of antibodies against type 1 poliovirus in human sera.,10.1016/j.jviromet.2010.07.037,,20691212.0,unk,blockingelisa procedure used quantify antibody serum human immunized poliovirus vaccine titer determined method demonstrated excellent correlation result neutralization test testing serum potency panel type poliovirus strain altered antigenically used evaluate composition polyclonal serum respect epitope specificity constituent antibody paratope profile various polyclonal serum determined new method differed depending type vaccine used immunization antibody induced response inactivated poliovirus vaccine ipv contained antibody directed primarily antigenic site serum recipient oral poliovirus vaccine opv contained antibody site antibody antigenic site minor constituent type serum preimmunization serum paratope profile similar opvinduced antiserum allowing discrimination antibody induced ipv maternal antibody new method may useful analyzing result clinical trial compare immunity induced different poliovirus vaccine,2010,"Rezapkin, Gennady; Neverov, Alexander; Cherkasova, Elena; Vidor, Emmanuel; Sarafanov, Andrei; Kouiavskaia, Diana; Dragunsky, Eugenia; Chumakov, Konstantin",Journal of virological methods,,,,,,https://doi.org/10.1016/j.jviromet.2010.07.037; https://www.ncbi.nlm.nih.gov/pubmed/20691212/,21117537.0,3
41174,41174,53537,mzui69t4,,Medline,H1N1 influenza vaccine compliance among hospital- and non-hospital-based healthcare personnel.,10.1086/666336,,22669237.0,unk,background pandemic hn influenza vaccine lower uptake compared seasonal influenza vaccine study examining uptake hn vaccine focused hospitalbased healthcare personnel hcp determinant hn vaccine uptake among hcp work setting need identified intervention developed use encouraging uptake future pandemic emerging infectious disease vaccine objective identify factor influencing nonhospital hcp hn influenza vaccine compliance design setting hn influenza vaccine compliance questionnaire administered hcp working myriad healthcare setting marchjune method survey used ass hn influenza vaccine compliance examine factor predicted hn influenza vaccine uptake result hcp completed survey hospitalbased hcp higher compliance nonhospitalbased personnel χ p logistic regression stratified hospital setting versus nonhospital setting determinant hn vaccination among nonhospitalbased hcp included extent hn vaccination mandated encouraged perceived importance vaccination access nocost vaccine provided onsite fear vaccine side effect trust public health official say influenza vaccine safe determinant hospitalbased hcp hn vaccine compliance included mandatory vaccination policy perceived importance vaccination fear vaccine side effect free vaccine perceived seriousness hn influenza trust public health official conclusion nonhospitalbased hcp versus hospitalbased hcp reason hn vaccine uptake differed targeted intervention needed increase compliance pandemicrelated vaccine,2012,"Rebmann, Terri; Iqbal, Ayesha; Anthony, John; Knaup, Richard C; Wright, Kathleen S; Peters, Eleanor B",Infection control and hospital epidemiology,,,,,,https://doi.org/10.1086/666336; https://www.ncbi.nlm.nih.gov/pubmed/22669237/,26820909.0,3
41509,41509,53925,eies1vre,,Medline,"Protection of chickens vaccinated with combinations of commercial live infectious bronchitis vaccines containing Massachusetts, Dutch and QX-like serotypes against challenge with virulent infectious bronchitis viruses 793B and IS/1494/06 Israel variant 2.",10.1080/03079457.2016.1203393,,27400065.0,unk,infectious bronchitis virus ibv coronavirus affect chicken age ibv mainly cause respiratory disease also result reduced weight gain reduced egg production increased frequency abnormal egg increased rate mortality vaccination important way control disease nevertheless novel strain infectious bronchitis ib continue emerge field order respond promptly combination existing ib vaccine frequently tested see whether provide crossprotection efficacy combination vaccine based massachusetts dutch qxlike ib strain emerging ib israel variant ib b strain assessed mean four challenge study least bird vaccinated ib h mass type combined ib dutch type followed qxlike ib vaccine booster vaccinated combination ib h ib qxlike ib protected challenge ib b addition ib mass type boosted qxlike ib showed protection following challenge ib b combination ib h ib boosted qxlike ib vaccine conferred protection whilst h ib combination showed protection israel variant challenge ib boosted qxlike ib vaccine showed protection ib israel variant therefore concluded combination ib h ib qxlike ib confers broad protection different nonrelated virulent ib strain,2017,"Bru, T; Vila, R; Cabana, M; Geerligs, H J",Avian pathology : journal of the W.V.P.A,,,,,,https://doi.org/10.1080/03079457.2016.1203393; https://www.ncbi.nlm.nih.gov/pubmed/27400065/,20593050.0,3
41541,41541,53960,jq0upsst,,Medline,The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.,10.1586/14760584.2013.811208,,23885825.0,unk,small molecule tolllike receptor tlr agonist demonstrated potential vaccine adjuvant since directly activate apc enhance humoral cellular immune response especially th response although natural ligand tlr tlr ssrna vast majority vaccine study performed thus far performed synthetic small molecule imidazoquinolines imiquimod resiquimod despite approved clinical use topical tlr agonist imiquimod aldara® imiquimod cream mn usa external genital wart superficial basal cell carcinoma actinic keratosis vaccine using tlr tlr tlr agonist progressed beyond earlyphase clinical study thus far review highlight nonclinical clinical study indicate promise tlr ligand vaccine adjuvant reason inconsistent result thus far problem current technology potential path forward tlr agonist vaccine adjuvant,2013,"Vasilakos, John P; Tomai, Mark A",Expert review of vaccines,,,,,,https://doi.org/10.1586/14760584.2013.811208; https://www.ncbi.nlm.nih.gov/pubmed/23885825/,207195297.0,3
41614,41614,54052,83phcmty,,Medline,Assessment of Lactobacillus gasseri as a candidate oral vaccine vector.,10.1128/cvi.05277-11,,21900526.0,unk,lactobacillus specie commensal bacteria long recognized probiotic microbe generally regarded safe gras human consumption investigated use l gasseri vaccine vector oral immunization mucosal pathogen recent research shown immune response different lactobacillus vary widely depending specie subspecies lactobacillus studied lactobacillus seem induce oral tolerance others induce adaptive immune response study characterized systemic mucosal immune response wildtype genetically modified l gasseri l gasseri primarily activates tlr additional activation tlr homodimer expand tolllike receptor tlr activation profile l gasseri immunogenicity vector plasmid containing flic gene encoding bacterial flagellin introduced resulted strong activation tlr treatment human myeloid dendritic cell recombinant lactobacillus expressing flagellin triggered phenotypic maturation release proinflammatory cytokine contrast bacterial treatment also resulted statistically significant increase il production vivo study established treatment l gasseri led diversification bcell population lamina propria murine colon furthermore treatment genetically modified l gasseri led significant decrease percentage foxp colonic lymphocyte taken together data clarify interaction l gasseri host immune system support investigation vivo immunogenicity l gasseri expressing flagellin candidate vaccine antigen,2011,"Stoeker, Laura; Nordone, Shila; Gunderson, Sara; Zhang, Lin; Kajikawa, Akinobu; LaVoy, Alora; Miller, Michael; Klaenhammer, Todd R; Dean, Gregg A",Clinical and vaccine immunology : CVI,,,,,,https://doi.org/10.1128/cvi.05277-11; https://www.ncbi.nlm.nih.gov/pubmed/21900526/,22005940.0,3
41725,41725,54181,k1alpf5w,,Medline,Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy.,10.1007/978-1-4939-3387-7_47,,27076169.0,unk,messenger rna mrnatransfected dendritic cell dc vaccine shown powerful modality eliciting antitumor immune response mouse human however application fully optimized since many factor contribute efficacy remain poorly understood work stemming laboratory recently demonstrated preconditioning vaccine site recall antigen prior administration dendritic cell vaccine creates systemic recall response resultantly enhances dendritic cell migration lymph node improved antitumor efficacy chapter describes generation murine mrnatransfected dc vaccine well method vaccine site preconditioning protein antigen formulation create potent recall response,2016,"Batich, Kristen A; Swartz, Adam M; Sampson, John H",Methods in molecular biology,,,,,,https://doi.org/10.1007/978-1-4939-3387-7_47; https://www.ncbi.nlm.nih.gov/pubmed/27076169/,206659898.0,3
41788,41788,54254,g0737pk6,,Medline,Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.,10.1128/jvi.01651-16,,27795425.0,unk,middle east respiratory syndrome coronavirus merscov bind cellular receptor dipeptidyl peptidase dpp via spike protein receptorbinding domain rbd rbd contains critical neutralizing epitope serf important vaccine target since rbd mutation occur different merscov isolates antibody escape mutant crossneutralization divergent merscov strain rbdinduced antibody remains unknown constructed four recombinant rbd rrbd protein single multiple mutation detected representative human merscov strain outbreak respectively one rrbd protein multiple change derived camel merscov strain like rbd prototype emc emcrbd five rbds maintained good antigenicity functionality ability bind rbdspecific neutralizing monoclonal antibody mabs dpp receptor high immunogenicity able elicit sspecific antibody induced potent neutralizing antibody crossneutralizing mers pseudoviruses expressing protein representative human camel merscov strain identified outbreak mab escape merscov mutant live human merscov strain constructed two rbds mutated multiple key residue receptorbinding motif rbm rbd demonstrated strong crossreactivity antiemcrbd antibody rbd mutant diminished dpp binding also led virus attenuation suggesting immunoevasion rbd immunization accompanied loss viral fitness therefore study demonstrates merscov rbd important vaccine target able induce highly potent broadspectrum neutralizing antibody infection divergent circulating human camel merscov strain importance merscov first identified june since spread human camel mutation spike protein receptorbinding domain rbd key vaccine target identified raising concern efficacy rbdbased mers vaccine circulating human camel merscov strain constructed five vaccine candidate designated rbd rbd rbd rbd camelrbd containing single multiple mutation rbd representative human camel merscov strain outbreak rbdbased vaccine candidate maintained good functionality antigenicity immunogenicity induced strong crossneutralizing antibody infection divergent pseudotyped live merscov strain well antibody escape merscov mutant study provides impetus development safe highly effective broadspectrum rbdbased subunit vaccine prevent merscov infection,2017,"Tai, Wanbo; Wang, Yufei; Fett, Craig A; Zhao, Guangyu; Li, Fang; Perlman, Stanley; Jiang, Shibo; Zhou, Yusen; Du, Lanying",Journal of virology,,,,,,https://doi.org/10.1128/jvi.01651-16; https://www.ncbi.nlm.nih.gov/pubmed/27795425/,28032006.0,3
41932,41932,54416,kom3p6gq,,Medline,Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.,10.1016/j.vaccine.2010.12.062,,21199697.0,unk,yersinia pestis pestis causative pathogen plague highly fatal disease effective vaccine especially mucosal transmission still available like many bacterial infection antigenspecific antibody response traditionally considered critical solely responsible vaccineinduced protection pestis study recent year suggested importance cell immune response pestis infection information still limited detail pestis antigenspecific cell immune response current report study conducted identify presence cd cell epitope lcrv protein leading antigen plague vaccine development furthermore depletion cd cell lcrv dna vaccinated balbc mouse led reduced protection lethal intranasal challenge pestis finding establish lcrv dna vaccine able elicit cd cell immune response specific epitope key plague antigen cd cell immune response involved lcrv dna vaccineelicited protection future study plague vaccine development need examine presence detectable cell immune response particular cd tcell immune response enhance protection pestis higher animal specie human,2011,"Wang, Shixia; Goguen, Jon D; Li, Fusheng; Lu, Shan",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2010.12.062; https://www.ncbi.nlm.nih.gov/pubmed/21199697/,539302.0,3
41949,41949,54441,ffidd0pm,,Medline,Limited Protection Conferred by Recombinant Newcastle Disease Virus Expressing Infectious Bronchitis Spike Protein.,10.1637/0005-2086-64.1.53,,32267125.0,unk,recombinant newcastle disease virus ndv lasota l expressing secreted trimeric spike sectodomain se infectious bronchitis virus ibv rlsibvse developed evaluated protection conferred ibv challenge ibv sectodomain protein excluding transmembrane anchor short cytoplasmic domain expressed recombinant l corresponds arkansas arktype ibv first experiment chicken primed day age primed day age boosted day age embryo infectious dos eidbird rlsibvse challenged virulent ark strain single vaccination proved completely ineffective protecting chicken challenge whereas priming boosting reduced clinical sign tracheal lesion reduce viral load lachrymal fluid experiment vaccine dose increased eidbird different virulent ark strain used challenge addition chicken singly immunized either day day hatch ndv antibody level detected vaccinated chicken moderate hemagglutination inhibition titer varying log slightly higher antibody level ndv observed chicken vaccinated day versus day without difference achieving statistical significance contrast antibody response measured using recombinant ibv proteincoated elisa plate significantly greater chicken vaccinated day day use higher rlsibvse dose substantially enhanced success single vaccination compared experiment sign tracheal lesion reduced effectively chicken vaccinated day hatch however experiment vaccination reduce viral load tear fluid challenged chicken similar result reduction viral load trachea apparent rlsibvs vaccination obtained others work needed understand immune response induced recombinant virus seems provide protection disease reduce viral load upper respiratory tract,2020-03-01,"Zegpi, R A; He, L; Yu, Q; Joiner, K S; van Santen, V L; Toro, H",Avian diseases,,,,,,https://doi.org/10.1637/0005-2086-64.1.53; https://www.ncbi.nlm.nih.gov/pubmed/32267125/,214763333.0,3
41971,41971,54467,4g6yw9kz,,Medline,Vaccines and global health: In search of a sustainable model for vaccine development and delivery.,10.1126/scitranslmed.aaw2888,,31217336.0,unk,vaccine disease low middleincome country fail developed weak absent market incentive conquering disease tuberculosis hiv malaria ebola well illness caused multidrugresistant pathogen requires considerable investment new sustainable model vaccine development involving close collaboration public private sector,2019,"Rappuoli, Rino; Black, Steven; Bloom, David E",Science translational medicine,,,,,,https://doi.org/10.1126/scitranslmed.aaw2888; https://www.ncbi.nlm.nih.gov/pubmed/31217336/,195191351.0,3
42011,42011,54511,r51a83y4,,Medline,Strategies for design and application of enteric viral vaccines.,10.1146/annurev-animal-022114-111038,,25387111.0,unk,enteric viral infection domestic animal cause significant economic loss recent emergence virulent enteric coronaviruses porcine epidemic diarrhea virus pedv north america asia vaccine available remains challenge global swine industry vaccination strategy rotavirus coronavirus transmissible gastroenteritis virus infection reviewed vaccination principle applicable emerging enteric infection pedv maternal vaccine induce lactogenic immunity transmission suckling neonate via colostrum milk critical early passive protection subsequently weaned animal oral vaccine incorporating novel mucosal adjuvant eg vitamin probiotic may provide active protection maternal immunity wane understanding intestinal systemic immune response experimental rotavirus transmissible gastroenteritis virus vaccine infection pig provides basis model development safe effective vaccine young animal child established emerging enteric infection,2015,"Chattha, Kuldeep S; Roth, James A; Saif, Linda J",Annual review of animal biosciences,,,,,,https://doi.org/10.1146/annurev-animal-022114-111038; https://www.ncbi.nlm.nih.gov/pubmed/25387111/,5340035.0,3
42018,42018,54519,v0z9daqm,,Medline,Employing XIAP to enhance the duration of antigen expression and immunity against an avian influenza H5 DNA vaccine.,10.3109/08820139.2014.988718,,25831080.0,unk,dna vaccine represents powerful approach prevention avian hn influenza infection yet dna vaccineinduced immune response might limited short duration antigen expression strategy enhance adaptive immune response elicited hemagglutinin h dna vaccine explored effect coadministration dna encoding xlinked inhibitor apoptosis protein xiap modulator apoptosis stimulator inflammatory signaling cultured cell early hour h found dna vaccine encoded h antigen potent stimulator apoptosis h proapoptotic activity significantly suppressed coexpression fulllength xiap mutant xiap δring however fulllength xiap showed higher potency mutant xiap δring inhibition hinduced apoptosis also compared immunizing ability transmembrane secretory form h mouse vaccinated twice week interval secretory form h showed higher hemagglutination inhibition hi antibody titer mouse vaccinated transmembrane form h furthermore coadministration xiap secretory form h resulted stronger antibody response transmembrane form h finding suggest design dna vaccine given proapoptotic antigen using antiapoptotic molecular adjuvant secretory form antigen may greater stimulus induce immune response,2015,"Tabatabaeizadeh, Seyed-Elias; Bassami, Mohammad Reza; Haghparast, Alireza; Dehghani, Hesam",Immunological investigations,,,,,,https://doi.org/10.3109/08820139.2014.988718; https://www.ncbi.nlm.nih.gov/pubmed/25831080/,35524289.0,3
42146,42146,54668,ube8ytcp,,Medline,Evaluation of Burkholderia mallei ΔtonB Δhcp1 (CLH001) as a live attenuated vaccine in murine models of glanders and melioidosis.,10.1371/journal.pntd.0007578,,31306423.0,unk,background glanders caused burkholderia malleus reemerging zoonotic disease affecting solipeds human furthermore b malleus genetically related b pseudomallei causative agent melioidosis facultative intracellular bacteria classified tier select biothreat agent previous study b malleus δtonb δhcp clh liveattenuated vaccine demonstrated attenuated safe protective b malleus wildtype strain susceptible balbc mouse model methodologyprincipal finding current work evaluated protective efficacy clh glanders melioidosis diseaseresistant cbl mouse strain humoral well cellular immune response also examined found clhimmunized mouse showed survival intranasal aerosol challenge b malleus atcc moreover vaccine also afforded significant crossprotection b pseudomallei k low level bacterial burden detected organ immunization prime boost regimen clh induced significantly greater level total subclass igg generated antigenspecific splenocyte production ifnγ ila interestingly protection induced clh primarily dependent humoral immunity cd cd cell played le critical protective role conclusionssignificance data indicate clh serf effective live attenuated vaccine prevent glanders melioidosis quantity quality antibody response well improving cellmediated immune response following vaccination need investigated prior advancement preclinical study,2019,"Khakhum, Nittaya; Bharaj, Preeti; Myers, Julia N; Tapia, Daniel; Walker, David H; Endsley, Janice J; Torres, Alfredo G",PLoS neglected tropical diseases,,,,,,https://doi.org/10.1371/journal.pntd.0007578; https://www.ncbi.nlm.nih.gov/pubmed/31306423/,196813615.0,3
42210,42210,54747,klg8rjpk,,Medline,Vaccines and Airline Travel: A Federal Role to Protect the Public Health.,10.1177/0098858816658279,,29086635.0,unk,article explores two way airline travel important vector spread infectious disease argues airline marketbased liabilitybased reason require passenger vaccinated going article explores whether federal government legal constitutional authorityespecially commerce clauseto encourage mandate airline implement vaccine screen disrupting spread disease key network node individual interact connect geographic region creating another incentive adult vaccination airline vaccine screen could effective legally viable tool protection public health,2016,"Robertson, Christopher T",American journal of law & medicine,,,,,,https://doi.org/10.1177/0098858816658279; https://www.ncbi.nlm.nih.gov/pubmed/29086635/,206438713.0,3
42262,42262,54809,ft690b6i,,Medline,The program of antiviral agents inhibits virus infection.,10.1007/s00203-018-1525-z,,29846759.0,unk,virus infection root cause epidemic world vaccine antiviral agent two important method control viral disease recent time rnamediated therapeutic prevention received much attention review provide overview current information regarding use vaccine antiviral agent rnamediated method controlling preventing viral infection stress specifically potential existing rnamediated method clinical application,2018,"Ding, Yao-Zhong; Lv, Jan-Liang; Zhang, Zhong-Wang; Ma, Xiao-Yuan; Zhang, Jie; Zhang, Yong-Guang",Archives of microbiology,,,,,,https://doi.org/10.1007/s00203-018-1525-z; https://www.ncbi.nlm.nih.gov/pubmed/29846759/,44142218.0,3
42457,42457,55040,22z937x8,,Medline,Ethical considerations for epidemic vaccine trials.,10.1136/medethics-2020-106235,,32414757.0,unk,vaccine powerful measure protect health individual combat outbreak covid pandemic ethical dilemma arises one effective vaccine successfully developed epidemic disease researcher seek test efficacy another vaccine pathogen clinical trial involving human subject one hand compelling reason would unethical trial novel vaccine effective product exists already first firm principle medical ethic effective treatment vaccine withheld patient life may depend second since epidemic outbreak often emerge setting lessresourced health system pronounced risk trial withholding effective vaccine would disproportionately affect vulnerable population historically exploited biomedical research third clinical trial novel vaccine may odds effort control active outbreak hand may justified conduct trial candidate vaccine expected certain advantage compared existing product essay discus key factor comparing vaccine epidemic pathogen including immunological logistical economic consideration alongside case study development vaccine ebola essay seek establish general framework expanded populated immunologist epidemiologist economist bioethicists ultimately could applied case covid vaccine,2020-05-15,"Monrad, Joshua Teperowski",Journal of medical ethics,,,,,,https://doi.org/10.1136/medethics-2020-106235; https://www.ncbi.nlm.nih.gov/pubmed/32414757/,218658706.0,3
42471,42471,55057,c647k035,,Medline,WHO Guide for standardisation of economic evaluations of immunization programmes.,10.1016/j.vaccine.2009.06.035,,19567247.0,unk,traditional epi vaccine considered among efficient us scarce health care resource today many underused new vaccine available short mediumterm vaccine cost cent per dose traditional vaccine multidollar vaccine decisionmakers need information among thing relative costeffectiveness number review indicated scope improving transparency completeness comparability economic evaluation vaccination programme thus need improve quality economic evaluation vaccination programme adherence general guideline would increase quality interpretability transferability future analysis however reason believe might also need specific advice vaccination programme example inconsistency method used estimate future benefit vaccination programme relative efficiency programme sensitive controversial aspect general guideline inclusion indirect cost discounting health outcome guide developed order meet need decisionmakers relevant reliable consistent economic information aim provide clear concise practical high quality guidance conduct economic evaluation,2010,"Walker, Damian G; Hutubessy, Raymond; Beutels, Philippe",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2009.06.035; https://www.ncbi.nlm.nih.gov/pubmed/19567247/,15754150.0,3
42662,42662,55281,g8kq97s0,,Medline,Bacteriophages and their derivatives for the treatment and control of food-producing animal infections.,10.1080/1040841x.2016.1271309,,28071145.0,unk,nowadays world facing increasing emergence antibiotic resistant bacteria simultaneously banning existing antibiotic lack development new antimicrobial created urgent need find new alternative animal infection bacteriophage phage naturally occurring predator bacteria ubiquitous environment high host specificity harmless animal reason phage derivative considered valuable antimicrobial alternative opportunity reduce current use antibiotic agrifood production increasing animal productivity providing environmental protection furthermore possibility combining phage genetic material foreign gene encoding peptide interest enabled use vaccine delivery tool case besides bacterial infection might used prevent viral infection review explores current data regarding advance use phage phageencoded protein endolysins exolysins depolymerases either therapeutic prophylactic application animal husbandry use recombinant phagederived particle genetically modified phage including phage vaccine also reviewed,2017,"Carvalho, Carla; Costa, Ana Rita; Silva, Filipe; Oliveira, Ana",Critical reviews in microbiology,,,,,,https://doi.org/10.1080/1040841x.2016.1271309; https://www.ncbi.nlm.nih.gov/pubmed/28071145/,205694247.0,3
42751,42751,55384,zq58ot3c,,Medline,"Use of S-[2,3-bispalmitoyiloxy-(2R)-propyl]-R-cysteinyl-amido-monomethoxy polyethylene glycol as an adjuvant improved protective immunity associated with a DNA vaccine encoding Cu,Zn superoxide dismutase of Brucella abortus in mice.",10.1128/cvi.00554-14,,25165025.0,unk,study conducted evaluate immunogenicity protective efficacy dna vaccine encoding brucella abortus cuzn superoxide dismutase sod using tolllike receptor agonist sbispalmitoyiloxyrpropylrcysteinylamidomonomethoxy polyethylene glycol bppcysmpeg adjuvant intranasal coadministration bppcysmpeg plasmid carrying sodencoding gene pcdnasod balbc mouse elicited antigenspecific humoral cellular immune response humoral response characterized stimulation igga igg presence sodspecific secretory iga nasal bronchoalveolar lavage fluid furthermore tcell proliferative response increased production gamma interferon also observed upon splenocyte restimulation recombinant sod cytotoxic response also stimulated demonstrated lysis rbsodinfected ja macrophage cell recovered immunized mouse pcdnasodbppcysmpeg formulation induced improved protection challenge virulent strain b abortus balbc mouse provided pcdnasod suggesting potential vaccination strategy brucella infection,2014,"Retamal-Díaz, Angello; Riquelme-Neira, Roberto; Sáez, Darwin; Rivera, Alejandra; Fernández, Pablo; Cabrera, Alex; Guzmán, Carlos A; Oñate, Angel",Clinical and vaccine immunology : CVI,,,,,,https://doi.org/10.1128/cvi.00554-14; https://www.ncbi.nlm.nih.gov/pubmed/25165025/,19231078.0,3
42910,42910,55567,6k09684o,,Medline,Failure of a vaccine using immunogenic recombinant proteins rNcSAG4 and rNcGRA7 against neosporosis in mice.,10.1016/j.vaccine.2009.09.050,,19782735.0,unk,development effective vaccine neospora caninum infection cattle important issue due significant economic impact parasitic disease worldwide work immune response safety efficacy different vaccine formulation using n caninum recombinant protein rncsag first bradyzoitespecific protein assayed vaccine rncgra evaluated mouse model survival curve pup vaccinated group showed slight delay time death compared control group difference statistically significant rncsagadjuvant group immune response mouse vaccinated rncsag characterized reduced specific igg cytokine level equilibrated ifngammail balance regarding mouse vaccinated rncgra strong humoral cellular immune response generated characterized hyperproduction ifngamma response accompanied significant protection vaccination mixture recombinant protein reduced infection lung brain acute chronic infection respectively although statistically significant summary significant protection obtained vaccine formulation present mouse model however study reveals positive result immune response efficacy recombinant protein result discussed order suggest new approach new chronic infection mouse model adjuvant,2009,"Aguado-Martínez, Adriana; Alvarez-García, Gema; Fernández-García, Aurora; Risco-Castillo, Verónica; Marugán-Hernández, Virginia; Ortega-Mora, Luis M",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2009.09.050; https://www.ncbi.nlm.nih.gov/pubmed/19782735/,39546927.0,3
43115,43115,55802,7q6xi2xx,,Medline,An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development.,10.12659/msm.924700,,32366816.0,unk,first outbreak coronavirus disease covid caused severe acute respiratory syndrome coronavirus sarscov occurred wuhan hubei province china late subsequent covid pandemic rapidly affected health economy world global approach pandemic isolate population reduce spread deadly virus vaccine began developed march first phase clinical trial novel lipid nanoparticle lnpencapsulated mrnabased vaccine mrna encodes spike protein protein sarscov began united state u production mrnabased vaccine promising recent development production vaccine however remain significant challenge development testing vaccine rapidly possible control covid requires international collaboration review aim describe background rationale development mrnabased sarscov vaccine current status mrna vaccine,2020-05-05,"Wang, Fuzhou; Kream, Richard M; Stefano, George B",Medical science monitor : international medical journal of experimental and clinical research,,,,,,https://doi.org/10.12659/msm.924700; https://www.ncbi.nlm.nih.gov/pubmed/32366816/,218503274.0,3
43220,43220,55916,3qku90ml,,Medline,Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks.,10.1089/hs.2020.0043,,32348165.0,unk,covid pandemic stark reminder heavy toll emerging infectious disease eids epidemic pandemic potential inflict vaccine development scaleup commercialization long expensive risky enterprise requires substantial upfront planning offer guarantee success eids particularly challenging target global health preparedness including vaccine development insufficient attention given challenge lesson learned potential solution support sustain vaccine industry engagement vaccine development eids drawing lesson recent ebola epidemic democratic republic congo well hn influenza ebola zika outbreak preceding offer perspective challenge facing eid vaccine development recommend additional solution prioritize near term recommendation focus reducing vaccine development timeline increasing business certainty reduce risk company global health security community opportunity build current momentum design sustainable model eid vaccine,2020-04-29,"Billington, John; Deschamps, Isabelle; Erck, Stanley C; Gerberding, Julie L; Hanon, Emmanuel; Ivol, Sabrina; Shiver, John W; Spencer, Julia A; Van Hoof, Johan",Health security,,,,,,https://doi.org/10.1089/hs.2020.0043; https://www.ncbi.nlm.nih.gov/pubmed/32348165/,217591851.0,3
43243,43243,55945,10my0twp,,Medline,Infectious Bronchitis Virus Population Structure Defines Immune Response and Protection.,10.1637/0005-2086-64.1.60,,32267126.0,unk,commercial arkansas ark delmarva poultry industry dpitype vaccine homogeneous population vaccine obtained previously adaptation chicken embryo kidney cek cell cekarkdpi used model understand impact population genetic structure generation immune response protection first experiment vaccinated chicken challenged ibv arktype virulent strain al despite extensive sequence similarity vaccine heterogeneous commercial arkdpi efficient reducing viral load challenged chicken respiratory sign tracheal lesion reduced similarly either vaccine distinct subpopulation ark challenge virus showing asparagine position consistently negatively selected immune pressure originating vaccination either vaccine antibody level antibody avidity arktype protein greater cekarkdpivaccinated chicken compared chicken vaccinated diverse commercial arkdpi vaccine synchronous replication homogeneous virus population likely elicits clonal expansion affinity maturation greater number responding b cell compared diverse virus population continuously changing proportion phenotype replication result second experiment showed initial vaccine virus replication hr postvaccination virus population showing increased diversity commercial arkdpi achieved higher concentration ibv rna trachea compared homogenous virus mrna expression gene associated innate immune response trachea hr postvaccination generally showed greater upregulation chicken vaccinated heterogeneous commercial arkdpi vaccine compared cekadapted virus greater upregulation gene likely associated higher virus replication achieved heterogeneous commercial vaccine thus adaptive antibody response favored homogenous structure cekarkdpi vaccine population higher antibody level antibody avidity innate immune response favored diverse viral population commercial arkdpi confirmed previous result distinct subpopulation wild ark challenge virus become selected immune pressure originating vaccination concluded population structure ibv vaccine impact innate immune response antibody avidity protection,2020-03-01,"Zegpi, R A; Joiner, K S; van Santen, V L; Toro, H",Avian diseases,,,,,,https://doi.org/10.1637/0005-2086-64.1.60; https://www.ncbi.nlm.nih.gov/pubmed/32267126/,214763346.0,3
43310,43310,56023,jw0sfrar,,Medline,"Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.",10.1016/s1473-3099(20)30001-3,,32251641.0,unk,background monovalent parenteral subunit rotavirus vaccine well tolerated immunogenic adult usa toddler infant south africa elicited poor response heterotypic rotavirus strain aimed evaluate safety immunogenicity trivalent vaccine formulation pvpp method doubleblind randomised placebocontrolled doseescalation phase study done three south african research site healthy adult aged year toddler aged year infant aged week ≥ week gestation without previous receipt rotavirus vaccination without hiv infection eligible enrolment doseescalation phase adult toddler randomly assigned block block size five receive μg μg vaccine placebo infant randomly assigned block block size four receive μg μg μg vaccine placebo expanded phase infant randomly assigned ratio receive μg μg μg vaccine placebo block size four participant parent participant clinical data laboratory staff masked treatment assignment adult received intramuscular injection vaccine placebo deltoid muscle day randomisation day day day toddler received single injection vaccine placebo anterolateral thigh day infant phase received injection vaccine placebo anterolateral thigh day approximately week age primary safety endpoint local systemic reaction grade worse within day adverse event serious adverse event within day injection participant received least one injection primary immunogenicity endpoint analysed infant either phase received planned injection blood sample analysed relevant timepoints presented major protocol violation considered effect immunogenicity result study included serum antipvp iga igg neutralising antibody geometric mean titre response measured week final injection vaccine compared placebo group trial registered clinicaltrialsgov nct finding feb dec adult μg μg group six placebo group toddler μg μg group six placebo group infant μg group μg group μg group placebo group randomly assigned received least one dose assessed safety significant difference local systemic adverse event unsolicited adverse event vaccine placebo group serious adverse event within day injection adult whereas one serious adverse event occurred toddler febrile convulsion μg group serious adverse event four placebo ten μg four μg five μg group occurred among infant commonly respiratory tract infection one death occurred infant within day injection due pneumococcal meningitis infant placebo μg μg μg group adjusted antipvp igg seroresponses ≥fold increase baseline p p p antigen significantly higher μg μg μg group placebo group p· although significantly higher placebo recipient antipvp iga seroresponses ≥fold increase baseline individual antigen modest across μg μg μg group adjusted neutralising antibody seroresponses infant ≥·fold increase baseline d p p wa p higher vaccine recipient placebo recipient p· comparison interpretation trivalent pvp vaccine well tolerated promising antipvp igg neutralising antibody response across three vaccine p type finding support advancing vaccine efficacy testing funding bill melinda gate foundation,2020-04-03,"Groome, Michelle J; Fairlie, Lee; Morrison, Julie; Fix, Alan; Koen, Anthonet; Masenya, Maysseb; Jose, Lisa; Madhi, Shabir A; Page, Nicola; McNeal, Monica; Dally, Len; Cho, Iksung; Power, Maureen; Flores, Jorge; Cryz, Stanley",The Lancet. Infectious diseases,,,,,,https://doi.org/10.1016/s1473-3099(20)30001-3; https://www.ncbi.nlm.nih.gov/pubmed/32251641/,215410555.0,3
43365,43365,56086,2d8u0upp,,Medline,Detection of different genotypes of infectious bronchitis virus and of infectious bursal disease virus in European broilers during an epidemiological study in 2013 and the consequences for the diagnostic approach.,10.1080/03079457.2017.1387231,,28972403.0,unk,gather recent data regarding infectious bronchitis ib infectious bursal disease ibd situation europe largescale field epidemiological survey using diagnostic sample implemented six month several european country france germany greece italy netherlands poland portugal republic ireland spain uk flock sampled strain different ibv genotype detected b genotype detected frequently followed qx massachusetts mass xindadilike strain strain belonging q ark italy b genotype detected well although le frequently separate sampling trachea kidney ibv detection using reverse transcriptase pcr useful different genotype significant difference sequence genotype detected organ data survey also provided valuable information replication ibd vaccine subsequent infectious bursal disease virus ibdv antibody response field condition detection five nonvvibdv field strain two different genotype show presence nonvvibdv nonvaccine strain easily undetected europe due focus sampling clinically ill bird detection vaccine virus bursa antibody response ibd vaccination flock vaccinated drinking water live attenuated vaccine compared vaccination hatchery using immunecomplex vaccine showed delayed replication vaccine applied drinking water indicating mistake timing andor application vaccine,2018,"de Wit, J J; Cazaban, C; Dijkman, R; Ramon, G; Gardin, Y",Avian pathology : journal of the W.V.P.A,,,,,,https://doi.org/10.1080/03079457.2017.1387231; https://www.ncbi.nlm.nih.gov/pubmed/28972403/,3477509.0,3
43435,43435,56165,wt7984kb,,Medline,The personal touch: strategies toward personalized vaccines and predicting immune responses to them.,10.1586/14760584.2014.905744,,24702429.0,unk,impact vaccine public health wellbeing profound smallpox eradicated polio nearing eradication multiple disease eliminated certain area world unfortunately face disease hepatitis c malaria tuberculosis well new reemerging pathogen lack effective vaccine empirical approach vaccine development successful past may current infectious disease challenge facing u new directed approach vaccine design development testing need developed ideally approach capitalize cuttingedge technology advanced analytical modeling strategy uptodate knowledge pathogen host approach pay particular attention cause interindividual variation vaccine response order develop new vaccine tailored unique need individual community within population,2014,"Kennedy, Richard B; Ovsyannikova, Inna G; Lambert, Nathaniel D; Haralambieva, Iana H; Poland, Gregory A",Expert review of vaccines,,,,,,https://doi.org/10.1586/14760584.2014.905744; https://www.ncbi.nlm.nih.gov/pubmed/24702429/,207195620.0,3
43474,43474,56217,no9k0z87,,Medline,Burkholderia mallei CLH001 Attenuated Vaccine Strain Is Immunogenic and Protects against Acute Respiratory Glanders.,10.1128/iai.00328-16,,27271739.0,unk,burkholderia malleus causative agent glanders incapacitating disease high mortality rate respiratory case endemicity ineffective treatment option emphasize public health threat highlight need vaccine live attenuated vaccine considered viable vaccine strategy burkholderia singlegenedeletion mutant provided complete protection study constructed selectagentexcluded b malleus δtonb δhcp clh vaccine strain investigated ability protect acute respiratory glanders show clh attenuated safe effective protecting lethal b malleus challenge intranasal administration clh balbc nod scid gamma nsg mouse resulted complete survival without detectable colonization abnormal organ histopathology additionally balbc mouse intranasally immunized clh primeboost regimen fully protected lethal challenge b malleus lux csm wildtype strain,2016,"Hatcher, Christopher L; Mott, Tiffany M; Muruato, Laura A; Sbrana, Elena; Torres, Alfredo G",Infection and immunity,,,,,,https://doi.org/10.1128/iai.00328-16; https://www.ncbi.nlm.nih.gov/pubmed/27271739/,28798008.0,3
43573,43573,56334,6tsieagr,,Medline,Infectious Bronchitis Virus Immune Responses in the Harderian Gland upon Initial Vaccination.,10.1637/0005-2086-64.1.92,,32267130.0,unk,recent year arkansas delmarva poultry industry arkdpiderived infectious bronchitis ib virus ibv vaccine used characterize immune response chicken subsequent vaccination day hatch beyond perhaps arkdpi vaccine display increased heterogeneity result cell immune response shown ambiguity current study investigated effect vaccination highly stable homogeneous massachusetts masstype vaccine day age harderian gland hg response confirming previous study ibv serum antibody lachrymal iga level greater upon vaccination day compared vaccination day age unlike result arkdpi virus clear trend detected b cell hg masstype vaccination consistent antibody response b thelper cdcd cell frequency higher bird vaccinated day age cytotoxic cell cdcd also increased compared chicken vaccinated day age depending likely age ib outbreak occur particular region postponing first ibv vaccination may optimize immune response,2020-03-01,"Zegpi, R A; Breedlove, C; Gulley, S; Toro, H",Avian diseases,,,,,,https://doi.org/10.1637/0005-2086-64.1.92; https://www.ncbi.nlm.nih.gov/pubmed/32267130/,214763350.0,3
43600,43600,56367,uwe7uwf6,,Medline,Vesicular stomatitis virus as a vector to deliver virus-like particles of human norovirus: a new vaccine candidate against an important noncultivable virus.,10.1128/jvi.02332-10,,21228240.0,unk,human norovirus hunov major causative agent foodborne gastroenteritis worldwide currently vaccine effective therapeutic intervention virus development attenuated vaccine hunov hampered inability grow virus cell culture thus vectorbased vaccine may ideal study constructed recombinant vesicular stomatitis virus rvsvvp expressing vp major capsid protein hunov expression capsid protein vsv resulted formation hunov viruslike particle vlps morphologically antigenically similar native virion recombinant rvsvvp attenuated cultured mammalian cell well mouse mouse inoculated single dose rvsvvp intranasal oral route stimulated significantly stronger humoral cellular immune response baculovirusexpressed vlp vaccination moreover demonstrated mouse inoculated rvsvvp triggered comparable level fecal vaginal iga antibody taken together vsv recombinant system provides new approach generate hunov vlps vitro also new avenue development vectored vaccine norovirus noncultivable virus,2011,"Ma, Yuanmei; Li, Jianrong",Journal of virology,,,,,,https://doi.org/10.1128/jvi.02332-10; https://www.ncbi.nlm.nih.gov/pubmed/21228240/,5437921.0,3
43691,43691,56468,i8jktx30,,Medline,Adjuvant Human Papillomavirus Vaccination for Secondary Prevention: A Systematic Review.,10.1001/jamaoto.2016.4736,,28334393.0,unk,importance human papillomavirus hpv vaccination recommended child younger adult older adult prior hpv exposure leaving large portion population risk hpvmediated disease emerging data suggest possible role vaccination adjuvant treatment individual hpvrelated clinical disease objective systematically review literature regarding hpv vaccination secondary disease prevention treatment active clinical disease across disease site serve platform management hpvrelated disease head neck evidence review systematic search august pubmed medline embase cinahl cochrane library web science biosis citation index current content connect scientific library online global health database used prisma guideline identify relevant article related adjuvant use hpv vaccination primary search term hpv vaccine human papillomavirus vaccine papillomarvirus vaccine alphapapillomavirus vaccine hpv human papillomavirus alphapapillomavirus papillomaviridae virus wart wart virus recurrence relapse reoccurrence recurrence relapse relapsing fortyfive full text english reviewed article included final review study subpopulation individual hpv dna positivity andor seropositivity extracted inclusion included study assessed bias separated based presence active clinical disease hpv dna positivity seropositivity finding nineteen study unique patient included review hpv vaccination used adjuvant treatment active clinical disease study reported decreased disease recurrence decreased disease burden increased intersurgical interval contrast none study vaccination individual hpv dna positivity andor seropositivity without clinical disease reported improved outcome conclusion relevance difference adjuvant vaccination hpvmediated clinical disease vaccination hpv dnapositive andor hpvseropositive population posit underlying difference disease immune process data suggest additional evaluation adjuvant hpv vaccination individual active clinical disease warranted,2017,"Dion, Gregory R; Teng, Stephanie; Boyd, Leslie R; Northam, Antonia; Mason-Apps, Charlotte; Vieira, Dorice; Amin, Milan R; Branski, Ryan C",JAMA otolaryngology-- head & neck surgery,,,,,,https://doi.org/10.1001/jamaoto.2016.4736; https://www.ncbi.nlm.nih.gov/pubmed/28334393/,205137647.0,3
43854,43854,56656,x9piyivm,,Medline,A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates.,10.1126/scitranslmed.aac7462,,26290414.0,unk,first identified middle east respiratory syndrome mers caused emerging human coronavirus distinct severe acute respiratory syndrome coronavirus sarscov represents novel member lineage c betacoronoviruses since identification mers coronavirus merscov linked infection manifesting severe morbidity often mortality death arabian peninsula europe recently united state humantohuman transmission documented nosocomial transmission appearing important route infection recent increase case mers middle east coupled lack approved antiviral therapy vaccine treat prevent infection cause concern report development synthetic dna vaccine merscov optimized dna vaccine encoding mers spike protein induced potent cellular immunity antigenspecific neutralizing antibody mouse macaque camel vaccinated rhesus macaque seroconverted rapidly exhibited high level virusneutralizing activity upon mers viral challenge monkey controlvaccinated group developed characteristic disease including pneumonia vaccinated macaque protected failed demonstrate clinical radiographic sign pneumonia study demonstrate consensus mers spike protein synthetic dna vaccine induce protective response viral challenge indicating strategy may value possible vaccine modality emerging pathogen,2015,"Muthumani, Karuppiah; Falzarano, Darryl; Reuschel, Emma L; Tingey, Colleen; Flingai, Seleeke; Villarreal, Daniel O; Wise, Megan; Patel, Ami; Izmirly, Abdullah; Aljuaid, Abdulelah; Seliga, Alecia M; Soule, Geoff; Morrow, Matthew; Kraynyak, Kimberly A; Khan, Amir S; Scott, Dana P; Feldmann, Friederike; LaCasse, Rachel; Meade-White, Kimberly; Okumura, Atsushi; Ugen, Kenneth E; Sardesai, Niranjan Y; Kim, J Joseph; Kobinger, Gary; Feldmann, Heinz; Weiner, David B",Science translational medicine,,,,,,https://doi.org/10.1126/scitranslmed.aac7462; https://www.ncbi.nlm.nih.gov/pubmed/26290414/,206688706.0,3
43870,43870,56674,9qwi5emc,,Medline,Analytic Vaccinology: Antibody-Driven Design of a Human Cytomegalovirus Subunit Vaccine.,10.1007/978-1-4939-3387-7_8,,27076130.0,unk,identification relevant protective antigen represented considerable obstacle development subunit vaccine viral infection including human cytomegalovirus hcmv infection chapter describes method analytic vaccinology centered clonal analysis human b cell response hcmv represents essential tool assessing impact individual viral antigen antiviral antibody response providing key information immunogenicity protective property antibody elicited viral protein analytic vaccinology method guide selection appropriate vaccine candidate discus methodology generation human monoclonal antibody b cell immune donor antibody screening vitro assay antigen binding virus neutralization strategy animal immunization useful preclinical evaluation selected viral antigen approach analytic vaccinology could universally applied characterization bcell immune response virus interest ultimately used vaccine development,2016,"Kabanova, Anna; Lilleri, Daniele",Methods in molecular biology,,,,,,https://doi.org/10.1007/978-1-4939-3387-7_8; https://www.ncbi.nlm.nih.gov/pubmed/27076130/,206659921.0,3
43942,43942,56756,2jeb1vcs,,Medline,Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice.,10.1128/cvi.00261-08,,18987164.0,unk,vaccine development severe acute respiratory syndrome coronavirus sarscov mainly focused spike protein however variation gene virus may affect efficacy vaccine particularly crossprotection sarslike cov slcov recently conserved groupspecific open reading frame orf gene found sarscov slcov studied immunogenicity human sarscov bat slcov dna vaccine mouse electroporation immunization followed enzymelinked immunosorbent enzymelinked immunospot flow cytometry assay result showed high level specific humoral response induced sarscov slcov dna vaccine furthermore strong thbased cellular immune response stimulated dna vaccine vaccine stimulated gamma interferon production mainly cd cell interleukin il mainly cd cell interest frequency ilpositive cell elicited sarscov dna vaccine significantly higher elicited slcov dna vaccine summary study provides reference designing crossprotective dna vaccine based groupspecific orfs covs,2009,"Lu, Baojing; Tao, Ling; Wang, Ting; Zheng, Zhenhua; Li, Bao; Chen, Ze; Huang, Yi; Hu, Qinxue; Wang, Hanzhong",Clinical and vaccine immunology : CVI,,,,,,https://doi.org/10.1128/cvi.00261-08; https://www.ncbi.nlm.nih.gov/pubmed/18987164/,29555816.0,3
43989,43989,56816,a9so3wmb,,Medline,Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection.,10.1080/21645515.2016.1261229,,27960596.0,unk,tuberculosis tb remains major health problem worldwide development effective vaccine urgently needed vaccination strategy based heterologous primeboost protocol using mycobacterium bovis bacillus calmetteguérin bcg primer modified vaccinia virus ankara strain expressing mycobacterial antigen aga mvaa booster may increase protective efficacy bcg addition vaccination recombinant viral vaccine vesicular stomatitis virus vsv rvc mtb rvc elicit remarkable tcellmediated immune response provide effective longterm protection bcg challenge study used vsv boost bcg evaluated immunogenicity balbc mouse primeboost approach boosting vsv significantly enhanced ifnγ cd cell response crucial antitb immune response moreover vsv boosting significantly reduced pathology compared mock vaccination decreased bacterial load lung tissue compared bcg vsv vaccination alone analysis vaccineinduced immunity identified polyfunctional cell might contribute enhanced protection vsv boosting study proved viral booster vsv mouse improved protection mycobacteria infection could helpful designing efficient vaccination strategy tb human,2017,"Zhang, Ming; Dong, Chunsheng; Xiong, Sidong",Human vaccines & immunotherapeutics,,,,,,https://doi.org/10.1080/21645515.2016.1261229; https://www.ncbi.nlm.nih.gov/pubmed/27960596/,205965143.0,3
44513,44513,57444,nkq39uo1,,Medline,A recombinant rabies vaccine expressing the trimeric form of the glycoprotein confers enhanced immunogenicity and protection in outbred mice.,10.1016/j.vaccine.2014.06.058,,24962755.0,unk,rabies disease characterized invariably lethal encephalitis viral origin controlled preventive vaccination program wildlife domestic animal human area high risk exposure currently available vaccine expensive cumbersome produce require intensive immunization booster scheme induce maintain protective immunity present study describe development candidate recombinant subunit rabies vaccine based glycoprotein g prototype rabies virus rabvg expressed either monomer rabvmg native trimeric configuration rabvtg without matrixm™ adjuvant immunogenicity protective efficacy respective candidate vaccine tested outbred nih swiss albino mouse rabvtg candidate vaccine proved superior rabvmg vaccine candidate term immunogenicity efficacy relatively poor immunogenicity rabvmg vaccine candidate greatly improved addition adjuvant single low dose rabvtg combination matrixm™ induced high level high avidity neutralizing antibody protected mouse challenge lethal dose rabv consequently rabvtg used combination matrixm™ promising vaccine candidate overcomes limitation currently used vaccine,2014,"Koraka, Penelope; Bosch, Berend-Jan; Cox, Manon; Chubet, Rick; Amerongen, Geert van; Lövgren-Bengtsson, Karen; Martina, Byron E E; Roose, Jouke; Rottier, Peter J M; Osterhaus, Albert D M E",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2014.06.058; https://www.ncbi.nlm.nih.gov/pubmed/24962755/,205596095.0,3
44528,44528,57460,5pf7dq12,,Medline,Virus-like particles in vaccine development.,10.1586/erv.10.115,,20923267.0,unk,viruslike particle vlps multiprotein structure mimic organization conformation authentic native virus lack viral genome potentially yielding safer cheaper vaccine candidate handful prophylactic vlpbased vaccine currently commercialized worldwide glaxosmithklines engerix hepatitis b virus cervarix human papillomavirus merck co inc recombivax hb hepatitis b virus gardasil human papillomavirus example vlpbased vaccine candidate clinical trial undergoing preclinical evaluation influenza virus parvovirus norwalk various chimeric vlps many others still restricted smallscale fundamental research despite success preclinical test article focus essential role vlp technology newgeneration vaccine prevalent emergent disease implication largescale vlp production discussed context process control monitorization optimization main downstream technical challenge identified discussed accordingly successful vlpbased vaccine blockbuster briefly presented concomitantly latest result clinical trial recent development chimeric vlpbased technology either therapeutic prophylactic vaccination,2010,"Roldão, António; Mellado, Maria Candida M; Castilho, Leda R; Carrondo, Manuel J T; Alves, Paula M",Expert review of vaccines,,,,,,https://doi.org/10.1586/erv.10.115; https://www.ncbi.nlm.nih.gov/pubmed/20923267/,29234945.0,3
44561,44561,57501,t8xvsj3e,,Medline,An iron oxide nanocarrier for dsRNA to target lymph nodes and strongly activate cells of the immune system.,10.1002/smll.201401353,,25123704.0,unk,success nanoparticlebased therapy depend part accurate delivery target receptor organ therefore considerable potential nanoparticles achieve delivery right drug using right route administration right location right time monitoring process noninvasive molecular imaging challenge harnessing immunotherapy via activation tolllike receptor tlrs development vaccine major infectious disease cancer immunotherapy delivery vaccine component lymph node lns essential effective stimulation immune response although promising advance made delivering therapeutic lns remains challenging shown ironoxide nanoparticles engineered combine single small nm nanocarrier complementary multimodal imaging feature immunostimulatory activity polyinosinicpolycytidylic acid poly ic whilst fluorescence property nanocarrier show effective delivery endosomes tlr antigen presenting cell mrispect imaging reveals effective delivery lns importantly vitro vivo study show using nanocarrier immunostimulatory activity poly ic greatly enhanced nanocarriers considerable potential cancer diagnosis development new targeted programmable immunotherapy,2014,"Cobaleda-Siles, Macarena; Henriksen-Lacey, Malou; Ruiz de Angulo, Ane; Bernecker, Anja; Gómez Vallejo, Vanessa; Szczupak, Boguslaw; Llop, Jordi; Pastor, Géraldine; Plaza-Garcia, Sandra; Jauregui-Osoro, Maite; Meszaros, Levente K; Mareque-Rivas, Juan C",Small,,,,,,https://doi.org/10.1002/smll.201401353; https://www.ncbi.nlm.nih.gov/pubmed/25123704/,28923764.0,3
44727,44727,57682,8b1ppt9t,,Medline,Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching.,10.1016/j.vaccine.2011.02.023,,21352940.0,unk,show immunogenicity modified vaccinia ankara mva vaccine strain improved deletion gene without diminishing ability virus replicate deletion gene resulted increased virusspecific immunoglobulin production class switching igg isotypes virusspecific ifnγsecreting splenocytes mva deletion virus provided excellent protective efficacy virulent virus challenge result suggest deletion mutant strain superior vaccine performance poxvirus vaccine well platform vaccine infectious disease cancer,2011,"Rehm, Kristina E; Roper, Rachel L",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2011.02.023; https://www.ncbi.nlm.nih.gov/pubmed/21352940/,5266132.0,3
44827,44827,57795,6fhuvt60,,Medline,Synthesis and immunological evaluation of a MUC1 glycopeptide incorporated into l-rhamnose displaying liposomes.,10.1021/bc300422a,,23444835.0,unk,muc variable number tandem repeat vntrs conjugated tumorassociated carbohydrate antigen tacas shown break selftolerance humanized muc transgenic mouse therefore hypothesize muc vntr tacaconjugate successfully formulated liposomebased anticancer vaccine immunogenicity vaccine augmented incorporating surfacedisplayed lrhamnose rha epitope onto liposome take advantage natural antibodydependent antigen uptake mechanism validate hypothesis synthesized aminoacid muc glycopeptide containing galnacothr tn taca spps conjugated functionalized tolllike receptor ligand tlrl lrhacholesterol conjugate prepared using tetraethylene glycol teg linker liposomebased anticancer vaccine formulated extrusion method using tlrlmuctn conjugate rhategcholesterol dipalmitoylsnglycerophosphocholine dppc total lipid concentration mm stability homogeneity size characterization liposome evaluated sem dl measurement formulated liposome demonstrated positive binding antirha mouse antihuman muc antibody group female balbc mouse immunized boosted rhamnoseficoll rhaficoll conjugate formulated alum adjuvant generate appropriate concentration antirha antibody mouse antirha antibody titer fold higher group mouse immunized rhaficoll conjugate nonimmunized control group mouse immunized tlrlmuctn liposomal vaccine formulated either without surface displaying rha epitope serum collected group mouse initially immunized rhaficoll later vaccinated rhadisplaying tlrlmuctn liposome showed fold increase antimuctn antitn antibody titer comparison group mouse receive rhaficoll tcells balbc mouse primed muctn peptide demonstrated increased proliferation rhaliposomal vaccine presence antibody isolated rhaficoll immunized mouse compared nonimmune mouse supporting proposed effect antigen presentation antimuctn antibody vaccinated mouse serum recognized muc human leukemia u cell vaccine us separate rhamnose antigenic epitope component vaccine easily targeted different antigen epitope changing peptide without change component,2013,"Sarkar, Sourav; Salyer, Alex C D; Wall, Katherine A; Sucheck, Steven J",Bioconjugate chemistry,,,,,,https://doi.org/10.1021/bc300422a; https://www.ncbi.nlm.nih.gov/pubmed/23444835/,5412179.0,3
44899,44899,57882,s8g465c5,,Medline,Chemical-free inactivated whole influenza virus vaccine prepared by ultrashort pulsed laser treatment.,10.1117/1.jbo.20.5.051008,,25423046.0,unk,urgent need rapid method develop vaccine response emerging viral pathogen whole inactivated virus wiv vaccine represent ideal strategy purpose however universal method producing safe immunogenic inactivated vaccine lacking conventional pathogen inactivation method formalin heat ultraviolet light gamma ray cause structural alteration vaccine lead reduced neutralizing antibody specificity case disastrous helper type mediated immune pathology evaluated potential visible ultrashort pulsed usp laser method generate safe immunogenic wiv vaccine without adjuvant specifically demonstrate vaccination mouse laserinactivated hn influenza virus fold lower dose required using conventional formalininactivated influenza vaccine result protection lethal hn challenge mouse virus inactivated usp laser irradiation shown retain surface protein structure hemagglutination assay unlike conventional inactivation method laser treatment generate carbonyl group protein thereby reducing risk adverse vaccineelicited helper type response therefore usp laser treatment attractive potential strategy generate wiv vaccine greater potency safety vaccine produced current inactivation technique,2015,"Tsen, Shaw-Wei David; Donthi, Nisha; La, Victor; Hsieh, Wen-Han; Li, Yen-Der; Knoff, Jayne; Chen, Alexander; Wu, Tzyy-Choou; Hung, Chien-Fu; Achilefu, Samuel; Tsen, Kong-Thon",Journal of biomedical optics,,,,,,https://doi.org/10.1117/1.jbo.20.5.051008; https://www.ncbi.nlm.nih.gov/pubmed/25423046/,206437833.0,3
45040,45040,58040,e9306xae,,Medline,Recommendations on vaccination for Latin American small animal practitioners: a report of the WSAVA Vaccination Guidelines Group.,10.1111/jsap.13125,,32227347.0,unk,world small animal veterinary association vaccination guideline group produced global guideline small companion animal practitioner best practice canine feline vaccination recognising unique aspect veterinary practice certain geographical region world vaccination guideline group undertook regional project latin america culminating present document vaccination guideline group gathered scientific demographic data visit argentina brazil mexico discussion national key opinion leader visiting veterinary practice review scientific literature questionnaire survey completed veterinarian five latin american country vaccination guideline group delivered continuing education seven event attended veterinarian vaccination guideline group recognised numerous challenge latin america example lack national oversight veterinary profession extraordinary growth private veterinary school undetermined quality socioeconomic constraint client engagement preventive health care high regional prevalence key infectious disease eg feline leukaemia virus infection canine visceral leishmaniosis almost complete lack minimal antigen vaccine product available market relative lack vaccine product extended duration immunity available market availability vaccine product withdrawn market eg giardia vaccine unique latin america eg leishmania vaccine accessibility vaccine directly pet owner breeder vaccination delivered veterinary supervision limited availability continuing education veterinary vaccinology lack compulsion continuing professional development limited peerreviewed published scientific data small companion animal infectious disease exception leishmaniosis lack support academic research document vaccination guideline group summarises finding project ass evidencebased fashion scientific literature pertaining companion animal vaccinepreventable disease latin america vaccination guideline group make recommendation undergraduate postgraduate education academic research recognising current product availability latin america permit veterinarian country vaccinate according global world small animal veterinary association guideline vaccination guideline group make series pragmatic recommendation might currently achievable series aspirational recommendation might desirable future concept vaccine husbandry addressed via simple guideline management vaccine product practice finally vaccination guideline group emphasis global trend towards delivery vaccination one part annual health check health care plan review holistically preventive health care need individual pet animal latin american practitioner transition towards important new practice well embedded developed veterinary market document also includes frequently asked question answer posed vaccination guideline group continuing education event small group discussion address many issue surrounding delivery vaccination latin american country spanish portuguese translation document made freely available online resource page vaccination guideline group,2020-03-30,"Day, M J; Crawford, C; Marcondes, M; Squires, R A",The Journal of small animal practice,,,,,,https://doi.org/10.1111/jsap.13125; https://www.ncbi.nlm.nih.gov/pubmed/32227347/,214733671.0,3
45150,45150,58167,0pn58np1,,Medline,The early kinetics of circulating pneumococcal-specific memory B cells following pneumococcal conjugate and plain polysaccharide vaccines in the elderly.,10.1016/j.vaccine.2010.04.103,,20471437.0,unk,young child polyvalent pneumococcal polysaccharide conjugate vaccine pcvs shown offer advantage plain polysaccharide vaccine ppvs immunogenicity priming memory response elderly potential benefit conjugate vaccine unclear explore early kinetics serum antibody circulating plasma memory b cell response pneumococcal capsular polysaccharide pps older adult n immunised ppv vaccine pneumovax pcv prevenar individual serum evidence preexisting serotypespecific immunity following immunisation day rise circulating ppsspecific plasma memory antibody secreting cell abscs detected vaccine group sustained day pcv recipient difference vaccine group serum antibody response kinetics early pbmcderived b cell response although sample cohort small data different profile younger individual early time point postimmunisation suggest pneumococcal conjugate vaccine may quantitatively enhance generation memory response elderly,2010,"Baxendale, Helen E; Keating, Sheila M; Johnson, Marina; Southern, Jo; Miller, Elizabeth; Goldblatt, David",Vaccine,,,,,,https://doi.org/10.1016/j.vaccine.2010.04.103; https://www.ncbi.nlm.nih.gov/pubmed/20471437/,205582466.0,3
45192,45192,58219,npftj93b,,Medline,The Hajj 2019 Vaccine Requirements and Possible New Challenges.,10.2991/jegh.k.190705.001,,31529930.0,unk,year million pilgrim perform annual hajj country around world one largest mass gathering event may result occurrence spread infectious disease mandatory vaccination pilgrim meningococcal vaccine annual hajj take place august thus review recommended mandated vaccination hajj umrah mandatory vaccine required secure visa include quadrivalent meningococcal vaccine pilgrim yellow fever poliomyelitis vaccine required pilgrim coming country endemic disease activity recommended vaccine influenza pneumococcal addition full compliance basic vaccine pilgrim diphtheria tetanus pertussis polio measles mumps imperative continue surveillance spread antimicrobial resistance occurrence infectious disease causing outbreak across globe last year like zika virus mdrtyphoid nipah ebola cholera chikungunya middle east respiratory syndrome coronavirus,2019,"Al-Tawfiq, Jaffar A; Memish, Ziad A",Journal of epidemiology and global health,,,,,,https://doi.org/10.2991/jegh.k.190705.001; https://www.ncbi.nlm.nih.gov/pubmed/31529930/,201433185.0,3
45278,45278,58319,8aq3ft1b,,Medline,The role of benzathine penicillin G in predicting and preventing all-cause acute respiratory disease in military recruits: 1991-2017.,10.1017/s0950268818001838,,29974837.0,unk,adenovirus vaccine benzathine penicillin g bpg used u military prevent acute respiratory disease ard trainee though intervention documented manufacturing problem fit poisson regression random forest model rf year weekly ard incidence data explore impact adenovirus vaccine bpg prophylaxis respiratory disease burden adenovirus vaccine availability among important predictor ard rf bpg ninth important bpg significant protective factor ard incidence rate ratio irr confidence interval ci le either old new adenovirus vaccine irr ci irr ci respectively result suggest bpg moderately predictive significantly protective ard though lesser extent either old new adenovirus vaccine,2018,"Ball, Jacob D; Prosperi, Mattia A; Brown, Alfonza; Chen, Xinguang; Kenah, Eben; Yang, Yang; Cummings, Derek A T; Rivers, Caitlin M",Epidemiology and infection,,,,,,https://doi.org/10.1017/s0950268818001838; https://www.ncbi.nlm.nih.gov/pubmed/29974837/,49695331.0,3
45320,45320,58373,70a4y0k6,,Medline,Influenza in the elderly: a mini-review.,10.1159/000319033,,20805683.0,unk,influenza important cause morbidity mortality elderly population year often subtle clinical manifestation frail geriatric patient may recognized initially impeding timely administration antiviral treatment effectiveness current influenza vaccine elderly population often diminished immune senescence increasing immunization rate among healthcare worker elderly caregiver finding effective vaccine elderly people likely significantly improve disease prevention population risk,2011,"Pop-Vicas, A; Gravenstein, S",Gerontology,,,,,,https://doi.org/10.1159/000319033; https://www.ncbi.nlm.nih.gov/pubmed/20805683/,8580049.0,3
45357,45357,58414,l58ygnso,,Medline,"Transcutaneous immunization: an overview of advantages, disease targets, vaccines, and delivery technologies.",10.1146/annurev-chembioeng-073009-100948,,22432578.0,unk,skin immunologically active tissue composed specialized cell agent capture process antigen confer immune protection transcutaneous immunization take advantage skin immune network inducing protective immune response topically applied antigen mode vaccination present novel attractive approach needlefree immunization safe noninvasive overcomes many limitation associated needlebased administration review discus development field transcutaneous immunization past decade special emphasis disease target vaccine delivery technology also briefly discus challenge need overcome translate early laboratory success transcutaneous immunization development effective clinical prophylactic,2010,"Karande, Pankaj; Mitragotri, Samir",Annual review of chemical and biomolecular engineering,,,,,,https://doi.org/10.1146/annurev-chembioeng-073009-100948; https://www.ncbi.nlm.nih.gov/pubmed/22432578/,207612266.0,3
45488,45488,58561,yejrcprn,,WHO,"J&J, BARDA advance coronavirus vaccine",10.1021/cen-09813-buscon17,,,unk,johnson johnson say identified lead vaccine candidate new coronavirus develop partnership u biomedical advanced research development authority barda jj began developing vaccine january soon virus ’ sequence became available firm say barda willing spend billion get adenoviral vaccine human clinical study september available emergency use early,2020,,C&amp;EN Global Enterprise,,#35169,,,,https://doi.org/10.1021/cen-09813-buscon17,216438054.0,3
45578,45578,58656,ptgpxpad,6223cad692f34946c464df4c8fd73bbf7f6115e2,MedRxiv,Financing Vaccines for Global Health Security,10.1101/2020.03.20.20039966,,,medrxiv,recent outbreak infectious pathogen zika ebola covid underscored need dependable availability vaccine emerging infectious disease eids cost risk rd program uniquely unpredictable demand eid vaccine discouraged vaccine developer government nonprofit agency unable provide timely sufficient incentive development sustained supply analyze economic return portfolio eid vaccine asset find realistic financing assumption expected return significantly negative implying private sector unlikely address need without publicsector intervention sized financing deficit portfolio propose several potential solution including price increase enhanced publicprivate partnership subscription model individual would pay annual fee obtain access portfolio vaccine event outbreak,2020-03-23,"Vu, J.; Kaplan, B.; Chaudhuri, S.; Mansoura, M.; Lo, A.",,,,,document_parses/pdf_json/6223cad692f34946c464df4c8fd73bbf7f6115e2.json,,http://medrxiv.org/cgi/content/short/2020.03.20.20039966v1?rss=1,216055067.0,3
45827,45827,58923,wtjlqhv4,,WHO,A Veterinary Vaccine Development Process Map to assist in the development of new vaccines,10.1016/j.vaccine.2020.05.007,,,unk,uk government recognised importance vaccine control new emerging disease threat established uk vaccine network focus specific area need one understanding involved development new vaccine potential bottleneck rapid response face epidemic ebola mers recently covid working group established initially produce vaccine development process map human vaccine however view importance animal wellbeing significant impact disease zoonotic potential similar map created outlining veterinary vaccine development process paper describes production map cover process generation target product profile tpp discovery feasibility product development registration,2020,"Francis, Michael James",Vaccine,,#186281,,,,https://doi.org/10.1016/j.vaccine.2020.05.007,218503624.0,3
45828,45828,58924,wtjlqhv4,be869bfcf6de85d42fca46f146b02f98f15bdd9a,Elsevier,A Veterinary Vaccine Development Process Map to assist in the development of new vaccines,10.1016/j.vaccine.2020.05.007,,,els-covid,uk government recognised importance vaccine control new emerging disease threat established uk vaccine network focus specific area need one understanding involved development new vaccine potential bottleneck rapid response face pandemic covid working group established initially produce vaccine development process map human vaccine however view importance animal wellbeing significant impact disease zoonotic potential similar map created outlining veterinary vaccine development process paper describes production map cover process generation target product profile tpp discovery feasibility product development registration,2020-05-06,"James Francis, Michael",,,,,document_parses/pdf_json/be869bfcf6de85d42fca46f146b02f98f15bdd9a.json,,https://api.elsevier.com/content/article/pii/S0264410X20306137; https://www.sciencedirect.com/science/article/pii/S0264410X20306137?v=s5,218503624.0,3
45887,45887,58985,85chebix,39575ab35c2df25be4ccf0e6efe4cefe5c9e7470,MedRxiv,Quantifying early COVID-19 outbreak transmission in South Africa and exploring vaccine efficacy scenarios,10.1101/2020.04.23.20077297,,,medrxiv,background covid emerged spread great speed globally presented one greatest public health challenge modern time proven cure vaccine africa still early epidemic therefore spectrum disease severity yet clear method used mathematical model fit observed case covid south africa estimate basic reproductive number critical vaccination coverage control disease different hypothetical vaccine efficacy scenario also estimated percentage reduction effective contact due social distancing measure implemented result early model estimate show covid outbreak south africa basic reproductive number credible interval cri vaccine efficacy capacity contain covid outbreak higher vaccination coverage crl vaccine efficacy requiring crl coverage social distancing measure put place far reduced number social contact crl conclusion finding suggest highly efficacious vaccine would required contain covid south africa therefore current social distancing measure reduce contact remain key controlling infection absence vaccine therapeutic,2020-04-29,"Mukandavire, Zindoga; Nyabadza, Farai; Malunguza, Noble J; Cuadros, Diego F; Shiri, Tinevimbo; Musuka, Godfrey",,,,,document_parses/pdf_json/39575ab35c2df25be4ccf0e6efe4cefe5c9e7470.json,,http://medrxiv.org/cgi/content/short/2020.04.23.20077297v1?rss=1,216588668.0,3
45897,45897,58995,fytdeu6i,,WHO,‘We have no choice.’ Pandemic forces polio eradication group to halt campaigns,10.1126/science.abc0263,,,unk,going doortodoor deliver oral polio vaccine would put community health worker risk covid covid pandemic imperiling worldwide decade drive wipe polio unprecedented move global polio eradication initiative gpei recommended suspending polio vaccination campaign help stop spread novel coronavirus march gpei ’ leadership called country postpone least second half year mass campaign boost immunity polio virus targeted campaign underway africa stop outbreak sparked live virus vaccine,2020,"Roberts, Leslie",Science,,#23957,,,,https://doi.org/10.1126/science.abc0263,216197496.0,3
45930,45930,59033,egzztatj,,WHO,The spread of the COVID-19 coronavirus: Health agencies worldwide prepare for the seemingly inevitability of the COVID-19 coronavirus becoming endemic,10.15252/embr.202050334,,,unk,late confine covid coronovirus outbreak china wealth data spur epidemiological vaccine research,2020,"Hunter, Philip",EMBO Rep,,#8905,,,,https://doi.org/10.15252/embr.202050334,212740267.0,3
46036,46036,59148,o4r34pff,9bc29db5852a315d576437636d2398ebf69ac52c,Elsevier,A systems framework for vaccine design,10.1016/j.coi.2013.09.014,,,els-covid,numerous challenge identified vaccine development including variable efficacy function population demographic lack characterization mechanistic understanding immune correlate protection able guide delivery dosing tremendous opportunity recent technological computational advance elucidate system level understanding pathogen–host interaction correlate immunity system biology approach vaccinology provides new paradigm rational vaccine design ‘ precision medicine ’ context,2013-10-31,"Mooney, Michael; McWeeney, Shannon; Canderan, Glenda; Sékaly, Rafick-Pierre",Current Opinion in Immunology,,,,document_parses/pdf_json/9bc29db5852a315d576437636d2398ebf69ac52c.json,,https://api.elsevier.com/content/article/pii/S0952791513001490; https://www.sciencedirect.com/science/article/pii/S0952791513001490,40059362.0,3
46362,46362,59494,fbpdyg2i,,WHO,Sanofi adds new virus to vaccine pact,10.1021/cen-09813-buscon16,,,unk,sanofis vaccine business translate bio work together develop mrna vaccine novel coronavirus collaboration build pact sanofi paid translate million develop five mrna vaccine infectious disease sanofi one world ’ leading vaccine maker agreement complement collaboration formed february u biomedical advanced research development authority develop cellbased vaccine virus,2020,,C&amp;EN Global Enterprise,,#35170,,,,https://doi.org/10.1021/cen-09813-buscon16,216240851.0,3
46804,46804,59970,7pm5kob9,,WHO,The online competition between pro- and anti-vaccination views,10.1038/s41586-020-2281-1,,,unk,distrust scientific expertise– dangerous opposition vaccination future vaccine sarscov causal agent covid example could amplify outbreaks– happened measles homemade remedy falsehood shared widely internet well dismissal expert advice– lack understanding distrust evolves system level provide map contention surrounding vaccine emerged global pool around three billion facebook user core reveals multisided landscape unprecedented intricacy involves nearly million individual partitioned highly dynamic interconnected cluster across city country continent language although smaller overall size antivaccination cluster manage become highly entangled undecided cluster main online network whereas provaccination cluster peripheral theoretical framework reproduces recent explosive growth antivaccination view predicts view dominate decade insight provided framework inform new policy approach interrupt shift negative view result challenge conventional thinking undecided individual issue contention surrounding health shed light issue contention climate change highlight key role network cluster dynamic multispecies ecology,2020,"Johnson, N. F.; Velásquez, N.; Restrepo, N. J.; Leahy, R.; Gabriel, N.; El Oud, S.; Zheng, M.; Manrique, P.; Wuchty, S.; Lupu, Y.",Nature,,#307789,,,,https://doi.org/10.1038/s41586-020-2281-1,218625185.0,3
46848,46848,60016,wzdgizoo,20f73c6c25ddb11e7cf6f26981a7d9bb829503f6,BioRxiv,Quantitative measurement of activity of JAK-STAT signaling pathways in blood samples and immune cells to predict innate and adaptive cellular immune response to viral infection and accelerate vaccine development,10.1101/2020.05.13.092759,,,biorxiv,host immune response determines clinical course viral infection example case covid infection effectiveness vaccination also depends induced immune response currently method measure cellular immune response blood sample functional activity cell innate adaptive immune system determined coordinated activity signaling pathway especially jakstat pathway using previously described approach developed mrnabased test measure activity signaling pathway show used measure quantitative manner cellular innate adaptive immune response viral infection vaccine whole blood pbmc specific immune cell type sample pathway activity level range healthy individual established enabling interpretation pathway activity score patient sample without need reference sample evidence presented pathway activity analysis may also useful vitro vaccine development assessment vaccine immunogenicity envisioned application lie development immunomodulatory drug drug response prediction monitoring test expected value covid crisis addition described affymetrix microarraybased pathway test measuring host immune response qpcrbased version development latter principle performed within three hour routine hospital lab,2020-05-15,"Bouwman, Wilbert; Verhaegh, Wim; Holtzer, Laurent; van de Stolpe, Anja",bioRxiv,,,,document_parses/pdf_json/20f73c6c25ddb11e7cf6f26981a7d9bb829503f6.json,,https://doi.org/10.1101/2020.05.13.092759,218686697.0,3
46854,46854,60023,xjg2e8be,,BioRxiv,In silico approach for designing of a multi-epitope based vaccine against novel Coronavirus (SARS-COV-2),10.1101/2020.03.31.017459,,,biorxiv,novel coronavirus sarscov become global pandemic considering severity infection associated mortality urgent need develop effective preventive measure virus study designed novel vaccine construct using computational strategy spike glycoprotein major antigenic component trigger host immune response detailed investigation protein various immunoinformatics tool enabled u identify mhc mhc ii bcell derived tcell epitope vaxijen score ic value nm epitope joined suitable adjuvant appropriate linkers form multiepitope based vaccine construct silico testing vaccine construct antigenicity allergenicity solubility physicochemical property showed safe immunogenic suitable tertiary structure vaccine protein generated using dpro scratch suite refined galaxyrefine validated prosa procheck errat server finally molecular docking study performed ensure favorable binding affinity vaccine construct tlr receptor designed multiepitope vaccine showed potential elicit specific immune response sarscov however wet lab validation necessary confirm actual effectiveness safety immunogenic potency vaccine construct derived study,2020-04-03,"Saha, Ratnadeep; Prasad, Burra V L S",bioRxiv,,,,,,https://doi.org/10.1101/2020.03.31.017459,215551253.0,3
46937,46937,60111,lmstdmyb,4f196a2c87a747cb03adee9b609d7d5c367e749a,BioRxiv,Scrutinizing the SARS-CoV-2 protein information for the designing an effective vaccine encompassing both the T-cell and B-cell epitopes,10.1101/2020.03.26.009209,,,biorxiv,novel sars coronavirus sarscov caused pandemic condition worldwide declared public health emergency international concern short span time community transmission highly infectious virus severely affected various part china italy spain usa among others prophylactic solution sarscov infection challenging due high mutation rate rna genome herein exploited next generation vaccinology approach construct multiepitope vaccine candidate sarscov high antigenicity safety efficacy combat deadly infectious agent whole proteome scrutinized screening highly conserved antigenic nonallergen nontoxic epitope high population coverage elicit humoral cellular mediated immune response covid infection epitope along four different adjuvant utilized construct multiepitope vaccine candidate generate strong immunological memory response high efficacy human various physiochemical analysis revealed formation stable vaccine product high propensity form protective solution detrimental sarscov strain high efficacy vaccine candidate interacted immunological receptor tlr high affinity depicting generation innate immunity codon optimization silico expression show plausibility high expression easy purification vaccine product thus present study provides initial platform rapid generation efficacious protective vaccine combating covid,2020-04-01,"Jain, Neha; Shankar, Uma; Majee, Prativa; Kumar, Amit",bioRxiv,,,,document_parses/pdf_json/4f196a2c87a747cb03adee9b609d7d5c367e749a.json,,https://doi.org/10.1101/2020.03.26.009209,214793758.0,3
47047,47047,60228,10ucu0lt,3438e9ea06fef6e6e8e6d77b679e2112db2c955c,BioRxiv,Robust computational design and evaluation of peptide vaccines for cellular immunity with application to SARS-CoV-2,10.1101/2020.05.16.088989,,,biorxiv,present combinatorial machine learning method evaluate optimize peptide vaccine formulation find sarscov provides superior predicted display viral epitope mhc class mhc class ii molecule population compared candidate vaccine method robust idiosyncratic error prediction mhc peptide display considers target population hla haplotype frequency optimization minimize clinical development time method validate vaccine multiple peptide presentation algorithm increase probability vaccine effective optimize objective function based presentation likelihood diverse set vaccine peptide conditioned target population hla haplotype distribution expected epitope drift produce separate peptide formulation mhc class locus hlaa hlab hlac class ii locus hladp hladq hladr permit signal sequence based cell compartment targeting using nucleic acid based vaccine platform sarscov mhc class vaccine formulation provide predicted population coverage least five vaccine peptidehla hit average individual ≥ peptide vaccine peptide perfectly conserved across geographically sampled sarscov genome mhc class ii vaccine formulation provide predicted coverage least five vaccine peptidehla hit average individual peptide observed mutation probability ≤ evaluate previously published peptide vaccine design evaluation tool requirement least five vaccine peptidehla hit per individual predicted maximum mhc class coverage mhc class ii coverage given haplotype based analysis provide open source implementation design method optivax vaccine evaluation tool evalvax well data used design effort,2020-05-17,"Liu, Ge; Carter, Brandon; Bricken, Trenton; Jain, Siddhartha; Viard, Mathias; Carrington, Mary; Gifford, David K.",bioRxiv,,,,document_parses/pdf_json/3438e9ea06fef6e6e8e6d77b679e2112db2c955c.json,,https://doi.org/10.1101/2020.05.16.088989,218764882.0,3
47322,47322,60523,p9507cwx,,BioRxiv,Design an efficient multi-epitope peptide vaccine candidate against SARS-CoV-2: An in silico analysis,10.1101/2020.04.20.051557,,,biorxiv,background date specific vaccine drug proven effective sarscov infection therefore implemented immunoinformatics approach design efficient multiepitopes vaccine sarscov result designed vaccine construct several immunodominant epitope structural protein spike nucleocapsid membrane envelope peptide promote cellular humoral immunity interferon gamma response addition epitope antigenicity ability allergenicity probability enhance vaccine immunogenicity used three potent adjuvant flagellin driven peptide high mobility group box hp human beta defensin protein physicochemical immunological property vaccine structure evaluated tertiary structure vaccine protein predicted refined itasser galaxi refine validated using rampage errat result ellipro showed residue vaccine might conformational b cell epitope docking vaccine tolllike receptor proved appropriate interaction vaccine receptor protein silico cloning demonstrated vaccine efficiently expressed escherichia coli conclusion designed multi epitope vaccine potentially antigenic nature ability induce humoral cellular immune response sarscov vaccine interact appropriately tlr also vaccine high quality structure suitable characteristic high stability potential expression escherichia coli,2020-04-20,"Yazdani, Zahra; Rafiei, Alireza; Yazdani, Mohammadreza; Valadan, Reza",bioRxiv,,,,,,https://doi.org/10.1101/2020.04.20.051557,216145463.0,3
47583,47583,60802,dgsc3hz0,,WHO,The Potential for Antibody-Dependent Enhancement of SARS-CoV-2 Infection: Translational Implications for Vaccine Development,10.1017/cts.2020.39,,,unk,urgent need vaccine coronavirus covidsarscov vaccine development may straightforward due antibodydependent enhancement ade antibody viral surface protein case increase infection severity ade phenomenon occurs sarscov mers hiv zika dengue virus infection vaccination lack highaffinity antisarscov igg child may explain decreased severity infection group discus evidence ade context sarscov infection address potential translational barrier vaccine development convalescent plasma targeted monoclonal antibody therapy,2020,"Wang, Jiong; Zand, Martin S.",Journal of Clinical and Translational Science,,#45990,,,,https://doi.org/10.1017/cts.2020.39,216426357.0,3
47730,47730,60957,i7oi7mfi,a739497a97eca8492ca84a8c7b3510e127d16a14,BioRxiv,Multi-epitope based peptide vaccine design against SARS-CoV-2 using its spike protein,10.1101/2020.04.23.055467,,,biorxiv,sars cov particularly efficient ensuring entire country brought standstill repercussion ranging rampant mortality fear paranoia economic recession virus brought together country order look possible therapeutic countermeasure prophylactic intervention possibly month away particularly effective slew measure possibility concerning design vaccine worked upon attempt structure based approach utilizing combination epitope prediction server develop multiepitope based subunit vaccine involves two major domain spike glycoprotein sars cov coupled substantially effective chimeric adjuvant acting triagonist substantially create stable vaccine construct md simulation designed construct evaluated based docking toll like receptor tlr finding provide epitopebased peptide fragment potential candidate development vaccine sarscov,2020-04-24,"Mitra, Debarghya; Shekhar, Nishant; Pandey, Janmejay; Jain, Alok; Swaroop, Shiv",bioRxiv,,,,document_parses/pdf_json/a739497a97eca8492ca84a8c7b3510e127d16a14.json,,https://doi.org/10.1101/2020.04.23.055467,218472221.0,3
48119,48119,61385,5sdzyj0q,475b615fd202273ccfb8b46a8135703d9874d4dc,MedRxiv,Optimal COVID-19 epidemic control until vaccine deployment,10.1101/2020.04.02.20049189,,,medrxiv,since dec covid epidemic spread globe creating one greatest pandemic ever witnessed epidemic wave begin roll back critical proportion population immunised either mounting natural immunity following infection vaccination latter option minimise cost term human life requires wait safe efficient vaccine developed period estimated last least month work use optimal control theory explore best strategy implement waiting vaccine seek solution minimizing death cost due implementation control strategy find solution lead increasing level control maximum reached near fourth month epidemic steady decrease vaccine deployment strategy strongly outperforms others constant cycling allocation amount resource control outbreak work open new perspective mitigate effect ongoing covid pandemic used proofofconcept using mathematical modelling technique enlighten decision,2020-04-06,"Djidjou-Demasse, Ramses; Michalakis, Yannis; Choisy, Marc; Sofonea, Micea T.; Alizon, Samuel",,,,,document_parses/pdf_json/475b615fd202273ccfb8b46a8135703d9874d4dc.json,,https://doi.org/10.1101/2020.04.02.20049189,214778675.0,3
48297,48297,61576,gb24x2kg,918eaf810578578653206d4c19d958bcdd0c5032,BioRxiv,Considerations for the design of vaccine efficacy trials during public health emergencies,10.1101/261875,,,biorxiv,public health emergency phes provide complex challenging environment vaccine evaluation rd blueprint plan action world health organization convened group expert agree standard procedure rapidly evaluate experimental vaccine phes maintaining highest scientific ethical standard blueprint priority disease selected likelihood cause phes lack adequate medical countermeasure used frame methodological discussion outline major vaccine study design used phes summarize highlevel recommendation use setting recognize epidemiology transmission dynamic blueprint priority disease may highly uncertain unique characteristic vaccine outbreak setting may affect study design address challenge group underscore need novel flexible responsive trial design conclude assignment study group using randomization key principle underlying rigorous study design utilized except exceptional circumstance advance planning vaccine trial design critical rapid effective response phe advance knowledge address mitigate future phes one sentence summary part research development blueprint action prevent epidemic describe key consideration design analysis trial study evaluate experimental vaccine public health emergency,2018-02-13,"Dean, Natalie E.; Gsell, Pierre-Stéphane; Brookmeyer, Ron; De Gruttola, Victor; Donnelly, Christl A.; Halloran, M. Elizabeth; Jasseh, Momodou; Nason, Martha; Riveros, Ximena; Watson, Conall; Henao-Restrepo, Ana Maria; Longini, Ira M.",bioRxiv,,,,document_parses/pdf_json/918eaf810578578653206d4c19d958bcdd0c5032.json,,https://doi.org/10.1101/261875,91019244.0,3
48334,48334,61617,3jmo35jc,7591f17a7b783209e918d13a7da0a7e0e8c02c3e,BioRxiv,Immuno-informatics Characterization SARS-CoV-2 Spike Glycoprotein for Prioritization of Epitope based Multivalent Peptide Vaccine,10.1101/2020.04.05.026005,,,biorxiv,covid pandemic caused sarscov publichealth emergency international concern thus calling development safe effective therapeutic prophylactic particularly vaccine protect infection sarscov spike glycoprotein attractive candidate vaccine antibody inhibitor development many role play attachment fusion entry host cell study characterized sarscov spike glycoprotein immuneinformatics technique put forward potential b cell epitope followed use epitope construction multiepitope peptide vaccine construct mepvc mepvc revealed robust host immune system simulation high production immunoglobulin cytokine interleukin stable conformation mepvc representative innate immune tlr receptor observed involving strong hydrophobic hydrophilic chemical interaction along enhanced contribution saltbridges towards intermolecular stability molecular dynamic simulation solution aided interpreting strong affinity mepvc tlr stability attribute several vital residue tlr mepvc shown radial distribution function rdf novel analytical tool axial frequency distribution afd comprehensive binding free energy estimation provided end concluded major domination electrostatic minor van der waals summing designed mepvc tremendous potential providing protective immunity covid thus potential considered experimental study,2020-04-12,"Ismail, Saba; Ahmad, Sajjad; Azam, Syed Sikander",bioRxiv,,,,document_parses/pdf_json/7591f17a7b783209e918d13a7da0a7e0e8c02c3e.json,,https://doi.org/10.1101/2020.04.05.026005,215791009.0,3
48341,48341,61627,4bdusuqq,,WHO,"Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China [version 1;peer review: awaiting peer review]",10.12688/f1000research.22211.1,,,unk,novel coronavirus ncov originating wuhan china present potential respiratory viral pandemic world population current effort focused containment quarantine infected individual ultimately outbreak could controlled protective vaccine prevent ncov infection vaccine research pursued intensely exists today therapy treat ncov upon infection despite urgent need find option help patient preclude potential death herein review potential option treat ncov patient emphasis necessity speed timeliness developing new effective therapy outbreak consider option drug repurposing developing neutralizing monoclonal antibody therapy oligonucleotide strategy targeting viral rna genome emphasizing promise pitfall approach finally advocate fastest strategy develop treatment could resistant mutation virus may future proposal biologic block ncov entry using soluble version viral receptor angiotensinconverting enzyme ace fused immunoglobulin fc domain providing neutralizing antibody maximal breath avoid viral escape also helping recruit immune system build lasting immunity sequence acefc protein provided investigator allowing possible use recombinant protein expression system start producing drug today treat patient compassionate use formal clinical trial later undertaken treatment could help infected patient protective vaccine developed widely available coming month year,2020,"Kruse, R. L.",F1000Research,,#115788,,,,https://doi.org/10.12688/f1000research.22211.1,211534163.0,3
48352,48352,61641,v367uyho,1a975a0b81c3e4c4c8797598e2ed4590e70d421a,BioRxiv,Skin Delivery of Modified Vaccinia Ankara Viral Vectors Generates Superior T Cell Immunity Against a Respiratory Viral Challenge,10.1101/2020.05.06.079046,,,biorxiv,modified vaccinia ankara mva recently approved smallpox vaccine transmission variola respiratory droplet mva delivered skin scarification s protected mouse far effectively lethal respiratory challenge vacv route delivery much lower dos comparison s intradermal subcutaneous intramuscular route showed mvaova ssgenerated cell abundant transcriptionally distinct mvaova s produced greater number lung ovaspecific cd trm superior protecting mouse lethal vacvova respiratory challenge nearly many lung trm generated mvaova s compared direct pulmonary immunization mvaova route vaccination protected mouse lethal pulmonary challenge vacvova strikingly mvaova ssgenerated effector cell exhibited overlapping gene transcriptional profile generated via direct pulmonary immunization overall data suggest heterologous mva vector delivered via s uniquely wellsuited vaccine vector respiratory pathogen like covid addition mva delivered via s could represent effective dosesparing smallpox vaccine,2020-05-08,"Pan, Youdong; Liu, Luzheng; Tian, Tian; Zhao, Jingxia; Park, Chang Ook; Lofftus, Serena Y.; Stingley, Claire A.; Mei, Shenglin; Liu, Xing; Kupper, Thomas S.",bioRxiv,,,,document_parses/pdf_json/1a975a0b81c3e4c4c8797598e2ed4590e70d421a.json,,https://doi.org/10.1101/2020.05.06.079046,218582549.0,3
48528,48528,61834,vsw5kuth,,BioRxiv,Design of an Epitope-Based Peptide Vaccine against the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): A Vaccine Informatics Approach,10.1101/2020.05.03.074930,,,biorxiv,recurrent recent global outbreak sarscov turned global concern infected one million people globe number increasing hour unfortunate vaccine specific treatment available make deadly immunoinformatics approach shown significant breakthrough peptidebased epitope mapping open new horizon vaccine development study identified total antigenic peptide including b cell surface glycoprotein sarscov found conserved sars coronaviruses furthermore population coverage analysis found cd tcell peptide showed higher cumulative population coverage cd peptide different geographical region world notably peptide ltdemiaqy irasanlaa fgaissvln vkqlssnfg famqmayrf fgagaalq vitpgtnts wtagaaayy qtqtnsprrars identity experimentally identified epitope different organism including sarscov likely beneficial quick progression vaccine design moreover docking analysis suggested peptide tightly bound groove hla molecule induce tcell response overall study allows u determine potent peptide antigen target surface glycoprotein intuitive ground open new horizon covid research however study need experimental validation vitro vivo,2020-05-03,"Khan, Arbaaz; Alam, Aftab; Imam, Nikhat; Siddiqui, Mohd Faizan; Ishrat, Romana",bioRxiv,,,,,,https://doi.org/10.1101/2020.05.03.074930,218539230.0,3
48623,48623,61933,6ubk3rv7,a33d15f6f4a93234644e0b5e6e72ab85cb72b0ca,BioRxiv,Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine induces equivalent preclinical antibody titers and viral neutralization to recovered COVID-19 patients,10.1101/2020.04.22.055608,,,biorxiv,spread sarscov global pandemic within month onset motivates development rapidly scalable vaccine present selfamplifying rna encoding sarscov spike protein encapsulated within lipid nanoparticle vaccine demonstrate induction robust neutralization pseudovirus proportional quantity specific igg higher quantity recovered covid patient data provide insight vaccine design evaluation immunogenicity enable rapid translation clinic,2020-04-25,"McKay, Paul F.; Hu, Kai; Blakney, Anna K.; Samnuan, Karnyart; Bouton, Clément R.; Rogers, Paul; Polra, Krunal; Lin, Paulo J.C.; Barbosa, Christopher; Tam, Ying; Shattock, Robin J.",bioRxiv,,,,document_parses/pdf_json/a33d15f6f4a93234644e0b5e6e72ab85cb72b0ca.json,,https://doi.org/10.1101/2020.04.22.055608,218472878.0,3
49139,49139,62475,pmj4sao7,53d98d208d9ba36fdb31b4fd5cf66d076b71e70a,MedRxiv,COVID-19 Related Mortality: Is the BCG Vaccine Truly Effective?,10.1101/2020.05.01.20087411,,,medrxiv,coronavirus disease covid pandemic become worldwide emergency attempt search intervention would improve outcome study looked potential benefit bcg vaccination past study found statistically significant reduction covid related mortality country current universal bacille calmetteguerin bcg vaccination policy however author noted nature ecological study make prone presence several confounders paper took account demographic difference economic difference different stage pandemic country gathering data publicly available source found statistically significant difference exists mortality rate country current prior bcg vaccination policy compared never program nevertheless immunostimulatory potential bcg vaccine might still prove useful development future vaccine prophylactic measure,2020-05-06,"Paredes Mogica, J. A.; Nava, V.; Torres, J.",,,,,document_parses/pdf_json/53d98d208d9ba36fdb31b4fd5cf66d076b71e70a.json,,http://medrxiv.org/cgi/content/short/2020.05.01.20087411v1?rss=1,218503814.0,3
49141,49141,62477,2fn25l6m,21d89a4db5e0514c93ebf5aa94813b013d23c818,BioRxiv,Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design,10.1101/2020.03.30.016832,,,biorxiv,sarscov pandemic rapidly progressing need development effective vaccine critical promising approach vaccine development generate codon pair deoptimization attenuated virus approach carry advantage requires limited knowledge specific virus question genome sequence therefore well suited emerging virus may extensive data performed comprehensive silico analysis several feature sarscov genomic sequence eg codon usage codon pair usage dinucleotidejunction dinucleotide usage rna structure around frameshift region comparison member coronaviridae family virus overall human genome transcriptome specific human tissue lung primarily targeted virus analysis identified spike nucleocapsid n protein promising target deoptimization suggests roadmap sarscov vaccine development generalizable virus,2020-03-31,"Kames, Jacob; Holcomb, David D.; Kimchi, Ofer; DiCuccio, Michael; Hamasaki-Katagiri, Nobuko; Wang, Tony; Komar, Anton A.; Alexaki, Aikaterini; Kimchi-Sarfaty, Chava",bioRxiv,,,,document_parses/pdf_json/21d89a4db5e0514c93ebf5aa94813b013d23c818.json,,https://doi.org/10.1101/2020.03.30.016832,215551079.0,3
49195,49195,62533,0yqyclxk,9d3a4c7e8c660f772f98ead796ab87aa6772d298,BioRxiv,"Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2 etiologic agent of global pandemic COVID-19: an in silico approach",10.1101/2020.03.30.015164,,,biorxiv,severe acute respiratory syndrome coronavirus sarscov cause ongoing pandemic coronavirus disease covid public health emergency international concern declared world health organization immunoinformatics approach along comparative genomic applied design multiepitopebased peptide vaccine sarscov combining antigenic epitope e protein tertiary structure predicted refined validated using advanced bioinformatics tool candidate vaccine showed average ≥ world population coverage different ethnic group molecular docking chimeric vaccine peptide immune receptor tlr tlr predicted efficient binding immune simulation predicted significant primary immune response increased igm secondary immune response high level igg igg also increased proliferation thelper cell cytotoxic tcells along increased infγ il cytokine codon optimization mrna secondary structure prediction revealed chimera suitable highlevel expression cloning overall constructed recombinant chimeric vaccine candidate demonstrated significant potential considered clinical validation fight global threat covid,2020-03-31,"Rahman, M. Shaminur; Hoque, M. Nazmul; Islam, M. Rafiul; Akter, Salma; Rubayet-Ul-Alam, A. S. M.; Siddique, Mohammad Anwar; Saha, Otun; Rahaman, Md. Mizanur; Sultana, Munawar; Hossain, M. Anwar",bioRxiv,,,,document_parses/pdf_json/9d3a4c7e8c660f772f98ead796ab87aa6772d298.json,,https://doi.org/10.1101/2020.03.30.015164,214793581.0,3
49424,49424,62777,fway438n,,WHO,"Sanofi, BARDA team for coronavirus vaccine",10.1021/cen-09808-buscon15,,,unk,sanofi pasteur working u biomedical advanced research development authority barda develop vaccine novel coronavirus known severe acute respiratory syndromecov feb infected people killed sanofi build work vaccine sars another coronavirus circulated early december barda awarded firm million contract expand manufacturing capacity use potential flu pandemic sanofi say new vaccine use technology,2020,,C&amp;EN Global Enterprise,,#1881,,,,https://doi.org/10.1021/cen-09808-buscon15,216359798.0,3
49473,49473,62834,a4ok5wqc,946b09567278806f34026d27bcdf230a839e5369,MedRxiv,Custommune: a web tool to design personalized and population-targeted vaccine epitopes,10.1101/2020.04.25.20079426,,,medrxiv,computational prediction immunogenic epitope promising platform therapeutic preventive vaccine design potential target strategy human immunodeficiency virus hiv despite decade effort vaccine available particular therapeutic vaccine devised eliminate infected cell would represent key component cure strategy hiv peptide designed based individual viroimmunological data people living hivaids recently shown able induce posttherapy viral set point abatement however reproducibility scalability method curtailed error arbitrariness associated manual peptide design well timeconsuming process herein introduce custommune userfriendly web tool design personalized populationtargeted vaccine applied hiv custommune predicted personalized epitope using patient specific human leukocyte antigen hla allele viral sequence well expected hlapeptide binding strength potential immune escape mutation note custommune prediction compared favorably manually designed peptide administered recent phase ii clinical trial nct furthermore utilized custommune design preventive vaccine targeted population highly affected covid result allowed identification peptide tailored population predicted elicit cd tcell immunity neutralizing antibody structurally conserved epitope severe acute respiratory syndrome coronavirus sarscov overall data describe new tool rapid development personalized populationbased immunotherapy chronic acute viral infection,2020-04-29,"Tarek, M.; Elhefnawi, M.; Maricato, J. T.; Diaz, R. S.; Shytaj, I. L.; Savarino, A.",,,,,document_parses/pdf_json/946b09567278806f34026d27bcdf230a839e5369.json,,http://medrxiv.org/cgi/content/short/2020.04.25.20079426v1?rss=1,216642803.0,3
49507,49507,62869,p3zjxo1h,3081cb514969570bbfb5d2e74de9660154d24047,MedRxiv,Determinants of COVID-19 Vaccine Acceptance in the U.S.,10.1101/2020.05.22.20110700,,,medrxiv,backgroundthe covid pandemic continues adversely affect u lead globally total case death covid vaccine development public health official policymakers need create strategic vaccineacceptance messaging effectively control pandemic prevent thousand additional death method using online platform surveyed u adult population may understand risk perception covid pandemic acceptance covid vaccine trust source information factor compared across basic demographic finding participant surveyed said would accept covid vaccine recommended male older adult ≥ year asian college andor graduate degree holder likely accept vaccine comparing reported influenza vaccine uptake reported acceptance covid vaccine participant complete high school low influenza vaccine uptake group said would accept covid vaccine unemployed participant reported lower influenza uptake lower covid vaccine acceptance compared employed retired black american reported lower influenza vaccine uptake lower covid vaccine acceptance nearly racial group lastly identified geographic difference department health human service region new york chicago reporting le percent covid vaccine acceptance interpretation although study found acceptance covid vaccine noticeable demographic geographical disparity vaccine acceptance covid vaccine introduced u public health official policymakers must prioritize effective covid vaccineacceptance messaging american especially vulnerable,2020-05-24,"Malik, A. A.; McFadden, S. M.; Elharake, J.; Omer, S. B.",,,,,document_parses/pdf_json/3081cb514969570bbfb5d2e74de9660154d24047.json,,http://medrxiv.org/cgi/content/short/2020.05.22.20110700v1?rss=1,218863491.0,3
49582,49582,62946,sribl7kt,105b393cecbb526e6f7dbe314ff0a886316ef702,MedRxiv,Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic,10.1101/2020.04.23.20076513,,,medrxiv,background world facing covid pandemic development vaccine challenging aim determine proportion people intend get vaccinated covid france participate vaccine clinical trial method conducted anonymous online survey th march th april primary endpoint intention get vaccinated covid vaccine available participate vaccine clinical trial result three thousand two hundred fifty nine individual answered survey woman accounted responder year age year year year year age according statement participant ci certainly probably agree get vaccinated covid older age male gender fear covid healthcare worker individual perceived risk associated covid vaccine acceptance vaccine hesitancy associated decrease covid vaccine acceptance one thousand five hundred fifty responder ci certainly probably agree participate covid vaccine clinical trial conclusion relevance nearly survey responder likely accept vaccination participation clinical trial covid vaccine hesitancy major barrier covid vaccine uptake,2020-04-27,"Detoc, Maelle; Bruel, Sebastien; Frappe, Paul; Botelho-Nevers, Elisabeth; Gagneux-Brunon, Amandine",,,,,document_parses/pdf_json/105b393cecbb526e6f7dbe314ff0a886316ef702.json,,http://medrxiv.org/cgi/content/short/2020.04.23.20076513v1?rss=1,216144979.0,3
49712,49712,63085,mdhfgo58,6db33b86aad853b3e8f1abb20144551d6c5f1ca2,MedRxiv,Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses,10.1101/2020.04.19.20070805,,,medrxiv,background several sarscov vaccine candidate currently pipeline study aim inform sarscov vaccine development licensure decisionmaking implementation determining key preferred vaccine product characteristic associated populationlevel impact method vaccination impact assessed various efficacy using agestructured mathematical model describing sarscov transmission disease progression application china result prophylactic vaccine efficacy acquisition f ≥ needed eliminate infection vaccine f still major impact may control infection reduces infectiousness infection duration among vaccinated acquire infection alternatively supplemented moderate socialdistancing intervention reduction contact rate complemented herd immunity vaccination costeffective vaccine f number vaccination needed avert one infection one severe disease case one critical disease case one death gain effectiveness achieved initially prioritizing ≥ year probability major outbreak virtually zero vaccine f ≥ regardless number virus introduction yet increase social contact rate among vaccinated behavior compensation undermine vaccine impact conclusion even partiallyefficacious vaccine offer fundamental solution control sarscov infection high costeffectiveness addition primary endpoint infection acquisition developer ass natural history disease progression outcome andor proxy biomarkers since secondary endpoint may prove critical licensure decisionmaking vaccine impact,2020-04-23,"Makhoul, Monia; Ayoub, Houssein H; Chemaitelly, Hiam; Seedat, Shaheen; Mumtaz, Ghina R; Al-Omari, Sarah; Abu-Raddad, Laith J",,,,,document_parses/pdf_json/6db33b86aad853b3e8f1abb20144551d6c5f1ca2.json,,http://medrxiv.org/cgi/content/short/2020.04.19.20070805v1?rss=1,216071659.0,3
49829,49829,63215,97gme3pl,614d785e21ecdf42b362d8d7f42c23422b6290ab,MedRxiv,Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome,10.1101/2020.04.11.20062349,,,medrxiv,covid associated lymphopenia cytokine storm information available specific cellular immune response sarscov characterized sarscovspecific cd cd tcells patient acute respiratory distress syndrome spike protein proved potent tcell antigen specific tcells predominantly produced th cytokine novel data important vaccine design facilitate evaluation vaccine candidate immunogenicity,2020-04-18,"Weiskopf, Daniela; Schmitz, Katharina S.; Raadsen, Matthijs P.; Grifoni, Alba; Okba, Nisreen M.A.; Endeman, Henrik; van den Akker, Johannes P.C.; Molenkamp, Richard; Koopmans, Marion P.G.; van Gorp, Eric C.M.; Haagmans, Bart L.; de Swart, Rik L.; Sette, Alessandro; de Vries, Rory Dylan",,,,,document_parses/pdf_json/614d785e21ecdf42b362d8d7f42c23422b6290ab.json,,https://doi.org/10.1101/2020.04.11.20062349,216055303.0,3
49876,49876,63263,uuwvmltw,7910bdf6039f2914e5cadb1eb6eb497237a7744e,BioRxiv,Rapid isolation of potent SARS-CoV-2 neutralizing antibodies and protection in a small animal model,10.1101/2020.05.11.088674,,,biorxiv,development countermeasure prevent treat covid global health priority week enrolled cohort sarscovrecovered participant developed neutralization assay interrogate serum monoclonal antibody response adapted high throughput antibody isolation production characterization pipeline rapidly screen antigenspecific antibody established animal model test protection report multiple highly potent neutralizing antibody nabs show passive transfer nab provides protection highdose sarscov challenge syrian hamster study suggests role nabs prophylaxis potentially therapy covid nabs define protective epitope guide vaccine design,2020-05-15,"Rogers, Thomas F.; Zhao, Fangzhu; Huang, Deli; Beutler, Nathan; Burns, Alison; He, Wan-ting; Limbo, Oliver; Smith, Chloe; Song, Ge; Woehl, Jordan; Yang, Linlin; Abbott, Robert K.; Callaghan, Sean; Garcia, Elijah; Hurtado, Jonathan; Parren, Mara; Peng, Linghang; Ricketts, James; Ricciardi, Michael J.; Rawlings, Stephen A.; Smith, Davey M.; Nemazee, David; Teijaro, John R.; Voss, James E.; Andrabi, Raiees; Briney, Bryan; Landais, Elise; Sok, Devin; Jardine, Joseph G.; Burton, Dennis R.",bioRxiv,,,,document_parses/pdf_json/7910bdf6039f2914e5cadb1eb6eb497237a7744e.json,,https://doi.org/10.1101/2020.05.11.088674,218644137.0,3
49923,49923,63321,b6to1v4u,3c4dd95808337f8b293cb67638dba0f8f19c0024,BioRxiv,Structure-based design of hepatitis C virus E2 glycoprotein improves serum binding and cross-neutralization,10.1101/2020.04.15.044073,,,biorxiv,effective vaccine hepatitis c virus hcv major unmet need requires antigen elicits immune response key conserved epitope based structure antibody targeting hcv envelope glycoprotein e designed immunogen modulate structure dynamic e favor induction bnabs context vaccine design include point mutation key conserved antigenic site stabilize conformation well redesigns immunogenic region add new nglycosylation site mask antibody binding design experimentally characterized binding panel human monoclonal antibody hmabs coreceptor cd confirm preservation epitope structure preferred antigenicity profile selected e design tested immunogenicity mouse without hypervariable region immunogenic region associated viral escape one design showed improvement polyclonal immune serum binding hcv pseudoparticles neutralization isolates associated antibody resistance result indicate antigen optimization structurebased design envelope glycoprotein promising route effective vaccine hcv,2020-04-17,"Pierce, Brian G.; Keck, Zhen-Yong; Wang, Ruixue; Lau, Patrick; Garagusi, Kyle; Elkholy, Khadija; Toth, Eric A.; Urbanowicz, Richard A.; Guest, Johnathan D.; Agnihotri, Pragati; Kerzic, Melissa C.; Marin, Alexander; Andrianov, Alexander K.; Ball, Jonathan K.; Mariuzza, Roy A.; Fuerst, Thomas R.; Foung, Steven K.H.",bioRxiv,,,,document_parses/pdf_json/3c4dd95808337f8b293cb67638dba0f8f19c0024.json,,https://doi.org/10.1101/2020.04.15.044073,216071670.0,3
50134,50134,63547,7zr1118b,70bd165842c7455de22a7695d09a3e41738b4080,BioRxiv,Antibody repertoire induced by SARS-CoV-2 spike protein immunogens,10.1101/2020.05.12.091918,,,biorxiv,multiple vaccine candidate sarscov based viral spike protein development however limited information quality antibody response generated following vaccination vaccine modality better understand antibody response induced spike proteinbased vaccine immunized rabbit various sarscov spike protein antigen sectodomain s aa lack cytoplasmic transmembrane domain cttm domain aa receptorbinding domain rbd aa domain aa control antibody response analyzed elisa surface plasmon resonance spr different spike protein native conformation pseudovirion neutralization assay measure quality function antibody elicited different spike antigen three antigen s ectodomain domain rbd generated strong neutralizing antibody sarscov vaccination induced antibody repertoire analyzed sarscov spike genome fragment phage display library sarscov gfpdl identified immunodominant epitope srbd domain furthermore analysis demonstrated surprisingly rbd immunogen elicited higher antibody titer fold higher affinity antibody native spike antigen compared spike antigen finding may help guide rational vaccine design facilitate development evaluation effective therapeutic vaccine covid disease one sentence summary sarscov spike induced immune response,2020-05-13,"Ravichandran, Supriya; Coyle, Elizabeth M.; Klenow, Laura; Tang, Juanjie; Grubbs, Gabrielle; Liu, Shufeng; Wang, Tony; Golding, Hana; Khurana, Surender",bioRxiv,,,,document_parses/pdf_json/70bd165842c7455de22a7695d09a3e41738b4080.json,,https://doi.org/10.1101/2020.05.12.091918,218666268.0,3
50266,50266,63695,ptvsie6m,2cd3b9c4a29e18712af4a7a4228d9e36219e5b7e,BioRxiv,A single dose SARS-CoV-2 simulating particle vaccine induces potent neutralizing activities,10.1101/2020.05.14.093054,,,biorxiv,coronavirus disease covid caused severe acute respiratory syndrome coronavirus sarscov vaccine urgently needed control spreading facilitate representation nativelike immunogen without infectious reported sarscov vaccine candidate designated shacovacc incorporating spikeencoding mrna inside decorating spike protein surface virus simulating particle vsps derived lentiviral particle characterized mrna copy number glycosylation status transduction efficiency innate immune property new vaccine platform importantly showed shacovacc induced strong spikespecific humoral immune response potent neutralizing activity single injection additionally disclosed epitope spikespecific antibody using peptide microarray revealed epitope susceptible specific neutralizing antibody result support development shacovacc candidate vaccine covid vsp may serve new vaccine platform emerging infectious disease,2020-05-15,"Yin, Di; Ling, Sikai; Tian, Xiaolong; Li, Yang; Xu, Zhijue; Jiang, Hewei; Zhang, Xue; Wang, Xiaoyuan; Shi, Yi; Zhang, Yan; Da, Lintai; Tao, Sheng-ce; Wang, Quanjun; Xu, Jianjiang; Ying, Tianlei; Hong, Jiaxu; Cai, Yujia",bioRxiv,,,,document_parses/pdf_json/2cd3b9c4a29e18712af4a7a4228d9e36219e5b7e.json,,https://doi.org/10.1101/2020.05.14.093054,218686880.0,3
50346,50346,63784,wx1v0h0q,546acd5b1cd1d57f50340e9987e9fde2ada459fe,BioRxiv,Designing a multi-epitope peptide-based vaccine against SARS-CoV-2,10.1101/2020.04.15.040618,,,biorxiv,covid pandemic resulted far confirmed case death country territory due multifacet issue challenge implementation safety preventive measure inconsistent coordination societiesgovernments importanly lack specific vaccine sarscov spread wuhan originated virus still uprising taking heavy toll human life present study mapped several immunogenic epitope bcell tcell ifngamma entire structural protein sarscov applying various computational immunoinformatics approach designed multiepitope peptide based vaccine predicted high immunogenic response largest proportion world ’ human population ensure high expression recombinant vaccine e coli codon optimization insilico cloning also carried designed vaccine high molecular affinity tlr tlr found capable initiate effective innate adaptive immune response immune simulation also suggested uprising high level bcell tcell mediated immunity subsequent exposure cleared antigen system proposed vaccine found promising yielding desired result hence tested practical experimentation functioning efficacy neutralize sarscov,2020-04-15,"Singh, Abhishek; Thakur, Mukesh; Sharma, Lalit Kumar; Chandra, Kailash",bioRxiv,,,,document_parses/pdf_json/546acd5b1cd1d57f50340e9987e9fde2ada459fe.json,,https://doi.org/10.1101/2020.04.15.040618,216071389.0,3
50497,50497,63939,041cf99j,ecb0294384c896e760ecda0467f6cf8cce2fa18a,Elsevier,Design of a Novel Multi Epitope-Based Vaccine for Pandemic Coronavirus Disease (COVID-19) by Vaccinomics and Probable Prevention Strategy against Avenging Zoonotics,10.1016/j.ejps.2020.105387,,,els-covid,emergence rapid expansion coronavirus disease covid require development effective countermeasure especially vaccine provide active acquired immunity virus study presented comprehensive vaccinomics approach applied complete protein data published far national center biotechnological information ncbi coronavirus data hub identified nonstructural protein nsp clike proteinase spike glycoprotein potential target immune response covid epitope prediction illustrated bcell tcell epitope associated mentioned protein shared b tcell epitope drdaamqrk qarsedkra nsp edmlnpnyedl eftpfdvvr clike proteinase vnnsyecdipi spike glycoprotein region high potential interest high likelihood recognized human immune system vaccine construct epitope show stimulation robust primary immune response high level interferon gamma also construct best conformation respect tested innate immune receptor involving vigorous molecular mechanic solvation energy designing vaccination strategy target immune response focusing conserved epitope could generate immunity provide cross protection across betacoronaviruses additionally resistant virus evolution,2020-05-23,"Ahmad, Sajjad; Navid, Afifa; Farid, Rabia; Abbas, Ghulam; Ahmad, Faisal; Zaman, Naila; Parvaiz, Nousheen; Azam, Syed Sikander",,,,,document_parses/pdf_json/ecb0294384c896e760ecda0467f6cf8cce2fa18a.json,,https://api.elsevier.com/content/article/pii/S0928098720301767; https://www.sciencedirect.com/science/article/pii/S0928098720301767?v=s5,218856573.0,3
50543,50543,63987,iznnqur2,,WHO,"To streamline coronavirus vaccine and drug efforts, NIH and firms join forces",10.1126/science.abc3180,,,unk,treatment vaccine development stem covid pandemic onlooker worried sprawling potentially duplicative effort wasting time resource hoping bring order chaos national institute health nih major drug company today announced plan stage carefully designed clinical trial drug vaccine decided highest priority testing development publicprivate partnership involves nih u government agency pharma company biotech nonprofit foundation national institute health fnih aim develop “ international strategy ” covid research press release state however nih director francis collins told reporter press call today “ primarily u focused effort ”,2020,"Kaiser, Jocelyn",Science,,#87086,,,,https://doi.org/10.1126/science.abc3180,218777190.0,3
50737,50737,64188,q2pjhmb9,d05684da9bd654a6ae90f72b1049661636d3192d,BioRxiv,Development of a potent and protective germline-like antibody lineage against Zika virus in a convalescent human,10.1101/661918,,,biorxiv,zika virus zikv specific neutralizing antibody hold great promise antibodybased intervention vaccine design zikv infection however development infected patient remain unknown report dynamic development potent protective zikvspecific human antibody zkb initially isolated zikv convalescent individual using nextgeneration sequencing ng unbiased repertoire analysis showed dramatic change many family heavy light chain variable region however lineage tracing zkb revealed limited somatic hypermutation throughout month since onset symptom particular ngsderived germlinelike somatic variant neutralized protected mouse lethal challenge zikv without detectable crossreactivity dengue virus denv sitedirected mutagenesis identified two residue within λ chain n essential functional maturation dynamic feature unveiled assist u better understand pathogenesis zikv infection inform rational design vaccine author summary recently emerged zikv associated severe neurological complication guillain–barré syndrome adult congenital microcephaly newborn zikvspecific therapeutic vaccine currently available others identified number neutralizing antibody capable protecting experimental animal zikv infection however development potent antibody zikv natural infection remains unknown report longitudinal analysis one antibody zkb using nextgeneration sequencing ng bioinformatics functional analysis found zkb germlinelike antibody posse strong neutralizing activity vitro impressive protectivity lethal zikv infection vivo finding suggest potent protective antibody response zikv generated within relative short term high germline identity provide great hope promise successful vaccine development zikv,2019-06-05,"Gao, Fei; Lin, Xiaohe; He, Linling; Wang, Ruoke; Wang, Han; Shi, Xuanling; Zhang, Fuchun; Yin, Chibiao; Zhang, Linqi; Zhu, Jiang; Yu, Lei",bioRxiv,,,,document_parses/pdf_json/d05684da9bd654a6ae90f72b1049661636d3192d.json,,https://doi.org/10.1101/661918,195426808.0,3
50922,50922,64383,fnrm6a79,a1759d318677c1e0158469a3fd231b3fe692e593,MedRxiv,Estimating Probabilities of Success of Clinical Trials for Vaccines and Other Anti-Infective Therapeutics,10.1101/2020.04.09.20059600,,,medrxiv,key driver biopharmaceutical investment decision probability success drug development program estimate probability success po clinical trial vaccine antiinfective therapeutic using unique triplet clinical trial drug disease january january yielding vaccine program nonvaccine program targeting infectious disease overall estimated po industrysponsored vaccine program industrysponsored antiinfective therapeutic among industrysponsored vaccine program disease category seen least one approval successful monkeypox rotavirus japanese encephalitis three infectious disease highest po industrysponsored nonvaccine therapeutic smallpox cmv onychomycosis nonindustrysponsored vaccine nonvaccine development program lower overall po respectively virus involved recent outbreaksmers sars ebola zikahave combined total nonvaccine development program initiated past two decade approved therapy date note data obtained covid outbreak contain information program targeting disease estimate offer guidance biopharma investor well policymakers seeking identify area likely undeserved privatesector engagement need publicsector support,2020-04-14,"Wong, C. H.; Siah, K. W.; Lo, A. W.",,,,,document_parses/pdf_json/a1759d318677c1e0158469a3fd231b3fe692e593.json,,http://medrxiv.org/cgi/content/short/2020.04.09.20059600v1?rss=1,215782055.0,3
51169,51169,64658,i21wf67n,2def385170922c5786ea00a64f0c139460d23e2c,PMC,Mucosal Delivery of ACNPV Baculovirus Driving Expression of the Gal-Lectin LC3 Fragment Confers Protection against Amoebic Liver Abscess in Hamster,,PMC3221370,22110386.0,cc-by-nc-nd,mucosal vaccination amoebiasis using gallectin e histolytica proposed one leading strategy controlling human disease however mucosal adjuvant used toxic identification safe delivery system necessary evaluate potential recombinant autographa californica baculovirus driving expression lc fragment gallectin confer protection amoebic liver abscess ala hamster following oral nasal immunization hamster immunized oral route showed complete absence partial development ala resulting protection animal compared wild type baculovirus sham control group contrast nasal immunization conferred protection efficacy level ala protection showed lineal correlation development antiamoebic cellular immune response evaluated spleen induction seric igg antiamoeba antibody result suggest baculovirus driving expression e histolytica vaccine candidate antigen useful inducing protective cellular humoral immune response following oral immunization therefore could used system mucosal delivery antiamoebic vaccine,2011-11-01,"Meneses-Ruiz, DM; Laclette, JP; Aguilar-Díaz, H; Hernández-Ruiz, J; Luz-Madrigal, A; Sampieri, A; Vaca, L; Carrero, JC",Int J Biol Sci,,,,document_parses/pdf_json/2def385170922c5786ea00a64f0c139460d23e2c.json,document_parses/pmc_json/PMC3221370.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3221370/,,3
51175,51175,64664,dmzn79tq,fb24be7627ebce76ab2862e689432a8a0de11343,PMC,Regulation of Immunogen Processing: Signal Sequences and Their Application for the New Generation of DNA-Vaccines,,PMC3347541,22649628.0,cc-by,immunization naked gene dna–immunization perspective modern approach prophylactic well therapeutic vaccination pathogen well cancer allergy panel dna immunogen developed already clinical trial however immunogenicity dna vaccine specifically applied human need considerable improvement several approach increase dna vaccine immunogenicity one approach implies modification encoded immunogen change processing presentation thus overall pattern anti–immunogen response eukaryotic expression vector constructed encode chimeric protein composed immunogen specialized targeting signal sequence review describes number signal fused immunogen target predefined subcellular compartment review give example application dna–immunization,2010-04-26,"Starodubova, E.S.; Isaguliants, M.G.; Karpov, V.L.",Acta Naturae,,,,document_parses/pdf_json/fb24be7627ebce76ab2862e689432a8a0de11343.json,document_parses/pmc_json/PMC3347541.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3347541/,,3
51201,51201,64691,o4r34pff,,PMC,A Systems Framework for Vaccine Design,,PMC3983719,24358511.0,unk,numerous challenge identified vaccine development including variable efficacy function population demographic lack characterization mechanistic understanding immune correlate protection able guide delivery dosing tremendous opportunity recent technological computational advance elucidate system level understanding pathogenhost interaction correlate immunity system biology approach vaccinology provides new paradigm rational vaccine design “ precision medicine ” context,2013-10-26,"Mooney, Michael; McWeeney, Shannon; Canderan, Glenda; Sékaly, Rafick-Pierre",,,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3983719/,,3
51202,51202,64692,l67avrkj,8c433501a618d6a3f93463393f4ce58007abec95,PMC,Malaria vaccines: high-throughput tools for antigens discovery with potential for their development,,PMC4002024,24892459.0,cc-by,malaria disease induced parasite plasmodium genus transmitted anopheles mosquito represents great socioeconomic burden worldwide plasmodium vivax second specie malaria worldwide prevalent latin america region planet currently considered vaccine represent costeffective strategy controlling transmissible disease could complement malaria control measure however chemical immunological complexity parasite hindered development effective vaccine recent availability several genome plasmodium specie well bioinformatic tool allowing selection large number protein analysis immune potential herein review recently developed strategy discovery novel antigen potential malaria vaccine development,2013-06-30,"Céspedes, Nora; Vallejo, Andrés; Arévalo-Herrera, Myriam; Herrera, Sócrates",,,,,document_parses/pdf_json/8c433501a618d6a3f93463393f4ce58007abec95.json,document_parses/pmc_json/PMC4002024.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4002024/,,3
51263,51263,64775,fu02qqsh,a85684483483909019d84ebf3061582317fc841e,PMC,Virus-Vectored Ebola Vaccines,,PMC5662269,29104771.0,cc-by,ebola virus disease evd one dangerous infection affecting human animal first evd outbreak occurred sudan zaire since outbreak occurred largest − evolved epidemic west africa claimed life people although vaccination effective way prevent epidemic licensed vaccine evd beginning latest outbreak development first vaccine evd started come long technological way inactivated genetically engineered vaccine based recombinant viral vector review focus virusvectored ebola vaccine demonstrated greatest efficacy preclinical trial currently different phase clinical trial particular attention paid mechanism immune response development important protection evd key vaccine parameter necessary inducing longterm protective immunity evd,2017,"Dolzhikova, I.V.; Tokarskaya, E.A.; Dzharullaeva, A. S.; Tukhvatulin, A. I.; Shcheblyakov, D. V.; Voronina, O.L.; Syromyatnikova, S. I.; Borisevich, S. V.; Pantyukhov, V. B.; Babira, V. F.; Kolobukhina, L. V.; Naroditsky, B. S.; Logunov, D. Y.; Gintsburg, A. L.",Acta Naturae,,,,document_parses/pdf_json/a85684483483909019d84ebf3061582317fc841e.json,document_parses/pmc_json/PMC5662269.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662269/,,3
51274,51274,64790,hxtk8zqm,24beb94c313a07be6b0c745a6ca8a3d810618506,PMC,Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein,,PMC6475872,31024747.0,cc-by,middle east respiratory syndrome coronavirus merscov identified first middle east respiratory syndrome mers outbreak merscov cause acute lowerrespiratory infection human fatality rate currently registered vaccine mean therapeutic protection mers world merscov glycoprotein play important role viral life cycle virus internalization protein immunodominant antigen main target neutralizing antibody present study immunogenicity five different form merscov glycoprotein compared fulllength glycoprotein fulllength glycoprotein transmembrane domain g glycoprotein vsv sg receptorbinding domain rbd glycoprotein membranefused rbd rbd fused transmembrane domain vsv g glycoprotein rbdg rbd fused fc human igg rbdfc recombinant vector based human adenovirus type rad used delivery vehicle vaccination developed rad vector elicited balanced thth response mouse robust humoral immune response induced animal vaccinated membranefused rbd radrbdg immunization membrane form glycoprotein rad radsg radrbdg elicited neutralizing antibody among vaccinated animal significant cellular immune response induced vaccination animal fulllength rad investigation suggest fulllength membrane form rbd rbdg promising vaccine candidate among studied form glycoprotein,2019,"Ozharovskaia, T. A.; Zubkova, O. V.; Dolzhikova, I. V.; Gromova, A. S.; Grousova, D. M.; Tukhvatulin, A. I.; Popova, O.; Shcheblyakov, D. V.; Scherbinin, D. N.; Dzharullaeva, A. S.; Erokhova, A. S.; Shmarov, M. M.; Loginova, S. Y.; Borisevich, S. V.; Naroditsky, B. S.; Logunov, D. Y.; Gintsburg, A. L.",Acta Naturae,,,,document_parses/pdf_json/24beb94c313a07be6b0c745a6ca8a3d810618506.json,document_parses/pmc_json/PMC6475872.xml.json,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6475872/,,3
51364,51364,64959,1yj7p7hq,,Medline,Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates.,,,12904795.0,unk,containment highly lethal ebola virus outbreak pose serious public health challenge although experimental vaccine successfully protected nonhuman primate disease six month required complete immunization making impractical limit acute epidemic report development accelerated vaccination ebola virus nonhuman primate antibody response immunization adenoviral adv vector encoding ebola glycoprotein gp induced rapidly dna priming adv boosting lower magnitude determine whether earlier immune response could nonetheless protect disease cynomolgus macaque challenged ebola virus vaccination advgp nucleoprotein np vector protection highly effective correlated generation ebolaspecific cd tcell antibody response even animal immunized advgpnp challenged day later remained resistant challenge either low high dos virus accelerated vaccine provides intervention may help limit epidemic spread ebola applicable virus,2003,"Sullivan, Nancy J; Geisbert, Thomas W; Geisbert, Joan B; Xu, Ling; Yang, Zhi-Yong; Roederer, Mario; Koup, Richard A; Jahrling, Peter B; Nabel, Gary J",Nature,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12904795/,4401681.0,3
51368,51368,64963,mlxi47tr,,Medline,Rotavirus virus-like particles administered mucosally induce protective immunity.,,,9343229.0,unk,evaluated immunogenicity protective efficacy rotavirus subunit vaccine administered mucosal route viruslike particle vlps produced selfassembly individual rotavirus structural protein coexpressed baculovirus recombinant insect cell subunit vaccine tested first compared immunogenicity protective efficacy vlps containing vp vp vlps g vlps mixed cholera toxin administered oral intranasal route adult mouse model rotavirus infection vlps administered orally induced serum antibody intestinal immunoglobulin iga igg highest oral dose microg vlps induced protection rotavirus challenge reduction virus shedding mouse vlps administered intranasally induced higher serum intestinal antibody response vlps administered orally mouse receiving vlps intranasally protected challenge virus shed challenge since difference immunogenicity protective efficacy vlps protection achieved without inclusion neutralization antigen vp vp also tested immunogenicity protective efficacy vlps administered intranasally without addition cholera toxin vlps administered intranasally without cholera toxin induced lower serum intestinal antibody titer vlps administered cholera toxin highest dose microg vlps administered intranasally without cholera toxin resulted mean reduction shedding cholera toxin added higher level protection achieved fold le immunogen vlps administered mucosally offer promising safe nonreplicating vaccine rotavirus,1997,"O'Neal, C M; Crawford, S E; Estes, M K; Conner, M E",Journal of virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/9343229/,1561359.0,3
51385,51385,64981,1f11gqpj,,Medline,Progress toward an HIV vaccine.,,,15660510.0,unk,development hiv vaccine proving unprecedented challenge difficulty creating vaccine arises enormous genetic variation virus unusual importance cytotoxic lymphocyte ctl controlling spread whereas traditional vaccine strategy unlikely confer safe effective hiv protection novel strategy eliciting ctl provided substantial clinical benefit nonhuman primate model system vaccine strategy including plasmid dna live recombinant vector currently evaluated human clinical trial,2005,"Letvin, Norman L",Annual review of medicine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15660510/,9769630.0,3
51428,51428,65031,6zlws8u5,,Medline,Induction of T-cell response by a DNA vaccine encoding a novel HLA-A*0201 severe acute respiratory syndrome coronavirus epitope.,,,17629360.0,unk,severe acute respiratory syndrome coronavirus nucleocapsid protein sarscov n one major target sars vaccine due high potency triggering immune response study identified novel hlaa restricted epitope n lalllldrl sarscov nprotein bioinformatics analysis nprotein peptide n show high binding affinity towards human mhc class tcells capable activating cytotoxic tcells human peripheral blood mononuclear cell pbmcs application using n peptide sequence singlechaintrimer sct approach produce potential dna vaccine candidate investigated hlaakb transgenic mouse cytotoxicity assay clearly showed tcells obtained vaccinated animal able kill nprotein expressing cell cytotoxicity level effector cellstarget cell ratio one week last vaccination significantly higher nprotein peptide previously described novel immunogenic nprotein peptide revealed present study provides valuable information therapeutic sars vaccine design,2007,"Cheung, Ying-Kit; Cheng, Samuel Chak-Sum; Sin, Fion Wan-Yee; Chan, Kin-Tak; Xie, Yong",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17629360/,23558554.0,3
51508,51508,65122,d1spxixk,,Medline,"Salmonella serotype enteritidis infections among workers producing poultry vaccine--Maine, November-December 2006.",,,17728692.0,unk,november maine department health human service mdhhs notified case salmonellosis nationally notifiable disease employee facility produced poultry vaccine second case salmonellosis another employee facility reported november mdhhs began outbreak investigation result investigation suggested employee facility became ill month period exposure strain salmonella serotype enteritidis se used vaccine production infection thought resulted environmental contamination spill liquid containing high concentration se result mdhhs recommended facility improve infectioncontrol procedure better protect worker outbreak highlight occupational risk associated manufacture veterinary biologics involving human pathogen,2007,,MMWR. Morbidity and mortality weekly report,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17728692/,44757345.0,3
51519,51519,65135,5z7hmmar,,Medline,Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies.,,,17258782.0,unk,infection sarsassociated coronavirus sarscov induces atypical pulmonary disease high lethality rate although initial sars epidemic contained sporadic outbreak disease still occur suggesting continuous need vaccine virus therefore explored exosomebased vaccine containing spike protein sarscov scontaining exosomes obtained replacing transmembrane cytoplasmic domain protein vsvg immunogenicity efficacy scontaining exosomes tested mouse compared adenoviral vector vaccine expressing protein scontaining exosomes adenoviral vector vaccine induced neutralizing antibody titer priming sars exosomal vaccine boosting adenoviral vector neutralizing antibody titer exceeded observed convalescent serum sars patient approach effective sarssexpressing tumor challenge model thus warrant investigation,2007,"Kuate, Seraphin; Cinatl, Jindrich; Doerr, Hans Wilhelm; Uberla, Klaus",Virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17258782/,34245972.0,3
51572,51572,65196,irvdwibh,,Medline,Infectious bronchitis virus subpopulations in vaccinated chickens after challenge.,,,23050466.0,unk,infectious bronchitis coronavirus ibv show extensive genotypic phenotypic variability evolutionary process involves generation genetic diversity mutation recombination followed replication phenotype favored selection current study examined change occurring wild arkansas ark challenge strain chicken vaccinated either ocularly commercially available attenuated arkdpiderived vaccine ovo replicationdefective recombinant adenovirus expressing codonoptimized ibv ark gene adarkibvsck commercial ibv ark vaccine b c provided slightly differing level protection homologous challenge importantly current study chicken vaccinated different vaccine displayed significant difference specific blymphocyte response harderian gland ie challenge virus encountered differing immune selective pressure invasion among host group based sequence five predominant population found different individual vaccinatedchallenged chicken chicken strongest immune response vaccine able successfully impede replication challenge virus chicken population predominant challenge strain detected ibvpositive bird contrast chicken showing le optimal specific immune response vaccine b c ibv detected chicken population different predominant one challenge strain selected became predominant result provide scientific evidence assumption poor vaccination contributes emergence new ibv strain via mutation andor selection ovo vaccination low dose adarkibvsck resulted mild increase systemic antibody reduced viral shedding protection ibv sign lesion condition detected virus population identical challenge virus possible explanation discussed broad perspective result indicate selection important force driving ibv evolution,2012,"Toro, Haroldo; Pennington, Daniela; Gallardo, Rodrigo A; van Santen, Vicky L; van Ginkel, Frederik W; Zhang, JianFeng; Joiner, Kellye S",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/23050466/,35861873.0,3
51614,51614,65243,ns6ftb1o,,Medline,Serologic response of domestic ferrets (Mustela putorius furo) to canine distemper and rabies virus vaccines.,,,2537273.0,unk,nine unrelated weekold naive domestic ferret mustela putorius furo used evaluate serologic response commercial canine distemper virus cdv rabies virus rv vaccine five ferret group inoculated time week interval multivalent modifiedlive virus vaccine canine cellline origin containing cdv inactivated rv vaccine four ferret group inoculated multivalent modifiedlive virus vaccine containing cdv inoculated rv vaccine group group ferret seroconverted cdv component vaccine group ferret also seroconverted rv vaccination maintained serum antibody titer cdv rv least month domestic ferret serum found igg epitope similar serum domestic dog cat domestic ferret serum contain antibody feline coronavirus felv antigen,1989,"Hoover, J P; Baldwin, C A; Rupprecht, C E",Journal of the American Veterinary Medical Association,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/2537273/,42209723.0,3
51673,51673,65315,c14uyh9x,,Medline,"Live, attenuated coronavirus vaccines through the directed deletion of group-specific genes provide protection against feline infectious peritonitis.",,,15047802.0,unk,feline infectious peritonitis fip fatal immunitymediated disease caused mutant ubiquitous coronavirus since previous attempt protect cat laboratory field condition largely unsuccessful used recently developed system reverse genetics b j haijema h volders p j rottier j virol development modified live fip vaccine objective deleted groupspecific gene cluster open reading frame abc ab obtained deletion mutant virus multiplied well cell culture also showed attenuated phenotype cat dos wildtype virus would fatal mutant gene deletion cause clinical symptom still induced immune response however judged high level virusneutralizing antibody fip virus fipv mutant lacking abc cluster lesser extent mutant missing ab cluster protected cat lethal homologous challenge protection obtained mutant devoid gene cluster study show deletion groupspecific gene coronavirus genome result live attenuated candidate vaccine fipv generally approach may allow development vaccine infection pathogenic coronaviruses including causing severe acute respiratory syndrome human,2004,"Haijema, Bert Jan; Volders, Haukeline; Rottier, Peter J M",Journal of virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15047802/,32124673.0,3
51739,51739,65396,u7gqjacb,,Medline,The control of necrotic enteritis in sucking piglets by means of a Clostridium perfringens toxoid vaccine.,,,10397319.0,unk,necrotic enteritis sucking piglet constitutes serious problem piglet rearing unit high morbidity mortality associated disease primary causal agent clostridium perfringens type c betatoxin play decisive role pathogenesis disease toxoid vaccine use sow developed studied field trial european pharmacopoeia monograph vaccine use animal lay method efficacy testing based immunization rabbit collection pooled serum subsequent assay antitoxin antibody mouse using appropriate test toxin vaccine regarded effective induces minimum iu betaantitoxin per ml rabbit serum established range iu betaantitoxin per ml rabbit serum induced sample c perfringens toxoid vaccine vaccine used field condition different rearing unit time mostly form emergency vaccination following outbreak disease outcome vaccination evaluated recording total number piglet born alive piglet loss use vaccine coupled measure resulted approximately reduction number loss,1999,"Springer, S; Selbitz, H J",FEMS immunology and medical microbiology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/10397319/,23708243.0,3
51803,51803,65481,375muzaw,,Medline,Enhanced induction of SARS-CoV nucleocapsid protein-specific immune response using DNA vaccination followed by adenovirus boosting in BALB/c mice.,,,16809936.0,unk,objective investigate immunogenicity induction humoral cellular immune response genetic vaccine recombinant severe acute respiratory syndromeassociated coronavirus sarscovn gene expressing protein plasmid pcdnan replicationdefective adenoviral vector radn pcdnan primeradn boost regimen reverse sequence radn primepcdnan boost regimen method mouse immunized intramuscularly andor intraperitoneally pcdnan radn primetriple boost immunization humoral cellular immune response detected result detection different level antin humoral cellular response shown compared control humoral immune response induced effectively dna priming recombinant adenovirus boosting regimen reverse sequence heterogeneous combination significant difference heterogeneous homologous vaccination however cytotoxic lymphocyte ctl response significantly altered different primeboost immunization recombinant adenovirus pcdnan primeradn boost regimen alone lymphoproliferation interferongamma ifngamma secretion enhanced heterologous combination immunization compared homologous combination reverse sequence immunization regimen lymphoproliferation ifngamma ctl response significantly weaker compared pcdnan primeradn boost regimen conclusion taken together combination primetriple boost immunization pcdnanpcdnanpcdnanradn effectively induce sarscovnspecific strong humoral cellular immune response mouse present result suggest dna immunization followed recombinant adenovirus boosting could used potential sarscov vaccine induction enhanced humoral cellular immune response,2006,"Chunling, Ma; Kun, Yao; Jian, Xu; Jian, Qin; Hua, Sun; Minsheng, Zhu",Intervirology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16809936/,9818725.0,3
51824,51824,65508,gnj6izmj,,Medline,The Hajj: updated health hazards and current recommendations for 2012.,,,23078811.0,unk,year hajj take place october recent outbreak ebola haemorrhagic fever uganda democratic republic congo cholera sierra leone infection associated novel coronavirus saudi arabia qatar required review health recommendation hajj current guideline foresee mandatory vaccination quadrivalent meningococcal vaccine pilgrim yellow fever poliomyelitis vaccine pilgrim highrisk country influenza vaccine strongly recommended,2012,"Al-Tawfiq, J A; Memish, Z A",Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/23078811/,35209822.0,3
51909,51909,65603,kvdeznws,,Medline,Production and characterization of egg yolk antibodies against bovine alimentary tract pathogens.,,,23971196.0,unk,aim study evaluate effect immunization hen bovine vaccine c r course igy antibody production selected bovine e coli strain rota coronaviruses egg yolk farm condition hen individual per group vaccinated twice subcutaneously four week interval egg harvested week control group consisted egg sampled nonvaccinated hen located neighbouring cage antibody activity measured elisa used vaccine induced rise igy antibody egg yolk based duration highest level igy antibody bovine alimentary tract pathogen c vaccine used next two trial vaccination hen time double immunization seems enough mounting response examined pathogen several week immunization c vaccine allowed harvest egg satisfactory level e coli rotavirus coronavirus igy antibody may used evaluate protective effect oral administration calf,2013,"Sitnik, O; Jawor, P; Kopeć, W; Skiba, T; Stefaniak, T",Polish journal of veterinary sciences,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/23971196/,27686334.0,3
51928,51928,65624,c9u0ikjr,,Medline,Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses.,,,16621188.0,unk,effective vaccine severe acute respiratory syndrome sars probably require generation maintenance humoral cellular immune response reported natural infection human immunization animal sarscov vaccine antibody produced persistent long period time present study mouse immunized im sarscov dna vaccine three different method elisa elispot facs used evaluate immune response cell stimulated vitro pool peptide overlapping entire sars spike protein result show primeimmunization sarscov dna vaccine induce cd cd cell response boosting vaccine enhances cd cd cell response lymphoid nonlymphoid organ persistent two month sarscov sspecific cd cd cell cdl marker memory cell cell expressed ilralpha cd marker capacity effector cell develop memory cell addition immunization dna vaccine elicited high level antibody production taken together data demonstrate immunization sarscov dna vaccine generate antigenspecific humoral cellular immune response may contribute longterm protection,2006,"Huang, Jun; Ma, Rui; Wu, Chang-you",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16621188/,26674617.0,3
51929,51929,65625,z0uipc0a,,Medline,Pneumonia in the elderly.,,,15021052.0,unk,purpose review review provides update new data etiology clinical characteristic outcome prevention communityacquired pneumonia impact severe acute respiratory syndrome older person also addressed recent finding streptococcus pneumoniae remains important cause communityacquired pneumonia elderly year pneumococcus also important etiologic agent pneumonia resident longterm care facility clinical sign symptom communityacquired pneumonia le distinct group compared younger patient new data influenza immunization reveal better mucosal immunity intranasal vaccine compared intramuscular vaccine review clinical trial evidence differs observational study demonstrate clear benefit polysaccharide pneumococcal vaccine elderly prospect severe acute respiratory syndrome older adult important new issue emerge older adult increased risk complication death summary many challenge preventing managing communityacquired pneumonia elderly pneumoniae remains important cause clinical presentation pneumonia elderly nonspecific given safety profile vaccine supportive observational evidence public health policymakers continue support use polysaccharide pneumococcal vaccine however research new vaccine strategy including use conjugate common antigen vaccine priority,2004,"Loeb, Mark",Current opinion in infectious diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15021052/,31882884.0,3
51951,51951,65650,cax41tcn,,Medline,Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector.,,,16977404.0,unk,recombinant vesicular stomatitis virus rvsv currently evaluation human immunodeficiency virus hiv vaccine vector compelling reason develop rvsv vaccine vector include low seroprevalence human ability infect robustly express foreign antigen broad range cell vigorous growth continuous cell line used vaccine manufacture numerous preclinical study rvsv vector expressing antigen variety human pathogen demonstrated versatility flexibility potential efficacy rvsv vaccine platform administered nonhuman primate nhps rvsv vector expressing hiv gag env elicited robust hivspecific cellular humoral immune response animal immunized rvsv vector expressing simian immunodeficiency virus siv gag hiv env protected aid challenge pathogenic sivhiv recombinant however result exploratory neurovirulence study nhps indicated prototypic rvsv vector might adequately attenuated widespread use human population address safety concern variety different attenuation strategy designed produce range attenuated rvsv vector currently investigation additional modification attenuated rvsv vector upregulate expression hiv antigen coexpress molecular adjuvant also developed effort balance immunogenicity attenuation,2006,"Clarke, David K; Cooper, David; Egan, Michael A; Hendry, R Michael; Parks, Christopher L; Udem, Stephen A",Springer seminars in immunopathology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16977404/,34633216.0,3
52033,52033,65753,bpaepojn,,Medline,Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants.,,,17194199.0,unk,background severe acute respiratory syndrome coronavirus sarscov identified etiological agent severe acute respiratory syndrome disease characterized severe pneumonia sometimes result death sarscov zoonotic virus crossed specie barrier likely originating bat specie including civet raccoon dog domestic cat swine rodent sarscov vaccine confer longterm protection especially vulnerable senescent population epidemic strain zoonotic strain may yet emerge animal reservoir report comprehensive investigation sars vaccine efficacy young senescent mouse following homologous heterologous challenge method finding using venezuelan equine encephalitis virus replicon particle vrp expressing epidemic urbani sarscov strain spike glycoprotein vrps nucleocapsid n protein strain vrpn demonstrate vrps vrpn vaccine provide complete short longterm protection homologous strain challenge young senescent mouse test vrp vaccine efficacy heterologous sarscov used phylogenetic analysis synthetic biology reverse genetics construct chimeric virus icgdos encoding synthetic glycoprotein gene genetically divergent human strain gdo cluster among zoonotic sarscov icgds replicated efficiently human airway epithelial cell lung young senescent mouse highly resistant neutralization antiserum directed urbani strain although vrps vaccine provided complete shortterm protection heterologous icgds challenge young mouse limited protection seen vaccinated senescent animal vrpn vaccine failed protect homologous heterologous challenge resulted enhanced immunopathology eosinophilic infiltrates within lung sarscovchallenged mouse vrpninduced pathology presented day peaked around day persisted day likely mediated cellular immune response conclusion study identifies gap challenge vaccine design controlling future sarscov zoonosis especially vulnerable elderly population availability sarscov virus bearing heterologous glycoprotein provides robust challenge inoculum evaluating vaccine efficacy zoonotic strain likely source future outbreak,2006,"Deming, Damon; Sheahan, Timothy; Heise, Mark; Yount, Boyd; Davis, Nancy; Sims, Amy; Suthar, Mehul; Harkema, Jack; Whitmore, Alan; Pickles, Raymond; West, Ande; Donaldson, Eric; Curtis, Kristopher; Johnston, Robert; Baric, Ralph",PLoS medicine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17194199/,16412919.0,3
52039,52039,65759,k1ysvz82,,Medline,Analyses of Merging Clinical and Viral Genetic Data for Influenza Surveillance.,,,26958299.0,unk,annual influenza vaccine one common public health intervention universally recommended individual older six month vaccine composition depends virus circulating past flu season estimated prevalent representative strain current season use clinical data outfitted viral genetics characterize confirmed influenza case past two flu season genetically compare strain vaccinated year show case similarity vaccine strain differ geographic region vaccine appear different level effectiveness region study demonstrates value merging viral genetics clinical data research needed formally evaluate whether improves biosurveillance effort enhances efficacy influenza vaccine,2015,"Magee, Daniel; Beard, Rachel; Scotch, Matthew",AMIA ... Annual Symposium proceedings. AMIA Symposium,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/26958299/,1700754.0,3
52126,52126,65860,8wbo6phm,,Medline,Genotypes of canine distemper virus determined by analysis of the hemagglutinin genes of recent isolates from dogs in Japan.,,,10449479.0,unk,canine distemper domestic dog caused canine distemper virus cdv member morbilliviruses highly contagious disease great veterinary importance century last several decade controlled satisfactorily modified live vaccine however described cdv strain genetically different vaccine strain may caused disease vaccinated dog highest antigenic variation found h protein therefore present study hemagglutinin h gene obtained current vaccine field isolates amplified directly clinical specimen genetically analyzed restriction fragment length polymorphism assay sequencing phylogenetic analysis hgene amino acid sequence revealed least two cdv genotype circulating among dog japan one genotype almost japanese cdv isolates belong previously described separate independent lineage genotype vaccine strain well european u cdv isolates result suggest cdv also evolved japan study needed evaluation possible improvement efficacy current cdv vaccine,1999,"Mochizuki, M; Hashimoto, M; Hagiwara, S; Yoshida, Y; Ishiguro, S",Journal of clinical microbiology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/10449479/,27294559.0,3
52218,52218,65972,q2my5f97,,Medline,Control of Mycoplasma hyopneumoniae infections in pigs.,,,17964089.0,unk,mycoplasma hyopneumoniae primary pathogen enzootic pneumonia occurs worldwide cause major economic loss pig industry organism adheres damage ciliated epithelium respiratory tract affected pig show chronic coughing susceptible respiratory infection reduced performance control disease accomplished number way first management practice housing condition herd optimized include allinallout production limiting factor may destabilize herd immunity maintaining optimal stocking density prevention respiratory disease optimal housing climatic condition strategic medication antimicrobial active hyopneumoniae preferably also major secondary bacteria may useful period pig risk respiratory disease finally commercial bacterins widely used control hyopneumoniae infection main effect vaccination include le clinical symptom lung lesion medication use improved performance however bacterins provide partial protection prevent colonization organism different vaccination strategy timing vaccination vaccination sow vaccination combined antimicrobial medication used depending type herd production system management practice infection pattern preference pig producer research new vaccine actively occurring including aerosol feedbased vaccine well subunit dna vaccine eradication infection herd level based agesegregation medication possible permanent risk reinfections,2008,"Maes, D; Segales, J; Meyns, T; Sibila, M; Pieters, M; Haesebrouck, F",Veterinary microbiology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17964089/,26094378.0,3
52229,52229,65987,zkbtnyfg,,Medline,Antibody- and Fc-receptor-based therapeutics for malaria.,,,16336201.0,unk,ab antibody complex glycoprotein play crucial role protective immunity malaria effectiveness mediating resistance enhanced genetically engineered modification improve nature ab also aid investigation immune mechanism operating control disease valuable tool developing neutralization assay vaccine design review explores might achieved,2006,"Shi, Jianguo; McIntosh, Richard S; Pleass, Richard J",Clinical science,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16336201/,42098535.0,3
52259,52259,66025,uw9lre3z,,Medline,Current vaccination strategies in puppies and kittens.,,,16564416.0,unk,motivation writing article stem many thing lack time spent veterinary curriculum discussing vaccine growing concernby general public veterinary community regarding adverse reaction associated vaccine desire prevent recurrence preventable infectious disease resulting feardriven cessation vaccine administration objective article present basic review immunology related vaccine discus general guideline pediatric vaccine canine feline patientsand offer suggestion positively influence patient health first visit,2006,"Davis-Wurzler, Gina M",The Veterinary clinics of North America. Small animal practice,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16564416/,34439605.0,3
52282,52282,66059,r9f8h4ep,,Medline,An overview of successful TGEV vaccination strategies and discussion on the interrelationship between TGEV and PRCV.,,,8209768.0,unk,porcine respiratory coronavirus prcv new variant tge altered pathogenesis prcv multiplies mainly tonsilar tissue respiratory tract enteric symptom experimentally infected pig even respiratory tract infection usually asymptomatic prcv spread aerogenically herd significance prcv pathogen swine yet determined despite difference pathogenesis tissue tropism behavior tgev prcv closely related antigenically prcv induces antibody response pig distinguished tgevinfected pig conventional serological assay prcv sensitized animal protected tgev challenge milk antibody provided nursing piglet completely effective prevention tgev infection thus prcv good vaccine candidate tgev infection prcv subclinical infection led several reported case enzootic tgev herd diagnosed tgev immune strictly basis serum neutralizing titer later found due exposure prcv vaccination study conducted ambico oral modified live tgev vaccine led startling new result use ambico tgev modified live vaccine shown provide complete protection subsequent prcv challenge effectiveness tgev vaccination actually enhanced previous exposure prcv weanling pig passively acquired circulating tgev neutralizing antibody protected subsequent prcv infection,1993,"Welter, M W; Horstman, M P; Welter, C J; Welter, L M",Advances in experimental medicine and biology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/8209768/,24361522.0,3
52313,52313,66096,4d5v5spl,,Medline,Prospects for a vaccine against otitis media.,,,16989632.0,unk,otitis medium major cause morbidity child le year age often go undiagnosed general population evidence suggest incidence otitis medium increasing major cause otitis medium infection middle ear microbe nasopharynx anatomical orientation eustachian tube association number risk factor predisposes infant young child infection bacteria responsible approximately case acute otitis medium streptococcus pneumoniae nontypeable haemophilus influenzae moraxella catarrhalis predominating causative agent respiratory virus respiratory syncytial virus rhinovirus parainfluenza influenza account acute otitis medium case past decade profound increase reported resistance antibiotic increased disease burden focussed attention vaccine development otitis medium polymicrobial formulation containing antigen major pathogen would greatest potential deliver sustained reduction disease burden globally disappointing outcome otitis medium seen polysaccharide pneumococcal conjugate vaccine raised major challenge vaccination strategy clearly knowledge required concerning immune mechanism middle ear well vaccine formulation containing antigen representative polymicrobial nature disease antigen extensively tested animal model available testing human subject,2006,"Cripps, Allan W; Otczyk, Diana C",Expert review of vaccines,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16989632/,12375449.0,3
52340,52340,66130,w0o5py8z,,Medline,DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques.,,,17205139.0,unk,previous study hiv pgag immunization mouse demonstrated usefulness targeting antigen cellular compartment containing major histocompatibility complex type ii mhc ii complex molecule use dna antigen formulation encoding gag chimera mouse lysosomeassociated membrane protein mlampgag present study analyzed magnitude breadth gagspecific tlymphocyte antibody response elicited rhesus macaque immunization dna encoding human lampgag hlampgag chimera elispot analysis indicated average gagspecific ifngamma response elicited hlampgag chimera detectable two three naked dna immunization five immunized macaque reached average spotforming cell sfc pbmcs high ifngamma elispot response detected cddepleted cell indicating cd tcells play major role response tcell response four macaque also tested use elispot overlapping amino acid aa peptide pool containing ten peptide encompassing complete gag protein sequence two mamu immunized macaque responded eight twelve pool mamu b six macaque five pool indicating hlampgag dna antigen formulation elicits broad tcell response gag additionally strong hivspecific igg response igg antibody titer increased dna injection indicating strong amnestic bcell response highly elevated macaque three immunization moreover serum macaque recognized peptide aa peptide library covering complete gag amino acid sequence addition hivspecific iga antibody present plasma external secretion including nasal wash data support finding increased immunogenicity genetic vaccine encoded lamp chimera including response dna vaccine nonhuman primate,2006,"Chikhlikar, Priya; Barros de Arruda, Luciana; Maciel, Milton; Silvera, Peter; Lewis, Mark G; August, J Thomas; Marques, Ernesto T A",PloS one,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17205139/,15988422.0,3
52346,52346,66138,xta8rvof,,Medline,Vaccinology at the beginning of the 21st century.,,,15950445.0,unk,today main challenge vaccinologists include improving vaccine yet undefeated pathogen rapid identification response emerging disease successful intervention chronic disease ongoing immune response insufficient reverse genetics reverse vaccinology used generate rapidly new vaccine strain mine whole genome search promising antigen rational design adjuvant become possible result discovery receptor recognize microbial pattern lead dendritic cell activation antigenloaded dendritic cell dna naked formulated viral form delivery system used maximize immune response although work easy vaccine already completed hoped combination conceptual technical innovation enable development complex sophisticated vaccine future,2005,"Wack, Andreas; Rappuoli, Rino",Current opinion in immunology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15950445/,30787851.0,3
52376,52376,66172,dgbk3icc,,Medline,Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus.,,,16716107.0,unk,replicationdeficient human adenovirus type adh vector induce strong transgene productspecific cellular humoral response however many adult human neutralizing antibody nabs adh result natural infection virus therefore chimpanzee adenovirus c adc vector developed circumvent interference preexisting immunity adh study evaluated impact preexisting immunity human adenovirus efficacy adenovirusbased vaccine coronavirus cause severe acute respiratory syndrome sarscov efficacy assessed intramuscular injection vector mouse measured frequency sarscovspecific cell nabs sarscov immunogenicity adhbased vaccine significantly attenuated completely abolished preexisting antiadh nab titer higher human serum sample united state tested far antiadh nab titer higher result suggested significant percentage human preexisting antiadh immunity would candidate vaccination adhbased genetic vaccine contrast preexisting antiadh nabs minimal effect potency adcbased genetic vaccine taken together study warrant development adc vaccine carrier human trial,2006,"Zhi, Yan; Figueredo, Joanita; Kobinger, Gary P; Hagan, Heather; Calcedo, Roberto; Miller, James R; Gao, Guangping; Wilson, James M",Human gene therapy,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16716107/,44801298.0,3
52389,52389,66190,z9rksmxy,,Medline,Formalin-treated UV-inactivated SARS coronavirus vaccine retains its immunogenicity and promotes Th2-type immune responses.,,,17515642.0,unk,demand rapid simple development vaccine newly emerging infectious disease increasing worldwide previously revealed uvinactivated severe acute respiratory syndrome sarsassociated coronavirus sarscov virion uvv elicited high level humoral immunity weak th response mouse immunized subcutaneously ensure safety whole inactivated sarscov vaccine additionally treated uvv vaccine formalin resulting uvfv vaccine analysis immunogenicity uvfvalum vaccine mouse revealed generated comparable neutralizing serum antisarscov igg antibody level uvvalum vaccine moreover vaccine induced similar frequency antisarscov igg antibodyproducing cell bone marrow interestingly uvfv vaccine induced fewer igga subtype antibody higher interleukin production vaccinated mouse uvv thus uvfv imposes thtype bias immune response unlike uvv propose doublyinactivated sarscov virion uv formalin constitute safe vaccine may effectively induce neutralizing antibody human,2007,"Tsunetsugu-Yokota, Yasuko; Ato, Manabu; Takahashi, Yoshimasa; Hashimoto, Shu-ichi; Kaji, Tomohiro; Kuraoka, Masayuki; Yamamoto, Ki-ichi; Mitsuki, Yu-ya; Yamamoto, Takuya; Oshima, Masamichi; Ohnishi, Kazuo; Takemori, Toshitada",Japanese journal of infectious diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17515642/,29797951.0,3
52464,52464,66275,kin2ss11,,Medline,Forty years of canine vaccination.,,,9890024.0,unk,last year vaccine developed greatly reduced incidence infectious disease dog general modified live product superior inactivated vaccine dog expected recombinant andor dna vaccine may dominate market future although vaccine market safe efficacious exception disease induced vaccination dog protected failure protection may part due variation individual vaccine batch potency test efficacy test required may sufficient example virus titer vaccine may meaningless minimum protective dose known overattenuated virus eg cdvond parvovirus cat cell may high titer tissue culture immunogenic question frequency vaccination dog addressed annual revaccinations cdv cpv cav probably needed however would desirable collect data support le frequent vaccination annual immunization bacterial disease kennel cough lyme disease leptospirosis continue also would desirable develop oronasal vaccine perhaps combined newly developed vector le likely induce undesirable side effect may seen parenteral vaccination finally word warning homeopathic nosodes replace tested canine vaccine appear highly effective long majority dog remain vaccinated soon nonvaccinated dog population large enough allow virulent agent spread disease outbreak occur back began year ago,1999,"Appel, M J",Advances in veterinary medicine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/9890024/,34930469.0,3
52488,52488,66308,gi1qyh1w,,Medline,Coping with genetic diversity: the contribution of pathogen and human genomics to modern vaccinology.,,,22030866.0,unk,vaccine development face major difficulty partly genetic variation infectious organism human cause antigenic variation infectious agent high interindividual variability human response vaccine exponential growth genome sequence information induced shift conventional culturebased genomebased vaccinology allows tackling challenge vaccine development due pathogen genetic variability additionally recent advance immunogenetics genomics help understanding influence genetic factor interindividual interpopulation variation immune response vaccine could useful developing new vaccine strategy accumulating result provide evidence existence number gene involved protective immune response induced either natural infection vaccine variation immune response could viewed result perturbation gene network help understanding particular polymorphism combination thereof could affect protective immune response present first genomebased vaccine served proof concept provided new critical insight vaccine development strategy ii overview genetic predisposition infectious disease genetic control response vaccine iii population genetic difference rationale behind grouptargeted vaccine iv outlook genetic control infectious disease special emphasis concept molecular network provide structure huge amount genomic data,2012,"Lemaire, D; Barbosa, T; Rihet, P",Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/22030866/,15170628.0,3
52555,52555,66386,b4l2twcm,,Medline,The challenge of PRRS immunology.,,,17644436.0,unk,porcine reproductive respiratory syndrome prrs one challenging subject research veterinary viral immunology immune response prrs virus prrsv still poorly understood infected pig develop strong rapid humoral response initial antibody confer protection even harmful mediating antibodydependent enhancement disease contrast development neutralising antibody na delayed generation cellmediated immune response prrsvspecific interferon ifngamma secreting cell initially erratic spite induction strong rapid na ifngamma response seem required effective vaccination prrsv strongly modulates host immune response virus inhibits key cytokine ifnalpha may induce regulatory cytokine interleukin il development na seems impaired existence decoy epitope close main neutralisation epitope glycoprotein ability modulate host immune response probably varies among strain isolates genetic diversity virus high shown diversity serious implication development vaccine since immunity induced one strain may partial different strain even within genotype panorama development newer universally efficacious prrsv vaccine challenging present state knowledge allows optimism collaborative effort undertaken scientific community,2008,"Mateu, E; Diaz, I",Veterinary journal,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17644436/,32864314.0,3
52596,52596,66433,sv7j5qqy,,Medline,Polio control after certification: major issues outstanding.,,,15106300.0,unk,global eradication wild poliovirus almost within sight planning postcertification era becoming priority issue agreed stockpile appropriate polio vaccine need established surveillance response capacity need maintained order protect world possible future outbreak attributable either persistence wild poliovirus vaccinederived poliovirus vdpvs unintentional intentional release poliovirus laboratory vaccine store although suggested stockpile consist monovalent oral poliovirus vaccine mopv many question remain concerning nature financing management usein particular uncertainty future national vaccination policy availability different vaccine certification wild poliovirus eradication uncertainty concerning possible role efficacy inactivated poliovirus vaccine ipv used either routinely outbreak control lowhygiene setting potential rapid geographical spread poliovirus outbreak occur certification risk inherent introducing additional oral polio vaccine opv virus population vaccine coverage prevalence immunity declined may thus favour spread vdpvs given important gap knowledge country discontinue polio vaccination coordinated policy postcertification era developed recommended measure put place,2004,"Fine, Paul E M; Oblapenko, George; Sutter, Roland W",Bulletin of the World Health Organization,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15106300/,38928254.0,3
52616,52616,66461,iw85as4l,,Medline,A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses.,,,16214268.0,unk,doubleinactivated candidate whole virus vaccine severe acute respiratory syndrome associated coronavirus sarscov developed manufactured large scale using fermenter culture serum protein free vero cell two step inactivation procedure involving sequential formaldehyde uv inactivation utilised order ensure extremely high safety margin respect residual infectivity immunogenicity doubleinactivated vaccine characterised mouse model mouse immunised twice candidate sarscov vaccine developed high antibody titre sarscov spike protein high level neutralising antibody use adjuvant aloh minor effect immunogenicity vaccine addition cell mediated immunity measured interferongamma interleukin stimulation elicited vaccination moreover vaccine confers protective immunity demonstrated prevention sarscov replication respiratory tract mouse intranasal challenge sarscov protection mouse correlated antibody titre sarscov protein neutralising antibody titre,2006,"Spruth, Martin; Kistner, Otfried; Savidis-Dacho, Helga; Hitter, Elisabeth; Crowe, Brian; Gerencer, Marijan; Brühl, Peter; Grillberger, Leopold; Reiter, Manfred; Tauer, Christa; Mundt, Wolfgang; Barrett, P Noel",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16214268/,22439297.0,3
52627,52627,66472,5rz7rckf,,Medline,Experimental inoculation of late term pregnant sows with a field isolate of porcine reproductive and respiratory syndrome vaccine-derived virus.,,,11731155.0,unk,use live attenuated porcine reproductive respiratory syndrome virus prrsv vaccine piglet associated reproductive disorder nonvaccinated sow vaccinederived virus vdv isolated foetus stillborn pig dead piglet indicating live vaccine spread vaccinated piglet nonvaccinated sow virus might implicated severe reproductive problem observed present study one vdv isolate used experimentally infect pregnant sow last trimester chosen isolate identity attenuated vaccine virus originated lung stillborn pig swine herd sudden high level stillborn pig increased piglet mortality nursing period intranasal inoculation sow virus isolate resulted congenital infection foetal death preweaning pig mortality present study showed vaccinederived prrsv cause disease swine consistent prrs,2002,"Nielsen, J; Bøtner, A; Bille-Hansen, V; Oleksiewicz, M B; Storgaard, T",Veterinary microbiology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/11731155/,12815108.0,3
52658,52658,66509,13p51dq2,,Medline,Epitope specificity of protective lactogenic immunity against swine transmissible gastroenteritis virus.,,,1383566.0,unk,epitope specificity protective immune response swine transmissible gastroenteritis tge investigated using circulating secretory antibody study carried sow vaccinated tgev antigenically related porcine respiratory coronavirus prcv tgev vaccination sow resulted greater lactogenic protection suckling piglet tgev challenge higher secretory immune response prcv vaccination difference immune response conditioned route antigen presentation result different tropism virus epitope protein particular contained antigenic site immunogenic epitope n protein group vaccinated sow determined competitive radioimmunoassay minor difference antibody response previously defined antigenic subsites aa ab ac also detected subsite ab antigenic tgev prcvimmune sow finding suggest antigenic site protein involved virus neutralization immunodominant site pregnant sow confer lactogenic protection also validate experiment secretory antibody antigenic map made murine monoclonal antibody therefore antigenic site considered vaccine diagnostic development,1992,"De Diego, M; Laviada, M D; Enjuanes, L; Escribano, J M",Journal of virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/1383566/,46424172.0,3
52714,52714,66575,dpjojmlp,,Medline,A placebo-controlled trial of two intranasal vaccines to prevent tracheobronchitis (kennel cough) in dogs entering a humane shelter.,,,15156996.0,unk,placebocontrolled field trial conducted compare effectiveness intranasal vaccine containing bordetella bronchiseptica canineparainfluenza virus inbpa without inbp canineadenovirus type prevention kennel cough humane shelter dog examined admission shelter without respiratory sign disease assigned daily rotating basis receive one three vaccine enrolled healthy dog dog monitored day postvaccination coughing clinical sign respiratory disease thirtythree confidence interval ci dog inbp group ci corrected dog inbpa group ci corrected dog inp group coughed spontaneously day within day vaccination p inbp inbpa vaccine effective respectively reducing coughing compared placebo vaccine strongest prognostic factor coughing regardless vaccine group number day spent shelter additional day increasing risk coughing ci corrected low incidence coughing shelter study precluded observation difference vaccine effectiveness difference vaccineassociated adverse event coughing sneezing nasal ocular discharge noted first day postadministration thereafter,2004,"Edinboro, Charlotte H; Ward, Michael P; Glickman, Larry T",Preventive veterinary medicine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15156996/,36416992.0,3
52776,52776,66648,0yqvtkek,,Medline,SARS vaccine development.,,,16022774.0,unk,developing effective safe vaccine urgently needed prevent infection severe acute respiratory syndrome sarsassociated coronavirus sarscov inactivated sarscov vaccine may first one available clinical use easy generate however safety main concern spike protein sarscov major inducer neutralizing antibody receptorbinding domain rbd subunit protein contains multiple conformational neutralizing epitope suggests recombinant protein containing rbd vector encoding rbd sequence used develop safe effective sars vaccine,2005,"Jiang, Shibo; He, Yuxian; Liu, Shuwen",Emerging infectious diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16022774/,8682191.0,3
52797,52797,66672,lcgo6osp,,Medline,DNA immunization with plasmids encoding fusion and nucleocapsid proteins of bovine respiratory syncytial virus induces a strong cell-mediated immunity and protects calves against challenge.,,,17459933.0,unk,respiratory syncytial virus rsv one important respiratory pathogen human cattle currently safe effective vaccine prophylaxis study designed two codonoptimized plasmid encoding bovine rsv fusion f nucleocapsid n protein assessed immunogenicity young calf two administration plasmid elicited low antibody level primed strong cellmediated immunity characterized lymphoproliferative response gamma interferon production vitro vivo interestingly strong cellular response drastically reduced viral replication clinical sign pulmonary lesion highly virulent challenge moreover calf vaccinated killedvirus vaccine developed high level neutralizing antibody fully protected following challenge result indicate dna vaccination could promising alternative classical vaccine rsv cattle could therefore open perspective vaccinating young infant,2007,"Boxus, Mathieu; Tignon, Marylène; Roels, Stefan; Toussaint, Jean-François; Walravens, Karl; Benoit, Marie-Ange; Coppe, Philippe; Letesson, Jean-Jacques; Letellier, Carine; Kerkhofs, Pierre",Journal of virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17459933/,33638786.0,3
52826,52826,66710,ofnr88cb,,Medline,Overview of plant-derived vaccine antigens: Dengue virus.,,,22202223.0,unk,review highlight advantage current status plantderived vaccine development special reference dengue virus numerous problem involved dengue vaccine development vaccine four dengue serotypes dengue vaccine development using traditional approach satisfactory term inducing neutralizing antibody recently issue addressed showing good response inducing neutralizing antibody plantderived dengue vaccine antigen indicates feasibility using plantderived vaccine antigen lowcost method combat dengue infectious disease application new method strategy dendritic cell targeting cancer therapy severe acute respiratory syndrome tuberculosis human immune deficiency virus malaria might play important role new method efficient traditional protocol expected near future plantderived vaccine antigen antibody play important role control human infectious disease,2011,"Malabadi, Ravindra B; Ganguly, Advaita; Silva, Jaime A Teixeira da; Parashar, Archana; Suresh, Mavanur R; Sunwoo, Hoon","Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques",,,,,,https://www.ncbi.nlm.nih.gov/pubmed/22202223/,15163059.0,3
52851,52851,66741,o2a5p4i1,,Medline,Generation of improved mucosal vaccines by induction of innate immunity.,,,16237500.0,unk,vaccination highly effective mean disease prevention saved countless life worldwide past year traditional vaccine based killed attenuated organism inactivated toxin constituted majority clinically used vaccine date novel vaccine based subunit organism increasingly represented future contrast attenuated whole cell vaccine subunit vaccine generally contain immunestimulatory component poorly immunogenic result new potent safe adjuvant delivery system needed enhance immunogenicity vaccine furthermore drive replace injected vaccine administered mucosal route since induction innate immunity crucial vaccine elicit potent antigen specific immune response greater understanding innate immunity mucosal surface mechanism action adjuvant delivery system required,2005,"Lavelle, E C",Cellular and molecular life sciences : CMLS,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16237500/,25657464.0,3
52945,52945,66850,76i7804n,,Medline,Canine viral vaccines at a turning point--a personal perspective.,,,9890023.0,unk,important canine viral infection distemper cpv problem variable cd vaccine safety efficacy persist cd vaccine greatly reduced prevalence disease case vaccinated dog rare canine hepatitis ich cav infection also controlled well vaccine year rare sporadic case seen usually occurred unvaccinated dog cav vaccine therefore continue given since proved safe effective prevent hepatitis well adenoviral tracheobronchitis failure vaccinate would likely result increase case ich serious disease never significant distemper cpv infection vaccinating often question complex dominant opinion yes smith question responded unequivocally however since manufacturer employ different strain vary immunizing capacity probably duration immunity question frequent distemper time many veterinarian tested batch vaccine used providing pre postvaccinal serum competent diagnostic laboratory practice appeared benefit veterinarian dog well quality vaccine unfortunately many owner veterinarian seem hold view infectious disease parvovirus infection controlled frequent vaccination alone common practice dog breeder vaccinating animal several time year senseless revaccination distemper parvovirus infection suggested year age recommendation regarding frequency vaccination given time unclear since distemper cpv vaccine probably provide immunity endures several year vaccination year interval first year seems reasonable practice data duration immunity become available many kind vaccine promoted dog distemper parvovirus vaccine essential canine adenovirus vaccine recommended since case brought attention recent year unvaccinated dog vaccination respiratory infection recommended dog especially kennel boarded need clearly established coronavirus vaccine lyme disease vaccine see useful preventing illness area disease exists unnecessary elsewhere since dog respond rapidly appropriate antibiotic current leptospira bacterins without benefit since contain serovars fail protect area noted lyme disease ld considered newer recombinant ospa vaccine available appear safe effective least year caused vaccineinduced postvaccinal lameness documented certain wholecell lyme disease bacterins lyme disease vaccine restricted dog entering endemic area infested tick reside ld case occur midatlantic northeastern state six midwestern state michigan minnesota wisconsin smaller percentage restricted area northern california pacific northwest leptospirosis also discussed vaccine commonly reported cause anaphylaxis current vaccine contain serovars prevalent region vast majority case diagnosed new york state diagnostic lab cornell grippotyphosa pomona serovars recent case caused canicola icterohemorrhagiae serovars leptospirosis important disease dog urgent need research development safer vaccine contain prevalent,1999,"Carmichael, L E",Advances in veterinary medicine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/9890023/,44550123.0,3
52957,52957,66866,420px62r,,Medline,The 2006 American Association of Feline Practitioners Feline Vaccine Advisory Panel report.,,,17078805.0,unk,vaccination medical procedure decision vaccinate based riskbased assessment cat vaccine,2006,"Richards, James R; Elston, Thomas H; Ford, Richard B; Gaskell, Rosalind M; Hartmann, Katrin; Hurley, Kate F; Lappin, Michael R; Levy, Julie K; Rodan, Ilona; Scherk, Margie; Schultz, Ronald D; Sparkes, Andrew H",Journal of the American Veterinary Medical Association,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17078805/,1262331.0,3
52964,52964,66873,rmi800hf,,Medline,"Influenza vaccination in patients with asthma: effect on peak expiratory flow, asthma symptoms and use of medication.",,,9261948.0,unk,pilot study undertaken examine whether killed influenza vaccine cause exacerbation asthmatic adult thirtythree stable asthmatic recorded peak expiratory flow pef asthma symptom use asthma medication week received killed influenza vaccine thereafter recorded pef asthma symptom use medication week comparison recording week vaccination revealed influenza vaccine associated reduction pef p increase asthma symptom p use asthma medication p similar result pef p asthma symptom p asthma medication p obtained analysis restricted day vaccination,1997,"Ahmed, A H; Nicholson, K G; Hammersley, V S; Kent, J",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/9261948/,24540306.0,3
52970,52970,66880,atd4zmqw,,Medline,Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets.,,,17922397.0,unk,background development vaccine prevent severe acute respiratory syndrome sars limited lack wellcharacterized animal model previous vaccine report noted robust neutralizing antibody inflammatory response ferret resulting enhanced hepatitis method evaluated humoral immune response pathological end point ferret challenged urbani strain sarsassociated coronavirus sarscov received formalininactivated wholevirus vaccine mock vaccine result humoral response observed ferret received inactivated virus vaccine histopathological finding lung showed infection ferret produced residual lung lesion seen mock vaccinated ferret sarscov infection demonstrated bronchial bronchiolar hyperplasia perivascular cuffing ferret lung tissue seen previously infected mouse evidence enhanced disease observed ferret ferret cleared virus day week earlier vaccinated conclusion vaccine provided mild immune protection ferret challenge however evidence enhanced liver lung disease induced inactivated wholevirus vaccine ferret may provide another useful model evaluating sars vaccine safety efficacy,2007,"Darnell, Miriam E R; Plant, Ewan P; Watanabe, Hisayoshi; Byrum, Russ; St Claire, Marisa; Ward, Jerrold M; Taylor, Deborah R",The Journal of infectious diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17922397/,1673199.0,3
52988,52988,66900,mfy2rf1f,,Medline,Plant cell factories and mucosal vaccines.,,,12732315.0,unk,many advance continue made field plantderived vaccine plant shown capable expressing multicomponent vaccine orally delivered induces thelper cell subset response enables passive immunization furthermore plantderived vaccine shown protect challenge target host increased antigen expression level total soluble protein obtained transformation chloroplast genome view finding plantderived vaccine proved valuable commodity world health system however application study need focus optimization immunization strategy investigate antigen stability,2003,"Walmsley, Amanda M; Arntzen, Charles J",Current opinion in biotechnology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12732315/,6999940.0,3
53047,53047,66967,4xrr9ni6,,Medline,Comparison of a fimbrial versus an autotransporter display system for viral epitopes on an attenuated Salmonella vaccine vector.,,,17169467.0,unk,attenuated salmonella used vector deliver foreign antigen live vaccine previously developed efficient surfacedisplay system genetically engineering p fimbria present transmissible gastroenteritis virus tgev c epitope induction antitgev antibody salmonella vaccine vector system compared autotransporter protein surface display system tgev c epitope fused passenger domain misl autotransporter salmonella expression misl p subunit fasafusions tgev epitope control vivoinduced promoter expression tgev epitope salmonella typhimurium c crp cya asd pgte vaccine strain greater epitope fused misl fused p fasa subunit however balbc mouse orally immunized salmonella vector expressing tgev epitope either one fusion construct together highest level antitgev antibody obtained ptgev immunogendisplaying vector result suggested better immune response towards specific epitope could obtained using polymeric display system fimbria,2007,"Chen, Huaiqing; Schifferli, Dieter M",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17169467/,39013103.0,3
53060,53060,66984,e2g1iu39,,Medline,Coronavirus Vaccines: Light at the End of the Tunnel.,,,32291382.0,unk,world currently facing unprecedented global pandemic caused severe acute respiratory syndrome coronavirus sarscov predicting next source pandemic challenging vaccination best way prevent infectious disease development effective vaccine sarscov reduce morbidity mortality associated also lessen economic impact traditional method vaccine development take many year vaccine available society vaccine development sarscov speeded using pandemic approach fasttrack approval regulatory authority various challenge associated developing vaccine pandemic technological hurdle clinical development pathway regulatory issue support global funding agency expressed,2020-04-15,"Ella, Krishna M; Mohan, V Krishna",Indian pediatrics,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/32291382/,215772698.0,3
53063,53063,66987,yzdoweut,,Medline,ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense.,,,15491873.0,unk,threat smallpox biological weapon spurred effort create stockpile vaccine emergency preparedness lieu preparing vaccine animal skin original method cloned vaccinia virus new york city board health strain dryvax plaque purification amplified clone cell culture overarching goal produce modern vaccine equivalent currently licensed dryvax preclinical clinical property could thus reliably protect human smallpox variety clone evaluated many unacceptably virulent animal model one clonal virus acam selected produced clinical grade mrc human diploid cell acam comparable dryvax immunogenicity protective activity le neurovirulent mouse nonhuman primate meet requirement large quantity vaccine event september th acam master virus seed used prepare vaccine designated acam large scale vero cell serumfree condition genome acam acam identical nucleotide sequence vaccine comparable biological phenotype acam acam evaluated three phase clinical trial vaccine produced major cutaneous reaction evoked neutralizing antibody cellmediated immune response vast majority subject reactogenicity profile similar dryvax,2004,"Monath, Thomas P; Caldwell, Joseph R; Mundt, Wolfgang; Fusco, Joan; Johnson, Casey S; Buller, Mark; Liu, Jian; Gardner, Bridget; Downing, Greg; Blum, Paul S; Kemp, Tracy; Nichols, Richard; Weltzin, Richard",International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15491873/,32141063.0,3
53072,53072,66997,f6iaqv48,,Medline,A systems framework for vaccine design.,,,24358511.0,unk,numerous challenge identified vaccine development including variable efficacy function population demographic lack characterization mechanistic understanding immune correlate protection able guide delivery dosing tremendous opportunity recent technological computational advance elucidate system level understanding pathogenhost interaction correlate immunity system biology approach vaccinology provides new paradigm rational vaccine design ‘ precision medicine ’ context,2013,"Mooney, Michael; McWeeney, Shannon; Canderan, Glenda; Sékaly, Rafick-Pierre",Current opinion in immunology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24358511/,40059362.0,3
53170,53170,67109,69dj8cbz,,Medline,Overview of new vaccines and technologies.,,,16723197.0,unk,molecular technology given u greater insight aetiology disease functioning immune system mode action veterinary pathogen knowledge gained used develop new vaccine specific reactive antigen elicit protective immune mediated response humoral andor cell mediated host vaccine burden immune system initiating response nonessential antigen however efficacy vaccine good delivery technology route used present immune system vaccine traditionally given parenteral route given natural route either orally intranasally two major advantage often interrelated rapid onset immunity stimulation local mucosal immunity new technology making impact current vaccine development balance found technologically feasible provide least good protective immunity current conventional vaccine new emerging disease appear globally new opportunity arise molecular conventional technology applied development delivery novel vaccine well improvement vaccine current use,2006,"Chalmers, W S K",Veterinary microbiology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16723197/,20249527.0,3
53208,53208,67157,qv1ftazm,,Medline,Phage display as a promising approach for vaccine development.,,,27680328.0,unk,bacteriophage specific antagonist bacterial host viral entity attracted growing interest optimal vaccine delivery vehicle phage wellmatched vaccine design due highly stable harsh environmental condition simple inexpensive large scale production potent adjuvant capacity phage vaccine efficient immunostimulatory effect present high safety profile virus made constant relationship mammalian body longstanding evolutionary period birth phage display technology turning point development phagebased vaccine phage display vaccine made expressing multiple copy antigen surface immunogenic phage particle thereby eliciting powerful effective immune response also ability produce combinatorial peptide library highly diverse pool randomized ligand transformed phage display straightforward versatile high throughput screening methodology identification potential vaccine candidate different disease particular microbial infection library conveniently screened affinity selectionbased strategy called biopanning wide variety target selection mimotopes high antigenicity immunogenicity also panned antiserum convalescent individual recognize novel peptidomimetics pathogenrelated epitope phage display represented enormous promise finding new strategy vaccine discovery production current breakthrough promise brilliant future development different phagebased vaccine platform,2016,"Aghebati-Maleki, Leili; Bakhshinejad, Babak; Baradaran, Behzad; Motallebnezhad, Morteza; Aghebati-Maleki, Ali; Nickho, Hamid; Yousefi, Mehdi; Majidi, Jafar",Journal of biomedical science,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/27680328/,3902072.0,3
53336,53336,67310,ejbtnlx2,,Medline,[A new polyvalent vaccine against enteral infections in newborn calves].,,,3029935.0,unk,frequent microbial causative agent massive diarrhea newborn calf kept large cattle farm cssr rotavirus coronaviruses enterotoxigenic strain e coli manifesting complicated virusbacterial infection inactivated polyvalent adjuvant vaccine developed prevention specific prophylaxis enteral infection vaccine contains bovine rotavirus bovine coronavirus three enterotoxigenic serotypes e coli protective antigen k rotavirus coronavirus propagated stable cellular line mdbk inactivated formalin escherichia strain submersed minca culture medium cultivation inactivated formalin vaccine prepared blend amount rotavirus coronavirus amount bacterin ml vaccine contain bacteria one part oil adjuvant added five part virusbacterial blend blend homogenized ultraturax apparatus vaccine used immunization pregnant cow heifer animal induces production specific antibody antigen contained vaccine immunogenic effect checked calf cow herd occurrence diarrhea caused enteropathogenic virus enterotoxigenic escherichia demonstrated inactivation influence either virus process inducing production specific antibody antibody response calf heifer application ml complete inactivated vaccine equally strong application live vaccine containing rotavirus coronavirus level rotavirus antibody increased average time time coronavirus antibody twice four time antibody response coronavirus negatively influenced relatively high level antibody vaccination antibody response antigen k expressive case,1987,"Stĕpánek, J; Salajka, E; Zuffa, A; Mensík, J; Franz, J",Veterinarni medicina,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/3029935/,39800000.0,3
53344,53344,67320,f35sf2ce,,Medline,A minor groove binder probe real-time PCR assay for discrimination between type 2-based vaccines and field strains of canine parvovirus.,,,16682086.0,unk,minor groove binder mgb probe assay developed discriminate type based vaccine field strain canine parvovirus cpv considering cpv vaccine contain old type longer circulating canine population two mgb probe specific cpv antigenic variant type b c respectively labeled different fluorophores mgb probe assay able discriminate correctly old type variant detection limit dna copy good reproducibility quantitation viral dna load accurate demonstrated comparing cpv dna titre calculated mean taqman assay recognising cpv type assay ensure resolution diagnostic problem dog showing cpv disease shortly cpv vaccination although discriminate field strain type bbased vaccine recently licensed market country,2006,"Decaro, Nicola; Elia, Gabriella; Desario, Costantina; Roperto, Sante; Martella, Vito; Campolo, Marco; Lorusso, Alessio; Cavalli, Alessandra; Buonavoglia, Canio",Journal of virological methods,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16682086/,20338916.0,3
53350,53350,67326,d9ov2mcn,,Medline,Modern veterinary vaccines and the Shaman's apprentice.,,,12818624.0,unk,paper overview assessment new commercially available veterinary vaccine placed historical context author critically evaluate current state field veterinary vaccine food companion animal promise future vaccine development author maintain considerable variability safety sustained efficacy among veterinary vaccine especially developed companion animal proposed establishment international vaccine advisory committee supported would function apprise veterinary profession current status vaccine use,2003,"Carter, Philip B; Carmichael, L E","Comparative immunology, microbiology and infectious diseases",,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12818624/,11106507.0,3
53363,53363,67343,w98dw28o,,Medline,Mild acute inflammatory stimulation induces transient negative mood.,,,15465075.0,unk,objective study aim ass mood change induced mild acute inflammatory stimulation typhoid vaccination method using double blind study design healthy volunteer underwent baseline assessment mood financial strain work stress randomised injection salmonella typhi vaccine placebo injection mood symptom body temperature assessed modified version profile mood state h post injection result typhoid vaccination induces increase physical symptom temperature mood improved day placebo vaccine condition negative change mood following injection correlated chronic stress financial strain vaccination condition r p conclusion mild acute inflammatory stimulus induces transient negative mood response modulated chronic stress implication depressed mood physical illness discussed,2004,"Strike, Philip C; Wardle, Jane; Steptoe, Andrew",Journal of psychosomatic research,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15465075/,37028460.0,3
53433,53433,67438,1smpg0ng,,Medline,Commensal bacteria as a novel delivery system for subunit vaccines directed against agents of bioterrorism.,,,15935879.0,unk,following anthrax attack recent sars outbreak concern emerging reemerging infectious disease catalyzed renewed interest developing new vaccination strategy provide rapid flexible response option future threat probability encountering one exotic agent unknown essential new vaccine formulation employ method provide effective protection extremely good safety profile used either military civilian population one approach potentially satisfies criterion use live recombinant grampositive commensal bacteria expression vector review provides overview system advantage limitation detail example grampositive commensal bacteria developed fifth generation vaccine class biowarfare pathogen namely smallpox,2005,"Wilson, Rebecca L; Hruby, Dennis E",Advanced drug delivery reviews,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15935879/,43683251.0,3
53459,53459,67472,dlkobtvj,,Medline,"Pathogenic epitopes, heterologous immunity and vaccine design.",,,17558423.0,unk,substantial research directed towards development new generation vaccine based inclusion immunogenic epitope recombinant vector examine evidence certain condition immunogenic epitope harm good might therefore considered pathogenic suggest specific removal pathogenic epitope vaccine might increase prophylactic potential minimizing risk sideeffects vaccine use,2007,"Welsh, Raymond M; Fujinami, Robert S",Nature reviews. Microbiology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17558423/,7716545.0,3
53513,53513,67535,5xr5qh8u,,Medline,Immunization of puppies in the presence of maternally derived antibodies against canine distemper virus.,,,17560592.0,unk,vaccination dam modifiedlive canine distemper virus cdv vaccine elicit high concentration colostral antibody although vital protection pup first week life interfere active vaccination virus present study pup week age maternally derived immunity cdv vaccinated canarypoxvectored cdv vaccine pup protected intravenous challenge cdv three littermate pup unvaccinated developed clinical sign infection challenge two control pup died,2007,"Pardo, M C; Tanner, P; Bauman, J; Silver, K; Fischer, L",Journal of comparative pathology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17560592/,31228134.0,3
53517,53517,67539,mq0lajgg,,Medline,Immunity to transmissible gastroenteritis virus and porcine respiratory coronavirus infections in swine.,,,7856068.0,unk,despite pioneering effort identify correlate passive immunity transmissible gastroenteritis virus tgev effective vaccine control tge suckling pig remained elusive initial concept enteromammary immunologic axis monogastrics originated study lactogenic immunity tgev swine study revealed infection pregnant swine virulent tgev stimulated high titer siga antibody milk correlated protection suckling pig tge parenteral oral inoculation live attenuated killed tgev vaccine induced mainly igg antibody milk generally provided poor protection suckling pig recent appearance prcv infection swine continuing study tgev infection present unique model study mucosal immunity research using virus increased understanding various component common mucosal immune system interaction although important consideration designing effective vaccine tgev stimulation galt intestinal virus replication study addressing contribution balt immunity tgev prcv may provide insight alternative vaccine approach mechanism exposure prcv elicits variabledegree immunity tgev challenge unknown virus replication gut respiratory tract major factor affecting magnitude immune response respective site may necessary recruitment specific immune cell mucosal inductive site ie galt balt balt galt migrationabstract truncated word,1994,"Saif, L J; van Cott, J L; Brim, T A",Veterinary immunology and immunopathology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/7856068/,24849681.0,3
53546,53546,67569,d5tl8o0s,,Medline,Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins.,,,21755021.0,unk,elicitation antibody potent broad neutralizing activity hiv immunization remains challenge several monoclonal antibody mabs isolated human hiv infection exhibit activity vaccine immunogen based structure containing epitope successful elicitation known broadly neutralizing mabs bnmabs immunoglobulin ig g igg highly somatically hypermutated could impede elicitation ig m igm average significantly le divergent germline antibody relevant development vaccine immunogen underexplored compared igg describe identification characterization several human igmderived mabs hiv selected large phagedisplayed naive human antibody library constructed blood lymph node spleen healthy donor antibody bound high affinity recombinant envelope glycoprotein gps envs hiv isolates different clade enhanced neutralize infection hiv primary isolates using ccr coreceptor neutralized cxcr isolates tested although weakly one antibody relatively low degree somatic hypermutation extensively characterized bound highly conserved region partially overlapping coreceptor binding site close overlapping cd binding site result suggest existence conserved structure could direct immune response nonneutralizing even enhancing antibody may represent strategy used virus escape neutralizing immune response study show whether strategy play role hiv infection human important role could mechanism infection enhancement newly identified mabs could used reagent characterize conserved nonneutralizing weakly neutralizing enhancing epitope modify remove candidate vaccine immunogen,2010,"Chen, Weizao; Zhu, Zhongyu; Liao, Huaxin; Quinnan, Gerald V; Broder, Christopher C; Haynes, Barton F; Dimitrov, Dimiter S",Viruses,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/21755021/,5701900.0,3
53560,53560,67584,2lne1fqe,,Medline,Epididymal stone formation and decreased sperm production in roosters vaccinated with a killed strain of avian infectious bronchitis virus.,,,17274299.0,unk,objective determine vaccination killed avian infectious bronchitis virus aibv cause epididymal calcium stone rooster seen following vaccination live attenuated aibv specificpathogenfree rooster divided three group nonvaccinated nonvac live attenuated aibvvaccinated lvac killed aibvvaccinated kvac group rooster vaccinated wk age epididymal region observed wk age epididymal stone present nonvac kvac lvac rooster histologically immune cell seen interstitium efferent ductule containing stone conclude use killed vaccine reduce incidence epididymal stone,2006,"Boltz, David A; Zimmerman, Claire R; Nakai, Masaaki; Bunick, David; Scherba, Gail; Bahr, Janice M",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17274299/,30952405.0,3
53567,53567,67592,p5wtldn6,,Medline,A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses.,,,16115319.0,unk,several study shown cellmediated immune response play crucial role controlling viral replication candidate sars vaccine elicit broad cd tcell immune response several group mouse immunized alone combination sarsnucleocapsid immunogen high level specific sarscd tcell response demonstrated mouse received dna encoding sarsnucleocapsid protein xiap adjuvant also observed coadministration plasmid expressing nucleocapsid recombinant protein montanidecpg induces high antibody titer immunized mouse moreover vaccine approach merit investigation potential candidate vaccine sars,2005,"Azizi, Ali; Aucoin, Susan; Tadesse, Helina; Frost, Rita; Ghorbani, Masoud; Soare, Catalina; Naas, Turaya; Diaz-Mitoma, Francisco",Genetic vaccines and therapy,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16115319/,8922488.0,3
53583,53583,67611,c2d021an,,Medline,Feline vaccination guidelines.,,,11446098.0,unk,report american association feline practitioner academy feline medicine advisory panel feline vaccine developed help veterinary practitioner formulate vaccination protocol cat current panel report update information address question speaks concern raised report addition review vaccine licensing labeling liability issue suggests way successfully incorporate vaccination protocol change private practice setting,2001,"Richards, J; Rodan, I",The Veterinary clinics of North America. Small animal practice,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/11446098/,24075518.0,3
53741,53741,67794,4aao9pjf,,Medline,DNA vaccine of SARS-Cov S gene induces antibody response in mice.,,,14732873.0,unk,spike protein main surface antigen sarscoronavirus sarscov one important antigen candidate vaccine design present study three fragment truncated protein expressed ecoli analyzed pooled serum convalescence phase sars patient full length gene dna vaccine constructed used immunize balbc mouse mouse serum igg antibody sarscov measured elisa e coli expressed truncated protein sarscov lysate diagnostic antigen result showed three fragment protein expressed ecoli able react serum sars patient gene dna candidate vaccine could induce production specific igg antibody sarscov efficiently mouse seroconversion ratio time immunization finding lay foundation understanding immunology sarscov developing sars vaccine,2004,"Zhao, Ping; Ke, Jin-Shan; Qin, Zhao-Lin; Ren, Hao; Zhao, Lan-Juan; Yu, Jian-Guo; Gao, Jun; Zhu, Shi-Ying; Qi, Zhong-Tian",Acta biochimica et biophysica Sinica,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/14732873/,6579695.0,3
53819,53819,67882,tmzec6q8,,Medline,Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins.,,,9256965.0,unk,objective evaluate safety efficacy live canarypox virus recombinantcanine distemper virus cdv combination vaccine virulent cdv challenge exposure document lack interference among modifiedlive virus mlv component animal specificpathogenfree spf beagle pup week old procedure canarypox virus recombinantcdv combination vaccine tested safety efficacy along mlv component canine adenovirus type canine coronavirus canine parainfluenza virus canine parvovirus spf beagle pup combination vaccine rehydrated either leptospira canicolal icterohaemorrhagiae combination bacterin vaccine sterile diluent vaccine additional group seronegative spf pup received control mlv component devoid combination vaccine vaccine two vaccination administered day apart either im sc dose combination vaccine used inoculate pup time lower recommended commercial dose day booster vaccination pup challenge exposed virulent cdv strain observed day record morbidity mortality result adverse local generalized reaction induced vaccination vaccinates seroconverted cdv serum antibody titer mlv component different without inclusion combination vaccine challenge exposure morbidity mortality vaccinates control dog value morbidity mortality brain impression smear slide made dog survive challenge exposure cdv positive use direct fluorescein isothiocyanate method conclusion canarypox viruscdv combination vaccine administered sc im safe product elicits cdv seroconversion interfere vaccine component protects vaccinated pup virulent cdv challenge exposure,1997,"Pardo, M C; Bauman, J E; Mackowiak, M",American journal of veterinary research,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/9256965/,8033490.0,3
53843,53843,67913,8egz3v5i,,Medline,Biochemical analysis and application of molecular display technology on Candida albicans for diagnosing and preventing candidiasis.,,,24189555.0,unk,medical facility advance therapeutic improved world recent time concomitant human population growing steadily however emerging infectious disease severe acute respiratory syndrome sars aid well reemerging infectious disease japanese encephalitis dengue fever spreading recent time three major infectious disease namely aid malaria tuberculosis killing around million people world annually although drug effective infectious disease available present drastic therapeutic developed yet addition vaccine disease often prevent infection pathogenic virus bacteria evade immune system host many disease emerging infection pathogenic bacteria controlled conventional pharmaceutic pathogen secrete regulatory factor produced regulatory factor attains certain level active factor produced pathogen destroy host considering phenomenon thought investigating characteristic regulatory active factor pave way developing novel vaccine diagnostic drug therefore candidiasis selected model application secretory protease candida albicans examined development novel drug screening novel candidate antigen c albicans vaccine development also underway paper strategy platform technology various infectious disease introduced,2013,"Shibasaki, Seiji; Aoki, Wataru; Ueda, Mitsuyoshi",Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24189555/,26010178.0,3
53844,53844,67916,7hzenz7c,,Medline,A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague.,,,15308359.0,unk,urgent need develop effective vaccine pneumonic plague highly lethal contagious disease caused gramnegative bacterium yersinia pestis demonstrate novel dna vaccine expressing modified v antigen lcrv pestis human tissue plasminogen activator tpa signal sequence elicited strong vspecific antibody response balbc mouse tpav dna vaccine protected mouse intranasal challenge lethal dos pestis comparison dna vaccine expressing wild type v antigen much le effective tpav formed oligomers spontaneously elicited higher igga antiv antibody response immunized mouse suggesting increased th type cellular immune response data indicate antigen engineering effective inducing high quality protective immune response conformationally sensitive antigen result support optimized dna vaccine potential protect bacterial pathogen generally recognized,2004,"Wang, Shixia; Heilman, Destin; Liu, Fangjun; Giehl, Theodore; Joshi, Swati; Huang, Xiaoyun; Chou, Te-hui; Goguen, Jon; Lu, Shan",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15308359/,3256090.0,3
53939,53939,68026,ruqe8s0w,,Medline,Progress towards achieving new vaccine and vaccination goals.,,,12823675.0,unk,viral bacterial vaccine especially childhood use one successful public health measure last two century good safety record however still many disease caused infectious agent vaccine available increasing ability manipulate immune system offer hope future least infection may prevented vaccination surprising recent development use vaccine technology test whether range generally noncommunicable disease prevented least controlled way investigation disease still mainly experimental level however list includes different type cancer allergy drug addiction neurodegenerative disease,2003,"Ada, G",Internal medicine journal,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12823675/,7719282.0,3
53956,53956,68043,tqmbqeuq,,Medline,Human monoclonal antibodies by immortalization of memory B cells.,,,18063358.0,unk,administration hyper immune serum prevent treat lifethreatening infection remarkable milestone medicine biotechnology achieved century ago yet therapeutic use monoclonal antibody field developed slowly last decade compare contrast current method generate human monoclonal antibody highlight advantage exploiting human antibody repertoire using novel method allows efficient immortalization cloning human memory b cell method successfully applied isolate broadly neutralizing antibody sars hn influenza virus expected accelerate development therapeutic field infectious disease providing neutralizing antibody passive serotherapy also generating relevant information vaccine design,2007,"Lanzavecchia, Antonio; Corti, Davide; Sallusto, Federica",Current opinion in biotechnology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18063358/,43039083.0,3
53958,53958,68046,tnkoc02s,,Medline,SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus.,,,15993989.0,unk,different form sars coronavirus sarscov spike proteinbased vaccine generation neutralizing antibody response sarscov compared using mouse model high igg level detected mouse immunized intraperitoneal ip recombinant spike polypeptide generated escherichia coli speptide mouse primed intramuscular im tpaoptimize dna vaccine tpasdna boosted ip speptide mouse primed im ctlahingesars dna vaccine ctlasdna boosted ip speptide mouse primed oral liveattenuated salmonella typhimurium salmonellasdnacontrol boosted ip speptide mouse primed oral liveattenuated typhimurium contained tpaoptimize dna vaccine salmonellatpasdna boosted ip speptide mouse primed oral liveattenuated typhimurium contained ctlahingesars dna vaccine salmonellatpasdna boosted ip speptide statistical significant difference observed among thth index among six group mouse high igg level serum six mouse immunized ip speptide im dna vaccine control oral salmonellasdnacontrol showed neutralizing antibody sarscov serum mouse immunized im tpasdna im ctlasdna oral salmonellasdnacontrol boosted ip speptide oral salmonellatpasdna oral salmonellatpasdna boosted ip speptide oral salmonellactlasdna oral salmonellactlasdna boosted ip speptide showed neutralizing antibody titer serum mouse immunized im tpasdna boosted ip speptide im ctlasdna boosted ip speptide showed neutralizing antibody titer present observation may major practical value immunization civet cat since production recombinant protein e coli far le expensive production recombinant protein using eukaryotic system,2005,"Woo, Patrick C Y; Lau, Susanna K P; Tsoi, Hoi-Wah; Chen, Zhi-Wei; Wong, Beatrice H L; Zhang, Linqi; Chan, Jim K H; Wong, Lei-Po; He, Wei; Ma, Chi; Chan, Kwok-Hung; Ho, David D; Yuen, Kwok-Yung",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15993989/,77319.0,3
54016,54016,68118,y4sek931,,Medline,Vaccine prevention of acute otitis media.,,,11892059.0,unk,incidence acute otitis medium aom infant young child increased dramatically recent year united state aom often follows upper respiratory tract infection due pathogen respiratory syncytial virus rsv influenza virus parainfluenza virus piv virus cause eustachian tube dysfunction critical pathogenesis aom vaccine virus would likely reduce incidence aom three previous study influenza virus vaccine reduced incidence aom vaccine prevent infection rsv piv type undergoing clinical testing time streptococcus pneumoniae nontypeable haemophilus influenzae nthi moraxella catarrhalis three common aom pathogen heptavalent pneumococcal conjugate vaccine effective preventing invasive disease aom caused serotypes contained vaccine vaccine candidate nthi catarrhalis development,2001,"Greenberg, D P; Hoberman, A",Current allergy and asthma reports,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/11892059/,20889785.0,3
54069,54069,68180,38pz1xlq,,Medline,[Analysis of the evidence on the efficacy and safety of CYD-TDV dengue vaccine and its potential licensing and implementation through Mexico's Universal Vaccination Program].,,,26879510.0,unk,dengue major global public health problem affecting latin america mexico prevention control measure focusing epidemiological surveillance vector control partially effective costly thus development vaccine dengue created great expectation among health authority scientific community worldwide cydtdv dengue vaccine produced sanofipasteur dengue vaccine evaluated phase controlled clinical trial notwithstanding significant contribution development vaccine dengue three phase clinical study cydtdv metaanalysis longterm follow study provided evidence vaccine exhibited partial vaccine efficacy protect virologically confirmed dengue lead four consideration adequate vaccine efficacy dengue virus denv infection le vaccine efficacy denv protection infection denv b decreased vaccine efficacy dengue seronegative individual beginning vaccination c protection hospitalization severe form dengue respectively month followup increased hospitalization dengue vaccinated group child nine year age time vaccination detected since third year followup benefit cydtdv vaccine summarized protection infection denv well protection hospitalization severe case people nine year previous dengue infection working mainly booster review identified element efficacy safety vaccine must taken account licensing process potential inclusion national vaccination program mexico available scientific evidence cydtdv vaccine show merit also lead relevant question answered properly ass safety profile product target population potential benefit regard consider would informative complete year followup starting vaccination according company study protocol recommended world health organization new vaccine potential licensing implementation cydtdv part mexico vaccination program requires clear definition balance expected benefit risk particularly vaccine variable efficacy sign risk probable case licensing postlicensed period must involve development detailed protocol immediately identify risk health event associated vaccination,2016,"Hernández-Ávila, Mauricio; Lazcano-Ponce, Eduardo; Hernández-Ávila, Juan Eugenio; Alpuche-Aranda, Celia M; Rodríguez-López, Mario Henry; García-García, Lourdes; Madrid-Marina, Vicente; López Gatell-Ramírez, Hugo; Lanz-Mendoza, Humberto; Martínez-Barnetche, Jesús; Díaz-Ortega, José Luis; Ángeles-Llerenas, Angélica; Barrientos-Gutiérrez, Tonatiuh; Bautista-Arredondo, Sergio; Santos-Preciado, José Ignacio",Salud publica de Mexico,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/26879510/,43582062.0,3
54090,54090,68203,lvsdktal,,Medline,Production of vaccines and therapeutic antibodies for veterinary applications in transgenic plants: an overview.,,,17436059.0,unk,past two decade antibody antibody derivative vaccine developed therapeutic diagnostic application human veterinary medicine numerous specie dicot monocot plant genetically modified produce antibody vaccine number diverse transformation method strategy enhance accumulation pharmaceutical protein available veterinary application specific focus article particular pathogenic virus bacteria eukaryotic parasite focus advantage remaining challenge plantbased therapeutic protein veterinary application emphasis expression platform technology economic consideration,2007,"Floss, Doreen Manuela; Falkenburg, Dieter; Conrad, Udo",Transgenic research,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17436059/,25023918.0,3
54122,54122,68241,w7mdom0j,,Medline,Adverse events diagnosed within three days of vaccine administration in dogs.,,,16220670.0,unk,objective determine incidence rate potential risk factor vaccineassociated adverse event vaaes diagnosed within day administration dog design retrospective cohort study animal dog vaccinated veterinary hospital procedure electronic record january december searched possible vaaes nonspecific vaccine reaction allergic reaction urticaria anaphylaxis diagnosed within day vaccine administration information included age weight sex neuter status breed specific clinical sign treatment reviewed random sample affected dog association potential risk factor vaae estimated use multivariate logistic regression result adverse event dog vaccinated associated administration dos vaccine dog vaae rate decreased significantly body weight increased risk greater neutered versus sexually intact dog greater dog approximately year old versus month old risk vaae significantly increased number vaccine dos administered per office visit increased additional vaccine significantly increased risk adverse event dog kg lb dog kg conclusion clinical relevance young adult smallbreed neutered dog received multiple vaccine per office visit greatest risk vaae within hour vaccination factor considered risk assessment risk communication client regarding vaccination,2005,"Moore, George E; Guptill, Lynn F; Ward, Michael P; Glickman, Nita W; Faunt, Karen K; Lewis, Hugh B; Glickman, Lawrence T",Journal of the American Veterinary Medical Association,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16220670/,8625559.0,3
54257,54257,68411,ez1canrp,,Medline,Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.,,,18178835.0,unk,previously reported subunit protein vaccine based receptorbinding domain rbd severe acute respiratory syndrome coronavirus sarscov spike protein recombinant adenoassociated virus raavbased rbd rbdraav vaccine could induce highly potent neutralizing ab response immunized animal study systemic mucosal cellular immune response longterm protective immunity induced rbdraav characterized balbc mouse model comparison im intranasal route administration result demonstrated vaccination induced systemic humoral immune response comparable strength shorter duration im vaccination local humoral immune response much stronger vaccination elicited stronger systemic local specific cytotoxic cell response im vaccination evidenced higher prevalence il andor ifngammaproducing cdcd cell lung spleen vaccination induced similar protection im vaccination sarscov challenge mouse higher titer mucosal iga serumneutralizing ab associated lower viral load le pulmonary pathological damage abmediated disease enhancement effect observed vaccination could provide longterm protection sarscov infection taken together finding suggest rbdraav developed vaccine candidate prevention sars vaccination may preferred route administration due ability induce sarscovspecific systemic mucosal immune response better safety profile,2008,"Du, Lanying; Zhao, Guangyu; Lin, Yongping; Sui, Hongyan; Chan, Chris; Ma, Selene; He, Yuxian; Jiang, Shibo; Wu, Changyou; Yuen, Kwok-Yung; Jin, Dong-Yan; Zhou, Yusen; Zheng, Bo-Jian",Journal of immunology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18178835/,24137041.0,3
54261,54261,68416,2xadbijw,,Medline,Rabies Control and Treatment: From Prophylaxis to Strategies with Curative Potential.,,,27801824.0,unk,rabies acute fatal neurological disease affect almost kind mammal vaccination using inactivated rabies vaccine combined administration rabies immune globulin approved effective method postexposure prophylaxis rabies human search novel rabies control treatment strategy liveattenuated virus recently emerged practical promising approach immunizing controlling rabies unlike conventional inactivated rabies vaccine liveattenuated virus genetically modified virus able replicate inoculated recipient without causing adverse effect still eliciting robust effective immune response rabies virus infection number virus intrinsic capacity could used putative candidate liveattenuated rabies vaccine intensively evaluated therapeutic purpose additional novel strategy monoclonal antibodybased approach nucleic acidbased vaccine small interfering rna sirnas interfering virus replication could add arena strategy combat rabies review highlight current advance rabies therapy discus role might future rabies treatment given pronounced complex impact rabies patient combination novel modality potential achieve maximal antirabies efficacy may even promising curative effect future however several hurdle regarding clinical safety consideration public awareness overcome approach ultimately become clinically relevant therapy,2016,"Zhu, Shimao; Guo, Caiping",Viruses,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/27801824/,4039960.0,3
54303,54303,68464,olbhs3dd,,Medline,Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease.,,,10930670.0,unk,recently developed transmissible vaccine immunize rabbit myxomatosis rabbit haemorrhagic disease based recombinant myxoma virus mv expressing rabbit haemorrhagic disease virus rhdv capsid protein bárcena et al horizontal transmissible protection myxomatosis rabbit haemorragic disease using recombinant myxoma virus j virol administration recombinant virus protects rabbit lethal rhdv mv challenge furthermore recombinant virus capable horizontal spreading promoting protection contact animal thus providing opportunity immunize wild rabbit population however potential risk must extensively evaluated considering field use study several safety issue concerning proposed vaccine evaluated laboratory condition result indicated vaccine administration safe even fold overdose undesirable effect detected upon administration immunosuppressed pregnant rabbit recombinant virus maintained attenuated phenotype passage vivo,2000,"Torres, J M; Ramírez, M A; Morales, M; Bárcena, J; Vázquez, B; Espuña, E; Pagès-Manté, A; Sánchez-Vizcaíno, J M",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/10930670/,16943519.0,3
54407,54407,68584,3x98kps6,,Medline,Overlapping synthetic peptides as vaccines.,,,16793181.0,unk,several vaccine strategy aim generate cellmediated immunity cmi microorganism tumor epitopebased vaccine offer advantage knowledge specific epitope frequency major histocompatibility complex mhc allele required show using promiscuous overlapping synthetic peptide osp immunogen generated peptidespecific cmi vaccinated outbred mouse different strain inbred mouse cmi response also recognized viral protein osp immunogen also induced cmi ex vivo dendritic celltcell cocultures involving cell individual different hla haplotype thus broad cmi induced osp different experimental setting using different immunogen without identifying either epitope mhc background vaccinee,2006,"Jiang, Shisong; Song, Ruijiang; Popov, Sergei; Mirshahidi, Saied; Ruprecht, Ruth M",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16793181/,13369333.0,3
54411,54411,68588,o47ocrmy,,Medline,Rapid generation of an anthrax immunotherapeutic from goats using a novel non-toxic muramyl dipeptide adjuvant.,,,17953756.0,unk,background clear need vaccine therapeutic potential biological weapon mass destruction emerging disease anthrax caused bacterium bacillus anthracis used biological warfare agent bioterrorist weapon previously although antibiotic therapy effective early stage anthrax infection effect exposed individual become symptomatic due b anthracis exotoxin accumulation bipartite exotoxin major contributing factor morbidity mortality observed acute anthrax infection method using recombinant b anthracis protective antigen pa covalently coupled novel nontoxic muramyl dipeptide ntmdp derivative hyperimmunized goat three time course week goat plasmapheresed igg fraction affinity purified fab derivative characterized vitro vivo protection lethal toxin mediated intoxication result antipa igg conferred protection mug cell toxin neutralization assay mouse exposed ld bacillus anthracis ames spore intranares inoculation demonstrated survival postinfection administered single bolus dose mgkg body weight antipa igg h post spore challenge antipa fab fragment retained similar neutralization protection level vitro vivo conclusion protection afforded gmpgrade caprine immunotherapeutics postexposure pilot murine model suggests could used effectively treat postexposure symptomatic human anthrax patient following bioterrorism event result also indicate recombinant pa coupled ntmdp potent inducer neutralizing antibody suggest would promising vaccine candidate anthrax ease production ease covalent attachment immunostimulatory activity ntmdp indicate would superior adjuvant alum traditional adjuvant vaccine formulation,2007,"Kelly, Cassandra D; O'Loughlin, Chris; Gelder, Frank B; Peterson, Johnny W; Sower, Laurie E; Cirino, Nick M",Journal of immune based therapies and vaccines,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17953756/,1893208.0,3
54415,54415,68592,46q8r5p7,,Medline,DNA vaccine.,,,16096015.0,unk,dna vaccine proven one promising application field gene therapy due unique ability readily induce humoral well cellular immune response attracted great interest concept first confirmed early thousand article related dna vaccine published scientist began realize although dna vaccine effective small animal model effectiveness recent clinical trail rather disappointing therefore current effort shifted understanding different performance dna vaccine mouse large animal model transfer success dna vaccine small animal large animal human,2005,"Cui, Zhengrong",Advances in genetics,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16096015/,45529147.0,3
54418,54418,68596,4629cd62,,Medline,Development of nonhuman adenoviruses as vaccine vectors.,,,16297508.0,unk,human adenoviral vector demonstrated great potential vaccine vector preclinical clinical study demonstrated feasibility vector design robust antigen expression protective immunity using system however clinical use adenoviral vector vaccine purpose anticipated limited vector immunity either preexisting develops rapidly following first inoculation adenoviral vector vector immunity inactivates vector particle rapidly remove transduced cell thereby limiting duration transgene expression due strong vector immunity subsequent use vector usually le efficient order circumvent limitation nonhuman adenoviral vector proposed alternative vector addition eluding immunity vector posse attractive feature vector several replicationcompetent replicationdefective nonhuman adenoviral vector developed investigated potential vaccinedelivery vector review recent advance design characterization various nonhuman adenoviral vector discus potential application human animal vaccination,2006,"Bangari, Dinesh S; Mittal, Suresh K",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16297508/,13152688.0,3
54589,54589,68795,cnbe9nyk,,Medline,Protection of cats from infectious peritonitis by vaccination with a recombinant raccoon poxvirus expressing the nucleocapsid gene of feline infectious peritonitis virus.,,,8830483.0,unk,feline infectious peritonitis virus fipv coronavirus induces often fatal systemic infection cat various vaccine designed prevent fipv infection shown exacerbate disease probably due immune enhancement mediated virusspecific immunoglobulin outer envelope protein effective vaccine would one induces cellmediated immunity without disease enhancing antibody report describe use recombinant raccoon poxvirus express gene encoding nucleocapsid protein fipv rrcnvfipv n effective vaccine fipvinduced disease cat parenterally orally vaccinated twice three week apart cat orally challenged feline enteric coronavirus fecv induces subclinical infection cause enhancement subsequent fipv infection three week later cat orally challenged fipv fipv challenge induced fatal infection control hand five cat vaccinated subcutaneously rrcnvfipv n showed sign disease challenge fipv four five subcutaneous vaccinates survived additional fipv challenge vaccination rrcnvfipv n induced serum igg antibody response fipv nucleocapsid protein fipv neutralizing antibody contrast control protected vaccinates maintained low fipv serum neutralizing antibody titer fipv challenge suggests protective immune response involves mechanism humoral immunity consisting fipv neutralizing antibody,1995,"Wasmoen, T L; Kadakia, N P; Unfer, R C; Fickbohm, B L; Cook, C P; Chu, H J; Acree, W M",Advances in experimental medicine and biology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/8830483/,25760219.0,3
54614,54614,68831,d8bwxxha,,Medline,Pandemic influenza preparedness: the critical role of the syringe.,,,16647790.0,unk,face almost unprecedented threat global pandemic influenza imperative stockpiling appropriate drug device begin one vital device appropriate syringe delivering vaccine potential million infected vaccine supply severely stretched imperative syringe used vaccinate waste little vaccine possible thus allow maximum number person vaccinated study tested seven leading candidate vaccine syrinx dosing accuracy dosecapacity per vial medication wastage battery ergonomic feature one device flutrade mark syringe proved superior others important category possibly due low deadspace volume dosing accuracy data suggest switching device others tested would provide additional vaccine dos per vial current dose vial used extrapolation data suggest many thousand million additional person could vaccinated mass campaign use syringe type vaccine saving would accrue would likely important reducing morbidity mortality event pandemic influenza,2006,"Strauss, Kenneth; van Zundert, André; Frid, Anders; Costigliola, Vincenzo",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16647790/,46696913.0,3
54651,54651,68872,9ywut79j,,Medline,Influenza and the vocal performer: update on prevention and treatment.,,,17134876.0,unk,summary upper respiratory tract infection uris major cause morbidity among vocal art professional acute impairment vocal mechanism predisposing influence development serious vocal sequela review present salient feature currently available treatment effective influenza virus family responsible serious form uri present include inactivated vaccine four antiviral drug approved united state many country prevention treatment influenza live attenuated vaccine also available vaccine antiviral drug development review detail current option available treating influenza noninfluenza related uris professional voice user,2008,"Bové, Michiel J; Kansal, Shalini; Rosen, Clark A",Journal of voice : official journal of the Voice Foundation,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17134876/,45710346.0,3
54653,54653,68874,pfpmj1qk,,Medline,The relationship between the occurrence of undifferentiated bovine respiratory disease and titer changes to Haemophilus somnus and Mannheimia haemolytica at 3 Ontario feedlots.,,,11480518.0,unk,association exposure haemophilus somnus mannheimia haemolytica formerly pasteurella haemolytica risk undifferentiated bovine respiratory disease ubrd investigated using serological evidence exposure coupled factorial design vaccine field trial measure previous exposure titer arrival current exposure titer increase study period agent used vaccine field trial involved systematic allocation animal group received either haemolytica vaccine h somnus vaccine combined haemolytica h somnus vaccine unvaccinated control group serum collected animal enrolled determine titer h somnus haemolytica bovine coronavirus bovine viral diarrhea virus vaccination h somnus combination haemolytica haemolytica alone reduced risk ubrd odds ratio vaccination h somnus alone ubrd risk suggested sparing effect confidence limit included unity association serological evidence concurrent exposure haemolytica ubrd occurrence association titer change h somnus ubrd risk however association changed time brd treatment animal diagnosed treated ubrd day showed little evidence exposure h somnus despite evidence natural h somnus exposure unvaccinated group association titer change h somnus ubrd occurrence seen study may consequence prolonged exposure antibiotic rather causal association,2001,"O'Connor, A; Martin, S W; Harland, R; Shewen, P; Menzies, P",Canadian journal of veterinary research = Revue canadienne de recherche veterinaire,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/11480518/,32017776.0,3
54719,54719,68955,d6acihci,,Medline,Occurrence of severe gastroenteritis in pups after canine parvovirus vaccine administration: a clinical and laboratory diagnostic dilemma.,,,17092616.0,unk,total faecal sample collected dog diarrhoea following canine parvovirus cpv vaccination tested minor groove binder mgb probe assay discrimination cpv vaccine field strain diagnostic test detection canine pathogen fifteen sample tested positive cpv field strain however vaccine field strain detected three sample eleven sample found contain vaccine strain although eight tested positive pathogen dog three sample found contain vaccine strain without evidence canine pathogen present study confirms case parvoviruslike disease occurring shortly vaccination related infection field strain canine parvovirus type cpv rather reversion virulence modified live virus contained vaccine,2007,"Decaro, Nicola; Desario, Costantina; Elia, Gabriella; Campolo, Marco; Lorusso, Alessio; Mari, Viviana; Martella, Vito; Buonavoglia, Canio",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17092616/,37255436.0,3
54722,54722,68959,0tsys7vu,,Medline,A strategic vaccine facility for the UK.,,,15755577.0,unk,paper describes proposed strategic vaccine facility svf provide capability uk deal new emerging disease threat would underpin vaccine manufacturing industry developing expertise technology enable rapid manufacture small batch vaccine emergency use agent bioterrorist agent emerging disease would rare ability work dangerous pathogen containment allowing production inactivated live vaccine would difficult conventional plant facility output include vaccine candidate manufacturing protocol transfer industry small vaccine batch emergency use clinical trial vaccine reference standard would also available manufacturing small batch experimental public health vaccine uk developing world allowing clinical trial undertaken key disease,2005,"Duggan, Jacqueline M; Brooks, Timothy J G",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15755577/,42627626.0,3
54908,54908,69168,awm3zuqc,,Medline,"Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys.",,,15837221.0,unk,inactivated vaccine severe acute respiratory syndrome sarsassociated coronavirus sarscov evaluated rhesus monkey monkey inoculated intramuscularly im microg vaccine pb control boosted day week challenged n strain sarscov humoral mucosal immune response clinical sign chemical index viremia monitored following immunization challenge control animal received pb developed atypical sarcov infection viral challenge according clinical virological pathological finding systematic side effect observed vaccinated animal postimmunization even high dose microg microg dosage vaccine elicited sarscov specific immune response viral infection compared partial immunity elicited microg dos result show inactivated vaccine induce effective concomitant humoral mucosal immunity sarscov infection safe monkey vaccine maybe good candidate clinical trial,2005,"Zhou, Jun; Wang, Wei; Zhong, Qiong; Hou, Wei; Yang, Zhanqiu; Xiao, Shu-Yuan; Zhu, Runqing; Tang, Zhijiao; Wang, Yong; Xian, Qiaoyang; Tang, Hongbing; Wen, Li",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15837221/,44991938.0,3
54910,54910,69170,glboqd6t,,Medline,"Construction, characterization, and immunogenicity of an attenuated Salmonella enterica serovar typhimurium pgtE vaccine expressing fimbriae with integrated viral epitopes from the spiC promoter.",,,12874347.0,unk,transmissible gastroenteritis virus tgev porcine coronavirus cause diarrhea leading near mortality neonatal piglet corresponding devastating economic consequence protection neonatal older animal oral live vaccine present attractive property inducing desired mucosal immune response including colostral antibody sowsan effective mean passively protect suckling piglet newly attenuated salmonella vaccine construct expressing tgev protein epitope studied evaluated improved humoral immune response tgev macrophageinducible salmonella ssah spicssab promoter compared ability express tgev c epitope context heterologous p fimbria salmonella vaccine compared ssah promoter salmonella cya crp vector elicited significantly higher level mucosal systemic antibody orally immunized mouse chimeric fimbria expressed spic promoter salmonella spic promoter construct induced highest level chimeric fimbria taken ja macrophagelike cell salmonella cya crp vaccine vector shown incorporate p partially degraded chimeric subunit lacking tgev epitope contrast isogenic pgte mutant produced fimbria consisting exclusively intact chimeric subunit mouse immunized orally salmonella pgte vaccine expressing chimeric fimbria spic promoter elicited significantly higher systemic mucosal antibody titer tgev epitope compared parental vaccine study indicates salmonella cya crp pgte vector spic promoter used successfully improve immune response toward heterologous antigen,2003,"Chen, Huaiqing; Schifferli, Dieter M",Infection and immunity,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12874347/,3137640.0,3
54938,54938,69199,2prcin1q,,Medline,Leptospirosis vaccines.,,,18072968.0,unk,leptospirosis serious infection disease caused pathogenic strain leptospira spirochete affect human also animal long expected find effective vaccine prevent leptospirosis immunization high risk human animal although leptospirosis vaccine obtained vaccination relatively unsuccessful clinical application despite decade research million dollar spent review recent advancement recombinant outer membrane protein omp vaccine lipopolysaccharide lp vaccine inactivated vaccine attenuated vaccine dna vaccine leptospirosis reviewed comparison vaccine may lead development new potential method combat leptospirosis facilitate leptospirosis vaccine research moreover vaccine ontology database built scientist working leptospirosis vaccine starting tool,2007,"Wang, Zhijun; Jin, Li; Wegrzyn, Alicja",Microbial cell factories,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18072968/,13712946.0,3
54969,54969,69237,dbpwhmff,,Medline,FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review.,,,12459160.0,unk,feline immunodeficiency virus fiv natural infection domestic cat result acquired immunodeficiency syndrome resembling human immunodeficiency virus hiv infection human worldwide prevalence fiv infection domestic cat reported range hence effective fiv vaccine important impact veterinary medicine addition used small animal aid model human since discovery fiv reported fiv vaccine research pursued molecular conventional vaccine approach toward development commercial product published fiv vaccine trial result present compiled update veterinary clinical research community immunologic experimental efficacy status vaccine brief report included outcome year collaborative work industry academia led recent usda approval first animal lentivirus vaccine dualsubtype fiv vaccine immunogenicity efficacy experimental prototype dualsubtype fiv vaccine efficacy currently approved commercial dualsubtype fiv vaccine felovax fiv discussed potential crossreactivity complication commercial fiv diagnostic test idexx snap combo test western blot assay serum previously vaccinated cat also discussed finally recommendation made unbiased critical testing new fiv vaccine currently usda approved vaccine future vaccine development,2002,"Uhl, E W; Heaton-Jones, T G; Pu, R; Yamamoto, J K",Veterinary immunology and immunopathology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12459160/,24668215.0,3
54989,54989,69260,5usn6gle,,Medline,The effects of injection of bovine vaccine into a human digit: a case report.,,,16219096.0,unk,background incidence needlestick injury farmer veterinary surgeon significant consequence injection serious case presentation report accidental injection bovine vaccine base little finger resulted increased pressure flexor sheath causing sign symptom ischemia amputation digit required despite repeated surgical debridement decompression conclusion previous report injection oilbased vaccine human hand resulting granulomatous inflammation sterile abscess causing morbidity tissue loss selfinjection veterinary vaccine occupational hazard farmer veterinary surgeon injection vaccine closed compartment human finger serious sequela including loss injected digit injury underestimated early debridement irrigation injected area decompression likely give best outcome frequent review necessary first procedure repeat operation may required,2005,"O'Neill, Jennifer K; Richards, Simon W; Ricketts, David M; Patterson, Marc H",Environmental health : a global access science source,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16219096/,17885560.0,3
55020,55020,69295,27o8lkgb,,Medline,Production and immunogenicity of chimeric virus-like particles containing the spike glycoprotein of infectious bronchitis virus.,,,24378590.0,unk,infectious bronchitis virus ibv pose severe threat poultry industry cause heavy economic loss worldwide vaccination effective method preventing infection controlling spread ibv currently available inactivated attenuated virus vaccine disadvantage developed chimeric viruslike particle vlpbased candidate vaccine ibv protection chimeric vlp composed matrix protein avian influenza hn virus fusion protein neuraminidase naspike generated fusing ibv protein cytoplasmic transmembrane domain na protein avian influenza hn virus chimeric vlps elicited significantly higher sspecific antibody response intramuscularly immunized mouse chicken inactivated ibv virus furthermore chimeric vlps induced significantly higher neutralization antibody level inactivated h virus spf chicken finally chimeric vlps induced significantly higher il production mouse result demonstrate chimeric vlps potential use vaccine ibv infection,2014,"Lv, Lishan; Li, Xiaoming; Liu, Genmei; Li, Ran; Liu, Qiliang; Shen, Huifang; Wang, Wei; Xue, Chunyi; Cao, Yongchang",Journal of veterinary science,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24378590/,15270065.0,3
55046,55046,69328,vqeps403,,Medline,"Protective efficacy of a broadly cross-reactive swine influenza DNA vaccine encoding M2e, cytotoxic T lymphocyte epitope and consensus H3 hemagglutinin.",,,22738661.0,unk,background pig implicated mixing reservoir generation new pandemic influenza strain control swine influenza veterinary public health significance unlike human influenza vaccine strain used commercially available swine influenza vaccine regularly replaced making vaccine provide limited protection antigenically diverse virus therefore necessary develop broadly protective swine influenza vaccine efficacious homologous heterologous virus infection study two form dna vaccine constructed one made fusing consensus hha mha represents majority ha sequence hn swine influenza virus another made fusing conserved ctl epitope np consensus hha mnha protective efficacy homologous heterologous challenge tested result balbc mouse immunized twice particlemediated epidermal delivery gene gun two dna vaccine shown two vaccine elicited substantial antibody response mnha induced significant cellmediated immune response mha two hn strain representative different evolutional antigenic cluster used challenge vaccineimmunized mouse homosubtypic challenge result indicated dna vaccine prevented homosubtypic virus infection completely vaccine heterologous protective efficacy tested challenging hn swine influenza virus reassortant pandemic strain found mnha reduced lung viral titer significantly challenge group histopathological observation showed obvious reduction lung pathogenesis compared mha control group conclusion combined utility consensus ha conserved ctl epitope confer complete partial protection homologous heterologous challenge respectively mouse model may provide basis development universal swine influenza vaccine,2012,"Wang, Bin; Yu, Hai; Yang, Fu-Ru; Huang, Meng; Ma, Ji-Hong; Tong, Guang-Zhi",Virology journal,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/22738661/,1849590.0,3
55104,55104,69389,ykpux3jm,,Medline,Immunization of macaques with formalin-inactivated respiratory syncytial virus (RSV) induces interleukin-13-associated hypersensitivity to subsequent RSV infection.,,,12388717.0,unk,respiratory syncytial virus rsv major cause severe respiratory disease infant elderly rsv vaccine development hampered result clinical trial formalininactivated wholersv preparation adjuvated alum firsv found predispose infant enhanced disease following subsequent natural rsv infection reproduced apparently immunopathological phenomenon infant cynomolgus macaque identified immunological pathological correlate vaccination firsv induced specific virusneutralizing antibody response accompanied strong lymphoproliferative response vaccineinduced rsvspecific cell predominantly produced th cytokine interleukin il il intratracheal challenge macaqueadapted wildtype rsv month third vaccination elicited hypersensitivity response associated lung eosinophilia challenge resulted rapid boosting ilproducing cell firsvvaccinated animal fimeasles virusvaccinated control animal two seven firsvvaccinated animal died day rsv challenge pulmonary hyperinflation surprisingly lung two animal show overt inflammatory lesion however upon vaccination animal shown strongest lymphoproliferative response associated pronounced th phenotype within group hypothesize ilassociated asthmalike mechanism resulted airway hyperreactivity animal nonhuman primate model important tool ass safety nonreplicating candidate rsv vaccine,2002,"De Swart, Rik L; Kuiken, Thijs; Timmerman, Helga H; van Amerongen, Geert; Van Den Hoogen, Bernadette G; Vos, Helma W; Neijens, Herman J; Andeweg, Arno C; Osterhaus, Albert D M E",Journal of virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12388717/,13859601.0,3
55129,55129,69420,u9f2xom7,,Medline,Wildlife population management: are contraceptive vaccines a feasible proposition?,,,28410124.0,unk,minimize humananimal conflict habitation burden zoonotic disease imperative develop new strategy wildlife population management direction contraceptive vaccine eliciting immune response hormonesproteins critical reproduction emerged one promising option contraceptive vaccine based neutralization gonadotropin releasing hormone gnrh used inhibition fertility various specie wild horse whitetailed deer pig cat dog etc used immunocastration male pig improve meat quality however additional safety study gnrh vaccine needed light presence receptor extrapituitary site native porcine zona pellucida pzpbased contraceptive vaccine shown utility management population captive freeranging wild horse whitetailed deer longterm use pzpbased contraceptive vaccine also demonstrated safety ideally single injection contraceptive vaccine elicit long lasting immune response desired contraceptive efficacy require development novel vaccine delivery platform potent adjuvant,2017,"Gupta, Satish Kumar; Minhas, Vidisha",Frontiers in bioscience,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/28410124/,52498.0,3
55133,55133,69425,u4fmg9ra,,Medline,Enhance immune response to DNA vaccine based on a novel multicomponent supramolecular assembly.,,,17686512.0,unk,dna vaccination tremendous potential treating preventing numerous disease traditional vaccine ineffective technique limited low immunogenicity current synthetic dna delivery system versatile safe substantially le efficient virus novel multicomponent supramolecular system involving preparation mannosebearing chitosan oligomers microspheres entrapping complex dna vaccine polyethylenimine developed mimic many beneficial property virus delivery intramuscular immunization balbc mouse microspheres induced enhanced serum antibody response two order magnitude greater naked dna vaccine additionally contrast naked dna microspheres induced potent cytotoxic lymphocyte response low dose consequently formulation dna vaccine multicomponent vector powerful mean increasing vaccine potency,2007,"Zhou, Xianfeng; Liu, Bin; Yu, Xianghui; Zha, Xiao; Zhang, Xizhen; Wang, Xueyun; Chen, Yu; Chen, Yan; Chen, Yue; Shan, Yaming; Jin, Yinghua; Wu, Yongge; Liu, Junqiu; Kong, Wei; Shen, Jiacong",Biomaterials,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17686512/,45838222.0,3
55228,55228,69536,1cgyp47n,,Medline,Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine.,,,16043204.0,unk,although recent sars coronavirus sarscov appeared contained possibility reemergence sarscov remains due threat reemergence overall fatality rate approximately rapid dispersion virus via international travel viable vaccine candidate providing protection sars clearly needed developed attenuated vsv recombinant vsvs expressing sars coronavirus sarscov spike protein cell infected recombinant protein synthesized glycosylated approximately asn residue transported via golgi cell surface mouse vaccinated vsvs developed sarsneutralizing antibody able control challenge sarscov performed month month single vaccination also demonstrated passive antibody transfer antibody response induced vaccine sufficient controlling sarscov infection vsvvectored sars vaccine could significant advantage sars vaccine candidate described date,2005,"Kapadia, Sagar U; Rose, John K; Lamirande, Elaine; Vogel, Leatrice; Subbarao, Kanta; Roberts, Anjeanette",Virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16043204/,21304314.0,3
55291,55291,69609,t6xtg8n9,,Medline,Infectious bronchitis virus: S1 gene characteristics of vaccines used in China and efficacy of vaccination against heterologous strains from China.,,,16990149.0,unk,entire protein gene eight infectious bronchitis ib vaccine strain used china compared ib virus isolates present field china nucleotide amino acid similarity eight ib vaccine strain field strain tlchldt isolated teal ana sp respectively phylogenetic analysis based gene showed vaccine field strain belonged different cluster showed larger evolutionary distance indicated different genotype four eight vaccine addition massachusetts type vaccine h used protection test challenge ib virus isolate tlchldt revealed five ib vaccine induced poor protection teal isolate assessed respiratory protection clinical sign mortality indicating necessity developing vaccine local strain ib control china,2006,"Liu, Shengwang; Chen, Jianfei; Han, Zongxi; Zhang, Qinxia; Shao, Yuhao; Kong, Xiangang; Tong, Guangzhi",Avian pathology : journal of the W.V.P.A,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16990149/,22176955.0,3
55304,55304,69626,u6q48lif,,Medline,Protection of chickens from infectious bronchitis by in ovo and intramuscular vaccination with a DNA vaccine expressing the S1 glycoprotein.,,,12887187.0,unk,constructed dna vaccine pdkarksdpi expressing glycoprotein arkansas dpi infectious bronchitis virus ibv examine protective immunity ovo intramuscular dna immunization bird receiving ovo dna followed live virus vaccination wk age protected clinical disease bird receiving live virus vaccine ovo dna vaccination protected ibv detected day postchallenge unvaccinated control group whereas bird receiving ovo dna live virus vaccination cleared ibv tracheal sample day postchallenge transcription gene confirmed lung tissue ovo vaccination antisense riboprobe protein detected immunohistology heart bursa separate experiment bird injected intramuscularly either microg dna vaccine day age either microg dna vaccine respectively day age day postchallenge clinical sign observed challenge virus reisolated bird vaccinated microg microg dna dnavaccinated bird nonvaccinated control bird statistical difference observed ibvspecific serum antibody detected enzymelinked immunosorbent assay virus neutralization test data indicate dna vaccination gene either ovo intramuscularly provide bird protection clinical disease homologous ibv challenge,2003,"Kapczynski, Darrell R; Hilt, Deborah A; Shapiro, David; Sellers, Holly S; Jackwood, Mark W",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12887187/,23337142.0,3
55343,55343,69675,fvb5d9ac,,Medline,"Animal models and antibody assays for evaluating candidate SARS vaccines: summary of a technical meeting 25-26 August 2005, London, UK.",,,16930781.0,unk,severe acute respiratory syndrome sars emerged guangdong province china late spread country end outbreak july cdc reported case case fatality rate disease caused previously unrecognized coronavirus sarscov drawing experience animal coronavirus vaccine several vaccine candidate developed evaluated preclinical trial available data suggest vaccine based kda viral spike protein significant neutralization antigen capable inducing protective immune response animal absence clinical case sars candidate vaccine evaluated efficacy animal model although uncertain whether united state food drug administration animal rule would apply licensure sars vaccine important develop standardized animal model immunological assay preparation eventuality report summarizes recommendation technical meeting animal model antibody assay evaluating candidate sars vaccine held august south mimms uk provides guidance use animal model outline step develop standard reagent assay immunological evaluation candidate sars vaccine,2006,"Roberts, Anjeanette; Wood, John; Subbarao, Kanta; Ferguson, Morag; Wood, David; Cherian, Thomas",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16930781/,25725086.0,3
55348,55348,69680,mplt4krv,,Medline,"SARS CTL vaccine candidates; HLA supertype-, genome-wide scanning and biochemical validation.",,,15104671.0,unk,effective severe acute respiratory syndrome sars vaccine likely include component induce specific cytotoxic tlymphocyte ctl response specificity response governed human leukocyte antigen hlarestricted presentation sarsderived peptide epitope exact knowledge immune system handle protein antigen would allow identification linear sequence directly genomicproteomic sequence information lauemoller et al rev immunogenet latter recently established causative coronavirus sarscov isolated fulllength sequenced marra et al science combined advanced bioinformatics highthroughput immunology perform hla supertype genomewide scan sarsspecific ctl epitope scan includes nine human hla supertypes total covering individual major human population sette sidney immunogenetics hla supertype selected top candidate test biochemical binding assay time approximately month genome established tested majority hla supertypes identified almost potential vaccine candidate validated sars survivor used vaccine formulation suggest immunobioinformatics may become fast valuable tool rational vaccine design,2004,"Sylvester-Hvid, C; Nielsen, M; Lamberth, K; Røder, G; Justesen, S; Lundegaard, C; Worning, P; Thomadsen, H; Lund, O; Brunak, S; Buus, S",Tissue antigens,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15104671/,34120610.0,3
55380,55380,69716,lcxfxby2,,Medline,Heterologous expression of Brucella abortus GroEL heat-shock protein in Lactococcus lactis.,,,16556312.0,unk,background brucella abortus facultative intracellular pathogen mainly infects cattle human current vaccine rely live attenuated strain b abortus revert pathogenic status thus totally safe use human therefore development mucosal live vaccine using foodgrade lactic acid bacterium lactococcus lactis antigen delivery vector attractive alternative safer vaccination strategy b abortus report construction l lactis strain genetically modified produce b abortus groel heatshock protein candidate antigen two cellular location intracellular secreted result secreted form groel stably produced l lactis suggesting detrimental effect groel protein intracellularly produced bacterium trace amount mature groel detected supernatant fraction induced lactococcal culture groel precursor remained stacked cell fraction attempt raise secretion yield made even groel fused synthetic propeptide secretion antigen improved conclusion found l lactis able produce secrete stable form groel extracellular medium despite low secretion efficiency groel suggest antigen interacts cell envelope l lactis secretion seems best way achieve production protein yield regardless cellular location l lactis strain secreting groel potential vivo immunization,2006,"Miyoshi, Anderson; Bermúdez-Humarán, Luis G; Ribeiro, Luciana A; Le Loir, Yves; Oliveira, Sérgio C; Langella, Philippe; Azevedo, Vasco",Microbial cell factories,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16556312/,18221595.0,3
55403,55403,69742,1xlop4lh,,Medline,An oral mucosal DNA vaccine for SARS coronavirus infections.,,,19258634.0,unk,different form sars coronavirus sarscov spike proteinbased vaccine generation neutralising antibody response sarscov injected mouse model mouse immunised intramuscular tpaoptimised dna vaccine boosted intraperitoneal recombinant spike polypeptide generated escherichia coli intramuscular ctlahinge sars dna vaccine boosted intraperitoneal speptide neutralising antibody titre observation may major practical value field study immunisation civet cat cost recombinant protein produced e coli much lower produced eukaryotic system study indicates type vaccine used priming crucial determining type immune response developedsubsequent dos boost immune response generated first dose vaccine,2009,"Yuen, K Y; Woo, P C Y; Lau, S K P",Hong Kong medical journal = Xianggang yi xue za zhi,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19258634/,35267163.0,3
55418,55418,69758,t0v7va02,,Medline,"A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines.",,,15337336.0,unk,viral vaccine could considered among important medical achievement th century prevented much suffering saved many life although curative antiviral drug exist desperately depend effort academic governmental industrial scientist advancement viral vaccine prevention control infectious disease next decade hope see advancement development current investigational viral vaccine childhood adult infection article review licensed viral vaccine safety concern advance development investigational viral vaccine,2004,"Huang, David B; Wu, Jashin J; Tyring, Stephen K",The Journal of infection,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15337336/,24648529.0,3
55463,55463,69809,hhq0wmgg,,Medline,"Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes.",,,17192403.0,unk,dengue virus infection cause hemorrhagic fever shock encephalitis even death worldwide approximately billion people live dengueinfested region million new case year although many infection believed silent four antigenically distinct serotypes dengue virus thus immunity one serotype crossprotect infection three difficulty hamper vaccine development include requirement natural conformation envelope glycoprotein induce neutralizing immune response necessity presenting antigen four serotypes currently way meet requirement use mixture four serotypes live attenuated dengue virus safety remains major problem study developed basis tetravalent dengue vaccine using novel complex adenovirus platform capable expressing multiple antigen de novo dengue vaccine constructed pair vector express premembrane envelope gene two different dengue virus serotypes upon vaccination vaccine expressed high level dengue virus antigen cell mimic natural infection induced humoral cellular immune response multiple serotypes dengue virus animal model analysis show humoral response indeed neutralizing four serotypes study demonstrate concept mimicking infection induce immune response synthesizing dengue virus membrane antigen de novo feasibility developing effective tetravalent dengue vaccine vectormediated expression glycoprotein four serotypes,2007,"Holman, David H; Wang, Danher; Raviprakash, Kanakatte; Raja, Nicholas U; Luo, Min; Zhang, Jianghui; Porter, Kevin R; Dong, John Y",Clinical and vaccine immunology : CVI,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17192403/,35366246.0,3
55471,55471,69819,m95l6qjv,,Medline,Immune responses elicited by bacterial minicells capable of simultaneous DNA and protein antigen delivery.,,,16806602.0,unk,recent event surrounding emerging infectious disease bioterrorism increasing multidrug antibiotic resistance bacteria drastically increased current need effective vaccine many year study shown live attenuated pathogen often effective delivering heterologous protein dna induce protective immune response however vaccine carrier inherent safety concern limited development use many patient population study using nonliving delivery mechanism shown providing protein antigen dna encoding antigen individual induces improved protective immune response rarely ever delivered simultaneously nonreplicating bacterial minicells derived commensal e coli strain shown effectively induce antigenspecific immune response simultaneous protein dna delivery data demonstrate potential use achromosomal bacterial minicells vaccine carrier,2006,"Giacalone, Matthew J; Sabbadini, Roger A; Chambers, Amy L; Pillai, Sabitha; Berkley, Neil L; Surber, Mark W; McGuire, Kathleen L",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16806602/,39186773.0,3
55526,55526,69878,ohegq232,,Medline,Speculation on whether a vaccine against cryptosporidiosis is a reality or fantasy.,,,10576579.0,unk,paper author question whether development vaccine cryptosporidiosis could taken consideration necessity feasibility vaccine human veterinary application discussed developmental stage within life cycle parasite might act possible target vaccine development summarised well target antigen offered molecular biology immunology study vaccination trial cryptosporidiosis carried far including active passive immunisation approach also overviewed seems respect cryptosporidium vaccine two target group considered child developing world neonatal ruminant antigen representing possible candidate subunit vaccine identified based function location andor immune response evoke active vaccination newborn calf lamb goat kid face number important limitation passive immunisation approach dam immunised protect progeny colostral transfer proven valuable alternative finally number point action near future put forward,1999,"de Graaf, D C; Spano, F; Petry, F; Sagodira, S; Bonnin, A",International journal for parasitology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/10576579/,483978.0,3
55541,55541,69895,sd01wrhc,,Medline,The proportion of specific viral subpopulations in attenuated Arkansas Delmarva poultry industry infectious bronchitis vaccines influences vaccination outcome.,,,23397834.0,unk,investigated significance differing proportion specific subpopulation among commercial arkansas ark delmarva poultry industry dpi vaccine regard vaccination outcome two arkdpiderived vaccine contain higher proportion virus gene become selected replication chicken exhibited rapid establishment selected subpopulation chicken produced significantly higher viral load tear induced higher antibody response compared two arkdpi vaccine lower proportion virus become selected chicken presence higher proportion selected subpopulation also associated significantly higher incidence respiratory sign early vaccination case severe tracheal lesion however one arkdpiderived vaccine lower proportion selected subpopulation despite producing lower viral load tear also induced higher incidence respiratory sign later vaccination severe tracheal lesion furthermore one arkdpiderived vaccine higher proportion selected subpopulation despite producing higher viral load tear resulted le severe tracheal damage discrepancy suggest infectious bronchitis virus ibv load tear may always predict degree tracheal damage phenotypic characteristic may also involved severity vaccine reaction following arkdpi vaccine administration observed lower antibody response vaccine produced lower viral load might contribute persistence ark serotype ibv vaccine observed commercial flock,2012,"Ndegwa, Eunice N; Joiner, Kellye S; Toro, Haroldo; van Ginkel, Frederik W; van Santen, Vicky L",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/23397834/,7154523.0,3
55565,55565,69924,5d0bvmdr,,Medline,Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections.,,,15297608.0,unk,persistent viral infection causing serious disease derive primarily altered function immune system knowledge complex composition function innate adaptive branch immune system essential understanding persistent infection best solution problem persistent infection prevention using prophylactic vaccine hit run virus evade immune destruction infecting new host rarely persist hit stay virus evade immune control sequestration blockade antigen presentation cytokine escape evasion natural killer cell activity escape apoptosis antigenic change twelve prophylactic vaccine hit run agent exist three vaccine hit stay virus dna composition several new vaccine hit stay virus feasible protective vaccine rna hiv hepatitis c agent highly unlikely short major breakthrough therapeutic vaccine improbable without magnitude favorable new discovery meantime antiviral chemotherapy chemotherapyprophylactic vaccination short interfering rna silencing worthy intense investigation,2004,"Hilleman, Maurice R",Proceedings of the National Academy of Sciences of the United States of America,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15297608/,10106653.0,3
55573,55573,69932,3e005ob2,,Medline,Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate.,,,24355931.0,unk,development vaccine preventing future pandemic severe acute respiratory syndrome sars caused sars coronavirus sarscov biodefense preparedness urgently needed previous study shown candidate sars vaccine antigen consisting receptorbinding domain rbd sarscov spike protein induce potent neutralizing antibody response protection sarscov challenge vaccinated animal optimize expression condition scaleup production rbd vaccine candidate hypothesized could potentially achieved removing glycosylation site rbd protein study constructed two rbd protein variant rbdwt aa residue deglycosylated form rbdn rbdn rbdn rbdwt aa residue deglycosylated form rbdn rbdn rbdn construct expressed recombinant protein yeast purified recombinant protein construct compared antigenicity functionality immunogenicity mouse using alum adjuvant found rbdn exhibited high expression yield maintained antigenicity functionality importantly rbdn induced significantly stronger rbdspecific antibody response higher level neutralizing antibody immunized mouse rbdwt rbdn rbdn rbdwt result suggest rbdn could selected optimal sars vaccine candidate development,2014,"Chen, Wen-Hsiang; Du, Lanying; Chag, Shivali M; Ma, Cuiqing; Tricoche, Nancy; Tao, Xinrong; Seid, Christopher A; Hudspeth, Elissa M; Lustigman, Sara; Tseng, Chien-Te K; Bottazzi, Maria Elena; Hotez, Peter J; Zhan, Bin; Jiang, Shibo",Human vaccines & immunotherapeutics,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24355931/,23492587.0,3
55577,55577,69938,boqhid3y,,Medline,Development of attenuated vaccines from Taiwanese infectious bronchitis virus strains.,,,16239054.0,unk,due variation serotypes among different strain avian infectious bronchitis virus ibv vaccination chick imported vaccine fails protect ibv infection taiwan therefore develop attenuated vaccine local strain taiwan taiwan group tw strain passaged time specific pathogenfree spf chicken embryonated egg tested spf chicken attenuated vaccine pathogenic weekold chick neutralization index ni greater efficacy inoculated bird challenged field ibv strain similar result obtained vaccine made taiwan group ii ibv strain additionally tw attenuated vaccine strain reversion virulence five back passage chick conclusion attenuated vaccine potential controlling local taiwanese ibv infection chicken,2006,"Huang, Yuan-Pin; Wang, Ching-Ho",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16239054/,31319380.0,3
55593,55593,69956,3m0n6w2r,,Medline,"[The use of genetic engineering in veterinary medicine with examples from epidemiology, diagnosis and drug production].",,,2112273.0,unk,result genetic engineering reached practical veterinary medicine already nevertheless great lack knowledge among veterinarian usually work method therefore want give introduction advantage danger technology concerning veterinary medicine important analytical method explained related virus wee eee canine parvovirus feline parvovirus mink enteritis virus related coronaviruses fipv tgev serve example possibility molecular diagnosis epidemic monitoring history gl mutant prv prescribed vaccine strain frg example development genetic engineered vaccine new generation vaccine based recombinant vaccinia virus imminent thus aware high risk responsibility everybody involved new system especially scientist produce genetically altered organism,1990,"Mayr, A; Hübert, P",Tierarztliche Praxis,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/2112273/,7903843.0,3
55706,55706,70087,mvrkg4bz,,Medline,"Pulmonary DNA vaccination: concepts, possibilities and perspectives.",,,16054263.0,unk,mucosal immunity establishes first line defence pathogen entering body via mucosal surface besides eliciting local systemic immunity mucosal vaccination strategy noninvasive nature may increase patient compliance reduce need vaccine application trained personnel relatively new concept mucosal immunization using dna vaccine advantage dna vaccine opportunity combine genetic information various antigen epitope stimulatory cytokine enhanced stability ease production make class vaccine attractive suitable mucosal application contrast area intranasal vaccination recent study focused pulmonary immunization involvement pulmonary immune system eliciting protective immune response inhaled pathogen review focus dna vaccine delivery lung promising approach prevent pulmonaryassociated disease caused inhaled pathogen attractive immunological feature lung site immunization mechanism action dna vaccine pulmonary application vaccine using novel delivery system discussed also examine pulmonary disease prone prevention therapeutical intervention application dna vaccine,2005,"Bivas-Benita, Maytal; Ottenhoff, Tom H M; Junginger, Hans E; Borchard, Gerrit",Journal of controlled release : official journal of the Controlled Release Society,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16054263/,6323398.0,3
56001,56001,70447,rgj12mz6,,Medline,Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines.,,,15064027.0,unk,background response emergence severe infection capable rapid global spread issue pandemic alert alert rare however feb pandemic alert issued response human infection caused avian hn influenza virus ahong kong hn noted human being killed third infected people variant seemed transmitted directly bird human being caused fatal pneumonia one two infected individual candidate vaccine sought avirulent virus antigenically similar pathogen available isolate killed embryonated chicken egg since traditional strategy vaccine production viable sought produce candidate reference virus using reverse genetics method removed polybasic aminoacids associated high virulence haemagglutinin cleavage site ahong kong using influenza reverse genetics technique reference vaccine virus produced apuerto rico pr backbone whoapproved vero cell assessed reference virus pathogenicity invivo invitro assay finding reference vaccine virus produced good manufacturing practice gmpgrade facility le week time virus isolation virus proved nonpathogenic chicken ferret shown stable multiple passage embryonated chicken egg interpretation ability produce candidate reference virus short period time set new standard rapid response emerging infectious disease threat clearly show usefulness reverse genetics influenza vaccine development technology procedure currently used create reference vaccine virus hn virus circulating asia,2004,"Webby, R J; Perez, D R; Coleman, J S; Guan, Y; Knight, J H; Govorkova, E A; McClain-Moss, L R; Peiris, J S; Rehg, J E; Tuomanen, E I; Webster, R G",Lancet,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15064027/,8662261.0,3
56036,56036,70488,sdtiyrab,,Medline,"Global efforts on vaccines for COVID-19: Since, sooner or later, we all will catch the coronavirus.",,,32385219.0,unk,covid emerging infectious disease turned pandemic spread droplet transmission new coronavirus sarscov rna virus displaying spike protein major surface protein significant sequence similarity sarscov cause severe acute respiratory syndrome receptor binding domain spike protein interacts human angiotensin converting enzyme considered antigenic determinant stimulating immune response multiple candidate vaccine currently different stage development known therapeutic intervention moment review describes key genetic feature considered generating vaccine candidate employing innovative technology also highlight global effort undertaken deliver vaccine covid unprecedented international cooperation future challenge post development,2020,"Mukherjee, Raju",Journal of biosciences,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/32385219/,218528546.0,3
56047,56047,70500,okqtlm2j,,Medline,"[Vaccines, biotechnology and their connection with induced abortion].",,,18611078.0,unk,diploid cell wi mrc vaccine origin induced abortion among vaccine fi nd following rubella measles mumps rabies polio smallpox hepatitis chickenpox herpes zoster nowadays abortion tainted vaccine cultivated transformed cell perc pipeline flu respiratory syncytial parainfluenza virus hiv west nile virus ebola marburg lassa hepatitis b c foot mouth disease japanese encephalitis dengue tuberculosis anthrax plague tetanus malaria method used production monoclonal antibody protein gene therapy genomics technology enables u develop aforementioned product without resorting induced abortion full disclosure cell origin labelling vaccine product must supported vaccine nonobjectionable source made available public alternative vaccine exist ethical research must promoted nonobjectionable source production monoclonal antibody gene therapy genomics must encouraged consistent abstain product originated embryonic stem cell time approve product obtained induced abortion paramount importance avoid induced abortion technology seeps every field medicine,2008,"Redondo Calderón, José Luís",Cuadernos de bioetica : revista oficial de la Asociacion Espanola de Bioetica y Etica Medica,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18611078/,12430673.0,3
56228,56228,70722,afa6aucu,,Medline,Vanishing vaccinations: why are so many Americans opting out of vaccinating their children?,,,15568260.0,unk,vaccination lifethreatening disease one greatest public health achievement history literally million premature death prevented countless child saved disfiguring illness vaccination carry unavoidable risk medical social economic benefit confer led fifty state enact compulsory childhood vaccination law stop spread preventable disease today however vaccine becoming victim successmany individual never witnessed debilitating disease vaccine protect allowing complacency toward immunization requirement build antivaccination sentiment growing fast united state large part due controversial hotly disputed link immunization autism internet worsens fear regarding vaccination safety least dozen website publish alarming information risk vaccine increasing number parent refusing immunization child seeking legally sanctioned exemption instead apparently fearing vaccine underlying disease protect variety factor play religious philosophical belief freedom individualism misinformation risk overperception risk state legislature health department face difficult challenge respecting individual right freedom also safeguarding public welfare nearly state allow vaccination exemption religious reason growing number provide philosophical optouts well however handful jurisdiction neither objection seriously documented verified often law requires parent simply check box indicating wish child receive immunization problem exacerbated financial incentive school encourage student opt vaccination rise parent opting caused ama grave concern many expert decrying rise socalled exemption convenience area nearly one five child received recommended vaccine consequence serious unprotected child rest society well herd immunity threatened parent free ride community dwindling immunity outbreak disease thought conquered already occurred lawsuit vaccine manufacturer threaten bankruptcy cost externalized onto healthcare legal system vulnerable population suffering harm even death interest social welfare state legislature health department consider method ensure exemption process carefully tailored prevent checkthebox optouts convenience still allowing exemption earnest informed conviction medical reason,2004,"Calandrillo, Steve P",University of Michigan journal of law reform. University of Michigan. Law School,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15568260/,34767231.0,3
56240,56240,70739,evqqed55,,Medline,The American Society for Virology--29th Annual Meeting.,,,20799142.0,unk,american society virology th annual meeting held bozeman mt usa included topic covering new vaccine technology delivery method treatment field virology conference report highlight selected presentation human norovirus hunov sars coronavirus rift valley fever virus vaccine technology programmed cell death pd blockade hyperacute alphagal platform technology method aerosol vaccination delivery novel technology produce influenza viruslike particle vlp mammalian cell line investigational human rotavirus vaccine,2010,"Minieri Arroyo, Jennifer",IDrugs : the investigational drugs journal,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/20799142/,23207479.0,3
56270,56270,70771,hnr2wc68,,Medline,Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine.,,,16919855.0,unk,studied immunogenicity antisars subunit vaccine comprised fragment sars coronavirus sarscov spike protein amino acid containing receptorbinding domain protein fragment purified culture supernatant stably transformed hekt cell secreting tagged version protein vaccine given subcutaneously ssvev mouse saline alum adjuvant alum plus cpg oligodeoxynucleotides odn mouse immunized adjuvanted antigen elicited strong antibody cellular immune response furthermore adding cpg odn alum resulted increased igga antibody titer higher number infgammasecreting murine splenocytes mouse vaccinated deglycosylated pngase f dg showed lower neutralizing antibody response similar number infgammaproducing cell spleen finding suggests carbohydrate important immunogenicity protein fragment provide useful information designing effective safe sars subunit vaccine,2007,"Zakhartchouk, Alexander N; Sharon, Chetna; Satkunarajah, Malathy; Auperin, Thierry; Viswanathan, Sathiyanarayanan; Mutwiri, George; Petric, Martin; See, Raymond H; Brunham, Robert C; Finlay, B Brett; Cameron, Cheryl; Kelvin, David J; Cochrane, Alan; Rini, James M; Babiuk, Lorne A",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16919855/,22542697.0,3
56400,56400,70932,jd3zgcjb,,Medline,[Novel Research Progress of the Recombinant Vaccine for MERS-CoV].,,,29995374.0,unk,respiratory syndrome coronavirus middle east mersco v caused wide attention since discovered design effective vaccine mersco v becomes hot area present therefore review aimed novel research progress recombinant vaccine mersco v including selection improvement animal model vaccine testconstruction optimization recombinant subunit vaccine attempt recombinant live vector vaccine based varies vector well advantage pseudovirus conclusion make summary novel research progress recombinant vaccine mersco v promising prospect development term safety effectiveness verification future demonstrated,2016,"Hu, Huizhen; Shen, Yuqing",Bing du xue bao = Chinese journal of virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/29995374/,51620095.0,3
56514,56514,71064,fg0h7a5t,,Medline,Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics.,,,11479124.0,unk,random peptide library antigenfragment library also known genefragment library used identify epitope protein antigen technology promise make significant contribution diagnostic vaccine development researcher number lab shown phage selected library protective antibody raised whole antigen used immunogen stimulate antibody response bind native antigen provide protection vivo others used serum patient idiopathic disease screen library approach identified candidate antigen involved immune disease may prove useful diagnosis possibly determining disease etiology,2001,"Irving, M B; Pan, O; Scott, J K",Current opinion in chemical biology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/11479124/,31079424.0,3
56554,56554,71113,7zhgomiy,,Medline,"Isolation, characterisation and preliminary cross-protection studies with a new pathogenic avian infectious bronchitis virus (strain PL-84084).",,,18766539.0,unk,virological examination severe infectious bronchitis iblike field case laying hen led isolation coronavirus antigenically different massachusetts connecticut four dutch ib variant strain virulence isolate fowl dual tropism respiratory genital tract demonstrated preliminary crossprotection study commercial vaccine protect challenge isolate point possible economic significance virus discussed,1986,"Picault, J P; Drouin, P; Guittet, M; Bennejean, G; Protais, J; L'Hospitalier, R; Gillet, J P; Lamande, J; Bachelier, A L",Avian pathology : journal of the W.V.P.A,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18766539/,40509998.0,3
56562,56562,71121,oswgi7w0,,Medline,Characterization of nephropathogenic infectious bronchitis virus DMV/1639/11 recovered from Delmarva broiler chickens in 2011.,,,23678731.0,unk,limited outbreak nephropathogenic infectious bronchitis nib occurred three delmarva dmv commercial broiler chicken flock isolates nib virus nibvdmv dmv dmvwere characterized sequence analysis nterminal subunit spike gene finding indicated isolates identical paa isolate poultry pennsylvania isolates appear originated nib outbreak pennsylvania dmv paa determined nephropathogenic susceptible chicken yielding virus reisolations kidney inducing characteristic interstitial nephritis microscopic lesion controlled laboratory study chicken vaccinated combination live vaccine containing infectious bronchitis virus ibv strain massachusetts mass connecticut conn positive virus isolation attempt challenge dmv compared mass arkansas ark vaccinates combination vaccine gave partial protection development dmvinduced renal lesion although numerically fewer chicken vaccinated mass conn interstitial nephritis compared vaccinated mass ark neither vaccine combination offered greater protection p observed unvaccinated chicken challenged dmv mass ark vaccination applied commercial condition hatchery spray onfarm spray protect trachea kidney dmv challenge serologic testing broiler flock found tested posse specific antibody dmv indicating virus become established region,2013,"Gelb, Jack; Ladman, Brian S; Pope, Conrad R; Ruano, J Miguel; Brannick, Erin M; Bautista, Daniel A; Coughlin, Colleen M; Preskenis, Lauren A",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/23678731/,11157782.0,3
56649,56649,71216,ugbmvvyw,,Medline,Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease.,,,17416434.0,unk,important effort performed emergence severe acute respiratory syndrome sars epidemic diagnose prevent virus spreading several type vaccine developed including inactivated virus subunit vaccine viruslike particle vlps dna vaccine heterologous expression system vaccine derived sarscov genome reverse genetics review describes several aspect essential develop sarscov vaccine correlate protection virus serotypes vaccination side effect biosafeguards engineered recombinant vaccine approach based sarscov genome production effective safe vaccine prevent sars led development promising vaccine candidate contrast design vaccine coronaviruses general le successful preclinical trial animal model efficacy safety evaluation promising vaccine candidate described performed human,2008,"Enjuanes, Luis; Dediego, Marta L; Alvarez, Enrique; Deming, Damon; Sheahan, Tim; Baric, Ralph",Virus research,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17416434/,23383833.0,3
56683,56683,71259,ptvvw120,,Medline,Levelling the playing field? Sharing of influenza viruses and access to vaccines and other benefits.,,,23156648.0,unk,adoption pandemic influenza preparedness framework including annex th world health assembly article investigates disproportionate burden risk benefit resourcepoor country developing south resourcerich industrialised developed nation north world health organisation standard material transfer agreement smta accessing sharing influenza virus concludes country south unique opportunity level playing field providing timely affordable access lifesaving vaccine meaningful benefitsharing deliver technology economic development importantly article also demonstrates smtas merely redirection existing resource north south offer solution ongoing shortage pandemic influenza vaccine enabling south access technology necessary sustainable vaccine production thus increasing global vaccine capacity,2012,"Jefferies, Nicole",Journal of law and medicine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/23156648/,31183963.0,3
56716,56716,71302,3g607hgx,,Medline,Emerging respiratory viruses: challenges and vaccine strategies.,,,17041137.0,unk,current threat avian influenza human population potential reemergence severe acute respiratory syndrome sarsassociated coronavirus identification multiple novel respiratory virus underline necessity development therapeutic preventive strategy combat viral infection vaccine development key component prevention widespread viral infection reduction morbidity mortality associated many viral infection review describe different approach currently evaluated development vaccine sarsassociated coronavirus avian influenza virus also highlight many obstacle encountered development vaccine lesson learned current vaccine study coupled increasing knowledge host viral factor involved viral pathogenesis help increase speed efficacious vaccine targeting newly emerging viral pathogen developed,2006,"Gillim-Ross, Laura; Subbarao, Kanta",Clinical microbiology reviews,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17041137/,25083362.0,3
56769,56769,71375,ypzsdg8j,,Medline,Evaluating viral interference between infectious bronchitis virus and Newcastle disease virus vaccine strains using quantitative reverse transcription-polymerase chain reaction.,,,18251404.0,unk,potential infectious bronchitis virus ibv newcastle disease virus ndv replication interference evaluated using quantitative reverse transcriptionpolymerase chain reaction qrtpcr fourteendayold broiler chicken inoculated via eyedrop live commercial vaccine strain ibv ndv alone combination directly evaluate ibv ndv replication trachea day vaccination commercial ndv vaccine strain used b vgga c vaccine strain ibv tested massachusetts mass arkansas ark ndv mass vaccine used commercially manufactured combined product ndv ark vaccine used commercial vaccine manufactured single entity product administered eyedrop opposite eye chicken measured qrtpcr replication ndv strain b vgga c interfere growth ibv mass ark strain vaccine combined vaccine treatment group combination vaccination using b vgga interfere ibv immunity based challenge serum antibody production c mass vaccination trial ibv immunity challenge reduced seem result reduced mass vaccine growth ability mass vaccine induce serum ibv antibody contrast replication ibv strain mass ark interfered growth ndv strain b vgga c measured qrtpcr however interference ndv replication reflected reduction newcastle disease challenge immunity finding combination mass ndv product manufactured vaccine company tested moreover ndv immunity compromised two three trial using single entity vaccine ndv ark ibv vaccine manufactured separately administered simultaneously however one trial ndv immunity decreased ndv single entity product c given ibv single entity ark vaccine finding emphasizes importance using manufactured combination vaccine whenever possible avoid potential interference,2007,"Gelb, J; Ladman, B S; Licata, M J; Shapiro, M H; Campion, L R",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18251404/,26031147.0,3
56772,56772,71378,gijrlu3k,,Medline,Immunizations in the United States: a rite of passage.,,,15925657.0,unk,today vaccination cornerstone pediatric preventive health care rite passage nearly approximately infant born daily united state article review u immunization program emphasis role ensuring vaccine effective safe available highlight several new vaccine recommendation affect health child adolescent practice pediatric medicine future decade,2005,"Cohn, Amanda C; Broder, Karen R; Pickering, Larry K",Pediatric clinics of North America,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15925657/,43276089.0,3
56791,56791,71400,91rm1uvs,,Medline,Efficacy of two canine parvovirus vaccines for inducing seroconversion in Rottweiler and Doberman pinscher pups with various levels of maternally derived antibodies.,,,19757563.0,unk,study reported investigated efficacy two commonly used modifiedlive virus vaccine induce seroconversion canine parvovirus cpv rottweiler doberman pinscher pup various titer maternally derived cpv antibody beginning week age pup given subcutaneous vaccination every day range day dorsal region neck shoulder area pup vaccinated vaccine aa received three vaccination completed vaccination series week age pup vaccinated vaccine bb received four vaccination completed vaccination series week age antibody titer cpv vaccine group similar vaccination pup vaccinea group seroconverted significantly earlier vaccineb group first vaccination pup cpvb hemagglutination inhibition hi titer responded vaccine vaccine b addition cpvb hi titer vaccination also significantly p higher pup vaccinea group first second third vaccination compared pup vaccineb group,2000,"Coyne, M J",Veterinary therapeutics : research in applied veterinary medicine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19757563/,12553404.0,3
56966,56966,71608,7h2b1eku,,Medline,Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice.,,,15231072.0,unk,tested ability inactivated sarscov vaccine induce neutralizing antibody balbc mouse inactivated vaccine prepared sarscov virus propagation vero cell subsequent betapropiolactone inactivation sepharose ff column chromatography purification one hundred forty balbc female mouse divided seven group mouse seven group three group inoculated microg vaccine without adjuvant three group inoculated three dosage vaccine aluminum hydroxide adjuvant respectively remaining group set blank control mouse inoculated twice interval week one week second immunization mouse serum collected detect serum neutralizing antibody assay determining neutralizing antibody titer developed result summarized follows higher dosage vaccine induced higher level neutralizing antibody titer level neutralizing antibody induced inoculation aluminum hydroxide adjuvant slightly higher without adjuvant difference statistically significant,2004,"Tang, Lin; Zhu, Qingyu; Qin, Ede; Yu, Man; Ding, Zhifen; Shi, Huiying; Cheng, Xiaojie; Wang, Caiping; Chang, Guohui; Zhu, Qiang; Fang, Fang; Chang, Haiyan; Li, Shuangli; Zhang, Xumin; Chen, Xishu; Yu, Jun; Wang, Jian; Chen, Ze",DNA and cell biology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15231072/,41520511.0,3
57099,57099,71758,o4l138ps,,Medline,Intragastric immunization with recombinant Lactobacillus casei expressing flagellar antigen confers antibody-independent protective immunity against Salmonella enterica serovar Enteritidis.,,,17287050.0,unk,recombinant lactobacillus casei expressing flagellar antigen salmonella enterica serovar enteritidis constructed evaluated mucosal vaccine intragastric immunization recombinant strain conferred protective immunity salmonella infection mouse immunization result antigenspecific antibody either feces serum induced release ifngamma restimulation primed lymphocyte ex vivo result suggested protective efficacy provided flagellinexpressing l casei mainly attributable cellmediated immune response addition adjuvanttype effect antigen delivery system l casei also observed,2007,"Kajikawa, Akinobu; Satoh, Eiichi; Leer, Rob J; Yamamoto, Shigeki; Igimi, Shizunobu",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17287050/,28735428.0,3
57156,57156,71826,h6kyh76x,,Medline,A human norovirus-like particle vaccine adjuvanted with ISCOM or mLT induces cytokine and antibody responses and protection to the homologous GII.4 human norovirus in a gnotobiotic pig disease model.,,,18022293.0,unk,inoculated gnotobiotic pig orallyintranasally human norovirus gii h strain viruslike particle vlp immunostimulating complex iscom mutant e coli lt toxin mlt rg mucosal adjuvant assessed intestinal systemic antibody cytokine response homologous protection vaccine induced high rate seroconversion coproconversion vlpmlt vaccine induced thth serum cytokine cytokine secreting cell whereas vlpiscom vaccine induced th biased response significantly elevated igm iga igg antibodysecreting cell intestine nevertheless vaccine induced increased protection rate viral shedding diarrhea compared control however control shed virus,2007,"Souza, Menira; Costantini, Veronica; Azevedo, Marli S P; Saif, Linda J",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18022293/,33489803.0,3
57172,57172,71844,c2spoa5o,,Medline,An ecological perspective on Brucella abortus in the western United States.,,,23837367.0,unk,hiatus outbreak brucella abortus cattle occurring frequently western state united state namely montana wyoming idaho increase coincidentwith increasing brucellosis seroprevalence elk cervus elaphus correlated elk density vaccine seductive solution use wildlife system remains limited logistical financial scientific constraint cattle vaccination ongoing region livestock regulation however tend based serological test test previous exposure available vaccine protect seroconversion author review recent ecological study brucellosis particular emphasis greater yellowstone area highlight management option implication work including potential utility habitat modification targeted hunt well scavenger predator finally author discus future research direction help u understand manage brucellosis wildlife,2013,"Cross, P C; Maichak, E J; Brennan, A; Scurlock, B M; Henningsen, J; Luikart, G",Revue scientifique et technique,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/23837367/,30037724.0,3
57210,57210,71890,d1k66kcg,,Medline,Introducing new vaccines in developing countries: concepts and approaches to estimating burden of Haemophilus influenzae type b-associated disease.,,,15609777.0,unk,past year great stride made immunizing infant child routinely developing country expanded programme immunization despite introduction haemophilus influenzae type b hib vaccine progressed rather slowly compared previouslyintroduced vaccine infant immunization slower uptake attributed partly need data burden invasive hib disease understand need conceptual underpinnings prerequisite explored hib diseaseburden study methodological approach also reviewed conducting hib diseaseburden study may considered developing country potential study span range design provide varying level clinical laboratory epidemiologic evidence burden invasive hib disease carefullyconducted study lay foundation complementary study longterm disability due invasive hib disease national economic analysis field evaluation vaccine study done collaboration national agency clinical investigator maximize study value provide critical data national decisionmakers make choice regarding introduction hib vaccine,2004,"Kilgore, Paul E; Nyambat, Batmunkh","Journal of health, population, and nutrition",,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15609777/,40796043.0,3
57333,57333,72034,h9855yhx,,Medline,History of the First-Generation Marek's Disease Vaccines: The Science and Little-Known Facts.,,,27902902.0,unk,shortly isolation mareks disease md herpesvirus mdv late vaccine developed england united state netherlands biggs associate houghton poultry research station hprs england attenuated hprs first cellcultureisolated mdv strain passaging hprs chick kidney cell although hprsatt first commercially available vaccine never became widely used soon replaced fc strain herpesvirus turkey hvt vaccine developed witter associate regional poultry research laboratory avian disease oncology laboratory adol east lansing mi ironically kawamura et al isolated herpesvirus kidney cell culture turkey never realized potential vaccine md rispens central veterinary institute cvi developed third vaccine associate maas found commercial flock chicken mdv antibody without md subsequently rispens isolated low pathogenic strain hen number md antibodypositive flock free avian leukosis virus clinical md isolate became cvi vaccine used mostly netherlands late hvt longer fully protective new emerging field strain addition sb isolated schat calnek hvt improved protection emerging virulent strain cvi became worldwide vaccine gold standard review present data published paper personal communication providing additional information exciting yr period isolation mdv development different vaccine,2016,"Schat, Karel A",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/27902902/,34467588.0,3
57355,57355,72060,b1ak68uj,,Medline,Placebo-controlled evaluation of a modified life virus vaccine against feline infectious peritonitis: safety and efficacy under field conditions.,,,9269053.0,unk,modified live virus vaccine feline infectious peritonitis fip evaluated double blind placebocontrolled field trial two highrisk population vaccine found safe efficacious one population cat low antibody titre feline coronavirus fcov time vaccination although clinically healthy time vaccination retrospectively vaccinee later came fip found rtpcr positive fcov plasma showed change blood parameter consistent early stage fip concluded vaccination protect cat low fcov antibody titre cat vaccine failure probably due preexisting infection,1997,"Fehr, D; Holznagel, E; Bolla, S; Hauser, B; Herrewegh, A A; Horzinek, M C; Lutz, H",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/9269053/,33612522.0,3
57368,57368,72075,730b3tey,,Medline,Viral diseases of the respiratory system.,,,9706079.0,unk,infectious bronchitis newcastle disease infectious laryngotracheitis avian influenza pneumovirus virus frequently affect respiratory tract chicken tendency change antigenic property infectious bronchitis currently viral disease present poultry producing area world new serotypes variant strain reported several country current commercially available vaccine always provide protection new field isolates vaccination program constantly adjusted attempt improve protection disease infectious laryngotracheitis appeared broiler industry serious disease improved vaccine needed control disease broiler u control highly pathogenic form avian influenza velogenic form newcastle disease achieved eradication country effective vaccine used control newcastle avian influenza avian pneumovirus infection also emerging disease chicken turkey,1998,"Villegas, P",Poultry science,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/9706079/,3617643.0,3
57380,57380,72092,6uwh1xo3,,Medline,Hatchery Spray Cabinet Administration Does Not Damage Avian Coronavirus Infectious Bronchitis Virus Vaccine Based on Analysis by Electron Microscopy and Virus Titration.,,,26292549.0,unk,study laboratory showed arkansasdelmarva poultry industry arkdpi vaccine given dayold chicken hatchery spray cabinet replicated poorly failed adequately protect broiler homologous virus challenge whereas vaccine given eyedrop replicate bird protected following homologous virus challenge determine mechanical damage following spray application play role failure arkdpi vaccine examined morphology three arkdpi vaccine different manufacturer using electron microscope included massachusetts mass vaccine control one arkdpi vaccine vaccine mass vaccine significantly p fewer spike two arkdpi vaccine also found arkdpi mass vaccine significantly p fewer spike protein per virus particle compared respective challenge virus observation interesting may provide insight mechanism behind infectious bronchitis virus attenuation obvious difference observed virus morphology consistent trend number spike per virion found afterspray sample also determined vaccine titer spray embryonated egg found arkdpi mass vaccine similar drop titer logi logi respecively based data appears mechanical damage arkdpi vaccine occurring delivered hatchery spray cabinet suggesting factor contributing failure vaccine given method,2015,"Roh, Ha-Jung; Jordan, Brian J; Hilt, Deborah A; Ard, Mary B; Jackwood, Mark W",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/26292549/,2216874.0,3
57441,57441,72169,nbntcx5x,,Medline,Coronavirus avian infectious bronchitis virus.,,,17296157.0,unk,infectious bronchitis virus ibv coronavirus chicken gallus gallus one foremost cause economic loss within poultry industry affecting performance meattype egglaying bird virus replicates epithelium upper lower respiratory tract tissue also many tissue along alimentary tract elsewhere eg kidney oviduct testis detected respiratory faecal material increasing evidence ibv infect specie bird chicken interestingly breed chicken vary respect severity infection ibv may related immune response probably major reason high profile ibv existence large number serotypes live inactivated ib vaccine used extensively latter requiring priming former effectiveness diminished poor crossprotection nature protective immune response ibv poorly understood known surface spike protein indeed aminoterminal half sufficient induce good protective immunity increasing evidence amino acid difference amongst protein sufficient detrimental impact crossprotection experimental vector ib vaccine genetically manipulated ibvswith heterologous spike protein geneshave produced promising result including context ovo vaccination,2007,"Cavanagh, Dave",Veterinary research,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17296157/,6519476.0,3
57460,57460,72189,qlyb859b,,Medline,Comparative immunization in BALB/c mice with recombinant replication-defective adenovirus vector and DNA plasmid expressing a SARS-CoV nucleocapsid protein gene.,,,17257500.0,unk,order investigate immunogenicity induction humoral cellular immune response severe acute respiratory syndrome associated coronavirus sarscovn gene recombinant replicationdefective adenoviral vector radn generated immunized balbc mouse pcdnan primeradn boost regimen humoral cellular immune response detection different level sarscov n protein specific antibody interferongamma ifngamma secretion shown compared control humoral immune response induced effectively dna priming recombinant adenovirus boosting regimen significant difference heterogeneous homologous vaccination heterogeneous combination higher homologous combination induction antin antibody response among three heterogeneous combination pcdnanpcdnanpcdnanradn induced strongest antibody response induction ifngamma production homologous combination radnradnradnradn significantly stronger pcdnanpcdnanpcdnanpcdnan relatively weaker heterogeneous combination pcdannpcdannpcdannradn combination efficient immunization regimen induction sarscovnspecific ifngamma secretion antibody response result suggest dna immunization followed recombinant adenovirus boosting could used potential sarscov vaccine,2006,"Ma, Chunling; Yao, Kun; Zhou, Feng; Zhu, Minsheng",Cellular & molecular immunology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17257500/,19926620.0,3
57485,57485,72224,bh3m8vlv,,Medline,Protection conferred by a recombinant Marek's disease virus that expresses the spike protein from infectious bronchitis virus in specific pathogen-free chicken.,,,22559869.0,unk,background many country predominant field isolates infectious bronchitis virus ibv classified qxlike strain since however commercial vaccine specific type ibv currently available therefore urgent need develop novel vaccine prevent qxlike ibv infection result recombinant mareks disease virus mdv rmdvs express subunit spike protein qxlike infectious bronchitis virus ibv constructed inserting ibv gene genome cvirispens strain mdv specific pathogenfree spf chicken vaccinated rmdvs protected challenged qxlike ibv observed mild clinical sign disease short virusshedding period low mortality additionally rmdvs conferred full protection chicken virulent mdv cvirispens strain conclusion result demonstrate rmdvs effective promising recombinant vaccine prevention qxlike ibv infection,2012,"Zhang, Xiaorong; Wu, Yantao; Huang, Yezhen; Liu, Xiufan",Virology journal,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/22559869/,13992668.0,3
57576,57576,72332,f3m33hwr,,Medline,Delivery technologies for human vaccines.,,,12176848.0,unk,currently intense research activity aimed development new delivery system vaccine goal identify optimal method presenting target antigen immune system manner elicit immune response appropriate protection treatment specific disease several different approach general goal developed empirical remain poorly understood others rational based example mimicking natural infection vivo targeting particular feature immune system article review three category delivery system adjuvant formulation ii antigen vector including live attenuated microorganism synthetic vector iii novel device vaccine administration review restricted late stage development field human vaccination,2002,"Moingeon, Philippe; de Taisne, Charles; Almond, Jeffrey",British medical bulletin,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12176848/,15635233.0,3
57578,57578,72335,lnjzey40,,Medline,Carbohydrate moieties as vaccine candidates.,,,16080094.0,unk,carbohydrate epitope glycotopes structurally diverse occur variety chemical context present surface cell body surface pathogen various structure mode presentation affect perceived processed body dictate outcome immune response directed review focus mechanism carbohydrate immunity emphasis carbohydrate vaccine developed protection encapsulated bacterial pathogen discus cellular basis carbohydrate immunity newly identified glycotope processing pathway recognition capability synthetic microarray technology developed permit new experimental approach carbohydrate vaccine development exploration interaction immune system self nonself glycans,2005,"Lucas, Alexander H; Apicella, Michael A; Taylor, Christopher E",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16080094/,17580796.0,3
57606,57606,72367,6gbzmtvu,,Medline,Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice.,,,15629440.0,unk,analyze immune response dna vaccine encoded different gene fragment severe acute respiratory syndrome coronavirus sarscov sarscov gene fragment membrane nucleocapsid n spike sa spike b sb protein cloned pcdna invitrogen vector form plasmid pcdnam pcdnan pcdnasa pcdnasb respectively mouse immunized intramuscularly pcdnam pcdnan pcdnasapcdnasb plasmid blood collected serum separated humoral immune response detected enzymelinked immunosorbent assay cellular immune response sarscov dna vaccine detected lymphoproliferation assay cytotoxic lymphocyte assay result show cellular humoral immune response detected immunization pcdnam pcdnan pcdnasapcdnasb plasmid balbc mouse however pcdnam stimulated highest cellular immune response plasmid pcdnasapcdnasb stimulated highest humoral immune response week present result suggest dna immunization pcdnam pcdnan pcdnasapcdnasb could used potential dna vaccination approach induce antibody balbc mouse also illustrate gene immunization sars dna vaccine different immune response character,2005,"Wang, Zhijun; Yuan, Zhenghong; Matsumoto, Mitsuharu; Hengge, Ulrich R; Chang, Yung-Fu",Biochemical and biophysical research communications,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15629440/,20019644.0,3
57612,57612,72375,y6w257bf,,Medline,Swollen-head syndrome in broiler chickens.,,,6326742.0,unk,swollenhead syndrome disease seen broiler chicken week age southern africa appears caused mixed coronavirus escherichia coli infection coronavirus appears hitherto unrecorded serotype disease controlled attenuated livevirus vaccine antibacterial medication,1984,"Morley, A J; Thomson, D K",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/6326742/,28166102.0,3
57628,57628,72394,fxr0u7v2,,Medline,Detection of influenza antigen with rapid antibody-based tests after intranasal influenza vaccination (FluMist).,,,14986264.0,unk,rapid test influenza antigen detection frequently used known receipt intranasal influenza vaccine affect result test tested healthy adult received either intranasal intramuscular influenza vaccine intranasal vaccine recipient direct fluorescent antibody test dfa result enzyme immunoassay eia result positive influenza antigen within day vaccination subject positive eia result day vaccination intranasal vaccine recipient rapid influenzaantigen detection test yield positive result within week vaccination,2004,"Ali, Tanya; Scott, Nathaniel; Kallas, Wendy; Halliwell, Mary Ellen; Savino, Carol; Rosenberg, Eric; Ferraro, MaryJane; Hohmann, Elizabeth",Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/14986264/,23445362.0,3
57632,57632,72401,5kqpl6cm,,Medline,Current situation in the development of a preventive HIV vaccine.,,,16373000.0,unk,uncontrolled progression aid epidemic made development efficacious human immunodeficiency virus hiv vaccine major objective scientific research effective preventive vaccine hiv currently available sterilizing immunity yet achieved animal model review analysis major challenge developing aid vaccine particular mechanism involved viral escape immune response summarizes result obtained different prototype therapeutic preventive vaccine finally social economic healthcare aspect research hiv vaccine current controversy regarding development clinical trial discussed,2005,"Alcamí, José; Joseph Munné, Joan; Muñoz-Fernández, María Angeles; Esteban, Mariano",Enfermedades infecciosas y microbiologia clinica,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16373000/,22618172.0,3
57662,57662,72438,hx9sv1k1,,Medline,[Recent developments in SARS vaccine studies].,,,21064002.0,unk,severe acute respiratory syndrome sars caused thousand human infection worldwide hundred death month evidence indicates sars coronavirus sarscov circulating animal human since outbreak suggesting another pandemic may occur possibility focused continuous action sars vaccine research inactivated vaccine viral bacterial vector vaccine recombinant protein vaccine subunit vaccine dna vaccine liveattenuated virus vaccine studied different animal model although different animal model used vaccine study appropriate model studying sars ferret since develops typical clinical sign viral replication pattern lung pathology compatible sars pathogenesis human much evidence various vaccine strategy sars safe immunogenic vaccinated animal still display significant disease upon challenge moreover potential vaccine enhancement sars also shown study data study give important information demand vaccine development research especially focusing mucosal immunization tcell immunity combination heterologous vaccine primeboost regimen review article development sars vaccine discussed light recent literature,2010,"Ruh, Emrah",Mikrobiyoloji bulteni,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/21064002/,25551819.0,3
57670,57670,72447,94dughd1,,Medline,Severe acute respiratory syndrome vaccine development: experiences of vaccination against avian infectious bronchitis coronavirus.,,,14676007.0,unk,vaccine infectious bronchitis chicken gallus gallus domesticus arguably successful certainly widely used vaccine disease caused coronaviruses others bovine canine feline porcine coronaviruses infectious bronchitis virus ibv together genetically related coronaviruses turkey meleagris gallopovo ringnecked pheasant phasianus colchicus group coronavirus severe acute respiratory syndrome sars coronavirus tentatively group known mammalian coronaviruses group ibv replicates respiratory tissue including nose trachea lung airsacs causing respiratory disease also kidney associated minor major nephritis oviduct many part alimentary tractthe oesophagus proventriculus duodenum jejunum bursa fabricius caecal tonsil near distal end tract rectum cloaca common opening release egg faeces usually without clinical effect virus persist reexcreted onset egg laying month age believed consequence stress coming lay genetic line chicken differ extent ibv cause mortality chick respect clearance virus acute phase live attenuated passage chicken embryonated egg ibv strain introduced vaccine followed couple decade later inactivated vaccine boosting protection egglaying bird live vaccine usually applied meattype chicken day age experimental situation result sterile immunity challenged virulent homologous virus although chicken may protected clinical sign loss ciliary activity trachea sometimes vaccinated chick respond protective immune response protection short lived start decline apparent week vaccination vaccine based highly attenuated strain ibv exists score serotypes defined neutralization test crossprotection often poor consequently chicken may revaccinated another serotype two three week later single application inactivated virus generally led protection chicken two application led protection report remaining others practice field inactivated vaccine used laying bird previously primed two three live attenuated virus vaccination increase protection laying bird egg production loss induces sustained level serum antibody passed progeny large spike glycoprotein comprises carboxyterminal subunit approximately amino acid residue anchor virus envelope aminoterminal subunit approximately residue believed largely form distal bulbous part subunit purified ibv virus expressed using baculovirus expressed bird fowlpoxvirus vector induced virus neutralizing antibody although protective immune response induced multiple inoculation required percentage protected chicken low commercial application remarkably expression bird using nonpathogenic fowl adenovirus vector induced protection chicken two experiment difference little sequence result poor crossprotection difference amino acid change serotype suggesting small number epitope immunodominant respect neutralizing antibody initial study role ibv nucleocapsid protein n immunity suggested immunization bacterially expressed n inducing protection directly improved induction protection subsequent inoculation inactivated ibv another study two intramuscular immunization plasmid expressing n induced protective immunity basis immunity ibv well understood serum antibody level correlate protection although local antibody believed play role adoptive transfer ibvinfectioninduced alphabeta cell bearing cd antigen protected chick challenge infection conclusion live attenuated ibv vaccine induce good although shortlived protection homologous challenge although minority individual may respond poorly inactivated ibv vaccine insufficiently efficacious applied absence priming live vaccine two application inactivated ibv much efficacious although commercially viable proposition poultry industry however cost logistics multiple application sars inactivated vaccine would acceptable protection human population especially limited targeted group eg health care worker highrisk contact application sars vaccine perhaps best limited minimal number targeted individual monitored vaccinated person might infected sars coronavirus become asymptomatic excretors virus thereby posing risk nonvaccinated people looking future high efficacy fowl adenovirus vector expressing ibv subunit provides optimism live sars vaccine deemed necessary possibility including n protein gene,2003,"Cavanagh, Dave",Avian pathology : journal of the W.V.P.A,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/14676007/,33855837.0,3
57674,57674,72451,nw8qnbzf,,Medline,Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge.,,,16893990.0,unk,infection mycobacterium tuberculosis remains major cause morbidity mortality world since effectiveness available tuberculosis vaccine mycobacterium bovis bacillus calmetteguérin bcg suboptimal strong demand develop new tuberculosis vaccine tuberculosis airborne disease intranasal route vaccination might preferable live influenza virus vaccine might considered potential vector mucosal immunization various viral bacterial pathogen including tuberculosis generated several subtypes attenuated recombinant influenza virus expressing kda early secretory antigenic target protein esat tuberculosis n reading frame able demonstrate potency influenza virus n vector induce tuberculosisspecific th immune response mouse moreover intranasal immunization mouse guinea pig vector induced protection mycobacterial challenge similar induced bcg vaccination,2006,"Sereinig, Sabine; Stukova, Marina; Zabolotnyh, Natalia; Ferko, Boris; Kittel, Christian; Romanova, Julia; Vinogradova, Tatiana; Katinger, Hermann; Kiselev, Oleg; Egorov, Andrej",Clinical and vaccine immunology : CVI,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16893990/,11474136.0,3
57733,57733,72518,lm3wmspn,,Medline,Use of adenoviral vectors as veterinary vaccines.,,,16231058.0,unk,vaccine effective inexpensive prophylactic tool veterinary medicine ideally vaccine induce lifelong protective immunity target pathogen causing clinical pathological sign disease vaccinated animal however ideal vaccine rare veterinary field many vaccine either limited effectiveness harmful side effect addition still severe disease effective vaccine important criterion ideal vaccine veterinary medicine low cost especially important developing country even poultry vaccination vaccine must sell cent dose traditional approach include inactivated vaccine attenuated live vaccine subunit vaccine recently genetic engineering applied design new improved vaccine adenovirus vector highly efficient gene transfer broad spectrum cell type specie moreover adenovirus often induce humoral mucosal cellular immune response antigen encoded inserted foreign gene thus adenovirus become vector choice delivery expression foreign protein vaccination consequently market requirement adenovirus vaccine increasing creating need production methodology concentrated vector warranted purity efficacy review summarizes recent development approach adenovirus production purification application vector including success failure clinical application date,2005,"Ferreira, T B; Alves, P M; Aunins, J G; Carrondo, M J T",Gene therapy,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16231058/,23422943.0,3
57762,57762,72556,h9sqqsbd,,Medline,"Attenuation, safety, and efficacy of an infectious bronchitis virus GA98 serotype vaccine.",,,14562890.0,unk,novel strain infectious bronchitis virus ibv identified chicken southeastern united state classified new serotype designated georgia ga widespread nature ga virus southeastern united state lack adequate protection de vaccine developed specific vaccine ga serotype ga isolate ibv passaged embryonating chicken egg time attenuation virus determined specificpathogenfree chick pas ga strain ibv given day age coarse spray day age drinking water x embryo infectious dosebird protected homologous ga challenge well provided good protection detype virus addition vaccine shown adequately attenuated safe x dosage,2003,"Jackwood, Mark W; Hilt, Deborah A; Brown, Thomas P",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/14562890/,28514556.0,3
57795,57795,72598,vndwm3f4,,Medline,Virus-like particles-universal molecular toolboxes.,,,18083549.0,unk,viruslike particle vlps highly organised sphere selfassemble virusderived structural antigen stable versatile subviral particle posse excellent adjuvant property capable inducing innate cognate immune response commercialised vlpbased vaccine successful protecting human hepatitis b virus hbv human papillomavirus hpv infection currently explored potential combat infectious disease cancer much insight vlpmediated immune stimulation optimised vlp design gained human immunodeficiency virus hivderived vlps presenting promising component current aid vaccine approach owing unique feature vlps virosomes vitroreconstituted vlp counterpart recently gained ground field nanobiotechnology organic template development new biomaterials,2007,"Ludwig, Christine; Wagner, Ralf",Current opinion in biotechnology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18083549/,43861203.0,3
57855,57855,72667,49r8a9v4,,Medline,The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice.,,,15755609.0,unk,investigated develop novel vaccine sars cov using cdna construct encoding structural antigen spike protein membrane protein envelope protein e nucleocapsid n protein derived sars cov mouse vaccinated sarsn dna using pcdna plasmid vector showed cell immune response ctl induction proliferation n protein respectively ctl response also detected sars dnatransfected type ii alveolar epithelial cell cell clone thought initial target cell sars virus infection human determine whether dna vaccine could induce cell immune response human well mouse scidpblhu mouse immunized dna vaccine expected virusspecific ctl response cell proliferation induced human cell sarsn sarsm dna vaccine scidpblhu mouse model important development protective vaccine,2005,"Okada, Masaji; Takemoto, Yuji; Okuno, Yoshinobu; Hashimoto, Satomi; Yoshida, Shigeto; Fukunaga, Yukari; Tanaka, Takao; Kita, Yoko; Kuwayama, Sachiko; Muraki, Yumiko; Kanamaru, Noriko; Takai, Hiroko; Okada, Chika; Sakaguchi, Yayoi; Furukawa, Izumi; Yamada, Kyoko; Matsumoto, Makoto; Kase, Tetsuo; Demello, Daphne E; Peiris, J S M; Chen, Pei-Jer; Yamamoto, Naoki; Yoshinaka, Yoshiyuki; Nomura, Tatsuji; Ishida, Isao; Morikawa, Shigeru; Tashiro, Masato; Sakatani, Mitsunori",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15755609/,34630612.0,3
57890,57890,72705,qsx3a42r,,Medline,[Bioinformatics-based Design of Peptide Vaccine Candidates Targeting Spike Protein of MERS-CoV and Immunity analysis in Mice].,,,27295887.0,unk,middle east respiratory syndrome coronavirus merscov identified novel human coronavirus posed great threat public health world widewhich call development effective safe vaccine urgently study peptide epitope tagrgeting spike antigen predicted based bioinformatics method nine polypeptide high score synthesized linked keyhole limpet hemocyanin klh female balbc mouse immunized individual polypeptideklh total igg detected elisa well cellular mediated immunity cmi analyzed using elispot assay result showed individual peptide yvdvgpdsvksacievdiqqtffdktwprpidvskadgi could induce highest level total igg well cmi high frequency ifnγ secretion merscov antigen mouse study identified promising peptide vaccine candidate merscov provided experimental support bioinformaticsbased design peptide vaccine,2016,"Lan, Jiaming; Lu, Shuai; Deng, Yao; Wen, Bo; Chen, Hong; Wang, Wen; Tan, Wenjie",Bing du xue bao = Chinese journal of virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/27295887/,24892193.0,3
57912,57912,72731,jxjzko6q,,Medline,Development of antibodies to feline IFN-gamma as tools to elucidate the cellular immune responses to FeLV.,,,12969548.0,unk,understanding nature immune protection role immune effector product interferongamma ifngamma control infectious disease fundamental rational design effective vaccine immunotherapeutic reagent murine monoclonal sheep polyclonal antibody mabs pabs feline ifngamma fifngamma generated firstly facilitate research role cellular immune response control feline infectious disease secondly enable evaluation efficacy novel immunotherapeutic approach hybridoma clone secreting igg antibody selected expansion mabs affinity purified vitro polyclonal antibody raised sheep recombinant fifngamma affinity purified sensitivity mab sheep antififngamma pab determined using indirect fifngamma enzymelinked immunosorbent assay elisa immunoblots antibody assessed ability detect production fifngamma specific feline cell population ex vivo following coculture mitogen feline leukaemia virus felv antigen h presence protein secretion inhibitor brefeldin bfa production fifngamma evaluated using flow cytometry simultaneously detect pelabelled surface molecule fluorescein isothiocyanate fitclabelled intracellular fifngamma using approach initial study revealed upregulation virusspecific fifngammasecreting cdt cell lymph node felv latently infected cat,2003,"Graham, Elizabeth M; Jarrett, Oswald; Flynn, J Norman",Journal of immunological methods,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12969548/,2778950.0,3
57961,57961,72789,n6zmlu2w,,Medline,Retrospective evidence that the MHC (B haplotype) of chickens influences genetic resistance to attenuated infectious bronchitis vaccine strains in chickens.,,,15763730.0,unk,infectious bronchitis respiratory disease chicken caused coronavirus infectious bronchitis virus ibv virtually broiler layer breeder flock routinely vaccinated ibv two hatch dayold chick four line mistakenly vaccinated infectious bronchitis using moderately attenuated vaccine designed chick older age vaccination resulted high mortality chick three four line died sign typical infectious bronchitis mortality occurred using lessattenuated vaccine significantly influenced genetic line mhc b haplotype chicken three b congenic line b congenic chicken possessing b haplotype resistant contrast chicken possessing b b haplotype chick two hatch four line vaccinated appropriately attenuated ibv vaccine limited chick mortality seen retrospective data two repeated hatch confirm earlier data indicating chicken gene influence resistance ibv indicate first time gene tightly linked b haplotype relevant resistance ibv due extenuating circumstance possible verify result chick f mating factor may enhance definition role b haplotype immune response ibv desirability analysis b haplotypelinked influence immunity ibv discussed,2004,"Bacon, L D; Hunter, D B; Zhang, H M; Brand, K; Etches, R",Avian pathology : journal of the W.V.P.A,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15763730/,2251428.0,3
58006,58006,72836,2k7r518z,,Medline,Recombinant fowlpox virus vaccines for poultry.,,,8270268.0,unk,intensive poultry industry rely heavily upon use vaccine disease control viral vector based vaccine offer new avenue development vaccine effective disease control poultry technique developed construction recombinant vaccinia virus readily adapted construction recombinant virus based fowlpox virus rfpv ability insert several gene large genome fowlpox may enable development multivalent vaccine vaccine incorporating immune response modifier lymphokine newcastle disease avian influenza infectious bursal disease mareks disease antigen expressed rfpv shown effective vaccine poultry none appear however provide substantial improvement vaccine efficacy recombinant fpv valuable adjunct conventional vaccine currently widespread use whether rfpv vector based vaccine circumvent problem vaccination presence high maternally derived antibody yet resolved observation avipoxvirus recombinant may suitable vaccination nonavian specie provides added dimension vaccine based fpv avipoxviruses recombinant fpv find useful role poultry disease control used conjunction conventional vaccine,1993,"Boyle, D B; Heine, H G",Immunology and cell biology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/8270268/,25569703.0,3
58054,58054,72899,h9bmkcrw,,Medline,Cross-typic specificity and immunotherapeutic potential of a human HPV16 E7-specific CTL line.,,,15609329.0,unk,cervical cancer cacx strongly associated human papillomavirus hpv infection particularly hpv type constitutive expression hpv e e protein cacx make attractive target ctl based immunotherapy however cervical carcinoma may feature eg antigen processing defect limit effectiveness hpv specific ctl furthermore vaccine development concentrated hpv type clear whether vaccine could induce ctl able crossreact related oncogenic hpv type eg hpv investigate potentially important parameter vitro used ctl specific hpv e able kill variety hpv cacx cell line including suspected caski known antigen processing defect ca low hpv dna copy number siha also able cross react related peptide hpv e hpv e analysis suggested cross reactivity related peptide influenced tcr contact residue certain threshold peptide binding hpv crossreactivity confirmed whole protein level also able recognize endogenously processed form hpv e e result suggest hpv e would useful epitope immunotherapy hpv tumour despite difficult generate ctl response vaccination emphasizing need definition novel epitope efficient vaccination strategy,2005,"Youde, Sarah J; McCarthy, Corinna M; Thomas, Karen J; Smith, Kelly L; Man, Stephen",International journal of cancer,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15609329/,12869460.0,3
58074,58074,72921,gdl74rdf,,Medline,Fecal immunoglobulin A antibodies in dogs infected or vaccinated with canine coronavirus.,,,14715553.0,unk,fecal secretory immunoglobulin iga antibody dog infected vaccinated canine coronavirus ccv evaluated enzymelinked immunosorbent assay study carried fecal sample collected inoculation day postinoculation five group studied naturally infected dog experimentally infected dog dog inoculated modified live ml ccv vaccine intramuscular route dog inoculated ml ccv vaccine oronasal route dog given inactivated ccv vaccine naturally experimentally infected dog developed high level fecal iga interestingly dog inoculated ml ccv vaccine oronasal route developed level fecal iga higher observed dog inoculated ccv vaccine intramuscular route observed dog inoculated inactivated vaccine relationship level fecal iga ccv degree protection ccv infection observed,2004,"Decaro, Nicola; Pratelli, Annamaria; Tinelli, Antonella; Martella, Vito; Camero, Michele; Buonavoglia, Domenico; Tempesta, Maria; Caroli, Anna Maria; Buonavoglia, Canio",Clinical and diagnostic laboratory immunology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/14715553/,34001589.0,3
58102,58102,72951,s1l5sncl,,Medline,Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice.,,,17640780.0,unk,feasibility developing prophylactic vaccine sars assessed comparing immune response elicited immunizing mouse recombinant sars spike glycoprotein sprotein formulated different adjuvant given different route young aged mouse intranasal protollinformulated sprotein vaccine elicited high level antigenspecific igg serum comparable elicited intramuscular alumadsorbed sprotein vaccine serum antibody shown virus neutralizing intranasal immunization young mouse protollinformulated vaccine elicited significant level antigenspecific lung iga contrast mouse immunized intramuscular vaccine antigenspecific lung iga detected following live virus challenge aged mouse virus detected lung intranasally immunized mouse contrast intramuscularly immunized mouse whose lung virus titer comparable observed control mouse,2007,"Hu, Mary C; Jones, Taff; Kenney, Richard T; Barnard, Dale L; Burt, David S; Lowell, George H",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17640780/,20733523.0,3
58126,58126,72985,nrzkdmj6,,Medline,Development of vaccines against common colds.,,,12176853.0,unk,respiratory tract virus particularly significant cause illness death child elderly vaccine offer possibility decreasing severity complication viral respiratory disease development delayed numerous factor first serologically distinct rna dna virus specie strain cause essentially similar spectrum disease reinfect high efficiency despite little antigenic variation others exhibit extensive coat protein variability vaccine candidate show variable efficacy partially immune adult immunocompromised elderly may ineffective pathogenic neonate presence maternal antibody however effective childhood vaccine essential prevent severe disease due respiratory syncytial virus rsv parainfluenza reduce virus transmission adult number promising vaccine clinical trial likely vaccine rsv parainfluenza licensed within next year mucosal delivery use novel adjuvant offer prospect better vaccine influenza ultimate goal develop multivalent mucosal vaccine offering protection spectrum respiratory infection,2002,"Olszewska, Wieslawa; Zambon, Maria; Openshaw, Peter J M",British medical bulletin,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12176853/,35019670.0,3
58192,58192,73063,9k2h57q3,,Medline,Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus.,,,16476986.0,unk,two different severe acute respiratory syndrome sars vaccine strategy evaluated ability protect live sars coronavirus cov challenge murine model infection whole killed inactivated betapropiolactone sarscov vaccine combination two adenovirusbased vector one expressing nucleocapsid n expressing spike protein collectively designated ad sn evaluated induction serum neutralizing antibody cellular immune response ability protect pulmonary sarscov replication whole killed virus wkv vaccine given subcutaneously ssvev mouse effective ad sn vaccine administered either intranasally intramuscularly inhibiting sarscov replication murine respiratory tract protective ability wkv vaccine correlated induction high serum neutralizingantibody titre cellular immune response measured gamma interferon secretion mouse splenocytes titre serum neutralizing antibody induced ad sn vaccine administered intranasally intramuscularly significantly lower induced wkv vaccine however ad sn administered intranasally intramuscularly significantly limited sarscov replication lung among vaccine group sarscovspecific iga found serum mouse immunized intranasally ad sn suggesting mucosal immunity may play role protection intranasal ad sn delivery system finally serum vaccinated mouse contained antibody suggesting role protein conferring protective immunity sarscov infection,2006,"See, Raymond H; Zakhartchouk, Alexander N; Petric, Martin; Lawrence, David J; Mok, Catherine P Y; Hogan, Robert J; Rowe, Thomas; Zitzow, Lois A; Karunakaran, Karuna P; Hitt, Mary M; Graham, Frank L; Prevec, Ludvik; Mahony, James B; Sharon, Chetna; Auperin, Thierry C; Rini, James M; Tingle, Aubrey J; Scheifele, David W; Skowronski, Danuta M; Patrick, David M; Voss, Thomas G; Babiuk, Lorne A; Gauldie, Jack; Roper, Rachel L; Brunham, Robert C; Finlay, B Brett",The Journal of general virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16476986/,27078041.0,3
58237,58237,73110,rp3p1kmp,,Medline,Chikungunya Virus Vaccines: Viral Vector-Based Approaches.,,,27920181.0,unk,major chikungunya virus chikv epidemic reached america past year million people infected light current epidemic million people north south america risk effort rapidly develop effective vaccine increased focus chikv vaccine use viralvector technology group vaccine candidate share ability potently induce humoral cellular immune response use highly attenuated safe vaccine backbone far welldescribed vector modified vaccinia virus ankara complex adenovirus vesicular stomatitis virus alphavirusbased chimera measles vaccine schwarz strain mvschw described potential vaccine summarize recent data experimental vaccine focus preclinical clinical activity mvschwbased candidate first chikvvectored vaccine completed clinical trial,2016,"Ramsauer, Katrin; Tangy, Frédéric",The Journal of infectious diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/27920181/,38954733.0,3
58272,58272,73150,g9yo91cx,,Medline,LC16m8: an attenuated smallpox vaccine.,,,17052815.0,unk,frequency moderate severe adverse reaction associated smallpox vaccine currently stockpiled u continued threat bioterrorism prompted development effective vaccine improved safety profile lcm attenuated replicating smallpox vaccine derived lister strain vaccinia currently licensed japan safely used child shown markedly le neurotoxicity unattenuated vaccine nonclinical study lcm immunogenic single dose recent study two different animal model demonstrated protective efficacy equivalent fdalicensed smallpox vaccine article review history available scientific literature regarding lcm provides comparison smallpox vaccine,2006,"Kenner, Julie; Cameron, Fiona; Empig, Cyril; Jobes, David V; Gurwith, Marc",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17052815/,730375.0,3
58324,58324,73211,ato68pue,,Medline,Rationally-designed vaccine adjuvants: separating efficacy from toxicity.,,,17981755.0,unk,adjuvant substance included many vaccine order improve immune response challenging develop license adjuvant compound stimulate strong protective immunity also frequently induce significant toxicity adjuvant design development recently largely empirical current knowledge adjuvant act via receptor innate immune system molecularbased approach rapidly advancing field data support concept proinflammatory pathway induced innate immune receptor triggering underlie many observed toxic effect importantly cellular signaling pathway lead inflammation known number innate immune receptor distinct involved costimulation protective adaptive immune response leading approach attenuating inflammatory signaling lead safer effective vaccine adjuvant article address whether clear rationale separation toxicity efficacy function adjuvant based upon innate immune receptor ligand,2008,"Hauguel, Travis M; Hackett, Charles J",Frontiers in bioscience : a journal and virtual library,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17981755/,46493981.0,3
58408,58408,73313,4oohqbns,,Medline,Duration of immunity in red wolves (Canis rufus) following vaccination with a modified live parvovirus and canine distemper vaccine.,,,25314821.0,unk,growing information available regarding duration immunity core vaccine domestic nondomestic specie vaccination protocol nondomestic canid frequently followed guideline developed domestic dog however protocol inappropriate nondomestic canid african wild dog lycaon pictus leaving animal susceptible infectious disease others risk contracting vaccineinduced disease study red wolf canis rufus vaccinated canine distemper virus cdv canine parvovirus cpv vaccination titer followed annually yr one hundred percent wolf developed maintained positive titer cdv yr wolf developed maintained positive titer cpv yr seroconversion canine adenovirus sporadic result study support decreasing frequency vaccine administration red wolf population triennial basis,2014,"Anderson, Kadie; Case, Allison; Woodie, Kathleen; Waddell, William; Reed, Holly H",Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/25314821/,35199961.0,3
58410,58410,73315,3kvb1yjn,,Medline,Studies of SARS virus vaccines.,,,18708674.0,unk,intranasal vaccination using inactivated sars coronavirus sarscov vaccine adjuvant induce strong systemic serum immunoglobulin ig g respiratory tract local tracheallung wash fluid iga antibody response neutralising activity rbdfc proteinbased vaccine able induce effective neutralising antibody able provide protection sarscov infection animal model single dose rbdraav vaccination induce adequate neutralising antibody sarscov infection additional dos vaccine increased production neutralising antibody fold compared single dose rbdraav vaccination provoked prolonged antibody response continually increasing level neutralising activity intranasal vaccination rbdraav induced local iga systemic igg neutralising antibody specific tcell response able protect sarscov infection animal model compared rbdraav primeboost vaccination rbdraav primerbdpeptide boost induced similar level th neutralising antibody response protected vaccinated mouse subsequent sarscov challengesbut stronger th ctl response overall finding suggest inactivated vaccine rbdfc rbdraav developed effective safe vaccine sars intranasal vaccination may preferred route administration,2008,"Zheng, B J; Du, L Y; Zhao, G Y; Lin, Y P; Sui, H Y; Chan, C; Ma, S; Guan, Y; Yuen, K Y",Hong Kong medical journal = Xianggang yi xue za zhi,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18708674/,9596158.0,3
58498,58498,73414,da8x2lwh,,Medline,Duration of immunity (DOI) and booster vaccination--dealing with the issue at practice level in the UK.,,,16872760.0,unk,presentation offer uk veterinary practitioner viewpoint issue booster vaccination reference dog cat vaccine current use vaccine issue surrounding use discussed including motivation vaccinating climate reduced fear disease increased suspicion vaccine attitude extended routine booster vaccination explored specific disease prevention issue concerning leptospirosis particular presented strategy tactic implementation extended vaccine general practice level discussed based author experience thought offered vaccine manufacturer might support process local national level well communicating positive message continued routine vaccination dog cat advantage extended offer,2006,"Hill, R James",Veterinary microbiology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16872760/,34023716.0,3
58507,58507,73427,g2x2rj43,,Medline,[High-efficiency expression of a receptor-binding domain of SARS-CoV spike protein in tobacco chloroplasts].,,,25212009.0,unk,chloroplastbased expression system promising hyperexpression plantderived recombinant therapeutic protein vaccine verify feasibility obtaining highlevel expression sars subunit vaccine provide suitable plantderived vaccine production platform severe acute respiratory syndrome coronavirus sarscov amino acid fragment sars cov spike protein receptorbinding domain rbd fused peptide vector cholera toxin b subunit ctb expressed tobacco chloroplast codonoptimized ctbrbd sequence integrated chloroplast genome homoplasmy obtained confirmed pcr southern blot analysis western blot showed expression recombinant fusion protein mostly soluble monomeric form quantification recombinant fusion protein ctbrbd conducted elisa analysis transplastomic leaf different developmental stage attachment position time point day different expression level ctbrbd observed highest expression total soluble protein obtained mature transplastomic leaf taken together result demonstrate feasibility highly expressing sars subunit vaccine rbd indicating potential subsequent development plantderived recombinant subunit vaccine reagent production antibody detection sars serological test,2014,"Zhong, Xue; Qi, Guangxun; Yang, Jing; Xing, Guojie; Liu, Jianfeng; Yang, Xiangdong",Sheng wu gong cheng xue bao = Chinese journal of biotechnology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/25212009/,29710209.0,3
58563,58563,73492,24h3upsh,,Medline,A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice.,,,15024391.0,unk,public health measure successfully identified contained outbreak severe acute respiratory syndrome sars coronavirus sarscov concern remain possibility future recurrence finding vaccine virus therefore remains high priority show dna vaccine encoding spike glycoprotein sarscov induces cell neutralizing antibody response well protective immunity mouse model alternative form analysed dna immunization expression vector induced robust immune response mediated cd cd cell well significant antibody titre measured enzymelinked immunosorbent assay moreover antibody response mouse vaccinated expression vector encoding form includes transmembrane domain elicited neutralizing antibody viral replication reduced six order magnitude lung mouse vaccinated plasmid dna expression vector protection mediated humoral tcelldependent immune mechanism genebased vaccination sarscov elicits effective immune response generate protective immunity animal model,2004,"Yang, Zhi-Yong; Kong, Wing-Pui; Huang, Yue; Roberts, Anjeanette; Murphy, Brian R; Subbarao, Kanta; Nabel, Gary J",Nature,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15024391/,4430920.0,3
58653,58653,73602,izh0nr3p,,Medline,Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox.,,,15078924.0,unk,two decade worldwide vaccination campaign used successfully eradicate naturally occurring smallpox threat bioterrorism led renewed vaccination program addition sporadic outbreak human monkeypox africa recent outbreak human monkeypox u made clear naturally occurring zoonotic orthopoxvirus disease remain public health concern much threat posed orthopoxviruses could eliminated vaccination however smallpox vaccine live orthopoxvirus vaccine vaccinia virus administered skin vaccine pose serious health risk demonstrate rhesus macaque vaccinated dna vaccine consisting four vaccinia virus gene lr al ar br protected severe disease otherwise lethal challenge monkeypox virus animal vaccinated single gene lr encodes target neutralizing antibody developed severe disease survived first demonstration subunit vaccine approach smallpoxmonkeypox immunization feasible,2004,"Hooper, J W; Thompson, E; Wilhelmsen, C; Zimmerman, M; Ichou, M Ait; Steffen, S E; Schmaljohn, C S; Schmaljohn, A L; Jahrling, P B",Journal of virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15078924/,41557208.0,3
58669,58669,73621,1n6yapf1,,Medline,Evidence of partial protection against foot-and-mouth disease in cattle immunized with a recombinant adenovirus vector expressing the precursor polypeptide (P1) of foot-and-mouth disease virus capsid proteins.,,,10092007.0,unk,recombinant live vector vaccine produced insertion cdna encoding structural protein p footandmouth disease virus fmdv replicationcompetent human adenovirus type vaccine strain ad wt group cattle n immunized twice subcutaneous andor intranasal route either ad wt vaccine recombinant fmdv adp vaccine animal challenged intranasal instillation fmdv week second immunization absence detectable antibody response fmdv significant protection viral challenge seen animal immunized twice subcutaneous route recombinant vaccine observed partial protection clinical disease associated reduction titre persistent fmdv infection oropharynx challenged cattle,1999,"Sanz-Parra, A; Vázquez, B; Sobrino, F; Cox, S J; Ley, V; Salt, J S",The Journal of general virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/10092007/,23141475.0,3
58678,58678,73630,f6ohslnc,,Medline,Serosurvey of ex situ giant pandas (Ailuropoda melanoleuca) and red pandas (Ailurus fulgens) in China with implications for species conservation.,,,18229861.0,unk,conservation strategy giant panda ailuropoda melanoleuca include development selfsustaining ex situ population study examined potential significance infectious pathogen giant panda ex situ serologic antibody titer canine distemper virus cdv canine parvovirus cpv canine adenovirus cav canine coronavirus ccv canine herpesvirus canine parainfluenza virus cpiv toxoplasma gondii neospora caninum leptospira interrogans measured sample taken giant panda chengdu research base giant panda breeding sichuan china seroassays also included sample obtained eight red panda ailurus fulgens housed institution individual vaccinated chinese canine vaccine included modified live cdv cpv cav ccv cpiv positive antibody titer found cdv cpv gondii serum negative antibody six pathogen result indicate quality vaccine may reliable considered protective safe giant panda red panda positive antibody titer gondii found seven giant panda clinical subclinical epidemiologic significance infection pathogen via natural exposure modified live vaccine giant panda unknown research area imperative sustaining viable population giant panda endangered specie,2007,"Loeffler, I Kati; Howard, JoGayle; Montali, Richard J; Hayek, Lee-Ann; Dubovi, Edward; Zhang, Zhihe; Yan, Qigui; Guo, Wanzhu; Wildt, David E",Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18229861/,13503045.0,3
58697,58697,73653,bw5p2t4i,,Medline,Lower respiratory viral infections in immunocompetent children.,,,8123226.0,unk,viral lower respiratory disease cause heavy burden society better understanding epidemiology virus combined new rapid diagnostic technique provide rapid reliable diagnosis agent future two agent commonly thought cause lri child rhinovirus coronaviruses added already long list effective drug exist prophylaxis influenza virus type therapy influenza virus type type b rsv new antiviral drug near clinical use time new antiviral agent constantly tested developed hightiter specific antiviral ivig appears promising therapy prophylaxis next decade improved influenza virus vaccine safe effective vaccine hpiv rsv expected adenoviral vaccine use immunocompromised patient possible generally available vaccine child le likely although basic clinical epidemiology virus well investigated last year new molecular technique greatly expanding understanding agent antigenic genetic variation found many virus previously thought homogeneous exact role biologic significance variation beginning explored already evidence difference pathogenicity immunogenicity many substrains information impact future vaccine antiviral drug development,1994,"Henrickson, K J",Advances in pediatric infectious diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/8123226/,41039988.0,3
58731,58731,73692,sk87nkbk,,Medline,Mucosal immunity: an overview and studies of enteric and respiratory coronavirus infections in a swine model of enteric disease.,,,8988861.0,unk,based tenet common mucosal immune system antigenic stimulation one mucosal site result distribution antigenspecific iga precursor cell distant mucosal site however recent study suggest functional compartmentalization limited reciprocity may exist within component common mucosal immune system although oral immunization often effective inducing immunity respiratory pathogen converse respiratory immunization prevent enteric disease may effective address question study interaction bronchusassociated balt gutassociated galt lymphoid tissue related protective immunity used model two antigenically related porcine coronaviruses replicate primarily intestine transmissible gastroenteritis virus tgev respiratory tract porcine respiratory coronavirus prcv tissue distribution magnitude antibody secreting cell asc response measured elispot cellmediated immune response measured lymphoproliferative assay lpa coincided viral tissue tropism immunization via galt gut infection tgev elicited high number iga asc high lpa response galt gut lamina propria lp mesenteric lymph node mln lower response balt bronchial lymph node bln induced complete protection enteric tgev challenge contrast immunization via balt respiratory infection prcv elicited systemic type response high number igg asc bln asc low lpa response gut lp mln induced partial protection enteric tgev challenge thus administration vaccine intranasally may optimally effective inducing intestinal immunity contrast reported efficacy oral vaccine inducing respiratory immunity,1996,"Saif, L J",Veterinary immunology and immunopathology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/8988861/,31478824.0,3
58739,58739,73702,olp8c2k5,,Medline,Replicating and non-replicating viral vectors for vaccine development.,,,18063357.0,unk,viral vector provide convenient mean deliver vaccine antigen select target cell tissue broad spectrum replicating nonreplicating vector available appropriate choice select application depend biology infectious agent targeted well factor whether vaccine intended prevent infection boost immunity already infected individual prior exposure target population vector safety number size gene insert needed several viral vector development hivaids vaccine reviewed vaccine strategy based initial priming replicating vector enlist innate immune system target mucosal inductive site prime cellular humoral systemic mucosal immune response proposed subsequently boosting replicating nonreplicating vector andor protein subunit could lead induction necessary level protective immunity,2007,"Robert-Guroff, Marjorie",Current opinion in biotechnology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18063357/,2191753.0,3
58800,58800,73783,lghwqz7d,,Medline,A corn-based delivery system for animal vaccines: an oral transmissible gastroenteritis virus vaccine boosts lactogenic immunity in swine.,,,15193404.0,unk,recombinant plant expression system offer mean produce large quantity selected antigen subunit vaccine cereal particularly wellsuited expression vehicle since expressed protein stored relatively high concentration extended period time without degradation dry seed formulated oral vaccine suitable commercial application subunit vaccine candidate directed porcine transmissible gastroenteritis virus expressed corn seed developed oral delivery swine show vaccine administered previously sensitized gilt boost neutralizing antibody level animal serum colostrum milk thus vaccine candidate effective boosting lactogenic immunity appropriate pursue largescale field trial preceding commercialization,2004,"Lamphear, Barry J; Jilka, Joseph M; Kesl, Lyle; Welter, Mark; Howard, John A; Streatfield, Stephen J",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15193404/,22162182.0,3
58803,58803,73786,8l5koqi6,,Medline,Novel adjuvants and vaccine delivery systems.,,,8988882.0,unk,conventionally efficiency adjuvant measured capacity induce enhanced antibody serum titre cell mediated immunity cmi given antigen nowadays capacity adjuvant also measured quality well magnitude induced immune response guided protective immune response required quality includes isotype igg subclass response thelper cell response characterized cytokine profile cytotoxic cell ctl early phase immunization adjuvant influence antigen administration uptake socalled depot effect exemplified aluminium hydroxide gel oil adjuvant possibly desired alledged modern depot exerted slow release formulation continuously releasing antigen period time pulse interval aiming single injection vaccine great effort made formulate efficient delivery formulation targeting antigen site administration draining lymph node distant lymphatic tissue mucosal surface parenteral mucosal administration nowadays nonreplicating carrier besides replicating vaccine formulated induce mucosal immune response encompassing secretory iga cmi effort evoke immune response mucosal membrane distant site administration resulted mostly little success long time considered ctl restriction mhc class could evoked replicating virus intracellular parasite however novel adjuvant delivery system readily induce ctl delivering antigen apc resulting intracellular transport cytosol mhc class presentation system well endosomal pathway mhc class ii presentation,1996,"Morein, B; Villacrés-Eriksson, M; Sjölander, A; Bengtsson, K L",Veterinary immunology and immunopathology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/8988882/,26522049.0,3
58854,58854,73845,97zhslbd,,Medline,Evidence for immunisation failure in vaccinated adult dogs infected with canine parvovirus type 2c.,,,18437851.0,unk,outbreak canine parvovirus type c cpvc infection vaccinated adult dog reported disease occurred breeding kennel italy affected dog aged month year repeatedly administered vaccine containing type old type cpv strain cpv infection demonstrated diseased dog immunochromatographic test cpv strain isolated intestinal content monthold pregnant bernese mountain bitch underwent fatal outcome strain characterised cpvc mean realtime pcr assay using minor groove binder probe present report provides concern real efficacy type based vaccine antigenic variant cpv stress need developing new vaccine prepared variant currently circulating dog population,2008,"Decaro, Nicola; Desario, Costantina; Elia, Gabriella; Martella, Vito; Mari, Viviana; Lavazza, Antonio; Nardi, Manuela; Buonavoglia, Canio",The new microbiologica,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18437851/,18611629.0,3
58928,58928,73932,r5tbb1wc,,Medline,"Immunoprophylaxis against important virus disease of horses, farm animals and birds.",,,19402200.0,unk,since refinement tissue culture technique virus isolation propagation mid onwards veterinary virology received much academic industrial interest become major global industry largely centred vaccine development economically important virus disease food animal biotech approach widely used improved vaccine development many viral disease controlled vaccination many still lack safe efficacious vaccine additional challenge faced academia industry government likely come virus jumping specie also emergence virulent variant established virus due natural mutation also viral ecology changing respective vector adapt new habitat shown recent incursion bluetongue virus europe paper current vaccine livestock horse bird described specie specie order new promising biotech approach using reverse genetics nonreplicating viral vector alpha virus vector genetic vaccine conjunction better adjuvant better way vaccine delivery discussed well,2009,"Patel, J R; Heldens, J G M",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19402200/,19323377.0,3
59124,59124,74169,g63x6ncu,,Medline,Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5- and 35-based vectors.,,,16361426.0,unk,adenovirus serotype ad promising vaccine platform human immunodeficiency virus hiv infection emerging infectious disease uncommon human worldwide distinct ad major vaccine serotype many individual preexisting immunity immunogenicity firstgeneration replicationcompetent adbased vaccine tested simian immunodeficiency virus siv rhesus macaque model evaluating capacity boost immunity generated adbased vector series four immunization replicationdefective ad vector expressing sivmac gag induced highfrequency response mediated cd cd cell directed several epitope adspecific neutralizing antibody response neutralize ad rapidly induced waned time subsequent immunization adbased vector minimally effective whereas immunization adbased vector generated strong increase frequency gagspecific cell specificity unchanged boosting response relatively transient challenge distinct pathogenic isolate sivdeltab generated robust selective recall response gag similar specificity induced vaccination elevated week relative control vaccination measurable albeit minor effect virus load unexpectedly regional hypervariability within gag sequence sivdeltab associated mutation conserved cd tcell epitope cm without concurrent flanking mutation absence immune pressure finding support development ad vaccine vector promote vaccine regimen utilize serial administration heterologous adenovirus,2006,"Barratt-Boyes, Simon M; Soloff, Adam C; Gao, Wentao; Nwanegbo, Edward; Liu, Xiangdong; Rajakumar, Premeela A; Brown, Kevin N; Robbins, Paul D; Murphey-Corb, Michael; Day, Richard D; Gambotto, Andrea",The Journal of general virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16361426/,36458032.0,3
59189,59189,74246,r8i4bfgt,,Medline,Epitope mapping: the first step in developing epitope-based vaccines.,,,17516710.0,unk,antibody effective line defense preventing infectious disease highly potent neutralizing antibody intercept virus attache target cell thus inactivate ability based antibody specific recognition epitope site antigen antibody bind thus understanding antibodyepitope interaction provides basis rational design preventive vaccine assumed immunization precise epitope corresponding effective neutralizing antibody would elicit generation similarly potent antibody vaccinee vaccine would bcell epitopebased vaccine implementation requires ability backtrack desired antibody corresponding epitope article discus range method enable epitope discovery based specific antibody reversed immunological approach first step rational design epitopebased vaccine undoubtedly gold standard epitope definition xray analysis crystal antigenantibody complex method provides atomic resolution epitope however readily applicable many antigen antibody requires high degree sophistication expertise method rely ability monitor binding antibody antigen fragment mutated variation mutagenesis antigen loss binding due point modification amino acid residue often considered indication epitope component addition computational combinatorial method epitope mapping also useful method rely ability antibody interest affinity isolate specific short peptide combinatorial phage display peptide library peptide regarded lead definition epitope corresponding antibody used screen peptide library epitope mapping computational algorithm developed mapitope recently found effective mapping conformational discontinuous epitope pro con various approach towards epitope mapping also discussed,2007,"Gershoni, Jonathan M; Roitburd-Berman, Anna; Siman-Tov, Dror D; Tarnovitski Freund, Natalia; Weiss, Yael","BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy",,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17516710/,29506607.0,3
59322,59322,74404,pmtjm6nt,,Medline,Developing a vaccine for human rhinoviruses.,,,25593706.0,unk,rhinovirus rv common human pathogen respiratory tract frequent cause mild disease upper respiratory tract common cold importantly major initiator acute exacerbation chronic airway disease infection life threatening latter context however rv induced common cold associated economic cost loss productivity due absence work school appropriate antiviral therapy available vaccine strategy failed large number viral serotypes lack crossserotype protection generated approach past present development vaccine widespread human pathogen highlighted,2014,"McLean, Gary R",Journal of vaccines & immunization,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/25593706/,19014629.0,3
59381,59381,74473,x9rbjpx0,,Medline,Alpha-beta T cells provide protection against lethal encephalitis in the murine model of VEEV infection.,,,17610927.0,unk,evaluated safety immunogenicity chimeric alphavirus vaccine candidate mouse selective immunodeficiency vaccine candidate highly attenuated mouse deficiency b cell compartment well mouse deficient gammainterferon responsiveness however level protection varied among strain tested wild type mouse protected lethal veev challenge contrast alphabeta alphabeta tcrdeficient mouse developed lethal encephalitis following veev challenge mouse deficient gammadelta gammadelta cell protected surprisingly vaccine potency diminished animal lacking interferongamma receptor alpha chain rchain minority vaccinated immunoglobulin heavy chaindeficient micromt mouse survived challenge suggests neutralizing antibody may absolutely required protection prolonged replication encephalitic veev brain preimmunized mouse lethal adoptive transfer experiment indicate cd cell required protection,2007,"Paessler, Slobodan; Yun, Nadezhda E; Judy, Barbara M; Dziuba, Natallia; Zacks, Michele A; Grund, Anna H; Frolov, Ilya; Campbell, Gerald A; Weaver, Scott C; Estes, D Mark",Virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17610927/,13238238.0,3
59400,59400,74494,jcq4hdrh,,Medline,"Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts.",,,16569728.0,unk,vaccine research center developed number vaccine candidate different diseasesinfectious agent hiv severe acute respiratory syndrome virus west nile virus ebola virus plus plasmid cytokine adjuvantilig based dna plasmid vaccine platform support clinical development vaccine candidate preclinical study performed screen potential toxicity intrinsic immunotoxicities treatmentrelated toxicity identified repeateddose toxicology study confined primarily site injection seem result delivery method seen control treated animal intended immune response vaccine occur greater frequency severity treated animal reactogenicity site injection generally seen reversible frequency severity diminished dos immediate recovery termination time point observation also correlated biodistribution data reported companion article sheet et al dna plasmid vaccine shown remain site injection rather biodistributing widely clear time result safety study submitted food drug administration support safety initiating clinical study related dna plasmid vaccine thus far standard repeateddose toxicology study identified target organ toxicity injection site dna plasmid vaccine dos mg per immunization regardless disease indication ie expressed geneinsert despite difference strength promoter used drive expression clinical data accumulate product possible retrospectively compare safety profile product clinic result repeateddose toxicology study order determine utility toxicology study signaling potential immunotoxicities intrinsic toxicity dna vaccine data build biodistribution study performed see companion article sheet et al demonstrate safety suitability investigational human use dna plasmid vaccine candidate variety infectious disease prevention indication,2006,"Sheets, Rebecca L; Stein, Judith; Manetz, T Scott; Andrews, Charla; Bailer, Robert; Rathmann, John; Gomez, Phillip L",Toxicological sciences : an official journal of the Society of Toxicology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16569728/,2547187.0,3
59479,59479,74584,8ce1qutz,,Medline,Protection of swine by live and inactivated vaccines prepared from a leader proteinase-deficient serotype A12 foot-and-mouth disease virus.,,,9711798.0,unk,previously demonstrated genetically engineered variant footandmouth disease virus fmdv serotype lacking leader proteinasecoding region allv attenuated induced immune response partially protected cattle fmd study allv tested swine live chemically inactivated vaccine animal vaccinated chemically inactivated allv wildtype wt virus oil adjuvant developed high level neutralizing antibody protected fmd upon challenge animal vaccinated live allv exhibit sign fmd spread virus animal developed neutralizing antibody response antibody nonstructural protein partially protected fmd animal given similar dose chemically inactivated allv absence adjuvant developed poor immune response protected fmd indicating limited replication responsible improved immune response found animal vaccinated live allv result demonstrate potential allv liveattenuated vaccine well safe source antigen chemically inactivated vaccine,1998,"Chinsangaram, J; Mason, P W; Grubman, M J",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/9711798/,25050998.0,3
59572,59572,74683,kexywqjs,,Medline,Intragastric administration of Lactobacillus casei expressing transmissible gastroentritis coronavirus spike glycoprotein induced specific antibody production.,,,15661381.0,unk,lactobacillus casei strain shirota selected bacterial carrier development live mucosal vaccine coronavirus kda fragment transmissible gastroenteritis coronavirus tgev spike glycoprotein used model coronavirus antigen glycoprotein cloned lactobacilluse coli shuttle vector plp expression secretion glycoprotein recombinant lactobacillus detected via immunoblotting oral immunization balbc mouse recombinant lcs constitutively express kda fragment glycoprotein induced local mucosal systemic immune response tgev maximum titer igg ngml serum iga ngml intestinal water attained day post oral inturbation induced antibody demonstrated neutralizing effect tgev infection,2005,"Ho, P S; Kwang, J; Lee, Y K",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15661381/,1721212.0,3
59631,59631,74752,dv8afzj5,,Medline,Animal vaccination and the veterinary pharmaceutical industry.,,,17892167.0,unk,market veterinary vaccine spread across specie limited size development vaccine becoming complex expensive vaccine amongst effective mean preventing disease animal human many case disease eradicated impact animal health welfare greatly reduced ethical responsibility ensure availability wide range vaccine even market need financially supported case le common animal specie le common condition commonly referred acronym mum minor use minor specie mass slaughter becoming unacceptable society must move vaccinate live policy wherever possible need use vaccine avoid high cost disease enhance food safety developing vaccine need minimise animal testing addition need ensure public acceptthe use vaccine foodproducing animal mean protecting health welfare animal look future vaccine vital ensure ability provide food growing global population european technology platform global animal health key role play identifying key research priority,2007,"O'Brien, D; Zanker, S",Revue scientifique et technique,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17892167/,24028982.0,3
59650,59650,74775,rxt3fkud,,Medline,Identification of SARS-COV spike protein-derived and HLA-A2-restricted human CTL epitopes by using a new muramyl dipeptidederivative adjuvant.,,,20378004.0,unk,severe acute respiratory syndrome sars spread winter attempt made develop vaccine sars corona virus sarscov present study provides strategy rapidly identify sarscovderived antigenic peptide recognized hlaarestricted cytotoxic lymphocyte ctls fortythree candidate peptide hlaabinding motif selected silico hlaadb chimeric mhc class itransgenic mouse immunized peptide new derivative muramyl dipeptide induce upregulation hladr cd cd cd human cd antigen presenting cell administered adjuvant six hlaarestricted mouse ctl epitope identified including two new epitope never reported one novel peptide naturally processed successfully induced hlaarestricted specific ctls hla transgenic mouse healthy donor method useful convenient efficient rapid identification ctl epitope derived sarscov protein possibly applicable pathogen develop peptidebased vaccine,2010,"Chen, Y-Z; Liu, G; Senju, S; Wang, Q; Irie, A; Haruta, M; Matsui, M; Yasui, F; Kohara, M; Nishimura, Y",International journal of immunopathology and pharmacology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/20378004/,41549049.0,3
59662,59662,74788,6dmswy8t,,Medline,A peptide vaccine based on a B-cell epitope on the VP1 protein of enterovirus 70 induces a strong antibody response.,,,23237090.0,unk,enterovirus ev causative agent acute hemorrhagic conjunctivitis ahc effective vaccine available study revealed high reactivity nterminal region ev vp vp antiev mouse serum analysis overlapping synthetic peptide vp identified bcell epitope region epeptide antveseikaelgvi showing highest reactivity antiev serum induced neutralizing antibody mouse reduced virus titer eye suggesting candidate vaccine ahc caused ev,2012,"Park, Kee-Bum; Lim, Byung-Kwan; Ye, Michael B; Chung, Soo-Young; Nam, Jae-Hwan",Acta virologica,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/23237090/,32329971.0,3
59673,59673,74801,c80973zd,,Medline,Preparing for pandemic vaccination: an international policy agenda for vaccine development.,,,15906873.0,unk,international use influenza vaccine growing especially developing country since avian hn influenza southeast asia caused several human infection high mortality expert warn next influenza pandemic imminent could severe prevention control depend rapid production worldwide distribution specific pandemic vaccine vaccine supply sufficient meet global demand issue related intellectual property right reverse genetics technology essential vaccine production must resolved addition candidate pandemiclike vaccine must developed tested clinical trial determine antigen sparing formulation best vaccination schedule study must involve vaccine company require international coordination public funding whether international policy agenda pandemic vaccine development succeed uncertain provide good indication whether good governance global public health achieved,2005,"Fedson, David S",Journal of public health policy,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15906873/,43025568.0,3
59719,59719,74854,8hon8anb,,Medline,Cross-protective immune responses elicited by a Korean variant of infectious bronchitis virus.,,,24283135.0,unk,infectious bronchitis virus ibv infection cause great economic loss poultry industry worldwide ibvs continuously evolve developing mutation antigenic site therefore ibv vaccine provides broad crossprotection highly relevant practical method ibv control strategy although ibv vaccine strain known provide protection multiple ibv serotypes general commercially available ibv vaccine strain provide protection antigenically related virus distinct heterologous virus present study characterized korean variant ibv k strain regard immunogenicity protective efficacy seven currently circulating ibv serotypes threeweekold specificpathogenfree chicken intraocularly immunized ibv k strain egg infective dose eid three week immunization bird challenged seven different strain eid chicken immunized ibv k strain showed significantly high level protection challenge virus trachea kidney level result suggest ibv k could useful ensure ibv vaccine effectiveness owing crossprotective ability therefore ibv k strain merit consideration vaccine candidate prevent infection well spread new ibv strain many ibv variant reported worldwide,2013,"Kim, Byoung-Yoon; Lee, Dong-Hun; Jang, Jun-Hyuk; Lim, Tae-Hyun; Choi, Soo-Won; Youn, Ha-Na; Park, Jae-Keun; Lee, Joong-Bok; Park, Seung-Yong; Choi, In-Soo; Song, Chang-Seon",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24283135/,10886359.0,3
59727,59727,74863,7jp56m5c,,Medline,Why aging T cells fail: implications for vaccination.,,,16782020.0,unk,decline cd cell function aging contributes reduced vaccine efficacy commentary discus factor leading agerelated change cell function propose may overcome enhance vaccine efficacy elderly,2006,"Haynes, Laura; Swain, Susan L",Immunity,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16782020/,43769737.0,3
59835,59835,74994,r3agptux,,Medline,Vaccines for viral and parasitic diseases produced with baculovirus vectors.,,,16997013.0,unk,baculovirusinsect cell expression system approved system production viral antigen vaccine potential human animal used production subunit vaccine parasitic disease well many candidate subunit vaccine expressed system immunization commonly led protective immunity pathogen challenge first vaccine produced insect cell animal use market chapter deal tailoring baculovirusinsect cell expression system vaccine production term expression level integrity immunogenicity recombinant protein baculovirus genome stability various expression strategy discussed including chimeric viruslike particle baculovirus display foreign antigen budded virion occlusion body specialized baculovirus vector mammalian promoter express antigen immunized individual historical overview show wide variety viral glycoprotein successfully expressed system vaccine purpose potential expression system antiparasite vaccine illustrated combination subunit vaccine marker test based antigen expressed insect cell provides powerful tool combat disease monitor infectious agent,2006,"van Oers, Monique M",Advances in virus research,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16997013/,6365299.0,3
59886,59886,75059,46env8w6,,Medline,Evaluation of the protection conferred by commercial vaccines and attenuated heterologous isolates in China against the CK/CH/LDL/97I strain of infectious bronchitis coronavirus.,,,17936045.0,unk,avian infectious bronchitis virus ibv cause tremendous economic loss poultry industry worldwide different serotypes virus show little crossprotection present study investigated genotypic relationship ckchldlitype strain reference ibvs based gene comparison protection provided vaccination commercial vaccine attenuated homologous heterologous strain phylogenetic analysis comparison showed ckchldlitype virus might new serotype compared vaccine strain type ibv isolates china protection efficacy evaluated morbidity mortality virus reisolation challenged chick complete protection ibv vaccination provided homologous strain sufficient respiratory protection provided commercial vaccine heterologous strain ckchldli challenge development vaccine ckchldlitype ibv necessary control infectious bronchitis disease poultry development attenuated ckchldli strain may provide valuable contribution towards goal,2009,"Liu, Shengwang; Zhang, Xiaonan; Wang, Yu; Li, Chengren; Liu, Qiaoran; Han, Zongxi; Zhang, Qinxia; Kong, Xiangang; Tong, Guangzhi",Veterinary journal,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17936045/,21332591.0,3
60015,60015,75209,zzzt200e,,Medline,Induction of mucosal immune responses and protection against enteric viruses: rotavirus infection of gnotobiotic pigs as a model.,,,12072229.0,unk,enteric virus major cause diarrhea animal human among rotavirus one important cause diarrhea young animal human infant lack understanding mechanism induce intestinal immunity correlate protective immunity neonate impaired development safe effective vaccine enteric virus study candidate vaccine using adult mouse model subclinical enteric viral infection often predict vaccine efficacy disease evaluated neonatal large animal series study conducted using neonatal gnotobiotic pig model rotavirus infection diarrhea identify correlate protective immunity evaluate traditional novel vaccine approach induction mucosal immune response protection enteric virus gnotobiotic pig recovered infection virulent wa human rotavirus hrv mimic natural infection high number intestinal iga rotavirusspecific primary antibodysecreting cell ascs memory bcells recall antigen measured elispot assay correlated complete protection rotavirus challenge shortterm iga memory bcells resident ileum major site rotavirus replication spleen bone marrow major resident site longerterm igg memory bcells candidate rotavirus vaccine evaluated pig ability induce intestinal systemic asc protection rotavirus infection diarrhea included attenuated live virus inactivated virus baculovirusexpressed doublelayered rotaviruslike particle vlps combination candidate vaccine various adjuvant delivery system immunization route tested including incomplete freunds adjuvant im immunization mutant escherichia coli heat labile enterotoxin rg mlt immunization shown orally administered replicating vaccine effective priming intestinal iga asc memory bcell response administered nonreplicating vlps plus mlt effective booster vaccine conclude protective immunity depends magnitude location viral proteinspecificity isotype antibody response induced vaccination therefore highly effective enteric viral vaccine induce sufficient level intestinal iga antibody ii include viral antigen induce neutralizing antibody iii require use effective mucosal adjuvant antigen delivery system nonreplicating oral vaccine,2002,"Yuan, Lijuan; Saif, Linda J",Veterinary immunology and immunopathology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12072229/,25715489.0,3
60026,60026,75221,4soge0nd,,Medline,[Current Status of Middle East Respiratory Syndrome Vaccines].,,,30004658.0,unk,middle east respiratory syndrome kind respiratory disease caused middle east respiratory syndrome coronavirus disease spread country around world people infected people killed four country reported case camel infection mers prevention disease important measure research development related vaccine order resource development safe effective vaccine article summarizes current candidate vaccine mers research progress prevention treatment disease could trigger global public health security problem ahead,2016,"Fan, Yi; Jiang, Zhiyi; Li, Ping; Den, Yicao; Huang, Jianbo; Zhu, Ling; Xu, Zhiwen",Bing du xue bao = Chinese journal of virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/30004658/,51625928.0,3
60111,60111,75319,0vjrewb6,,Medline,Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus.,,,15078946.0,unk,severe acute respiratory syndrome sars serious threat public health economy global scale sars coronavirus sarscov identified etiological agent sars thus vaccination sarscov may represent effective approach controlling sars dna vaccine attractive approach sars vaccine development offer many advantage conventional vaccine including stability simplicity safety investigator previously shown dna vaccination antigen linked calreticulin crt dramatically enhances major histocompatibility complex class presentation linked antigen cd cell study employed crtbased enhancement strategy create effective dna vaccine using sarscov nucleocapsid n protein target antigen vaccination naked crtn dna generated potent nspecific humoral tcellmediated immune response vaccinated cbl mouse among dna construct tested furthermore mouse vaccinated crtn dna capable significantly reducing titer challenging vaccinia virus expressing n protein sars virus result show dna vaccine encoding crt linked sarscov antigen capable generating strong nspecific humoral cellular immunity may potentially useful control infection sarscov,2004,"Kim, Tae Woo; Lee, Jin Hyup; Hung, Chien-Fu; Peng, Shiwen; Roden, Richard; Wang, Mei-Cheng; Viscidi, Raphael; Tsai, Ya-Chea; He, Liangmei; Chen, Pei-Jer; Boyd, David A K; Wu, T-C",Journal of virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15078946/,32226658.0,3
60192,60192,75408,d9ij4o06,,Medline,Vaccination of mice with recombinant baculovirus expressing spike or nucleocapsid protein of SARS-like coronavirus generates humoral and cellular immune responses.,,,17905435.0,unk,continuous effort made develop prophylactic vaccine severe acute respiratory syndrome coronavirus sarscov study two recombinant baculoviruses vacn vac constructed contained mammaliancell activate promoter element human elongation factor alphasubunit efalpha human cytomegalovirus cmv immediateearly promoter nucleocapsid n spike gene bat sarslike cov slcov control cmv promoter mouse subcutaneously intraperitoneally injected recombinant baculovirus humoral cellular immune response induced vaccinated group secretion level ifngamma much higher il vacn vac immunized group suggesting strong th bias towards cellular immune response additionally marked increase cd cell immune response high level antisarscov humoral response also detected vacn vac immunized group contrast significantly weaker cellular immune response well le antibody production control group data demonstrates recombinant baculovirus serve effective vaccine strategy addition effective sars vaccine act prevent reemergence sarscov also provide crossprotection slcov finding study may implication developing crossprotective vaccine,2008,"Bai, Bingke; Lu, Xinya; Meng, Jin; Hu, Qinxue; Mao, Panyong; Lu, Baojing; Chen, Ze; Yuan, Zhiming; Wang, Hanzhong",Molecular immunology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17905435/,28722465.0,3
60237,60237,75458,i188s6oi,,Medline,"Prevention of pertussis, tetanus, and diphtheria among pregnant and postpartum women and their infants recommendations of the Advisory Committee on Immunization Practices (ACIP).",,,18509304.0,unk,two tetanus toxoid reduced diphtheria toxoid acellular pertussis tdap vaccine licensed recommended use adult adolescent united state adacel sanofi pasteur swiftwater pennsylvania licensed use person aged year boostrix glaxosmithkline biologicals rixensart belgium licensed use person aged year tdap vaccine licensed singledose use add protection pertussis replace next dose tetanus diphtheria toxoid vaccine td available evidence address safety tdap pregnant woman fetus pregnancy outcome sufficiently available data also indicate whether tdapinduced transplacental maternal antibody provide early protection pertussis infant interfere infant immune response routinely administered pediatric vaccine additional information available cdc advisory committee immunization practice recommends pregnant woman vaccinated previously tdap receive tdap immediate postpartum period discharge hospital birthing center may receive tdap interval short year since recent td vaccine receive td pregnancy tetanus diphtheria protection indicated defer td vaccine indicated pregnancy substitute tdap vaccine immediate postpartum period woman likely sufficient protection tetanus diphtheria although pregnancy contraindication receiving tdap vaccine healthcare provider weigh theoretical risk benefit choosing administer tdap vaccine pregnant woman report describes clinical feature pertussis tetanus diphtheria among pregnant postpartum woman infant review available evidence pertussis vaccination pregnancy strategy prevent infant pertussis summarizes tdap vaccination policy united state present recommendation use td tdap vaccine among pregnant postpartum woman,2008,"Murphy, Trudy V; Slade, Barbara A; Broder, Karen R; Kretsinger, Katrina; Tiwari, Tejpratap; Joyce, Patricia M; Iskander, John K; Brown, Kristin; Moran, John S",MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18509304/,43809441.0,3
60340,60340,75580,7tre38z4,,Medline,SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens.,,,16387339.0,unk,correspondence tcell epitope response vaccine immunogen pathogen antigen critical vaccine efficacy present study analyzed spectrum immune response mouse three different form sars coronavirus nucleocapsid n exogenous recombinant protein ngst freunds adjuvant dna encoding unmodified n endogenous cytoplasmic protein pn dna encoding n lamp chimera targeted lysosomal mhc ii compartment plampn lysosomal trafficking lampn chimera transfected cell documented confocal immunoelectron microscopy response immunized mouse differed markedly strongest tcell ifngamma ctl response lampn chimera followed pn immunogen contrast ngst elicited strong cell il minimal ifngamma response much greater antibody response despite difference however immunodominant tcell elispot response three immunogen elicited n peptide greatest response generated cluster five overlapping peptide n contained nonameric hd binding domain high binding score class except n class ii allele result demonstrate processing presentation n whether exogenously endogenously derived resulted common immunodominant epitope supporting usefulness modified antigen delivery trafficking form particular lamp chimera vaccine candidate nevertheless profile tcell response distinctly different pronounced th humoral response n protein plus adjuvant contrast balanced ifngamma il response strong memory ctl response lampn chimera,2006,"Gupta, Vandana; Tabiin, Tani M; Sun, Kai; Chandrasekaran, Ananth; Anwar, Azlinda; Yang, Kun; Chikhlikar, Priya; Salmon, Jerome; Brusic, Vladimir; Marques, Ernesto T A; Kellathur, Srinivasan N; August, Thomas J",Virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16387339/,23202413.0,3
60395,60395,75643,io4yz3g3,,Medline,Evaluation of the effectiveness of two infectious bronchitis virus vaccine programs for preventing disease caused by a California IBV field isolate.,,,17626488.0,unk,infectious bronchitis virus ca serotype isolated several broiler flock northern california virus caused lateonset respiratory disease increased airsacculitis condemnation affected flock despite use established infectious bronchitis virus vaccination program experimental study compared hollandarkansas massachusettsarkansas vaccination protocol determine efficacy commercial infectious bronchitis virus vaccine reducing respiratory disease airsacculitis lesion found processing associated ca field isolate vaccination group given massachusettsconnecticut strain infectious bronchitis virus vaccine age day followed vaccination either holland arkansas massachusettsarkansas vaccine strain day age bird challenged age day ca field isolate gross pathology histopathology virus isolation evaluated chicken vaccinated hollandarkansas marginally better protection ca challenge chicken vaccinated massachusettsarkansas although difference statistically significant,2007,"Martin, Michael P; Wakenell, P S; Woolcock, P; O'Connor, B",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17626488/,20052427.0,3
60465,60465,75729,fmxdwq4j,,Medline,Evaluation of a prototype sub-unit vaccine against equine arteritis virus comprising the entire ectodomain of the virus large envelope glycoprotein (G(L)): induction of virus-neutralizing antibody and assessment of protection in ponies.,,,11562536.0,unk,escherichia coliexpressed recombinant protein hisglecto comprising entire ectodomain aa equine arteritis virus eav glycoprotein gl immunodominant viral antigen induced higher neutralizing antibody titre glderived polypeptide compared immunization study pony potential recombinant gl ectodomain act subunit vaccine eav evaluated three group four pony vaccinated dos microg protein vaccinated animal developed virusneutralizing antibody vnab response peak titre week administration booster week vnab titre vnab titre vnab titre vaccinated unvaccinated control pony infected eav different time postvaccination obtain information degree protection relative level prechallenge vnab vaccination conferred varying level protection indicated reduced absent pyrexia viraemia virus excretion nasopharynx degree protection correlated well level prechallenge vnab particular level virus excretion result provide first evidence subunit vaccine protects horse eav use subunit vaccine combination differential diagnostic test based eav antigen would enable serological discrimination naturally infected vaccinated equine,2001,"Castillo-Olivares, J; de Vries, A A; Raamsman, M J; Rottier, P J; Lakhani, K; Westcott, D; Tearle, J P; Wood, J L; Mumford, J A; Hannant, D; Davis-Poynter, N J",The Journal of general virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/11562536/,7366424.0,3
60515,60515,75791,q0spblgo,,Medline,Field study of bovine coronavirus vaccine enriched with hemagglutinating antigen for winter dysentery in dairy cows.,,,12418784.0,unk,field study vaccine prepared solubilizing cell infected bovine coronavirus triton x mixing oil adjuvant performed farm prefecture cattle tested holstein dairy cow aged year vaccination group consisted animal including pregnant cow nonvaccinated control group consisted animal cow received intramuscular injection vaccine ml week interval vaccinated cow develop abnormality decrease milk production volume pregnant animal calved normally geometric mean hemagglutination inhibition antibody titer vaccination test cow titer increased week st injection peaked month nd injection high antibody titer persisted month nd injection respectively confirms safety high antibodyresponse induced prototype vaccine therefore vaccine may useful prevention winter dysentery caused bovine coronavirus infection,2002,"Takamura, Keizo; Matsumoto, Yuichi; Shimizu, Yukio",Canadian journal of veterinary research = Revue canadienne de recherche veterinaire,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12418784/,41614212.0,3
60590,60590,75878,rim78ujh,,Medline,Viral diseases of ferrets.,,,15585193.0,unk,distemper rabies vaccination highly recommended almost invariable fatal outcome condition vaccination constitute important part ferret preventative medicine program current anticipated development licensing new vaccine practitioner invited gain awareness latest vaccine information establishment practice vaccination protocol regard site administration rabies distemper vaccine paramount document future abnormal tissue reaction influenza common zoonotic disease seen ferret although generally benign ferret veterinarian must take condition seriously characteristic continuous antigenic variation virus may lead virulent strain recent emergence avian influenza virus outbreak increased susceptibility elderly young immunosuppressed individual,2005,"Langlois, Isabelle",The veterinary clinics of North America. Exotic animal practice,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15585193/,45784403.0,3
60606,60606,75900,9teb24ni,,Medline,Rotavirus typing methods and algorithms.,,,15027000.0,unk,vaccination current strategy control prevention severe rotavirus infection major cause acute dehydrating diarrhoea young child worldwide public health intervention aimed improving water food sanitation unlikely adequately control disease development vaccine severe rotavirus diarrhoea based upon homotypic heterotypic protection provided either single common g serotype monovalent vaccine multiple serotypes multivalent vaccine rotavirus strain surveillance high priority disease control programme worldwide continued identification common g p serotypes inclusion vaccine important priority subsequent introduction vaccine candidate monitoring circulating strain recommended also surveillance potential reassortment animal rotavirus gene vaccine human rotavirus strain critical conventional method used characterisation rotavirus strain enzyme immunoassay serotyping reversetranscription pcrbased genotyping often fail identify uncommon newly appearing strain application newer molecular approach including sequencing oligonucleotide microarray hybridisation may required characterise strain present paper present brief overview variety standard method available followed suggestion systematic approach routine rotavirus strain surveillance well characterisation incompletely typed rotavirus strain improved detection characterisation incompletely typed strain help develop comprehensive strain surveillance may required tailoring effective rotavirus vaccine,2004,"Fischer, Thea K; Gentsch, Jon R",Reviews in medical virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15027000/,24782867.0,3
60658,60658,75960,3enmzfw3,,Medline,Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease.,,,9178474.0,unk,inflammatory change following infection central clinical manifestation disease however information regarding change animal disease limited canine parvovirus infected puppy measured level acute phase protein change leukocyte phenotype cell trafficking flow cytometry parameter correlated conventional assessment clinical disease vaccine efficacy study seropositive cpv weekold puppy given three dos cpv containing vaccine developed significant antibody titer remained healthy experimental infection cpvb unvaccinated control developed clinical sign shed virus importantly acute phase protein became elevated lymphopenia neutropenia modulation neutrophilcd detected control vaccinates,1997,"Yule, T D; Roth, M B; Dreier, K; Johnson, A F; Palmer-Densmore, M; Simmons, K; Fanton, R",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/9178474/,2941719.0,3
60666,60666,75968,kf85auq6,,Medline,Type IVB pilus operon promoter controlling expression of the severe acute respiratory syndrome-associated coronavirus nucleocapsid gene in Salmonella enterica Serovar Typhi elicits full immune response by intranasal vaccination.,,,17596427.0,unk,attenuated salmonella enterica serovar typhi strain considered attractive potential live oral delivery vector vaccine ability elicit full array immune response human study constructed attenuated enterica serovar typhi strain stably expressing conserved nucleocapsid n protein severe acute respiratory syndromeassociated coronavirus sarscov integrating n gene pilv gene control type ivb pilus operon promoter enterica serovar typhi balbc mouse immunized recombinant strain different route intranasally orogastrically intraperitoneally intravenously result showed intranasal route caused highest production specific immunoglobulin g igg igga secretory iga igga imprinted th cell bias moreover recombinant live vaccine induced significantly high level specific cytotoxic tlymphocyte activity increased gamma interferonproducing cell compared parental strain work provides insight type ivb pilus operon promoter controlling sarscov n gene expression salmonella might attractive livevector vaccine srascov infection could induce mucosal humoral cellular immune response work also indicates type ivb pilus operon promoter controlling foreign gene expression salmonella elicit full immune response intranasal vaccination,2007,"Luo, Fengling; Feng, Yong; Liu, Min; Li, Pingfei; Pan, Qin; Jeza, Victor Tunje; Xia, Bing; Wu, Jianguo; Zhang, Xiao-Lian",Clinical and vaccine immunology : CVI,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17596427/,20704791.0,3
60670,60670,75973,qmya3gng,,Medline,"Biodistribution of DNA plasmid vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile virus is similar, without integration, despite differing plasmid backbones or gene inserts.",,,16569729.0,unk,vaccine research center developed number vaccine candidate different diseasesinfectious agent hiv severe acute respiratory syndrome virus west nile virus ebola virus plus plasmid cytokine adjuvantilig based dna plasmid vaccine platform support clinical development vaccine candidate preclinical study performed mouse rabbit determine body plasmid vaccine would biodistribute rapidly would clear course study observed regardless gene insert expressing vaccine immunogen cytokine adjuvant regardless promoter used drive expression gene insert plasmid backbone plasmid vaccine biodistribute widely remain essentially site injection muscle overlying subcutis even though approximately molecule inoculated study rabbit day approximately week postinoculation already order molecule per microgram dna extracted tissue cleared injection site course month plasmid clear site injection small percentage animal generally retaining small number copy generally around copy muscle injection site pattern biodistribution confined injection site clearance within month consistent regardless difference promoter plasmid backbone difference gene insert expressed plasmid vaccine addition integration observed plasmid vaccine candidate inoculated im biojector needle syringe data build repeateddose toxicology study performed see companion article sheet et al demonstrate safety suitability investigational human use dna plasmid vaccine candidate variety infectious disease prevention indication,2006,"Sheets, Rebecca L; Stein, Judith; Manetz, T Scott; Duffy, Chris; Nason, Martha; Andrews, Charla; Kong, Wing-Pui; Nabel, Gary J; Gomez, Phillip L",Toxicological sciences : an official journal of the Society of Toxicology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16569729/,13908804.0,3
60679,60679,75983,1y0htupi,,Medline,Current vaccine adjuvants: an overview of a diverse class.,,,15353330.0,unk,numerous compound evaluation immunological adjuvant improvement vaccine performance review briefly summarize many diverse substance currently utilized vaccine adjuvant preclinical clinical study,2004,"Kensil, Charlotte Read; Mo, Annie Xiaoyan; Truneh, Alemseged",Frontiers in bioscience : a journal and virtual library,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15353330/,20233626.0,3
60773,60773,76089,sq03q8ex,,Medline,Eradicating infectious disease using weakly transmissible vaccines.,,,27798311.0,unk,viral vaccine remarkable positive impact human health well health domestic animal population despite impressive vaccine success however many infectious disease yet efficiently controlled eradicated vaccination often impossible vaccinate sufficient proportion population recent advance molecular biology suggest centuriesold method individualbased vaccine delivery may cusp major revolution specifically genetic engineering brings life possibility live transmissible vaccine unfortunately releasing highly transmissible vaccine pose substantial evolutionary risk including reversion high virulence documented oral polio vaccine alternative far safer approach rely genetically engineered weakly transmissible vaccine reduced scope evolutionary reversion use mathematical model evaluate potential efficacy weakly transmissible vaccine result demonstrate vaccine even modest ability transmit significantly lower incidence infectious disease facilitate eradication effort consequently weakly transmissible vaccine could provide important tool controlling infectious disease wild domestic animal population reducing risk emerging infectious disease human,2016,"Nuismer, Scott L; Althouse, Benjamin M; May, Ryan; Bull, James J; Stromberg, Sean P; Antia, Rustom",Proceedings. Biological sciences,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/27798311/,14876588.0,3
60944,60944,76282,w7agftdl,,Medline,Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters.,,,17076905.0,unk,background one major obstacle design effective vaccine hiv hypervariability hiv envelope glycoprotein hiv vaccine candidate utilized envelope glycoprotein single virus isolate date none elicited broadly reactive humoral immunity herein hypothesised cocktail hiv gp protein containing multiple epitope may increase breadth immune response hiv compared evaluated immunogenicity hiv vaccine containing either gp protein alone combination four fourteen gps different primary hiv isolates immunized hamster result amplified characterized different gps primary subtype b isolates syncytium nonsyncytium inducing property expressed protein chinese hamster ovary cho cell line purified protein used either alone combination four fourteen different gps vaccinate golden hamster polyvalent vaccine showed higher antibody titer hiv subtype b isolates mn sf compared group received one four gp protein however polyvalent vaccine able show higher neutralizing antibody response hiv primary isolates interestingly polyvalent vaccine group highest proliferative immune response showed substantial proportion crosssubtype cd reactivity hiv subtypes b c ae conclusion although polyvalent approach achieved modest increase breadth humoral cellular immunity qualitative change vaccine v gp resulted quantitative improvement vaccineinduced immunity,2006,"Azizi, Ali; Anderson, David E; Ghorbani, Masoud; Gee, Katrina; Diaz-Mitoma, Francisco",BMC immunology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17076905/,13638232.0,3
60965,60965,76312,xcvzgyud,,Medline,Recent advances in the discovery and delivery of vaccine adjuvants.,,,12951579.0,unk,adjuvant design historically touch alchemy heart due reliance complex biology innate immune activation however new mechanistic understanding innate immunity combined new adjuvant delivery platform exploiting knowledge led significant advance recently although many challenge remain field moving rapidly proper tool methodology place use traditional drug discovery engine guiding development vaccine adjuvant review outline current trend immune potentiator delivery system adjuvant design shape vaccine future,2003,"O'Hagan, Derek T; Valiante, Nicholas M",Nature reviews. Drug discovery,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12951579/,7753366.0,3
61060,61060,76427,mfsvfnj7,,Medline,Measles control and the prospect of eradication.,,,19203110.0,unk,remarkable progress made reducing measles incidence mortality consequence implementing measles mortality reduction strategy world health organization united nation childrens fund unicef revised global measles mortality reduction goal set forth whounicef global immunization vision strategy reduce measles death compared estimated death possibility measles eradication discussed almost year measles meet many criterion eradication global measles eradication face number challenge achieving sustaining high level vaccine coverage population immunity including population growth demographic change conflict political instability public perception vaccine safety achieve measles mortality reduction goal continued progress need made delivering measles vaccine world child,2009,"Moss, W J",Current topics in microbiology and immunology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19203110/,31760967.0,3
61178,61178,76568,zgp780o2,,Medline,Safety and efficacy of an infectious bronchitis virus used for chicken embryo vaccination.,,,16860445.0,unk,commercial vaccine ovo vaccination yet developed infectious bronchitis virus ibv major coronavirus poultry industry recombinant ibvs based beaudette strain expressing beaudette spike protein beaur virulent strain beaurms assessed potential prototype vaccine application dayold embryo pathogenicity assessed observing effect hatchability andor production nasal discharge andor effect ciliary activity trachea various time point post hatch contrast commercial ibv vaccine given ovo beaur beaurms strain reduce hatchability cause nasal discharge caused minimal damage ciliated epithelium trachea presence spike protein virulent virus increase pathogenicity virus according criterion used assessment beaurms strain efficacy showed protected chick challenge virulent ib virus dose dependent manner egg passage beaurms strain beaurms ep increase pathogenicity though improve efficacy based serology protection virulent challenge beaurms ep efficacious beaurms protecting bird virulent challenge providing better serological antibody response beaurms ep induced serological response similar commercial vaccine given dayold though commercial vaccine provided slightly higher efficacy result promising development embryo safe efficacious ibv vaccine ovo application,2006,"Tarpey, I; Orbell, S J; Britton, P; Casais, R; Hodgson, T; Lin, F; Hogan, E; Cavanagh, D",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16860445/,21080220.0,3
61236,61236,76640,ssw85ga8,,Medline,[SARS vaccines].,,,18939499.0,unk,severe acute respiratory syndrome sars emerging disease derived wild animal highly pathogenic high mortality novel coronavirus sars coronavirus identified causative agent sars since discovery many trial executed establish prophylactic therapeutic toward sars using laboratory animal number different type vaccine inactivated virus vaccine subunit vaccine dna vaccine vaccine using viral expression vector well attenuated live vaccine far reported indicate neutralizing antibody play important role protection however vaccine applicable human high efficacy safety yet reported,2008,"Taguchi, Fumihiro",Nihon rinsho. Japanese journal of clinical medicine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18939499/,33950449.0,3
61241,61241,76645,12v60rsq,,Medline,Mice protected by oral immunization with Lactobacillus reuteri secreting fusion protein of Escherichia coli enterotoxin subunit protein.,,,17651125.0,unk,green fluorescent protein gfp gene ligated lactobacillus reuterispecific nisininducible expressionsecretion vector pnies generating pniesgfp vector capable secreting cloned gene gfpfusion protein fluorescent activity develop system live vehicle carrying heatstable enterotoxin st heatlabile enterotoxin b ltb enterotoxigenic escherichia coli etec recombinant stltb dna fragment cloned pniesgfp resulting l reuteripniesgfpstltb system found posse capability adhering mouse gut secreting gfpstltb product pgcell induced noninduced condition respectively analysis gfpstltb product confirmed gangliosidebinding ability ltb antigenicity relative freedom stassociated toxicity making suitable use oral vaccine mouse oral inoculation l reuteripniesgfpstltb culture mouse elicited significant p serum igg mucosal iga antibody stltb antigen immunized mouse subsequently challenged etec showed full protection fluid influx response gut first report using l reuteri vaccine carrier induce complete immunologic protection etec,2007,"Wu, Chi-Ming; Chung, Tung-Ching",FEMS immunology and medical microbiology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17651125/,116863.0,3
61305,61305,76715,vtl38e2c,,Medline,Current status of veterinary vaccines.,,,17630337.0,unk,major goal veterinary vaccine improve health welfare companion animal increase production livestock costeffective manner prevent animaltohuman transmission domestic animal wildlife diverse aim led different approach development veterinary vaccine crude effective wholepathogen preparation molecularly defined subunit vaccine genetically engineered organism chimera vectored antigen formulation naked dna injection final successful outcome vaccine research development generation product available marketplace used field achieve desired outcome detailed review successful veterinary vaccine produced viral bacterial protozoal multicellular pathogen many way led field application adaptation novel technology veterinary vaccine continue major impact animal health production also human health increasing safe food supply preventing animaltohuman transmission infectious disease continued interaction animal human researcher health professional major importance adapting new technology providing animal model disease confronting new emerging infectious disease,2007,"Meeusen, Els N T; Walker, John; Peters, Andrew; Pastoret, Paul-Pierre; Jungersen, Gregers",Clinical microbiology reviews,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17630337/,14703587.0,3
61365,61365,76786,bgg3d6n6,,Medline,Malaria vaccines: high-throughput tools for antigens discovery with potential for their development.,,,24892459.0,unk,malaria disease induced parasite plasmodium genus transmitted anopheles mosquito represents great socioeconomic burden worldwide plasmodium vivax second specie malaria worldwide prevalent latin america region planet currently considered vaccine represent costeffective strategy controlling transmissible disease could complement malaria control measure however chemical immunological complexity parasite hindered development effective vaccine recent availability several genome plasmodium specie well bioinformatic tool allowing selection large number protein analysis immune potential herein review recently developed strategy discovery novel antigen potential malaria vaccine development,2013,"Céspedes, Nora; Vallejo, Andrés; Arévalo-Herrera, Myriam; Herrera, Sócrates",Colombia medica,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24892459/,16790652.0,3
61479,61479,76920,qtzdv837,,Medline,Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus.,,,17581748.0,unk,severe acute respiratory syndrome sars caused novel coronavirus cov sarscov previous study showed sarscov spike glycoproteinbased modified vaccinia ankara mvas vaccine could induce strong neutralizing antibody nab response might played critical role protecting chinese rhesus monkey pathogenic viral challenge date however remains unknown minimal level nab required achieve sterile immunity human therefore important explore technique maximize level nab response vivo evaluate various vaccination regimen using combination dna mvas adenovirus type ad vaccine show vaccinated mouse rabbit heterologous mvas prime ad boost regimen induces highest persistent level nab response compared combination interestingly initial level nab prime necessarily predict magnitude secondary response boost thus data provides promising optimal regimen vaccine development human sarscov infection,2007,"Ba, Lei; Yi, Christopher E; Zhang, Linqi; Ho, David D; Chen, Zhiwei",Applied microbiology and biotechnology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17581748/,1563693.0,3
61518,61518,76966,usidtza9,,Medline,Serologic response of captive coyotes (Canis latrans Say) to canine parvovirus and accompanying profiles of canine coronavirus titers.,,,6325726.0,unk,fiftyfive coyote pup bitch vaccinated canine parvovirus cpv seropositive cpv antibody birth cpv antibody titer pup declined halflife day th week two pup seropositive cpv antibody wk pup vaccinated cpv killed feline origin vaccine one positive cpv antibody wk wkold pup either young respond cpv vaccine sufficient undetectable maternallyderived cpv antibody block active immunization wk sufficient time immunological response pup vaccine poorly antigenic twenty pup seropositive canine coronavirus ccv antibody birth three whelped bitch also seropositive ccv antibody vaccination female prior whelping appeared provide protection pup cpvinduced mortality,1984,"Green, J S; Bruss, M L; Evermann, J F; Bergstrom, P K",Journal of wildlife diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/6325726/,8473609.0,3
61545,61545,76996,atmprxpq,,Medline,The rational design of vaccines.,,,16257375.0,unk,review provides insight various opportunity vaccine intervention analysis strategy vaccine development vaccine ability modulate immune response resultant rational vaccine design addition wider aspect considered biotechnological advance advance immunological understanding hostpathogen interaction key question addressed research understanding reached new echelon vaccine development rational design,2005,"Bramwell, Vincent W; Perrie, Yvonne",Drug discovery today,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16257375/,45048133.0,3
61643,61643,77102,woejw7m0,,Medline,Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein.,,,31024747.0,unk,middle east respiratory syndrome coronavirus merscov identified first middle east respiratory syndrome mers outbreak merscov cause acute lowerrespiratory infection human fatality rate currently registered vaccine mean therapeutic protection mers world merscov glycoprotein play important role viral life cycle virus internalization protein immunodominant antigen main target neutralizing antibody present study immunogenicity five different form merscov glycoprotein compared fulllength glycoprotein fulllength glycoprotein transmembrane domain g glycoprotein vsv sg receptorbinding domain rbd glycoprotein membranefused rbd rbd fused transmembrane domain vsv g glycoprotein rbdg rbd fused fc human igg rbdfc recombinant vector based human adenovirus type rad used delivery vehicle vaccination developed rad vector elicited balanced thth response mouse robust humoral immune response induced animal vaccinated membranefused rbd radrbdg immunization membrane form glycoprotein rad radsg radrbdg elicited neutralizing antibody among vaccinated animal significant cellular immune response induced vaccination animal fulllength rad investigation suggest fulllength membrane form rbd rbdg promising vaccine candidate among studied form glycoprotein,2019,"Ozharovskaia, T A; Zubkova, O V; Dolzhikova, I V; Gromova, A S; Grousova, D M; Tukhvatulin, A I; Popova, O; Shcheblyakov, D V; Scherbinin, D N; Dzharullaeva, A S; Erokhova, A S; Shmarov, M M; Loginova, S Y; Borisevich, S V; Naroditsky, B S; Logunov, D Y; Gintsburg, A L",Acta naturae,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/31024747/,131773704.0,3
61659,61659,77120,tlt2junj,,Medline,Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen.,,,16919703.0,unk,recent study established feasibility subunitbased experimental vaccine protect animal lethal poxvirus infection individual outer membrane protein intracellular extracellular virion vaccinia virus delivered form either dna vaccine recombinant protein vaccine produced baculovirusinfected insect cell able protect mouse vaccinia virus challenge rhesus macaque monkeypox virus challenge polyvalent formulation various combination four poxvirus antigen l b achieved better protection monovalent formulation using one antigen however clear whether remaining outer membrane poxvirus protein improve efficacy current polyvalent formulation study conducted detailed analysis immunogenicity previously reported protective antigen intracellular mature virion result indicated induced strong protective antibody response effective improving efficacy previously reported polyvalent poxvirus vaccine formulation therefore excellent candidate antigen included final polyvalent subunitbased poxvirus vaccine,2006,"Sakhatskyy, Pavlo; Wang, Shixia; Chou, Te-Hui W; Lu, Shan",Virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16919703/,37009243.0,3
61704,61704,77175,1o1bspqv,,Medline,Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain.,,,15837220.0,unk,immunogenicity candidateinactivated vaccine prepared sarscov f strain evaluated balbc mouse potent humoral immune response induced elicitation three time immunization week interval vaccine combined three type adjuvant freunds adjuvant aloh adjuvant cpg adjuvant titer specific igg antibody three test group peaked sixth week first vaccination significant difference existed kinetics specific igg antibody level strong neutralizing capacity exhibited microcytopathic effect neutralization test indicated specific antibody protective western blot assay demonstrated specificity induced serum antibody,2005,"Zhang, Chuan-hai; Lu, Jia-hai; Wang, Yi-fei; Zheng, Huan-ying; Xiong, Sheng; Zhang, Mei-ying; Liu, Xin-jian; Li, Jiu-xiang; Wan, Zhuo-yue; Yan, Xin-ge; Qi, Shu-Yuan; Cui, Zhiyong; Zhang, Biliang",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15837220/,25905505.0,3
61807,61807,77295,vfukcjge,,Medline,A retrospective study on adverse reactions to canine vaccines in Japan.,,,12399614.0,unk,adverse reaction vaccine examined canine case reported ministry agriculture forestry fishery japan period year april march classified according clinical symptom case adverse reaction rabies virus vaccine gastrointestinal symptom frequently observed followed respiratory andor cardiovascular symptom dermatologic symptom case adverse reaction nonrabies monovalent vaccine mixed vaccine dermatologic symptom frequently observed followed gastrointestinal symptom respiratory andor cardiovascular symptom total case died adverse reaction vaccine,2002,"Ohmori, Keitaro; Masuda, Kenichi; Sakaguchi, Masahiro; Kaburagi, Yukiko; Ohno, Koichi; Tsujimoto, Hajime",The Journal of veterinary medical science,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12399614/,19783696.0,3
61809,61809,77297,fy7dbcua,,Medline,Adenoviral vector-based strategies against infectious disease and cancer.,,,27105067.0,unk,adenoviral vector widely employed infectious disease cancer elicit specific antibody response cell response armed foreign gene vaccine carrier induce apoptosis cancer cell genetically modified cancer therapy review summarize biological characteristic adenovirus ad latest development ad vectorbased strategy prevention control emerging infectious disease cancer strategy circumvent preexisting neutralizing antibody dampen immunogenicity adbased vaccine also discussed,2016,"Zhang, Chao; Zhou, Dongming",Human vaccines & immunotherapeutics,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/27105067/,17905096.0,3
61867,61867,77358,aadobu1m,,Medline,Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?,,,15560976.0,unk,safetytested modified vaccinia virus ankara mva established potent vector system development candidate recombinant vaccine versatility vector system recently demonstrated rapid production experimental mva vaccine immunization severe acute respiratory syndrome associated coronavirus promising result also obtained delivery epsteinbarr virus human cytomegalovirus antigen clinical testing mva vector vaccination immunodeficiency virus papilloma virus plasmodium falciparum melanoma moreover mva considered prime candidate vaccine safer protection orthopoxvirus infection thus vector development challenge dilemma vaccinology immunization poxvirus biothreat seems possible yet right choice made beneficial use,2004,"Drexler, Ingo; Staib, Caroline; Sutter, Gerd",Current opinion in biotechnology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15560976/,24355967.0,3
61901,61901,77403,yn9jm512,,Medline,Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs.,,,16683867.0,unk,background ebola virus cause hemorrhagic fever syndrome associated high mortality human absence effective therapy ebola virus infection development vaccine becomes important strategy contain outbreak immunization dna andor replicationdefective adenoviral vector rad encoding ebola glycoprotein gp nucleoprotein np previously shown confer specific protective immunity nonhuman primate gp exert cytopathic effect transfected cell vitro multiple gp form identified nature raising question would optimal human vaccine method finding address question explored efficacy mutant gps multiple ebola virus strain reduced vitro cytopathicity analyzed protective effect primate challenge model without np deletion gp transmembrane domain eliminated vitro cytopathicity reduced protective efficacy least one order magnitude contrast point mutation identified abolished cytopathicity retained immunogenicity conferred immune protection absence np minimal effective rad dose established particle two log lower used previously conclusion expression specific gps alone vectored rad sufficient confer protection lethal challenge relevant nonhuman primate model elimination np vaccine dose reduction rad particle diminish protection simplify vaccine providing basis selection human vaccine candidate,2006,"Sullivan, Nancy J; Geisbert, Thomas W; Geisbert, Joan B; Shedlock, Devon J; Xu, Ling; Lamoreaux, Laurie; Custers, Jerome H H V; Popernack, Paul M; Yang, Zhi-Yong; Pau, Maria G; Roederer, Mario; Koup, Richard A; Goudsmit, Jaap; Jahrling, Peter B; Nabel, Gary J",PLoS medicine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16683867/,1133745.0,3
61929,61929,77435,i6v1t51u,,Medline,Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune vaccine.,,,17630055.0,unk,order ass immunotherapeutic potential canine visceral leishmaniasis leishmune vaccine formulated increased adjuvant concentration mg saponin rather mg mongrel dog infected leishmania l chagasi enrichedleishmune vaccine injected month infection animal seropositive symptomatic control group injected saline solution leishmunetreated dog showed significantly higher level antifml igg antibody anova p higher stable igg decreasing igg response pointing th cell mediated response vaccine following effect led positive delayed type hypersensitivity reaction leishmania lysate vaccinated dog control decreased average cd leishmaniaspecific lymphocyte saline control fell outside confidence interval vaccinee ci increased average clinical score saline control fall outside confidence interval leishmune immunotherapytreated dog ci dog received vaccine clustered showed lower clinical score normal cd count whereas untreated dog showed diminished cd higher clinical score increase clinical sign saline treated group correlated increase antifml antibody p parasitological evidence p decrease leishmaniaspecific cd lymphocyte proportion p result confirm immunotherapeutic potential enrichedleishmune vaccine vaccine reduced clinical symptom evidence parasite modulating outcome infection dog potential infectiosity phlebotomines enrichedleishmune vaccine subjected safety analysis found well tolerated safe,2007,"Santos, F N; Borja-Cabrera, G P; Miyashiro, L M; Grechi, J; Reis, A B; Moreira, M A B; Martins Filho, O A; Luvizotto, M C R; Menz, I; Pessôa, L M; Gonçalves, P R; Palatnik, M; Palatnik-de-Sousa, C B",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17630055/,46408915.0,3
61967,61967,77481,tg0xnb9w,,Medline,Developing vaccines to counter bioterrorist threats.,,,16026243.0,unk,large innovative research program underway define immune parameter vaccine wide array pathogen considered represent potential bioterrorist threat however development utilization vaccine present number predicament previously addressed field vaccinology,2005,"Altmann, Daniel M",Expert review of vaccines,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16026243/,21191438.0,3
61991,61991,77509,yurkxm0h,,Medline,Adventitious agents and smallpox vaccine in strategic national stockpile.,,,16022785.0,unk,keeping current standard urge old smallpox vaccine made animal skin still key part strategic national stockpile tested adventitious infectious agent advisory especially applies virus potential zoonotic transmission human vaccine recipient,2005,"Murphy, Frederick A; Osburn, Bennie I",Emerging infectious diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16022785/,962249.0,3
61998,61998,77516,wpr2jicd,,Medline,Managing the effect of TRIPS on availability of priority vaccines.,,,16710544.0,unk,stated purpose intellectual property protection stimulate innovation agreement traderelated aspect intellectual property right trip requires member world trade organization wto enact national law conferring minimum standard intellectual property protection certain deadline critic agreement fear action inconsistent ensuring access medicine developing world convened meeting intellectual property right vaccine developing country paper based found evidence trip stimulated innovation developing market vaccine development market weak protection intellectual property right negative effect access vaccine however access future vaccine developing world could threatened compliance trip management threat requires adherence country doha declaration trip protection guaranteed agreement vigilance tripsplus element free trade agreement developing framework licensing technology transfer promoting innovative vaccine development developing country role international organization defining best practice dissemination information monitoring trip impact crucial ensuring optimal access priority new vaccine developing world,2006,"Milstien, Julie; Kaddar, Miloud",Bulletin of the World Health Organization,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16710544/,20129423.0,3
62148,62148,77695,21gpsaci,,Medline,Effects of infection with transmissible gastroenteritis virus on concomitant immune responses to dietary and injected antigens.,,,15013985.0,unk,normal piglet weaned onto soy eggbased diet generated antibody response fed protein concurrent infection transmissible gastroenteritis virus tgev affect response dietary antigen weaning affect subsequent development tolerance however tgev infection enhance primary immunoglobulin igm igg igg antibody response injected soy comparison uninfected animal paradoxically tgevinfected animal showed enhanced primary igg antibody response injected soy week age subsequently showed reduced secondary response intraperitoneal challenge week age comparison uninfected animal result suggest enteric virus either used vaccine vector present subclinical infection may significant effect development dietary allergy may effect primary response subsequent recall response systemic antigen animal exposed concurrently virus antigen,2004,"Bailey, Michael; Haverson, Karin; Miller, Bevis; Jones, Philip; Sola, Isabel; Enjuanes, Luis; Stokes, Christopher R",Clinical and diagnostic laboratory immunology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15013985/,28938545.0,3
62178,62178,77728,pri1afxu,,Medline,Live bacterial vaccines--a review and identification of potential hazards.,,,16796731.0,unk,use live bacteria induce immune response carried vaccine component attractive vaccine strategy advantage live bacterial vaccine include mimicry natural infection intrinsic adjuvant property possibility administered orally derivative pathogenic nonpathogenic food related bacteria currently evaluated live vaccine however pathogenic bacteria demand attenuation weaken virulence use bacteria vaccine delivery vehicle implies construction recombinant strain contain gene cassette encoding antigen increased knowledge mucosal immunity availability genetic tool heterologous gene expression concept live vaccine vehicle gain renewed interest however administration live bacterial vaccine pose risk addition vaccination using recombinant bacteria result release live recombinant organism nature place vaccine debate application genetically modified organism review give overview live bacterial vaccine market describe development new live vaccine focus attenuated bacteria foodrelated lactic acid bacteria furthermore outline safety concern identify hazard associated live bacterial vaccine try give suggestion consider development,2006,"Detmer, Ann; Glenting, Jacob",Microbial cell factories,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16796731/,10277988.0,3
62183,62183,77737,lnun5lkn,,Medline,Protective immunity and antibody-secreting cell responses elicited by combined oral attenuated Wa human rotavirus and intranasal Wa 2/6-VLPs with mutant Escherichia coli heat-labile toxin in gnotobiotic pigs.,,,11533185.0,unk,two combined rotavirus vaccination regimen evaluated gnotobiotic pig model rotavirus infection disease compared previously tested rotavirus vaccination regimen first atthrvvlpx involved oral inoculation one dose attenuated att wa human rotavirus hrv followed two intranasal dos rotaviruslike particle vlps vaccine derived wa vp bovine rf vp rotavirus strain vlps coadministered mutant escherichia coli heatlabile toxin ltrg mlt adjuvant second regimen vlpxatthrv two dos vlpsmlt given followed one oral dose attenuated wa hrv compare protective efficacy immune response induced combined vaccine regimen individual rotavirus vaccine regimen included experiment following vaccine group one oral dose attenuated wa hrv atthrvx mockxatthrv respectively three oral dos attenuated wa hrv atthrvx three dos vlps plus mlt vlpx three dos purified doublelayered inactivated wa hrv plus mlt inacthrvx mlt alone mockinoculated pig isotype magnitude tissue distribution antibodysecreting cell ascs intestinal systemic lymphoid tissue evaluated using enzymelinked immunospot assay atthrvvlpx regimen stimulated highest mean number intestinal immunoglobulin iga ascs prechallenge among vaccine group regimen induced partial protection virus shedding diarrhea upon challenge pig virulent wa hrv reverse vlpxatthrv regimen le efficacious atthrvvlpx regimen inducing iga asc response protection diarrhea protection rate efficacious vlpx inacthrvx protection conclusion atthrvvlpx vaccination regimen stimulated strongest bcell response intestinal mucosal immune system challenge conferred moderately high protection rate rotavirus disease indicating priming mucosal inductive site portal natural infection replicating vaccine followed boosting nonreplicating vaccine second mucosal inductive site may highly effective approach stimulate mucosal immune system induce protective immunity various mucosal pathogen,2001,"Yuan, L; Iosef, C; Azevedo, M S; Kim, Y; Qian, Y; Geyer, A; Nguyen, T V; Chang, K O; Saif, L J",Journal of virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/11533185/,24080850.0,3
62230,62230,77786,aft8veel,,Medline,Antibody induction after combined application of an adjuvanted recombinant FeLV vaccine and a multivalent modified live virus vaccine with a chlamydial component.,,,16343700.0,unk,compatibility safety interaction antibody induction combined vaccine application assessed specific pathogenfree cat vaccinated either modified live virus vaccine containing feline calici fcv herpes fhv parvovirus fpv chlamydophila felis c felis adjuvanted recombinant feline leukaemia virus felv vaccine vaccine one syringe combined application felv elisa antibody titre unaltered however antibody production based indirect immunofluorescence assay remarkably enhanced fcv selected time point also enhanced fhv c felis diminished fpv use vaccine combination safe simplify vaccination schedule veterinary practice,2006,"Brunner, Chantal; Kanellos, Theo; Meli, Marina L; Sutton, David J; Gisler, Ricarda; Gomes-Keller, Maria Alice; Hofmann-Lehmann, Regina; Lutz, Hans",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16343700/,42770497.0,3
62247,62247,77805,gycnp87o,,Medline,Development of vaccines and passive immunotherapy against SARS coronavirus using mouse and SCID-PBL/hu mouse models.,,,17037598.0,unk,investigated novel vaccine strategy severe acute respiratory syndrome sars cov infection using cdna construct encoding structural antigen spike membrane envelope e nucleocapsid n protein derived sars cov strain hku tw ffm sarscov thought infect alveolar epithelial cell lungin present study type ii alveolar epithelial cell clone used analyze mechanism ctl sars cov membrane antigen mouse vaccinated sars cov n dna dna using pcdna plasmid vector showed tcell immune response ctl induction proliferation type ii alveolar epithelial cell transfected sars n dna respectively determine whether dna vaccine could induce tcell immune response human well mouse scidpblhu mouse immunized dna vaccine pbl healthy human volunteer administered ip il receptor gammachaindisrupted nodscid mouse ilr nodscid scidpblhu mouse thus constructed used analyze human immune response vivo scidpblhu mouse immunized sars n dna dna analyzed human tcell immune response dna vaccine enhanced ctl activity proliferation presence peptide scidpblhu mouse furthermore sars n dna vaccine induced ctl activity ifngamma production recombinant n protein n proteinpulsed autologous b blast cell proliferation spleen cell scidpblhu mouse result demonstrate sars n dna vaccine induced human ctl human tcell proliferative response hand developed sars dna vaccine induce human neutralizing antibody human monoclonal antibody sars cov transgenic mouse expressing sarscov receptor angiotensin converting enzyme also development vaccine expected induce immune response specific sars cov human provide useful tool development protective vaccine,2006,"Okada, Masaji; Takemoto, Yuji; Okuno, Yoshinobu; Hashimoto, Satomi; Fukunaga, Yukari; Tanaka, Takao; Kita, Yoko; Kuwayama, Sechiko; Muraki, Yumiko; Kanamaru, Noriko; Takai, Hiroko; Okada, Chika; Sakaguchi, Yayoi; Furukawa, Izumi; Yamada, Kyoko; Izumiya, Miwa; Yoshida, Shigeto; Matsumoto, Makoto; Kase, Tetsuo; Peiris, J S M; DeMello, Daphne E; Chen, Pei-Jer; Yamamoto, Naoki; Yoshinaka, Yoshiyuki; Nomura, Tatsuji; Ishida, Isao; Morikawa, Shigeru; Tashiro, Masato; Sakatani, Mitsunori",Advances in experimental medicine and biology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17037598/,34918555.0,3
62293,62293,77857,yp8atkz1,,Medline,Uncertain benefit: the public policy of approving smallpox vaccine research.,,,15249295.0,unk,without accurate assessment prospect bioterrorist attack especially challenging evaluate protocol testing smallpox vaccine pediatric population usual regulatory mechanism shepherd research protocol benefit characterized uncertain face minimal risk protocol placed government forum analysis public unique opportunity debate balancing research risk benefit behalf child unable assent research well express view vaccination policy broadly model review pediatric research may without benefit especially important challenging study various vaccine range infectious property anthrax severe acute respiratory syndrome sars emerge,2004,"Quigley, Rosemary B",American journal of public health,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15249295/,40351649.0,3
62304,62304,77868,mlnyq42b,,Medline,Distribution of infectious bronchitis virus strains in different organs and evidence of vertical transmission in natural infection.,,,27586414.0,unk,basis partial sequencing infectious bronchitis virus ibv gene study investigated molecular diversity virus two life period batch breeding hen field level chick vaccinated ibv second day life vaccine age day exhibited clinical sign macroscopic lesion compatible avian infectious bronchitis ib clinical disease stage vaccine strain detected trachea lung small intestine chick ibv variant detected bursa fabricius kidney subsequently new sample collected batch end production cycle phase vaccine strain detected kidney small intestine oviduct hen however previously unidentified ibv variant found cecal tonsil additionally fragment viral rna completely identical corresponding region vaccine detected allantoic fluid viable embryo hen study day incubation finding suggest addition vaccine strain ibv variant coexist seeming establish chronic infection chicken potentially transmitted vertically result may assist immunoprophylaxis control program ibv,2016,"Pereira, Claiton Gonçalves; Saraiva, Giuliana Loreto; Vidigal, Pedro Marcus Pereira; Fietto, Juliana Lopes Rangel; Bressan, Gustavo Costa; Moreira, Maria Aparecida Scatamburlo; de Almeida, Márcia Rogéria; Júnior, Abelardo Silva",Archives of virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/27586414/,38094905.0,3
62390,62390,77970,vpes6y4o,,Medline,Japanese Encephalitis Vaccines.,,,23125946.0,unk,japanese encephalitis je significant human health concern asia indonesia part australia billion people potentially risk infection japanese encephalitis virus jev causative agent je given risk human health theoretical potential jev use bioweapon development safe effective vaccine prevent jev infection vital preserving human health development vaccine je began formalininactivated mouse brainderived vaccine vaccine shown induce protective immune response effective mouse brainderived vaccine still use may last lot biken® jevax® expired development modern je vaccine utilizes cell culturederived virus improvement manufacturing process well removal potential allergen toxin significantly improved vaccine safety china developed liveattenuated vaccine proven induce protective immunity following single inoculation addition chimeric vaccine virus incorporating prm e structural protein derived liveattenuated je vaccine liveattenuated yellow fever vaccine virus backbone currently clinical trial article provide summary je vaccine development ongoing clinical trial also discus potential risk jev bioweapon focus virus sustainability used weapon,2011,"McArthur, Monica A; Holbrook, Michael R",Journal of bioterrorism & biodefense,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/23125946/,13760371.0,3
62491,62491,78098,d5zuwyhd,,Medline,Expression of immunogenic glycoprotein S polypeptides from transmissible gastroenteritis coronavirus in transgenic plants.,,,9791026.0,unk,use transgenic plant vaccine production system described recently report immunological response elicited two recombinant version glycoprotein swinetransmissible gastroenteritis coronavirus tgev expressed transgenic plant arabidoposis plant genetically transformed cdna construct encoding either nterminal domain amino acid residue fulllength glycoprotein tgev responsible neutralizing antibody induction virus control cauliflower mosaic virus camv promoter genomic dna mrna analysis leaf extract transformed plant demonstrated incorporation foreign cdna arabidopsis genome well transcription expression recombinant polypeptide observed transgenic plant elisa using specific antibody mouse immunized leaf extract transgenic plant developed antibody reacted specifically tgev elisa immunoprecipitated virusinduced protein neutralized virus infectivity result conclude transgenic plant expressing glycoprotein polypeptide may possibly used source recombinant antigen vaccine production,1998,"Gómez, N; Carrillo, C; Salinas, J; Parra, F; Borca, M V; Escribano, J M",Virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/9791026/,13379502.0,3
62505,62505,78114,iokem65w,,Medline,Protection of chickens after live and inactivated virus vaccination against challenge with nephropathogenic infectious bronchitis virus PA/Wolgemuth/98.,,,12495055.0,unk,protection provided live inactivated virus vaccination challenge virulent nephropathogenic infectious bronchitis virus nibv strain pawolgemuth assessed vaccination combination live attenuated strain massachusetts mass connecticut conn mass arkansas ark given eyedrop wkold specificpathogenfree leghorn chicken live infectious bronchitis virus ibv vaccination chicken wk age received injection either oil emulsion vaccine containing inactivated ibv strain mass ark autogenous vaccine prepared nibv pawolgemuth challenge pawolgemuth given via eyedrop wk age serum ibv enzymelinked immunosorbent assay antibody geometric mean titer gmt vaccination combination live attenuated strain low ranging prior nibv challenge wk age inactivated vaccine induced anamnestic response similar magnitude serum gmt assessment protection following nibv challenge based several criterion virus reisolation trachea kidney renal microscopic pathology ibvspecific antigen immunohistochemistry ihc live attenuated virus vaccination alone combination strain mass conn mass ark protect respiratory tract kidney chicken pawolgemuth challenge chicken given live combination vaccination mass conn boosted inactivated mass ark vaccine also susceptible nibv challenge basis virus isolation trachea kidney butshowed protection basis renal microscopic pathology ihc live ibvprimed chicken vaccinated autogenous inactivated pawolgemuth vaccine highest protection homologous virulent nibv challenge basis virus isolation,2002,"Ladman, B S; Pope, C R; Ziegler, A F; Swieczkowski, T; Callahan, C J M; Davison, S; Gelb, J",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12495055/,40415284.0,3
62555,62555,78177,1bo30m1t,,Medline,Trends in US approvals: new biopharmaceuticals and vaccines.,,,16759723.0,unk,efficient development approval new therapeutic vaccine vital health welfare patient tuft center study drug development collected analyzed data new protein therapeutic vaccine approved usa past decade result suggest trend toward longer clinical approval phase therapeutic particularly oncology product opinion article discus various legislative act fda initiative might improve efficiency drug development approval furthermore new vaccine approved past year owing least part lack incentive development product predict might change future government industry respond twin threat global spread infectious disease potential bioterrorism,2006,"Reichert, Janice M",Trends in biotechnology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16759723/,44467304.0,3
62556,62556,78178,tgybigvn,,Medline,"Myositis, lameness, and recumbency after use of water-in-oil adjuvanted vaccines in near-term beef cattle.",,,15690947.0,unk,producer administered u department agriculturelicensed adjuvanted veterinary vaccine inactivated bovine rotaviruscoronavirus vaccine clostridium perfringens type cescherichia coli bacterintoxoid muscle left right hip pregnant beef cow within hour cattle recumbent another nonweight bearing pelvic limb lameness affected next day herd developed firm swelling cm vaccination site muscle hip histological sample revealed granulomatous myositis intralesional oil lesion resolved slowly next month six cattle injected experimentally vaccine none became lame developed foreign body granulomatous myositis similar affected herd maximum diameter experimentally induced lesion muscle necropsy day injection recommended dose bacterintoxoid vaccine cm histological examination revealed pyogranulomatous myositis fibrosis myonecrosis inactivated viral vaccine induced milder granulomatous myositis intralesional lipid scant fibrosis acute transient lameness ranch attributed use irritating biological vaccine hip muscle cow close parturition,2005,"O'Toole, D; Steadman, L; Raisbeck, M; Torpy, R","Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc",,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15690947/,21141758.0,3
62582,62582,78207,gc3ogrpi,,Medline,Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.,,,16987975.0,unk,effective antibody response provide crucial immunity influenza virus infection hemagglutinin ha protein major target protective antibody response induced viral infection vaccination inactivated liveattenuated flu vaccine knowledge optimal design protective ha antigen different flu serotypes still limited study significantly improved immunogenicity haexpressing dna vaccine using codonoptimized ha sequence either h serotype anewcal h serotype apanama human influenza virus used construct model antigen identify optimal ha antigen design elicit highlevel protective antibody response two form ha antigen wildtype fulllength ha secreted form transmembrane tm domaintruncated ha produced form ha dna vaccine either h h serotypes able elicit high level haspecific immunoglobulin g response immunized rabbit measured enzymelinked immunosorbent assay interestingly ability h ha h ha antigen elicit hemagglutination inhibition hi neutralizing antibody nab response differ h ha antigen fulllength ha induced significantly higher hi nab response tmtruncated ha h ha antigen fulllength ha tmtruncated ha induced high level hi nab response data indicate h h antigen different expression requirement induction optimal protective antibody response structure integrity ha antigen critical eliciting typespecific protective antibody response finding important impact future subunitbased flu vaccine development,2006,"Wang, Shixia; Taaffe, Jessica; Parker, Christopher; Solórzano, Alicia; Cao, Hong; García-Sastre, Adolfo; Lu, Shan",Journal of virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16987975/,26451227.0,3
62645,62645,78279,7qmah4f7,,Medline,Infectious bronchitis virus S2 expressed from recombinant virus confers broad protection against challenge.,,,24758118.0,unk,developed recombinant newcastle disease virus ndv lasota rls expressing infectious bronchitis virus ibv gene rlsibvs recombinant virus showed somewhatreduced pathogenicity compared parental lentogenic lasota strain effectively elicited hemagglutination inhibition antibody ndv protected chicken lethal challenge virulent ndvca ibv heterotypic protection assessed using primeboost approach commercially available attenuated ibv massachusetts masstype vaccine specificpathogenfree chicken primed ocularly rlsibvs day age boosted mass day age completely protected challenge day age virulent arktype strain second experiment compared protection conferred priming rlsibvs boosting mass rlsibvsmass versus priming boosting mass massmass also modified timing vaccination prime day age boost day age challenge virulent ark performed day age based clinical sign vaccinated group appeared equally protected challenge compared unvaccinated challenged chicken viral load lachrymal fluid bird receiving rlsibvsmass showed clear tendency improved protection compared massmass however difference achieve statistical significance significant difference p determined group regarding incidence detection challenge ibv rna trachea viral rna detected rlsibvsmassvaccinated chicken chicken vaccinated massmass unvaccinated challenged control showed incidence ibv rna detection trachea respectively result demonstrate overexposing ibv chicken immune system mean vectored vaccine followed boost whole virus protects chicken ibv showing dissimilar,2014,"Toro, Haroldo; Zhao, Wei; Breedlove, Cassandra; Zhang, Zhenyu; Yu, Qingzhong; Van Santen, Vicky",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24758118/,46012605.0,3
62743,62743,78392,wmbphnot,,Medline,Identification of Leukotoxin and other vaccine candidate proteins in a Mannheimia haemolytica commercial antigen.,,,27699279.0,unk,bovine respiratory disease costly disease affect beef dairy cattle industry etiology multifactorial arising predisposing environmental stress condition well action several different respiratory pathogen situation hindered development effective control strategy although different type vaccine available many currently marketed vaccine based inactivated culture main viral bacterial agent involved pathology molecular composition commercial veterinary vaccine critical issue present work aim define proteomic level relevant valence line commercial respiratory vaccine widely used central south america since mannheimia haemolytica responsible disease associated morbidmortality focused main protein secreted pathogen particular leukotoxin main virulence factor western blot analysis mass spectrometry leukotoxin identified major component haemolytica culture supernatant also identified ten haemolytica protein including outer membrane protein periplasmic transmembrane solute transporter iron binding protein relevant achieve protective immunity pathogen work allowed detailed molecular characterization vaccine component providing evidence quality efficacy furthermore result contributed identification several protein interest subunit vaccine candidate,2016,"Tucci, Paula; Estevez, Verónica; Becco, Lorena; Cabrera-Cabrera, Florencia; Grotiuz, Germán; Reolon, Eduardo; Marín, Mónica",Heliyon,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/27699279/,15303860.0,3
62798,62798,78463,mykay3k2,,Medline,Rotavirus infection enhances lipopolysaccharide-induced intussusception in a mouse model.,,,17005639.0,unk,unexpected report intussusception vaccination live tetravalent rotavirus vaccine rotashield resulted voluntary withdrawal vaccine intussusception condition intestine acutely invaginates upon common cause intestinal obstruction child report development mouse model study rotavirusinduced intussusception model homologous murine heterologous simian rotavirus strain significantly enhanced rate lipopolysaccharide lpsinduced intussusception enhancement replication dependent requiring rotavirus dos greater one infectious dose rotavirusinduced intussusception observable lymphoid lead point despite induction intestinal lymphoid hyperplasia rotavirus infection intussusception also postulated result altered intestinal motility rotavirus infection effect gastrointestinal transit lpsinduced intussusception associated induction inflammatory mediator intussusception rate modified inflammatory antagonist show rotavirus infection significantly enhanced serum tumor necrosis factor alpha gamma interferon cytokine level lp treatment compared uninfected mouse together data suggest rotavirus infection sensitized mouse inflammatory effect subsequent lp treatment enhance intussusception rate,2006,"Warfield, Kelly L; Blutt, Sarah E; Crawford, Sue E; Kang, Gagandeep; Conner, Margaret E",Journal of virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17005639/,4674318.0,3
62939,62939,78635,9qorks1j,,Medline,Contagious bovine pleuropneumonia: a rationale for the development of a mucosal sub-unit vaccine.,,,17706775.0,unk,contagious bovine pleuropneumonia cbpp remains major cattle disease africa serious socioeconomic consequence eradication requires development improved vaccine knowledge disease causing agent mycoplasma mycoides subsp mycoides biotype small colony mmmsc progressing significantly last year opening new area vaccine design advance achieved understanding protective immune response mmmsc infection immunopathological mechanism allowing pathogen escape host immune response based sequencing genomic study virulence factor metabolic pathway unraveled leading identification potential mmmsc vaccine candidate based finding review present scientific strategy design multicomponent subunit vaccine mucosal delivery promising approach efficient longterm protective vaccine prevent cbpp,2008,"Dedieu-Engelmann, Laurence","Comparative immunology, microbiology and infectious diseases",,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17706775/,22247716.0,3
62945,62945,78643,mh6lau72,,Medline,The business of making vaccines.,,,16273061.0,unk,growing need better plentiful vaccine traditional vaccine company responding increasing manufacturing capacity biotech industry innovative product surely needed,2005,"Sheridan, Cormac",Nature biotechnology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16273061/,10426777.0,3
62947,62947,78646,yy58nkb4,,Medline,Enhanced immune responses to viral epitopes by combining macrophage-inducible expression with multimeric display on a Salmonella vector.,,,11282213.0,unk,study immunogenicity chimeric p fimbria salmonella vaccine strain improved optimizing fimbrial expression constitutive teta promoter vivo activated nirb pagc promoter evaluated use express two epitope transmissible gastroenteritis virus tgev spike protein carried fimbria displayed salmonella vaccine strain construct pagc promoter shown drive increased expression chimeric p fimbria macrophage well mgpoor medium mimicking major environmental signal found salmonellacontaining endocytic vacuole macrophage mouse immunized orally salmonella vaccine strain expressed chimeric fimbria pagc promoter elicited significantly higher mucosal systemic immune response p fimbria tgev epitope mouse immunized strain hosting teta nirb promoterdriven expression plasmid moreover salmonella vaccine strain harboring plasmid pagc promoter without additional teta promoter tandem elicited neutralizing antibody tgev indicated pagc promoter used successfully improve epitopedisplay chimeric fimbria salmonella vaccine strain induction desired immune response,2001,"Chen, H; Schifferli, D M",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/11282213/,11790883.0,3
62959,62959,78659,co92gywc,,Medline,Reducing outbreaks: using international governmental risk pools to fund research and development of infectious disease medicines and vaccines.,,,25506281.0,unk,deadliest ebola outbreak world ever seen currently ravaging west africa despite concerted effort world health organization many national government current picture troubling altogether unexpected ebola initially identified since time drug developed combat true myriad dangerous infectious disease world currently susceptible one proposal might prevent outbreak scale magnitude recurring would world health organization technical partner ass member state high risk disease either directly indirectly facilitate creation international governmental risk pool member state risk pool would offer openindexed grant contract fund vaccine drug development particular disease pharmaceutical company could browse index apply grant riskpool state particular company sign contract mutually agreed upon amount vaccine drug would produced belowmarket purchase price state return company would keep patent intellectual property right developed vaccine drug riskpool country use vaccine drug could resell supply secondary market country outside risk pool arrangement increase supply tested drug vaccine candidate available combatting unexpected outbreak previously discovered major infectious disease future,2014,"Erfe, J Mark",The Yale journal of biology and medicine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/25506281/,17695141.0,3
62979,62979,78682,gqq222yr,,Medline,Immunodominant viral peptides as determinants of cross-reactivity in the immune system--Can we develop wide spectrum viral vaccines?,,,16051445.0,unk,look back edward jenner vaccination young man help thinking lucky crazy crazy decided test human hypothesis based mainly traditional belief people acquired cowpox udder cow thereafter resistant smallpox quite devastating disease lucky even considering know time succeeded induce protection pathogen induction immune response directed different agent able protect young man took first step towards development vast new field vaccination acceptable say jenner lucky succeeded promoting protection smallpox using cowpox virus induction protection crossreactive way believed quite rare nevertheless example crossreactive immune response described beginning admit crossreactivity far common important used think review crossreactivity immune system plasticity cell recognition based existence cell receptor promiscuous recognition crossrecognition conserved viral immunodominant epitope propose two approach develop wide spectrum viral vaccine first one based identification characterization cloning immunodominant viral epitope able stimulate response different virus produced peptide could purified serve basis vaccine therapy second strategy based identification conserved pattern immunodominant viral peptide production synthetic peptide containing amino acid residue necessary mhc anchoring tcr contact although still far complete knowledge crossreactivity phenomenon immune system analysis immunodominant viral epitope identification particular viral pattern seems important step towards development wide spectrum viral vaccine,2005,"Vieira, G F; Chies, J A B",Medical hypotheses,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16051445/,25699190.0,3
62999,62999,78708,2aaprmv5,,Medline,Humoral immune responses in rabbits induced by an experimental inactivated severe acute respiratory syndrome coronavirus vaccine prepared from F69 strain.,,,15569476.0,unk,background etiologic agent severe acute respiratory syndrome sars confirmed novel coronavirus cov namely sarscov developing safe effective sarscov vaccine essential u prevent possible reemergence epidemic previous experience indicate inactivated vaccine conventional hopeful successfully developed immunogenicity evaluation experimental inactivated sarscov vaccine rabbit conducted reported paper method largescale cultured sarscov f strain inactivated formaldehyde purified used immunogen combined freunds adjuvant eight adult new zealand rabbit immunized four time experimental inactivated vaccine twelve set rabbit serum sampled third day seventyfourth day first vaccination titer specific antisarscov igg antibody determined indirect enzymelinked immunosorbent assay neutralizing antibody titer detected microcytopathic effect neutralization test result rapid potent humoral immune response induced inactivated sarscov vaccine eight test rabbit titer specific igg antibody neutralizing antibody peaked six week first vaccination maximum value respectively serum antibody level remained plateau slight decrease though two booster given succedent week cross neutralization response existed sarscov f strain zy strain conclusion inactivated sarscov vaccine made f strain owns strong immunogenicity cross neutralization response two different sarscov strain give hint similar neutralizing epitope provide stable base development inactivated sarscov vaccine,2004,"Zhang, Chuan-Hai; Guo, Zhong-Min; Zheng, Huan-Ying; Lu, Jia-Hai; Wang, Yi-Fei; Yan, Xin-Ge; Zhao, Yong; DU, Xiong-Wei; Zhang, Xin; Fang, Ling; Ling, Wen-Hua; Qi, Shu-Yuan; Yu, Xin-Bing; Zhong, Nan-Shan",Chinese medical journal,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15569476/,25434974.0,3
63031,63031,78747,0pk8e2jf,,Medline,Vaccines for emerging infections.,,,17633303.0,unk,emerging infectious disease represent grave threat animal human population term impact global health agriculture economy vaccine developed emerging infection animal protect animal health prevent transmission zoonotic disease human example paper illustrate industry public health collaborate develop vaccine prevent emerging disease horse west nile virus vaccine poultry vaccination protect animal prevent transmission people avian influenza vaccine regulatory change pave way vaccine control carrier state animal thus prevent infection human bartonella henselae vaccine cat novel technology could applied vaccinate wildlife reservoir specie rabies stemming realisation zoonotic disease predominant source human emerging infectious disease behoves academic public health animal health agency consider creative constructive approach combat serious public health challenge vaccination vectorreservoir specie efficacious vaccine available offer significant advantage combating zoonotic human disease,2007,"Marano, N; Rupprecht, C; Regnery, R",Revue scientifique et technique,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17633303/,28724949.0,3
63165,63165,78903,rpvjtmj3,,Medline,Delivery of subunit vaccines in maize seed.,,,12480322.0,unk,use recombinant gene technology vaccine industry revolutionized way antigen generated provided safer effective mean protecting animal human bacterial viral pathogen viral bacterial antigen recombinant subunit vaccine produced variety organism transgenic plant recognized legitimate source protein especially developing area oral vaccine antigen shown correctly processed plant form elicit immune response fed animal human antigen expressed maize zea may particularly attractive since deposited natural storage vessel corn seed conveniently delivered organism consumes grain previously demonstrated high level expression bsubunit escherichia coli heatlabile enterotoxin spike protein swine transmissible gastroenteritis corn demonstrated antigen delivered seed elicit protective immune response provide additional data support potency efficacy stability recombinant subunit vaccine delivered maize seed,2002,"Lamphear, Barry J; Streatfield, Stephen J; Jilka, Joseph M; Brooks, Christopher A; Barker, Donna K; Turner, Debra D; Delaney, Donna E; Garcia, Martin; Wiggins, Barry; Woodard, Susan L; Hood, Elizabeth E; Tizard, Ian R; Lawhorn, Bruce; Howard, John A",Journal of controlled release : official journal of the Controlled Release Society,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/12480322/,20590613.0,3
63182,63182,78922,arvmip79,,Medline,Adenoviruses as vaccine vectors.,,,15451446.0,unk,adenovirus transitioned tool gene replacement therapy bona fide vaccine delivery vehicle attractive vaccine vector induce innate adaptive immune response mammalian host currently adenovirus vector tested subunit vaccine system numerous infectious agent ranging malaria hiv additionally explored vaccine multitude tumorassociated antigen review describe molecular biology adenovirus well way adenovirus vector manipulated enhance efficacy vaccine carrier describe method evaluating immune response transgene product expressed adenoviral vector discus data adenoviral vaccine selected number pathogen last comment limitation using human adenoviral vector provide alternative circumvent problem field growing exciting rapid pace thus limited scope use adenoviral vector vaccine viral pathogen,2004,"Tatsis, Nia; Ertl, Hildegund C J",Molecular therapy : the journal of the American Society of Gene Therapy,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15451446/,38852121.0,3
63243,63243,78992,l9l6z1o0,,Medline,[At least 68 vaccine candidates under development].,,,32293018.0,unk,development vaccine sarscov progressing unparalleled speed th march least vaccine candidate comprising several different vaccine design including whole killed virus subunit attenuated viral vector dna mrna vaccine whilst usually take year develop vaccine taken week publication viral genetic sequence first vaccine candidate reach clinical testing development expediated using existing technological platform performing preclinical clinical testing simultaneously,2020-04-06,"Leach, Susannah",Lakartidningen,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/32293018/,215772913.0,3
63282,63282,79035,ud1chuxk,,Medline,Virus-Vectored Ebola Vaccines.,,,29104771.0,unk,ebola virus disease evd one dangerous infection affecting human animal first evd outbreak occurred sudan zaire since outbreak occurred largest evolved epidemic west africa claimed life people although vaccination effective way prevent epidemic licensed vaccine evd beginning latest outbreak development first vaccine evd started come long technological way inactivated genetically engineered vaccine based recombinant viral vector review focus virusvectored ebola vaccine demonstrated greatest efficacy preclinical trial currently different phase clinical trial particular attention paid mechanism immune response development important protection evd key vaccine parameter necessary inducing longterm protective immunity evd,2017,"Dolzhikova, I V; Tokarskaya, E A; Dzharullaeva, A S; Tukhvatulin, A I; Shcheblyakov, D V; Voronina, O L; Syromyatnikova, S I; Borisevich, S V; Pantyukhov, V B; Babira, V F; Kolobukhina, L V; Naroditsky, B S; Logunov, D Y; Gintsburg, A L",Acta naturae,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/29104771/,19338014.0,3
63433,63433,79202,8wvb1wr5,,Medline,"Vaccines: past, present and future.",,,15812490.0,unk,vaccine developed first two hundred year since jenner lifetime accomplished striking reduction infection disease wherever applied pasteur early approach vaccine development attenuation inactivation even two pole vaccine technology today purification microbial element genetic engineering improved knowledge immune protection allow direct creation attenuated mutant expression vaccine protein live vector purification even synthesis microbial antigen induction variety immune response manipulation dna rna protein polysaccharide noninfectious infectious disease within realm vaccinology profusion new vaccine enables new population targeted vaccination requires development route administration additional injection come new problem production regulation distribution vaccine,2005,"Plotkin, Stanley A",Nature medicine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15812490/,5765435.0,3
63477,63477,79252,8lznpmct,,Medline,Control of canine distemper.,,,8588329.0,unk,control canine distemper realistically achieved use vaccination type vaccine current use described together problem encountered interference maternal antibody usage specie dog modified live viral vaccine used thirty year proved effective nevertheless scope improvement vaccine efficacy recent development genetic recombinant method described,1995,"Chappuis, G",Veterinary microbiology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/8588329/,38789406.0,3
63561,63561,79353,bu8a6i4o,,Medline,Mice immunogenicity after vaccination by DNA vaccines containing individual genes of a new type of reovirus.,,,24294952.0,unk,study investigated humoral cellular immune response mouse dna vaccine containing individual gene new type reovirus nrv isolate severe acute respiratory syndrome sars patient beijing china mouse immunized intramuscularly im μg dna vaccine time week interval assayed humoral igg igg igg iggb antibody elisa cellular immune response particularly ifnγ induction elispot assay moreover cd cd cell level peripheral blood mononuclear cell assayed flow cytometry found dna vaccine induced igg antibody predominantly igga class dna vaccine strongest inducer dna vaccine elicited th thbased immune response respectively dna vaccine induced mixed thth response dna vaccine poorly immunogenic knowledge first report characterizing mammalian reovirus dna vaccine applied mouse model,2013,"Bai, B; Shen, H; Hu, Y; Hou, J; Li, R; Liu, Z; Luo, S; Mao, P",Acta virologica,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24294952/,39062411.0,3
63566,63566,79358,7ntn9jm4,,Medline,Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice.,,,17494640.0,unk,dna vaccine induce humoral cellular immune response animal model human analyze immunogenicity severe acute respiratory syndrome sars coronavirus cov sarscov spike dna vaccine immunoregulatory activity interleukin il dna vaccine plasmid pcdnas pcdnail constructed inoculated balbc mouse without pcdnail using three different immunization route intramuscular route electroporation oral route live attenuated salmonella enterica serovar typhimurium cellular humoral immune response assessed enzymelinked immunosorbent assay lymphocyte proliferation assay enzymelinked immunospot assay fluorescenceactivated cell sorter analysis result showed specific humoral cellular immunity could induced mouse inoculating sarscov spike dna vaccine alone coinoculation ilexpressing plasmid addition immune response level coinoculation group significantly higher group receiving spike dna vaccine alone comparison three vaccination route indicated oral vaccination evoked vigorous tcell response weak response predominantly subclass immunoglobulin ga igga antibody however intramuscular immunization evoked vigorous antibody response weak tcell response vaccination electroporation evoked vigorous response predominant subclass igg antibody response moderate tcell response finding show spike dna vaccine good immunogenicity induce specific humoral cellular immunity balbc mouse il play immunoadjuvant role enhances humoral cellular immune response different vaccination route also evoke distinct immune response study provides basic information design dna vaccine sarscov,2007,"Hu, Hui; Lu, Xinya; Tao, Ling; Bai, Bingke; Zhang, Zhenfeng; Chen, Yao; Zheng, Fangliang; Chen, Jianjun; Chen, Ze; Wang, Hanzhong",Clinical and vaccine immunology : CVI,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17494640/,22764950.0,3
63630,63630,79433,aeie56g5,,Medline,Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.,,,15280455.0,unk,human papillomavirus hpv particularly type hpv present cervical cancer hpv oncoproteins e e constantly expressed therefore represent ideal target hpv vaccine development previously developed dna vaccine encoding calreticulin crt linked hpv e generated potent especific cd tcell immune response antitumor effect eexpressing tumor since vaccine targeting e also represent important strategy controlling hpvassociated lesion developed dna vaccine encoding crt linked e crte result indicated crte dna vaccine wildtype e dna vaccine generated significant especific cd tcell immune response vaccinated mouse mapping immunodominant epitope e revealed e peptide comprising amino acid aa e aa presented hkb optimal peptide region e comprising aa represents minimal core sequence required activating especific cd lymphocyte also demonstrated e aa contains cytotoxic tlymphocyte epitope naturally presented eexpressing tc cell vaccination crte crtmte lacking aa e dna vaccine could protect vaccinated mouse challenge eexpressing tc tumor thus data indicate e aa contains immunodominant epitope crte dna vaccine may useful control hpv infection hpvassociated lesion,2004,"Peng, Shiwen; Ji, Hongxiu; Trimble, Cornelia; He, Liangmei; Tsai, Ya-Chea; Yeatermeyer, Jessica; Boyd, David A K; Hung, Chien-Fu; Wu, T-C",Journal of virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15280455/,11403967.0,3
63634,63634,79438,xaal79za,,Medline,Evaluation of infectious bronchitis virus Arkansas-type vaccine failure in commercial broilers.,,,24689182.0,unk,infectious bronchitis virus ibv cause upper respiratory tract disease chicken highly contagious many different type virus exist type used attenuated live vaccine commercial poultry industry vaccine type used arkansas arktype virus frequently reisolated vaccinated broiler previous research suggested incomplete clearance arktype vaccine virus play role inadequate protection observed vaccinated broiler challenged pathogenic ark virus study examine route vaccine administration using multiple ibv type including ark effort understand ark vaccine provide good protection persist commercial broiler found interference different type ibv vaccine occurring combined administered using commercial hatchery spray cabinet also ark vaccine virus efficacious dayold broiler sprayed using hatchery spray cabinet gave good protection administrated eyedrop inoculation also found amount ark vaccine virus low undetectable choanal swab day postvaccination vaccine administered eyedrop drinking water alternatively subpopulation ark vaccine isolated vaccinated bird arkriep showed peak titer day age given route suggesting arkriep fit regard infection replication bird moreover found detection ibv vaccine virus early administration regardless strain route correlated protection homologous challenge may thus good indicator vaccine efficacy field humoral antibody titer typically low undetectable vaccination experiment provided key finding used direct effort improving efficacy ibv arktype vaccine given hatchery also elucidated factor contributing persistence ark vaccine field,2013,"Roh, Ha-Jung; Hilt, Deborah A; Williams, Susan M; Jackwooda, Mark W",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/24689182/,25305001.0,3
63660,63660,79473,ykm5gjjp,,Medline,The interference by maternally-derived antibody with active immunization of farm animals against foot-and-mouth disease.,,,7552194.0,unk,footandmouth disease fmd highly contagious disease affecting ruminant pig country control fmd relies predominantly vaccination young stock ingest specific antifmd virus antibody colostrum maternallyderived antibody mda provides immediate protection infection fmd virus also interferes development active immunity following vaccination however susceptibility infection precedes ability respond vaccination presence mda currently available vaccine overcome inhibitory effect mda protection young stock provided isolation fmd virus,1995,"Kitching, R P; Salt, J S",The British veterinary journal,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/7552194/,44527018.0,3
63727,63727,79556,1mqsjexn,,Medline,Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine.,,,18018769.0,unk,background emergence severe acute respiratory syndrome sars winter spring caused serious threat public health method evaluate safety immunogenicity inactivated sars coronavirus sarscov vaccine subject received two dos sarscov unit su su inactivated sarscov vaccine placebo control result day seroconversion reached vaccine group day participant group receiving su group receiving su seroconverted geometric mean titre neutralizing antibody peaked week second vaccination decreased week later conclusion inactivated vaccine safe well tolerated elicit sarscovspecific neutralizing antibody,2007,"Lin, Jiang-Tao; Zhang, Jian-San; Su, Nan; Xu, Jian-Guo; Wang, Nan; Chen, Jiang-Ting; Chen, Xin; Liu, Yu-Xuan; Gao, Hong; Jia, Yu-Ping; Liu, Yan; Sun, Rui-Hua; Wang, Xu; Yu, Dong-Zheng; Hai, Rong; Gao, Qiang; Ning, Ye; Wang, Hong-Xia; Li, Ma-Chao; Kan, Biao; Dong, Guan-Mu; An, Qi; Wang, Ying-Qun; Han, Jun; Qin, Chuan; Yin, Wei-Dong; Dongs, Xiao-Ping",Antiviral therapy,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18018769/,6422043.0,3
63746,63746,79579,q0qwhp0e,,Medline,Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines.,,,16793110.0,unk,development effective vaccine severe acute respiratory syndrome sars remains priority prevent possible reemergence sars coronavirus sarscov previously demonstrated receptorbinding domain rbd sarscov protein major target neutralizing antibody suggests rbd may serve ideal vaccine candidate recombinant adenoassociated virus raav proven effective system gene delivery vaccine development study novel vaccine sarscov developed based raav delivery system gene encoding rbd cloned paavireshrgfp plasmid immunogenicity induced resulting recombinant rbdraav evaluated balbc mouse result demonstrated single dose rbdraav vaccination could induce sufficient neutralizing antibody sarscov infection two repeated dos vaccination boosted neutralizing antibody time level achieved single dose immunization level antibody continued increase entire duration experiment month result suggested rbdraav promising sars candidate vaccine,2006,"Du, Lanying; He, Yuxian; Wang, Yijia; Zhang, Haojie; Ma, Selene; Wong, Charlotte K L; Wu, Sharon H W; Ng, Fai; Huang, Jian-Dong; Yuen, Kwok-Yung; Jiang, Shibo; Zhou, Yusen; Zheng, Bo-Jian",Virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16793110/,28283190.0,3
63823,63823,79669,mcgr5m4k,,Medline,Protection of newborn animals through maternal immunization.,,,17559866.0,unk,providing protective immunity neonatal animal early life associated numerous challenge regarding vaccine safety efficacy much simpler approach maternal vaccination either pregnancy provide neonate passively transferred immunity human medical societal legal risk immunizing pregnant woman important consideration undertaking approach contrast maternal vaccination successfully employed animal health industry decade veterinary vaccine proven safe efficient although passively transferred antibody extensively studied immunological mechanism may equally important providing maternally derived immunity,2007,"Pravieux, J J; Poulet, H; Charreyre, C; Juillard, V",Journal of comparative pathology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17559866/,44837294.0,3
63849,63849,79697,kluwb0oa,,Medline,Demand for nonhuman primate resources in the age of biodefense.,,,15644560.0,unk,demand nonhuman primate undoubtedly increase meet biomedical need current age biodefense availability funding increased research select agent created requirement validate result relevant primate model review provides description current potential biological threat likely require nonhuman primate development vaccine therapeutic primate invaluable resource dissection viral disease pathogenesis well testing vaccine efficacy dna vaccine approach studied successfully ebola lassa anthrax nonhuman primate model nonhuman primate research monkeypox provided insight role cytokine limiting disease severity biodefense research focused select agent bacterial origin also benefited nonhuman primate study rhesus macaque traditionally model choice anthrax research yielded successful finding vaccine development plague research african green monkey contributed vaccine development however disadvantage current vaccine undoubtedly require generation new vaccine thus increasing need nonhuman primate research unfortunately current biosafety level bsl bsl facility equipped perform research limited may ultimately impede progress era biodefense,2005,"Patterson, Jean L; Carrion, Richardo",ILAR journal,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15644560/,11607587.0,3
63877,63877,79728,6i8zeg1n,,Medline,"Emergence of Avian Infectious Bronchitis Virus and its variants need better diagnosis, prevention and control strategies: a global perspective.",,,26035949.0,unk,growth poultry sector challenged due increased incidence reemergence disease caused due evolution several viral pathogen use live vaccine pile economic loss encountered due disease avian infectious bronchitis ib caused corona virus oielisted disease characterized respiratory renal urogenital involvement causing high mortality economic loss encountered due loss productive performance egg meattype chicken variant virus evolve due spontaneous mutation recombination causing disease vaccinated flock age serotyping genotyping common method classification ibv strain virus cluster grouped serotypes important strain massachusetts connecticut arkansas gray holte florida along numerous others distributed round globe several conventional molecular diagnostic method described diagnosis ib chicken allinallout operation rearing along good biosafety measure form basis prevention whereas vaccination form backbone ib control programme live inactivated oil emulsified conventional vaccine available new generation vaccine recombinant vectorbased developed locally prevailing ibv strain may helpful avoid reversion virulence live vaccine virus present review deal perspective important emerging poultry pathogen,2014,"Dhama, Kuldeep; Singh, Shambhu Dayal; Barathidasan, Rajamani; Desingu, P A; Chakraborty, Sandip; Tiwari, Ruchi; Kumar, M Asok",Pakistan journal of biological sciences : PJBS,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/26035949/,39339057.0,3
63900,63900,79755,c5en2ic8,,Medline,Group A rotavirus veterinary vaccines.,,,8752298.0,unk,group rotavirus cause diarrhea young livestock poultry consequently vaccination strategy focused induction active passive immunity gnotobiotic pig calf serve useful model evaluate induction active immunity candidate animal human rotavirus vaccine however live attenuated rotavirus vaccine lacked efficacy administered orally calf pig field presumably colostral antibody inhibited vaccine virus replication widespread occurrence rotavirus antibody colostrum led strategy maternal rotavirus vaccination boost lactogenic immunity transfer passive antibody neonate via colostrum milk variable success maternal rotavirus vaccine field influenced vaccine dose strain inactivating agent adjuvant route administration environmental rotavirus exposure level use genetically engineered rotaviruslike particle vaccine cow boost antibody mammary secretion show promise subunit vaccine posse potential advantage existing vaccine,1996,"Saif, L J; Fernandez, F M",The Journal of infectious diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/8752298/,24026649.0,3
63901,63901,79757,lamwgyzd,,Medline,Regulation of Immunogen Processing: Signal Sequences and Their Application for the New Generation of DNA-Vaccines.,,,22649628.0,unk,immunization naked gene dnaimmunization perspective modern approach prophylactic well therapeutic vaccination pathogen well cancer allergy panel dna immunogen developed already clinical trial however immunogenicity dna vaccine specifically applied human need considerable improvement several approach increase dna vaccine immunogenicity one approach implies modification encoded immunogen change processing presentation thus overall pattern antiimmunogen response eukaryotic expression vector constructed encode chimeric protein composed immunogen specialized targeting signal sequence review describes number signal fused immunogen target predefined subcellular compartment review give example application dnaimmunization,2010,"Starodubova, E S; Isaguliants, M G; Karpov, V L",Acta naturae,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/22649628/,14159757.0,3
63905,63905,79761,v1lazumc,,Medline,[Application of bioactive mutant TNF alpha to a mucosal vaccine adjuvant].,,,20046066.0,unk,large number emerging pathogen severe acute respiratory syndrome sars human immunodeficiency virus hiv influenza virus mucosally transmitted must cross mucosal barrier infect host thus induce maximal protective effect desirable apply vaccine mucosal route virus infection start mucosal vaccine administered either orally nasally shown effective inducing antigenspecific immune response systemic mucosal compartment however mucosal antigenspecific immune response weak protein antigen evoke weak immune response applied mucosally therefore one strategy overcome weakness immune response coadministration mucosal adjuvant vaccine antigen unfortunately development safe effective mucosal adjuvant proved challenging cytokine promising adjuvant humanderived safe material display potent immunemodulating function regard created mutant tumor necrosis factoralpha tnfalpha mtnfkr exhibit high bioactivity resistance protease report examined potential mtnfkr mucosal adjuvant evaluated effectiveness safety,2010,"Kayamuro, Hiroyuki; Yoshioka, Yasuo; Abe, Yasuhiro; Kamada, Haruhiko; Tsunoda, Shin-ichi; Tsutsumi, Yasuo",Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/20046066/,32057664.0,3
63967,63967,79836,4sm6xj4b,,Medline,Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs.,,,17913311.0,unk,cellular humoral immune response dog candidate vaccine composed leishmania braziliensis promastigote protein plus saponin adjuvant investigated prerequisite understanding mechanism immunogenicity canine visceral leishmaniasis cvl candidate vaccine elicited strong antigenicity related increase antileishmania igg isotypes together higher level lymphocyte particularly circulating cd tlymphocytes leishmania chagasi antigenspecific cd tlymphocytes indicated intense cell proliferation increased nitric oxide production vitro stimulation l chagasi soluble antigen candidate vaccine elicited immune activation status potentially compatible effective control etiological agent cvl,2007,"Giunchetti, Rodolfo Cordeiro; Corrêa-Oliveira, Rodrigo; Martins-Filho, Olindo Assis; Teixeira-Carvalho, Andréa; Roatt, Bruno Mendes; de Oliveira Aguiar-Soares, Rodrigo Dian; de Souza, Juliana Vitoriano; das Dores Moreira, Nádia; Malaquias, Luiz Cosme Cotta; Mota e Castro, Luciana Lisboa; de Lana, Marta; Reis, Alexandre Barbosa",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17913311/,14378221.0,3
64032,64032,79922,f1rh9xuk,,Medline,Induction of mucosal immunity in cotton rats to haemagglutinin-esterase glycoprotein of bovine coronavirus by recombinant adenovirus.,,,7590874.0,unk,effective vaccine enteric bovine coronavirus bcv must able induce mucosal immunity recently described construction recombinant human adenovirus type carrying bcv haemagglutininesterase gene early transcription region adenovirus genome study examined induction systemic mucosal immune response vector carrying bcv gene adbche following intranasal enteric immunization cotton rat regardless route administration mucosal immunization adbche induced significant level antihe igg antibody serum addition following intranasal immunization adbche significant level antihe iga antibody found lung wash immunized cotton rat furthermore specific antihe antibody serum mucosal secretion efficiently neutralized bcv infectivity vitro tcell proliferation cellmediated cytotoxic response bcv elicited spleen intranasally immunized animal result demonstrate mucosal immunization adbche capable inducing systemic mucosal immunity bcv immune response may important protecting animal bcv infection,1995,"Baca-Estrada, M E; Liang, X; Babiuk, L A; Yoo, D",Immunology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/7590874/,10953414.0,3
64078,64078,79979,5msiohm0,,Medline,Viral and bacterial vectors of immunogenes.,,,4002835.0,unk,recent development production experimental vaccine use smallpox vaccine virus vaccinia virus carrier vector gene immunogenes code protectioninducing protein immunogen unrelated virus potential vector vaccine lie hope vaccine would cheaper safer andor effective existing vaccine pathogen vaccinia virus vector attracted attention date several immunogenes inserted genome without destroying infectivity immunogen appear produced normally vaccinia virus used highly successfully eradicate smallpox wide hostrange thus might find veterinary well human medical application experimental vaccine successfully tested animal prepared using immunogenes influenza virus hepatitis b virus herpes simplex virus apathogenic enteric bacteria potential vector probably enteric pathogen although potential viral vector likely realized first parasitic worm protozoa devastate million people immunogen organism identified added impetus investigate potential vector vaccine pathogen,1985,"Cavanagh, D",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/4002835/,25990396.0,3
64163,64163,80077,v90fu364,,Medline,Protective lactogenic immunity conferred by an edible peptide vaccine to bovine rotavirus produced in transgenic plants.,,,15218166.0,unk,vaccine produced transgenic plant constitute promising alternative conventional immunogen presenting possibility stimulating secretory systemic immunity enteric pathogen administered orally protection enteric pathogen affecting newborn animal requires case stimulation lactogenic immunity group present development experimental immunogen based expression immunorelevant peptide ebrv vp protein bovine rotavirus brv described harbouring least one neutralizing epitope well responsible adsorption virus epithelial cell ebrv epitope efficiently expressed transgenic alfalfa translational fusion protein highly stable reporter enzyme betaglucuronidase betagus served carrier stabilized synthesized peptide facilitated screening higher expression level plant correlation expression ebrv epitope plant presenting highest betagus activity confirmed western blot assay specific brv peptide ebrv epitope expressed plant effective inducing antirotavirus antibody response adult female mouse administered either intraperitoneally orally importantly suckling mouse born immunized female mouse protected oral challenge virulent rotavirus result demonstrate feasibility inducing lactogenic immunity enteric pathogen using edible vaccine produced transgenic plant,2004,"Wigdorovitz, Andrés; Mozgovoj, Marina; Santos, María J Dus; Parreño, Viviana; Gómez, Cristina; Pérez-Filgueira, Daniel M; Trono, Karina G; Ríos, Raúl D; Franzone, Pascual M; Fernández, Fernando; Carrillo, Consuelo; Babiuk, Lorne A; Escribano, José M; Borca, Manuel V",The Journal of general virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15218166/,22427724.0,3
64177,64177,80095,6e493t4x,,Medline,Comparative studies of the capsid precursor polypeptide P1 and the capsid protein VP1 cDNA vectors for DNA vaccination against foot-and-mouth disease virus.,,,15693054.0,unk,background footandmouth disease virus fmdv cause severe livestock disease virus interesting target virology vaccine study material method evaluated comparatively three different viral antigenencoding dna sequence delivered via two physical mean ie gene gun delivery skin electroporation delivery muscle naked dnamediated vaccination mouse system result method gave similar result demonstrating commonality observed dna vaccine effect immunization cdna vector expressing major viral antigen vp alone routinely failed induce production antivp neutralizing antibody test mouse second approach plasmid lvp produce transgenic membraneanchored vp protein elicited strong antibody response test mouse failed fmdv challenge experiment contrast mouse immunized viral capsid precursor protein p cdna expression vector neutralizing antibody protection test mouse detected conclusion strategy using whole capsid precursor protein p cdna vaccination intentionally without use virusspecific protease encoding gene safety reason may thus employed relevant experimental system induction upgrading effective neutralizing antibody response convenient surrogate test system dna vaccination study fmdv presumably viral disease,2005,"Yang, Ning-Sun; Wang, Jeng-Hwan; Lin, Ku-Feng; Wang, Chien-Yu; Kim, Suk-Am; Yang, Yu-Ling; Jong, Ming-Hwa; Kuo, Tsun-Yung; Lai, Shiow-Suey; Cheng, R Holland; Chan, Ming-Tsair; Liang, Shu-Mei",The journal of gene medicine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15693054/,25758603.0,3
64337,64337,80290,n4o6atll,,Medline,Obstacles and advances in SARS vaccine development.,,,16191455.0,unk,emergence severe acute respiratory syndrome sars resulted pandemic spurred flurry interest development vaccine prevent treat potentially deadly viral infection researcher around world pooled scientific resource shared early data unprecedented manner light impending public health crisis still large gap knowledge pathogenesis virus significant advance made development animal model practicality use may hampered lack pathological similarity human disease described issue related progress vaccine development obstacle lie ahead researcher regulatory agency,2006,"Taylor, Deborah R",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16191455/,27344206.0,3
64353,64353,80311,7vtinleb,,Medline,Development and use of the H strain of avian infectious bronchitis virus from the Netherlands as a vaccine: a review.,,,15763721.0,unk,h strain infectious bronchitis ib one earliest live attenuated ib vaccine developed continued use part world almost year developed used nd h th h vaccine level ability provide heterologous crossprotection number ib virus different serotypes proved one enduring live attenuated ib vaccine fact h vaccine possibly widely used live attenuated ib vaccine globally day use h however declined introduction safe highly efficacious inactivated ib vaccine review document original study isolate attenuate h strain serial embryo passage describes early study demonstrate efficacy laboratory study field condition efficacy h vaccine providing crossprotection many ib variant reported worldwide also discussed possible future vaccination strategy ib considered,2004,"Bijlenga, Gosse; Cook, Jane K A; Gelb, Jack; de Wit, J J",Avian pathology : journal of the W.V.P.A,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15763721/,27193918.0,3
64515,64515,80498,rbyik31b,,Medline,Evaluation of the protection conferred by commercial vaccines against the California 99 isolate of infectious bronchitis virus.,,,14708975.0,unk,infectious bronchitis virus ibv isolated commercial broiler state california exhibiting respiratory distress inflamed trachea airsaculitis edematous lung reverse transcriptasepolymerase chain reaction rtpcr california isolate exhibited identical restriction fragment length polymorphism rflp pattern isolates obtained california known california isolates commercial massconn massark vaccine used vaccinate commercial broiler chicken via eye drop day age twice day age day age bird challenged via eye drop isolated ibv california strain protection measured failure reisolate challenge virus trachea day postchallenge complemented withthe tracheal epithelium thickness score massark vaccine included vaccination program protection challenge ibv california isolate massconn vaccine conferred protection used day age twice day age however total protection achieved used vaccine day age since one replicates positive virus isolation significant difference p epithelium thickness tracheal score observed unvaccinatedunchallenged group group vaccinated twice massconn vaccine based result chicken protected california isolate ibv arkansas type used vaccine,2003,"Alvarado, I R; Villegas, P; El-Attrache, J; Brown, T P",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/14708975/,24585395.0,3
64568,64568,80562,okjxolym,,Medline,Neonatal immunity and immunisation in early age: lessons from veterinary medicine.,,,9711790.0,unk,objective paper review adaptive immunity young animal using example experience literature trial carried u modified live inactivated canine parvovirus vaccine newborn puppy provide evidence immune capacity puppy regard transfer immunity mother offspring role transplacental colostral immunity example passive protection young animal different infection include passive protection kitten feline immunodeficiency virus however passive immunity though useful early age varies duration make implementation standard vaccination schedule difficult experiment demonstrate certain condition possible overcome residual maternallyderived antibody induce postvaccinal immunity,1998,"Chappuis, G",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/9711790/,20488533.0,3
64621,64621,80624,winq16mq,,Medline,Infectious bronchitis virus field vaccination coverage and persistence of Arkansas-type viruses in commercial broilers.,,,19630221.0,unk,determine coverage infectious bronchitis virus ibv vaccine field boost commercial broiler estimate relative amount vaccine virus trachea follow clearance vaccine collected approximately tracheal swab various time postvaccination different flock used realtime reverse transcriptasepcr rtpcr detect virus allowed u detect vaccine virus bird flock bird confidence level found number bird positive ibv vaccine following vaccination field resembled parabolicshaped curve peaked around day postvaccination resembled sinusoidaltype wave frequency wk pattern appear correlate water spray vaccination method correlate type backpack sprayer used highest number positive bird flock ranged viral genome copy tracheal swab determined realtime rtpcr ranged x ml x ml study positive correlation number bird positive vaccine virus flock last sample day study day postvaccination bird still positive vaccine virus although different ibv vaccine type used study arkansas vaccine virus identified selected sample day arkansas vaccine virus also virus identified selected sample day postvaccination clearly indicating arkansas vaccine virus persisting bird protection study conducted bird vaccinated arkansas delawaretype vaccine removed field day postvaccination showed complete protection challenge delaware except one bird whereas protection arkansas challenge finding show introduction ibv vaccine commercial broiler flock necessarily follow seemingly logical pattern high number bird infected followed clearance trachea resembled either parabolic curve sinusoidaltype wave addition arkansas vaccine virus clearly persisting commercial broiler may incomplete protection observed ibv type,2009,"Jackwood, Mark W; Hilt, Deborah A; McCall, Amber W; Polizzi, Crystal N; McKinley, Enid T; Williams, Susan M",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19630221/,7047757.0,3
64660,64660,80669,9uqwkeep,,Medline,"Immunisation registers in Canada: progress made, current situation, and challenges for the future.",,,22551496.0,unk,immunisation register capacity capture data administration vaccine dos individual level within population represent important tool assessing immunisation coverage vaccine uptake national advisory committee immunization recommended network immunisation register established canada canadian immunization registry network cirn established coordinate development standard facilitate sharing knowledge experience develop national network register national immunization strategy identified immunisation register important component improving national immunisation surveillance addition consistent public professional interest national immunisation register available considerable progress made developing technology facilitate capture immunisationrelated data specifically automated identification vaccine use barcodes vaccine facilitate collection data related administered vaccine dos nevertheless challenge remain implementation immunisation register canadian province territory canada still currently fully functional network immunisation register capacity interoperable jurisdiction allow data captured national level,2012,"Laroche, J A; Diniz, A J",Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/22551496/,2302778.0,3
64669,64669,80679,414ql5d3,,Medline,Evolutionary implications of Avian Infectious Bronchitis Virus (AIBV) analysis.,,,16541132.0,unk,developing efficient vaccine essential identify amino acid change important survival virus investigate amino acid substitution feature avian infectious bronchitis virus aibv antigenic domain vaccine serotype de virulent viral strain ga better understand adaptive evolution aibv addition sars coronavirus sarscov also analyzed way interesting find extreme comparability exists aibv sars amino acid substitution pattern suggests amino acid change result overall shift residue charge polarity paid special attention development vaccine,2006,"Shi, Peng; Yu, Li; Fu, Yun-Xin; Huang, Jing-Fei; Zhang, Ke-Qin; Zhang, Ya-ping",Cell research,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16541132/,19801937.0,3
64709,64709,80725,8dnzl5z8,,Medline,Adenoviruses as vectors for delivering vaccines to mucosal surfaces.,,,11000466.0,unk,immunization mucosal surface become attractive route vaccine delivery ability induce mucosal immunity although various method inducing mucosal immunity developed laboratory focused developing adenovirus replicationcompetent replicationincompetent vector present report summarize progress sequencing entire bovine adenovirus genome identifying region deleted subsequently used insertion site foreign gene developing recombinant viral vaccine using recombinant virus demonstrated proofofprinciple developing mucosal immunity importantly inducing protection bovine herpes virus natural hostcattle finally demonstrated immunity protection occurred even animal preexisting antibody vector,2000,"Babiuk, L A; Tikoo, S K",Journal of biotechnology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/11000466/,45289086.0,3
64740,64740,80758,6chjuqcg,,Medline,Heterogeneity of porcine reproductive and respiratory syndrome virus: implications for current vaccine efficacy and future vaccine development.,,,10831854.0,unk,porcine reproductive respiratory syndrome virus prrsv continues major problem pork industry worldwide increasing data indicate prrsv strain differ virulence infected pig biologically antigenically genetically heterogeneous evident current vaccine based single prrsv strain effective protecting infection genetically diverse field strain prrsv recent outbreak atypical acute prrs vaccinated pig raised serious concern efficacy current vaccine provided impetus developing effective vaccine special attention review given published work antigenic pathogenic genetic variation prrsv potential implication vaccine efficacy development although ample data documenting heterogeneous nature prrsv strain information regarding heterogeneity generated clinical impact may scarce observed heterogeneity likely pose major obstacle effective prevention control prrs remains urgent need fundamental research virus understand basic biology mechanism heterogeneity pathogenesis prrsv,2000,"Meng, X J",Veterinary microbiology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/10831854/,39527845.0,3
64823,64823,80856,o5kg1sd9,,Medline,IgE reactivity to vaccine components in dogs that developed immediate-type allergic reactions after vaccination.,,,15734545.0,unk,allergic reaction vaccination considered important practical problem dog however immunological mechanism well understood present study designed investigate relationship ige reactivity vaccine immediatetype allergic reaction vaccination dog serum dog developed immediatetype allergic reaction circulatory collapse cyanosis dyspnea facial edema vomiting within h vaccination nonrabies monovalent combined vaccine serum dog develop allergic reaction vaccination collected serum ige reactivity injected vaccine measured fluorometric elisa using mouse monoclonal antidog ige antibody ige reactivity fetal calf serum fcs stabilizer protein gelatin casein peptone included vaccine measured serum high level ige vaccine level serum specific ige vaccine dog immediatetype allergic reaction fluorescence unit fu mean sd fu significantly higher control dog fu fu p eight dog developed immediatetype allergic reaction high level serum specific ige vaccine seven specific ige directed fcs ige reactivity vaccine serum dog almost completely inhibited fcs one dog serum ige directed gelatin casein included vaccine stabilizer result obtained study suggest immediatetype allergic reaction vaccination dog induced type hypersensitivity mediated ige directed vaccine component addition fcs gelatin casein included vaccine could causative allergen induced immediatetype allergic reaction vaccination dog,2005,"Ohmori, Keitaro; Masuda, Kenichi; Maeda, Sadatoshi; Kaburagi, Yukiko; Kurata, Keigo; Ohno, Koichi; Deboer, Douglas J; Tsujimoto, Hajime; Sakaguchi, Masahiro",Veterinary immunology and immunopathology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15734545/,19082315.0,3
64881,64881,80923,99o9te4j,,Medline,Animal coronavirus vaccines: lessons for SARS.,,,15742624.0,unk,severe acute respiratory syndrome sars emerged china spread globally human pandemic caused new coronavirus cov suspect animal origin emergence sars stunned medical scientist veterinary virologist previously recognized covs causing fatal respiratory enteric disease animal interspecies transmission wildlife reservoir public health impact major effort focused development sars vaccine occurrence cov disease mucosal surface necessitates stimulation local immunity impact vaccine type delivery adjuvant needed achieve mucosal immunity immunity often shortlived requires frequent boosting may prevent reinfection factor complicating cov vaccine design sars vaccine effort enhanced understanding correlate protection reason success failure animal cov vaccine review focus study immunity protection swine enteric cov transmissible gastroenteritis tgev versus respiratory variant porcine respiratory cov prcv comparing live inactivated subunit vaccine various vaccine vector route adjuvant addition avian infectious bronchitis cov ibv vaccine targeted protection upper respiratory tract chicken discussed unfortunately despite longterm effort effective vaccine prevent enteric cov infection remain elusive generally live killed vaccine induced consistent protection animal covs confirmation pathogenesis sars human animal model mimic sars may aid vaccine design evaluation,2004,"Saif, L J",Developments in biologicals,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15742624/,21528738.0,3
64894,64894,80938,tggmwgtt,,Medline,Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines.,,,16005746.0,unk,studied immunogenicity dna sarsvaccine whole killed virus whole killed dna vaccine combination dna vaccine contained plasmid encoding sars coronavirus sarscov protein control human cmv promoter intron whole killed virus vaccine comprised sarscov propagated veroe cell subsequent betapropilactone inactivation formulated aluminum hydroxide adjuvant mouse immunized twice dna vaccine whole killed virus elicited higher antibody response mouse immunized three time dna vaccine whole killed virus vaccine mouse immunized twice whole killed virus vaccine elicited higher antibody response mouse immunized three time dna vaccine whole killed virus vaccine however combination vaccine induced thelper type th immune response whole killed virus vaccine induced helper type th immune response result demonstrate combination dna vaccine whole killed virus vaccine used enhance magnitude change bias immune response sarscov,2005,"Zakhartchouk, Alexander N; Liu, Qiang; Petric, Martin; Babiuk, Lorne A",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16005746/,19903144.0,3
64906,64906,80955,pvdetf6c,,Medline,Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus.,,,18069096.0,unk,japanese encephalitis virus jev serocomplexgroup consists mosquitoborne flavivirus include west nile virus wnv jev may cause severe encephalitis human wnv spread rapidly across united state since introduction geographical distribution within western hemisphere expected expand whereas jev common cause viral encephalitis southeast asia china india currently registered human vaccine specific therapy prevent treat wnv infection describe efficacy recombinant domain iii diii wnv glycoprotein e mouse model induces high neutralizing antibody titer well protection lethal wnv infection cbl mouse vaccine preparation also afforded partial protection lethal jev infection,2008,"Martina, Byron E; Koraka, Penelopie; van den Doel, Petra; van Amerongen, Geert; Rimmelzwaan, Guus F; Osterhaus, Albert D M E",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/18069096/,26420674.0,3
64929,64929,80984,j2q06g4c,,Medline,Avian infectious bronchitis virus: a possible cause of reduced fertility in the rooster.,,,15666874.0,unk,formation epididymal stone rooster epididymis widespread problem detrimental effect sperm production fertility cause epididymal stone unknown infectious agent avian infectious bronchitis virus aibv implicated goal study determine administering live attenuated aibv vaccine male chick increase incidence stone epididymal region adult rooster specific pathogen free spf leghorn rooster divided two group vaccinefree group n group vaccinated aibv n vaccine administered orally wk age blood drawn weekly monitor antibody aibv wk age blood obtained determine testosterone concentration reproductive tract removed analyze daily sperm production detect epididymal stone nine vaccinated rooster developed stone whereas given vaccine develop stone serum testosterone concentration significantly p reduced vaccinated rooster epididymal stone ngml compared nonvaccinated rooster epididymal stone ngml testis weight significantly p reduced vaccinated rooster epididymal stone g compared nonvaccinated rooster without epididymal stone g daily sperm production significantly p decreased vaccinated rooster epididymal stone x spermtestisday compared nonvaccinated rooster without epididymal stone x spermtestisday comparing daily sperm production per gram basis vaccinated rooster epididymal stone x spermg testis significantly p smaller nonvaccinated rooster without epididymal stone x spermg testis conclude use live attenuated aibv vaccine increase incidence epididymal stone rooster resulting decreased sperm production decreased serum testosterone concentration,2004,"Boltz, David A; Nakai, Masaaki; Bahra, Janice M",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15666874/,1374997.0,3
65035,65035,81118,mi9d60u1,,Medline,Immunology and prevention of infection in feedlot cattle.,,,9704413.0,unk,article review basic type immunity factor relevant feedlot cattle shown suppress immune function known basis protective acquired immunity common bovine respiratory pathogen characteristic efficacy vaccine respiratory disease pathogen also reviewed recommendation optimizing vaccination presented,1998,"Roth, J A; Perino, L J",The Veterinary clinics of North America. Food animal practice,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/9704413/,35097990.0,3
65074,65074,81162,ha7tq32a,,Medline,Applications and optimization of immunization procedures.,,,15953832.0,unk,classical immunization protocol produced antibodybased humoral response effective susceptible infectious disease immunization introduces external substance induce host immune system respond specifically typically antigen used dna primed preexisting leukocyte antigenpresenting cell also used immunization currently used investigated prevention treatment infectious disease cancer addiction allergy pregnancy autoimmune disease also used produce biologically active material polyclonal monoclonal antibody antivenin antitoxin treating wide range condition animal integral development immunization technique producer toxoid antitoxin model eg validate material protocol used immunization understand impact immunization immune system help investigator devise method determining efficacy vaccine beneficiary vaccine antitoxin choice immunization protocol complex result may affected many factor dose concentration antigen choice adjuvant time inoculation response measurement method detection immune system response antigen also complex continue develop advancing age anatomical physiological immune system difference specie influence response immunization purity presentation antigen adjuvant directly comparing result animal sourced supplier review highlight many us immunization technique introduces important consideration choice protocol animal model,2005,"Schunk, Michael K; Macallum, G Eileen",ILAR journal,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15953832/,5900305.0,3
65108,65108,81199,aco4x51x,,Medline,Mucosal and systemic immune responses to chimeric fimbriae expressed by Salmonella enterica serovar typhimurium vaccine strains.,,,10816454.0,unk,recombinant live oral vaccine expressing pathogenderived antigen offer unique set attractive property among simplicity administration capacity induce mucosal systemic immunity advantage permitting genetic manipulation optimal antigen presentation study benefit heterologous antigen expressed surface live vector rather intracellularly evaluated accordingly immune response mouse immunized salmonella enterica serovar typhimurium vaccine strain expressing escherichia coli p fimbrial antigen surface fa compared expression periplasmic compartment fa orally immunized balbc mouse showed p fimbriated salmonella serovar typhimurium c aroa asd pc fa asd elicited significantly higher level pspecific systemic immunoglobulin g igg mucosal iga serovar typhimurium c pc fasd mutant asd expressing p periplasmic antigen study aimed determining whether p fimbria expressed serovar typhimurium chi cya crp asd could used carrier foreign epitope vaccine strain genetically engineered express chimeric fimbria carrying transmissible gastroenteritis virus tgev c epitope spike protein inserted p major fimbrial subunit fasa balbc mouse administered orally serovar typhimurium chi expressing chimeric fimbria tet promoter pc fa asd produced systemic antibody fimbria tgev c epitope tgev epitope improve immunogenicity chimeric fimbria vivo inducible nirb promoter inserted pc upstream fa gene create pc comparison previously used vaccine balbc mouse immunized orally serovar typhimurium chipcs demonstrated significantly higher level serum igg mucosal iga p fimbria moreover mucosal iga tgev c epitope detected serovar typhimurium chipcs induced antibody also recognized epitope context fulllength tgev spike protein hence immune response heterologous chimeric fimbria salmonella vaccine vector optimized using promoter known activated vivo,2000,"Chen, H; Schifferli, D M",Infection and immunity,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/10816454/,34754693.0,3
65124,65124,81217,zk04k1nw,,Medline,"Evaluation of the efficacy and duration of immunity of a canine combination vaccine against virulent parvovirus, infectious canine hepatitis virus, and distemper virus experimental challenges.",,,15578450.0,unk,result study confirmed dog vaccinated subcutaneously commercially available multivalent vaccine containing modifiedlive canine distemper virus canine adenovirus type canine parvovirus type b canine parainfluenza virus antigen protected sequential experimental challenge month initial vaccination given week age vaccinates protected clinical disease mortality following parvovirus infectious canine hepatitis experimental infection vaccinates protected mortality clinical disease following distemper challenge data support least year duration immunity three core fraction combination vaccine,2004,"Abdelmagid, Omar Y; Larson, Laurie; Payne, Laurie; Tubbs, Anna; Wasmoen, Terri; Schultz, Ronald",Veterinary therapeutics : research in applied veterinary medicine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15578450/,30975980.0,3
65183,65183,81282,ukbevpr7,,Medline,Modulation of the immune response to the severe acute respiratory syndrome spike glycoprotein by gene-based and inactivated virus immunization.,,,16254327.0,unk,although initial isolates severe acute respiratory syndrome sars coronavirus cov sensitive neutralization antibody spike glycoprotein variant since identified resistant inhibition optimal vaccine strategy would therefore make use additional determinant immune recognition either cellular expanded crossreactive humoral immunity cellular humoral immune response elicited different combination genebased inactivated viral particle various adjuvant assessed tcell response altered different primeboost immunization optimal cd immunity induced dna priming replicationdefective adenoviral vector boosting humoral immune response enhanced effectively use inactivated virus adjuvant either mf alum associated stimulation cd cd response use inactivated sars virus mf enhanced cd antibody response even genebased vaccination cellular humoral immune response generated genebased vaccination inactivated viral boosting strategy may prove useful generation sarscov vaccine,2005,"Kong, Wing-pui; Xu, Ling; Stadler, Konrad; Ulmer, Jeffrey B; Abrignani, Sergio; Rappuoli, Rino; Nabel, Gary J",Journal of virology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16254327/,23667015.0,3
65254,65254,81368,xidvx2dk,,Medline,Rapid-response vaccines--does DNA offer a solution?,,,16151391.0,unk,responding future influenza pandemic infectious agent plasmid dna overcomes many limitation conventional vaccine production approach,2005,"Forde, Gareth M",Nature biotechnology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16151391/,29983961.0,3
65289,65289,81415,ysec7wt5,,Medline,The role of reverse genetics in the development of vaccines against respiratory viruses.,,,15833074.0,unk,despite significance available vaccine respiratory virus prevention influenza attempt made produce vaccine respiratory virus using traditional technique met little success reverse genetics although still relatively new tool manipulation negativestrand rna virus great potential preparation vaccine many common respiratory virus preparation live vaccine reverse genetics system allow direct modification specific region genome negativestranded rna virus concerned attenuation ultimate goal introduction sitespecific mutation cdna intermediate order develop strain requisite attenuation antigenic growth property needed vaccine technique also used disarm potentially highly pathogenic virus emerging hn avian influenza virus order facilitate largescale preparation virus use inactivated vaccine condition manufacturing safety vaccine become available residual issue concerned intellectual property right technology application need resolved,2005,"Marsh, G A; Tannock, G A",Expert opinion on biological therapy,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15833074/,37412613.0,3
65351,65351,81494,2usk0vtn,,Medline,"Pandemic influenza: imminent threat, preparedness and the divided globe.",,,19242025.0,unk,generic consensus certainty impending influenza pandemic concern mounting devastating global impact preparedness preventive approach adopted nation state polarised resource rich resource challenged country india rightly taken middle path seems nonpharmaceutical intervention would preventive modality available large part world production pandemic vaccine would take minimum month isolation novel virus antiviral may available required effort create universal pool resource stockpile antiviral antibiotic vaccine use first affected country need strengthened urgency,2009,"Chaturvedi, Sanjay",Indian pediatrics,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19242025/,20419768.0,3
65422,65422,81572,521zj5u2,,Medline,Construction of a eukaryotic expression plasmid encoding partial S gene fragments of the SARS-CoV and its potential utility as a DNA vaccine.,,,16101350.0,unk,spike protein main surface antigen sars coronavirus sarscov considered one important protective antigen candidate target vaccine design virus study secreted recombinant expression plasmid pvaxs encoding partial protein signal peptide constructed used immunize balbc mouse electroporation demonstrated eukaryotic expression vector pvaxs successfully constructed restriction enzyme sequence analysis expressed protein could detected specifically western blot analysis serum igg level vaccine group mouse significantly higher corresponding control group day vaccination p vaccine group demonstrated significantly higher protein lymphocyte proliferation index lpi control group p furthermore experimental group decrease ratio cd cd tlymphocytes increase level ifngamma serum observed however interleukin il detectable two group result strongly demonstrated pvaxs plasmid could induce humoral cellular immune response mouse may potential candidate dna vaccine sars coronavirus,2005,"He, Hongxuan; Tang, Yi; Qin, Ximing; Xu, Wenbo; Wang, Yifei; Liu, Xiangjun; Liu, Xingyou; Xiong, Sheng; Li, Jiuxiang; Zhang, Meiying; Duan, Mingxing",DNA and cell biology,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16101350/,43914087.0,3
65434,65434,81584,3qp119dw,,Medline,Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models.,,,17289225.0,unk,investigated novel vaccine strategy severe acute respiratory syndrome sars cov using cdna construct encoding structural antigen e n protein derived sars cov pbl healthy human volunteer administered ip il receptor gammachain disrupted scid mouse scidpblhu mouse constructed mouse used analyze human immune response vivo sars dna vaccine n dna vaccine induced human ctl specific sars cov antigen alternatively sars dna vaccine inducing human neutralizing antibody human monoclonal antibody sars cov developed result show vaccine induce virusspecific immune response provide useful tool development protective therapeutic vaccine,2007,"Okada, Masaji; Okuno, Yoshinobu; Hashimoto, Satomi; Kita, Yoko; Kanamaru, Noriko; Nishida, Yasuko; Tsunai, Yoshie; Inoue, Ruriko; Nakatani, Hitoshi; Fukamizu, Reiko; Namie, Yumi; Yamada, Junko; Takao, Kyoko; Asai, Ritsuko; Asaki, Ryoko; Kase, Tetsuo; Takemoto, Yuji; Yoshida, Shigeto; Peiris, J S M; Chen, Pei-Jer; Yamamoto, Naoki; Nomura, Tatsuji; Ishida, Isao; Morikawa, Shigeru; Tashiro, Masato; Sakatani, Mitsunori",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17289225/,22825287.0,3
65575,65575,81745,uxys23xj,,Medline,A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice.,,,16497416.0,unk,recombinant sarscov spike glycoprotein vaccine produced insect cell preclinical development stage described truncated version glycoprotein containing ectodomain well histagged fulllength version cloned expressed serumfree insect cell line expressf protein purified apparent homogeneity liquid column chromatography formulated without adjuvant microg per dose phosphate saline used immunize mouse antigen formulation elicited strong immune response two three vaccination antigen neutralizing antibody titer correlated closely standard elisa reactivity glycoprotein truncated protein also formulated adjuvant aluminum hydroxide microg per dose adjuvant microg per dose adjuvant significantly enhanced immune response manifested higher titer serum elisa viral neutralizing antibody achieved adjuvanted group fewer dos lower concentration glycoprotein finding indicate ectodomain sarscov glycoprotein vaccine without adjuvant immunogenic induces high titer virus neutralizing antibody level similar achieved full glycoprotein vaccine,2006,"Zhou, Zhimin; Post, Penny; Chubet, Rick; Holtz, Katherine; McPherson, Clifton; Petric, Martin; Cox, Manon",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16497416/,1619228.0,3
65618,65618,81794,rmirt5yu,,Medline,Immunoglobulin A as an early humoral responder after mucosal avian coronavirus vaccination.,,,25055633.0,unk,infectious bronchitis virus ibv highly contagious coronavirus prevalent country extensive poultry industry continues cause economic loss ibv strain ark serotype highly prevalent southeastern united state despite extensive vaccination one explanation observation high genetic variability ibv addition ibv arktype vaccine may induce suboptimal mucosal immune response contributing prevalence persistence ark serotype test hypothesis chicken ocularly vaccinated commercially available live attenuated ibv arkdelmarva poultry industry vaccine strain mucosal systemic antibody response measured highest immunoglobulin iga spotforming cell sfc response observed harderian gland hg lesser extent spleen conjunctivaassociated lymphoid tissue limited igg sfc response observed either mucosal systemic immune compartment interestingly peak iga sfc response occurred day earlier spleen headassociated lymphoid tissue despite ocular vaccination furthermore iga ibvspecific antibody level significantly increased control day earlier tear day earlier plasma igg antibody iga antibody level higher igg antibody level throughout primary response tear similar magnitude plasma addition early increase iga antibody day postvaccination observed tear response observed plasma early increase consistent mucosal tindependent iga response ibv secondary response ibv antibody level significantly increased control starting day boosting igg antibody level higher iga antibody level tear plasma summary ocular vaccination induced higher iga antibody primary ibv response memory response dominated igg antibody thus lower mucosal iga antibody level observed upon secondary exposure ibv may contribute vulnerability host epithelial cell infection ibv persistence ark serotype,2014,"Orr-Burks, Nichole; Gulley, Stephen L; Toro, Haroldo; van Ginkel, Frederik W",Avian diseases,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/25055633/,10154133.0,3
65631,65631,81809,dufre0ri,,Medline,Canine viral enteritis.,,,6316616.0,unk,canine viral enteritis suspected dog acute onset vomiting diarrhea especially puppy several animal affected simultaneously definitive diagnosis requires laboratory confirmation often detection viral particle stool diagnostic test entirely specific absolutely sensitive however laboratory finding weighed accordingly immunization key successful control effective vaccine canine parvovirus available maternal antibody suppresses response vaccination young pup major problem control infection vaccine canine rotavirus coronavirus available need vaccine feasibility effective use yet clearly demonstrated,1983,"Pollock, R V; Carmichael, L E",The Veterinary clinics of North America. Small animal practice,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/6316616/,9154839.0,3
65638,65638,81816,wik8nfde,,Medline,[Coronaviruses in pathology].,,,6246565.0,unk,crownlike projection surface particle permit differentiation coronaviruses riboviruses individualization distinct family recognition role aetiology respiratory enteral encephalitic infection promoted investigation finding preventive vaccine selection strain showed immunogenicity depends upon density salience crownlike projection antigenic relationship projection determining cross serologic reaction different specie present experiment carried animal vaccine prepared antigenically related heterologous cornavirus specie pathogenic host subunitary vaccine prepared projection homologous specie coronaviridae family established morphologic criterion thus confirmed immunologic relationship specificity member,1980,"Diosi, P; Plavoşin, L; Herzog, G","Revista de igiena, bacteriologie, virusologie, parazitologie, epidemiologie, pneumoftiziologie. Bacteriologia, virusologia, parazitologia, epidemiologia",,,,,,https://www.ncbi.nlm.nih.gov/pubmed/6246565/,22751964.0,3
65650,65650,81830,u5itvucf,,Medline,Immunogenicity of SARS inactivated vaccine in BALB/c mice.,,,15388253.0,unk,severe acute respiratory syndrome sars serious infectious threat public health create novel trial vaccine evaluate potency attempted generate sars inactivated vaccine using sars coronavirus sarscov strain f treated formaldehyde mixed aloh three dos vaccine used challenge three group balbc mouse found mouse exhibited specific igm day igg day peak titer igg day lowdose group highdose group whereas middledose group peak day day igg level reached plateau neutralization assay demonstrated antiserum could protect veroe cell sarscovs infection analysis antibody specificity revealed mouse antiserum contained mixture antibody specifically structure protein sarscov furthermore mouse antiserum conferred higher amount antibody protein n polypeptide protein cl finding suggest inactivated sarscov could preserve antigenicity inactivated vaccine stimulate mouse produce high level antibody neutralization activity result also suggest polypeptide originating protein n might potential target generation recombinant sars vaccine,2004,"Xiong, Sheng; Wang, Yi-Fei; Zhang, Mei-Ying; Liu, Xin-Jian; Zhang, Chuan-Hai; Liu, Shi-Sheng; Qian, Chui-Wen; Li, Jiu-Xiang; Lu, Jia-Hai; Wan, Zhuo-Yue; Zheng, Huan-Yin; Yan, Xin-Ge; Meng, Min-Jie; Fan, Jiang-lin",Immunology letters,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15388253/,32927614.0,3
65697,65697,81885,g9rl99pp,,Medline,Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination.,,,17573530.0,unk,capable inducing antigenspecific immune response systemic mucosal compartment without use syringe needle mucosal vaccination considered ideal global control infectious disease study developed ricebased oral vaccine expressing cholera toxin b subunit ctb control endospermspecific expression promoter kb glutelin glub codon usage optimization expression rice seed average mug ctb per seed stored protein body storage organelle rice mucosally fed rice seed expressing ctb taken cell covering peyers patch induced ctbspecific serum igg mucosal iga antibody neutralizing activity expressed rice ctb protected pepsin digestion vitro riceexpressed ctb also remained stable thus maintained immunogenicity room temperature year meaning antigenspecific mucosal immune response induced much lower dos necessary purified recombinant ctb require neither refrigeration coldchain management needle ricebased mucosal vaccine offer highly practical costeffective strategy orally vaccinating large population mucosal infection including may result act bioterrorism,2007,"Nochi, Tomonori; Takagi, Hidenori; Yuki, Yoshikazu; Yang, Lijun; Masumura, Takehiro; Mejima, Mio; Nakanishi, Ushio; Matsumura, Akiko; Uozumi, Akihiro; Hiroi, Takachika; Morita, Shigeto; Tanaka, Kunisuke; Takaiwa, Fumio; Kiyono, Hiroshi",Proceedings of the National Academy of Sciences of the United States of America,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/17573530/,3190892.0,3
65701,65701,81890,794kqbxk,,Medline,Vaccines in the public eye.,,,15812485.0,unk,preventive vaccine widely acknowledged best hope protection infectious pathogen avian flu hiv sars result received much recent attention medium exposed challenge involved optimally using vaccine technology,2005,"Ritvo, Paul; Wilson, Kumanan; Willms, Dennis; Upshur, Ross; Goldman, Adam; Kelvin, David; Rosenthal, Kenneth L; Rinfret, Aline; Kaul, Rupert; Krahn, Murray",Nature medicine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15812485/,6562373.0,3
66526,66526,83289,qk11c754,,WHO,Coronavirus Vaccines: Light at the End of the Tunnel,,,,unk,world currently facing unprecedented global pandemic caused severe acute respiratory syndrome coronavirus sarscov predicting next source pandemic challenging vaccination best way prevent infectious disease development effective vaccine sarscov reduce morbidity mortality associated also lessen economic impact traditional method vaccine development take many year vaccine available society vaccine development sarscov speeded using pandemic approach fasttrack approval regulatory authority various challenge associated developing vaccine pandemic technological hurdle clinical development pathway regulatory issue support global funding agency expressed,2020,"Ella, Krishna M.; Mohan, V. Krishna",Indian pediatrics,,#60460,,,,,215772698.0,3
66618,66618,83423,yijkyld0,,WHO,Viruses to fight other viruses: the influenza vaccine case,,,,unk,undoubtedly vaccination one health intervention showing major impact humankind vaccine remain one effective safest way tackle infection current coronavirus pandemic exception hope ongoing international effort succeed developing vaccine soon scenario present work published edition embo molecular medicine demminger colleague demminger et al timeliness exemplify step needed develop effective vaccine,2020,"Bengoechea, Jose A",EMBO Mol Med,,#102293,,,,,216074186.0,3
67170,67170,84346,7yq8zqxq,,WHO,SARS-CoV-2 Vaccines: Status Report,,,,unk,sarscov causal agent covid first emerged late china since infected individual caused death globally discus therapeutic prophylactic intervention sarscov focus vaccine development challenge vaccine rapidly developed likely come late affect first wave potential pandemic nevertheless critical lesson learned development vaccine rapidly emerging virus importantly sarscov vaccine essential reducing morbidity mortality virus establishes population,2020,"Amanat, Fatima; Krammer, Florian",Immunity,,#20439,,,,,214753433.0,3
67677,67677,85215,m88ha8ry,,WHO,The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines,,,,unk,outbreak novel coronavirus disease covid caused sarscov spread rapidly china developed public health emergency international concern however specific antiviral treatment vaccine available yet work aim share strategy candidate antigen develop safe effective vaccine sarscov outbreak novel coronavirus sarscov cause atypical pneumonia covid raged china since middecember spread country february epidemic identified first four case confirmed december traced huanan seafood wholesale market wuhan city hubei province china total case sarscov infection confirmed date february people died china covid spread rapidly humantohuman transmission median incubation period day range time symptom onset developing pneumonia day range respiratory droplet direct contact conventional transmission route sarscov fecaltooral transmission might also role fever dry cough fatigue common symptom onset covid patient lymphopenia bilateral groundglass opacity change chest ct scan specific antiviral treatment vaccine available new emerging viral disease development sarscovbased vaccine urgently required entire virus particlebased preparation vaccine including inactivated attenuated virus vaccine advisable based previous study prevention control seasonal influenza vaccine first sarscov wuhanhu successfully sequenced genomic sequence submitted genbank january accession mn subsequently largescale culture sarscov quickly performed inactivated virus vaccine could prepared employment established physical chemical method uv light formaldehyde βpropiolactone development attenuatedvirus vaccine also possible carefully screening serially propagated sarscov reduced pathogenesis induced minimal lung injury diminished limited neutrophil influx increased antiinflammatory cytokine expression compared wildtype virus inactivated attenuated virus vaccine disadvantage side effect table alternatively new vaccine design based putative protective antigenpeptides derived sarscov considered,2020,"Shang, Weilong; Yang, Yi; Rao, Yifan; Rao, Xiancai",,,#5211,,,,,212421568.0,3
67754,67754,85342,tr8qztda,,WHO,Will plant-made biopharmaceuticals play a role in the fight against COVID-19?,,,,unk,given dramatic impact covid pandemic imperative divulge available technology potential fight virus plant biotechnology offer potential solution pandemic development lowcost vaccine antibody useful therapy prophylaxis diagnosis technology produce plantmade biopharmaceuticals already established two example therapeutic enzyme entered market influenza vaccine currently clinical trial encouraging result thus far company started developing anticovid antibody vaccine particular plantmade antibody might timely produced approved human use short term development vaccine take longer time clinical evaluation could concluded end nonetheless candidate obtained valuable tool future outbreak key aspect define exploitation technology fight covid discussed,2020,"Rosales-Mendoza, Sergio",Expert Opin Biol Ther,,#35089,,,,,214810726.0,3
67790,67790,85402,7moy4oho,,WHO,Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department,,,,unk,march th total case total death sarscov united state number case expected rise supportive care sarscov specific treatment available patient discharged emergency department ed admitted hospital addition vaccine available protect atrisk healthcare worker national institute health conducting phase clinical trial evaluate potential vaccine recipient started receive investigational vaccine present brief overview potential prophylactic treatment agent investigation could initiated ed proven effective,2020,"Brown, Cortlyn; Noble, Jeanne; Coralic, Zlatan",West J Emerg Med,,#32302280,,,,,215809415.0,3
67848,67848,85502,0fu1fya0,,WHO,Safely conducting essential research in the face of COVID-19,,,,unk,staying home option scientist working potential vaccine caring research animal around world university closed covid — forcing increasing number researcher work teach home scientist ’ simply stop going laboratory — especially overseeing clinical trial could offer lifesaving vaccine therapy particularly new coronavirus research activity must continue even face shutdown “ animal need looked breeding line must kept going many unique ’ regenerated ” say mike turner director science wellcome researchfunding charity london,2020,"Gewin, Virginia",Nature,,#31693,,,,,214786187.0,3
67867,67867,85529,um3fa49r,,WHO,Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development,,,,unk,background coronaviruses pose serious threat global health evidenced severe acute respiratory syndrome sars middle east respiratory syndrome mers covid sars coronavirus sarscov mers coronavirus merscov novel coronavirus previously dubbed ncov officially named sarscov causative agent sars mers covid disease outbreak respectively safe vaccine rapidly induce potent longlasting virusspecific immune response infectious agent urgently needed coronavirus spike protein characteristic structural component viral envelope considered key target vaccine prevention coronavirus infection method first generated codon optimized merss subunit vaccine fused foldon trimerization domain mimic native viral structure variant construct engineered immune stimulant r flagellin tlr tlr agonist respectively trimeric design comprehensively tested preclinical immunogenicity merscov vaccine mouse delivered subcutaneously traditional needle injection intracutaneously dissolving microneedle array mnas evaluating virus specific igg antibody serum vaccinated mouse elisa using virus neutralization assay driven urgent need covid vaccine utilized strategy rapidly develop mna sarscov subunit vaccine tested preclinical immunogenicity vivo exploiting substantial experience mna merscov vaccine finding describe development mna delivered merscov vaccine preclinical immunogenicity specifically mna delivered merss subunit vaccine elicited strong longlasting antigenspecific antibody response building ongoing effort develop merscov vaccine promising immunogenicity mnadelivered merscov vaccine experience mna fabrication delivery including clinical trial rapidly designed produced clinicallytranslatable mna sarscov subunit vaccine within week identification sarscov sequence importantly mna delivered sarscov subunit vaccine elicited potent antigenspecific antibody response evident beginning week immunization interpretation mna delivery coronavirusess subunit vaccine promising immunization strategy coronavirus infection progressive scientific technological effort enable quicker response emerging pandemic ongoing effort develop mnamerss subunit vaccine enabled u rapidly design produce mna sarscov subunit vaccine capable inducing potent virusspecific antibody response collectively result support clinical development mna delivered recombinant protein subunit vaccine sars mers covid emerging infectious disease,2020,"Kim, Eun; Erdos, Geza; Huang, Shaohua; Kenniston, Thomas W; Balmert, Stephen C; Carey, Cara Donahue; Raj, V Stalin; Epperly, Michael W; Klimstra, William B; Haagmans, Bart L; Korkmaz, Emrullah; Falo, Louis D; Gambotto, Andrea",EBioMedicine,,#27911,,,,,214757099.0,3
67905,67905,85590,71n1tgrw,4a25736404bcee2542d089477aaae5e791e7f4e4,ArXiv,In Silico Trial to test COVID-19 candidate vaccines: a case study with UISS platform,,,,arxiv,sarscov severe respiratory infection infects human outburst entitled pandemic emergence get grip outbreak specific preventive therapeutic intervention urgently needed must said existing vaccine coronaviruses promptly rapidly respond pandemic event application silico trial used designing testing medicine sarscov speedup vaccine discovery pipeline predicting therapeutic failure minimizing undesired effect present silico platform showed good agreement latest literature predicting sars cov dynamic related immune system host response moreover used predict outcome one latest suggested approach design effective vaccine based monoclonal antibody uiss potentially ready used silico trial platform predict outcome vaccination strategy sarscov,2020-05-05,"Russo, Giulia; Pennisi, Marzio; Viceconti, Marco; Pappalardo, Francesco",,,,2005.02289,document_parses/pdf_json/4a25736404bcee2542d089477aaae5e791e7f4e4.json,,https://arxiv.org/pdf/2005.02289v1.pdf,218502484.0,3
68483,68483,86579,pa5i13fj,,WHO,Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic,,,,unk,world witnessing epidemic covid disease caused novel coronavirus sarscov emerging genetics clinical evidence suggest similar path sars mers rapid genomic sequencing open access data together advanced vaccine technology expected give u knowledge pathogen including host immune response well plan therapeutic vaccine near future review aim provide comparative view among sarscov merscov newly epidemic sarscov hope gain better understanding hostpathogen interaction host immune response pathogen immune evasion strategy predictive view may help designing immune intervention preventive vaccine covid near future,2020,"Prompetchara, Eakachai; Ketloy, Chutitorn; Palaga, Tanapat",Asian Pac J Allergy Immunol,,#32105090,,,,,211535628.0,3
68504,68504,86615,xsuksp5h,,WHO,"Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection",,,,unk,middle east respiratory syndrome coronavirus merscov cause severe fatal acute respiratory disease human remains endemic middle east since first identified currently approved vaccine therapy available merscov study evaluated parainfluenza virus pivbased vaccine expressing merscov envelope spike protein pivmerss human dpp knockin cbl congenic mouse model hdpp ki following singledose intranasal immunization pivmerss induced neutralizing antibody robust cell response hdpp ki mouse single intranasal administration pfu pivmerss provided complete protection lethal challenge mouseadapted merscov mersma improved virus clearance lung comparison singledose intramuscular immunization pfu uvinactivated mersma mixed imject alum provided protection immunized mouse intriguingly influx eosinophil observed lung mouse immunized inactivated merscov suggestive hypersensitivitytype response overall study indicated pivmerss promising effective vaccine candidate merscov infectionimportance merscov cause lethal infection human vaccine work demonstrates piv promising vector developing mers vaccine furthermore success pivbased mers vaccine employed develop vaccine emerging covs sarscov cause covid,2020,"Li, Kun; Li, Zhuo; Wohlford-Lenane, Christine; Meyerholz, David K; Channappanavar, Rudragouda; An, Dong; Perlman, Stanley; McCray, Paul B; He, Biao",mBio (Online),,#38355,,,,,215407363.0,3
68639,68639,86833,8i22n76t,,WHO,PAK1-blockers: Potential Therapeutics against COVID-19,,,,unk,pak raccdcactivated kinase major pathogenic kinase whose abnormal activation cause wide variety diseasesdisorders including cancer inflammation malaria pandemic viral infection including influenza hiv covid since louis pateur developed vaccine rabies general series specific vaccine used treatment viral infection mainly antibiotic general ineffective treatment viral infection however take â¯months till effective vaccine becomes available ventilator supplier would common tool saving life covid patient thus alternative potentially direct broadspectrum covid therapeutic several natural synthetic pakblockers propolis melatonin ciclesonide hydroxy chloroquine hq ivermection ketorolac readily available market introduced,2020,"Maruta, Hiroshi; He, Hong",Med Drug Discov,,#72020,,,,,215808237.0,3
68868,68868,87210,icy55inc,,WHO,Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach,,,,unk,recently novel coronavirus sarscov emerged responsible recent outbreak wuhan china genetically closely related sarscov merscov situation getting worse worse therefore urgent need designing suitable peptide vaccine component sarscov characterized spike glycoprotein obtain immunogenic epitope next chose major histocompatibility complexmhc mhcii epitope antigenic property epitope usually linked specific linkers build vaccine component molecularly dock tolllike receptor get binding affinity therefore provide fast immunogenic profile epitope performed immunoinformatics analysis rapid development vaccine might bring disastrous situation end earlier,2020,"Bhattacharya, Manojit; Sharma, Ashish R; Patra, Prasanta; Ghosh, Pratik; Sharma, Garima; Patra, Bidhan C; Lee, Sang-Soo; Chakraborty, Chiranjib",J. med. virol,,#141989,,,,,211555036.0,3
69544,69544,88383,8oot9b12,,WHO,Host Factors Affecting Generation of Immunity Against Porcine Epidemic Diarrhea Virus in Pregnant and Lactating Swine and Passive Protection of Neonates,,,,unk,porcine epidemic diarrhea virus pedv highly virulent reemerging enteric coronavirus cause acute diarrhea dehydration mortality neonatal suckling piglet despite safe effective pedv vaccine highly virulent strain unavailable making pedv prevention control challenging lactogenic immunity induced via gutmammary glandsecretory iga siga axis remains promising effective way protect suckling piglet pedv therefore successful pedv vaccine must induce protective maternal iga antibody passively transfer colostrum milk identifying variable influence lymphocyte migration iga secretion gestation lactation imperative designing maternal immunization strategy generate highest amount lactogenic immune protection pedv suckling piglet pregnancyassociated immune alteration influence viral pathogenesis adaptive immune response many different specie better understanding host immune response pedv pregnant swine may translate improved maternal immunization strategy enteric pathogen multiple specie review discus role host factor pregnancy antiviral immunity implication generating protective lactogenic immunity suckling neonate,2020,"Langel, Stephanie N.; Wang, Qiuhong; Vlasova, Anastasia N.; Saif, Linda J.",Pathogens,,#1292,,,,,211245098.0,3
69593,69593,88476,ugarnrgs,,WHO,Defining Protective Epitopes for COVID-19 Vaccination Models,,,,unk,recent paper journal provide tangible avenue covid vaccine production immunoreactive epitope brought forefront many emerging study development consistent predictable animal model covid infection evidently also welcome event preliminary antiviral vaccine assessment surely brings u another level progression article protected copyright right reserved,2020,"Cimolai, Nevio",J. med. virol,,#52558,,,,,215757377.0,3
69596,69596,88481,t9gbq4yu,,WHO,"Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China",,,,unk,novel coronavirus ncov originating wuhan china present potential respiratory viral pandemic world population current effort focused containment quarantine infected individual ultimately outbreak could controlled protective vaccine prevent ncov infection vaccine research pursued intensely exists today therapy treat ncov upon infection despite urgent need find option help patient preclude potential death herein review potential option treat ncov patient emphasis necessity speed timeliness developing new effective therapy outbreak consider option drug repurposing developing neutralizing monoclonal antibody therapy oligonucleotide strategy targeting viral rna genome emphasizing promise pitfall approach finally advocate fastest strategy develop treatment could resistant mutation virus may future proposal biologic block ncov entry using soluble version viral receptor angiotensinconverting enzyme ace fused immunoglobulin fc domain providing neutralizing antibody maximal breath avoid viral escape also helping recruit immune system build lasting immunity sequence acefc protein provided investigator allowing possible use recombinant protein expression system start producing drug today treat patient compassionate use formal clinical trial later undertaken treatment could help infected patient protective vaccine developed widely available coming month year,2020,"Kruse, Robert L",F1000Res,,#32117569,,,,,211534163.0,3
69884,69884,88969,binxayw2,,WHO,[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)],,,,unk,outbreak novel coronavirus ncov infection pose serious threat global public health vaccination effective way prevent epidemic virus ncov along severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus merscov belong ßgenus coronavirus family base previous experience technical platform developing sarscov merscov vaccine scientist world working hard quickly related field substantial progress field including characterizing ncov virus identification candidate antigen epitope establishment animal model characterizing immune response design vaccine development ncov vaccine cover type inactivated virus vaccine recombinant protein vaccine viral vectorbased vaccine mrna vaccine dna vaccine et al march two ncov vaccine entered phase clinical trial one named adncov developed chinese institute biotechnology academy military medical science tianjin cansino biotechnology inc adncov based replicationdefective adenovirus type vector express ncov spike protein another vaccine mrna developed national institute allergy infectious disease moderna inc rna mrna vaccine expressing ncov spike protein although rapid development ncov vaccine still face many challenge unknown knowledge including antigenic characteristic ncov influence antigenic variation protective immune response host protection elderly population downstream manufacturing process new vaccine safety efficacy vaccine first priority vaccine development carefully evaluated,2020,"Shi, Y; Wang, N; Zou, Q M",Zhonghua Yu Fang Yi Xue Za Zhi,,#27060,,,,,214771730.0,3
70357,70357,89808,ri91u0f1,,WHO,Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains,,,,unk,emergence strain coronavirus sarscov severe acute respiratory syndrome coronavirus impact global health made imperative development effective safe vaccine lethal strain sarscov add list coronavirus disease threatened global health along sars severe acute respiratory syndrome mers middle east respiratory syndrome coronaviruses emerged respectively april vaccine commercially available coronavirus strain nevertheless knowledge obtained vaccine development effort mers sars high value covid coronavirus disease review past ongoing vaccine development effort clinically relevant coronavirus strain intention information help development effective safe vaccine covid addition information naturally exposed individual animal model coronavirus strain described purpose helping development effective vaccine covid,2020,"Padron-Regalado, Eriko",Infect Dis Ther,,#108914,,,,,216076468.0,3
70397,70397,89877,ko8owym3,,WHO,Genetically modified live attenuated vaccine: a potential strategy to combat visceral leishmaniasis,,,,unk,visceral leishmaniasis vl caused protozoan parasite leishmania donovani mainly influencing population tropical subtropical region across globe arsenal drug available limited prolonged use drug make parasite become resistant therefore imperative develop safe costeffective inexpensive vaccine vl although recent year many strategy pursued researcher far vaccine candidate reached clinical trial half still pipeline broad consent among leishmania researcher perseverance parasite essential eliciting protective immune response may perhaps attained live attenuated parasite vaccination making live attenuated parasite essential ensure parasite deficient virulence study genetically modified parasite perceive mechanism pathogenesis believed near future complete understanding leishmania genome explore clear strategy discover novel vaccine review describes need genetically modified live attenuated vaccine vl obstacle associated development,2020,"Pandey, Satish Chandra; Kumar, Awanish; Samant, Mukesh",Parasite Immunol,,#32418227,,,,,218680451.0,3
70440,70440,89962,vbqgyll9,4e4ae835d7adc8fb0f60b3b1a36dd96864b858d9,ArXiv,Strategic Spatiotemporal Vaccine Distribution Halves Deaths due to an Infectious Disease,,,,arxiv,covid caused hundred thousand death economic damage amounting trillion dollar creating desire rapid development vaccine available vaccine gradually produced evoking question distribute best official vaccination guideline largely focus question vaccine provided first eg risk group propose generic strategy distribution time space sequentially prioritizes region high local infection growth rate demonstrate strategy develop agentbased model describing timeevolution infection pattern response vaccination heterogeneous infection pattern proposed strategy least half number death simulation compared standard practice distributing vaccine proportionally population density applies wide range reproduction number vaccine production rate might stimulate discussion importance spatiotemporal distribution vaccine official guideline,2020-05-08,"Grauer, Jens; Lowen, Hartmut; Liebchen, Benno",,,,2005.04056,document_parses/pdf_json/4e4ae835d7adc8fb0f60b3b1a36dd96864b858d9.json,,https://arxiv.org/pdf/2005.04056v1.pdf,218571374.0,3
70476,70476,90020,vqxrjtgb,,WHO,Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure,,,,unk,controlled human challenge trial sarscov vaccine candidate could accelerate testing potential rollout efficacious vaccine replacing conventional phase testing vaccine candidate trial may subtract many month licensure process making efficacious vaccine available quickly obviously challenging volunteer live virus risk inducing severe disease possibly even death however argue study accelerating vaccine evaluation could reduce global burden coronavirusrelated mortality morbidity volunteer study could autonomously authorize risk net risk could acceptable participant comprise healthy young adult relatively low risk serious disease following natural infection high baseline risk natural infection trial receive frequent monitoring following infection best available care,2020,"Eyal, Nir; Lipsitch, Marc; Smith, Peter G",J Infect Dis,,#20494,,,,,214751151.0,3
71154,71154,91205,v3xe5w8p,,WHO,Vaccine confidence in the time of COVID-19,,,,unk,early month covid epidemic wondered force global experience solve problem vaccine refusal vexed preoccupied global public health community last several decade drawing historical epidemiological analysis critique contemporary approach reducing vaccine hesitancy articulate notion vaccine confidence expanded way conceptualizing problem respond intervening rush vaccine optimism see pervading present discourse around covid epidemic call reimagination culture public health meaning vaccine safety regulation public confidence vaccination program depends work communitysocial political moral well biological concept public health program must broader delivery vaccine technology narrative work policy action entailed actualizing change expect essential achieving true vaccine confidence however public reacts specific vaccine may developed covid,2020,"Harrison, Emily A; Wu, Julia W",Eur J Epidemiol,,#99145,,,,,216048930.0,3
71166,71166,91230,kw127ul5,,WHO,Rapid COVID-19 vaccine development,,,,unk,finding fastest pathway vaccine availability includes avoidance safety pitfall,2020,"Graham, Barney S",Science (Wash.),,#209690,,,,,218563830.0,3
71974,71974,92669,1kjzat11,,WHO,Ethical considerations for epidemic vaccine trials,,,,unk,vaccine powerful measure protect health individual combat outbreak covid pandemic ethical dilemma arises one effective vaccine successfully developed epidemic disease researcher seek test efficacy another vaccine pathogen clinical trial involving human subject one hand compelling reason would unethical trial novel vaccine effective product exists already first firm principle medical ethic effective treatment vaccine withheld patient life may depend second since epidemic outbreak often emerge setting lessresourced health system pronounced risk trial withholding effective vaccine would disproportionately affect vulnerable population historically exploited biomedical research third clinical trial novel vaccine may odds effort control active outbreak hand may justified conduct trial candidate vaccine expected certain advantage compared existing product essay discus key factor comparing vaccine epidemic pathogen including immunological logistical economic consideration alongside case study development vaccine ebola essay seek establish general framework expanded populated immunologist epidemiologist economist bioethicists ultimately could applied case covid vaccine,2020,"Monrad, Joshua Teperowski",J. med. ethics,,#32414757,,,,,218658706.0,3
72153,72153,92949,dcg6ui9d,,WHO,An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development,,,,unk,first outbreak coronavirus disease covid caused severe acute respiratory syndrome coronavirus sarscov occurred wuhan hubei province china late subsequent covid pandemic rapidly affected health economy world global approach pandemic isolate population reduce spread deadly virus vaccine began developed march first phase clinical trial novel lipid nanoparticle lnpencapsulated mrnabased vaccine mrna encodes spike protein protein sarscov began united state u production mrnabased vaccine promising recent development production vaccine however remain significant challenge development testing vaccine rapidly possible control covid requires international collaboration review aim describe background rationale development mrnabased sarscov vaccine current status mrna vaccine,2020,"Wang, Fuzhou; Kream, Richard M; Stefano, George B",Med Sci Monit,,#258401,,,,,218503274.0,3
72154,72154,92950,xbze5s3c,,WHO,An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development,,,,unk,first outbreak coronavirus disease covid caused severe acute respiratory syndrome coronavirus sarscov occurred wuhan hubei province china late subsequent covid pandemic rapidly affected health economy world global approach pandemic isolate population reduce spread deadly virus vaccine began developed march first phase clinical trial novel lipid nanoparticle lnpencapsulated mrnabased vaccine mrna encodes spike protein protein sarscov began united state u production mrnabased vaccine promising recent development production vaccine however remain significant challenge development testing vaccine rapidly possible control covid requires international collaboration review aim describe background rationale development mrnabased sarscov vaccine current status mrna vaccine,2020,"Wang, Fuzhou; Kream, Richard M; Stefano, George B",Med Sci Monit,,#175793,,,,,218503274.0,3
72177,72177,92986,b396qg74,,WHO,Developing Vaccines for SARS-CoV-2 and Future Epidemics and Pandemics: Applying Lessons from Past Outbreaks,,,,unk,covid pandemic stark reminder heavy toll emerging infectious disease eids epidemic pandemic potential inflict vaccine development scaleup commercialization long expensive risky enterprise requires substantial upfront planning offer guarantee success eids particularly challenging target global health preparedness including vaccine development insufficient attention given challenge lesson learned potential solution support sustain vaccine industry engagement vaccine development eids drawing lesson recent ebola epidemic democratic republic congo well hn influenza ebola zika outbreak preceding offer perspective challenge facing eid vaccine development recommend additional solution prioritize near term recommendation focus reducing vaccine development timeline increasing business certainty reduce risk company global health security community opportunity build current momentum design sustainable model eid vaccine,2020,"Billington, John; Deschamps, Isabelle; Erck, Stanley C; Gerberding, Julie L; Hanon, Emmanuel; Ivol, Sabrina; Shiver, John W; Spencer, Julia A; Van Hoof, Johan",Health Secur,,#141511,,,,,217591851.0,3
72200,72200,93032,2diba6z5,,WHO,"Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial",,,,unk,background monovalent parenteral subunit rotavirus vaccine well tolerated immunogenic adult usa toddler infant south africa elicited poor response heterotypic rotavirus strain aimed evaluate safety immunogenicity trivalent vaccine formulation pvpp method doubleblind randomised placebocontrolled doseescalation phase study done three south african research site healthy adult aged year toddler aged year infant aged week week gestation without previous receipt rotavirus vaccination without hiv infection eligible enrolment doseescalation phase adult toddler randomly assigned block block size five receive µg µg vaccine placebo infant randomly assigned block block size four receive µg µg µg vaccine placebo expanded phase infant randomly assigned ratio receive µg µg µg vaccine placebo block size four participant parent participant clinical data laboratory staff masked treatment assignment adult received intramuscular injection vaccine placebo deltoid muscle day randomisation day day day toddler received single injection vaccine placebo anterolateral thigh day infant phase received injection vaccine placebo anterolateral thigh day approximately week age primary safety endpoint local systemic reaction grade worse within day adverse event serious adverse event within day injection participant received least one injection primary immunogenicity endpoint analysed infant either phase received planned injection blood sample analysed relevant timepoints presented major protocol violation considered effect immunogenicity result study included serum antipvp iga igg neutralising antibody geometric mean titre response measured week final injection vaccine compared placebo group trial registered clinicaltrialsgov nct finding feb dec adult µg µg group six placebo group toddler µg µg group six placebo group infant µg group µg group µg group placebo group randomly assigned received least one dose assessed safety significant difference local systemic adverse event unsolicited adverse event vaccine placebo group serious adverse event within day injection adult whereas one serious adverse event occurred toddler febrile convulsion µg group serious adverse event four placebo ten µg four µg five µg group occurred among infant commonly respiratory tract infection one death occurred infant within day injection due pneumococcal meningitis infant placebo µg µg µg group adjusted antipvp igg seroresponses fold increase baseline p p p antigen significantly higher µg µg µg group placebo group p· although significantly higher placebo recipient antipvp iga seroresponses fold increase baseline individual antigen modest across µg µg µg group adjusted neutralising antibody seroresponses infant ·fold increase baseline d p p wa p higher vaccine recipient placebo recipient p· comparison interpretation trivalent pvp vaccine well tolerated promising antipvp igg neutralising antibody response across three vaccine p type finding support advancing vaccine efficacy testing funding bill melinda gate foundation,2020,"Groome, Michelle J; Fairlie, Lee; Morrison, Julie; Fix, Alan; Koen, Anthonet; Masenya, Maysseb; Jose, Lisa; Madhi, Shabir A; Page, Nicola; McNeal, Monica; Dally, Len; Cho, Iksung; Power, Maureen; Flores, Jorge; Cryz, Stanley",Lancet infect. dis,,#31312,,,,,215410555.0,3
72209,72209,93048,7815we3p,,WHO,"United States should allow volunteers to be infected with coronavirus to test vaccines, lawmakers argue",,,,unk,political support building regulator united state embrace controversial strategy intentionally infecting volunteer virus cause covid order test experimental vaccine human challenge trial could greatly accelerate development effective vaccine member house representative argue letter sent yesterday head u food drug administration fda parent agency department health human service hhs,2020,"Cohen, Jon",Science,,#95067,,,,,218786884.0,3
72689,72689,93891,46qtm56y,fb8496716ecbdac7a40b01f6940d3d3fa2a020ad,Elsevier; Medline; PMC,Response to the 2009 pandemic: Effect on influenza control in wealthy and poor countries,10.1016/j.vaccine.2011.06.113,PMC7131421,21763381.0,els-covid,declaration world health organization appearance swineorigin novel influenza virus represented pandemic based previously adopted guideline new international health regulation severity pandemic part definition used stated le severe time declaration necessary still uncertainty overall impact pandemic vaccine production begin timely availability country arranged vaccine population attempted secure supply underresourced country world concerned next pandemic might severe one based specter avian influenza case fatality human clear pandemic severe accusation especially europe country secured vaccine supply mainly benefit manufacturer charge even refuted may undermine public confidence process assures vaccine supply availability vaccine seasonal use production pandemic vaccine conditioned supply seasonal influenza vaccine unrealistic expect vaccine available pandemic use none used seasonal influenza particularly applies poorer county traditionally recognized influenza problem although attitude changing go forward need keep mind global nature threat influenza pandemic severe demand would greater poorer county would little vaccine meet need taking broad view influenza annual basis vaccine supply ensured country world,2011-09-02,"Monto, Arnold S.; Black, Steven; Plotkin, Stanley A.; Orenstein, Walter A.",Vaccine,,,,document_parses/pdf_json/fb8496716ecbdac7a40b01f6940d3d3fa2a020ad.json,document_parses/pmc_json/PMC7131421.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/21763381/; https://doi.org/10.1016/j.vaccine.2011.06.113; https://www.sciencedirect.com/science/article/pii/S0264410X11010073; https://api.elsevier.com/content/article/pii/S0264410X11010073,8299815.0,3
72698,72698,93902,usvpk1na,c7d034bf9668a6fed9f627ae21fff8b6ec35d9ec,Medline; PMC,Vaccines for epidemic infections and the role of CEPI,10.1080/21645515.2017.1306615,PMC5718831,28375764.0,bronze-oa,author review foundation coalition epidemic preparedness innovation choice made funding vaccine development epidemic disease comment decision well proposing cepi could remain relevant long term,2017-04-04,"Plotkin, Stanley A.",Human Vaccines & Immunotherapeutics,,,,document_parses/pdf_json/c7d034bf9668a6fed9f627ae21fff8b6ec35d9ec.json,document_parses/pmc_json/PMC5718831.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28375764/; https://doi.org/10.1080/21645515.2017.1306615; https://www.tandfonline.com/doi/pdf/10.1080/21645515.2017.1306615?needAccess=true,205965455.0,3
72712,72712,93919,h560slug,8466f11ac556bca1bac29ec93d802b49e020122f,Medline; PMC,The C-terminal domain of Clostridium perfringens alpha toxin as a vaccine candidate against bovine necrohemorrhagic enteritis,10.1186/s13567-016-0336-y,PMC4847199,27121298.0,cc-by,bovine necrohemorrhagic enteritis caused clostridium perfringens lead sudden death alpha toxin together perfringolysin identified principal toxin involved pathogenesis assessed potential alpha toxin vaccine antigen using intestinal loop model calf investigated protection afforded antiserum raised native alpha toxin nontoxic cterminal fragment c perfringensinduced intestinal necrosis immunization calf either vaccine preparation induced strong antibody response resulting antiserum able neutralize alpha toxin activity c perfringensinduced endothelial cytotoxicity vitro antiserum raised native toxin stronger neutralizing activity cterminal fragment however antibody alpha toxin alone sufficient completely neutralize c perfringensinduced necrosis intestinal loop model development multivalent vaccine combining cterminal fragment alpha toxin c perfringens virulence factor might necessary complete protection bovine necrohemorrhagic enteritis,2016-04-27,"Goossens, Evy; Verherstraeten, Stefanie; Valgaeren, Bonnie R.; Pardon, Bart; Timbermont, Leen; Schauvliege, Stijn; Rodrigo-Mocholí, Diego; Haesebrouck, Freddy; Ducatelle, Richard; Deprez, Piet R.; Van Immerseel, Filip",Vet Res,,,,document_parses/pdf_json/8466f11ac556bca1bac29ec93d802b49e020122f.json,document_parses/pmc_json/PMC4847199.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/27121298/; https://doi.org/10.1186/s13567-016-0336-y,21468863.0,3
72742,72742,93963,26uuczmi,653c1744be45d5e3ba3e9fb48edf6c6997976324,Medline; PMC,Vaccinia Virus LC16m8∆ as a Vaccine Vector for Clinical Applications,10.3390/vaccines2040755,PMC4494248,26344890.0,cc-by,lcm strain vaccinia virus active ingredient japanese smallpox vaccine derived listerelstree strain lcm replicationcompetent administered infant adult serious adverse reaction despite outstanding safety profile occurrence spontaneouslygenerated large plaqueforming virulent lcm revertants following passage cell culture major drawback identified gene responsible reversion deleted gene br lcm derive lcmδ lcm∆ nonpathogenic immunodeficient severe combined immunodeficiency scid mouse geneticallystable reverse largeplaque phenotype upon passage cell culture even condition lcm population replaced revertants moreover lcm∆ fold effective nonreplicating vaccinia virus vv modified vaccinia ankara mva inducing murine immune response pathogenic vv lcm∆ express siv gag gene also induced antigag cd tcells efficiently mva another nonreplicating vv dairen minutepock variant dis moreover lcm∆ expressing hiv env combination sendai virus vector induced production antienv antibody cd tcells thus safety efficacy lcm∆ mean represents outstanding platform development human vaccine vector,2014-10-17,"Kidokoro, Minoru; Shida, Hisatoshi",Vaccines (Basel),,,,document_parses/pdf_json/653c1744be45d5e3ba3e9fb48edf6c6997976324.json,document_parses/pmc_json/PMC4494248.xml.json,https://doi.org/10.3390/vaccines2040755; https://www.ncbi.nlm.nih.gov/pubmed/26344890/,6944156.0,3
72752,72752,93974,qfdxri93,a22adb3d7ef0c66ada6270d213af060dbd790333,Elsevier; PMC,Vaccinology at the beginning of the 21st century,10.1016/j.coi.2005.05.005,PMC7125631,15950445.0,els-covid,today main challenge vaccinologists include improving vaccine yet undefeated pathogen rapid identification response emerging disease successful intervention chronic disease ongoing immune response insufficient reverse genetics reverse vaccinology used generate rapidly new vaccine strain mine whole genome search promising antigen rational design adjuvant become possible result discovery receptor recognize microbial pattern lead dendritic cell activation antigenloaded dendritic cell dna naked formulated viral form delivery system used maximize immune response although work ‘ easy ’ vaccine already completed hoped combination conceptual technical innovation enable development complex sophisticated vaccine future,2005-08-31,"Wack, Andreas; Rappuoli, Rino",Current Opinion in Immunology,,,,document_parses/pdf_json/a22adb3d7ef0c66ada6270d213af060dbd790333.json,document_parses/pmc_json/PMC7125631.xml.json,https://www.sciencedirect.com/science/article/pii/S0952791505000816; https://api.elsevier.com/content/article/pii/S0952791505000816,30787851.0,3
72765,72765,93991,imyvmgdk,a2edd17a944bc5fc7506fd4e5d519d552cf19951,Medline; PMC,"Preventive behaviors, beliefs, and anxieties in relation to the swine flu outbreak among college students aged 18–24 years",10.1007/s10389-010-0373-3,PMC7087647,32215244.0,no-cc,aim objective study ass belief misconception anxiety relation swine flu outbreak whether perception outbreak predicted change behavior subject method november conducted internetbased crosssectional survey college student aged – year midwestern state usa collected information swine flu knowledge perception immunization safety perceived efficacy recommended behavior changed behavior anxiety result respondent anxiety swine flu believed avoiding crowded place preventive believed swine flu vaccine safe showed interest receiving vaccine misconception swine flu contagion via eating cooked pork water source insect bite common respondent unaware transmission via contaminated object droplet satisfied governmental effort woman likely wash hand frequently men odds ratio p conclusion gap swine flu knowledge minimal risk reduction increased amount anxiety skepticism swine flu vaccine safety gap warrant serious attention inform public specific action regarding swine flu,2010-10-16,"Kanadiya, Mehulkumar K.; Sallar, Anthony M.",Z Gesundh Wiss,,,,document_parses/pdf_json/a2edd17a944bc5fc7506fd4e5d519d552cf19951.json,document_parses/pmc_json/PMC7087647.xml.json,https://doi.org/10.1007/s10389-010-0373-3; https://www.ncbi.nlm.nih.gov/pubmed/32215244/,33378807.0,3
72824,72824,94065,28h18zrg,902ec7158906ac390bdc04cd55350a12c8a39281,Medline; PMC,The Evolution of Poxvirus Vaccines,10.3390/v7041726,PMC4411676,25853483.0,cc-by,edward jenner established human vaccination year ago attenuated poxvirus became key player contain deadliest virus family variola virus varv causative agent smallpox cowpox virus cpxv horsepox virus hspv extensively used end passaged cattle human appearance vaccinia virus vacv used final campaign aimed eradicate disease endeavor accomplished world health organization ever since naturally evolved strain used vaccination introduced research laboratory vacv poxvirus improved safety profile generated recombinant dna technology along dna genome feature virus family allowed generation vaccine heterologous disease specific insertion deletion poxvirus gene generated even broader spectrum modified virus new property increase immunogenicity safety profile vaccine vector review highlight evolution poxvirus vaccine first generation current status pointing different vaccine emerged approach followed development rational vaccine wide range disease,2015-04-07,"Sánchez-Sampedro, Lucas; Perdiguero, Beatriz; Mejías-Pérez, Ernesto; García-Arriaza, Juan; Di Pilato, Mauro; Esteban, Mariano",Viruses,,,,document_parses/pdf_json/902ec7158906ac390bdc04cd55350a12c8a39281.json,document_parses/pmc_json/PMC4411676.xml.json,https://doi.org/10.3390/v7041726; https://www.ncbi.nlm.nih.gov/pubmed/25853483/,25838728.0,3
72866,72866,94120,hnuogpqn,96fa7b0201a495e59794b2b1c2e8cd794d1ba413,Medline; PMC,An Overview of Current Approaches Toward the Treatment and Prevention of West Nile Virus Infection,10.1007/978-1-4939-3670-0_19,PMC7120145,27188563.0,no-cc,persistence west nile virus wnv infection throughout usa since inception continuous spread throughout globe call urgent need effective treatment prevention measure although licensing several wnv vaccine veterinary use provides proof concept similar effort development effective vaccine human remain still unsuccessful increased understanding biology pathogenesis wnv together recent technological advancement raised hope effective wnv vaccine may available near future addition rapid progress structural functional characterization wnv flaviviral protein provided solid base design development several class inhibitor potential wnv therapeutic moreover therapeutic monoclonal antibody demonstrate excellent efficacy wnv animal model represent promising class wnv therapeutic however challenge design development safe efficient wnv vaccine therapeutic chapter discus current approach progress challenge toward development wnv vaccine therapeutic antibody antiviral drug,2016-05-18,"Acharya, Dhiraj; Bai, Fengwei",West Nile Virus,,,,document_parses/pdf_json/96fa7b0201a495e59794b2b1c2e8cd794d1ba413.json,document_parses/pmc_json/PMC7120145.xml.json,https://doi.org/10.1007/978-1-4939-3670-0_19; https://www.ncbi.nlm.nih.gov/pubmed/27188563/,3924821.0,3
72920,72920,94190,3463iule,d1d6cfcd65bfc9b918ef9ad6fdc7d3702d755ccb,Elsevier; Medline; PMC,Immunogenicity and protective efficacy in dogs of an MF59™-adjuvanted vaccine against recombinant canine/porcine coronavirus,10.1016/j.vaccine.2011.01.028,PMC7115603,21272607.0,els-covid,recently canine coronavirus ccov strain putative recombinant origin porcine transmissible gastroenteritis virus tgev shown widespread europe study killed vaccine tgevlike ccov strain included new subtype ccoviib developed inactivation betapropiolactone emulsification mf™ adjuvant safety immunogenicity efficacy developed vaccine evaluated vivo five weekold beagle pup administered three week apart two vaccine dos whereas two animal served unvaccinated control vaccine shown safe local neither systemic reaction observed first second dose administration serum antibody ccov detected vaccinates starting study day enzymelinked immunosorbent assay virus neutralisation test subsequent challenge virulent ccoviib resulted development mild gastroenteric disease control pup whereas vaccinates display clinical sign faecal shedding challenge virus occurred treatment group vaccinated dog found shed low viral titre comparison control developed vaccine may help control ccoviibinduced disease active virus circulation environment kennel shelter pathogenic potential virus greater consequence predisposing factor concurrent infection,2011-03-03,"Decaro, Nicola; Mari, Viviana; Sciarretta, Rossana; Colao, Valeriana; Losurdo, Michele; Catella, Cristiana; Elia, Gabriella; Martella, Vito; Del Giudice, Giuseppe; Buonavoglia, Canio",Vaccine,,,,document_parses/pdf_json/d1d6cfcd65bfc9b918ef9ad6fdc7d3702d755ccb.json,document_parses/pmc_json/PMC7115603.xml.json,https://doi.org/10.1016/j.vaccine.2011.01.028; https://api.elsevier.com/content/article/pii/S0264410X11000569; https://www.sciencedirect.com/science/article/pii/S0264410X11000569; https://www.ncbi.nlm.nih.gov/pubmed/21272607/,5533600.0,3
72923,72923,94194,oh6sypat,b463342e6ef8e2537568f371e7e15b3020f37ab8; a9eec435999ab4cd18d878153a834c72521ad604,Medline; PMC,"VaccHemInf project: protocol for a prospective cohort study of efficacy, safety and characterisation of immune functional response to vaccinations in haematopoietic stem cell transplant recipients",10.1136/bmjopen-2018-026093,PMC6398679,30772864.0,cc-by-nc,introduction immune reconstitution haematopoietic stem cell transplantation hsct complex dynamic process varying state nearly complete immunosuppression expected full immune recovery specific vaccination guideline recommend reimmunisation hsct data regarding vaccine efficacy unique population scarce new immune functional assay could enable prediction vaccine response setting hsct method analysis prospective longitudinal singlecentre cohort study autologous allogeneic hsct recipient designed order determine vaccine response five vaccine target pneumococcus hepatitis b virus haemophilus influenzae type b tetanus diphtheria correlate immune function parameter workflow set study serological response vaccine describe functional immune status hsct recipient autologous allogeneic month primary immunisation time point ‘ basic ’ immune status recording serology immunophenotyping lymphocyte subset flow cytometry assessed immune response furthermore evaluated month primary vaccination two ex vivo immune functional assay assessing tumour necrosis factor alpha interferon gamma production host messenger rna expression wholeblood stimulation lipopolysaccharide staphylococcus aureus enterotoxin b tlymphocyte proliferation response standard mitogen phytohaemagglutinin selected recall antigen reference interval determined cohort healthy volunteer translational study provide data describing vaccine response immune functionality hsct recipient time allow mapping hsct recipient regard immune function ethic dissemination ethical approval obtained institutional review board hcl result communicated scientific meeting submitted publication peerreviewed journal trial registration number nct preresults,2019-02-15,"Conrad, Anne; Boccard, Mathilde; Valour, Florent; Alcazer, Vincent; Tovar Sanchez, Aydee-Tamara; Chidiac, Christian; Laurent, Frédéric; Vanhems, Philippe; Salles, Gilles; Brengel-Pesce, Karen; Meunier, Boris; Trouillet-Assant, Sophie; Ader, Florence",BMJ Open,,,,document_parses/pdf_json/b463342e6ef8e2537568f371e7e15b3020f37ab8.json; document_parses/pdf_json/a9eec435999ab4cd18d878153a834c72521ad604.json,document_parses/pmc_json/PMC6398679.xml.json,https://doi.org/10.1136/bmjopen-2018-026093; https://www.ncbi.nlm.nih.gov/pubmed/30772864/,73494993.0,3
72941,72941,94219,xw3n0fhi,3769fc772f7e3fb0d0822bb2887ae12c0dbaf0d2,Elsevier; Medline; PMC,The development of Chinese specific human cytomegalovirus polyepitope recombinant vaccine,10.1016/j.antiviral.2011.12.005,PMC7114286,22197248.0,els-covid,human cytomegalovirus hcmv infection major cause morbidity recipient organ transplant congenitally infected infant hcmv vaccine emerged effective approach prevent hcmv infection particularly development multiple viral antigen vaccination human leukocyte antigen hlarestricted polyepitope technology chinese population make one fifth population worldwide important develop hcmv vaccine specific chinese population targeting chineserestricted hla allele antigen present study designed novel chimeric polyepitope vaccine based replicationdeficient adenovirus adf encodes hcmv cell epitope different hcmv antigen restricted hla hla ii allele cover chinese population result show recombinant adenovirus vaccine adfctl·th efficiently transfected expressed peripheral blood mononuclear cell pbmcs little cytopathic activity adfctl·th also endogenously processed presented pbmcs adfctl·thstimulated hcmvspecific cytotoxic lymphocyte ctls showed strong cytolytic activity hcmv polyepitopesensitized target cell ctl activity accompanied high level ifnγ production adfctl·th stimulation specificity vigorous response recombinant adenovirus vaccine vitro make potential candidate used transplantation recipient congenitally infected infant,2012-02-29,"Zhao, Ping; Ma, Dao-Xin; Yu, Shuang; Xue, Fu-Zhong; Zhu, Wei-Wei; Shao, Na; Zhang, Jing-Ru; Ji, Chun-Yan",Antiviral Research,,,,document_parses/pdf_json/3769fc772f7e3fb0d0822bb2887ae12c0dbaf0d2.json,document_parses/pmc_json/PMC7114286.xml.json,https://www.sciencedirect.com/science/article/pii/S0166354211005249; https://www.ncbi.nlm.nih.gov/pubmed/22197248/; https://api.elsevier.com/content/article/pii/S0166354211005249; https://doi.org/10.1016/j.antiviral.2011.12.005,38155973.0,3
72978,72978,94269,kw62j3sd,4a8c9c478390ac17e92e8873e5b921cfcd6c06b5,Elsevier; Medline; PMC,Bacillus anthracis: Balancing innocent research with dual-use potential,10.1016/j.ijmm.2007.09.007,PMC7106442,18375178.0,els-covid,anthrax euronet coordination action eu th framework programme designed strengthen networking activity anthrax research group europe harmonise protocol testing anthrax vaccine therapeutic inevitably project also addressed aspect current political issue biosecurity dualuse research ie research agent important disease man livestock agriculture could used agent bioterrorism review provides comprehensive overview biology bacillus anthracis pathogenesis epidemiology diagnosis anthrax well vaccine therapeutic intervention strategy proposed requirement code conduct working dualuse agent anthrax bacillus also discussed,2008-07-01,"Hudson, Michael J.; Beyer, Wolfgang; Böhm, Reinhard; Fasanella, Antonio; Garofolo, Giuliano; Golinski, Robert; Goossens, Pierre L.; Hahn, Ulrike; Hallis, Bassam; King, Annemarie; Mock, Michèle; Montecucco, Cesare; Ozin, Amanda; Tonello, Fiorella; Kaufmann, Stefan H.E.",International Journal of Medical Microbiology,,,,document_parses/pdf_json/4a8c9c478390ac17e92e8873e5b921cfcd6c06b5.json,document_parses/pmc_json/PMC7106442.xml.json,https://api.elsevier.com/content/article/pii/S143842210800009X; https://www.ncbi.nlm.nih.gov/pubmed/18375178/; https://www.sciencedirect.com/science/article/pii/S143842210800009X; https://doi.org/10.1016/j.ijmm.2007.09.007,36322434.0,3
72979,72979,94270,pho6dksc,45dd2260efb45c535375c93e97d80e9144b7ad15,Elsevier; PMC,Immunization with SARS-CoV S DNA vaccine generates memory CD4+ and CD8+ T cell immune responses,10.1016/j.vaccine.2006.03.058,PMC7115633,16621188.0,els-covid,effective vaccine severe acute respiratory syndrome sars probably require generation maintenance humoral cellular immune response reported natural infection human immunization animal sarscov vaccine antibody produced persistent long period time present study mouse immunized im sarscov dna vaccine three different method elisa elispot facs used evaluate immune response cell stimulated vitro pool peptide overlapping entire sars spike protein result show primeimmunization sarscov dna vaccine induce cd cd cell response boosting vaccine enhances cd cd cell response lymphoid nonlymphoid organ persistent two month sarscov sspecific cd cd cell cdl− marker memory cell − cell expressed ilrα cd marker capacity effector cell develop memory cell addition immunization dna vaccine elicited high level antibody production taken together data demonstrate immunization sarscov dna vaccine generate antigenspecific humoral cellular immune response may contribute longterm protection,2006-06-05,"Huang, Jun; Ma, Rui; Wu, Chang-you",Vaccine,,,,document_parses/pdf_json/45dd2260efb45c535375c93e97d80e9144b7ad15.json,document_parses/pmc_json/PMC7115633.xml.json,https://api.elsevier.com/content/article/pii/S0264410X06003847; https://www.sciencedirect.com/science/article/pii/S0264410X06003847,26674617.0,3
73019,73019,94322,e80jztg3,b8915fde10e62d4b033a9141910e5639590f0bae,Medline; PMC,Plant-based solutions for veterinary immunotherapeutics and prophylactics,10.1186/s13567-014-0117-4,PMC4280687,25559098.0,cc-by,alarming increase emergence antibiotic resistance among pathogen worldwide become serious threat ability treat infectious disease according world health organization extensive use antibiotic livestock producer promotes spread new resistant strain zoonotic concern increase foodborne illness human cause significant economic burden healthcare system furthermore consumer preference meatpoultryfish produced without use antibiotic shape today ’ market demand viewed inevitable one health initiative human need reduce use antibiotic turn alternative improved mean control disease vaccination prophylactic besides intense research focused novel therapeutic molecule strategy rely heavily availability costeffective efficient scalable production platform allow largevolume manufacturing vaccine antibody biopharmaceuticals within context plantbased platform production recombinant therapeutic protein offer significant advantage conventional expression system including lack animal pathogen low production cost fast turnaround response time rapid nearlyunlimited scalability also dried leaf seed stored room temperature lengthy period without loss recombinant protein plant expression system potential offer lucrative benefit development edible vaccine prophylactic would require “ cold chain ” storage transportation could administered mass volume minimal processing several biotechnology company currently developed adopted plantbased platform commercial production recombinant protein therapeutic manuscript outline challenge process livestock immunization well current plant biotechnology development aimed address challenge,2014-12-31,"Kolotilin, Igor; Topp, Ed; Cox, Eric; Devriendt, Bert; Conrad, Udo; Joensuu, Jussi; Stöger, Eva; Warzecha, Heribert; McAllister, Tim; Potter, Andrew; McLean, Michael D; Hall, J Christopher; Menassa, Rima",Vet Res,,,,document_parses/pdf_json/b8915fde10e62d4b033a9141910e5639590f0bae.json,document_parses/pmc_json/PMC4280687.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25559098/; https://doi.org/10.1186/s13567-014-0117-4,3463020.0,3
73070,73070,94384,b77eg866,e7482377b6836c860bc4ea714ea5dd757a293ad0,Medline; PMC,Protective Efficacy of Different Live Attenuated Infectious Bronchitis Virus Vaccination Regimes Against Challenge With IBV Variant-2 Circulating in the Middle East,10.3389/fvets.2019.00341,PMC6794438,31649942.0,cc-by,six vaccination regime using classical masstype variant ibvar ibb live vaccine evaluated middle eastern variant infectious bronchitis virus challenge six group spf chick birdsgroup vaccinated using primeboost regime day day using ibmibvar ibvaribvar ibvaribm ibmaibb ibbibb ibbibma respectively ciliostasis lesion score evaluated day vaccination bird challenged intranasally day post nd vaccination using eid mlbird wildtype ibv egb day post challenge dpc virus shedding monitored realtime rtpcr five chicksgroup euthanized dpc ciliostasis lesion scoring histopathology conducted chicksgroup seroconversion evaluated dpc group primed b vaccine showed relatively higher ciliostasis score compared group ibvar vaccinated group showed highest protection rate – high protection score – compared b vaccine group – virus shedding significantly reduced dpc group received ibvvar prime booster compared received b vaccine conclusion homologous ibvvar vaccine showed superior result compared b masstype vaccine confirming importance ibv vaccine seed homology circulating ibv strain,2019-10-09,"Sultan, Hesham A.; Ali, Ahmed; El Feil, Wael K.; Bazid, Abdel Hamid I.; Zain El-Abideen, Mohamed A.; Kilany, Walid H.",Front Vet Sci,,,,document_parses/pdf_json/e7482377b6836c860bc4ea714ea5dd757a293ad0.json,document_parses/pmc_json/PMC6794438.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31649942/; https://doi.org/10.3389/fvets.2019.00341,203912121.0,3
73078,73078,94392,yb5kf0u2,49f4c2847c6701324210ee8ab2c8878928554527,Elsevier; Medline; PMC,Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development,10.1016/j.ebiom.2020.102743,PMC7128973,32249203.0,els-covid,background coronaviruses pose serious threat global health evidenced severe acute respiratory syndrome sars middle east respiratory syndrome mers covid sars coronavirus sarscov mers coronavirus merscov novel coronavirus previously dubbed ncov officially named sarscov causative agent sars mers covid disease outbreak respectively safe vaccine rapidly induce potent longlasting virusspecific immune response infectious agent urgently needed coronavirus spike protein characteristic structural component viral envelope considered key target vaccine prevention coronavirus infection method first generated codon optimized merss subunit vaccine fused foldon trimerization domain mimic native viral structure variant construct engineered immune stimulant r flagellin tlr tlr agonist respectively trimeric design comprehensively tested preclinical immunogenicity merscov vaccine mouse delivered subcutaneously traditional needle injection intracutaneously dissolving microneedle array mnas evaluating virus specific igg antibody serum vaccinated mouse elisa using virus neutralization assay driven urgent need covid vaccine utilized strategy rapidly develop mna sarscov subunit vaccine tested preclinical immunogenicity vivo exploiting substantial experience mna merscov vaccine finding describe development mna delivered merscov vaccine preclinical immunogenicity specifically mna delivered merss subunit vaccine elicited strong longlasting antigenspecific antibody response building ongoing effort develop merscov vaccine promising immunogenicity mnadelivered merscov vaccine experience mna fabrication delivery including clinical trial rapidly designed produced clinicallytranslatable mna sarscov subunit vaccine within week identification sarscov sequence importantly mna delivered sarscov subunit vaccine elicited potent antigenspecific antibody response evident beginning week immunization interpretation mna delivery coronavirusess subunit vaccine promising immunization strategy coronavirus infection progressive scientific technological effort enable quicker response emerging pandemic ongoing effort develop mnamerss subunit vaccine enabled u rapidly design produce mna sarscov subunit vaccine capable inducing potent virusspecific antibody response collectively result support clinical development mna delivered recombinant protein subunit vaccine sars mers covid emerging infectious disease,2020-04-02,"Kim, Eun; Erdos, Geza; Huang, Shaohua; Kenniston, Thomas W.; Balmert, Stephen C.; Carey, Cara Donahue; Raj, V. Stalin; Epperly, Michael W.; Klimstra, William B.; Haagmans, Bart L.; Korkmaz, Emrullah; Falo, Louis D.; Gambotto, Andrea",EBioMedicine,,,,document_parses/pdf_json/49f4c2847c6701324210ee8ab2c8878928554527.json,document_parses/pmc_json/PMC7128973.xml.json,https://www.sciencedirect.com/science/article/pii/S2352396420301183; https://doi.org/10.1016/j.ebiom.2020.102743; https://api.elsevier.com/content/article/pii/S2352396420301183; https://www.ncbi.nlm.nih.gov/pubmed/32249203/,214757099.0,3
73172,73172,94500,0nrejsgr,cd05be991e31e44acba14989bdfe61c4a2ceb860,Elsevier; Medline; PMC,Exploring barriers to and facilitators of preventive measures against infectious diseases among Australian Hajj pilgrims: cross-sectional studies before and after Hajj,10.1016/j.ijid.2016.02.005,PMC7110465,26875699.0,els-covid,summary objective reason yet elucidated uptake preventive measure infectious disease hajj pilgrim variable aim study identify preventive advice intervention received australian pilgrim hajj barrier facilitator use hajj method two crosssectional survey australian pilgrim aged ≥ year undertaken one one hajj result pilgrim completed survey response rate influenza vaccine pneumococcal vaccine pertussis vaccine concern contracting disease hajj cited reason vaccination aware vaccine availability main reason nonreceipt obtained pretravel advice twice likely vaccinated seek advice pilgrim surveyed upon return reported practicing hand hygiene hajj citing ease use belief effectiveness main reason compliance university education significant predictor hand hygiene adherence fiftythree percent used facemasks breathing discomfort feeling suffocation main obstacle compliance conclusion study indicates significant opportunity improve awareness among australian hajj pilgrim importance using preventive health measure,2016-06-30,"Alqahtani, Amani S.; Wiley, Kerrie E.; Tashani, Mohamed; Willaby, Harold W.; Heywood, Anita E.; BinDhim, Nasser F.; Booy, Robert; Rashid, Harunor",International Journal of Infectious Diseases,,,,document_parses/pdf_json/cd05be991e31e44acba14989bdfe61c4a2ceb860.json,document_parses/pmc_json/PMC7110465.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26875699/; https://www.sciencedirect.com/science/article/pii/S1201971216000254; https://api.elsevier.com/content/article/pii/S1201971216000254; https://doi.org/10.1016/j.ijid.2016.02.005,205277481.0,3
73206,73206,94538,vg6d6cmv,22977df2b5a35dfe536faa4bd77a21ab316dc9f8,Medline; PMC,Long-Term Single-Dose Efficacy of a Vesicular Stomatitis Virus-Based Andes Virus Vaccine in Syrian Hamsters,10.3390/v6020516,PMC3939469,24492621.0,cc-by,andes virus andv highly pathogenic human primary etiologic agent hantavirus cardiopulmonary syndrome hcps south america casefatality rate high approved vaccine specific therapy infection laboratory recently developed replicationcompetent recombinant vesicular stomatitis virus vsvbased vaccine expressed glycoprotein andes virus place native vsv glycoprotein g vaccine highly efficacious syrian hamster model hcps given day challenge andv given around time challenge periexposure even protects administered postexposure herein sought test durability immune response single dose vaccine syrian hamster vaccine efficacious hamster challenged intranasally andv month vaccination p animal significantly protected following year vaccination p decrease protection correlated reduction measurable neutralizing antibody response suggests robust vaccination schedule might required provide longterm immunity,2014-01-31,"Prescott, Joseph; DeBuysscher, Blair L.; Brown, Kyle S.; Feldmann, Heinz",Viruses,,,,document_parses/pdf_json/22977df2b5a35dfe536faa4bd77a21ab316dc9f8.json,document_parses/pmc_json/PMC3939469.xml.json,https://doi.org/10.3390/v6020516; https://www.ncbi.nlm.nih.gov/pubmed/24492621/,14211769.0,3
73225,73225,94558,mz4y5am2,44d9ad484dc917e82daa41c802c2157d3f20dda4,Medline; PMC,Co-administration with DNA encoding papillomavirus capsid proteins enhances the antitumor effects generated by therapeutic HPV DNA vaccination,10.1186/s13578-015-0025-y,PMC4480891,26113972.0,cc-by,background dna vaccine emerged attractive candidate control human papillomavirus hpvassociated malignancy however dna vaccine suffer limited immunogenicity thus strategy enhance dna vaccine potency needed previously demonstrated dna vaccine encoding hpv e antigen crte linkage calreticulin crt linked enhances especific cd cell immune response antitumor effect eexpressing tumor current study aim introduce approach elicit potent cd cell help enhancement antigenspecific cd cell immune response generated crte dna vaccination using coadministration dna vector expressing papillomavirus major minor capsid antigen l l result showed coadministration vector containing codonoptimized bovine papillomavirus type bpv l l combination dna vaccine could elicit enhanced antigenspecific cd crte ovalbumin ovum antigenic system also demonstrated coadministration vector expressing bpv l andor l dna crte dna led generation llspecific cd cell immune response lspecific neutralizing antibody furthermore showed coadministration dna encoding bpv l significantly enhances therapeutic antitumor effect generated crte dna vaccination addition observed enhancement cd cell immune response dna encoding l l also found extend hpv system conclusion strategy elicits potent neutralizing antibody therapeutic response may potentially extended antigenic system beyond papillomavirus control infection andor cancer,2015-06-25,"Yang, Benjamin; Yang, Andrew; Peng, Shiwen; Pang, Xiaowu; Roden, Richard B.S.; Wu, T.-C.; Hung, Chien-Fu",Cell Biosci,,,,document_parses/pdf_json/44d9ad484dc917e82daa41c802c2157d3f20dda4.json,document_parses/pmc_json/PMC4480891.xml.json,https://doi.org/10.1186/s13578-015-0025-y; https://www.ncbi.nlm.nih.gov/pubmed/26113972/,17332996.0,3
73254,73254,94594,69kl9n8e,1fc0f041190515780cb40d25a061fe8893b942c5,Elsevier; Medline; PMC,Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity,10.1016/j.vaccine.2020.02.089,PMC7102565,32173095.0,els-covid,zika virus zikv reemergence pose significant health threat especially due risk fetal development necessitating safe effective vaccine protect pregnant woman zika envelope domain iii ze identified safe effective vaccine candidate however poorly immunogenic previously showed plantmade recombinant immune complex ric vaccine robust platform improve immunogenicity weak antigen study altered antigen fusion site ric platform accommodate nterminal fusion igg heavy chain nric thus wider range antigen resulting improvement ric expression normal cterminal fusion cric type rics containing ze efficiently assembled plant purified homogeneity simple onestep purification ze rics strongly bound complement receptor cq elicited strong zespecific antibody titer correlated zikv neutralization either nric cric codelivered plantproduced hepatitis b core hbc viruslike particle vlp displaying ze combination elicited fold greater antibody titer strongly neutralized zikv either rics vlps alone two dos without adjuvant finding demonstrate antigen require free nterminus optimal antigen display used ric system plantmade rics vlps highly effective vaccine targeting ze thus ric platform generally applied wider variety antigen,2020-04-16,"Diamos, Andrew G.; Pardhe, Mary D.; Sun, Haiyan; Hunter, Joseph G.L.; Mor, Tsafrir; Meador, Lydia; Kilbourne, Jacquelyn; Chen, Qiang; Mason, Hugh S.",Vaccine,,,,document_parses/pdf_json/1fc0f041190515780cb40d25a061fe8893b942c5.json,document_parses/pmc_json/PMC7102565.xml.json,https://doi.org/10.1016/j.vaccine.2020.02.089; https://www.ncbi.nlm.nih.gov/pubmed/32173095/; https://www.sciencedirect.com/science/article/pii/S0264410X20303376; https://api.elsevier.com/content/article/pii/S0264410X20303376,212729626.0,3
73260,73260,94600,gxmae2rs,5078f271f0b8d13359084747a8244563005d720a,Elsevier; Medline; PMC,Generation and evaluation of a recombinant genotype VII Newcastle disease virus expressing VP3 protein of Goose parvovirus as a bivalent vaccine in goslings,10.1016/j.virusres.2015.04.006,PMC7114436,25882914.0,els-covid,newcastle disease virus ndv goose parvovirus gpv considered two important widespread virus infecting goose study generated recombinant rmnavp expressing gpv vp using modified gooseorigin ndv na changing multibasic cleavage site motif rrqkr↓f f protein dibasic motif grqgr↓l avirulent strain lasota vaccine vector expression vp protein rmnavp infected cell detected immunofluorescence western blot assay genetic stability examined serially passaging time dayold embryonated spf chicken egg gosling inoculated rmnavp showed apparent sign disease developed strong gpv ndv neutralizing antibody response first study demonstrating recombinant ndv potential serve bivalent live vaccine goose parvovirus newcastle disease virus infection bird,2015-05-04,"Wang, Jianzhong; Cong, Yanlong; Yin, Renfu; Feng, Na; Yang, Songtao; Xia, Xianzhu; Xiao, Yueqiang; Wang, Wenxiu; Liu, Xiufan; Hu, Shunlin; Ding, Chan; Yu, Shengqing; Wang, Chunfeng; Ding, Zhuang",Virus Research,,,,document_parses/pdf_json/5078f271f0b8d13359084747a8244563005d720a.json,document_parses/pmc_json/PMC7114436.xml.json,https://doi.org/10.1016/j.virusres.2015.04.006; https://api.elsevier.com/content/article/pii/S0168170215001409; https://www.sciencedirect.com/science/article/pii/S0168170215001409; https://www.ncbi.nlm.nih.gov/pubmed/25882914/,44931737.0,3
73282,73282,94630,g9jsnug4,5d1d1c08fdd38bb6ceddf7afe34f4f96d41ee669; 2d0bf8e99a1cce19ef3bc0bf437bc1a1b5e875e5,Elsevier; Medline; PMC,Receptor-binding domain-based subunit vaccines against MERS-CoV,10.1016/j.virusres.2014.11.013,PMC4439384,25445336.0,bronze-oa,development effective vaccine particular subunitbased vaccine emerging middle east respiratory syndrome mers caused mers coronavirus merscov provide safest mean preventing continuous spread mers human camel review briefly describes structure merscov spike protein receptorbinding domain rbd discus current status mers vaccine development illustrates strategy used develop rbdbased subunit vaccine mers also summarizes currently available animal model merscov proposes future direction mers vaccine taken together review assist researcher working develop effective safe subunit vaccine merscov emerging coronaviruses might cause future pandemic,2015-04-01,"Zhang, Naru; Tang, Jian; Lu, Lu; Jiang, Shibo; Du, Lanying",Virus Research,,,,document_parses/pdf_json/5d1d1c08fdd38bb6ceddf7afe34f4f96d41ee669.json; document_parses/pdf_json/2d0bf8e99a1cce19ef3bc0bf437bc1a1b5e875e5.json,document_parses/pmc_json/PMC4439384.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25445336/; https://doi.org/10.1016/j.virusres.2014.11.013; https://api.elsevier.com/content/article/pii/S0168170214004730; https://www.sciencedirect.com/science/article/pii/S0168170214004730,29308101.0,3
73354,73354,94717,0ks8m213,b89c9f18eafb7b03e9fcd76f700870a1a8602b74,Elsevier; Medline; PMC,Structure-based immunogen design—leading the way to the new age of precision vaccines,10.1016/j.sbi.2018.06.002,PMC7127059,29980105.0,els-covid,vaccine one successful intervention global health however traditional vaccine development proven insufficient deal pathogen elude immune system highly variable nonfunctional epitope emerging b cell technology yielded potent monoclonal antibody targeting conserved epitope structural characterization provided template rational immunogen design review immunogen design strategy leverage structural information steer bulk immune response towards induction precise antibody specificity targeting key antigenic site immunogen designed elicit welldefined antibody response become basis dubbed precision vaccine immunogen used tackle longstanding vaccine problem demonstrated potential seed nextgeneration vaccine,2018-08-31,"Sesterhenn, Fabian; Bonet, Jaume; Correia, Bruno E",Current Opinion in Structural Biology,,,,document_parses/pdf_json/b89c9f18eafb7b03e9fcd76f700870a1a8602b74.json,document_parses/pmc_json/PMC7127059.xml.json,https://www.sciencedirect.com/science/article/pii/S0959440X18300514; https://www.ncbi.nlm.nih.gov/pubmed/29980105/; https://doi.org/10.1016/j.sbi.2018.06.002; https://api.elsevier.com/content/article/pii/S0959440X18300514,49714166.0,3
73432,73432,94814,08n9d0au,4b4172aaacc335716fb778b02bd6f264644ba3c0; a6ad701ec0c2ef70b398f81f4656332ed78addf2,Medline; PMC,Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome,10.1586/erv.12.126,PMC3586247,23252385.0,bronze-oa,subunit vaccine rbds development prevent severe acute respiratory syndrome sars caused sars coronavirus sarscov classified u nih category c pathogen vaccine comprised recombinant receptorbinding domain rbd sarscov spike protein formulated alum together synthetic glucopyranosyl lipid vaccine would induce neutralizing antibody without causing thtype immunopathology vaccine development led nonprofit product development partnership sabin vaccine institute texas child ’ hospital center vaccine development collaboration two academic partner new york blood center university texas medical branch industrial partner immune design corporation walter reed army institute research roadmap product development rbds sars vaccine outlined goal manufacture vaccine clinical testing within next year,2012-12-01,"Jiang, Shibo; Bottazzi, Maria Elena; Du, Lanying; Lustigman, Sara; Tseng, Chien-Te Kent; Curti, Elena; Jones, Kathryn; Zhan, Bin; Hotez, Peter J",Expert Review of Vaccines,,,,document_parses/pdf_json/4b4172aaacc335716fb778b02bd6f264644ba3c0.json; document_parses/pdf_json/a6ad701ec0c2ef70b398f81f4656332ed78addf2.json,document_parses/pmc_json/PMC3586247.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/23252385/; https://doi.org/10.1586/erv.12.126; https://www.tandfonline.com/doi/pdf/10.1586/erv.12.126?needAccess=true,10366209.0,3
73560,73560,94981,m7dw96rc,26456447f82d0213de7a9cb40db7eb5cdda8d507,Medline; PMC,Evaluation of the genetic variability found in Brazilian commercial vaccines for infectious bronchitis virus,10.1007/s11262-017-1515-2,PMC7089498,29128885.0,no-cc,infectious bronchitis virus ibv currently one important pathogen poultry industry h viral strain approved brazilian government constituent vaccine despite systematic vaccination brazil ibv yet controlled disease associated virus reported vaccinated chicken investigated genetic variability h strain present ibv vaccine different brazilian manufacturer performed dna sequencing analysis spike glycoprotein gene investigate genetic variability presence viral subpopulation among vaccine batch also vaccine single passage performed chicken embryonated egg result revealed amino acid substitution among vaccine localized region glycoprotein play role virus–host interaction secondary nucleotide peak identified chromatogram gene sequence revealed original vaccine h composed different subpopulation ibv moreover new viral subpopulation also found vaccine single passage chicken embryonated egg finding indicate h viral strain used vaccine market brazil still mutate rapidly replication leading amino acid substitution protein involved stimulation immune response glycoprotein therefore data suggest genetic variability viral strain taken consideration ensure effective immune response ibv electronic supplementary material online version article doi contains supplementary material available authorized user,2017-11-11,"Saraiva, Giuliana Loreto; Santos, Marcus Rebouças; Pereira, Claiton Gonçalves; Vidigal, Pedro Marcus Pereira; Fietto, Juliana Lopes Rangel; de Oliveira Mendes, Tiago Antonio; Bressan, Gustavo Costa; Soares-Martins, Jamária A. P.; de Almeida, Márcia Rogéria; Silva-Júnior, Abelardo",Virus Genes,,,,document_parses/pdf_json/26456447f82d0213de7a9cb40db7eb5cdda8d507.json,document_parses/pmc_json/PMC7089498.xml.json,https://doi.org/10.1007/s11262-017-1515-2; https://www.ncbi.nlm.nih.gov/pubmed/29128885/,3532939.0,3
73596,73596,95027,l5xw1u8x,443aa07a6f57cab4c25fcdb0add50527028d6769,Medline; PMC,Emerging Cancer Vaccines: The Promise of Genetic Vectors,10.3390/cancers3033687,PMC3759217,24212974.0,cc-by,therapeutic vaccination cancer important approach combined therapy improve longterm control cancer fact induction adaptive immune response tumor associated antigen taas well innate immunity important factor tumor stabilizationeradication variety immunization technology explored last decade currently active evaluation cellbased protein peptide heatshock proteinbased cancer vaccine genetic vaccine emerging promising methodology elicit immune response wide variety antigen including taas amongst adenovirus adbased vector show excellent immunogenicity profile achieved immunological proof concept human vivo electroporation plasmid dna dnaep also desirable vaccine technology cancer vaccine repeatable several time parameter required longterm maintenance antitumor immunity recent finding show combination different modality immunization heterologous primeboost able induce superior immune reaction compared singlemodality vaccine review discus challenge requirement emerging cancer vaccine particularly focusing genetic cancer vaccine currently active development promise shown ad dnaep heterologous primeboost,2011-09-22,"Aurisicchio, Luigi; Ciliberto, Gennaro",Cancers (Basel),,,,document_parses/pdf_json/443aa07a6f57cab4c25fcdb0add50527028d6769.json,document_parses/pmc_json/PMC3759217.xml.json,https://doi.org/10.3390/cancers3033687; https://www.ncbi.nlm.nih.gov/pubmed/24212974/,15846548.0,3
73600,73600,95031,30f8kmx7,e10a3c96080f79b0406b3f938edd28236ab6b439,Elsevier; PMC,Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs,10.1016/j.vaccine.2007.08.009,PMC7115514,17913311.0,els-covid,cellular humoral immune response dog candidate vaccine composed leishmania braziliensis promastigote protein plus saponin adjuvant investigated prerequisite understanding mechanism immunogenicity canine visceral leishmaniasis cvl candidate vaccine elicited strong antigenicity related increase antileishmania igg isotypes together higher level lymphocyte particularly circulating cd tlymphocytes leishmania chagasi antigenspecific cd tlymphocytes indicated intense cell proliferation increased nitric oxide production vitro stimulation l chagasi soluble antigen candidate vaccine elicited immune activation status potentially compatible effective control etiological agent cvl,2007-11-01,"Giunchetti, Rodolfo Cordeiro; Corrêa-Oliveira, Rodrigo; Martins-Filho, Olindo Assis; Teixeira-Carvalho, Andréa; Roatt, Bruno Mendes; de Oliveira Aguiar-Soares, Rodrigo Dian; de Souza, Juliana Vitoriano; das Dores Moreira, Nádia; Malaquias, Luiz Cosme Cotta; Mota e Castro, Luciana Lisboa; de Lana, Marta; Reis, Alexandre Barbosa",Vaccine,,,,document_parses/pdf_json/e10a3c96080f79b0406b3f938edd28236ab6b439.json,document_parses/pmc_json/PMC7115514.xml.json,https://api.elsevier.com/content/article/pii/S0264410X07009255; https://www.sciencedirect.com/science/article/pii/S0264410X07009255,14378221.0,3
73602,73602,95033,x7ng4ifv,e0b4da2b03d88f5df075fb094d8fcda6d7238f83,Medline; PMC,Communicable Diseases: Achievements and Challenges for Public Health,10.1007/bf03391594,PMC7100685,32226190.0,no-cc,past two century seen enormous achievement control infectious disease previously leading cause death large measure due sanitation food safety vaccine antibiotic improved nutrition led people put faith notion medical science would succeed overcoming remaining obstacle vaccination eradicated smallpox nearly eradicated poliomyelitis greatly reduced many highly dangerous infection diphtheria tetanus measles new disease hiv new form influenza taken professional popular opinion surprise renewed challenge world public health community emergence antibioticresistant strain common organism due overuse antibiotic lack vaccine many dangerous microorganism pose problem humanity stress need new vaccine effective antibiotic strengthened environmental control measure new knowledge microbiological origin cancer cervix stomach liver strengthened primary prevention brought hope new cure found chronic disease infectious origin tragically long delay adopting “ new ” cost effective vaccine cause hundred thousand preventable death year developing midlevel developed country gain made control many tropical disease malaria tuberculosis infectious disease remain enormous global problem research acquisition new knowledge risk communication application currently available mean fair distribution great challenge public health coming decade,2010-06-09,"Schlipköter, Ursula; Flahault, Antoine",Public Health Rev,,,,document_parses/pdf_json/e0b4da2b03d88f5df075fb094d8fcda6d7238f83.json,,https://www.ncbi.nlm.nih.gov/pubmed/32226190/; https://doi.org/10.1007/bf03391594,79723543.0,3
73648,73648,95088,qkfxfmxb,149fee3f610ddebf8ad1045779c8af5fb1f40940,Medline; PMC,"Improving influenza vaccine virus selectionReport of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14–16 June 2010",10.1111/j.1750-2659.2011.00277.x,PMC4954460,21819547.0,no-cc,• almost year global influenza surveillance response system gisrs key player monitoring evolution spread influenza virus recommending strain used human influenza vaccine gisrs also worked continually monitor ass risk posed potential pandemic virus guide appropriate public health response • expanded enhanced role gisrs following adoption international health regulation recognition continuing threat posed avian hn aftermath hn pandemic provide opportune time critically review process influenza vaccine virus selected addition identifying potential area improvement review also help promote greater appreciation wider influenza policy‐making community complexity influenza vaccine virus selection • selection process highly coordinated involves continual year‐round integration virological data epidemiological information national influenza centre nics thorough antigenic genetic characterization virus collaborating centre whoccs part selecting suitable candidate vaccine virus preparation suitable reassortants corresponding reagent vaccine standardization essential regulatory laboratory erls • ensuring optimal effectiveness vaccine assisted recent year advance molecular diagnosis availability extensive genetic sequence data however remain number challenging constraint including variation assay used possibility complication resulting non‐antigenic change limited availability suitable vaccine virus requirement recommendation made year advance peak influenza season production constraint • effective collaboration coordination human animal influenza network increasingly recognized essential requirement improved integration data animal human virus identification unusual influenza virus infecting human evaluation pandemic risk selection candidate virus pandemic vaccine • training workshop assessment donation led significant increase trained laboratory personnel equipment resulting expansion geographical surveillance coverage capacity nics laboratory resulted significant increase volume information reported spread intensity impact influenza addition initiative shipment fund project facilitated timely sharing clinical specimen virus isolates contributed comprehensive understanding global distribution temporal circulation different virus important sustain build upon gain made area • although haemagglutination inhibition hai assay likely remain assay choice antigenic characterization virus foreseeable future alternative assay – example based upon advanced recombinant dna protein technology – may adaptable automation technology microtitre neuraminidase inhibition assay may also significant implication vaccine virus selection vaccine development • microneutralization assay provide important adjunct hai assay virus antigenic characterization improvement use potential automation assay facilitate large‐scale serological study advanced technique epitope mapping allow accurate assessment quality protective immune response aid development additional criterion measuring immunity • standardized seroepidemiological survey ass impact influenza population could help establish well‐characterized bank age‐stratified representative serum national regional global resource providing direct evidence specific benefit vaccination • advance high‐throughput genetic sequencing coupled advanced bioinformatics tool together x‐ray crystallographic data accelerate understanding genetic phenotypic change underlie virus evolution specifically help predict influence amino acid change virus antigenicity • complex mathematical modelling technique increasingly used gain insight evolution epidemiology influenza virus however value predicting timing nature future antigenic genetic change likely limited present application simpler non‐mechanistic statistical algorithm already used basis antigenic cartography phylogenetic modelling likely useful facilitating vaccine virus selection aiding assessment pandemic potential avian animal influenza virus • adoption alternative vaccine technology – live‐attenuated quadrivalent non‐ha‐based vaccine – significant implication vaccine virus selection well vaccine regulatory manufacturing process recent collaboration gisrs vaccine manufacturer resulted increased availability egg isolates high‐growth reassortants vaccine production development qualified cell culture investigation alternative method vaccine potency testing continue support effort increase reliability timeliness global influenza vaccine supply • gisrs partner continually working identify improvement harness new technology strengthen sustain collaboration continue central role coordinating worldwide expertise meet increasing public health need influenza vaccine support effort improve vaccine virus selection process including convening periodic international consultation,2011-08-08,"Ampofo, William K.; Baylor, Norman; Cobey, Sarah; Cox, Nancy J.; Daves, Sharon; Edwards, Steven; Ferguson, Neil; Grohmann, Gary; Hay, Alan; Katz, Jacqueline; Kullabutr, Kornnika; Lambert, Linda; Levandowski, Roland; Mishra, A. C.; Monto, Arnold; Siqueira, Marilda; Tashiro, Masato; Waddell, Anthony L.; Wairagkar, Niteen; Wood, John; Zambon, Maria; Zhang, Wenqing",Influenza Other Respir Viruses,,,,document_parses/pdf_json/149fee3f610ddebf8ad1045779c8af5fb1f40940.json,,https://www.ncbi.nlm.nih.gov/pubmed/21819547/; https://doi.org/10.1111/j.1750-2659.2011.00277.x,5623469.0,3
73668,73668,95114,92wtqk53,b3fe63ea9f4794d58f37083f3430c6e5238449c3,Medline; PMC,Evaluation of a Novel Non-Penetrating Electrode for Use in DNA Vaccination,10.1371/journal.pone.0019181,PMC3084774,21559474.0,cc-by,current progress development vaccine decreased incidence fatal nonfatal infection increased longevity however new technology need developed combat emerging generation infectious disease dna vaccination demonstrated great potential use wide variety disease alone technology generate significant immune response vaccination combined delivery electroporation ep enhance plasmid expression immunity ep system effective invasive painful making le desirable use vaccination lab recently developed noninvasive electrode known multielectrode array mea lie flat surface skin without penetrating tissue study evaluated mea use dna vaccination using hepatitis b virus infectious model utilized guinea pig model skin similar thickness morphology human plasmid encoding hepatitis b surface antigen hbsag delivered intradermally mea guinea pig skin result show increased protein expression resulting plasmid delivery using mea compared injection alone within hour treatment influx cellular infiltrate experimental group humoral response also increased significantly duration intensity compared injection group electrode requires study result suggest mea potential use electrically mediated intradermal dna vaccination,2011-04-29,"Donate, Amy; Coppola, Domenico; Cruz, Yolmari; Heller, Richard",PLoS One,,,,document_parses/pdf_json/b3fe63ea9f4794d58f37083f3430c6e5238449c3.json,document_parses/pmc_json/PMC3084774.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/21559474/; https://doi.org/10.1371/journal.pone.0019181,16475316.0,3
73738,73738,95203,33h22ikl,ed94f0bd0fe17c099f8cdff4bf9edbbd29ebf41f,Medline; PMC,Structural basis of development of multi-epitope vaccine against Middle East respiratory syndrome using in silico approach,10.2147/idr.s175114,PMC6254671,30538505.0,cc-by-nc,background middle east respiratory syndrome mers caused mers coronavirus merscov thus far mers outbreak reported saudi arabia south korea specific vaccine yet reported mers purpose address urgent need mers vaccine present study designed two multiepitope vaccine mevs mers utilizing several silico method tool method design multiepitope vaccine mevs composed cytotoxic lymphocyte ctl helper lymphocyte htl epitope screened form thirteen different protein merscov mevs also carry potential bcell linear epitope region bcell discontinuous epitope well interferonγinducing epitope human βdefensin βdefensin used adjuvant enhance immune response mevs design mevs short peptide molecular linkers utilized link screened potential ctl epitope htl epitope adjuvant tertiary model mevs generated refined studied molecular interaction tolllike receptor cdna mevs generated analyzed silico expression mammalian host cell line human result screened ctl htl epitope found high propensity stable molecular interaction hla allele molecule ctl epitope also found favorable molecular interaction within cavity transporter associated antigen processing selected ctl htl epitope jointly cover upto worldwide human population ctl htl mevs molecular model shown stable binding complex formation propensity tolllike receptor cdna analysis mevs shown high expression tendency mammalian host cell line human conclusion multistage silico analysis mevs predicted elicit humoral well cell mediated immune response epitope designed mevs predicted cover large human population worldwide hence designed mevs could tried vivo potential vaccine candidate mers,2018-11-21,"Srivastava, Sukrit; Kamthania, Mohit; Singh, Soni; Saxena, Ajay K; Sharma, Nishi",Infect Drug Resist,,,,document_parses/pdf_json/ed94f0bd0fe17c099f8cdff4bf9edbbd29ebf41f.json,document_parses/pmc_json/PMC6254671.xml.json,https://doi.org/10.2147/idr.s175114; https://www.ncbi.nlm.nih.gov/pubmed/30538505/,54472893.0,3
73756,73756,95224,r8lymmec,81f7fa665ac3b3b7782de7c0a0a1505eeb927729,Medline; PMC,Vaccine confidence in the time of COVID-19,10.1007/s10654-020-00634-3,PMC7174145,32318915.0,no-cc,early month covid epidemic wondered force global experience solve problem vaccine refusal vexed preoccupied global public health community last several decade drawing historical epidemiological analysis critique contemporary approach reducing vaccine hesitancy articulate notion vaccine confidence expanded way conceptualizing problem respond intervening rush vaccine optimism see pervading present discourse around covid epidemic call reimagination culture public health meaning vaccine safety regulation public confidence vaccination program depends work community—social political moral well biological concept public health program must broader delivery vaccine technology narrative work policy action entailed actualizing change expect essential achieving true vaccine confidence however public reacts specific vaccine may developed covid,2020-04-22,"Harrison, Emily A.; Wu, Julia W.",Eur J Epidemiol,,,,document_parses/pdf_json/81f7fa665ac3b3b7782de7c0a0a1505eeb927729.json,document_parses/pmc_json/PMC7174145.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32318915/; https://doi.org/10.1007/s10654-020-00634-3,216048930.0,3
73786,73786,95260,lhdw50il,9a6631817877e5924183cd6e4c88ac6aade44978,Medline; PMC,"Preparation, characterization and preliminary in vivo studies of inactivated SARS-CoV vaccine",10.1360/03wc464,PMC7088751,32214708.0,no-cc,large quantity sarscov virus proliferated vero cell inactivated βpropiolactone purified sepharose ff column chromatography prepare inactivated vaccine vaccine identified western blot mass spectrographic analysis elisa electron microscopy vaccine without aluminum hydroxide adjuvant inoculated female balbc mouse different dosage result showed antibody sarscov induced mouse antibody level induced vaccine aluminum hydroxide higher without aluminum hydroxide,2003,"Tang, Lin; Wang, Jian; Qin, Ede; Zhu, Qingyu; Yu, Man; Ding, Zhifen; Shi, Huiying; Cheng, Xiaojie; Wang, Caiping; Chang, Guohui; Li, Shuangli; Zhang, Xumin; Chen, Xishu; Yu, Jun; Chen, Ze",Chin Sci Bull,,,,document_parses/pdf_json/9a6631817877e5924183cd6e4c88ac6aade44978.json,,https://doi.org/10.1360/03wc464; https://www.ncbi.nlm.nih.gov/pubmed/32214708/,59423211.0,3
73875,73875,95373,25t4p4n8,045e3571c820280e2d7b89537c1cd78ece60ab7b,Elsevier; Medline; PMC,Rapid response to an emerging infectious disease – Lessons learned from development of a synthetic DNA vaccine targeting Zika virus,10.1016/j.micinf.2018.03.001,PMC6593156,29555345.0,els-covid,vaccine considered one greatest advance modern medicine global burden numerous infectious disease significantly reduced case effectively eradicated deployment specific vaccine however effort develop effective new vaccine infectious pathogen influenza human immunodeficiency virus hiv dengue virus denv chikungunya virus chikv ebola virus zika virus zikv proven challenging zika virus mosquitovectored flavivirus responsible periodic outbreak disease africa southeast asia pacific island dating back year period zikv infection subclinical infected individual resulted mild case fever arthralgia rash others concern zikv changed past two year however outbreak brazil central american country caribbean island revealed novel aspect infection including vertical sexual transmission mode case reported showing dramatic neurological pathology including microcephaly neurodevelopmental problem baby born zikv infected mother well increased risk guillainbarre syndrome adult finding prompted world health organization declare zikv public health emergency resulted expanded effort develop zikv vaccine immunotherapeutics several zikv vaccine candidate immunogenic effective blocking zikv infection animal model since developed evaluated clinic additional therapeutic investigation include antizikv monoclonal antibody mabs shown neutralize infection vitro well protect morbidity mouse model zikv infection review summarize current understanding zikv biology describe effort rapidly develop vaccine zikv,2018-12-31,"Kudchodkar, Sagar B.; Choi, Hyeree; Reuschel, Emma L.; Esquivel, Rianne; Jin-Ah Kwon, Jackie; Jeong, Moonsup; Maslow, Joel N.; Reed, Charles C.; White, Scott; Kim, J. Joseph; Kobinger, Gary P.; Tebas, Pablo; Weiner, David B.; Muthumani, Kar",Microbes and Infection,,,,document_parses/pdf_json/045e3571c820280e2d7b89537c1cd78ece60ab7b.json,document_parses/pmc_json/PMC6593156.xml.json,https://doi.org/10.1016/j.micinf.2018.03.001; https://api.elsevier.com/content/article/pii/S1286457918300704; https://www.sciencedirect.com/science/article/pii/S1286457918300704; https://www.ncbi.nlm.nih.gov/pubmed/29555345/,4871206.0,3
73908,73908,95415,bs8vqa40,7270ff5e268e22e5d15f9637967f9b006f54af7e,Elsevier; Medline; PMC,Defining the interval for monitoring potential adverse events following immunization (AEFIs) after receipt of live viral vectored vaccines,10.1016/j.vaccine.2018.08.085,PMC6535369,30497831.0,els-covid,live viral vector express heterologous antigen target pathogen investigated development novel vaccine serious infectious agent like hiv ebola live recombinant vectored vaccine may replicationcompetent key challenge defining length time monitoring potential adverse event following immunization aefi clinical trial epidemiologic study time period must chosen care based consideration preclinical clinical trial data biological plausibility practical feasibility available option include adapting current relevant regulatory guideline convening panel expert review evidence systematic literature search narrow list likely potential known aefi establish optimal risk window conducting “ near realtime “ prospective monitoring unknown clustering ’ aefi validated large linked vaccine safety database using rapid cycle analysis prespecified adverse event special interest aesi treescan identify previously unsuspected outcome risk window established option could used along establishing registry clinically validated prespecified aesi include casecontrol study depending infrastructure human resource database available different country appropriate option combination option determined regulatory agency investigator,2019-09-10,"Kochhar, Sonali; Excler, Jean-Louis; Bok, Karin; Gurwith, Marc; McNeil, Michael M.; Seligman, Stephen J.; Khuri-Bulos, Najwa; Klug, Bettina; Laderoute, Marian; Robertson, James S.; Singh, Vidisha; Chen, Robert T.",Vaccine,,,,document_parses/pdf_json/7270ff5e268e22e5d15f9637967f9b006f54af7e.json,document_parses/pmc_json/PMC6535369.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X18312350; https://api.elsevier.com/content/article/pii/S0264410X18312350; https://www.ncbi.nlm.nih.gov/pubmed/30497831/; https://doi.org/10.1016/j.vaccine.2018.08.085,54167101.0,3
73915,73915,95425,fitiikdn,88d38d1cbeeb119278c244e168b8289c599de138,Elsevier; Medline; PMC,Human vaccine research in the European Union,10.1016/j.vaccine.2008.11.064,PMC7115654,19059446.0,els-covid,use vaccine saving million life every year across globe number important disease hivaids malaria tb hepatitis c continue frustrate attempt produce effective vaccine confronting challenge require new approach increased research effort scientific community sixth framework programme fp – european commission ec important catalyst direction allocating financial contribution eur million wide variety vaccine research activity ranging basic vaccinology translational research clinical application vaccine taken together around research group country participating vaccine activity fp impressive number signal new spirit collaborative research facilitate exploitation immense possibility modern vaccinology,2009-01-29,"Olesen, Ole F.; Lonnroth, Anna; Mulligan, Bernard",Vaccine,,,,document_parses/pdf_json/88d38d1cbeeb119278c244e168b8289c599de138.json,document_parses/pmc_json/PMC7115654.xml.json,https://doi.org/10.1016/j.vaccine.2008.11.064; https://api.elsevier.com/content/article/pii/S0264410X08015788; https://www.sciencedirect.com/science/article/pii/S0264410X08015788; https://www.ncbi.nlm.nih.gov/pubmed/19059446/,38980081.0,3
73937,73937,95455,r8n0x6s9,1e8198cb2eac9d910c4f14712025d90ddb958204,Medline; PMC,Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas,10.3390/v11030212,PMC6466352,30832356.0,cc-by,merscov present dromedary camel throughout middle east africa dromedary camel primary zoonotic reservoir human infection interruption zoonotic transmission chain camel human therefore may effective strategy control ongoing merscov outbreak show vaccination adjuvanted merscov spike protein subunit vaccine confers complete protection merscov disease alpaca result reduced delayed viral shedding upper airway dromedary camel protection alpaca correlate high serum neutralizing antibody titer lower titer serum neutralizing antibody correlate delayed significantly reduced shedding nasal turbinate dromedary camel together data indicate induction robust neutralizing humoral immune response vaccination naïve animal reduces shedding potentially could diminish risk zoonotic transmission,2019-03-02,"Adney, Danielle R.; Wang, Lingshu; van Doremalen, Neeltje; Shi, Wei; Zhang, Yi; Kong, Wing-Pui; Miller, Megan R.; Bushmaker, Trenton; Scott, Dana; de Wit, Emmie; Modjarrad, Kayvon; Petrovsky, Nikolai; Graham, Barney S.; Bowen, Richard A.; Munster, Vincent J.",Viruses,,,,document_parses/pdf_json/1e8198cb2eac9d910c4f14712025d90ddb958204.json,document_parses/pmc_json/PMC6466352.xml.json,https://doi.org/10.3390/v11030212; https://www.ncbi.nlm.nih.gov/pubmed/30832356/,73475809.0,3
73939,73939,95457,kwavs4mx,c952f2e27eb6de54c65f23fa1fda34e4c00de5b4,Elsevier; PMC,Chapter 28 Vaccines for Emerging Viral Diseases,10.1016/b978-0-12-802174-3.00028-x,PMC7149656,,els-covid,infectious disease continue plague mankind evolve keep pace effort control sir william osler captured ongoing fear infectious pathogen said “ humanity three great enemy fever famine war far greatest far terrible fever ” despite significant impact antimicrobial vaccine public health one major human pathogen eradicated—variola virus agent smallpox place series new reemerging microbe responsible isolated infection regional outbreak global pandemic bacterial fungal parasitic pathogen capacity cause widespread epidemic “ black death ” caused yersinia pestis th century europe however bacteria fungi parasite le likely cause widespread human pandemic point history le amenable vaccine strategy viral disease focusing virus catalog newly discovered human pathogen beginning th century show predictable nearly linear rate new agent discovered time however virus family associated human infection number seems plateaued chapter concentrate vaccine emerging viral disease,2016-12-31,"DeZure, Adam; Graham, Barney S.",The Vaccine Book,,,,document_parses/pdf_json/c952f2e27eb6de54c65f23fa1fda34e4c00de5b4.json,document_parses/pmc_json/PMC7149656.xml.json,https://api.elsevier.com/content/article/pii/B978012802174300028X; https://www.sciencedirect.com/science/article/pii/B978012802174300028X,89195800.0,3
73996,73996,95525,bb8k1v73,872c5e6e8028d2477552d7970c45124d5a4b2ab8; d14d3af5767b34cf3c202149c52feb8568e02fc3; 07270df0848b50751a878475a863cd66b25907f1; 2f2339c3dc2dea779f9459f4ef758ed9c42be553,Elsevier; Medline; PMC,Unique Safety Issues Associated with Virus Vectored Vaccines: Potential for and Theoretical Consequences of Recombination with Wild Type Virus Strains,10.1016/j.vaccine.2016.04.060,PMC5204448,27346303.0,green-oa,world health organization convened informal consultation characterization quality aspect vaccine based live virus vector resulting report one several issue raised future study potential recombination virusvectored vaccine wild type pathogenic virus strain paper present assessment issue formulated brighton collaboration provide appropriate context understanding potential recombination virusvectored vaccine review briefly current status virus vectored vaccine mechanism recombination virus experience recombination involving live attenuated vaccine field concern raised previously literature regarding recombination virusvectored vaccine wild type virus strain present discussion major variable could influence recombination virusvectored vaccine circulating wild type virus consequence recombination including intrinsic recombination property parent virus used vector sequence relatedness vector wild virus virus host range pathogenesis transmission replication competency vector target host mechanism vector attenuation additional factor potentially affecting virulence circulation multiple recombinant vector target population finally present guiding principle vector design testing intended anticipate mitigate potential consequence recombination virusvectored vaccine wild type pathogenic virus strain,2016-12-01,"Condit, Richard C.; Williamson, Anna-Lise; Sheets, Rebecca; Seligman, Stephen J.; Monath, Thomas P.; Excler, Jean-Louis; Gurwith, Marc; Bok, Karin; Robertson, James S.; Kim, Denny; Hendry, Michael; Singh, Vidisha; Mac, Lisa M.; Chen, Robert T.",Vaccine,,,,document_parses/pdf_json/872c5e6e8028d2477552d7970c45124d5a4b2ab8.json; document_parses/pdf_json/d14d3af5767b34cf3c202149c52feb8568e02fc3.json; document_parses/pdf_json/07270df0848b50751a878475a863cd66b25907f1.json; document_parses/pdf_json/2f2339c3dc2dea779f9459f4ef758ed9c42be553.json,document_parses/pmc_json/PMC5204448.xml.json,http://europepmc.org/articles/pmc5204448?pdf=render; https://api.elsevier.com/content/article/pii/S0264410X16302250; https://www.ncbi.nlm.nih.gov/pubmed/27346303/; https://www.sciencedirect.com/science/article/pii/S0264410X16302250; https://doi.org/10.1016/j.vaccine.2016.04.060,46742044.0,3
74031,74031,95569,658lmb7d,8b840366cc384dbc56e835f14d86c7d2fec88ea5,Elsevier; Medline; PMC,Identification and characterisation of T-cell epitopes for incorporation into dendritic cell-delivered Listeria vaccines,10.1016/j.jim.2015.05.009,PMC7127673,26031451.0,els-covid,dendritic cell loaded antigenic peptide safety robust immune stimulation would ideal induction immunity protect listeriosis however currently accepted method predict peptide derived listeria proteome might confer protection elution peptide mhc molecule listeria infection yield highaffinity immunedominant epitope individual epitope reliably confer listeria protection instead applied bioinformatic prediction mhc class ii epitope generate antigenic peptide formulated advax™ novel polysaccharide particulate adjuvant able enhance crosspresentation prior screened ability induce protective tcell response combination least four intermediate strength mhci binding epitope one weak mhcii binding epitope expressed single peptide sequence formulated advax adjuvant induced potent tcell response high tnfα il production dendritic cell resulting robust listeriosis protection susceptible mouse tcell vaccine approach might useful design vaccine protect listeriosis intracellular infection,2015-09-30,"Calderon-Gonzalez, Ricardo; Tobes, Raquel; Pareja, Eduardo; Frande-Cabanes, Elisabet; Petrovsky, Nikolai; Alvarez-Dominguez, Carmen",Journal of Immunological Methods,,,,document_parses/pdf_json/8b840366cc384dbc56e835f14d86c7d2fec88ea5.json,document_parses/pmc_json/PMC7127673.xml.json,https://api.elsevier.com/content/article/pii/S0022175915300028; https://www.sciencedirect.com/science/article/pii/S0022175915300028; https://www.ncbi.nlm.nih.gov/pubmed/26031451/; https://doi.org/10.1016/j.jim.2015.05.009,22857485.0,3
74036,74036,95575,v7z62tld,0be19bfb83d9eb0a6b6f1c7ce8b75a58d8b1ed6f,Elsevier; Medline; PMC,Porcine epidemic diarrhea virus papain-like protease 2 can be noncompetitively inhibited by 6-thioguanine,10.1016/j.antiviral.2018.08.011,PMC7113753,30138642.0,els-covid,porcine epidemic diarrhea virus pedv coronavirus cov discovered infects intestinal tract pig resulting diarrhea vomiting cause extreme dehydration death neonatal piglet asia modified live attenuated vaccine used control pedv infection recent year however new strain pedv belongs genogroup appeared usa quickly spread canada mexico well asian european country due le effective protective immunity provided vaccine new strain caused considerable agricultural economic loss worldwide emergence new strain increase importance understanding pedv well strategy inhibiting coronaviral protease including main protease papainlike protease ideal antiviral target essential role viral maturation provide first description expression purification structural characteristic recombinant pedv papainlike protease moreover present finding thioguanine chemotherapeutic drug contrast competitive inhibition sars merscov papainlike protease noncompetitive inhibitor pedv papainlike protease,2018-10-31,"Chu, Hsu-Feng; Chen, Chiao-Che; Moses, David C.; Chen, Yau-Hung; Lin, Chao-Hsiung; Tsai, Ying-Chieh; Chou, Chi-Yuan",Antiviral Research,,,,document_parses/pdf_json/0be19bfb83d9eb0a6b6f1c7ce8b75a58d8b1ed6f.json,document_parses/pmc_json/PMC7113753.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30138642/; https://api.elsevier.com/content/article/pii/S0166354218302183; https://doi.org/10.1016/j.antiviral.2018.08.011; https://www.sciencedirect.com/science/article/pii/S0166354218302183,52075749.0,3
74124,74124,95688,gbwb7fqi,fd955af6faa247ced61613abf842cf3affac6bb2,Medline; PMC,Broad-Spectrum Drugs Against Viral Agents,10.3390/ijms9091561,PMC2635754,19325820.0,cc-by,development antiviral focused primarily vaccine treatment specific viral agent although effective approach may limited situation etiologic agent unknown target virus undergone mutation recombination reassortment augmentation innate immune response may effective alternative disease amelioration nonspecific broadspectrum immune response induced doublestranded dsrnas poly iclc oligonucleotides odns containing unmethylated deocycytidyldeoxyguanosinyl cpg motif may offer protection various bacterial viral pathogen regardless genetic makeup zoonotic origin drug resistance,2008-09-01,"Christopher, Mary E.; Wong, Jonathan P.",Int J Mol Sci,,,,document_parses/pdf_json/fd955af6faa247ced61613abf842cf3affac6bb2.json,document_parses/pmc_json/PMC2635754.xml.json,https://doi.org/10.3390/ijms9091561; https://www.ncbi.nlm.nih.gov/pubmed/19325820/,7772838.0,3
74170,74170,95746,gptjqti7,03fea4a49ce80db75ae5c76eeaa176a87ce668a6,Elsevier; Medline; PMC,Comparative protective immunity provided by live vaccines of Newcastle disease virus or avian metapneumovirus when co-administered alongside classical and variant strains of infectious bronchitis virus in day-old broiler chicks,10.1016/j.vaccine.2019.09.081,PMC7127460,31607602.0,els-covid,study report simultaneous administration live ndv ampv subtype b vaccine alongside two live ibv massachusettsh bcr vaccine dayold maternalantibody positive commercial broiler chick first experiment chick divided four group one unvaccinated three group vaccinated live ndv vggaavinew live h cr vggaavinew h cr second experiment live ampv subtype b vaccine used place ndv clinical sign monitored daily oropharyngeal swab taken regular interval vaccine virus detection blood collected dpv serology chick group challenged virulent strain qx ampv subtype b ibv day post challenge dpc tracheal ciliary protection assessed ampv clinical score recorded dpc ndv haemagglutination inhibition hi antibody titre assayed indicator protective immunity experiment ciliary protection ibv vaccinated group maintained protection virulent ampv challenge compromised ampv h cr coadministered ndv hi mean titre single combined ndvvaccinated group remained protective titre log experiment demonstrated simultaneous administration live ndv vggaavinew ampv subtype b alongside h cr vaccine interfere protection conferred ndv ibv ampv,2019-12-10,"Ball, Christopher; Forrester, Anne; Herrmann, Andreas; Lemiere, Stephane; Ganapathy, Kannan",Vaccine,,,,document_parses/pdf_json/03fea4a49ce80db75ae5c76eeaa176a87ce668a6.json,document_parses/pmc_json/PMC7127460.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X19313234; https://doi.org/10.1016/j.vaccine.2019.09.081; https://www.ncbi.nlm.nih.gov/pubmed/31607602/; https://api.elsevier.com/content/article/pii/S0264410X19313234,204544777.0,3
74175,74175,95752,m5x1nn19,cd50536bcd80b20330a1382bbcb0f895748e338a,Medline; PMC,Porcine parvovirus VP1/VP2 on a time series epitope mapping: exploring the effects of high hydrostatic pressure on the immune recognition of antigens,10.1186/s12985-019-1165-1,PMC6547530,31159841.0,cc-by,porcine parvovirus ppv dna virus cause reproductive failure gilt sow resulting embryonic fetal loss worldwide epitope mapping ppv important developing new vaccine study used spot synthesis analysis epitope mapping capsid protein ppv nadl strain correlated finding predictive data immunoinformatics virus exposed three condition prior inoculation pig native untreated high hydrostatic pressure mpa h room temperature high hydrostatic pressure mpa h − °c compared commercial vaccine produced using inactivated ppv screening serum sample detected positive spot corresponding antigenic site type inoculated antigen elicited distinct epitope set silico prediction located linear discontinuous epitope b cell coincided several epitope detected spot synthesis serum pig received different preparation inoculum condition tested elicited antibody vpvp antigen differed relation response time profile structurally available region recognized electronic supplementary material online version article contains supplementary material available authorized user,2019-06-03,"de Souza, Ancelmo Rabelo; Yamin, Marriam; Gava, Danielle; Zanella, Janice Reis Ciacci; Gatti, Maria Sílvia Viccari; Bonafe, Carlos Francisco Sampaio; de Lima Neto, Daniel Ferreira",Virol J,,,,document_parses/pdf_json/cd50536bcd80b20330a1382bbcb0f895748e338a.json,document_parses/pmc_json/PMC6547530.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31159841/; https://doi.org/10.1186/s12985-019-1165-1,174805822.0,3
74206,74206,95788,02pjdufw,d7df17379b5a79dd5917ea5f26051eef8bfe5011,Medline; PMC,Fractional Dosing of Yellow Fever Vaccine to Extend Supply: A Modeling Study,10.1016/s0140-6736(16)31838-4,PMC5161610,27837923.0,cc-by-nc-nd,background ongoing yellow fever yf epidemic angola strain global vaccine supply prompting adopt dose sparing vaccination campaign kinshasa july–august although fold fractionaldose vaccine similar standarddose vaccine safety immunogenicity efficacy untested urgent need ensure robustness fractionaldose vaccination elucidating condition dose fractionation would reduce transmission method estimate effective reproductive number yf angola using disease natural history case report data simple mathematical model yf transmission calculate infection attack rate iar proportion population infected course epidemic varying level transmissibility fivefold fractionaldose vaccine efficacy two vaccination scenario random vaccination hypothetical population completely susceptible ii kinshasa vaccination campaign july–august different age cutoff fractionaldose vaccine finding estimate effective reproductive number early angola outbreak · · vaccine action allornothing ie proportion vaccinee receives complete remainder receive protection nfold fractionation dramatically reduce iar long efficacy exceeds n benefit threshold becomes stringent vaccine action leaky ie susceptibility vaccinee reduced factor equal vaccine efficacy age cutoff fractionaldose vaccine chosen kinshasa vaccination campaign namely year provides largest reduction iar efficacy fivefold fractionaldose vaccine exceeds interpretation dose fractionation effective strategy reducing infection attack rate would robust large margin error case fractionaldose lower expected,2016-11-10,"Wu, Joseph T.; Peak, Corey M.; Leung, Gabriel M.; Lipsitch, Marc",Lancet,,,,document_parses/pdf_json/d7df17379b5a79dd5917ea5f26051eef8bfe5011.json,document_parses/pmc_json/PMC5161610.xml.json,https://doi.org/10.1016/s0140-6736(16)31838-4; https://www.ncbi.nlm.nih.gov/pubmed/27837923/,11528111.0,3
74208,74208,95790,scwy859p,c5b89811fed3ea7f07b4fcf09b46bddac9358b29,Elsevier; PMC,Control of canine distemper,10.1016/0378-1135(95)00028-9,PMC7117223,8588329.0,els-covid,control canine distemper realistically achieved use vaccination type vaccine current use described together problem encountered interference maternal antibody usage specie dog modified live viral vaccine used thirty year proved effective nevertheless scope improvement vaccine efficacy recent development genetic recombinant method described,1995-05-31,"Chappuis, G.",Veterinary Microbiology,,,,document_parses/pdf_json/c5b89811fed3ea7f07b4fcf09b46bddac9358b29.json,,https://api.elsevier.com/content/article/pii/0378113595000289; https://www.sciencedirect.com/science/article/pii/0378113595000289,38789406.0,3
74217,74217,95802,7t9e4lgn,df2e53b25082a4e53014a171f7f255ba30363874,Elsevier; Medline; PMC,Immunogenicity and protective efficacy of recombinant fusion proteins containing spike protein of infectious bronchitis virus and hemagglutinin of H3N2 influenza virus in chickens,10.1016/j.virusres.2016.07.010,PMC7114550,27497621.0,els-covid,infectious bronchitis ib acute highly contagious viral respiratory disease chicken vaccination main method disease control protein contains several virus neutralization epitope considered target site vaccine development however although protective immune response could induced recombinant protein protection rate chicken still low generated fused protein ha protein rsha transmembrane domain cytoplasmic tail rshtm hemagglutinin hn influenza virus immunization animal vaccinated fusion protein rsha rshtm demonstrated stronger robust humoral cellular immune response r inactivated vaccine protection rate group immunized rsha significantly higher group inoculated r inactivated vaccine chicken injected rshtm similar level protection comparing chicken vaccinated r p data suggest protein fused ha tm protein hemagglutinin hn influenza virus may provide new strategy high efficacy recombinant vaccine development ibv,2016-09-02,"Yin, Lijuan; Zeng, Yuyao; Wang, Wei; Wei, Ying; Xue, Chunyi; Cao, Yongchang",Virus Research,,,,document_parses/pdf_json/df2e53b25082a4e53014a171f7f255ba30363874.json,document_parses/pmc_json/PMC7114550.xml.json,https://doi.org/10.1016/j.virusres.2016.07.010; https://api.elsevier.com/content/article/pii/S016817021630274X; https://www.sciencedirect.com/science/article/pii/S016817021630274X; https://www.ncbi.nlm.nih.gov/pubmed/27497621/,46803675.0,3
74232,74232,95822,vr4c59hy,22f1766a29396444ca55e944cb8afca66021dd9f; 51a5319303e2d4ec0191b060a38d661e17103fd5,Elsevier; Medline; PMC,A host-restricted viral vector for antigen-specific immunization against Lyme disease pathogen,10.1016/j.vaccine.2011.05.010,PMC3138909,21600949.0,green-oa,newcastle disease virus ndv avian virus attenuated primate potential vaccine vector human use evaluated ndv vector expressing selected antigen lyme disease pathogen borrelia burgdorferi series recombinant ndvs generated expressed intracellular extracellular form two borrelia burgdorferi antigen namely basic membrane protein bmpa outer surface protein c ospc expression intracellular extracellular form antigen confirmed cultured chicken cell ch balbc mouse immunized intranasally ndv vector mounted vigorous serum antibody response ndv vector failed mount robust response either intracellular extracellular form bmpa ospc contrast single immunization hamster ndv vector via intranasal intramuscular intraperitoneal route resulted rapid rigorous antibody response intracellular extracellular form bmpa ospc group hamster separately inoculated various ndv vector challenged b burgdorferi cellsanimal immunization vector expressing either intracellular extracellular bmpa associated significant reduction pathogen load joint taken together study highlighted importance ndv vaccine vector used simple yet effective immunization host bacterial infection including lyme disease,2011-07-01,"Xiao, Sa; Kumar, Manish; Yang, Xiuli; Akkoyunlu, Mustafa; Collins, Peter L.; Samal, Siba K.; Pal, Utpal",Vaccine,,,,document_parses/pdf_json/22f1766a29396444ca55e944cb8afca66021dd9f.json; document_parses/pdf_json/51a5319303e2d4ec0191b060a38d661e17103fd5.json,document_parses/pmc_json/PMC3138909.xml.json,https://api.elsevier.com/content/article/pii/S0264410X11007080; http://europepmc.org/articles/pmc3138909?pdf=render; https://www.sciencedirect.com/science/article/pii/S0264410X11007080; https://www.ncbi.nlm.nih.gov/pubmed/21600949/; https://doi.org/10.1016/j.vaccine.2011.05.010,25941600.0,3
74248,74248,95842,z9780v62,3f8beb2781bb92d1e2fffd8361b1feec3fd834e9,Medline; PMC,"Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Infection, Immunological Response, and Vaccine Development",10.1155/2019/6491738,PMC6476043,31089478.0,cc-by,middle east respiratory syndrome coronavirus merscov first emerged late since emergence total patient country infected across globe according world health organization report feb th approximately patient died virus us spike protein adhesive factor proinflammatory host entry specific receptor called dipeptidyl peptidase dpp receptor considered key factor signaling activation acquired innate immune response infected patient using potent antigen combination strong adjuvant may effectively trigger activation specific merscov cellular response well production neutralizing antibody unfortunately date effective approved treatment vaccine merscov thus urgent need development novel merscov therapy well vaccine help minimize spread virus infected patient thereby mitigating risk potential pandemic main goal highlight describe current knowledge innate adaptive immune response merscov current state merscov vaccine development believe study increase understanding mechanism enhance merscov immune response subsequently contribute control merscov infection,2019-04-07,"Mubarak, Ayman; Alturaiki, Wael; Hemida, Maged Gomaa",J Immunol Res,,,,document_parses/pdf_json/3f8beb2781bb92d1e2fffd8361b1feec3fd834e9.json,document_parses/pmc_json/PMC6476043.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31089478/; https://doi.org/10.1155/2019/6491738,131832596.0,3
74368,74368,95993,9ad0fw6z,85ea38dbeba7ee82244edfd40942043e4de2777d,Elsevier; Medline; PMC,Vaccines against diseases transmitted from animals to humans: A one health paradigm,10.1016/j.vaccine.2013.09.029,PMC7130581,24060567.0,els-covid,review focus immunization animal mean preventing human disease zoonosis three framework use vaccine context described example provided success failure framework vaccine used protection human economically valuable animal neither play role transmission cycle benefit collaboration animal health human health industry regulator developing product discussed one example west nile vaccine single product developed use animal human described framework ii vaccine indicated domesticated animal mean preventing disease animal human agent concern transmitted directly indirectly eg via arthropod vector animal human number example use framework ii vaccine provided eg brucellosis escherischia coli rabies rift valley fever venezuelan equine encephalitis hendra virus framework iii vaccine used immunize wild animal mean preventing transmission disease agent human domesticated animal example reservoirtargeted oral bait rabies mycobacterium bovis lyme disease vaccine given speed lost cost veterinary vaccine development intervention based immunization animal could lead rapid relatively inexpensive advance public health opportunity vaccinebased approach preventing zoonotic emerging disease integrate veterinary human medicine one health paradigm emphasized,2013-11-04,"Monath, Thomas P.",Vaccine,,,,document_parses/pdf_json/85ea38dbeba7ee82244edfd40942043e4de2777d.json,document_parses/pmc_json/PMC7130581.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/24060567/; https://api.elsevier.com/content/article/pii/S0264410X1301270X; https://doi.org/10.1016/j.vaccine.2013.09.029; https://www.sciencedirect.com/science/article/pii/S0264410X1301270X,12460480.0,3
74429,74429,96071,m4u96x2v,,Medline; WHO,Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): Immunoinformatics approach,10.1002/jmv.25736,,32108359.0,unk,recently novel coronavirus sarscov emerged responsible recent outbreak wuhan china genetically closely related sarscov merscov situation getting worse worse therefore urgent need designing suitable peptide vaccine component sarscov characterized spike glycoprotein obtain immunogenic epitope next chose major histocompatibility complexmhc mhcii epitope antigenic property epitope usually linked specific linkers build vaccine component molecularly dock tolllike receptor get binding affinity therefore provide fast immunogenic profile epitope performed immunoinformatics analysis rapid development vaccine might bring disastrous situation end earlier,2020,"Bhattacharya, Manojit; Sharma, Ashish R; Patra, Prasanta; Ghosh, Pratik; Sharma, Garima; Patra, Bidhan C; Lee, Sang-Soo; Chakraborty, Chiranjib",J. med. virol,,#2731,,,,https://www.ncbi.nlm.nih.gov/pubmed/32108359/; https://doi.org/10.1002/jmv.25736,211555036.0,3
74436,74436,96079,6ojmmmuj,d804bde249ed35784ae7ee4350a4acde52c83c3d; 74b00f19c3af87d1081644f02490ba250f57b7ca,BioRxiv; MedRxiv,Design of multi epitope-based peptide vaccine against E protein of human COVID-19: An immunoinformatics approach,10.1101/2020.02.04.934232,,,medrxiv,new endemic disease spread across wuhan city china december within week world health organization announced novel coronavirus designated coronavirus disease covid late january declared outbreak “ publichealth emergency international concern ” due rapid increasing spread disease worldwide currently vaccine approved treatment emerging infection thus objective study design multi epitope peptide vaccine covid using immunoinformatics approach several technique facilitating combination immunoinformatics approach comparative genomic approach used order determine potential peptide designing cell epitopesbased peptide vaccine using envelope protein ncov target extensive mutation insertion deletion discovered comparative sequencing covid strain additionally ten peptide binding mhc class mhc class ii found promising candidate vaccine design adequate world population coverage respectively cell epitopesbased peptide vaccine designed covid using envelope protein immunogenic target nevertheless proposed vaccine rapidly needed validated clinically order ensure safety immunogenic profile help stopping epidemic lead devastating global outbreak,2020-02-11,"Abdelmageed, Miyssa I.; Abdelmoneim, Abdelrahman H.; Mustafa, Mujahed I.; Elfadol, Nafisa M.; Murshed, Naseem S.; Shantier, Shaza W.; Makhawi, Abdelrafie M.",bioRxiv,,,,document_parses/pdf_json/d804bde249ed35784ae7ee4350a4acde52c83c3d.json; document_parses/pdf_json/74b00f19c3af87d1081644f02490ba250f57b7ca.json,,https://doi.org/10.1101/2020.02.04.934232,214290906.0,3
74515,74515,96176,w332jtpx,c64363f606997414a68bb7d808442d596f2ace19,Elsevier; PMC,Pandemic influenza preparedness: The critical role of the syringe,10.1016/j.vaccine.2006.02.056,PMC7115405,16647790.0,els-covid,face almost unprecedented threat global pandemic influenza imperative stockpiling appropriate drug device begin one vital device appropriate syringe delivering vaccine potential million infected vaccine supply severely stretched imperative syringe used vaccinate waste little vaccine possible thus allow maximum number person vaccinated study tested seven leading candidate vaccine syrinx dosing accuracy dosecapacity per vial medication wastage battery ergonomic feature one device flu™ syringe proved superior others important category possibly due low deadspace volume dosing accuracy data suggest switching device others tested would provide additional vaccine dos per vial current dose vial used extrapolation data suggest many thousand million additional person could vaccinated mass campaign use syringe type vaccine saving would accrue would likely important reducing morbidity mortality event pandemic influenza,2006-05-29,"Strauss, Kenneth; van Zundert, André; Frid, Anders; Costigliola, Vincenzo",Vaccine,,,,document_parses/pdf_json/c64363f606997414a68bb7d808442d596f2ace19.json,document_parses/pmc_json/PMC7115405.xml.json,https://api.elsevier.com/content/article/pii/S0264410X06002490; https://www.sciencedirect.com/science/article/pii/S0264410X06002490,46696913.0,3
74518,74518,96179,mxtry60e,2f3faad8f8d1f41e7f4ee0d936f5f19121664061,Elsevier; PMC,19 Xenogenic Adenoviral Vectors,10.1016/b978-0-12-800276-6.00019-x,PMC7149625,,els-covid,many nonhuman adenovirus advs simian bovine porcine canine ovine murine fowl origin developed gene delivery system recombinant vaccine gene therapy application addition circumventing preexisting human adv hadv immunity nonhuman adv vector utilize coxsackievirusadenovirus receptor receptor vector internalization thereby expanding range cell type targeted nonhuman adv vector also provide excellent platform veterinary vaccine specific nonhuman adv vector used specie origin could provide excellent animal model evaluating vector efficacy pathogenesis vector useful prime–boost approach adv vector gene delivery system including dna immunization viral bacterial vector multiple vector inoculation required nonhuman adv vector could supplement hadv viral vector,2016-12-31,"Mittal, Suresh K.; Ahi, Yadvinder S.; Vemula, Sai V.",Adenoviral Vectors for Gene Therapy,,,,document_parses/pdf_json/2f3faad8f8d1f41e7f4ee0d936f5f19121664061.json,document_parses/pmc_json/PMC7149625.xml.json,https://www.sciencedirect.com/science/article/pii/B978012800276600019X; https://api.elsevier.com/content/article/pii/B978012800276600019X,86884690.0,3
74559,74559,96228,eciaisz9,740a93c04a1ec5b28780fda41258cc880379636c,Elsevier; PMC,Neutralizing antiviral antibody responses,10.1016/s0065-2776(01)79001-3,PMC7130890,11680006.0,els-covid,publisher summary neutralizing antibody evolutionarily important effector immunity virus evaluation revealed number basic insight specificity rule reactivity tolerance memory—namely specificity neutralizing antibody defined capacity distinguish virus serotypes b cell reactivity determined antigen structure concentration time availability secondary lymphoid organ b cell memory provided elevated protective antibody titer serum depending antigen stimulation perhaps slightly overstated rule simple correlate vivo evidence well clinical observation appear largely demystify many speculation antibody b cell physiology chapter also considers successful vaccine compare infectious disease efficient protective vaccine lacking striking note successful vaccine induce high level neutralizing antibody nabs necessary sufficient protect host disease successful vaccination infectious disease tuberculosis leprosy hiv would require induction additional longlasting cell response control infection,2001-12-31,"Zinkernagel, Rolf M.; Lamarre, Alain; Ciurea, Adrian; Hunziker, Lukas; Ochsenbein, Adrian F.; Mccoy, Kathy D.; Fehr, Thomas; Bachmann, Martin F.; Kalinke, Ulrich; Hengartner, Hans",Advances in Immunology,,,,document_parses/pdf_json/740a93c04a1ec5b28780fda41258cc880379636c.json,,https://api.elsevier.com/content/article/pii/S0065277601790013; https://www.sciencedirect.com/science/article/pii/S0065277601790013,41907475.0,3
74584,74584,96258,88ste7p0,61c9ab1d4b7162b712975c3ba666e6f2a4f1ea0c,Medline; PMC,The challenges in developing effective canine infectious respiratory disease vaccines,10.1111/jphp.12380,PMC7166679,25736813.0,no-cc,objective canine infectious respiratory disease cird disease multifactorial aetiology multiple pathogen act sequentially synergistically cause disease common within large dog population re‐homing training kennel vaccine vital management cird often fail prevent disease recently number novel pathogen identified cird outbreak represent new target vaccination key finding innate immune response provide vital first line defence infectious agent involved development cird breeched adaptive mucosal immunity necessary prevent infection limit spread current vaccine target agent involved cird evidence limited amount published data indicates although vaccinating agent reduces infection rate duration shedding severity disease induce sterilising immunity important consequence management disease future cird vaccine development summary process considering development novel cird vaccine paper focus immunological mechanism provide protection respiratory tract current recommendation canine vaccination challenge surrounding existing cird vaccine future development,2015-03-03,"Mitchell, Judy A.; Brownlie, Joe",J Pharm Pharmacol,,,,document_parses/pdf_json/61c9ab1d4b7162b712975c3ba666e6f2a4f1ea0c.json,document_parses/pmc_json/PMC7166679.xml.json,https://doi.org/10.1111/jphp.12380; https://www.ncbi.nlm.nih.gov/pubmed/25736813/,23538058.0,3
74623,74623,96306,t9u7d029,,Elsevier; WHO,This really is nothing like flu,10.1016/s0262-4079(20)30519-4,,,els-covid,downplaying coronavirus ignore lack immunity vaccine,2020-03-14,,New Scientist,,#8336,,,,https://doi.org/10.1016/s0262-4079(20)30519-4; https://www.sciencedirect.com/science/article/pii/S0262407920305194; https://api.elsevier.com/content/article/pii/S0262407920305194,214756150.0,3
74641,74641,96326,4ywrzyse,0a69e9d5ea277f43e879728a3d974843110dee49; 3fdc7c236b854cbc809e10b2cc1628102f5c7e6c,Elsevier; Medline; PMC,DNA Vaccine Encoding Middle East Respiratory Syndrome Coronavirus S1 Protein Induces Protective Immune Responses in Mice,10.1016/j.vaccine.2017.02.063,PMC5411280,28314561.0,bronze-oa,middle east respiratory syndrome coronavirus merscov emerging pathogen continues cause outbreak arabian peninsula traveler region raising concern global pandemic could occur show dna vaccine encoding first amino acid merscov spike protein induces antigenspecific humoral cellular immune response mouse three immunization high titer neutralizing antibody generated without adjuvant dna vaccination merscov gene markedly increased frequency antigenspecific cd cd cell secreting ifnγ cytokine pcdnas dna vaccine immunization passive transfer immune serum pcdnas vaccinated mouse protected adhdpptransduced mouse merscov challenge result demonstrate dna vaccine encoding merscov protein induces strong protective immune response merscov infection,2017-04-01,"Chi, Hang; Zheng, Xuexing; Wang, Xiwen; Wang, Chong; Wang, Hualei; Gai, Weiwei; Perlman, Stanley; Yang, Songtao; Zhao, Jincun; Xia, Xianzhu",Vaccine,,,,document_parses/pdf_json/0a69e9d5ea277f43e879728a3d974843110dee49.json; document_parses/pdf_json/3fdc7c236b854cbc809e10b2cc1628102f5c7e6c.json,document_parses/pmc_json/PMC5411280.xml.json,https://doi.org/10.1016/j.vaccine.2017.02.063; https://api.elsevier.com/content/article/pii/S0264410X17302888; https://www.sciencedirect.com/science/article/pii/S0264410X17302888; https://www.ncbi.nlm.nih.gov/pubmed/28314561/,46817446.0,3
74659,74659,96346,zkk5d6gd,b90d85915f51ab637584d162d5bd78a7e02cdae3,Elsevier; Medline; PMC,"Vaccine supply, demand, and policy: A primer",10.1331/japha.2009.09007,PMC7185851,19589753.0,no-cc,objective provide overview supply demand issue vaccine industry policy option implemented resolve issue data source medline policy file international pharmaceutical abstract searched locate academic journal article source reviewed included text topic vaccine history policy government agency report report independent think tank keywords included vaccine immunization supply demand policy study selection search criterion limited english language human study article pertaining vaccine demand supply public policy selected reviewed inclusion data extraction author data synthesis vaccine biologic medication therefore making development production difficult costly compared “ smallmolecule ” drug research development cost vaccine exceed million development may require year strict manufacturing regulation facility upgrade add cost policy option increase stabilize supply vaccine include aimed increasing supply government subsidy basic vaccine research liability protection manufacturer fasttrack approval new vaccine option increase vaccine demand include advance purchase commitment government stockpile government financing select population conclusion high development cost multiple barrier entry led decline number vaccine manufacturer although number vaccine policy met mixed success increasing supply demand vaccine variety concern remain including developing vaccine complex pathogen increasing immunization rate available vaccine new policy innovation advance market commitment medicare part vaccine coverage implemented may aid resolving problem vaccine industry,2016-01-01,"Muzumdar, Jagannath M.; Cline, Richard R.",J Am Pharm Assoc (2003),,,,document_parses/pdf_json/b90d85915f51ab637584d162d5bd78a7e02cdae3.json,document_parses/pmc_json/PMC7185851.xml.json,https://api.elsevier.com/content/article/pii/S1544319115310359; https://www.sciencedirect.com/science/article/pii/S1544319115310359; https://www.ncbi.nlm.nih.gov/pubmed/19589753/; https://doi.org/10.1331/japha.2009.09007,7577544.0,3
74680,74680,96369,6fhltomk,cdaf4366490562074139a826e40ee8ffc01071dc,Medline; PMC,Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus,10.1093/infdis/jiw111,PMC4936642,27001960.0,bronze-oa,background vaccination passive antibody therapy critical controlling infectious disease passive antibody administration limitation including necessity purification multiple injection efficacy vaccination associated lag phase generation immunity novel approach reported utilize benefit method rapid generation effective immunity method novel antibodybased prophylaxistherapy entailing electroporationmediated delivery synthetic dna plasmid encoding biologically active anti–chikungunya virus chikv envelope monoclonal antibody dmab designed evaluated antiviral efficacy well ability overcome shortcoming inherent conventional active vaccination passive immunotherapy result one intramuscular injection dmab produced antibody vivo rapidly active vaccination antichikv dna vaccine dmab neutralized diverse chikv clinical isolates protected mouse viral challenge combination dmab chikv dna vaccine afforded rapid longlived protection conclusion dnabased dmab strategy induced rapid protection emerging viral infection method combined dna vaccination novel strategy provide short longterm protection emerging infectious disease study implication pathogen treatment control strategy,2016-03-21,"Muthumani, Karuppiah; Block, Peter; Flingai, Seleeke; Muruganantham, Nagarajan; Chaaithanya, Itta Krishna; Tingey, Colleen; Wise, Megan; Reuschel, Emma L.; Chung, Christopher; Muthumani, Abirami; Sarangan, Gopalsamy; Srikanth, Padma; Khan, Amir S.; Vijayachari, Paluru; Sardesai, Niranjan Y.; Kim, J. Joseph; Ugen, Kenneth E.; Weiner, David B.",Journal of Infectious Diseases,,,,document_parses/pdf_json/cdaf4366490562074139a826e40ee8ffc01071dc.json,document_parses/pmc_json/PMC4936642.xml.json,https://doi.org/10.1093/infdis/jiw111; https://academic.oup.com/jid/article-pdf/214/3/369/17411824/jiw111.pdf; https://www.ncbi.nlm.nih.gov/pubmed/27001960/,28040953.0,3
74681,74681,96370,jwzny6vx,e78a31fc6fa0f5a64e0cafd103bccbf76f824409,Medline; PMC,Analyzing Vaccine Trials in Epidemics With Mild and Asymptomatic Infection,10.1093/aje/kwy239,PMC6357804,30329134.0,bronze-oa,vaccine efficacy susceptibility infection f regardless symptom important endpoint vaccine trial pathogen high proportion asymptomatic infection infection may contribute onward transmission longterm sequela congenital zika syndrome however estimating f resourceintensive aimed identify approach accurately estimating f limited information available resource constrained modeled individually randomized vaccine trial generating network individual simulating epidemic disease natural history followed “ susceptibleexposedinfectioussymptomatic infectiousasymptomaticrecovered ” model used approach estimate f also estimated vaccine efficacy progression symptom vep corrected relative risk intervalcensored cox model accurately estimate f require serological testing participant cox model using symptomatic infection return biased estimate acquiring serological endpoint sample imputing remaining infection status yield unbiased f estimate across value basic reproduction number r accurate estimate vep higher r value identifying resourcepreserving method accurately estimating f vep important designing trial disease high proportion asymptomatic infection,2018-10-17,"Kahn, Rebecca; Hitchings, Matt; Wang, Rui; Bellan, Steven E; Lipsitch, Marc",American Journal of Epidemiology,,,,document_parses/pdf_json/e78a31fc6fa0f5a64e0cafd103bccbf76f824409.json,document_parses/pmc_json/PMC6357804.xml.json,https://doi.org/10.1093/aje/kwy239; https://www.ncbi.nlm.nih.gov/pubmed/30329134/; https://academic.oup.com/aje/article-pdf/188/2/467/27689961/kwy239.pdf,53524834.0,3
74691,74691,96382,591iufv1,4f3779b1939f10a5db0201232905b3c821010c1b,Elsevier; PMC,Adenoviruses as vectors for delivering vaccines to mucosal surfaces,10.1016/s0168-1656(00)00314-x,PMC7126179,11000466.0,els-covid,immunization mucosal surface become attractive route vaccine delivery ability induce mucosal immunity although various method inducing mucosal immunity developed laboratory focused developing adenovirus replication–competent replication–incompetent vector present report summarize progress sequencing entire bovine adenovirus genome identifying region deleted subsequently used insertion site foreign gene developing recombinant viral vaccine using recombinant virus demonstrated ‘ proofofprinciple ’ developing mucosal immunity importantly inducing protection bovine herpes virus natural host–cattle finally demonstrated immunity protection occurred even animal preexisting antibody vector,2000-09-29,"Babiuk, L. A; Tikoo, S. K",Journal of Biotechnology,,,,document_parses/pdf_json/4f3779b1939f10a5db0201232905b3c821010c1b.json,document_parses/pmc_json/PMC7126179.xml.json,https://api.elsevier.com/content/article/pii/S016816560000314X; https://www.sciencedirect.com/science/article/pii/S016816560000314X,45289086.0,3
74794,74794,96507,f3duj360,4d1cc919114cd1f5a24e66191a11812dca3c1062,Elsevier; Medline; PMC,Infection with equine infectious anemia virus vaccine strain EIAVDLV121 causes no visible histopathological lesions in target organs in association with restricted viral replication and unique cytokine response,10.1016/j.vetimm.2016.01.006,PMC7112881,26832985.0,els-covid,live equine infectious anemia virus eiav vaccine strain eiavdlv developed vitro attenuation virulent strain eiavln demonstrated induce protective immunity laboratory natural eiav infection condition detailed biological feature attenuated virus remain investigated experimental inoculation eiavdlv result clinical symptom even immunosuppressive treatment previous study investigated whether replication vaccine strain eiavdlv experimentally infected horse cause histopathological lesion develop targeted organ lung spleen demonstrated support eiav replication evaluating gross macroscopic histological change found eiavdlv cause detectable histopathological lesion replicated several hundred time slowly parental virulent strain eiavln tissue immunochemical assay tissue indicated primary target cell eiavdlv monocytesmacrophages eiavln also infected alveolar epithelial cell vascular endothelial cell addition viral strain promoted downregulation expression various cytokine chemokines implicating potential involvement cellular factor pathological outcome eiav infection host immune response taken together result demonstrate eiav vaccine strain cause obvious histopathological lesion clinical symptom induces unique cytokine response profile feature considered essential eiavdlv function effective live vaccine,2016-02-29,"Liu, Qiang; Ma, Jian; Wang, Xue-Feng; Xiao, Fei; Li, Li-Jia; Zhang, Jiao-Er; Lin, Yue-Zhi; Du, Cheng; He, Xi-Jun; Wang, Xiaojun; Zhou, Jian-Hua",Veterinary Immunology and Immunopathology,,,,document_parses/pdf_json/4d1cc919114cd1f5a24e66191a11812dca3c1062.json,document_parses/pmc_json/PMC7112881.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26832985/; https://api.elsevier.com/content/article/pii/S016524271630006X; https://doi.org/10.1016/j.vetimm.2016.01.006; https://www.sciencedirect.com/science/article/pii/S016524271630006X,20412986.0,3
74838,74838,96558,hl5x2tm0,6b1d17b31523708ac03b323ba761260ecb7cacb1,Elsevier; PMC,Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus,10.1016/j.vaccine.2007.10.055,PMC7127062,18069096.0,els-covid,summary japanese encephalitis virus jev serocomplexgroup consists mosquitoborne flavivirus include west nile virus wnv jev may cause severe encephalitis human wnv spread rapidly across united state since introduction geographical distribution within western hemisphere expected expand whereas jev common cause viral encephalitis southeast asia china india currently registered human vaccine specific therapy prevent treat wnv infection describe efficacy recombinant domain iii diii wnv glycoprotein e mouse model induces high neutralizing antibody titer well protection lethal wnv infection cbl mouse vaccine preparation also afforded partial protection lethal jev infection,2008-01-10,"Martina, Byron E.; Koraka, Penelopie; van den Doel, Petra; van Amerongen, Geert; Rimmelzwaan, Guus F.; Osterhaus, Albert D.M.E.",Vaccine,,,,document_parses/pdf_json/6b1d17b31523708ac03b323ba761260ecb7cacb1.json,document_parses/pmc_json/PMC7127062.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X07012479; https://api.elsevier.com/content/article/pii/S0264410X07012479,26420674.0,3
74860,74860,96586,p4dy2eo3,a14d35088cce19357a14f6c1d4984d3d1dcf6ab0,Elsevier; Medline; PMC,Oral immunization with LacVax® OmpA induces protective immune response against Shigella flexneri 2a ATCC 12022 in a murine model,10.1016/j.vaccine.2019.04.053,PMC7115592,31047673.0,els-covid,shigellosis acute invasive disease lower intestine afflicts million people worldwide estimated one million fatality per annum despite extensive research last two decade vaccine multidrug resistant shigella yet available market provide safe effective broadspectrum vaccine shigella explored food grade bacteria lactococcus lactis l lactis delivery conserved antigenic protein outer membrane protein ompa mucosal site effective elicitation systemic mucosal immunity previously confirmed immunogenic potential recombinant l lactis expressing ompa lacvax® ompa balbc mouse present study characterized humoral cellular immune profile lacvax® ompa assessed protective efficacy using newly developed human like murine shigellosis model significant increase ompa specific serum igg fecal siga th dominant immune response indicated high infγil ratio lacvax® ompa immunized mouse revealed successful activation humoral cellular immunity lacvax® ompa immunized animal also protected humanlike shigellosis challenged flexneri atcc antigen specific serum igg fecal siga infγ il level found significant correlate protection collectively result suggest lacvax® ompa promising prophylactic candidate shigellosis however protective efficacy lacvax® ompa higher animal would strengthen future application human,2019-05-21,"Yagnik, Bhrugu; Sharma, Drashya; Padh, Harish; Desai, Priti",Vaccine,,,,document_parses/pdf_json/a14d35088cce19357a14f6c1d4984d3d1dcf6ab0.json,document_parses/pmc_json/PMC7115592.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X19305274; https://api.elsevier.com/content/article/pii/S0264410X19305274; https://doi.org/10.1016/j.vaccine.2019.04.053; https://www.ncbi.nlm.nih.gov/pubmed/31047673/,143434633.0,3
74933,74933,96681,jlmuo37x,abd5833ba0f868ce51622b090b9121b3be9c08dc,Medline; PMC,Animal models for dengue vaccine development and testing,10.7774/cevr.2017.6.2.104,PMC5540958,28775974.0,cc-by-nc,dengue fever tropical endemic disease however climate change may become problem south korea near future research vaccine dengue fever outbreak preparedness currently insufficient addition appropriate animal model controversial result vaccine efficacy assessment clinical trial reported therefore study mechanism dengue fever test immunogenicity vaccine appropriate animal model urgently needed addition mouse model suitable model using animal humanized need constructed report look current status model animal construction discus model require development,2017-07-26,"Na, Woonsung; Yeom, Minjoo; Choi, Il-Kyu; Yook, Heejun; Song, Daesub",Clin Exp Vaccine Res,,,,document_parses/pdf_json/abd5833ba0f868ce51622b090b9121b3be9c08dc.json,document_parses/pmc_json/PMC5540958.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28775974/; https://doi.org/10.7774/cevr.2017.6.2.104,29810945.0,3
75030,75030,96798,xdg5mkum,d5f104ad571284de9a97619066155866b729870c; 43e23cb209c2ee3419efcca67f10e66c790a5e4d,Elsevier; Medline; PMC,Purified coronavirus Spike protein nanoparticles induce coronavirus neutralizing antibodies in mice,10.1016/j.vaccine.2014.04.016,PMC4058772,24736006.0,bronze-oa,development vaccination strategy emerging pathogen particularly challenging sudden nature emergence virus long process needed traditional vaccine development therefore need development rapid method vaccine development respond emerging pathogen short time frame emergence severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome merscov late demonstrate importance coronaviruses emerging pathogen spike glycoprotein coronaviruses reside surface virion responsible virus entry spike glycoprotein major immunodominant antigen coronaviruses proven excellent target vaccine design seek block coronavirus entry promote antibody targeting infected cell vaccination strategy coronaviruses involved live attenuated virus recombinant virus nonreplicative viruslike particle expressing coronavirus protein dna plasmid expressing coronavirus gene none strategy progressed approved human coronavirus vaccine ten year since sarscov emerged describe novel method generating merscov sarscov fulllength spike nanoparticles combination adjuvant able produce high titer antibody mouse,2014-05-01,"Coleman, Christopher M; Liu, Ye V; Mu, Haiyan; Taylor, Justin K; Massare, Michael; Flyer, David C; Smith, Gale E; Frieman, Matthew B",Vaccine,,,,document_parses/pdf_json/d5f104ad571284de9a97619066155866b729870c.json; document_parses/pdf_json/43e23cb209c2ee3419efcca67f10e66c790a5e4d.json,document_parses/pmc_json/PMC4058772.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X14005180; https://doi.org/10.1016/j.vaccine.2014.04.016; https://api.elsevier.com/content/article/pii/S0264410X14005180; https://www.ncbi.nlm.nih.gov/pubmed/24736006/,9926972.0,3
75073,75073,96848,i8qvat3o,179e23cae17b70aab44cef424080cf37832c3e3f,Medline; PMC,Progress in the development of virus-like particle vaccines against respiratory viruses,10.1080/14760584.2020.1711053,PMC7103727,31903811.0,no-cc,introduction influenza virus human respiratory syncytial virus rsv human metapneumovirus hmpv important human respiratory pathogen recombinant viruslike particle vlp vaccine suggested potential promising platform protect respiratory virus review update important progress development vlp vaccine respiratory virus area covered review summarizes progress developing vlp nanoparticlebased vaccine influenza virus rsv hmpv pubmed mainly used search important research article published since although earlier key article also referenced research area covered includes vlp nanoparticle platform vaccine seasonal pandemic avian influenza virus well rsv hmpv respiratory virus production method immunogenic property vaccine efficacy respiratory vlp vaccine preclinical animal model clinical study reviewed article expert opinion previous current preclinical clinical study suggest recombinant vlp nanoparticle vaccine expected developed promising alternative platform respiratory virus future therefore continued research effort warranted,2020-01-18,"Quan, Fu-Shi; Basak, Swarnendu; Chu, Ki-Back; Kim, Sung Soo; Kang, Sang-Moo",Expert Rev Vaccines,,,,document_parses/pdf_json/179e23cae17b70aab44cef424080cf37832c3e3f.json,document_parses/pmc_json/PMC7103727.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31903811/; https://doi.org/10.1080/14760584.2020.1711053,209894833.0,3
75095,75095,96877,yc2wxgid,7aefa79c2389a8b586bcd0e72060a57e229738b6,Medline; PMC,Ebola Virus Infection: Overview and Update on Prevention and Treatment,10.1007/s40121-015-0079-5,PMC4675769,26363787.0,no-cc,largest ebola virus disease evd outbreak history affected large population across west africa goal report provide update epidemic review current progress development evaluation deployment prevention treatment strategy evd relevant information identified comprehensive literature search using medline pubmed cinahl complete using search term ebola ebola virus disease ebola hemorrhagic fever west africa outbreak ebola transmission ebola symptom sign ebola diagnosis ebola treatment vaccine ebola clinical trial ebola july total evd case death reported affected country several therapeutic agent novel vaccine evd developed undergoing evaluation concurrent active case investigation contact tracing surveillance supportive care patient community rapid progress development new therapy vaccine evd continued focus strengthening clinical public health infrastructure direct benefit controlling spread evd provide strong foundation deployment new drug vaccine affected country become available unprecedented west africa ebola outbreak response measure ensuing drug vaccine development suggest new tool ebola control may available near future electronic supplementary material online version article doi contains supplementary material available authorized user,2015-09-12,"Martínez, Miguel J.; Salim, Abdulbaset M.; Hurtado, Juan C.; Kilgore, Paul E.",Infect Dis Ther,,,,document_parses/pdf_json/7aefa79c2389a8b586bcd0e72060a57e229738b6.json,document_parses/pmc_json/PMC4675769.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26363787/; https://doi.org/10.1007/s40121-015-0079-5,7035292.0,3
75170,75170,96968,bb5dnbbt,27ee82e4db05cf49d789f25d14660daffe743cfd,Medline; PMC,Recent Advances in the Vaccine Development Against Middle East Respiratory Syndrome-Coronavirus,10.3389/fmicb.2019.01781,PMC6688523,31428074.0,cc-by,middle east respiratory syndrome mers deadly viral respiratory disease caused merscoronavirus merscov infection date specific treatment proven effective viral disease addition vaccine licensed prevent merscov infection thus far therefore current review focus recent study search effective mers vaccine overall vaccine candidate merscov mainly based upon viral spike protein due vital role viral infectivity although several study focused viral protein nucleocapsid n protein envelope e protein nonstructural protein nsp also reported general potential vaccine candidate classified six type viral vectorbased vaccine dna vaccine subunit vaccine nanoparticlebased vaccine inactivatedwhole virus vaccine liveattenuated vaccine discussed detail besides immune response potential antibody dependent enhancement merscov infection extensively reviewed addition animal model used study merscov evaluate vaccine candidate discussed intensively,2019-08-02,"Yong, Chean Yeah; Ong, Hui Kian; Yeap, Swee Keong; Ho, Kok Lian; Tan, Wen Siang",Front Microbiol,,,,document_parses/pdf_json/27ee82e4db05cf49d789f25d14660daffe743cfd.json,document_parses/pmc_json/PMC6688523.xml.json,https://doi.org/10.3389/fmicb.2019.01781; https://www.ncbi.nlm.nih.gov/pubmed/31428074/,199379218.0,3
75177,75177,96976,u1uvnlk2,f3e85a35ab89c9a55eeb83c6e17f881d5c497d82,Medline; PMC,Genome-wide host responses against infectious laryngotracheitis virus vaccine infection in chicken embryo lung cells,10.1186/1471-2164-13-143,PMC3353197,22530940.0,cc-by,background infectious laryngotracheitis virus iltv gallid herpesvirus infection cause high mortality huge economic loss poultry industry protect chicken iltv infection chickenembryo origin ceo tissueculture origin tco vaccine used however transmission vaccine iltv vaccinated unvaccinated chicken cause severe respiratory disease previously host cell response virulent iltv infection determined microarray analysis study microarray analysis performed understand hostvaccine iltv interaction host gene transcription level result k chicken oligo microarrays used result compared found virulent iltv infection total rna extracted vaccine iltv infected chicken embryo lung cell day post infection dpi compared dpi subjected microarray assay using two color hybridization method data analysis using jmp genomics ingenuity pathway analysis ipa program showed differentially expressed gene could grouped number functional category including tissue development cellular growth proliferation cellular movement inflammatory response moreover possible gene network created ipa program show intermolecular connection interestingly differentially expressed gene bmp corf f npy expressed distinctly vaccine iltv infection compared virulent iltv infection conclusion comprehensive knowledge gene expression biological functionality host factor vaccine iltv infection provide insight host cellular defense mechanism compared virulent iltv,2012-04-24,"Lee, Jeongyoon; Bottje, Walter G; Kong, Byung-Whi",BMC Genomics,,,,document_parses/pdf_json/f3e85a35ab89c9a55eeb83c6e17f881d5c497d82.json,document_parses/pmc_json/PMC3353197.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/22530940/; https://doi.org/10.1186/1471-2164-13-143,9321104.0,3
75183,75183,96982,r66vadck,ae0144eb4ec61e7765eed001bc8a9c775cd31b67,Medline; PMC,"Public Health Responses to Reemergence of Animal Rabies, Taiwan, July 16–December 28, 2013",10.1371/journal.pone.0132160,PMC4498755,26162074.0,cc-by,taiwan free indigenous human animal rabies case since canine rabies eliminated july rabies confirmed among three wild ferretbadgers prompting public health response prevent human rabies case descriptive study report immediate response reemergence rabies taiwan response included enhanced surveillance human rabies case testing stored cerebrospinal fluid csf patient encephalitis unknown cause rtpcr prioritizing vaccine use postexposure prophylaxis pep period vaccine shortage subsequent expansion pep surveillance animal bite using information obtained vaccine application roll preexposure prophylaxis prep vaccine stock restoration surveillance adverse event following immunization aefi ensuring surge capacity respond general public inquiry phone training healthcare professional enhanced surveillance human rabies found case testing stored csf specimen collected january –july july december received rabies pep application consistent recommendation among person received least one dose rabies vaccine postexposure person bitten dog person bitten ferretbadgers study period person received preexposure prophylaxis report aefi anaphylaxis guillainbarré syndrome acute disseminated encephalomyelitis found study period call taiwan center disease control hotline related rabies recent identification rabies among ferretbadgers previously rabiesfree country prompted rapid response date human rabies identified continued multifaceted surveillance interministerial collaboration crucial achieve goal rabiesfree status taiwan,2015-07-10,"Huang, Angela Song-En; Chen, Wan-Chin; Huang, Wan-Ting; Huang, Shih-Tse; Lo, Yi-Chun; Wei, Sung-Hsi; Kuo, Hung-Wei; Chan, Pei-Chun; Hung, Min-Nan; Liu, Yu-Lun; Mu, Jung-Jung; Yang, Jyh-Yuan; Liu, Ding-Ping; Chou, Jih-Haw; Chuang, Jen-Hsiang; Chang, Feng-Yee",PLoS One,,,,document_parses/pdf_json/ae0144eb4ec61e7765eed001bc8a9c775cd31b67.json,document_parses/pmc_json/PMC4498755.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26162074/; https://doi.org/10.1371/journal.pone.0132160,1187260.0,3
75215,75215,97023,mjkzf2ka,98ce22d0a0cab728f1aab48170f1769bb0bc3454; 549ecd5271e2f5d8e14450001ff82f7c6a0f084d,Medline; PMC,Population- and Variant-Based Genome Analyses of Viruses from Vaccine-Derived Rabies Cases Demonstrate Product Specific Clusters and Unique Patterns,10.3390/v12010115,PMC7020022,31963517.0,cc-by,rabies wildlife successfully controlled part europe north america using oral rabies vaccination ie distribution bait containing liveattenuated virus strain occasionally vaccine caused vaccine virusinduced rabies case elucidate mechanism genetic selection effect viral population rabies case next generation sequencing approach well comprehensive data analysis genetic diversity street alabama dufferin sad era vaccine virus strain vaccineinduced rabies case canada several european country conducted result twelve newly generated set sequencing data canada poland added pool previously investigated sample populationbased analysis showed segregation virus era vaccineinduced rabies case sad bern original sad bernorigderived rabies case indepth variant analysis revealed three distinct combination selected variant era vaccineinduced case suggesting presence multiple replicationcompetent haplotype investigated erabhk vaccine finding demonstrate potential deep sequencing approach combination comprehensive analysis consensus population variant level,2020-01-17,"Calvelage, Sten; Smreczak, Marcin; Orłowska, Anna; Freuling, Conrad Martin; Müller, Thomas; Fehlner-Gardiner, Christine; Nadin-Davis, Susan; Höper, Dirk; Trębas, Paweł",Viruses,,,,document_parses/pdf_json/98ce22d0a0cab728f1aab48170f1769bb0bc3454.json; document_parses/pdf_json/549ecd5271e2f5d8e14450001ff82f7c6a0f084d.json,document_parses/pmc_json/PMC7020022.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31963517/; https://doi.org/10.3390/v12010115,210871044.0,3
75238,75238,97053,kb2wrxio,fab11f842979b0ca95927e6919ed0740a5ccc3be,Medline; PMC,Strategies for intranasal delivery of vaccines,10.1007/s13346-012-0085-z,PMC3539070,23316448.0,no-cc,vast majority human pathogen colonize invade mucosal surface preventing infection site via mucosally active vaccine promising rational approach vaccine development however recently stimulation local immunity mucosal surface become primary objective addition inducing systemic immunity review describes vaccine formulation designed mucosal delivery nasalassociated lymphoid tissue via intranasal administration association antigen mucosal adjuvant delivery system emphasised,2012-07-12,"Zaman, Mehfuz; Chandrudu, Saranya; Toth, Istvan",Drug Deliv Transl Res,,,,document_parses/pdf_json/fab11f842979b0ca95927e6919ed0740a5ccc3be.json,document_parses/pmc_json/PMC3539070.xml.json,https://doi.org/10.1007/s13346-012-0085-z; https://www.ncbi.nlm.nih.gov/pubmed/23316448/,16500774.0,3
75316,75316,97158,v1t564l2,9bad9c5864165815b35dd2c78cd0ed7b285f0517,Medline; PMC,Receptor Binding Domain Based HIV Vaccines,10.1155/2015/594109,PMC4312573,25667925.0,cc-by,paper analyzes main trend development acquired immunodeficiency syndrome aid vaccine recent year designing hiv vaccine provides robust protection hiv infection remains challenge despite many year effort therefore describe receptor binding domain gp target developing aid vaccine recommend measure could induce efficiently produce crossreactive neutralizing antibody high binding affinity measure may offer new way research development potent broad aid vaccine,2015-01-15,"Liu, Huan; Bi, Wenwen; Wang, Qian; Lu, Lu; Jiang, Shibo",Biomed Res Int,,,,document_parses/pdf_json/9bad9c5864165815b35dd2c78cd0ed7b285f0517.json,document_parses/pmc_json/PMC4312573.xml.json,https://doi.org/10.1155/2015/594109; https://www.ncbi.nlm.nih.gov/pubmed/25667925/,13457687.0,3
75318,75318,97160,8jzjrtpe,47657978dd272aff0e0be8c8aa3877b8db673067,Elsevier; Medline; PMC,A vesicular stomatitis virus-based mucosal vaccine promotes dendritic cell maturation and elicits preferable immune response against coxsackievirus B3 induced viral myocarditis,10.1016/j.vaccine.2014.05.052,PMC7115516,24874923.0,els-covid,recombinant vesicular stomatitis virus vsv widely used vaccine platform however capacity vsvbased vaccine induce mucosal immunity fully investigated present study recombinant vsv expressing coxsackievirus b cvb major immunogen vp generated immune protection elicited vsvvp evaluated demonstrated intranasal delivery vsvvp induce potent antigenspecific mucosal immune response well systemic immune response particularly induction polyfunctional cell importantly mouse immunized vsvvp better protected cvbinduced viral myocarditis receiving chitosanformulated dna vaccine increased dendritic cell dc maturation mesenteric lymph node mln observed mouse vaccinated vsvvp could potential mechanism protective immune response finding support vsv viral delivery vector induce robust mucosal immunity considered vaccine development,2014-06-30,"Wu, Fei; Fan, Xingjuan; Yue, Yan; Xiong, Sidong; Dong, Chunsheng",Vaccine,,,,document_parses/pdf_json/47657978dd272aff0e0be8c8aa3877b8db673067.json,document_parses/pmc_json/PMC7115516.xml.json,https://doi.org/10.1016/j.vaccine.2014.05.052; https://www.sciencedirect.com/science/article/pii/S0264410X14007282; https://www.ncbi.nlm.nih.gov/pubmed/24874923/; https://api.elsevier.com/content/article/pii/S0264410X14007282,40900839.0,3
75319,75319,97161,wb2tkl0y,bb371a2fe0584ee10d4a7c9244495c3b10b983e7,Medline; PMC,Challenges in Veterinary Vaccine Development and Immunization,10.1007/978-1-4939-3389-1_1,PMC7123657,27076287.0,no-cc,approaching development veterinary vaccine researcher must choose bewildering array option combined enhance benefit choice combination option driven efficacy also consideration cost practicality challenge faced licensing product review set different choice faced veterinary vaccine developer highlight issue propose pressing need addressed,2015-12-14,"Chambers, Mark A.; Graham, Simon P.; La Ragione, Roberto M.",Vaccine Design,,,,document_parses/pdf_json/bb371a2fe0584ee10d4a7c9244495c3b10b983e7.json,document_parses/pmc_json/PMC7123657.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/27076287/; https://doi.org/10.1007/978-1-4939-3389-1_1,6823052.0,3
75326,75326,97171,dxbvfwqu,fb9a554c308de802220fea4a907827a158580bbf,Elsevier; Medline; PMC,Non-animal replacement methods for human vaccine potency testing: state of the science and future directions,10.1016/j.provac.2011.10.002,PMC7129268,32288913.0,els-covid,niceatm iccvam convened international workshop review state science human veterinary vaccine potency safety testing method identify opportunity advance new improved method reduce refine replace animal use report address method strategy identified workshop participant replacement animal used potency testing human vaccine vaccine considered highest priority future effort vaccine antigen quantification method already developed validated vaccinescomponents require largest number animal vaccine require vivo challenge test vaccine vivo test highly variable cause significant number invalid test vaccine potency test identified highest priority replacement diphtheria tetanus pertussis whole cell acellular rabies anthrax polio vaccine inactivated complex combination vaccine based dt dtwpap research understanding precise mechanism protection afforded vaccine identification clinically relevant immunological marker needed facilitate successful implementation vitro testing alternative report also identifies several priority human vaccine associated research objective necessary successfully implement vitro vaccine potency testing alternative,2011-12-31,"McFarland, Richard; Verthelyi, Daniela; Casey, Warren; Arciniega, Juan; Isbrucker, Richard; Schmitt, Michael; Finn, Theresa; Descamps, Johan; Horiuchi, Yoshinobu; Sesardic, Dorothea; Stickings, Paul; Johnson, Nelson W; Lipscomb, Elizabeth; Allen, David",Procedia in Vaccinology,,,,document_parses/pdf_json/fb9a554c308de802220fea4a907827a158580bbf.json,,https://api.elsevier.com/content/article/pii/S1877282X11000208; https://www.sciencedirect.com/science/article/pii/S1877282X11000208; https://www.ncbi.nlm.nih.gov/pubmed/32288913/; https://doi.org/10.1016/j.provac.2011.10.002,42086223.0,3
75388,75388,97251,1drhyrx3,3c24923ebefe15cfec2dee6a0f80698c8dfe56fe,Medline; PMC,"Viral respiratory diseases (ILT, aMPV infections, IB): are they ever under control?(1)",10.1080/00071660903541378,PMC7154308,20390564.0,no-cc,use vaccine main approach control economically important poultry viral respiratory disease infectious laryngotracheitis ilt avian metapneumovirus ampv infection infectious bronchitis ib paper appraises current method vaccine control light nature virus epidemiological factor associated disease infectious laryngotracheitis virus iltv exists single type wide range disease severity serious disease certain region world recent work distinguished molecular difference vaccine field strain vaccine virus cause disease vaccine remained unaltered many year new one developed counter vaccine side effect reversion reactivation latent virus avian metapneumoviruses cause turkey rhinotracheitis respiratory disease chicken exists subtypes b c b widespread vaccine work well provided accurate dos given newer vaccine development designed eliminate reversion possibly counter appearance newer field strain may break established vaccine coverage ib present biggest problem three unstable rna virus part viral genome code spike gene undergo mutation recombination important antigenic variant appear irregularly may evade existing vaccine protection conventional vaccine work well homologous type new strategy needed counter instability molecular approach involving tailoring virus suit field challenge progress however simple use two genetically different vaccine protect wide range heterologous type widespread practice effective none three disease described claim satisfactorily controlled remains seen whether newer generation vaccine efficacious cost effective importance constant surveillance emphasised testing novel vaccine achieved without use vaccinechallenge experiment poultry,2010-03-03,"Jones, Richard C.",Br Poult Sci,,,,document_parses/pdf_json/3c24923ebefe15cfec2dee6a0f80698c8dfe56fe.json,document_parses/pmc_json/PMC7154308.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/20390564/; https://doi.org/10.1080/00071660903541378,205399629.0,3
75466,75466,97353,w14i2466,6d9e891da1d47e911424f3679f3d0ff18b1911f4,Elsevier; PMC,Trends in US approvals: new biopharmaceuticals and vaccines,10.1016/j.tibtech.2006.05.003,PMC7119034,16759723.0,els-covid,efficient development approval new therapeutic vaccine vital health welfare patient tuft center study drug development collected analyzed data new protein therapeutic vaccine approved usa past decade result suggest trend toward longer clinical approval phase therapeutic particularly oncology product opinion article discus various legislative act fda initiative might improve efficiency drug development approval furthermore new vaccine approved past year owing least part lack incentive development product predict might change future government industry respond twin threat global spread infectious disease potential bioterrorism,2006-07-31,"Reichert, Janice M.",Trends in Biotechnology,,,,document_parses/pdf_json/6d9e891da1d47e911424f3679f3d0ff18b1911f4.json,document_parses/pmc_json/PMC7119034.xml.json,https://www.sciencedirect.com/science/article/pii/S0167779906001260; https://api.elsevier.com/content/article/pii/S0167779906001260,44467304.0,3
75471,75471,97358,0xo2fiop,c07b96b0ac94d1403d44dff3bc6ad12a64d171c1,Medline; PMC,Alternative Methods of Vaccine Delivery: An Overview of Edible and Intradermal Vaccines,10.1155/2019/8303648,PMC6425294,30949518.0,cc-by,vaccine recognized worldwide one important tool combating infectious disease despite tremendous value conferred currently available vaccine toward public health implementation additional vaccine platform also key importance fact currently available vaccine posse shortcoming inefficient triggering cellmediated immune response lack protective mucosal immunity regard recent work focused vaccine delivery system alternative injectable vaccine increase antigen stability improve overall immunogenicity particular novel strategy based edible intradermal vaccine formulation demonstrated trigger systemic mucosal immune response novel vaccination delivery system offer several advantage injectable preparation including selfadministration reduced cost stability elimination cold chain review latest finding accomplishment regarding edible intradermal vaccine described context system used immunogen expression molecular feature capacity induce protective systemic mucosal response,2019-03-04,"Criscuolo, E.; Caputo, V.; Diotti, R. A.; Sautto, G. A.; Kirchenbaum, G. A.; Clementi, N.",J Immunol Res,,,,document_parses/pdf_json/c07b96b0ac94d1403d44dff3bc6ad12a64d171c1.json,document_parses/pmc_json/PMC6425294.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30949518/; https://doi.org/10.1155/2019/8303648,92463087.0,3
75476,75476,97363,pidar1gz,2024e4d5d7bced06b7a1673457a3063a5f4bc567,Medline; PMC; WHO,Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases,10.1021/acscentsci.0c00272,PMC7094090,32226821.0,no-cc,since outbreak novel coronavirus disease covid caused sarscov virus disease spread rapidly around globe considering potential threat pandemic scientist physician racing understand new virus pathophysiology disease uncover possible treatment regimen discover effective therapeutic agent vaccine support current research development ca produced special report provide overview published scientific information emphasis patent ca content collection highlight antiviral strategy involving small molecule biologics targeting complex molecular interaction involved coronavirus infection replication drugrepurposing effort documented herein focus primarily agent known effective rna virus including sarscov merscov patent analysis coronavirusrelated biologics includes therapeutic antibody cytokine nucleic acidbased therapy targeting virus gene expression well various type vaccine patent disclose methodology four biologics potential treating preventing coronavirus infection may applicable covid information included report provides strong intellectual groundwork ongoing development therapeutic agent vaccine,2020-03-12,"Liu, Cynthia; Zhou, Qiongqiong; Li, Yingzhu; Garner, Linda V.; Watkins, Steve P.; Carter, Linda J.; Smoot, Jeffrey; Gregg, Anne C.; Daniels, Angela D.; Jervey, Susan; Albaiu, Dana",ACS Cent Sci,,#8271,,document_parses/pdf_json/2024e4d5d7bced06b7a1673457a3063a5f4bc567.json,document_parses/pmc_json/PMC7094090.xml.json,https://doi.org/10.1021/acscentsci.0c00272; https://www.ncbi.nlm.nih.gov/pubmed/32226821/,214693775.0,3
75487,75487,97375,kzj263xj,ea917dc676d2025d36bfb18fff0a3da25643ac40,Elsevier; PMC,A Strategic Vaccine Facility for the UK,10.1016/j.vaccine.2005.01.066,PMC7131621,15755577.0,els-covid,paper describes proposed strategic vaccine facility svf provide capability uk deal new emerging disease threat would underpin vaccine manufacturing industry developing expertise technology enable rapid manufacture small batch vaccine emergency use agent bioterrorist agent emerging disease would rare ability work dangerous pathogen containment allowing production inactivated live vaccine would difficult conventional plant facility output include vaccine candidate manufacturing protocol transfer industry small vaccine batch emergency use clinical trial vaccine reference standard would also available manufacturing small batch experimental public health vaccine uk developing world allowing clinical trial undertaken key disease,2005-03-18,"Duggan, Jacqueline M.; Brooks, Timothy J.G.",Vaccine,,,,document_parses/pdf_json/ea917dc676d2025d36bfb18fff0a3da25643ac40.json,document_parses/pmc_json/PMC7131621.xml.json,https://api.elsevier.com/content/article/pii/S0264410X05000721; https://www.sciencedirect.com/science/article/pii/S0264410X05000721,42627626.0,3
75512,75512,97407,gu2mt6zp,,Medline; PMC; WHO,Emergence of Novel Coronavirus 2019-nCoV: Need for Rapid Vaccine and Biologics Development,10.3390/pathogens9020148,PMC7168632,32098302.0,cc-by,novel coronavirus ncov emerging pathogen first identified wuhan china late december virus responsible ongoing outbreak cause severe respiratory illness pneumonialike infection human due increasing number case china outside china declared coronavirus global health emergency nearly case reported least country territory reported coronavirus case early february interhuman transmission reported country including united state neither effective antiviral vaccine currently available treat infection virus newly emerging pathogen many question remain unanswered regarding virus ’ reservoir pathogenesis transmissibility much unknown collaborative effort researcher needed fill knowledge gap new virus develop proper diagnostic tool effective treatment combat infection recent advancement plant biotechnology proved plant ability produce vaccine biopharmaceuticals rapidly short time review outbreak ncov china need rapid vaccine development potential plant system biopharmaceutical development discussed,2020-02-22,"Shanmugaraj, Balamurugan; Malla, Ashwini; Phoolcharoen, Waranyoo",Pathogens,,#1502,,,document_parses/pmc_json/PMC7168632.xml.json,https://doi.org/10.3390/pathogens9020148; https://www.ncbi.nlm.nih.gov/pubmed/32098302/,211525171.0,3
75551,75551,97457,ftzhlm5r,d18b93f5d069aa61178bce4a7bfe0c69f9d6af22,Medline; PMC,Ebola and Marburg virus vaccines,10.1007/s11262-017-1455-x,PMC7089128,28447193.0,no-cc,filovirus ebola virus ebov marburg virus marv among pathogenic virus known man causative agent viral hemorrhagic fever outbreak africa case fatality rate nearly infection observed latest ebov epidemic west africa previous outbreak much smaller typically affecting le hundred people compared disease aid malaria million case annually filovirus hemorrhagic fever fhf one neglected infectious disease licensed vaccine therapeutic available treat ebov marv infection therefore pathogen handled maximum containment laboratory classified select agent limitation laboratory worldwide conducted basic research countermeasure development ebov marv since respective discovery marv ebov review discus several vaccine platform ebov marv assessed protective efficacy animal model fhf focus promising approach accelerated clinical development phase i–iii trial ebov epidemic west africa,2017-04-26,"Reynolds, Pierce; Marzi, Andrea",Virus Genes,,,,document_parses/pdf_json/d18b93f5d069aa61178bce4a7bfe0c69f9d6af22.json,document_parses/pmc_json/PMC7089128.xml.json,https://doi.org/10.1007/s11262-017-1455-x; https://www.ncbi.nlm.nih.gov/pubmed/28447193/,11550110.0,3
75574,75574,97489,j90daoiq,842a27764db3007473a47c80750835bdee93402c,Elsevier; Medline; PMC,"Cytokine and nitric oxide patterns in dogs immunized with LBSap vaccine, before and after experimental challenge with Leishmania chagasi plus saliva of Lutzomyia longipalpis",10.1016/j.vetpar.2013.09.011,PMC7115768,24129068.0,els-covid,study presented dog vaccinated leishmania leishmania chagasi challenge infection using preparation leishmania braziliensis promastigote protein saponin adjuvant lbsap vaccination lbsap induced prominent type immune response characterized increased level interleukin il interferon gamma ifnγ production peripheral blood mononuclear cell pbmc upon stimulation soluble vaccine antigen importantly result showed type responsiveness sustained challenge infection day l chagasi challenge infection pbmcs lbsap vaccinated dog produced il ifnγ concomitant nitric oxide stimulated leishmania antigen compared pbmcs respective control group saponin lb treated nontreated control dog moreover transforming growth factor tgfβ decreased supernatant slcastimulated pbmcs lbsap group day bone marrow parasitological analysis revealed decreased frequency parasitism presence vaccine antigen concluded vaccination dog lbsap vaccine induced longlasting type immune response l chagasi challenge infection,2013-12-06,"Resende, Lucilene Aparecida; Roatt, Bruno Mendes; Aguiar-Soares, Rodrigo Dian de Oliveira; Viana, Kelvinson Fernandes; Mendonça, Ludmila Zanandreis; Lanna, Mariana Ferreira; Silveira-Lemos, Denise; Corrêa-Oliveira, Rodrigo; Martins-Filho, Olindo Assis; Fujiwara, Ricardo Toshio; Carneiro, Cláudia Martins; Reis, Alexandre Barbosa; Giunchetti, Rodolfo Cordeiro",Veterinary Parasitology,,,,document_parses/pdf_json/842a27764db3007473a47c80750835bdee93402c.json,document_parses/pmc_json/PMC7115768.xml.json,https://api.elsevier.com/content/article/pii/S0304401713005050; https://www.sciencedirect.com/science/article/pii/S0304401713005050; https://doi.org/10.1016/j.vetpar.2013.09.011; https://www.ncbi.nlm.nih.gov/pubmed/24129068/,35446887.0,3
75581,75581,97498,nb6c8buz,53ad783bd651dab3f1ff08e681a286db611075aa,Elsevier; Medline; PMC,Cricket paralysis virus internal ribosome entry site-derived RNA promotes conventional vaccine efficacy by enhancing a balanced Th1/Th2 response,10.1016/j.vaccine.2019.07.070,PMC7115557,31371226.0,els-covid,ideal adjuvant increase vaccine efficacy balanced thth response safe use recombinant proteinbased vaccine usually formulated aluminum alumbased adjuvant ensure adequate immune response however use alum trigger thbiased immune induction hence optimal although adjuvanticity rna reported systematic overall investigation efficacy lacking found single strand rna termed rna adjuvant derived cricket paralysis virus intergenic region internal ribosome entry site induced expression various adjuvantfunctionrelated gene type interferon ifn tolllike receptor tlr cell activation leukocyte chemotaxis human peripheral blood mononuclear cell furthermore innate ifn transcriptome profile pattern similar liveattenuated yellow fever vaccine suggests proteinbased vaccine formulated using rna adjuvant function liveattenuated vaccine application rna adjuvant mouse enhanced efficacy middle east respiratory syndrome spike protein proteinsubunit vaccine human papillomavirus l protein viruslike particle vaccine activating innate immune response tlr enhancing papc chemotaxis leading balanced thth response moreover combination alum rna adjuvant synergistically induced humoral cellular immune response endowed longterm immunity therefore rna adjuvant broad applicability used conventional vaccine improve vaccine efficacy qualitatively quantitively,2019-08-23,"Kwak, Hye Won; Park, Hyo-Jung; Ko, Hae Li; Park, Hyelim; Cha, Min Ho; Lee, Sang-Myeong; Kang, Kyung Won; Kim, Rhoon-Ho; Ryu, Seung Rok; Kim, Hye-Jung; Kim, Jae-Ouk; Song, Manki; Kim, Hun; Jeong, Dae Gwin; Shin, Eui-Cheol; Nam, Jae-Hwan",Vaccine,,,,document_parses/pdf_json/53ad783bd651dab3f1ff08e681a286db611075aa.json,document_parses/pmc_json/PMC7115557.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X19309910; https://www.ncbi.nlm.nih.gov/pubmed/31371226/; https://api.elsevier.com/content/article/pii/S0264410X19309910; https://doi.org/10.1016/j.vaccine.2019.07.070,199381105.0,3
75588,75588,97506,7p8mw6e6,db3e25fcf0c4192d5f0f580a64dd4bfb69052de6,Medline; PMC,Antiviral B cell and T cell immunity in the lungs,10.1038/ni.3056,PMC7097128,25521681.0,no-cc,respiratory virus frequent cause repeated common cold bronchitis pneumonia often occur unpredictably epidemic pandemic despite decimating effect health decade intensive research treatment remain largely supportive commonly available vaccine influenza virus even need improvement lung share feature mucosal site preservation especially delicate anatomical structure necessitates fine balance pro antiinflammatory response welltimed appropriately placed tightly regulated cell b cell response essential protection infection limitation symptom whereas poorly regulated inflammation contributes tissue damage disease recent advance understanding adaptive immunity facilitate vaccine development reduce global effect respiratory virus,2014-12-18,"Chiu, Christopher; Openshaw, Peter J",Nat Immunol,,,,document_parses/pdf_json/db3e25fcf0c4192d5f0f580a64dd4bfb69052de6.json,document_parses/pmc_json/PMC7097128.xml.json,https://doi.org/10.1038/ni.3056; https://www.ncbi.nlm.nih.gov/pubmed/25521681/,29412122.0,3
75647,75647,97577,vql8e2j3,71e571db52c00a9c67fffc6f075580fe0732cde1,Medline; PMC,Effects of Adjuvants on the Immunogenicity and Efficacy of a Zika Virus Envelope Domain III Subunit Vaccine,10.3390/vaccines7040161,PMC6963592,31717890.0,cc-by,zika virus zikv mosquitoborne flavivirus attracted global attention due close association congenital zika syndrome neurological disease transmission additional route sexual contact currently vaccine approved zikv thus urgent need develop effective safe zikv vaccine domain iii diii zikv envelope e protein important vaccine target vaccine developed using mutant diii e ediii protein protects adult pregnant mouse unborn offspring zikv infection used immunocompetent balbc mouse treated antiinterferonαβ receptor ifnar antibody investigate whether three adjuvant aluminum alum monophosphoryl lipid mpl mf either alone combination could improve efficacy ediii subunit vaccine data show although vaccine formulated single adjuvant induced specific antibody cellular immune response reduced viral load mouse challenged zikv combination alum mpl adjuvant led robust balanced immune response stronger neutralizing activity three recent zikv human strain greater protection highdose zikv challenge particularly combination alum mpl significantly reduced viral titer viral rna copy number serum tissue including male reproductive organ overall study identified combination alum mpl effective adjuvant zikv ediii subunit vaccine important implication subunit vaccine enveloped virus including nonzikv flavivirus,2019-10-27,"Wang, Xinyi; Tai, Wanbo; Zhang, Xiaolu; Zhou, Yusen; Du, Lanying; Shen, Chuanlai",Vaccines (Basel),,,,document_parses/pdf_json/71e571db52c00a9c67fffc6f075580fe0732cde1.json,document_parses/pmc_json/PMC6963592.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31717890/; https://doi.org/10.3390/vaccines7040161,207937145.0,3
75697,75697,97637,e7arljd8,13d8c3280d32c72dc262a6eeb4a6b56f9da4d99c,Elsevier; PMC,Experimental inoculation of late term pregnant sows with a field isolate of porcine reproductive and respiratory syndrome vaccine-derived virus,10.1016/s0378-1135(01)00450-3,PMC7117428,11731155.0,els-covid,use live attenuated porcine reproductive respiratory syndrome virus prrsv vaccine piglet associated reproductive disorder nonvaccinated sow vaccinederived virus vdv isolated foetus stillborn pig dead piglet indicating live vaccine spread vaccinated piglet nonvaccinated sow virus might implicated severe reproductive problem observed present study one vdv isolate used experimentally infect pregnant sow last trimester chosen isolate identity attenuated vaccine virus originated lung stillborn pig swine herd sudden high level stillborn pig increased piglet mortality nursing period intranasal inoculation sow virus isolate resulted congenital infection foetal death preweaning pig mortality present study showed vaccinederived prrsv cause disease swine consistent prrs,2002-01-03,"Nielsen, J; Bøtner, A; Bille-Hansen, V; Oleksiewicz, M. B; Storgaard, T",Veterinary Microbiology,,,,document_parses/pdf_json/13d8c3280d32c72dc262a6eeb4a6b56f9da4d99c.json,document_parses/pmc_json/PMC7117428.xml.json,https://www.sciencedirect.com/science/article/pii/S0378113501004503; https://api.elsevier.com/content/article/pii/S0378113501004503,12815108.0,3
75737,75737,97689,b45cmsc4,06a58628c1ebc8e8d49a5a70ba3597acffba0304; d7ab06cd82de87b9742f8109305b567b1126efd8,Elsevier; Medline; PMC,A Replication-incompetent Rift Valley Fever Vaccine: Chimeric Virus-like Particles Protect Mice and Rats Against Lethal Challenge,10.1016/j.virol.2009.11.001,PMC2813982,19932911.0,green-oa,viruslike particle vlps present viral antigen native conformation effectively recognized immune system therefore considered suitable safe vaccine candidate many viral disease demonstrate chimeric vlps containing rift valley fever virus rvfv glycoprotein gn gc nucleoprotein n gag protein moloney murine leukemia virus represent effective vaccine candidate rift valley fever deadly disease human livestock longlasting humoral cellular immune response demonstrated mouse model analysis neutralizing antibody titer cytokine secretion profile vaccine efficacy study performed mouse rat lethal challenge model resulting high protection rate taken together result demonstrate replicationincompetent chimeric rvf vlps efficient rvfv vaccine candidate,2010-02-01,"Mandell, Robert B.; Koukuntla, Ramesh; Mogler, Laura J. K.; Carzoli, Andrea K.; Freiberg, Alexander N.; Holbrook, Michael R.; Martin, Brian K.; Staplin, William R.; Vahanian, Nicholas N.; Link, Charles J.; Flick, Ramon",Virology,,,,document_parses/pdf_json/06a58628c1ebc8e8d49a5a70ba3597acffba0304.json; document_parses/pdf_json/d7ab06cd82de87b9742f8109305b567b1126efd8.json,document_parses/pmc_json/PMC2813982.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19932911/; https://www.sciencedirect.com/science/article/pii/S004268220900693X; http://europepmc.org/articles/pmc2813982?pdf=render; https://doi.org/10.1016/j.virol.2009.11.001; https://api.elsevier.com/content/article/pii/S004268220900693X,28685517.0,3
75817,75817,97790,50i6cxby,4e741d57fb2db417d3a82fae701233ed7d4c5b55,Medline; PMC,Chinese immigrant parents’ vaccination decision making for children: a qualitative analysis,10.1186/1471-2458-14-133,PMC3937074,24507384.0,cc-by,background immunization coverage rate childhood routine vaccine hong kong almost uptake rate optional vaccine remain suboptimal understanding parental decisionmaking child ’ vaccination important particularly among minority group vulnerable underserved study explored subsample new immigrant mother mainland china rapidlygrowing subpopulation hong kong made decision various childhood adolescent vaccine offspring identified key influence affecting decision making method semistructured indepth interview conducted chinese new immigrant mother recruited purposive sampling interview audiotaped transcribed analyzed using grounded theory approach result participant ’ conversation revealed five underlying theme influenced parent ’ vaccination decisionmaking institutional factor insufficient vaccination knowledge advice affective impact motivation vaccination barrier social influence role social norm appeared overwhelmingly salient influencing parent ’ vaccination decision making institutional factor shaped parent ’ perception vaccination necessity fear vaccinetargeted disease key motivating factor parent adopting vaccination insufficient knowledge vaccine targeted disease lack advice health professional provided suspicion regarding motivation advice common issue vaccination cost major barrier many new immigrant parent conclusion social norm play key role influencing parental vaccination decisionmaking insight gained study help inform healthcare provider vaccination communication policymakers future vaccination programme,2014-02-07,"Wang, Linda DL; Lam, Wendy WT; Wu, Joseph T; Liao, Qiuyan; Fielding, Richard",BMC Public Health,,,,document_parses/pdf_json/4e741d57fb2db417d3a82fae701233ed7d4c5b55.json,document_parses/pmc_json/PMC3937074.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/24507384/; https://doi.org/10.1186/1471-2458-14-133,18250129.0,3
76059,76059,98087,jxv1ntp8,e4d5a1e02bd76428a784494b4977d6dd055905e3; 55192a65c0043b544fdb241b0a9ed9a47b4139d4,Elsevier; Medline; PMC,Vaccination Strategies to Promote Mucosal Antibody Responses,10.1016/j.immuni.2010.09.013,PMC3045856,21029959.0,green-oa,great interest demand development vaccine prevent treat diverse microbial infection mucosal vaccine elicit immune protection stimulating production antibody mucosal surface systemic district positioned close proximity large community commensal microbe mucosal immune system deploys heterogeneous population cell complex regulatory network maintain balance surveillance tolerance successful mucosal vaccine relies leveraging function immune cell regulatory component article review important cellular interaction molecular pathway underlying induction regulation mucosal antibody response discus implication mucosal vaccination,2010-10-01,"Chen, Kang; Cerutti, Andrea",Immunity,,,,document_parses/pdf_json/e4d5a1e02bd76428a784494b4977d6dd055905e3.json; document_parses/pdf_json/55192a65c0043b544fdb241b0a9ed9a47b4139d4.json,document_parses/pmc_json/PMC3045856.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/21029959/; http://europepmc.org/articles/pmc3045856?pdf=render; https://doi.org/10.1016/j.immuni.2010.09.013; https://api.elsevier.com/content/article/pii/S1074761310003560; https://www.sciencedirect.com/science/article/pii/S1074761310003560,32924568.0,3
76065,76065,98094,j52z6pki,61515abcd14687feeb6f17310e9190b99ad07b94,Elsevier; PMC,Chapter 65 Mucosal Vaccines from Plant Biotechnology,10.1016/b978-0-12-415847-4.00065-3,PMC7158328,,els-covid,use plant production recombinant protein evolved past year first plantbased vaccine expressed stably transgenic plant idea conveniently deliver “ edible vaccine ” ingestion antigencontaining plant material system provided proof concept oral delivery vaccine crude plant material could stimulate antigenspecific serum mucosal antibody transgenic grain like rice particular provide stable robust vehicle antigen delivery however issue exist stably transgenic plant including relatively low expression level regulatory issue thus many recent study use transient expression plant viral vector achieve rapid high expression nicotiana benthamiana followed purification antigen intranasal delivery effective stimulation mucosal immune response,2015-12-31,"Mason, Hugh S.; Thuenemann, Eva; Kiyono, Hiroshi; Kessans, Sarah; Matoba, Nobuyuki; Mor, Tsafrir",Mucosal Immunology,,,,document_parses/pdf_json/61515abcd14687feeb6f17310e9190b99ad07b94.json,document_parses/pmc_json/PMC7158328.xml.json,https://www.sciencedirect.com/science/article/pii/B9780124158474000653; https://api.elsevier.com/content/article/pii/B9780124158474000653,83337931.0,3
76104,76104,98140,593n7614,4eef3e22d5f9baefaf7365a18637bd1ae71f0f39,Elsevier; PMC,VACCINATIONS | Viral,10.1016/b0-12-370879-6/00418-x,PMC7150349,,els-covid,vaccine preparation weakened killed virus viral subunit trigger specific protective immunity vaccination single effective tool preventing communicable disease highlighted achievement smallpox poliomyelitis eradication program rise infection effective vaccine available human immunodeficiency virus malaria worm tuberculosis world health organization initiative target acute respiratory disease infancy early childhood novel immunization approach effective vaccine needed urgently viral respiratory disease progress disappointingly slow vaccine candidate often show reduced efficacy infancy partially immune adult immunocompromised elderly however several promising vaccine clinical trial likely vaccine respiratory syncytial virus parainfluenza licensed within next – year mucosally delivered influenza vaccine available novel adjuvant offer prospect better immunogenicity ideally multivalent mucosal vaccine developed provide protection spectrum respiratory infection specific target age group,2006-12-31,"Olszewska, W.; Openshaw, P.J.M.; Helson, R.",Encyclopedia of Respiratory Medicine,,,,document_parses/pdf_json/4eef3e22d5f9baefaf7365a18637bd1ae71f0f39.json,document_parses/pmc_json/PMC7150349.xml.json,https://api.elsevier.com/content/article/pii/B012370879600418X; https://www.sciencedirect.com/science/article/pii/B012370879600418X,214755903.0,3
76122,76122,98165,sgy2wh8m,ae44f456afccca76e1eec1637ce1af6041956c64,Medline; PMC,"Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies",10.1007/s13238-015-0164-2,PMC4491048,25944045.0,cc-by,pathogen initiate infection human mucosal surface therefore mucosal vaccination especially oral intranasal administration route highly desired infectious disease meanwhile proteinbased antigen provide safer alternative whole pathogen dna based one vaccine development however unique biopharmaceutical hurdle intranasally orally delivered protein vaccine need overcome reach site targeting relatively low immunogenicity well low stability protein antigen require thoughtful finetuned mucosal vaccine formulation including selection immunostimulants identification suitable vaccine delivery system determination exact composition manufacturing condition review aim provide uptodate survey protein antigenbased vaccine formulation development including usage immunostimulants optimization vaccine delivery system intranasal oral administration electronic supplementary material online version article doi contains supplementary material available authorized user,2015-05-06,"Wang, Shujing; Liu, Huiqin; Zhang, Xinyi; Qian, Feng",Protein Cell,,,,document_parses/pdf_json/ae44f456afccca76e1eec1637ce1af6041956c64.json,document_parses/pmc_json/PMC4491048.xml.json,https://doi.org/10.1007/s13238-015-0164-2; https://www.ncbi.nlm.nih.gov/pubmed/25944045/,16811582.0,3
76144,76144,98191,i71cxlip,7029c7a6a61bbb35e96f8b90b87b2d49659fef04; a8448e0c9df61442dd233ee8ee838ea3c7e59a63; a0b5e0b254ac970c673a8201cb5c22fa4d12a7ff,Elsevier; Medline; PMC,Antibody treatment of Ebola and Sudan virus infection via a uniquely exposed epitope within the glycoprotein receptor-binding site,10.1016/j.celrep.2016.04.026,PMC4871745,27160900.0,gold-oa,previous effort identify crossneutralizing antibody receptor binding site rb ebolavirus glycoprotein unsuccessful largely rb occluded viral surface report monoclonal antibody fvm target uniquely exposed epitope within rb crossneutralizes ebola ebov sudan sudv lesser extent bundibugyo virus show protection ebov sudv mouse guinea pig antibody cocktail zmapp™ remarkably effective ebov zaire crossneutralize ebolaviruses replacing one zmapp™ component fvm retained antiebov efficacy extending breadth protection sudv thereby generating cross protective antibody cocktail addition report several mutation base ebolavirus glycoprotein enhance binding fvm crossreactive antibody finding important implication panebolavirus vaccine development defining broadly protective antibody cocktail,2016-05-01,"Howell, Katie A.; Qiu, Xiangguo; Brannan, Jennifer M.; Bryan, Christopher; Davidson, Edgar; Holtsberg, Frederick W.; Wec, Anna Z.; Shulenin, Sergey; Biggins, Julia E.; Douglas, Robin; Enterlein, Sven G.; Turner, Hannah L.; Pallesen, Jesper; Murin, Charles D.; He, Shihua; Kroeker, Andrea; Vu, Hong; Herbert, Andrew S.; Fusco, Marnie L.; Nyakatura, Elisabeth K.; Lai, Jonathan R.; Keck, Zhen-Yong; Foung, Steven K. H.; Saphire, Erica Ollmann; Zeitlin, Larry; Ward, Andrew B.; Chandran, Kartik; Doranz, Benjamin J.; Kobinger, Gary P.; Dye, John M.; Aman, M. Javad",Cell Reports,,,,document_parses/pdf_json/7029c7a6a61bbb35e96f8b90b87b2d49659fef04.json; document_parses/pdf_json/a8448e0c9df61442dd233ee8ee838ea3c7e59a63.json; document_parses/pdf_json/a0b5e0b254ac970c673a8201cb5c22fa4d12a7ff.json,document_parses/pmc_json/PMC4871745.xml.json,https://www.sciencedirect.com/science/article/pii/S2211124716304399; https://doi.org/10.1016/j.celrep.2016.04.026; https://www.ncbi.nlm.nih.gov/pubmed/27160900/; https://api.elsevier.com/content/article/pii/S2211124716304399; http://www.cell.com/article/S2211124716304399/pdf,20813522.0,3
76156,76156,98207,ibac3d0q,2dc8bfca1a97eeaac8f3cad9dd3aa5779fc6336a,Medline; PMC,Development of a SARS Coronavirus Vaccine from Recombinant Spike Protein Plus Delta Inulin Adjuvant,10.1007/978-1-4939-3387-7_14,PMC7139448,27076136.0,no-cc,given periodic outbreak fatal human infection caused coronaviruses development optimal coronavirus vaccine platform capable rapid production ongoing priority chapter describes use insect cell expression system rapid production recombinant vaccine severe acute respiratory syndrome coronavirus sars detailed method presented expression purification release testing sars recombinant spike protein antigen followed adjuvant formulation animal testing method herein described rapid development highly protective sars vaccine equally suited rapid development vaccine fatal human coronavirus infection eg mers coronavirus,2015-12-17,"McPherson, Clifton; Chubet, Richard; Holtz, Kathy; Honda-Okubo, Yoshikazu; Barnard, Dale; Cox, Manon; Petrovsky, Nikolai",Vaccine Design,,,,document_parses/pdf_json/2dc8bfca1a97eeaac8f3cad9dd3aa5779fc6336a.json,document_parses/pmc_json/PMC7139448.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/27076136/; https://doi.org/10.1007/978-1-4939-3387-7_14,31320842.0,3
76162,76162,98214,9ivlag00,,Medline; WHO,"Early impact of the coronavirus disease (COVID-19) pandemic and physical distancing measures on routine childhood vaccinations in England, January to April 2020",10.2807/1560-7917.es.2020.25.19.2000848,,32431288.0,unk,childhood vaccination coverage united kingdom uk routinely monitored quarterly timely monitoring required disruption pandemic analysed electronic patient record primary care describe change delivery first dos hexavalent vaccine diphtheria tetanus pertussis polio haemophilus influenzae type b hepatitis b measlesmumpsrubella mmr vaccine part routine childhood vaccination programme england coronavirus disease covid outbreak april week near realtime record routine childhood vaccination primary carego section two key milestone routine childhood immunisation programme delivered primary care first universal vaccination age week include hexavalent vaccine vaccination age year include first dose mmr vaccine aggregated weekly count first hexavalent vaccination delivered infant younger month first mmr vaccination delivered child aged month provided phoenix partnership tpp systmone first week systmone software system provides electronic patient record primary care practice uk child health provider age range selected describe vaccination delivered part routine vaccination programme rather catchup campaign match age range national routine surveillance vaccine coverage data anonymous throughout originally extracted aggregated weekly vaccination count purpose systmone data check use population level data minimise change denominator provider active systmone since contributed dataset majority vaccination entered systmone entered general practice real time however vaccination delivered general practice use patient record software may recorded delay systmone integrated patient record local child health system coordinating vaccination scheduling avoid artefact lag data recording included vaccination recorded day delivered comprised total hexavalent mmr vaccination dos recorded delivered week week dataset included hexavalent dos delivered well mmr dos delivered,2020,"McDonald, Helen I; Tessier, Elise; White, Joanne M; Woodruff, Matthew; Knowles, Charlotte; Bates, Chris; Parry, John; Walker, Jemma L; Scott, J Anthony; Smeeth, Liam; Yarwood, Joanne; Ramsay, Mary; Edelstein, Michael",Eurosurveillance,,#259289,,,,https://www.ncbi.nlm.nih.gov/pubmed/32431288/; https://doi.org/10.2807/1560-7917.es.2020.25.19.2000848,218760143.0,3
76197,76197,98256,rvxxeg32,3382972f793a12e7f7a6e1e5d48d4795b3d21f85,Medline; PMC,Vaccines against Middle East respiratory syndrome coronavirus for humans and camels,10.1002/rmv.1917,PMC7169231,27786402.0,no-cc,middle east respiratory syndrome coronavirus mers‐cov caused novel betacoronavirus isolated late saudi arabia viral infection reported human ranging asymptomatic mild case severe pneumonia mortality rate well documented dromedary camel contract infection shed virus without notable symptom animal infected least early mechanism camel human transmission still clear several primary case associated camel contact approved antiviral drug vaccine mers‐cov despite active research area vaccine candidate developed using various platform regimen tested several animal model article review published study mers‐cov vaccine focus vaccine tested large animal including camel foreseeable ‐health approach could best way tackling mers‐cov endemic arabian peninsula using mass vaccination camel affected area block camel human transmission camel vaccine developed faster time fewer regulation lower cost could clear virus arabian peninsula accompanied efficient public health measure,2016-10-27,"Alharbi, Naif Khalaf",Rev Med Virol,,,,document_parses/pdf_json/3382972f793a12e7f7a6e1e5d48d4795b3d21f85.json,document_parses/pmc_json/PMC7169231.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/27786402/; https://doi.org/10.1002/rmv.1917,46785874.0,3
76244,76244,98310,x3ru6qgq,5caced13bcb8a42cca41369c5a71ae7df5381ca8,Medline; PMC,Mucosal immune responses induced by oral administration recombinant Bacillus subtilis expressing the COE antigen of PEDV in newborn piglets,10.1042/bsr20182028,PMC6418403,30808716.0,cc-by,porcine epidemic diarrhea ped highly contagious disease newborn piglet cause substantial economic loss world ped virus pedv spread fecal–oral contact prevented oral immunization therefore necessary develop effective oral vaccine pedv infection currently bacillus subtilis recombinant vaccine carrier used antigen delivery proved well immune effect safety present study evaluated immunogenicity recombinant bacillus subtilis b subtilisrc piglet via oral administration oral immunization piglet b subtilisrc significantly increased local mucosal immune response oral administration b subtilisrc significantly improved level specific mucosal immunoglobulin iga antibody pedv infection enlarging area peyer ’ patch pps increasing number ileum iga secreting siga cell meantime b subtilisrc remarkably increased number intraepithelial lymphocyte iels also observed oral administration b subtilisrc significantly increased cdt lymphocyte ’ number upregulated ratio cdcd cell furthermore high titer specific serum immunoglobulin g igg revealed satisfactory systemic immune response pedv infection summary study demonstrated oral administration b subtilisrc could trigger high level local systemic immune response would promising candidate vaccine pedv infection piglet,2019-03-15,"Wang, Jialu; Huang, Lulu; Mou, Chunxiao; Zhang, En; Wang, Yongheng; Cao, Yanan; Yang, Qian",Biosci Rep,,,,document_parses/pdf_json/5caced13bcb8a42cca41369c5a71ae7df5381ca8.json,document_parses/pmc_json/PMC6418403.xml.json,https://doi.org/10.1042/bsr20182028; https://www.ncbi.nlm.nih.gov/pubmed/30808716/,73460830.0,3
76271,76271,98343,hb2lieh3,962c58e6dc9c1ea550eb51ce70b0d7c83dc7eff6,Medline; PMC,Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus,10.1371/journal.pone.0035421,PMC3335060,22536382.0,cc-by,background severe acute respiratory syndrome sars emerged china spread country brought control concern reemergence deliberate release sars coronavirus vaccine development initiated evaluation inactivated whole virus vaccine ferret nonhuman primate viruslikeparticle vaccine mouse induced protection infection challenged animal exhibited immunopathologictype lung disease design four candidate vaccine human without alum adjuvant evaluated mouse model sars vlp vaccine vaccine given ferret nhp another whole virus vaccine rdnaproduced protein balbc cbl mouse vaccinated im day sacrificed serum antibody measurement challenged live virus day day challenged mouse sacrificed lung obtained virus histopathology result vaccine induced serum neutralizing antibody increasing dosage andor alum significantly increasing response significant reduction sarscov two day challenge seen vaccine prior live sarscov mouse exhibited histopathologic change lung two day challenge including animal vaccinated balbc cbl given live virus influenza vaccine pb suggesting infection occurred histopathology seen animal given one sarscov vaccine uniformly thtype immunopathology prominent eosinophil infiltration confirmed special eosinophil stain pathologic change seen control group lacked eosinophil prominence conclusion sarscov vaccine induced antibody protection infection sarscov however challenge mouse given vaccine led occurrence thtype immunopathology suggesting hypersensitivity sarscov component induced caution proceeding application sarscov vaccine human indicated,2012-04-20,"Tseng, Chien-Te; Sbrana, Elena; Iwata-Yoshikawa, Naoko; Newman, Patrick C.; Garron, Tania; Atmar, Robert L.; Peters, Clarence J.; Couch, Robert B.",PLoS One,,,,document_parses/pdf_json/962c58e6dc9c1ea550eb51ce70b0d7c83dc7eff6.json,document_parses/pmc_json/PMC3335060.xml.json,https://doi.org/10.1371/journal.pone.0035421; https://www.ncbi.nlm.nih.gov/pubmed/22536382/,13765865.0,3
76291,76291,98369,pnem74ij,7abd3b3fc21fc2ff41ef6a23f988236f2065a045,Medline; PMC,"Progress in Vaccine-Preventable and Respiratory Infectious Diseases—First 10 Years of the CDC National Center for Immunization and Respiratory Diseases, 2006–2015",10.3201/eid2407.171699,PMC6038744,29916350.0,no-cc,need closer linkage scientific programmatic area focused addressing vaccinepreventable acute respiratory infection led establishment national center immunization respiratory disease ncird center disease control prevention first year – ncird worked partner improve preparedness response pandemic influenza emergent respiratory infection provide evidence base addition newly recommended vaccine modernize vaccine distribution clinical tool developed improved conversation parent helped sustain childhood immunization social norm coverage increased vaccine protect adolescent pertussis meningococcal meningitis human papillomavirus–associated cancer ncird program supported outbreak response new respiratory pathogen oversaw response center disease control prevention influenza ahn pandemic national public health institute might also find closer linkage epidemiology laboratory immunization program useful,2018-07-26,"Schuchat, Anne; Anderson, Larry J.; Rodewald, Lance E.; Cox, Nancy J.; Hajjeh, Rana; Pallansch, Mark A.; Messonnier, Nancy E.; Jernigan, Daniel B.; Wharton, Melinda",Emerg Infect Dis,,,,document_parses/pdf_json/7abd3b3fc21fc2ff41ef6a23f988236f2065a045.json,document_parses/pmc_json/PMC6038744.xml.json,https://doi.org/10.3201/eid2407.171699; https://www.ncbi.nlm.nih.gov/pubmed/29916350/,215778560.0,3
76311,76311,98393,x0ro1vub,81230f87c0f91c179b1111a9d7841b3426bd4a51,Elsevier; Medline; PMC,UK vaccines network: Mapping priority pathogens of epidemic potential and vaccine pipeline developments,10.1016/j.vaccine.2019.09.009,PMC7127063,31522809.0,els-covid,– ebola outbreak west africa expert panel established instruction uk prime minister identify priority pathogen outbreak disease potential cause future epidemic total priority pathogen identified led prioritisation spending emerging disease vaccine research development uk meeting report summarises process used develop uk pathogen priority list compare list generated organisation world health organisation national institute allergy infectious disease summarises clinical progress towards development vaccine priority disease clear technical progress towards development vaccine however availability vaccine dependent sustained funding clinical trial preparation clinically acceptable manufactured material interepidemic period,2019-10-08,"Noad, Rob J.; Simpson, Karl; Fooks, Anthony R.; Hewson, Roger; Gilbert, Sarah C.; Stevens, Mark P.; Hosie, Margaret J.; Prior, Joann; Kinsey, Anna M.; Entrican, Gary; Simpson, Andrew; Whitty, Christopher J.M.; Carroll, Miles W",Vaccine,,,,document_parses/pdf_json/81230f87c0f91c179b1111a9d7841b3426bd4a51.json,document_parses/pmc_json/PMC7127063.xml.json,https://api.elsevier.com/content/article/pii/S0264410X19311971; https://doi.org/10.1016/j.vaccine.2019.09.009; https://www.ncbi.nlm.nih.gov/pubmed/31522809/; https://www.sciencedirect.com/science/article/pii/S0264410X19311971,202581599.0,3
76315,76315,98397,bx04ldmn,3f50d334193fa8cd216e4c4166e43fb0c8109709,Medline; PMC,Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus,10.1038/cmi.2015.03,PMC4786625,25640653.0,cc-by-nc-nd,middle east respiratory syndrome mers emerging infectious disease caused mers coronavirus merscov garnered worldwide attention consequence continuous spread pandemic potential making development effective vaccine high priority previously demonstrated residue – merscov spike protein receptorbinding domain rbd promising mers subunit vaccine candidate capable inducing potent neutralization antibody response study sought identify adjuvant optimally enhanced immunogenicity s– protein fused fc human igg s–fc specifically compared several commercially available adjuvant including freunds adjuvant aluminum monophosphoryl lipid montanide isa mf regard capacity enhance immunogenicity subunit vaccine absence adjuvant s–fc alone induced readily detectable neutralizing antibody tcell response immunized mouse however incorporating adjuvant improved immunogenicity particularly among aforementioned adjuvant evaluated mf potent judged superior ability induce highest titer igg igg igga subtypes neutralizing antibody addition mf significantly augmented immunogenicity s–fc induce strong igg neutralizing antibody response well protection merscov infection mouse suggesting mf optimal adjuvant merscov rbdbased subunit vaccine,2015-02-02,"Zhang, Naru; Channappanavar, Rudragouda; Ma, Cuiqing; Wang, Lili; Tang, Jian; Garron, Tania; Tao, Xinrong; Tasneem, Sumaiya; Lu, Lu; Tseng, Chien-Te K; Zhou, Yusen; Perlman, Stanley; Jiang, Shibo; Du, Lanying",Cell Mol Immunol,,,,document_parses/pdf_json/3f50d334193fa8cd216e4c4166e43fb0c8109709.json,document_parses/pmc_json/PMC4786625.xml.json,https://doi.org/10.1038/cmi.2015.03; https://www.ncbi.nlm.nih.gov/pubmed/25640653/,10093517.0,3
76347,76347,98434,banzkms3,2e1c74a0b309efa66b9e0bab938a1265a81c37be,Elsevier; Medline; PMC,Sustainable vaccine development: a vaccine manufacturer's perspective,10.1016/j.coi.2018.04.019,PMC7126290,29751212.0,els-covid,vaccination remains costeffective public health intervention clean water benefit impressively outweigh cost effort needed fulfill steadily growing demand nextgeneration novel vaccine designed emerging pathogen new indication realizable sustainable business model vaccine development fasttracked strengthening international collaboration continuous innovation technology accelerate design development manufacturing however process supported balanced project portfolio managing sustainable vaccine procurement strategy different type market collectively allow gradual shift streamlined profitable vaccine production significantly contribute worldwide effort shape global health,2018-08-31,"Rappuoli, Rino; Hanon, Emmanuel",Current Opinion in Immunology,,,,document_parses/pdf_json/2e1c74a0b309efa66b9e0bab938a1265a81c37be.json,document_parses/pmc_json/PMC7126290.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29751212/; https://api.elsevier.com/content/article/pii/S0952791518300074; https://doi.org/10.1016/j.coi.2018.04.019; https://www.sciencedirect.com/science/article/pii/S0952791518300074,29153591.0,3
76429,76429,98531,yjzcsdu2,420654b9c54695e0170eda6821ee9efa34c6a221,Medline; PMC,Toxic and Immunomodulatory Properties of an Iron(II) Coordination Complex of Isoleucyltryptophan Dipeptide,10.1007/s11094-017-1632-1,PMC7089118,32214539.0,no-cc,result toxicological pharmacological study ironii coordination complex immunoactive dipeptide isoleucyltryptophan timofer presented established timofer practically nontoxic exhibited high immunostimulatory activity combined viral bacterial vaccine,2017-10-10,"Kholnazarov, B. M.; Bunyatyan, N. D.; Olefir, Yu. V.; Bobizoda, G. M.; Prokof’ev, A. B.",Pharm Chem J,,,,document_parses/pdf_json/420654b9c54695e0170eda6821ee9efa34c6a221.json,document_parses/pmc_json/PMC7089118.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32214539/; https://doi.org/10.1007/s11094-017-1632-1,103244584.0,3
76451,76451,98559,8yu6xqlw,2cf23712be389cb2970e91da35d19cf25829eb4d,Elsevier; Medline; PMC,iTRAQ-based comparative proteomic analysis of Vero cells infected with virulent and CV777 vaccine strain-like strains of porcine epidemic diarrhea virus,10.1016/j.jprot.2015.09.002,PMC7102838,26361011.0,no-cc,reemerging porcine epidemic diarrhea virus pedv variant related diarrhea documented china since late global distribution currently virulent pedv chynkm cv vaccine strainlike ahm successfully isolated clinical sample dissect underlying pathogenic mechanism virulent pedv clarify difference virulent cv vaccine strainlike pedv infection performed itraqbased comparative quantitative proteomic study vero cell infected pedv strain total differentially expressed protein identified upon virulent cv vaccine strainlike isolates infection respectively ingenuity pathway analysis employed investigate canonical pathway functional network involved pedv infection comprehensive study revealed pedv virulent strain suppressed protein synthesis vero cell downregulating mtor well downstream target ebp psk activity validated immunoblotting addition virulent strain could activate nfκb pathway intensively cv vaccine strainlike isolate elicit stronger inflammatory cascade well data might provide new insight elucidating specific pathogenesis pedv infection pave way development effective therapeutic strategy biological significance porcine epidemic diarrhea worldwide distributed causing huge economic loss swine industry immunomodulation pathogenesis pedv host well difference virulent attenuated strain pedv infection still largely unknown study presented first application proteomic analysis compare whole cellular protein alteration induced virulent cv vaccine strainlike pedv infection might contribute understand pathogenesis pedv antiviral strategy development,2016-01-01,"Guo, Xiaozhen; Hu, Han; Chen, Fangzhou; Li, Zhonghua; Ye, Shiyi; Cheng, Shuang; Zhang, Mengjia; He, Qigai",J Proteomics,,,,document_parses/pdf_json/2cf23712be389cb2970e91da35d19cf25829eb4d.json,document_parses/pmc_json/PMC7102838.xml.json,https://www.sciencedirect.com/science/article/pii/S1874391915301184; https://doi.org/10.1016/j.jprot.2015.09.002; https://api.elsevier.com/content/article/pii/S1874391915301184; https://www.ncbi.nlm.nih.gov/pubmed/26361011/,25599730.0,3
76463,76463,98572,oxybanjl,bc857b3d3f00b258346c09ec347d70d3e942f156,Medline; PMC,Viromimetic STING Agonist‐Loaded Hollow Polymeric Nanoparticles for Safe and Effective Vaccination against Middle East Respiratory Syndrome Coronavirus,10.1002/adfm.201807616,PMC7161765,32313544.0,no-cc,continued threat emerging highly lethal infectious pathogen middle east respiratory syndrome coronavirus mers‐cov call development novel vaccine technology offer safe effective prophylactic measure novel nanoparticle vaccine developed deliver subunit viral antigen sting agonist virus‐like fashion sting agonist first encapsulated capsid‐like hollow polymeric nanoparticles show multiple favorable attribute including ph‐responsive release profile prominent local immune activation reduced systemic reactogenicity upon subsequent antigen conjugation nanoparticles carry morphological semblance native virion facilitate codelivery antigen sting agonist draining lymph node immune cell immune potentiation nanoparticle vaccine effectiveness supported elicitation potent neutralization antibody antigen‐specific cell response mouse immunized mers‐cov nanoparticle vaccine candidate using mers‐cov‐permissive transgenic mouse model shown mouse immunized nanoparticle‐based mers‐cov vaccine protected lethal challenge mers‐cov without triggering undesirable eosinophilic immunopathology together biocompatible hollow nanoparticle described herein provides excellent strategy delivering subunit vaccine candidate novel adjuvant enabling accelerated development effective safe vaccine emerging viral pathogen,2019-04-12,"Lin, Leon Chien‐Wei; Huang, Chen‐Yu; Yao, Bing‐Yu; Lin, Jung‐Chen; Agrawal, Anurodh; Algaissi, Abdullah; Peng, Bi‐Hung; Liu, Yu‐Han; Huang, Ping‐Han; Juang, Rong‐Huay; Chang, Yuan‐Chih; Tseng, Chien‐Te; Chen, Hui‐Wen; Hu, Che‐Ming Jack",Adv Funct Mater,,,,document_parses/pdf_json/bc857b3d3f00b258346c09ec347d70d3e942f156.json,document_parses/pmc_json/PMC7161765.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32313544/; https://doi.org/10.1002/adfm.201807616,145916135.0,3
76495,76495,98612,dqvgng2s,e8fa6ff57f5e18b27fa9d70df3d3c90f4633264d,Medline; PMC,A versatile platform technology for recombinant vaccines using non-propagative human parainfluenza virus type 2 vector,10.1038/s41598-019-49579-y,PMC6733870,31501502.0,cc-by,ectopic protein proper steric structure efficiently loaded onto envelope f genedefective bcpiv vector derived human parainfluenza virus type hpiv reverse genetics method recombinant virus production ectopic antigenic peptide successfully loaded either outside inside side envelope vector bcpiv vector harboring ebola virus gp gene able elicit neutralizing antibody mouse addition bcpiv antigenic epitope melanoma gp wt tumor antigen induced cd tcellmediated response tumortransplanted syngeneic mouse considering low pathogenicity recurrent infection parental hpiv bcpiv used versatile vector high safety recombinant vaccine development addressing unmet medical need,2019-09-09,"Ohtsuka, Junpei; Fukumura, Masayuki; Furuyama, Wakako; Wang, Shujie; Hara, Kenichiro; Maeda, Mitsuyo; Tsurudome, Masato; Miyamoto, Hiroko; Kaito, Aika; Tsuda, Nobuyuki; Kataoka, Yosky; Mizoguchi, Akira; Takada, Ayato; Nosaka, Tetsuya",Sci Rep,,,,document_parses/pdf_json/e8fa6ff57f5e18b27fa9d70df3d3c90f4633264d.json,document_parses/pmc_json/PMC6733870.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31501502/; https://doi.org/10.1038/s41598-019-49579-y,201966043.0,3
76642,76642,98793,hqgwj8vs,77763ae1a4b82f01304096021e844ff741ebcd25,Elsevier; PMC,Placebo-controlled evaluation of a modified life virus vaccine against feline infectious peritonitis: safety and efficacy under field conditions,10.1016/s0264-410x(97)00006-6,PMC7131199,9269053.0,els-covid,modified live virus vaccine feline infectious peritonitis fip evaluated double blind placebocontrolled field trial two highrisk population vaccine found safe efficacious one population cat low antibody titre feline coronavirus fcov time vaccination although clinically healthy time vaccination retrospectively vaccinee later came fip found rtpcr positive fcov plasma showed change blood parameter consistent early stage fip concluded vaccination protect cat low fcov antibody titre cat vaccine failure probably due preexisting infection,1997-07-31,"Fehr, Daniela; Holznagel, Edgar; Bolla, Stefania; Hauser, Beat; Herrewegh, Arnold A.P.M.; Horzinek, Marian C.; Lutz, Hans",Vaccine,,,,document_parses/pdf_json/77763ae1a4b82f01304096021e844ff741ebcd25.json,,https://api.elsevier.com/content/article/pii/S0264410X97000066; https://www.sciencedirect.com/science/article/pii/S0264410X97000066,33612522.0,3
76676,76676,98840,u55ibep9,eeed3ffbb9e4731570065f7634b6b7927a729862,Elsevier; Medline; PMC,Non-animal replacement methods for veterinary vaccine potency testing: state of the science and future directions,10.1016/j.provac.2011.10.005,PMC7129755,32288914.0,els-covid,niceatm iccvam convened international workshop review state science human veterinary vaccine potency safety testing method identify opportunity advance new improved method reduce refine replace animal use six topic addressed detail speaker workshop participant reported series six report workshop report second series provides recommendation current future use nonanimal method strategy veterinary vaccine potency testing workshop participant recommended future effort replace animal use give priority vaccine use large number animal per test many serial produced annually involve significant animal pain distress procedure functional protective antigen identified involve foreign animalzoonotic organism dangerous human involve pathogen easily spread wildlife population vaccine identified highest priority rabies leptospira spp clostridium spp erysipelas foreign animal disease fad poultry disease fish disease research identification purification characterization vaccine protective antigen veterinary vaccine also identified priority workshop participant recommended priority research development validation activity address critical knowledge data gap including opportunity apply new science technology recommendation included investigation relative impact various adjuvant antigen quantification assay investigation extraction method could used vaccine containing adjuvant interfere antigen assay review current status rabies tetanus human vaccine vitro potency method potential application corresponding veterinary vaccine workshop participant recommended enhanced international harmonization cooperation closer collaboration human veterinary researcher expedite progress implementation workshop recommendation expected advance alternative vitro method veterinary vaccine potency testing benefit animal welfare replace animal use ensuring continued protection human animal health,2011-12-31,"Kulpa-Eddy, Jodie; Srinivas, Geetha; Halder, Marlies; Hill, Richard; Brown, Karen; Roth, James; Draayer, Hans; Galvin, Jeffrey; Claassen, Ivo; Gifford, Glen; Woodland, Ralph; Doelling, Vivian; Jones, Brett; Stokes, William S",Procedia in Vaccinology,,,,document_parses/pdf_json/eeed3ffbb9e4731570065f7634b6b7927a729862.json,,https://api.elsevier.com/content/article/pii/S1877282X11000233; https://doi.org/10.1016/j.provac.2011.10.005; https://www.sciencedirect.com/science/article/pii/S1877282X11000233; https://www.ncbi.nlm.nih.gov/pubmed/32288914/,35280993.0,3
76688,76688,98853,w8kfwd7v,3cf293e94ea274dd923cf81401eb26e42475bf77,Elsevier; Medline; PMC,Targeting the porcine immune system—Particulate vaccines in the 21st century,10.1016/j.dci.2008.07.015,PMC7103233,18771683.0,no-cc,last decade propagation immunological knowledge describing critical role dendritic cell dc induction efficacious immune response promoted research development vaccine systematically targeting dc based promise rational design vaccine platform current review provide update particlebased vaccine viral synthetic origin giving example recombinant virus carrier adenovirus biodegradable particulate carrier viral carrier carry pathogenassociated molecular pattern pamp used original virus targeting dc particularly efficient versatile gene delivery vector effort field synthetic vaccine carrier focussing decorating particle surface ligand dc receptor heparan sulphate glycosaminoglycan structure integrins siglecs galectins ctype lectin tolllike receptor emphasis review placed targeting porcine immune system reference made advance murine human vaccine delivery system information dc targeting available,2008-09-02,"McCullough, Kenneth C.; Summerfield, Artur",Dev Comp Immunol,,,,document_parses/pdf_json/3cf293e94ea274dd923cf81401eb26e42475bf77.json,document_parses/pmc_json/PMC7103233.xml.json,https://api.elsevier.com/content/article/pii/S0145305X08001717; https://www.sciencedirect.com/science/article/pii/S0145305X08001717; https://doi.org/10.1016/j.dci.2008.07.015; https://www.ncbi.nlm.nih.gov/pubmed/18771683/,26688031.0,3
76720,76720,98892,knepla2b,9d2aeea53bf88de18dbc06eb2486457923f3cd1f,Elsevier; Medline; PMC,Helminth Vaccines in Ruminants: From Development to Application,10.1016/j.cvfa.2019.10.001,PMC7125739,32029181.0,no-cc,article summarizes state art vaccine research parasitic helminth sheep cattle optimization antigen production eg recombinant expression antigen delivery followed extensive field testing still required development vaccine helminth vaccine sufficiently reduce parasite transmission protect vaccinated animal parasiteinduced disorder production loss vaccine efficacy requirement depend parasite ’ epidemiology farm management vary different geographic region influenced climate vaccination likely part integrated worm control together worm control measure,2020-02-03,"Claerebout, Edwin; Geldhof, Peter",Vet Clin North Am Food Anim Pract,,,,document_parses/pdf_json/9d2aeea53bf88de18dbc06eb2486457923f3cd1f.json,document_parses/pmc_json/PMC7125739.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32029181/; https://www.sciencedirect.com/science/article/pii/S0749072019300477; https://api.elsevier.com/content/article/pii/S0749072019300477; https://doi.org/10.1016/j.cvfa.2019.10.001,211046714.0,3
76726,76726,98900,ve9s8zmd,09a248034a8e29a2341c707ef66771cda8bd7b1b,Elsevier; PMC,Speculation on whether a vaccine against cryptosporidiosis is a reality or fantasy,10.1016/s0020-7519(99)00082-x,PMC7130201,10576579.0,els-covid,paper author question whether development vaccine cryptosporidiosis could taken consideration necessity feasibility vaccine human veterinary application discussed developmental stage within life cycle parasite might act possible target vaccine development summarised well target antigen offered molecular biology immunology study vaccination trial cryptosporidiosis carried far including active passive immunisation approach also overviewed seems respect cryptosporidium vaccine two target group considered child developing world neonatal ruminant antigen representing possible candidate subunit vaccine identified based function location andor immune response evoke active vaccination newborn calf lamb goat kid face number important limitation passive immunisation approach dam immunised protect progeny colostral transfer proven valuable alternative finally number point action near future put forward,1999-08-31,"de Graaf, Dirk C.; Spano, Furio; Petry, Franz; Sagodira, Serge; Bonnin, Alain",International Journal for Parasitology,,,,document_parses/pdf_json/09a248034a8e29a2341c707ef66771cda8bd7b1b.json,document_parses/pmc_json/PMC7130201.xml.json,https://www.sciencedirect.com/science/article/pii/S002075199900082X; https://api.elsevier.com/content/article/pii/S002075199900082X,483978.0,3
76727,76727,98901,4xkux5z4,0e3d8af76d99d494c136a1f8c054b761c73438ba,Elsevier; Medline; PMC,Recent Advances in Vaccine Technologies,10.1016/j.cvsm.2017.10.002,PMC7132473,29217317.0,els-covid,brief review discus recent advance vaccine technology particular reference application within veterinary medicine highlight key inactivatedkilled approach vaccination including natural splitproduct subunit vaccine recombinant subunit protein vaccine peptide vaccine also cover liveattenuated vaccine strategy including modified live markerdifferentiating infected vaccinated animal vaccine live vector vaccine nucleic acid vaccine,2018-03-31,"Francis, Michael James",Veterinary Clinics of North America: Small Animal Practice,,,,document_parses/pdf_json/0e3d8af76d99d494c136a1f8c054b761c73438ba.json,document_parses/pmc_json/PMC7132473.xml.json,https://doi.org/10.1016/j.cvsm.2017.10.002; https://www.sciencedirect.com/science/article/pii/S0195561617301195; https://api.elsevier.com/content/article/pii/S0195561617301195; https://www.ncbi.nlm.nih.gov/pubmed/29217317/,46878554.0,3
76803,76803,98994,hbfby8vr,dc72fd0cdf600e4f5c15adb8700bcd68970cf52e,Elsevier; Medline; PMC,Vaccine development for emerging virulent infectious diseases,10.1016/j.vaccine.2017.02.015,PMC7115543,28216184.0,els-covid,recent outbreak zaire ebola virus west africa altered classical paradigm vaccine development emerging infectious disease eids general paper precept vaccine discovery advancement preclinical clinical assessment discussed context recent ebola virus middle east respiratory syndrome coronavirus merscov zika virus outbreak clinical trial design disease high mortality rate andor high morbidity face global perception immediate need factor drive design face changing epidemiology presented vaccine eids thus present unique paradigm standard development precept,2017-10-04,"Maslow, Joel N.",Vaccine,,,,document_parses/pdf_json/dc72fd0cdf600e4f5c15adb8700bcd68970cf52e.json,document_parses/pmc_json/PMC7115543.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X17301962; https://doi.org/10.1016/j.vaccine.2017.02.015; https://www.ncbi.nlm.nih.gov/pubmed/28216184/; https://api.elsevier.com/content/article/pii/S0264410X17301962,3865394.0,3
76817,76817,99009,oke1d1vn,3e6bdc670f8de6f68e4218c5140677dd620cfc14,Medline; PMC,Including 793/B type avian infectious bronchitis vaccine in 1-day-old chicken increased the protection against QX genotype,10.1007/s11250-018-1730-4,PMC7088605,30374823.0,no-cc,infectious bronchitis virus ibv highly infectious pathogen affect respiratory tract reproductive system kidney chicken many different genotype ibv recognized cause different clinical manifestation according antigenic difference different serotypes virus crossprotect massachusetts serotype induces best crossprotection serotypes recently ibv qx genotype detected iran qx genotype cause permanent damage oviduct layer breeder flock occurs early life cycle study compared two vaccination program using b type massachusetts type vaccine onedayold spf chicken divided four group group unvaccinated group group vaccinated h vaccine day b day eye drop group vaccinated hb eye drop first day b day group challenged oculonasal qx genotype eid day five day post challenge sample clollected ciliostasis test histopathology quantitative realtime rtpcr trachea lung kidney result showed two vaccination program created protection challenge virus significant difference recorded two program based result concluded vaccination two mixed vaccine hb first day life chick make difference comparison single vaccine h reducing pathological damage viral load long second vaccination ib may applied properly farm situation applying mixture b type vaccine h day ocular spray may help increase vaccination program efficacy,2018-10-29,"Karimi, Vahid; Mohammadi, Peyman; Ghalyanchilangeroudi, Arash; Ghafouri, Seyed Ali; Hashemzadeh, Masoud; Farahani, Reza Khaltabadi; Maghsouldoo, Hussein; Isakakroudi, Nima",Trop Anim Health Prod,,,,document_parses/pdf_json/3e6bdc670f8de6f68e4218c5140677dd620cfc14.json,document_parses/pmc_json/PMC7088605.xml.json,https://doi.org/10.1007/s11250-018-1730-4; https://www.ncbi.nlm.nih.gov/pubmed/30374823/,53104854.0,3
76852,76852,99054,4xvkql68,7649a2fc203b3f32bb54f9226adcd108152094d5; e638c32460a466670deb0dd292265d65f4f8f971,Elsevier; Medline; PMC,Immunization of cattle with recombinant Newcastle disease virus expressing bovine herpesvirus-1 (BHV-1) glycoprotein D induces mucosal and serum antibody responses and provides partial protection against BHV-1,10.1016/j.vaccine.2010.02.051,PMC3428038,20189484.0,green-oa,bovine herpesvirus bhv major cause respiratory tract disease cattle vaccination cattle bhv high priority major concern currently modified live bhv vaccine ability cause latent infection subsequent reactivation resulting many outbreak thus need alternative strategy generated two recombinant newcastle disease virus ndvs expressing glycoprotein gd bhv added gene one recombinant rlasotagdfl expressed gd without modification recombinant rlasotagdf expressed chimeric gd ectodomain gd fused transmembrane domain cytoplasmic tail ndv fusion f glycoprotein remarkably native gd expressed rlasotagdfl virus incorporated ndv virion fold efficiently native ndv protein whereas chimeric gd detectably incorporated even though abundantly expressed infected cell surface expression gd increase virulence rndv vector chicken single intranasal intratracheal inoculation calf either recombinant ndv elicited mucosal systemic antibody specific bhv response rlasotagdfl higher rlasotagdf following challenge bhv calf immunized recombinant ndvs lower titer earlier clearance challenge virus compared empty vector control reduced disease observed rlasotagdfl following challenge titer serum antibody specific bhv higher animal immunized rndv vaccine compared rndv parent virus indicating vaccine primed secondary response data suggest ndv used vaccine vector bovine bhv gd may useful mucosal vaccine bhv infection might require augmentation second dose inclusion additional bhv antigen,2010-04-01,"Khattar, Sunil K.; Collins, Peter L.; Samal, Siba K.",Vaccine,,,,document_parses/pdf_json/7649a2fc203b3f32bb54f9226adcd108152094d5.json; document_parses/pdf_json/e638c32460a466670deb0dd292265d65f4f8f971.json,document_parses/pmc_json/PMC3428038.xml.json,https://doi.org/10.1016/j.vaccine.2010.02.051; https://www.sciencedirect.com/science/article/pii/S0264410X10002197; https://api.elsevier.com/content/article/pii/S0264410X10002197; https://www.ncbi.nlm.nih.gov/pubmed/20189484/; http://europepmc.org/articles/pmc3428038?pdf=render,10695547.0,3
76897,76897,99105,iu9cwad8,11b32fd959131a10c460119368638178a512b2da,Medline; PMC,Immunogenicity of transmissible gastroenteritis virus (TGEV) M gene delivered by attenuated Salmonella typhimurium in mice,10.1007/s11262-016-1296-z,PMC7088643,26837896.0,no-cc,attenuated salmonella typhimurium typhimurium selected transgenic vehicle development live mucosal vaccine transmissible gastroenteritis virus tgev based gene approximate kb dna fragment encoding glycoprotein amplified rtpcr cloned eukaryotic expression vector pvax recombinant plasmid pvaxm transformed electroporation attenuated typhimurium sl expression translation pvaxm delivered recombinant typhimurium sl pvaxm detected vitro vivo balbc mouse inoculated orally sl pvaxm different dosage evaluate safety vaccine bacterium safe mouse dosage × cfu almost eliminated spleen liver week postimmunization eventually cleared week mouse immunized × cfu sl pvaxm elicited specific antitgev local mucosal humoral response including level iga igg il ifnγ measured indirect elisa assay moreover control group pvax group pb group maintained normal level week – postimmunization result indicated attenuated typhimurium could used delivery vector oral immunization tgev gene vaccine,2016-02-02,"Qing, Ying; Liu, Jiawen; Huang, Xiaobo; Li, Yaqing; Zhang, Yudi; Chen, Jie; Wen, Xintian; cao, Sanjie; Wen, Yiping; Wu, Rui; Yan, Qigui; Ma, Xiaoping",Virus Genes,,,,document_parses/pdf_json/11b32fd959131a10c460119368638178a512b2da.json,document_parses/pmc_json/PMC7088643.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26837896/; https://doi.org/10.1007/s11262-016-1296-z,18756461.0,3
76932,76932,99147,gs8x2rnj,7633ee09c0059b99608c1cfbeefd19775c0317ff,Medline; PMC,Field Efficacy of an Attenuated Infectious Bronchitis Variant 2 Virus Vaccine in Commercial Broiler Chickens,10.3390/vetsci5020049,PMC6024885,29747397.0,cc-by,egyptian poultry suffer frequent respiratory disease outbreak associated infectious bronchitis virus ibv variant strain egyvarii different vaccination program using imported vaccine failed protect flock field challenge recent study confirmed successful protection using homologous strain live attenuated vaccine study newly developed live attenuated ibvar vaccine representing gi middle east ibv lineage evaluated dayold commercial broiler ibvendemic area commercial broiler flock vaccinated ibvar vaccine dayold age followed ibh day vaccinated flock monitored weekly basis till slaughter age health status growth performance monitored selected viral pathogen realtime rtpcr rrtpcr detection conducted weekly basis finally flock compared nearby farm classical ibh vaccination program result showed ibvar vaccine tolerable dayold broiler chick ibv virus rrtpcr detection limited trachea compared nephropathogenic parent virus respiratory disease problem high mortality reported ibhonly vaccinated flock exposure wildtype egyvarii strain confirmed flock indicated partial ibv gene sequence even though ibvarvaccinated flock performance better flock received ibh ibv elisa enzymelinked immunosorbent assay log haemagglutination inhibition hi antibody mean titer remained high ± ≥ log respectively th day age current study demonstrates safety effectiveness ibvar live attenuated vaccine dayold commercial broiler also combination ibvar classical ibv vaccine confers broader protective immune response ibv endemic area,2018-05-09,"Elhady, Mohamed A.; Ali, Ahmed; Kilany, Walid H.; Elfeil, Wael K.; Ibrahim, Hytham; Nabil, Ahmed; Samir, Ahmed; El Sayed, Magdy",Vet Sci,,,,document_parses/pdf_json/7633ee09c0059b99608c1cfbeefd19775c0317ff.json,document_parses/pmc_json/PMC6024885.xml.json,https://doi.org/10.3390/vetsci5020049; https://www.ncbi.nlm.nih.gov/pubmed/29747397/,13668788.0,3
76955,76955,99173,cvv77f10,04f0b99777001507f9923a8b6d87016c71d5da49,Elsevier; PMC,Canine parvovirus vaccine elicits protection from the inflammatory and clinical consequences of the disease,10.1016/s0264-410x(96)00232-0,PMC7131570,9178474.0,els-covid,inflammatory change following infection central clinical manifestation disease however information regarding change animal disease limited canine parvovirus infected puppy measured level acute phase protein change leukocyte phenotype cell trafficking flow cytometry parameter correlated conventional assessment clinical disease vaccine efficacy study seropositive cpv weekold puppy given three dos cpv containing vaccine developed significant antibody titer remained healthy experimental infection cpvb unvaccinated control developed clinical sign shed virus importantly acute phase protein became elevated lymphopenia neutropenia modulation neutrophilcd detected control vaccinates,1997-05-31,"Yule, Terecita D.; Roth, Mark B.; Dreier, Kimberly; Johnson, Anthony F.; Palmer-Densmore, Melissa; Simmons, Kris; Fanton, Robert",Vaccine,,,,document_parses/pdf_json/04f0b99777001507f9923a8b6d87016c71d5da49.json,,https://www.sciencedirect.com/science/article/pii/S0264410X96002320; https://api.elsevier.com/content/article/pii/S0264410X96002320,2941719.0,3
77013,77013,99244,3c8phatx,b0e519e2224e5ee8dd2303ed3f347e049cb599a2,Medline; PMC,The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses,10.3390/v10040197,PMC5923491,29662026.0,cc-by,although effective antibodybased vaccine developed multiple virus approach far failed human immunodeficiency virus type hiv despite success antiretroviral therapy art turned hiv infection chronic disease reduced number new infection worldwide vaccine hiv still urgently needed discus major reason failure “ classical ” vaccine approach mostly due biological property virus hiv developed multiple mechanism immune escape also account vaccine failure far vaccine candidate able induce broadly neutralizing antibody bnabs primary patient virus different clade however antibody identified subset patient chronic infection shown protect infection animal model reduce viremia first clinical trial detailed characterization guided structurebased reverse vaccinology approach design better hiv envelope env immunogen furthermore conserved env epitope identified promising candidate view clinical application together new vectorbased technology considerable progress achieved recent year towards development effective antibodybased hiv vaccine,2018-04-15,"Ringel, Oliver; Vieillard, Vincent; Debré, Patrice; Eichler, Jutta; Büning, Hildegard; Dietrich, Ursula",Viruses,,,,document_parses/pdf_json/b0e519e2224e5ee8dd2303ed3f347e049cb599a2.json,document_parses/pmc_json/PMC5923491.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29662026/; https://doi.org/10.3390/v10040197,4957751.0,3
77032,77032,99266,lxyvkgdd,703481e322f6c0cc6ee0808b0ed750bb769bf029,Elsevier; Medline; PMC,Development and statistical validation of a guinea pig model for vaccine potency testing against Infectious Bovine Rhinothracheitis (IBR) virus,10.1016/j.vaccine.2010.01.035,PMC7115698,20123054.0,els-covid,infectious bovine rhinothracheitis ibr caused bovine herpesvirus bohv infection distributed worldwide bohv either alone association respiratory cattle pathogen cause significant economic loss livestock industry aim work validate guinea pig model alternative method current bohv vaccine potency testing calf guinea pig immunized two dos vaccine day apart sampled day post vaccination dpv bohv antibody ab response vaccination guinea pig measured elisa virus neutralization vn statistically compared ab response cattle guinea pig model showed dose–response relationship bovh antigen concentration vaccine able discriminate among vaccine containing log difference bohv concentration good repeatability reproducibility cv≤ regression analysis ab titer obtained guinea pig bovine dpv respectively allowed u classify vaccine three potency category “ satisfactory ” “ satisfactory ” “ unsatisfactory ” bovine immunized vaccine corresponding three category experimentally challenged bovh virus level protection measured reduction virus shedding disease severity correlated well vaccine category used data generated experiment included vaccination calf guinea pig reference vaccine known potency placebo commercial vaccine subjected statistical analysis concordance analysis indicated almost perfect agreement model target specie ab titer measured elisa almost perfect substantial agreement ab titer measured vn taken together result indicate developed guinea pig model represents novel reliable tool estimate batchtobatch vaccine potency predict efficacy killed bohv veterinary vaccine,2010-03-16,"Parreño, Viviana; López, María Virginia; Rodriguez, Daniela; Vena, María Marta; Izuel, Mercedes; Filippi, Jorge; Romera, Alejandra; Faverin, Claudia; Bellinzoni, Rodolfo; Fernandez, Fernando; Marangunich, Laura",Vaccine,,,,document_parses/pdf_json/703481e322f6c0cc6ee0808b0ed750bb769bf029.json,document_parses/pmc_json/PMC7115698.xml.json,https://doi.org/10.1016/j.vaccine.2010.01.035; https://api.elsevier.com/content/article/pii/S0264410X10000678; https://www.ncbi.nlm.nih.gov/pubmed/20123054/; https://www.sciencedirect.com/science/article/pii/S0264410X10000678,28281948.0,3
77171,77171,99431,xg3gfpb9,baa0c5016f5f660ff8a76ebed2ed1c2725f41fd0,Medline; PMC,Plant‐made vaccines for humans and animals,10.1111/j.1467-7652.2010.00507.x,PMC7167690,20233333.0,no-cc,concept using plant produce high‐value pharmaceutical vaccine year old year brink realisation established technology original reliance transgenic plant largely given way transient expression proof concept human animal vaccine efficacy animal vaccine established several plant‐produced vaccine phase clinical trial human scheduled regulatory requirement clear ever facility exist manufacture clinic‐grade material original concept cheap edible vaccine given way realisation formulated product required may well injectable technology proven worth mean cheap easily scalable production material need find niche competition established technology realised achievement field well promising new development reviewed rapid‐response vaccine emerging virus pandemic potential bioterror agent,2010-03-11,"Rybicki, Edward P.",Plant Biotechnol J,,,,document_parses/pdf_json/baa0c5016f5f660ff8a76ebed2ed1c2725f41fd0.json,document_parses/pmc_json/PMC7167690.xml.json,https://doi.org/10.1111/j.1467-7652.2010.00507.x; https://www.ncbi.nlm.nih.gov/pubmed/20233333/,42153048.0,3
77174,77174,99434,m5ho8jqp,0020ab317ef923b740c1d3db52083a4e48495f8a,Elsevier; Medline; PMC,SARS-CoV-2 Vaccines: Status Report,10.1016/j.immuni.2020.03.007,PMC7136867,32259480.0,els-covid,sarscov causal agent covid first emerged late china since infected individual caused death globally discus therapeutic prophylactic intervention sarscov focus vaccine development challenge vaccine rapidly developed likely come late affect first wave potential pandemic nevertheless critical lesson learned development vaccine rapidly emerging virus importantly sarscov vaccine essential reducing morbidity mortality virus establishes population,2020-04-06,"Amanat, Fatima; Krammer, Florian",Immunity,,,,document_parses/pdf_json/0020ab317ef923b740c1d3db52083a4e48495f8a.json,document_parses/pmc_json/PMC7136867.xml.json,https://www.sciencedirect.com/science/article/pii/S1074761320301205; https://api.elsevier.com/content/article/pii/S1074761320301205; https://www.ncbi.nlm.nih.gov/pubmed/32259480/; https://doi.org/10.1016/j.immuni.2020.03.007,214753433.0,3
77252,77252,99529,s2v0tpsg,2f254a3799bc354fda7890b34b1d2bea1151e58f,Elsevier; Medline; PMC,Biodegradable polymers for modern vaccine development,10.1016/j.jiec.2019.04.044,PMC7129903,32288512.0,els-covid,traditional vaccine composed either whole pathogen part vaccine however always effective even harmful additional agent known adjuvant necessary increase vaccine safety efficacy review summarizes potential biodegradable material including synthetic natural polymer vaccine delivery material highly biocompatible minimal toxicity biomaterialbased vaccine delivering antigen adjuvant shown improve immune response compared formulation consisting antigen alone therefore material applied modern vaccine development,2019-09-25,"Bose, Rajendran JC; Kim, Minwoo; Chang, Ji Hyun; Paulmurugan, Ramasamy; Moon, James J.; Koh, Won-Gun; Lee, Soo-Hong; Park, Hansoo",Journal of Industrial and Engineering Chemistry,,,,document_parses/pdf_json/2f254a3799bc354fda7890b34b1d2bea1151e58f.json,document_parses/pmc_json/PMC7129903.xml.json,https://api.elsevier.com/content/article/pii/S1226086X19302060; https://www.sciencedirect.com/science/article/pii/S1226086X19302060; https://doi.org/10.1016/j.jiec.2019.04.044; https://www.ncbi.nlm.nih.gov/pubmed/32288512/,149912753.0,3
77270,77270,99549,175igdfk,125b3f6dd69d07e5dac7fa45b6567008bd1244ae,Medline; PMC,Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?,10.3390/v9110318,PMC5707525,29109380.0,cc-by,modified vaccinia virus ankara mva vector choice human veterinary application due strong safety profile immunogenicity vivo use mva mvavectored vaccine human animal disease must comply regulatory requirement pertain environmental risk assessment particularly characterization potential adverse effect human animal environment mva recombinant mva widely believed pose low negligible risk ecosystem health however key aspect mva biology require research order provide data needed evaluate potential risk may occur due use mva mvavectored vaccine purpose paper identify knowledge gap biology mva recombinant mva relevance hazard characterization discus ongoing future experiment aimed providing data necessary fill knowledge gap addition presented argument inclusion uncertainty analysis experimental investigation verifiable worstcase scenario environmental risk assessment mva recombinant mva contribute improved risk assessment mva recombinant mva vaccine,2017-10-29,"Okeke, Malachy I.; Okoli, Arinze S.; Diaz, Diana; Offor, Collins; Oludotun, Taiwo G.; Tryland, Morten; Bøhn, Thomas; Moens, Ugo",Viruses,,,,document_parses/pdf_json/125b3f6dd69d07e5dac7fa45b6567008bd1244ae.json,document_parses/pmc_json/PMC5707525.xml.json,https://doi.org/10.3390/v9110318; https://www.ncbi.nlm.nih.gov/pubmed/29109380/,4802780.0,3
77281,77281,99562,4cia91cq,d690e4df20380e92f907315e831f39116b1c460d,Medline; PMC,Recombinant vesicular stomatitis virus vector vaccines for WHO blueprint priority pathogens,10.1080/21645515.2019.1649532,PMC6816421,31368826.0,cc-by-nc-nd,devastating ebola virus ebov outbreak west africa – flagged need timely development vaccine highthreat pathogen better prepared new epidemic compiled list priority pathogen likely cause future outbreak rd effort therefore paramount rd blueprint httpswwwwhointblueprintprioritydiseasesen end detailed characterization vaccine platform needed vesicular stomatitis virus vsv established robust vaccine vector backbone infectious disease well decade recent clinical trial testing vaccine candidate vsvebov ebov disease added substantial amount clinical data suggest vsv ideal vaccine vector candidate outbreak pathogen review discus insight gained clinical vsvebov vaccine trial well animal study investigating vaccine candidate blueprint pathogen,2019-09-05,"Fathi, Anahita; Dahlke, Christine; Addo, Marylyn M.",Hum Vaccin Immunother,,,,document_parses/pdf_json/d690e4df20380e92f907315e831f39116b1c460d.json,document_parses/pmc_json/PMC6816421.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31368826/; https://doi.org/10.1080/21645515.2019.1649532,199056858.0,3
77325,77325,99614,jjluocxz,fc16b666ad077c0384553e2d04d29128eed3b998,Elsevier; Medline; PMC,Virus-like particle-based vaccines for animal viral infections,10.1016/j.inmuno.2012.08.002,PMC7115488,32287712.0,els-covid,vaccination considered one effective way control pathogen prevent disease human well veterinary field traditional vaccine animal viral disease based inactivated attenuated virus new subunit vaccine gaining attention researcher animal vaccinology among viruslike particle vlps represent one appealing approach opening interesting frontier animal vaccine vlps robust protein scaffold exhibiting welldefined geometry uniformity mimic overall structure native virion lack viral genome often antigenically indistinguishable virus derived present important advantage term safety vlps stimulate strong humoral cellular immune response shown exhibit selfadjuvanting ability addition suitability vaccine homologous virus derived vlps also used vector multimeric presentation foreign antigen vlps therefore shown dramatic effectiveness candidate vaccine nevertheless one veterinary vlpbase vaccine licensed review examine detail current status vlps vaccine strategy veterinary field discus potential advantage challenge technology,2013-09-30,"Crisci, Elisa; Bárcena, Juan; Montoya, María",Inmunología,,,,document_parses/pdf_json/fc16b666ad077c0384553e2d04d29128eed3b998.json,document_parses/pmc_json/PMC7115488.xml.json,https://www.sciencedirect.com/science/article/pii/S021396261200087X; https://api.elsevier.com/content/article/pii/S021396261200087X; https://doi.org/10.1016/j.inmuno.2012.08.002; https://www.ncbi.nlm.nih.gov/pubmed/32287712/,84229205.0,3
77338,77338,99630,b6c46ebn,a6b4e2dd6ed077a4df8600ef70834dbe197895c1,Medline; PMC,Immunogenicity and protective efficacy of orally administered recombinant Lactobacillus plantarum expressing VP2 protein against IBDV in chicken,10.1111/jam.14073,PMC7166448,30118165.0,no-cc,aim develop effective oral vaccine virulent infectious bursal disease virus vvibdv generated two recombinant lactobacillus plantarum strain ppg‐vplp ppg‐tg‐vplp carried tg translational enhancer displayed vp protein surface compared humoral cellular immune response vvibdv chicken method result genetically engineered l plantarum strain ppg‐vplp ppg‐tg‐vplp constitutively expressing vp protein vvibdv found tg enhancer efficiently upregulates vp expression ppg‐tg‐vplp orally administered ppg‐tg‐vplp exhibited significant level protection · vvibdv chicken indicating improved immunogenicity chicken ppg‐tg‐vplp group produced higher level interferon ifn‐γ interleukin il‐ il‐ ppg‐vplp group cd cd lymphocyte count indicated greater stimulation ppg‐tg‐vplp group · · respectively ppg‐vplp group · · respectively thus ppg‐tg‐vplp could induce strong humoral cellular immune response vvibdv conclusion recombinant l plantarum express ppg‐tg‐vp promising candidate oral vaccine development vvibdv significance impact study recombinant lactobacillus delivery system provides promising strategy vaccine development vvibdv chicken,2018-09-27,"Maqsood, I.; Shi, W.; Wang, L.; Wang, X.; Han, B.; Zhao, H.; Nadeem, A.M.; Moshin, B.S.; Saima, K.; Jamal, S.S.; Din, M.F.; Xu, Y.; Tang, L.; Li, Y.",J Appl Microbiol,,,,document_parses/pdf_json/a6b4e2dd6ed077a4df8600ef70834dbe197895c1.json,document_parses/pmc_json/PMC7166448.xml.json,https://doi.org/10.1111/jam.14073; https://www.ncbi.nlm.nih.gov/pubmed/30118165/,52017058.0,3
77384,77384,99686,uea9kwge,caacab8201dadba7c322aaebad07309ef12e3c93,Medline; PMC,Bacterial Outer Membrane Vesicles (OMVs)-Based Dual Vaccine for Influenza A H1N1 Virus and MERS-CoV,10.3390/vaccines7020046,PMC6631769,31141982.0,cc-by,vaccination functional medical intervention prophylactically control severe disease caused humantohuman animaltohuman transmissible viral pathogen annually seasonal influenza epidemic attack human population leading – thousand deathsyear worldwide recently novel middle east respiratory syndrome coronavirus emerged together two virus present significant public health burden area circulate herein generated bacterial outer membrane vesicle omvsbased vaccine presenting antigenic stable chimeric fusion protein htype haemagglutinin ha pandemic influenza virus hn strain hnpdm receptor binding domain rbd middle east respiratory syndrome coronavirus merscov omvshrbd result showed chimeric antigen could induce specific neutralizing antibody strain leading protection immunized mouse hnpdm efficient neutralization merscov study demonstrate omvsbased vaccine presenting viral antigen provide safe reliable approach protect two different viral infection,2019-05-28,"Shehata, Mahmoud M.; Mostafa, Ahmed; Teubner, Lisa; Mahmoud, Sara H.; Kandeil, Ahmed; Elshesheny, Rabeh; Boubak, Thamer A.; Frantz, Renate; Pietra, Luigi La; Pleschka, Stephan; Osman, Ahmed; Kayali, Ghazi; Chakraborty, Trinad; Ali, Mohamed A.; Mraheil, Mobarak Abu",Vaccines (Basel),,,,document_parses/pdf_json/caacab8201dadba7c322aaebad07309ef12e3c93.json,document_parses/pmc_json/PMC6631769.xml.json,https://doi.org/10.3390/vaccines7020046; https://www.ncbi.nlm.nih.gov/pubmed/31141982/,169040645.0,3
77408,77408,99712,3z6yvnje,,Elsevier; Medline; PMC; WHO,A vaccine is still a long way off,10.1016/s0262-4079(20)30831-9,PMC7195342,32372831.0,els-covid,trial way cant count vaccine get u crisis,2020-05-02,"Arnold, Carrie",New Scientist,,#155182,,,,https://www.ncbi.nlm.nih.gov/pubmed/32372831/; https://www.sciencedirect.com/science/article/pii/S0262407920308319; https://api.elsevier.com/content/article/pii/S0262407920308319; https://doi.org/10.1016/s0262-4079(20)30831-9,218468733.0,3
77452,77452,99766,l0xleflo,ab26098d2e9876c05c8c1fd3d30d45a749b944e3,Medline; PMC,The Development of an AIDS Mucosal Vaccine,10.3390/v2010283,PMC3185548,21994611.0,cc-by,well known mucosal tissue contain largest surface area human body front line natural host defense various pathogen fact infectious disease pathogen probably gain entry susceptible human host open mucosal surface human immunodeficiency virus type one hiv mainly sexually transmitted virus also primarily target vaginal gastrointestinal mucosa entry site viral transmission seeding replication amplification since hiv establishes early replication vaginal rectal mucosal tissue induction sufficient mucosal immunity initial site hiv transmission becomes essential protective vaccine however despite fact current conventional vaccine strategy remained unsuccessful preventing hiv infection sufficient financial support resource yet given develop vaccine able elicit protective mucosal immunity sexual transmission interestingly chinese ancestor invented variolation intranasal administration one thousand year ago led discovery successful smallpox vaccine final eradication disease hope mankind development mucosal aid vaccine ultimately help control aid pandemic order discover effective mucosal aid vaccine necessary deep understanding mucosal immunology test various mucosal vaccination strategy,2010-01-22,"Tang, Xian; Chen, Zhiwei",Viruses,,,,document_parses/pdf_json/ab26098d2e9876c05c8c1fd3d30d45a749b944e3.json,document_parses/pmc_json/PMC3185548.xml.json,https://doi.org/10.3390/v2010283; https://www.ncbi.nlm.nih.gov/pubmed/21994611/,114031.0,3
77548,77548,99878,hf3ke33v,c7482fd487c4a1a40e25b393ba04466922d434b1; 210a017c1867396ae38e39ad420311e3fadbb897,Elsevier; Medline; PMC,Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys,10.1016/j.vaccine.2010.01.050,PMC2844349,20139039.0,green-oa,human parainfluenza virus hpivs common cause severe pediatric respiratory viral disease characterized wildtype hpiv infection vitro model human airway epithelium hae found virus replicates high titer shed apically target ciliated cell induces minimal cytopathology replication experimental live attenuated hpiv vaccine strain containing temperature sensitive t nonts attenuating mutation restricted fold compared rhpivwt hae °c exhibited little productive replication °c restriction paralleled attenuation upper lower respiratory tract african green monkey supporting hae model appropriate convenient system characterizing hpiv vaccine candidate,2010-03-01,"Schaap-Nutt, Anne; Scull, Margaret A.; Schmidt, Alexander C.; Murphy, Brian R.; Pickles, Raymond J.",Vaccine,,,,document_parses/pdf_json/c7482fd487c4a1a40e25b393ba04466922d434b1.json; document_parses/pdf_json/210a017c1867396ae38e39ad420311e3fadbb897.json,document_parses/pmc_json/PMC2844349.xml.json,http://europepmc.org/articles/pmc2844349?pdf=render; https://www.ncbi.nlm.nih.gov/pubmed/20139039/; https://api.elsevier.com/content/article/pii/S0264410X10001040; https://doi.org/10.1016/j.vaccine.2010.01.050; https://www.sciencedirect.com/science/article/pii/S0264410X10001040,24149410.0,3
77553,77553,99885,b855tj7x,a9881c47e8acfdbe2fd93305c77d6fd48fbbf24c,Elsevier; Medline; PMC,"Report from the World Health Organization’s third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8–10th June 2016",10.1016/j.vaccine.2016.10.090,PMC7131228,28262332.0,els-covid,third meeting ’ product development vaccine advisory committee pdvac held june remit revisit pathogen area significant progress occurred since recommendation meeting well consider new advance development vaccine pathogen since previous meeting significant progress made regulatory approval first malaria dengue vaccine first phase iii trial respiratory syncytial virus rsv vaccine candidate started elderly pregnant woman addition pdvac also supported vaccine development effort important emerging pathogen including middle eastern coronavirus mers cov zika virus trial hiv tuberculosis vaccine candidate steadily progressing towards pivotal data point leading norovirus vaccine candidate entered phase iib efficacy study ’ immunization vaccine biologicals ivb department actively working several pathogen area recommendation pdvac well continuing horizon scanning advance development vaccine may benefit low middle income country lmics recent licensure enterovirus ev vaccine china following discussion ’ strategic advisory group expert sage immunization pdvac also look beyond licensure consider data need vaccine recommendation implementation reduce delay vaccine approval vaccine impact,2019-11-28,"Giersing, Birgitte K.; Vekemans, Johan; Nava, Samantha; Kaslow, David C.; Moorthy, Vasee",Vaccine,,,,document_parses/pdf_json/a9881c47e8acfdbe2fd93305c77d6fd48fbbf24c.json,document_parses/pmc_json/PMC7131228.xml.json,https://doi.org/10.1016/j.vaccine.2016.10.090; https://www.ncbi.nlm.nih.gov/pubmed/28262332/; https://api.elsevier.com/content/article/pii/S0264410X16312051; https://www.sciencedirect.com/science/article/pii/S0264410X16312051,205602961.0,3
77614,77614,99955,bs194n2m,5a1dd8ceedf59e4e8746320cdac85836e6cfc751,Elsevier; Medline; PMC,Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administrated with different routes in mouse model,10.1016/j.vaccine.2009.01.021,PMC7115532,19186202.0,els-covid,development strategy augment immunogenicity dna vaccine critical improving clinical utility one strategy involves using different immune route dna vaccine present study immunogenicity sarscov nucleocapsid dna vaccine induced using current routine vaccination route intramuscularly electroporation orally using liveattenuated salmonella typhimurium compared mouse model comparison three vaccination route indicated immunization intramuscularly induced moderate cell response antibody response mouse administrated electroporation induced highest antibody response among three immunization group midlevel cellular response contrast orally dna vaccine evoked vigorous cell response weak antibody production result indicated distinct type immune response generated different route dna immunization addition result also show delivery dna vaccine electroporation orally using liveattenuated salmonella vivo effective method increase immune response study could carried using combination strategy oral electroporation immunization stimulate higher cellular humoral immune response,2009-03-10,"Hu, Hui; Huang, Xianqing; Tao, Ling; Huang, Yi; Cui, Bao-an; Wang, Hanzhong",Vaccine,,,,document_parses/pdf_json/5a1dd8ceedf59e4e8746320cdac85836e6cfc751.json,document_parses/pmc_json/PMC7115532.xml.json,https://api.elsevier.com/content/article/pii/S0264410X09000590; https://doi.org/10.1016/j.vaccine.2009.01.021; https://www.sciencedirect.com/science/article/pii/S0264410X09000590; https://www.ncbi.nlm.nih.gov/pubmed/19186202/,5442217.0,3
77674,77674,100024,djyd1bbd,8cef766849d0d8ad7a5ff33d7f66299de03cf583,Medline; PMC,Pathogenicity and immunogenicity of attenuated porcine epidemic diarrhea virus PC22A strain in conventional weaned pigs,10.1186/s12917-018-1756-x,PMC6329175,30634958.0,cc-by,background porcine epidemic diarrhea virus pedv cause diarrhea age pig – mortality rate neonatal piglet united state inactivated subunit pedv vaccine pregnant sow available fail induce sufficient protection neonatal piglet farrowed pedv naïve sow safe efficacious live attenuated vaccine prime mucosal immune response urgently needed study evaluated safety efficacy two attenuated pedv vaccine candidate emerging nons indel pedv strain pca th cell culture passage level clone pc th passage level p weaned pig result four group dayold weaned pig inoculated orally pedv pcap virulent pc p mock respectively challenged p virus day postinoculation dpi inoculation p caused diarrhea pig high level fecal viral rna shedding pc p cause diarrhea pig although viral rna detected feces pig except one pcinoculated pig compared p group p pcinoculated pig higher serum pedvspecific igg viral neutralizing vn antibody ab titer dpi challenge pig p group pig pc p mock group diarrhea compared p group pig pc group rapid decline fecal pedv rna shedding titer higher titer serum pedvspecific igg iga vn ab higher number intestinal iga absecreting cell conclusion pedv pca pc p fully attenuated weaned pig failed elicit protection virulent p challenge pc induced higher pedvspecific antibody response p post inoculation resulting greater anamnestic response post challenge therefore pc potentially could tested priming vaccine modified using reverse genetics also administered multiple dos combined inactivated subunit vaccine adjuvant pedv vaccination regimen whose efficacy tested future electronic supplementary material online version article sx contains supplementary material available authorized user,2019-01-11,"Lin, Chun-Ming; Ghimire, Shristi; Hou, Yixuan; Boley, Patricia; Langel, Stephanie N.; Vlasova, Anastasia N.; Saif, Linda J.; Wang, Qiuhong",BMC Vet Res,,,,document_parses/pdf_json/8cef766849d0d8ad7a5ff33d7f66299de03cf583.json,document_parses/pmc_json/PMC6329175.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30634958/; https://doi.org/10.1186/s12917-018-1756-x,58011549.0,3
77708,77708,100065,mt8zsbhb,,Medline; WHO,Coronavirus Pandemic—Therapy and Vaccines,10.3390/biomedicines8050109,,32375268.0,unk,current coronavirus covid pandemic originated wuhan china raised significant social psychological economic concern addition direct medical issue rapid spread severe acute respiratory syndromecoronavirus sarscov almost every country globe failure contain infection contributed fear panic worldwide lack available efficient antiviral drug vaccine worsened situation reason overstated accelerated effort development novel drug vaccine needed context novel approach gene therapy vaccine development essential previous experience sars merscoronavirus vaccine drug development project targeted glycoprotein epitope monoclonal antibody angiotensin receptor blocker gene silencing technology may useful covid moreover existing antiviral used type viral infection considered urgent action necessary review aim providing background coronavirus genetics biology example therapeutic vaccine strategy taken potential innovative novel approach progress,2020,"Lundstrom, Kenneth","Biomedicines 2020, Vol. 8, Page 109",,#155051,,,,https://www.ncbi.nlm.nih.gov/pubmed/32375268/; https://doi.org/10.3390/biomedicines8050109,218533946.0,3
77716,77716,100073,neclg3gb,f6d2afb2ec44d8656972ea79f8a833143bbeb42b,Medline; PMC,Virus-Vectored Influenza Virus Vaccines,10.3390/v6083055,PMC4147686,25105278.0,cc-by,despite availability inactivated vaccine licensed year influenza virus continues cause morbidity mortality worldwide constant evolution circulating influenza virus strain emergence new strain diminishes effectiveness annual vaccine rely match circulating influenza strain thus continued need new efficacious vaccine conferring crossclade protection avoid need biannual reformulation seasonal influenza vaccine recombinant virusvectored vaccine appealing alternative classical inactivated vaccine virus vector enable native expression influenza antigen even virulent influenza virus expressed context vector improve immunogenicity addition vectored vaccine often enables delivery vaccine site inductive immunity respiratory tract enabling protection influenza virus infection moreover ability readily manipulate virus vector produce novel influenza vaccine may provide quickest path toward universal vaccine protecting influenza virus review discus experimental virusvectored vaccine use human comparing licensed vaccine hurdle faced licensure nextgeneration influenza virus vaccine,2014-08-07,"Tripp, Ralph A.; Tompkins, S. Mark",Viruses,,,,document_parses/pdf_json/f6d2afb2ec44d8656972ea79f8a833143bbeb42b.json,document_parses/pmc_json/PMC4147686.xml.json,https://doi.org/10.3390/v6083055; https://www.ncbi.nlm.nih.gov/pubmed/25105278/,24036862.0,3
77728,77728,100088,gl0wiyt2,,Medline; WHO,Progress and Prospects on Vaccine Development against SARS-CoV-2,10.3390/vaccines8020153,,32235387.0,unk,december outbreak pneumonia caused novel coronavirus severe acute respiratory syndrome coronavirus sarscov led serious pandemic china country worldwide far confirmed case diagnosed nearly country causing globally death currently epidemic still spreading effective mean prevent infection vaccine proved effective economical mean prevent control infectious disease several country company institution announced program progress vaccine development virus vaccine design preparation entered efficacy evaluation animal initial clinical trial review mainly focused progress prospect field vaccine development sarscov,2020,"Zhang, Jinyong; Zeng, Hao; Gu, Jiang; Li, Haibo; Zheng, Lixin; Zou, Quanming","Vaccines 2020, Vol. 8, Page 153",,#17464,,,,https://www.ncbi.nlm.nih.gov/pubmed/32235387/; https://doi.org/10.3390/vaccines8020153,214768183.0,3
77739,77739,100100,xorj8tnz,2813c9a864720f35199261a3ab219750d3a5daeb,Medline; PMC,The Characterization of Immunoprotection Induced by a cDNA Clone Derived from the Attenuated Taiwan Porcine Epidemic Diarrhea Virus Pintung 52 Strain,10.3390/v10100543,PMC6213177,30287770.0,cc-by,porcine epidemic diarrhea virus pedv pose great threat global swine industry unreliable protection induced currently available vaccine remains major challenge previously generated genogroup b gb pedv taiwan pintung pedvpt strain pedvptp determined promising host immune response virulent pedvptp strain study attenuation determinant pedvptp establish pedvptpbased recombinant vector vaccine platform antigenicity modification ipedvptp fulllength cdna clone pedvptp established comparing parental pedvptp virus ipedvptp virus showed efficient replication kinetics delayed decline viral load similar much uniform plaque size vero cell weekold piglet model fecal viral shedding observed pedvptpinoculated piglet whereas inoculated ipedvptp showed neither detectable fecal viral shedding pedvassociated clinical sign moreover inoculation ipedvptp elicited comparable level antipedv specific plasma igg fecalsalivary iga neutralizing antibody titer similar le effective immunoprotection virulent pedvptp challenge compared parental pedvptp present study infectious cdna clone attenuated gb pedv strain successfully generated first time vitro vivo data indicate ipedvptp attenuated remains immunogenic compared parental pedvptp viral stock successful development ipedvptp cdna clone could allow manipulation viral genome study viral pathogenesis facilitate rapid development effective vaccine,2018-10-04,"Kao, Chi-Fei; Chiou, Hue-Ying; Chang, Yen-Chen; Hsueh, Cheng-Shun; Jeng, Chian-Ren; Tsai, Pei-Shiue; Cheng, Ivan-Chen; Pang, Victor Fei; Chang, Hui-Wen",Viruses,,,,document_parses/pdf_json/2813c9a864720f35199261a3ab219750d3a5daeb.json,document_parses/pmc_json/PMC6213177.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30287770/; https://doi.org/10.3390/v10100543,52922423.0,3
77744,77744,100105,0p93a2o2,99b26ec52b0fa51de665f2897a4273ffe6eccabd,Elsevier; Medline; PMC,Efficient priming of CD4 T cells by Langerin-expressing dendritic cells targeted with porcine epidemic diarrhea virus spike protein domains in pigs,10.1016/j.virusres.2016.10.007,PMC7114527,27784629.0,els-covid,porcine epidemic diarrhea virus pedv first emerged united state causing high mortality morbidity neonatal piglet immense economic loss swine industry pedv alphacoronavirus replicating primarily porcine intestinal cell pedv vaccine available asia europe conditionallylicensed vaccine recently became available united state efficacy vaccine eliminating pedv swine population questionable study immunogenicity subunit vaccine based spike protein pedv directly targeted porcine dendritic cell dc expressing langerin assessed pedv antigen delivered dendritic cell singlechain antibody specific langerin targeted cell stimulated cholera toxin adjuvant approach known “ dendritic cell targeting ” greatly improved pedv antigenspecific cell interferonγ response cdposcdpos cell compartment pig early day upon transdermal administration vaccine protein targeted langerinpos dc systemically intramuscular vaccination induced higher serum igg iga response pig though response require booster dose magnitude cell response lower compared transdermal vaccination conclude pedv spike protein domain targeting langerinexpressing dendritic cell significantly increased cd cell immune response pig result indicate immunogenicity protein subunit vaccine greatly enhanced direct targeting vaccine antigen desirable dendritic cell subset pig,2017-01-02,"Subramaniam, Sakthivel; Cao, Dianjun; Tian, Debin; Cao, Qian M.; Overend, Christopher; Yugo, Danielle M.; Matzinger, Shannon R.; Rogers, Adam J.; Heffron, C. Lynn; Catanzaro, Nicholas; Kenney, Scott P.; Opriessnig, Tanja; Huang, Yao-Wei; Labarque, Geoffrey; Wu, Stephen Q.; Meng, Xiang-Jin",Virus Research,,,,document_parses/pdf_json/99b26ec52b0fa51de665f2897a4273ffe6eccabd.json,document_parses/pmc_json/PMC7114527.xml.json,https://www.sciencedirect.com/science/article/pii/S0168170216304968; https://api.elsevier.com/content/article/pii/S0168170216304968; https://www.ncbi.nlm.nih.gov/pubmed/27784629/; https://doi.org/10.1016/j.virusres.2016.10.007,12708864.0,3
77769,77769,100133,138mbii8,7eb68a38a675a7317fdf4ca2c2030d96f3226861,Elsevier; PMC,Overlapping synthetic peptides as vaccines,10.1016/j.vaccine.2006.04.070,PMC7127786,16793181.0,els-covid,several vaccine strategy aim generate cellmediated immunity cmi microorganism tumor epitopebased vaccine offer advantage knowledge specific epitope frequency major histocompatibility complex mhc allele required show using promiscuous overlapping synthetic peptide osp immunogen generated peptidespecific cmi vaccinated outbred mouse different strain inbred mouse cmi response also recognized viral protein osp immunogen also induced cmi ex vivo dendritic celltcell cocultures involving cell individual different hla haplotype thus broad cmi induced osp different experimental setting using different immunogen without identifying either epitope mhc background vaccinee,2006-09-11,"Jiang, Shisong; Song, Ruijiang; Popov, Sergei; Mirshahidi, Saied; Ruprecht, Ruth M.",Vaccine,,,,document_parses/pdf_json/7eb68a38a675a7317fdf4ca2c2030d96f3226861.json,document_parses/pmc_json/PMC7127786.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X06005949; https://api.elsevier.com/content/article/pii/S0264410X06005949,13369333.0,3
77786,77786,100156,b6bm8do1,17b715fd64ea139c0ed35b555de365b47585da64,Medline; PMC,Developing vaccines against epidemic-prone emerging infectious diseases,10.1007/s00103-019-03061-2,PMC6925075,31776599.0,cc-by,today ’ world characterized increasing population density human mobility urbanization climate ecological change global dynamic various effect including increased appearance emerging infectious disease eids pose growing threat global health security outbreak eids like – ebola outbreak west africa current ebola outbreak democratic republic congo drc put population low middleincome country lmic risk term morbidity mortality also significant impact economic growth affected region beyond coalition epidemic preparedness innovation cepi innovative global partnership public private philanthropic civil society organization launched result consensus coordinated international intergovernmental plan needed develop deploy new vaccine prevent future epidemic cepi focusing supporting candidate vaccine world health organization blueprint priority pathogen merscov nipah virus lassa fever virus rift valley fever virus well chikungunya virus watch list current vaccine portfolio contains wide variety technology ranging across recombinant viral vector nucleic acid recombinant protein support accelerate vaccine development cepi also support science project related development biological standard assay animal model epidemiological study diagnostics well build capacity future clinical trial riskprone context,2019-11-27,"Bernasconi, Valentina; Kristiansen, Paul A.; Whelan, Mike; Román, Raúl Gómez; Bettis, Alison; Yimer, Solomon Abebe; Gurry, Céline; Andersen, Svein R.; Yeskey, Debra; Mandi, Henshaw; Kumar, Arun; Holst, Johan; Clark, Carolyn; Cramer, Jakob P.; Røttingen, John-Arne; Hatchett, Richard; Saville, Melanie; Norheim, Gunnstein",Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz,,,,document_parses/pdf_json/17b715fd64ea139c0ed35b555de365b47585da64.json,document_parses/pmc_json/PMC6925075.xml.json,https://doi.org/10.1007/s00103-019-03061-2; https://www.ncbi.nlm.nih.gov/pubmed/31776599/,208302266.0,3
77790,77790,100162,m2nupp4k,dc4f4242dc4a46aa24d1361fcb30f100b046f0f0,Elsevier; Medline; PMC; WHO,The Challenges of Vaccine Development against a New Virus during a Pandemic,10.1016/j.chom.2020.04.021,PMC7219397,32407708.0,no-cc,rapid emergence highly pathogenic readily transmissible coronavirus resulted global pandemic affecting million destabilizing economy catastrophe triggered clarion call immediate deployment protective vaccine describe unique challenge developing vaccine sarscov pandemic setting,2020-05-13,"Diamond, Michael S.; Pierson, Theodore C.",Cell Host Microbe,,#245639,,document_parses/pdf_json/dc4f4242dc4a46aa24d1361fcb30f100b046f0f0.json,document_parses/pmc_json/PMC7219397.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32407708/; https://api.elsevier.com/content/article/pii/S1931312820302481; https://www.sciencedirect.com/science/article/pii/S1931312820302481; https://doi.org/10.1016/j.chom.2020.04.021,218615167.0,3
77838,77838,100224,y4wq215a,cda3a66723cc2ddc6d3caa37dd77c539eeff01d7,Elsevier; Medline; PMC,The immunoreactivity of a chimeric multi-epitope DNA vaccine against IBV in chickens,10.1016/j.bbrc.2008.09.125,PMC7117539,18840402.0,els-covid,epitopebased vaccine designed induce cellular immune response antibody response specific infectious bronchitis virus ibv developed mean increasing vaccine potency study selected seven epitope spike spike nucleocapsid n protein constructed multiepitope dna vaccine dayold chicken immunized intramuscularly multiepitope dna vaccine encapsulated liposome boosted two week later challenged virulent ibv strain five week post booster result showed multiepitope dna vaccine led dramatic augmentation humoral cellular response provided rate immune protection novel immunogenic chimeric multiepitope dna vaccine revealed study provided new candidate target ibv vaccine development,2008-12-05,"Tian, Lang; Wang, Hong-ning; Lu, Dan; Zhang, Yun-fei; Wang, Ting; Kang, Run-ming",Biochemical and Biophysical Research Communications,,,,document_parses/pdf_json/cda3a66723cc2ddc6d3caa37dd77c539eeff01d7.json,document_parses/pmc_json/PMC7117539.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/18840402/; https://www.sciencedirect.com/science/article/pii/S0006291X08018822; https://api.elsevier.com/content/article/pii/S0006291X08018822; https://doi.org/10.1016/j.bbrc.2008.09.125,1884089.0,3
77889,77889,100288,djfz1jcq,f663de9a2ea65a8e0a356b0ad74de465208e0a78,Elsevier; Medline; PMC,Evaluating interest in an influenza A(H5N1) vaccine among laboratory workers who work with highly-pathogenic avian influenza viruses in the United States,10.1016/j.vaccine.2017.10.104,PMC5759037,29199043.0,green-oa,background highly pathogenic avian influenza hpai virus found poultry wild bird occasionally infect human cause serious disease advisory committee immunization practice acip reviewed data one licensed asoadjuvanted influenza ahn vaccine consideration use interpandemic period among person occupational exposure guide vaccine policy decision conducted survey laboratory worker ass demand hpai vaccination method designed anonymous web survey epiinfo collect information demographic type work time spent hpai virus interest hpai vaccination eligible participant identified entity registered united state department agriculture ’ agricultural select agent program emailed electronic survey personnel biosafety level enhanced bsle laboratory access surveyed descriptive analysis performed result overall response received principal investigator research scientist technician postdoctoral fellow student others estimated response rate among laboratory personnel responding principal investigator one hundred respondent reported working bsle area hpai experiment occurred mean time – h per week overall interested receiving ahn vaccine role interest highest among student among spent time bsle area said might interested vaccine believed would provide additional protection current safety practice conclusion half responding laboratory worker interested receiving influenza ahn vaccine hpai vaccination laboratory worker risk occupational exposure could used along existing safety practice protect population,2018-01-01,"Russell, Kate E.; Bresee, J.S.; Katz, J.M.; Olsen, S.J.",Vaccine,,,,document_parses/pdf_json/f663de9a2ea65a8e0a356b0ad74de465208e0a78.json,document_parses/pmc_json/PMC5759037.xml.json,https://doi.org/10.1016/j.vaccine.2017.10.104; https://www.ncbi.nlm.nih.gov/pubmed/29199043/; https://www.sciencedirect.com/science/article/pii/S0264410X17315360; https://api.elsevier.com/content/article/pii/S0264410X17315360,4787611.0,3
77909,77909,100313,43pomco2,8725525a25df106483e3c6d8ea5794519bb695c5,Elsevier; Medline; PMC,The use of genomics in microbial vaccine development,10.1016/j.drudis.2008.12.007,PMC7108364,19150507.0,els-covid,vaccination one effective tool prevention infectious disease availability complete genome sequence together progression highthroughput technology functional structural genomics led new paradigm vaccine development pangenomic reverse vaccinology comparison sequence data multiple isolates specie pathogen increase opportunity identification novel vaccine candidate overall conventional empiric approach vaccine development replaced vaccine design recent development synthetic genomics may provide opportunity design vaccine,2009-03-31,"Bambini, Stefania; Rappuoli, Rino",Drug Discovery Today,,,,document_parses/pdf_json/8725525a25df106483e3c6d8ea5794519bb695c5.json,document_parses/pmc_json/PMC7108364.xml.json,https://doi.org/10.1016/j.drudis.2008.12.007; https://www.ncbi.nlm.nih.gov/pubmed/19150507/; https://api.elsevier.com/content/article/pii/S1359644608004340; https://www.sciencedirect.com/science/article/pii/S1359644608004340,45810143.0,3
77955,77955,100373,3br89vgb,e0ef85a120c99787e1ec818a0d0251410d3d04c0,Elsevier; PMC,A minor groove binder probe real-time PCR assay for discrimination between type 2-based vaccines and field strains of canine parvovirus,10.1016/j.jviromet.2006.03.030,PMC7119799,16682086.0,els-covid,minor groove binder mgb probe assay developed discriminate type based vaccine field strain canine parvovirus cpv considering cpv vaccine contain old type longer circulating canine population two mgb probe specific cpv antigenic variant type b c respectively labeled different fluorophores mgb probe assay able discriminate correctly old type variant detection limit dna copy good reproducibility quantitation viral dna load accurate demonstrated comparing cpv dna titre calculated mean taqman assay recognising cpv type assay ensure resolution diagnostic problem dog showing cpv disease shortly cpv vaccination although discriminate field strain type bbased vaccine recently licensed market country,2006-09-30,"Decaro, Nicola; Elia, Gabriella; Desario, Costantina; Roperto, Sante; Martella, Vito; Campolo, Marco; Lorusso, Alessio; Cavalli, Alessandra; Buonavoglia, Canio",Journal of Virological Methods,,,,document_parses/pdf_json/e0ef85a120c99787e1ec818a0d0251410d3d04c0.json,document_parses/pmc_json/PMC7119799.xml.json,https://api.elsevier.com/content/article/pii/S0166093406001248; https://www.sciencedirect.com/science/article/pii/S0166093406001248,20338916.0,3
78021,78021,100456,7vrm081c,af1dcae16eae4f6bca52da94618bc14aacc46342; 73c8af41cfdbf52c0dfba37727e3b94cb56b495e,BioRxiv; MedRxiv,The Essential Facts of Wuhan Novel Coronavirus Outbreak in China and Epitope-based Vaccine Designing against COVID-19,10.1101/2020.02.05.935072,,,medrxiv,wuhan novel coronavirus disease covid outbreak become global outbreak raised concern scientific community design discover definitive cure deadly virus caused death numerous infected people upon infection spreading date antiviral therapy vaccine available effectively combat infection caused virus study conducted design possible epitopebased subunit vaccine sarscov virus using approach reverse vaccinology immunoinformatics upon continual computational experimentation three possible vaccine construct designed one vaccine construct selected best vaccine based molecular docking study supposed effectively act sarscov later molecular dynamic simulation silico codon adaptation experiment carried order check biological stability find effective mass production strategy selected vaccine hopefully study contribute uphold present effort research secure definitive treatment lethal virus,2020-02-11,"Sarkar, Bishajit; Ullah, Md. Asad; Johora, Fatema Tuz; Taniya, Masuma Afrin; Araf, Yusha",bioRxiv,,,,document_parses/pdf_json/af1dcae16eae4f6bca52da94618bc14aacc46342.json; document_parses/pdf_json/73c8af41cfdbf52c0dfba37727e3b94cb56b495e.json,,https://doi.org/10.1101/2020.02.05.935072,211096261.0,3
78063,78063,100512,ep46lzeo,cc2e1459e6af042a520cfd46845a69f9767fc604,Medline; PMC,Recent advances in influenza vaccines,10.12688/f1000research.22611.1,PMC7194468,32399192.0,cc-by,seasonal influenza remains major public health problem responsible hundred thousand death every year mostly elderly people despite wide availability vaccine multiple problem decreasing effectiveness vaccination program include viral variability hence requirement match strain estimating become prevalent season problem associated vaccine adjuvant production route administration well perceived lower vaccine efficiency older adult clinical protection still suboptimal reason vaccine uptake remains low country effort improve effectiveness influenza vaccine include developing universal vaccine independent circulating strain particular season stimulating cellular well humoral response especially elderly commentary ass progress last year towards achieving aim since beginning unprecedented international academic industrial effort develop effective vaccine new coronavirus sarscov diverted attention away influenza many lesson learned one synergize mutual advantage unlike sars epidemic hope sarscov pandemic influenza eliminated thus effort improve influenza vaccine remain crucial importance,2020-04-28,"Pawelec, Graham; McElhaney, Janet",F1000Res,,,,document_parses/pdf_json/cc2e1459e6af042a520cfd46845a69f9767fc604.json,document_parses/pmc_json/PMC7194468.xml.json,https://doi.org/10.12688/f1000research.22611.1; https://www.ncbi.nlm.nih.gov/pubmed/32399192/,216651155.0,3
78069,78069,100520,u441gk55,c247bb2306aa92b3e07dab90141653dd34c92254,Medline; PMC,Immunosenescence and Influenza Vaccine Efficacy,10.1007/978-3-540-92165-3_20,PMC7121450,19768417.0,no-cc,number protective immune function decline age along physiological anatomical change contributing increased susceptibility older adult infectious disease suboptimal protective immune response vaccination influenza vaccination costeffective strategy prevent complication influenza viral infection however immunogenicity effectiveness currently licensed vaccine united state – preventing complication arising influenza preventing death cause winter month older adult hence crucial understand molecular mechanism lead immune dysfunction function age appropriate strategy developed enhance disease resistance immunogenicity preventive vaccine including influenza vaccine older adult population,2009-06-15,"Sambhara, Suryaprakash; McElhaney, Janet E.",Vaccines for Pandemic Influenza,,,,document_parses/pdf_json/c247bb2306aa92b3e07dab90141653dd34c92254.json,document_parses/pmc_json/PMC7121450.xml.json,https://doi.org/10.1007/978-3-540-92165-3_20; https://www.ncbi.nlm.nih.gov/pubmed/19768417/,22008128.0,3
78109,78109,100572,vt9pbw85,c3fe4fb2909b5d4ca97c2a19c69bb3ed1102a555,Medline; PMC,Virus like particle-based vaccines against emerging infectious disease viruses,10.1007/s12250-016-3756-y,PMC7090901,27405928.0,no-cc,emerging infectious disease major threat human health severe viral disease outbreak occur developing region health condition poor increased international travel business possibility eventually transmitting infectious virus different country increasing effective approach preventing viral disease vaccination however vaccine currently available numerous viral disease viruslike particle vlps engineered vaccine candidate studied decade vlps constructed viral protein expression various expression system promote selfassembly protein structure resembling virus particle vlps antigenicity similar native virus noninfectious lack key viral genetic material vlp vaccine attracted considerable research interest offer several advantage traditional vaccine study shown vlp vaccine stimulate humoral cellular immune response may offer effective antiviral protection review recent development vlpbased vaccine several highly virulent emerging reemerging infectious disease infectious agent discussed include rna virus different virus family arenaviridae bunyaviridae caliciviridae coronaviridae filoviridae flaviviridae orthomyxoviridae paramyxoviridae togaviridae family,2016-07-11,"Liu, Jinliang; Dai, Shiyu; Wang, Manli; Hu, Zhihong; Wang, Hualin; Deng, Fei",Virol Sin,,,,document_parses/pdf_json/c3fe4fb2909b5d4ca97c2a19c69bb3ed1102a555.json,,https://www.ncbi.nlm.nih.gov/pubmed/27405928/; https://doi.org/10.1007/s12250-016-3756-y,15492156.0,3
78145,78145,100612,3c68yz4j,54fb86ff6dd6fae05b49336d96dbf7823f73f3d6,Elsevier; PMC,Chapter 9 Global Regulatory Guidelines for Vaccines,10.1016/b978-0-12-394810-6.00009-5,PMC7149671,,els-covid,past vaccine considered inherently safe limited nonclinical testing used required however stringent nonclinical testing guideline introduced novel vaccine case marketed vaccine attempting registration new market given vaccine typically administered healthy individual often infant safety consideration become even important technology allowing development novel vaccine type developed dna vaccine delivered vector system adenoviral vector use adjuvant standard aluminumbased one novel delivery system electrostimulation also led additional testing requirement chapter describes current regulatory expectation preclinical development vaccine,2013-12-31,"Plitnick, Lisa M.","Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics",,,,document_parses/pdf_json/54fb86ff6dd6fae05b49336d96dbf7823f73f3d6.json,document_parses/pmc_json/PMC7149671.xml.json,https://www.sciencedirect.com/science/article/pii/B9780123948106000095; https://api.elsevier.com/content/article/pii/B9780123948106000095,68821871.0,3
78168,78168,100640,ywb26cq6,a3d6f4f84b0b2642247143314bb8f6788ad6a115,Medline; PMC,Selection of adjuvants for vaccines targeting specific pathogens,10.1080/14760584.2019.1604231,PMC7103699,31009255.0,no-cc,introduction adjuvant form integral component inactivated subunit vaccine formulation careful proper selection adjuvant help promoting appropriate immune response target pathogen innate adaptive level protective immunity elicited area covered herein describe recent progress understanding mode action adjuvant licensed use human vaccine clinical preclinical stage innate adaptive level different pathogen distinct characteristic require host mount appropriate immune response adjuvant selected elicit tailormade immune response specific pathogen based unique property identification biomarkers adjuvanticity several candidate vaccine using omicsbased technology unravel mechanism action modern experimental adjuvant expert opinion adjuvant technology revolutionized last two decade indepth understanding role adjuvant activating innate immune system combined system vaccinology approach led development nextgeneration novel adjuvant used vaccine challenging pathogen specific target population,2019-04-22,"Sarkar, Indranil; Garg, Ravendra; van Drunen Littel-van den Hurk, Sylvia",Expert Rev Vaccines,,,,document_parses/pdf_json/a3d6f4f84b0b2642247143314bb8f6788ad6a115.json,document_parses/pmc_json/PMC7103699.xml.json,https://doi.org/10.1080/14760584.2019.1604231; https://www.ncbi.nlm.nih.gov/pubmed/31009255/,128359267.0,3
78175,78175,100649,gmoq1i5x,a138ff680ae9e158019717356e8fcab523e7cad2,Medline; PMC,Epitope-Based Vaccine Target Screening against Highly Pathogenic MERS-CoV: An In Silico Approach Applied to Emerging Infectious Diseases,10.1371/journal.pone.0144475,PMC4671582,26641892.0,cc-by,middle east respiratory syndrome coronavirus merscov pandemic potential major worldwide threat public health however vaccine development pathogen lag behind immunity associated protection currently largely unknown study immunoinformaticsdriven genomewide screening strategy vaccine target performed thoroughly screen vital effective dominant immunogen merscov conservancy population coverage analysis epitope done immune epitope database result showed nucleocapsid n protein merscov might better protective immunogen high conservancy potential eliciting neutralizing antibody tcell response compared spike protein bcell helper tcell cytotoxic lymphocyte ctl epitope screened mapped n protein total linear conformal bcell epitope may induce protective neutralizing antibody obtained additionally total peptide mer core sequence identified helper tcell epitope peptide identified ctl epitope based maximum hla binding allele top helper tcell epitope ctl epitope may elicit protective cellular immune response merscov selected mers vaccine candidate population coverage analysis showed putative helper tcell epitope ctl epitope could cover vast majority population geographic region considered vaccine would employed b tcell stimulation potential screened epitope validated efficient use vaccine merscov collectively study provides novel vaccine target candidate may prompt development vaccine merscov emerging infectious disease,2015-12-07,"Shi, Jiandong; Zhang, Jing; Li, Sijin; Sun, Jing; Teng, Yumei; Wu, Meini; Li, Jianfan; Li, Yanhan; Hu, Ningzhu; Wang, Haixuan; Hu, Yunzhang",PLoS One,,,,document_parses/pdf_json/a138ff680ae9e158019717356e8fcab523e7cad2.json,document_parses/pmc_json/PMC4671582.xml.json,https://doi.org/10.1371/journal.pone.0144475; https://www.ncbi.nlm.nih.gov/pubmed/26641892/,14300044.0,3
78209,78209,100688,68sbqdi3,3015d59a4ae7dcbd0072c2d8cd7accf4d6dd679c,Medline; PMC; WHO,"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics",10.1080/21645515.2020.1735227,PMC7103671,32186952.0,no-cc,novel coronavirus infection covid coronavirus disease emerged wuhan hubei province china spread many country worldwide effort made develop vaccine human coronavirus cov infection mers sars past decade however date licensed antiviral treatment vaccine exists mers sars effort developing cov vaccine drug target spike glycoprotein protein major inducer neutralizing antibody although candidate shown efficacy vitro study many progressed randomized animal human trial hence may limited use counter covid infection article highlight ongoing advance designing vaccine therapeutic counter covid also focusing experience advance made earlier sars merscovs together could enable effort halt emerging virus infection,2020-03-18,"Dhama, Kuldeep; Sharun, Khan; Tiwari, Ruchi; Dadar, Maryam; Malik, Yashpal Singh; Singh, Karam Pal; Chaicumpa, Wanpen",Hum Vaccin Immunother,,#9699,,document_parses/pdf_json/3015d59a4ae7dcbd0072c2d8cd7accf4d6dd679c.json,document_parses/pmc_json/PMC7103671.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32186952/; https://doi.org/10.1080/21645515.2020.1735227,213186483.0,3
78211,78211,100690,fcyd8hrb,6c88b82336b5fe551cc4ce0599825f0eca69b1d3,Medline; PMC,Immunization with inactivated Middle East Respiratory Syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus,10.1080/21645515.2016.1177688,PMC5027702,27269431.0,bronze-oa,determine hypersensitivetype lung pathology might occur mouse given inactivated merscov vaccine challenged infectious virus seen sarscov vaccine prepared vaccinated mouse inactivated merscov vaccine neutralizing antibody induced vaccine without adjuvant lung virus reduced vaccinated mouse challenge lung mononuclear infiltrates occurred group virus challenge increased infiltrates contained eosinophil increase eosinophil promoting il il cytokine vaccine group inactivated merscov vaccine appears carry hypersensitivetype lung pathology risk merscov infection similar found inactivated sarscov vaccine sarscov infection,2016-06-07,"Agrawal, Anurodh Shankar; Tao, Xinrong; Algaissi, Abdullah; Garron, Tania; Narayanan, Krishna; Peng, Bi-Hung; Couch, Robert B.; Tseng, Chien-Te K.",Human Vaccines & Immunotherapeutics,,,,document_parses/pdf_json/6c88b82336b5fe551cc4ce0599825f0eca69b1d3.json,document_parses/pmc_json/PMC5027702.xml.json,https://doi.org/10.1080/21645515.2016.1177688; https://www.tandfonline.com/doi/pdf/10.1080/21645515.2016.1177688?needAccess=true; https://www.ncbi.nlm.nih.gov/pubmed/27269431/,9222915.0,3
78310,78310,100807,zbc6tbdc,7bb973611fdfdbfb74d3edf94324fa9f723a8965,Elsevier; Medline; PMC,Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults,10.1016/j.jinf.2019.02.003,PMC7172982,30742894.0,no-cc,objective respiratory syncytial virus rsv cause respiratory infection across world infant elderly particular risk developing severe disease death replicationdefective chimpanzee adenovirus panadrsv modified vaccinia virus ankara mvarsv vaccine shown safe immunogenic young healthy adult report extension firstinman vaccine trial include healthy older adult aged – year method evaluated safety immunogenicity single dose mvarsv given intramuscular im injection n two dos im panadrsv given week apart n im panadrsv prime im mvarsv boost week later n intranasal spray panadrsv prime im mvarsv boost week later n vaccine n safety measure included adverse event within one week vaccination blood monitoring immunogenicity measure included serum antibody response rsv panadneutralising antibody titre measured plaquereduction neutralisation seap assay respectively peripheral bcell immune response frequency fspecific igg iga antibody secreting cell memory bcells ex vivo cultured dualcolour elispot assay respectively peripheral rsvspecific tcell immune response frequency ifnγproducing tcells ex vivo elispot cdcdtfhlike cell frequency icsfacs assay result vaccine safe well tolerated compared individual baseline immunity mean foldchanges serum rsvneutralising antibody appearance magnitude fspecific igg iga ascs expansion cdcd ifnγproducing tcells peripheral circulation comparable result seen younger healthy adult received vaccine combination dose littleno iga memory bcell response younger older adult expansion ifnγproducing tcells marked older adult following im prime balanced cd cd cell response rsvspecific immune response vaccination appear attenuated presence panad vector neutralising antibody conclusion panadrsv mvarsv safe immunogenic older adult parallel induction rsvspecific humoral cellular immunity merit assessment providing protection severe disease,2019-02-08,"Green, Christopher A.; Sande, Charles J.; Scarselli, Elisa; Capone, Stefania; Vitelli, Alessandra; Nicosia, Alfredo; Silva-Reyes, Laura; Thompson, Amber J.; de Lara, Catherine M.; Taylor, Kathryn S.; Haworth, Kathryn; Hutchings, Claire L.; Cargill, Tamsin; Angus, Brian; Klenerman, Paul; Pollard, Andrew J.",J Infect,,,,document_parses/pdf_json/7bb973611fdfdbfb74d3edf94324fa9f723a8965.json,document_parses/pmc_json/PMC7172982.xml.json,https://www.sciencedirect.com/science/article/pii/S0163445319300386; https://www.ncbi.nlm.nih.gov/pubmed/30742894/; https://api.elsevier.com/content/article/pii/S0163445319300386; https://doi.org/10.1016/j.jinf.2019.02.003,73436661.0,3
78319,78319,100816,fmda6klr,71d047965ff6d3d2dc68d07cb90770fce84edcb8,Medline; PMC,Recent advances in delivery of veterinary DNA vaccines against avian pathogens,10.1186/s13567-019-0698-z,PMC6785882,31601266.0,cc-by,veterinary vaccine need desired characteristic effective inexpensive easy administer suitable mass vaccination stable field condition dna vaccine proposed potential solution poultry disease since subunit vaccine risk infection reversion virulence dna vaccine utilized simultaneous immunization multiple pathogen relatively easy design inexpensive manufacture store administration dna vaccine shown stimulate immune response provide protection challenge different animal model although dna vaccine offer advantage setback including inability induce strong immunity fact currently applicable mass vaccination impede use dna vaccine poultry industry use either biological physical carrier proposed solution overcome current delivery limitation dna vaccine veterinary application review present overview recent development carrier delivery veterinary dna vaccine avian pathogen,2019-10-10,"Jazayeri, Seyed Davoud; Poh, Chit Laa",Vet Res,,,,document_parses/pdf_json/71d047965ff6d3d2dc68d07cb90770fce84edcb8.json,document_parses/pmc_json/PMC6785882.xml.json,https://doi.org/10.1186/s13567-019-0698-z; https://www.ncbi.nlm.nih.gov/pubmed/31601266/,203987011.0,3
78361,78361,100868,aad3el57,7450f11f3687405152ad83ddd74ee1088d997342,Elsevier; Medline; PMC,Kinetics of cell migration to the dermis and hypodermis in dogs vaccinated with antigenic compounds of Leishmania braziliensis plus saponin,10.1016/j.vaccine.2008.04.084,PMC7115368,18555567.0,els-covid,search new immunobiologicals canine visceral leishmaniasis cvl intensified last decade however still remains elucidated mechanism innate immune response situ immunization ai aim study investigate kinetics cell migration skin dog distinct antigenic compound lbsap vaccine major finding indicated saponin adjuvant alone combined leishmania braziliensis antigen induced strong local acute inflammatory reaction however reaction progressed ulcerated lesion overall cell profile found sap lbsap composed neutrophil lymphocyte eosinophil also increased production inos sap lbsap group thus conclude dog immunized lbsap saponin adjuvant elicited potential innateimmune activation status compatible effective control resistance infection leishmania contributing better understanding innateimmunity event induced lbsap vaccine,2008-07-23,"Vitoriano-Souza, Juliana; Reis, Alexandre B.; Moreira, Nádia D.; Giunchetti, Rodolfo C.; Correa-Oliveira, Rodrigo; Carneiro, Cláudia M.",Vaccine,,,,document_parses/pdf_json/7450f11f3687405152ad83ddd74ee1088d997342.json,document_parses/pmc_json/PMC7115368.xml.json,https://doi.org/10.1016/j.vaccine.2008.04.084; https://api.elsevier.com/content/article/pii/S0264410X08005537; https://www.sciencedirect.com/science/article/pii/S0264410X08005537; https://www.ncbi.nlm.nih.gov/pubmed/18555567/,205576085.0,3
78392,78392,100903,wyanwvxa,75662e9515101f5b72f81b1bdc2d3917b1338b24,Elsevier; PMC,"Chapter 40 The Role of Innate Immunity in Regulating Rotavirus Replication, Pathogenesis, and Host Range Restriction and the Implications for Live Rotaviral Vaccine Development",10.1016/b978-0-12-811924-2.00041-9,PMC7148637,,els-covid,rotavirus rv important causative agent viral gastroenteritis young mammalian specie studied including human important cause severe gastroenteritis worldwide despite availability several safe effective vaccine replication rv restricted host speciesspecific manner barrier determined predominantly host interferon ifn signaling ability different rv strain successfully negate ifn activation amplification pathway addition viral attachment target intestinal epithelial cell also regulates host range restriction several study focused role innate immune response regulating rv replication pathogenesis knowledge accrued effort likely result rational attenuation rv vaccine closely match circulating host speciesmatched virus strain chapter review prevalent model rv interaction innate immune factor viral strategy employed regulate function implication finding improved rv vaccine development,2020-12-31,"Sen, Adrish; Ding, Siyuan; Greenberg, Harry B.",Mucosal Vaccines,,,,document_parses/pdf_json/75662e9515101f5b72f81b1bdc2d3917b1338b24.json,document_parses/pmc_json/PMC7148637.xml.json,https://www.sciencedirect.com/science/article/pii/B9780128119242000419; https://api.elsevier.com/content/article/pii/B9780128119242000419,208564180.0,3
78416,78416,100932,4c099rim,25fb4884567c7d5d80e42fca0b057e93a8fb19db,Medline; PMC,Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus,10.1111/imm.12462,PMC4515128,25762305.0,green-oa,ideal vaccine mucosal pathogen middle east respiratory syndrome coronavirus merscov confer sustained protective immunity systemic mucosal level evaluated vivo systemic mucosal antigenspecific immune response induced single intramuscular intragastric administration recombinant adenoviral type ad type ad based vaccine expressing merscov spike protein intragastric administration either ad ad induced antigenspecific igg neutralizing antibody serum however antigenspecific tcell response detected contrast single intramuscular dose ad ad functional antigenspecific tcell response elicited spleen pulmonary lymphocyte mouse persisted several month radbased vaccine administered intramuscularly induced systemic humoral immune response neutralizing igg antibody result show single dose ad adsbased vaccine represents appealing strategy control merscov infection transmission,2015-04-21,"Guo, Xiaojuan; Deng, Yao; Chen, Hong; Lan, Jiaming; Wang, Wen; Zou, Xiaohui; Hung, Tao; Lu, Zhuozhuang; Tan, Wenjie",Immunology,,,,document_parses/pdf_json/25fb4884567c7d5d80e42fca0b057e93a8fb19db.json,document_parses/pmc_json/PMC4515128.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25762305/; https://doi.org/10.1111/imm.12462,1068299.0,3
78427,78427,100946,qxkwjkif,1ff38c46bce64adb553080443f72ff90e61dcbc3,Medline; PMC,Vesicular Stomatitis Virus-Based Ebola Vaccine Is Well-Tolerated and Protects Immunocompromised Nonhuman Primates,10.1371/journal.ppat.1000225,PMC2582959,19043556.0,cc0,ebola virus ebov significant human pathogen present public health concern emergingreemerging virus potential biological weapon substantial progress made last decade developing candidate preventive vaccine protect nonhuman primate ebov among prospect vaccine based recombinant vesicular stomatitis virus vsv particularly robust also confer protection administered postexposure treatment concern raised regarding replicationcompetent vsv vector express ebov glycoprotein vector would tolerated individual altered compromised immune system patient infected hiv especially important ebov outbreak date occurred area central western africa high hiv incidence rate population order address concern evaluated safety recombinant vsv vector expressing zaire ebolavirus glycoprotein vsvδgzebovgp six rhesus macaque infected simianhuman immunodeficiency virus shiv six animal showed evidence illness associated vsvδgzebovgp vaccine suggesting vaccine may safe immunocompromised population one goal study evaluate safety candidate vaccine platform also interest determine altered immune status would affect vaccine efficacy vaccine protected shivinfected macaque death following zebov challenge evaluation cd cell animal showed animal succumbed lethal zebov challenge lowest cd count suggesting cd cell may play role mediating protection zebov,2008-11-28,"Geisbert, Thomas W.; Daddario-DiCaprio, Kathleen M.; Lewis, Mark G.; Geisbert, Joan B.; Grolla, Allen; Leung, Anders; Paragas, Jason; Matthias, Lennox; Smith, Mark A.; Jones, Steven M.; Hensley, Lisa E.; Feldmann, Heinz; Jahrling, Peter B.",PLoS Pathog,,,,document_parses/pdf_json/1ff38c46bce64adb553080443f72ff90e61dcbc3.json,document_parses/pmc_json/PMC2582959.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19043556/; https://doi.org/10.1371/journal.ppat.1000225,9370848.0,3
78465,78465,100994,0pmsfrcx,419d68a46a18476650fecb51115ae40c9b6b9e76,Elsevier; Medline; PMC,Zika Vaccine Development: Current Status,10.1016/j.mayocp.2019.05.016,PMC7094556,31806107.0,els-covid,zika virus outbreak explosive unpredictable led significant adverse health effects—as well considerable public anxiety significant scientific work resulted multiple candidate vaccine undergoing clinical development several vaccine phase clinical trial review survey current vaccine effort preclinical clinical result ethical concern directly bear vaccine development clear world need safe effective vaccine protect zika virus infection whether vaccine developed licensure public availability absent significant financial investment country barrier discussed within article remains uncertain,2019-12-31,"Poland, Gregory A.; Ovsyannikova, Inna G.; Kennedy, Richard B.",Mayo Clinic Proceedings,,,,document_parses/pdf_json/419d68a46a18476650fecb51115ae40c9b6b9e76.json,document_parses/pmc_json/PMC7094556.xml.json,https://www.sciencedirect.com/science/article/pii/S0025619619304835; https://doi.org/10.1016/j.mayocp.2019.05.016; https://www.ncbi.nlm.nih.gov/pubmed/31806107/; https://api.elsevier.com/content/article/pii/S0025619619304835,208743709.0,3
78470,78470,100999,hyqn9m1d,1358b278b691bdd7439d849fa8a002f9f9b8fe95,Medline; PMC,Molecular and Antigenic Characterization of GI-13 and GI-16 Avian Infectious Bronchitis Virus Isolated in Chile from 2009 to 2017 Regarding 4/91 Vaccine Introduction,10.3390/ani9090656,PMC6770500,31491868.0,cc-by,simple summary high adaptation recombination ability infectious bronchitis virus ib proven study aim verify genetic antigenic variation eight field ib strain regarding strain vaccination chilean chicken phylogenetic serologic challenge study carried accomplish goal genetic analysis indicate virus isolated prior introduction belong genetic group gi three isolates hand one virus isolated strain vaccine introduction chile showed relationship gi lineage remaining four virus belong gi group strain previously classified three virus chosen perform antigenic protective study antigenically high relationship vaccine isolate remarkable could observed isolates vaccine also showed better protection isolate isolates result suggest introduction vaccine chile could imply change virus showing ability interact field virus important monitor circulating virus include result future governmental decision introduction vaccine infectious bronchitis chile lineage described time country led looking change induced action study considers eight isolates obtained us maximum likelihood approach classify field isolates three isolates selected analyze antigenic relationship virus neutralization test perform protection test measured trough rtqpcr isolates showed relationship gi related gi though field isolates classified two different phylogenetic lineage showed minor variation subtype r isolate exhibited high antigenic relatedness vaccine expected massachusetts vaccine antigenically related vaccinated bird vaccine showed le tracheal virus replication r challenge sp sp isolates result indicated genetic antigenic diversity recent infectious bronchitis virus ibv isolates chile moreover vaccine would involved generation current field virus must considered vaccination program public policy,2019-09-05,"Guzmán, Miguel; Sáenz, Leonardo; Hidalgo, Héctor",Animals (Basel),,,,document_parses/pdf_json/1358b278b691bdd7439d849fa8a002f9f9b8fe95.json,document_parses/pmc_json/PMC6770500.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31491868/; https://doi.org/10.3390/ani9090656,201869041.0,3
78505,78505,101047,b2mg6lmc,16e918d0a2f2dacb1901178d6316f4850d8da9ef; 1933cc6ec95592bad4f8bd0017ca197779e844ad,Elsevier; Medline; PMC,Transmissible Viral Vaccines,10.1016/j.tim.2017.09.007,PMC5777272,29033339.0,hybrid-oa,genetic engineering enables design live viral vaccine potentially transmissible design merely modify single viral genome improve ageold method attenuation whereas design create chimera viral genome transmission benefit increasing herd immunity achieved direct vaccination alone also increase opportunity vaccine evolution typically undermines vaccine utility different design different epidemiological consequence also experience different evolution approach integrate vaccine engineering understanding evolution epidemiology reap greatest benefit vaccine transmission,2018-01-01,"Bull, James J.; Smithson, Mark W.; Nuismer, Scott L.",Trends in Microbiology,,,,document_parses/pdf_json/16e918d0a2f2dacb1901178d6316f4850d8da9ef.json; document_parses/pdf_json/1933cc6ec95592bad4f8bd0017ca197779e844ad.json,document_parses/pmc_json/PMC5777272.xml.json,https://www.sciencedirect.com/science/article/pii/S0966842X17302123; https://doi.org/10.1016/j.tim.2017.09.007; https://api.elsevier.com/content/article/pii/S0966842X17302123; http://www.cell.com/article/S0966842X17302123/pdf; https://www.ncbi.nlm.nih.gov/pubmed/29033339/,41828345.0,3
78528,78528,101078,3qnva664,7958b1ebf2a14c0fa7482e96e7cc0b43fe156b2e; f7de41208aece195ba22060365f3e3eb91e43d88,Medline; PMC,Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels,10.1038/s41598-019-52730-4,PMC6841732,31705137.0,cc-by,merscov seronegative seropositive camel received single intramuscular dose chadox mers replicationdeficient adenoviral vectored vaccine expressing merscov spike protein group receiving control vaccination infectious camel active naturally acquired merscov infection cohoused vaccinated camel ratio infectedvaccinated nasal discharge virus titre monitored day overall vaccination reduced virus shedding nasal discharge p p respectively antibody response seropositive camel enhancedby vaccine camel higher average age seronegative older seronegative camel responded strongly vaccination younger animal neutralising antibody detected nasal swab work required optimise vaccine regimen younger seronegative camel,2019-11-08,"Alharbi, Naif Khalaf; Qasim, Ibrahim; Almasoud, Abdulrahman; Aljami, Haya A.; Alenazi, Mohamed W.; Alhafufi, Ali; Aldibasi, Omar S.; Hashem, Anwar M.; Kasem, Samy; Albrahim, Raed; Aldubaib, Musaad; Almansour, Ali; Temperton, Nigel J.; Kupke, Alexandra; Becker, Stephan; Abu-obaidah, Ali; Alkarar, Ali; Yoon, In-Kyu; Azhar, Esam; Lambe, Teresa; Bayoumi, Faisal; Aldowerij, Ali; Ibrahim, Osman H.; Gilbert, Sarah C.; Balkhy, Hanan H.",Sci Rep,,,,document_parses/pdf_json/7958b1ebf2a14c0fa7482e96e7cc0b43fe156b2e.json; document_parses/pdf_json/f7de41208aece195ba22060365f3e3eb91e43d88.json,document_parses/pmc_json/PMC6841732.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31705137/; https://doi.org/10.1038/s41598-019-52730-4,207964706.0,3
78531,78531,101081,3zduon0f,34dbc74805291ff544a0944fd54d1e4f1a470080,Medline; PMC,Current research for a vaccine against Lassa hemorrhagic fever virus,10.2147/dddt.s147276,PMC6097522,30147299.0,cc-by-nc,lassa virus lasv rodentborne arenavirus endemic several west african country cause lassa fever lf lf typically mild cause severe disease characterized hemorrhagic fever multiorgan failure current outbreak lasv nigeria seen greater case case fatality rate currently limited treatment option vaccine candidate approved prevent lasv infection coalition epidemic preparedness innovation identified lasv emerging pathogen high consequence resulted push several preclinical vaccine candidate advanced toward clinical trial discus several important aspect lasv infection including immunobiology immune evasion correlate protection lf identified animal model human infection addition discus several vaccine candidate shown efficacy animal model could advanced toward clinical trial increased fatality rate seen recent lasv outbreak nigeria highlight importance developing effective treatment prevention strategy lf spike lasv case seen west africa potential increased mortality humantohuman transmission making development testing effective vaccine lasv critical,2018-08-14,"Warner, Bryce M; Safronetz, David; Stein, Derek R",Drug Des Devel Ther,,,,document_parses/pdf_json/34dbc74805291ff544a0944fd54d1e4f1a470080.json,document_parses/pmc_json/PMC6097522.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30147299/; https://doi.org/10.2147/dddt.s147276,52082498.0,3
78540,78540,101091,l80w3h0z,7cf3b88c42da6e87294d50416e8c5987d68db94d; ee714e9529ef2965c4a5b980d6b9482ea494b1ef,Elsevier; Medline; PMC,Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens,10.1016/j.bbrc.2009.09.029,PMC2787893,19748484.0,green-oa,several human monoclonal antibody hmabs including b g f exhibit relatively potent broad hiv neutralizing activity however elicitation vivo vaccine immunogen based hiv envelope glycoprotein env successful hypothesized hiv evolved strategy reduce eliminate immunogenicity highly conserved epitope antibody using “ hole ” absence weak binding epitope germline antibody sufficient initiate andor maintain efficient immune response human germline b cell receptor bcr repertoire begin test hypothesis designed germlinelike antibody corresponding closely b g f well x crossreactive relatively weak neutralizing activity natively occurring antibody due size andor effect germlinelike x bound relatively high affinity tested envs contrast germlinelike b g f lacked measurable binding envs elisa assay although corresponding mature antibody result provide initial evidence env structure containing conserved vulnerable epitope may initiate humoral response binding germline antibody even response initiated weak binding undetectable assay likely outcompeted response structure containing epitope x antibody bind germline bcrs much higher affinityavidity hypothesis supported data could contribute understanding hiv evades immune response offer new concept design effective vaccine immunogen,2009-12-01,"Xiao, Xiaodong; Chen, Weizao; Feng, Yang; Zhu, Zhongyu; Prabakaran, Ponraj; Wang, Yanping; Zhang, Mei-Yun; Longo, Nancy S.; Dimitrov, Dimiter S.",Biochemical and Biophysical Research Communications,,,,document_parses/pdf_json/7cf3b88c42da6e87294d50416e8c5987d68db94d.json; document_parses/pdf_json/ee714e9529ef2965c4a5b980d6b9482ea494b1ef.json,document_parses/pmc_json/PMC2787893.xml.json,https://doi.org/10.1016/j.bbrc.2009.09.029; https://www.sciencedirect.com/science/article/pii/S0006291X09018178; https://api.elsevier.com/content/article/pii/S0006291X09018178; https://www.ncbi.nlm.nih.gov/pubmed/19748484/; http://europepmc.org/articles/pmc2787893?pdf=render,13767920.0,3
78548,78548,101100,zhjyxa8x,408c98fbba5d5584cc7fda96ec9b307d1cbd73bc,Medline; PMC,Recombinant porcine rotavirus VP4 and VP4-LTB expressed in Lactobacillus casei induced mucosal and systemic antibody responses in mice,10.1186/1471-2180-9-249,PMC2797526,19958557.0,cc-by,background porcine rotavirus infection significant cause morbidity mortality swine industry necessitating development effective vaccine prevention infection immune response associated protection primarily mucosal nature induction mucosal immunity important preventing porcine rotavirus infection result lactobacillus casei expressing major protective antigen vp porcine rotavirus ppgvp vpltb heatlabile toxin b subunit echerichia coli ppgvpltb fusion protein used immunize mouse orally expression recombinant ppgvp ppgvpltb confirmed sdspage western blot analysis surfacedisplayed expression l casei verified immunofluorescence mouse orally immunized recombinant proteinexpressing l casei produced high level serum immunoglobulin g igg mucosal iga iga titter mouse immunized ppgvpltb higher titter ppgvpimmunized mouse induced antibody demonstrated neutralizing effect rv infection conclusion result demonstrated vp administered context l casei expression system effective method stimulating mucosal immunity ltb served stimulate mucosal immunity suggesting strategy adapted use pig,2009-12-04,"Qiao, Xinyuan; Li, Guiwei; Wang, Xiangqing; Li, Xiaojing; Liu, Min; Li, Yijing",BMC Microbiol,,,,document_parses/pdf_json/408c98fbba5d5584cc7fda96ec9b307d1cbd73bc.json,document_parses/pmc_json/PMC2797526.xml.json,https://doi.org/10.1186/1471-2180-9-249; https://www.ncbi.nlm.nih.gov/pubmed/19958557/,2375442.0,3
78550,78550,101102,kium6c11,78bd3748cb2fbedfe782af342c3d2feb470ab0c4,Medline; PMC,First-in-human clinical trials with vaccines—what regulators want,10.1038/nbt0910-910,PMC7096781,20829825.0,no-cc,several factor taken account come first exposure human novel vaccine,2010,"Goetz, Karen B; Pfleiderer, Michael; Schneider, Christian K",Nat Biotechnol,,,,document_parses/pdf_json/78bd3748cb2fbedfe782af342c3d2feb470ab0c4.json,document_parses/pmc_json/PMC7096781.xml.json,https://doi.org/10.1038/nbt0910-910; https://www.ncbi.nlm.nih.gov/pubmed/20829825/,36346268.0,3
78595,78595,101157,6t0wpiqy,58e5b4767a000ba416763edd6ca1c5f1fba9a42c,Elsevier; PMC,Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines,10.1016/s0140-6736(04)15892-3,PMC7112480,15064027.0,els-covid,summary background response emergence severe infection capable rapid global spread issue pandemic alert alert rare however feb pandemic alert issued response human infection caused avian hn influenza virus ahong kong hn noted human being killed third infected people variant seemed transmitted directly bird human being caused fatal pneumonia one two infected individual candidate vaccine sought avirulent virus antigenically similar pathogen available isolate killed embryonated chicken egg since traditional strategy vaccine production viable sought produce candidate reference virus using reverse genetics method removed polybasic aminoacids associated high virulence haemagglutinin cleavage site ahong kong using influenza reverse genetics technique reference vaccine virus produced apuerto rico pr backbone whoapproved vero cell assessed reference virus pathogenicity invivo invitro assay finding reference vaccine virus produced good manufacturing practice gmpgrade facility le week time virus isolation virus proved nonpathogenic chicken ferret shown stable multiple passage embryonated chicken egg interpretation ability produce candidate reference virus short period time set new standard rapid response emerging infectious disease threat clearly show usefulness reverse genetics influenza vaccine development technology procedure currently used create reference vaccine virus hn virus circulating asia,2004-04-03,"Webby, RJ; Perez, DR; Coleman, JS; Guan, Y; Knight, JH; Govorkova, EA; McClain-Moss, LR; Peiris, JS; Rehg, JE; Tuomanen, EI; Webster, RG",The Lancet,,,,document_parses/pdf_json/58e5b4767a000ba416763edd6ca1c5f1fba9a42c.json,document_parses/pmc_json/PMC7112480.xml.json,https://api.elsevier.com/content/article/pii/S0140673604158923; https://www.sciencedirect.com/science/article/pii/S0140673604158923,8662261.0,3
78600,78600,101163,14a5861f,e60a7630d751366b6ea36f9c0b60eed8e20a00f6,Medline; PMC,Rotavirus vaccine efficacy: current status and areas for improvement,10.1080/21645515.2018.1520583,PMC6663136,30215578.0,cc-by-nc-nd,difference noted rotavirus vaccine efficiency high low income country correlate lack universal access clean water higher standard hygiene overcoming obstacle require great investment also time therefore effective vaccine developed meet need would benefit increasing current knowledge mucosal immunity response rotavirus infection modulation circadian rhythm could point actionable pathway improve vaccination efficacy especially case individual affected environmental enteropathy also better understanding validation rotavirus entry factor well systematic monitoring dominant strain could assist tailoring vaccine individual ’ need another aspect could improve vaccine efficiency targeting cell new ligand could potentially sought finally alternative mucosal adjuvant vaccine expression storage delivery system could positive impact outcome rotavirus vaccination,2018-09-19,"Carvalho, Miguel F.; Gill, Davinder",Hum Vaccin Immunother,,,,document_parses/pdf_json/e60a7630d751366b6ea36f9c0b60eed8e20a00f6.json,document_parses/pmc_json/PMC6663136.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30215578/; https://doi.org/10.1080/21645515.2018.1520583,52271592.0,3
78663,78663,101237,r077ybzg,0806026a204dcf0cc37e859f2e8dd27518c56f90,Elsevier; Medline; PMC,The application of self-assembled nanostructures in peptide-based subunit vaccine development,10.1016/j.eurpolymj.2017.02.014,PMC7094324,32226094.0,els-covid,peptide basedvaccines becoming one widely investigated prophylactic therapeutic health care intervention variety disease including cancer however lack safe highly efficient adjuvant immune stimulant regarded biggest obstacle vaccine development incorporation peptide antigen nanostructurebased delivery system recently shown overcome obstacle nanostructures often formed antigen conjugated molecule polymer lipid peptide help selfassembly phenomenon review describes application selfassembly process production peptidebased vaccine candidate ability nanostructures stimulate humoral cellular immune response,2017-08-31,"Zhao, Guangzu; Chandrudu, Saranya; Skwarczynski, Mariusz; Toth, Istvan",European Polymer Journal,,,,document_parses/pdf_json/0806026a204dcf0cc37e859f2e8dd27518c56f90.json,document_parses/pmc_json/PMC7094324.xml.json,https://www.sciencedirect.com/science/article/pii/S0014305716314161; https://doi.org/10.1016/j.eurpolymj.2017.02.014; https://www.ncbi.nlm.nih.gov/pubmed/32226094/; https://api.elsevier.com/content/article/pii/S0014305716314161,99443050.0,3
78667,78667,101242,6uk3og8s,c458bb1b510f90c3fc4952f19c71a2bc3a6170f5,Elsevier; PMC,Why Aging T Cells Fail: Implications for Vaccination,10.1016/j.immuni.2006.06.003,PMC7129126,16782020.0,els-covid,summary decline cd cell function aging contributes reduced vaccine efficacy commentary discus factor leading agerelated change cell function propose may overcome enhance vaccine efficacy elderly,2006-06-30,"Haynes, Laura; Swain, Susan L.",Immunity,,,,document_parses/pdf_json/c458bb1b510f90c3fc4952f19c71a2bc3a6170f5.json,document_parses/pmc_json/PMC7129126.xml.json,https://api.elsevier.com/content/article/pii/S1074761306002706; https://www.sciencedirect.com/science/article/pii/S1074761306002706,43769737.0,3
78685,78685,101263,hbd44euq,c910cf0f8b98839fbb32df6b58ea93644962566c,Elsevier; Medline; PMC,Vaccines in a hurry,10.1016/j.vaccine.2009.02.030,PMC7172988,19460599.0,no-cc,preparing population health threat including threat new reemerging infectious disease recognised important public health priority development production application emergency vaccination important measure threat vaccine costeffective tool prevent disease emergency vaccine may mean prevent true disaster global society event new pandemic potential cause morbidity mortality comparable spanish flu polio epidemic sars outbreak spread contained time given early recognition new threat given advance biotechnology vaccinology information system unrealistic goal promising prototype vaccine candidate available short time span following identification new infectious agent based assumption emerging infection followed natural immunity however major bottleneck deployment emergency vaccine lack established system fasttrack regulatory approval candidate limited international vaccine production capacity present discussion paper propose mechanism facilitate development emergency vaccine europe focusing public–private scientific partnership fasttrack approval emergency vaccine regulatory agency proposing incentive emergency vaccine production private vaccine company,2009-05-26,"Søborg, Christian; Mølbak, Kåre; Doherty, T. Mark; Ulleryd, Peter; Brooks, Tim; Coenen, Claudine; van der Zeijst, Ben",Vaccine,,,,document_parses/pdf_json/c910cf0f8b98839fbb32df6b58ea93644962566c.json,document_parses/pmc_json/PMC7172988.xml.json,https://api.elsevier.com/content/article/pii/S0264410X09002448; https://www.sciencedirect.com/science/article/pii/S0264410X09002448; https://www.ncbi.nlm.nih.gov/pubmed/19460599/; https://doi.org/10.1016/j.vaccine.2009.02.030,35646039.0,3
78708,78708,101291,rvrp5zvv,6f6397ff2cc785076b76b648693ac358b60da6ae,Elsevier; Medline; PMC,Search for potential target site of nucleocapsid gene for the design of an epitope-based SARS DNA vaccine,10.1016/j.imlet.2008.03.003,PMC7112843,18440652.0,els-covid,believed today nucleocapsid protein n severe acute respiratory syndrome sarscov one promising antigen candidate vaccine design study three fragment n residue – n residue – n residue – n protein sarscov expressed escherichia coli analyzed pooled serum convalescence phase sars patient three gene fragment n – nt n – nt n – nt—expressing protein n n n respectively sarsn cloned pvax used immunize balbc mouse electroporation humoral enzymelinked immunosorbent assay elisa cellular cell proliferation cdcd assay immunity detected using recombinant n n specific antigen result showed n n fragment n protein expressed e coli able react serum sars patient n could specific humoral cellular immunity mouse could induced significantly inoculating sarscov n n dna vaccine addition immune response level n significantly higher antibody response igg igg igga cell proliferation cdcd assay compared n vaccine identification antigenic n protein fragment implication provide basic information design dna vaccine sarscov present result suggest dna immunization pvaxn could used potential dna vaccination approach induce antibody balbc mouse also illustrates gene immunization sars dna vaccine generate different immune response,2008-06-15,"Dutta, Noton Kumar; Mazumdar, Kaushiki; Lee, Byoung-Hee; Baek, Min-Won; Kim, Dong-Jae; Na, Yi-Rang; Park, Sung-Hoon; Lee, Hyun-Kyoung; Kariwa, Hiroaki; Mai, Le Quynh; Park, Jae-Hak",Immunology Letters,,,,document_parses/pdf_json/6f6397ff2cc785076b76b648693ac358b60da6ae.json,document_parses/pmc_json/PMC7112843.xml.json,https://doi.org/10.1016/j.imlet.2008.03.003; https://api.elsevier.com/content/article/pii/S0165247808000874; https://www.ncbi.nlm.nih.gov/pubmed/18440652/; https://www.sciencedirect.com/science/article/pii/S0165247808000874,39999811.0,3
78717,78717,101303,dpwzgake,e219c275f151e3823e9a4866b5509d1b4ed0a14d,Elsevier; Medline; PMC,Plants as bioreactors for the production of vaccine antigens,10.1016/j.biotechadv.2009.03.006,PMC7126855,19356740.0,no-cc,plant identified promising expression system commercial production vaccine antigen phase clinical trial several plantderived vaccine antigen found safe induce sufficiently high immune response thus transgenic plant including edible plant part suggested excellent alternative production vaccine economic scaleup cultivation improved understanding plant molecular biology consequent refinement genetic engineering technique led designing approach high level expression vaccine antigen plant last decade several efficient plantbased expression system examined recombinant protein including plantderived vaccine antigen expressed different plant tissue estimate suggest may become possible obtain antigen sufficient vaccinating million individual one acre crop expressing antigen seed edible legume like peanut soybean near future plethora protein product developed ‘ naturalized bioreactors ’ may reach market effort improvement technology need directed mainly towards validation applicability plantbased standardized mucosal edible vaccine regulatory pharmacology formulation development commercially viable glp protocol article review current status development area use plant development vaccine antigen,2009-04-06,"Tiwari, Siddharth; Verma, Praveen C.; Singh, Pradhyumna K.; Tuli, Rakesh",Biotechnol Adv,,,,document_parses/pdf_json/e219c275f151e3823e9a4866b5509d1b4ed0a14d.json,document_parses/pmc_json/PMC7126855.xml.json,https://www.sciencedirect.com/science/article/pii/S0734975009000500; https://api.elsevier.com/content/article/pii/S0734975009000500; https://www.ncbi.nlm.nih.gov/pubmed/19356740/; https://doi.org/10.1016/j.biotechadv.2009.03.006,25041529.0,3
78728,78728,101317,w9zyshzb,,Medline; WHO,DNA vaccine protection against SARS-CoV-2 in rhesus macaques,10.1126/science.abc6284,,32434945.0,unk,global covid pandemic caused sarscov virus made development vaccine top biomedical priority study developed series dna vaccine candidate expressing different form sarscov spike protein evaluated rhesus macaque vaccinated animal developed humoral cellular immune response including neutralizing antibody titer comparable found convalescent human macaque infected sarscov following vaccination animal challenged sarscov vaccine encoding fulllength protein resulted gt gt log reduction median viral load bronchoalveolar lavage nasal mucosa respectively compared sham control vaccineelicited neutralizing antibody titer correlated protective efficacy suggesting immune correlate protection data demonstrate vaccine protection sarscov nonhuman primate,2020,"Yu, Jingyou; Tostanoski, Lisa H.; Peter, Lauren; Mercado, Noe B.; McMahan, Katherine; Mahrokhian, Shant H.; Nkolola, Joseph P.; Liu, Jinyan; Li, Zhenfeng; Chandrashekar, Abishek; Martinez, David R.; Loos, Carolin; Atyeo, Caroline; Fischinger, Stephanie; Burke, John S.; Slein, Matthew D.; Chen, Yuezhou; Zuiani, Adam; N Lelis, Felipe J.; Travers, Meghan; Habibi, Shaghayegh; Pessaint, Laurent; Van Ry, Alex; Blade, Kelvin; Brown, Renita; Cook, Anthony; Finneyfrock, Brad; Dodson, Alan; Teow, Elyse; Velasco, Jason; Zahn, Roland; Wegmann, Frank; Bondzie, Esther A.; Dagotto, Gabriel; Gebre, Makda S.; He, Xuan; Jacob-Dolan, Catherine; Kirilova, Marinela; Kordana, Nicole; Lin, Zijin; Maxfield, Lori F.; Nampanya, Felix; Nityanandam, Ramya; Ventura, John D.; Wan, Huahua; Cai, Yongfei; Chen, Bing; Schmidt, Aaron G.; Wesemann, Duane R.; Baric, Ralph S.; Alter, Galit; Andersen, Hanne; Lewis, Mark G.; Barouch, Dan H.","Science (New York, N.Y.)",,#326877,,,,https://doi.org/10.1126/science.abc6284; https://www.ncbi.nlm.nih.gov/pubmed/32434945/,218767206.0,3
78757,78757,101351,sesfydlg,d72ac6be48b1932844be27f8cd5a3b91d9010165; 38005d94ec9d0850ac5322665d6a7dc76336fd6d,Elsevier; Medline; PMC,Vaccinology in the third millennium: scientific and social challenges,10.1016/j.coviro.2016.03.003,PMC4902778,27039875.0,green-oa,epidemiology death due vaccinepreventable disease significantly positively altered use vaccine despite significant challenge remain vaccine development use third millennium new ebola chikungunya west nile reemerging disease measles mumps influenza require development new nextgeneration vaccine global aging population accumulating number immunocompromised person require new vaccine adjuvant development protect large segment population vaccine development significant challenge remain globally cost efficient use acceptance vaccine public article raise issue two area suggests way forward benefit current future generation,2016-04-01,"Poland, Gregory A.; Whitaker, Jennifer A.; Poland, Caroline M.; Ovsyannikova, Inna G.; Kennedy, Richard B.",Current Opinion in Virology,,,,document_parses/pdf_json/d72ac6be48b1932844be27f8cd5a3b91d9010165.json; document_parses/pdf_json/38005d94ec9d0850ac5322665d6a7dc76336fd6d.json,document_parses/pmc_json/PMC4902778.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/27039875/; http://europepmc.org/articles/pmc4902778?pdf=render; https://api.elsevier.com/content/article/pii/S1879625716300189; https://doi.org/10.1016/j.coviro.2016.03.003; https://www.sciencedirect.com/science/article/pii/S1879625716300189,3716223.0,3
78775,78775,101375,ipv8awq7,61d619975b1d560811f05b5aad82fbeed380f2d8,Medline; PMC,The economy-wide impact of pandemic influenza on the UK: a computable general equilibrium modelling experiment,10.1136/bmj.b4571,PMC2779854,19926697.0,cc-by-nc,objective estimate potential economic impact pandemic influenza associated behavioural response school closure vaccination united kingdom design computable general equilibrium model uk economy specified various combination mortality morbidity pandemic influenza vaccine efficacy school closure prophylactic absenteeism using published data setting uk economy date available suitable economic data main outcome measure economic impact various scenario different pandemic severity vaccination school closure prophylactic absenteeism specified term gross domestic product output different economic sector equivalent variation result cost related illness alone ranged gross domestic product £bn £bn low fatality scenario £bn £bn high fatality scenario larger still extreme pandemic school closure increase economic impact particularly mild pandemic widespread behavioural change take place large scale prophylactic absence work economic impact would notably increased health benefit vaccination prepandemic vaccine could save gross domestic product £bn £bn single dose matched vaccine could save £bn £bn two dos matched vaccine could limit overall economic impact gross domestic product disease scenario conclusion balancing school closure “ business usual ” obtaining sufficient stock effective vaccine important factor determining economic impact influenza pandemic disease prophylactic absence work response fear infection add considerably economic impact,2009-11-19,"Smith, Richard D; Keogh-Brown, Marcus R; Barnett, Tony; Tait, Joyce",BMJ,,,,document_parses/pdf_json/61d619975b1d560811f05b5aad82fbeed380f2d8.json,document_parses/pmc_json/PMC2779854.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19926697/; https://doi.org/10.1136/bmj.b4571,17501143.0,3
78816,78816,101431,q3vegepi,3c7a2bc73e390cf72261519f241cd12b363c7444,Medline; PMC,Strategies Using Bio-Layer Interferometry Biosensor Technology for Vaccine Research and Development,10.3390/bios7040049,PMC5746772,29088096.0,cc-by,biolayer interferometry bli realtime labelfree technology greatly contributed advance vaccine research development bli octet platform offer highthroughput ease use reliability high precision analysis compared common labeling technique many different strategy used immobilize pathogen host molecule bli biosensors realtime kinetics affinity analysis quantification highthroughput titer strategy used multiple application shed light onto structural functional aspect molecule play pathogenhost interaction also provide crucial information achieve protection review summarizes key bli strategy used human vaccine research development,2017-10-31,"Petersen, Rejane L.",Biosensors (Basel),,,,document_parses/pdf_json/3c7a2bc73e390cf72261519f241cd12b363c7444.json,document_parses/pmc_json/PMC5746772.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29088096/; https://doi.org/10.3390/bios7040049,24650180.0,3
78837,78837,101453,za1ujmiq,727deac30ded319581af8a020111caf2113c7fc6; e349403c88f101828154ddf9cbaf72d4b62a1137,Elsevier; Medline; PMC,Vaccination Management of Beef Cattle: Delayed Vaccination and Endotoxin Stacking,10.1016/j.cvfa.2019.07.003,PMC7125876,31590903.0,no-cc,vaccination critical component cattle health management effective cattle vaccine program consider timing vaccination relation expected disease challenge risk wildtype exposure various bovine pathogen host factor vaccination nearly consulting veterinarian recommend vaccination stressed highrisk calf feedlot arrival however recommendation fails consider several factor associated vaccine efficiency research evaluating vaccine interaction stressed cattle potential additive effect endotoxin multiple bacterin administration may reveal new evidencebased vaccination guideline cattle various segment beef dairy production system,2019-10-04,"Richeson, John T.; Hughes, Heather D.; Broadway, Paul R.; Carroll, Jeffery A.",Vet Clin North Am Food Anim Pract,,,,document_parses/pdf_json/727deac30ded319581af8a020111caf2113c7fc6.json; document_parses/pdf_json/e349403c88f101828154ddf9cbaf72d4b62a1137.json,document_parses/pmc_json/PMC7125876.xml.json,https://api.elsevier.com/content/article/pii/S0749072019300258; https://www.sciencedirect.com/science/article/pii/S0749072019300258; https://www.ncbi.nlm.nih.gov/pubmed/31590903/; https://doi.org/10.1016/j.cvfa.2019.07.003,203923607.0,3
78839,78839,101456,dfh3b9ln,f2a3bd788194db3626ddc6650be02da7061b84cc,Elsevier; Medline; PMC,Social and political determinants of vaccine hesitancy: Lessons learned from the H1N1 pandemic of 2009-2010,10.1016/j.ajic.2015.06.031,PMC7132648,26521933.0,els-covid,background public acceptance vaccination program essential vaccine preventable disease however increasing sector population expressed hesitancy participating program leading reemergence vaccine preventable disease study rely recreancy hypothesis test association confidence government local hospital willingness take vaccine method secondary analysis survey used large sample u population conducted october used n result result indicate respondent expressed willingness vaccinated greatest trust government likely vaccinated least confident least willing one reporting confident local health system willing vaccinated confident willing vaccinated conclusion decision get vaccinated midst contagious outbreak involves many consideration trust government technical organization skill deal infectious outbreak along trust medical organization predict adoption recommended protection measure result indicate public compliance vaccination plan health crisis requires development social institutional trust,2015-11-01,"Mesch, Gustavo S.; Schwirian, Kent P.",American Journal of Infection Control,,,,document_parses/pdf_json/f2a3bd788194db3626ddc6650be02da7061b84cc.json,document_parses/pmc_json/PMC7132648.xml.json,https://www.sciencedirect.com/science/article/pii/S0196655315007506; https://www.ncbi.nlm.nih.gov/pubmed/26521933/; https://api.elsevier.com/content/article/pii/S0196655315007506; https://doi.org/10.1016/j.ajic.2015.06.031,24404604.0,3
78843,78843,101460,b18hnqsl,af400a711649c6703b915e8a935dfe778bc42132; aae1603af1bb84087248441716a5c0bd373603b7,Medline; PMC,H1N1pdm09 Adjuvanted Vaccination in HIV-Infected Adults: A Randomized Trial of Two Single versus Two Double Doses,10.1371/journal.pone.0039310,PMC3382468,22761759.0,cc-by,background since human immunodeficiency virus hivinfected individual increased risk severe disease pandemic influenza hnpdm vaccination recommended prevention strategy aim present study evaluate safety immunogenicity persistence immune response vaccination pandemic influenza hnpdm adjuvanted vaccine human immunodeficiency virus hivinfected adult using two single two double dos methodologyprincipal finding open label randomized trial evaluate immune response following hnpdm vaccination hivinfected participant compared hivnegative control nct hivinfected participant randomized receive single µg hemagglutinin double µg hemagglutinin dos vaccine day apart control received one dose vaccine primary endpoint seroconversion measured hemagglutination inhibition assay two hundred fifty six hivinfected participant randomized single double dos respectively hivnegative control enrolled among hivinfected participant seroconversion increased first dose second dose vaccine using single double dos respectively participant aged year showed higher seroconversion compared younger participant seroconversion among hivinfected woman nadir cd cellsmm significantly higher double dos persistence protective antibody six month vaccination achieved hivinfected participant received single double dos respectively conclusionssignificance result support recommendation two double dos adjuvanted hnpdm vaccine hivinfected individual particularly woman aged year nadir cd cellsmm achieve antibody level higher sustained trial registration clinicaltrialsgov nct,2012-06-25,"Santini-Oliveira, Marilia; Camacho, Luiz A. B.; Souza, Thiago M. L.; Luz, Paula M.; Vasconcellos, Mauricio T. L.; Giacoia-Gripp, Carmem B. W.; Morgado, Mariza G.; Nunes, Estevão P.; Lemos, Alberto S.; Ferreira, Ana C. G.; Moreira, Ronaldo I.; Veloso, Valdiléa G.; Siqueira, Marilda M.; Grinsztejn, Beatriz",PLoS One,,,,document_parses/pdf_json/af400a711649c6703b915e8a935dfe778bc42132.json; document_parses/pdf_json/aae1603af1bb84087248441716a5c0bd373603b7.json,document_parses/pmc_json/PMC3382468.xml.json,https://doi.org/10.1371/journal.pone.0039310; https://www.ncbi.nlm.nih.gov/pubmed/22761759/,10686110.0,3
78853,78853,101475,f38pftlm,3970ee2ea0ca0f8a7b38a8cdc6f6da5360a25b9b,Medline; PMC,Why are vaccines against many human viral diseases still unavailable; an historic perspective?,10.1002/jmv.25593,PMC7166819,31502669.0,no-cc,number new improved human viral vaccine licensed recent year contrast sharply could termed golden era ‐ vaccine polio‐ measles mumps rubella hepatitis b virus first became available attempt explain vaccine mainly virus human immunodeficiency virus hepatitis c virus still unavailable include human herpesviruses varicella‐zoster virus respiratory syncytial respiratory enteric arthropod‐borne virus improved oral poliovirus vaccine also urgently required unavailability attributable regulatoryeconomic factor property individual virus also absence relevant animal model ethical problem conduct clinical trial pediatric critical population portent likely difficulty licensing effective vaccine emerging pathogen avian influenza ebola zika virus,2019-10-03,"Tannock, Gregory A.; Kim, Hyunsuh; Xue, Lumin",J Med Virol,,,,document_parses/pdf_json/3970ee2ea0ca0f8a7b38a8cdc6f6da5360a25b9b.json,document_parses/pmc_json/PMC7166819.xml.json,https://doi.org/10.1002/jmv.25593; https://www.ncbi.nlm.nih.gov/pubmed/31502669/,202402801.0,3
78972,78972,101610,sflndhb3,203339b042e51e4489fd7a1ffd7911a5443b9a82,Medline; PMC,"Haemophilus influenzae Type a Meningitis in Immunocompetent Child, Oman, 2015",10.3201/eid2307.170311,PMC5512487,28628438.0,no-cc,meningitis caused haemophilus influenzae type b hib eliminated oman introduction hib vaccine however case h influenzae type meningitis diagnosed child oman highlight need monitor incidence invasive nonhib h influenzae disease,2017-07-26,"Sawardekar, Kiran P.",Emerg Infect Dis,,,,document_parses/pdf_json/203339b042e51e4489fd7a1ffd7911a5443b9a82.json,document_parses/pmc_json/PMC5512487.xml.json,https://doi.org/10.3201/eid2307.170311; https://www.ncbi.nlm.nih.gov/pubmed/28628438/,4324518.0,3
78990,78990,101636,gckqphhp,022abf5f202c04e2bbf88d829db9844746e0fb71,Medline; PMC,Recent vaccine technology in industrial animals,10.7774/cevr.2016.5.1.12,PMC4742593,26866019.0,cc-by-nc,various new technology applied developing vaccine various animal disease viruslike particle vlp vaccine technology used manufacturing porcine circovirus type rna particle vaccine based alphavirus vector porcine epidemic diarrhea ped although vlp classified killedvirus vaccine structure similar original virus induce longterm cellmediated immunity rna particle vaccine used venezuela equine encephalitis vee virus gene vector vee virus partial gene substituted ped virus spike gene recombinant vaccine produced substitution target gene vee vector new vaccine technology made possible control infectious disease efficiently relatively short time,2016-01-27,"Kim, Hyunil; Lee, Yoo-kyoung; Kang, Sang Chul; Han, Beom Ku; Choi, Ki Myung",Clin Exp Vaccine Res,,,,document_parses/pdf_json/022abf5f202c04e2bbf88d829db9844746e0fb71.json,document_parses/pmc_json/PMC4742593.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26866019/; https://doi.org/10.7774/cevr.2016.5.1.12,999243.0,3
79025,79025,101679,7tscp04v,0f93d30fe8e5f0277c822d5cbc8c04cb5bb60d41; 9484af8bce6df5d0a9912a686e44a1db4a381635; 66ee6c750afeb7f2f0ae49100a5b3c08f91dc2bf; c8e37f08a80fe7f78bcb5ca1e9598bc65c470d07,Elsevier; Medline; PMC,Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV,10.1016/j.celrep.2017.08.023,PMC5583508,28854372.0,cc-by-nc-nd,predicting vaccine efficacy remains challenge used system vaccinology approach identify early innate immune correlate antibody induction human receiving ebola vaccine rvsvzebov blood sample day analyzed change cytokine level innate immune cell subset gene expression integrative statistical analysis crossvalidation identified signature early innate marker correlating antibody titer day beyond among ip day mfi cxcr nk cell day independent correlate consistently found early gene expression signature linked ip comprehensive characterization early innate immune response rvsvzebov vaccine human revealed immune signature linked ip result suggest correlate vaccineinduced antibody induction provide rationale explore strategy augmenting effectiveness vaccine manipulation ip,2017-08-29,"Rechtien, Anne; Richert, Laura; Lorenzo, Hadrien; Martrus, Gloria; Hejblum, Boris; Dahlke, Christine; Kasonta, Rahel; Zinser, Madeleine; Stubbe, Hans; Matschl, Urte; Lohse, Ansgar; Krähling, Verena; Eickmann, Markus; Becker, Stephan; Thiébaut, Rodolphe; Altfeld, Marcus; Addo, Marylyn",Cell Rep,,,,document_parses/pdf_json/0f93d30fe8e5f0277c822d5cbc8c04cb5bb60d41.json; document_parses/pdf_json/9484af8bce6df5d0a9912a686e44a1db4a381635.json; document_parses/pdf_json/66ee6c750afeb7f2f0ae49100a5b3c08f91dc2bf.json; document_parses/pdf_json/c8e37f08a80fe7f78bcb5ca1e9598bc65c470d07.json,document_parses/pmc_json/PMC5583508.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28854372/; https://doi.org/10.1016/j.celrep.2017.08.023; https://api.elsevier.com/content/article/pii/S2211124717311154; https://www.sciencedirect.com/science/article/pii/S2211124717311154,7264026.0,3
79034,79034,101688,itvfw787,,Medline; WHO,U.S. 'Warp Speed' vaccine effort comes out of the shadows,10.1126/science.368.6492.692,,32409451.0,unk,conventional wisdom vaccine covid least year away organizer u government push called operation warp speed little use conventional wisdom project vaguely described date likely formally announced white house coming day pick diverse set vaccine candidate pour essentially limitless resource unprecedented comparative study animal fasttracked human trial manufacturing eschewing international cooperation—and vaccine candidate china—it hope million dos january proven product reserved american,2020,"Cohen, Jon",Science,,#261166,,,,https://www.ncbi.nlm.nih.gov/pubmed/32409451/; https://doi.org/10.1126/science.368.6492.692,218648519.0,3
79059,79059,101716,p1twn3lt,ab20b60352a4865b7e9e55dffbe0d17951cb4c50; 00aa9cbf61505e3fa77ef009eafe04300a5c39b2,Elsevier; Medline; PMC,Current status of rabies and prospects for elimination,10.1016/s0140-6736(13)62707-5,PMC7159301,24828901.0,no-cc,rabies one deadly infectious disease casefatality rate approaching disease established continent apart antarctica case reported africa asia thousand death recorded annually however estimated annual figure almost human rabies fatality probably underestimate almost case human rabies result bite infected dog therefore costeffective approach elimination global burden human rabies control canine rabies rather expansion availability human prophylaxis mass vaccination campaign parenteral vaccine advance oral vaccine wildlife allowed elimination rabies terrestrial carnivore several country worldwide subsequent reduction case human rabies region advocate multidisciplinary one health approach rabies control mass vaccination dog control canine population,2014-05-11,"Fooks, Anthony R; Banyard, Ashley C; Horton, Daniel L; Johnson, Nicholas; McElhinney, Lorraine M; Jackson, Alan C",Lancet,,,,document_parses/pdf_json/ab20b60352a4865b7e9e55dffbe0d17951cb4c50.json; document_parses/pdf_json/00aa9cbf61505e3fa77ef009eafe04300a5c39b2.json,document_parses/pmc_json/PMC7159301.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/24828901/; https://www.sciencedirect.com/science/article/pii/S0140673613627075; https://api.elsevier.com/content/article/pii/S0140673613627075; https://doi.org/10.1016/s0140-6736(13)62707-5,7924711.0,3
79070,79070,101730,wnwip3rs,e582bc041b65f0b488e292996f0c07d6dae95143; 8372200a0a5a24d19771c584a403e2b4281eddfb,Elsevier; Medline; PMC,Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments – the importance of immunofocusing in subunit vaccine design,10.1016/j.vaccine.2014.08.086,PMC4194190,25240756.0,bronze-oa,newly emerged middle east respiratory syndrome coronavirus merscov currently spreading among human making development effective mers vaccine high priority defined receptorbinding domain rbd merscov spike protein potentially serve subunit vaccine candidate merscov infection identify ideal vaccine candidate constructed five different version rbd fragment sfc sfc sfc sfc sfc name indicate residue range spike protein cterminal fc tag investigated receptor binding affinity antigenicity immunogenicity neutralizing potential result showed sfc among rbd fragment demonstrated highest dppbinding affinity induced highesttiter igg antibody mouse addition sfc elicited highertiter neutralizing antibody rbd fragment mouse also induced hightiter neutralizing antibody immunized rabbit structural analysis suggests sfc contains stably folded rbd structure full receptorbinding site major neutralizing epitope additional structure fragment introduce nonneutralizing epitope may also alter tertiary structure rbd taken together data suggest rbd fragment encompassing spike residue critical neutralizing receptorbinding fragment ideal candidate development effective mers vaccine adding nonneutralizing structure rbd fragment diminishes neutralizing potential therefore viral vaccine design important identify stable neutralizing viral rbd fragment eliminating unnecessary nonneutralizing structure mean “ immunofocusing ”,2014-10-01,"Ma, Cuiqing; Wang, Lili; Tao, Xinrong; Zhang, Naru; Yang, Yang; Tseng, Chien-Te K; Li, Fang; Zhou, Yusen; Jiang, Shibo; Du, Lanying",Vaccine,,,,document_parses/pdf_json/e582bc041b65f0b488e292996f0c07d6dae95143.json; document_parses/pdf_json/8372200a0a5a24d19771c584a403e2b4281eddfb.json,document_parses/pmc_json/PMC4194190.xml.json,https://api.elsevier.com/content/article/pii/S0264410X14012559; https://doi.org/10.1016/j.vaccine.2014.08.086; https://www.sciencedirect.com/science/article/pii/S0264410X14012559; https://www.ncbi.nlm.nih.gov/pubmed/25240756/,205596611.0,3
79072,79072,101732,de0b27nq,d5e257eb542dd3f05e052663701a22b5d1f10860,Elsevier; Medline; PMC,Kunjin replicon-based simian immunodeficiency virus gag vaccines,10.1016/j.vaccine.2008.04.001,PMC7115363,18462846.0,els-covid,rnabased noncytopathic replicon vector system based flavivirus kunjin shown considerable promise new vaccine delivery system describe testing mouse four different sivmac gag vaccine delivered kunjin replicon viruslikeparticles four vaccine encoded wild type gag gene rnaoptimised gag gene codonoptimised gag gene modified gagpol gene construct vaccine behaved quite differently induction effector memory central memory response mediation protection respect insert stability siv gagpol vaccine providing optimal performance result illustrate rnabased vector rna sequence antigen profound unforeseen consequence vaccine behaviour,2008-06-19,"Anraku, Itaru; Mokhonov, Vladislav V.; Rattanasena, Paweena; Mokhonova, Ekaterina I.; Leung, Jason; Pijlman, Gorben; Cara, Andrea; Schroder, Wayne A.; Khromykh, Alexander A.; Suhrbier, Andreas",Vaccine,,,,document_parses/pdf_json/d5e257eb542dd3f05e052663701a22b5d1f10860.json,document_parses/pmc_json/PMC7115363.xml.json,https://api.elsevier.com/content/article/pii/S0264410X08004234; https://doi.org/10.1016/j.vaccine.2008.04.001; https://www.ncbi.nlm.nih.gov/pubmed/18462846/; https://www.sciencedirect.com/science/article/pii/S0264410X08004234,7816087.0,3
79073,79073,101733,z3o4t7mz,6bda166e9d6eaf0f88a4d1d43288b4ff8340d184,Elsevier; PMC,Protection of swine by live and inactivated vaccines prepared from a leader proteinase-deficient serotype A12 foot-and-mouth disease virus,10.1016/s0264-410x(98)00029-2,PMC7172646,9711798.0,els-covid,previously demonstrated genetically engineered variant footandmouth disease virus fmdv serotype lacking leader proteinasecoding region allv attenuated induced immune response partially protected cattle fmd study allv tested swine live chemically inactivated vaccine animal vaccinated chemically inactivated allv wildtype wt virus oil adjuvant developed high level neutralizing antibody protected fmd upon challenge animal vaccinated live allv exhibit sign fmd spread virus animal developed neutralizing antibody response antibody nonstructural protein partially protected fmd animal given similar dose chemically inactivated allv absence adjuvant developed poor immune response protected fmd indicating limited replication responsible improved immune response found animal vaccinated live allv result demonstrate potential allv liveattenuated vaccine well safe source antigen chemically inactivated vaccine,1998-10-31,"Chinsangaram, Jarasvech; Mason, Peter W.; Grubman, Marvin J.",Vaccine,,,,document_parses/pdf_json/6bda166e9d6eaf0f88a4d1d43288b4ff8340d184.json,,https://www.sciencedirect.com/science/article/pii/S0264410X98000292; https://api.elsevier.com/content/article/pii/S0264410X98000292,25050998.0,3
79089,79089,101750,hmwkf6is,166b70bab11b13953f7a074daa76bbe53d7300b7,Medline; PMC,Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral Vector,10.3389/fmicb.2011.00220,PMC3207220,22065964.0,no-cc,recombinant adenoassociated viral raav vector promote longterm gene transfer many animal specie significant effort focused evaluation raav delivery immune response murine canine model neuromuscular disease however canine provided research purpose routinely vaccinated canine parvovirus cpv raav cpv posse significant homology parvovirus thus immune response generated cpv vaccination potential crossreact raav vector study investigated immune response raav delivery cohort cpvvaccinated canine evaluated multiple vaccination regimen mouse model cpvvaccination show cpvvaccination stimulates production neutralizing antibody minimal crossreactivity raav addition significant difference observed magnitude raavdirected immune response cpvvaccinated animal control moreover cpvvaccination inhibit raavmediated transduction also evaluated immune response early raavvaccination neonatal mouse influence maternal hormone cytokine lead relatively permissive state neonate hypothesized immaturity immune system would permit induction tolerance raav delivered neonatal period mouse vaccinated raav day age subsequently challenged raav exposure adulthood via two sequential im injection month apart vaccinated animal generated significant neutralizing antibody response raavvaccination enhanced following im injection adulthood taken together data demonstrate immune response raised raav distinct elicited standard parvoviral vaccine sufficient prevent stable tolerization neonatal mouse,2011-11-03,"Arnett, Andrea L. H.; Garikipati, Dilip; Wang, Zejing; Tapscott, Stephen; Chamberlain, Jeffrey S.",Front Microbiol,,,,document_parses/pdf_json/166b70bab11b13953f7a074daa76bbe53d7300b7.json,document_parses/pmc_json/PMC3207220.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/22065964/; https://doi.org/10.3389/fmicb.2011.00220,3100757.0,3
79110,79110,101776,6m9vdjgl,a67536cd819cdbd860efe4a755233eb8eaa770b0,Medline; PMC,A novel TLR7 agonist as adjuvant to stimulate high quality HBsAg-specific immune responses in an HBV mouse model,10.1186/s12967-020-02275-2,PMC7055022,32131853.0,cc-by,background global burden hepatitis b virus hbv infection term morbidity mortality immense novel treatment induce protective immune response urgently needed effectively control hbv epidemic eventually eradicate chronic hbv infection method designed evaluated hbv therapeutic vaccine consisting novel tolllike receptor tlr agonist tea alum adjuvant recombinant hbsag protein used rnaseq elisa htlr reporting assay characterize tea vitro realtime pcr evaluate tissueretention characteristic vivo evaluate adjuvant potential administrated tea intraperitoneally formulation alum adjuvant hbsag normal hbv mouse evaluated hbsagspecific immune response elisa elispot assay result tea acted htlrspecific agonist induced similar gene expression pattern unmodified tlr ligand raw cell exposed tea however tea potent unmodified tlr ligand vivo study showed tea tissueretaining activity stimulating local cytokine chemokine expression day tea could induce thtype immune response evidenced increased hbsagspecific igga titer tcell response normal mouse compared mouse received traditional alumadjuvant hbv vaccine importantly tea could break immune tolerance induce persistent hbsagspecific antibody tcell response hbv mouse model conclusion tea might candidate adjuvant prophylactic therapeutic hbv vaccine,2020-03-04,"Hu, Yunlong; Tang, Li; Zhu, Zhengyu; Meng, He; Chen, Tingting; Zhao, Sheng; Jin, Zhenchao; Wang, Zhulin; Jin, Guangyi",J Transl Med,,,,document_parses/pdf_json/a67536cd819cdbd860efe4a755233eb8eaa770b0.json,document_parses/pmc_json/PMC7055022.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32131853/; https://doi.org/10.1186/s12967-020-02275-2,211836110.0,3
79126,79126,101792,0t4uxmj2,0aab3823dd11220b278bb89cc745bf21ad294b99,Elsevier; PMC,A corn-based delivery system for animal vaccines: an oral transmissible gastroenteritis virus vaccine boosts lactogenic immunity in swine,10.1016/j.vaccine.2003.11.066,PMC7126512,15193404.0,els-covid,recombinant plant expression system offer mean produce large quantity selected antigen subunit vaccine cereal particularly wellsuited expression vehicle since expressed protein stored relatively high concentration extended period time without degradation dry seed formulated oral vaccine suitable commercial application subunit vaccine candidate directed porcine transmissible gastroenteritis virus expressed corn seed developed oral delivery swine show vaccine administered previously sensitized gilt boost neutralizing antibody level animal ’ serum colostrum milk thus vaccine candidate effective boosting lactogenic immunity appropriate pursue largescale field trial preceding commercialization,2004-06-23,"Lamphear, Barry J.; Jilka, Joseph M.; Kesl, Lyle; Welter, Mark; Howard, John A.; Streatfield, Stephen J.",Vaccine,,,,document_parses/pdf_json/0aab3823dd11220b278bb89cc745bf21ad294b99.json,document_parses/pmc_json/PMC7126512.xml.json,https://api.elsevier.com/content/article/pii/S0264410X04002518; https://www.sciencedirect.com/science/article/pii/S0264410X04002518,22162182.0,3
79152,79152,101822,q28h5zi8,89d98e705490a5ab2eb7fd40de4541bba9051abb,Medline; PMC,HIV Vaccine Mystery and Viral Shell Disorder,10.3390/biom9050178,PMC6572542,31072073.0,cc-by,hundred billion dollar spent three decade search effective human immunodeficiency virus hiv vaccine success also least two sexually transmitted virus vaccine available herpes simplex virus hsv hepatitis c virus hcv traditional textbook explanatory paradigm rapid mutation retrovirus adequately address unavailability vaccine many sexually transmissible virus since hsv hcv dna nonretroviral rna virus respectively whereas effective vaccine horseflytransmitted retroviral cousin hiv equine infectious anemia virus eiav found reported earlier highly disordered nature protein outer shell hiv hcv hsv level disorder completely absent among classical virus smallpox rabies yellow fever polio virus efficient vaccine discovered review analyzes physiology shell disorder various related nonrelated virus argue eiav classical virus need harder shell survive harsher condition nonsexual transmission thus making vulnerable antibody detection neutralization contrast outer shell hiv preferential sexual transmission highly disordered thereby allowing large scale motion surface glycoprotein making difficult antibody bind theoretical underpinning concept retrospectively traced classical experiment legendary scientist oswald avery concept viral shapeshifting implication improved treatment cancer infection via immune evasion,2019-05-08,"Goh, Gerard Kian-Meng; Dunker, A. Keith; Foster, James A.; Uversky, Vladimir N.",Biomolecules,,,,document_parses/pdf_json/89d98e705490a5ab2eb7fd40de4541bba9051abb.json,document_parses/pmc_json/PMC6572542.xml.json,https://doi.org/10.3390/biom9050178; https://www.ncbi.nlm.nih.gov/pubmed/31072073/,149446387.0,3
79202,79202,101887,jna496x7,c75b2dcbddee584a18274cd1f49782e4e9f2a010,Elsevier; Medline; PMC,SARS vaccine based on a replication-defective recombinant vesicular stomatitis virus is more potent than one based on a replication-competent vector,10.1016/j.virol.2008.03.002,PMC7103385,18396306.0,els-covid,sars vaccine based liveattenuated vesicular stomatitis virus vsv recombinant expressing sarscov protein provides longterm protection immunized mouse sarscov infection kapadia su rose j k lamirande e vogel l subbarao k robert longterm protection sars coronavirus infection conferred single immunization attenuated vsvbased vaccine virology – difficult obtain regulatory approval vaccine based live virus constructed replicationdefective singlecycle vsv vector replaced vsv glycoprotein g gene sarscov gene virus able infect cell pseudotyped vsv g protein measured effectiveness immunization singlecycle vaccine mouse found vaccine given intramuscularly induced neutralizing antibody response sarscov approximately tenfold greater required protection sarscov infection significantly greater generated replicationcompetent vector expressing sarscov protein given route result along earlier study showing potent induction tcell response singlecycle vector indicate vector excellent alternative liveattenuated vsv,2008-06-20,"Kapadia, Sagar U.; Simon, Ian D.; Rose, John K.",Virology,,,,document_parses/pdf_json/c75b2dcbddee584a18274cd1f49782e4e9f2a010.json,document_parses/pmc_json/PMC7103385.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/18396306/; https://doi.org/10.1016/j.virol.2008.03.002; https://www.sciencedirect.com/science/article/pii/S0042682208001736; https://api.elsevier.com/content/article/pii/S0042682208001736,23021284.0,3
79258,79258,101953,mpoqcfja,c7d45ee67540ca49e9d47a3939ad3f494bb54445,Elsevier; Medline; PMC,Load reduction in live PRRS vaccines using oil and polymer adjuvants,10.1016/j.provac.2012.04.018,PMC7128483,32288919.0,els-covid,prrsv live vaccine widely used pig farming practice usually adjuvanted safety issue would useful reduce antigenic load vaccine preserving efficacy study show addition polymer oil adjuvant prrs live vaccine enhanced protection challenge vaccinated animal compared nonadjuvanted commercial reference moreover type adjuvant despite lower antibody titer protection challenge given adjuvanted vaccine containing antigen load equivalent protection given nonadjuvanted vaccine result demonstrate addition relevant adjuvant enhance efficacy protection conferred animal live vaccine,2012-12-31,"Deville, Sebastien; Arous, Juliette Ben; Ionkoff, Ghislaine; Kukushkin, François Bertranda Sergey; Baybikov, Taufik; Borisov, Vladimir; Dupuis, Laurent",Procedia in Vaccinology,,,,document_parses/pdf_json/c7d45ee67540ca49e9d47a3939ad3f494bb54445.json,,https://doi.org/10.1016/j.provac.2012.04.018; https://www.sciencedirect.com/science/article/pii/S1877282X12000203; https://www.ncbi.nlm.nih.gov/pubmed/32288919/; https://api.elsevier.com/content/article/pii/S1877282X12000203,85229826.0,3
79284,79284,101987,ghsil7jz,6cab413e00675285c0dafb8c2824114a3358b403,Elsevier; Medline; PMC,Large-scale production and purification of VLP-based vaccines,10.1016/j.jip.2011.05.004,PMC7094596,21784230.0,els-covid,viruslike particle vlps hold tremendous potential vaccine candidate innovative biopharmaceuticals present remarkable advantage closely mimicking threedimensional nature actual virus lacking virus genome packaged inside capsid result equally efficient safer prophylaxis anticipated compared inactivated live attenuated viral vaccine advent successful case approved vlpbased vaccine pharmaceutical company indeed redirecting resource development product paper review current choice trend largescale production purification vlpbased vaccine generated baculovirus expression vector system using insect cell,2011-07-31,"Vicente, Tiago; Roldão, António; Peixoto, Cristina; Carrondo, Manuel J.T.; Alves, Paula M.",Journal of Invertebrate Pathology,,,,document_parses/pdf_json/6cab413e00675285c0dafb8c2824114a3358b403.json,document_parses/pmc_json/PMC7094596.xml.json,https://api.elsevier.com/content/article/pii/S0022201111000772; https://doi.org/10.1016/j.jip.2011.05.004; https://www.ncbi.nlm.nih.gov/pubmed/21784230/; https://www.sciencedirect.com/science/article/pii/S0022201111000772,10553284.0,3
79321,79321,102031,z26xlqv8,ae7eb643b9434689092354a21abd88ea9c65926a,Elsevier; Medline; PMC,One time intranasal vaccination with a modified vaccinia Tiantan strain MVTTZCI protects animals against pathogenic viral challenge,10.1016/j.vaccine.2009.12.038,PMC7127290,20045097.0,els-covid,combat variola virus bioterrorist attack desirable develop noninvasive vaccine based vaccinia tiantan vtt strain historically used eradicate smallpox china generated modified vtt mvttzci removing hemagglutinin gene bp genomic region hindiii fragment cl fl mvttzci characterized host cell range vitro preclinical safety efficacy profile mouse despite replicationcompetency cell line unlike vtt mvttzci cause death intracranial injection body weight loss intranasal inoculation mvttzci replicate mouse brain safe immunodeficient mouse mvttzci induced neutralizing antibody via intranasal route immunization one time intranasal immunization protected animal challenge pathogenic vaccinia wr strain study established proofofconcept attenuated replicating mvttzci may serve safe noninvasive smallpox vaccine candidate,2010-02-25,"Yu, Wenbo; Fang, Qing; Zhu, Weijun; Wang, Haibo; Tien, Po; Zhang, Linqi; Chen, Zhiwei",Vaccine,,,,document_parses/pdf_json/ae7eb643b9434689092354a21abd88ea9c65926a.json,document_parses/pmc_json/PMC7127290.xml.json,https://api.elsevier.com/content/article/pii/S0264410X09019422; https://doi.org/10.1016/j.vaccine.2009.12.038; https://www.ncbi.nlm.nih.gov/pubmed/20045097/; https://www.sciencedirect.com/science/article/pii/S0264410X09019422,43545039.0,3
79428,79428,102165,imatoqzt,72c8ff2d461245f6e4d636548537484c0391735d,Elsevier; Medline; PMC,Attitudes and perception of influenza vaccines among older people in Singapore: A qualitative study,10.1016/j.vaccine.2019.09.037,PMC7130882,31542261.0,els-covid,background despite recommendation influenza vaccination people aged uptake rate influenza vaccine remains low study aim understand barrier motivator behind older adult ’ decision influenza vaccination method face face interview participant aged conducted audio recorded geylang polyclinic singapore thematic content analysis used organise data result older adult interviewed aged year old vaccine refusers defaulter acceptor perceived lack vulnerability fear side effect trivialisation influenza common reason taking vaccine encouragement family friend travel previous positive vaccination experience motivator getting vaccinated healthcare worker played role influencing many participant ’ decisionmaking common misconception included vaccine considered necessary travel cure rather prevention participant exhibited ambivalence giving reason vaccine uptake discussion older adult perceive influenza potentially serious disease trust influenza vaccine ’ efficacy misconception played significant role vaccine decline novel finding include importance family unit decision making prioritization chronic health problem vaccination misconception vaccine needed travelling country healthcare worker family member appear important influencers decision making older adult actively engaged future health promotion initiative,2019-10-16,"Teo, L. M.; Smith, H. E.; Lwin, M. O.; Tang, W. E.",Vaccine,,,,document_parses/pdf_json/72c8ff2d461245f6e4d636548537484c0391735d.json,document_parses/pmc_json/PMC7130882.xml.json,https://api.elsevier.com/content/article/pii/S0264410X19312460; https://doi.org/10.1016/j.vaccine.2019.09.037; https://www.sciencedirect.com/science/article/pii/S0264410X19312460; https://www.ncbi.nlm.nih.gov/pubmed/31542261/,202731342.0,3
79442,79442,102179,cxcsblpg,35292b492d52cd4d91967a43338fb6ab4347352a,Medline; PMC,Regulatory T cells as adjuvant target for enhancing the viral disease vaccine efficacy,10.1007/s13337-013-0187-3,PMC3889236,24426307.0,green-oa,cdcdfoxp regulatory cell tregs critical immune homeostasis tolerance however capacity suppress antigen presenting cell apc b cell tregs could also inhibit protective immune response virus vaccine several virus shown exploit tregs evade immune response modulating apc particular weakening function dendritic cell ability secrete polarizing cytokine expression costimulatory molecule virus could support differentiation expansion tregs note proof concept depletion tregs significantly enhanced protective immune response virus vaccine suggesting tregs viable target enhance immunogenicity vaccine treg depletion inhibition function could lead deleterious autoimmune inflammatory disorder tregbased approach vaccination aim depletion tregs inhibition function transient recent study targeted interaction ccr expressed tregs ligand ccl ccl inhibit transiently recruitment tregs site immunization importantly use ccr antagonist ‘ molecular adjuvant ’ vivo experimental model amplified cellular humoral immune response injected combination various vaccine antigen significant adjuvant activity observed diverse model without noticeable side effect provided strong evidence ccr sustainable target rational adjuvant design,2013-11-29,"Bayry, Jagadeesh",VirusDisease,,,,document_parses/pdf_json/35292b492d52cd4d91967a43338fb6ab4347352a.json,document_parses/pmc_json/PMC3889236.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/24426307/; https://doi.org/10.1007/s13337-013-0187-3; http://europepmc.org/articles/pmc3889236?pdf=render,12790966.0,3
79447,79447,102186,odyb4slr,3cf41b596058f2d1b07760563aa6c5316b014af2,Medline; PMC,Genetic manipulation of porcine deltacoronavirus reveals insights into NS6 and NS7 functions: a novel strategy for vaccine design,10.1080/22221751.2019.1701391,PMC6968670,31859605.0,cc-by,porcine deltacoronavirus pdcov emerging swine coronavirus cause severe diarrhea resulting high mortality neonatal piglet despite widespread outbreak many country effective pdcov vaccine currently available generated first time fulllength infectious cdna clone pdcov manipulated infectious clone replacing n gene green fluorescent protein gfp generate rpdcovδnsgfp likewise rpdcovδns constructed removing atg start codon n gene growth kinetics study suggest rpdcovδns could replicate similarly wildtype pdcov whereas rpdcovδnsgfp exhibited substantial reduction viral titer vitro vivo piglet inoculated rpdcovδns wildtype pdcov showed similar diarrheic score pathological injury contrast rpdcovδnsgfpinfected piglet show clinical sign indicating n protein important virulence factor pdcov nsdeficient mutant virus might promising liveattenuated vaccine candidate taken together reverse genetics platform described provides insight role pdcov accessory protein viral replication pathogenesis also allows development novel vaccine pdcov infection,2019-12-20,"Zhang, Mengjia; Li, Wan; Zhou, Peng; Liu, Dejian; Luo, Rui; Jongkaewwattana, Anan; He, Qigai",Emerg Microbes Infect,,,,document_parses/pdf_json/3cf41b596058f2d1b07760563aa6c5316b014af2.json,document_parses/pmc_json/PMC6968670.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31859605/; https://doi.org/10.1080/22221751.2019.1701391,209427704.0,3
79475,79475,102225,8ohcvrq8,ec47b828779bbf11f1f28a9196c87c24662bfe4c,Elsevier; Medline; PMC,Effect of different vaccination strategies on IBV QX population dynamics and clinical outbreaks,10.1016/j.vaccine.2016.09.014,PMC7173296,27670071.0,no-cc,extreme variability rapid evolution infectious bronchitis virus ibv always represented key challenge control limited crossprotection among different strain several experimental trial proven broadening protection spectrum animal vaccinated multiple genotype nevertheless condition vaccine administration field different generalization experimental result least questionable present study large scale epidemiologicalphylodynamic approach used reconstruct demographic history major field genotype ie qx one circulating italy spain two country selected even share comparable epidemiological scenario implemented vaccination protocol vary spain changed dramatically italy time period considered one hundred ninetyfive italian spanish nonrecombinant sequence hypervariable region gene obtained analyzed using serial coalescentbased approach reconstruct viral population history time ibv qx population dynamic remained constant spain much complex pattern evidenced italy term viral population size clinical outbreak frequency remarkably strong association change vaccination strategy recognized allowed demonstrating accomplishing hill ’ criterion causation causeeffect relationship vaccine administrationwithdrawal variation viral population dynamic ibv related outbreak thus robust confirmation efficacy ibv vaccination field condition provided additionally history herein reported testifies primary importance rigorously planning intervention strategy also monitoring evaluation,2016-11-04,"Franzo, Giovanni; Tucciarone, Claudia Maria; Blanco, Angela; Nofrarías, Miquel; Biarnés, Mar; Cortey, Marti; Majó, Natàlia; Catelli, Elena; Cecchinato, Mattia",Vaccine,,,,document_parses/pdf_json/ec47b828779bbf11f1f28a9196c87c24662bfe4c.json,document_parses/pmc_json/PMC7173296.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/27670071/; https://api.elsevier.com/content/article/pii/S0264410X16308271; https://doi.org/10.1016/j.vaccine.2016.09.014; https://www.sciencedirect.com/science/article/pii/S0264410X16308271,205602523.0,3
79483,79483,102233,tlw3dpfa,5d1dda983b4e851da348765ac777b82cd66569ae,Medline; PMC,Viral Vaccines in India: An Overview,10.1007/s40011-011-0014-9,PMC7100346,32226202.0,no-cc,virus cause large number disease human fatal others highly debilitating majority viral disease attack infant young child others strike people prime development preventive measure viral disease therefore paramount importance vaccination costeffective medical intervention preventing mortality morbidity infectious disease number effective safe vaccine currently available several viral disease significant medical importance many manufactured india par international standard affordable many viral disease vaccine currently available research underway various national laboratory well private sector company india present overview highlight various vaccine preventable viral disease special importance india aim provide glimpse various vaccine currently available development india,2012-01-17,"Bharati, Kaushik; Vrati, Sudhanshu",Proc Natl Acad Sci India Sect B Biol Sci,,,,document_parses/pdf_json/5d1dda983b4e851da348765ac777b82cd66569ae.json,document_parses/pmc_json/PMC7100346.xml.json,https://doi.org/10.1007/s40011-011-0014-9; https://www.ncbi.nlm.nih.gov/pubmed/32226202/,14505001.0,3
79602,79602,102378,oo3ykjro,bbd8e61d7f7ce1f7be22bc0c34d381a2fc585ac7,Medline; PMC,Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure,10.1093/infdis/jiaa152,PMC7184325,32232474.0,cc-by,controlled human challenge trial sarscov vaccine candidate could accelerate testing potential rollout efficacious vaccine replacing conventional phase testing vaccine candidate trial may subtract many month licensure process making efficacious vaccine available quickly obviously challenging volunteer live virus risk inducing severe disease possibly even death however argue study accelerating vaccine evaluation could reduce global burden coronavirusrelated mortality morbidity volunteer study could autonomously authorize risk net risk could acceptable participant comprise healthy young adult relatively low risk serious disease following natural infection high baseline risk natural infection trial receive frequent monitoring following infection best available care,2020-03-31,"Eyal, Nir; Lipsitch, Marc; Smith, Peter G",J Infect Dis,,,,document_parses/pdf_json/bbd8e61d7f7ce1f7be22bc0c34d381a2fc585ac7.json,document_parses/pmc_json/PMC7184325.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32232474/; https://doi.org/10.1093/infdis/jiaa152,214751151.0,3
79608,79608,102388,oqtu87f5,28db8e9fcf106e7e3392f627f6f5770e180ec33a,Elsevier; Medline; PMC; WHO,A cutting-edge immunoinformatics approach for design of multi-epitope oral vaccine against dreadful human malaria,10.1016/j.ijbiomac.2020.04.191,PMC7189201,32360460.0,no-cc,human malaria pathogenic disease mainly caused plasmodium falciparum responsible death globally year date several vaccine candidate evaluated prevention failed produce optimal output various preclinicalclinical stage study based designing polypeptide vaccine pvs human malaria cover almost stage life cycle plasmodium genome derived predicted antigenic protein gdpap used development multiimmune inducer pvs initially designed using cell epitope ensemble covered human population well linear b cell epitope without adjuvant immune simulation pvs showed higher level tcell bcell activity compared positive negative vaccine control furthermore silico cloning pvs codon optimization followed enhanced expression within lactococcus lactis host system also explored although study sound theoretical silico finding vitroin vivo evaluation seems imperative warrant immunogenicity safety pvs towards management p falciparum infection future,2020-04-29,"Pritam, Manisha; Singh, Garima; Swaroop, Suchit; Singh, Akhilesh Kumar; Pandey, Brijesh; Singh, Satarudra Prakash",Int J Biol Macromol,,#141701,,document_parses/pdf_json/28db8e9fcf106e7e3392f627f6f5770e180ec33a.json,document_parses/pmc_json/PMC7189201.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32360460/; https://doi.org/10.1016/j.ijbiomac.2020.04.191; https://api.elsevier.com/content/article/pii/S0141813020330506; https://www.sciencedirect.com/science/article/pii/S0141813020330506?v=s5,216588853.0,3
79624,79624,102407,hy708ia4,4476687d4a23df5d5428626f81d9621abf94e679,Medline; PMC,Synergistic effect of ribavirin and vaccine for protection during early infection stage of foot-and-mouth disease,10.4142/jvs.2018.19.6.788,PMC6265586,30304889.0,cc-by-nc,many country vaccine used prevention footandmouth disease fmd however protection fmd immediately vaccination research development antiviral agent conducted induce protection immunological competence produced study tested whether wellknown chemical used rna virus treatment agent inhibitory effect fmd virus fmdvs demonstrated ribavirin showed antiviral effect fmdv vitroin vivo addition observed combining administration antiviral agent orally complementary therapy vaccine synergistically enhanced antiviral activity preserved survival rate body weight experimental animal antiviral agent mixed adjuvant inoculated intramuscularly along vaccine thereby inhibiting virus replication injection verifying possible induce early protection viral infection prior immunity achieved vaccine finally pig treated antiviral agent vaccine showed clinical sign low virus excretion based result expected combined approach could therapeutic preventive treatment early protection fmd,2018-11-28,"Choi, Joo-Hyung; Jeong, Kwiwan; Kim, Su-Mi; Ko, Mi-Kyeong; You, Su-Hwa; Lyoo, Young S.; Kim, Byounghan; Ku, Jin-Mo; Park, Jong-Hyeon",J Vet Sci,,,,document_parses/pdf_json/4476687d4a23df5d5428626f81d9621abf94e679.json,document_parses/pmc_json/PMC6265586.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30304889/; https://doi.org/10.4142/jvs.2018.19.6.788,17209849.0,3
79639,79639,102426,wh39sbx6,,Medline; WHO,Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic,10.12932/ap-200220-0772,,32105090.0,unk,world witnessing epidemic covid disease caused novel coronavirus sarscov emerging genetics clinical evidence suggest similar path sars mers rapid genomic sequencing open access data together advanced vaccine technology expected give u knowledge pathogen including host immune response well plan therapeutic vaccine near future review aim provide comparative view among sarscov merscov newly epidemic sarscov hope gain better understanding hostpathogen interaction host immune response pathogen immune evasion strategy predictive view may help designing immune intervention preventive vaccine covid near future,2020,"Prompetchara, E.; Ketloy, C.; Palaga, T.",Asian Pacific journal of allergy and immunology,,#2922,,,,https://www.ncbi.nlm.nih.gov/pubmed/32105090/; https://doi.org/10.12932/ap-200220-0772,211535628.0,3
79697,79697,102494,3qc56c7d,b16661737670c31ebba2bef5a7c8a6466f72b8eb,Elsevier; Medline; PMC,An unusual case of influenza-like illness after yellow fever vaccination,10.1016/j.jcv.2014.01.020,PMC7128991,24594082.0,els-covid,yellow fever yf important public health concern area disease endemic year highly effective live attenuated vaccine available widespread use resulting dramatic decrease number case rare occasion yf vaccine cause mild severe disease rare adverse vaccineassociated event reported additionally average viremia – day administration yf vaccine published present case yf vaccine isolated cell culture respiratory swab collected patient presenting influenzalike illness best knowledge first report finding replicating yf vaccine respiratory sample post inoculated individual,2014-05-31,"Lamson, Daryl M.; Ramani, Rama; Kleabonas, Matthew; Metcalfe, Maureen; Humphrey, Charles; St. George, Kirsten",Journal of Clinical Virology,,,,document_parses/pdf_json/b16661737670c31ebba2bef5a7c8a6466f72b8eb.json,document_parses/pmc_json/PMC7128991.xml.json,https://doi.org/10.1016/j.jcv.2014.01.020; https://api.elsevier.com/content/article/pii/S1386653214000407; https://www.sciencedirect.com/science/article/pii/S1386653214000407; https://www.ncbi.nlm.nih.gov/pubmed/24594082/,19779562.0,3
79723,79723,102534,gevrlcvy,4d77c1be3e298496537c5d106afeb77655b9ca13,Elsevier; Medline; PMC,Challenges in mucosal vaccination of cattle,10.1016/j.vetimm.2008.10.297,PMC7127216,19046777.0,els-covid,recognition mucosal portal entry many infectious disease relevance mucosal immune response protection encouraged development vaccine administered mucosal route principally oral intranasal stimulation intestinal nasopharyngeal lymphoid tissue respectively oral route problematic cattle ruminant antigen degradation rumen likely prior transit intestine hand rumination exploited exposure nasopharyngeal tissue cudding vaccine antigen expressed fibrous feed like alfalfa increase antileukotoxin lkt iga demonstrated nasal secretion calf following feeding alfalfa expressing truncated lkt mannheimia haemolytica evidence suggesting vaccination may protect experimentally induced pneumonia intranasal vaccination alternative approach use preruminating calf intranasal administration iscoms carrying soluble antigen haemolytica including native lkt induced lkt specific iga nasal secretion vaccination week age subcutaneous sc administration vaccine induced lkt specific igg serum nasal secretion whereas sc administration commercial haemolytica vaccine regardless vaccination strategy employed difficult ass immunogenicity mucosally administered vaccine production secreted antibody tends transient persist mucosal surface absence ongoing antigenic stimulation additional challenge demonstration vaccine efficacy response experimental infection protection mucosally vaccinated animal probably result recall response may amplify sufficiently counter effect experimental pulmonary delivery large bolus virulent bacteria even though response would suffice prolonged gradual infection occurs natural induction pneumonia,2009-03-15,"Shewen, P. E.; Carrasco-Medina, L.; McBey, B. A.; Hodgins, D. C.",Veterinary Immunology and Immunopathology,,,,document_parses/pdf_json/4d77c1be3e298496537c5d106afeb77655b9ca13.json,document_parses/pmc_json/PMC7127216.xml.json,https://www.sciencedirect.com/science/article/pii/S0165242708004030; https://doi.org/10.1016/j.vetimm.2008.10.297; https://www.ncbi.nlm.nih.gov/pubmed/19046777/; https://api.elsevier.com/content/article/pii/S0165242708004030,23009559.0,3
79746,79746,102558,7c6o674b,2a0c4d90adbec7a1d5263e5c197904e83cd8f7e1,Elsevier; Medline; PMC,A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats,10.1016/j.vaccine.2008.05.016,PMC6186147,18556094.0,green-oa,nipah virus niv hendra virus hev closely related deadly zoonotic paramyxovirus emerged reemerged last year study subunit vaccine formulation containing recombinant soluble attachment glycoprotein hev sghev cpg adjuvant evaluated potential niv vaccine cat model different amount sghev employed sginduced immunity examined vaccinated animal demonstrated varying level niv–specific ig systemically importantly vaccinated cat possessed antigenspecific iga mucosa upon oronasal challenge niv tcid vaccinated animal protected disease although virus detected day postchallenge one animal ability elicit protective systemic mucosal immunity animal model provides significant progress towards development human subunit vaccine henipaviruses,2008-07-01,"McEachern, Jennifer A.; Bingham, John; Crameri, Gary; Green, Diane J.; Hancock, Tim J.; Middleton, Deborah; Feng, Yan-Ru; Broder, Christopher C.; Wang, Lin-Fa; Bossart, Katharine N.",Vaccine,,,,document_parses/pdf_json/2a0c4d90adbec7a1d5263e5c197904e83cd8f7e1.json,document_parses/pmc_json/PMC6186147.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/18556094/; https://doi.org/10.1016/j.vaccine.2008.05.016; https://api.elsevier.com/content/article/pii/S0264410X08005720; https://www.sciencedirect.com/science/article/pii/S0264410X08005720,13239602.0,3
79756,79756,102570,sp212tai,281fd5c29156a80cab2f647142f635712680a58d,Medline; PMC,A phase trial of the oral Lactobacillus casei vaccine polarizes Th2 cell immunity against transmissible gastroenteritis coronavirus infection,10.1007/s00253-016-7424-9,PMC7080089,27020282.0,no-cc,transmissible gastroenteritis coronavirus tgev member genus coronavirus family coronaviridae order nidovirales tgev enteropathogenic coronavirus cause highly fatal acute diarrhoea newborn pig oral lactobacillus casei l casei vaccine antitransmissible gastroenteritis virus developed laboratory used study mucosal immune response l casei vaccine repetitive peptide expressed l casei specifically mdp tuftsin fusion protein mt repeated time antigenic site tgev spike protein repeated time immunization recombinant lactobacillus crucial investigation effect immunization first immunization time dose first immunization important last immunization series recombinant lactobacillus elicited specific systemic mucosal immune response recombinant l casei strong potentiating effect cellular immunity induced oral l casei vaccine however tgev infection systemic local immune response switched th thbased immune response systemic humoral immune response stronger cellular immune response tgev infection found recombinant lactobacillus stimulated il expression systemic mucosal immune response tgev infection furthermore lactobacillus vaccine stimulated antitgev infection th pathway histopathological examination showed tremendous potential recombinant lactobacillus enable rapid effective treatment tgev intestinal tropism piglet tgev immune protection primarily dependent mucosal immunity,2016-03-28,"Jiang, Xinpeng; Hou, Xingyu; Tang, Lijie; Jiang, Yanping; Ma, Guangpeng; Li, Yijing",Appl Microbiol Biotechnol,,,,document_parses/pdf_json/281fd5c29156a80cab2f647142f635712680a58d.json,document_parses/pmc_json/PMC7080089.xml.json,https://doi.org/10.1007/s00253-016-7424-9; https://www.ncbi.nlm.nih.gov/pubmed/27020282/,18427025.0,3
79759,79759,102574,4vnsq8h6,577d9959d2b1b065cfae2ed5e7ac503e92cc8c69,Elsevier; Medline; PMC,Genomic and antigenic characterization of bovine parainfluenza-3 viruses in the United States including modified live virus vaccine (MLV) strains and field strains from cattle,10.1016/j.virusres.2017.04.009,PMC7172726,28416404.0,no-cc,study investigated genetic antigenic characterization parainfluenza virus piv cattle using molecular test including real time pcr viral genome sequencing piv strain could separated piv type including piv piv b piv c isolates cattle bovine respiratory disease clinical sign commercial vaccine u mlv piv typed using molecular test mlv vaccine strain tested piv case piv field strain calf receiving mlv vaccine type heterologous vaccine type also antigenic difference noted piv c strain lower antibody level piv serum cattle receiving mlv piv vaccine study demonstrates genetic variability u piv strain also antigenic variability addition isolates cattle brd sign receiving mlv vaccine may heterologous type vaccine molecular test performed differentiate field vaccine strain potentially efficacy current piv vaccine evaluated type piv b piv c,2017-05-02,"Fulton, R.W.; Neill, J.D.; Saliki, J.T.; Landis, C.; Burge, L.J.; Payton, M.E.",Virus Res,,,,document_parses/pdf_json/577d9959d2b1b065cfae2ed5e7ac503e92cc8c69.json,document_parses/pmc_json/PMC7172726.xml.json,https://www.sciencedirect.com/science/article/pii/S0168170217301107; https://api.elsevier.com/content/article/pii/S0168170217301107; https://doi.org/10.1016/j.virusres.2017.04.009; https://www.ncbi.nlm.nih.gov/pubmed/28416404/,13049901.0,3
79763,79763,102578,3qyn3ka5,52fd553c11cbb5847e82f6679eddb6f205266cfb,Elsevier; Medline; PMC,Isatis indigotica root polysaccharides as adjuvants for an inactivated rabies virus vaccine,10.1016/j.ijbiomac.2016.02.023,PMC7112441,26875535.0,els-covid,adjuvant enhance vaccine immunogenicity induce longterm enhancement immune response thus adjuvant important vaccine research polysaccharide isolated select chinese herb demonstrated posse various beneficial function excellent adjuvant ability present study polysaccharide iipa iip isolated isatis indigotica root compared common vaccine adjuvant aluminum hydroxide via intramuscular coadministration inactivated rabies virus rcvsg mouse blood collected determine virus neutralizing antibody vna titer b lymphocyte activation status inguinal lymph node sample collected used measure b lymphocyte proliferation splenocytes isolated antigenspecific cellular immune response detected via elispot elisa intracellular cytokine staining result revealed type polysaccharide induce rapid change higher vna titer aluminum hydroxide flow cytometry assay revealed polysaccharide activated b lymphocyte lymph node b lymphocyte blood aluminum hydroxide antigenspecific cellular immune response showed iip strongly induced lymphocyte proliferation spleen high level cytokine secretion splenocytes whereas aluminum hydroxide induced proliferation small number lymphocyte secretion small quantity cytokine collectively data suggest polysaccharide iip exhibit excellent adjuvant activity enhance cellular humoral immunity,2016-06-30,"Zhang, Weijiao; Zheng, Xuexing; Cheng, Nan; Gai, Weiwei; Xue, Xianghong; Wang, Yuxia; Gao, Yuwei; Shan, Junjie; Yang, Songtao; Xia, Xianzhu",International Journal of Biological Macromolecules,,,,document_parses/pdf_json/52fd553c11cbb5847e82f6679eddb6f205266cfb.json,document_parses/pmc_json/PMC7112441.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26875535/; https://doi.org/10.1016/j.ijbiomac.2016.02.023; https://www.sciencedirect.com/science/article/pii/S0141813016301556; https://api.elsevier.com/content/article/pii/S0141813016301556,22463397.0,3
79801,79801,102621,0bma2749,aa14d6de32495ec579e30a5c6f1ae21666c01c8a,Medline; PMC,Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives,10.3390/pharmaceutics6030378,PMC4190526,25014738.0,cc-by,intranasal delivery dna vaccine become popular research area recently offer distinguished advantage parenteral route vaccine administration nasal mucosa site vaccine administration stimulate respiratory mucosal immunity interacting nasopharyngealassociated lymphoid tissue nalt different kind dna vaccine investigated provide protection respiratory infectious disease including tuberculosis coronavirus influenza respiratory syncytial virus rsv etc dna vaccine several attractive development potential producing crossprotection towards different virus subtypes enabling possibility mass manufacture relatively short time better safety profile biggest obstacle dna vaccine low immunogenicity one approach enhance efficacy dna vaccine improve dna delivery efficiency review provides insight development intranasal dna vaccine respiratory infection special attention paid strategy improve delivery dna vaccine using nonviral delivery agent,2014-07-10,"Xu, Yingying; Yuen, Pak-Wai; Lam, Jenny Ka-Wing",Pharmaceutics,,,,document_parses/pdf_json/aa14d6de32495ec579e30a5c6f1ae21666c01c8a.json,document_parses/pmc_json/PMC4190526.xml.json,https://doi.org/10.3390/pharmaceutics6030378; https://www.ncbi.nlm.nih.gov/pubmed/25014738/,2465438.0,3
79820,79820,102646,77klmmo6,fa9d5bbf9793d156a4a0f58e8dc9ba221378ee89,Elsevier; Medline; PMC,Comparable humoral response after two doses of adjuvanted influenza A/H1N1pdm2009 vaccine or natural infection in allogeneic stem cell transplant recipients,10.1016/j.vaccine.2013.11.073,PMC7115606,24333120.0,els-covid,background present study evaluated immunogenicity tolerance twodose influenza ahnpdm vaccination allogeneic hematopoietic stem cell transplantation hsct recipient compared vaccineinduced humoral response triggered natural infection another group hsct patient method adult allogeneic hsct recipient vaccinated two dos influenza ahnpdm vaccine separated week patient proven influenza ahnpdm infection included antibody response measured hemagglutinationinhibition assay day month first vaccine injection vaccinated patient pandemic influenza ahnpdm infection patient presented natural infection result baseline recipient adjuvanted vaccine infected patient seroprotected antibody titer≥ seroprotection rate observed day vaccination different observed natural infection respectively p vaccinated patient seroprotection rate increased significantly day p moreover month seroprotection rate vaccinated patient similar observed infected patient evaluated least day infection d– respectively p multivariate analysis immunosuppressive treatment chronic graftversushost disease gvhd longer time transplantation vaccinationinfection associated stronger humoral response adjuvanted vaccine safe low rate gvhd worsening conclusion hsct recipient two dos influenza ahnpdm adjuvanted vaccine safe induced humoral response comparable triggered natural infection patient,2014-01-23,"Dhédin, Nathalie; Krivine, Anne; Le Corre, Nicole; Mallet, Alain; Lioure, Bruno; Bay, Jacques-Olivier; Rubio, Marie-Thérèse; Agape, Philippe; Thiébaut, Anne; Le Goff, Jérôme; Autran, Brigitte; Ribaud, Patricia",Vaccine,,,,document_parses/pdf_json/fa9d5bbf9793d156a4a0f58e8dc9ba221378ee89.json,document_parses/pmc_json/PMC7115606.xml.json,https://doi.org/10.1016/j.vaccine.2013.11.073; https://api.elsevier.com/content/article/pii/S0264410X13016629; https://www.sciencedirect.com/science/article/pii/S0264410X13016629; https://www.ncbi.nlm.nih.gov/pubmed/24333120/,22913279.0,3
79844,79844,102672,atswrwjh,2b0ea50c37e4bc913cc1f55438b92074e09cb090,Elsevier; Medline; PMC,Next generation deep sequencing and vaccine design: today and tomorrow,10.1016/j.tibtech.2012.05.005,PMC7127335,22721705.0,els-covid,next generation sequencing ng technology redefined modus operandi human microbial genetics research allowing unprecedented generation large sequencing datasets short time scale affordable cost vaccine development research rapidly taking full advantage advent ng review provides concise summary current application ng relation research seeking develop vaccine human infectious disease incorporating study pathogen host focus rapidly mutating viral pathogen major target current vaccine research ng unraveling complex dynamic viral evolution host response virus thus contributing substantially likelihood successful vaccine development,2012-09-30,"Luciani, Fabio; Bull, Rowena A.; Lloyd, Andrew R.",Trends in Biotechnology,,,,document_parses/pdf_json/2b0ea50c37e4bc913cc1f55438b92074e09cb090.json,document_parses/pmc_json/PMC7127335.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/22721705/; https://www.sciencedirect.com/science/article/pii/S0167779912000765; https://api.elsevier.com/content/article/pii/S0167779912000765; https://doi.org/10.1016/j.tibtech.2012.05.005,29805395.0,3
79940,79940,102787,swwz4kzd,d5e96d010d0c08646164d722ab81f2ab64ab94c9,Elsevier; PMC,The rational design of vaccines,10.1016/s1359-6446(05)03600-7,PMC7108399,16257375.0,els-covid,review provides insight various opportunity vaccine intervention analysis strategy vaccine development vaccine ability modulate immune response resultant rational vaccine design addition wider aspect considered biotechnological advance advance immunological understanding host–pathogen interaction key question addressed research understanding reached new echelon vaccine development rational design,2005-11-15,"Bramwell, Vincent W.; Perrie, Yvonne",Drug Discovery Today,,,,document_parses/pdf_json/d5e96d010d0c08646164d722ab81f2ab64ab94c9.json,document_parses/pmc_json/PMC7108399.xml.json,https://www.sciencedirect.com/science/article/pii/S1359644605036007; https://api.elsevier.com/content/article/pii/S1359644605036007,45048133.0,3
79949,79949,102796,rc3ayjf6,7df88a5f0d6cff0488f514c87d88cd8daef258c7,Elsevier; Medline; PMC,The viral innate immune antagonism and an alternative vaccine design for PRRS virus,10.1016/j.vetmic.2017.03.014,PMC7111430,28341332.0,els-covid,porcine reproductive respiratory syndrome prrs remains one economically significant disease swine industry worldwide current vaccine le satisfactory confer protection heterologous infection longterm persistence need better vaccine urgent immunological hallmark prrsvinfected pig include unusually poor production type interferon ifnsαβ aberrant delayed adaptive immune response indicating prrsv ability suppress innate adaptive immune response host type ifns potent antiviral cytokine recent study reveal pleiotropic function priming expansion maturation adaptive immunity thus ifn antagonismnegative prrsv hypothesized attenuated build effective broad spectrum innate adaptive immune response pig vaccine promising alternative traditional vaccine prrsv,2017-09-30,"Ke, Hanzhong; Yoo, Dongwan",Veterinary Microbiology,,,,document_parses/pdf_json/7df88a5f0d6cff0488f514c87d88cd8daef258c7.json,document_parses/pmc_json/PMC7111430.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28341332/; https://www.sciencedirect.com/science/article/pii/S0378113516306320; https://api.elsevier.com/content/article/pii/S0378113516306320; https://doi.org/10.1016/j.vetmic.2017.03.014,205627477.0,3
79980,79980,102836,m7ys95z7,596ce34c3cad3b0a98085bd4779fd786f3ceacaa,Medline; PMC,Assessment of the Efficacy of Commercially Available and Candidate Vaccines against a Pandemic H1N1 2009 Virus,10.1086/651171,PMC7109664,20170374.0,no-cc,background emergence global spread pandemic hn influenza virus raised question regarding protective effect available seasonal vaccine efficacy newly produced matched vaccine method ferret immunized – formulation commercially available live attenuated flumist medimmune splitinactivated fluviral glaxosmithkline vaccine commercial swine vaccine flusure pfizer laboratoryproduced matched inactivated wholevirus vaccine amexicoindre adaptive immune response monitored animal challenged amexicoindre week result animal received swine matched vaccine developed detectable hemagglutination inhibiting antibody challenge virus whereas cell response exclusively detected animal vaccinated flumist challenge animal high level virus replication upper respiratory tract however preexisting anti—pandemic hn antibody resulted reduced clinical sign improved survival surprisingly flumist associated slight increase mortality greater lung damage correlated early upregulation interleukin conclusion present study demonstrates single dose matched inactivated vaccine confers partial protection pandemic hn virus suggests higher dose primeboost regimen may required consequence mismatched immunity influenza merit investigation,2010-04-01,"Kobinger, Gary P.; Meunier, Isabelle; Patel, Ami; Pillet, Stéphane; Gren, Jason; Stebner, Shane; Leung, Anders; Neufeld, James L.; Kobasa, Darwyn; von Messling, Veronika",J Infect Dis,,,,document_parses/pdf_json/596ce34c3cad3b0a98085bd4779fd786f3ceacaa.json,document_parses/pmc_json/PMC7109664.xml.json,https://doi.org/10.1086/651171; https://www.ncbi.nlm.nih.gov/pubmed/20170374/,5364577.0,3
80092,80092,102969,5g0n9na8,f9daabd834fda1a065a169d0da404604fd0a3544,Medline; PMC,Engineering a Live Attenuated Porcine Epidemic Diarrhea Virus Vaccine Candidate via Inactivation of the Viral 2'-O-Methyltransferase and the Endocytosis Signal of the Spike Protein,10.1128/jvi.00406-19,PMC6639265,31118255.0,bronze-oa,porcine epidemic diarrhea virus pedv cause high mortality neonatal piglet however effective safe vaccine still available hypothesized inactivation ′omethyltransferase ′omtase activity nsp endocytosis signal spike protein attenuates pedv yet retains immunogenicity pig generated recombinant pedv kdkea quadruple alanine substitution catalytic tetrad ′omtase using virulent infectious cdna clone icpca backbone next constructed another mutant kdkeasya abolishing endocytosis signal spike protein kdkea compared icpca kdkea kdkeasya mutant replicated le efficiently vitro induced stronger type type iii interferon response pathogenesis immunogenicity mutant evaluated gnotobiotic piglet virulence kdkeasya kdkea significantly reduced compared icpca mortality rate icpca kdkea kdkeasyainoculated group respectively day postinoculation dpi surviving pig challenged orally high dose icpca kdkeasya kdkeainoculated pig protected challenge kdkeasya one kdkeainoculated pig developed diarrhea whereas pig mockinoculated group severe diarrhea died furthermore serially passaged kdkeasya mutant pig three time find reversion introduced mutation data suggest kdkeasya may pedv vaccine candidate importance pedv economically important porcine enteric viral pathogen caused immense economic loss pork industry many country effective safe vaccine desperately required still available ′omtase nsp highly conserved among coronaviruses covs inactivation nsp live attenuated vaccine attempted several betacoronaviruses show inactivation ′omtase endocytosis signal spike protein approach designing promising live attenuated vaccine pedv vivo passaging data also validated stability kdkeasya mutant kdkeasya warrant evaluation sow piglet may used platform optimization finding confirmed nsp universal target cov vaccine development aid development vaccine emerging covs,2019-05-22,"Hou, Yixuan; Ke, Hanzhong; Kim, Jineui; Yoo, Dongwan; Su, Yunfang; Boley, Patricia; Chepngeno, Juliet; Vlasova, Anastasia N.; Saif, Linda J.; Wang, Qiuhong",Journal of Virology,,,,document_parses/pdf_json/f9daabd834fda1a065a169d0da404604fd0a3544.json,document_parses/pmc_json/PMC6639265.xml.json,https://doi.org/10.1128/jvi.00406-19; https://www.ncbi.nlm.nih.gov/pubmed/31118255/; https://jvi.asm.org/content/jvi/93/15/e00406-19.full.pdf,162180042.0,3
80152,80152,103044,fxr8ywxx,b2fc5ae2867a0bc478fbd993c240bd7e59531e66; f174e535b5e88cadd50d5684bed11710973f598e,Elsevier; Medline; PMC,Self-assembling protein nanoparticles in the design of vaccines,10.1016/j.csbj.2015.11.001,PMC4706605,26862374.0,cc-by,year vaccine one effective medical intervention reducing infectious disease estimated save million life globally year nevertheless many disease yet preventable vaccination large unmet medical need demand research development novel vaccine high efficacy safety compared th early th century vaccine made killed inactivated liveattenuated pathogen modern vaccine containing isolated highly purified antigenic protein subunit safer tend induce lower level protective immunity one strategy overcome latter design antigen nanoparticles assembly polypeptide present multiple copy subunit antigen wellordered array defined orientation potentially mimic repetitiveness geometry size shape natural hostpathogen surface interaction nanoparticles offer collective strength multiple binding site avidity provide improved antigen stability immunogenicity several exciting advance emerged lately including preclinical evidence strategy may applicable development innovative new vaccine example protecting influenza human immunodeficiency virus respiratory syncytial virus provide concise review critical selection data demonstrate potential field addition highlight use selfassembling protein nanoparticles effectively combined emerging discipline structural vaccinology maximum impact rational design vaccine antigen,2015-11-26,"López-Sagaseta, Jacinto; Malito, Enrico; Rappuoli, Rino; Bottomley, Matthew J.",Comput Struct Biotechnol J,,,,document_parses/pdf_json/b2fc5ae2867a0bc478fbd993c240bd7e59531e66.json; document_parses/pdf_json/f174e535b5e88cadd50d5684bed11710973f598e.json,document_parses/pmc_json/PMC4706605.xml.json,https://www.sciencedirect.com/science/article/pii/S200103701530009X; https://api.elsevier.com/content/article/pii/S200103701530009X; https://doi.org/10.1016/j.csbj.2015.11.001; https://www.ncbi.nlm.nih.gov/pubmed/26862374/,14211978.0,3
80230,80230,103137,ojx5ls42,a4ba2880d3601e026eec4cea53adacc2063ef9f6,Elsevier; Medline; PMC,Efficacy of intranasal and spray delivery of adjuvanted live vaccine against infectious bronchitis virus in experimentally infected poultry,10.1016/j.provac.2012.04.012,PMC7128841,32288918.0,els-covid,live vaccine widely used avian industry vaccine either injected delivered animal mucosa usually adjuvanted study show live vaccine efficacy improved formulation adjuvant model mucosal delivery live infectious bronchitis vaccine chicken three adjuvant technology tested using intranasal spray delivery method poultry technology water oil water emulsion nanoparticles polymer adjuvant intranasal delivery polymer nanoparticles adjuvanted live vaccine improved significantly antibody titer protection challenge observed compared commercial nonadjuvanted reference moreover spray delivery polymer adjuvanted vaccine showed significantly higher protection compared nonadjuvanted reference data demonstrates use montanidetm adjuvant formulation live poultry vaccine mucosal delivery confer vaccinated animal significantly improved protection pathogen,2012-12-31,"Deville, Sebastien; Arous, Juliette Ben; Bertrand, François; Borisov, Vladimir; Dupuis, Laurent",Procedia in Vaccinology,,,,document_parses/pdf_json/a4ba2880d3601e026eec4cea53adacc2063ef9f6.json,,https://api.elsevier.com/content/article/pii/S1877282X12000148; https://www.sciencedirect.com/science/article/pii/S1877282X12000148; https://www.ncbi.nlm.nih.gov/pubmed/32288918/; https://doi.org/10.1016/j.provac.2012.04.012,85351648.0,3
80335,80335,103259,ypv68w8a,4f626c150b229617c096dc92ecf7f19ee51af205,Medline; PMC,Role of water chemistry and stabilizers on the Vero-cells-based infectivity of Newcastle disease virus live vaccine,10.3382/japr/pfx049,PMC7109991,32288460.0,no-cc,newcastle disease virus ndv live vaccine supplied lyophilized form usually administered conventional route drinking water spray eye drop following reconstitution diluent virus inactivation due physicochemical property diluent time administration may lead vaccine failure present study aimed evaluate survival ndv live vaccine strain immersed phamended water sample ph ph ph ph ph sequential determination virus infectivity vero cell hour minimum reduction virus infectivity recorded water neutral slightly alkaline ph virus relatively le stable extreme ph condition maximum reduction infectivity observed water ph virus completely inactivated within hour addition stabilizer cevamune® skimmed milk slightly altered ph total dissolved solid tds value viruscharged water sample stabilizeradded water sample minimum reduction infectivity observed water neutral ph followed one ph type water sample value time required reduction virus infectivity highest minute neutral ph ph lowest min extreme alkaline condition ph result present study indicate water ph range suitable administration ndv live vaccine however addition cevamune® skimmed milk may beneficial effect preserving infectivity virus even extreme ph condition,2017-10-05,"Tariq, S; Rabbani, M; Javeed, A; Ghafoor, A; Anees, M; Najiullah, M; Hameed, M; Younus, M; Nazir, J",J Appl Poult Res,,,,document_parses/pdf_json/4f626c150b229617c096dc92ecf7f19ee51af205.json,document_parses/pmc_json/PMC7109991.xml.json,https://doi.org/10.3382/japr/pfx049; https://www.ncbi.nlm.nih.gov/pubmed/32288460/,90680412.0,3
80359,80359,103290,1d3xthbh,40d1dd0f992de32e06c688811ecc8445826cee20,Medline; PMC,Recent Advances in Nanovaccines Using Biomimetic Immunomodulatory Materials,10.3390/pharmaceutics11100534,PMC6835828,31615112.0,cc-by,development vaccine play vital role effective control several fatal disease however effective prophylactic therapeutic vaccine yet developed completely curing deadly disease cancer malaria hiv serious microbial infection thus suitable vaccine candidate need designed elicit appropriate immune response nanotechnology found play unique role design vaccine providing enhanced specificity potency nanoscaled material viruslike particle liposome polymeric nanoparticles np protein np received considerable attention past decade potential carrier delivery vaccine antigen adjuvant due beneficial advantage like improved antigen stability targeted delivery longtime release antigensadjuvants either encapsulated within decorated np surface flexibility design nanomedicine allows programming immune response thereby addressing many challenge encountered vaccine development biomimetic np emerged innovative natural mimicking biosystems used wide range biomedical application review discus recent advance biomimetic nanovaccines use antibacterial therapy antihiv therapy antimalarial therapy antimelittin therapy antitumor immunity,2019-10-14,"Vijayan, Veena; Mohapatra, Adityanarayan; Uthaman, Saji; Park, In-Kyu",Pharmaceutics,,,,document_parses/pdf_json/40d1dd0f992de32e06c688811ecc8445826cee20.json,document_parses/pmc_json/PMC6835828.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31615112/; https://doi.org/10.3390/pharmaceutics11100534,204739594.0,3
80400,80400,103338,omdwsw0k,d5b8a603f8793693d971cc87de4b7e8f1dd5e211,Elsevier; Medline; PMC,The art of partnerships for vaccines,10.1016/j.vaccine.2019.07.088,PMC6739625,31447125.0,els-covid,developing country vaccine manufacturer network dcvmn convened vaccine manufacturing expert leader local global public health organization th annual general meeting lecture panel discussion centered international cooperation better access vaccine partnership area ranging vaccine research process development clinical study regulatory supply chain emergency preparedness response global vaccine market trend change impact vaccine financing procurement method discussed well capital source including funding development new improved vaccine dcvmn member presented progress developing novel hexavalent meningitis pneumococcal conjugate vaccine shigella mumps rotavirus yellow fever polio hepatitis e dengue vaccine novel monoclonal antibody cocktail postbite prophylaxis rabies infection access availability vaccine enhanced sharing best practice vaccine quality control reducing redundant testing promoting development harmonized common standard eligible stakeholder encouraged join whonational control laboratory network biologicals serf platform collaboration technical exchange area increasing regulatory convergence regional global level mechanism joint dossier review collaborative registration procedure help accelerate vaccine access globally additionally four proposal streamlining procedure alignment dossier discussed successful partnership broad range stakeholder including international organization manufacturer academic research institute regulator provided support case accelerated vaccine innovation clinical trial registration prequalification vaccine introduction access strong partnership based experience trust help leverage opportunity critically important advancing shared goal providing quality vaccine people,2019-09-20,"Pagliusi, Sonia; Che, Yanchun; Dong, Shaozhong",Vaccine,,,,document_parses/pdf_json/d5b8a603f8793693d971cc87de4b7e8f1dd5e211.json,document_parses/pmc_json/PMC6739625.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31447125/; https://doi.org/10.1016/j.vaccine.2019.07.088; https://www.sciencedirect.com/science/article/pii/S0264410X19310096; https://api.elsevier.com/content/article/pii/S0264410X19310096,201749399.0,3
80440,80440,103384,tm8fzbue,14626b4b98947a5534bdcc578b6659c258f7e7dd,Medline; PMC,Immunogenicity and Protection from Receptor-Binding Domains of Toxins as Potential Vaccine Candidates for Clostridium difficile,10.3390/vaccines7040180,PMC6963439,31717334.0,cc-by,receptorbinding domain rbds located toxin toxin b clostridium difficile known nontoxic immunogenic need develop new type vaccine based rbds study expressed purified recombinant protein named rbdtcda rbdtcdb vaccine candidate containing rbds toxin toxin b respectively c difficile reference strain vpi immunogenicity protection vaccine candidate rbdtcda rbdtcdb rbdtcdab evaluated elisa survival assay data indicated mouse immunized vaccine candidate displayed potent level rbdspecific serum igg following intramuscular immunization mouse rbdtcda andor rbdtcdb vaccine candidate triggered immune response protected mouse compared mouse immunized aluminum hydroxide alone taken together result study reveal recombinant protein containing rbds c difficile toxin used vaccine development additionally found rbdtcdab vaccine elicit stronger humoral immune response provide better immunoprotection univalent vaccine rbd vaccine candidate conferred significant protection disease symptom death caused toxin wildtype c difficile strain,2019-11-08,"Luo, Deyan; Liu, Xuechao; Xing, Li; Sun, Yakun; Huang, Jie; Zhang, Liangyan; Li, Jiajia; Wang, Hui",Vaccines (Basel),,,,document_parses/pdf_json/14626b4b98947a5534bdcc578b6659c258f7e7dd.json,document_parses/pmc_json/PMC6963439.xml.json,https://doi.org/10.3390/vaccines7040180; https://www.ncbi.nlm.nih.gov/pubmed/31717334/,207942952.0,3
80452,80452,103398,rydgncys,c6aeb8940f7cd316ba9493e2c1fbc63d973a6e66,Elsevier; Medline; PMC,"Willingness to accept a future influenza A(H7N9) vaccine in Beijing, China",10.1016/j.vaccine.2017.12.008,PMC7115431,29246476.0,els-covid,background present study aimed estimate resident ’ willingness accept future hn vaccine determinant general adult population beijing china method conducted multistage sampling crosssectional survey using selfadministered anonymous questionnaire may june main outcome variable resident ’ willingness accept future hn vaccine logistic regression used identify predictor vaccination willingness result eligible participant beijing resident reported heard hn among heard hn general adult population would willing accept future hn vaccine approximately half reported ‘ afraid infected hn ’ ‘ hn vaccine prevent infection ’ reported ‘ daily life affected hn ’ variable significantly associated higher likelihood reporting willingness younger adult aged – year ci – aged – year ci – farmer ci – unemployed people ci – living suburban area ci – ≥ child family ci – perceived risk china ci – perceived susceptibility disease ci – perceived negative effect daily life ci – perceived effectiveness vaccination ci – recent uptake influenza vaccine ci – conclusion great number beijing resident doubt vaccine ’ effectiveness concerned disease risk factor affecting willingness vaccinated targeted education program disease risk well vaccine ’ effectiveness needed improve willingness vaccination potential hn pandemic preparedness,2018-01-25,"Wu, Shuangsheng; Su, Jianting; Yang, Peng; Zhang, Haiyan; Li, Hongjun; Chu, Yanhui; Hua, Weiyu; Li, Chao; Tang, Yaqing; Wang, Quanyi",Vaccine,,,,document_parses/pdf_json/c6aeb8940f7cd316ba9493e2c1fbc63d973a6e66.json,document_parses/pmc_json/PMC7115431.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29246476/; https://api.elsevier.com/content/article/pii/S0264410X17317462; https://doi.org/10.1016/j.vaccine.2017.12.008; https://www.sciencedirect.com/science/article/pii/S0264410X17317462,4573687.0,3
80453,80453,103399,ty3cxcdt,7307753da247144e66cc91b8f48c33e5a9ceff2b,Medline; PMC,Immune protection conferred by three commonly used commercial live attenuated vaccines against the prevalent local strains of avian infectious bronchitis virus in southern China,10.1292/jvms.18-0249,PMC6160892,30022779.0,cc-by-nc-nd,live attenuated vaccine critical control avian infectious bronchitis necessary know protection conferred commonly used commercial live vaccine study specific pathogenfree chick vaccinated commercial live vaccine h ldta blood sample collected weekly interval detection ibvspecific antibody quantification cd cd lymphocyte day postinoculation vaccinated bird challenged ibv prevalent local strain gxyl gxgl gxnn respectively trachea kidney sample collected day postchallenge detection virus result showed h group exhibited medium antibody level lowest percentage cd cd lymphocyte highest viral load group showed lowest antibody level highest percentage cd cd lymphocyte lowest viral load ldta group showed highest antibody level medium percentage cd cd lymphocyte medium viral load protection rate h ldta group – – – respectively present study demonstrated vaccine h ldta could stimulate immunized chick produce different level humoral cellular immunity resist infection ibv ’ provide complete protection prevalent local strain ibv southern china also vaccine offered best immune protection among three vaccine,2018-07-18,"FAN, Wen-Sheng; LI, He-Ming; HE, Yi-Ning; TANG, Ning; ZHANG, Li-Hua; WANG, Hai-Yong; ZHONG, Lian; CHEN, Jian-Cai; WEI, Tian-Chao; HUANG, Teng; MO, Mei-Lan; WEI, Ping",J Vet Med Sci,,,,document_parses/pdf_json/7307753da247144e66cc91b8f48c33e5a9ceff2b.json,document_parses/pmc_json/PMC6160892.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30022779/; https://doi.org/10.1292/jvms.18-0249,51697130.0,3
80502,80502,103462,8ufvich9,b244e664dffc282730675cb95200cc047ebdeaa2; 12d35c12218f230c49f4dc892814ba9f1037f251,Medline; PMC,OX40:OX40L axis: emerging targets for improving poxvirus-based CD8(+) T-cell vaccines against respiratory viruses,10.1111/j.1600-065x.2011.01062.x,PMC3422077,22017437.0,green-oa,human respiratory tract entry point known virus collectively contribute million annual death worldwide consequently world health organization designated respiratory viral infection priority vaccine development despite enormous advance understanding attribute protective mucosal antiviral immune response current vaccine continue fail effectively generating longlived protective cd tcell immunity date majority licensed human vaccine afford protection infectious pathogen generation specific immunoglobulin response recent year selective manipulation specific costimulatory pathway critical regulating tcellmediated immune response generated increasing interest impressive result animal model shown tumor necrosis factor receptor tnfr family member ox cd binding partner oxl cd key costimulatory molecule involved generation protective cd tcell response mucosal surface lung review highlight new finding particular emphasis potential immunological adjuvant enhance poxvirusbased cd tcell vaccine,2011-10-21,"Goulding, John; Tahiliani, Vikas; Salek-Ardakani, Shahram",Immunological Reviews,,,,document_parses/pdf_json/b244e664dffc282730675cb95200cc047ebdeaa2.json; document_parses/pdf_json/12d35c12218f230c49f4dc892814ba9f1037f251.json,document_parses/pmc_json/PMC3422077.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/22017437/; https://doi.org/10.1111/j.1600-065x.2011.01062.x; http://europepmc.org/articles/pmc3422077?pdf=render,25942621.0,3
80528,80528,103495,hi7z3nob,8d7d39313cd9791fca858c229b4af66a8e0927ad,Medline; PMC,SAROTUP: Scanner and Reporter of Target-Unrelated Peptides,10.1155/2010/101932,PMC2842971,20339521.0,no-cc,epitope mimic mimotopes widely utilized study epitope prediction development new diagnostics therapeutic vaccine screening random peptide library constructed phage display surface display technology provides efficient convenient approach acquire mimotopes however targetunrelated peptide creep mimotopes time time binding contaminant component screening system study present sarotup free web tool scanning reporting excluding possible targetunrelated peptide real mimotopes preliminary test show sarotup efficient capable improving accuracy mimotopebased epitope mapping also helpful development mimotopebased diagnostics therapeutic vaccine,2010-03-21,"Huang, Jian; Ru, Beibei; Li, Shiyong; Lin, Hao; Guo, Feng-Biao",J Biomed Biotechnol,,,,document_parses/pdf_json/8d7d39313cd9791fca858c229b4af66a8e0927ad.json,document_parses/pmc_json/PMC2842971.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/20339521/; https://doi.org/10.1155/2010/101932,14783217.0,3
80559,80559,103533,hiact7xj,877f699149aa8d62fdea2e7e6373195eb67a27f7,Elsevier; PMC,Modern veterinary vaccines and the Shaman's apprentice,10.1016/s0147-9571(03)00022-5,PMC7134149,12818624.0,no-cc,paper overview assessment new commercially available veterinary vaccine placed historical context author critically evaluate current state field veterinary vaccine food companion animal promise future vaccine development author maintain considerable variability safety sustained efficacy among veterinary vaccine especially developed companion animal proposed establishment international vaccine advisory committee supported would function apprise veterinary profession current status vaccine use,2003-04-15,"Carter, Philip B.; Carmichael, L.E.",Comp Immunol Microbiol Infect Dis,,,,document_parses/pdf_json/877f699149aa8d62fdea2e7e6373195eb67a27f7.json,document_parses/pmc_json/PMC7134149.xml.json,https://api.elsevier.com/content/article/pii/S0147957103000225; https://www.sciencedirect.com/science/article/pii/S0147957103000225,11106507.0,3
80569,80569,103544,dqikrmk7,b533e6c2f49910960a6de8f0c5a892fbc73823f2,Elsevier; PMC,Vaccination against Viruses,10.1016/b978-0-12-374279-7.14016-0,PMC7152391,,els-covid,vaccine use today result empirical development mechanism action many vaccine common use remains incompletely understood understanding vaccine protect ongoing subject study using increasingly sophisticated immunological tool b cell cell repertoire transcriptome analysis tool also applied design vaccine viral target evaded vaccinemediated protection thus far basic immunological science intersects practicality assuring vaccine safety tolerability efficacy consistency clinic practical utility sophisticated immunological measure vaccine development may determined whether reduced simply executed highly standardized reproducible assay outcome clear interpretation vaccine development use basic immunology empirical vaccine testing regulatory science necessary contributor developing next generation vaccine including vaccine effective pathogen vaccine currently available,2016-12-31,"Greenberg, Harry B.; Dormitzer, Philip R.",Encyclopedia of Immunobiology,,,,document_parses/pdf_json/b533e6c2f49910960a6de8f0c5a892fbc73823f2.json,document_parses/pmc_json/PMC7152391.xml.json,https://api.elsevier.com/content/article/pii/B9780123742797140160; https://www.sciencedirect.com/science/article/pii/B9780123742797140160,77055625.0,3
80581,80581,103558,npwqz958,c1f9694bb7aeabd1e8f30ec0847b5aefdc930d9e,Elsevier; PMC,Chapter Eight Nanoparticle-Based Peptide Vaccines,10.1016/b978-0-323-39981-4.00008-7,PMC7152328,,els-covid,use peptide antigen vaccination compared traditional vaccine advantage purity low risk adverse effect disadvantage weak immunogenicity necessitates administration adjuvant benefit advantage time overcome disadvantage wide variety nanoparticles actively studied development peptidebased vaccine antigen either loaded particle surface present within particle chapter provide brief overview synthetic peptide–based vaccine research special attention multiple antigenpresenting peptide vaccine introduce current approach development nanoparticlebased peptide vaccine use wellcharacterized synthetic peptide antigen facile chemical modification eg attachment lipid chain selfassembling peptide sequence modification employed induce peptide selfassembly nanoparticles present multiple copy peptide antigen surface,2017-12-31,"Fujita, Y.; Taguchi, H.",Micro and Nanotechnology in Vaccine Development,,,,document_parses/pdf_json/c1f9694bb7aeabd1e8f30ec0847b5aefdc930d9e.json,document_parses/pmc_json/PMC7152328.xml.json,https://www.sciencedirect.com/science/article/pii/B9780323399814000087; https://api.elsevier.com/content/article/pii/B9780323399814000087,90267731.0,3
80621,80621,103603,wfaqim7d,eb78c049ddae3d4769515ac771c1285446939f89,Elsevier; Medline; PMC,MERS-CoV vaccine candidates in development: The current landscape,10.1016/j.vaccine.2016.03.104,PMC7115572,27083424.0,els-covid,middle east respiratory syndrome coronavirus merscov emerging infectious disease growing global importance caused severe acute respiratory disease people resulting death high case fatality rate growing geographic distribution vaguely defined epidemiology merscov created urgent need effective public health countermeasure paramount effective mean prevention vaccine antibody prophylaxis despite relatively number case todate research development merscov vaccine candidate advancing quickly review survey landscape effort across multiple group academia government industry,2016-06-03,"Modjarrad, Kayvon",Vaccine,,,,document_parses/pdf_json/eb78c049ddae3d4769515ac771c1285446939f89.json,document_parses/pmc_json/PMC7115572.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X16301013; https://www.ncbi.nlm.nih.gov/pubmed/27083424/; https://doi.org/10.1016/j.vaccine.2016.03.104; https://api.elsevier.com/content/article/pii/S0264410X16301013,5535815.0,3
80697,80697,103694,x2r7otj0,,Elsevier; WHO,Race for a vaccine,10.1016/s0262-4079(20)30600-x,,,els-covid,coronavirus pandemic getting worse turning new technique deliver vaccine record time done asks carrie arnold,2020-03-21,"Arnold, Carrie",New Scientist,,#11595,,,,https://www.sciencedirect.com/science/article/pii/S026240792030600X; https://doi.org/10.1016/s0262-4079(20)30600-x; https://api.elsevier.com/content/article/pii/S026240792030600X,214755454.0,3
80764,80764,103776,aw1g82bc,2c3d72e2a38c567380c7c3a9745da2168c47e6ab,Medline; PMC,A Sabin 1 poliovirus-based vaccine vector transfects Vero cells with high efficiency,10.1007/s10616-007-9085-0,PMC2267503,19003009.0,green-oa,past year live oral poliovirus pv vaccine contributed eradication wild pv country live vaccine strain high safety record stimulate cellular humoral immune response factor critical characteristic good vaccine aimed modify oral pv vaccine create powerful vaccine vector extraneous antigen expression study amplified three separate fragment sabin virus genome rtpcr cloned pgemteasy vector cassette containing engineered protease cleavage site polylinker introduced one fragment f front translation start site construction facilitated insertion foreign gene vector subsequent release cotranslated antigen digestion endogenous protease also placed ribozyme rz sequence promoter viral genomic dna vitro transcription rz cleavage recreated authentic ′ end pv genome rna polya tail added ′ end genome stabilize transcribed rna three pv genome fragment derivative cloned various type vector transfected vero cell virus rescue experiment demonstrated rz polya element required high transfection efficiency vectorderived rna,2007-07-01,"Li, Changgui; Han, Wei; Zhang, Yingqi; Wang, Junzhi",Cytotechnology,,,,document_parses/pdf_json/2c3d72e2a38c567380c7c3a9745da2168c47e6ab.json,document_parses/pmc_json/PMC2267503.xml.json,http://europepmc.org/articles/pmc2267503?pdf=render; https://www.ncbi.nlm.nih.gov/pubmed/19003009/; https://doi.org/10.1007/s10616-007-9085-0,207109217.0,3
80782,80782,103800,f6q6q3io,db633ad6a8771828545a8f3d7419722897c4fa9f,Medline; PMC,Sublingual Delivery of Vaccines for the Induction of Mucosal Immunity,10.4110/in.2013.13.3.81,PMC3718922,23885221.0,cc-by-nc,mucosal surface constantly exposed incoming pathogen cause infection result severe morbidity andor mortality study reported mucosal immunity important providing protection pathogen mucosal vaccination effective preventing local infection many year sublingual mucosa targeted deliver immunotherapy treat allergic hypersensitivity however potential vaccine delivery via sublingual mucosal received little attention recently recent study exploring potential documented safety effectiveness sublingual immunization demonstrating ability sublingual immunization induce systemic mucosal immune response variety antigen including soluble protein inter particulate antigen liveattenuated virus review summarize recent finding address promising potential sublingual immunization proving protection various mucosal pathogen,2013-06-30,"Shim, Byoung-Shik; Choi, Youngjoo; Cheon, In Su; Song, Man Ki",Immune Netw,,,,document_parses/pdf_json/db633ad6a8771828545a8f3d7419722897c4fa9f.json,document_parses/pmc_json/PMC3718922.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/23885221/; https://doi.org/10.4110/in.2013.13.3.81,14478409.0,3
80815,80815,103838,woo75hnn,fd327f9faf6b47f5efd8e3b8790018f654114878,Elsevier; PMC,Evaluation of the protection conferred by commercial vaccines and attenuated heterologous isolates in China against the CK/CH/LDL/97I strain of infectious bronchitis coronavirus,10.1016/j.tvjl.2007.08.018,PMC7110898,17936045.0,els-covid,avian infectious bronchitis virus ibv cause tremendous economic loss poultry industry worldwide different serotypes virus show little crossprotection present study investigated genotypic relationship ckchldlitype strain reference ibvs based gene comparison protection provided vaccination commercial vaccine attenuated homologous heterologous strain phylogenetic analysis comparison showed ckchldlitype virus might new serotype compared vaccine strain type ibv isolates china protection efficacy evaluated morbidity mortality virus reisolation challenged chick complete protection ibv vaccination provided homologous strain sufficient respiratory protection provided commercial vaccine heterologous strain ckchldli challenge development vaccine ckchldlitype ibv necessary control infectious bronchitis disease poultry development attenuated ckchldli strain may provide valuable contribution towards goal,2009-01-31,"Liu, Shengwang; Zhang, Xiaonan; Wang, Yu; Li, Chengren; Liu, Qiaoran; Han, Zongxi; Zhang, Qinxia; Kong, Xiangang; Tong, Guangzhi",The Veterinary Journal,,,,document_parses/pdf_json/fd327f9faf6b47f5efd8e3b8790018f654114878.json,document_parses/pmc_json/PMC7110898.xml.json,https://www.sciencedirect.com/science/article/pii/S1090023307003036; https://api.elsevier.com/content/article/pii/S1090023307003036,21332591.0,3
80827,80827,103858,xdpajuit,989b3ab9e08bcef68a844c9a522771d41ddf7cad,Medline; PMC,Single Dose of Consensus Hemagglutinin-Based Virus-Like Particles Vaccine Protects Chickens against Divergent H5 Subtype Influenza Viruses,10.3389/fimmu.2017.01649,PMC5711813,29230222.0,cc-by,h subtype highly pathogenic avian influenza hpai virus one greatest threat global poultry industry develop broadly protective h subunit vaccine recombinant consensus ha sequence rha constructed expressed viruslike particle rha vlps baculovirusinsect cell system efficacy rha vlps vaccine without immunopotentiator cvcva assessed chicken compared commercial recvcva vaccine single dose immunization chicken rha vlps rhacvcva vaccine induced higher level serum hemagglutinin inhibition titer neutralization titer mucosal antibody ifnγ il cytokine serum cytotoxic lymphocyte response rha vlps vaccine superior commercial vaccine conferring crossprotection different clade h subtype virus study report h subtype consensus ha vlp single dose vaccination provides broad protection hpai virus chicken,2017-11-27,"Wu, Peipei; Lu, Jihu; Zhang, Xuehua; Mei, Mei; Feng, Lei; Peng, Daxin; Hou, Jibo; Kang, Sang-Moo; Liu, Xiufan; Tang, Yinghua",Front Immunol,,,,document_parses/pdf_json/989b3ab9e08bcef68a844c9a522771d41ddf7cad.json,document_parses/pmc_json/PMC5711813.xml.json,https://doi.org/10.3389/fimmu.2017.01649; https://www.ncbi.nlm.nih.gov/pubmed/29230222/,13927438.0,3
80881,80881,103930,txi5enyw,0b6936373351a029b06b8784ff8077d755e7ee96,Elsevier; Medline,Conserved B and T cell epitopes prediction of ebola virus glycoprotein for vaccine development: An immuno-informatics approach,10.1016/j.micpath.2019.05.010,,31075428.0,els-covid,ebola virus ebov nonsegmented singlestranded rna virus oftenmost transmitted body fluid like sweat tear saliva nasal secretion till date licensed vaccine ebov available market however world increasingly vulnerable emerging threat hence need time develop vaccine ebov hinder dissemination current study designed identification characterization potential b tcell epitope using immunoinformatics tool helped finding potent vaccine candidate ebov prediction antigenicity allergenicity testing predicted b cell epitope done well identify potential vaccine candidate measure safety level respectively among bcell epitope “ wipagigvtgviia ” showed high antigenicity score would play important role evoking immune response tcell epitope peptide “ aiglawipy ” “ irgfprcry ” presented high antigenicity score bind mhc classi mhc classii allele respectively predicted epitope analyzed compared already reported peptide carefully comparatively peptide predicted present study showed immunogenicity score already reported peptide used positive control immunogenic compared peptide reported present study target zaire ebov zebov previous study also specie ie tai forest ebov tafv sudan ebov sudv bundibugyo ebov bdbv reston ebov restv would bring promising result potent vaccine candidate,2019-07-31,"Ahmad, Bilal; Ashfaq, Usman Ali; Rahman, Mahmood-ur; Masoud, Muhammad Shareef; Yousaf, Muhammad Zubair",Microbial Pathogenesis,,,,document_parses/pdf_json/0b6936373351a029b06b8784ff8077d755e7ee96.json,,https://www.ncbi.nlm.nih.gov/pubmed/31075428/; https://api.elsevier.com/content/article/pii/S0882401018306053; https://doi.org/10.1016/j.micpath.2019.05.010; https://www.sciencedirect.com/science/article/pii/S0882401018306053,149454897.0,3
80883,80883,103932,utklvcw3,3ca43ade94501268228e5239d1717d4f6333d462,Medline; PMC,Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 Trial,10.3390/vaccines1040398,PMC4494211,26344340.0,cc-by,mark milestone year plasmid dna vaccine development firstinclass cytomegalovirus cmv dna vaccine enters pivotal phase testing vaccine consists two plasmid expressing cmv antigen glycoprotein b gb phosphoprotein pp formulated crl poloxamer benzalkonium chloride bak delivery system designed enhance plasmid expression vaccine ’ planned initial indication investigation prevention cmv reactivation cmvseropositive cmv recipient allogeneic hematopoietic stem cell transplant hct randomized doubleblind placebocontrolled phase proofofconcept study provided initial evidence safety product cmv hct recipient underwent immune ablation conditioning regimen study revealed significant reduction viral load endpoint increased frequency ppspecific interferonγproducing cell vaccine recipient compared placebo recipient result endpointdefining trial provided basis defining primary secondary endpoint global phase trial hct recipient case study presented describing development history vaccine product concept initiation phase trial,2013-09-25,"Smith, Larry R.; Wloch, Mary K.; Chaplin, Jennifer A.; Gerber, Michele; Rolland, Alain P.",Vaccines (Basel),,,,document_parses/pdf_json/3ca43ade94501268228e5239d1717d4f6333d462.json,document_parses/pmc_json/PMC4494211.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26344340/; https://doi.org/10.3390/vaccines1040398,17984120.0,3
80887,80887,103936,unjz4kzi,8f92e63e66110b0e8c72eb9385ddfa957c404aea,Medline; PMC,Current status of multiple antigen-presenting peptide vaccine systems: Application of organic and inorganic nanoparticles,10.1186/1752-153x-5-48,PMC3178480,21861904.0,no-cc,many study currently investigating development safe effective vaccine prevent various infectious disease multiple antigenpresenting peptide vaccine system developed avoid adverse effect associated conventional vaccine ie liveattenuated killed inactivated pathogen carrier protein cytotoxic adjuvant recently two main approach used develop multiple antigenpresenting peptide vaccine system addition functional component eg tcell epitope cellpenetrating peptide lipophilic moiety synthetic approach using sizedefined nanomaterials eg selfassembling peptide nonpeptidic dendrimers gold nanoparticles antigendisplaying platform review summarizes recent experimental study directed development multiple antigenpresenting peptide vaccine system,2011-08-23,"Fujita, Yoshio; Taguchi, Hiroaki",Chem Cent J,,,,document_parses/pdf_json/8f92e63e66110b0e8c72eb9385ddfa957c404aea.json,document_parses/pmc_json/PMC3178480.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/21861904/; https://doi.org/10.1186/1752-153x-5-48,18658400.0,3
80890,80890,103940,o8383rfh,992c3caed35095ac078a5e29175047033b8846a3,Elsevier; PMC,Chapter 12 Clinical Trials of Vaccines for Biodefense and Emerging and Neglected Diseases,10.1016/b978-0-12-369408-9.00012-3,PMC7150179,,els-covid,development safe effective vaccine prevention control emerging neglected infectious disease international priority development similar control measure bioterrorist threat international standard established ensure protection human subject scientific integrity clinical trial study design data collection general overview history regulatory guideline ethical principle underpinning vaccine development process provided emphasis clinical trial conducted united state contemporary vaccine development process involves sequential assessment safety immunogenicity efficacy phase clinical trial process always linear straightforward adaptive flexible clinical trial design increase likelihood successful outcome efficacy vaccine number disease discussed volume tested directly human alternative approach developed address challenge major element typical clinical trial protocol discussed checklist essential document supporting trial provided novel vaccine approach technology emerge regulatory ethical consideration need revisited adapted respond everchanging landscape,2009-12-31,"Keitel, Wendy A.",Vaccines for Biodefense and Emerging and Neglected Diseases,,,,document_parses/pdf_json/992c3caed35095ac078a5e29175047033b8846a3.json,document_parses/pmc_json/PMC7150179.xml.json,https://www.sciencedirect.com/science/article/pii/B9780123694089000123; https://api.elsevier.com/content/article/pii/B9780123694089000123,78927318.0,3
80924,80924,103982,ubi3p0k2,483dd65eb6b06ffb4f69b0da8e3a1f9ea1a92fb0; 32a76c6098177841292dd6c2fe22aaee715e97ca,Elsevier; Medline; PMC,Operational issues and network effects in vaccine markets,10.1016/j.ejor.2013.05.034,PMC7126193,32288068.0,no-cc,one important concern managing public health prevention infectious disease although vaccine provide effective mean preventing infectious disease two main reason often difficult reach socially optimal level vaccine coverage emergence operational issue yield uncertainty supply side ii existence negative network effect consumption side particular uncertainty production yield vaccine imperfection often make manufacturing vaccine risky process may lead manufacturer produce socially optimal level time negative network effect provide incentive potential consumer free ride immunity vaccinated population research consider central policymaker induce socially optimal vaccine coverage use incentive consumer vaccine manufacturer consider monopoly market imperfect vaccine show fixed twopart subsidy unable coordinate market derive twopart menu subsidy lead socially efficient level coverage,2013-12-01,"Adida, Elodie; Dey, Debabrata; Mamani, Hamed",Eur J Oper Res,,,,document_parses/pdf_json/483dd65eb6b06ffb4f69b0da8e3a1f9ea1a92fb0.json; document_parses/pdf_json/32a76c6098177841292dd6c2fe22aaee715e97ca.json,document_parses/pmc_json/PMC7126193.xml.json,https://api.elsevier.com/content/article/pii/S0377221713004335; https://www.ncbi.nlm.nih.gov/pubmed/32288068/; https://www.sciencedirect.com/science/article/pii/S0377221713004335; https://doi.org/10.1016/j.ejor.2013.05.034,2285373.0,3
80947,80947,104011,0s2gow7a,c9bcd70bf18a413b1af105124cc232f2fe0fd5b9,Medline; PMC,A Replicating Modified Vaccinia Tiantan Strain Expressing an Avian-Derived Influenza H5N1 Hemagglutinin Induce Broadly Neutralizing Antibodies and Cross-Clade Protective Immunity in Mice,10.1371/journal.pone.0083274,PMC3866202,24358269.0,cc-by,combat possibility zoonotic hn pandemic timely fashion necessary develop vaccine would confer protection homologous heterologous human hn influenza virus using replicating modified vaccinia virus tian tan strain mvtt vaccine vector constructed mvtthaqh mvtthaah express h gene goosederived qinghai strain abarheaded gooseqinghai humanderived anhui strain aanhui immunogenicity profile vaccine candidate evaluated vaccination mvtthaqh induced significant level neutralizing antibody nabs homologous strain wide range hn pseudoviruses clade neutralization test nt haemagglutination inhibition hi antibody inhibit live autologous virus well homologous axingjiang heterologous avietnam representing two human isolates clade clade respectively importantly mouse vaccinated intranasal mvtthaqh completely protected challenge lethal dosage abarheaded gooseqinghai aviet nam respectively control mouse received mock mvtts vaccine however mvtthaah induced much lower level nt autologous strain result suggest feasible use h gene abarheaded gooseqinghai construct effective vaccine using mvtt vector prevent infection homologous genetically divergent human hn influenza virus,2013-12-17,"Xiao, Haixia; Liu, Li; Zhu, Qingyu; Tan, Zhiwu; Yu, Wenbo; Tang, Xian; Zhan, Dawei; Du, Yanhua; Wang, Haibo; Liu, Di; Li, Zhixin; Yuen, Kwok-Yung; Ho, David D.; Gao, George F.; Chen, Zhiwei",PLoS One,,,,document_parses/pdf_json/c9bcd70bf18a413b1af105124cc232f2fe0fd5b9.json,document_parses/pmc_json/PMC3866202.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/24358269/; https://doi.org/10.1371/journal.pone.0083274,14468763.0,3
80985,80985,104055,t2tl5w91,7ec733f3684d6294483b03df183878ad777a78d9,Medline; PMC,Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine,10.3389/fimmu.2018.02371,PMC6198790,30386336.0,cc-by,tuberculosis tb infectious disease caused mycobacterium tuberculosis mtb kill people per day globally rapid development spread various multi drugresistant strain mtb emphasize effective vaccine still costeffectives efficient way controlling eradicating tb bacillus calmetteguerin bcg licensed tb vaccine still remains widely administered human vaccine inefficient protecting pulmonary tb adult protective immunity afforded bcg thought wane time considered last adolescent year heterologous boosting bcgprimed immune response using subunit vaccine represents promising vaccination approach promote strong cellular response mtb earlier study discovered lipopeptides esat antigen strong potential subunit vaccine candidate investigated potential booster bcg vaccine preexposure preventive vaccine postexposure therapeutic vaccine setting surprisingly result demonstrated boosting bcg subunit vaccine shortly mtb challenge improve bcgprimed immunity whereas subunit vaccine boost mtb challenge markedly improved quantity quality effector cell response significantly reduced mtb load lung liver spleen mouse study suggest esat lipopeptidebased subunit vaccine ineffective overcoming apparent immunomodulation induced bcg vaccine mtb uninfected mouse upon infection subunit vaccine effective reeducating protective immunity mtb infection important result significant implication design investigation effective vaccine strategy immunotherapeutic approach individual preimmunized bcg vaccine still get infected mtb,2018-10-16,"Gupta, Nancy; Garg, Saurabh; Vedi, Satish; Kunimoto, Dennis Y.; Kumar, Rakesh; Agrawal, Babita",Front Immunol,,,,document_parses/pdf_json/7ec733f3684d6294483b03df183878ad777a78d9.json,document_parses/pmc_json/PMC6198790.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30386336/; https://doi.org/10.3389/fimmu.2018.02371,53161928.0,3
81121,81121,104222,2hxlx1j2,93d77f602ff27ef1575dd6f700d3f39033bba576,Medline; PMC,Generation and protective efficacy of a cold-adapted attenuated genotype 2b porcine epidemic diarrhea virus,10.4142/jvs.2019.20.e32,PMC6669205,31364317.0,cc-by-nc,recent emergence reemergence porcine epidemic diarrhea virus pedv underscore urgent need development novel safe effective vaccine prevailing strain study generated coldadapted live attenuated vaccine candidate arampca shortterm passage virulent pedv isolate successively lower temperature vero cell whole genome sequencing identified amino acid change coldadapted strain insertion deletion throughout genome animal inoculation experiment confirmed attenuated phenotype arampca virus natural host pregnant sow orally administered pca live vaccine two dos week interval prior parturition newborn piglet challenged parental virus oral homologous primeboost vaccination pca significantly improved survival rate piglet notably mitigated severity diarrhea pedv fecal shedding challenge furthermore strong antibody response pedv detected serum colostrum immunized sow serum offspring result demonstrated coldadapted attenuated virus used live vaccine maternal vaccination strategy provide durable lactogenic immunity confer passive protection litter pedv,2019-07-09,"Won, Hokeun; Lee, Dong-Uk; Jang, Guehwan; Noh, Yun-Hee; Lee, Seung-Chul; Choi, Hwan-Won; Yoon, In-Joong; Yoo, Han Sang; Lee, Changhee",J Vet Sci,,,,document_parses/pdf_json/93d77f602ff27ef1575dd6f700d3f39033bba576.json,document_parses/pmc_json/PMC6669205.xml.json,https://doi.org/10.4142/jvs.2019.20.e32; https://www.ncbi.nlm.nih.gov/pubmed/31364317/,198998698.0,3
81172,81172,104286,3j5gwsu2,15c9fa3a8688b37209548ba87ed5e94fe0acdc86,Elsevier; Medline; PMC,Optimizing the refolding conditions of self-assembling polypeptide nanoparticles that serve as repetitive antigen display systems,10.1016/j.jsb.2011.11.011,PMC7118850,22115997.0,els-covid,nanoparticles show great promise potent vaccine candidate since readily taken antigen presenting cell immune system particle size density b cell epitope surface particle greatly influence strength humoral immune response developed novel type nanoparticle composed peptide building block raman et al used particle design vaccine malaria sars kaba et al pimentel et al investigate biophysical property refolding condition prototype selfassembling polypeptide nanoparticles sapns sapns formed peptide containing pentameric trimeric coiledcoil domain near physiological condition peptide selfassembles nm roughly spherical sapns average size sapns increase salt concentration optimal ph formation aggregation occurs lower higher value glycerol concentration vv required formation sapns regular spherical shape study help optimize immunological property sapns,2012-01-31,"Yang, Yongkun; Ringler, Philippe; Müller, Shirley A.; Burkhard, Peter",Journal of Structural Biology,,,,document_parses/pdf_json/15c9fa3a8688b37209548ba87ed5e94fe0acdc86.json,document_parses/pmc_json/PMC7118850.xml.json,https://www.sciencedirect.com/science/article/pii/S1047847711003261; https://doi.org/10.1016/j.jsb.2011.11.011; https://api.elsevier.com/content/article/pii/S1047847711003261; https://www.ncbi.nlm.nih.gov/pubmed/22115997/,5156699.0,3
81217,81217,104340,mqitzpkx,62af1f3f3018efa9f8dc92944af412ebd65ed379,Elsevier; Medline; PMC,Nanotechnology in vaccine delivery,10.1016/j.addr.2007.05.017,PMC7103321,18325628.0,els-covid,adjuvant currently used marketed human vaccine critical need exists novel immunopotentiators delivery vehicle capable eliciting humoral cellular mucosal immunity crucial vaccine component could facilitate development novel vaccine viral parasitic infection hepatitis hiv malaria cancer etc review discus clinical trial result various vaccine adjuvant delivery vehicle developed approximately nanoscale nm size humoral immune response observed adjuvant delivery platform viral vector iscoms montanide™ isa shown cytotoxic cell response clinic mf mpl® elicited th response viruslike particle nondegradable nanoparticles liposome also generated cellular immunity vaccine component also evaluated alternative route administration clinical success reported intranasal delivery viral vector proteosome oral delivery vlp vaccine,2008-05-22,"Peek, Laura J.; Middaugh, C. Russell; Berkland, Cory",Advanced Drug Delivery Reviews,,,,document_parses/pdf_json/62af1f3f3018efa9f8dc92944af412ebd65ed379.json,document_parses/pmc_json/PMC7103321.xml.json,https://api.elsevier.com/content/article/pii/S0169409X08000458; https://doi.org/10.1016/j.addr.2007.05.017; https://www.sciencedirect.com/science/article/pii/S0169409X08000458; https://www.ncbi.nlm.nih.gov/pubmed/18325628/,33880771.0,3
81229,81229,104356,b7e9grj0,d38e5f2006c9a906fc1427aafd8f0f05ee869470; 889ba9338ea71cd42c3bc675db30a1928d487f43,Elsevier; Medline; PMC,Relative Immunogenicity and Protection Potential of Candidate Yersinia Pestis Antigens against Lethal Mucosal Plague Challenge in Balb/C Mice,10.1016/j.vaccine.2008.01.024,PMC2288748,18291562.0,green-oa,yersinia pestis outer protein plasminogen activator protease yop secretion protein f necessary full virulence yesinia pestis proposed potential protective antigen vaccine plague current study used dna immunization tool study relative protective immunity protein standardized intranasal challenge system mouse natural full length gene sequence pestis protein display good level protein expression vitro delivered dna vaccine vector overall immunogenicity wild type gene dna vaccine low eliciting antigenspecific antibody response gene sequence modification improved parameter however even modified yopd yopo yscf antigen able partially protect immunized mouse various level lethal challenge pestis kim strain protection observed either yopb pla antigen result demonstrate dna immunization effective screening optimizing comparing optimal antigen design immunogenicity candidate antigen development subunitbased plague vaccine,2008-03-01,"Wang, Shixia; Joshi, Swati; Mboudjeka, Innocent; Liu, Fangjun; Ling, Tzufan; Goguen, Jon D.; Lu, Shan",Vaccine,,,,document_parses/pdf_json/d38e5f2006c9a906fc1427aafd8f0f05ee869470.json; document_parses/pdf_json/889ba9338ea71cd42c3bc675db30a1928d487f43.json,document_parses/pmc_json/PMC2288748.xml.json,http://europepmc.org/articles/pmc2288748?pdf=render; https://www.ncbi.nlm.nih.gov/pubmed/18291562/; https://doi.org/10.1016/j.vaccine.2008.01.024; https://www.sciencedirect.com/science/article/pii/S0264410X08000832; https://api.elsevier.com/content/article/pii/S0264410X08000832,27419545.0,3
81239,81239,104369,sllrzyq9,f72f4443be3e73ec7e6e37ae426caaf5a4924abe,Medline; PMC,Lactobacillus Mucosal Vaccine Vectors: Immune Responses against Bacterial and Viral Antigens,10.1128/msphere.00061-18,PMC5956152,29769376.0,cc-by,lactic acid bacteria lab utilized since therapeutic heterologous gene expression ability lab elicit immune response expressed foreign antigen led exploration potential mucosal vaccine candidate lab vaccine vector offer many attractive advantage simple noninvasive administration usually oral intranasal acceptance stability genetic modification relatively low cost highest level safety possible experimentation using lab genus lactobacillus become popular recent year due ability elicit strong systemic mucosal immune response article review lactobacillus vaccine construct including lactobacillus specie antigen expression model organism vivo immune response primary focus viral bacterial antigen,2018-05-16,"LeCureux, Jonathan S.; Dean, Gregg A.",mSphere,,,,document_parses/pdf_json/f72f4443be3e73ec7e6e37ae426caaf5a4924abe.json,document_parses/pmc_json/PMC5956152.xml.json,https://doi.org/10.1128/msphere.00061-18; https://www.ncbi.nlm.nih.gov/pubmed/29769376/,21726851.0,3
81253,81253,104388,ypwtg3wj,33701f97e53598fc01372c298ba2f26bce70bf87,Medline; PMC,"Isolation and molecular characterization of nephropathic infectious bronchitis virus isolates of Gujarat state, India",10.1007/s13337-015-0248-x,PMC4585062,26436120.0,green-oa,infectious bronchitis ib common highly contagious acute economically important viral disease chicken caused infectious bronchitis virus ibv sp avian coronavirus five pooled tissue suspension layer bird one reference massachusetts vaccine strain inoculated specific pathogen free spf chicken egg isolation ibv reversetranscription polymerase chain reaction rtpcr carried using post inoculated allontoic fluid amplify spike glycoprotein subunit ibv egg inoculated five pooled tissue sample vaccine sample showed dwarfing curling spf embryo indicative ibv five sample vaccine sample produced expected amplicons bp rtpcr sequencing five isolates revealed five sequence – similar among showed – nucleotide identity vaccine strain multiple sequence alignment found isolates similar subunit nucleotide level reference h vaccine strain reference mass strain sequence anand isolates revealed genetic change circulating ibv comparison previous isolate gujarat well higher difference strain isolated state showing substantial change genetic level indian ibv isolates may partially explain increasing incidence ib country spite vaccination electronic supplementary material online version article doisx contains supplementary material available authorized user,2015-03-29,"Patel, B. H.; Bhimani, M. P.; Bhanderi, B. B.; Jhala, M. K.",VirusDisease,,,,document_parses/pdf_json/33701f97e53598fc01372c298ba2f26bce70bf87.json,document_parses/pmc_json/PMC4585062.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26436120/; http://europepmc.org/articles/pmc4585062?pdf=render; https://doi.org/10.1007/s13337-015-0248-x,13805081.0,3
81272,81272,104408,ipa017wz,8cb8963c16ddd02891876e6bb59978b38289666d,Elsevier; Medline; PMC,Personalized Vaccinology: A Review,10.1016/j.vaccine.2017.07.062,PMC5792371,28774561.0,green-oa,current time field vaccinology remains empirical many respect vaccine development vaccine immunogenicity vaccine efficacy part historically driven empiric “ isolateinactivateinject ” paradigm turn populationlevel public health paradigm “ dose everyone every disease ” model normative thinking regard prevention vaccinepreventable infectious disease addition recently vaccine specifically designed overcome immunosenescence aging consistent postwwii mentality developing vaccine vaccine program child recognized current lack knowledge concerning immune response vaccine generated critical barrier understanding poor vaccine response elderly immunoimmaturity discovery new correlate vaccine immunogenicity vaccine response biomarkers directed approach new vaccine development new field vaccinomics adversomics provide model permit global profiling innate humoral cellular immune response integrated system biology level advanced science beyond reductionist scientific approach revealing novel interaction within immune system biological system beyond transcriptional level critical developing “ downstream ” adaptive humoral cellular response infectious pathogen vaccine others applied system level approach study antibody response aka “ system serology ” high dimensional cell subset immunophenotyping cytof vaccine induced metabolic change turn knowledge utilized better understand following identifying risk infection level risk exists regarding poor immunogenicity andor serious adverse event type dose vaccine needed fully protect individual toto approach allow personalized approach practice vaccinology analogous substantial inroad individualized medicine playing field human health medicine herein briefly review field vaccinomics adversomics personalized vaccinology,2018-08-01,"Poland, GA; Ovsyannikova, IG; Kennedy, RB",Vaccine,,,,document_parses/pdf_json/8cb8963c16ddd02891876e6bb59978b38289666d.json,document_parses/pmc_json/PMC5792371.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28774561/; https://doi.org/10.1016/j.vaccine.2017.07.062; https://www.sciencedirect.com/science/article/pii/S0264410X17309702; https://api.elsevier.com/content/article/pii/S0264410X17309702,25021031.0,3
81284,81284,104424,nl1aice2,7e5d2f2f71fb4805189a54658fb8aa715d45d0cd; 680fb6a1caf3ad6cf8e730498317b5d400cea1d4,Elsevier; Medline; PMC,Stressor-Induced Alterations of Adaptive Immunity to Vaccination and Viral Pathogens,10.1016/j.iac.2010.09.002,PMC3339561,21094924.0,green-oa,stress response influence immune system study laboratory animal indicate response stress significantly reduces resistance infectious challenge study however determined impact stress response human susceptibility infectious challenge due part difficulty using live replicating pathogen human research result many study assessed immune response vaccination surrogate immune response infectious challenge thus much known stress response influence adaptive immunity memory response vaccination study yielded data concerning interaction nervous immune system provided important information clinician administering vaccine susceptible population review provides brief overview immune response commonly used vaccine impact stress vaccinespecific immunity,2011-02-01,"Powell, Nicole D.; Allen, Rebecca G.; Hufnagle, Amy R.; Sheridan, John F.; Bailey, Michael T.",Immunology and Allergy Clinics of North America,,,,document_parses/pdf_json/7e5d2f2f71fb4805189a54658fb8aa715d45d0cd.json; document_parses/pdf_json/680fb6a1caf3ad6cf8e730498317b5d400cea1d4.json,document_parses/pmc_json/PMC3339561.xml.json,https://api.elsevier.com/content/article/pii/S0889856110000731; https://www.ncbi.nlm.nih.gov/pubmed/21094924/; https://doi.org/10.1016/j.iac.2010.09.002; http://europepmc.org/articles/pmc3339561?pdf=render; https://www.sciencedirect.com/science/article/pii/S0889856110000731,8992730.0,3
81291,81291,104436,i0gp9ehw,5c1dd2b19bb6b3016ba2654f69905bf4ec65bd54,Medline; PMC,"“Running the Gauntlet”: Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a “Call to Action”",10.1080/21645515.2019.1629254,PMC6816440,31180271.0,cc-by-nc-nd,translational science new biotechnology eg drug vaccine device diagnostics depend development robust ‘ business case ’ driven complex scientific technical logistical financial operational element determine feasibility probability traversing “ valley death ” leading licensure potential result term profitability financial realization called ‘ product value proposition ’ play crucial role establishing incentive investment development review goal summarize challenge taking vaccine neglected tropical disease ntds development licensure provide perspective vaccine measurable public health economic profitability market success understanding process challenge would open opportunity accelerate advance essential ntd vaccine last mile towards licensure delivery afflicted population low middleincome country,2019-07-10,"Bottazzi, Maria Elena; Hotez, Peter J.",Hum Vaccin Immunother,,,,document_parses/pdf_json/5c1dd2b19bb6b3016ba2654f69905bf4ec65bd54.json,document_parses/pmc_json/PMC6816440.xml.json,https://doi.org/10.1080/21645515.2019.1629254; https://www.ncbi.nlm.nih.gov/pubmed/31180271/,182952169.0,3
81309,81309,104458,7rmzaau4,c70c3c551bfefd529707fe77679a63afd37bb2ee,Elsevier; PMC,Chapter 19 Current and New Approaches for Mucosal Vaccine Delivery,10.1016/b978-0-12-811924-2.00019-5,PMC7149853,,els-covid,mucosal surface interface host ’ internal milieu external environment dual function serving physical barrier foreign antigen accepting site vital material mucosal vaccine favored prevent mucosal infection portal entry although mucosal vaccination many advantage licensed mucosal vaccine scarce widely studied mucosal route oral intranasal licensed oral intranasal vaccine composed mostly whole cell killed live attenuated microorganism serving delivery system builtin adjuvant future mucosal vaccine made purified antigen component relatively le immunogenic induce robust protective immune response wellpurified vaccine antigen effective mucosal delivery system essential requisite recent development biomaterials nanotechnology enabled many innovative mucosal vaccine trial oral vaccination vaccine delivery system able stably carry antigen adjuvant resist harsh physicochemical condition stomach intestinal tract besides many nanomicrocarrier tool generated using natural chemical material development oral vaccine delivery system using food material robustly researched expand vaccine coverage gastrointestinal infection developing country intranasal vaccination vaccine delivery system survive active mucociliary clearance mechanism prove safety anatomical location nasal cavity separated thin barrier future mucosal vaccine carrier regardless administration route certain common characteristic maintain stability given environment mucoadhesive ability target specific tissue cell,2020-12-31,"Rhee, Joon Haeng",Mucosal Vaccines,,,,document_parses/pdf_json/c70c3c551bfefd529707fe77679a63afd37bb2ee.json,document_parses/pmc_json/PMC7149853.xml.json,https://www.sciencedirect.com/science/article/pii/B9780128119242000195; https://api.elsevier.com/content/article/pii/B9780128119242000195,208403283.0,3
81328,81328,104480,i3f50lys,0b26d9ec6dfae866ae3f1a3f773036b1c8627147,Medline; PMC,Complete Genome of Avian coronavirus Vaccine Strains Ma5 and BR-I,10.1128/genomea.00201-17,PMC5465604,28596385.0,cc-by,avian coronavirus avcov ubiquitous multipleserotype pathogen poultry control mainly based use vaccine report previously unknown full genome nucleotide nt bri nt avcov vaccine strain gi massachusetts gi brazil type,2017-06-08,"Brandão, Paulo E.; Taniwaki, Sueli A.; Berg, Mikael; Hora, Aline S.",Genome Announc,,,,document_parses/pdf_json/0b26d9ec6dfae866ae3f1a3f773036b1c8627147.json,document_parses/pmc_json/PMC5465604.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28596385/; https://doi.org/10.1128/genomea.00201-17,23558103.0,3
81406,81406,104582,3a7jxl34,4f673458ff8e464dab793d271b770820e4540ee3,Elsevier; PMC,Immunizations in the United States: A Rite of Passage,10.1016/j.pcl.2005.03.001,PMC7119020,15925657.0,els-covid,today vaccination cornerstone pediatric preventive health care rite passage nearly approximately infant born daily united state article review u immunization program emphasis role ensuring vaccine effective safe available highlight several new vaccine recommendation affect health child adolescent practice pediatric medicine future decade,2005-06-30,"Cohn, Amanda C.; Broder, Karen R.; Pickering, Larry K.",Pediatric Clinics of North America,,,,document_parses/pdf_json/4f673458ff8e464dab793d271b770820e4540ee3.json,document_parses/pmc_json/PMC7119020.xml.json,https://api.elsevier.com/content/article/pii/S0031395505000647; https://www.sciencedirect.com/science/article/pii/S0031395505000647,43276089.0,3
81430,81430,104611,tdvb0fhv,,Medline; WHO,COVID-19 vaccines: knowing the unknown.,10.1002/eji.202048663,,32437587.0,unk,vaccine development sarscov drawn attention around globe due exploding pandemic although covid caused new coronavirus sarscov previous research coronavirus vaccine fipv sars mers provided valuable information rapid development covid vaccine however important knowledge gap remain specific sarscov others fundamental immunology vaccinology discus area need addressed covid vaccine development learned example vaccine development past since beginning outbreak research progress covid remarkable therefore optimistic rapid development covid vaccine article protected copyright right reserved,2020-05-21,"Lv, Huibin; Wu, Nicholas C; Mok, Chris K P",European journal of immunology,,#327069,,,,https://doi.org/10.1002/eji.202048663; https://www.ncbi.nlm.nih.gov/pubmed/32437587/,218834229.0,3
81489,81489,104681,n8pvv4ej,fcbb724663950efb0447ea4cc269d1cd1b7781a9,Elsevier; Medline; PMC,Continued use of IBV 793B vaccine needs reassessment after its withdrawal led to the genotype's disappearance,10.1016/j.vaccine.2014.10.006,PMC7172084,25446828.0,no-cc,period almost two year broiler chicken several hundred italian farm monitored infectious bronchitis virus detection genotyped using hypervariable region gene coding segment spike protein range genotype detected comprised qx q mass b sequence b virus detected chicken vaccinated either two commonly used b type vaccine almost identical sequence one vaccine strong indication vaccine association led withdrawal live b vaccine use farm study except one sample collected soon b vaccination ceased longer possible detect b vaccine farm appears field b strain disappeared region italy tested thus obviating need current vaccine protection b,2014-11-28,"Franzo, Giovanni; Naylor, Clive John; Lupini, Caterina; Drigo, Michele; Catelli, Elena; Listorti, Valeria; Pesente, Patrizia; Giovanardi, Davide; Morandini, Emilio; Cecchinato, Mattia",Vaccine,,,,document_parses/pdf_json/fcbb724663950efb0447ea4cc269d1cd1b7781a9.json,document_parses/pmc_json/PMC7172084.xml.json,https://doi.org/10.1016/j.vaccine.2014.10.006; https://www.ncbi.nlm.nih.gov/pubmed/25446828/; https://www.sciencedirect.com/science/article/pii/S0264410X14013668; https://api.elsevier.com/content/article/pii/S0264410X14013668,205596821.0,3
81511,81511,104705,oxjd263z,5d13cd0bf64f462281d34e7fcf845b5ddc541c83,Medline; PMC,The development of inovirus-associated vector vaccines using phage-display technologies,10.1080/14760584.2019.1651649,PMC7103683,31373843.0,no-cc,introduction inovirusassociated vector iavs derived bacterial filamentous virus phage vaccine carrier elicited cellular humoral response variety pathogen causing infectious disease noninfectious disease displaying specific antigen epitope protein coat protein iavs merited much study unique ability exploited widespread vaccine development area covered architectural trait filamentous virus derivative iavs facilitate display specific antigenic peptide induce antibody production prevent curtail infection inoviruses provide foundation costefficient largescale specific phage display paper development different application inovirusbased phage display vaccine across broad range pathogen host reviewed reference cited review selected established database based author ’ knowledge study subject expert commentary importance phagedisplay technology recently highlighted nobel prize chemistry awarded george p smith sir gregory p winter furthermore symbiotic nature filamentous virus infecting intestinal f e coli strain offer attractive platform development novel vaccine stimulate mucosal immunity,2019-09-08,"Stern, Zachariah; Stylianou, Dora C.; Kostrikis, Leondios G.",Expert Rev Vaccines,,,,document_parses/pdf_json/5d13cd0bf64f462281d34e7fcf845b5ddc541c83.json,document_parses/pmc_json/PMC7103683.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31373843/; https://doi.org/10.1080/14760584.2019.1651649,199389143.0,3
81518,81518,104713,vc9ytkio,6505fbce198f1d5eedbd0a982ed33c47fcafc471,Elsevier; Medline; PMC,Antigen delivery systems for veterinary vaccine development Viral-vector based delivery systems,10.1016/j.vaccine.2008.09.044,PMC7131726,18838097.0,els-covid,recent advance molecular genetics pathogenesis immunology provided optimal framework developing novel approach rational design vaccine effective viral epizootic disease paper review viralvector based antigen delivery system ad recently developed vaccine testing veterinary specie including attenuated virus dna rna viral vector besides usefulness vaccinology ad constitute invaluable tool researcher understanding nature protective response different specie opening possibility modulating potentiating relevant immune mechanism involved protection,2008-12-02,"Brun, Alejandro; Albina, Emmanuel; Barret, Tom; Chapman, David A.G.; Czub, Markus; Dixon, Linda K.; Keil, Günther M.; Klonjkowski, Bernard; Le Potier, Marie-Frédérique; Libeau, Geneviève; Ortego, Javier; Richardson, Jennifer; Takamatsu, Haru-H.",Vaccine,,,,document_parses/pdf_json/6505fbce198f1d5eedbd0a982ed33c47fcafc471.json,document_parses/pmc_json/PMC7131726.xml.json,https://api.elsevier.com/content/article/pii/S0264410X08012930; https://www.ncbi.nlm.nih.gov/pubmed/18838097/; https://www.sciencedirect.com/science/article/pii/S0264410X08012930; https://doi.org/10.1016/j.vaccine.2008.09.044,37149935.0,3
81547,81547,104744,g5rmv9s8,17114faf3bbc2a82ef49762ce4f3f922cb213f4e,Medline; PMC,Laser microporation of the skin: prospects for painless application of protective and therapeutic vaccines,10.1517/17425247.2013.773970,PMC3667678,23425032.0,cc-by-nc,introduction contrast muscle subcutaneous tissue skin easily accessible provides unique immunological property increasing knowledge complex interplay skinassociated cell type development cutaneous immune response fueled effort target skin vaccination well immunotherapy area covered review provides overview skin layer resident immunocompetent cell type advantage shortcoming standard method innovative technology circumvent outermost skin barrier addressed study employing fractional skin ablation infrared laser cutaneous delivery drug well high molecular weight molecule protein antigen antibody reviewed laserporation introduced versatile transcutaneous vaccination platform specific targeting epidermis dermis different laser setting resulting kinetics uptake transport immune response type elicited discussed potential transcutaneous delivery platform allergenspecific immunotherapy demonstrated expert opinion needlefree painless vaccination approach potential replace standard method due improved safety optimal patient compliance use fractional laser device stepwise ablation skin layer might advantageous vaccination microbial pathogen well immunotherapeutic approach allergenspecific immunotherapy thorough investigation underlying immunological mechanism help provide knowledge rational design transcutaneous protectivetherapeutic vaccine,2013-02-21,"Scheiblhofer, Sandra; Thalhamer, Josef; Weiss, Richard",Expert Opin Drug Deliv,,,,document_parses/pdf_json/17114faf3bbc2a82ef49762ce4f3f922cb213f4e.json,document_parses/pmc_json/PMC3667678.xml.json,https://doi.org/10.1517/17425247.2013.773970; https://www.ncbi.nlm.nih.gov/pubmed/23425032/,17461503.0,3
81587,81587,104790,m4p4lqc5,8f3fffb6a99b0baa471ddd963ee04bfa71e1bb97,Elsevier; Medline; PMC,Characterization of a novel live attenuated infectious bronchitis virus vaccine candidate derived from a Korean nephropathogenic strain,10.1016/j.vaccine.2010.01.062,PMC7125847,20153350.0,els-covid,nephropathogenic k strain infectious bronchitis virus ibv attenuated serial passage embryonated chicken egg possible use future ibv vaccine strain highgrowth property narrow tissue tropism limited replication respiratory tract achieved adaptation process unlike parent strain attenuated strain kp safe dayold specificpathogenfree chick since replication virus induce mortality nephritis rarely induced histological change trachea kidney intraocular administration dayold broiler even though coarse spray administration kp induced clinical sign ciliostasis histopathological lesion trachea kidney comparable bird vaccinated commercial h vaccine despite restriction viral replication respiratory tract kp elicited production antiserum neutralization index kp provided almost complete protection two distinct subgroup korean nephropathogenic strain kmlike qxlike subgroup furthermore kp provided significantly greater crossprotection two heterologous strain massachusetts korean respiratory strain conferred commercial h vaccine kp also virulence reversion five back passage chicken conclusion kp exhibit fine balance attenuation immunogenicity posse crossprotective efficacy merit investigation potential live vaccine alternative mean protection recently emergent nephropathogenic ibv infection many eurasian country,2010-04-01,"Lee, Hyun Jeong; Youn, Ha Na; Kwon, Ji Sun; Lee, Youn Jeong; Kim, Jae Hong; Lee, Joong Bok; Park, Seung Yong; Choi, In Soo; Song, Chang Seon",Vaccine,,,,document_parses/pdf_json/8f3fffb6a99b0baa471ddd963ee04bfa71e1bb97.json,document_parses/pmc_json/PMC7125847.xml.json,https://api.elsevier.com/content/article/pii/S0264410X10001386; https://www.sciencedirect.com/science/article/pii/S0264410X10001386; https://www.ncbi.nlm.nih.gov/pubmed/20153350/; https://doi.org/10.1016/j.vaccine.2010.01.062,1154412.0,3
81696,81696,104920,oc0zd11h,4bef591a0af76de32c50959f47cd4d9261a09015,Elsevier; Medline; PMC,"Quality vaccines for all people Report on the 16th annual general meeting of the Developing Countries Vaccine Manufacturers' Network, 05–07th October 2015, Bangkok, Thailand",10.1016/j.vaccine.2016.02.067,PMC7127051,26947496.0,els-covid,developing country vaccine manufacturer network dcvmn assembled highprofile leader global health organisation vaccine manufacture th annual general meeting work towards common goal providing quality vaccine people vaccine contribute healthy community robust health system ebola outbreak raised awareness threat damage one single infectious disease make clear world prepared however research better understand emerging infectious agent might lead suitable vaccine help prevent future outbreak dcvmn member presented progress developing novel vaccine dengue hpv chikungunya cholera cellbased influenza vaccine demonstrating commitment towards eliminating eradicating preventable disease worldwide global collaboration technology transfer successful introduction novel sabinipv oral cholera vaccine china korea respectively highlighted order achieve global immunisation local authority community leader play important role decisionmaking vaccine introduction uptake based ability vaccine protect vaccinated people protect nonvaccinated community herd immunity reducing risk vaccine shortage also achieved increasing regulatory convergence regional international level combatting preventable disease remains challenging collective effort improving multicentre clinical trial creating regional vaccine security strategy fostering developing vaccine market procurement building trust vaccine discussed,2016-06-30,"Pagliusi, Sonia; Ting, Ching-Chia; Khomvilai, Sumana; Homma, Akira; Meng, Li; Suhardono, Mahendra; Tippoo, Patrick; Jadhav, Suresh; Gao, Steven; Prasad, Ray; Suri, Rajinder K.; Thai, Pan Hong; Vonghangool, Vitoon",Vaccine,,,,document_parses/pdf_json/4bef591a0af76de32c50959f47cd4d9261a09015.json,document_parses/pmc_json/PMC7127051.xml.json,https://doi.org/10.1016/j.vaccine.2016.02.067; https://www.ncbi.nlm.nih.gov/pubmed/26947496/; https://api.elsevier.com/content/article/pii/S0264410X16002620; https://www.sciencedirect.com/science/article/pii/S0264410X16002620,13685354.0,3
81793,81793,105041,ndgzt2n5,db2773bfab2b81fdcf13212b9c7b4fef0af57fcf,Medline; PMC,KILchip v1.0: A Novel Plasmodium falciparum Merozoite Protein Microarray to Facilitate Malaria Vaccine Candidate Prioritization,10.3389/fimmu.2018.02866,PMC6298441,30619257.0,cc-by,passive transfer study human clearly demonstrated protective role igg antibody malaria identifying precise parasite antigen mediate immunity essential vaccine design proved difficult completion plasmodium falciparum genome revealed thousand potential vaccine candidate significant bottleneck remains validation prioritization evaluation clinical trial focusing initially plasmodium falciparum merozoite proteome used peerreviewed publication multiple proteomic bioinformatic approach select prioritize potential immune target expressed p falciparum recombinant protein majority obtained using mammalian expression system shown produce biologically functional extracellular protein used create kilchip v novel protein microarray facilitate highthroughput multiplexed antibody detection individual sample microarray assay highly specific antibody p falciparum protein detected exclusively serum malariaexposed malarianaïve individual intensity antibody reactivity varied expected strong weak across wellstudied antigen ama rh kruskal–wallis h test trend p interassay intraassay variability minimal reproducible result obtained reassays using chip duration month antibody quantified using multiplexed format kilchip v highly correlated measured goldstandard monoplex elisa median range spearmans r – kilchip v robust scalable adaptable protein microarray broad applicability study naturally acquired immunity malaria providing standardized tool detection antibody correlate protection facilitate rapid highthroughput validation prioritization potential plasmodium falciparum merozoitestage antigen paving way urgently needed clinical trial next generation malaria vaccine,2018-12-11,"Kamuyu, Gathoni; Tuju, James; Kimathi, Rinter; Mwai, Kennedy; Mburu, James; Kibinge, Nelson; Chong Kwan, Marisa; Hawkings, Sam; Yaa, Reuben; Chepsat, Emily; Njunge, James M.; Chege, Timothy; Guleid, Fatuma; Rosenkranz, Micha; Kariuki, Christopher K.; Frank, Roland; Kinyanjui, Samson M.; Murungi, Linda M.; Bejon, Philip; Färnert, Anna; Tetteh, Kevin K. A.; Beeson, James G.; Conway, David J.; Marsh, Kevin; Rayner, Julian C.; Osier, Faith H. A.",Front Immunol,,,,document_parses/pdf_json/db2773bfab2b81fdcf13212b9c7b4fef0af57fcf.json,document_parses/pmc_json/PMC6298441.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30619257/; https://doi.org/10.3389/fimmu.2018.02866,54577205.0,3
81813,81813,105061,ikomc19t,6276adaeca8fcd42c9565718ac6bbdc4f97aa10f,Medline; PMC,A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters,10.1371/journal.pntd.0007462,PMC6581282,31170144.0,cc0,nipah virus niv highly pathogenic reemerging virus cause outbreak south east asia currently approved licensed vaccine antiviral exist investigated efficacy chadox nivb simian adenovirusbased vaccine encoding niv glycoprotein g bangladesh syrian hamster primeonly well primeboost vaccination resulted uniform protection lethal challenge niv bangladesh animal survived challenge unable find infectious virus either oral swab lung brain tissue furthermore pathological lung damage observed singledose chadox nivb also prevented disease lethality heterologous challenge niv malaysia unable detect infectious virus swab tissue animal challenged heterologous strain limited amount viral rna could found lung tissue situ hybridization single dose chadox nivb also provided partial protection hendra virus passive transfer antibody elicited chadox nivb vaccination partially protected syrian hamster niv bangladesh data conclude chadox nivb suitable candidate niv vaccine preclinical development,2019-06-06,"van Doremalen, Neeltje; Lambe, Teresa; Sebastian, Sarah; Bushmaker, Trenton; Fischer, Robert; Feldmann, Friederike; Haddock, Elaine; Letko, Michael; Avanzato, Victoria A.; Rissanen, Ilona; LaCasse, Rachel; Scott, Dana; Bowden, Thomas A.; Gilbert, Sarah; Munster, Vincent",PLoS Negl Trop Dis,,,,document_parses/pdf_json/6276adaeca8fcd42c9565718ac6bbdc4f97aa10f.json,document_parses/pmc_json/PMC6581282.xml.json,https://doi.org/10.1371/journal.pntd.0007462; https://www.ncbi.nlm.nih.gov/pubmed/31170144/,174817809.0,3
81869,81869,105130,43jz55qs,c0cf63f8bf9e265aad0cccce3540f8887f338a58; 5eabc0c891d233364fcbca7577a77d5538d4f134; 3098665c745483c20e78d994c68c8fcf3b45cddf; 16da1a723a94177f637e745981853cd923d0098f,Elsevier; Medline; PMC,Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site,10.1016/j.cell.2015.07.043,PMC4757492,26279189.0,hybrid-oa,epsteinbarr virus ebv represents major global health problem though associated infectious mononucleosis cancer annually worldwide vaccine available major target immunity ebv glycoprotein gp mediates attachment b cell complement receptor crcd created selfassembling nanoparticles displayed different domain gp symmetric array focusing presentation crbinding domain nanoparticles potent neutralizing antibody elicited mouse nonhuman primate structurally designed nanoparticle vaccine improved vaccineinduced protection mouse model targeting functionally conserved site vulnerability fold increased neutralization compared soluble gp rational approach ebv vaccine design elicited potent neutralizing antibody response focusing conserved viral entry domain strategy applied virus,2015-08-01,"Kanekiyo, Masaru; Bu, Wei; Joyce, M. Gordon; Meng, Geng; Whittle, James R.R.; Baxa, Ulrich; Yamamoto, Takuya; Narpala, Sandeep; Todd, John-Paul; Rao, Srinivas S.; McDermott, Adrian B.; Koup, Richard A.; Rossmann, Michael G.; Mascola, John R.; Graham, Barney S.; Cohen, Jeffrey I.; Nabel, Gary J.",Cell,,,,document_parses/pdf_json/c0cf63f8bf9e265aad0cccce3540f8887f338a58.json; document_parses/pdf_json/5eabc0c891d233364fcbca7577a77d5538d4f134.json; document_parses/pdf_json/3098665c745483c20e78d994c68c8fcf3b45cddf.json; document_parses/pdf_json/16da1a723a94177f637e745981853cd923d0098f.json,document_parses/pmc_json/PMC4757492.xml.json,https://doi.org/10.1016/j.cell.2015.07.043; https://www.ncbi.nlm.nih.gov/pubmed/26279189/; http://www.cell.com/article/S0092867415009599/pdf; https://api.elsevier.com/content/article/pii/S0092867415009599; https://www.sciencedirect.com/science/article/pii/S0092867415009599,13778984.0,3
81910,81910,105177,rhff3a2t,ab70ed497469460f2ec13fcfe51611005fab867a,Medline; PMC,Acute systemic DNA damage in youth does not impair immune defense with aging,10.1111/acel.12478,PMC4933672,27072188.0,cc-by,aging‐related decline immunity believed main driver behind decreased vaccine efficacy reduced resistance infection older adult unrepaired dna damage known precipitate cellular senescence hypothesized underlying cause certain age‐related phenotype consistent hallmark immune aging prevalent individual exposed whole‐body irradiation wbi leaf anatomical repository undamaged hematopoietic cell decisively test whether extent wbi youth leave mark immune system age exposed young male cbl mouse sublethal wbi – gy mimicking human survivor exposure nuclear catastrophe followed lymphocyte homeostasis thorough lifespan response vaccination ability resist lethal viral challenge old age none irradiated group showed significant difference compared mock‐irradiated gy animal parameter measured even mouse received highest dose sublethal wbi youth gy exhibited equilibrated lymphocyte homeostasis robust t‐ b‐cell response live attenuated west nile virus wnv vaccine full survival following vaccination upon lethal wnv challenge therefore single dose nonlethal wbi youth resulting widespread dna damage repopulation stress hematopoietic cell leaf significant trace increased immune aging lethal vaccine challenge model,2016-04-13,"Pugh, Jason L.; Foster, Sarah A.; Sukhina, Alona S.; Petravic, Janka; Uhrlaub, Jennifer L.; Padilla‐Torres, Jose; Hayashi, Tomonori; Nakachi, Kei; Smithey, Megan J.; Nikolich‐Žugich, Janko",Aging Cell,,,,document_parses/pdf_json/ab70ed497469460f2ec13fcfe51611005fab867a.json,document_parses/pmc_json/PMC4933672.xml.json,https://doi.org/10.1111/acel.12478; https://www.ncbi.nlm.nih.gov/pubmed/27072188/,2666936.0,3
81953,81953,105225,u896icp9,eff3310317521aed7abe06ef1fa9963ca9d6caf3,Medline; PMC,The Adjuvanticity of an O. volvulus-Derived rOv-ASP-1 Protein in Mice Using Sequential Vaccinations and in Non-Human Primates,10.1371/journal.pone.0037019,PMC3355165,22615877.0,cc-by,adjuvant potentiate antigenspecific protective immune response key element promoting vaccine effectiveness previously reported onchocerca volvulus recombinant protein rovasp induce activation maturation naïve human dc therefore could used innate adjuvant promote balanced th th response bystander vaccine antigen mouse vaccine antigen also promoted thbiased response based pronounced induction thassociated igga iggb antibody response upregulated production th cytokine including il ifnγ tnfα il however protein rovasp adjuvant may also induce antiselfantibodies therefore important verify host response self affect adjuvanticity rovasp used subsequent vaccination different vaccine antigen study established rovasps adjuvanticity mouse course two sequential vaccination using two vaccine model system receptorbinding domain rbd sarscov spike protein commercial influenza virus hemagglutinin ha vaccine comprised three virus strain moreover adjuvanticity rovasp retained efficacy similar obtained used first vaccination even though high level antirovasp antibody present serum mouse administration second vaccine demonstrate utility adjuvant human use also immunized nonhuman primate nhps rbd plus rovasp showed rovasp could induce high titre functional protective antirbd antibody response nhps notably rovasp adjuvant induce high titer antibody self nhps thus present study provided sound scientific foundation future strategy development novel protein adjuvant,2012-05-17,"Wang, Jing; Tricoche, Nancy; Du, Lanying; Hunter, Meredith; Zhan, Bin; Goud, Gaddam; Didier, Elizabeth S.; Liu, Jing; Lu, Lu; Marx, Preston A.; Jiang, Shibo; Lustigman, Sara",PLoS One,,,,document_parses/pdf_json/eff3310317521aed7abe06ef1fa9963ca9d6caf3.json,document_parses/pmc_json/PMC3355165.xml.json,https://doi.org/10.1371/journal.pone.0037019; https://www.ncbi.nlm.nih.gov/pubmed/22615877/,16772471.0,3
81974,81974,105250,2mycdwst,62835611a546dbb9daa051060f54a72e2fcf417c,Elsevier; Medline; PMC,A Novel Therapeutic and Prophylactic Vaccine (HVJ-Envelope / Hsp65 DNA + IL-12 DNA) against Tuberculosis Using the Cynomolgus Monkey Model,10.1016/j.provac.2010.03.007,PMC7129898,32288910.0,els-covid,developed novel tuberculosis tb vaccine combination dna vaccine expressing mycobacterial heat shock protein hsp interleukin il delivered hemagglutinating virus japan hvjenvelope –liposome hsp ilhvj il expression vector ildna encoding singlechain il protein comprised p p subunit constructed vaccine provided remarkable protective efficacy mouse guinea pig model compared bcg vaccine basis cfu number tb survival induction cd positive ctl activity improvement histopathological tuberculosis lesion vaccine also provided therapeutic efficacy multidrug resistant tb mdrtb extremely drug resistant tb xdrtb prolongation survival time decrease number tb lung murine model furthermore extended study cynomolgus monkey model currently best animal model human tuberculosis novel vaccine provided higher level protective efficacy bcg based upon assessment mortality esr body weight chest xray finding immune response monkey control group saline died within month monkey hsphilhvj group survived month postinfection termination period experiment furthermore bcg priming hsp ilhvj vaccine booster primingbooster method showed synergistic effect tbinfected cynomolgus monkey survival contrast monkey bcg tokyo alone group alive survival furthermore vaccine exerted therapeutic efficacy survival augmentation immune response tbinfected monkey data indicate novel dna vaccine might useful mycobacterium tuberculosis including xdrtb mdrtb human therapeutic clinical trial,2010-12-31,"Okada, M; Kita, Y; Nakajima, T; Kanamaru, N; Hashimoto, S; Nishida, Y; Nakatani, H; Takao, K; Kishigami, C; Nishimatsu, S; Sekine, Y; Inoue, Y; Nagasawa, T; Kaneda, Y; Yoshida, S; Matsumoto, M; Paul, Saunderson; Tan, E. V.; Cruz, E.C.Dela; N. McMurray, D; Sakatani, M",Procedia in Vaccinology,,,,document_parses/pdf_json/62835611a546dbb9daa051060f54a72e2fcf417c.json,,https://www.sciencedirect.com/science/article/pii/S1877282X10000081; https://api.elsevier.com/content/article/pii/S1877282X10000081; https://www.ncbi.nlm.nih.gov/pubmed/32288910/; https://doi.org/10.1016/j.provac.2010.03.007,58728070.0,3
81986,81986,105263,35soeg7l,4d44402d0831ef5a86694ff70f9764a46fa06deb,Medline; PMC,Sublingual Immunization of Trivalent Human Papillomavirus DNA Vaccine in Baculovirus Nanovector for Protection against Vaginal Challenge,10.1371/journal.pone.0119408,PMC4366369,25789464.0,cc-by,report immunogenicity sublingually delivered trivalent human papillomavirus hpv dna vaccine encapsidated human endogenous retrovirus herv envelopecoated nonreplicable baculovirus nanovector herv envelopecoated nonreplicable baculovirusbased dna vaccine encoding hpvl l l achervtrihpv constructed sublingually administered mouse without adjuvant following sublingual sl administration achervtrihpv absorbed distributed throughout body minute day postdose distribution achervtrihpv lung higher tissue day postdose level achervtrihpv diminished throughout body six week first three dos × copy sl achervtrihpv induced hpv typespecific serum igg neutralizing antibody degree comparable im immunization × copy achervtrihpv induced hpv typespecific vaginal iga titer dosedependent manner sl immunization × copy achervtrihpv induced th th cellular response comparable im immunization × copy molecular imaging revealed sl achervtrihpv mouse provided complete protection vaginal challenge hpv hpv hpv pseudoviruses result support potential sl immunization using multivalent dna vaccine baculovirus nanovector induction mucosal systemic cellular immune response,2015-03-19,"Lee, Hee-Jung; Cho, Hansam; Kim, Mi-Gyeong; Heo, Yoon-Ki; Cho, Yeondong; Gwon, Yong-Dae; Park, Ki Hoon; Jin, Hyerim; Kim, Jinyoung; Oh, Yu-Kyoung; Kim, Young Bong",PLoS One,,,,document_parses/pdf_json/4d44402d0831ef5a86694ff70f9764a46fa06deb.json,document_parses/pmc_json/PMC4366369.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25789464/; https://doi.org/10.1371/journal.pone.0119408,15748701.0,3
81989,81989,105266,i40hi1em,508dd51b385f006ef2f6f2fb81f93c2cf4cb5fcc,Medline; PMC,A heterologous ‘prime‐boost’ anti‐PEDV immunization for pregnant sows protects neonatal piglets through lactogenic immunity against PEDV,10.1111/lam.13197,PMC7165963,31278766.0,no-cc,porcine epidemic diarrhoea virus pedv cause severe diarrhoea neonatal suckling piglet high mortality maternal vaccine induce lactogenic immunity protect suckling piglet via colostrum milk pivotal prevention control pedv infection neonatal suckling piglet study group pregnant sow first orally immunized coated pedv‐loaded microspheres boosted killed pedv vaccine heterologous prime‐boost detected level pedv‐specific antibody igg iga serum milk higher negative group p · p · furthermore proved neutralization assay induced antibody could significantly inhibit virus infection compared negative group p · p · importantly pedv challenge suckling piglet delivered sow heterologous prime‐boost group completely protected overall result show ‘ heterologous prime‐boost ’ form efficient effective way provide protection suckling piglet pedv lactogenic immunity significance impact study widespread swine pathogen pedv affect swine industry enormously cause enteritis swine age often fatal neonatal piglet data show pregnant sow immunized ‘ coated pedv‐loaded microspheres killed pedv vaccine ’ heterologous prime‐boost immunization could protect suckling piglet delivered sow virus finding provide new model developing safe effective immunization newborn animal established emerging enteric infection,2019-07-30,"Wen, Z.; Xu, Z.; Zhou, Q.; Li, W.; Wu, Y.; Du, Y.; Chen, L.; Xue, C.; Cao, Y.",Lett Appl Microbiol,,,,document_parses/pdf_json/508dd51b385f006ef2f6f2fb81f93c2cf4cb5fcc.json,document_parses/pmc_json/PMC7165963.xml.json,https://doi.org/10.1111/lam.13197; https://www.ncbi.nlm.nih.gov/pubmed/31278766/,195812339.0,3
82024,82024,105307,vq72zw0n,8d9570dc2bc7eecd456528a0e10de0530388d002,Elsevier; Medline; PMC,Buccal and sublingual vaccine delivery,10.1016/j.jconrel.2014.05.060,PMC7114675,24911355.0,els-covid,large surface area immunological competence mucosal tissue attractive administration target site vaccination important characteristic mucosal vaccination ability elicit local immune response act infection site pathogen entry however mucosal surface endowed potent sophisticated tolerance mechanism prevent immune system overreacting many environmental antigen hence mucosal vaccination may suppress immune system instead induce protective immune response therefore mucosal adjuvant andor special antigen delivery system well appropriate dosage form required order develop potent mucosal vaccine whereas oral nasal pulmonary vaccine delivery strategy described extensively sublingual buccal route received considerably le attention review characteristic approach sublingual buccal vaccine delivery described compared mucosal vaccine delivery site discus recent progress highlight promising development search vaccine formulation including adjuvant suitable dosage form likely critical designing successful sublingual buccal vaccine finally outline challenge hurdle overcome formulation issue relevant sublingual buccal vaccine delivery,2014-09-28,"Kraan, Heleen; Vrieling, Hilde; Czerkinsky, Cecil; Jiskoot, Wim; Kersten, Gideon; Amorij, Jean-Pierre",Journal of Controlled Release,,,,document_parses/pdf_json/8d9570dc2bc7eecd456528a0e10de0530388d002.json,document_parses/pmc_json/PMC7114675.xml.json,https://doi.org/10.1016/j.jconrel.2014.05.060; https://www.ncbi.nlm.nih.gov/pubmed/24911355/; https://api.elsevier.com/content/article/pii/S0168365914003861; https://www.sciencedirect.com/science/article/pii/S0168365914003861,33848988.0,3
82061,82061,105350,vet8lnka,3b2570e7e519aca156e600d4f4b2c033e8cb452b,Elsevier; PMC,Contagious bovine pleuropneumonia: A rationale for the development of a mucosal sub-unit vaccine,10.1016/j.cimid.2007.07.009,PMC7132392,17706775.0,no-cc,contagious bovine pleuropneumonia cbpp remains major cattle disease africa serious socioeconomic consequence eradication requires development improved vaccine knowledge disease causing agent mycoplasma mycoides subsp mycoides biotype small colony mmmsc progressing significantly last year opening new area vaccine design advance achieved understanding protective immune response mmmsc infection immunopathological mechanism allowing pathogen escape host immune response based sequencing genomic study virulence factor metabolic pathway unraveled leading identification potential mmmsc vaccine candidate based finding review present scientific strategy design multicomponent subunit vaccine mucosal delivery promising approach efficient longterm protective vaccine prevent cbpp,2007-08-17,"Dedieu-Engelmann, Laurence",Comp Immunol Microbiol Infect Dis,,,,document_parses/pdf_json/3b2570e7e519aca156e600d4f4b2c033e8cb452b.json,document_parses/pmc_json/PMC7132392.xml.json,https://www.sciencedirect.com/science/article/pii/S0147957107000732; https://api.elsevier.com/content/article/pii/S0147957107000732,22247716.0,3
82128,82128,105429,1pasuw68,28bbe60a2737d2dbae4aa103f493b46298512829,Elsevier; Medline; PMC,DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials,10.1016/s1473-3099(11)70240-7,PMC7185472,21975270.0,no-cc,background general population largely naive hn influenza antibody generated h allow analysis novel influenza vaccine independent background immunity previous infection assessed safety immunogenicity dna encoding h priming vaccine improve antibody response inactivated influenza vaccination method vrc vrc two sequentially enrolled phase openlabel randomised clinical trial healthy adult age – year randomly assigned receive intramuscular h dna mg day twice day week followed hn monovalent inactivated vaccine miv μg week compared twodose regimen hn miv either week interval antibody response assessed haemagglutination inhibition hai elisa neutralisation id immunoassay stemdirected antibody cell response assessed intracellular cytokine staining enrolment investigator individual masked group assignment vrc vrc registered clinicaltrialsgov number nct nct respectively finding vrc individual randomly assigned four group received vaccination vrc individual enrolled received vaccination nine received twodose regimen hn miv received h dna day followed hn miv week h dna priming safe enhanced hspecific antibody titre following hn miv boost especially interval dna prime miv boost extended week two study dna priming week miv boost interval induced protective hai titre individual increase geometric mean titre gmt four time individual given mivmiv regimen week gmt – v gmt – additionally neutralising antibody directed conserved stem region h induced primeboost regimen several individual vaccinerelated serious adverse event recorded interpretation dna priming week advance influenza vaccine boosting increased magnitude protective antibody response hai case induced haemagglutininstemspecific neutralising antibody dnamiv vaccine regimen could enhance efficacy h influenza vaccine show antistem antibody elicited vaccination man funding national institute health,2011-10-03,"Ledgerwood, Julie E; Wei, Chih-Jen; Hu, Zonghui; Gordon, Ingelise J; Enama, Mary E; Hendel, Cynthia S; McTamney, Patrick M; Pearce, Melissa B; Yassine, Hadi M; Boyington, Jeffrey C; Bailer, Robert; Tumpey, Terrence M; Koup, Richard A; Mascola, John R; Nabel, Gary J; Graham, Barney S",Lancet Infect Dis,,,,document_parses/pdf_json/28bbe60a2737d2dbae4aa103f493b46298512829.json,document_parses/pmc_json/PMC7185472.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/21975270/; https://api.elsevier.com/content/article/pii/S1473309911702407; https://www.sciencedirect.com/science/article/pii/S1473309911702407; https://doi.org/10.1016/s1473-3099(11)70240-7,25250308.0,3
82215,82215,105542,36jv8r34,7bbc1ea49a5caefdf52953d806743e90d6c8c4fd; cddfb172f712d389f6e585455d328afca8c0fe5c,Elsevier; Medline; PMC,Subviral Particle as Vaccine and Vaccine Platform,10.1016/j.coviro.2014.02.009,PMC4072748,24662314.0,green-oa,recombinant subvirual particle retain similar antigenic feature authentic viral capsid thus applied nonreplicating subunit vaccine viral infection illness additionally selfassembled polyvalent subviral particle excellent platform display foreign antigen immune enhancement vaccine development subviral particlebased vaccine noninfectious thus safer conventional live attenuated inactivated vaccine several vlp vaccine available market numerous others including dual vaccine one pathogen clinical preclinical development article provides update effort,2014-06-01,"Tan, Ming; Jiang, Xi",Current Opinion in Virology,,,,document_parses/pdf_json/7bbc1ea49a5caefdf52953d806743e90d6c8c4fd.json; document_parses/pdf_json/cddfb172f712d389f6e585455d328afca8c0fe5c.json,document_parses/pmc_json/PMC4072748.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/24662314/; http://europepmc.org/articles/pmc4072748?pdf=render; https://doi.org/10.1016/j.coviro.2014.02.009; https://www.sciencedirect.com/science/article/pii/S1879625714000601; https://api.elsevier.com/content/article/pii/S1879625714000601,26560476.0,3
82241,82241,105574,eyejnexx,2299d886d109d5d0e2b0b8191a452b94d567e522,Elsevier; Medline; PMC,Assembly and immunogenicity of coronavirus-like particles carrying infectious bronchitis virus M and S proteins,10.1016/j.vaccine.2013.09.024,PMC7115625,24099870.0,els-covid,infectious bronchitis virus ibv avian coronavirus still posing persistent imminent threat poultry industry worldwide report transfection sf cell single recombinant baculovirus encoding protein resulted assembly ibv vlps first report protein plus protein alone able assembled vlps coronaviruses showed generated ibv vlps could induce humoral immune response level comparable inactivated ibv vaccine importantly ibv vlps could elicit significantly higher cellular immune response inactivated ibv vaccine summary assembly ibv vlps protein provided simple strategy generating vlps coronaviruses generated ibv vlps laid feasible foundation development effective vaccine infection ibv future,2013-11-12,"Liu, Genmei; Lv, Lishan; Yin, Lijuan; Li, Xiaoming; Luo, Dongu; Liu, Kang; Xue, Chunyi; Cao, Yongchang",Vaccine,,,,document_parses/pdf_json/2299d886d109d5d0e2b0b8191a452b94d567e522.json,document_parses/pmc_json/PMC7115625.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X13012656; https://www.ncbi.nlm.nih.gov/pubmed/24099870/; https://api.elsevier.com/content/article/pii/S0264410X13012656; https://doi.org/10.1016/j.vaccine.2013.09.024,26919218.0,3
82259,82259,105596,zo1465i3,8918879fa25a9d2caa472764dd3ae609deddd645,Medline; PMC,Perspectives towards antiviral drug discovery against Ebola virus,10.1002/jmv.25357,PMC7166701,30431654.0,no-cc,ebola virus disease evd caused ebola virus resulted death according recent report mortality rate nowadays one deadly infectious disease however food drug administration‐approved ebola drug vaccine available yet mainstay therapy supportive care high fatality rate absence effective treatment vaccination make ebola virus category‐a biothreat pathogen fortunately series investigational countermeasure developed control prevent global threat review summarizes recent therapeutic advance ongoing research progress research development clinical trial development small‐molecule antiviral drug small‐interference rna molecule phosphorodiamidate morpholino oligomers full‐length monoclonal antibody vaccine moreover difficulty highlighted search effective countermeasure evd additional focus interplay available silico prediction method evidenced potential antiviral drug discovery,2019-09-30,"Mirza, Muhammad Usman; Vanmeert, Michiel; Ali, Amjad; Iman, Kanzal; Froeyen, Matheus; Idrees, Muhammad",J Med Virol,,,,document_parses/pdf_json/8918879fa25a9d2caa472764dd3ae609deddd645.json,document_parses/pmc_json/PMC7166701.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30431654/; https://doi.org/10.1002/jmv.25357,53435516.0,3
82263,82263,105600,v7asfaxc,da2e0ca79c487a5339e95bee7b75b10854c77152; 656ef218f7dcea5555a59cdc29d0f9ec8d5c2a82,BioRxiv; MedRxiv,MERS-CoV NSP16 necessary for IFN resistance and viral pathogenesis,10.1101/173286,,,medrxiv,coronaviruses encode mix highly conserved novel gene well genetic element necessary infection pathogenesis raising possibility common target attenuation therapeutic design study focus highly conserved nonstructural protein nsp viral ’ methyltransferase mtase encodes critical function immune modulation infection using reverse genetics disrupted key motif conserved kdke motif mers nsp da evaluated effect viral infection pathogenesis absence ’ mtase activity marginal impact propagation replication vero cell mers dnsp mutant demonstrated significant attenuation relative control primary human airway culture vivo examination indicated mers dnsp mutant type ifn based attenuation partially restored absence ifit molecule importantly robust attenuation permitted use mers dnsp live attenuated vaccine platform protecting challenge mouse adapted merscov strain study demonstrate importance conserved ’ mtase activity cov pathogenesis highlight nsp conserved universal target rapid live attenuated vaccine design expanding cov outbreak setting coronavirus emergence human livestock represents significant threat global public health evidenced sudden emergence sarscov merscov pedv swine delta coronavirus st century study describe approach effectively target highly conserved ’ methyltransferase activity coronaviruses attenuation clear understanding ifnifit based mechanism nsp mutant provide suitable target live attenuated vaccine platform well therapeutic development current future emergent cov strain importantly approach targeting conserved pancoronavirus function yet proven effective merscov illustrating broad applicability targeting viral ’ mtase function across coronaviruses,2017-08-08,"Menachery, Vineet D.; Gralinski, Lisa E.; Mitchell, Hugh D.; Dinnon, Kenneth H.; Leist, Sarah R.; Yount, Boyd L.; Graham, Rachel L.; McAnarney, Eileen T.; Stratton, Kelly G.; Cockrell, Adam S.; Debbink, Kari; Sims, Amy C.; Waters, Katrina M.; Baric, Ralph S.",bioRxiv,,,,document_parses/pdf_json/da2e0ca79c487a5339e95bee7b75b10854c77152.json; document_parses/pdf_json/656ef218f7dcea5555a59cdc29d0f9ec8d5c2a82.json,,https://doi.org/10.1101/173286,90191868.0,3
82302,82302,105648,far6zmwf,6a9ef100908ba7ae243e76a17806b56590cf30a8,Medline; PMC,Plant‐produced candidate countermeasures against emerging and reemerging infections and bioterror agents,10.1111/pbi.12475,PMC7167919,26387510.0,no-cc,despite progress prevention treatment infectious disease continue present major threat public health frequency emerging reemerging infection risk bioterrorism warrant significant effort towards development prophylactic therapeutic countermeasure vaccine mainstay infectious disease prophylaxis traditional vaccine however failing satisfy global demand limited scalability production system long production timeline product safety concern subunit vaccine highly promising alternative traditional vaccine subunit vaccine well monoclonal antibody therapeutic protein produced heterologous expression system based bacteria yeast insect cell mammalian cell shorter time higher quantity efficacious safe however current recombinant system certain limitation associated production capacity cost plant emerging promising platform recombinant protein production due time cost efficiency scalability lack harboured mammalian pathogen possession machinery eukaryotic post‐translational protein modification far variety subunit vaccine monoclonal antibody therapeutic protein antiviral produced plant candidate countermeasure emerging reemerging bioterrorism‐related infection many extensively evaluated animal model shown safety immunogenicity clinical trial overview ongoing effort producing plant‐based countermeasure,2015-09-21,"Streatfield, Stephen J.; Kushnir, Natasha; Yusibov, Vidadi",Plant Biotechnol J,,,,document_parses/pdf_json/6a9ef100908ba7ae243e76a17806b56590cf30a8.json,document_parses/pmc_json/PMC7167919.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26387510/; https://doi.org/10.1111/pbi.12475,206249609.0,3
82327,82327,105680,b1s4stvz,82391145ab2bc6754f496b31ccab1eb457a8101a,Elsevier; Medline; PMC,"Vaccines, adjuvants and autoimmunity",10.1016/j.phrs.2015.08.003,PMC7129276,26275795.0,els-covid,vaccine autoimmunity linked field vaccine efficacy based whether host immune response antigen elicit memory tcell response time although described side effect thus far mostly transient acute vaccine able elicit immune system towards autoimmune reaction diagnosis definite autoimmune disease occurrence fatal outcome postvaccination le frequently reported since vaccine given previously healthy host may never developed disease immunized adverse event carefully accessed evaluated even represent limited number occurrence review literature evidence vaccineinduced autoimmunity adjuvantinduced autoimmunity experimental model well human patient adjuvant infectious agent may exert immuneenhancing effect various functional activity encompassed adjuvant effect mechanism shared different condition triggered adjuvant leading autoimmuneinflammatory syndrome induced adjuvant asia syndrome conclusion several case report autoimmune disease following vaccine however due limited number case different classification symptom long latency period disease every attempt epidemiological study far failed deliver connection despite effort unveil connection triggering immune system adjuvant development autoimmune condition undertaken vaccinomics field may bring light novel customized personalized treatment approach future,2015-10-31,"Guimarães, Luísa Eça; Baker, Britain; Perricone, Carlo; Shoenfeld, Yehuda",Pharmacological Research,,,,document_parses/pdf_json/82391145ab2bc6754f496b31ccab1eb457a8101a.json,document_parses/pmc_json/PMC7129276.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26275795/; https://doi.org/10.1016/j.phrs.2015.08.003; https://www.sciencedirect.com/science/article/pii/S1043661815001711; https://api.elsevier.com/content/article/pii/S1043661815001711,29364825.0,3
82396,82396,105766,aw8p35c5,69c2b0a469521e87cf9807566d9763d4e32b6890,Elsevier; PMC,Adenoviruses as vaccine vectors,10.1016/j.ymthe.2004.07.013,PMC7106330,15451446.0,els-covid,adenovirus transitioned tool gene replacement therapy bona fide vaccine delivery vehicle attractive vaccine vector induce innate adaptive immune response mammalian host currently adenovirus vector tested subunit vaccine system numerous infectious agent ranging malaria hiv additionally explored vaccine multitude tumorassociated antigen review describe molecular biology adenovirus well way adenovirus vector manipulated enhance efficacy vaccine carrier describe method evaluating immune response transgene product expressed adenoviral vector discus data adenoviral vaccine selected number pathogen last comment limitation using human adenoviral vector provide alternative circumvent problem field growing exciting rapid pace thus limited scope use adenoviral vector vaccine viral pathogen,2004-10-31,"Tatsis, Nia; Ertl, Hildegund C.J.",Molecular Therapy,,,,document_parses/pdf_json/69c2b0a469521e87cf9807566d9763d4e32b6890.json,document_parses/pmc_json/PMC7106330.xml.json,https://www.sciencedirect.com/science/article/pii/S1525001604013425; https://api.elsevier.com/content/article/pii/S1525001604013425,38852121.0,3
82406,82406,105778,w8w9aorl,4a80fc8045f1a85c35e038160bee95c2be0c2fd2,Medline; PMC,Efficacy of genogroup 1 based porcine epidemic diarrhea live vaccine against genogroup 2 field strain in Japan,10.1186/s12985-018-0940-8,PMC5797392,29394943.0,cc-by,background porcine epidemic diarrhea ped lethal infectious disease suckling piglet symptom including watery diarrhea caused ped virus pedv since late ’ live vaccine based genogroup virus used japan significant amount vaccine used even new genogroups invaded study evaluated effect conventional ped live vaccine newly prevalent genogroup field strain experimental field situation method two pregnant sow administered twice live vaccine farrowing pregnant sow served negative control newborn piglet challenged genogroup virus clinical sign monitored day post challenge pedvspecific immune response serum milk sow assayed virus neutralization assay efficacy ped live vaccine vaccinated nonvaccinated farm evaluated comparing mortality rate suckling piglet onset ped result challenged piglet exhibited watery diarrhea without vaccination however clinical score piglet born vaccinated sow significantly improved th day challenge survival rate piglet vaccinated group end experimental period whereas control group neutralizing antibody titer serum milk control sow negative throughout experimental period whereas high titer observed vaccinated sow vaccinated farm significantly reduced mortality rate suckling piglet onset ped compared farm vaccinated conclusion conventional ped live vaccine induced lactogenic immunity vaccinated sow showed partial protection genogroup virus experimental field condition electronic supplementary material online version article contains supplementary material available authorized user,2018-02-02,"Sato, Tetsuo; Oroku, Kazuki; Ohshima, Yoshiyuki; Furuya, Yoshiaki; Sasakawa, Chihiro",Virol J,,,,document_parses/pdf_json/4a80fc8045f1a85c35e038160bee95c2be0c2fd2.json,document_parses/pmc_json/PMC5797392.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29394943/; https://doi.org/10.1186/s12985-018-0940-8,31960127.0,3
82541,82541,105947,3538jmqd,7f923809d6875b38e21636801b4a50f8fbac6aef,Medline; PMC,Protection against Virulent Infectious Bronchitis Virus Challenge Conferred by a Recombinant Baculovirus Co-Expressing S1 and N Proteins,10.3390/v10070347,PMC6071288,29954092.0,cc-by,avian infectious bronchitis virus ibv causative agent infectious bronchitis result considerable economic loss imperative develop safe efficient candidate vaccine control ibv infection current study recombinant baculoviruses coexpressing n protein monoexpressing n protein gxyl strain ibv constructed prepared subunit vaccine rhbmsn rhbms rhbmn level immune protection subunit vaccine evaluated inoculating specific pathogenfree spf chicken day age giving booster dose day later challenging virulent gxyl strain ibv day postbooster dpb commercial vaccine strain h used control ibvspecific antibody level well percentage cd cd lymphocyte detected within day postvaccination dpv morbidity mortality reisolation virus trachea kidney challenged bird evaluated five day postchallenge dpc result showed ibvspecific antibody level percentage cd cd lymphocyte higher rhbmsn vaccinated bird compared bird vaccinated rhbms rhbmn vaccine dpc mortality morbidity virus reisolation rate bird vaccinated rhbmsn vaccine slightly higher vaccinated h control vaccine lower vaccinated rhbms rhbmn vaccine present study demonstrated protection recombinant baculovirus coexpressing n protein better recombinant baculoviruses monoexpressing n protein thus recombinant baculovirus coexpressing n protein could serve potential ibv vaccine demonstrates bivalent subunit vaccine including n protein might strategy development ibv subunit vaccine,2018-06-27,"Yuan, Yuan; Zhang, Zhi-Peng; He, Yi-Ning; Fan, Wen-Sheng; Dong, Zhi-Hua; Zhang, Li-Hua; Sun, Xin-Kuan; Song, Li-Li; Wei, Tian-Chao; Mo, Mei-Lan; Wei, Ping",Viruses,,,,document_parses/pdf_json/7f923809d6875b38e21636801b4a50f8fbac6aef.json,document_parses/pmc_json/PMC6071288.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29954092/; https://doi.org/10.3390/v10070347,49603968.0,3
82609,82609,106023,lurb82s4,2ce9a3225e5e3bb3b0c5fd62107f93e7d1be1191,Elsevier; PMC,CHAPTER 14 Microbial Forensics Host Factors,10.1016/b978-012088483-4/50017-2,PMC7150301,,els-covid,publisher summary chapter present element host response simplified fashion microbial forensics aim identifying biological agent source individual responsible biothreat event analytic approach differ suspected biothreat agent encountered container environment opposed human animal however microbe toxin living host preceding item except microbial nucleic acid analyzed nevertheless host response biological agent available analysis host response foreign substance often well orchestrated series event designed protect individual harm modern technique help elucidate pathway component host response similar live microbe vaccine also provoke antibody response vaccine compose live attenuated microbe whole nonproliferating microbe antigenic part microbe regardless intent vaccine produce protection often protective antibody likely future understanding immune system evolving technology microarrays enhance analytic power,2005-12-31,"SCHUTZER, STEVEN E.",Microbial Forensics,,,,document_parses/pdf_json/2ce9a3225e5e3bb3b0c5fd62107f93e7d1be1191.json,document_parses/pmc_json/PMC7150301.xml.json,https://api.elsevier.com/content/article/pii/B9780120884834500172; https://www.sciencedirect.com/science/article/pii/B9780120884834500172,89395262.0,3
82627,82627,106045,wyub1zq2,a0b13baa35ff28471952e5011f9411529d217f50,Medline; PMC,Efficacy of a live attenuated vaccine in classical swine fever virus postnatally persistently infected pigs,10.1186/s13567-015-0209-9,PMC4496848,26159607.0,cc-by,classical swine fever csf cause major loss pig farming various degree disease severity efficient live attenuated vaccine classical swine fever virus csfv used routinely endemic country however despite intensive vaccination program area year csf eradicated molecular epidemiology study region suggests virus circulating field evolved positive selection pressure exerted immune response vaccine leading new attenuated viral variant recent work group demonstrated high proportion persistently infected piglet generated early postnatal infection low moderately virulent csfv strain studied immune response hog cholera lapinised virus vaccine hclv cstrain sixweekold persistently infected pig following postnatal infection csfvnegative pig vaccinated control humoral interferon gamma response well csfv rna load monitored day postvaccination vaccine viral rna detected serum sample tonsil csfv postnatally persistently infected pig day postvaccination furthermore especific antibody response neutralising antibody titre shown csfv persistently infected vaccinated animal likewise ifngamma producing cell response csfv pha observed knowledge first report demonstrating absence response vaccination csfv persistently infected pig,2015-07-09,"Muñoz-González, Sara; Perez-Simó, Marta; Muñoz, Marta; Bohorquez, José Alejandro; Rosell, Rosa; Summerfield, Artur; Domingo, Mariano; Ruggli, Nicolas; Ganges, Llilianne",Vet Res,,,,document_parses/pdf_json/a0b13baa35ff28471952e5011f9411529d217f50.json,document_parses/pmc_json/PMC4496848.xml.json,https://doi.org/10.1186/s13567-015-0209-9; https://www.ncbi.nlm.nih.gov/pubmed/26159607/,3000658.0,3
82633,82633,106052,wczw4vn1,41ff8966b05ab778bb135d48143800f2792807fa,Medline; PMC,Vaxign: The First Web-Based Vaccine Design Program for Reverse Vaccinology and Applications for Vaccine Development,10.1155/2010/297505,PMC2910479,20671958.0,no-cc,vaxign first webbased vaccine design system predicts vaccine target based genome sequence using strategy reverse vaccinology predicted feature vaxign pipeline include protein subcellular location transmembrane helix adhesin probability conservation human andor mouse protein sequence exclusion genome nonpathogenic strain epitope binding mhc class class ii precomputed vaxign database contains prediction vaccine target genome vaxign also performs dynamic vaccine target prediction based input sequence demonstrate utility program vaccine candidate uropathogenic escherichia coli upec predicted using vaxign compared various experimental study result indicate vaxign accurate efficient vaccine design program,2010-07-04,"He, Yongqun; Xiang, Zuoshuang; Mobley, Harry L. T.",J Biomed Biotechnol,,,,document_parses/pdf_json/41ff8966b05ab778bb135d48143800f2792807fa.json,document_parses/pmc_json/PMC2910479.xml.json,https://doi.org/10.1155/2010/297505; https://www.ncbi.nlm.nih.gov/pubmed/20671958/,18825440.0,3
82681,82681,106109,4ua0oqbz,d5ad926afb0860117c4bc646191a47a3d6b23dbc; 2e6263111a76ff0d43e7e3cde2692df04533e4f7,Elsevier; Medline; PMC,T-cell immunosenescence: lessons learned from mouse models of aging,10.1016/j.it.2009.04.007,PMC3755270,19541537.0,green-oa,well established increasing age associated decreased capacity immune system mediate effective immune response vaccination invading pathogen inherent limitation conducting experiment human much learned owed utility experimental mouse model aging recent study performed mouse demonstrated mechanism responsible agerelated decline function cd cd cell review describes key finding regarding agerelated defect tcell function discus impact defect vaccine efficacy immunity,2009-07-01,"Maue, Alexander C.; Yager, Eric J.; Swain, Susan L.; Woodland, David L.; Blackman, Marcia A.; Haynes, Laura",Trends in Immunology,,,,document_parses/pdf_json/d5ad926afb0860117c4bc646191a47a3d6b23dbc.json; document_parses/pdf_json/2e6263111a76ff0d43e7e3cde2692df04533e4f7.json,document_parses/pmc_json/PMC3755270.xml.json,http://europepmc.org/articles/pmc3755270?pdf=render; https://api.elsevier.com/content/article/pii/S1471490609001069; https://www.sciencedirect.com/science/article/pii/S1471490609001069; https://www.ncbi.nlm.nih.gov/pubmed/19541537/; https://doi.org/10.1016/j.it.2009.04.007,45163510.0,3
82724,82724,106155,cy45w8vq,dcc46888d647f293c6f9d136aaf7d3a708558372,Medline; PMC,Middle East Respiratory Syndrome Vaccine Candidates: Cautious Optimism,10.3390/v11010074,PMC6356267,30658390.0,cc-by,effort towards developing vaccine middle east respiratory syndrome coronavirus merscov yielded promising result utilizing variety platform several vaccine approach shown efficacy animal model begun enter clinical trial review summarize current progress towards merscov vaccine highlight potential roadblock identified previous attempt generate coronavirus vaccine,2019-01-17,"Schindewolf, Craig; Menachery, Vineet D.",Viruses,,,,document_parses/pdf_json/dcc46888d647f293c6f9d136aaf7d3a708558372.json,document_parses/pmc_json/PMC6356267.xml.json,https://doi.org/10.3390/v11010074; https://www.ncbi.nlm.nih.gov/pubmed/30658390/,58551245.0,3
82822,82822,106270,h07a3s6d,51a731857c1606428ec1eb47a97a290d2084c460,Medline; PMC,Growth enhancement of porcine epidemic diarrhea virus (PEDV) in Vero E6 cells expressing PEDV nucleocapsid protein,10.1371/journal.pone.0212632,PMC6402621,30840701.0,cc-by,recently emerging strain porcine epidemic diarrhea virus pedv cause severe diarrhea especially high mortality rate infected piglet leading substantial economic loss worldwide swine industry outbreak urgently call updated effective pedv vaccine better understanding pedv biology improvement technological platform virus production immensely assist accelerate pedv vaccine development study explored ability pedv nucleocapsid n protein improving viral yield cell culture system demonstrated pedv n expression positively affected recovery pedv infectious clone pedv propagation cell culture compared vero e cell vero e cell expressing pedv n could accelerate growth slowgrowing pedv strain higher peak titer hour enhance yield vaccine candidate strain two order magnitude interestingly pedv n also slightly enhances replication porcine reproductive respiratory virus pedv relative nidovirales order result solidify importance n pedv recovery propagation suggest potentially useful consideration designing vaccine production platform pedv closely related pathogen,2019-03-06,"Liwnaree, Benjamas; Narkpuk, Jaraspim; Sungsuwan, Suttipun; Jongkaewwattana, Anan; Jaru-Ampornpan, Peera",PLoS One,,,,document_parses/pdf_json/51a731857c1606428ec1eb47a97a290d2084c460.json,document_parses/pmc_json/PMC6402621.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30840701/; https://doi.org/10.1371/journal.pone.0212632,73516467.0,3
82861,82861,106318,61wibso4,3e7204f7030a9956a95b58d84d283d85229cc117,Elsevier; Medline; PMC,Synthetic virus-like particles prepared via protein corona formation enable effective vaccination in an avian model of coronavirus infection,10.1016/j.biomaterials.2016.08.018,PMC7112462,27552321.0,els-covid,ongoing battle current rising viral infectious threat prompted increasing effort development vaccine technology major thrust vaccine research focus developing formulation viruslike feature towards enhancing antigen presentation immune processing herein facile approach formulate synthetic viruslike particle svlps demonstrated exploiting phenomenon protein corona formation induced highenergy surface synthetic nanoparticles using avian coronavirus spike protein model antigen svlps prepared incubating nm gold nanoparticles solution containing optimized concentration viral protein following removal free protein antigenladen particle recovered showed morphological semblance natural viral particle nanoparticle tracking analysis transmission electron microscopy compared inoculation free protein vaccination svlps showed enhanced lymphatic antigen delivery stronger antibody titer increased splenic tcell response reduced infectionassociated symptom avian model coronavirus infection comparison commercial whole inactivated virus vaccine also showed evidence superior antiviral protection svlps study demonstrates simple yet robust method bridging viral antigen synthetic nanoparticles improved vaccine application practical implication management human viral infection well animal agriculture,2016-11-30,"Chen, Hui-Wen; Huang, Chen-Yu; Lin, Shu-Yi; Fang, Zih-Syun; Hsu, Chen-Hsuan; Lin, Jung-Chen; Chen, Yuan-I; Yao, Bing-Yu; Hu, Che-Ming J.",Biomaterials,,,,document_parses/pdf_json/3e7204f7030a9956a95b58d84d283d85229cc117.json,document_parses/pmc_json/PMC7112462.xml.json,https://www.sciencedirect.com/science/article/pii/S0142961216304045; https://www.ncbi.nlm.nih.gov/pubmed/27552321/; https://api.elsevier.com/content/article/pii/S0142961216304045; https://doi.org/10.1016/j.biomaterials.2016.08.018,5753793.0,3
82888,82888,106354,yk0xxv16,27b5e440dae0a1a99d41de1870e1e0d30d76d732,Medline; PMC,Recombinant adenovirus carrying a core neutralizing epitope of porcine epidemic diarrhea virus and heat-labile enterotoxin B of Escherichia coli as a mucosal vaccine,10.1007/s00705-019-04492-7,PMC7087028,31950289.0,no-cc,porcine epidemic diarrhea virus pedv target intestinal mucosa pig protect pedv invasion mucosal vaccine utilized effectively study generated recombinant adenovirus vaccine encoding heatlabile enterotoxin b ltb core neutralizing epitope coe pedv radltbcoe fusion protein ltbcoe successfully expressed recombinant adenovirus hek cell immunogenicity vaccine candidate assessed balbc mouse piglet three intramuscular oral vaccination radltbcoe twoweek interval induced robust humoral mucosal immune response moreover cellmediated immune response promoted immunized mouse neutralizing antibody inhibited vaccine strain emerging pedv isolate immunization experiment piglet revealed radltbcoe immunogenic induced good immune response piglet study required evaluate efficacy radltbcoe highly virulent pedv challenge,2020-01-16,"Do, Van Tan; Jang, Jisung; Park, Jeongho; Dao, Hoai Thu; Kim, Kiju; Hahn, Tae-Wook",Arch Virol,,,,document_parses/pdf_json/27b5e440dae0a1a99d41de1870e1e0d30d76d732.json,document_parses/pmc_json/PMC7087028.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31950289/; https://doi.org/10.1007/s00705-019-04492-7,210221663.0,3
82895,82895,106363,0jqhu890,153a9c1bd90f72ada3b85a5d9aa41fb131f97217,Elsevier; Medline; PMC,Basic aspects of immunomodulation through active immunization,10.1016/0301-6226(95)00014-c,PMC7131546,32287875.0,els-covid,paper review immunomodulation active vaccination evolved past year although initially progressed isolated main stream immunological research vaccine development lately merged main stream taking full advantage newest development vaccinology first immunomodulation vaccine already market various others close least one major stumbling block immunomodulation active vaccination inherent low immunogenicity ‘ self ’ antigen number case solved progress made veterinary application helped formulate practical rule necessary break immunotolerance unlikely rule used design better immunomodulation vaccine used human notably control fertility combat tumour,1995-06-30,"Meloen, R. H.",Livestock Production Science,,,,document_parses/pdf_json/153a9c1bd90f72ada3b85a5d9aa41fb131f97217.json,,https://www.sciencedirect.com/science/article/pii/030162269500014C; https://api.elsevier.com/content/article/pii/030162269500014C; https://doi.org/10.1016/0301-6226(95)00014-c; https://www.ncbi.nlm.nih.gov/pubmed/32287875/,71633630.0,3
82930,82930,106406,c3d2rpzh,023b89a5ec6dec38e943ec4cfc67598845d3b0ff,Elsevier; PMC,Chapter 1 Agents of Emerging Infectious Diseases,10.1016/b978-0-12-369408-9.00001-9,PMC7149645,,els-covid,dramatic improvement control infectious disease developed country owing socioeconomic change vaccine antibiotic first seven decade th century led mistakened concept infectious disease would longer concern since declaration victory war infectious disease approximately new disease agent identified nearly every type etiologic agent clinical manifestation involved including acute respiratory infection eg hn influenza sars hantaviral cardiopulmonary syndrome legionnaire ’ disease central nervous system involvement eg west nile encephalitis nipah virus encephalitis prion disease enteric infection eg helicobacter pylorus gastric duodenal disease cryptosporidiosis microsporidioses shiga toxin disease systemic bacterial disease eg lyme disease six new rickettsioses three new human ehrlichioses bartonelloses staphylococcal streptococcal toxic shock syndrome viral hemorrhagic fever eg marburg ebola lassa bolivian argentine venezuelan hemorrhagic fever human retroviral infection eg hiv htlvi ii new human herpesviruses hhv hhv hhv viral agent hepatitis b c e reciprocal threat bioterror agent eg smallpox virus could cause newly emerging infectious disease eid agent emerging infection eg sarscoronavirus rift valley fever virus could disseminated terrorist vaccine offer critically important potential countermeasure effect future eids aggressive approach developing prototype vaccine new class etiologic agent must driven public health initiative commercial interest undertake project microbe must completely characterized biologically molecularly genetically accurate animal model human infectious disease developed mechanism vaccineinduced protective immunity must elucidated antigen stimulate mechanism protective immune memory identified preclinical testing vaccine candidate completed animal model would effective subunit vaccine platform developed new antigen cassette could inserted fda approval obtained using one prototype experience manufacturing track record effectiveness safety vaccine numerous emerging infectious agent could achieved veterinary disease caused organism also cause emerging human infection eg west nile virus ehrlichioses united state approach driven currently individual investigator initiative pursuing scientific question grant national institute allergy infectious disease progress occurs desired level emerging infection high transmissibility eg r casefatality rate would cause global devastating effect level order magnitude nuclear war effort prepare eids fall far short nuclear attack preparedness cold war,2009-12-31,"Olano, Juan P.; Walker, David H.",Vaccines for Biodefense and Emerging and Neglected Diseases,,,,document_parses/pdf_json/023b89a5ec6dec38e943ec4cfc67598845d3b0ff.json,document_parses/pmc_json/PMC7149645.xml.json,https://www.sciencedirect.com/science/article/pii/B9780123694089000019; https://api.elsevier.com/content/article/pii/B9780123694089000019,88603901.0,3
82935,82935,106412,fma8wq4z,399ad090293d88da72a192acfa03c4e77cda6d9b,Elsevier; Medline; PMC,Newcastle disease virus-based MERS-CoV candidate vaccine elicits high-level and lasting neutralizing antibodies in Bactrian camels,10.1016/s2095-3119(17)61660-5,PMC7128255,32288953.0,els-covid,middle east respiratory syndrome coronavirus merscov member coronaviridae family causative pathogen mers characterized high fever pneumonia acute respiratory distress syndrome ards well extrapulmonary manifestation currently approved treatment regimen vaccine mers generated recombinant nonvirulent newcastle disease virus ndv lasota strain expressing merscov protein designated rlamerss evaluated immunogenicity mouse bactrian camel result revealed rlamerss showed similar growth property lasota embryonated chicken egg animal immunization study showed rlamerss induced merscov neutralizing antibody mouse camel finding suggest recombinant rlamerss may potential merscov veterinary vaccine candidate camel animal affected mers,2017-10-31,"LIU, Ren-qiang; GE, Jin-ying; WANG, Jin-ling; SHAO, Yu; ZHANG, Hui-lei; WANG, Jin-liang; WEN, Zhi-yuan; BU, Zhi-gao",Journal of Integrative Agriculture,,,,document_parses/pdf_json/399ad090293d88da72a192acfa03c4e77cda6d9b.json,,https://www.sciencedirect.com/science/article/pii/S2095311917616605; https://www.ncbi.nlm.nih.gov/pubmed/32288953/; https://api.elsevier.com/content/article/pii/S2095311917616605; https://doi.org/10.1016/s2095-3119(17)61660-5,89696782.0,3
82982,82982,106464,th7jtbhm,82dd4eaf936b517aadae03d135484331843e2b30,Medline; PMC,Recent Advances in the Use of Plant Virus-Like Particles as Vaccines,10.3390/v12030270,PMC7150928,32121192.0,cc-by,vaccination one effective public health intervention th century vaccine classified different type vaccine infectious disease anticancer vaccine vaccine autoimmune disease recent decade recombinant technology enabled design experimental vaccine wide range disease using plant virus viruslike particle central element stimulate protective longlasting immune response analysis recent publication show least experimental vaccine constructed based plant virus including vaccine infectious agent anticancer vaccine therapeutic vaccine autoimmune disorder several plant virus already used development vaccine platform tested human veterinary study suggesting plant virusbased vaccine introduced clinical veterinary practice near future,2020-02-28,"Balke, Ina; Zeltins, Andris",Viruses,,,,document_parses/pdf_json/82dd4eaf936b517aadae03d135484331843e2b30.json,document_parses/pmc_json/PMC7150928.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32121192/; https://doi.org/10.3390/v12030270,211833063.0,3
83041,83041,106535,visvv73i,e2cef67ca136f4b301736031caac1aa1085abcb6,Medline; PMC,The Safety of an Adjuvanted Autologous Cancer Vaccine Platform in Canine Cancer Patients,10.3390/vetsci5040087,PMC6313922,30322015.0,cc-by,canine cancer rate similar human though therapeutic option might limited inducing patient ’ immune system antitumor response attractive approach cancer therapy safety study autologous tumor vaccine produced specifically canine patient combined advax™ novel noninflammatory immunomodulator vaccine adjuvant tested safety diverse range patient presentation alone combination treatment canine patient tumor biopsied debulked resected tumor antigen processed autologous vaccine formulated advax™ adjuvant without rhizavidin additional immune stimulant patient treated early trial received two intramuscular im dos week apart study progressed issue safety observed protocol changed weekly vaccination week followed monthly booster shot im injection delivered date vaccine found safe significant adverse reaction observed result justify ongoing development future controlled study autologous vaccine approach,2018-10-12,"Weir, Chris; Oksa, Annika; Millar, Jennifer; Alexander, Miles; Kynoch, Nicola; Walton-Weitz, Zoe; Mackenzie-Wood, Peter; Tam, Felicia; Richards, Hope; Naylor, Richard; Cheng, Katrina; Bennett, Peter; Petrovsky, Nikolai; Allavena, Rachel",Vet Sci,,,,document_parses/pdf_json/e2cef67ca136f4b301736031caac1aa1085abcb6.json,document_parses/pmc_json/PMC6313922.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30322015/; https://doi.org/10.3390/vetsci5040087,53506585.0,3
83061,83061,106559,xfoy3i7d,3b3b32c96347c31043a806a565d3790bdf5df946,Elsevier; Medline; PMC,Innate and adaptive immunity against Porcine Reproductive and Respiratory Syndrome Virus,10.1016/j.vetimm.2015.07.003,PMC7112826,26209116.0,els-covid,many highly effective vaccine produced virus whose virulent infection elicits strong durable protective immunity case characterization immune effector mechanism identification protective epitopesimmunogens informative development successful vaccine program disease immune system rapidly clear acute infection andor convalescent immunity provide highly effective protection secondary challenge pose major hurdle clinician scientist porcine reproductive respiratory syndrome virus prrsv fall primarily category though entirely prrsv cause prolonged infection though host eventually clear virus neutralizing antibody provide passive protection present prior challenge though infection controlled absence detectable neutralizing antibody addition primed pig natural exposure vaccination modifiedlive vaccine show protection secondary challenge peripheral prrsvspecific cell response examined direct contribution antibodymediated immunity viral clearance fully elucidated innate immune response following prrsv infection particularly antiviral type interferon response meager provided exogenously ifnα enhances prrsv immunity viral control overall quality immunity induced natural prrsv infection ideal informing vaccine development program epitope necessary protection may identified natural exposure modifiedlive vaccine subsequently applied vaccine delivery platform accelerate induction protective immunity following vaccination collectively work identify protective b cell epitope mechanism prrsv eludes innate immunity enhance ability develop effective method control eliminate prrs disease,2015-09-15,"Loving, Crystal L.; Osorio, Fernando A.; Murtaugh, Michael P.; Zuckermann, Federico A.",Veterinary Immunology and Immunopathology,,,,document_parses/pdf_json/3b3b32c96347c31043a806a565d3790bdf5df946.json,document_parses/pmc_json/PMC7112826.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26209116/; https://api.elsevier.com/content/article/pii/S0165242715001464; https://www.sciencedirect.com/science/article/pii/S0165242715001464; https://doi.org/10.1016/j.vetimm.2015.07.003,42073089.0,3
83090,83090,106594,axkdf5vu,a51a3f793ea6a59523eff2c0fe6555b729840084,Medline; PMC,Newcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary Vaccines,10.3390/v8070183,PMC4974518,27384578.0,cc-by,viral vaccine vector shown effective inducing robust immune response vaccine antigen newcastle disease virus ndv avian paramyxovirus promising vaccine vector human veterinary pathogen avirulent ndv strain lasota b long track record safety efficacy therefore use strain vaccine vector highly safe avian nonavian specie ndv replicates efficiently respiratory track host induces strong local systemic immune response foreign antigen vaccine vector ndv accommodate foreign sequence good degree stability rna virus limited possibility recombination host cell dna using ndv vaccine vector human offer several advantage viral vaccine vector ndv safe human due host range restriction preexisting antibody ndv human population ndv antigenically distinct common human pathogen ndv replicates high titer cell line acceptable human vaccine development therefore ndv attractive vaccine vector human pathogen vaccine currently available ndv also attractive vaccine vector animal pathogen,2016-07-04,"Kim, Shin-Hee; Samal, Siba K.",Viruses,,,,document_parses/pdf_json/a51a3f793ea6a59523eff2c0fe6555b729840084.json,document_parses/pmc_json/PMC4974518.xml.json,https://doi.org/10.3390/v8070183; https://www.ncbi.nlm.nih.gov/pubmed/27384578/,2365868.0,3
83097,83097,106601,4qlk6y7h,c75994b5485339cdf4180bedab58e60366e49740,Medline; PMC,Potential Vaccines and Post-Exposure Treatments for Filovirus Infections,10.3390/v4091619,PMC3499823,23170176.0,cc-by,virus family filoviridae represent significant health risk emerging infectious disease well potentially engineered biothreats many research effort published offering possibility toward mitigation filoviral infection remain sanctioned therapeutic vaccine strategy current progress development filovirus therapeutic vaccine outlined herein respect current level testing evaluation proximity toward human implementation specifically regard human clinical trial nonhuman primate study small animal study vitro development contemporary method supportive care previous treatment approach human patient also discussed,2012-09-21,"Friedrich, Brian M.; Trefry, John C.; Biggins, Julia E.; Hensley, Lisa E.; Honko, Anna N.; Smith, Darci R.; Olinger, Gene G.",Viruses,,,,document_parses/pdf_json/c75994b5485339cdf4180bedab58e60366e49740.json,document_parses/pmc_json/PMC3499823.xml.json,https://doi.org/10.3390/v4091619; https://www.ncbi.nlm.nih.gov/pubmed/23170176/,537181.0,3
83120,83120,106630,vevsgkp6,f3c5dbfd682af9f81d55a8feda2e808a0b4f22a0,Elsevier; Medline; PMC,ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice,10.1016/j.vaccine.2017.05.032,PMC5516308,28579232.0,cc-by,middle east respiratory syndrome coronavirus merscov infected human since syndrome range asymptomatic mild case severe pneumonia death virus believed circulating dromedary camel without notable symptom since therefore dromedary camel considered animal source infection neither antiviral drug vaccine approved veterinary medical use despite active research area developed four vaccine candidate merscov based chadox mva viral vector two candidate per vector vaccine contained fulllength spike gene merscov chadox mers vaccine produced without leader sequence human tissue plasminogen activator gene tpa mva mers vaccine produced tpa either mh f promoter driving expression spike gene vaccine candidate evaluated mouse model prime primeboost regimen chadox mers tpa induced higher neutralising antibody chadox mers without tpa single dose chadox mers tpa elicited cellular immune response well neutralising antibody boosted significantly higher level mva mers humoral immunogenicity single dose chadox mers tpa equivalent two dos mva mers also tpa mva mers mh f promoter induced similar antibody level however f promoter enhanced cellular immunogenicity mva mers significantly higher magnitude conclusion study showed merscov vaccine candidate could optimized utilising different viral vector various genetic design vector different regimen increase immunogenicity chadox mva vectored vaccine safely evaluated camel human mers vaccine candidate tested camel clinical trial,2017-06-27,"Alharbi, Naif Khalaf; Padron-Regalado, Eriko; Thompson, Craig P.; Kupke, Alexandra; Wells, Daniel; Sloan, Megan A.; Grehan, Keith; Temperton, Nigel; Lambe, Teresa; Warimwe, George; Becker, Stephan; Hill, Adrian V.S.; Gilbert, Sarah C.",Vaccine,,,,document_parses/pdf_json/f3c5dbfd682af9f81d55a8feda2e808a0b4f22a0.json,document_parses/pmc_json/PMC5516308.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28579232/; https://api.elsevier.com/content/article/pii/S0264410X17306564; https://doi.org/10.1016/j.vaccine.2017.05.032; https://www.sciencedirect.com/science/article/pii/S0264410X17306564,3661509.0,3
83135,83135,106648,mn8r972x,f362dc95e20dda789fdab139a27dc72af5886b71,Elsevier; PMC,Chapter 68 Mucosal Veterinary Vaccines Comparative Vaccinology,10.1016/b978-0-12-415847-4.00068-9,PMC7149859,,els-covid,infection mucosal surface major cause morbidity mortality economic loss specie veterinary interest concern animal welfare vaccine used extensively veterinary medicine innovative vaccine technology recombinant dnavectored distinguishing infected vaccinated animal diva vaccine automated ovo vaccination embryonated chicken egg rapidly adopted commercially immunological research using outbred nonrodent animal model contributed broader understanding mucosal defense provided initial impetus investigation common mucosal immune system study potential novel adjuvant improve vaccine efficacy genetically unstable immunesubverting rna virus porcine reproductive respiratory syndrome virus pig assist control pathogen similar characteristic specie successful development vaccine prevent treat ascending infection reproductive tract cattle set precedent application specie including human study mucosal adjuvant delivery system continue interface passive active immunity goal inducing earliest possible protection enteric respiratory pathogen neonate,2015-12-31,"Hodgins, Douglas C.; Chattha, Kuldeep; Vlasova, Anastasia; Parreño, Viviana; Corbeil, Lynette B.; Renukaradhya, Gourapura J.; Saif, Linda J.",Mucosal Immunology,,,,document_parses/pdf_json/f362dc95e20dda789fdab139a27dc72af5886b71.json,document_parses/pmc_json/PMC7149859.xml.json,https://api.elsevier.com/content/article/pii/B9780124158474000689; https://www.sciencedirect.com/science/article/pii/B9780124158474000689,90518934.0,3
83204,83204,106736,45tre8rn,3f3e46abb51fffc3d562bd26117eed795c3febe6,Medline; PMC,Baculovirus Surface Display of Immunogenic Proteins for Vaccine Development,10.3390/v10060298,PMC6024371,29857561.0,cc-by,vaccination efficient way prevent occurrence many infectious disease human date several viral vector utilized generation vaccine among baculovirus—categorized nonhuman viral vector—has used wider application versatile feature like large cloning capacity nonreplicative nature mammalian cell broad tissue tropism hold excellent position among vaccine vector addition ease safety swift production recent key improvement existing baculovirus vector inclusion hybrid promoter immunostimulatory element etc led significant improvement immunogenicity efficacy surfacedisplayed antigen furthermore promising preclinical result reported mirror scope practicality baculovirus vaccine vector human application near future herein review provides overview induced immune response baculovirus surfacedisplayed vaccine influenza infectious disease animal model highlight strategy applied enhance protective immune response displayed antigen,2018-05-31,"Premanand, Balraj; Zhong Wee, Poh; Prabakaran, Mookkan",Viruses,,,,document_parses/pdf_json/3f3e46abb51fffc3d562bd26117eed795c3febe6.json,document_parses/pmc_json/PMC6024371.xml.json,https://doi.org/10.3390/v10060298; https://www.ncbi.nlm.nih.gov/pubmed/29857561/,46918616.0,3
83219,83219,106756,66omwit2,7fdd6624e91af464e7763c7916ba310e518a9a85; 180a76b34ddfc772fa71463c92ba899d13630b60,Elsevier; Medline; PMC,Respiratory tract immunization of non-human primates with a Newcastle disease virus-vectored vaccine against Ebola virus elicits a neutralizing antibody response,10.1016/j.vaccine.2010.10.024,PMC3428043,21034822.0,green-oa,previously developed respiratory tract vaccine ebola virus ebov based human parainfluenza virus type hpiv respiratory paramyxovirus expressing ebov gp envelope protein hpivgp added gene two dos vaccine delivered intranasal intratracheal route protected monkey intraperitoneal challenge ebov however concern exist vaccine may reduced immunogenicity adult human population due preexisting immunity hpiv developed new vaccine ndvgp based newcastle disease virus ndv avian paramyxovirus antigenically distinct human viral pathogen highly attenuated monkey following one intranasal intratracheal inoculation rhesus monkey ndvgp titer ebovspecific antibody respiratory tract secretion serum sample determined elisa well serum ebovneutralizing antibody undetectable low compared induced hpivgp second immunization resulted substantial boost serum igg elisa titer yet titer remained lower induced second dose hpivgp contrast elisa iga titer respiratory tract secretion importantly serum ebovneutralizing antibody titer equal induced second dose hpivgp data suggest ndvgp effective immunization ebov alone combination either hpivgp another vaccine platform heterologous primeboost regimen,2010-12-01,"DiNapoli, Joshua M.; Yang, Lijuan; Samal, Siba K.; Murphy, Brian R.; Collins, Peter L.; Bukreyev, Alexander",Vaccine,,,,document_parses/pdf_json/7fdd6624e91af464e7763c7916ba310e518a9a85.json; document_parses/pdf_json/180a76b34ddfc772fa71463c92ba899d13630b60.json,document_parses/pmc_json/PMC3428043.xml.json,http://europepmc.org/articles/pmc3428043?pdf=render; https://www.sciencedirect.com/science/article/pii/S0264410X10014933; https://api.elsevier.com/content/article/pii/S0264410X10014933; https://doi.org/10.1016/j.vaccine.2010.10.024; https://www.ncbi.nlm.nih.gov/pubmed/21034822/,13788928.0,3
83238,83238,106784,xyxdk875,fbb769061e6af30c3b6665b7bf5b31b5c5d030df,Medline; PMC,Panblok-H1+advax H1N1/2009pdm vaccine: Insights into rapid development of a delta inulin adjuvanted recombinant pandemic influenza vaccine,10.1080/21645515.2017.1279765,PMC5489286,28301280.0,bronze-oa,timely vaccine supply critical influenza pandemic impeded current virusbased manufacturing method hnpdm ‘ swine flu ’ pandemic reinforced need innovation pandemic vaccine design report insight gained rapid development pandemic vaccine based recombinant haemagglutinin rha formulated advax™ delta inulin adjuvant panblokhadvax panblokhadvax designed manufactured within month pandemic declaration successfully entered human clinical testing month first isolation sequencing novel pandemic virus requiring several major challenge overcome panblokhadvax successfully induced neutralising antibody pandemic strain also induced crossneutralising antibody subset subject hn strain apuerto rico derived spanish flu highlighting possibility use advax induce broadly crossprotective antibody response interestingly rha hnpdm exhibited variant receptor binding domain major impact receptor binding hemagglutination ability used silico structural modeling approach better understand unusual behavior novel hemagglutinin thereby demonstrating power computational modeling approach rapid characterization new pandemic virus challenge remain ensuring ultrafast vaccine access entire population response future pandemic adjuvanted recombinant panblokhadvax vaccine proved utility reallife pandemic situation,2017-02-14,"Honda-Okubo, Yoshikazu; Rajapaksha, Harinda; Sajkov, Dimitar; Gordon, David; Cox, Manon M. J.; Petrovsky, Nikolai",Human Vaccines & Immunotherapeutics,,,,document_parses/pdf_json/fbb769061e6af30c3b6665b7bf5b31b5c5d030df.json,document_parses/pmc_json/PMC5489286.xml.json,https://www.tandfonline.com/doi/pdf/10.1080/21645515.2017.1279765?needAccess=true; https://www.ncbi.nlm.nih.gov/pubmed/28301280/; https://doi.org/10.1080/21645515.2017.1279765,46852136.0,3
83255,83255,106809,lbv4s7m8,57ce591f30113a9d4fadb1448adccfaecc924fd8; bf473015ec0534efc1d29bbdc3a9c37034eeb749,Elsevier; Medline; PMC,"Vaccines, inspiring innovation in health()",10.1016/j.vaccine.2018.05.035,PMC6238075,29789241.0,cc-by,report cover topic pandemic epidemic partnership including regulatory convergence initiative new technology novel vaccine discussed leading public private sector stakeholder th annual general meeting agm developing country vaccine manufacturer ’ network dcvmn contribution gavi vaccine industry emerging country growing global vaccine market improving supply base manufacturer developing country contributing dos highlighted coalition epidemic preparedness innovation cepi international vaccine institute ivi others reported new strategy ensure speedy progress preclinical clinical development innovative vaccine future mers zika outbreak response priority vaccine stockpiling assure readiness emergency prevent outbreak due reemerging disease yellow fever cholera poliomyelitis outlined role partnership improving global vaccine access procurement immunization coverage shared concern reviewed world health organization international collaborating partner provided update product price procurement database prequalification vaccine control neglected tropical disease particularly new rabies elimination initiative regulatory convergence proposal accelerate vaccine registration developing country update supply chain innovation novel vaccine platform presented discussion enabled member partner reflect efficiency research development supply chain tool trend packaging technology improving delivery existing vaccine allowing deeper understanding current publichealth objective industry financing global policy required ensure optimal investment alignment stability vaccine supply developing country,2018-11-19,"Pagliusi, Sonia; Dennehy, Maureen; Kim, Hun",Vaccine,,,,document_parses/pdf_json/57ce591f30113a9d4fadb1448adccfaecc924fd8.json; document_parses/pdf_json/bf473015ec0534efc1d29bbdc3a9c37034eeb749.json,document_parses/pmc_json/PMC6238075.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X18306558; https://www.ncbi.nlm.nih.gov/pubmed/29789241/; https://api.elsevier.com/content/article/pii/S0264410X18306558; https://doi.org/10.1016/j.vaccine.2018.05.035,46894457.0,3
83269,83269,106825,gi7ktelw,b3bbada03f4e8f7a0164a31a88698c73e0aea72a,Medline; PMC,Enhancing immune responses against SARS-CoV nucleocapsid DNA vaccine by co-inoculating interleukin-2 expressing vector in mice,10.1007/s10529-009-0061-y,PMC7088336,19579009.0,no-cc,immunogenicity sarscov nucleocapsid dna vaccine immunoregulatory activity interleukin il investigated dna vaccine plasmid pcdnan pcdnail constructed inoculated balbc mouse without pcdnail intramuscular injection cellular humoral immune response assessed indirect elisa lymphocyte proliferation assay elispot facs nucleocapsid dna vaccine good immunogenicity induce specific humoral cellular immunity balbc mouse il play immunoadjuvant role enhances specific immune response study provides frame reference design dna vaccine sarscov,2009-07-05,"Hu, Hui; Tao, Ling; Wang, Yabin; Chen, Liying; Yang, Jihong; Wang, Hanzhong",Biotechnol Lett,,,,document_parses/pdf_json/b3bbada03f4e8f7a0164a31a88698c73e0aea72a.json,document_parses/pmc_json/PMC7088336.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19579009/; https://doi.org/10.1007/s10529-009-0061-y,20047780.0,3
83328,83328,106909,ldwx1wyc,ceabb750f6de4f2e3527db125ed62b4528ac958e,Medline; PMC,"Toward Developing a Preventive MERS-CoV Vaccine—Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14–15, 2015",10.3201/eid2208.160229,PMC4982192,27439020.0,no-cc,middle east respiratory syndrome mers remains serious international public health threat goal accelerating development countermeasure mers coronavirus merscov funding agency nongovernmental organization researcher across world assembled riyadh saudi arabia november – discus vaccine development challenge meeting spearheaded saudi ministry health coorganized international vaccine institute south korea accelerating development preventive vaccine requires better understanding mers epidemiology transmission pathogenesis human animal combination rodent nonhuman primate model considered evaluating developing preventive therapeutic vaccine candidate dromedary camel considered development veterinary vaccine several vaccine technology platform targeting merscov spike protein discussed mechanism maximize investment provide robust data affect public health urgently needed,2016-08-26,"Excler, Jean-Louis; Delvecchio, Christopher J.; Wiley, Ryan E.; Williams, Marni; Yoon, In-Kyu; Modjarrad, Kayvon; Boujelal, Mohamed; Moorthy, Vasee S.; Hersi, Ahmad Salah; Kim, Jerome H.",Emerg Infect Dis,,,,document_parses/pdf_json/ceabb750f6de4f2e3527db125ed62b4528ac958e.json,document_parses/pmc_json/PMC4982192.xml.json,https://doi.org/10.3201/eid2208.160229; https://www.ncbi.nlm.nih.gov/pubmed/27439020/,7993150.0,3
83358,83358,106946,ylwcf6cd,31d093e41e871ccc4472ec4bcfccb4a94a46653e,Medline; PMC,Experimental screening studies on rabies virus transmission and oral rabies vaccination of the Greater Kudu (Tragelaphus strepsiceros),10.1038/s41598-018-34985-5,PMC6226427,30413745.0,cc-by,rabies greater kudu tragelaphus strepsiceros namibia unique found magnitude reported elsewhere southern africa reason kudu appear exceptionally susceptible rabies still remain speculative best current severe rabies endemic kudu continues enormous negative impact namibian agricultural sector set question existing dogma regarding epidemiology disease unique experimental setting addition explored effective measure protect antelope although able confirm high susceptibly kudu rabies sporadic horizontal rabies virus transmission contact animal contend observation plausibly explain rapid spread disease kudu large territory since parenteral vaccination freeroaming kudu virtually impossible oral rabies vaccination using modified life virus vaccine high safety profile would ultimate solution problem proofofconcept study using rd generation oral rabies virus vaccine construct spbn gasgas found evidence kudu vaccinated oral route protected subsequent rabies infection second phase targeted study need initiated focusing optimizing oral vaccine uptake delivery,2018-11-09,"Hassel, Rainer; Vos, Ad; Clausen, Peter; Moore, Susan; van der Westhuizen, Jolandie; Khaiseb, Siegfried; Kabajani, Juliet; Pfaff, Florian; Höper, Dirk; Hundt, Boris; Jago, Mark; Bruwer, Floris; Lindeque, Pauline; Finke, Stefan; Freuling, Conrad M.; Müller, Thomas",Sci Rep,,,,document_parses/pdf_json/31d093e41e871ccc4472ec4bcfccb4a94a46653e.json,document_parses/pmc_json/PMC6226427.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30413745/; https://doi.org/10.1038/s41598-018-34985-5,53240402.0,3
83382,83382,106977,8zfxklef,77cdb9f7f5451fd710304093391bca2637411c85,Medline; PMC,Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China,10.1038/emi.2014.30,PMC4051363,26038738.0,cc-by-nc-sa,hand foot mouth disease hfmd important public health problem emerged past several year hfmd predominantly infects child seven year old occasionally cause severe disease adult among enterovirus enterovirus ev coxsackievirus ca major causative agent hfmd addition adenovirus cocirculates enterovirus become possible additional pathogenic factor hfmd case investigated neutralizing antibody response enterovirus adenovirus adult aim exploring prevalence trend virus nature protective immunity human viral infection serum healthy adult province city china tested presence antibody ev ca adenovirus human serotype adhu chimpanzee adenovirus pan adc using neutralization test high seroprevalence rate ev ca adhu found population respectively coseropositivity rate three virus median neutralizing antibody titer respectively neutralizing antibody titer ev found correlated ca adhu adc found rare adenovirus serotype human population seropositivity rate suggesting could good choice vaccine carrier could used vaccine development,2014-05-07,"Wang, Xiang; Xing, Man; Zhang, Chao; Yang, Yong; Chi, Yudan; Tang, Xinying; Zhang, Hongbo; Xiong, Sidong; Yu, Luogang; Zhou, Dongming",Emerg Microbes Infect,,,,document_parses/pdf_json/77cdb9f7f5451fd710304093391bca2637411c85.json,document_parses/pmc_json/PMC4051363.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26038738/; https://doi.org/10.1038/emi.2014.30,13977490.0,3
83391,83391,106989,kqhbfnq3,7f3ca4133a2788e02072b7c38d2fd7dca26b7458,Elsevier; Medline; PMC,Recombinant vesicular stomatitis virus expressing the spike protein of genotype 2b porcine epidemic diarrhea virus: A platform for vaccine development against emerging epidemic isolates,10.1016/j.virol.2019.05.009,PMC7112030,31128495.0,els-covid,emerging porcine epidemic diarrhea virus pedvs caused large economic loss since gb prevalent globally epidemic genotype given fastidious isolation emerging pedv cell culture difficulty retaining isolate infectivity upon vitro passage highly attenuated recombinant vesicular stomatitis virus rvsvmt used vector express pedv spike protein aiming develop subunit vaccine gb virus protein cytoplasmic domain amino acid deleted could incorporated vsv particle generating rvsvmt vsvmtsδ high efficiency result suggest vsvmtsδ could effectively induce pedvspecific immunity pig via intramuscular intranasal immunization notably immunization sow vsv mtsδ provided protective lactogenic immunity virulent gb pedv challenge piglet consequently recombinant vsvmt may promising platform preparing subunit vaccine pedv,2019-07-31,"Ke, Yong; Yu, Dayi; Zhang, Fanqing; Gao, Jing; Wang, Xiaoyu; Fang, Xinkui; Wang, Hengan; Sun, Tao",Virology,,,,document_parses/pdf_json/7f3ca4133a2788e02072b7c38d2fd7dca26b7458.json,document_parses/pmc_json/PMC7112030.xml.json,https://www.sciencedirect.com/science/article/pii/S0042682219301291; https://api.elsevier.com/content/article/pii/S0042682219301291; https://www.ncbi.nlm.nih.gov/pubmed/31128495/; https://doi.org/10.1016/j.virol.2019.05.009,165163141.0,3
83404,83404,107005,1xt46g8j,5ad06be75e9c306aa10fea704f93d4ba90623a15,Elsevier; PMC,Random-peptide libraries and antigen-fragment libraries for epitope mapping and the development of vaccines and diagnostics,10.1016/s1367-5931(00)00208-8,PMC7129944,11479124.0,els-covid,random peptide library antigenfragment library also known genefragment library used identify epitope protein antigen technology promise make significant contribution diagnostic vaccine development researcher number lab shown phage selected library protective antibody raised whole antigen used immunogen stimulate antibody response bind native antigen provide protection vivo others used serum patient idiopathic disease screen library approach identified candidate antigen involved immune disease may prove useful diagnosis possibly determining disease etiology,2001-06-01,"Irving, Melita B; Pan, Oscar; Scott, Jamie K",Current Opinion in Chemical Biology,,,,document_parses/pdf_json/5ad06be75e9c306aa10fea704f93d4ba90623a15.json,document_parses/pmc_json/PMC7129944.xml.json,https://api.elsevier.com/content/article/pii/S1367593100002088; https://www.sciencedirect.com/science/article/pii/S1367593100002088,31079424.0,3
83415,83415,107020,w1l8h8g8,713add2e6d55053d57b23e65e94893ac7d6195ab,Elsevier; Medline; PMC,Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches,10.1016/j.coviro.2017.03.007,PMC7102752,28412285.0,els-covid,middle east respiratory syndrome coronavirus merscov cause severe respiratory infection human specifically elderly people comorbidities reemergence lethal coronaviruses call international collaboration produce coronavirus vaccine still lacking date ongoing effort develop merscov vaccine consider different target population dromedary camel human correlate protection extending current knowledge mers vaccination dromedary camel induce mucosal immunity could promising approach diminish merscov transmission human addition equally important develop vaccine human induce broader reactivity various coronaviruses prepared potential next cov outbreak,2017-04-30,"Okba, Nisreen MA; Raj, V Stalin; Haagmans, Bart L",Current Opinion in Virology,,,,document_parses/pdf_json/713add2e6d55053d57b23e65e94893ac7d6195ab.json,document_parses/pmc_json/PMC7102752.xml.json,https://doi.org/10.1016/j.coviro.2017.03.007; https://www.sciencedirect.com/science/article/pii/S1879625716301481; https://www.ncbi.nlm.nih.gov/pubmed/28412285/; https://api.elsevier.com/content/article/pii/S1879625716301481,3404186.0,3
83429,83429,107036,y8ynk50h,65b6cc079b3c31133dd5d20ade29e8bbab46be98,Elsevier; PMC,Immunotherapy against experimental canine visceral leishmaniasis with the saponin enriched-Leishmune® vaccine,10.1016/j.vaccine.2007.06.005,PMC7115527,17630055.0,els-covid,order ass immunotherapeutic potential canine visceral leishmaniasis leishmune® vaccine formulated increased adjuvant concentration mg saponin rather mg mongrel dog infected leishmania l chagasi enrichedleishmune® vaccine injected month infection animal seropositive symptomatic control group injected saline solution leishmune®treated dog showed significantly higher level antifml igg antibody anova p higher stable igg decreasing igg response pointing th cell mediated response vaccine following effect led positive delayed type hypersensitivity reaction leishmania lysate vaccinated dog control decreased average cd leishmaniaspecific lymphocyte saline control fell outside confidence interval vaccinee ci – increased average clinical score saline control fall outside confidence interval leishmune® immunotherapytreated dog ci – dog received vaccine clustered showed lower clinical score normal cd count whereas untreated dog showed diminished cd higher clinical score increase clinical sign saline treated group correlated increase antifml antibody p parasitological evidence p decrease leishmaniaspecific cd lymphocyte proportion p result confirm immunotherapeutic potential enrichedleishmune® vaccine vaccine reduced clinical symptom evidence parasite modulating outcome infection dog potential infectiosity phlebotomines enrichedleishmune® vaccine subjected safety analysis found well tolerated safe,2007-08-14,"Santos, F. N.; Borja-Cabrera, G. P.; Miyashiro, L. M.; Grechi, J.; Reis, A. B.; Moreira, M.A.B.; Martins Filho, O. A.; Luvizotto, M.C.R.; Menz, I.; Pessôa, L. M.; Gonçalves, P. R.; Palatnik, M.; Palatnik-de-Sousa, C. B.",Vaccine,,,,document_parses/pdf_json/65b6cc079b3c31133dd5d20ade29e8bbab46be98.json,document_parses/pmc_json/PMC7115527.xml.json,https://api.elsevier.com/content/article/pii/S0264410X07006810; https://www.sciencedirect.com/science/article/pii/S0264410X07006810,46408915.0,3
83439,83439,107049,26cn718f,3b05296a3d936880e2aa2f0b51a0de80e1cbf797,Elsevier; Medline; PMC,A gene-based avian influenza vaccine in poultry1,10.3382/ps.2008-00360,PMC7194532,19276436.0,els-covid,highly pathogenic avian influenza hpai virus specifically hn strain cause widespread morbidity mortality domestic wild bird population recent outbreak resulted severe economic loss although still largely confined bird human case resulting death reported world health organization sporadic human case result direct transmission infected bird however sustained outbreak hpai hn increase potential emergence human pandemic strain one approach containment hpai hn development vaccine use poultry currently majority avian influenza vaccine poultry traditional wholevirus vaccine produced egg although highly efficacious vaccine hindered long production time inflexibility quickly altering antigenic composition limited breadth protection newer vaccine efficient manufacturing process enhanced efficacy crossprotection multiple strain would improve preparedness reverse genetics technology provided one method emerging genebased vaccine offer another approach reduces dependence eggbased production human exposure pathogenic virus genebased vaccine also provide rapid manufacturing enhanced precision versatility capacity protect broad range viral subtypes vector vaccine include replicationdefective virus bacterial vector dna review feature genebased vaccination may facilitate control hpai hn poultry highlight development hemagglutininbased multivalent dna vaccine confers protection mouse chicken,2009-04-01,"Rao, S. S.; Styles, D.; Kong, W.; Andrews, C.; Gorres, J. P.; Nabel, G. J.",Poultry Science,,,,document_parses/pdf_json/3b05296a3d936880e2aa2f0b51a0de80e1cbf797.json,document_parses/pmc_json/PMC7194532.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19276436/; https://api.elsevier.com/content/article/pii/S0032579119391631; https://doi.org/10.3382/ps.2008-00360; https://www.sciencedirect.com/science/article/pii/S0032579119391631,17881393.0,3
83461,83461,107073,9durbi65,d233b4a031a21ce4991d2ce5ef41ca2ab39ec6ac,Elsevier; Medline; PMC,A DNA prime-protein boost vaccination strategy targeting turkey coronavirus spike protein fragment containing neutralizing epitope against infectious challenge,10.1016/j.vetimm.2013.01.009,PMC7112546,23428360.0,els-covid,present study undertaken determine immune response protection efficacy spike protein fragment containing neutralizing epitope fr turkey coronavirus tcov priming dna vaccine boosting recombinant protein corresponding dna vaccine gene segment turkey vaccinated priming either one dose gdp two dos gddp μg dna vaccine expressing fr fragment boosting one dose μg fr fragment one dose μg dna vaccine mixed polyethyleneimine pei sodium hyaluronate ha followed one dose μg dna vaccine one dose μg fr fragment given turkey group gdph infectious challenge tcov clinical sign tcov detected immunofluorescence antibody ifa assay observed le number turkey vaccination group challenge control group tcov viral rna load measured quantitative realtime reverse transcriptionpcr lower vaccinated turkey challenge control turkey turkey gddp produced highest level tcov proteinspecific antibody virus neutralization vn titer comparing turkey gdp significantly le tcov detected ifa turkey gdph receiving extra dose μg dna mixed pei ha result indicated dnaprime proteinboost dna vaccination regimen targeting tcov fragment encompassing neutralizing epitope induced humoral immune response partially protected turkey infectious challenge tcov,2013-04-15,"Chen, Yi-Ning; Wu, Ching Ching; Yeo, Yoon; Xu, Peisheng; Lin, Tsang Long",Veterinary Immunology and Immunopathology,,,,document_parses/pdf_json/d233b4a031a21ce4991d2ce5ef41ca2ab39ec6ac.json,document_parses/pmc_json/PMC7112546.xml.json,https://doi.org/10.1016/j.vetimm.2013.01.009; https://www.sciencedirect.com/science/article/pii/S0165242713000305; https://www.ncbi.nlm.nih.gov/pubmed/23428360/; https://api.elsevier.com/content/article/pii/S0165242713000305,5488119.0,3
83550,83550,107184,9pc7ngr3,205c7a303fe67af7465f9d425213536470d979ce,Elsevier; PMC,Vaccines and Vaccination Practices: Key to Sustainable Animal Production,10.1016/b978-0-444-52512-3.00189-3,PMC7152402,,els-covid,protection food animal disease essential meet current future demand animal protein human consumption vaccination crucial component overall strategy achieve goal article address type vaccine vaccination technique cattle swine poultry fish including brief introduction defining pathogen immune response genetic resistance biosecurity,2014-12-31,"Schat, K. A.",Encyclopedia of Agriculture and Food Systems,,,,document_parses/pdf_json/205c7a303fe67af7465f9d425213536470d979ce.json,document_parses/pmc_json/PMC7152402.xml.json,https://api.elsevier.com/content/article/pii/B9780444525123001893; https://www.sciencedirect.com/science/article/pii/B9780444525123001893,82557265.0,3
83612,83612,107257,kira7mz6,17ccb5c5c6c8351cc8258712ab9cf4e0810fdc85,Elsevier; PMC,Mild acute inflammatory stimulation induces transient negative mood,10.1016/s0022-3999(03)00569-5,PMC7125976,15465075.0,els-covid,objective study aim ass mood change induced mild acute inflammatory stimulation typhoid vaccination method using double blind study design healthy volunteer underwent baseline assessment mood financial strain work stress randomised injection salmonella typhi vaccine placebo injection mood symptom body temperature assessed modified version profile mood state h post injection result typhoid vaccination induces increase physical symptom temperature mood improved day placebo vaccine condition negative change mood following injection correlated chronic stress financial strain vaccination condition r− p conclusion mild acute inflammatory stimulus induces transient negative mood response modulated chronic stress implication depressed mood physical illness discussed,2004-08-31,"Strike, Philip C.; Wardle, Jane; Steptoe, Andrew",Journal of Psychosomatic Research,,,,document_parses/pdf_json/17ccb5c5c6c8351cc8258712ab9cf4e0810fdc85.json,document_parses/pmc_json/PMC7125976.xml.json,https://www.sciencedirect.com/science/article/pii/S0022399903005695; https://api.elsevier.com/content/article/pii/S0022399903005695,37028460.0,3
83644,83644,107300,ytxrrslz,0080d3bd9fb92e022c27715c2d1249042aa998b8,Medline; PMC,Rational Design of a Live Attenuated Dengue Vaccine: 2′-O-Methyltransferase Mutants Are Highly Attenuated and Immunogenic in Mice and Macaques,10.1371/journal.ppat.1003521,PMC3731252,23935499.0,cc-by,dengue virus transmitted aedes mosquito infects least million people every year progressive urbanization asia southcentral america geographic expansion aedes mosquito habitat accelerated global spread dengue resulting continuously increasing number case costeffective safe vaccine conferring protection ideally single injection could stop dengue transmission current vaccine candidate require several booster injection provide protection four serotypes demonstrate dengue virus mutant lacking ′omethyltransferase activity highly sensitive type ifn inhibition mutant virus attenuated mouse rhesus monkey elicit strong adaptive immune response monkey immunized single dose ′omethyltransferase mutant virus showed seroconversion even dose low plaque forming unit administrated animal fully protected homologous challenge furthermore mosquito feeding blood containing mutant virus infected whereas feeding blood containing wildtype virus infected thus able transmit result show potential ′omethyltransferase mutant virus safe rationally designed dengue vaccine restrains due increased susceptibility host innate immune response,2013-08-01,"Züst, Roland; Dong, Hongping; Li, Xiao-Feng; Chang, David C.; Zhang, Bo; Balakrishnan, Thavamalar; Toh, Ying-Xiu; Jiang, Tao; Li, Shi-Hua; Deng, Yong-Qiang; Ellis, Brett R.; Ellis, Esther M.; Poidinger, Michael; Zolezzi, Francesca; Qin, Cheng-Feng; Shi, Pei-Yong; Fink, Katja",PLoS Pathog,,,,document_parses/pdf_json/0080d3bd9fb92e022c27715c2d1249042aa998b8.json,document_parses/pmc_json/PMC3731252.xml.json,https://doi.org/10.1371/journal.ppat.1003521; https://www.ncbi.nlm.nih.gov/pubmed/23935499/,8111607.0,3
83673,83673,107336,cpl0zcct,,Elsevier; PMC,Chapter 9 Vaccines and Immunotherapy,10.1016/b978-0-12-816572-0.00009-7,PMC7149523,,els-covid,chapter examines general topic vaccine goal develop perspective active passive immunization vaccination infectious agent multiple class discussion also demonstrate principle immunology combine biotechnology advance field vaccinology,2019-12-31,"Actor, Jeffrey K.",Introductory Immunology,,,,,,https://api.elsevier.com/content/article/pii/B9780128165720000097; https://www.sciencedirect.com/science/article/pii/B9780128165720000097,214757101.0,3
83696,83696,107366,ovsngppo,a5fcd22ab930b1a3a866097b5e1d38b6bfcb050c,Elsevier; Medline; PMC,Traitors of the immune system—Enhancing antibodies in HIV infection: Their possible implication in HIV vaccine development,10.1016/j.vaccine.2007.12.028,PMC7115406,18241961.0,els-covid,summary considering recent hiv vaccine failure author believe would important find new target vaccineinduced immunity analyze data previous trial using innovative approach review article author briefly summarize significance antibodydependent enhancement infection different viral disease discus role type antibody obstacle vaccine development finding indicate complementmediated antibodydependent enhancement cade present also hivinfected patient summarized previous result author suggesting cade play important role progression hiv infection described data reflecting enhancing antibody may develop even vaccinated animal human volunteer may responsible paradoxical result obtained subgroup vaccinee discussed finally based hypothesis author offer suggestion future development vaccine,2008-06-06,"Beck, Zoltán; Prohászka, Zoltán; Füst, George",Vaccine,,,,document_parses/pdf_json/a5fcd22ab930b1a3a866097b5e1d38b6bfcb050c.json,document_parses/pmc_json/PMC7115406.xml.json,https://api.elsevier.com/content/article/pii/S0264410X07014831; https://www.ncbi.nlm.nih.gov/pubmed/18241961/; https://www.sciencedirect.com/science/article/pii/S0264410X07014831; https://doi.org/10.1016/j.vaccine.2007.12.028,21275693.0,3
83712,83712,107384,aql0vrzv,d9c979a55f748d623b30a4370927167d01e29ac2,Medline; PMC,Evolutionary and bioinformatic analysis of the spike glycoprotein gene of H120 vaccine strain protectotype of infectious bronchitis virus from India,10.1002/bab.1298,PMC7161789,25311758.0,no-cc,infectious bronchitis virus causative agent avian infectious bronchitis aib important disease produce severe economic loss poultry industry worldwide recent aib outbreak india associated poor growth broiler drop egg production thin egg shell layer complete spike gene indian aib vaccine strain amplified sequenced using conventional reverse transcription polymerase chain reaction submitted genbank accession kf phylogenetic analysis revealed vaccine strain currently used belongs h genotype attenuated strain massachusetts mass serotype nucleotide amino acid sequence comparison shown reported spike gene indian isolates – – genetic similarity sequenced h strain study identifies live attenuated ibv vaccine strain routinely used vaccination first time based nucleotide amino acid relatedness study vaccine strain reported ibv sequence india shown current vaccine strain efficient controlling ibv infection continuous monitoring ibv outbreak sequencing genotyping vivo cross protection study serotyping important epidemiological investigation also evaluation efficacy current vaccine,2016-02-12,"Kamble, Nitin Machindra; Pillai, Aravind S.; Gaikwad, Satish S.; Shukla, Sanjeev Kumar; Khulape, Sagar Aashok; Dey, Sohini; Mohan, C. Madhan",Biotechnol Appl Biochem,,,,document_parses/pdf_json/d9c979a55f748d623b30a4370927167d01e29ac2.json,document_parses/pmc_json/PMC7161789.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25311758/; https://doi.org/10.1002/bab.1298,3491649.0,3
83814,83814,107512,kpmwn0c2,,Medline; WHO,Design of multi-epitope vaccine candidate against SARS-CoV-2: a In-Silico study,10.1080/07391102.2020.1770127,,32419646.0,unk,best therapeutic strategy find effective vaccine sarscov explore target structural protein present study novel multiepitope vaccine designed using silica tool potentially trigger cd cd tcell immune response novel coronavirus vaccine candidate designed using b tcell epitope act immunogen elicits immune response host system ncbi used retrieval surface spike glycoprotein novel corona virus sarscov strain vaxijen server screen important immunogen protein iedb server give prediction analysis b cell epitope final vaccine construct designed silico composed amino acid including ribosomal protein adjuvant construct computationally validated term antigenicity allergenicity stability considering critical parameter consideration result subjected modeling docking study vaccine validated molecular docking study revealed proteinprotein binding interaction vaccine construct tlr immune receptor md simulation confirmed stability binding pose immune simulation result showed significant response immune cell finding study confirmed final vaccine construct chimeric peptide could able enhance immune response ncov,2020,"K, Abraham Peele; T, Srihansa; S, Krupanidhi; A, Vijaya Sai; Tc, Venkateswarulu",J Biomol Struct Dyn,,#291387,,,,https://doi.org/10.1080/07391102.2020.1770127; https://www.ncbi.nlm.nih.gov/pubmed/32419646/,218679413.0,3
83825,83825,107526,w643jf90,b3c71d9d7dd9758f8328933f47d7d460bf24c98e,Medline; PMC,Efficacy of inactivated variant porcine epidemic diarrhea virus vaccines in growing pigs,10.7774/cevr.2018.7.1.61,PMC5795046,29399581.0,cc-by-nc,purpose first aim study develop novel inactivated porcine epidemic diarrhea virus pedv vaccine using recently isolated korean pedv qiap strain evaluate protective efficacy growing pig second determine optimum adjuvant formulation inactivated pedv vaccine induces protection viral challenge material method generate high titer infectious pedv qiap isolate passaged vero cell experimental vaccine prepared binary ethyleneimineinactivated qiap strain passaged sequentially time qiapp formulated four commercial adjuvant administered twice intramuscularly growing pig challenge study using virulent homologous strain pedv qiapp passaged time isolation performed ass protection disease progression viral shedding day observation period vaccineinduced antibody response measured serum sample collected predetermined time point indirect enzymelinked immunosorbent assay virus neutralization test result qiapp strain amino acid aa mutation including aa deletion selected inactivated pedv vaccine candidate although none pig received experimental vaccine completely protected subsequent viral challenge exhibited significantly higher immune response nonvaccinated control pig among vaccine group highest antibody response observed pig received oilbased multiphasic wateroilwater wow emulsion adjuvanted vaccine delayed onset clinical symptom viral shedding conclusion novel inactivated pedv vaccine formulated wow emulsion adjuvant immunogenic protective viral challenge,2018-01-29,"Lee, Seung Heon; Yang, Dong-Kun; Kim, Ha-Hyun; Cho, In-Soo",Clin Exp Vaccine Res,,,,document_parses/pdf_json/b3c71d9d7dd9758f8328933f47d7d460bf24c98e.json,document_parses/pmc_json/PMC5795046.xml.json,https://doi.org/10.7774/cevr.2018.7.1.61; https://www.ncbi.nlm.nih.gov/pubmed/29399581/,37974159.0,3
83826,83826,107527,uqhhigb1,,Medline; WHO,"China coronavirus should be on ""everybody's agenda,"" says vaccine expert",10.1136/bmj.m476,,32024634.0,unk,novel coronavirus ncov “ everybody ’ agenda ” say seth berkley chief executive officer gavi vaccine alliance said response may “ overreaching ” currently known virus suggests treated seriouslyberkley spoke briefing london february told bmj although “ know enough right honestly answer question overreaction ” better prepare wait see “ mean travel ban everywhere world response think certainly thing overreaching think world taking …,2020,"Mahase, Elisabeth",BMJ,,#295,,,,https://doi.org/10.1136/bmj.m476; https://www.ncbi.nlm.nih.gov/pubmed/32024634/,211045917.0,3
83829,83829,107530,jwvz1ux2,52a61f0348480cb8c5b29d22307b8a1449e64f0e,Medline; PMC,A Minimally Replicative Vaccine Protects Vaccinated Piglets Against Challenge With the Porcine Epidemic Diarrhea Virus,10.3389/fvets.2019.00347,PMC6817509,31696121.0,cc-by,porcine epidemic diarrhea virus pedv economically important enteric coronavirus mortality rate neonatal piglet virus emerged u resulting severe production loss effective vaccine development pedv challenge inactivated vaccine questionable efficacy attenuated vaccine effective require relatively long lead development time associated safety concern also unable prevent new field outbreak combine safety efficacy advantage inactivated attenuated pedv vaccine respectively study tested hypothesis subjecting pedv virion heat treatment °c min reversibly unfold structural protein followed exposure rnase fragment genome would result vaccine preparation intact viral structureantigenicity highly diminished replicative ability expected vaccine safe effective piglet challenge model following heat rnase treatment pedv virion intact electron microscopic ultrastructure amplified rd passage vero cell indicating diminished replication achieved vitro strong pedv spikeprotein specific virus neutralizing antibody response elicited vaccinated piglet upon challenge vaccinated pig protected fecal viral shedding intestinal pathology unvaccinated control vaccine virus detected fecal matter vaccinated pig prior challenge develop intestinal lesion thus described approach significant promise improving current approach pedv immunization,2019-10-22,"Singh, Gagandeep; Singh, Pankaj; Pillatzki, Angela; Nelson, Eric; Webb, Brett; Dillberger-Lawson, Steven; Ramamoorthy, Sheela",Front Vet Sci,,,,document_parses/pdf_json/52a61f0348480cb8c5b29d22307b8a1449e64f0e.json,document_parses/pmc_json/PMC6817509.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31696121/; https://doi.org/10.3389/fvets.2019.00347,204811413.0,3
83859,83859,107571,xxypq3wd,5f2f9331f025b22fbe79c576656f7d0471a8f9d4,Medline; PMC,Design and immunogenicity assessment of HIV-1 virus-like particles as a candidate vaccine,10.1007/s11427-011-4244-0,PMC7089044,22173311.0,cc-by-nc,rapid growth global hivaids epidemic make high priority develop effective vaccine since live attenuated inactivated hiv vaccine likely approved clinical application due safety concern hiv virus like particle vlps offer attractive alternative considered safer since lack viral genome got stable eukaryotic cell line g resistance selection engineered express hiv structure protein gag env efficiently stably confirmed presence gag env protein cell culture supernatant could selfassemble vlps vlps found able elicit specific humoral cellular immune response immunization without adjuvant,2011-12-16,"Zhang, XiZhen; Wang, XiaoDan; Zhao, DongHai; Meng, XiangYu; Zhao, XingHong; Yu, XiangHui; Kong, Wei",Sci China Life Sci,,,,document_parses/pdf_json/5f2f9331f025b22fbe79c576656f7d0471a8f9d4.json,,https://doi.org/10.1007/s11427-011-4244-0; https://www.ncbi.nlm.nih.gov/pubmed/22173311/,30606369.0,3
83956,83956,107682,e0ccq2b3,8df2059007d938efd74aca9a370b93bd3536edde,Elsevier; PMC,Control of Mycoplasma hyopneumoniae infections in pigs,10.1016/j.vetmic.2007.09.008,PMC7130725,17964089.0,els-covid,mycoplasma hyopneumoniae primary pathogen enzootic pneumonia occurs worldwide cause major economic loss pig industry organism adheres damage ciliated epithelium respiratory tract affected pig show chronic coughing susceptible respiratory infection reduced performance control disease accomplished number way first management practice housing condition herd optimized include allinallout production limiting factor may destabilize herd immunity maintaining optimal stocking density prevention respiratory disease optimal housing climatic condition strategic medication antimicrobial active hyopneumoniae preferably also major secondary bacteria may useful period pig risk respiratory disease finally commercial bacterins widely used control hyopneumoniae infection main effect vaccination include le clinical symptom lung lesion medication use improved performance however bacterins provide partial protection prevent colonization organism different vaccination strategy timing vaccination vaccination sow vaccination combined antimicrobial medication used depending type herd production system management practice infection pattern preference pig producer research new vaccine actively occurring including aerosol feedbased vaccine well subunit dna vaccine eradication infection herd level based agesegregation medication possible permanent risk reinfections,2008-01-25,"Maes, D.; Segales, J.; Meyns, T.; Sibila, M.; Pieters, M.; Haesebrouck, F.",Veterinary Microbiology,,,,document_parses/pdf_json/8df2059007d938efd74aca9a370b93bd3536edde.json,document_parses/pmc_json/PMC7130725.xml.json,https://www.sciencedirect.com/science/article/pii/S0378113507004506; https://api.elsevier.com/content/article/pii/S0378113507004506,26094378.0,3
83997,83997,107730,co72yq2s,e32ca590308847cb6da6373f7160cbaf924c0a02,Elsevier; Medline; PMC,Virus-like particles: the future of microbial factories and cell-free systems as platforms for vaccine development,10.1016/j.copbio.2013.02.008,PMC7127385,23481378.0,els-covid,vaccine based viruslike particle proved success human health year approval first vaccine based technology substantial effort expand range application target disease beginning bear fruit incursion highthroughput screening technology combined new development protein engineering chemical coupling accelerated development system capable producing macrostructures useful vaccinology gene delivery immunotherapy bionanotechnology review summarizes recent development microbial cell factory cellfree system viruslike particle production discus future impact technology human animal health,2013-12-31,"Rodríguez-Limas, William A; Sekar, Karthik; Tyo, Keith EJ",Current Opinion in Biotechnology,,,,document_parses/pdf_json/e32ca590308847cb6da6373f7160cbaf924c0a02.json,document_parses/pmc_json/PMC7127385.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/23481378/; https://doi.org/10.1016/j.copbio.2013.02.008; https://api.elsevier.com/content/article/pii/S0958166913000220; https://www.sciencedirect.com/science/article/pii/S0958166913000220,39734997.0,3
84010,84010,107745,w1dhk6kc,2027d9c3fb68436bbc32d7525e4a5fa5055ccfec,Elsevier; PMC,Mucosal immunity: an overview and studies of enteric and respiratory coronavirus infections in a swine model of enteric disease,10.1016/s0165-2427(96)05702-9,PMC7119851,8988861.0,els-covid,based tenet common mucosal immune system antigenic stimulation one mucosal site result distribution antigenspecific iga precursor cell distant mucosal site however recent study suggest functional compartmentalization limited reciprocity may exist within component common mucosal immune system although oral immunization often effective inducing immunity respiratory pathogen converse respiratory immunization prevent enteric disease may effective address question study interaction bronchusassociated balt gutassociated galt lymphoid tissue related protective immunity used model two antigenically related porcine coronaviruses replicate primarily intestine transmissible gastroenteritis virus tgev respiratory tract porcine respiratory coronavirus prcv tissue distribution magnitude antibody secreting cell asc response measured elispot cellmediated immune response measured lymphoproliferative assay lpa coincided viral tissue tropism immunization via galt gut infection tgev elicited high number iga asc high lpa response galt gut lamina propria lp mesenteric lymph node mln lower response balt bronchial lymph node bln induced complete protection enteric tgev challenge contrast immunization via balt respiratory infection prcv elicited systemic type response high number igg asc bln asc low lpa response gut lp mln induced partial protection enteric tgev challenge thus administration vaccine intranasally may optimally effective inducing intestinal immunity contrast reported efficacy oral vaccine inducing respiratory immunity,1996-11-30,"Saif, Linda J.",Veterinary Immunology and Immunopathology,,,,document_parses/pdf_json/2027d9c3fb68436bbc32d7525e4a5fa5055ccfec.json,,https://www.sciencedirect.com/science/article/pii/S0165242796057029; https://api.elsevier.com/content/article/pii/S0165242796057029,31478824.0,3
84046,84046,107788,e1lywk7i,11cf6b6e850c012a4e3aae6b61d213f261e968ab,Medline; PMC,Cocirculation of Four Infectious Bronchitis Virus Lineages in Broiler Chickens in the Eastern Region of Saudi Arabia from 2012 to 2014,10.1155/2020/6037893,PMC7150681,32292579.0,cc-by,avian infectious bronchitis virus ibv evolving dynamic virus cause major economic loss poultry industry worldwide continuous evolution emergence new variant virus major challenge controlling disease routine vaccination successful vaccination usually requires use homologous vaccine turn necessitates continuous investigation circulating strain herein performed reverse transcriptasepolymerase chain reaction rtpcr based investigation broiler chicken flock eastern region saudi arabia ibv detected tested flock january march direct sequencing hypervariable region hvr spike gene performed followed phylogenetic analysis determine circulating ibv genotype four lineage appear coexist region including gi ibv gi ckchldli ibv gi mass ibv gi middle east ibv latter lineage include two subgroup ibv isvariant ibv detection made mass lineage expected belong vaccine strain lineage without homologous vaccine use ckchldli middle east represent isolates recovered study based identity vaccine sequence field observation frequent detection two lineage appear coverage ibv vaccine used saudi arabia first time identify middle east lineage ibv isvariant ibv eastern region saudi arabia,2020-03-31,"Al-Mubarak, Abdullah I. A.; Al-Kubati, Anwar A. G.",Vet Med Int,,,,document_parses/pdf_json/11cf6b6e850c012a4e3aae6b61d213f261e968ab.json,document_parses/pmc_json/PMC7150681.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32292579/; https://doi.org/10.1155/2020/6037893,215755174.0,3
84120,84120,107882,kr11qpeo,0f953604a06ea594d767cab663c06310c128a8e7,Elsevier; PMC,Immunogenicity of SARS inactivated vaccine in BALB/c mice,10.1016/j.imlet.2004.06.014,PMC7112924,15388253.0,els-covid,severe acute respiratory syndrome sars serious infectious threat public health create novel trial vaccine evaluate potency attempted generate sars inactivated vaccine using sars coronavirus sarscov strain f treated formaldehyde mixed aloh three dos vaccine used challenge three group balbc mouse found mouse exhibited specific igm day igg day peak titer igg day lowdose group highdose group whereas middledose group peak day day igg level reached plateau neutralization assay demonstrated antiserum could protect veroe cell sarscovs infection analysis antibody specificity revealed mouse antiserum contained mixture antibody specifically structure protein sarscov furthermore mouse antiserum conferred higher amount antibody protein n polypeptide protein cl finding suggest inactivated sarscov could preserve antigenicity inactivated vaccine stimulate mouse produce high level antibody neutralization activity result also suggest polypeptide originating protein n might potential target generation recombinant sars vaccine,2004-09-30,"Xiong, Sheng; Wang, Yi-Fei; Zhang, Mei-Ying; Liu, Xin-Jian; Zhang, Chuan-Hai; Liu, Shi-Sheng; Qian, Chui-Wen; Li, Jiu-Xiang; Lu, Jia-Hai; Wan, Zhuo-Yue; Zheng, Huan-Yin; Yan, Xin-Ge; Meng, Min-Jie; Fan, Jiang-lin",Immunology Letters,,,,document_parses/pdf_json/0f953604a06ea594d767cab663c06310c128a8e7.json,document_parses/pmc_json/PMC7112924.xml.json,https://api.elsevier.com/content/article/pii/S0165247804001749; https://www.sciencedirect.com/science/article/pii/S0165247804001749,32927614.0,3
84126,84126,107889,w932k1v6,cb376e295f1eea19a3946187ab2ccceb7f249116,Elsevier; Medline; PMC,Recombinant protein vaccines produced in insect cells,10.1016/j.vaccine.2012.01.016,PMC7115678,22265860.0,els-covid,baculovirusinsect cell expression system well known tool production complex protein technology also used commercial manufacture various veterinary human vaccine review paper provides overview technology applied produce multitude vaccine candidate key advantage recombinant protein manufacturing platform universal “ plug play ” process may used producing broad range proteinbased prophylactic therapeutic vaccine human veterinary use offering potential low manufacturing cost large scale mammalian cell culture facility previously established manufacturing monoclonal antibody become obsolete due yield improvement could deployed manufacturing vaccine alternatively manufacturing capacity could established geographic region vaccine production capability dependent health care priority different vaccine could manufactured maintaining ability rapidly convert producing pandemic influenza vaccine need arises,2012-02-27,"Cox, Manon M.J.",Vaccine,,,,document_parses/pdf_json/cb376e295f1eea19a3946187ab2ccceb7f249116.json,document_parses/pmc_json/PMC7115678.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X1200031X; https://doi.org/10.1016/j.vaccine.2012.01.016; https://www.ncbi.nlm.nih.gov/pubmed/22265860/; https://api.elsevier.com/content/article/pii/S0264410X1200031X,12415227.0,3
84203,84203,107985,gql5xgod,6013e1ba3e4b727cf9b6d3289d49585a1a257147; 4593d1ecbaa167a2d3e910ccc986f5c4b5ecbbc8,Medline; PMC,CEPI: Driving Progress Toward Epidemic Preparedness and Response,10.1093/epirev/mxz012,PMC7108492,31673694.0,cc-by-nc,coalition epidemic preparedness innovation cepi formed aftermath – ebola outbreak west africa support development vaccine could improve world ’ preparedness outbreak epidemic infectious disease since launch cepi mobilized u million support mission develop vaccine agent lassa virus middle east respiratory syndrome coronavirus nipah virus well several rapidresponse vaccine platform accelerate response time unexpected epidemic threat cepi also played leading role fostering institutional partnership public privatesector organization optimize allocation resource vaccine development priority pathogen cepi ’ priority include diversification current vaccine research development investment portfolio include additional pathogen rift valley fever chikungunya establishment technical regulatory pathway vaccine development across cepi ’ portfolio development sustainable manufacturing solution vaccine candidate nearing completion safety immunogenicity testing human creation investigational stockpile vaccine candidate use emergency situation commentary provides overview global health challenge cepi established address achievement date indicates priority funding coordination coming year,2019-11-01,"Gouglas, Dimitrios; Christodoulou, Mario; Plotkin, Stanley A; Hatchett, Richard",Epidemiol Rev,,,,document_parses/pdf_json/6013e1ba3e4b727cf9b6d3289d49585a1a257147.json; document_parses/pdf_json/4593d1ecbaa167a2d3e910ccc986f5c4b5ecbbc8.json,document_parses/pmc_json/PMC7108492.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31673694/; https://doi.org/10.1093/epirev/mxz012,207816422.0,3
84240,84240,108032,w4emoao6,595b4da638d33d86ed49b55090e444a9aad479fd,Elsevier; PMC,Development of antibodies to feline IFN-γ as tools to elucidate the cellular immune responses to FeLV,10.1016/s0022-1759(03)00244-8,PMC7125904,12969548.0,els-covid,understanding nature immune protection role immune effector product interferonγ ifnγ control infectious disease fundamental rational design effective vaccine immunotherapeutic reagent murine monoclonal sheep polyclonal antibody mabs pabs feline ifnγ fifnγ generated firstly facilitate research role cellular immune response control feline infectious disease secondly enable evaluation efficacy novel immunotherapeutic approach hybridoma clone secreting igg antibody selected expansion mabs affinity purified vitro polyclonal antibody raised sheep recombinant fifnγ affinity purified sensitivity mab sheep antififnγ pab determined using indirect fifnγ enzymelinked immunosorbent assay elisa immunoblots antibody assessed ability detect production fifnγ specific feline cell population ex vivo following coculture mitogen feline leukaemia virus felv antigen h presence protein secretion inhibitor brefeldin bfa production fifnγ evaluated using flow cytometry simultaneously detect pelabelled surface molecule fluorescein isothiocyanate fitclabelled intracellular fifnγ using approach initial study revealed upregulation virusspecific fifnγsecreting cdt cell lymph node felv latently infected cat,2003-08-31,"Graham, Elizabeth M.; Jarrett, Oswald; Flynn, J.Norman",Journal of Immunological Methods,,,,document_parses/pdf_json/595b4da638d33d86ed49b55090e444a9aad479fd.json,document_parses/pmc_json/PMC7125904.xml.json,https://www.sciencedirect.com/science/article/pii/S0022175903002448; https://api.elsevier.com/content/article/pii/S0022175903002448,2778950.0,3
84268,84268,108067,cf1v5k55,b1e1916811dfbfbcad17706bfd487b755adf029d; 5a197bcfacdeee303d1ff432b9e6e02934766e1c; d916acf07a1481d215616a95d38aea70b19001ce,Elsevier; Medline; PMC,Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study,10.1016/s2214-109x(18)30346-2,PMC7164811,30342925.0,no-cc,background coalition epidemic preparedness innovation established develop vaccine contribute preparedness outbreak epidemic infectious disease evidence vaccine development cost disease scarce goal estimate minimum cost achieving vaccine research development preparedness target portfolio epidemic infectious disease accounting vaccine pipeline constraint uncertainty research development preparedness outcome method assembled pipeline vaccine candidate preclinical phase priority epidemic infectious disease used linear regression model identify driver development cost preclinical end phase drawing published estimate vaccine research development probability success simulated cost advancing vaccine candidate end phase combined finding determine minimum cost progressing least one vaccine end phase per epidemic infectious disease mean stochastic optimisation model finding cost developing single epidemic infectious disease vaccine preclinical trial end phase us– million us– million range assuming risk failure found previous licensure experience indirect cost upward driver research development cost accounting probability success average cost successfully advancing least one epidemic infectious disease vaccine end phase vary us– million million– million range starting phase – million million–· billion range starting preclinical cost includes cumulative cost failed vaccine candidate research development process assuming candidate funding made available progressing least one vaccine end phase epidemic infectious disease would cost minimum ·–· billion · billion–· billion range interpretation analysis provides new evidence vaccine research development pipeline associated cost epidemic infectious disease highlighting funding need research development gap achieving vaccine research development preparedness target funding work partly supported research council norway global health vaccination programme globvac,2018-10-18,"Gouglas, Dimitrios; Thanh Le, Tung; Henderson, Klara; Kaloudis, Aristidis; Danielsen, Trygve; Hammersland, Nicholas Caspersen; Robinson, James M; Heaton, Penny M; Røttingen, John-Arne",Lancet Glob Health,,,,document_parses/pdf_json/b1e1916811dfbfbcad17706bfd487b755adf029d.json; document_parses/pdf_json/5a197bcfacdeee303d1ff432b9e6e02934766e1c.json; document_parses/pdf_json/d916acf07a1481d215616a95d38aea70b19001ce.json,document_parses/pmc_json/PMC7164811.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30342925/; https://api.elsevier.com/content/article/pii/S2214109X18303462; https://doi.org/10.1016/s2214-109x(18)30346-2; https://www.sciencedirect.com/science/article/pii/S2214109X18303462,53044602.0,3
84290,84290,108091,2tazu4y6,5d492015c79953419dd1cfc47ebf6b50297e0334,Medline; PMC,A novel method for synthetic vaccine construction based on protein assembly,10.1038/srep07266,PMC4248271,25434527.0,cc-by-nc-sa,history vaccine development synthetic vaccine milestone stark contrast traditional vaccine based liveattenuated inactivated microorganism synthetic vaccine safer attenuated inactivated microorganism also provide opportunity vaccine design specific purpose first generation synthetic vaccine largely based dna recombination technology genetic manipulation de novo generation occasionally time consuming costly especially era genomics facing pandemic outbreak infectious disease accelerate simplify rd process vaccine developed improved method synthetic vaccine construction based protein assembly optimized employed recently developed spytagspycatcher technique establish protein assembly system vaccine generation preprepared subunit protein proof principle chose dendritic cell dctargeting molecule specific model antigen generate desired vaccine result demonstrated new vaccine generated way hamper individual function different vaccine component efficient inducing b cell response protein assembly strategy may especially useful highthroughput antigen screening rapid vaccine generation,2014-12-01,"Liu, Zhida; Zhou, Hang; Wang, Wenjun; Tan, Wenjie; Fu, Yang-Xin; Zhu, Mingzhao",Sci Rep,,,,document_parses/pdf_json/5d492015c79953419dd1cfc47ebf6b50297e0334.json,document_parses/pmc_json/PMC4248271.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25434527/; https://doi.org/10.1038/srep07266,10707804.0,3
84313,84313,108115,yw7cu976,d6a5a00ad9468ae27a3a1c7cc33c2131297fbaa9,Medline; PMC,Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells,10.2147/ijn.s32813,PMC3405891,22848163.0,no-cc,dendritic cell dc key regulator adaptive tcell response capturing exogenous antigen presenting antigenderived peptide via major histocompatibility complex molecule naïve cell dc induce antigenspecific immune response vivo order induce effective host immune response active delivery exogenous antigen dc considered important future vaccine development recently generated bionanocapsules bncs consisting hepatitis b virus surface antigen mediate stringent vivo cell targeting efficient endosomal escape fusion liposome lp containing therapeutic material bnclp complex deliver human liverderived tissue vivo bncs modified present immunoglobulin g igg fcinteracting domain z domain derived staphylococcus aureus protein tandem mixed igg modified bncs zzbncs displayed igg fv region outwardly efficient binding antigen orientedimmobilization manner due affinity displayed igg iggzzbnc complex accumulated specific cell tissue vitro vivo mixing zzbncs antibody dc used immunocytochemistry examine antibody delivered zzbncs mouse splenic dc following intravenous injection zzbncs zzbncs displaying anticdc monoclonal antibody αcdczzbncs found accumulate approximately splenic dc reside within fusion liposome containing antigen αcdczzbncs could elicit respective antibody efficiently nontargeting control vaccine suggesting dcspecific nanocarrier promising future vaccine,2012-07-03,"Matsuo, Hidenori; Yoshimoto, Nobuo; Iijima, Masumi; Niimi, Tomoaki; Jung, Joohee; Jeong, Seong-Yun; Choi, Eun Kyung; Sewaki, Tomomitsu; Arakawa, Takeshi; Kuroda, Shun’ichi",Int J Nanomedicine,,,,document_parses/pdf_json/d6a5a00ad9468ae27a3a1c7cc33c2131297fbaa9.json,document_parses/pmc_json/PMC3405891.xml.json,https://doi.org/10.2147/ijn.s32813; https://www.ncbi.nlm.nih.gov/pubmed/22848163/,14929349.0,3
84354,84354,108162,6z2avwqx,5c59d9e3c66ccee9b1e671f475954e581af7a320,Medline; PMC,Mucosal Immunization Induces a Higher Level of Lasting Neutralizing Antibody Response in Mice by a Replication-Competent Smallpox Vaccine: Vaccinia Tiantan Strain,10.1155/2011/970424,PMC3134386,21765641.0,no-cc,possible bioterrorism threat using variola virus causative agent smallpox promoted u investigate immunogenicity profile existing vaccine study first time immunogenicity profile replicationcompetent smallpox vaccine vaccinia tiantan vtt strain inducing neutralizing antibody nabs mucosal vaccination noninvasive critical implication massive vaccination program four different route vaccination tested parallel including intramuscular im intranasal oral io subcutaneous sc inoculation mouse found one time vaccination optimal dose vtt able induce antivtt nabs via four route higher level antiviral nabs however induced via io inoculation compared im sc route moreover io vaccination also induced higher sustained level nabs overtime conferred better protection homologous alternating mucosal route viral challenge six month post vaccination vttinduced immunity via four route however partially effective intramuscular viral challenge data implication understanding potential application mucosal smallpox vaccination developing vttbased vaccine overcome preexisting antivaccinia immunity,2011-06-20,"Lu, Bin; Yu, Wenbo; Huang, Xiaoxing; Wang, Haibo; Liu, Li; Chen, Zhiwei",J Biomed Biotechnol,,,,document_parses/pdf_json/5c59d9e3c66ccee9b1e671f475954e581af7a320.json,document_parses/pmc_json/PMC3134386.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/21765641/; https://doi.org/10.1155/2011/970424,11984227.0,3
84364,84364,108173,b4u4yzjh,,Elsevier; PMC,Vaccine Strategies,10.1016/b978-012374410-4.00597-5,PMC7150003,,no-cc,new technology genomics proteomics molecular immunology led impressive increase knowledge aspect virology providing insight guide new vaccine concept developing new vaccine choice approach made much casebycase basis given virus driven knowledge pathogenesis serotype diversity antigenic variation immune evasion mechanism latency route transmission high importance given type immunity arises result natural infection whether pathogen cause persistent andor repeated infection single host article discus medical need new human viral vaccine focus strategy available development challenge posed difficult target,2008-07-30,"Kusters, I.; Almond, J.W.",Encyclopedia of Virology,,,,,document_parses/pmc_json/PMC7150003.xml.json,https://api.elsevier.com/content/article/pii/B9780123744104005975; https://www.sciencedirect.com/science/article/pii/B9780123744104005975,214758128.0,3
84485,84485,108320,x3at6mgp,482b1f552312749d1d549d4914856e99d0a18ec3,Elsevier; PMC,Chapter 8 DNA Vaccines for Biodefense and Emerging and Neglected Infectious Diseases,10.1016/b978-0-12-369408-9.00008-1,PMC7150048,,els-covid,continued improvement vaccination technology led remarkable progress control human infectious disease fundamental view nature vaccine changed discovery dna immunization early determined genetic material encodes antigen rather actual antigen effective eliciting immune response given ever increasing threat emerging reemerging infectious disease renewed concern regarding use biological agent bioterrorism purpose opportunity dna vaccine technology provides could come critical time history since inception dna vaccination technology undergone significant advancement many candidate human vaccine formulation already developed improved mode administration use codon antigen gene optimization implementation vaccination dna primeboost regimen led quick progression dna vaccine research laboratory bench human clinical trial significant progress made developing dna vaccine various biodefense emerging infectious disease target hiv influenza severe acute respiratory syndrome associated coronavirus sarscov ebola viral encephalitis anthrax plague botulism among others already moving early phase clinical trial promising result ability respond potential bioterrorism threat emerging infectious disease outbreak crucial advancement associated dna vaccination technology allow u prompt rational matter,2009-12-31,"Lu, Shan; Grimes-Serrano, Jill M.; Wang, Shixia",Vaccines for Biodefense and Emerging and Neglected Diseases,,,,document_parses/pdf_json/482b1f552312749d1d549d4914856e99d0a18ec3.json,document_parses/pmc_json/PMC7150048.xml.json,https://www.sciencedirect.com/science/article/pii/B9780123694089000081; https://api.elsevier.com/content/article/pii/B9780123694089000081,80968599.0,3
84569,84569,108423,e2r38v29,c526fbee33eed355a7c7437950603c4835418b0e,Medline; PMC,Large-Scale Preparation of UV-Inactivated SARS Coronavirus Virions for Vaccine Antigen,10.1007/978-1-59745-181-9_11,PMC7122600,19057880.0,no-cc,general whole virion serf simple vaccine antigen often essential material analysis immune response virus infection however work highly contagious pathogen necessary take precaution laboratoryacquired infection learned many lesson recent outbreak severe acute respiratory syndrome sars order develop effective vaccine diagnostic tool prepared uvinactivated sars coronavirus large scale strict biosafety level bsl regulation protocol largescale preparation uvinactivated sarscov including virus expansion titration inactivation ultracentrifugation applicable newly emerging virus might encounter future,2007-11-28,"Tsunetsugu-Yokota, Yasuko",SARS- and Other Coronaviruses,,,,document_parses/pdf_json/c526fbee33eed355a7c7437950603c4835418b0e.json,document_parses/pmc_json/PMC7122600.xml.json,https://doi.org/10.1007/978-1-59745-181-9_11; https://www.ncbi.nlm.nih.gov/pubmed/19057880/,42469848.0,3
84601,84601,108460,ekzfdbby,3c35d5d138487c2999331ff6c6dcb489ec52cbbf; 06dbf9dc0dbe752f642f941977d34444c7007706,Elsevier; Medline; PMC,Antigen Sparing and Enhanced Protection Using A Novel rOv-ASP-1 Adjuvant in Aqueous Formulation with Influenza Vaccines,10.1016/j.vaccine.2014.03.046,PMC4080630,24681229.0,green-oa,influenza one common infectious disease endangering health human especially young child elderly although vaccination effective mean protection influenza frequent mutation viral surface antigen low protective efficacy influenza vaccine elderly slow production process potential vaccine supply shortage pandemic significant limitation current vaccine adjuvant used enhance efficacy variety vaccine however adjuvant included current influenza vaccine approved united state study found novel adjuvant rovasp coadministrated inactivated influenza vaccine using aqueous formulation substantially improved influenzaspecific antibody response protection lethal infection mouse model rovasp enhanced magnitude specific antibody response immunization low dos influenza vaccine allowing antigensparring fold rovasp formulated vaccine induced rapid response stronger thassociated antibody response compared vaccine alone vaccine formulated adjuvant alum importantly rovasp significantly enhanced crossreactive antibody response protection challenge antigenically distinct strain result demonstrate rovasp effective adjuvant accelerates enhances specific antibody response induced influenza vaccine allows antigen sparing augments thbiased crossreactive antibody response confers protection antigenically distinct strain,2014-05-01,"Jiang, Jiu; Fisher, Erin M.; Hensley, Scott E.; Lustigman, Sara; Murasko, Donna M.; Shen, Hao",Vaccine,,,,document_parses/pdf_json/3c35d5d138487c2999331ff6c6dcb489ec52cbbf.json; document_parses/pdf_json/06dbf9dc0dbe752f642f941977d34444c7007706.json,document_parses/pmc_json/PMC4080630.xml.json,http://europepmc.org/articles/pmc4080630?pdf=render; https://api.elsevier.com/content/article/pii/S0264410X14004150; https://www.sciencedirect.com/science/article/pii/S0264410X14004150; https://www.ncbi.nlm.nih.gov/pubmed/24681229/; https://doi.org/10.1016/j.vaccine.2014.03.046,41862501.0,3
84639,84639,108513,3t75dbb7,97aa36776b5325e16f124c1ecc1617bf8144dc7d; 2da0a7ba851e53d21dba05042a397eafcdab093d,BioRxiv; MedRxiv,Combination attenuation offers strategy for live-attenuated coronavirus vaccines,10.1101/309591,,,medrxiv,ongoing threat posed circulating zoonotic strain new strategy required prepare next emergent coronavirus cov previously group targeted conserved coronavirus protein strategy generate liveattenuated vaccine strain current future covs mind explored whether manipulation cov nsp conserved ’ methyltransferase mtase could provide broad attenuation platform future emergent strain using sarscov mouse model nsp mutant vaccine evaluated protection heterologous challenge efficacy aging host potential reversion pathogenesis despite success concern virulence aged potential reversion make targeting nsp alone untenable approach however combining ’ mtase mutation previously described cov fidelity mutant produced vaccine strain capable protection heterologous virus challenge efficacy aged mouse evidence reversion together result indicate targeting cov ’ mtase parallel conserved attenuating mutation may provide platform strategy rapidly generating liveattenuated coronavirus vaccine emergent coronaviruses remain significant threat global public health rapid response vaccine platform needed stem future outbreak however failure many previous cov vaccine formulation clearly highlighted need test efficacy different condition especially vulnerable population like aged immunecompromised study illustrates despite success young model nsp mutant carry much risk pathogenesis reversion vulnerable model used standalone vaccine strategy importantly nsp mutation paired attenuating approach provide robust protection heterologous challenge vulnerable population coupled increased safety reduced pathogenesis study highlight potential nsp attenuation major component future liveattenuated coronavirus vaccine,2018-04-28,"Menachery, Vineet D.; Gralinski, Lisa E.; Mitchell, Hugh D.; Dinnon, Kenneth H.; Leist, Sarah R.; Yount, Boyd L.; McAnarney, Eileen T.; Graham, Rachel L.; Waters, Katrina M.; Baric, Ralph S.",bioRxiv,,,,document_parses/pdf_json/97aa36776b5325e16f124c1ecc1617bf8144dc7d.json; document_parses/pdf_json/2da0a7ba851e53d21dba05042a397eafcdab093d.json,,https://doi.org/10.1101/309591,196632297.0,3
84675,84675,108560,5hxha7pb,7cd5321d8b9deb046502c0f1ab1581e7200bc378; a2f53651474ffa6ede94371fa2d2e735395d965e,Medline; PMC,DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial,10.1371/journal.pone.0059340,PMC3620125,23577062.0,cc0,background dna vaccine immunogenicity limited inefficient delivery needlefree delivery dna using copowered biojector® device compared delivery needle syringe evaluated safety immunogenicity method forty adult – year randomly assigned intramuscular im vaccination dna vaccine vrchivdnavp week biojector® ™ needle syringe n boosted im week vrchivadvvp rad n particle unit pu equal number per assigned schedule low ≤ high reciprocal titer preexisting ad neutralizing antibody result dna rad injection given subject completed followup research sample collection ifnγ elispot response rate biojector® n delivery week week post rad boost magnitude elispot response fold higher biojector® compared n group similar effect response rate magnitude observed cd cd tcell response ic envspecific antibody response fold higher biojectorprimed subject conclusion dna vaccination biojector® welltolerated compared needle injection primed greater ifnγ elispot cd tcell antibody response rad boosting trial registration clinicaltrialsgov nct,2013-04-08,"Graham, Barney S.; Enama, Mary E.; Nason, Martha C.; Gordon, Ingelise J.; Peel, Sheila A.; Ledgerwood, Julie E.; Plummer, Sarah A.; Mascola, John R.; Bailer, Robert T.; Roederer, Mario; Koup, Richard A.; Nabel, Gary J.",PLoS One,,,,document_parses/pdf_json/7cd5321d8b9deb046502c0f1ab1581e7200bc378.json; document_parses/pdf_json/a2f53651474ffa6ede94371fa2d2e735395d965e.json,document_parses/pmc_json/PMC3620125.xml.json,https://doi.org/10.1371/journal.pone.0059340; https://www.ncbi.nlm.nih.gov/pubmed/23577062/,17851337.0,3
84678,84678,108564,nh06fp82,a18d1ecb921ed3e98c0d90d922d4b88fbc36b6f3,Elsevier; Medline; PMC,"Genetic, antigenic, and pathogenic characteristics of avian infectious bronchitis viruses genotypically related to 793/B in China",10.1016/j.vetmic.2017.01.039,PMC7117474,28619134.0,els-covid,study infectious bronchitis virus ibv strain genotypically related b assessed gene comparison complete genomic sequence analysis isolated identified china phylogenetic analysis network tree similarity plot analysis recombination detection program rdp sequence comparison revealed isolates likely reisolated vaccine virus one isolate ckchlsd shown originated recombination event h like vaccine strain result change antigenicity pathogenicity remaining seven ibv isolates shown originated recombination event like vaccine strain gxlylike virus responsible emergence novel serotype vaccinationchallenge test found vaccination vaccine strain provide protection challenge recombinant virus addition result showed recombination event vaccine field strain resulted altered genetics serotype antigenicity pathogenicity compared deduced parental virus result important virus economic importance poultry industry also important elucidating origin evolution coronaviruses,2017-05-31,"Han, Zongxi; Zhao, Wenjun; Chen, Yuqiu; Xu, Qianqian; Sun, Junfeng; Zhang, Tingting; Zhao, Yan; Liang, Shuling; Gao, Mengying; Wang, Qiuling; Kong, Xiangang; Liu, Shengwang",Veterinary Microbiology,,,,document_parses/pdf_json/a18d1ecb921ed3e98c0d90d922d4b88fbc36b6f3.json,document_parses/pmc_json/PMC7117474.xml.json,https://doi.org/10.1016/j.vetmic.2017.01.039; https://www.sciencedirect.com/science/article/pii/S0378113517301438; https://api.elsevier.com/content/article/pii/S0378113517301438; https://www.ncbi.nlm.nih.gov/pubmed/28619134/,205627332.0,3
84684,84684,108571,ltyqrg81,b8e18afdd99dbb8dc855b5a0e188a0e869f4600f,Elsevier; Medline; PMC,Protection from SARS coronavirus conferred by live measles vaccine expressing the spike glycoprotein,10.1016/j.virol.2014.01.002,PMC7111909,24606680.0,els-covid,recent identification novel human coronavirus responsible sarslike illness middleeast decade sars pandemic demonstrates reemergence sarslike coronavirus animal reservoir remains credible threat sars contracted aerosolized contamination respiratory tract vaccine inducing mucosal longterm protection would asset control new epidemic aim generated live attenuated recombinant measles vaccine mv candidate expressing either membraneanchored sarscov spike protein secreted soluble ectodomain ssol mouse susceptible measles virus recombinant mv expressing anchored fulllength induced highest titer neutralizing antibody fully protected immunized animal intranasal infectious challenge sarscov compared immunization adjuvanted recombinant ssol protein recombinant mv induced stronger thbiased response hallmark live attenuated virus highly desirable feature antiviral vaccine,2014-03-31,"Escriou, Nicolas; Callendret, Benoît; Lorin, Valérie; Combredet, Chantal; Marianneau, Philippe; Février, Michèle; Tangy, Frédéric",Virology,,,,document_parses/pdf_json/b8e18afdd99dbb8dc855b5a0e188a0e869f4600f.json,document_parses/pmc_json/PMC7111909.xml.json,https://doi.org/10.1016/j.virol.2014.01.002; https://www.ncbi.nlm.nih.gov/pubmed/24606680/; https://api.elsevier.com/content/article/pii/S0042682214000051; https://www.sciencedirect.com/science/article/pii/S0042682214000051,29352955.0,3
84714,84714,108611,f6q6gf2v,,Elsevier; PMC,Design of synthetic peptides for oral vaccination,10.1016/0169-409x(95)00074-h,PMC7130186,,els-covid,rational design effective oral vaccine based synthetic peptide ambitious undertaking involves solution huge problem related protection antigen degradation alimentary tract efficient uptake antigen relevant cell efficient induction long lasting systemic immunity local immunity paper summarises step necessary develop synthetic oral vaccine step involve definition bcell epitope definition tcell epitope definition carrier backbone molecule definition immunomodulating element definition adjuvant element definition targeting element good progress made respect first three step step still provide major challenge notably definition targeting element nevertheless first synthetic oral vaccine may become reality near future depending speed new technology area molecular recognition develop ie appropriate chemistry organic chemistry molecular modelling resolution molecular interaction key molecule microbiology immunology,1995-12-15,"Meloen, R. H.",Advanced Drug Delivery Reviews,,,,,,https://www.sciencedirect.com/science/article/pii/0169409X9500074H; https://api.elsevier.com/content/article/pii/0169409X9500074H,83780943.0,3
84715,84715,108612,5zn2vrj5,f04ae49e396269b6fc64538613ea9a6d53583bd6; ffd791c34aa1431d8571663c1fa722086d0ad90f,Medline; PMC,Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice,10.1186/1743-422x-10-349,PMC4235025,24304565.0,cc-by,background rift valley fever rvf viral zoonosis historically affect livestock production human health subsaharan africa though epizootics also occurred arabian peninsula whilst effective liveattenuated vaccine available livestock currently licensed human rvf vaccine replicationdeficient chimpanzee adenovirus chad vector ideal platform development human rvf vaccine given low prevalence neutralizing antibody human population excellent safety immunogenicity profile human clinical trial vaccine wide range pathogen method balbc mouse evaluated immunogenicity efficacy replicationdeficient chimpanzee adenovirus vector chadox encoding rvf virus envelope glycoprotein gn gc target virus neutralizing antibody chadoxgngc vaccine assessed comparison replicationdeficient human adenovirus type vector encoding gn gc hadvgngc strategy previously shown confer protective immunity rvf mouse result single immunization either vaccine conferred protection rvf virus challenge eight week postimmunization vaccine elicited rvf virus neutralizing antibody robust cd cell response conclusion together result support development rvf vaccine based replicationdeficient adenovirus vector chadoxgngc potential candidate use future human clinical trial,2013-12-05,"Warimwe, George M; Lorenzo, Gema; Lopez-Gil, Elena; Reyes-Sandoval, Arturo; Cottingham, Matthew G; Spencer, Alexandra J; Collins, Katharine A; Dicks, Matthew DJ; Milicic, Anita; Lall, Amar; Furze, Julie; Turner, Alison V; Hill, Adrian VS; Brun, Alejandro; Gilbert, Sarah C",Virol J,,,,document_parses/pdf_json/f04ae49e396269b6fc64538613ea9a6d53583bd6.json; document_parses/pdf_json/ffd791c34aa1431d8571663c1fa722086d0ad90f.json,document_parses/pmc_json/PMC4235025.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/24304565/; https://doi.org/10.1186/1743-422x-10-349,163383.0,3
84730,84730,108629,5qt63e48,c49595869663e8dff3487af03ed03d87efd3aa1d,Elsevier; PMC,Novel adjuvants and vaccine delivery systems,10.1016/s0165-2427(96)05697-8,PMC7119835,8988882.0,els-covid,conventionally efficiency adjuvant measured capacity induce enhanced antibody serum titre cell mediated immunity cmi given antigen nowadays capacity adjuvant also measured quality well magnitude induced immune response guided protective immune response required quality includes isotype igg subclass response thelper cell response characterized cytokine profile cytotoxic cell ctl early phase immunization adjuvant influence antigen administration uptake called depot effect exemplified aluminium hydroxide gel oil adjuvant possibly desired alledged modern depot exerted slow release formulation continuously releasing antigen period time pulse interval aiming ‘ single injection ’ vaccine great effort made formulate efficient delivery formulation targeting antigen site administration draining lymph node distant lymphatic tissue mucosal surface parenteral mucosal administration nowadays nonreplicating carrier besides replicating vaccine formulated induce mucosal immune response encompassing secretory iga cmi effort evoke immune response mucosal membrane distant site administration resulted mostly little success long time considered ctl restriction mhc class could evoked replicating virus intracellular parasite however novel adjuvant delivery system readily induce ctl delivering antigen apc resulting intracellular transport cytosol mhc class presentation system well endosomal pathway mhc class ii presentation,1996-11-30,"Morein, Bror; Villacrés-Eriksson, María; Sjölander, Anders; Lövgren Bengtsson, Karin",Veterinary Immunology and Immunopathology,,,,document_parses/pdf_json/c49595869663e8dff3487af03ed03d87efd3aa1d.json,,https://api.elsevier.com/content/article/pii/S0165242796056978; https://www.sciencedirect.com/science/article/pii/S0165242796056978,26522049.0,3
84757,84757,108663,itrv27tm,5f1985c2a2b2dbb9c75d9197d0d4a83186579711,Medline; PMC; WHO,"Gold nanoparticle‐adjuvanted S protein induces a strong antigen‐specific IgG response against severe acute respiratory syndrome‐related coronavirus infection, but fails to induce protective antibodies and limit eosinophilic infiltration in lungs",10.1111/1348-0421.12754,PMC7168429,31692019.0,no-cc,spike protein coronavirus bind cellular receptor mediates membrane fusion cell entry candidate vaccine target blocking coronavirus infection however animal study suggested inadequate immunization severe acute respiratory syndrome coronavirus sars‐cov induces lung eosinophilic immunopathology upon infection present study evaluated two kind vaccine adjuvant use recombinant protein gold nanoparticles aunps expected function antigen carrier adjuvant immunization toll‐like receptor tlr agonist previously shown effective adjuvant ultraviolet‐inactivated sars‐cov vaccine mouse immunized µg protein without adjuvant escaped sars infection mouse‐adapted sars‐cov however eosinophilic infiltration observed lung almost immunized mouse aunp‐adjuvanted protein induced strong igg response failed improve vaccine efficacy reduce eosinophilic infiltration highly allergic inflammatory response whereas similar virus titer observed control animal animal immunized protein without aunps type interferon pro‐inflammatory response moderate mouse treated protein without aunps hand tlr agonist‐adjuvanted vaccine induced highly protective antibody without eosinophilic infiltration well th cytokine response finding study support development vaccine severe pneumonia‐associated coronaviruses,2019-11-18,"Sekimukai, Hanako; Iwata‐Yoshikawa, Naoko; Fukushi, Shuetsu; Tani, Hideki; Kataoka, Michiyo; Suzuki, Tadaki; Hasegawa, Hideki; Niikura, Kenichi; Arai, Katsuhiko; Nagata, Noriyo",Microbiol Immunol,,#70,,document_parses/pdf_json/5f1985c2a2b2dbb9c75d9197d0d4a83186579711.json,document_parses/pmc_json/PMC7168429.xml.json,https://doi.org/10.1111/1348-0421.12754; https://www.ncbi.nlm.nih.gov/pubmed/31692019/,207896109.0,3
84827,84827,108755,uycgov7q,6efd9d7ed926ebe9979cc13990888257507e2e19,Medline; PMC,Disease Prevention: An Opportunity to Expand Edible Plant-Based Vaccines?,10.3390/vaccines5020014,PMC5492011,28556800.0,cc-by,lethality infectious disease decreased due implementation crucial sanitary procedure vaccination however resurgence pathogenic disease different part world revealed importance identifying novel rapid concrete solution control prevention edible vaccine pose interesting alternative could overcome constraint traditional vaccine term “ edible vaccine ” refers use edible part plant genetically modified produce specific component particular pathogen generate protection disease aim review present critically examine “ edible vaccine ” option global immunization pathogenic disease outbreak discus necessary step production control list plant may already used edible vaccine additionally review discus required standard ethical regulation well advantage disadvantage associated powerful biotechnology tool,2017-05-30,"Concha, Christopher; Cañas, Raúl; Macuer, Johan; Torres, María José; Herrada, Andrés A.; Jamett, Fabiola; Ibáñez, Cristian",Vaccines (Basel),,,,document_parses/pdf_json/6efd9d7ed926ebe9979cc13990888257507e2e19.json,document_parses/pmc_json/PMC5492011.xml.json,https://doi.org/10.3390/vaccines5020014; https://www.ncbi.nlm.nih.gov/pubmed/28556800/,2383044.0,3
84869,84869,108809,ivoukz7h,2405cad36d3f5751f68591976e740793d2d704e8,Medline; PMC,Vaccines for the 21st century,10.1002/emmm.201403876,PMC4203350,24803000.0,cc-by,last century vaccination effective medical intervention reduce death morbidity caused infectious disease believed vaccine save least – million life per year worldwide smallpox eradicated polio almost disappeared worldwide global vaccine campaign viral bacterial infection traditionally affected child drastically reduced thanks national immunization program developed country however many disease yet preventable vaccination vaccine fully exploited target population elderly pregnant woman review focus state art recent clinical trial vaccine major unmet medical need hiv malaria tb cancer addition describe innovative technology currently used vaccine research development including adjuvant vector nucleic acid vaccine structure‐based antigen design hope thanks technology disease addressed st century novel preventative therapeutic vaccine,2014-05-06,"Delany, Isabel; Rappuoli, Rino; De Gregorio, Ennio",EMBO Mol Med,,,,document_parses/pdf_json/2405cad36d3f5751f68591976e740793d2d704e8.json,document_parses/pmc_json/PMC4203350.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/24803000/; https://doi.org/10.1002/emmm.201403876,2773423.0,3
84937,84937,108893,oiwcn4t2,c9e02996db684081f7f9b32af4276c5163c86cb6,Elsevier; PMC,"Influenza vaccination in patients with asthma: effect on peak expiratory flow, asthma symptoms and use of medication",10.1016/s0264-410x(96)00285-x,PMC7130951,9261948.0,els-covid,pilot study undertaken examine whether killed influenza vaccine cause exacerbation asthmatic adult thirtythree stable asthmatic recorded peak expiratory flow pef asthma symptom use asthma medication week received killed influenza vaccine thereafter recorded pef asthma symptom use medication week comparison recording week vaccination revealed influenza vaccine associated reduction pef p increase asthma symptom p use asthma medication p similar result pef p asthma symptom p asthma medication p obtained analysis restricted day vaccination,1997-06-30,"Ahmed, Ala'Eldin H.; Nicholson, Karl G.; Hammersley, Victoria S.; Kent, Julie",Vaccine,,,,document_parses/pdf_json/c9e02996db684081f7f9b32af4276c5163c86cb6.json,,https://api.elsevier.com/content/article/pii/S0264410X9600285X; https://www.sciencedirect.com/science/article/pii/S0264410X9600285X,24540306.0,3
84973,84973,108935,rshpyyfj,edf6ca59e90c583d527dd4e44499a4cfc5867412,Elsevier; PMC,Delivery of subunit vaccines in maize seed,10.1016/s0168-3659(02)00282-1,PMC7127645,12480322.0,els-covid,use recombinant gene technology vaccine industry revolutionized way antigen generated provided safer effective mean protecting animal human bacterial viral pathogen viral bacterial antigen recombinant subunit vaccine produced variety organism transgenic plant recognized legitimate source protein especially developing area oral vaccine antigen shown correctly processed plant form elicit immune response fed animal human antigen expressed maize zea may particularly attractive since deposited natural storage vessel corn seed conveniently delivered organism consumes grain previously demonstrated high level expression bsubunit escherichia coli heatlabile enterotoxin spike protein swine transmissible gastroenteritis corn demonstrated antigen delivered seed elicit protective immune response provide additional data support potency efficacy stability recombinant subunit vaccine delivered maize seed,2002-12-13,"Lamphear, Barry J; Streatfield, Stephen J; Jilka, Joseph M; Brooks, Christopher A; Barker, Donna K; Turner, Debra D; Delaney, Donna E; Garcia, Martin; Wiggins, Barry; Woodard, Susan L; Hood, Elizabeth E; Tizard, Ian R; Lawhorn, Bruce; Howard, John A",Journal of Controlled Release,,,,document_parses/pdf_json/edf6ca59e90c583d527dd4e44499a4cfc5867412.json,document_parses/pmc_json/PMC7127645.xml.json,https://www.sciencedirect.com/science/article/pii/S0168365902002821; https://api.elsevier.com/content/article/pii/S0168365902002821,20590613.0,3
84981,84981,108945,grml98oa,8efed0e2f2116f528ef08e76585ba0fc56cb261f,Elsevier; PMC,Plant cell factories and mucosal vaccines,10.1016/s0958-1669(03)00026-0,PMC7135315,12732315.0,els-covid,many advance continue made field plantderived vaccine plant shown capable expressing multicomponent vaccine orally delivered induces thelper cell subset response enables passive immunization furthermore plantderived vaccine shown protect challenge target host increased antigen expression level total soluble protein obtained transformation chloroplast genome view finding plantderived vaccine proved valuable commodity world ’ health system however application study need focus optimization immunization strategy investigate antigen stability,2003-04-30,"Walmsley, Amanda M; Arntzen, Charles J",Current Opinion in Biotechnology,,,,document_parses/pdf_json/8efed0e2f2116f528ef08e76585ba0fc56cb261f.json,document_parses/pmc_json/PMC7135315.xml.json,https://api.elsevier.com/content/article/pii/S0958166903000260; https://www.sciencedirect.com/science/article/pii/S0958166903000260,6999940.0,3
84984,84984,108948,rme6b022,39244c86324ed37f0b32222540efeefd2144d458,Medline; PMC,Porcine IL-12 plasmid as an adjuvant improves the cellular and humoral immune responses of DNA vaccine targeting transmissible gastroenteritis virus spike gene in a mouse model,10.1292/jvms.18-0682,PMC6863717,31474664.0,cc-by-nc-nd,transmissible gastroenteritis tge caused transmissible gastroenteritis virus tgev highly infectious disease pig vaccination effective approach prevent tgev infection evaluated potential tgev dna vaccine porcine interleukin pil adjuvant mouse model dna vaccine constructed tgev gene induce immune response experimental mouse model pil chosen immunological adjuvant within dna vaccine pvaxtgevs pvaxpil vector transfected bhk cell expressed vitro experimental mouse separately immunized recombinant plasmid control intramuscular route lymphocyte isolated blood spleen analyzed proliferation cytotoxic activity population cd cd cell titer tgev enzymelinked immunosorbent assay elisa tgev neutralizing antibody concentration interferon ifnγ il also analyzed serum plasmid pvaxtgevs pvaxpil could expressed bhk cell combination pvaxtgevs pvaxpil could induce significant increase marker pil could act immunological adjuvant dna vaccine tgevs furthermore dna vaccine prepared using tgevs porcine il could induce excellent humoral cellular immune response,2019-09-02,"LI, Xunliang; LI, Pengchong; CAO, Liyan; BAI, Yunyun; CHEN, Huijie; LIU, He; REN, Xiaofeng; LI, Guangxing",J Vet Med Sci,,,,document_parses/pdf_json/39244c86324ed37f0b32222540efeefd2144d458.json,document_parses/pmc_json/PMC6863717.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31474664/; https://doi.org/10.1292/jvms.18-0682,201712861.0,3
84999,84999,108965,tt761tte,5e5908b9f7ad23dd332a32e1dfa411c4b0e88f59,Elsevier; PMC,Influenza and the Vocal Performer: Update on Prevention and Treatment,10.1016/j.jvoice.2006.09.012,PMC7135439,17134876.0,els-covid,summary upper respiratory tract infection uris major cause morbidity among vocal art professional acute impairment vocal mechanism predisposing influence development serious vocal sequela review present salient feature currently available treatment effective influenza virus family responsible serious form uri present include inactivated vaccine four antiviral drug approved united state many country prevention treatment influenza live attenuated vaccine also available vaccine antiviral drug development review detail current option available treating influenza noninfluenza related uris professional voice user,2008-05-31,"Bové, Michiel J.; Kansal, Shalini; Rosen, Clark A.",Journal of Voice,,,,document_parses/pdf_json/5e5908b9f7ad23dd332a32e1dfa411c4b0e88f59.json,document_parses/pmc_json/PMC7135439.xml.json,https://api.elsevier.com/content/article/pii/S0892199706001329; https://www.sciencedirect.com/science/article/pii/S0892199706001329,45710346.0,3
85022,85022,108995,ydq687u6,,Medline; WHO,COVID-19 needs a big science approach,10.1126/science.abb8654,,32213646.0,unk,unprecedented race develop vaccine severe acute respiratory syndrome coronavirus sarscov least vaccine earlystage development outcome expect first vaccine cross finish line safest effective wellfunded vaccine first become available perhaps using vaccine technology fewest regulatory hurdle answer could vaccine tick box want maximize chance success however enough dos end coronavirus disease covid pandemic current piecemeal effort wont enough ever case coordinated global vaccine development effort using “ big science ” approach,2020,"Berkley, Seth",Science (Wash.),,#17397,,,,https://doi.org/10.1126/science.abb8654; https://www.ncbi.nlm.nih.gov/pubmed/32213646/,214671150.0,3
85035,85035,109011,0bxwv6b7,fbf7143172cc18e911174a7ce32856a0a63afc1c,Medline; PMC,Self-reported adverse reactions in 4337 healthcare workers immunizations against novel H1N1 influenza,10.1186/1756-0500-4-297,PMC3170337,21849040.0,cc-by,purpose use hn vaccine generated much debate concerning safety issue among general population physician questioned safe vaccine therefore investigated safety inactivated monovalent hn pandemic influenza vaccine method focused hn pandemic influenza vaccine pandemrix® applied self reporting questionnaire population healthcare worker hcws medical student major university hospital result total individual vaccinated consisting hcws medical student vaccination rate employee higher majority individual vaccinated november total vaccination reported lead one adverse reaction local reaction reported myalgia arthralgia fatigue headache conclusion data together available data several national international institution point safe pandemic influenza vaccine,2011-08-17,"Bias, Harald; Quarcoo, David; Meier-Wronski, Claus; Wicker, Sabine; Seybold, Joachim; Nienhaus, Albert; Groneberg, David A; Roux, Andres de",BMC Res Notes,,,,document_parses/pdf_json/fbf7143172cc18e911174a7ce32856a0a63afc1c.json,document_parses/pmc_json/PMC3170337.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/21849040/; https://doi.org/10.1186/1756-0500-4-297,16549273.0,3
85089,85089,109079,gysf0vbv,e804c69a56260774f663e3948a5e926a4d7f647f; 357ecba25af78078e54800e90def3223f93d162b,Elsevier; PMC,Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease,10.1016/j.virusres.2007.01.021,PMC2633062,17416434.0,bronze-oa,important effort performed emergence severe acute respiratory syndrome sars epidemic diagnose prevent virus spreading several type vaccine developed including inactivated virus subunit vaccine viruslike particle vlps dna vaccine heterologous expression system vaccine derived sarscov genome reverse genetics review describes several aspect essential develop sarscov vaccine correlate protection virus serotypes vaccination side effect biosafeguards engineered recombinant vaccine approach based sarscov genome production effective safe vaccine prevent sars led development promising vaccine candidate contrast design vaccine coronaviruses general le successful preclinical trial animal model efficacy safety evaluation promising vaccine candidate described performed human,2008-04-01,"Enjuanes, Luis; DeDiego, Marta L.; Álvarez, Enrique; Deming, Damon; Sheahan, Tim; Baric, Ralph",Virus Research,,,,document_parses/pdf_json/e804c69a56260774f663e3948a5e926a4d7f647f.json; document_parses/pdf_json/357ecba25af78078e54800e90def3223f93d162b.json,document_parses/pmc_json/PMC2633062.xml.json,https://www.sciencedirect.com/science/article/pii/S0168170207000640; https://api.elsevier.com/content/article/pii/S0168170207000640,23383833.0,3
85093,85093,109089,3ij0n387,c9c113247df3932d3dbbabc25b9b927efa03c115,Medline; PMC,Moving from Empirical to Rational Vaccine Design in the ‘Omics’ Era,10.3390/vaccines7030089,PMC6789792,31416125.0,cc-by,ideal vaccine provides long lasting protection pathogen eliciting wellrounded immune response engages innate adaptive immunity however limited understanding component innate immunity antibody cellmediated adaptive immunity interact function together system level advance highthroughput ‘ omics ’ methodology become possible capture global change host cellular molecular level induced vaccination infection analysis datasets shown promise discovering mechanism behind vaccine mediated protection immunological memory adverse effect well development efficient antigen adjuvant review discus system vaccinology take advantage new technology platform big data analysis enable rational development better vaccine,2019-08-14,"Sharma, Mansi; Krammer, Florian; García-Sastre, Adolfo; Tripathi, Shashank",Vaccines (Basel),,,,document_parses/pdf_json/c9c113247df3932d3dbbabc25b9b927efa03c115.json,document_parses/pmc_json/PMC6789792.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31416125/; https://doi.org/10.3390/vaccines7030089,201019732.0,3
85105,85105,109103,4hyp1956,ddbf31002935c6a62e177e3085670455ec4121ec,Medline; PMC,Progress and Challenges toward the Development of Vaccines against Avian Infectious Bronchitis,10.1155/2015/424860,PMC4411447,25954763.0,cc-by,avian infectious bronchitis ib widely distributed poultry disease huge economic impact poultry industry continuous emergence new ibv genotype lack cross protection among different ibv genotype important challenge although live attenuated ib vaccine remarkably induce potent immune response potential risk reversion virulence neutralization maternal antibody recombination mutation event important concern usage hand inactivated vaccine induce weaker immune response may require multiple dosing andor use adjuvant probably potential safety risk increased economic burden consequently alternative ib vaccine widely sought recent advance recombinant dna technology resulted experimental ib vaccine show promise antibody tcells response comparable live attenuated vaccine recombinant dna vaccine also enhanced target multiple serotypes efficacy improved using delivery vector nanoadjuvants ovo vaccination approach although recombinant ib dna vaccine yet licensed expected type vaccine may hold sway future vaccine inducing cross protection multiple ibv serotypes,2015-04-14,"Bande, Faruku; Arshad, Siti Suri; Hair Bejo, Mohd; Moeini, Hassan; Omar, Abdul Rahman",J Immunol Res,,,,document_parses/pdf_json/ddbf31002935c6a62e177e3085670455ec4121ec.json,document_parses/pmc_json/PMC4411447.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25954763/; https://doi.org/10.1155/2015/424860,15922545.0,3
85113,85113,109112,et1sli23,e4854e380bdd61dc0fbfdf751fe1b922778450ba,Elsevier; Medline; PMC,A novel glycoprotein D-specific monoclonal antibody neutralizes herpes simplex virus,10.1016/j.antiviral.2017.10.013,PMC7113901,29061442.0,els-covid,worldwide prevalence herpes simplex virus hsv shortage efficient vaccine novel therapeutic strategy hsv widely global concern abundance virion major stimulus virusneutralizing antibody make gd predominant candidate cure hsv infection study generated monoclonal antibody mab termed mf targeting glycoprotein gd hsv also crossreactivity hsv gd high level neutralizing activity hsv hsv bind highly conserved region residue – within profusion domain gd effectively block hsv celltocell spread vitro pre postattachment neutralization assay syncytium formation inhibition assay revealed mf neutralizes hsv postbinding stage moreover therapeutic administration mf completely prevented infectionrelated mortality mouse challenged lethal dose hsv newly identified epitope neutralizing antibody would facilitate study gdbased hsv entry vaccine design mf demonstrated high potential adaptation protective therapeutic drug hsv,2017-11-30,"Du, Ruikun; Wang, Lili; Xu, Hao; Wang, Zhiying; Zhang, Tao; Wang, Manli; Ning, Yunjia; Deng, Fei; Hu, Zhihong; Wang, Hualin; Li, Yi",Antiviral Research,,,,document_parses/pdf_json/e4854e380bdd61dc0fbfdf751fe1b922778450ba.json,document_parses/pmc_json/PMC7113901.xml.json,https://www.sciencedirect.com/science/article/pii/S0166354217304710; https://doi.org/10.1016/j.antiviral.2017.10.013; https://api.elsevier.com/content/article/pii/S0166354217304710; https://www.ncbi.nlm.nih.gov/pubmed/29061442/,24864673.0,3
85120,85120,109120,3ywtkd3k,deea74c59b21622d228c43adea5340e8a2447081,Medline; PMC,Systems vaccinology and big data in the vaccine development chain,10.1111/imm.13012,PMC6283655,30317555.0,cc-by-nc,system vaccinology proven fascinating development last decade traditionally vaccine development dominated trial error system vaccinology tool provides novel comprehensive understanding properly used data set retrieved systems‐based study endorse rational design effective development safe efficacious vaccine review first describe different omics‐techniques form pillar system vaccinology second part application system vaccinology different stage vaccine development described overall review show system vaccinology become important tool anywhere vaccine development chain,2018-11-13,"Raeven, René H. M.; van Riet, Elly; Meiring, Hugo D.; Metz, Bernard; Kersten, Gideon F. A.",Immunology,,,,document_parses/pdf_json/deea74c59b21622d228c43adea5340e8a2447081.json,document_parses/pmc_json/PMC6283655.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30317555/; https://doi.org/10.1111/imm.13012,52981890.0,3
85159,85159,109170,vm8usoay,9b4970858a35a4a456f2a0764c7e8fbd87e6c8ef,Elsevier; Medline; PMC,Molecular and antigenic characteristics of Massachusetts genotype infectious bronchitis coronavirus in China,10.1016/j.vetmic.2015.10.003,PMC7117242,26482289.0,els-covid,study ibvs isolated sample chicken flock twentynine isolates classified massachusetts genotype isolates well two previously isolated massachusetts genotype ibv strain studied strain hlike two mlike isolates determined complete genomic sequence analysis indicating ibv isolates likely reisolated vaccine virus remaining five ibv isolates ckchlhb ckchlsd ckchlhb ckchldl ckchlhb shown originated natural recombination event hlike vaccine strain type virus virus crossneutralization test found antigenicity ckchlhb ckchlsd ckchlhb similar h vaccination h vaccine offered complete protection challenge isolates however isolates ckchldl ckchlhb serotypically different parental virus serotypes study furthermore vaccination h vaccine provide protection challenge two isolates result study demonstrated recombination mechanism responsible emergence new serotype strain ability alter virus serotypes therefore ibv surveillance chicken flock vaccinated ibv live vaccine well consideration new strategy effectively control ibv infection using inactivated orand genetically engineered vaccine great importance,2015-12-31,"Chen, Lingfeng; Zhang, Tingting; Han, Zongxi; Liang, Shuling; Xu, Yang; Xu, Qianqian; Chen, Yuqiu; Zhao, Yan; Shao, Yuhao; Li, Huixin; Wang, Kexiong; Kong, Xiangang; Liu, Shengwang",Veterinary Microbiology,,,,document_parses/pdf_json/9b4970858a35a4a456f2a0764c7e8fbd87e6c8ef.json,document_parses/pmc_json/PMC7117242.xml.json,https://api.elsevier.com/content/article/pii/S0378113515300432; https://www.sciencedirect.com/science/article/pii/S0378113515300432; https://www.ncbi.nlm.nih.gov/pubmed/26482289/; https://doi.org/10.1016/j.vetmic.2015.10.003,24892322.0,3
85187,85187,109202,i8xi0h4g,b6ed892b894ed62251a8cb78b5bca37318a03a4d,Medline; PMC,A VLP vaccine for epidemic Chikungunya virus protects non-human primates against infection,10.1038/nm.2105,PMC2834826,20111039.0,no-cc,chikungunya virus chikv infected million people africa europe asia since reemergence kenya severity disease spread epidemic virus present serious public health threat absence vaccine antiviral therapy describe novel vaccine protects emerging chikv infection nonhuman primate nhp show selective expression viral structural protein give rise viruslike particle vlps vitro resemble replicationcompetent alphavirus immunization vlps elicited neutralizing antibody envelope protein different chikv strain monkey immunized vlps produced high titer neutralizing antibody protected viremia high dose challenge transferred antibody immunodeficient mouse protected subsequent lethal chikv challenge establishing humoral mechanism protection immunization alphavirus vlp vaccine represents strategy contain spread chikv related pathogenic virus human,2010-01-28,"Akahata, Wataru; Yang, Zhi-yong; Andersen, Hanne; Sun, Siyang; Holdaway, Heather A.; Kong, Wing-Pui; Lewis, Mark G.; Higgs, Stephen; Rossmann, Michael G.; Rao, Srinivas; Nabel, Gary J.",Nat Med,,,,document_parses/pdf_json/b6ed892b894ed62251a8cb78b5bca37318a03a4d.json,document_parses/pmc_json/PMC2834826.xml.json,https://doi.org/10.1038/nm.2105; https://www.ncbi.nlm.nih.gov/pubmed/20111039/,13766592.0,3
85278,85278,109309,urhiubn6,2d0664c3be770994d502f1d1baae42684652aad4,Medline; PMC,Future Challenges for Vaccinologists,10.1007/978-1-4939-3387-7_2,PMC7121569,27076124.0,no-cc,vaccination one cheapest healthcare intervention saved life drug therapy due successful immunization program rarely hear common disease early twentieth century including small pox polio vaccination program also helped increase food production notably poultry cattle milk production due lower incidence infectious disease farm animal though vaccination program eradicated several disease increased quality life several disease effective vaccine currently vaccine cancer neurodegenerative disease autoimmune disease well infectious disease like tuberculosis aid parasitic disease including malaria abuse antibiotic resulted generation several antibioticresistant bacterial strain hence need develop novel vaccine antibioticresistant microorganism change climate another concern vaccinologists climate change could lead generation new strain infectious microorganism would require development novel vaccine use conventional vaccination strategy develop vaccine severe limitation hence innovative strategy essential development novel effective vaccine,2015-12-17,"Thomas, Sunil; Dilbarova, Rima; Rappuoli, Rino",Vaccine Design,,,,document_parses/pdf_json/2d0664c3be770994d502f1d1baae42684652aad4.json,document_parses/pmc_json/PMC7121569.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/27076124/; https://doi.org/10.1007/978-1-4939-3387-7_2,42921373.0,3
85362,85362,109410,2upc2spn,da3dea36182741e1b3699e372f16e1f0bb2fd315; 99b91c8b0a5455bca54167c5abb7c0dfdbf032c6; 0eda9491295d6a851db35c358ac0c4fe956dce1c,Medline; PMC,CE-BLAST makes it possible to compute antigenic similarity for newly emerging pathogens,10.1038/s41467-018-04171-2,PMC5932059,29720583.0,cc-by,major challenge vaccine development include rapidly selecting designing immunogen raising crossprotective immunity different intra intersubtypic pathogen especially newly emerging variety propose computational method conformational epitope ceblast calculating antigenic similarity among different pathogen stable high performance independent prior bindingassay information unlike currently available model heavily rely historical experimental data tool validation incorporates influenzarelated experimental data sufficient stability reliability determination application denguerelated data demonstrates high harmonization computed cluster experimental serological data undetectable classical grouping ceblast identifies potential crossreactive epitope recent zika pathogen dengue virus precisely corroborated experimental data high performance pathogen without experimental binding data suggests potential utility ceblast rapidly design crossprotective vaccine promptly determine efficacy currently marketed vaccine emerging pathogen critical factor containing emerging disease outbreak,2018-05-02,"Qiu, Tianyi; Yang, Yiyan; Qiu, Jingxuan; Huang, Yang; Xu, Tianlei; Xiao, Han; Wu, Dingfeng; Zhang, Qingchen; Zhou, Chen; Zhang, Xiaoyan; Tang, Kailin; Xu, Jianqing; Cao, Zhiwei",Nat Commun,,,,document_parses/pdf_json/da3dea36182741e1b3699e372f16e1f0bb2fd315.json; document_parses/pdf_json/99b91c8b0a5455bca54167c5abb7c0dfdbf032c6.json; document_parses/pdf_json/0eda9491295d6a851db35c358ac0c4fe956dce1c.json,document_parses/pmc_json/PMC5932059.xml.json,https://doi.org/10.1038/s41467-018-04171-2; https://www.ncbi.nlm.nih.gov/pubmed/29720583/,19157016.0,3
85377,85377,109429,uk5khcoz,c5dc7ecfd8e3bbf6c0e7b1d81e201ca0b8da596f,Elsevier; Medline; PMC,Measles-derived vaccines to prevent emerging viral diseases,10.1016/j.micinf.2018.01.005,PMC7110469,29410084.0,els-covid,infectious disease epidemic match war natural disaster capacity threaten life damage economy like sars previously zika recently ebola crisis showed vulnerable world epidemic people dying outbreak addition causing immense human suffering epidemic particularly affect low middleincome country many deadly infectious disease epidemic potential become global health emergency absence effective vaccine vaccine threat developed create proven medical product measles vaccine efficient live attenuated replicating virus safely administered billion child last year affording lifelong protection single dose taking advantage characteristic attenuated virus transformed versatile chimeric recombinant vaccine vector demonstrated proofofprinciple human preclinical track record rapid adaptability effectiveness variety pathogen clinical trial shown safety immunogenicity vaccine platform individual preexisting immunity measles review describes potential platform develop new vaccine emerging viral disease,2018-11-30,"Frantz, Phanramphoei N.; Teeravechyan, Samaporn; Tangy, Frédéric",Microbes and Infection,,,,document_parses/pdf_json/c5dc7ecfd8e3bbf6c0e7b1d81e201ca0b8da596f.json,document_parses/pmc_json/PMC7110469.xml.json,https://api.elsevier.com/content/article/pii/S1286457918300388; https://www.ncbi.nlm.nih.gov/pubmed/29410084/; https://www.sciencedirect.com/science/article/pii/S1286457918300388; https://doi.org/10.1016/j.micinf.2018.01.005,46832689.0,3
85574,85574,109675,swi0klrl,ea0c05149334ecf5663921078794008a464d7a36; c08c3b98a956287a6eaf99f6d90969d7dd1410d1,BioRxiv; MedRxiv,The deubiquitinating activity of Middle East respiratory syndrome coronavirus papain-like protease delays the innate immune response and enhances virulence in a mouse model,10.1101/751578,,,medrxiv,middle east respiratory syndrome coronavirus merscov continues cause zoonotic infection serious disease primarily arabian peninsula due repeated spillover dromedary camel subsequent nosocomial transmission approved mers vaccine use animal human currently available merscov replication requires virusencoded papainlike protease plpro cleave multiple site viral replicase polyproteins thereby releasing functional nonstructural protein additionally plpro deubiquitinating enzyme dub remove ubiquitinlike moiety substrate presumably counteract host antiviral response previous work determined crystal structure merscov plpro complex ubiquitin facilitating design plpro mutation impair dub activity without affecting viral polyprotein cleavage introduced dubinactivating mutation viral genome examined impact merscov infection cell culture lethal mouse model although overall replication dubnegative wildtype wt recombinant merscov comparable multiple cell line infection dubnegative virus markedly increased mrna level interferon ifnβ ifnstimulated gene moreover compared wt virus infection survival rate significantly increased dubnegative merscov used infect transgenic mouse expressing human merscov receptor interestingly dubnegative wt merscov replicated titer lung infected mouse dubnegative virus cleared faster likely due observed accelerated betterregulated innate immune response contrast delayed subsequently excessive response wt virusinfected mouse study provides first direct evidence dub activity coronaviral protease contributes innate immune evasion profoundly enhance virulence animal model thus reduction removal innate immunesuppressive dub activity plpros promising strategy coronavirus attenuation context rational vaccine development although zoonotic coronaviruses middle east respiratory coronavirus merscov pandemic potential therapeutic vaccine counteract public health threat currently available coronaviruses typically employ multiple strategy evade host ’ innate immune response may enhance clinical disease andor reduce efficacy modified live vaccine merscovencoded papainlike protease plpro crucial expression functional replicase protein also postulated antagonize ubiquitinationdependent step activation innate immune response report generation engineered merscovs mutant plpro ’ deubiquitinating dub activity specifically disrupted without affecting virus viability manner could demonstrate dub activity plpro suppresses interferon response merscovinfected cell strikingly lung mouse infected dubnegative merscov innate immune response induced earlier stage infection wt virusinfected mouse group also showed clearly increased survival indicating dub activity important merscov virulence factor proofofconcept study establishes engineering dubnegative coronaviruses elicit effective immune response host viable strategy vaccine development,2019-08-29,"Knaap, Robert C. M.; Fernández-Delgado, Raúl; Dalebout, Tim J.; Oreshkova, Nadia; Bredenbeek, Peter J.; Enjuanes, Luis; Sola, Isabel; Snijder, Eric J.; Kikkert, Marjolein",bioRxiv,,,,document_parses/pdf_json/ea0c05149334ecf5663921078794008a464d7a36.json; document_parses/pdf_json/c08c3b98a956287a6eaf99f6d90969d7dd1410d1.json,,https://doi.org/10.1101/751578,202848189.0,3
85581,85581,109682,qla8ee8m,50fa3228f8067d61d3debffbe06c53deaf9dc863,Medline; PMC,Recombinant Vesicular Stomatitis Virus Vaccine Vectors Expressing Filovirus Glycoproteins Lack Neurovirulence in Nonhuman Primates,10.1371/journal.pntd.0001567,PMC3308941,22448291.0,cc0,filovirus marburg virus ebola virus cause severe hemorrhagic fever high mortality human nonhuman primate among promising filovirus vaccine development system based recombinant vesicular stomatitis virus rvsv express individual filovirus glycoprotein gp place vsv glycoprotein g main concern replicationcompetent vaccine including rvsv filovirus gp vector safety address concern performed neurovirulence study using cynomolgus macaque vaccine administered intrathalamically seven animal received rvsv vector expressing zaire ebolavirus zebov gp seven animal received rvsv vector expressing lake victoria marburgvirus marv gp three animal received rvsvwild type wt vector four animal received vehicle control two three animal given rvsvwt showed severe neurological symptom whereas animal receiving vehicle control rvsvzebovgp rvsvmarvgp develop symptom histological analysis revealed major lesion neural tissue three rvsvwt animal however significant lesion observed animal filovirus vaccine vehicle control group data strongly suggest rvsv filovirus gp vaccine vector lack neurovirulence property associated rvsvwt parent vector support development vaccine platform human use,2012-03-20,"Mire, Chad E.; Miller, Andrew D.; Carville, Angela; Westmoreland, Susan V.; Geisbert, Joan B.; Mansfield, Keith G.; Feldmann, Heinz; Hensley, Lisa E.; Geisbert, Thomas W.",PLoS Negl Trop Dis,,,,document_parses/pdf_json/50fa3228f8067d61d3debffbe06c53deaf9dc863.json,document_parses/pmc_json/PMC3308941.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/22448291/; https://doi.org/10.1371/journal.pntd.0001567,7034481.0,3
85623,85623,109730,e8k72955,aef8022f38dee0b0eadc00eb8a955384b87f3626,Medline; PMC,Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine,10.3390/vaccines6020018,PMC6027237,29587436.0,cc-by,nextgeneration vaccine utilize cell could potentially overcome limitation current influenza vaccine rely antibody provide narrow subtypespecific protection prone antigenic mismatch circulating strain evidence animal model show cell provide heterosubtypic protection crucial immune control influenza virus infection provided hope design universal vaccine able prime diverse influenza virus strain subtypes however multiple hurdle exist realisation universal cell vaccine overall primary concern extrapolating human clinical study seeding durable effective cell resident memory trm population human leucocyte antigen hla coverage potential cellmediated immune escape comprehensive human clinical data needed natural infection validate protective role cell play infection absence antibody furthermore fundamental question still exist regarding site longevity duration quantity phenotype cell needed optimal protection standardised experimental method eventually simplified commercial assay ass peripheral influenzaspecific cell response needed largerscale clinical study cell correlate protection influenza infection design implementation cellinducing vaccine require consensus level protection acceptable community may provide sterilizing immunity could protect individual severe disease reduce length infection potentially reduce transmission community therefore increasing standard care potentially offered cell vaccine considered context pandemic preparedness zoonotic infection combination improved antibody vaccine targeting method current pandemic vaccine preparedness measure ongoing clinical trial underutilise cellinducing vaccine reflecting myriad question remain cell needed fight influenza virus infection review aim bring together basic fundamental cell biology human clinical data need considered implementation universal vaccine influenza harness power cell,2018-03-26,"Clemens, E. Bridie; van de Sandt, Carolien; Wong, Sook San; Wakim, Linda M.; Valkenburg, Sophie A.",Vaccines (Basel),,,,document_parses/pdf_json/aef8022f38dee0b0eadc00eb8a955384b87f3626.json,document_parses/pmc_json/PMC6027237.xml.json,https://doi.org/10.3390/vaccines6020018; https://www.ncbi.nlm.nih.gov/pubmed/29587436/,4378145.0,3
85659,85659,109775,dh4jvbmi,6dd1ec85b2f97b3abdee90713f44171377b378cf,Elsevier; Medline; PMC,In vivo assessment of equine arteritis virus vaccine improvement by disabling the deubiquitinase activity of papain-like protease 2,10.1016/j.vetmic.2015.04.018,PMC7117436,25975520.0,els-covid,arteriviruses family positivestranded rna virus includes prototypic equine arteritis virus eav porcine reproductive respiratory syndrome virus prrsv although several vaccine virus commercially available room improvement especially case prrsv ability arteriviruses counteract immune response thought decrease efficacy current modified live virus vaccine recently shown deubiquitinase dub activity eav papainlike protease plp important inhibition innate immune activation infection vaccine virus lacking plp dub activity may therefore immunogenic provide improved protection subsequent challenge dubcompetent counterpart test hypothesis twenty shetland mare randomly assigned one three group two group vaccinated either dubpositive n dubnegative n recombinant eav third group n vaccinated horse subsequently challenged virulent ky strain eav vaccine virus proved replication competent vivo addition dubnegative virus provided similar degree protection clinical disease dubpositive parental counterpart owing already high level protection provided parental virus possible improvement due inactivation plp dub activity could detected experimental condition taken together data obtained study warrant vivo investigation potential using dubmutant virus improvement arterivirus vaccine,2015-07-09,"van Kasteren, Puck B.; Knaap, Robert C.M.; van den Elzen, Paul; Snijder, Eric J.; Balasuriya, Udeni B.R.; van den Born, Erwin; Kikkert, Marjolein",Veterinary Microbiology,,,,document_parses/pdf_json/6dd1ec85b2f97b3abdee90713f44171377b378cf.json,document_parses/pmc_json/PMC7117436.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25975520/; https://www.sciencedirect.com/science/article/pii/S0378113515001637; https://doi.org/10.1016/j.vetmic.2015.04.018; https://api.elsevier.com/content/article/pii/S0378113515001637,205625554.0,3
85749,85749,109881,ig4hsts2,b99136512970c5ad4257f21b5ac40218654de94b,Elsevier; Medline; PMC,"Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico",10.1016/j.vaccine.2011.07.099,PMC7126971,21816199.0,els-covid,viruslike particle vlps rapidly developed influenza virus genetic sequence order supply vaccine onset pandemic safety immunogenicity one two dos recombinant hn influenza vlp vaccine evaluated twostage phase randomized doubleblind placebocontrolled study conducted healthy adult – year age hn pandemic mexico part subject randomized four treatment group μg μg μg hemagglutinin ha vlp vaccine placebo vaccinated day apart serum collected day hemagglutination inhibition hai testing review safety immunogenicity data part additional subject immunized single dose μg vlp vaccine n placebo n assessed safety part b result showed hn vlp vaccine safe welltolerated systemic solicited event similar placebo vlp vaccinated group vaccinerelated serious adverse event dose response trend solicited local adverse event observed higher incidence local pain swelling tenderness redness reported higher vlp dose group μg μg compared placebo μg vlp group following vaccination although majority local aes mild severity dose trend event moderate greater severity also noted solicited event vlp vaccine group demonstrated robust hai immune response single vaccination high rate seroprotection ≥ hai titer – subject – subject seronegative time immunization hai geometric mean titer gmt geometric mean ratio gmrs seroconversion rate also statistically higher vlp group compared placebo postbaseline time point based data additional clinical trial development evaluate influenza vaccine candidate antigen manufactured using spodoptera frugiperda sfbaculovirusbased vlp technology,2011-10-13,"López-Macías, Constantino; Ferat-Osorio, Eduardo; Tenorio-Calvo, Alejandra; Isibasi, Armando; Talavera, Juan; Arteaga-Ruiz, Oscar; Arriaga-Pizano, Lourdes; Hickman, Somia P.; Allende, María; Lenhard, Kathy; Pincus, Steven; Connolly, Kevin; Raghunandan, Ramadevi; Smith, Gale; Glenn, Gregory",Vaccine,,,,document_parses/pdf_json/b99136512970c5ad4257f21b5ac40218654de94b.json,document_parses/pmc_json/PMC7126971.xml.json,https://doi.org/10.1016/j.vaccine.2011.07.099; https://www.sciencedirect.com/science/article/pii/S0264410X11011492; https://www.ncbi.nlm.nih.gov/pubmed/21816199/; https://api.elsevier.com/content/article/pii/S0264410X11011492,938973.0,3
85828,85828,109974,mopz7bqa,,Medline; WHO,Audio Interview: Capitalizing on Immune Responses to Covid-19,10.1056/nejme2019020,,32433859.0,unk,capitalizing immune response covid audio interview conducted may editor discus recent advance involving convalescent plasma monoclonal antibody vaccine,2020,"Rubin, Eric J.; Baden, Lindsey R.; Morrissey, Stephen",New England Journal of Medicine,,#326986,,,,https://doi.org/10.1056/nejme2019020; https://www.ncbi.nlm.nih.gov/pubmed/32433859/,218765751.0,3
85837,85837,109987,wdpatr2z,0d1cff78c70dbc0bead309c5770130206ee6b156,Elsevier; Medline; PMC,Resiquimod enhances mucosal and systemic immunity against avian infectious bronchitis virus vaccine in the chicken,10.1016/j.micpath.2018.04.012,PMC7127065,29635053.0,no-cc,adjuvant enhancing mucosal immune response preferred controlling many pathogen portal entry earlier reported tolllikereceptor tlr agonist resiquimod r stimulated systemic immunity adjuvanted inactivated newcastle disease virus vaccine chicken report effect r adjuvanted live inactivated avian infectious bronchitis virus ibv vaccine special emphasis mucosal immunity specific pathogen free spf chick n equally divided six group two week age immunized either inactivated live ibv vaccine adjuvanted without r group received either pb r served control booster given day postimmunization dpi r enhanced antigen specific humoral cellular immune response coadministered vaccine evidenced increase antibody titre elisa stimulation index lymphocyte transformation test ltt till dpi increased proportion cd cd cell dpi flow cytometry interestingly potentiated iga response tear intestinal secretion used live inactivated ibv vaccine combination ibv vaccine r significantly upregulated transforming growth factor beta tgfβ transcript peripheral blood mononuclear cell pbmcs respective vaccine per se enhanced secretory iga response likely due upregulation tgfβ responsible class switching iga conclusion coadministration r inactivated live ibv vaccine enhanced systemic well mucosal immune response chicken,2018-04-07,"Matoo, Javaid Jeelani; Bashir, Khalid; Kumar, Ajay; Krishnaswamy, Narayanan; Dey, Sohini; Chellappa, Madhan Mohan; Ramakrishnan, Saravanan",Microb Pathog,,,,document_parses/pdf_json/0d1cff78c70dbc0bead309c5770130206ee6b156.json,document_parses/pmc_json/PMC7127065.xml.json,https://doi.org/10.1016/j.micpath.2018.04.012; https://www.ncbi.nlm.nih.gov/pubmed/29635053/; https://api.elsevier.com/content/article/pii/S0882401018302948; https://www.sciencedirect.com/science/article/pii/S0882401018302948,206932117.0,3
85880,85880,110047,1wzvcy88,6a109eb5b0e889ef933943ebf4db5c26cacf85b8,Elsevier; PMC,Intragastric immunization with recombinant Lactobacillus casei expressing flagellar antigen confers antibody-independent protective immunity against Salmonella enterica serovar Enteritidis,10.1016/j.vaccine.2007.01.055,PMC7115604,17287050.0,els-covid,recombinant lactobacillus casei expressing flagellar antigen salmonella enterica serovar enteritidis constructed evaluated mucosal vaccine intragastric immunization recombinant strain conferred protective immunity salmonella infection mouse immunization result antigenspecific antibody either feces serum induced release ifnγ restimulation primed lymphocyte ex vivo result suggested protective efficacy provided flagellinexpressing l casei mainly attributable cellmediated immune response addition adjuvanttype effect antigen delivery system l casei also observed,2007-05-04,"Kajikawa, Akinobu; Satoh, Eiichi; Leer, Rob J.; Yamamoto, Shigeki; Igimi, Shizunobu",Vaccine,,,,document_parses/pdf_json/6a109eb5b0e889ef933943ebf4db5c26cacf85b8.json,document_parses/pmc_json/PMC7115604.xml.json,https://api.elsevier.com/content/article/pii/S0264410X07000837; https://www.sciencedirect.com/science/article/pii/S0264410X07000837,28735428.0,3
85890,85890,110058,10817qo9,,Medline; WHO,Pustulan Activates Chicken Bone Marrow-Derived Dendritic Cells In Vitro and Promotes Ex Vivo CD4+ T Cell Recall Response to Infectious Bronchitis Virus.,10.3390/vaccines8020226,,32429204.0,unk,infectious bronchitis virus ibv highly contagious avian coronavirus ibv cause substantial worldwide economic loss poultry industry vaccination liveattenuated viral vaccine therefore critical importance liveattenuated viral vaccine however exhibit potential reversion virulence recombination virulent field strain therefore alternative subunit vaccine needed together identification suitable adjuvant subunit vaccine le immunogenic liveattenuated vaccine several glycanbased adjuvant directly targeting mammalian ctype lectin receptor assessed vitro using chicken bone marrowderived dendritic cell bmdcs βglucan pustulan induced upregulation mhc class ii mhcii cell surface expression potentiated strong proinflammatory cytokine response increased endocytosis cationdependent manner ex vivo coculture peripheral blood monocyte ibvimmunised chicken bmdcs pulsed pustulanadjuvanted recombinant ibv n protein rn induced strong recall response pustulanadjuvanted rn induced significantly higher cd blast percentage compared either rn pustulan medium however cd tcrγδ blast percentage significantly lower pustulanadjuvanted rn compared pustulan medium thus pustulan enhanced efficacy mhcii antigen presentation apparently crosspresentation mhci conclusion found immunopotentiating effect pustulan vitro using chicken bmdcs thus future vivo study might show pustulan promising glycanbased adjuvant use poultry industry contain spread coronaviridiae well avian viral pathogen,2020-05-15,"Larsen, Frederik T; Guldbrandtsen, Bernt; Christensen, Dennis; Pitcovski, Jacob; Kjærup, Rikke B; Dalgaard, Tina S",Vaccines,,#276493,,,,https://www.ncbi.nlm.nih.gov/pubmed/32429204/; https://doi.org/10.3390/vaccines8020226,218757917.0,3
85922,85922,110099,8gncbgot,a73af08311f81abb995c85cf95358fedbbaec26a,Medline; PMC; WHO,"Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review",10.3390/jcm9030623,PMC7141113,32110875.0,cc-by,rapid diagnostics vaccine therapeutic important intervention management novel coronavirus ncov outbreak timely systematically review potential intervention including middle east respiratory syndromecoronavirus merscov severe acute respiratory syndrome sarscov guide policymakers globally prioritization resource research development systematic search carried three major electronic database pubmed embase cochrane library identify published study accordance preferred reporting item systematic review metaanalyses prisma guideline supplementary strategy google search personal communication used total study fulfilled criterion review several laboratory protocol confirmation suspected ncov case using realtime reverse transcription polymerase chain reaction rtpcr published commercial rtpcr kit developed beijing genomic institute currently widely used china likely asia however serological assay well pointofcare testing kit developed likely near future several vaccine candidate pipeline likely earliest phase vaccine trial synthetic dnabased candidate number novel compound well therapeutic licensed condition appear vitro efficacy ncov tested clinical trial merscov sarscov others listed clinical trial ncov however currently effective specific antiviral drug combination supported highlevel evidence,2020-02-26,"Pang, Junxiong; Wang, Min Xian; Ang, Ian Yi Han; Tan, Sharon Hui Xuan; Lewis, Ruth Frances; Chen, Jacinta I-Pei; Gutierrez, Ramona A; Gwee, Sylvia Xiao Wei; Chua, Pearleen Ee Yong; Yang, Qian; Ng, Xian Yi; Yap, Rowena K.S.; Tan, Hao Yi; Teo, Yik Ying; Tan, Chorh Chuan; Cook, Alex R.; Yap, Jason Chin-Huat; Hsu, Li Yang",J Clin Med,,#2155,,document_parses/pdf_json/a73af08311f81abb995c85cf95358fedbbaec26a.json,document_parses/pmc_json/PMC7141113.xml.json,https://doi.org/10.3390/jcm9030623; https://www.ncbi.nlm.nih.gov/pubmed/32110875/,211564596.0,3
85962,85962,110148,xr3r5fli,1971eaa26ca2a0c50b8c1ed62cfb6fb9107cf498,Elsevier; Medline; PMC,Multiple recombination events between field and vaccine strains resulted in the emergence of a novel infectious bronchitis virus with decreased pathogenicity and altered replication capacity,10.1016/j.psj.2019.11.056,PMC7102566,32241473.0,els-covid,study isolated identified infectious bronchitis virus ibv strain layer chicken soon vaccination massachusetts–connecticut bivalent vaccine conn h booster vaccine china result crossvirusneutralization test phylogenetic analysis subunit spike gene vaccine strain reference strain showed strain ljl gi lineage whereas lln gi lineage conn serotype comparative genomic analysis revealed lln ibv strain novel trait originated multiple recombination event least recombination site gi conn vaccine strain lln pathogenic specific pathogenfree spf chicken prime importance ibv prevention measure worldwide mainly dependent modified live vaccine strain result showed recombination field vaccine strain produced novel pathogenic ibv strain addition lln showed relatively broad tissue tropism trachea lung kidney cecal tonsil infected spf chicken result emphasize importance ibv surveillance chicken flock,2020-04-30,"Ren, Mengting; Han, Zongxi; Zhao, Yan; Sun, Junfeng; Liu, Shengwang; Ma, Deying",Poultry Science,,,,document_parses/pdf_json/1971eaa26ca2a0c50b8c1ed62cfb6fb9107cf498.json,document_parses/pmc_json/PMC7102566.xml.json,https://www.sciencedirect.com/science/article/pii/S0032579119580579; https://www.ncbi.nlm.nih.gov/pubmed/32241473/; https://doi.org/10.1016/j.psj.2019.11.056; https://api.elsevier.com/content/article/pii/S0032579119580579,213470432.0,3
85993,85993,110183,odeksech,c9de91274929687bd8d4250a953d9bae36378ef4,Elsevier; PMC,21 Adenoviral Vector Vaccines Antigen Transgene,10.1016/b978-0-12-800276-6.00021-8,PMC7150117,,els-covid,past decade adenovirusbased vaccine progressed preclinical study universally showed vector ’ high immunogenicity testing human clinical trial showed adenovirus vector well tolerated human induce robust immune response expanded booster immunization effect preexisting neutralizing antibody vector ’ immunogenicity appears le severe observed experimental animal readily circumvented using vector human lack neutralizing antibody additional clinical study needed firmly establish efficacy adenoviral vector vaccine,2016-12-31,"Ertl, Hildegund C.J.",Adenoviral Vectors for Gene Therapy,,,,document_parses/pdf_json/c9de91274929687bd8d4250a953d9bae36378ef4.json,document_parses/pmc_json/PMC7150117.xml.json,https://www.sciencedirect.com/science/article/pii/B9780128002766000218; https://api.elsevier.com/content/article/pii/B9780128002766000218,87009642.0,3
86129,86129,110349,4ub3q2zu,b8e9fcc34571f9c29e04f9feb34197250556cb9a,Medline; PMC,"Mechanisms of protective immune responses induced by the Plasmodium falciparum circumsporozoite protein-based, self-assembling protein nanoparticle vaccine",10.1186/1475-2875-12-136,PMC3765086,23607541.0,cc-by,background lack defined correlate immunity malaria combined inability induce longlived sterile immune response human host demonstrate need improved understanding potentially protective immune mechanism enhanced vaccine efficacy protective sterile immunity plasmodium falciparum circumsporozoite protein csp achieved using transgenically modified plasmodium berghei sporozoite tgpbpfcsp selfassembling protein nanoparticle sapn vaccine presenting csp epitope pfcspsapn several possible mechanism involved independently protective humoral cellular response induced following sapn immunization described method inbred mouse vaccinated pfcspsapn pb serum antibody harvested effect p falciparum sporozoite mobility integrity examined using phase contrast microscopy functionality sapninduced antibody inhibition sporozoite invasion growth within primary human hepatocytes also examined internal processing sapn bone marrowderived dendritic cell bmddc using organellespecific fluorescenttagged antibody goldencapsulated sapn observed using confocal electron microscopy respectively result result work demonstrate pfcspsapn induces epitopespecific antibody titer predominantly th isotype igg serum antibody pfcspsapnimmunized mouse appear target p falciparum sporozoite via classical pathway complement result sporozoite death indicated cessation motility circumsporozoite precipitation reaction moreover pfcspsapninduced antibody able inhibit wildtype p falciparum sporozoite invasion growth within cultured primary human hepatocytes addition observation pfcspsapn processed presented immune system dendritic cell slow continuous fashion via transporter associated antigen processing tap recruitment early endosome ee partially delayed processing endoplasmic reticulum potential induce longlived effector memory cd tcells described previously conclusion paper describes examination humoral cellular immune mechanism induced pfcspsapn vaccination result sterile host protection transgenic p berghei malaria sporozoite expressing p falciparum csp significantly inhibits native p falciparum sporozoite invading developing within cultured human hepatocytes result may indicate type mode action protective antibody needed control p falciparum sporozoite infecting human well potential mechanism induction protective longlived effector memory cd tcells,2013-04-22,"McCoy, Margaret E; Golden, Hannah E; Doll, Tais APF; Yang, Yongkun; Kaba, Stephen A; Burkhard, Peter; Lanar, David E",Malar J,,,,document_parses/pdf_json/b8e9fcc34571f9c29e04f9feb34197250556cb9a.json,document_parses/pmc_json/PMC3765086.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/23607541/; https://doi.org/10.1186/1475-2875-12-136,7087724.0,3
86132,86132,110352,f5g2r4n9,,Medline; WHO,A spike with which to beat COVID-19?,10.1038/s41579-020-0383-2,,32415242.0,unk,month ’ lens discus structural study sarscov spike glycoprotein might guide path towards vaccine,2020-05-15,"Alam, Nawsad; Higgins, Matthew K",Nature reviews. Microbiology,,#261176,,,,https://www.ncbi.nlm.nih.gov/pubmed/32415242/; https://doi.org/10.1038/s41579-020-0383-2,218642712.0,3
86136,86136,110356,4bdusuqq,,Medline; WHO,"Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China",10.12688/f1000research.22211.1,,32117569.0,unk,novel coronavirus ncov originating wuhan china present potential respiratory viral pandemic world population current effort focused containment quarantine infected individual ultimately outbreak could controlled protective vaccine prevent ncov infection vaccine research pursued intensely exists today therapy treat ncov upon infection despite urgent need find option help patient preclude potential death herein review potential option treat ncov patient emphasis necessity speed timeliness developing new effective therapy outbreak consider option drug repurposing developing neutralizing monoclonal antibody therapy oligonucleotide strategy targeting viral rna genome emphasizing promise pitfall approach finally advocate fastest strategy develop treatment could resistant mutation virus may future proposal biologic block ncov entry using soluble version viral receptor angiotensinconverting enzyme ace fused immunoglobulin fc domain providing neutralizing antibody maximal breath avoid viral escape also helping recruit immune system build lasting immunity sequence acefc protein provided investigator allowing possible use recombinant protein expression system start producing drug today treat patient compassionate use formal clinical trial later undertaken treatment could help infected patient protective vaccine developed widely available coming month year,2020,"Kruse, Robert L.",F1000Research,,#3717,,,,https://doi.org/10.12688/f1000research.22211.1; https://www.ncbi.nlm.nih.gov/pubmed/32117569/,211534163.0,3
86157,86157,110383,w4pbq2lb,c3116b5f9a9a500febbe20c50a770d958fb42188,Elsevier; PMC,"Chapter 18 Mineral Adjuvants ∗ ∗ The present chapter is an updated version of the chapter “Mineral Adjuvants,” published in Immunopotentiators in Modern Vaccines, p. 217–233. Ed. Virgil Schijns & Derek O'Hagan, Elsevier Science Publishers (2005).",10.1016/b978-0-12-804019-5.00018-9,PMC7149584,,els-covid,mineral adjuvant comprise aluminum hydroxide phosphate adjuvant well calcium phosphate adjuvant particular aluminum salt achieved undisputed status commonly used adjuvant human veterinary vaccine calcium phosphate adjuvant later discovered edgar relyveld constitutes interesting alternative also applied human veterinary vaccine new analytical tool applied adjuvant research take u next level understanding mineral adjuvant tool used characterize mineral adjuvant far particular aluminumbased adjuvant term surface marker expression profile isotypic profile cytokine profile past year discovery adjuvantmediated induction nalp inflammasome impact secretion interleukin ilβ il proinflammatory mediator early phase immune response described important mechanism function adjuvant,2017-12-31,"Lindblad, E. B.; Duroux, L.",Immunopotentiators in Modern Vaccines,,,,document_parses/pdf_json/c3116b5f9a9a500febbe20c50a770d958fb42188.json,document_parses/pmc_json/PMC7149584.xml.json,https://www.sciencedirect.com/science/article/pii/B9780128040195000189; https://api.elsevier.com/content/article/pii/B9780128040195000189,91789099.0,3
86214,86214,110464,ben6r7n3,0ea02653a85f4ad7fd8a9e0d7d80bf8e3be885c5,Elsevier; Medline; PMC,Avian reovirus sigma C enhances the mucosal and systemic immune responses elicited by antigen-conjugated lactic acid bacteria,10.1016/j.vaccine.2012.04.043,PMC7115360,22531554.0,els-covid,mucosal surface common site pathogen colonizationentry effective mucosal immunity vaccination provide protection primary infection site aim develop new vaccination strategy elicits mucosal immune response new strain enterococcus faecium non pathogenic lactic acid bacteria lab strong cell adhesion ability identified used vaccine vector deliver two model antigen specifically sigma σ c protein avian reovirus arv functional homolog mammalian reovirus σ protein responsible mcell targeting administered together subfragment spike protein infectious bronchitis virus ibv next effect immunization route immune response assessed delivering antigen via lab strain intranasal immunization induced stronger humoral response intragastic ig immunization immunization produced antigen specific iga systemically lung higher iga titer induced lab arv σc protein attached moreover serum mouse immunized lab displaying divalent antigen much stronger immune reactivity arv σc protein compared ibvs result indicate arv σc protein delivered lab via route elicits strong mucosal immunity needlefree delivery approach convenient cost effective method vaccine administration especially respiratory infection economic animal furthermore arv σc strong immunogen arv may able serve immunoenhancer vaccine especially avian vaccine,2012-07-13,"Lin, Kuan-Hsun; Hsu, Ai-Ping; Shien, Jui-Hung; Chang, Tien-Jye; Liao, Jiunn-Wang; Chen, Jeng-Rung; Lin, Chuen-Fu; Hsu, Wei-Li",Vaccine,,,,document_parses/pdf_json/0ea02653a85f4ad7fd8a9e0d7d80bf8e3be885c5.json,document_parses/pmc_json/PMC7115360.xml.json,https://doi.org/10.1016/j.vaccine.2012.04.043; https://www.sciencedirect.com/science/article/pii/S0264410X12005749; https://www.ncbi.nlm.nih.gov/pubmed/22531554/; https://api.elsevier.com/content/article/pii/S0264410X12005749,32632043.0,3
86219,86219,110474,aozxvxxs,ccb21efaed2edb86c05dd860b5f61beaf856e2a8,Medline; PMC,Pregnancy and infection: using disease pathogenesis to inform vaccine strategy,10.1038/s41541-017-0042-4,PMC5794984,29423318.0,cc-by,vaccination mainstay preventative medicine many infectious disease pregnant woman unborn fetus neonate represent three atrisk population simultaneously protected strategic vaccination protocol pathogenesis different infectious microbe varies based tissue tropism timing infection host susceptibility goal immunization uniform across vaccine mechanistic understanding infectious disease pathogenesis immune response therefore essential inform vaccine design implementation appropriate immunization protocol optimize protection pregnant woman fetus neonate,2018-02-01,"Vermillion, Meghan S.; Klein, Sabra L.",NPJ Vaccines,,,,document_parses/pdf_json/ccb21efaed2edb86c05dd860b5f61beaf856e2a8.json,document_parses/pmc_json/PMC5794984.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29423318/; https://doi.org/10.1038/s41541-017-0042-4,4378287.0,3
86252,86252,110508,d3bs7yzc,ea7f67509abea3170a860a23663068eb03b45917,Elsevier; PMC,Bioinformatics in Design of Antiviral Vaccines,10.1016/b978-0-12-801238-3.10878-5,PMC7149942,,els-covid,viral disease epidemic occurring across world increasing frequency incidence new old virus renewed vigor traditional drug vaccine long developmental time incidence allergenic reaction growth resistant strain issue proving inadequate curb menace advancement computer science technology genetics immunology growth new science bioinformatics leading focused approach new paradigm vaccine design challenge traditional approach promise effective lead time get much shorter preselection peptide antiviral designed preclude allergenic reaction stability mutational change viral strain much assured coverage immunological status enable communityspecific vaccine development outline article basic virus immune response traditional vaccine move describe bioinformatics method development new vaccine,2019-12-31,"Nandy, Ashesh; Basak, Subhash C.",Encyclopedia of Biomedical Engineering,,,,document_parses/pdf_json/ea7f67509abea3170a860a23663068eb03b45917.json,document_parses/pmc_json/PMC7149942.xml.json,https://www.sciencedirect.com/science/article/pii/B9780128012383108785; https://api.elsevier.com/content/article/pii/B9780128012383108785,188919481.0,3
86268,86268,110526,bc0un6kb,58ed24ffb06bd86deebcf31ccf9bc5984b3d8703,Medline; PMC,Safety and efficacy of attenuated classic and variant 2 infectious bronchitis virus candidate vaccines,10.3382/ps/pey312,PMC7107197,30085298.0,no-cc,vaccination program infectious bronchitis virus ibv egypt depend classical andor imported variant ibv strain vaccine however many ibv outbreak associated respiratory distress nephropathy high mortality attributed circulation classical new nephropathogenic ibv variant strain present study report development attenuated ibv candidate vaccine using classic ibv strain ibm ib nephropathogenic strain ibvar wildtype wt virus attenuated serial passage embryonated specific pathogen free spf chicken egg virulence attenuated virus tested via ocular route inoculation vivo back passage dayold spf chicken efficacy homologous challenge investigated also dayold spf chicken result showed virus successfully adapted embryo th ibm ib th passage ibvar attenuated virus safe showed change virulence dayold spf chicken th back passage efficacy experiment showed attenuated vaccine showed protection homologous challenge based ciliostasis score protection percent attibm attib vaccine able reduce shedding challenge day postinfection dpi virus shedding detected vaccinated group dpi attibvar vaccinated bird vaccinated bird shed challenge virus low titer ± eidml dpi conclusion attenuated strain ibm ib ibvar efficient vaccine candidate currently circulating classic variant ib virus respectively study evaluate field efficacy combining attenuated ibv strain induce wider protection heterologous ibv challenge suggested,2018-08-06,"Ali, Ahmed; Kilany, Walid H; Zain El-Abideen, Mohamed A; Sayed, Magdy El; Elkady, Magdy",Poult Sci,,,,document_parses/pdf_json/58ed24ffb06bd86deebcf31ccf9bc5984b3d8703.json,document_parses/pmc_json/PMC7107197.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30085298/; https://doi.org/10.3382/ps/pey312,51929258.0,3
86324,86324,110589,q9tycobt,be900433da9f3130008dff4bd6e5b69d463cdbb3,Medline; PMC,Pneumonia and Streptococcus pneumoniae vaccine,10.1007/s12272-017-0933-y,PMC7090487,28735461.0,no-cc,pneumonia inflammatory disease lung responsible high morbidity mortality worldwide caused bacteria virus fungi microorganism streptococcus pneumoniae grampositive bacterium serotypes common causative agent moreover comorbid factor including heart failure renal disease pulmonary disease could increase risk pneumococcal pneumonia since advent pneumococcal vaccine incidence pneumonia decreased significantly however current vaccine confer limited protection serotypes included vaccine thus overcome limitation new type pneumococcal vaccine sought clinical trial review discus pneumonia summarize various type pneumococcal vaccine progress,2017-07-22,"Kim, Gyu-Lee; Seon, Seung-Han; Rhee, Dong-Kwon",Arch Pharm Res,,,,document_parses/pdf_json/be900433da9f3130008dff4bd6e5b69d463cdbb3.json,document_parses/pmc_json/PMC7090487.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28735461/; https://doi.org/10.1007/s12272-017-0933-y,37280580.0,3
86328,86328,110594,ah0dvnxv,14d3c2c1c254df91ee7c9a24625494d39774b8c4,Elsevier; Medline; PMC,Nasal delivery of Protollin-adjuvanted H5N1 vaccine induces enhanced systemic as well as mucosal immunity in mice,10.1016/j.vaccine.2017.05.004,PMC7115484,28499553.0,els-covid,sporadic yet frequent human infection avian hn influenza virus continue pose potential pandemic threat poor immunogenicity unadjuvanted hn vaccine warrant developing novel adjuvant formulation well alternate delivery system improve immunogenicity efficacy show protollin nasal adjuvant composed neisseria meningitides outer membrane protein noncovalently linked shigella flexneri lipopolysaccharide potent nasal adjuvant inactivated split virion hn clade aviet nam avn vaccine mouse model protollinadjuvanted vaccine elicited enhanced serum protective hemagglutination inhibition titer mucosal iga response hnspecific cellmediated immunity resulted complete protection lethal challenge homologous virus well heterologous clade virus aindonesia detailed analysis adaptive immunity revealed protollin increased frequency lymphoid well local tissueresident antibodysecreting cell local germinal center reaction b cell broadspectrum cd cell response finding suggest nasal delivery hn vaccine protollin adjuvant overcome poor immunogenicity hn vaccine induce cellular humoral immune response enhance protection challenge clade clade hn virus achieve significant antigen dosesparing,2017-06-05,"Cao, Weiping; Kim, Jin Hyang; Reber, Adrian J.; Hoelscher, Mary; Belser, Jessica A.; Lu, Xiuhua; Katz, Jacqueline M.; Gangappa, Shivaprakash; Plante, Martin; Burt, David S.; Sambhara, Suryaprakash",Vaccine,,,,document_parses/pdf_json/14d3c2c1c254df91ee7c9a24625494d39774b8c4.json,document_parses/pmc_json/PMC7115484.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28499553/; https://doi.org/10.1016/j.vaccine.2017.05.004; https://www.sciencedirect.com/science/article/pii/S0264410X1730600X; https://api.elsevier.com/content/article/pii/S0264410X1730600X,3793975.0,3
86372,86372,110650,jkbfu23m,08a1b1757d3252fc3037c8b72028095dae895b7a,Elsevier; Medline; PMC,"French Hajj pilgrims' experience with pneumococcal infection and vaccination: A knowledge, attitudes and practice (KAP) evaluation",10.1016/j.tmaid.2015.02.002,PMC7110623,25725996.0,els-covid,summary background transmission respiratory infection pose major public health challenge hajj umrah kingdom saudi arabia acquisition streptococcus pneumoniae hajj studied past recommendation vaccination pneumoniae made high risk group method purpose study ass knowledge attitude french hajj pilgrim towards pneumococcal vaccination adult pilgrim departing marseille france mecca hajj season administered facetoface questionnaire ascertain knowledge attitude towards pneumococcal vaccination departing hajj result total participant took part overall knowledge severity pneumonia existence vaccine low participant indication pneumococcal vaccination irrespective travel status advised vaccine general practitioner conclusion result reinforce need better dissemination information either pretravel counselling visit travel clinic receiving mandatory meningococcal vaccination hajj good opportunity update routine immunization including pneumococcal vaccination,2015-06-30,"Sridhar, Shruti; Belhouchat, Khadidja; Drali, Tassadit; Benkouiten, Samir; Parola, Philippe; Brouqui, Philippe; Gautret, Philippe",Travel Medicine and Infectious Disease,,,,document_parses/pdf_json/08a1b1757d3252fc3037c8b72028095dae895b7a.json,document_parses/pmc_json/PMC7110623.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25725996/; https://api.elsevier.com/content/article/pii/S1477893915000290; https://www.sciencedirect.com/science/article/pii/S1477893915000290; https://doi.org/10.1016/j.tmaid.2015.02.002,205422286.0,3
86415,86415,110700,c4s4tnwr,7b61662b3c79d469f73e49be8aadf1c075203be2; dbbf18835a5e074a299f4020fbf2218f144c3e17,Elsevier; PMC,Replicating and Non-replicating Viral Vectors for Vaccine Development,10.1016/j.copbio.2007.10.010,PMC2245896,18063357.0,green-oa,viral vector provide convenient mean deliver vaccine antigen select target cell tissue broad spectrum replicating nonreplicating vector available appropriate choice select application depend biology infectious agent targeted well factor whether vaccine intended prevent infection boost immunity already infected individual prior exposure target population vector safety number size gene insert needed several viral vector development hivaids vaccine reviewed vaccine strategy based initial priming replicating vector enlist innate immune system target mucosal inductive site prime cellular humoral systemic mucosal immune response proposed subsequently boosting replicating nonreplicating vector andor protein subunit could lead induction necessary level protective immunity,2007-12-01,"Robert-Guroff, Marjorie",Current Opinion in Biotechnology,,,,document_parses/pdf_json/7b61662b3c79d469f73e49be8aadf1c075203be2.json; document_parses/pdf_json/dbbf18835a5e074a299f4020fbf2218f144c3e17.json,document_parses/pmc_json/PMC2245896.xml.json,https://api.elsevier.com/content/article/pii/S0958166907001322; https://www.sciencedirect.com/science/article/pii/S0958166907001322; http://europepmc.org/articles/pmc2245896?pdf=render,2191753.0,3
86424,86424,110710,nomfciyu,a2de079e8ca0e2dabc1a08c859c682e1b305fae7,Medline; PMC,Middle East respiratory syndrome: pathogenesis and therapeutic developments,10.2217/fvl-2018-0201,PMC7080179,32201499.0,cc-by,first case middle east respiratory syndrome coronavirus merscov identified year spread rapidly increased highly pathogenic virus high mortality rate among one major public health concern saudi arabia remains affected region majority merscov case currently effective drug vaccine available prevention treatment large amount information available regarding virus structure route transmission pathophysiology therefore review summarizes current understanding merscovs pathogenesis treatment option recent scientific advancement vaccine therapeutic development major step taken mers prevention control,2019-04-18,"Choudhry, Hani; Bakhrebah, Muhammed A; Abdulaal, Wesam H; Zamzami, Mazin A; Baothman, Othman A; Hassan, Mohammed A; Zeyadi, Mustafa; Helmi, Nawal; Alzahrani, Faisal; Ali, Ashraf; Zakaria, Mohammad Khalid; Kamal, Mohammad Azhar; Warsi, Mohiuddin Khan; Ahmed, Firoz; Rasool, Mahmood; Jamal, Mohammad Sarwar",Future Virol,,,,document_parses/pdf_json/a2de079e8ca0e2dabc1a08c859c682e1b305fae7.json,document_parses/pmc_json/PMC7080179.xml.json,https://doi.org/10.2217/fvl-2018-0201; https://www.ncbi.nlm.nih.gov/pubmed/32201499/,146055700.0,3
86429,86429,110716,fb832hlp,17e72ee178b183ee417e8827681663db38f08d4c,Elsevier; PMC,Chapter 3 SARS coronavirus infections of the lower respiratory tract and their prevention,10.1016/b978-0-12-804543-5.00003-8,PMC7149758,,els-covid,severe acute respiratory syndrome sars coronavirus first identified caused epidemic fatal human pneumonia case rapidly spread multiple country epicenter hong kong outbreak eventually controlled quarantine measure caused many fatality original zoonotic source sars virus caused outbreak still unknown suspected bat attempt made develop prophylactic vaccine sars epidemic vaccine could tested human efficacy discussed chapter coronavirus vaccine present many challenge including low rapidly waning immunity fact coronavirus vaccine particularly formulated thbiased alum adjuvant exacerbate coronavirus infectionassociated eosinophilic lung immunopathology fortunately problem avoided formulation coronavirus vaccine thtype adjuvant enhance cell ifnγ response delta inulin tlr agonist hence appropriate adjuvant selection vitally important development safe effective coronavirus vaccine chapter describe current state development sars vaccine issue coronavirusassociated eosinophilic lung immunopathology adjuvant used reduce risk complication,2016-12-31,"Petrovsky, N.",The Microbiology of Respiratory System Infections,,,,document_parses/pdf_json/17e72ee178b183ee417e8827681663db38f08d4c.json,document_parses/pmc_json/PMC7149758.xml.json,https://api.elsevier.com/content/article/pii/B9780128045435000038; https://www.sciencedirect.com/science/article/pii/B9780128045435000038,88706968.0,3
86448,86448,110739,7y8rj9h5,00ff5fc677c5f3d5da1c30677d78070eea52be8b; 46b617f08b25e2a7da5c11a206f612fac568a6ce,Elsevier; Medline; PMC,Innovations in structure-based antigen design and immune monitoring for next generation vaccines,10.1016/j.coi.2020.03.013,PMC7174181,32387642.0,no-cc,recent explosion atomiclevel structure glycoprotein comprise surface antigen human enveloped virus rsv influenza hiv provide tremendous opportunity rational structurebased vaccine design several concept structurebased vaccine design put practice well along preclinical clinical implementation testing designed immunogen provide key insight ability induce desired immune response namely neutralizing antibody many immunogen human clinical trial represent first wave design likely require continued tweaking elaboration achieve ultimate goal enhanced breadth potency considerable effort invested germline targeting epitope focusing improved immune presentation multivalent nanoparticle incorporation review highlight recent advance area prepare next generation immunogen subsequent round iterative vaccine development,2020-04-22,"Ward, Andrew B; Wilson, Ian A",Curr Opin Immunol,,,,document_parses/pdf_json/00ff5fc677c5f3d5da1c30677d78070eea52be8b.json; document_parses/pdf_json/46b617f08b25e2a7da5c11a206f612fac568a6ce.json,document_parses/pmc_json/PMC7174181.xml.json,https://doi.org/10.1016/j.coi.2020.03.013; https://www.ncbi.nlm.nih.gov/pubmed/32387642/; https://www.sciencedirect.com/science/article/pii/S0952791520300364?v=s5; https://api.elsevier.com/content/article/pii/S0952791520300364,216044785.0,3
86548,86548,110856,6qctb9bk,7c10988e4f107c4fa8bc2ea3dae8df800de06ce9,Elsevier; Medline; PMC,Process Characterization and Biophysical Analysis for a Yeast-Expressed Phlebotomus papatasi Salivary Protein (PpSP15) as a Leishmania Vaccine Candidate,10.1016/j.xphs.2020.02.004,PMC7125844,32070701.0,els-covid,cutaneous leishmaniasis neglected tropical disease caused parasite leishmania transmitted sandfly become major health problem many tropical subtropical country especially region conflict political instability currently limited drug treatment available licensed vaccine thus need therapeutic intervention remains urgent previously dna vaccine encoding kda sandfly phlebotomus papatasi salivary protein ppsp recombinant nonpathogenic leishmania tarentolae secreting ppsp shown induce protective immunity leishmania major mouse demonstrating ppsp promising vaccine candidate study developed fermentation process yeast yield g ppspl scalable purification process consisting chromatographic purification step high binding capacity ppsp suggesting ppsp produced economically biophysicalbiochemical analysis purified ppsp indicated protein high purity conformationally stable ph importantly recombinant protein defined structure similar related pdsp phlebotomus duboscqi implying suitability yeast expression system producing correctly folded ppsp,2020-02-15,"Chen, Wen-Hsiang; Nyon, Mun Peak; Poongavanam, Mohan V.; Liu, Zhuyun; Biter, Amadeo B.; Kundu, Rakhi T.; Strych, Ulrich; Hotez, Peter J.; Bottazzi, Maria Elena",J Pharm Sci,,,,document_parses/pdf_json/7c10988e4f107c4fa8bc2ea3dae8df800de06ce9.json,document_parses/pmc_json/PMC7125844.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32070701/; https://api.elsevier.com/content/article/pii/S0022354920300770; https://www.sciencedirect.com/science/article/pii/S0022354920300770; https://doi.org/10.1016/j.xphs.2020.02.004,211191295.0,3
86566,86566,110880,0o05oskr,,Medline; WHO,"Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review).",10.3892/ijmm.2020.4596,,32377694.0,unk,current context pandemic triggered sarscov immunization population vaccination recognized public health priority case sars‑cov‑ genetic sequencing done quickly one month since worldwide research focused obtaining vaccine major economic impact new technological platform advanced genetic engineering procedure required obtain covid‑ vaccine difficult scientific challenge future vaccine obtained laboratory proof clinical safety efficacy biggest challenge manufacturing construction validation production platform capable making vaccine large scale,2020-05-06,"Calina, Daniela; Docea, Anca Oana; Petrakis, Demetrios; Egorov, Alex M; Ishmukhametov, Aydar A; Gabibov, Alexsandr G; Shtilman, Michael I; Kostoff, Ronald; Carvalho, Félix; Vinceti, Marco; Spandidos, Demetrios A; Tsatsakis, Aristidis",International journal of molecular medicine,,#197747,,,,https://www.ncbi.nlm.nih.gov/pubmed/32377694/; https://doi.org/10.3892/ijmm.2020.4596,218533239.0,3
86602,86602,110925,34dn7vxf,8dc402c1d9094683f65a385a921fc1c511e4fef1,Elsevier; Medline; PMC,MT-PCR panel detection of canine parvovirus (CPV-2): Vaccine and wild-type CPV-2 can be difficult to differentiate in canine diagnostic fecal samples,10.1016/j.mcp.2017.02.007,PMC7125668,28254505.0,no-cc,canine parvovirus cpv remains important cause devastating enteritis young dog successfully prevented live attenuated cpv vaccine given appropriate age absence maternal antibody interference rapid diagnosis parvoviral enteritis young dog essential ensuring suitable barrier nursing protocol within veterinary hospital current diagnostic trend use multiplexed pcr panel detect array pathogen commonly responsible diarrhea dog multiplexed pcr assay distinguish wild vaccine cpv highly sensitive detect even low level virus shedding caused cpv vaccine aim study identify cpv subtypes detected diagnostic specimen rule occult shedding cpv vaccine strain total sample tested positive cpv small animal fecal pathogen diagnostic multiplexed tandem pcr mtpcr panel – partially characterized vp gene cpv vaccine cpv strain wild type cpva subtypes vaccinelike cpvb subtypes detected high copy number indicative wildtype cpva presence presence vaccinelike cpvb variable copy number fecal sample yardstick approach copy number ctvalue discriminate vaccine strain wild type virus cpv case potentially misleading therefore discriminating vaccine strain wild type subtype cpv remains ambitious,2017-03-01,"Meggiolaro, Maira N.; Ly, Anna; Rysnik-Steck, Benjamin; Silva, Carolina; Zhang, Joshua; Higgins, Damien P.; Muscatello, Gary; Norris, Jacqueline M.; Krockenberger, Mark; Šlapeta, Jan",Mol Cell Probes,,,,document_parses/pdf_json/8dc402c1d9094683f65a385a921fc1c511e4fef1.json,document_parses/pmc_json/PMC7125668.xml.json,https://www.sciencedirect.com/science/article/pii/S0890850817300191; https://api.elsevier.com/content/article/pii/S0890850817300191; https://doi.org/10.1016/j.mcp.2017.02.007; https://www.ncbi.nlm.nih.gov/pubmed/28254505/,206839503.0,3
86603,86603,110926,71omypkg,64f48f817331fc485485f543207eee3d76f1b022; 0a003aa69f43cee4357f1e943df79a8b87c0a88e,Elsevier; PMC,Identification of Leukotoxin and other vaccine candidate proteins in a Mannheimia haemolytica commercial antigen,10.1016/j.heliyon.2016.e00158,PMC5035357,27699279.0,cc-by-nc-nd,bovine respiratory disease costly disease affect beef dairy cattle industry etiology multifactorial arising predisposing environmental stress condition well action several different respiratory pathogen situation hindered development effective control strategy although different type vaccine available many currently marketed vaccine based inactivated culture main viral bacterial agent involved pathology molecular composition commercial veterinary vaccine critical issue present work aim define proteomic level relevant valence line commercial respiratory vaccine widely used central south america since mannheimia haemolytica responsible disease associated morbidmortality focused main protein secreted pathogen particular leukotoxin main virulence factor western blot analysis mass spectrometry leukotoxin identified major component haemolytica culture supernatant also identified ten haemolytica protein including outer membrane protein periplasmic transmembrane solute transporter iron binding protein relevant achieve protective immunity pathogen work allowed detailed molecular characterization vaccine component providing evidence quality efficacy furthermore result contributed identification several protein interest subunit vaccine candidate,2016-09-19,"Tucci, Paula; Estevez, Verónica; Becco, Lorena; Cabrera-Cabrera, Florencia; Grotiuz, Germán; Reolon, Eduardo; Marín, Mónica",Heliyon,,,,document_parses/pdf_json/64f48f817331fc485485f543207eee3d76f1b022.json; document_parses/pdf_json/0a003aa69f43cee4357f1e943df79a8b87c0a88e.json,document_parses/pmc_json/PMC5035357.xml.json,https://api.elsevier.com/content/article/pii/S2405844016310933; https://www.sciencedirect.com/science/article/pii/S2405844016310933,15303860.0,3
86623,86623,110949,rrsgl377,20a583ee54e4ed8389e04fb951243da1a2286c54,Elsevier; Medline; PMC,Funding of drugs: do vaccines warrant a different approach?,10.1016/s1473-3099(08)70258-5,PMC7129011,18992409.0,els-covid,summary vaccine feature require special consideration assessing costeffectiveness feature related herd immunity qualityoflife loss young child parental care work loss time preference uncertainty eradication macroeconomics tiered pricing advisory committee public funding vaccine pharmaceutical general knowledgable special feature discus key issue difficulty decision making vaccine rotavirus human papillomavirus varicellazoster virus influenza virus streptococcus pneumoniae argue guideline economic evaluation reconsidered generally recommend modelling option assessment intervention infectious disease wider perspective account impact third party relevant wider scope cost healthcare system cost alone appropriate alternative discounting technique explore social time preference long period,2008-11-30,"Beutels, Philippe; Scuffham, Paul A; MacIntyre, C Raina",The Lancet Infectious Diseases,,,,document_parses/pdf_json/20a583ee54e4ed8389e04fb951243da1a2286c54.json,document_parses/pmc_json/PMC7129011.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/18992409/; https://api.elsevier.com/content/article/pii/S1473309908702585; https://doi.org/10.1016/s1473-3099(08)70258-5; https://www.sciencedirect.com/science/article/pii/S1473309908702585,23901443.0,3
86627,86627,110954,o2fkh02e,6c9c09c364d2fbd8d8f319029e60693060b6c756,Medline; PMC,A Caprine Herpesvirus 1 Vaccine Adjuvanted with MF59™ Protects against Vaginal Infection and Interferes with the Establishment of Latency in Goats,10.1371/journal.pone.0034913,PMC3325274,22511971.0,cc-by,immunogenicity efficacy betapropiolactoneinactivated caprine herpesvirus cphv vaccine adjuvanted mf™ tested goat following two subcutaneous immunization goat developed high titer cphvspecific serum vaginal igg high serum virus neutralization vn titer peripheral blood mononuclear cell pbmc stimulated vitro inactivated cphv produced high level soluble ifngamma exhibited high frequency ifngamma producing cell soluble il undetectable hand control goat receiving inactivated cphv vaccine without adjuvant produced low serum antibody response vaginal challenge virulent cphv performed vaccinated goat naïve goat ass efficacy two vaccine vaginal disease detected goat vaccinated inactivated cphv plus mf™ animal undetectable level infectious challenge virus vaginal wash goat vaccinated inactivated cphv absence adjuvant exhibited le severe disease compared naïve goat shed titer challenge virus similar naïve goat detection quantitation latent cphv dna sacral ganglion challenged goat revealed inactivated cphv plus mf™ vaccine able significantly reduce latent viral load compared either naïve goat goat vaccinated inactivated cphv absence adjuvant thus vaccine composed inactivated cphv plus mf™ adjuvant strongly immunogenic induced effective immunity vaginal cphv infection goat,2012-04-12,"Marinaro, Mariarosaria; Rezza, Giovanni; Del Giudice, Giuseppe; Colao, Valeriana; Tarsitano, Elvira; Camero, Michele; Losurdo, Michele; Buonavoglia, Canio; Tempesta, Maria",PLoS One,,,,document_parses/pdf_json/6c9c09c364d2fbd8d8f319029e60693060b6c756.json,document_parses/pmc_json/PMC3325274.xml.json,https://doi.org/10.1371/journal.pone.0034913; https://www.ncbi.nlm.nih.gov/pubmed/22511971/,7608278.0,3
86635,86635,110965,ujabzic4,590f9456e9205d551114d2aa7b44cdddd8277984,Elsevier; Medline; PMC,Comparison between dot-immunoblotting assay and clinical sign determination method for quantifying avian infectious bronchitis virus vaccine by titration in embryonated eggs,10.1016/j.jviromet.2016.01.008,PMC7119534,26802454.0,els-covid,sensitive specific method measuring vaccine titer infectious bronchitis virus ibv important commercial manufacturer improving vaccine quality typically ibv titrated embryonated chicken egg infectivity virus dilution determined assessing clinical sign embryo evidence viral propagation study used dotimmunoblotting assay dia measure titer ibv vaccine originated different pathogenic strain attenuation method embryonated egg compared assay currently used method clinical sign evaluation compare two method used realtime reverse transcriptionpcr lowest limit detection propagated ibv clinical sign infection dwarfism embryo quantified using embryo egg ee index dia showed higher sensitivity higher specificity clinical sign determination method dia particularly useful measuring titer ibv vaccine cause apparent stunting propagated embryonated chicken egg heatadapted vaccine strain result study indicate dia rapid sensitive reliable method determining ibv vaccine titer embryonated egg relatively low cost,2016-04-30,"Yuk, Seong-su; Kwon, Jung-Hoon; Noh, Jin-Yong; Hong, Woo-tack; Gwon, Gyeong-Bin; Jeong, Jei-Hyun; Jeong, Sol; Youn, Ha-Na; Heo, Yong-Hwan; Lee, Joong-Bok; Park, Seung-Yong; Choi, In-Soo; Song, Chang-Seon",Journal of Virological Methods,,,,document_parses/pdf_json/590f9456e9205d551114d2aa7b44cdddd8277984.json,document_parses/pmc_json/PMC7119534.xml.json,https://api.elsevier.com/content/article/pii/S0166093416000239; https://doi.org/10.1016/j.jviromet.2016.01.008; https://www.ncbi.nlm.nih.gov/pubmed/26802454/; https://www.sciencedirect.com/science/article/pii/S0166093416000239,12545428.0,3
86752,86752,111117,9o0xbmme,b6b06d62a3af9c36824d3c674f4d43d6d78d9073,Medline; PMC,Validation of γ-radiation and ultraviolet as a new inactivators for foot and mouth disease virus in comparison with the traditional methods,10.14202/vetworld.2015.1088-1098,PMC4774778,27047204.0,cc-by,aim present work deal different method foot mouth disease virus fmdv inactivation serotypes opan asia airan sat heat gamma radiation ultraviolet uv comparison traditional method effect antigenicity virus production inactivated vaccine material method fmdv type opan asia airan sat propagated baby hamster kidney bhk titrated divided five part first part inactivated heat second part inactivated gamma radiation third part inactivated uv light fourth part inactivated binary ethylamine last part inactivated combination binary ethylamine formaldehyde beifa evaluate method inactivation via inoculation bhk inoculation suckling baby mouse complement fixation test formulate vaccine using different method inactivation applying quality control test evaluate formulated vaccine result effect heat gamma radiation uv ability replication fmdv “ opan asia airan sat ” determined bhk cell line passage virus aliquot titer tcid strain exposed °c min similarly another aliquot strain contain mm depth exposed sample petridish exposed uv light nm wavelength one foot distance min different dos gamma radiation kgy applied dose rate gy strain repeated time dose fmdv opan asia airan sat inactivated exposed heat ≥°c min uv inactivation fmdv opan asia sat obtained within min min type airan ideal dose inactivation fmdv opan asia airan sat gamma radiation kgy respectively inactivation fmdv binary hr opan asia airan sat respectively inactivation beifa determined hr opanasia airan sat respectively antigenicity control virus inactivation changed inactivation case gamma radiation beifa slightly decrease case binary declined case heat uv inactivation respectively immune response induced inactivated fmd vaccine gamma radiation beifa lasted month postvaccination binary still month postvaccination heat uvinactivated vaccine effective conclusion gamma radiation could considered good new inactivator inducing result inactivated vaccine binary formaldehyde beifa,2015-09-19,"Mahdy, Safy El din; Hassanin, Amr Ismail; Gamal El-Din, Wael Mossad; Ibrahim, Ehab El-Sayed; Fakhry, Hiam Mohamed",Vet World,,,,document_parses/pdf_json/b6b06d62a3af9c36824d3c674f4d43d6d78d9073.json,document_parses/pmc_json/PMC4774778.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/27047204/; https://doi.org/10.14202/vetworld.2015.1088-1098,24201139.0,3
86767,86767,111134,00t28df6,dd8738920d2fdd2f606f249d47665b32dc33f1ea,Elsevier; Medline; PMC,Bovine Neonatal Pancytopenia: Is this alloimmune syndrome caused by vaccine-induced alloreactive antibodies?,10.1016/j.vaccine.2011.05.012,PMC7126856,21605614.0,els-covid,bovine neonatal pancytopenia bnp new emerging disease observed since germany neighbouring country syndrome affect newborn calf characterized pancytopenia severe bleeding high lethality far causative role infectious toxic agent ruled instead syndrome induced ingestion colostrum first milk supply calf maternal antibody analogy similar disease human therefore postulated bnp caused alloreactive maternal antibody striking association bnp previous vaccination respective dam particular vaccine bovine virus diarrhoea bvd association led suspension marketing authorisation vaccine european commission current study investigates role vaccine pathogenesis bnp flow cytometry able demonstrate serum bnp dam dam gave birth bnp calf harbour alloreactive antibody binding surface antigen bovine leukocyte significantly weaker alloreactivity observed serum nonbnp dam vaccinated vaccine delivered healthy calf binding seen nonbvdvaccinated control cow animal vaccinated inactivated bvd vaccine far associated bnp binding functionally relevant opsonization bovine leukocyte alloantibody led elevated cytophagocytosis bovine macrophage test whether vaccine induces alloreactive antibody two strategy employed guinea pig vaccinated panel commercially available bvdvaccines incriminated vaccine induced antibody binding surface antigen bovine leukocyte additionally two calf repeatedly vaccinated suspected vaccine development alloreactivity monitored dependence number booster immunization induction alloreactive antibody could observed finally affinity purification able directly demonstrate bnp associated alloantibody cross react bovine kidney cell line used vaccine production together provides strong evidence particular bvd vaccine potential induce bnp associated alloantibody,2011-07-18,"Bastian, Max; Holsteg, Mark; Hanke-Robinson, Heidrun; Duchow, Karin; Cussler, Klaus",Vaccine,,,,document_parses/pdf_json/dd8738920d2fdd2f606f249d47665b32dc33f1ea.json,document_parses/pmc_json/PMC7126856.xml.json,https://api.elsevier.com/content/article/pii/S0264410X11007213; https://www.ncbi.nlm.nih.gov/pubmed/21605614/; https://www.sciencedirect.com/science/article/pii/S0264410X11007213; https://doi.org/10.1016/j.vaccine.2011.05.012,24963801.0,3
86778,86778,111148,1ay8y7li,2f446f5b176d426f14b28a4898d83c43291ae82d,Medline; PMC,Vaccination with recombinant adenovirus expressing multi-stage antigens of Toxoplasma gondii by the mucosal route induces higher systemic cellular and local mucosal immune responses than with other vaccination routes,10.1051/parasite/2017013,PMC5399536,28367800.0,cc-by,toxoplasmosis caused toxoplasma gondii obligate intracellular protozoan cause congenital disease abortion human animal various vaccination strategy toxoplasmosis rodent model used past decade however effective vaccine remain challenge recombinant adenovirus vaccine expressing ubiquitinconjugated multistage antigen segment adumas derived different lifecycle stage gondii constructed previously compared immune response protection effect vaccination mouse adumas five vaccination route including intramuscular im intravenous iv subcutaneous sc intraoral io intranasal much higher level gondiispecific igg iga antibody detected serum intraoral intranasal vaccination group day compared control p percentage cd tcells mouse immunized intranasally intraorally larger mouse immunized intramuscularly p highest level il ifnγ detected group nasal immunization splenocyte proliferation activity significantly enhanced mouse immunized via oral nasal route furthermore higher survival rate lower cyst number observed intraoral intranasal group indicate adumas far effective protecting mouse gondii infection via mucosal route adumas could effective safe mucosal candidate vaccine protect animal human gondii infection,2017-04-03,"Wang, Ting; Yin, Huiquan; Li, Yan; Zhao, Lingxiao; Sun, Xiahui; Cong, Hua",Parasite,,,,document_parses/pdf_json/2f446f5b176d426f14b28a4898d83c43291ae82d.json,document_parses/pmc_json/PMC5399536.xml.json,https://doi.org/10.1051/parasite/2017013; https://www.ncbi.nlm.nih.gov/pubmed/28367800/,2461237.0,3
86881,86881,111279,lvf1z9i4,6223b84467e6bdc875ce49a403acf34055e4d141,Medline; PMC,Modified Vaccinia Virus Ankara (MVA) as Production Platform for Vaccines against Influenza and Other Viral Respiratory Diseases,10.3390/v6072735,PMC4113791,25036462.0,cc-by,respiratory virus infection caused influenza virus human parainfluenza virus hpiv respiratory syncytial virus rsv coronaviruses eminent threat public health currently licensed vaccine available hpiv rsv coronaviruses available seasonal influenza vaccine considerable limitation regard pandemic preparedness important procedure place respond rapidly produce tailor made vaccine respiratory virus short notice moreover especially influenza great need development universal vaccine induces broad protective immunity influenza virus various subtypes modified vaccinia virus ankara mva replicationdeficient viral vector hold great promise vaccine platform mva encode one foreign antigen thus function multivalent vaccine vector used biosafety level intrinsic adjuvant capacity induces humoral cellular immune response however practical regulatory issue need addressed order develop mvabased vaccine short notice verge pandemic review discus promising novel influenza virus vaccine target use mva vaccine development various respiratory virus,2014-07-17,"Altenburg, Arwen F.; Kreijtz, Joost H. C. M.; de Vries, Rory D.; Song, Fei; Fux, Robert; Rimmelzwaan, Guus F.; Sutter, Gerd; Volz, Asisa",Viruses,,,,document_parses/pdf_json/6223b84467e6bdc875ce49a403acf34055e4d141.json,document_parses/pmc_json/PMC4113791.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25036462/; https://doi.org/10.3390/v6072735,15683774.0,3
86950,86950,111365,spt0oea0,bf53ac5d3025a2378cd9827e43bd1bc366024f8e,Elsevier; Medline; PMC,Advancements in prophylactic and therapeutic nanovaccines,10.1016/j.actbio.2020.03.020,PMC7163188,32268235.0,no-cc,vaccine activate suitable immune response fight disease posse limitation compromised efficacy immunogenic response poor stability requirement adherence multiple dos ‘ nanovaccines ’ explored elicit strong immune response advantage nanosized range high antigen loading enhanced immunogenicity controlled antigen presentation retention lymph node promote patient compliance lower frequency dosing various type nanoparticles diverse pathogenic foreign antigen help overcome immunotolerance alleviate need booster dos required conventional vaccine nanovaccines potential induce cellmediated antibodymediated immunity render longlasting immunogenic memory property nanovaccines shown high potential prevention infectious disease acquired immunodeficiency syndrome aid malaria tuberculosis influenza cancer therapeutic potential also explored treatment cancer various kind nanomaterials used vaccine development effect immune system activation discussed special relevance implication various pathological condition statement significance interaction nanoparticles immune system opened multiple avenue combat variety infectious noninfectious pathological condition limitation conventional vaccine paved path nanomedicine associated benefit hope producing effective nanovaccines review highlight role different type nanovaccines role nanoparticles modulating immune response vaccine application nanovaccines infectious noninfectious disease like malaria tuberculosis aid influenza cancer discussed help reader develop understanding mechanism immune activation nanovaccines design appropriate strategy novel nanovaccines,2020-04-05,"Bhardwaj, Prateek; Bhatia, Eshant; Sharma, Shivam; Ahamad, Nadim; Banerjee, Rinti",Acta Biomater,,,,document_parses/pdf_json/bf53ac5d3025a2378cd9827e43bd1bc366024f8e.json,document_parses/pmc_json/PMC7163188.xml.json,https://api.elsevier.com/content/article/pii/S1742706120301616; https://doi.org/10.1016/j.actbio.2020.03.020; https://www.sciencedirect.com/science/article/pii/S1742706120301616; https://www.ncbi.nlm.nih.gov/pubmed/32268235/,214806955.0,3
86973,86973,111394,vmtfn78x,9517ad2f875609944240d775fa528dcc95d9e19d,Medline; PMC,"Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection",10.1128/mbio.00554-20,PMC7157776,32265331.0,cc-by,middle east respiratory syndrome coronavirus merscov cause severe fatal acute respiratory disease human remains endemic middle east since first identified currently approved vaccine therapy available merscov study evaluated parainfluenza virus pivbased vaccine expressing merscov envelope spike protein pivmerss human dpp knockin cbl congenic mouse model hdpp ki following singledose intranasal immunization pivmerss induced neutralizing antibody robust cell response hdpp ki mouse single intranasal administration pfu pivmerss provided complete protection lethal challenge mouseadapted merscov mersma improved virus clearance lung comparison singledose intramuscular immunization pfu uvinactivated mersma mixed imject alum provided protection immunized mouse intriguingly influx eosinophil observed lung mouse immunized inactivated merscov suggestive hypersensitivitytype response overall study indicated pivmerss promising effective vaccine candidate merscov infection,2020-04-07,"Li, Kun; Li, Zhuo; Wohlford-Lenane, Christine; Meyerholz, David K.; Channappanavar, Rudragouda; An, Dong; Perlman, Stanley; McCray, Paul B.; He, Biao",mBio,,,,document_parses/pdf_json/9517ad2f875609944240d775fa528dcc95d9e19d.json,document_parses/pmc_json/PMC7157776.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32265331/; https://doi.org/10.1128/mbio.00554-20,215407363.0,3
87001,87001,111426,6urjeil1,91388764b01e051b00401e4efb12caca8b979484,Elsevier; Medline; PMC,A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines,10.1016/j.vaccine.2008.03.076,PMC7115387,18468737.0,els-covid,influenza vaccine production traditionally relied use embryonated chicken egg virus isolation propagation recently cellculturederived manufacturing method introduced influenza vaccine production either conventional cell culture method risk incidental contamination adventitious agent thus riskassessment model developed qualitatively ass potential risk vaccine process contamination viral pathogen model take account basic growth characteristic virus ability grow different cell substrate resistance processing step vaccine manufacture riskassessment model applied various pathogen determine potential risk relevance different manufacturing scenario using different cell substrate virus propagation including madin–darby canine kidney mdck cell avian virus introduced via use embryonated egg virus isolation found present greatest risk irrespective substrate used influenza virus propagation use mdck cell propagate vaccine virus eggisolated influenza virus strain introduce new greater adventitious virus risk compared eggbased vaccine production indeed adventitious virus risk potentially reduced fewer virus able grow mdck cell,2008-06-19,"Gregersen, Jens-Peter",Vaccine,,,,document_parses/pdf_json/91388764b01e051b00401e4efb12caca8b979484.json,document_parses/pmc_json/PMC7115387.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X08004143; https://api.elsevier.com/content/article/pii/S0264410X08004143; https://doi.org/10.1016/j.vaccine.2008.03.076; https://www.ncbi.nlm.nih.gov/pubmed/18468737/,36338506.0,3
87069,87069,111510,07iwwsfz,7b96a98291fe154a1abf59e93e00f52ac9ac230b,Medline; PMC,Alphavirus-Based Vaccines,10.3390/v6062392,PMC4074933,24937089.0,cc-by,alphavirus vector demonstrated high level transient heterologous gene expression vitro vivo therefore posse attractive feature vaccine development commonly used delivery vector based three singlestranded encapsulated alphavirus namely semliki forest virus sindbis virus venezuelan equine encephalitis virus alphavirus vector applied replicationdeficient recombinant viral particle recently replicationproficient particle moreover vitro transcribed rna well layered dna vector applied immunization large number highly immunogenic viral structural protein expressed alphavirus vector elicited strong neutralizing antibody response multispecies animal model furthermore immunization study demonstrated robust protection challenge lethal dos virus rodent primate similarly vaccination alphavirus vector expressing tumor antigen resulted prophylactic protection challenge tumorinducing cancerous cell certain alphavirus chikungunya virus associated epidemic animal human attention also paid development vaccine alphavirus recent progress alphavirus vector development vaccine technology allowed conducting clinical trial human,2014-06-16,"Lundstrom, Kenneth",Viruses,,,,document_parses/pdf_json/7b96a98291fe154a1abf59e93e00f52ac9ac230b.json,document_parses/pmc_json/PMC4074933.xml.json,https://doi.org/10.3390/v6062392; https://www.ncbi.nlm.nih.gov/pubmed/24937089/,6652709.0,3
87073,87073,111515,7mu530yp,316c73a11f0ca258c4d40d515023a15704ef146d,Medline; PMC,Virus-Like Particles as an Instrument of Vaccine Production,10.1134/s0026893319030154,PMC7088979,32214478.0,no-cc,paper discus technique currently implemented vaccine production based viruslike particle vlps factor determine characteristic vlp monomer assembly provided detail analysis literature demonstrates development technique vlp production immobilization target antigen surface led development universal platform make possible virtually known antigen exposed particle surface highly concentrated form result focus attention shifted approach vlp production development precise interface organism ’ immune system peptide inducing strong immune response pathogen organism ’ pathological cell immunomespecified method vaccine design prospect immunoprophylaxis discussed certain example vaccine viral disease cancer considered,2019-06-17,"Syomin, B. V.; Ilyin, Y. V.",Mol Biol,,,,document_parses/pdf_json/316c73a11f0ca258c4d40d515023a15704ef146d.json,document_parses/pmc_json/PMC7088979.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32214478/; https://doi.org/10.1134/s0026893319030154,189927381.0,3
87089,87089,111535,hw8swbt5,22e2b04516fb11694e588124e849615311b27e5b,Medline; PMC; WHO,BCG-induced trained immunity: can it offer protection against COVID-19?,10.1038/s41577-020-0337-y,PMC7212510,32393823.0,no-cc,bacillus calmette–guérin bcg vaccination reported decrease susceptibility respiratory tract infection effect proposed mediated general longterm boosting innate immune mechanism also termed trained immunity discus nonspecific beneficial effect bcg viral infection whether vaccine may afford protection covid,2020-05-11,"O’Neill, Luke A. J.; Netea, Mihai G.",Nat Rev Immunol,,#232792,,document_parses/pdf_json/22e2b04516fb11694e588124e849615311b27e5b.json,document_parses/pmc_json/PMC7212510.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32393823/; https://doi.org/10.1038/s41577-020-0337-y,218573269.0,3
87142,87142,111599,0o3mryu1,c34f4c4955eecac198e21ad27a9f0031e6691686,Medline; PMC,DNA vaccines and their applications in veterinary practice: current perspectives,10.1007/s11259-008-9040-3,PMC7089108,18425596.0,no-cc,inoculation plasmid dna encoding immunogenic protein gene infectious agent stand novel approach developing new generation vaccine prevention infectious disease animal potential dna vaccine act presence maternal antibody stability cost effectiveness nonrequirement cold chain heightened prospect even though great stride made nucleic acid vaccination still many area need research wholesome practical implementation major area concern vaccine delivery designing suitable vector cytotoxic cell response also induction immune response dna vaccine inconclusive due lack knowledge regarding concentration protein expressed vivo alternative delivery system higher transfection efficiency use cytokine immunomodulators need explored recently effort made modulate prolong active life dendritic cell order make antigen presentation efficacious one combating disease like acquired immunodeficiency syndrome aid influenza malaria tuberculosis human foot mouth disease aujesky ’ disease swine fever rabies canine distemper brucellosis animal dna vaccine clinical trial underway review highlight salient feature dna vaccine measure enhance efficacy devise effective novel vaccination strategy animal disease,2008-04-19,"Dhama, K.; Mahendran, Mahesh; Gupta, P. K.; Rai, A.",Vet Res Commun,,,,document_parses/pdf_json/c34f4c4955eecac198e21ad27a9f0031e6691686.json,document_parses/pmc_json/PMC7089108.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/18425596/; https://doi.org/10.1007/s11259-008-9040-3,1872776.0,3
87193,87193,111667,s9k5ej8l,,Elsevier; PMC; WHO,Immunoinformatics-guided designing of epitope-based subunit vaccine against the SARS Coronavirus-2 (SARS-CoV-2),10.1016/j.imbio.2020.151955,PMC7211625,,no-cc,sars coronavirus sarscov pandemic become global issue raised concern scientific community design discover countermeasure deadly virus caused death numerous infected people upon infection spreading date effective vaccine available combat infection caused virus study conducted design possible epitopebased subunit vaccine sarscov virus using approach reverse vaccinology immunoinformatics upon continual computational experimentation three possible vaccine construct designed one vaccine construct selected best vaccine based molecular docking study supposed effectively act sarscov thereafter molecular dynamic simulation silico codon adaptation experiment carried order check biological stability find effective mass production strategy selected vaccine study contribute uphold present effort research secure definitive treatment lethal disease,2020-05-11,"Sarkar, Bishajit; Ullah, Md. Asad; Johora, Fatema Tuz; Taniya, Masuma Afrin; Araf, Yusha",Immunobiology,,#309013,,,document_parses/pmc_json/PMC7211625.xml.json,https://www.sciencedirect.com/science/article/pii/S0171298520301431?v=s5; https://api.elsevier.com/content/article/pii/S0171298520301431; https://doi.org/10.1016/j.imbio.2020.151955,218571707.0,3
87198,87198,111674,1nm1tbig,9adb9a55bc7756ff69f23f66796941b73f40f4a1,Medline; PMC,Modulation of HIV-1 immunity by adjuvants,10.1097/coh.0000000000000052,PMC3984023,24670321.0,cc-by-nc-nd,purpose review summarize role adjuvant eliciting desirable antibody response hiv particular emphasis historical context recent development recent finding increased understanding role pattern recognition receptor tolllike receptor recruiting directing immune system increased variety adjuvant formulation tested animal model human across vaccine platform adjuvant formulation shown enhance desirable immune response higher antibody titer increased functional activity although vaccine formulation yet succeeded eliciting broad neutralizing antibody hiv ability adjuvant direct immune response immunogen suggests critically important successful hiv vaccine summary parallel development adjuvant along better hiv immunogen needed successful aid vaccine additional comparative testing required determine optimal adjuvant immunogen regimen elicit antibody response capable blocking hiv transmission,2014-04-10,"Moody, M. Anthony",Curr Opin HIV AIDS,,,,document_parses/pdf_json/9adb9a55bc7756ff69f23f66796941b73f40f4a1.json,document_parses/pmc_json/PMC3984023.xml.json,https://doi.org/10.1097/coh.0000000000000052; https://www.ncbi.nlm.nih.gov/pubmed/24670321/,16008545.0,3
87259,87259,111751,cl6unuj8,93f3bab5586286cdbac230994a7492e8ad85eed0,Elsevier; PMC,Enhanced immune responses to viral epitopes by combining macrophage-inducible expression with multimeric display on a Salmonella vector,10.1016/s0264-410x(00)00541-7,PMC7126928,11282213.0,els-covid,study immunogenicity chimeric p fimbria salmonella vaccine strain improved optimizing fimbrial expression constitutive teta promoter vivo activated nirb pagc promoter evaluated use express two epitope transmissible gastroenteritis virus tgev spike protein carried fimbria displayed salmonella vaccine strain construct pagc promoter shown drive increased expression chimeric p fimbria macrophage well mgpoor medium mimicking major environmental signal found salmonellacontaining endocytic vacuole macrophage mouse immunized orally salmonella vaccine strain expressed chimeric fimbria pagc promoter elicited significantly higher mucosal systemic immune response p fimbria tgev epitope mouse immunized strain hosting teta nirb promoterdriven expression plasmid moreover salmonella vaccine strain harboring plasmid pagc promoter without additional teta promoter tandem elicited neutralizing antibody tgev indicated pagc promoter used successfully improve epitopedisplay chimeric fimbria salmonella vaccine strain induction desired immune response,2001-04-06,"Chen, Huaiqing; Schifferli, Dieter M.",Vaccine,,,,document_parses/pdf_json/93f3bab5586286cdbac230994a7492e8ad85eed0.json,document_parses/pmc_json/PMC7126928.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X00005417; https://api.elsevier.com/content/article/pii/S0264410X00005417,11790883.0,3
87275,87275,111769,038xu4hq,d98506ff441ed8f170bf41774e46aa7f0f385cbd,Elsevier; PMC,Obstacles and advances in SARS vaccine development,10.1016/j.vaccine.2005.08.102,PMC7115537,16191455.0,els-covid,emergence severe acute respiratory syndrome sars resulted pandemic spurred flurry interest development vaccine prevent treat potentially deadly viral infection researcher around world pooled scientific resource shared early data unprecedented manner light impending public health crisis still large gap knowledge pathogenesis virus significant advance made development animal model practicality use may hampered lack pathological similarity human disease described issue related progress vaccine development obstacle lie ahead researcher regulatory agency,2006-02-13,"Taylor, Deborah R.",Vaccine,,,,document_parses/pdf_json/d98506ff441ed8f170bf41774e46aa7f0f385cbd.json,document_parses/pmc_json/PMC7115537.xml.json,https://api.elsevier.com/content/article/pii/S0264410X05009163; https://www.sciencedirect.com/science/article/pii/S0264410X05009163,27344206.0,3
87276,87276,111770,33nmtbew,0d4a35d668a5b651ed34f13cc02525e6aee26634,Medline; PMC,"Lactic acid bacteria — promising vaccine vectors: possibilities, limitations, doubts",10.1111/jam.13446,PMC7166332,28295939.0,no-cc,gram‐positive nonpathogenic lactic acid bacteria lab considered promising candidate development novel safe production delivery system heterologous protein recombinant lab strain shown elicit specific systemic mucosal immune response selected antigen reason group bacteria considered potential replacement classical often pathogenic attenuated microbial carrier mucosal administration recombinant lab especially via best explored universal oral route offer many advantage comparison systemic inoculation attractive immunological practical point view research aimed designing efficient mucosally applied vaccine combination improved immunization efficiency monitoring vivo antigen production determination optimal dose vaccination strain selection characterization priority modern vaccinology paper summarizes organizes available knowledge application lab live oral vaccine vector constitutes valuable source general information researcher interested mucosal vaccine development constructing lab strain vaccine potential,2017-04-04,"Szatraj, K.; Szczepankowska, A.K.; Chmielewska‐Jeznach, M.",J Appl Microbiol,,,,document_parses/pdf_json/0d4a35d668a5b651ed34f13cc02525e6aee26634.json,document_parses/pmc_json/PMC7166332.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28295939/; https://doi.org/10.1111/jam.13446,206013203.0,3
87294,87294,111794,7vlxa0i7,5b2945b68e31dfe32f721791a52b95f09b6a31bc,Medline; PMC,Vaccines for emerging pathogens: prospects for licensure,10.1111/cei.13284,PMC6797873,30972733.0,cc-by-nc,globally number emerging pathogen licensed vaccine available human use although ongoing research development however given extensive increasing list emerging pathogen investment required bring vaccine clinical use task huge overlaid task risk anti‐microbial resistance amr acquisition micro‐organisms endow relatively harmless organism pathogenic potential furthermore climate change also introduces challenge causing insect vector environmental condition prevalent tropical region begin spread traditional area thus increasing risk migration zoonotic disease vaccination provides defence emerging pathogen however vaccine pathogen cause severe occasional disease outbreak endemic pocket suffered lack commercial incentive development clinical standard encompassing phase iii clinical trial efficacy alternative develop vaccine request u emergency use authorization eua equivalent status united state canada european union making use considerable number regulatory mechanism available prior licensing review cover status vaccine development emerging pathogen hurdle need overcome achieve eua equivalent regional national status consideration may impact vaccine development future comprehensive stockpile promising vaccine achieved,2019-04-11,"Williamson, E. D.; Westlake, G. E.",Clin Exp Immunol,,,,document_parses/pdf_json/5b2945b68e31dfe32f721791a52b95f09b6a31bc.json,document_parses/pmc_json/PMC6797873.xml.json,https://doi.org/10.1111/cei.13284; https://www.ncbi.nlm.nih.gov/pubmed/30972733/,108295250.0,3
87313,87313,111821,ykkowgl0,f493774ca28f4c97b2618e90a920bbce35dc407d,Medline; PMC,Could BCG be used to protect against COVID-19?,10.1038/s41585-020-0325-9,PMC7184546,32341531.0,no-cc,nearly year since first used human vaccine tuberculosis bacillus calmette–guérin bcg suggested possible agent prevent coronavirus disease covid number study underway investigate possibility — even prove effective — many question remain,2020-04-27,"Redelman-Sidi, Gil",Nat Rev Urol,,,,document_parses/pdf_json/f493774ca28f4c97b2618e90a920bbce35dc407d.json,document_parses/pmc_json/PMC7184546.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32341531/; https://doi.org/10.1038/s41585-020-0325-9,216146993.0,3
87322,87322,111836,eme869tk,09dd79dc2dd8710c23ef3c713c8245332385d681,Elsevier; Medline; PMC,Bovine coronaviruses from the respiratory tract: Antigenic and genetic diversity,10.1016/j.vaccine.2012.12.006,PMC7115418,23246548.0,els-covid,bocv isolated respiratory tract nasal swab broncho alveolar washing fluid sample evaluated genetic antigenic difference bocv respiratory tract healthy clinically ill cattle brd sign compared reference vaccine strain based spike protein coding sequence vnt using convalescent antiserum based study bocv isolates belong one two genomic clade clade differentiated antigenically respiratory isolates oklahoma study divided genetic difference three subclades b c reference enteric bocv strain vaccine strain clade currently available vaccine designed control enteric disease based virus one clade virus isolated respiratory tract study belong clade,2013-01-30,"Fulton, R. W.; Ridpath, J. F.; Burge, L. J.",Vaccine,,,,document_parses/pdf_json/09dd79dc2dd8710c23ef3c713c8245332385d681.json,document_parses/pmc_json/PMC7115418.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X12017586; https://www.ncbi.nlm.nih.gov/pubmed/23246548/; https://doi.org/10.1016/j.vaccine.2012.12.006; https://api.elsevier.com/content/article/pii/S0264410X12017586,205592017.0,3
87334,87334,111850,3qdjmb2j,d99acb4e99be7852aa61a688c9fbd38d44b5a252,Medline; PMC,Evaluation of Measles Vaccine Virus as a Vector to Deliver Respiratory Syncytial Virus Fusion Protein or Epstein-Barr Virus Glycoprotein gp350,10.2174/1874357901206010012,PMC3286841,22383906.0,cc-by-nc,live attenuated recombinant measles vaccine virus mv edmonstonzagreb ez strain evaluated viral vector express ectodomains fusion protein respiratory syncytial virus rsv f glycoprotein epsteinbarr virus ebv gp candidate vaccine prophylaxis rsv ebv glycoprotein gene inserted st rd position measles virus genome recombinant virus generated insertion foreign gene rd position minimal impact viral replication vitro rsv f ebv gp protein secreted infected cell cotton rat ezrsv f ezebv gp induced mv insertspecific antibody response addition vaccine also induced insert specific interferon gamma ifnγ secreting cell response ezrsv f protected cotton rat pulmonary replication rsv challenge infection rhesus macaque although ezrsv f ezebv gp induced mv specific neutralizing antibody response rsv f specific antibody response detected thus immunogenicity foreign antigen delivered measles vaccine virus dependent nature insert animal model used vaccine evaluation,2012-02-16,"Mok, Hoyin; Cheng, Xing; Xu, Qi; Zengel, James R; Parhy, Bandita; Zhao, Jackie; Wang, C. Kathy; Jin, Hong",Open Virol J,,,,document_parses/pdf_json/d99acb4e99be7852aa61a688c9fbd38d44b5a252.json,document_parses/pmc_json/PMC3286841.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/22383906/; https://doi.org/10.2174/1874357901206010012,17052880.0,3
87371,87371,111893,ixfrp8ub,43e165a782295ab6c95843d80d8406960bc1f2b5,Medline; PMC,Recent advancements in combination subunit vaccine development,10.1080/21645515.2016.1229719,PMC5287306,27649319.0,bronze-oa,viral structural protein share common nature homotypic interaction drive viral capsid formation natural process mimicked vitro recombinant technology generate various viruslike particle vlps small subviral particle exhibit similar structural antigenic property authentic virus therefore selfassembled polyvalent highly immunogenic vlps small subviral particle excellent subunit vaccine individual virus vlp vaccine hepatitis b virus human papilloma virus hepatitis e virus already market addition various antigen epitope fused vlps small subviral particle protein polymer forming chimeric mono bi trivalent vaccine owing easyproduction uninfectiousness polyvalence recombinant chimeric vaccine offer new approach development safe lowcost high efficient subunit vaccine single pathogen disease first vlpbased combination vaccine malaria approved human use many others development promising future summarized commentary,2017-01-02,"Tan, Ming; Jiang, Xi",Human Vaccines & Immunotherapeutics,,,,document_parses/pdf_json/43e165a782295ab6c95843d80d8406960bc1f2b5.json,document_parses/pmc_json/PMC5287306.xml.json,https://doi.org/10.1080/21645515.2016.1229719; https://www.ncbi.nlm.nih.gov/pubmed/27649319/; https://www.tandfonline.com/doi/pdf/10.1080/21645515.2016.1229719?needAccess=true,27032626.0,3
87504,87504,112062,6s7ubbxl,fd654cbce111313949e079eb36bb6a2320c4c56a,Elsevier; Medline; PMC,Process mapping of vaccines: Understanding the limitations in current response to emerging epidemic threats,10.1016/j.vaccine.2019.01.050,PMC7173310,30910404.0,no-cc,vaccination remains successful effective mechanism pathogen control however development deployment epidemic setting limited ebola outbreak west africa identified several bottleneck linked lack investment pathogen research infrastructure regulation shortly outbreak uk government established uk vaccine network ensure uk better prepared respond pathogen outbreak epidemic potential part work network commissioned creation vaccine development tool httpwwwvaccinedevelopmentorguk serve guide key stage vaccine development tool also set capture key ratelimiting bottleneck development vaccine emerging infectious disease corrective action could taken research funding infrastructure policy uk internationally main research bottleneck related understanding pathogen biology identification appropriate animal model investment manufacturing science especially process development infrastructure gap gmp manufacturing fillfinish also identified limitation gmo regulation regulatory ethical approval especially outbreak pathogen required new policy initiative uk vaccine network since begun work correct limitation series funding call development programme paper seek summarise vaccine development tool key finding,2019-04-17,"Drury, Georgina; Jolliffe, Siobhan; Mukhopadhyay, Tarit K.",Vaccine,,,,document_parses/pdf_json/fd654cbce111313949e079eb36bb6a2320c4c56a.json,document_parses/pmc_json/PMC7173310.xml.json,https://doi.org/10.1016/j.vaccine.2019.01.050; https://api.elsevier.com/content/article/pii/S0264410X19301264; https://www.sciencedirect.com/science/article/pii/S0264410X19301264; https://www.ncbi.nlm.nih.gov/pubmed/30910404/,85516184.0,3
87539,87539,112109,ywu6nn5j,a9e4babb9ee829a0dbb6118a4b47b0669b2c01b7,Elsevier; PMC,ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain) – a second-generation smallpox vaccine for biological defense,10.1016/j.ijid.2004.09.002,PMC7110559,15491873.0,els-covid,summary threat smallpox biological weapon spurred effort create stockpile vaccine emergency preparedness lieu preparing vaccine animal skin original method cloned vaccinia virus new york city board health strain dryvax® plaque purification amplified clone cell culture overarching goal produce modern vaccine equivalent currently licensed dryvax® preclinical clinical property could thus reliably protect human smallpox variety clone evaluated many unacceptably virulent animal model one clonal virus acam selected produced clinical grade mrc human diploid cell acam comparable dryvax® immunogenicity protective activity le neurovirulent mouse nonhuman primate meet requirement large quantity vaccine event september th acam master virus seed used prepare vaccine designated acam large scale vero cell serumfree condition genome acam acam identical nucleotide sequence vaccine comparable biological phenotype acam acam evaluated three phase clinical trial vaccine produced major cutaneous reaction evoked neutralizing antibody cellmediated immune response vast majority subject reactogenicity profile similar dryvax®,2004-10-31,"Monath, Thomas P.; Caldwell, Joseph R.; Mundt, Wolfgang; Fusco, Joan; Johnson, Casey S.; Buller, Mark; Liu, Jian; Gardner, Bridget; Downing, Greg; Blum, Paul S.; Kemp, Tracy; Nichols, Richard; Weltzin, Richard",International Journal of Infectious Diseases,,,,document_parses/pdf_json/a9e4babb9ee829a0dbb6118a4b47b0669b2c01b7.json,document_parses/pmc_json/PMC7110559.xml.json,https://api.elsevier.com/content/article/pii/S1201971204001341; https://www.sciencedirect.com/science/article/pii/S1201971204001341,32141063.0,3
87558,87558,112129,7q2wkwrf,05a12a1fb4a86a4158ad027b911092cfc25bc40b,Medline; PMC,Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune Potentiation,10.7150/ntno.19796,PMC5646730,29071191.0,cc-by-nc,synthetic nanoparticles play increasingly significant role vaccine design development many nanoparticle vaccine show improved safety efficacy conventional formulation nanoformulations structurally similar virus nanoscale pathogenic organism served key selective pressure driving evolution immune system result mechanism behind benefit nanoparticle vaccine often find analogue interaction dynamic immune system virus review cover advance vaccine nanotechnology perspective advantage virus mimicry towards immune potentiation provides overview different type nanomaterials utilized nanoparticle vaccine development including functionalization strategy bestow nanoparticles viruslike feature understanding human immunity vaccine mechanism continue evolve recognizing fundamental semblance synthetic nanoparticles virus may offer explanation superiority nanoparticle vaccine conventional vaccine may spur new design rationale future vaccine research nanoformulations poised provide solution towards pressing emerging human disease,2017-06-09,"Chattopadhyay, Saborni; Chen, Jui-Yi; Chen, Hui-Wen; Hu, Che-Ming Jack",Nanotheranostics,,,,document_parses/pdf_json/05a12a1fb4a86a4158ad027b911092cfc25bc40b.json,document_parses/pmc_json/PMC5646730.xml.json,https://doi.org/10.7150/ntno.19796; https://www.ncbi.nlm.nih.gov/pubmed/29071191/,32100534.0,3
87572,87572,112146,66nxk4e8,fb4cdfdd952f7140a732d294b97f611c456aa6f0,Medline; PMC,Vectored immunoprophylaxis: an emerging adjunct to traditional vaccination,10.1186/s40794-017-0046-0,PMC5531025,28883973.0,cc-by,successful development effective vaccine elusive many world ’ important infectious disease additionally much population aged immunocompromised unable mount effective immunologic response existing vaccine vectored immunoprophylaxis vip novel approach designed address challenge rather utilizing antigen trigger response host ’ immune system normally done traditional vaccine vip genetically engineer production tailored antibody nonhematopoietic cell bypassing humoral immune system direct administration gene encoding neutralizing antibody proven effective preventing treating several infectious disease animal model significant amount work focused hiv including ongoing clinical trial approach also shown effective malaria dengue hepatitis c influenza addition presenting potentially efficient approach solving longstanding vaccine challenge approach may best method vaccinate immunocompromised individual many issue still need addressed including tissue make suitable platform vector efficient transducing platform tissue used secrete antibody longterm effect treatment provide brief overview approach potential application treating world ’ intractable infectious disease,2017-02-10,"Sanders, John W.; Ponzio, Todd A.",Trop Dis Travel Med Vaccines,,,,document_parses/pdf_json/fb4cdfdd952f7140a732d294b97f611c456aa6f0.json,document_parses/pmc_json/PMC5531025.xml.json,https://doi.org/10.1186/s40794-017-0046-0; https://www.ncbi.nlm.nih.gov/pubmed/28883973/,25746980.0,3
87574,87574,112148,g9ev443o,6f6a250f3aff31bb8315d124050ec9d064d2cd50,Medline; PMC,Neonatal vaccine effectiveness and the role of adjuvants,10.1080/1744666x.2019.1642748,PMC6678067,31293189.0,no-cc,introduction neonate le responsive vaccine adult making harder protect newborn infection neonatal difference antigenpresenting cell b cell function likely contribute key question whether novel adjuvant might able make neonatal vaccine effective area covered review address issue improve neonatal vaccine defined vaccine given first week life human infant first week life mouse search performed using keywords including ‘ neonatal immunity ’ ‘ neonatal immunisation ’ ‘ vaccine ’ ‘ adjuvant ’ pubmed article published expert opinion sugarlike structure recently shown prime infant adaptive immune system respond vaccine potentially effective traditional adjuvant sugarbased compound beneficial adjuvant effect neonatal vaccine model include delta inulin advax curdlan trehalose ʹdibehenate compound make interesting neonatal adjuvant candidate either used alone combination traditional innate immune adjuvant,2019-07-25,"Sakala, Isaac G.; Eichinger, Katherine Marie; Petrovsky, Nikolai",Expert Rev Clin Immunol,,,,document_parses/pdf_json/6f6a250f3aff31bb8315d124050ec9d064d2cd50.json,document_parses/pmc_json/PMC6678067.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31293189/; https://doi.org/10.1080/1744666x.2019.1642748,195878786.0,3
87599,87599,112178,3g4exugc,79403f1e0493faea3d46af2cc97e19727b030bc6,Elsevier; Medline; PMC,Frequency of PRRS live vaccine virus (European and North American genotype) in vaccinated and non-vaccinated pigs submitted for respiratory tract diagnostics in North-Western Germany,10.1016/j.prevetmed.2009.07.010,PMC7114236,19700211.0,els-covid,frequency prrsv corresponding live vaccine wildtype determined pig northwestern germany submitted postmortem examination overall sample positive eu wildtype virus eu genotype vaccine virus detected na genotype vaccine virus sample detection eu vaccine significantly higher pig vaccinated corresponding vaccine pig vaccinated na genotype significantly higher detection chance corresponding vaccine virus compared nonvaccinated animal animal however na vaccine also frequently detected nonvaccinated pig concluding dynamic na genotype vaccine eu wildtype virus corresponds study prrsv spread endemically infected herd potential spontaneous spread na genotype vaccine considered planning eradication program,2009-11-01,"grosse Beilage, Elisabeth; Nathues, Heiko; Meemken, Diana; Harder, Timm C.; Doherr, Marcus G.; Grotha, Inga; Greiser-Wilke, Irene",Preventive Veterinary Medicine,,,,document_parses/pdf_json/79403f1e0493faea3d46af2cc97e19727b030bc6.json,document_parses/pmc_json/PMC7114236.xml.json,https://www.sciencedirect.com/science/article/pii/S0167587709002086; https://www.ncbi.nlm.nih.gov/pubmed/19700211/; https://doi.org/10.1016/j.prevetmed.2009.07.010; https://api.elsevier.com/content/article/pii/S0167587709002086,25841938.0,3
87617,87617,112205,npzri0rh,7fe6f937e90be12b43939d53e5beb7daba32d6b0,Medline; PMC,COVID-19 vaccine design: the Janus face of immune enhancement,10.1038/s41577-020-0323-4,PMC7187801,32346094.0,no-cc,previous work severe acute respiratory syndrome coronavirus sarscov vaccine identified cellular immunopathology antibodydependent enhancement potential safety issue discus implication finding covid vaccine development approach optimizing safety efficacy,2020-04-28,"Hotez, Peter J.; Corry, David B.; Bottazzi, Maria Elena",Nat Rev Immunol,,,,document_parses/pdf_json/7fe6f937e90be12b43939d53e5beb7daba32d6b0.json,document_parses/pmc_json/PMC7187801.xml.json,https://doi.org/10.1038/s41577-020-0323-4; https://www.ncbi.nlm.nih.gov/pubmed/32346094/,216597527.0,3
87645,87645,112236,uxtkks8d,390b4e40d86e389acf5cb47705c7c02eca264c8a,Medline; PMC,Nanoparticle-Based Vaccines Against Respiratory Viruses,10.3389/fimmu.2019.00022,PMC6353795,30733717.0,cc-by,respiratory mucosa primary portal entry numerous virus respiratory syncytial virus influenza virus parainfluenza virus pathogen initially infect upper respiratory tract reach lower respiratory tract leading disease vaccination affordable way control pathogenicity virus constitutes strategy choice fight infection including leading pulmonary disease conventional vaccine based liveattenuated pathogen present risk reversion pathogenic virulence inactivated pathogen vaccine often lead weak immune response subunit vaccine developed overcome issue however vaccine may suffer limited immunogenicity case protection induced partial new generation vaccine based nanoparticles shown great potential address limitation conventional subunit vaccine due recent advance chemical biological engineering allow design nanoparticles precise control size shape functionality surface property leading enhanced antigen presentation strong immunogenicity short review provides overview advantage associated use nanoparticles vaccine delivery platform immunize respiratory virus highlight relevant example demonstrating potential safe effective affordable vaccine,2019-01-24,"Al-Halifa, Soultan; Gauthier, Laurie; Arpin, Dominic; Bourgault, Steve; Archambault, Denis",Front Immunol,,,,document_parses/pdf_json/390b4e40d86e389acf5cb47705c7c02eca264c8a.json,document_parses/pmc_json/PMC6353795.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30733717/; https://doi.org/10.3389/fimmu.2019.00022,59159388.0,3
87712,87712,112332,3azvj66s,57daf0775c2c532e619741179b006a0471f30278,Elsevier; Medline; PMC; WHO,Rational Vaccine Design in the Time of COVID-19,10.1016/j.chom.2020.04.022,PMC7219357,32407707.0,no-cc,scientist consider sarscov vaccine design discus problem may encountered tackle term “ rational vaccine design ” discus approach pancoronavirus vaccine draw experience recent research several virus including hiv influenza well coronaviruses,2020-05-13,"Burton, Dennis R.; Walker, Laura M.",Cell Host Microbe,,#245700,,document_parses/pdf_json/57daf0775c2c532e619741179b006a0471f30278.json,document_parses/pmc_json/PMC7219357.xml.json,https://www.sciencedirect.com/science/article/pii/S1931312820302493; https://doi.org/10.1016/j.chom.2020.04.022; https://api.elsevier.com/content/article/pii/S1931312820302493; https://www.ncbi.nlm.nih.gov/pubmed/32407707/,218615110.0,3
87721,87721,112343,6q92742u,76f4818047800fedb8deb664b66ff5c50fa76568,Medline; PMC,Evaluating the promise of recombinant transmissible vaccines,10.1016/j.vaccine.2017.12.037,PMC5811206,29279283.0,cc-by-nc-nd,transmissible vaccine potential revolutionize infectious disease control reducing vaccination effort required protect population disease recent effort develop transmissible vaccine focus recombinant transmissible vaccine design rtvs pose reduced risk intrahost evolution cause vaccine revert vector form however shared antigenicity vaccine vector may confer vaccineimmunity host infected vector thwarting ability vaccine spread population build mathematical model test whether rtv facilitate disease management instance reversion likely introduce vector population vector organism already established host population vector vaccine share perfect crossimmunity result show rtv autonomously eradicate pathogen protect population pathogen invasion crossimmunity vaccine vector absent crossimmunity vaccine vector exists however result show rtv substantially reduce vaccination effort necessary control eradicate pathogen continuously augmented direct manual vaccination result demonstrate estimating extent crossimmunity vector vaccine critical step rtv design herpesvirus vector showing facile reinfection weak crossimmunity promising,2017-12-24,"Basinski, Andrew J.; Varrelman, Tanner J.; Smithson, Mark W.; May, Ryan H.; Remien, Christopher H.; Nuismer, Scott L.",Vaccine,,,,document_parses/pdf_json/76f4818047800fedb8deb664b66ff5c50fa76568.json,document_parses/pmc_json/PMC5811206.xml.json,https://doi.org/10.1016/j.vaccine.2017.12.037; https://www.ncbi.nlm.nih.gov/pubmed/29279283/,3283574.0,3
87743,87743,112367,sjcanw19,0a00a6df208e068e7aa369fb94641434ea0e6070,Medline; PMC,Novel genome polymorphisms in BCG vaccine strains and impact on efficacy,10.1186/1471-2164-9-413,PMC2553098,18793412.0,cc-by,bacille calmetteguérin bcg attenuated strain mycobacterium bovis currently used vaccine tuberculosis global distribution propagation bcg contributed vitro evolution vaccine strain thought partially account different outcome bcg vaccine trial previous effort several molecular technique effectively identified large sequence polymorphism among bcg daughter strain lacked resolution identify smaller change study used nimblegen tiling array whole genome comparison bcg strain using approach tandem dna resequencing identified six novel large sequence polymorphism including four deletion two duplication specific bcg strain moreover uncovered various polymorphism phopphor locus importantly polymorphism affect gene encoding established virulence factor including cell wall complex lipid esx secretion system phopphor twocomponent system study demonstrates major virulence factor different among bcg strain provide molecular mechanism important vaccine phenotype including adverse effect profile tuberculin reactivity protective efficacy finding important implication development new generation vaccine,2008-09-15,"Leung, Andrea S; Tran, Vanessa; Wu, Zuowei; Yu, Xuping; Alexander, David C; Gao, George Fu; Zhu, Baoli; Liu, Jun",BMC Genomics,,,,document_parses/pdf_json/0a00a6df208e068e7aa369fb94641434ea0e6070.json,document_parses/pmc_json/PMC2553098.xml.json,https://doi.org/10.1186/1471-2164-9-413; https://www.ncbi.nlm.nih.gov/pubmed/18793412/,779621.0,3
87750,87750,112375,8oc5rgj0,ec2c2beee69ee9964aa777293d0d4f2a22db8360,Medline; PMC,Salmonella Typhi: from a Human Pathogen to a Vaccine Vector,10.1038/cmi.2008.11,PMC4651240,18445338.0,no-cc,salmonella typhi important intracellular pathogen among closelyrelated salmonella serovars bacteria recognized typhi one pathogenic exclusively human cause typhoid enteric fever pathogen around many year many study done effort combat molecular biologic feature typhi host factor immune response involved salmonella invasion extensively study vaccine developed notably vi polysaccharide tya however result show still long way go also shown multidrug resistance occurred available antibiotic study shown salmonella used vaccine vector carrying antigen pathogen promising immune system elicited response salmonella bacteria antigen pathogen question review aim highlight milestone attained fight disease time typhi seen pathogen causing typhoid fever use salmonella vaccine vector,2008-04-26,"Zhang, Xiao-Lian; Jeza, Victor Tunje; Pan, Qin",Cell Mol Immunol,,,,document_parses/pdf_json/ec2c2beee69ee9964aa777293d0d4f2a22db8360.json,,https://www.ncbi.nlm.nih.gov/pubmed/18445338/; https://doi.org/10.1038/cmi.2008.11,205125051.0,3
87779,87779,112412,z14zgpdt,2ea9c457b5f33101f1f6c72213806ab1e790e8cb,Elsevier; PMC,Intragastric administration of Lactobacillus casei expressing transmissible gastroentritis coronavirus spike glycoprotein induced specific antibody production,10.1016/j.vaccine.2004.09.015,PMC7115493,15661381.0,els-covid,lactobacillus casei strain shirota selected bacterial carrier development live mucosal vaccine coronavirus kda fragment transmissible gastroenteritis coronavirus tgev spike glycoprotein used model coronavirus antigen glycoprotein cloned lactobacilluse coli shuttle vector plp expression secretion glycoprotein recombinant lactobacillus detected via immunoblotting oral immunization balbc mouse recombinant lcs constitutively express kda fragment glycoprotein induced local mucosal systemic immune response tgev maximum titer igg ±ngml serum iga ±ngml intestinal water attained day post oral inturbation induced antibody demonstrated neutralizing effect tgev infection,2005-02-03,"Ho, P. S.; Kwang, J.; Lee, Y. K.",Vaccine,,,,document_parses/pdf_json/2ea9c457b5f33101f1f6c72213806ab1e790e8cb.json,document_parses/pmc_json/PMC7115493.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X04006942; https://api.elsevier.com/content/article/pii/S0264410X04006942,1721212.0,3
87856,87856,112502,w9rqnz9h,35e9c75424f8bfe88bfeadf917721a4c79728476,Elsevier; PMC,Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine,10.1016/j.virol.2005.06.016,PMC7111745,16043204.0,els-covid,although recent sars coronavirus sarscov appeared contained possibility reemergence sarscov remains due threat reemergence overall fatality rate ∼ rapid dispersion virus via international travel viable vaccine candidate providing protection sars clearly needed developed attenuated vsv recombinant vsvs expressing sars coronavirus sarscov spike protein cell infected recombinant protein synthesized glycosylated approximately asn residue transported via golgi cell surface mouse vaccinated vsvs developed sarsneutralizing antibody able control challenge sarscov performed month month single vaccination also demonstrated passive antibody transfer antibody response induced vaccine sufficient controlling sarscov infection vsvvectored sars vaccine could significant advantage sars vaccine candidate described date,2005-09-30,"Kapadia, Sagar U.; Rose, John K.; Lamirande, Elaine; Vogel, Leatrice; Subbarao, Kanta; Roberts, Anjeanette",Virology,,,,document_parses/pdf_json/35e9c75424f8bfe88bfeadf917721a4c79728476.json,document_parses/pmc_json/PMC7111745.xml.json,https://www.sciencedirect.com/science/article/pii/S0042682205003569; https://api.elsevier.com/content/article/pii/S0042682205003569,21304314.0,3
87881,87881,112530,gug45wqz,a5fe908c8d8ccf3fdd985e33062eef817caeb98f,Medline; PMC,Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule,10.1038/nrmicro2129,PMC7097244,19369954.0,no-cc,ebola virus infection highly lethal disease effective therapeutic preventive treatment several vaccine provided immune protection laboratory animal outbreak occur unpredictably sporadically vaccine efficacy proven human trial required traditional regulatory approval food drug administration introduced animal rule allow laboratory animal data used show efficacy human trial logistically feasible review describe immune correlate vaccine protection ebola virus animal research provides basis bridging gap basic research human vaccine response support licensing vaccine animal rule,2009,"Sullivan, Nancy J.; Martin, Julie E.; Graham, Barney S.; Nabel, Gary J.",Nat Rev Microbiol,,,,document_parses/pdf_json/a5fe908c8d8ccf3fdd985e33062eef817caeb98f.json,document_parses/pmc_json/PMC7097244.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19369954/; https://doi.org/10.1038/nrmicro2129,10798129.0,3
87888,87888,112539,xu9wvtys,ec4b8e0c2f24ac6ca2df1566fc4672d2a57cf2d0,Elsevier; Medline; PMC,An opportunity to incentivize innovation to increase vaccine safety in the United States by improving vaccine delivery using vaccine patches,10.1016/j.vaccine.2020.04.044,PMC7172634,32345447.0,no-cc,vaccine represent costeffective safe intervention provide substantial health economic benefit individual population u vaccine enterprise support aspect immunization continues encourage innovation despite limited historical recommendation create fund support investment vaccine safety recent legislation support innovation new vaccine st century cure act public law date u lack financial incentive fund innovation vaccine delivery technology building separate review u vaccine injury compensation program vicp state development vaccine patch innovative vaccine delivery platform suggest opportunity allocate vicp trust fund resource prevent future vicp claim creating new incentive fund support translational study improving vaccine delivery technology identify shoulder injury related vaccine administration sirva test case,2020-04-21,"Thompson, Kimberly M.; Orenstein, Walter A.; Hinman, Alan R.",Vaccine,,,,document_parses/pdf_json/ec4b8e0c2f24ac6ca2df1566fc4672d2a57cf2d0.json,document_parses/pmc_json/PMC7172634.xml.json,https://doi.org/10.1016/j.vaccine.2020.04.044; https://api.elsevier.com/content/article/pii/S0264410X20305387; https://www.ncbi.nlm.nih.gov/pubmed/32345447/; https://www.sciencedirect.com/science/article/pii/S0264410X20305387?v=s5,216044833.0,3
87914,87914,112568,hs6t53wn,cdf724f87f8634e6a5dbaa48a294eddaa45a9989,Elsevier; Medline; PMC,Two highly similar LAEDDTNAQKT and LTDKIGTEI epitopes in G glycoprotein may be useful for effective epitope based vaccine design against pathogenic Henipavirus,10.1016/j.compbiolchem.2016.03.001,PMC7172312,26970211.0,no-cc,nipah virus hendra virus two member genus henipavirus newly emerging zoonotic pathogen cause acute respiratory illness severe encephalitis human lack effective antiviral therapy endorses urgency development vaccine deadly virus study employed various computational approach identify epitope potential vaccine development analyzing immune parameter conserved sequence g glycoprotein using various database bioinformatics tool identified two potential epitope may used peptide vaccine using different b cell epitope prediction server four highly similar b cell epitope identified immunoinformatics analysis revealed laeddtnaqkt highly flexible accessible bcell epitope antibody highly similar putative ctl epitope analyzed binding hlac molecule docking simulation assay revealed ltdkigtei significantly lower binding energy bolstered potential epitopebased vaccine design finally cytotoxicity analysis also justified potential promising epitopebased vaccine candidate sum computational analysis indicates either laeddtnaqkt ltdkigtei epitope hold promise development universal vaccine kind pathogenic henipavirus vivo vitro study necessary validate obtained finding,2016-03-03,"Parvege, Md. Masud; Rahman, Monzilur; Nibir, Yead Morshed; Hossain, Mohammad Shahnoor",Comput Biol Chem,,,,document_parses/pdf_json/cdf724f87f8634e6a5dbaa48a294eddaa45a9989.json,document_parses/pmc_json/PMC7172312.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26970211/; https://doi.org/10.1016/j.compbiolchem.2016.03.001; https://api.elsevier.com/content/article/pii/S1476927116300986; https://www.sciencedirect.com/science/article/pii/S1476927116300986,35452019.0,3
87935,87935,112592,k1dqe4lk,0688fc392b60f5058c8dc02c9de55caaad8073f3,Medline; PMC,Vaccines as alternatives to antibiotics for food producing animals. Part 2: new approaches and potential solutions,10.1186/s13567-018-0561-7,PMC6066917,30060759.0,cc-by,vaccine alternative product central future success animal agriculture help minimize need antibiotic preventing controlling infectious disease animal population ass scientific advancement related alternative antibiotic provide actionable strategy support development united state department agriculture support world organisation animal health organized second international symposium alternative antibiotic focused six key area vaccine microbialderived product nonnutritive phytochemical immunerelated product chemical enzyme innovative drug regulatory pathway enable development licensure alternative antibiotic article second part twopart series highlight new approach potential solution development vaccine alternative antibiotic food producing animal opportunity challenge need development vaccine discussed first part series discussed part manuscript many current vaccine fall short ideal vaccine one respect promising breakthrough overcome limitation include new biotechnology technique new oral vaccine approach novel adjuvant new delivery strategy based bacterial spore live recombinant vector also include new vaccination strategy inovo strategy simultaneously protect multiple pathogen however translating research commercial vaccine effectively reduce need antibiotic require close collaboration among stakeholder instance public–private partnership targeted research development investment concerted effort affected needed realize potential vaccine improve animal health safeguard agricultural productivity reduce antibiotic consumption resulting resistance risk,2018-07-31,"Hoelzer, Karin; Bielke, Lisa; Blake, Damer P.; Cox, Eric; Cutting, Simon M.; Devriendt, Bert; Erlacher-Vindel, Elisabeth; Goossens, Evy; Karaca, Kemal; Lemiere, Stephane; Metzner, Martin; Raicek, Margot; Collell Suriñach, Miquel; Wong, Nora M.; Gay, Cyril; Van Immerseel, Filip",Vet Res,,,,document_parses/pdf_json/0688fc392b60f5058c8dc02c9de55caaad8073f3.json,document_parses/pmc_json/PMC6066917.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30060759/; https://doi.org/10.1186/s13567-018-0561-7,51873651.0,3
87948,87948,112607,szpktvq4,627b268e38efc54e037c978d2b578632b875f44f,Elsevier; Medline; PMC,Immunogenicity of next-generation HPV vaccines in non-human primates: Measles-vectored HPV vaccine versus Pichia pastoris recombinant protein vaccine,10.1016/j.vaccine.2016.07.051,PMC7126718,27523740.0,els-covid,human papillomavirus hpv infection common sexually transmitted disease worldwide hpvs oncogenic small doublestranded dna virus primary causal agent cervical cancer type cancer including anus oropharynx vagina vulva penis prophylactic vaccination hpv attractive strategy preventing cervical cancer type cancer however safe effective vaccine hpv infection current firstgeneration commercial hpv vaccine expensive produce deliver goal study develop alternate potent hpv recombinant lbased vaccine producing hpv viruslike particle vaccine currently used worldwide live attenuated measles virus mv vaccine wellestablished safety efficacy record recombinant mv rmv produced reverse genetics may useful generating candidate hpv vaccine meet need developing world studied nonhuman primate rmvvectored hpv vaccine parallel classical alum adjuvant recombinant hpvl l protein vaccine produced pichia pastoris combined primeboost approach using vaccine evaluated well immune interference due preexisting immunity mv humoral immune response induced mv pichiaexpressed vaccine combination priming boosting approach found elicit hpvl l specific total igg neutralizing antibody titre preexisting antibody measles prevent immune response hpvl l,2016-09-07,"Gupta, Gaurav; Giannino, Viviana; Rishi, Narayan; Glueck, Reinhard",Vaccine,,,,document_parses/pdf_json/627b268e38efc54e037c978d2b578632b875f44f.json,document_parses/pmc_json/PMC7126718.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X16306491; https://doi.org/10.1016/j.vaccine.2016.07.051; https://www.ncbi.nlm.nih.gov/pubmed/27523740/; https://api.elsevier.com/content/article/pii/S0264410X16306491,20604467.0,3
87964,87964,112629,z5q82rmp,105cdd82765a29310ab4d66f4c44a24e76527afd,PMC; WHO,"Global efforts on vaccines for COVID-19: Since, sooner or later, we all will catch the coronavirus",10.1007/s12038-020-00040-7,PMC7203076,,no-cc,covid emerging infectious disease turned pandemic spread droplet transmission new coronavirus sarscov rna virus displaying spike protein major surface protein significant sequence similarity sarscov cause severe acute respiratory syndrome receptor binding domain spike protein interacts human angiotensin converting enzyme considered antigenic determinant stimulating immune response multiple candidate vaccine currently different stage development known therapeutic intervention moment review describes key genetic feature considered generating vaccine candidate employing innovative technology also highlight global effort undertaken deliver vaccine covid unprecedented international cooperation future challenge post development,2020-05-07,"Mukherjee, Raju",J Biosci,,#197454,,document_parses/pdf_json/105cdd82765a29310ab4d66f4c44a24e76527afd.json,document_parses/pmc_json/PMC7203076.xml.json,https://doi.org/10.1007/s12038-020-00040-7,218528546.0,3
87997,87997,112672,52l63ss3,2337891ac00776800e86643b9efefd63c835c86a,Elsevier; PMC,Immune responses elicited by bacterial minicells capable of simultaneous DNA and protein antigen delivery,10.1016/j.vaccine.2006.04.063,PMC7125846,16806602.0,els-covid,recent event surrounding emerging infectious disease bioterrorism increasing multidrug antibiotic resistance bacteria drastically increased current need effective vaccine many year study shown live attenuated pathogen often effective delivering heterologous protein dna induce protective immune response however vaccine carrier inherent safety concern limited development use many patient population study using nonliving delivery mechanism shown providing protein antigen dna encoding antigen individual induces improved protective immune response rarely ever delivered simultaneously nonreplicating bacterial minicells derived commensal e coli strain shown effectively induce antigenspecific immune response simultaneous protein dna delivery data demonstrate potential use achromosomal bacterial minicells vaccine carrier,2006-08-14,"Giacalone, Matthew J.; Sabbadini, Roger A.; Chambers, Amy L.; Pillai, Sabitha; McGuire, Kathleen L.",Vaccine,,,,document_parses/pdf_json/2337891ac00776800e86643b9efefd63c835c86a.json,document_parses/pmc_json/PMC7125846.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X06004622; https://api.elsevier.com/content/article/pii/S0264410X06004622,39186773.0,3
88063,88063,112758,uei9zw6q,71086ed3550e091de785138cbe73a343bd0f9dc4,Elsevier; PMC; WHO,Is Global BCG Vaccination Coverage Relevant To The Progression Of SARS-CoV-2 Pandemic?,10.1016/j.mehy.2020.109707,PMC7136957,,els-covid,lower expected number sarscov case country fragile health system puzzling herein hypothesize bcg vaccination policy adopted different country might influence sarscov transmission pattern andor covid associated morbidity mortality vaccine ’ capacity confer heterologous protection also postulate specific vaccine developed sarscov vulnerable population could immunized bcg vaccine attain heterologous nonspecific protection new coronavirus,2020-04-06,"Gursel, Mayda; Gursel, Ihsan",Med Hypotheses,,#34968,,document_parses/pdf_json/71086ed3550e091de785138cbe73a343bd0f9dc4.json,document_parses/pmc_json/PMC7136957.xml.json,https://doi.org/10.1016/j.mehy.2020.109707; https://www.sciencedirect.com/science/article/pii/S0306987720305193?v=s5; https://api.elsevier.com/content/article/pii/S0306987720305193,214806878.0,3
88075,88075,112771,o79mdupz,94fc08607ba07e9f5a0239d27251d4cdcc6bfd9a,Medline; PMC,Predominant Bacteria Detected from the Middle Ear Fluid of Children Experiencing Otitis Media: A Systematic Review,10.1371/journal.pone.0150949,PMC4783106,26953891.0,cc-by,background otitis medium om amongst common childhood disease associated multiple microbial pathogen within middle ear global temporal monitoring predominant bacterial pathogen important inform new treatment strategy vaccine development monitor impact vaccine implementation improve progress toward global om prevention method systematic review published report microbiology acute otitis medium aom otitis medium effusion ome january august performed using pubmed database result review confirmed streptococcus pneumoniae haemophilus influenzae remain predominant bacterial pathogen pneumoniae predominant bacterium majority report aom patient contrast h influenzae predominant bacterium patient experiencing chronic ome recurrent aom aom treatment failure result consistent even improved detection sensitivity use polymerase chain reaction pcr rather bacterial culture conducted average pcr analysis increased frequency detection pneumoniae h influenzae fold compared culture whilst moraxella catarrhalis time frequently identified pcr molecular method also improve monitoring regional change serotypes identification frequency pneumoniae h influenzae time vaccine implementation introduction valent pneumococcal conjugate vaccine conclusion globally pneumoniae h influenzae remain predominant otopathogens associated om identified bacterial culture however molecular method continue improve frequency accuracy detection individual serotypes ongoing monitoring appropriate detection method om pathogen support development improved vaccine provide protection complex combination otopathogens within middle ear ultimately aiming reduce risk chronic recurrent om vulnerable population,2016-03-08,"Ngo, Chinh C.; Massa, Helen M.; Thornton, Ruth B.; Cripps, Allan W.",PLoS One,,,,document_parses/pdf_json/94fc08607ba07e9f5a0239d27251d4cdcc6bfd9a.json,document_parses/pmc_json/PMC4783106.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26953891/; https://doi.org/10.1371/journal.pone.0150949,19018235.0,3
88094,88094,112793,1a5u7uux,c9df58c92109a1057c10b24867cb3566ffb46408,Medline; PMC,Prospects for control of emerging infectious diseases with plasmid DNA vaccines,10.1186/1476-8518-7-3,PMC2746192,19735569.0,cc-by,experiment almost year ago demonstrated injection sequence dna encoding part pathogen could stimulate immunity soon realized dna vaccination numerous potential advantage conventional vaccine approach including inherent safety rapid production time attribute make dna vaccine ideal development emerging pathogen recent advance optimizing various aspect dna vaccination accelerated approach concept reality contemporary human trial although yet licensed human use several dna vaccine approved animal health indication rapid manufacturing capability dna vaccine may particularly important emerging infectious disease including current novel hn influenza pandemic preexisting immunity limited recent advance dna vaccination approach potential powerful new weapon protecting emerging potentially pandemic human pathogen,2009-09-07,"Moss, Ronald B",J Immune Based Ther Vaccines,,,,document_parses/pdf_json/c9df58c92109a1057c10b24867cb3566ffb46408.json,document_parses/pmc_json/PMC2746192.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19735569/; https://doi.org/10.1186/1476-8518-7-3,3006716.0,3
88100,88100,112800,ttcaxqyy,d9417715e7bba6686a48259826d7167995a669ee,Medline; PMC,Vaccine platform recombinant measles virus,10.1007/s11262-017-1486-3,PMC7089060,28710608.0,no-cc,classic development vaccine lengthy tedious may necessarily successful demonstrated case hiv especially problem emerging pathogen newly introduced human population carry inherent risk pandemic spread naïve population situation considerable number different platform technology development also development pathogen directly derived vaccine regarded complicated even dangerous due induction inefficient unwanted immune response causing considerable sideeffects dengue virus among platform technology plasmidbased dna vaccine rna replicons singleround infectious vector particle replicating vaccinebased vector encoding critical antigen target pathogen among latter recombinant measles virus derived vaccine strain tested measles vaccine among effective safest lifeattenuated vaccine known therefore development schwarz moraten aikcstrain derived recombinant vaccine wide range mostly viral also bacterial pathogen quite straightforward vaccine generally induce powerful humoral cellular immune response appropriate animal model ie transgenic mouse nonhuman primate also recent first clinical phase trial result quite encouraging trial indicated expected safety efficacy also human patient interestingly independent level prevalent antimeasles immunity trial thereby recombinant measles vaccine expressing additional antigen promising platform future vaccine,2017-07-14,"Mühlebach, Michael D.",Virus Genes,,,,document_parses/pdf_json/d9417715e7bba6686a48259826d7167995a669ee.json,document_parses/pmc_json/PMC7089060.xml.json,https://doi.org/10.1007/s11262-017-1486-3; https://www.ncbi.nlm.nih.gov/pubmed/28710608/,3911706.0,3
88163,88163,112868,hf9nwz1t,176a9159206a6bde18152a197a946ee73d33f07f,Elsevier; Medline; PMC,Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime®) and the recombinant Leish-110f® +MPL-SE® vaccine to treat canine visceral leishmaniasis,10.1016/j.vaccine.2008.01.026,PMC7127155,18328956.0,els-covid,summary evaluation efficacy immunochemotherapy protocol treat symptomatic dog naturally infected leishmania chagasi studied clinical trial purpose test combination nmethyl meglumine antimoniate glucantime® second generation recombinant vaccine leishf® plus adjuvant mplse® treat canine leishmaniasis canl thirty symptomatic naturally infected mongrel dog divided five group animal received standard treatment glucantime® treatment glucantime®leishf® mplse® immunochemotherapy protocol additional group received leishf® mplse® mplse® placebo evaluation haematological biochemical renal hepatic function plasmatic protein immunological humoral cellular immune response parasitological test revealed improvement clinical parameter parasitological cure dog chemotherapy alone immunochemotherapy cohort however immunotherapy immunochemotherapy cohort reduced number death higher survival probability specific cellular reactivity leishmanial antigen comparison chemotherapy cohort control group adjuvant alone placebo result support notion using wellcharacterized recombinant vaccine adjunct improve current chemotherapy canl,2008-03-17,"Miret, Jorge; Nascimento, Evaldo; Sampaio, Weverton; França, João Carlos; Fujiwara, Ricardo Toshio; Vale, André; Dias, Edelberto Santos; Vieira, Edvá; Costa, Roberto Teodoro da; Mayrink, Wilson; Neto, Antonio Campos; Reed, Steven",Vaccine,,,,document_parses/pdf_json/176a9159206a6bde18152a197a946ee73d33f07f.json,document_parses/pmc_json/PMC7127155.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X08000340; https://www.ncbi.nlm.nih.gov/pubmed/18328956/; https://doi.org/10.1016/j.vaccine.2008.01.026; https://api.elsevier.com/content/article/pii/S0264410X08000340,205575227.0,3
88165,88165,112870,jqy7lcbk,2141f65d307159d96e111b2f68dff9fe7499054e,Elsevier; PMC,SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens,10.1016/j.virol.2005.11.042,PMC7111852,16387339.0,els-covid,correspondence tcell epitope response vaccine immunogen pathogen antigen critical vaccine efficacy present study analyzed spectrum immune response mouse three different form sars coronavirus nucleocapsid n exogenous recombinant protein ngst freunds adjuvant dna encoding unmodified n endogenous cytoplasmic protein pn dna encoding n lamp chimera targeted lysosomal mhc ii compartment plampn lysosomal trafficking lampn chimera transfected cell documented confocal immunoelectron microscopy response immunized mouse differed markedly strongest tcell ifnγ ctl response lampn chimera followed pn immunogen contrast ngst elicited strong cell il minimal ifnγ response much greater antibody response despite difference however immunodominant tcell elispot response three immunogen elicited n peptide greatest response generated cluster five overlapping peptide n– contained nonameric hd binding domain high binding score class except n– class ii allele result demonstrate processing presentation n whether exogenously endogenously derived resulted common immunodominant epitope supporting usefulness modified antigen delivery trafficking form particular lamp chimera vaccine candidate nevertheless profile tcell response distinctly different pronounced th humoral response n protein plus adjuvant contrast balanced ifnγ il response strong memory ctl response lampn chimera,2006-03-30,"Gupta, Vandana; Tabiin, Tani M.; Sun, Kai; Chandrasekaran, Ananth; Anwar, Azlinda; Yang, Kun; Chikhlikar, Priya; Salmon, Jerome; Brusic, Vladimir; Marques, Ernesto T.A.; Kellathur, Srinivasan N.; August, Thomas J.",Virology,,,,document_parses/pdf_json/2141f65d307159d96e111b2f68dff9fe7499054e.json,document_parses/pmc_json/PMC7111852.xml.json,https://api.elsevier.com/content/article/pii/S004268220500783X; https://www.sciencedirect.com/science/article/pii/S004268220500783X,23202413.0,3
88236,88236,112956,wlvgcq2n,322e9f87ee07bd71dd82ebf7e431c34580feef25,Medline; PMC,Oral Delivery of Probiotics Expressing Dendritic Cell-Targeting Peptide Fused with Porcine Epidemic Diarrhea Virus COE Antigen: A Promising Vaccine Strategy against PEDV,10.3390/v9110312,PMC5707519,29068402.0,cc-by,porcine epidemic diarrhea virus pedv enteric coronavirus causative agent porcine epidemic diarrhea ped damage intestinal epithelial cell result severe diarrhea dehydration neonatal suckling pig mortality oral vaccine route reported promising approach inducing protective immunity pedv invasion furthermore dendritic cell dc professional antigenpresenting cell link humoral cellular immune response homeostasis intestinal immune environment study order explore efficient oral vaccine pedv infection mucosal dctargeting oral vaccine developed using lactobacillus casei deliver dctargeting peptide dcpep fused pedv core neutralizing epitope coe antigen probiotic vaccine could efficiently elicit secretory immunoglobulin sigabased mucosal immunoglobulin g iggbased humoral immune response via oral vaccination vivo significant difference p immune response level observed probiotic expressing coedcpep fusion protein coe antigen alone suggesting better immune efficiency probiotic vaccine expressing dctargeting peptide fused pedv coe antigen mucosal dctargeting oral vaccine delivery effectively enhances vaccine antigen delivery efficiency providing useful strategy induce efficient immune response pedv infection,2017-10-25,"Wang, Xiaona; Wang, Li; Huang, Xuewei; Ma, Sunting; Yu, Meiling; Shi, Wen; Qiao, Xinyuan; Tang, Lijie; Xu, Yigang; Li, Yijing",Viruses,,,,document_parses/pdf_json/322e9f87ee07bd71dd82ebf7e431c34580feef25.json,document_parses/pmc_json/PMC5707519.xml.json,https://doi.org/10.3390/v9110312; https://www.ncbi.nlm.nih.gov/pubmed/29068402/,4775292.0,3
88241,88241,112961,roj8ksvc,c9e24b269c1f1772454a1e93cc72c85251aeda6b,Medline; PMC,Tailoring Subunit Vaccine Immunity with Adjuvant Combinations and Delivery Routes Using the Middle East Respiratory Coronavirus (MERS-CoV) Receptor-Binding Domain as an Antigen,10.1371/journal.pone.0112602,PMC4236105,25405618.0,cc-by,development effective vaccine critical prevention middle east respiratory syndrome coronavirus merscov pandemic study indicated receptorbinding domain rbd protein merscov spike good candidate antigen merscov subunit vaccine however highly purified protein typically inherently immunogenic hypothesised humoral cellmediated immunity would improved modification vaccination regimen therefore immunogenicity novel merscov rbdbased subunit vaccine tested mouse using different adjuvant formulation delivery route different vaccination regimen compared balbc mouse immunized time intramuscularly im vaccine containing µg recombinant merscov rbd combination either aluminium hydroxide alum alone alum polyriboinosinic acid poly ic alum cysteinephosphateguanine cpg oligodeoxynucleotides odn immune response mouse vaccinated rbd incomplete freund ’ adjuvant ifa cpg odn subcutaneous sc route also investigated evaluated induction rbdspecific humoral immunity total igg neutralizing antibody cellular immunity elispot assay ifnγ spotforming cell splenocyte cytokine production finding indicated combination alum cpg odn optimized development rbdspecific humoral cellular immunity following subunit vaccination interestingly robust rbdspecific antibody tcell response induced mouse immunized rrbd protein combination ifa cpg odn low level neutralizing antibody elicited data suggest murine immunity following subunit vaccination tailored using adjuvant combination delivery route vaccination regimen used study promising could improve protection offered merscov subunit vaccine eliciting effective humoral cellular immune response,2014-11-18,"Lan, Jiaming; Deng, Yao; Chen, Hong; Lu, Guangwen; Wang, Wen; Guo, Xiaojuan; Lu, Zhuozhuang; Gao, George F.; Tan, Wenjie",PLoS One,,,,document_parses/pdf_json/c9e24b269c1f1772454a1e93cc72c85251aeda6b.json,document_parses/pmc_json/PMC4236105.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25405618/; https://doi.org/10.1371/journal.pone.0112602,17953769.0,3
88243,88243,112963,5ibowkyq,2dc628f8092de38b705b1c159ef93a45425f9643,Medline; PMC,B-cell restriction – an alternative piece to the puzzle,10.1080/21645515.2019.1600989,PMC6773388,30945969.0,cc-by-nc-nd,effective vaccination based three critical aspect bcell response towards infectious agent bcells generate specific antibody towards vast molecular diversity antigen protein sugar dna lipid seems limit ability raise antibody everything ii stimulated bcells perfect antibody affinity maturation complement every nook cranny epitope iii pathogen remains genetically stable change great extent thus antibody produced vaccine subsequent boost recognize viral virulent field isolates future encounter effectively knock however vaccine target flu virus hiv extremely genetically dynamic rapid genetic drift virus render moving target assist ability evade immune surveillance postulate case hypervariable pathogen bcell response actually might “ good ” propose restricting bcell activity may prove effective counteracting genetic diversity variant virus flu hiv suggest two level “ bcell restriction ” focus bcell response exclusively towards neutralizing epitope creating epitopebased immunogen ii restrict affinity maturation bcells prevent production overly optimized exquisitely specific antibody together “ bcell restriction ” provide new modality vaccine design,2019-04-23,"Gershoni, Jonathan M.",Hum Vaccin Immunother,,,,document_parses/pdf_json/2dc628f8092de38b705b1c159ef93a45425f9643.json,document_parses/pmc_json/PMC6773388.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30945969/; https://doi.org/10.1080/21645515.2019.1600989,92999466.0,3
88258,88258,112980,7odykzds,fe817bf2cc5f310e1f37e696365f7fc3194e06f4,Elsevier; PMC,Chapter 10 Plant-Based Peroral Vaccines,10.1016/b978-0-323-52725-5.00010-1,PMC7152130,,els-covid,data development plantmade peroral vaccine stated base transgenic plant different aspect plant made vaccine pmv peculiarity plethora advantage discussed comparison traditional vaccine result disclosing characteristic creation pmv preventive therapeutic action presented role regulatory gene increase production antigenic protein activation glycosylation enhances efficiency pmv discussed according preventive therapeutic vaccine plantibodies,2017-12-31,"Salyaev, Rurik K.; Rekoslavskaya, Natalya I.","Multifunctional Systems for Combined Delivery, Biosensing and Diagnostics",,,,document_parses/pdf_json/fe817bf2cc5f310e1f37e696365f7fc3194e06f4.json,document_parses/pmc_json/PMC7152130.xml.json,https://api.elsevier.com/content/article/pii/B9780323527255000101; https://www.sciencedirect.com/science/article/pii/B9780323527255000101,89915150.0,3
88268,88268,112992,5kjhrmmb,59a34f8561b8a70870682450d318e81fc0820676,Medline; PMC,Antibody Quality and Protection from Lethal Ebola Virus Challenge in Nonhuman Primates Immunized with Rabies Virus Based Bivalent Vaccine,10.1371/journal.ppat.1003389,PMC3667758,23737747.0,cc0,previously described generation novel ebola virus ebov vaccine platform based replicationcompetent rabies virus rabv b replicationdeficient rabv c chemically inactivated rabv expressing ebov glycoprotein gp mouse study demonstrated safety immunogenicity protective efficacy live inactivated rabvebov vaccine evaluated vaccine nonhuman primate result indicate three vaccine induce potent immune response rabv ebov protection immunized animal ebov largely dependent quality humoral immune response ebov gp also determined induced antibody ebov gp differ target affinity isotype result show iggbiased humoral response well high level gpspecific antibody beneficial control ebov infection immunization result support concept successful ebov vaccine need induce strong antibody ebov also showed dual vaccine rabv filovirus achievable therefore addressing concern marketability urgently needed vaccine,2013-05-30,"Blaney, Joseph E.; Marzi, Andrea; Willet, Mallory; Papaneri, Amy B.; Wirblich, Christoph; Feldmann, Friederike; Holbrook, Michael; Jahrling, Peter; Feldmann, Heinz; Schnell, Matthias J.",PLoS Pathog,,,,document_parses/pdf_json/59a34f8561b8a70870682450d318e81fc0820676.json,document_parses/pmc_json/PMC3667758.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/23737747/; https://doi.org/10.1371/journal.ppat.1003389,17001150.0,3
88275,88275,112999,fef9qsik,c494cde4f249216cdacd266d37aaf76fa3b7c1c5,Medline; PMC,Verification with the utility of an established rapid assessment of brain safety for newly developed vaccines,10.1186/s42826-019-0027-8,PMC7081575,32219059.0,cc-by,twentyfirst century high contagious infectious disease sars severe acute respiratory syndrome mers middle east respiratory syndrome fmd footandmouth disease ai avian influenza become prevalent causing treat harm human animal aspect public health economical issue critical problem newlyreported infectious disease human firstly experience expected continue emerge disease spreading rapidly therefore rapid safe supply effective vaccine pivotal prevent rapid prevalent new infection international standard assessing protocol safety urgent vaccine established well previous study since established module ass brain safety urgent vaccine therefore necessary verify established module assessing brain safety could work effectively commercially available two vaccine one killed livevaccines compared result evans blue eb assay qpcr analysis injection two kind vaccine pb lipopolysaccharide lp condition module previously reported confirmed brain safety test module urgent vaccine established reproducible therefore believed vaccine safety testing method used validate brain safety prompt supply newly developed vaccine needed,2019-11-29,"Kim, Gwang-Ho; Yi, Sun Shin",Lab Anim Res,,,,document_parses/pdf_json/c494cde4f249216cdacd266d37aaf76fa3b7c1c5.json,document_parses/pmc_json/PMC7081575.xml.json,https://doi.org/10.1186/s42826-019-0027-8; https://www.ncbi.nlm.nih.gov/pubmed/32219059/,208497046.0,3
88291,88291,113016,3l620qej,6bd909db67202372c9d945f9678b91aedd952ca1,Elsevier; Medline; PMC,Long-term viremia and fecal shedding in pups after modified-live canine parvovirus vaccination,10.1016/j.vaccine.2014.04.050,PMC7115601,24793948.0,els-covid,canine parvovirus cpv modified live virus vaccine able infect vaccinated dog replicating bloodstream enteric mucosa however exact duration extent cpv vaccineinduced viremia fecal shedding known aim fill gap dog administered two commercial vaccine containing cpv cpvb strain monitored day vaccination using realtime pcr vaccineinduced viremia shedding found long lasting vaccinal strain vaccinal cpvb shedding detected shorter period cpv mean day greater viral load whereas viremia occurred longer period mean day higher titer cpvb seroconversion appeared early day postvaccination cpvb cpv vaccine respectively vaccine diagnostic interference using inclinic hemagglutination test since positive result obtained fecal realtime pcr testing present study add new insight cpv vaccine persistence organism possible interference diagnostic test,2014-06-24,"Decaro, Nicola; Crescenzo, Giuseppe; Desario, Costantina; Cavalli, Alessandra; Losurdo, Michele; Colaianni, Maria Loredana; Ventrella, Gianpiero; Rizzi, Stefania; Aulicino, Stefano; Lucente, Maria Stella; Buonavoglia, Canio",Vaccine,,,,document_parses/pdf_json/6bd909db67202372c9d945f9678b91aedd952ca1.json,document_parses/pmc_json/PMC7115601.xml.json,https://api.elsevier.com/content/article/pii/S0264410X1400588X; https://www.sciencedirect.com/science/article/pii/S0264410X1400588X; https://www.ncbi.nlm.nih.gov/pubmed/24793948/; https://doi.org/10.1016/j.vaccine.2014.04.050,41906669.0,3
88389,88389,113141,cirzyldz,a288a5fe4cb9adbee0ceb4884c8ec044dd2a8e2f,Elsevier; PMC,Neonatal immunity and immunisation in early age: lessons from veterinary medicine,10.1016/s0264-410x(98)00110-8,PMC7130764,9711790.0,els-covid,objective paper review adaptive immunity young animal using example experience literature trial carried u modified live inactivated canine parvovirus vaccine newborn puppy provide evidence immune capacity puppy regard transfer immunity mother offspring role transplacental colostral immunity example passive protection young animal different infection include passive protection kitten feline immunodeficiency virus however passive immunity though useful early age varies duration make implementation standard vaccination schedule difficult experiment demonstrate certain condition possible overcome residual maternallyderived antibody induce postvaccinal immunity,1998-09-30,"Chappuis, G.",Vaccine,,,,document_parses/pdf_json/a288a5fe4cb9adbee0ceb4884c8ec044dd2a8e2f.json,,https://www.sciencedirect.com/science/article/pii/S0264410X98001108; https://api.elsevier.com/content/article/pii/S0264410X98001108,20488533.0,3
88392,88392,113145,n9q99hdn,44c73e155f1c27e1d6fcbff9751faf8eb76a9755,Elsevier; Medline; PMC,Infectious bronchitis virus Mass-type (GI-1) and QX-like (GI-19) genotyping and vaccine differentiation using SYBR green RT-qPCR paired with melting curve analysis,10.1016/j.jviromet.2019.113771,PMC7113787,31712091.0,els-covid,infectious bronchitis virus ibv highly contagious virus chicken causing huge economic loss poultry industry many genotype circulate given area optimal protection relies vaccination live attenuated vaccine genotype live vaccine derived field virus circulate understanding prevalence different ibv genotype area complex recent study genome comparison ibv qx vaccine progenitor field strain led identification vaccine marker developed simplex sybrgreen rtqpcr assay differentiation qxlike field vaccine strain multiplex sybrgreen rtqpcr assay ibv genotyping melting curve analysis virus produced distinct reliable melting peak simplex multiplex assay showed excellent efficiency sensitivity specificity representing low cost diagnostic tool ibv genotyping vaccine differentiation,2020-01-31,"Laconi, Andrea; Berends, Alinda J.; de Laat, Esther C.H.; Urselmann, Tara A.P.M.P.; Verheije, Hélène M.",Journal of Virological Methods,,,,document_parses/pdf_json/44c73e155f1c27e1d6fcbff9751faf8eb76a9755.json,document_parses/pmc_json/PMC7113787.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31712091/; https://api.elsevier.com/content/article/pii/S0166093419303180; https://www.sciencedirect.com/science/article/pii/S0166093419303180; https://doi.org/10.1016/j.jviromet.2019.113771,207939646.0,3
88437,88437,113198,4z286b5j,0dbfaa6ddc08bef9b502de5cd6c0a2a3b7af0106,Medline; PMC,One Group's Historical Reflections on DNA Vaccine Development,10.1089/hum.2018.066,PMC6152846,30129778.0,cc-by,dna vaccine pioneered several group early article present reflection one group work retroviral vector chicken contributed discovery early development dna vaccine although finding initially met skepticism work presented combined others founded new method vaccination direct inoculation purified dna encoding target antigen,2018-09-01,"Fynan, Ellen F.; Lu, Shan; Robinson, Harriet L.",Hum Gene Ther,,,,document_parses/pdf_json/0dbfaa6ddc08bef9b502de5cd6c0a2a3b7af0106.json,document_parses/pmc_json/PMC6152846.xml.json,https://doi.org/10.1089/hum.2018.066; https://www.ncbi.nlm.nih.gov/pubmed/30129778/,52049152.0,3
88503,88503,113278,4x7xf3s3,16e2ff012b5aa4f065f29068537d18fcda3874b8,Elsevier; Medline; PMC,Dengue conundrums,10.1016/j.ijantimicag.2010.06.019,PMC7135181,20696556.0,els-covid,dengue virus common arboviral infection human tropical subtropical region world review briefly describes challenge present dengue emerging disease increasing geographical distribution severity despite significantly underreported world health organization case definition generally severe manifestation infection dengue haemorrhagic fever dhf controversial name dhf something misnomer disease infrequently result frank haemorrhage hallmark dhf actually plasma leakage existence four closely related dengue virus serotypes contributes difficulty diagnosis original antigenic sin serological response infection existence multiple serotypes result severe disease upon second infection complicates vaccine development nevertheless safe effective vaccine greatest prospect stemming tide dengue,2010-11-30,"Gibbons, Robert V.",International Journal of Antimicrobial Agents,,,,document_parses/pdf_json/16e2ff012b5aa4f065f29068537d18fcda3874b8.json,document_parses/pmc_json/PMC7135181.xml.json,https://www.sciencedirect.com/science/article/pii/S0924857910002608; https://api.elsevier.com/content/article/pii/S0924857910002608; https://www.ncbi.nlm.nih.gov/pubmed/20696556/; https://doi.org/10.1016/j.ijantimicag.2010.06.019,21852133.0,3
88549,88549,113331,df36w6l7,,Medline; WHO,What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19?,10.3390/vaccines8020183,,32295153.0,unk,emergence new pathogenic viral strain constant threat global health new coronavirus strain covid latest example covid caused sarscov virus quickly spread around globe pandemic demand rapid development drug vaccine plantbased vaccine technology proven viability led promising result candidate evaluated clinical level meaning technology could contribute towards fight covid herein perspective plantbased vaccine developed covid presented injectable vaccine could generated using transient expression system offer highest protein yield already adopted industrial level produce vlpsvaccines biopharmaceuticals gmpcprocesses stablytransformed plant another option approach requires time development antigenproducing line nonetheless approach offer possibility developing oral vaccine plant cell could act antigen delivery agent therefore attractive approach term cost easy delivery mucosal immunity induction development multiepitope rationallydesigned vaccine also discussed regarding experience gained expression chimeric immunogenic protein plant system,2020,"Rosales-Mendoza, Sergio; Márquez-Escobar, Verónica A.; González-Ortega, Omar; Nieto-Gómez, Ricardo; Arévalo-Villalobos, Jaime I.","Vaccines 2020, Vol. 8, Page 183",,#52482,,,,https://doi.org/10.3390/vaccines8020183; https://www.ncbi.nlm.nih.gov/pubmed/32295153/,215794081.0,3
88645,88645,113448,sb55ybtb,1cff4f38e4614ab793a89acb897ed57f3b85e5cd,Elsevier; Medline; PMC,Evaluation of protection conferred by a vaccination program based on the H120 and CR88 commercial vaccines against a field variant of avian infectious bronchitis virus,10.3382/japr.2013-00828,PMC7109893,32288459.0,els-covid,due serotype variation among different avian infectious bronchitis virus isolated tunisia since protection chick especially broiler flock mass h vaccine often fails therefore association cr b type h vaccine used better response challenge experiment conducted evaluate tracheal renal crossprotection chicken immunized via nasal eye drop conferred protection measured clinical sign macroscopic lesion observed based score attributed according severity result showed low protection conferred h alone vaccination reduce tracheal kidney lesion scored tn virus challenge also led mortality conversely challenge result indicated combination strain hcr allow high protection based result challenge experiment vaccination protocol coupling cr h applied industrial broiler flock clinical observation serological result confirmed association heterologous serotypes h cr vaccine increased level protection infectious bronchitis virus compared h vaccine given alone,2014-06-01,"Bourogâa, Hager; Larbi, Imen; Miled, Khaled; Hellal, Ymene Kort; Hassen, Jihene; Behi, Imen; Nsiri, Jihene; Ghram, Abdeljelil",Journal of Applied Poultry Research,,,,document_parses/pdf_json/1cff4f38e4614ab793a89acb897ed57f3b85e5cd.json,document_parses/pmc_json/PMC7109893.xml.json,https://doi.org/10.3382/japr.2013-00828; https://www.ncbi.nlm.nih.gov/pubmed/32288459/; https://www.sciencedirect.com/science/article/pii/S1056617119303745; https://api.elsevier.com/content/article/pii/S1056617119303745,86662553.0,3
88740,88740,113562,2cxexuua,7aaffdb8cf80ab9dd167a26a44abfa21d30d2af5,Medline; PMC,Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus,10.1371/journal.pone.0220196,PMC6645677,31329652.0,cc-by,middle east respiratory syndrome coronavirus merscov cause acute severe lower respiratory illness well vomiting diarrhea renal failure licensed merscov vaccine currently available preventive therapeutic measure urgently needed surface spike glycoprotein merscov bind cellular receptor dipeptidyl peptidase dpp considered major target merscov vaccine development designed recombinant replicationdeficient adenovirusbased vaccine expressing nterminal domain radntd receptorbinding domain radrbd merscov subunit fulllength spike protein radspike found immunization candidate vaccine via intranasal route induced sspecific igg antibody neutralizing antibody mers spike pseudotyped virus especially radspike induced highest neutralizing antibody titer strongest cytokineinduced cell response among three candidate vaccine compare immune response induced different administration route radspike administered via intranasal sublingual intramuscular route administration route exhibited neutralizing effect serum merscovspecific neutralizing iga antibody bronchoalveolar lavage fluid induced intranasal sublingual administration intramuscular administration intranasal administration radspike also created resident memory cd cell airway lung parenchyma taken together result showed humoral cellular immune response highly induced radspike administration suggesting radspike may confer protection merscov infection,2019-07-22,"Kim, Myung Hee; Kim, Hyun Jik; Chang, Jun",PLoS One,,,,document_parses/pdf_json/7aaffdb8cf80ab9dd167a26a44abfa21d30d2af5.json,document_parses/pmc_json/PMC6645677.xml.json,https://doi.org/10.1371/journal.pone.0220196; https://www.ncbi.nlm.nih.gov/pubmed/31329652/,207376745.0,3
88754,88754,113580,topg6wg0,923790fd2479fb7f8888db709fc87e2445b0d209,Elsevier; Medline; PMC,Accidental Introduction of Viruses into Companion Animals by Commercial Vaccines,10.1016/j.cvsm.2008.02.010,PMC7114570,18501287.0,els-covid,use biologics veterinary medicine tremendous value safeguarding animal population debilitating oftentimes fatal disease article review principle vaccination extensive quality control effort incorporated preparing vaccine example adverse event occurred past enhanced vigilance level veterinarian veterinary diagnostic laboratory help curtail event discussed emphasis understanding ecology viral infection dog cat introduced together concept potential role vaccine interspecies spread virus,2008-07-31,"Evermann, James F.",Veterinary Clinics of North America: Small Animal Practice,,,,document_parses/pdf_json/923790fd2479fb7f8888db709fc87e2445b0d209.json,document_parses/pmc_json/PMC7114570.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/18501287/; https://api.elsevier.com/content/article/pii/S0195561608000715; https://www.sciencedirect.com/science/article/pii/S0195561608000715; https://doi.org/10.1016/j.cvsm.2008.02.010,27830926.0,3
88791,88791,113627,hrotztfm,4b42de92c323a16164cb8e497b2043a8b6bfc58d,Elsevier; Medline; PMC,Chapter 9 Rabies Virus as a Research Tool and Viral Vaccine Vector,10.1016/b978-0-12-387040-7.00009-3,PMC7150175,21601047.0,els-covid,recently singlestranded negative sense rna virus ssnsvs one important human viral pathogen could created cdna inability manipulate genome hindered detailed genetic analysis key paper conzelmanns laboratory changed publication method recover rabies virus rabv cdna discovery dramatically changed broader field ssnsv biology also opened whole new avenue studying rabv pathogenicity developing novel rabv vaccine well new generation rabvbased vaccine vector creating research tool important neuroscience neuronal tracing,2011-12-31,"Gomme, Emily A.; Wanjalla, Celestine N.; Wirblich, Christoph; Schnell, Matthias J.",Advances in Virus Research,,,,document_parses/pdf_json/4b42de92c323a16164cb8e497b2043a8b6bfc58d.json,document_parses/pmc_json/PMC7150175.xml.json,https://www.sciencedirect.com/science/article/pii/B9780123870407000093; https://api.elsevier.com/content/article/pii/B9780123870407000093; https://doi.org/10.1016/b978-0-12-387040-7.00009-3; https://www.ncbi.nlm.nih.gov/pubmed/21601047/,38435331.0,3
88796,88796,113636,13adnvav,93438defafc923d1ec78059c50ef42886f9c468e,Elsevier; Medline; PMC,Overview of the CSIRO Australian Animal Health Laboratory,10.1016/j.jiph.2016.04.007,PMC7102798,27118215.0,no-cc,emerging infectious disease arising livestock wildlife pose serious threat global human health shown series continuous outbreak involving highly pathogenic influenza sars ebola mers risk pandemic bioterrorism threat ever present growing ability combat limited lack available vaccine therapeutic rapid diagnostics use high biocontainment facility csiro australian animal health laboratory play key role studying dangerous pathogen facilitates development countermeasure combat disease like mers must take holistic approach involves development early biomarkers infection suite treatment option vaccine antiviral drug antibody therapeutic appropriate animal model test safety efficacy candidate treatment,2016-04-24,"Lowenthal, John",J Infect Public Health,,,,document_parses/pdf_json/93438defafc923d1ec78059c50ef42886f9c468e.json,document_parses/pmc_json/PMC7102798.xml.json,https://api.elsevier.com/content/article/pii/S1876034116300247; https://www.ncbi.nlm.nih.gov/pubmed/27118215/; https://doi.org/10.1016/j.jiph.2016.04.007; https://www.sciencedirect.com/science/article/pii/S1876034116300247,34180955.0,3
88805,88805,113654,hwvkvdlk,20212e62a16fab28c74374c71e5a716dd9de34da,Elsevier; PMC,Occurrence of severe gastroenteritis in pups after canine parvovirus vaccine administration: A clinical and laboratory diagnostic dilemma,10.1016/j.vaccine.2006.10.020,PMC7130793,17092616.0,els-covid,total faecal sample collected dog diarrhoea following canine parvovirus cpv vaccination tested minor groove binder mgb probe assay discrimination cpv vaccine field strain diagnostic test detection canine pathogen fifteen sample tested positive cpv field strain however vaccine field strain detected three sample eleven sample found contain vaccine strain although eight tested positive pathogen dog three sample found contain vaccine strain without evidence canine pathogen present study confirms case parvoviruslike disease occurring shortly vaccination related infection field strain canine parvovirus type cpv rather reversion virulence modified live virus contained vaccine,2007-01-26,"Decaro, Nicola; Desario, Costantina; Elia, Gabriella; Campolo, Marco; Lorusso, Alessio; Mari, Viviana; Martella, Vito; Buonavoglia, Canio",Vaccine,,,,document_parses/pdf_json/20212e62a16fab28c74374c71e5a716dd9de34da.json,document_parses/pmc_json/PMC7130793.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X06011352; https://api.elsevier.com/content/article/pii/S0264410X06011352,37255436.0,3
88820,88820,113672,a6m8elu9,c011219f5dd677b4dfa1842539501bb1d1e01f0f,Elsevier; Medline; PMC,Utilizing poxviral vectored vaccines for antibody induction—Progress and prospects,10.1016/j.vaccine.2013.05.091,PMC7131268,23746455.0,els-covid,last decade poxviral vector emerged mainstay approach induction cellmediated immunity vaccination suitability human use led widespread clinical testing candidate vector infectious intracellular pathogen cancer contrast poxvirus widely perceived vaccine field poor choice vector induction humoral immunity however growing body data animal model recent clinical trial suggests vector successfully utilized prime boost b cell effective antibody response significant progress made context heterologous prime–boost immunization regime whereby poxvirus able boost response primed vector leading induction hightitre antigenspecific antibody response case poxviral vector shown stimulate humoral immunity encoded transgene particular viral surface protein influenza haemagglutinin veterinary field recombinant poxviral vector made significant impact numerous vector licensed use variety animal virus ongoing study continue explore potential poxviral vector modulate qualitative aspect humoral response well amenability adjuvantation seeking improve quantitative antibody immunogenicity nevertheless underlying mechanism b cell induction recombinant poxvirus remain poorly defined work necessary help guide rational optimization future poxviral vaccine candidate aiming induce antibody,2013-09-06,"Draper, Simon J.; Cottingham, Matthew G.; Gilbert, Sarah C.",Vaccine,,,,document_parses/pdf_json/c011219f5dd677b4dfa1842539501bb1d1e01f0f.json,document_parses/pmc_json/PMC7131268.xml.json,https://doi.org/10.1016/j.vaccine.2013.05.091; https://www.ncbi.nlm.nih.gov/pubmed/23746455/; https://api.elsevier.com/content/article/pii/S0264410X13007081; https://www.sciencedirect.com/science/article/pii/S0264410X13007081,24496356.0,3
88831,88831,113686,buzyani0,b9a8782661a61d1562b8d6a2098fd35c76b35349,Medline; PMC,"Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing",10.3389/fmicb.2012.00277,PMC3410596,22876240.0,cc-by,understanding antibody generated function could help develop effective vaccine antibodybased therapeutic virus hiv sars coronavirus sars cov hendra nipah virus henipaviruses although broadly neutralizing antibody bnabs hiv observed patient elicitation bnabs remains major challenge compared viral target previously hypothesized hiv could evolved strategy evade immune system due absent weak binding germline antibody conserved epitope may sufficient initiate andor maintain effective immune response explore hypothesis used sequence analysis large naïve library human igm antibody used selecting antibody sars cov receptorbinding domain rbd soluble g protein sg henipaviruses found human igm repertoire sequencing diverse germline usage recombination pattern junction diversity lower extent somatic mutation study identified antibody maturation intermediate related bnabs hiv virus observed normal individual compared genetic diversity somatic mutation level along available structural functional data computational analysis provide framework understanding underlying genetic molecular determinant related maturation pathway antiviral bnabs could useful applying novel approach design effective vaccine immunogen antibodybased therapeutic,2012-08-02,"Prabakaran, Ponraj; Zhu, Zhongyu; Chen, Weizao; Gong, Rui; Feng, Yang; Streaker, Emily; Dimitrov, Dimiter S.",Front Microbiol,,,,document_parses/pdf_json/b9a8782661a61d1562b8d6a2098fd35c76b35349.json,document_parses/pmc_json/PMC3410596.xml.json,https://doi.org/10.3389/fmicb.2012.00277; https://www.ncbi.nlm.nih.gov/pubmed/22876240/,9851506.0,3
88877,88877,113744,nu0awxbk,d8fe47627699dd17cdd8dede6c6bd40bba033b8f,Medline; PMC,Antibody Repertoire of Human Polyclonal Antibodies Against Ebola Virus Glycoprotein Generated After Deoxyribonucleic Acid and Protein Vaccination of Transchromosomal Bovines,10.1093/infdis/jiy325,PMC7107430,29939294.0,no-cc,several ebola vaccine therapeutic clinical development however limited knowledge exists quality antibody response generated different ebola vaccine study antibody repertoire induced vaccination transchromosomal bovine tcb ebola virus ebov glycoprotein gp recombinant gp rgp encoded either deoxyribonucleic acid dna nanoparticlebased vaccine platform analyzed using ebov genome fragment phage display library surface plasmon resonance sprbased realtime kinetics assay measure antibody affinity maturation native partially denatured ebola gp well gp containing receptor binding domain lacking mucinlike domain immunoglobulin igg obtained rgp nanoparticlevaccinated tcb demonstrated fold higher binding affinity compared dnavaccinated tcbinduced igg native rgp ’ rgp nanoparticle vaccine generated robust diverse antibody immune response native ebovgp compared dna vaccine may explain protective efficacy observed antibody preparation,2018-12-15,"Fuentes, Sandra; Ravichandran, Supriya; Khurana, Surender",J Infect Dis,,,,document_parses/pdf_json/d8fe47627699dd17cdd8dede6c6bd40bba033b8f.json,document_parses/pmc_json/PMC7107430.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29939294/; https://doi.org/10.1093/infdis/jiy325,49415140.0,3
88952,88952,113830,rsqif2x8,2e0cf17cdd3b6fc7dcdd21a52a5d61c30b6b63ea,Elsevier; Medline; PMC,Lactococcus lactis-expressing listeriolysin O (LLO) provides protection and specific CD8+ T cells against Listeria monocytogenes in the murine infection model,10.1016/j.vaccine.2008.07.047,PMC7115502,18691625.0,els-covid,lactococcus lactis previously proposed vaccine platform safe delivery heterologous antigen utilized l lactis live vector expression listeriolysin llo major listeria monocytogenes antigen virulence factor variety plasmid construct designed permit either constitutive nisininducible expression secreted nonsecreted llo l lactis recombinant strain subsequently tested murine model vaccination efficacy l monocytogenes infection cd lymphocyte specific llo– epitope detected strain administered via intraperitoneal ip oral route challenge live l monocytogenes revealed different level protection among three vaccine strain tested nisininducible llosecreting l lactis strain providing greatest protection secondary infection work highlight usefulness gras generally regarded safe organism l lactis basis live vaccine vector l monocytogenes work suggests lloexpressing l lactis strain may also potential act platform directing coexpressed antigen towards cytosolic mhc class pathway enhanced stimulation cd tcell response,2008-09-26,"Bahey-El-Din, Mohammed; Casey, Pat G.; Griffin, Brendan T.; Gahan, Cormac G.M.",Vaccine,,,,document_parses/pdf_json/2e0cf17cdd3b6fc7dcdd21a52a5d61c30b6b63ea.json,document_parses/pmc_json/PMC7115502.xml.json,https://doi.org/10.1016/j.vaccine.2008.07.047; https://www.ncbi.nlm.nih.gov/pubmed/18691625/; https://www.sciencedirect.com/science/article/pii/S0264410X08009754; https://api.elsevier.com/content/article/pii/S0264410X08009754,23672283.0,3
88955,88955,113833,m74agsr8,18c87ac63c04723a939961675d43ff749f929e87,Elsevier; Medline; PMC,Heterologous prime–boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus,10.1016/j.vaccine.2018.04.082,PMC7115429,29739720.0,els-covid,middle east respiratory syndrome coronavirus merscov highly pathogenic zoonotic virus fatality rate human although several vaccine candidate developed still clinically available vaccine merscov study developed two type merscov vaccine recombinant adenovirus serotype encoding merscov spike gene admers spike protein nanoparticles formulated aluminum alum adjuvant next tested heterologous prime–boost vaccine strategy compared priming admers boosting spike protein nanoparticles vice versa homologous prime–boost vaccination comprising priming boosting either spike protein nanoparticles admers although type vaccine could induce specific immunoglobulin g merscov neutralizing antibody merscov induced heterologous prime–boost immunization homologous immunization spike protein nanoparticles interestingly th cell activation induced immunization schedule including admers including spike protein nanoparticles heterologous prime–boost vaccination regimen including admers elicited simultaneous th th response homologous prime–boost regimen thus heterologous prime–boost may induce longerlasting immune response merscov appropriate balance thth response however heterologous prime–boost homologous spike protein nanoparticles vaccination could provide protection merscov challenge mouse result demonstrate heterologous immunization priming admers boosting spike protein nanoparticles could efficient prophylactic strategy merscov infection,2018-06-07,"Jung, Seo-Yeon; Kang, Kyung Won; Lee, Eun-Young; Seo, Dong-Won; Kim, Hong-Lim; Kim, Hak; Kwon, TaeWoo; Park, Hye-Lim; Kim, Hun; Lee, Sang-Myeong; Nam, Jae-Hwan",Vaccine,,,,document_parses/pdf_json/18c87ac63c04723a939961675d43ff749f929e87.json,document_parses/pmc_json/PMC7115429.xml.json,https://api.elsevier.com/content/article/pii/S0264410X1830598X; https://www.ncbi.nlm.nih.gov/pubmed/29739720/; https://doi.org/10.1016/j.vaccine.2018.04.082; https://www.sciencedirect.com/science/article/pii/S0264410X1830598X,13701468.0,3
88993,88993,113877,o0o3djz9,44f29967d1ac81b105a6e60032f9dafb0894f3ab; a7960070f97e42542f5a3a758e454edffc32ad89,Elsevier; Medline; PMC,MERS-CoV spike nanoparticles protect mice from MERS-CoV infection,10.1016/j.vaccine.2017.02.012,PMC5423355,28237499.0,bronze-oa,middle east respiratory syndrome coronavirus merscov first discovered late gone cause infection death currently approved therapeutic vaccination merscov merscov spike protein responsible receptor binding virion entry cell immunodominant induces neutralizing antibody vivo make protein ideal target antimerscov vaccine study demonstrate protection induced vaccination recombinant merscov nanoparticle vaccine matrixm adjuvant combination mouse merscov nanoparticle vaccine produced high titer anti neutralizing antibody protected mouse merscov infection vivo,2017-03-01,"Coleman, Christopher M.; Venkataraman, Thiagarajan; Liu, Ye V.; Glenn, Gregory M.; Smith, Gale E.; Flyer, David C.; Frieman, Matthew B.",Vaccine,,,,document_parses/pdf_json/44f29967d1ac81b105a6e60032f9dafb0894f3ab.json; document_parses/pdf_json/a7960070f97e42542f5a3a758e454edffc32ad89.json,document_parses/pmc_json/PMC5423355.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28237499/; https://doi.org/10.1016/j.vaccine.2017.02.012; https://api.elsevier.com/content/article/pii/S0264410X17301937; https://www.sciencedirect.com/science/article/pii/S0264410X17301937,3833266.0,3
88994,88994,113878,qmfh7ifi,,Elsevier; PMC,Adenovirus vectors for high-efficiency gene transfer into mammalian cells,10.1016/s0167-5699(00)01676-5,PMC7172170,10953094.0,no-cc,characteristic versatility stability highlevel expression make adenovirus vector invaluable tool expression transgene mammalian cell development recombinant viral vaccine delivery therapeutic gene,2000-09-01,"Graham, Frank L",Immunol Today,,,,,document_parses/pmc_json/PMC7172170.xml.json,https://api.elsevier.com/content/article/pii/S0167569900016765; https://www.sciencedirect.com/science/article/pii/S0167569900016765,33106562.0,3
89017,89017,113908,b0izt9hq,6d04e85d2c994d73c9a7e2692af91470f407ddeb,Medline; PMC,"Advancements in DNA vaccine vectors, non-mechanical delivery methods, and molecular adjuvants to increase immunogenicity",10.1080/21645515.2017.1330236,PMC5718814,28604157.0,cc-by-nc-nd,major advantage dna vaccination ability induce humoral cellular immune response dna vaccine currently used veterinary medicine achieved widespread acceptance use human due low immunogenicity early clinical study however recent clinical data reestablished value dna vaccine particularly priming highlevel antigenspecific antibody response several approach investigated improving dna vaccine efficacy including advancement dna vaccine vector design inclusion genetically engineered cytokine adjuvant novel nonmechanical delivery method strategy shown promise resulting augmented adaptive immune response mouse also large animal model review advancement area show promise increasing immunogenicity dna vaccine,2017-06-12,"Suschak, John J.; Williams, James A.; Schmaljohn, Connie S.",Hum Vaccin Immunother,,,,document_parses/pdf_json/6d04e85d2c994d73c9a7e2692af91470f407ddeb.json,document_parses/pmc_json/PMC5718814.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28604157/; https://doi.org/10.1080/21645515.2017.1330236,25408619.0,3
89033,89033,113925,hw57silv,6a5ef516f5458dfd7a221c905db137d6e5bd3a91,Elsevier; Medline; PMC,Newsprint media representations of the introduction of the HPV vaccination programme for cervical cancer prevention in the UK (2005–2008),10.1016/j.socscimed.2009.11.027,PMC2835855,20064682.0,els-covid,september human papillomavirus hpv immunisation programme introduced uk schoolgirl aged year age vaccine show high efficacy preventing infection hpv type responsible cervical cancer however effective vaccine need administered exposure virus therefore ideally young people become sexually active introduction new vaccine perhaps particularly one given young teenage girl prevent sexually transmitted cancercausing virus potential attract great deal medium attention paper report content analysis article published january december uk newspaper includes manifest latent analysis examine newsprint medium coverage introduction hpv vaccination programme role hpv advocacy concluded newspaper generally positive towards new hpv vaccination year period newsworthiness hpv vaccination programme increased two event dominated coverage firstly introduction hpv programme september secondly august diagnosis camera cervical cancer given jade goody year old mother two gained fame notoriety uk participation several reality television show two conclusion study firstly positive medium coverage surrounding introduction hpv vaccination programme welcomed likely contribute towards influencing public perception acceptability need hpv vaccination secondly focus prevalence rate hpv infection among woman woman sexual behaviour relation hpv vaccination ‘ encouraging ’ promiscuity unhelpful aspect medium coverage,2010-03-31,"Hilton, Shona; Hunt, Kate; Langan, Mairi; Bedford, Helen; Petticrew, Mark",Social Science & Medicine,,,,document_parses/pdf_json/6a5ef516f5458dfd7a221c905db137d6e5bd3a91.json,document_parses/pmc_json/PMC2835855.xml.json,https://api.elsevier.com/content/article/pii/S0277953609008417; https://www.sciencedirect.com/science/article/pii/S0277953609008417; https://www.ncbi.nlm.nih.gov/pubmed/20064682/; https://doi.org/10.1016/j.socscimed.2009.11.027,28143890.0,3
89072,89072,113967,cg7wqc0q,f89f59f83ceac24af9ecf26e7f76d5865f92b572,Medline; PMC,"Vaccines, emerging viruses, and how to avoid disaster",10.1186/s12915-014-0100-6,PMC4247664,25432510.0,cc-by,rino rappuoli graduate siena university also earned phd moving sclavo research center italian vaccine institute also siena spent two year usa mostly harvard john murphy alwin pappenheimer working new diphtheria vaccine based nontoxic mutant diphtheria toxin since become basis conjugate vaccine haemophilus meningococcus pneumococcal infection returning sclavo research center developed acellular vaccine based mutant pertussis toxin many achievement vaccine development credit global head vaccine research development novartis vaccine siena recently pioneered reverse vaccinology genome pathogen screened candidate antigenic immunogenic vaccine component spoke potential outbreak kind seeing ebolavirus west africa done prevent,2014-11-29,"Rappuoli, Rino",BMC Biol,,,,document_parses/pdf_json/f89f59f83ceac24af9ecf26e7f76d5865f92b572.json,document_parses/pmc_json/PMC4247664.xml.json,https://doi.org/10.1186/s12915-014-0100-6; https://www.ncbi.nlm.nih.gov/pubmed/25432510/,5444100.0,3
89112,89112,114014,0lsobcnl,cdb6748d297a7329b905186e48611af6d932b62f,Medline; PMC,Nanoparticles for transcutaneous vaccination,10.1111/j.1751-7915.2011.00284.x,PMC3815776,21854553.0,no-cc,living epidermis dermis rich antigen presenting cell apc activation elicit strong humoral cellular immune response well mucosal immunity therefore skin attractive site vaccination intradermal application antigen may much effective subcutaneous intramuscular injection however stratum corneum sc effective barrier invasion topically applied vaccine product reached stage clinical testing avoid problem injecting nano‐vaccine intradermally employing barrier disrupting method applying vaccine relatively large skin area needle‐free vaccination desirable number aspect ease application improved patient acceptance le risk infection among nanocarriers designed way overcome sc also incorporation nanocarriers protects instable antigen degradation improves uptake processing apc facilitates endosomal escape nuclear delivery dna vaccine addition sustained release system may build depot tissue gradually releasing antigen may avoid booster dos therefore nanoformulations vaccine transcutaneous immunization currently dynamic field research among huge variety nanocarrier system investigated hope lie ultra‐flexible liposome superfine rigid nanoparticles nanocarriers taken hair follicle potential pitfall associated three class carrier discussed,2012-02-20,"Hansen, Steffi; Lehr, Claus‐Michael",Microb Biotechnol,,,,document_parses/pdf_json/cdb6748d297a7329b905186e48611af6d932b62f.json,document_parses/pmc_json/PMC3815776.xml.json,https://doi.org/10.1111/j.1751-7915.2011.00284.x; https://www.ncbi.nlm.nih.gov/pubmed/21854553/,8230109.0,3
89198,89198,114121,i55tm3hh,a2a6e262098539eb875a26800d9f6d3d0d5d1875; 58775a594ee313c6c9388225a4e15ded732f9e9e,BioRxiv; MedRxiv,An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design,10.1101/2020.02.25.963546,,,medrxiv,west africa ebov epidemic biggest ebov outbreak date analysis virusspecific cd tcell immunity survivor showed individual cd response least one ebov protein dominant response subject specific ebov nucleocapsid protein np suggested epitope ebov np could form important part effective tcell vaccine ebola zaire show aminoacid peptide np yqvnnleei located conserved region ebov np provides protection morbidity mortality mouse adapted ebov challenge single vaccination cbl mouse using adjuvanted microsphere peptide vaccine formulation containing np enough confer immunity mouse work suggests peptide vaccine based cd tcell immunity ebov survivor conceptually sound feasible nucleocapsid protein within sarscov contain multiple class epitope predicted hla restriction consistent broad population coverage similar approach ctl vaccine design may possible virus,2020-02-27,"Herst, CV; Burkholz, S; Sidney, J; Sette, A; Harris, PE; Massey, S; Brasel, T; Cunha-Neto, E; Rosa, DS; Chao, WCH; Carback, R; Hodge, T; Wang, L; Ciotlos, S; Lloyd, P; Rubsamen, R",bioRxiv,,,,document_parses/pdf_json/a2a6e262098539eb875a26800d9f6d3d0d5d1875.json; document_parses/pdf_json/58775a594ee313c6c9388225a4e15ded732f9e9e.json,,https://doi.org/10.1101/2020.02.25.963546,213055489.0,3
89237,89237,114166,aup1gq7l,c12218076acf8b30d83de43257cc18b18a4ddf64,Elsevier; Medline; PMC,The presence of viral subpopulations in an infectious bronchitis virus vaccine with differing pathogenicity – A preliminary study,10.1016/j.vaccine.2012.04.054,PMC7115607,22542436.0,els-covid,currently four commercially available vaccine australia protect chicken infectious bronchitis virus ibv predominantly ibv cause clinical sign associated respiratory kidney disease subsequently cause increase mortality rate three current vaccine belong subgroup subgroup however vics vaccine reported cause increased vaccinal reaction compared subgroup vaccine molecular anomaly detected vics suggested presence two major subspecies vicsv vicsdel present commercial preparation vics notable anomaly absence bp sequence ′utr vicsdel investigation two subspecies isolated shown grow independently similar titre embryonated chicken egg vivo investigation involved group chicken found vicsdel grew significantly lesser extent chicken tissue collected vicsv group inoculated even ratio isolated subspecies scored severe clinical sign longest duration result indicate potential cooperative instead expected competitive relationship vicsv vicsdel infect host reminiscent rna viral quasispecies,2012-06-13,"Hewson, Kylie A.; Scott, Peter C.; Devlin, Joanne M.; Ignjatovic, Jagoda; Noormohammadi, Amir H.",Vaccine,,,,document_parses/pdf_json/c12218076acf8b30d83de43257cc18b18a4ddf64.json,document_parses/pmc_json/PMC7115607.xml.json,https://api.elsevier.com/content/article/pii/S0264410X12005907; https://doi.org/10.1016/j.vaccine.2012.04.054; https://www.sciencedirect.com/science/article/pii/S0264410X12005907; https://www.ncbi.nlm.nih.gov/pubmed/22542436/,28982690.0,3
89289,89289,114228,rxtptyaj,00adbbcc70c39794b7d91a479943c84cc33db30a,Elsevier; PMC,Immunology and Prevention of Infection in Feedlot Cattle,10.1016/s0749-0720(15)30252-8,PMC7135391,9704413.0,els-covid,article review basic type immunity factor relevant feedlot cattle shown suppress immune function known basis protective acquired immunity common bovine respiratory pathogen characteristic efficacy vaccine respiratory disease pathogen also reviewed recommendation optimizing vaccination presented,1998-07-31,"Roth, James A.; Perino, Louis J.",Veterinary Clinics of North America: Food Animal Practice,,,,document_parses/pdf_json/00adbbcc70c39794b7d91a479943c84cc33db30a.json,,https://www.sciencedirect.com/science/article/pii/S0749072015302528; https://api.elsevier.com/content/article/pii/S0749072015302528,35097990.0,3
89291,89291,114230,41vy9elp,f88e22cb3c38c82226b07f7cdc3bd73cd3abea36,Elsevier; PMC,Immunité et vaccinations antivirales : exemple de la muqueuse respiratoire,10.1016/s1294-5501(07)88778-4,PMC7146774,,els-covid,rèsumè objectifs le surface muqueuses de l ’ arbre respiratoire constituant une porte ’ entrée très importante pour de nombreux agent pathogènes bactériens ou viraux elles apparaissent comme un site critique pour la réponse immune ainsi de vaccins stimulant cette immunité locale sembleraient constituer une approche intéressante dans la prévention de ce infection après avoir détaillé le différents mécanismes mi en jeu dans cette immunité muqueuse cette étude pour ’ analyser le principe ’ une telle vaccination et le différents vaccins administrables par voie respiratoire immunité muqueuse le principaux anticorps sécrétés localement appartiennent à l ’ isotype iga siga le anticorps de type igm sigm et igg sigg ayant un rôle encore largement discuté le cellules effectrices qui dominent au niveau de la muqueuse ne sont pa de cellules iga de type b mais de lymphocyte qui peuvent représenter jusqu ’ à de la totalité de population lymphocytaires de la muqueuse immunoprophylaxie par voie respiratoire de immunoglobulines spécifiques administrées localement peuvent prévenir de infection virales comme cela été démontré pour le vrs mais le quantités ’ anticorps nécessaires pour être active sont très importantes et difficiles à obtenir parmi le facteurs susceptibles ’ induire une réponse immune muqueuse et une immunité à médiation cellulaire retrouve la voie orale ou respiratoire et de virus réplicatifs à ce jour très peu de vaccins antiviraux muqueux ont vu le jour et le seul exemple pour le virus respiratoires reste le vaccin grippal atténué administré par voie nasale ’ autres vaccins commercialisés par voie parentérale ont été utilisés expérimentalement par voie nasale qu ’ il ’ agisse de vaccins vivants varicelle rougeole ou inactivés grippe injectable il n ’ induisent par cette voie inhabituelle qu ’ une réponse locale modérée conclusion il apparaît donc dans l ’ état actuel de no connaissances et de vaccins disponibles que la voie muqueuse ne constitue pa une voie essentielle et incontournable pour élaborer un vaccin actif contre de virus respiratoires mais l ’ exemple du vaccin grippe atténué administré par voie nasale est à lui seul prometteur pour l ’ avenir de la vaccination par voie muqueuse et ’ autres approches plus sophistiquées pourraient voir le jour dans le années à venir objective mucosal surface respiratory tract represent major portal entry human virus many bacteria seem critical component mammalian immunologic repertoire thus vaccine stimulating local immunity could represent interesting approach prevent infection detailing different mechanism implied mucosal immunity aim study analyze basis vaccination different vaccine available mucosal respiratory tract use mucosal immunity major antibody isotype external secretion secretory immunoglobin siga role igm sigm igg sigg actually questionned however interesting major effector cell mucosal surface iga b cell lymphocyte may represent entire mucosal lymphoid cell population immunoprophylaxis mucosal route passive antibody shown protect mucosal viral infection caused rsv high quantity passive antibody needed restrict virus replication mucosal surface general factor favor development mucosal antibody cell mediated immune response include oral respiratory immunization replicating nature vaccine agent however date vaccine become available mucosal respiratory tract use coldadapted influenza virus vaccine one available using nasal route parenteral licensed vaccine recommended mucosal administration experimentally used nasal administration replicating agent varicella measles vaccine non replicating agent influenza inactivated vaccine found induce low mucosal response conclusion based experience existing vaccine development mucosal immunity administration vaccine via mucosal route clearly prerequisite today control prevention viral infectious respiratory disease disease respiratory tract route contamination example live attenuated intranasal influenza vaccine inducing systemic local immune response without immunopathology promising future mucosal immunization respiratory viral infection,2007-05-31,"Denis, F.; Hantz, S.; Alain, S.",Antibiotiques,,,,document_parses/pdf_json/f88e22cb3c38c82226b07f7cdc3bd73cd3abea36.json,,https://api.elsevier.com/content/article/pii/S1294550107887784; https://www.sciencedirect.com/science/article/pii/S1294550107887784,72681028.0,3
89327,89327,114280,b54jv4xc,,Medline; WHO,Mers-cov spike protein vaccine and inactivated influenza vaccine formulated with single strand rna adjuvant induce t-cell activation through intranasal immunization in mice,10.3390/pharmaceutics12050441,,32397649.0,unk,effectiveness vaccine enhanced adding adjuvant furthermore selection inoculation route depends type adjuvant used important achieving optimum vaccine efficacy investigated immunological difference two type vaccines—spike protein middle east respiratory syndrome virus inactivated influenza virus vaccine combination singlestranded rna adjuvant—administered various route intramuscular intradermal intranasal balbc mouse intramuscular immunization rna adjuvantformulated spike protein elicited highest humoral immune response characterized igg neutralizing antibody production although intranasal immunization elicit humoral response showed extensive tcell activation largescale induction interferonγand interleukinsecreting cell well cd tcell activation mouse splenocytes moreover intranasal immunization induced iga production immunized inactivated influenza vaccine administration rna adjuvant via route led protection viral challenge regardless presence vaccinespecific antibody therefore inoculation route depend type immune response neededi e intramuscular route suitable eliciting humoral immune response whereas intranasal route useful tcell activation iga induction,2020,"Kim, H. J.; Kwak, H. W.; Kang, K. W.; Bang, Y. J.; Lee, Y. S.; Park, H. J.; Kim, J. Y.; Hwang, K. A.; Lee, S. M.; Nam, J. H.",Pharmaceutics,,#326674,,,,https://www.ncbi.nlm.nih.gov/pubmed/32397649/; https://doi.org/10.3390/pharmaceutics12050441,218618665.0,3
89365,89365,114328,jd91k19z,3c9db7ee30074667f9fe308de9910b013aa1f163,Medline; PMC,Recombinant adenoviral vaccine encoding the spike 1 subunit of the Middle East Respiratory Syndrome Coronavirus elicits strong humoral and cellular immune responses in mice,10.14202/vetworld.2019.1554-1562,PMC6868266,31849416.0,cc-by,background aim middle east respiratory syndrome coronavirus merscov rapidly spread throughout middle east since discovery virus pose significant global public health threat potentially devastating effect study recombinant adenoviralbased vaccine encoding spike subunit merscov genome constructed humoral cellular immune response evaluated mouse material method mouse immunized initially intramuscular injection boosted week later intranasal application expression protein lung kidney detected using conventional polymerase chain reaction pcr immunohistochemistry ihc targeting specific region within subunit week first vaccination antigenspecific humoral cellular immune response evaluated serum cell culture following vitro stimulation specific mer epitope within protein cysslildy result protein expression detected ihc kidney admerss group week first immunization lung kidney admerss group conventional pcr week postprime vaccine elicited specific simmunoglobulin g antibody response detected serum vaccinated mouse week onset first immunization significant increase amount threlated cytokine interferonγ interleukin il significant decrease threlated cytokine il splenocyte cell culture vaccinated group compared control group conclusion result study suggest recombinant adenovirus vaccine encoding subunit merscov elicits potentially protective antigenspecific humoral cellular immune response mouse study demonstrates promising vaccine control andor prevention merscov infection human,2019-10-11,"Ababneh, Mustafa; Alrwashdeh, Mu’men; Khalifeh, Mohammad",Vet World,,,,document_parses/pdf_json/3c9db7ee30074667f9fe308de9910b013aa1f163.json,document_parses/pmc_json/PMC6868266.xml.json,https://doi.org/10.14202/vetworld.2019.1554-1562; https://www.ncbi.nlm.nih.gov/pubmed/31849416/,208591710.0,3
89416,89416,114392,1vp8r4er,a9b89e25eda369c143f0185f03fec7efbc0221ca,Elsevier; Medline; PMC,Distribution and absence of generalized lesions in mice following single dose intramuscular inoculation of the vaccine candidate MVA-MERS-S,10.1016/j.biologicals.2018.05.004,PMC7128986,29759890.0,els-covid,modified vaccinia virus ankara mva highly attenuated replicationdeficient virus serving vaccine infectious disease assessed vivo distribution recombinant mva candidate vaccine middle eastern respiratory syndrome mvamerss mouse intramuscularly inoculated mouse necropsied different time point examined histology immunohistochemistry realtime pcr detected inflammation myonecrosis parenteral site hyperplasia draining lymph node mvamerss result detectable lesion tissue peripheral parenteral site draining lymph node realtime pcr analysis tissue sample detected mvadna predominantly injection site draining lymph node suggested continuous clearance candidate vaccine observation period level parenteral site inflammation hyperplasia draining lymph node considered line immunological response vaccine inoculation,2018-07-31,"Langenmayer, Martin C.; Lülf-Averhoff, Anna-Theresa; Adam-Neumair, Silvia; Fux, Robert; Sutter, Gerd; Volz, Asisa",Biologicals,,,,document_parses/pdf_json/a9b89e25eda369c143f0185f03fec7efbc0221ca.json,document_parses/pmc_json/PMC7128986.xml.json,https://api.elsevier.com/content/article/pii/S1045105618301374; https://doi.org/10.1016/j.biologicals.2018.05.004; https://www.ncbi.nlm.nih.gov/pubmed/29759890/; https://www.sciencedirect.com/science/article/pii/S1045105618301374,46891621.0,3
89455,89455,114435,9ladxjji,1cedac13a5c2517a61ac6f6295b24ba2ad7c11ab,Elsevier; PMC,Development of attenuated vaccines from Taiwanese infectious bronchitis virus strains,10.1016/j.vaccine.2005.08.081,PMC7115542,16239054.0,els-covid,due variation serotypes among different strain avian infectious bronchitis virus ibv vaccination chick imported vaccine fails protect ibv infection taiwan therefore develop attenuated vaccine local strain taiwan taiwan group tw strain passaged time specific pathogenfree spf chicken embryonated egg tested spf chicken attenuated vaccine pathogenic weekold chick neutralization index ni greater efficacy inoculated bird challenged field ibv strain similar result obtained vaccine made taiwan group ii ibv strain additionally tw attenuated vaccine strain reversion virulence five back passage chick conclusion attenuated vaccine potential controlling local taiwanese ibv infection chicken,2006-02-06,"Huang, Yuan-Pin; Wang, Ching-Ho",Vaccine,,,,document_parses/pdf_json/1cedac13a5c2517a61ac6f6295b24ba2ad7c11ab.json,document_parses/pmc_json/PMC7115542.xml.json,https://api.elsevier.com/content/article/pii/S0264410X05009060; https://www.sciencedirect.com/science/article/pii/S0264410X05009060,31319380.0,3
89477,89477,114460,cwc0flt0,789d8f8e801484da5740462f088a39aaf4e2a411,Medline; PMC,Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies,10.3390/v1030802,PMC3185542,21994570.0,cc-by,several human monoclonal antibody hmabs antibody fragment including best characterized term structurefunction b fab x exhibit relatively potent broad hiv neutralizing activity however elicitation b blike antibody vivo vaccine immunogen based hiv envelope glycoprotein env successful b highly divergent closest corresponding germline antibody x le divergent hypothesized relatively high degree specific somatic hypermutations may preclude binding hiv envelope glycoprotein env closest germline antibody identifying antibody intermediate pathway maturation could help design novel vaccine immunogen guide immune system enhanced elicitation support hypothesis previously found germlinelike b monovalent bivalent scfv fc fusion protein igg lack measurable binding env measured elisa sensitivity μm range present evidence confirming expanding finding panel envs contrast germlinelike scfv x bound env high nm affinity begin explore maturation pathway antibody identified several possible b intermediate antibody tested neutralizing activity intermediate antibody neutralized hiv isolates relatively weak potency contrast germlinelike scfv x neutralized subset tested hiv isolates comparable efficiency mature x result could help explain relatively high immunogenicity coreceptor binding site gp abundance cdinduced cdi antibody hivinfected patient x cdi antibody well maturation pathway x also help identify antigen bind specifically b germline intermediate antibody together envs could used conceptually novel type candidate vaccine candidate vaccine based two immunogen could help guiding immune system complex maturation pathway elicitation antibody similar identical antibody known property,2009-11-06,"Xiao, Xiaodong; Chen, Weizao; Feng, Yang; Dimitrov, Dimiter S.",Viruses,,,,document_parses/pdf_json/789d8f8e801484da5740462f088a39aaf4e2a411.json,document_parses/pmc_json/PMC3185542.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/21994570/; https://doi.org/10.3390/v1030802,936394.0,3
89485,89485,114469,q8i2gfut,cd20636717b2150e71b69c9d62945a8f3a49b809; 26e505b0228a95ae17d9dfee8ce18ff2af4ddb0c,Elsevier; Medline; PMC,Recombinant Receptor Binding Domain Protein Induces Partial Protective Immunity in Rhesus Macaques Against Middle East Respiratory Syndrome Coronavirus Challenge(),10.1016/j.ebiom.2015.08.031,PMC4634622,26629538.0,cc-by-nc-nd,background development effective vaccine middle east respiratory syndrome coronavirus merscov urgent limited information available vaccination nonhuman primate nhp model herein report evaluating recombinant receptorbinding domain rrbd protein vaccine rhesus macaque model method nine monkey randomly assigned highdose lowdose mock groupswhich immunized different dos rrbd plus alum adjuvant adjuvant alone different time point week immunological analysis conducted immunisation monkey challenged merscov day final immunisation followed observation clinical sign chest xrays nasal oropharyngeal rectal swab also collected analysis monkey euthanized day challenge multiple specimen tissue collected pathological virological immunological test conclusion robust sustained immunological response including neutralisation antibody elicited rrbd vaccination besides rrbd vaccination alleviated pneumonia evidence reduced tissue impairment clinical manifestation monkey furthermore rrbd vaccine decreased viral load lung trachea oropharyngeal swab monkey data nhp pave way development effective human vaccine merscov infection,2015-08-18,"Lan, Jiaming; Yao, Yanfeng; Deng, Yao; Chen, Hong; Lu, Guangwen; Wang, Wen; Bao, Linlin; Deng, Wei; Wei, Qiang; Gao, George F.; Qin, Chuan; Tan, Wenjie",EBioMedicine,,,,document_parses/pdf_json/cd20636717b2150e71b69c9d62945a8f3a49b809.json; document_parses/pdf_json/26e505b0228a95ae17d9dfee8ce18ff2af4ddb0c.json,document_parses/pmc_json/PMC4634622.xml.json,https://api.elsevier.com/content/article/pii/S2352396415301158; https://www.sciencedirect.com/science/article/pii/S2352396415301158; https://doi.org/10.1016/j.ebiom.2015.08.031; https://www.ncbi.nlm.nih.gov/pubmed/26629538/,17876983.0,3
89513,89513,114504,cbx5xvxw,33aceb941234a4f2da4bf9412fbb1bccbe98eb78,Elsevier; PMC,Chapter 20 Vaccines the tugboat for prevention-based animal production,10.1016/b978-0-12-816352-8.00020-5,PMC7149732,,els-covid,world population growing faster rate daybyday demand animal product also increasing meet food security worldwide sustained production animal product healthy livestock poultry farming major concern animal susceptible various infectious agent viz bacteria virus parasite leading huge economical loss form livestock ’ morbidity mortality besides zoonotic nature infectious pathogen animal also raising concern human safety vaccination animal various disease present different geographical region best known strategy prevention different disease outbreak organized unorganized livestock poultry sector vaccine played major role eradication different dreaded disease livestock sector globally article discussed different vaccine type various vaccine strategy used development efficacious safe vaccine commercially available vaccine livestock poultry,2020-12-31,"Nimmanapalli, Ramadevi; Gupta, Vikas","Genomics and Biotechnological Advances in Veterinary, Poultry, and Fisheries",,,,document_parses/pdf_json/33aceb941234a4f2da4bf9412fbb1bccbe98eb78.json,document_parses/pmc_json/PMC7149732.xml.json,https://api.elsevier.com/content/article/pii/B9780128163528000205; https://www.sciencedirect.com/science/article/pii/B9780128163528000205,204654378.0,3
89518,89518,114509,qjlhoi7l,c3617dc2a70b0046f95b857cb09cafeebf0a8ce4,Medline; PMC,Lassa virus diversity and feasibility for universal prophylactic vaccine,10.12688/f1000research.16989.1,PMC6357994,30774934.0,cc-by,lassa virus lasv highly prevalent mammarenavirus west africa maintained nature persistently infected rodent host mastomys natalensis widely spread subsaharan africa lasv infection human cause lassa fever lf disease associated high morbidity significant mortality recent evidence indicates lasv expansion outside traditional endemic area world health organization included lasv toppriority pathogen released target product profile tpp vaccine development likewise u food drug administration added lf priority review voucher program encourage development preventive therapeutic measure article review recent progress lasv vaccine research development focus impact lasv genetic biological diversity design development vaccine candidate meeting ’ tpp lasv vaccine,2019-01-31,"Lukashevich, Igor S.; Paessler, Slobodan; de la Torre, Juan Carlos",F1000Res,,,,document_parses/pdf_json/c3617dc2a70b0046f95b857cb09cafeebf0a8ce4.json,document_parses/pmc_json/PMC6357994.xml.json,https://doi.org/10.12688/f1000research.16989.1; https://www.ncbi.nlm.nih.gov/pubmed/30774934/,61809167.0,3
89524,89524,114516,ya410nbj,f8abd9e10df6beeffec38bc7dd7083318e0d69ed,Medline; PMC,Improvement of different vaccine delivery systems for cancer therapy,10.1186/1476-4598-10-3,PMC3024302,21211062.0,cc-by,cancer vaccine promising tool hand clinical oncologist many tumorassociated antigen excellent target immune therapy vaccine design optimally designed cancer vaccine combine best tumor antigen effective immunotherapy agent andor delivery strategy achieve positive clinical result various vaccine delivery system different route immunization physicalchemical delivery method used cancer therapy goal induce immunity tumorassociated antigen two basic delivery approach including physical delivery achieve higher level antigen production formulation microparticles target antigenpresenting cell apc demonstrated effective animal model new development vaccine delivery system improve efficiency clinical trial near future among nanoparticles np dendrimers polymeric np metallic np magnetic np quantum dot emerged effective vaccine adjuvant infectious disease cancer therapy furthermore cellpenetrating peptide cpp known attractive carrier application drug delivery gene transfer dna vaccination review focus utilization different vaccine delivery system prevention treatment cancer discus clinical application future prospect cancer vaccine development,2011-01-07,"Bolhassani, Azam; Safaiyan, Shima; Rafati, Sima",Mol Cancer,,,,document_parses/pdf_json/f8abd9e10df6beeffec38bc7dd7083318e0d69ed.json,document_parses/pmc_json/PMC3024302.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/21211062/; https://doi.org/10.1186/1476-4598-10-3,2520075.0,3
89528,89528,114520,w38jpqvo,09ac772e6db1145039c752875cfeac062be7e90c,Elsevier; PMC,"Effect of essential oils on the immune response to some viral vaccines in broiler chickens, with special reference to Newcastle disease virus",10.1016/j.psj.2020.03.008,PMC7141634,,els-covid,trial assessed efficacy commercial essential oil eos product immune response vaccination newcastle disease nd subsequent challenge virulent nd virus genotype vii vndv genotype vii using following experimental group broiler chicken group bird three replicates nseven nc negative control pc positive control vc vaccinated vtc vaccinated treated eos moreover trial study effect eos vndv genotype vii vivo preventive therapeutic measure two additional ndvaccinated group used prv medicated one day vndv challenge day ttt medicated two day post vndv challenge day addition immunemodulatory effect eos avian influenza ai infectious bronchitis ib infectious bursal disease ibd vaccine assessed serological response use eos along administration nd vaccine vtc revealed lower mortality rate clinical sign post mortem lesion score comparing nd vaccine alone vc mortality score addition lower hemagglutination inhibition hi p ± viral shedding log ± titre one week post challenge comparison vc ± log ± respectively nevertheless eos mixture vtc ± significantly p improve growth performance compared nontreated bird nc vc ± ± essential oil showed antiviral effect vndv vivo chicken preventive measure prv well therapeutic effect ttt decreasing viral shedding titre lonc mortality rate severity clinical sign post mortem lesion addition serum malondialdhyde mda level regarding virus eos mixture improve immune response ai ib vaccine significantly p increased elisa antibody titre ibd virus th day age ± studied eos mixture showed immune stimulating response nd ibd vaccine antiviral effect nd virus especially administered challenge however growth promoting effect,2020-04-08,"El-Shall, Nahed A.; Shewita, Ramadan S.; Abd El-Hack, Mohamed E.; AlKahtane, Abdullah; Alarifi, Saud; Alkahtani, Saad; Abdel-Daim, Mohamed M.; Sedeik, Mahmoud E.",Poult Sci,,,,document_parses/pdf_json/09ac772e6db1145039c752875cfeac062be7e90c.json,document_parses/pmc_json/PMC7141634.xml.json,https://api.elsevier.com/content/article/pii/S0032579120301681; https://www.sciencedirect.com/science/article/pii/S0032579120301681?v=s5,215403695.0,3
89578,89578,114579,dn2z3alc,6969a0ec11f133c8d770ad40f1e44da7be705641,Elsevier; PMC,Chapter 15 Antiviral Vaccines: Challenges and Advances,10.1016/b978-0-12-802174-3.00015-1,PMC7150210,,els-covid,vaccination effective mean preventing controlling viral infection eradication smallpox significant progress made toward polio eradication clear example great impact antiviral vaccine however viral infection remain major public health threat significant cause death antiviral vaccine introduced past century empirically developed poliomyelitis measles mumps rubella example disease largely controlled thanks empirically developed vaccine however growing list viral pathogen effective vaccine yet developed recent technological advance potentially provide u new platform could harnessed develop vaccine emerging reemerging viral pathogen,2016-12-31,"Ellebedy, Ali H.; Ahmed, Rafi",The Vaccine Book,,,,document_parses/pdf_json/6969a0ec11f133c8d770ad40f1e44da7be705641.json,document_parses/pmc_json/PMC7150210.xml.json,https://www.sciencedirect.com/science/article/pii/B9780128021743000151; https://api.elsevier.com/content/article/pii/B9780128021743000151,88552111.0,3
89603,89603,114609,y4eyse0y,e9ee637040a204668c5d9950fba63fe4e5841bec,Medline; PMC,SARS vaccines: where are we?,10.1586/erv.09.43,PMC7105754,19538115.0,no-cc,review current state vaccine development human severe acute respiratory syndrome sars coronavirus focusing recently published data assessed discus strategy assessed immunologically evaluated sars coronavirus challenge model discus inactivated vaccine virally bacterially vectored vaccine recombinant protein dna vaccine well use attenuated vaccine data regarding correlate protection animal model available evidence regarding potential vaccine enhancement sars disease discussed much evidence various vaccine strategy sars safe immunogenic vaccinated animal still display significant disease upon challenge current data suggest intranasal vaccination may crucial new combination strategy may required good protective efficacy sars human,2014-01-09,"Roper, Rachel L; Rehm, Kristina E",Expert Rev Vaccines,,,,document_parses/pdf_json/e9ee637040a204668c5d9950fba63fe4e5841bec.json,document_parses/pmc_json/PMC7105754.xml.json,https://doi.org/10.1586/erv.09.43; https://www.ncbi.nlm.nih.gov/pubmed/19538115/,10433997.0,3
89611,89611,114619,3kod0oah,e5a9ff92cb7827fa7f053d56a4776f4b91461cf9,Elsevier; PMC,Protection of Newborn Animals through Maternal Immunization,10.1016/j.jcpa.2007.04.009,PMC7094439,17559866.0,els-covid,summary providing protective immunity neonatal animal early life associated numerous challenge regarding vaccine safety efficacy much simpler approach maternal vaccination either pregnancy provide neonate passively transferred immunity human medical societal legal risk immunizing pregnant woman important consideration undertaking approach contrast maternal vaccination successfully employed animal health industry decade veterinary vaccine proven safe efficient although passively transferred antibody extensively studied immunological mechanism may equally important providing maternally derived immunity,2007-07-31,"Pravieux, J. J.; Poulet, H.; Charreyre, C.; Juillard, V.",Journal of Comparative Pathology,,,,document_parses/pdf_json/e5a9ff92cb7827fa7f053d56a4776f4b91461cf9.json,document_parses/pmc_json/PMC7094439.xml.json,https://api.elsevier.com/content/article/pii/S0021997507000576; https://www.sciencedirect.com/science/article/pii/S0021997507000576,44837294.0,3
89614,89614,114623,9w0b806e,2c4ed9a5c00939f378accbc12965f7cbd60d2baf; 392e54953ce16d79761e04d9505cf9e9339afe03; 40d5ffccc33011c153c0fc1fbdd663507c851d65,Elsevier; Medline; PMC,MIDDLE EAST RESPIRATORY SYNDROME VACCINES,10.1016/j.ijid.2016.04.008,PMC4969153,27062985.0,gold-oa,middle east respiratory syndromecoronavirus merscov infected individual nearly death since first identified human population antiviral therapy vaccine treatment prophylaxis available discus approach developing mers vaccine including summary previous effort develop vaccine useful human nonhuman coronaviruses striking feature mers important role camel transmission camel vaccination may novel approach preventing human infection,2016-06-01,"Perlman, Stanley; Vijay, Rahul",International Journal of Infectious Diseases,,,,document_parses/pdf_json/2c4ed9a5c00939f378accbc12965f7cbd60d2baf.json; document_parses/pdf_json/392e54953ce16d79761e04d9505cf9e9339afe03.json; document_parses/pdf_json/40d5ffccc33011c153c0fc1fbdd663507c851d65.json,document_parses/pmc_json/PMC4969153.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/27062985/; http://www.ijidonline.com/article/S1201971216310219/pdf; https://www.sciencedirect.com/science/article/pii/S1201971216310219; https://doi.org/10.1016/j.ijid.2016.04.008; https://api.elsevier.com/content/article/pii/S1201971216310219,19136000.0,3
89618,89618,114629,v7zvecx3,ffe133ed880d6c77ae340c5374817232e21f8315,Medline; PMC,Rational Design of Peptide Vaccines Against Multiple Types of Human Papillomavirus,10.4137/cin.s39071,PMC4890726,27279731.0,no-cc,human papillomavirus hpv occurs many type cause cervical genital cancer vaccination available major cancercausing hpv type many others covered preventive measure herein present bioinformatics study designing multivalent peptide vaccine multiple hpv type alternative strategy viruslike particle vaccine used technique rational design peptide vaccine expected ensure stability vaccine many cycle mutational change elicit immune response negate autoimmune possibility using l capsid protein sequence identified several peptide potential vaccine design hpv type although concern epitopebinding affinity peptide identified process technique indicates possibility multivalent adjuvanted peptide vaccine wider range hpv type tailormade different combination peptide address frequency variation type different population group required prophylaxis lower cost use present time,2016-06-01,"Dey, Sumanta; De, Antara; Nandy, Ashesh",Cancer Inform,,,,document_parses/pdf_json/ffe133ed880d6c77ae340c5374817232e21f8315.json,document_parses/pmc_json/PMC4890726.xml.json,https://doi.org/10.4137/cin.s39071; https://www.ncbi.nlm.nih.gov/pubmed/27279731/,623616.0,3
89632,89632,114644,bhdly6oh,ae74d70ee40f4b11007c54068b0ba2de0f2fe23a,Elsevier; Medline; PMC,"Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation",10.1016/j.vaccine.2010.08.108,PMC7126493,20951666.0,els-covid,likely genebased vaccine enter human vaccine area soon veterinary vaccine employing concept already licensed multitude clinical trial infectious disease different form cancer ongoing highly important developing novel vaccine safety aspect also new adjuvant delivery technique need carefully investigated meet short longterm safety requirement one novel vivo delivery method plasmid vaccine electroporation application short pulse electric current immediately site injection genetic vaccine method shown significantly augment transfection efficacy subsequent vaccinespecific immune response however dramatic increase delivery efficacy offered electroporation raised concern potential increase risk integration plasmid dna host genome demonstrate safety lack integration immunization high dose multigene hiv vaccine delivered intradermally using needle free device biojector together electroporation using derma vax™ dna vaccine skin delivery system demonstrate plasmid persist skin site injection least four month immunization however association plasmid dna genomic dna could detected analyzed qpcr following field inversion gel electrophoresis separating heavy light dna fraction shortly initiate phase clinical trial healthy volunteer immunized multiplasmid hiv vaccine using combination delivery method jetinjection intradermal electroporation,2010-11-29,"Bråve, Andreas; Gudmundsdotter, Lindvi; Sandström, Eric; Haller, B. Kristian; Hallengärd, David; Maltais, Anna-Karin; King, Alan D.; Stout, Richard R.; Blomberg, Pontus; Höglund, Urban; Hejdeman, Bo; Biberfeld, Gunnel; Wahren, Britta",Vaccine,,,,document_parses/pdf_json/ae74d70ee40f4b11007c54068b0ba2de0f2fe23a.json,document_parses/pmc_json/PMC7126493.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X10014489; https://doi.org/10.1016/j.vaccine.2010.08.108; https://www.ncbi.nlm.nih.gov/pubmed/20951666/; https://api.elsevier.com/content/article/pii/S0264410X10014489,35921358.0,3
89650,89650,114672,z348xbn0,50c268968326f133eeacd3745e43a4226d867ce8,Medline; PMC,In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine,10.1038/s41598-019-51679-8,PMC6811573,31645650.0,cc-by,human papillomavirus hpv common sexually transmitted infection world main cause cervical cancer nowadays viruslike particle vlps based l protein considered best candidate vaccine development hpv infection two commercial hpv gardasil cervarix available hpv vlp vaccine induce genotypelimited protection major impediment economic barrier especially gap financing obstructed optimal delivery vaccine developing country thus many effort underway develop next generation vaccine type highrisk hpv study developed dna construct based l l gene potentially immunogenic highly conserved among highrisk hpv type framework analysis include bcell epitope mapping tcell epitope mapping ie cd cd cell allergenicity assessment tap transport proteasomal cleavage population coverage global templatebased docking data collection analysis design l l dna construct data indicated epitope candidate helper tcell ctl l l sequence l l construct combination peptide single universal vaccine could involve world population rate respectively vitro study showed high expression rate multiepitope l l dna construct hekt cell moreover vivo study indicated combination l l dna construct without adjuvant delivery system induced effective immune response protected mouse c tumor cell percentage tumorfree mouse thus designed l l dna construct would represent promising application hpv vaccine development,2019-10-23,"Namvar, Ali; Bolhassani, Azam; Javadi, Gholamreza; Noormohammadi, Zahra",Sci Rep,,,,document_parses/pdf_json/50c268968326f133eeacd3745e43a4226d867ce8.json,document_parses/pmc_json/PMC6811573.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31645650/; https://doi.org/10.1038/s41598-019-51679-8,204835540.0,3
89677,89677,114708,8f4eoeix,20d7551ecd14f5f02421184c2e2a68f8cf6d204d,Elsevier; Medline; PMC,"Chapter 9 Infections caused by rubella, reoviridae, retro, Norwalk and ronaviruses",10.1016/s0168-7069(08)70017-x,PMC7134074,32287581.0,els-covid,publisher summary chapter focus infection caused rubella reoviridae retro norwalk coronaviruses high incidence acute gastroenteritis caused rotavirus call prophylactic therapeutic measure although vaccine presently available seems likely vaccine developed next year also several rotavirus enzyme useful target antiviral drug however antiviral drug shown therapeutic effect rotavirus infection newly discovered human retrovirus htlv yet investigated detail predict usefulness vaccine antiviral drug several compound known inhibit retrovirus enzyme implication chemotherapy htlv infection unknown present possibility need vaccination chemotherapy norwalk virus related agent unclear little work carried date human coronaviruses either point view vaccine development specific antiviral approach may usefully investigated future genetic cloning may particularly useful development inactivated vaccine virus would difficult replicate purify large quantity conventional vaccine,1985-12-31,,Perspectives in Medical Virology,,,,document_parses/pdf_json/20d7551ecd14f5f02421184c2e2a68f8cf6d204d.json,,https://www.ncbi.nlm.nih.gov/pubmed/32287581/; https://doi.org/10.1016/s0168-7069(08)70017-x; https://www.sciencedirect.com/science/article/pii/S016870690870017X; https://api.elsevier.com/content/article/pii/S016870690870017X,214757040.0,3
89684,89684,114717,2h7fi1g9,80460fea573744e05caa7ce9d61089d3d1ab0015,Elsevier; Medline; PMC,Colostrum from cows immunized with a veterinary vaccine against bovine rotavirus displays enhanced in vitro anti-human rotavirus activity,10.3168/jds.2018-16016,PMC7127701,30981494.0,els-covid,human rotavirus represent major cause severe diarrheal disease infant young child limited impact oral vaccine global estimate rotavirus mortality suboptimal use oral rehydration justify need alternative prophylactic therapeutic strategy especially immunocompromised host protective effect colostrum—the first milk produced initial h parturition—are well documented literature particular ingestion hyperimmune bovine colostrum proposed alternative preventive approach human rotavirus gastroenteritis although immunization pregnant cow human rotavirus boost release specific immunoglobulin g bovine colostrum raise regulatory safety issue study demonstrated conventional bovine rotavirus vaccine sufficient enhance antihuman rotavirus protective efficacy bovine colostrum thus providing conservative approach produce hyperimmune bovine colostrum making exploitable functional food,2019-06-30,"Civra, Andrea; Altomare, Alessandra; Francese, Rachele; Donalisio, Manuela; Aldini, Giancarlo; Lembo, David",Journal of Dairy Science,,,,document_parses/pdf_json/80460fea573744e05caa7ce9d61089d3d1ab0015.json,document_parses/pmc_json/PMC7127701.xml.json,https://doi.org/10.3168/jds.2018-16016; https://api.elsevier.com/content/article/pii/S0022030219303443; https://www.sciencedirect.com/science/article/pii/S0022030219303443; https://www.ncbi.nlm.nih.gov/pubmed/30981494/,115200148.0,3
89711,89711,114749,h9m51dim,6dde6bd27d632a48fdedc6ccc3b396c0d5f3e2d6,Medline; PMC,"Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools",10.3389/fimmu.2020.00442,PMC7154102,32318055.0,cc-by,computational vaccinology includes epitope mapping antigen selection immunogen design using computational tool tool facilitate silico prediction immune response biothreats emerging infectious disease cancer accelerate design novel next generation vaccine delivery clinic past year vaccinologists bioinformatics expert advanced programmer based providence rhode island usa advanced development integrated toolkit vaccine design called ivax secure useraccessible internet integrated set immunoinformatic tool comprises algorithm scoring triaging candidate antigen selecting immunogenic conserved cell epitope reengineering eliminating regulatory cell epitope redesigning antigen induce immunogenicity protection disease human livestock commercial academic application ivax included identifying immunogenic cell epitope development tcell based human multiepitope q fever vaccine designing novel influenza vaccine identifying crossconserved cell epitope malaria vaccine analyzing immune response clinical vaccine study animal vaccine application date included viral infection pig swine influenza pcv african swine fever “ rapidfire ” application biodefense included demonstration project lassa fever q fever recent infectious disease outbreak underscore significance vaccinedriven preparedness integrated set tool available ivax toolkit stand ready help vaccine developer deliver genomederived epitopedriven vaccine,2020-04-07,"De Groot, Anne S.; Moise, Leonard; Terry, Frances; Gutierrez, Andres H.; Hindocha, Pooja; Richard, Guilhem; Hoft, Daniel Fredric; Ross, Ted M.; Noe, Amy R.; Takahashi, Yoshimasa; Kotraiah, Vinayaka; Silk, Sarah E.; Nielsen, Carolyn M.; Minassian, Angela M.; Ashfield, Rebecca; Ardito, Matt; Draper, Simon J.; Martin, William D.",Front Immunol,,,,document_parses/pdf_json/6dde6bd27d632a48fdedc6ccc3b396c0d5f3e2d6.json,document_parses/pmc_json/PMC7154102.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32318055/; https://doi.org/10.3389/fimmu.2020.00442,214807168.0,3
89713,89713,114751,usu6laaq,b55482ebf03a9f847fc1affc39f20eead244c788,Elsevier; Medline; PMC; WHO,Finding equipoise: CEPI revises its equitable access policy,10.1016/j.vaccine.2019.12.055,PMC7130943,32005536.0,els-covid,launched davos january funding sovereign investor philanthropic institution coalition epidemic preparedness innovation cepi innovative partnership public private philanthropic civil organisation whose mission stimulate finance coordinate vaccine development disease epidemic potential case market incentive fail december cepi committed investing million vaccine development includes vaccine candidate priority pathogen lassa fever virus middle east respiratory syndrome coronavirus nipah virus chikungunya rift valley fever three vaccine platform develop vaccine disease x novel unanticipated pathogen entity largely supported public fund ensuring equitable access vaccine whose development support low middleincome country cepi ’ primary focus cepi developed initial equitable access policy shortly formation key stakeholder expressing strong view content prescriptive nature cepi board instructed revisited year paper describes process revising policy key issue resolved cepi continue take iterative rather prescriptive approach policy—one reflects need multiple stakeholder ensures meet equitable access goal,2020-02-24,"Huneycutt, Brenda; Lurie, Nicole; Rotenberg, Sara; Wilder, Richard; Hatchett, Richard",Vaccine,,#1835,,document_parses/pdf_json/b55482ebf03a9f847fc1affc39f20eead244c788.json,document_parses/pmc_json/PMC7130943.xml.json,https://doi.org/10.1016/j.vaccine.2019.12.055; https://www.ncbi.nlm.nih.gov/pubmed/32005536/; https://api.elsevier.com/content/article/pii/S0264410X19317190; https://www.sciencedirect.com/science/article/pii/S0264410X19317190,210998073.0,3
89738,89738,114786,ocrfclzj,cdc06acb5635da09978b60894c373dc644e826a9,Elsevier; Medline; PMC,Extraneous agent detection in vaccines − A review of technical aspects,10.1016/j.biologicals.2012.04.004,PMC7106550,22575785.0,els-covid,quality safety commercial vaccine profound importance contrary precaution effort use biological material vaccine development production may lead potential contamination vaccine known unknown extraneous agent ea veterinary field official list ea compiled legal framework describe potential agent must tested manufacture vaccine nevertheless detection known unknown contaminant vaccine common duty manufacturer authority veterinary human field sharing similar need special technical approach stateofart molecular method randomly primed pcr combined massive parallel sequencing mp microarrays may open new perspective extraneous agent testing robustness efficacy technical approach vaccine control clearly demonstrated human vaccine example porcine circovirus type pcv contamination revealed rotarix human rotavirus vaccine consequence implication reviewed hereby veterinary regulatory point view,2012-07-31,"Farsang, Attila; Kulcsár, Gábor",Biologicals,,,,document_parses/pdf_json/cdc06acb5635da09978b60894c373dc644e826a9.json,document_parses/pmc_json/PMC7106550.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/22575785/; https://doi.org/10.1016/j.biologicals.2012.04.004; https://api.elsevier.com/content/article/pii/S104510561200067X; https://www.sciencedirect.com/science/article/pii/S104510561200067X,9048549.0,3
89808,89808,114873,ztkru6ce,28d792b94b7a02294ff7c3171dcc9c9165337083,Elsevier; Medline; PMC,Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents,10.1016/j.vaccine.2014.08.028,PMC7115511,25173474.0,els-covid,ebola virus ebov infection cause lethal hemorrhagic fever human resulting mortality ebov outbreak sporadic unpredictable nature therefore vaccine able provide durable immunity needed protect risk exposure virus study ass longterm efficacy vesicular stomatitis virus vsvbased vaccine vsvδgebovgp two rodent model ebov infection mouse guinea pig first immunized × × plaque forming unit pfu vsvδgebovgp respectively challenge mouse lethal dose mouseadapted ebov maebov month vaccination provided complete protection survivor protection month vaccination challenge guinea pig lethal dose guinea pigadapted ebov gaebov month vaccination resulted survivor month vaccination survival month vaccination weight loss clinical sign observed surviving animal antibody response analyzed using serum individual rodent level ebov glycoproteinspecific igg antibody measured immediately challenge appeared correlate protection study confirm vaccination vsvδgebovgp able confer longterm protection ebola infection mouse guinea pig support followup study nonhuman primate,2014-09-29,"Wong, Gary; Audet, Jonathan; Fernando, Lisa; Fausther-Bovendo, Hugues; Alimonti, Judie B.; Kobinger, Gary P.; Qiu, Xiangguo",Vaccine,,,,document_parses/pdf_json/28d792b94b7a02294ff7c3171dcc9c9165337083.json,document_parses/pmc_json/PMC7115511.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25173474/; https://doi.org/10.1016/j.vaccine.2014.08.028; https://api.elsevier.com/content/article/pii/S0264410X14011517; https://www.sciencedirect.com/science/article/pii/S0264410X14011517,2462352.0,3
89880,89880,114961,nip7epn6,2c6556c5052130c07d62e29c63db0be9d86e3a2d,Elsevier; Medline; PMC,A survey of recommended practices made by veterinary practitioners to cow-calf operations in the United States and Canada,10.15232/pas.2017-01642,PMC7147640,32288480.0,els-covid,practicing veterinarian n service commercial beef cowcalf herd responded survey describing general recommendation made client term vaccine protocol health production practice responding veterinarian represented state united state province canada responding veterinarian devote practice service commercial cowcalf producer largest group veterinarian practice yr thirtynine percent responding veterinarian serviced cow genetic advice provided practicing veterinarian vaccinating branding common recommended vaccine clostridial infectious bovine rhinotracheitis ibr bovine respiratory syncytial virus brsv parainfluenza pi bovine viral diarrhea bvd type respectively vaccinating weaning common recommended vaccine ibr brsv bvd type pi clostridial mannheimia haemolytica vaccinating weaning common recommended vaccine bvd type ibr bvd type brsv pi responding veterinarian recommended last preventative vaccine administered cattle shipping largest number respondent recommended earliest age client wean calf castrating bull calf age recommended respondent calf nutrition considered extremely important preconditioning program responding veterinarian,2017-12-31,"Fike, G. D.; Simroth, J. C.; Thomson, D. U.; Schwandt, E. F.; Spare, R.; Tarpoff, A. J.",The Professional Animal Scientist,,,,document_parses/pdf_json/2c6556c5052130c07d62e29c63db0be9d86e3a2d.json,document_parses/pmc_json/PMC7147640.xml.json,https://api.elsevier.com/content/article/pii/S1080744617301353; https://www.ncbi.nlm.nih.gov/pubmed/32288480/; https://doi.org/10.15232/pas.2017-01642; https://www.sciencedirect.com/science/article/pii/S1080744617301353,80171307.0,3
89950,89950,115048,nm9d4mf5,fcd9e38e06549c39625f00187d5b8f4a769b584f,Medline; PMC,Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses,10.1038/s41426-017-0007-8,PMC5837162,29362446.0,cc-by,zika virus zikv infection remains serious health threat due close association congenital zika syndrome czs includes microcephaly severe birth defect vaccine available human use continuous effort needed develop effective safe vaccine prevent zikv infection study constructed three recombinant protein comprising respectively residue – e – e – e zikv envelope e protein domain iii ediii fused cterminal fc human igg result demonstrated e induced highest titer neutralizing antibody infection nine zikv strain isolated different host country time period maintained longterm antizikv immunogenicity induce neutralizing antibody pup born mouse immunized e fully protected lethal challenge two epidemic human zikv strain honduras r colombia flr passive transfer antie mouse serum protected pup born naive mouse well type interferon receptordeficient adult mouse lethal challenge human zikv strain r flr protection positively correlated neutralizing antibody data suggest critical neutralizing fragment ie fragment induce highly potent neutralizing antibody divergent zikv strain zikv ediii good candidate development effective safe zikv subunit vaccine protect pregnant mother fetus zikv infection especific antibody used passive immunization prevent zikv infection newborn immunocompromised adult,2018-01-24,"Tai, Wanbo; He, Lei; Wang, Yufei; Sun, Shihun; Zhao, Guangyu; Luo, Chuming; Li, Pei; Zhao, Haiyan; Fremont, Daved H.; Li, Fang; Jiang, Shibo; Zhou, Yusen; Du, Lanying",Emerg Microbes Infect,,,,document_parses/pdf_json/fcd9e38e06549c39625f00187d5b8f4a769b584f.json,document_parses/pmc_json/PMC5837162.xml.json,https://doi.org/10.1038/s41426-017-0007-8; https://www.ncbi.nlm.nih.gov/pubmed/29362446/,3298675.0,3
89992,89992,115098,w813iar2,44113f3391248bc8e6737917ddf20ea938e4755f; 01f0ffeafb753f0a54cde6d40252d74b7c64f6b9,Elsevier; Medline; PMC,Respiratory nanoparticle-based vaccines and challenges associated with animal models and translation,10.1016/j.jconrel.2015.09.047,PMC4760633,26410807.0,hybrid-oa,vaccine development huge impact human health however significant need develop efficacious vaccine several existing well emerging respiratory infectious disease several challenge need overcome develop efficacious vaccine translational potential review focus two aspect overcome barrier – development nanoparticlebased vaccine choice suitable animal model respiratory infectious disease allow translation nanoparticlebased vaccine including subunit vaccine involving synthetic andor natural polymeric adjuvant carrier well based viruslike particle offer several key advantage help overcome barrier effective vaccine development include ability deliver combination antigen target vaccine formulation specific immune cell enable crossprotection divergent strain act adjuvant immunomodulators allow sustained release antigen enable single dose delivery potentially obviate cold chain mouse model provided several important insight mechanism infectious disease often limiting step translation new vaccine clinic overview different animal model involved vaccine research respiratory infection advantage disadvantage model discussed taken together advance nanotechnology combined right animal model evaluating vaccine efficacy potential revolutionize vaccine development respiratory infection,2015-12-01,"Renukaradhya, Gourapura J.; Narasimhan, Balaji; Mallapragada, Surya K.",Journal of Controlled Release,,,,document_parses/pdf_json/44113f3391248bc8e6737917ddf20ea938e4755f.json; document_parses/pdf_json/01f0ffeafb753f0a54cde6d40252d74b7c64f6b9.json,document_parses/pmc_json/PMC4760633.xml.json,https://doi.org/10.1016/j.jconrel.2015.09.047; https://www.ncbi.nlm.nih.gov/pubmed/26410807/; https://www.sciencedirect.com/science/article/pii/S0168365915301474; https://api.elsevier.com/content/article/pii/S0168365915301474; https://manuscript.elsevier.com/S0168365915301474/pdf/S0168365915301474.pdf,28163565.0,3
90001,90001,115109,vtgdqart,e192e65a6546583fe49086c4d3ac29a0620d5bd5,Medline; PMC,Effect of Pullet Vaccination on Development and Longevity of Immunity,10.3390/v11020135,PMC6409539,30717342.0,cc-by,avian respiratory disease cause significant economic loss commercial poultry need protect longlived poultry respiratory tract pathogen early age vaccination program pullet typically involve serial administration variety vaccine including infectious bronchitis virus ibv newcastle disease virus ndv infectious laryngotracheitis virus iltv often interval vaccination matter week yet unknown whether development immunity protection challenge vaccine given short succession occurs bird something known viral interference objective determine whether serially administered live attenuated vaccine ibv ndv iltv influence development longevity immunity protection challenge longlived bird based typical pullet vaccination program specificpathogenfree white leghorn administered multiple live attenuated vaccine ibv ndv iltv week age woa certain group challenged ibv ndv iltv woa five day postchallenge viral load clinical sign ciliostasis tracheal histopathology antibody titer serum tear evaluated demonstrate pullet serially administered live attenuated vaccine ibv ndv iltv protected homologous challenge ibv ndv iltv least week conclude interval vaccination used study least week interfere protection information important show typical pullet vaccination program consisting serially administered live attenuated vaccine multiple respiratory pathogen result development protective immunity disease agent,2019-02-02,"Aston, Emily J.; Jordan, Brian J.; Williams, Susan M.; García, Maricarmen; Jackwood, Mark W.",Viruses,,,,document_parses/pdf_json/e192e65a6546583fe49086c4d3ac29a0620d5bd5.json,document_parses/pmc_json/PMC6409539.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30717342/; https://doi.org/10.3390/v11020135,73415621.0,3
90047,90047,115167,i2o6rs29,cd91b0910feaeeeaf41e37cf3fbf1f65d0c41926,Elsevier; Medline; PMC,Vaccines: Shaping global health,10.1016/j.vaccine.2017.02.017,PMC7127343,28237501.0,els-covid,developing country vaccine manufacturer ’ network dcvmn gathered leader immunization program vaccine manufacturing representative argentinean health authority pan american health organization among global health stakeholder th annual general meeting buenos aire reflect vaccine shaping global health polio eradication elimination measles rubella america result successful collaboration made possible timely supply affordable vaccine decade intense competition highvalue market collaboration developing country become critical involvement multiple manufacturer well public privatesector investment essential developing new vaccine emerging infectious disease recent zika virus outbreak accelerated ebola vaccine development exemplify need international partnership combat infectious disease new player coalition epidemic preparedness innovation cepi made entrance global health community aiming stimulate research preparedness emerging infection facetoface panel discussion facilitated dialogue around challenge risk viability vaccine development regulatory convergence improve access sustainable vaccine supply discussed joint effort optimizing regulatory pathway developing country reducing registration time required outbreak emerging infection global polio eradication containment challenge reminder importance vaccine ’ access importance new publicprivate partnership,2017-03-14,"Pagliusi, Sonia; Ting, Ching-Chia; Lobos, Fernando; Datla, Mahima; Gao, Steven; Homma, Akira; Meng, Li; Suhardono, Mahendra; Suri, Rajinder; Tippoo, Patrick",Vaccine,,,,document_parses/pdf_json/cd91b0910feaeeeaf41e37cf3fbf1f65d0c41926.json,document_parses/pmc_json/PMC7127343.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28237501/; https://www.sciencedirect.com/science/article/pii/S0264410X17301986; https://api.elsevier.com/content/article/pii/S0264410X17301986; https://doi.org/10.1016/j.vaccine.2017.02.017,46798497.0,3
90067,90067,115193,fbuegmb5,8caebe5bb197ded1ab2a9c0e40f0a1bf6f7bfe0a,Medline; PMC,Tools to therapeutically harness the human antibody response,10.1038/nri3285,PMC7097371,23007571.0,no-cc,natural human antibody response rich source highly specific neutralizing selftolerant therapeutic reagent recent advance made isolating characterizing monoclonal antibody generated response natural infection vaccination study human antibody response led discovery crucial epitope could serve new target vaccine design creation potentially powerful immunotherapy focus influenza virus hiv herein summarize technological tool used identify characterize human monoclonal antibody describe tool might used fight infectious disease,2012-09-25,"Wilson, Patrick C.; Andrews, Sarah F.",Nat Rev Immunol,,,,document_parses/pdf_json/8caebe5bb197ded1ab2a9c0e40f0a1bf6f7bfe0a.json,document_parses/pmc_json/PMC7097371.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/23007571/; https://doi.org/10.1038/nri3285,10345219.0,3
90105,90105,115238,5sctqkwr,1a8436e348051d8046fcd0a558a8225470b6a8c7,Elsevier; PMC,Current situation in the development of a preventive HIV vaccine,10.1016/s0213-005x(05)75157-0,PMC7130212,,els-covid,uncontrolled progression aid epidemic made development efficacious human immunodeficiency virus hiv vaccine major objective scientific research effective preventive vaccine hiv currently available sterilizing immunity yet achieved animal model review analysis major challenge developing aid vaccine particular mechanism involved viral escape immune response summarizes result obtained different prototype therapeutic preventive vaccine finally social economic healthcare aspect research hiv vaccine current controversy regarding development clinical trial discussed,2005-07-31,"Alcamí, José; Joseph Munné, Joan; Muñoz-Fernández, María Ángeles; Esteban, Mariano",Enfermedades Infecciosas y Microbiología Clínica,,,,document_parses/pdf_json/1a8436e348051d8046fcd0a558a8225470b6a8c7.json,,https://api.elsevier.com/content/article/pii/S0213005X05751570; https://www.sciencedirect.com/science/article/pii/S0213005X05751570,22618172.0,3
90197,90197,115352,9guym4a9,e1b6ff0ee167175edab0ef907646ecc453d2b5a1,Medline; PMC,From empiricism to rational design: a personal perspective of the evolution of vaccine development,10.1038/nri3694,PMC7096907,24925139.0,no-cc,vaccination effective medical intervention ever introduced originated observation individual survived plague smallpox would get disease twice mimic protective effect natural infection jenner — later pasteur — inoculated individual attenuated killed diseasecausing agent empirical approach inspired century vaccine development effective prophylaxis many infectious disease several wave new technology enabled development novel vaccine would possible using empirical approach technological revolution field vaccination continuing delivering novel safer vaccine timeline article provide view transition empiricism rational vaccine design supplementary information online version article doinri contains supplementary material available authorized user,2014-06-13,"De Gregorio, Ennio; Rappuoli, Rino",Nat Rev Immunol,,,,document_parses/pdf_json/e1b6ff0ee167175edab0ef907646ecc453d2b5a1.json,document_parses/pmc_json/PMC7096907.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/24925139/; https://doi.org/10.1038/nri3694,10258698.0,3
90213,90213,115371,e9ft15kq,409bca8a559a720f63f94a8d26a94f6524f56601,Elsevier; Medline; PMC,Highly conserved epitopes of DENV structural and non-structural proteins: Candidates for universal vaccine targets,10.1016/j.gene.2019.02.001,PMC7125761,30738967.0,els-covid,dengue severe emerging arthropod borne viral disease occurring globally around two fifth world population billion people risk dengue infection infection induces lifelong protective immunity homologous serotype confers partial transient protection subsequent infection caused serotypes thus need vaccine capable providing life long protection serotypes dengue virus study comparative genomics dengue virus denv conducted explore potential candidate novel vaccine target analysis successfully found conserved epitope envelope protein rcptqge n saaqrrgr pgtsgspi nsa qrtpqdnql nsb lqakatreaqkra n protein qrgsgqv denv serotypes serotype specific conserved motif also found n n capsid prm envelope protein using comparative genomics immunoinformatics approach could find conserved epitope explored peptide vaccine candidate combat dengue worldwide serotype specific epitope also exploited rapid diagnostics ten protein explored find conserved epitope denv serotypes thus making extensively studied viral genome far,2019-05-05,"Verma, Mansi; Bhatnagar, Shradha; Kumari, Kavita; Mittal, Nidhi; Sukhralia, Shivani; Gopirajan AT, Shruthi; Dhanaraj, P. S.; Lal, Rup",Gene,,,,document_parses/pdf_json/409bca8a559a720f63f94a8d26a94f6524f56601.json,document_parses/pmc_json/PMC7125761.xml.json,https://doi.org/10.1016/j.gene.2019.02.001; https://api.elsevier.com/content/article/pii/S0378111919300988; https://www.sciencedirect.com/science/article/pii/S0378111919300988; https://www.ncbi.nlm.nih.gov/pubmed/30738967/,73446050.0,3
90221,90221,115381,uscd264p,27b2c6072c3f0ea86e1cb4c527a825e73a56cc4e,Elsevier; Medline; PMC,Lactogenic immunity and vaccines for porcine epidemic diarrhea virus (PEDV): Historical and current concepts,10.1016/j.virusres.2016.05.016,PMC7111331,27212686.0,els-covid,morbidity mortality loss productivity enteric disease neonatal piglet cost swine producer million dollar annually – porcine epidemic diarrhea virus pedv outbreak led million billion annual loss u swine producer passive lactogenic immunity remains promising effective way protect neonatal suckling piglet enteric disease like pedv protecting suckling piglet lactogenic immunity dependent trafficking pathogenspecific iga plasmablast mammary gland accumulation secretory iga siga antibody milk defined gutmammarysiga axis due impermeable placenta piglet born agammaglobulinic highly susceptible plethora infectious agent rely solely colostrum milk antibody maternal lactogenic immunity previous advance development live attenuated vaccine another devastating diarrheal virus pig transmissible gastroenteritis virus tgev provide insight mechanism maternal immunity piglet protection chapter review previous research tgevinduced lactogenic immunity provide historical perspective current effort pedv control vaccine swine industry identifying factor influence lactogenic immunity gutmammarysiga axis may lead improved vaccine regimen pedv enteric pathogen gestating swine improved overall herd immunity swine health industry productivity,2016-12-02,"Langel, Stephanie N.; Paim, Francine Chimelo; Lager, Kelly M.; Vlasova, Anastasia N.; Saif, Linda J.",Virus Research,,,,document_parses/pdf_json/27b2c6072c3f0ea86e1cb4c527a825e73a56cc4e.json,document_parses/pmc_json/PMC7111331.xml.json,https://doi.org/10.1016/j.virusres.2016.05.016; https://www.sciencedirect.com/science/article/pii/S0168170216302155; https://www.ncbi.nlm.nih.gov/pubmed/27212686/; https://api.elsevier.com/content/article/pii/S0168170216302155,46760359.0,3
90259,90259,115428,6mx4o0eb,09d903250451ae770a551ad46d3df9861d947438,Elsevier; Medline; PMC,Enhancement of safety and immunogenicity of the Chinese Hu191 measles virus vaccine by alteration of the S-adenosylmethionine (SAM) binding site in the large polymerase protein,10.1016/j.virol.2018.02.022,PMC6413878,29525671.0,els-covid,liveattenuated measles virus mv vaccine based hu strain played significant role controlling measles china however considerable adverse effect may cause public health burden hypothesize safety efficacy mv vaccine improved altering sadenosylmethionine sam binding site conserved region vi large polymerase protein test hypothesis established efficient reverse genetics system rmvhu strain generated two recombinant mvhu carrying mutation sam binding site two mutant grew high titer vero cell genetically stable significantly attenuated vitro vivo compared parental rmvhu vaccine strain importantly mvhu mutant triggered higher neutralizing antibody rmvhu vaccine provided complete protection mv challenge result demonstrate potential improved mv vaccine candidate,2018-05-31,"Wang, Yilong; Liu, Rongxian; Lu, Mijia; Yang, Yingzhi; Zhou, Duo; Hao, Xiaoqiang; Zhou, Dongming; Wang, Bin; Li, Jianrong; Huang, Yao-Wei; Zhao, Zhengyan",Virology,,,,document_parses/pdf_json/09d903250451ae770a551ad46d3df9861d947438.json,document_parses/pmc_json/PMC6413878.xml.json,https://api.elsevier.com/content/article/pii/S0042682218300655; https://www.ncbi.nlm.nih.gov/pubmed/29525671/; https://www.sciencedirect.com/science/article/pii/S0042682218300655; https://doi.org/10.1016/j.virol.2018.02.022,5005428.0,3
90294,90294,115470,a6merb92,b63e39a5ddbfc6e1c9a66f2bede0aa960e999f30,Medline; PMC,Host receptors: the key to establishing cells with broad viral tropism for vaccine production,10.1080/1040841x.2020.1735992,PMC7113910,32202955.0,no-cc,cell culturebased vaccine technology flexible convenient approach vaccine production requires adaptation vaccine strain new cell driven motivation develop broadly permissive cell line infection wide range virus identified set relevant host receptor involved viral attachment entry identification done review different viral entry pathway host cell line context baltimore classification virus addition indicated potential technical problem proposed solution regarding modify host cell genome order meet industrial requirement mass production antiviral vaccine work contributes finer understanding importance breaking host–virus recognition specificity possibility creating cell line feasible production vaccine broad spectrum virus,2020-03-23,"Dai, Xiaofeng; Zhang, Xuanhao; Ostrikov, Kostya; Abrahamyan, Levon",Crit Rev Microbiol,,,,document_parses/pdf_json/b63e39a5ddbfc6e1c9a66f2bede0aa960e999f30.json,document_parses/pmc_json/PMC7113910.xml.json,https://doi.org/10.1080/1040841x.2020.1735992; https://www.ncbi.nlm.nih.gov/pubmed/32202955/,214629387.0,3
90305,90305,115484,wxma7s9n,27f951fa0a4f404978a50dcb7e8ca046963bacd5,Elsevier; Medline; PMC,Development of a real-time reverse-transcription-PCR method for detection of RD114 virus in canine vaccines,10.1016/j.biologicals.2011.01.004,PMC7129332,21345697.0,els-covid,known certain feline cell line crandellrees feline kidney cell produce rdlike virus feline endogenous retrovirus rd virus exists genome cat assumed contamination virus feline canine live vaccine manufactured culturing cell feline origin occurs detect infectious rd virus vitro lacz marker rescue assay recently established feline canine live vaccine approved japan feline cell line widely used produce vaccine especially containing canine parvovirus component lacz marker rescue assay detects infectious viral particle realtime reversetranscriptionpcr detects infectious defective virus canine live vaccine manufactured cell feline origin showed positive result env gene realtime reversetranscriptionpcr including vaccine produced feline cell line negative lacz marker rescue assay conclusion present investigation suggests newly developed method advantage shorter time requirement applied valuable screening method detect rd viral rna vaccine,2011-03-31,"Narushima, Rie; Shimazaki, Tomoaki; Takahashi, Toshio",Biologicals,,,,document_parses/pdf_json/27f951fa0a4f404978a50dcb7e8ca046963bacd5.json,document_parses/pmc_json/PMC7129332.xml.json,https://api.elsevier.com/content/article/pii/S1045105611000200; https://www.sciencedirect.com/science/article/pii/S1045105611000200; https://doi.org/10.1016/j.biologicals.2011.01.004; https://www.ncbi.nlm.nih.gov/pubmed/21345697/,46453335.0,3
90306,90306,115485,lezuom0z,,Medline; WHO,Coronavirus disease (COVID-19) - impact on vaccine preventable diseases.,10.2807/1560-7917.es.2020.25.18.2000756,,32400359.0,unk,read interest short notice launch european vaccination information portal conjunction european immunization week believe launch come critical time response coronavirus disease covid consumes government public health clinical resource mean vaccine preventable disease vpdsmany country confirmed covid case initiated ‘ lockdown ’ response pandemic implementation strict social distancing isolation quarantine likely reduce community transmission many vpds lockdown also present huge challenge general practitioner gps community healthcare deliver immunisation birth cohort initiate catchup campaign older cohort deliver immunisation atrisk group household isolation covid illness family newborn child combined disruption vaccine supply healthcare staffing shortage enhanced infection prevention procedure likely significantly reduce opportunity timely delivery routine immunisation uptake vaccine europe continued decline recent year including united kingdom uk fall mmr vaccine coverage followed large outbreak measles confirmed case globally single year since,2020-05-01,"Hungerford, Daniel; Cunliffe, Nigel A",Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin,,#197025,,,,https://www.ncbi.nlm.nih.gov/pubmed/32400359/; https://doi.org/10.2807/1560-7917.es.2020.25.18.2000756,218617464.0,3
90369,90369,115562,p2rhqdem,a7eb563733dde1b81b2bd1953087e34925f966c6; 1cf4faa405e1bd03ac04596491a0261cfdd68449,Elsevier; Medline; PMC,rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment,10.1016/j.jvacx.2019.100009,PMC6668225,31384731.0,cc-by-nc-nd,brighton collaboration viral vector vaccine safety working group vswg formed evaluate safety characteristic live recombinant viral vector vaccine recent publication vswg described live attenuated recombinant vesicular stomatitis virus rvsv chimeric virus vaccine hiv clarke et al rvsv vector system explored platform development multiple vaccine paper review molecular biological feature rvsv vector system followed template detail safety characteristic rvsv vaccine zaire ebolavirus zebov rvsvzebov vaccine live replication competent vector vsv glycoprotein g gene replaced glycoprotein gp gene zebov multiple copy gp expressed assembled viral envelope responsible inducing protective immunity vaccine designated v originally constructed national microbiology laboratory public health agency canada developed newlink genetics corp merck co final stage registration merck vaccine attenuated deletion principal virulence factor vsv g protein also remove primary target antivector immunity v vaccine caused toxicity intramuscular im intracranial injection nonhuman primate reproductive developmental toxicity rat model multiple study cynomolgus macaque immunized im wide range virus dos rapidly developed zebovspecific antibody measured igg elisa neutralization assay fully protected lethal challenge zebov virus people received vaccine clinical trial vaccine proven safe well tolerated first day vaccination many vaccinee experience mild acutephase reaction fever headache myalgia arthralgia short duration period associated lowlevel viremia activation antiviral gene increased level chemokines cytokine oligoarthritis rash appearing second week occur low incidence typically mildmoderate severity selflimited v vaccine used phase iii efficacy trial west african ebola epidemic showing protection ebola virus disease subsequently deployed emergency control ebola outbreak central africa template provided provides comprehensive picture first rvsv vector reach final stage development provide solution control alarming human disease,2019-01-29,"Monath, Thomas P.; Fast, Patricia E.; Modjarrad, Kayvon; Clarke, David K.; Martin, Brian K.; Fusco, Joan; Nichols, Richard; Heppner, D. Gray; Simon, Jakub K.; Dubey, Sheri; Troth, Sean P.; Wolf, Jayanthi; Singh, Vidisha; Coller, Beth-Ann; Robertson, James S.",Vaccine X,,,,document_parses/pdf_json/a7eb563733dde1b81b2bd1953087e34925f966c6.json; document_parses/pdf_json/1cf4faa405e1bd03ac04596491a0261cfdd68449.json,document_parses/pmc_json/PMC6668225.xml.json,https://doi.org/10.1016/j.jvacx.2019.100009; https://www.sciencedirect.com/science/article/pii/S2590136219300105; https://api.elsevier.com/content/article/pii/S2590136219300105; https://www.ncbi.nlm.nih.gov/pubmed/31384731/,91325931.0,3
90392,90392,115594,8mw2kpmr,87803e612b25ef18cacde9c0dbad130d30482583,Elsevier; Medline; PMC,Vaccines in Veterinary Medicine: A Brief Review of History and Technology,10.1016/j.cvsm.2010.02.001,PMC7124274,20471523.0,els-covid,use vaccine veterinary medicine progressed experimental adventure routine relatively safe practice common aggressive use efficacious vaccine responsible control eradication several disease despite progress research technology diagnostic capability manufacturing method remain many infectious disease effective vaccine exist global availability field compliance effectiveness safety also significant concern review address history current practice potential future improvement vaccine use veterinary medicine,2010-05-31,"McVey, Scott; Shi, Jishu",Veterinary Clinics of North America: Small Animal Practice,,,,document_parses/pdf_json/87803e612b25ef18cacde9c0dbad130d30482583.json,document_parses/pmc_json/PMC7124274.xml.json,https://www.sciencedirect.com/science/article/pii/S0195561610000239; https://www.ncbi.nlm.nih.gov/pubmed/20471523/; https://doi.org/10.1016/j.cvsm.2010.02.001; https://api.elsevier.com/content/article/pii/S0195561610000239,45250629.0,3
90444,90444,115656,tewfm8it,329b4aa757557f56f89d796a0034cd3fe4bf983c,Elsevier; Medline; PMC,Adjuvant effects of mannose-binding lectin ligands on the immune response to infectious bronchitis vaccine in chickens with high or low serum mannose-binding lectin concentrations,10.1016/j.imbio.2013.10.013,PMC7114666,24305086.0,els-covid,mannosebinding lectin mbl play major role immune response soluble patternrecognition receptor mbl deficiency susceptibility different type infection subject extensive study last decade human chicken several study shown mbl participates protection host virus infection infectious bronchitis ib highly contagious disease economic importance poultry industry caused coronavirus infectious bronchitis virus ibv mbl earlier described play potential role pathogenesis ibv infection production ibvspecific antibody may exploited optimising ibv vaccine strategy present study show mbl capability bind ibv vitro chicken two inbred line lh selected high low mbl serum concentration respectively vaccinated ibv without addition mbl ligand mannan chitosan fructooligosaccharide fo addition mbl ligand ibv vaccine especially fo enhanced production ibvspecific igg antibody production lh chicken chicken second vaccination addition fo vaccine also increased number circulating cd cell lh chicken compared chicken lh chicken well chicken also showed increased number cd−cdα−γδ tcells mbl ligand added vaccine pronouncedly first vaccination mbl ligand coadministered ibv vaccine induced difference two chicken line result indirectly suggest mbl involved immune response ibv vaccination furthermore higher antibody response lh chicken receiving vaccine fo make fo potential adjuvant candidate ibv vaccine,2014-04-30,"Kjærup, Rikke M.; Dalgaard, Tina S.; Norup, Liselotte R.; Bergman, Ingrid-Maria; Sørensen, Poul; Juul-Madsen, Helle R.",Immunobiology,,,,document_parses/pdf_json/329b4aa757557f56f89d796a0034cd3fe4bf983c.json,document_parses/pmc_json/PMC7114666.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/24305086/; https://api.elsevier.com/content/article/pii/S0171298513001964; https://doi.org/10.1016/j.imbio.2013.10.013; https://www.sciencedirect.com/science/article/pii/S0171298513001964,20003739.0,3
90515,90515,115744,99lpdu81,b233ca2dc15696ccb328ab3eed768e1ec006f55a,Medline; PMC,From farm management to bacteriophage therapy: strategies to reduce antibiotic use in animal agriculture,10.1111/nyas.14034,PMC6850639,30924542.0,cc-by-nc,reduce use antibiotic animal agriculture number effective commercially viable alternative implemented food animal producer development perhaps well‐established strategy flock herd management practice mitigate disease introduction spread subsequently reduce need antibiotic use vaccine food animal production used prevent bacterial viral disease historically vaccine targeted viral disease though vaccine viral disease help reduce need antibiotic use controlling spread secondary bacterial infection recent vaccine development specifically target bacteria new development selecting potentially tailoring bacteriophage provide promising avenue controlling pathogenic bacteria without need traditional small‐molecule antibiotic article discus established emerging strategy anticipated reduce reliance antibiotic food animal production reduce prevalence transmission human antimicrobial resistant bacteria system,2019-03-29,"Kahn, Laura H.; Bergeron, Gilles; Bourassa, Megan W.; De Vegt, Bert; Gill, Jason; Gomes, Filomena; Malouin, François; Opengart, Ken; Ritter, G. Donald; Singer, Randall S.; Storrs, Carina; Topp, Edward",Ann N Y Acad Sci,,,,document_parses/pdf_json/b233ca2dc15696ccb328ab3eed768e1ec006f55a.json,document_parses/pmc_json/PMC6850639.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30924542/; https://doi.org/10.1111/nyas.14034,85566255.0,3
90549,90549,115783,k5tm7obh,dced76983861e1bb7a73bf0c54549922c7e07950,Elsevier; PMC,Collard and cauliflower as a base for production of recombinant antigens,10.1016/j.plantsci.2006.06.017,PMC7114678,,els-covid,plant emerged modern production system produce recombinant proteins—antigens used subunit vaccine ideal plant candidate purpose capable sustain high level expression foreign protein without adverse effect growth development also essential large biomass edible suitable longterm storage delivery work part effort develop cruciferaebased production system using transgenic vegetable plant collard cauliflower several parameter tested optimized achieve efficient stable transformation recalcitrant specie construct containing expression cassette known viral antigen using original procedure obtained transgenic collard cv morris heading express high level smallpox vaccine candidate b leaf retain normal phenotype transgenic cauliflower plant cv early snowball obtained similar procedure shown detectable amount sars coronavirus spikeprotein sarscov floret tissue mature curd knowledge first report generation transgenic collard plant ever first successful attempt use vegetable production pharmaceutical protein,2006-12-31,"Pogrebnyak, Natalia; Markley, Karen; Smirnov, Yuriy; Brodzik, Robert; Bandurska, Katarzyna; Koprowski, Hilary; Golovkin, Maxim",Plant Science,,,,document_parses/pdf_json/dced76983861e1bb7a73bf0c54549922c7e07950.json,document_parses/pmc_json/PMC7114678.xml.json,https://www.sciencedirect.com/science/article/pii/S0168945206001890; https://api.elsevier.com/content/article/pii/S0168945206001890,84351808.0,3
90557,90557,115792,2rnvmbnz,c28845dc44f29502a6012256075760eab1d62af0,Medline; PMC,Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model,10.1038/s41541-017-0029-1,PMC5643297,29263883.0,cc-by,middle east respiratory syndrome coronavirus merscov novel zoonotic virus cause severe respiratory disease human case fatality rate close vaccine available evaluated utility chadox promising replicationdeficient simian adenovirus vaccine vector platform established safety profile human dromedary camel merscov vaccine development using transgenic lethal balbc merscov mouse model showed single dose intranasal intramuscular immunisation chadox mers encoding fulllength merscov spike glycoprotein highly immunogenic confers protection lethal viral challenge immunogenicity efficacy comparable immunisation route together data provide support evaluation chadox mers vaccine human dromedary camel animal reservoir infection,2017-10-16,"Munster, Vincent J.; Wells, Daniel; Lambe, Teresa; Wright, Daniel; Fischer, Robert J.; Bushmaker, Trenton; Saturday, Greg; van Doremalen, Neeltje; Gilbert, Sarah C.; de Wit, Emmie; Warimwe, George M.",NPJ Vaccines,,,,document_parses/pdf_json/c28845dc44f29502a6012256075760eab1d62af0.json,document_parses/pmc_json/PMC5643297.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29263883/; https://doi.org/10.1038/s41541-017-0029-1,3326923.0,3
90609,90609,115852,er3sm4u8,f71c5fc3040dbc1fa7419bf6004a53353f32590b,Medline; PMC,Time for T? Immunoinformatics addresses vaccine design for neglected tropical and emerging infectious diseases,10.1586/14760584.2015.955478,PMC4743591,25193104.0,no-cc,vaccine invaluable global health saving life reducing healthcare cost also raising quality human life however newly emerging infectious disease eid wellestablished tropical disease pathogen present complex challenge vaccine developer particular neglected tropical disease prevalent among world ’ poorest include many pathogen large size multistage life cycle variety nonhuman vector eid merscov hn highly pathogenic human many pathogen genome available immune correlate protection currently unknown complexity make developing vaccine eid neglected tropical disease difficult review describe implementation immunoinformaticsdriven approach systematically search key determinant immunity newly available genome sequence data design vaccine approach hold promise development st century vaccine improving human health everywhere,2015-01-02,"Terry, Frances E; Moise, Leonard; Martin, Rebecca F; Torres, Melissa; Pilotte, Nils; Williams, Steven A; De Groot, Anne S",Expert Rev Vaccines,,,,document_parses/pdf_json/f71c5fc3040dbc1fa7419bf6004a53353f32590b.json,document_parses/pmc_json/PMC4743591.xml.json,https://doi.org/10.1586/14760584.2015.955478; https://www.ncbi.nlm.nih.gov/pubmed/25193104/,16860790.0,3
90694,90694,115953,o05yp746,feb187c73b33d8dc25b4cb33724e98c7906bfeb7,Elsevier; Medline; WHO,High throughput and comprehensive approach to develop multiepitope vaccine against minacious COVID-19,10.1016/j.ejps.2020.105375,,32417398.0,els-covid,ongoing enigmatic covid outbreak first reported wuhan china last day year spread country territoriesareas till th april threatens hundred thousand human soul devastating viral infection stimulated urgent development viable vaccine covid across research institute around globe world health organization also confirmed recent pandemic causing public health emergency international apprehension moreover earlier two pathogenic sarscov merscov many others yet identified pose universal menace piece work utilized silico structural biology advanced immunoinformatic strategy devise multiepitope subunit vaccine ongoing covid infection engineered vaccine sequence adjuvanted ß defensin comprised bcell epitope htl epitope ctl epitope likely vaccine able elicit strong immune response specific binding engineered vaccine immune cell receptor tlr estimated molecular interaction study strong interaction binding groove well good docking score affirmed stringency engineered vaccine interaction stable minimal deviation rootmean square deviation rootmeansquare fluctuation confirmed molecular dynamic simulation experiment immunesimulation cimmsim server mimic natural immune environment yielded potent immune response data bcells th cell tc cell igg vaccine encouraging data obtained various insilico work indicated vaccine effective therapeutic covid,2020-05-14,"Ojha, Rupal; Gupta, Nidhi; Naik, Biswajit; Singh, Satyendra; Verma, Vijay Kumar; Prusty, Dhaneswar; Prajapati, Vijay Kumar",European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,,#260291,,document_parses/pdf_json/feb187c73b33d8dc25b4cb33724e98c7906bfeb7.json,,https://www.ncbi.nlm.nih.gov/pubmed/32417398/; https://doi.org/10.1016/j.ejps.2020.105375; https://www.sciencedirect.com/science/article/pii/S0928098720301640?v=s5; https://api.elsevier.com/content/article/pii/S0928098720301640,218631973.0,3
90730,90730,115996,34nnp9cv,766fa939d995f6dfff5361142c3abac07e2bd846,Elsevier; PMC,Overview of new vaccines and technologies,10.1016/j.vetmic.2006.04.006,PMC7131788,16723197.0,els-covid,molecular technology given u greater insight aetiology disease functioning immune system mode action veterinary pathogen knowledge gained used develop new vaccine specific reactive antigen elicit protective immune mediated response humoral andor cell mediated host vaccine burden immune system initiating response nonessential antigen however efficacy vaccine good delivery technology route used present immune system vaccine traditionally given parenteral route given natural route either orally intranasally two major advantage often interrelated rapid onset immunity stimulation local mucosal immunity new technology making impact current vaccine development balance found technologically feasible provide least good protective immunity current conventional vaccine new emerging disease appear globally new opportunity arise molecular conventional technology applied development delivery novel vaccine well improvement vaccine current use,2006-10-05,"Chalmers, W.S.K.",Veterinary Microbiology,,,,document_parses/pdf_json/766fa939d995f6dfff5361142c3abac07e2bd846.json,document_parses/pmc_json/PMC7131788.xml.json,https://api.elsevier.com/content/article/pii/S0378113506001404; https://www.sciencedirect.com/science/article/pii/S0378113506001404,20249527.0,3
90757,90757,116034,cgdlhpvb,be179ef4eaf04a9b155ac385eeabc06620a791b2,Medline; PMC,Polyionic vaccine adjuvants: another look at aluminum salts and polyelectrolytes,10.7774/cevr.2015.4.1.23,PMC4313107,25648619.0,cc-by-nc,adjuvant improve adaptive immune response vaccine antigen modulating innate immunity facilitating transport presentation selection appropriate adjuvant become vital new vaccine trend toward narrower composition expanded application improved safety functionally adjuvant act directly indirectly antigen presenting cell apc including dendritic cell dc perceived molecular pattern associated either pathogen invasion endogenous cell damage known pathogen associated molecular pattern pamps damage associated molecular pattern damp thereby initiating sensing response pathway pamptype adjuvant ligand tolllike receptor tlrs directly affect dc alter strength potency speed duration bias breadth scope adaptive immunity damptype adjuvant signal via proinflammatory pathway promote immune cell infiltration antigen presentation effector cell maturation class adjuvant includes mineral salt oil emulsion nanoparticles polyelectrolyte comprises colloid molecular assembly exhibiting complex heterogeneous structure today innovation adjuvant technology driven rapidly expanding knowledge immunology crossfertilization area including system biology material science regulatory requirement quality safety efficacy understanding part vaccine product standardization aid effort better define compare structure function safety adjuvant article briefly survey genesis adjuvant technology reexamines polyionic macromolecule polyelectrolyte material adjuvant currently known employ tlr specific update provided aluminumbased formulation polyelectrolyte example improvement oldest emerging class vaccine adjuvant use,2015-01-30,"Powell, Bradford S.; Andrianov, Alexander K.; Fusco, Peter C.",Clin Exp Vaccine Res,,,,document_parses/pdf_json/be179ef4eaf04a9b155ac385eeabc06620a791b2.json,document_parses/pmc_json/PMC4313107.xml.json,https://doi.org/10.7774/cevr.2015.4.1.23; https://www.ncbi.nlm.nih.gov/pubmed/25648619/,10838503.0,3
90762,90762,116040,704p47er,2514b6a3286c805992743bbf6b8c51a2075c622d,Medline; PMC,The Effect of 13-Valent Pneumococcal Conjugate Vaccine on the Serotype Distribution and Antibiotic Resistance Profiles in Children With Invasive Pneumococcal Disease,10.1093/jpids/piw005,PMC7107452,26907814.0,no-cc,background invasive pneumococcal disease ipd continues significant burden child despite implementation two generation conjugate vaccine serotype replacement nonvaccine serotypes reported multiple area around world study continuation previous study describes incidence serotype distribution antibiotic resistance pattern streptococcus pneumoniae serotypes causing ipd childrens medical center dallas introduction valent pneumococcal conjugate vaccine pcv method streptococcus pneumoniae isolates normally sterile site collected january june demographic clinical information extracted analysis incidence ipd calculated using inpatient emergency center admission childrens medical center dallas denominator isolates serotyped penicillincefotaxime susceptibility determined selected nontypeable isolates characterized multilocus sequence typing χ test cochran–armitage trend test trend analysis used evaluate change serotype antibiotic susceptibility pattern time result comparison different study period showed significant reduction incidence ipd pcv era compared prevaccine era pcv era p child younger month showed largest reduction disease incidence patient ipd documented comorbidity case pneumonia continued decrease pcv era p common nonpcv serotypes vaccine introduction follows b c nl penicillin resistance meningitis breakpoint decreased significantly pcv era conclusion introduction pcv dallas incidence ipd caused strain contained vaccine penicillin resistance continued decrease serotype replacement phenomenon persistence pcv serotypes documented patient comorbidities represented large percentage patient ipd concern geographic variation serotype replacement phenomenon arise present study,2016-02-23,"Gaviria-Agudelo, Claudia L; Jordan-Villegas, Alejandro; Garcia, Carla; McCracken, George H",J Pediatric Infect Dis Soc,,,,document_parses/pdf_json/2514b6a3286c805992743bbf6b8c51a2075c622d.json,document_parses/pmc_json/PMC7107452.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26907814/; https://doi.org/10.1093/jpids/piw005,3788572.0,3
90814,90814,116101,9wflr4u3,7e92581ed1b5f05b3002790d3cd71974982f7a3f,Medline; PMC,Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines,10.1038/emi.2012.1,PMC3630917,26038424.0,cc-by-nc-nd,number emerging reemerging virus caused epidemic pandemic infectious disease leading major devastation throughout human history therefore developing effective safe vaccine virus clearly important protection atrisk population previous study shown receptorbinding domain rbd spike protein severe acute respiratory syndrome sarsassociated coronavirus sarscov key target development sars vaccine review highlight key advance development antiviral vaccine targeting rbds spike protein emerging reemerging virus using sarscov influenza virus hendra virus hev nipah virus niv example,2012-08-08,"Jiang, Shibo; Lu, Lu; Liu, Qi; Xu, Wei; Du, Lanying",Emerg Microbes Infect,,,,document_parses/pdf_json/7e92581ed1b5f05b3002790d3cd71974982f7a3f.json,document_parses/pmc_json/PMC3630917.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26038424/; https://doi.org/10.1038/emi.2012.1,205138013.0,3
90868,90868,116173,8oki8xr2,0185df64da339e8d1b822db72fee79a25edeb759,Elsevier; Medline; PMC,"The effect of diatomaceous earth in live, attenuated infectious bronchitis vaccine, immune responses, and protection against challenge",10.3382/ps/pex093,PMC7107116,28419351.0,els-covid,live virus vaccine commonly used poultry production particularly broiler massive application generation protective local mucosal humoral immunity adverse effect main goal strategy live virus vaccine improved adding adjuvant boost mucosal innate adaptive response previous study showed diatomaceous earth de used adjuvant inactivated vaccine aim study test de adjuvant arkdpi live infectious bronchitis virus ibv vaccine ocular spray application titrating virus alone addition de showed de detrimental effect vaccine virus however adding de vaccine induce higher igg titer serum iga titer tear also affect frequency cd cell cd cell monocytesmacrophages blood spleen determined flow cytometry addition protection generated ibv homologous challenge measured viral load tear respiratory sign histopathology trachea vary de present vaccine formulation finally confirmed observation ark vaccine administered hatchery spray cabinet elicit weaker immune response protection ibv homologous challenge compared vaccine delivered via ocular route,2017-08-01,"Nazmi, Ali; Hauck, Rüdiger; Corbeil, Lynette B.; Gallardo, Rodrigo A.",Poultry Science,,,,document_parses/pdf_json/0185df64da339e8d1b822db72fee79a25edeb759.json,document_parses/pmc_json/PMC7107116.xml.json,https://doi.org/10.3382/ps/pex093; https://www.sciencedirect.com/science/article/pii/S0032579119314592; https://api.elsevier.com/content/article/pii/S0032579119314592; https://www.ncbi.nlm.nih.gov/pubmed/28419351/,25045183.0,3
90870,90870,116175,v5n1gupw,cc39d839697c9a6791be6cdce7a556d8d1ed324c; a416350e5da8a35128cc4ab5d293c85d48f3e53d,Elsevier; PMC,Development of nonhuman adenoviruses as vaccine vectors,10.1016/j.vaccine.2005.08.101,PMC1462960,16297508.0,green-oa,human adenoviral vector demonstrated great potential vaccine vector preclinical clinical study demonstrated feasibility vector design robust antigen expression protective immunity using system however clinical use adenoviral vector vaccine purpose anticipated limited vector immunity either preexisting develops rapidly following first inoculation adenoviral vector vector immunity inactivates vector particle rapidly remove transduced cell thereby limiting duration transgene expression due strong vector immunity subsequent use vector usually le efficient order circumvent limitation nonhuman adenoviral vector proposed alternative vector addition eluding immunity vector posse attractive feature vector several replicationcompetent replicationdefective nonhuman adenoviral vector developed investigated potential vaccine delivery vector review recent advance design characterization various nonhuman adenoviral vector discus potential application human animal vaccination,2006-02-01,"Bangari, Dinesh S.; Mittal, Suresh K.",Vaccine,,,,document_parses/pdf_json/cc39d839697c9a6791be6cdce7a556d8d1ed324c.json; document_parses/pdf_json/a416350e5da8a35128cc4ab5d293c85d48f3e53d.json,document_parses/pmc_json/PMC1462960.xml.json,http://europepmc.org/articles/pmc1462960?pdf=render; https://api.elsevier.com/content/article/pii/S0264410X05009151; https://www.sciencedirect.com/science/article/pii/S0264410X05009151,13152688.0,3
90888,90888,116195,2neggz5v,01bb742453c2437b1e8a7fac34fe475ac6cc0f24; 8a5bf2b16d131fbee41247f16dc53c0fd3511c3e,Elsevier; Medline; PMC,"Characterization of a Monoclonal Antibody to a Novel Glycan-Dependent Epitope in the V1/V2 Domain of the HIV-1 Envelope Protein, gp120",10.1016/j.molimm.2014.06.025,PMC4157072,25016576.0,green-oa,recent study described several broadly neutralizing monoclonal antibody bnmabs recognize glycandependent epitope gdes hiv envelope protein gp recovered hiv infected subject several eg pg pg ch ch target glycans first second variable vv domain gp vv domain thought play important role conformational masking antibody vv domain recently identified immune response correlated protection rv hiv vaccine trial importance antibody polymeric glycans well established vaccine targeting bacterial disease importance antibody glycans vaccine targeting hiv recently recognized antibody gdes may particularly significant hiv vaccine based gp molecular mass envelope protein contributed nlinked carbohydrate however study reported antibody gdes human animal immunized candidate hiv vaccine report describe isolation mouse mab b immunization extracellular domain hiv envelope protein gp epitope mapping using glycopeptide fragment vitro mutagenesis showed binding antibody depends nlinked glycosylation asparagine n hxb numbering gp vv domain result demonstrate addition natural hiv infection immunization recombinant protein elicit antibody gdes vv domain gp although little known regarding condition favor antibody response gdes study demonstrate antibody arise shortterm immunization regimen result suggest antibody gdes common previously suspected analysis antibody response hiv envelope protein lead discovery additional antibody gdes,2014-11-01,"Doran, Rachel C.; Morales, Javier F.; To, Briana; Morin, Trevor J.; Theolis, Richard; O’Rourke, Sara M.; Yu, Bin; Mesa, Kathryn A.; Berman, Phillip W.",Molecular Immunology,,,,document_parses/pdf_json/01bb742453c2437b1e8a7fac34fe475ac6cc0f24.json; document_parses/pdf_json/8a5bf2b16d131fbee41247f16dc53c0fd3511c3e.json,document_parses/pmc_json/PMC4157072.xml.json,https://www.sciencedirect.com/science/article/pii/S0161589014001564; http://europepmc.org/articles/pmc4157072?pdf=render; https://doi.org/10.1016/j.molimm.2014.06.025; https://www.ncbi.nlm.nih.gov/pubmed/25016576/; https://api.elsevier.com/content/article/pii/S0161589014001564,17540732.0,3
90903,90903,116216,kzaowysv,19f55b3421782d278b0dd53f586f5fb1860fd122,Medline; PMC,Passive immunity to porcine epidemic diarrhea virus following immunization of pregnant gilts with a recombinant orf virus vector expressing the spike protein,10.1007/s00705-018-3855-1,PMC7086649,29725899.0,no-cc,passive immunity critical protection neonatal piglet porcine epidemic diarrhea virus pedv investigated immunogenicity orf virus orfv vector expressing fulllength spike protein pedv orfvpedvs pregnant gilt ability confer passive immunity protection piglet three dos orfvpedvs given two group pedvnegative pregnant gilt last dose administered two week prior farrowing one two group immunized orfvpedvs recombinant virus also exposed live pedv orally day postimmunization pi antibody response assessed serum colostrum milk immunized gilt passive transfer antibody evaluated piglet serum protective efficacy orfvpedvs evaluated challenge piglet pedv pedvspecific igg iga neutralizing antibody na response detected orfvpedvsimmunized orfvpedvsimmunizedpedvexposed gilt pedv na igg iga detected serum piglet born immunized gilt demonstrating transfer antibody colostrum milk piglet born immunized gilt showed reduced morbidity marked reduction mortality pedv challenge comparison control piglet piglet born gilt received orfvpedvs exposed live pedv showed stronger na response lower clinical score compared piglet born gilt immunized orfvpedvs alone result demonstrate potential orfv vaccine delivery platform capable eliciting passive immunity pedv,2018-05-03,"Joshi, Lok R.; Okda, Faten A.; Singrey, Aaron; Maggioli, Mayara F.; Faccin, Tatiane C.; Fernandes, Maureen H. V.; Hain, Kyle S.; Dee, Scott; Bauermann, Fernando V.; Nelson, Eric A.; Diel, Diego G.",Arch Virol,,,,document_parses/pdf_json/19f55b3421782d278b0dd53f586f5fb1860fd122.json,document_parses/pmc_json/PMC7086649.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29725899/; https://doi.org/10.1007/s00705-018-3855-1,19241089.0,3
90911,90911,116226,cmbg0ty8,3ff423438d2142229c5615b6ff80ed6d354fa81e,Medline; PMC,Development of Recombinant Measles Virus-Based Vaccines,10.1007/978-1-4939-6869-5_9,PMC7121886,28374248.0,no-cc,chapter describes development recombinant measles virus mvbased vaccine starting plasmid dna liveattenuated measles vaccine efficient safe since availability reverse genetic system manipulate mv genome generate respective recombinant virus considerable number recombinant virus generated present antigen foreign pathogen mv replication thereby robust humoral cellular immune response induced shown protective capacity substantial number experiment purpose foreign antigenencoding gene cloned additional transcription unit plasmid based fulllength mv vaccine strain genome turn used rescue recombinant mv providing fulllength viral rna genome respective antigenomes together protein component viral ribonucleoprotein complex transient transfection socalled rescue cell infectious center form among transfected cell allow clonal isolation single recombinant virus subsequently amplified characterized vitro evaluated immunogenicity appropriate preclinical animal model,2016-11-26,"Mühlebach, Michael D.; Hutzler, Stefan",Recombinant Virus Vaccines,,,,document_parses/pdf_json/3ff423438d2142229c5615b6ff80ed6d354fa81e.json,document_parses/pmc_json/PMC7121886.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28374248/; https://doi.org/10.1007/978-1-4939-6869-5_9,46844807.0,3
90927,90927,116244,mw788874,2d4c4ef9c5def66606502be9eb38c63d756640da,Medline; PMC,Voluntary vaccination: the pandemic effect,10.1111/lest.12144,PMC7165755,32336855.0,no-cc,justification voluntary vaccination policy england wale rest tenuous foundation two argument voluntary vaccination gaining ground first globalisation necessitates preparedness strategy pandemic assuming sufficient supply compulsory vaccination adult child constitutes potential policy option context severe vaccine‐preventable pandemic outbreak second argument child right preventive medicine thus vaccination influence un convention right child emphasis parent trustee childrens best interest increasingly global nature collective individual responsibility respect transmission vaccine‐preventable disease present challenge right refuse vaccination behalf behalf child exploring method compulsion persuasion utilised across europe usa australia paper argues necessity proportionality must reassessed national public health law policy setting graduated proportionate approach compulsory vaccination developed matter priority,2016-12-01,"Cave, Emma",Leg Stud (Soc Leg Scholars),,,,document_parses/pdf_json/2d4c4ef9c5def66606502be9eb38c63d756640da.json,,https://doi.org/10.1111/lest.12144; https://www.ncbi.nlm.nih.gov/pubmed/32336855/,151583666.0,3
90969,90969,116293,wly18gdz,d0c8e2e83670f588fa1673bb2234b520aa4f8242,Elsevier; Medline; PMC,The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection,10.1016/j.vaccine.2016.11.064,PMC7115548,27899228.0,els-covid,persistent public health threat infection middle east respiratory syndrome coronavirus merscov highlight need effective merscov vaccine previous study focused mainly receptorbinding domain rbd spike protein merscov herein investigated immunogenicity protective potential recombinant nterminal domain rntd spike protein vaccine candidate balbc mouse vaccinated μg rntd protein demonstrated significant humoral immune response serum igg neutralizing activity additionally according enzymelinked immunospot intracellular cytokine staining cytometric bead array assay significant functional tcell immunity induced μg rntd vaccination aluminum cpg adjuvant furthermore rntdimmunized mouse showed reduced lung abnormality merscovchallenge mouse model transfected adenoviral vector expressing human dpp showing protection consistent found rrbd vaccination data show rntd induced potent cellular immunity antigenspecific neutralizing antibody mouse demonstrated protective capacity viral challenge indicating rntd vaccine candidate merscov infection,2017-01-03,"Jiaming, Lan; Yanfeng, Yao; Yao, Deng; Yawei, Hu; Linlin, Bao; Baoying, Huang; Jinghua, Yan; Gao, George F.; Chuan, Qin; Wenjie, Tan",Vaccine,,,,document_parses/pdf_json/d0c8e2e83670f588fa1673bb2234b520aa4f8242.json,document_parses/pmc_json/PMC7115548.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X16311355; https://www.ncbi.nlm.nih.gov/pubmed/27899228/; https://api.elsevier.com/content/article/pii/S0264410X16311355; https://doi.org/10.1016/j.vaccine.2016.11.064,46807588.0,3
90979,90979,116303,zpi7uis1,9cb9aa20e0df0b2c63589d0d85b1abeb0eeda1cf,Elsevier; PMC,"Animal models and antibody assays for evaluating candidate SARS vaccines: Summary of a technical meeting 25–26 August 2005, London, UK",10.1016/j.vaccine.2006.07.009,PMC7130694,16930781.0,els-covid,severe acute respiratory syndrome sars emerged guangdong province china late spread country end outbreak july cdc reported case case fatality rate disease caused previously unrecognized coronavirus sarscov drawing experience animal coronavirus vaccine several vaccine candidate developed evaluated preclinical trial available data suggest vaccine based kda viral spike protein significant neutralization antigen capable inducing protective immune response animal absence clinical case sars candidate vaccine evaluated efficacy animal model although uncertain whether united state food drug administration “ animal rule ” would apply licensure sars vaccine important develop standardized animal model immunological assay preparation eventuality report summarizes recommendation technical meeting animal model antibody assay evaluating candidate sars vaccine held – august south mimms uk provides guidance use animal model outline step develop standard reagent assay immunological evaluation candidate sars vaccine,2006-11-30,"Roberts, Anjeanette; Wood, John; Subbarao, Kanta; Ferguson, Morag; Wood, David; Cherian, Thomas",Vaccine,,,,document_parses/pdf_json/9cb9aa20e0df0b2c63589d0d85b1abeb0eeda1cf.json,document_parses/pmc_json/PMC7130694.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X06008231; https://api.elsevier.com/content/article/pii/S0264410X06008231,25725086.0,3
90996,90996,116322,tk3h4f92,01b81edbe97777de40d5b8a9eaa77a21b905db5f,Elsevier; Medline; PMC,Microbes and Infection turns 20,10.1016/j.micinf.2018.05.002,PMC7173021,29857123.0,no-cc,journal microbe infection celebrating vigintennial anniversary reunited occasion two dozen review illustrating achievement past well future challenge field infectious disease topnotch vaccine development strategy highthroughput powered analysis complex hostpathogen interaction innovative therapeutic design issue cover entire spectrum pathogen area confrontation host,2018-05-30,"Häfner, Sophia J.; Ojcius, David M.",Microbes Infect,,,,document_parses/pdf_json/01b81edbe97777de40d5b8a9eaa77a21b905db5f.json,document_parses/pmc_json/PMC7173021.xml.json,https://www.sciencedirect.com/science/article/pii/S1286457918301084; https://api.elsevier.com/content/article/pii/S1286457918301084; https://www.ncbi.nlm.nih.gov/pubmed/29857123/; https://doi.org/10.1016/j.micinf.2018.05.002,46923411.0,3
91021,91021,116353,cmjfqkjz,7b8a5807787e87b541322eb4d45593d7f3e00631,Elsevier; Medline; PMC,Vectored vaccines to protect against PRRSV,10.1016/j.virusres.2010.06.017,PMC7114413,20600388.0,els-covid,prrsv causative agent important infectious disease affecting swine herd worldwide producing great economic loss commercially available vaccine partially effective protection prrsv moreover modified live vaccine may allow virus shedding could revert generating virulent phenotype therefore new efficient vaccine required vaccine based recombinant virus genome virus vectored vaccine prrsv could represent safe alternative generation modified live vaccine paper current vectored vaccine protect prrsv revised including based pseudorabies virus poxvirus adenovirus virus replicons special attention provided use transmissible gastroenteritis virus tgev vector expression prrsv antigen vector capability expressing high level heterologous gene potent interferonα inducer present antigen mucosal surface eliciting secretory systemic immunity tgev derived vector rtgev generated expressing prrsv wild type modified gp protein described main inducer neutralizing antibody cellular immune response respectively protection experiment showed vaccinated animal developed faster stronger humoral immune response nonvaccinated one partial protection challenged animal observed vaccinated pig showed decreased lung damage compared nonvaccinated one nevertheless level neutralizing antibody low may explain limited protection observed several strategy proposed improve current rtgev vector expressing prrsv antigen,2010-12-31,"Cruz, Jazmina L.G.; Zúñiga, Sonia; Bécares, Martina; Sola, Isabel; Ceriani, Juan E.; Juanola, Sandra; Plana, Juan; Enjuanes, Luis",Virus Research,,,,document_parses/pdf_json/7b8a5807787e87b541322eb4d45593d7f3e00631.json,document_parses/pmc_json/PMC7114413.xml.json,https://doi.org/10.1016/j.virusres.2010.06.017; https://www.sciencedirect.com/science/article/pii/S0168170210002017; https://www.ncbi.nlm.nih.gov/pubmed/20600388/; https://api.elsevier.com/content/article/pii/S0168170210002017,29822695.0,3
91103,91103,116454,6vk2yx4j,ee17beb088764da5cee76084ffb093fb4b4ff396,Medline; PMC,Evaluation of 793/B-like and Mass-like vaccine strain kinetics in experimental and field conditions by real-time RT-PCR quantification,10.3382/ps/pex292,PMC7107209,29077954.0,no-cc,infectious bronchitis virus ibv great economic burden productive loss cost control strategy many different vaccination protocol applied region even consecutive cycle farm order find perfect balance cost benefit northern italy usual second vaccination often moved chick first life second strain administration together common mass priming spray hatchery allows saving money time reducing animal stress present work compared different vaccine strain masslike b kinetics field condition daylong experimental trial broiler monitoring viral replication upper respiratory tract swabbing vaccine specific real time reverse transcription pcr rtpcr quantification field experimental condition titer vaccine showed increasing trend first wk decrease though still remaining detectable whole monitored period ibv field strain avian metapneumovirus ampv presence also also investigated rtpcr sequencing multiplex realtime rtpcr respectively revealing consistency pathogen introduction timing around correspondence vaccine titer main decrease finding suggest need accurate knowledge live vaccine kinetics whose replication compete pathogen one providing additional protection added conferred adaptive immune response,2017-10-25,"Tucciarone, C M; Franzo, G; Berto, G; Drigo, M; Ramon, G; Koutoulis, K C; Catelli, E; Cecchinato, M",Poult Sci,,,,document_parses/pdf_json/ee17beb088764da5cee76084ffb093fb4b4ff396.json,document_parses/pmc_json/PMC7107209.xml.json,https://doi.org/10.3382/ps/pex292; https://www.ncbi.nlm.nih.gov/pubmed/29077954/,44464935.0,3
91116,91116,116470,moor7dfc,528ff30231b4f8688e255549425c4ca693236c38,Elsevier; PMC,Feline Vaccination Guidelines,10.1016/s0195-5616(01)50602-6,PMC7134452,11446098.0,els-covid,report american association feline practitioner academy feline medicine advisory panel feline vaccine developed help veterinary practitioner formulate vaccination protocol cat current panel report update information address question speaks concern raised report addition review vaccine licensing labeling liability issue suggests way successfully incorporate vaccination protocol change private practice setting,2001-05-31,"Richards, James; Rodan, Ilona",Veterinary Clinics of North America: Small Animal Practice,,,,document_parses/pdf_json/528ff30231b4f8688e255549425c4ca693236c38.json,,https://api.elsevier.com/content/article/pii/S0195561601506026; https://www.sciencedirect.com/science/article/pii/S0195561601506026,24075518.0,3
91118,91118,116472,i62js12f,8b231253df7ff84b23af65dd9728d1e89ce459d3,Elsevier; Medline; PMC,A quantitative risk assessment of exposure to adventitious agents in a cell culture-derived subunit influenza vaccine,10.1016/j.vaccine.2008.03.075,PMC7131715,18485545.0,els-covid,riskassessment model demonstrated ability new cell culturebased vaccine manufacturing process reduce level adventitious agent millionfold infectious level cell culturederived subunit influenza vaccine optaflu® novartis vaccine diagnostics produced using madin–darby canine kidney mdck cell propagate seasonal viral strain alternative embryonated chickeneggs limited range mammalian virus grow mdck cell similar embryonated egg mdck cell act effective filter wide range adventitious agent might introduced vaccine production however introduction alternative cell substrate example mdck cell vaccine manufacturing process requires thorough investigation ass potential adventitious agent risk final product unlikely event contamination occur risk assessment take account entire manufacturing process initial influenza virus isolation blending trivalent subunit vaccine worstcase residual titre final vaccine formulation calculated virus virus family maximum residual titre virus tested range − − infectious unit per vaccine dose thus new cell culturebased vaccine manufacturing process reduce adventitious agent level unable cause infection,2008-06-19,"Gregersen, Jens-Peter",Vaccine,,,,document_parses/pdf_json/8b231253df7ff84b23af65dd9728d1e89ce459d3.json,document_parses/pmc_json/PMC7131715.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/18485545/; https://doi.org/10.1016/j.vaccine.2008.03.075; https://api.elsevier.com/content/article/pii/S0264410X08004118; https://www.sciencedirect.com/science/article/pii/S0264410X08004118,31650927.0,3
91187,91187,116561,h8fe0zio,839df627ece5b5fc7bb1ce3b4f96127677fd0494,Medline; PMC,Preferential production of IgM-secreting hybridomas by immunization with DNA vaccines coding for Ebola virus glycoprotein: use of protein boosting for IgG-secreting hybridoma production,10.7774/cevr.2017.6.2.135,PMC5540962,28775978.0,cc-by-nc,purpose goal study investigate utility dna vaccine encoding ebola virus glycoprotein gp vaccine type production gpspecific hybridoma antibody material method dna vaccine constructed express ebola virus gp mouse injected gp dna vaccine splenocytes used hybridoma production enzymelinked immunosorbent assay elisa limiting dilution subcloning antibody purification method western blot assay used select gpspecific hybridoma purify monoclonal antibody mabs hybridoma cell result twelve hybridoma cell supernatant displayed gpbinding activity selected elisa purified mabs hybridoma tested reactivity gp mabs except mab hybridoma displaying igga type identified igm isotypes mabs failed recognize gp however mab recognized mucinlike region gp remained reactive antigen lowest tested concentration ngml result suggests igmsecreting hybridoma predominantly generated dna vaccination however boosting gp resulted greater production iggsecreting hybridoma gp dna vaccination alone conclusion dna vaccination may preferentially generate igmsecreting hybridoma boosting protein antigen reverse propensity thus protein boosting approach may implication production iggspecific hybridoma context dna vaccination platform addition purified monoclonal igg antibody may useful therapeutic antibody controlling ebola virus infection,2017-07-26,"Lee, Si-Hyeong; Han, Baek-Sang; Choe, Jongseon; Sin, Jeong-Im",Clin Exp Vaccine Res,,,,document_parses/pdf_json/839df627ece5b5fc7bb1ce3b4f96127677fd0494.json,document_parses/pmc_json/PMC5540962.xml.json,https://doi.org/10.7774/cevr.2017.6.2.135; https://www.ncbi.nlm.nih.gov/pubmed/28775978/,29192492.0,3
91206,91206,116584,blnn9q3r,a1e2a2f6e79ba001e0509a93237be6b79721a9bd,Elsevier; PMC,The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice,10.1016/j.vaccine.2005.01.036,PMC7115605,15755609.0,els-covid,investigated develop novel vaccine sars cov using cdna construct encoding structural antigen spike protein membrane protein envelope protein e nucleocapsid n protein derived sars cov mouse vaccinated sarsn dna using pcdna plasmid vector showed cell immune response ctl induction proliferation n protein respectively ctl response also detected sars dnatransfected type ii alveolar epithelial cell cell clone thought initial target cell sars virus infection human determine whether dna vaccine could induce cell immune response human well mouse scidpblhu mouse immunized dna vaccine expected virusspecific ctl response cell proliferation induced human cell sarsn sarsm dna vaccine scidpblhu mouse model important development protective vaccine,2005-03-18,"Okada, Masaji; Takemoto, Yuji; Okuno, Yoshinobu; Hashimoto, Satomi; Yoshida, Shigeto; Fukunaga, Yukari; Tanaka, Takao; Kita, Yoko; Kuwayama, Sachiko; Muraki, Yumiko; Kanamaru, Noriko; Takai, Hiroko; Okada, Chika; Sakaguchi, Yayoi; Furukawa, Izumi; Yamada, Kyoko; Matsumoto, Makoto; Kase, Tetsuo; deMello, Daphne E.; Peiris, J.S.M.; Chen, Pei-Jer; Yamamoto, Naoki; Yoshinaka, Yoshiyuki; Nomura, Tatsuji; Ishida, Isao; Morikawa, Shigeru; Tashiro, Masato; Sakatani, Mitsunori",Vaccine,,,,document_parses/pdf_json/a1e2a2f6e79ba001e0509a93237be6b79721a9bd.json,document_parses/pmc_json/PMC7115605.xml.json,https://api.elsevier.com/content/article/pii/S0264410X05000393; https://www.sciencedirect.com/science/article/pii/S0264410X05000393,34630612.0,3
91215,91215,116596,kzp3b3l1,efd40f6d57dc6711af5055746c60cd05b83a4e17,Elsevier; PMC,Immunization of Puppies in the Presence of Maternally Derived Antibodies Against Canine Distemper Virus,10.1016/j.jcpa.2007.04.015,PMC7094307,17560592.0,els-covid,summary vaccination dam modifiedlive canine distemper virus cdv vaccine elicit high concentration colostral antibody although vital protection pup first week life interfere active vaccination virus present study pup – week age maternally derived immunity cdv vaccinated canarypoxvectored cdv vaccine pup protected intravenous challenge cdv three littermate pup unvaccinated developed clinical sign infection challenge two control pup died,2007-07-31,"Pardo, M. C.; Tanner, P.; Bauman, J.; Silver, K.; Fischer, L.",Journal of Comparative Pathology,,,,document_parses/pdf_json/efd40f6d57dc6711af5055746c60cd05b83a4e17.json,document_parses/pmc_json/PMC7094307.xml.json,https://www.sciencedirect.com/science/article/pii/S0021997507000655; https://api.elsevier.com/content/article/pii/S0021997507000655,31228134.0,3
91261,91261,116658,e05ktb83,c4fc28f1a66e4664a3dc12f5b121ee97aa9f122d,Medline; PMC,A Novel Replication-Competent Vaccinia Vector MVTT Is Superior to MVA for Inducing High Levels of Neutralizing Antibody via Mucosal Vaccination,10.1371/journal.pone.0004180,PMC2613559,19159014.0,cc-by,mucosal vaccination offer great advantage inducing protective immune response prevent viral transmission dissemination report finding headtohead comparison two viral vector modified vaccinia ankara mva novel replicationcompetent modified vaccinia tian tan mvtt inducing neutralizing antibody nabs via intramuscular mucosal vaccination mouse mvtt attenuated variant wildtype vtt historically used smallpox vaccine million chinese people spike glycoprotein sarscov used test antigen gene constructed identical genomic location two vector generate vaccine candidate mvtts mvas using identical dos mvtts induced lower level ∼fold anti sarscov neutralizing antibody nabs mvas intramuscular inoculation mvtts however capable inducing consistently tofold higher level nabs mvas inoculated via either intranasal intraoral route level mvttsinduced nab response substantially ∼fold higher induced via intramuscular route experiment moreover preexposure wildtype vtt via intranasal intraoral route impaired nab response via route mvtts vaccination probably due preexisting antivtt nab response efficacy intranasal intraoral vaccination however still tofold better intramuscular inoculation despite subcutaneous preexposure wildtype vtt data implication people maintain low level antivtt nabs historical smallpox vaccination mvtt therefore attractive live viral vector mucosal vaccination,2009-01-13,"Huang, Xiaoxing; Lu, Bin; Yu, Wenbo; Fang, Qing; Liu, Li; Zhuang, Ke; Shen, Tingting; Wang, Haibo; Tian, Po; Zhang, Linqi; Chen, Zhiwei",PLoS One,,,,document_parses/pdf_json/c4fc28f1a66e4664a3dc12f5b121ee97aa9f122d.json,document_parses/pmc_json/PMC2613559.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19159014/; https://doi.org/10.1371/journal.pone.0004180,31559.0,3
91268,91268,116666,c7c9ycew,75a8ca179e8e0405a9c150507809c0f5c38aedb5,Medline; PMC,Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus,10.1038/srep34108,PMC5040956,27682426.0,cc-by,lack licensed vaccine respiratory syncytial virus rsv partly attributed regulatory hurdle resulting vaccine enhanced respiratory disease erd subsequent natural rsv infection observed clinical trial formalininactivated rsv firsv antigennaïve infant develop effective vaccine enhance rsv illness important understand formalin heat inactivation affected antigenicity immunogenicity firsv compared native virus informed atomic structure rsv fusion f glycoprotein prefusion pref postfusion postf conformation demonstrate firsv predominately present postf virion surface whereas infectious rsv present pref postf conformation significant antigenic distinction previously appreciated thus stabilized pref antigen representative live rsv f postf conformation displayed surface firsv finding major implication discriminating current prefbased immunogen firsv used historical vaccine trial,2016-09-29,"Killikelly, April M.; Kanekiyo, Masaru; Graham, Barney S.",Sci Rep,,,,document_parses/pdf_json/75a8ca179e8e0405a9c150507809c0f5c38aedb5.json,document_parses/pmc_json/PMC5040956.xml.json,https://doi.org/10.1038/srep34108; https://www.ncbi.nlm.nih.gov/pubmed/27682426/,14813621.0,3
91296,91296,116699,wxf60gww,8e615240758a285de829308e4db562cfea5fef1f,Elsevier; PMC,Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice,10.1016/j.vaccine.2007.06.017,PMC7115497,17640780.0,els-covid,feasibility developing prophylactic vaccine sars assessed comparing immune response elicited immunizing mouse recombinant sars spike glycoprotein sprotein formulated different adjuvant given different route young aged mouse intranasal protollinformulated sprotein vaccine elicited high level antigenspecific igg serum comparable elicited intramuscular alumadsorbed sprotein vaccine serum antibody shown virus neutralizing intranasal immunization young mouse protollinformulated vaccine elicited significant level antigenspecific lung iga contrast mouse immunized intramuscular vaccine antigenspecific lung iga detected following live virus challenge aged mouse virus detected lung intranasally immunized mouse contrast intramuscularly immunized mouse whose lung virus titer comparable observed control mouse,2007-08-21,"Hu, Mary C.; Jones, Taff; Kenney, Richard T.; Barnard, Dale L.; Burt, David S.; Lowell, George H.",Vaccine,,,,document_parses/pdf_json/8e615240758a285de829308e4db562cfea5fef1f.json,document_parses/pmc_json/PMC7115497.xml.json,https://api.elsevier.com/content/article/pii/S0264410X07006950; https://www.sciencedirect.com/science/article/pii/S0264410X07006950,20733523.0,3
91308,91308,116713,ep7ezoko,16715be315ab1392947070e15252a60ae2b745f8,Medline; PMC,Current progress in the development of a prophylactic vaccine for HIV-1,10.2147/dddt.s6959,PMC3023272,21267356.0,no-cc,since discovery characterization early virus attack immune system success treatment human immunodeficiency virus hiv infection however due overwhelming public health impact virus vaccine needed urgently despite tireless effort scientist clinician still safe effective vaccine provides sterilizing immunity vaccine provides sterilizing immunity hiv infection remains elusive part due following reason degree diversity virus ability virus evade host ’ immunity lack appropriate animal model test vaccine candidate several attempt stimulate immune system provide protection hivinfection discus attempt made induce sterilizing immunity including traditional vaccination attempt induction broadly neutralizing antibody production dna vaccine use viral vector attempt show promise pending continued research effort,2010-12-22,"Gamble, Lena J; Matthews, Qiana L",Drug Des Devel Ther,,,,document_parses/pdf_json/16715be315ab1392947070e15252a60ae2b745f8.json,document_parses/pmc_json/PMC3023272.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/21267356/; https://doi.org/10.2147/dddt.s6959,13294447.0,3
91348,91348,116757,xasktk5c,517e17bb00ead902d4837093f97f18b933c067b1,Medline; PMC,Plant Production of Veterinary Vaccines and Therapeutics,10.1007/978-3-540-70868-1_5,PMC7122226,19401822.0,no-cc,plantderived biologicals use animal health becoming increasingly important target research alternative improved method disease control although commercial product market yet development testing oral plantbased vaccine beyond proofofprinciple stage vaccine developed porcine transmissible gastroenteritis virus potential stimulate mucosal systemic well lactogenic immunity already seen target animal trial plant promising production system must compete existing vaccine protein production platform addition regulatory hurdle need overcome industry public acceptance technology important establishing successful product,2009,"Hammond, R. W.; Nemchinov, L. G.",Plant-produced Microbial Vaccines,,,,document_parses/pdf_json/517e17bb00ead902d4837093f97f18b933c067b1.json,,https://www.ncbi.nlm.nih.gov/pubmed/19401822/; https://doi.org/10.1007/978-3-540-70868-1_5,19571270.0,3
91362,91362,116772,e8l9w41u,7a1da051f66f6951fbd91f49609ed1fa884321f9,Elsevier; Medline; PMC,Virus-like particles: The new frontier of vaccines for animal viral infections,10.1016/j.vetimm.2012.04.026,PMC7112581,22705417.0,els-covid,vaccination continues main approach protect animal infectious disease recently licensed vaccine developed using conventional technology subunit vaccine however gaining attention researcher field veterinary vaccinology among viruslike particle vlps represent one appealing approach vlps robust protein cage nanometer range mimic overall structure native virion lack viral genome often antigenically indistinguishable virus derived present important advantage term safety vlps stimulate strong humoral cellular immune response shown exhibit selfadjuvanting ability addition suitability vaccine homologous virus derived vlps also used vector multimeric presentation foreign antigen vlps therefore shown dramatic effectiveness candidate vaccine review current status vlps vaccine technology veterinary field discus potential advantage challenge technology,2012-08-15,"Crisci, Elisa; Bárcena, Juan; Montoya, María",Veterinary Immunology and Immunopathology,,,,document_parses/pdf_json/7a1da051f66f6951fbd91f49609ed1fa884321f9.json,document_parses/pmc_json/PMC7112581.xml.json,https://api.elsevier.com/content/article/pii/S016524271200181X; https://www.ncbi.nlm.nih.gov/pubmed/22705417/; https://www.sciencedirect.com/science/article/pii/S016524271200181X; https://doi.org/10.1016/j.vetimm.2012.04.026,205612810.0,3
91366,91366,116776,zoxb300y,111e82fd55d8b42cd523cf365b53dfcdaa2165d3,Medline; PMC,A Recombinant La Sota Vaccine Strain Expressing Multiple Epitopes of Infectious Bronchitis Virus (IBV) Protects Specific Pathogen-Free (SPF) Chickens against IBV and NDV Challenges,10.3390/vaccines7040170,PMC6963182,31683905.0,cc-by,infectious bronchitis ib newcastle disease nd two major infectious disease threat domestic poultry industry study successfully generated recombinant lasota candidate vaccine strain rndvibvtb express short synthetic previously identified ibv multiepitope cassette using reverse genetic system recombinant virus propagated ninedayold embryonated chicken egg passage genetic stability confirmed whole genome dna sequencing recombinant virus hemagglutination ha titer mean death time mdt hour intracerebral pathogenicity index icpi none significantly different parental newcastle disease virus ndv lasota strain p vaccination white leghorn chicken one day age eid rndvibvtb provided protection virulent ibv challenge three week age significantly higher protection control group vaccinated phosphatebuffered saline pb p ciliostasis score rndvibvtbvaccinated lasotavaccinated group respectively indicated rndvibvtb vaccination reduced pathogenicity ibv toward trachea furthermore realtime rtpcr assay showed rndvibvtb vaccination resulted low level viral load ± rna copy trachea four day postchallenge significantly lower group vaccinated pb ± rna copy lasota ± rna copy p meanwhile dose rndvibvtb vaccination provided complete protection velogenic ndv fe challenge result demonstrate rndvibvtb strain promising vaccine candidate control ib nd simultaneously furthermore epitopebased live vector vaccine provide alternative strategy development costeffective broadly crossprotective vaccine,2019-11-01,"Tan, Lei; Wen, Guoyuan; Qiu, Xusheng; Yuan, Yanmei; Meng, Chunchun; Sun, Yingjie; Liao, Ying; Song, Cuiping; Liu, Weiwei; Shi, Yonghong; Shao, Huabin; Ding, Chan",Vaccines (Basel),,,,document_parses/pdf_json/111e82fd55d8b42cd523cf365b53dfcdaa2165d3.json,document_parses/pmc_json/PMC6963182.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31683905/; https://doi.org/10.3390/vaccines7040170,207892520.0,3
91391,91391,116804,v812zn3r,f5bdf18567bb3760e1ce05008135f0270badbd5c,Medline; PMC,Pre-existing immunity against vaccine vectors – friend or foe?,10.1099/mic.0.049601-0,PMC3542731,23175507.0,cc-by,last century successful attenuation multiple bacterial viral pathogen led effective robust safe form vaccination recently vaccine evaluated delivery vector heterologous antigen mean simultaneous vaccination two pathogen general consensus published study vaccine vector potential safe efficacious however commonly employed vector example salmonella adenovirus often preexisting immune response host potential modify subsequent immune response vectored antigen review examines literature topic concludes bacterial vector fact case enhancement immunogenicity typically humoral viral vector preexisting immunity hindrance subsequent induction cellmediated response,2013-01-26,"Saxena, Manvendra; Van, Thi Thu Hao; Baird, Fiona J.; Coloe, Peter J.; Smooker, Peter M.",Microbiology,,,,document_parses/pdf_json/f5bdf18567bb3760e1ce05008135f0270badbd5c.json,document_parses/pmc_json/PMC3542731.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/23175507/; https://doi.org/10.1099/mic.0.049601-0,17622006.0,3
91419,91419,116834,mgi6aelt,b6d8a9871b1a110c041a697da61c63f891f462f0; 63b80a4b22332acddf8340291bb099eb4d9194de,Elsevier; Medline; PMC,Optimizing the design of protein nanoparticles as carriers for vaccine applications,10.1016/j.nano.2015.05.003,PMC4587294,26051652.0,green-oa,successful vaccine development remains huge challenge infectious disease malaria hiv influenza novel way present antigenic epitope immune system developed icosahedral selfassembling protein nanoparticles sapns serve prototypical vaccine platform infectious disease examine biophysical factor affect selfassembly nanoparticles basic building block coiledcoil oligomerization domain joined short linker region relying silico computer modeling prediction selected five different linker region rcsb protein database connect oligomerization domain studied selfassembly stability vitro produced nanoparticles biophysical characterization formed particle one design particular ti revealed excellent selfassembly homogeneity thus paving way towards optimized nanoparticle vaccine application,2015-10-01,"Doll, Tais A.P.F.; Neef, Tobias; Duong, Nha; Lanar, David E.; Ringler, Philippe; Müller, Shirley A.; Burkhard, Peter","Nanomedicine: Nanotechnology, Biology and Medicine",,,,document_parses/pdf_json/b6d8a9871b1a110c041a697da61c63f891f462f0.json; document_parses/pdf_json/63b80a4b22332acddf8340291bb099eb4d9194de.json,document_parses/pmc_json/PMC4587294.xml.json,http://europepmc.org/articles/pmc4587294?pdf=render; https://api.elsevier.com/content/article/pii/S1549963415001185; https://www.ncbi.nlm.nih.gov/pubmed/26051652/; https://www.sciencedirect.com/science/article/pii/S1549963415001185; https://doi.org/10.1016/j.nano.2015.05.003,25798709.0,3
91433,91433,116854,wc72cvlr,080811568194d661e9f8563f629db32dc9335948,Elsevier; PMC,Duration of immunity (DOI) and booster vaccination—dealing with the issue at practice level in the UK,10.1016/j.vetmic.2006.06.007,PMC7131776,16872760.0,els-covid,presentation offer uk veterinary practitioner viewpoint issue booster vaccination reference dog cat vaccine current use vaccine issue surrounding use discussed including motivation vaccinating climate reduced fear disease increased suspicion vaccine attitude extended routine booster vaccination explored specific disease prevention issue concerning leptospirosis particular presented strategy tactic implementation extended vaccine general practice level discussed based author experience thought offered vaccine manufacturer might support process local national level well communicating positive message continued routine vaccination dog cat advantage extended offer,2006-10-05,"Hill, R. James",Veterinary Microbiology,,,,document_parses/pdf_json/080811568194d661e9f8563f629db32dc9335948.json,document_parses/pmc_json/PMC7131776.xml.json,https://api.elsevier.com/content/article/pii/S0378113506002215; https://www.sciencedirect.com/science/article/pii/S0378113506002215,34023716.0,3
91434,91434,116855,b264k3gy,30e0d37ac4b4360802b1c717c0ad52de23be7609,Medline; PMC,Edible Vaccines: Promises and Challenges,10.1007/s12033-019-00222-1,PMC7090473,31758488.0,no-cc,vaccine biological preparation improve immunity particular disease form important innovation th century research contains protein resembles diseasecausing microorganism often made weak killed form microbe vaccine agent stimulate body ’ immune system recognize antigen new form vaccine introduced power mask risk side conventional vaccine type vaccine produced plant genetically modified production edible vaccine geneencoding bacterial viral diseasecausing agent incorporated plant without losing immunogenic property main mechanism action edible vaccine activate systemic mucosal immunity response foreign diseasecausing organism edible vaccine produced incorporating transgene selected plant cell present edible vaccine developed veterinary human use main challenge faced edible vaccine acceptance population necessary make aware society use benefit compared traditional vaccine edible vaccine cost effective efficient safe promise better prevention option disease,2019-11-22,"Kurup, Vrinda M; Thomas, Jaya",Mol Biotechnol,,,,document_parses/pdf_json/30e0d37ac4b4360802b1c717c0ad52de23be7609.json,document_parses/pmc_json/PMC7090473.xml.json,https://doi.org/10.1007/s12033-019-00222-1; https://www.ncbi.nlm.nih.gov/pubmed/31758488/,208210822.0,3
91456,91456,116885,s8qh1wwl,1588440f1bbd34d1cdd1b194e892b0ee0eb884aa,Elsevier; Medline; PMC,Production of virus-like particles for vaccines,10.1016/j.nbt.2017.07.010,PMC7102714,28778817.0,no-cc,viruslike particle vlps nanostructures resemble structure virus composed one structural protein arranged several layer also contain lipid outer envelope vlps trigger high humoral cellular immune response due repetitive structure key factor regarding vlp safety lack viral genomic material enhances safety manufacture administration contemporary vlp production may take advantage several system including bacterial yeast insect mammalian cell choice production platform depends several factor including cost need posttranslational modification ptms essential generating optimal immune response vlpbased vaccine designed prevent several infectious disease already approved market many others clinical trial research stage interest technology recently increased due advantage classical vaccine paper review stateoftheart vlp production system newest generation vlpbased vaccine available,2017-10-25,"Fuenmayor, J.; Gòdia, F.; Cervera, L.",N Biotechnol,,,,document_parses/pdf_json/1588440f1bbd34d1cdd1b194e892b0ee0eb884aa.json,document_parses/pmc_json/PMC7102714.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28778817/; https://www.sciencedirect.com/science/article/pii/S1871678416325511; https://doi.org/10.1016/j.nbt.2017.07.010; https://api.elsevier.com/content/article/pii/S1871678416325511,28331014.0,3
91482,91482,116917,egzztatj,c498c184be9d2eff60d08f904d79590e587d7d2c,Medline; PMC; WHO,The spread of the COVID‐19 coronavirus: Health agencies worldwide prepare for the seemingly inevitability of the COVID‐19 coronavirus becoming endemic,10.15252/embr.202050334,PMC7132190,32181577.0,no-cc,late confine covid‐ coronovirus outbreak china wealth data spur epidemiological vaccine research image see text,2020-03-17,"Hunter, Philip",EMBO Rep,,#8904,,document_parses/pdf_json/c498c184be9d2eff60d08f904d79590e587d7d2c.json,document_parses/pmc_json/PMC7132190.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32181577/; https://doi.org/10.15252/embr.202050334,212740267.0,3
91514,91514,116962,1ksahg3o,975a8b4abe4cc0181522e859a92c5ddc22f50c29,Medline; PMC,A questionnaire-based survey on the uptake and use of cattle vaccines in the UK,10.1136/vropen-2014-000042,PMC4562447,26392877.0,cc-by-nc,background vaccination widely used strategy disease control cattle uk abroad however limited research describing uptake use cattle vaccine uk farm aim describe current uptake usage cattle vaccine uk design questionnaire available paper online format distributed cattle farmer convenience sampling participant uk cattle farmer eligible participate study result eightysix per cent respondent n vaccinated cattle past year disease commonly vaccinated bovine viral diarrhoea leptospirosis infectious bovine rhinotracheitis vaccination compliance limited certain area example per cent respondent stated administered second dose primary course within recommended timeframe per cent respondent stated vaccinated earlier youngest recommended age although outside scope study work needed establish extent inadequate compliance effect vaccine efficacy role veterinarian highlighted main supplier vaccine preferred source vaccination information respondent preferred receive recommendation regarding vaccination facetoface communication veterinarian conclusion result provide description current uptake usage cattle vaccine uk uptake generally high area usage vaccine could improved upon veterinarian play key role supplier vaccine source information majority farmer although outside scope study work needed establish extent inadequate compliance effect vaccine efficacy although respondent study represent biased population farmer finding indicate area future investigation order improve vaccination strategy cattle uk,2014-07-11,"Cresswell, E.; Brennan, M. L.; Barkema, H. W.; Wapenaar, W.",Vet Rec Open,,,,document_parses/pdf_json/975a8b4abe4cc0181522e859a92c5ddc22f50c29.json,document_parses/pmc_json/PMC4562447.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26392877/; https://doi.org/10.1136/vropen-2014-000042,17988866.0,3
91614,91614,117080,jqrinz7l,98ed38e298aad18a168191f79479df6c25d4a5ed,Elsevier; Medline; PMC,Pathogenicity of a GI-22 genotype infectious bronchitis virus isolated in China and protection against it afforded by GI-19 vaccine,10.1016/j.virusres.2019.05.006,PMC7172295,31082454.0,no-cc,avian infectious bronchitis ib globally circulating bird disease caused infectious bronchitis virus ibv china prevalent ibv genotype giqxlike protective efficiency classical ibv vaccine low new gi vaccine development gi genotype strain ckchlgd abbreviated ‘ lgd ’ isolated northern china caused – morality hvaccinated chicken phylogenetic analysis showed new isolate display novel feature compared earlierisolated reference strain monitor epidemic trend ibv china pathogenicity lgd first evaluated dayold specificpathogenfree chicken lgd induced classical ibv damage trachea kidney whereas also infected damaged bursa fabricius important immune organ chicken efficacy earlierdeveloped gi vaccine strain sz lgd also evaluated study gi genotype vaccine provided sufficient protection new gi genotype strain may promising candidate vaccine control wild gi gi strain future,2019-07-02,"Zhao, Ye; Xie, Deqiong; Zhang, Keran; Cheng, Jinlong; Xu, Gang; Zhang, Guozhong",Virus Res,,,,document_parses/pdf_json/98ed38e298aad18a168191f79479df6c25d4a5ed.json,document_parses/pmc_json/PMC7172295.xml.json,https://api.elsevier.com/content/article/pii/S0168170219301601; https://www.sciencedirect.com/science/article/pii/S0168170219301601; https://doi.org/10.1016/j.virusres.2019.05.006; https://www.ncbi.nlm.nih.gov/pubmed/31082454/,153311686.0,3
91628,91628,117097,188gnf8j,866943e037d3b683d0405a9d65d94568074ed592,Elsevier; PMC,Induction of T-cell response by a DNA vaccine encoding a novel HLA-A*0201 severe acute respiratory syndrome coronavirus epitope,10.1016/j.vaccine.2007.05.025,PMC7115375,17629360.0,els-covid,severe acute respiratory syndrome coronavirus nucleocapsid protein sarscov n one major target sars vaccine due high potency triggering immune response study identified novel hlaa restricted epitope n lalllldrl sarscov nprotein bioinformatics analysis nprotein peptide n show high binding affinity towards human mhc class tcells capable activating cytotoxic tcells human peripheral blood mononuclear cell pbmcs application using n peptide sequence singlechaintrimer sct approach produce potential dna vaccine candidate investigated hlaakb transgenic mouse cytotoxicity assay clearly showed tcells obtained vaccinated animal able kill nprotein expressing cell cytotoxicity level effector cellstarget cell ratio one week last vaccination significantly higher nprotein peptide previously described novel immunogenic nprotein peptide revealed present study provides valuable information therapeutic sars vaccine design,2007-08-10,"Cheung, Ying-Kit; Cheng, Samuel Chak-Sum; Sin, Fion Wan-Yee; Chan, Kin-Tak; Xie, Yong",Vaccine,,,,document_parses/pdf_json/866943e037d3b683d0405a9d65d94568074ed592.json,document_parses/pmc_json/PMC7115375.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X07005932; https://api.elsevier.com/content/article/pii/S0264410X07005932,23558554.0,3
91629,91629,117098,b24ujorz,,Medline; WHO,Emergence of Drift Variants That May Affect COVID-19 Vaccine Development and Antibody Treatment.,10.3390/pathogens9050324,,32357545.0,unk,new coronavirus sarscov treatment vaccine development combat covid several approach used scientist investigation including various small molecule approach targeting rna polymerase clike protease rna endonuclease exploration antibody obtained convalescent plasma patient recovered covid coronavirus genome highly prone mutation lead genetic drift escape immune recognition thus imperative substrains different mutation also accounted vaccine development disease grown become pandemic bcell tcell epitope predicted sars coronavirus reported using epitope information along variant virus found several variant might cause drift among variant ag variant pdg spike protein bcell epitope observed frequently european country netherlands switzerland france seldom observed china,2020-04-26,"Koyama, Takahiko; Weeraratne, Dilhan; Snowdon, Jane L; Parida, Laxmi",Pathogens,,#116559,,,,https://www.ncbi.nlm.nih.gov/pubmed/32357545/; https://doi.org/10.3390/pathogens9050324,218479814.0,3
91646,91646,117118,2jq626ye,5a17ed3e4abf295f5820c65f56398266c1baae98,PMC; WHO,"Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China",10.12688/f1000research.22211.2,PMC7029759,32117569.0,cc-by,novel coronavirus ncov originating wuhan china present potential respiratory viral pandemic world population current effort focused containment quarantine infected individual ultimately outbreak could controlled protective vaccine prevent ncov infection vaccine research pursued intensely exists today therapy treat ncov upon infection despite urgent need find option help patient preclude potential death herein review potential option treat ncov patient emphasis necessity speed timeliness developing new effective therapy outbreak consider option drug repurposing developing neutralizing monoclonal antibody therapy oligonucleotide strategy targeting viral rna genome emphasizing promise pitfall approach finally advocate fastest strategy develop treatment could resistant mutation virus may future proposal biologic block ncov entry using soluble version viral receptor angiotensinconverting enzyme ace fused immunoglobulin fc domain acefc providing neutralizing antibody maximal breath avoid viral escape also helping recruit immune system build lasting immunity acefc therapy would also supplement decreased ace level lung infection thereby directly treating acute respiratory distress pathophysiology third mechanism action sequence acefc protein provided investigator allowing possible use recombinant protein expression system start producing drug today treat patient compassionate use formal clinical trial later undertaken treatment could help infected patient protective vaccine developed widely available coming month year,2020-02-07,"Kruse, Robert L.",F1000Res,,#1971,,document_parses/pdf_json/5a17ed3e4abf295f5820c65f56398266c1baae98.json,document_parses/pmc_json/PMC7029759.xml.json,https://doi.org/10.12688/f1000research.22211.2,213712940.0,3
91707,91707,117189,uyim084w,f0ea24dbad758b4ef547b8e2c54bd4bb721caf01,Elsevier; Medline; PMC,A mathematical design of vector vaccine against autoimmune disease,10.1016/j.jtbi.2008.09.038,PMC7185877,18996399.0,els-covid,virus implicated initiation progression exacerbation several human autoimmune disease evidence also exists virus protect autoimmune disease several proposed mechanism explain viral effect one mechanism “ molecular mimicry ” represents shared immunologic epitope microbe host consider using simple mathematical model whether viral infection molecular mimicry beneficial detrimental autoimmune disease furthermore consider possibility development vector therapeutic vaccine relieve autoimmune disease symptom finding demonstrate vaccine therapy success necessitates appropriate immune response function ii appropriate affinity self nonself antigen iii replicative vector vaccine moreover model show viral infection cause autoimmune relapse,2009-02-07,"Iwami, Shingo; Takeuchi, Yasuhiro; Iwamoto, Kentaro; Naruo, Yoshimi; Yasukawa, Masahiro",Journal of Theoretical Biology,,,,document_parses/pdf_json/f0ea24dbad758b4ef547b8e2c54bd4bb721caf01.json,document_parses/pmc_json/PMC7185877.xml.json,https://www.sciencedirect.com/science/article/pii/S0022519308005146; https://api.elsevier.com/content/article/pii/S0022519308005146; https://doi.org/10.1016/j.jtbi.2008.09.038; https://www.ncbi.nlm.nih.gov/pubmed/18996399/,23874758.0,3
91723,91723,117207,jfe8neec,db45f2007d78df7576da75c82b8b5068479cf47f,Elsevier; Medline; PMC; WHO,"SARS – CoV -2: reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis)",10.1016/j.mehy.2020.109779,PMC7175879,32387756.0,no-cc,novel coronavirus covid follows transmission route clinical presentation communityacquired coronaviruses instead rate transmission significative higher faster spread virus responsible worldwide outbreak significative higher mortality rate due development severe lung injury noteworthy distribution death rate among age group child younger people almost protected severe clinical presentation possible explanation phenomenon could ability past vaccination especially tetanic diphtheria toxoid inactivated bacteria pertussis stimulate immune system generate scattered immunity nonself antigen transit coronaviruses communitycirculating virus make immune system readier develop specific immunity covid first support hypothesis distribution mortality rate historical pandemic “ spanish flu ” “ asian flu ” “ hong kong flu ” among age group introduction vaccine immunological support hypothesis derives recent study immunotherapy malignancy propose use oncolytic vaccine combined toxoid order exploit cd memory cell recall supporting ongoing antitumour response according hypothesis vaccine formulation tetanus diphtheria bordetella pertussis could readministrate first contact covid better development respiratory severe illness course fullblown ards acute respiratory distress syndrome cd memory exploiting could help immune system recall immunity already know antigen coronaviruses avoiding limiting “ lung crash ” virus specific immunity develops making faster prolonged finally administration could helpful already infected patient also infection fact people could immune system ready contact covid occur,2020-04-22,"Ietto, Giuseppe",Med Hypotheses,,#101927,,document_parses/pdf_json/db45f2007d78df7576da75c82b8b5068479cf47f.json,document_parses/pmc_json/PMC7175879.xml.json,https://doi.org/10.1016/j.mehy.2020.109779; https://www.sciencedirect.com/science/article/pii/S0306987720304242?v=s5; https://api.elsevier.com/content/article/pii/S0306987720304242; https://www.ncbi.nlm.nih.gov/pubmed/32387756/,216061044.0,3
91735,91735,117220,65vq6ldc,,Medline; WHO,"Covid-19: Trump sought to buy vaccine developer exclusively for US, say German officials",10.1136/bmj.m1100,,32184216.0,unk,u president donald trump made secret overture german company curevac—one leading contender create covid vaccine—in hope luring united state say senior official german government germany ’ welt sonntag newspaper reported offer valued bn £m €m stipulated vaccine company developed would “ usa ” company often said product would offered country senior german official confirmed report criticised u government ’ action horst seehofer interior minister asked …,2020,"Dyer, Owen",BMJ,,#9171,,,,https://www.ncbi.nlm.nih.gov/pubmed/32184216/; https://doi.org/10.1136/bmj.m1100,212751190.0,3
91760,91760,117253,6i9p58mi,e234b6a4a22e1c5b7819d8ba8914062ddd76808f,Elsevier; Medline; PMC,Morbillivirus vaccines: Recent successes and future hopes,10.1016/j.vaccine.2014.03.053,PMC7115685,24703852.0,els-covid,impact morbilliviruses human animal population well documented history mankind indeed prior development vaccine disease morbilliviruses plagued human livestock heavily relied upon food motor power within community measles virus mev responsible death million people annually across world fortunate enough escape disease often faced starvation livestock died following infection rinderpest virus rpv peste de petits ruminant virus pprv canine distemper virus affected dog population century past decade appears jumped specie causing disease number noncanid specie pushed brink extinction virus age vaccination introduction successful application vaccine rinderpest measles led eradication former greater control latter vaccine ppr canine distemper also generated however disease still pose threat susceptible specie review currently available vaccine four morbilliviruses discus prospect development new generation vaccine,2014-05-30,"Buczkowski, Hubert; Muniraju, Murali; Parida, Satya; Banyard, Ashley C.",Vaccine,,,,document_parses/pdf_json/e234b6a4a22e1c5b7819d8ba8914062ddd76808f.json,document_parses/pmc_json/PMC7115685.xml.json,https://doi.org/10.1016/j.vaccine.2014.03.053; https://www.sciencedirect.com/science/article/pii/S0264410X14004228; https://api.elsevier.com/content/article/pii/S0264410X14004228; https://www.ncbi.nlm.nih.gov/pubmed/24703852/,30914155.0,3
91794,91794,117300,6rtra9ts,94b2ec1ac048a6dd05e47fa2e8ae7e7975f0395b; 5ba4131247e6e2bc501fad8c35e35476ea5f6738; 0f8c4f27905d383beb993ff8ff112ba63d80b058,Elsevier; Medline; PMC,Plant-made vaccine antigens and biopharmaceuticals,10.1016/j.tplants.2009.09.009,PMC2787751,19836291.0,green-oa,plant cell ideal bioreactors production oral delivery vaccine biopharmaceuticals eliminating need expensive fermentation purification cold storage transportation sterile delivery plantmade vaccine developed two decade none advanced beyond phase however two plantmade biopharmaceuticals advancing phase ii phase iii human clinical trial review evaluate advantage disadvantage different plant expression system stable nuclear chloroplast transient viral current limitation challenge provide suggestion advancing valuable concept clinical application conclude greater research emphasis needed large scale production purification functional characterization oral delivery preclinical evaluation,2009-12-01,"Daniell, Henry; Singh, Nameirakpam D.; Mason, Hugh; Streatfield, Stephen J.",Trends in Plant Science,,,,document_parses/pdf_json/94b2ec1ac048a6dd05e47fa2e8ae7e7975f0395b.json; document_parses/pdf_json/5ba4131247e6e2bc501fad8c35e35476ea5f6738.json; document_parses/pdf_json/0f8c4f27905d383beb993ff8ff112ba63d80b058.json,document_parses/pmc_json/PMC2787751.xml.json,http://europepmc.org/articles/pmc2787751?pdf=render; https://www.sciencedirect.com/science/article/pii/S1360138509002520; https://www.ncbi.nlm.nih.gov/pubmed/19836291/; https://doi.org/10.1016/j.tplants.2009.09.009; https://api.elsevier.com/content/article/pii/S1360138509002520,16082030.0,3
91809,91809,117320,xrg6gg9n,2033671f63b46d3f8de49a62a080d28c6c162c15,Elsevier; PMC,The safety of vaccines,10.1016/s1359-6446(04)03234-9,PMC7128484,15381137.0,els-covid,vaccine considerable impact society eliminating threat several infectious disease although vaccine generally proven safe safety issue arisen resulted member public poor perception vaccine however technological advance made recent year make development even safer vaccine possibility new generation vaccine based pure recombinant protein conjugate killed virus addition study conducted large number individual allay unjustified fear vaccine safety data increase public confidence ensure vaccine become better appreciated valuable product widespread confidence inspired effective communication reality benefittorisk ratio vaccine,2004-10-01,"O'Hagan, Derek T.; Rappuoli, Rino",Drug Discovery Today,,,,document_parses/pdf_json/2033671f63b46d3f8de49a62a080d28c6c162c15.json,document_parses/pmc_json/PMC7128484.xml.json,https://www.sciencedirect.com/science/article/pii/S1359644604032349; https://api.elsevier.com/content/article/pii/S1359644604032349,1672845.0,3
91863,91863,117387,8jnrc01n,5407b1aabede9eeed76c59a7b890be9f513712b7,Medline; PMC,A simple and safe antibody neutralization assay based on polio pseudoviruses,10.1080/21645515.2018.1526553,PMC6422504,30273512.0,cc-by-nc-nd,evaluation immunogenicity sabin strain based inactivated poliovirus vaccine sipv necessitates use wild strain neutralization assay ass potential crossreactivity antibody live virus strain including wild sabin strain must handled level biocontainment laboratory develop alternative assay without use live virus constructed mahoney mef saukett pseudovirions inserting luciferase reporter gene intact capsid protein afterward developed pseudovirusbased neutralization test pnt evaluated specificity reproducibility tested serum sample clinical trial sipv vaccine pnt compared result obtained conventional neutralization test cnt strong correlation observed two method correlation coefficient three type ipv vaccine greater p geometric mean titer gmt value obtained pnt approximately four time higher cnt revealing better sensitivity pnt conclusion pnt safe rapid sensitive quantitative assay potential alternative evaluation potency polio vaccine,2018-10-16,"Jiang, Zheng; Liu, Guixiu; Guo-yang, Liao; Sun, Mingbo; Xu, Kangwei; Ying, Zhifang; Wang, Jianfeng; Li, Xuguang; Li, Changgui",Hum Vaccin Immunother,,,,document_parses/pdf_json/5407b1aabede9eeed76c59a7b890be9f513712b7.json,document_parses/pmc_json/PMC6422504.xml.json,https://doi.org/10.1080/21645515.2018.1526553; https://www.ncbi.nlm.nih.gov/pubmed/30273512/,52898049.0,3
91905,91905,117437,rl2qxd03,d9077423f925951898cae6412d7bf0e68b482cf7,Medline; PMC; WHO,The SARS-CoV-2 Vaccine Pipeline: an Overview,10.1007/s40475-020-00201-6,PMC7094941,32219057.0,no-cc,purpose review goal review provide timely overview effort develop vaccine novel coronavirus sarscov causative agent coronavirus disease covid recent finding previous research effort develop severe acute respiratory syndrome coronavirus sarscov vaccine year following pandemic opened door investigator design vaccine concept approach covid epidemic china sarscov sarscov exhibit high degree genetic similarity bind host cell ace receptor based previous experience sarscov vaccine expected covid vaccine require careful safety evaluation immunopotentiation could lead increased infectivity eosinophilic infiltration besides covid vaccine target product profile must address vaccinating atrisk human population including frontline healthcare worker individual age underlying debilitating chronic condition among vaccine technology evaluation whole virus vaccine recombinant protein subunit vaccine nucleic acid vaccine summary current vaccine strategy distinct advantage disadvantage therefore paramount multiple strategy advanced quickly evaluated safety efficacy ultimately safety study minimize undesired immunopotentiation become significant bottleneck term time,2020-03-03,"Chen, Wen-Hsiang; Strych, Ulrich; Hotez, Peter J; Bottazzi, Maria Elena",Curr Trop Med Rep,,#3200,,document_parses/pdf_json/d9077423f925951898cae6412d7bf0e68b482cf7.json,document_parses/pmc_json/PMC7094941.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32219057/; https://doi.org/10.1007/s40475-020-00201-6,211730278.0,3
91924,91924,117457,sbct075z,bf942766e5690450c1c6e5278e8062526367f4c4,Elsevier; Medline; PMC,Maternally-derived neutralizing antibodies reduce vaccine efficacy against porcine reproductive and respiratory syndrome virus infection,10.1016/j.vaccine.2019.06.045,PMC7115427,31248683.0,els-covid,modified live virus mlv vaccine commonly used reduce impact porcine reproductive respiratory syndrome prrs limited efficacy achieved field condition evaluated impact maternallyderived neutralizing antibody mdnas vaccine efficacy prrs virus prrsv challenge piglet low a− high mdna level derived commercial pig herd moved experimental facility vaccinated v v− prrsv mlv vaccine week age woa unexpectedly low vaccine detection a−v piglet postvaccination pv v piglet received second vaccination woa five week w pv piglet inoculated prrsv field strain evaluate vaccine protection mingled h later noninoculated piglet similar immune status ass viral transmission vaccine strain detected w pv a−v av piglet w pv a−v av piglet respectively w pv a−v av piglet seroconverted significant ifng response induction a−v group challenge compared v− inoculated group viremia fold lower day postinfection a−v whereas viremia significantly reduced av piglet lower transmission rate estimated a−v group – versus – – av v− group respectively investigation low vaccine strain detection first vaccination suggested relationship ifna level vaccine strain detection a−v piglet showed mdnas impair vaccine efficacy prrsv inoculated contact piglet probably reducing vaccine replication ifna may also interfere prrsv vaccination new data could help improving vaccination protocol,2019-07-18,"Renson, Patricia; Fablet, Christelle; Andraud, Mathieu; Normand, Valérie; Lebret, Arnaud; Paboeuf, Frédéric; Rose, Nicolas; Bourry, Olivier",Vaccine,,,,document_parses/pdf_json/bf942766e5690450c1c6e5278e8062526367f4c4.json,document_parses/pmc_json/PMC7115427.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X19308072; https://doi.org/10.1016/j.vaccine.2019.06.045; https://api.elsevier.com/content/article/pii/S0264410X19308072; https://www.ncbi.nlm.nih.gov/pubmed/31248683/,195757952.0,3
91925,91925,117458,wu77xf6c,fab32444594a7c25009ffcd48e91c923f5f0316f,Medline; PMC,The imperative to develop a human vaccine for the Hendra virus in Australia,10.3402/iee.v5.29619,PMC4627939,26519254.0,cc-by-nc,hendra virus hev pose significant challenge public health australia expanding migratory pattern observed among bat mutation virus seek successfully infect new host significant departure generalized epidemiological trend recent discovery equinerelated infection death addition canine infection demonstrates inadequacy current equine vaccine developed traditional model controlling spread vector futile given rapid pace bat habitat eroded recent ongoing zoonotic epidemic example ebola middle east respiratory syndrome coronavirus demonstrate humantohuman transmission distinct reality rather obscure possibility development human hev vaccine essential biosecurity australia part multipronged strategy control hev australia,2015-10-29,"Zahoor, Bilal A.; Mudie, Lucy I.",Infect Ecol Epidemiol,,,,document_parses/pdf_json/fab32444594a7c25009ffcd48e91c923f5f0316f.json,document_parses/pmc_json/PMC4627939.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26519254/; https://doi.org/10.3402/iee.v5.29619,32135037.0,3
91968,91968,117512,1r3doeic,a7b1bcb7b1806dce219451f289d56b14434f7ac1,Medline; PMC,S1 domain of the porcine epidemic diarrhea virus spike protein as a vaccine antigen,10.1186/s12985-016-0512-8,PMC4818391,27036203.0,cc-by,background porcine epidemic diarrhea virus pedv highly contagious virus infecting pig age high morbidity mortality among newborn piglet currently effective vaccine available protect pig pedv nterminal subunit spike protein responsible virus binding cellular receptor contains number neutralizing antibody epitope thus expressed produced recombinant protein protect newborn piglet immunization sow method affinity tagged pedv protein expressed secretory form yeast insect mammalian cell identify suitable production system purified recombinant protein analysed sdspage western blot deglycosylation assay pregnant sow intramuscularly immunized three time adjuvanted recombinant protein prior farrowing pedvspecific immune response serum colostrum sow piglet assayed elisa virus neutralization assay piglet challenged orally pedv clinical parameter monitored day postchallenge result conclusion three eukaryotic expression system tested yeast insectcell mammalian expression hek cell gave highest yield protein nglycosylated appropriate candidate vaccination administration subunit vaccine sow resulted induction sspecific igg iga passively transferred suckling piglet also high virus neutralization titre observed serum vaccinated sow piglet pedv challenge piglet born vaccinated sow exhibited le severe sign disease significantly lower mortality compared piglet control sow however significant difference diarrhea body weight virus shedding thus vaccination subunit vaccine failed provide complete protection suckling piglet challenge exposure improvement needed development subunit vaccine fully protects pedv infection,2016-04-01,"Makadiya, Niraj; Brownlie, Robert; van den Hurk, Jan; Berube, Nathalie; Allan, Brenda; Gerdts, Volker; Zakhartchouk, Alexander",Virol J,,,,document_parses/pdf_json/a7b1bcb7b1806dce219451f289d56b14434f7ac1.json,document_parses/pmc_json/PMC4818391.xml.json,https://doi.org/10.1186/s12985-016-0512-8; https://www.ncbi.nlm.nih.gov/pubmed/27036203/,14791114.0,3
92044,92044,117614,guciupc8,d85a85112817de11b60dd2e8f8177a48c3015442,Medline; PMC,Vaccines Through Centuries: Major Cornerstones of Global Health,10.3389/fpubh.2015.00269,PMC4659912,26636066.0,cc-by,multiple cornerstone shaped history vaccine may contain liveattenuated virus inactivated organismsviruses inactivated toxin merely segment pathogen could elicit immune response story began hippocrates bc description mumps diphtheria discovery recorded ad smallpox vaccine described eighteenth century vaccine cholera yellow fever reported edward jenner father vaccination immunology published work smallpox nineteenth century major landmark “ germ theory disease ” louis pasteur discovery germ tubercle bacillus tuberculosis robert koch isolation pneumococcus organism george miller sternberg another landmark discovery diphtheria toxin emile roux serological treatment emil von behring paul ehrlih addition pasteur able generate first liveattenuated viral vaccine rabies typhoid vaccine developed followed plague vaccine yersin beginning world war tetanus toxoid introduced followed pertussis vaccine expanded program immunization established within bacille calmette–guerin polio dtp measles yellow fever hepatitis b year witnessed launching international aid vaccine initiative passed resolution eradicate polio year first vaccine prevent cervical cancer developed “ decade vaccine ” launched april st united nation launched “ shotlife ” campaign brief armamentarium vaccine continues grow emphasis safety availability accessibility mini review highlight major historical event pioneer course development vaccine eradicated many lifethreatening disease despite vaccination attitude wave appearing history,2015-11-26,"Hajj Hussein, Inaya; Chams, Nour; Chams, Sana; El Sayegh, Skye; Badran, Reina; Raad, Mohamad; Gerges-Geagea, Alice; Leone, Angelo; Jurjus, Abdo",Front Public Health,,,,document_parses/pdf_json/d85a85112817de11b60dd2e8f8177a48c3015442.json,document_parses/pmc_json/PMC4659912.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26636066/; https://doi.org/10.3389/fpubh.2015.00269,17951141.0,3
92083,92083,117657,gos4w1pc,96e9bf5d58a1ba692047da7ffc07a3e1fb86c4da,Elsevier; PMC,A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice,10.1016/j.vaccine.2006.01.059,PMC7115485,16497416.0,els-covid,recombinant sarscov spike glycoprotein vaccine produced insect cell preclinical development stage described truncated version glycoprotein containing ectodomain well histagged fulllength version cloned expressed serumfree insect cell line expressf® protein purified apparent homogeneity liquid column chromatography formulated without adjuvant μg per dose phosphate saline used immunize mouse antigen formulation elicited strong immune response two three vaccination antigen neutralizing antibody titer correlated closely standard elisa reactivity glycoprotein truncated protein also formulated adjuvant aluminum hydroxide μg per dose ±adjuvant μg per dose ±adjuvant significantly enhanced immune response manifested higher titer serum elisa viral neutralizing antibody achieved adjuvanted group fewer dos lower concentration glycoprotein finding indicate ectodomain sarscov glycoprotein vaccine without adjuvant immunogenic induces high titer virus neutralizing antibody level similar achieved full glycoprotein vaccine,2006-04-24,"Zhou, Zhimin; Post, Penny; Chubet, Rick; Holtz, Katherine; McPherson, Clifton; Petric, Martin; Cox, Manon",Vaccine,,,,document_parses/pdf_json/96e9bf5d58a1ba692047da7ffc07a3e1fb86c4da.json,document_parses/pmc_json/PMC7115485.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X06001071; https://api.elsevier.com/content/article/pii/S0264410X06001071,1619228.0,3
92118,92118,117698,6yxe820s,18bad8a83984c5c3eeb80c785d7450890ded7e9d,Elsevier; Medline; PMC,Innovations in HIV-1 Vaccine Design,10.1016/j.clinthera.2020.01.009,PMC7102617,32035643.0,no-cc,purpose field hiv vaccinology evolved last thirty year first viral vectorhiv gene insert construct vaccination regimen using myriad strategy strategy include germlinetargeting lineagebased structureguided immunogen design narrative review outline historical context hiv vaccinology subsequently highlight scientific discovery last six year promise propel field forward method conducted search two electronic database pubmed® embase® experimental study involving novel hiv immunogen design title review publication excluded written nonenglish language andor letter editor commentary conference presentation used clinicaltrialsgov® identify completed ongoing clinical trial using strategy finding hiv vaccinology field undergone period significant growth last three decade finding elucidated preclinical study revealed importance interaction cellular humoral immune system result several novel rationallydesigned vaccine strategy developed explored last six year including nativelike env trimer nanoparticle mrna vaccine design strategy among others several strategy demonstrated enough promise animal model progress toward firstinhuman phase clinical trial implication rapid development preclinical early phase clinical study suggest safe effective hiv vaccine may horizon,2020-02-05,"Jones, Letitia D.; Moody, M. Anthony; Thompson, Amelia B.",Clin Ther,,,,document_parses/pdf_json/18bad8a83984c5c3eeb80c785d7450890ded7e9d.json,document_parses/pmc_json/PMC7102617.xml.json,https://doi.org/10.1016/j.clinthera.2020.01.009; https://www.sciencedirect.com/science/article/pii/S0149291820300448; https://www.ncbi.nlm.nih.gov/pubmed/32035643/; https://api.elsevier.com/content/article/pii/S0149291820300448,211072616.0,3
92138,92138,117727,hf21hl41,37d90c9ba4f40fc21721415f54f821f1ee796317,Elsevier; PMC,SARS coronavirus spike polypeptide DNA vaccine priming with recombinant spike polypeptide from Escherichia coli as booster induces high titer of neutralizing antibody against SARS coronavirus,10.1016/j.vaccine.2005.05.023,PMC7115571,15993989.0,els-covid,different form sars coronavirus sarscov spike proteinbased vaccine generation neutralizing antibody response sarscov compared using mouse model high igg level detected mouse immunized intraperitoneal ip recombinant spike polypeptide generated escherichia coli speptide mouse primed intramuscular im tpaoptimize dna vaccine tpasdna boosted ip speptide mouse primed im ctlahingesars dna vaccine ctlasdna boosted ip speptide mouse primed oral liveattenuated salmonella typhimurium salmonellasdnacontrol boosted ip speptide mouse primed oral liveattenuated typhimurium contained tpaoptimize dna vaccine salmonellatpasdna boosted ip speptide mouse primed oral liveattenuated typhimurium contained ctlahingesars dna vaccine salmonellatpasdna boosted ip speptide statistical significant difference observed among thth index among six group mouse high igg level serum six mouse immunized ip speptide im dna vaccine control oral salmonellasdnacontrol showed neutralizing antibody sarscov serum mouse immunized im tpasdna im ctlasdna oral salmonellasdnacontrol boosted ip speptide oral salmonellatpasdna oral salmonellatpasdna boosted ip speptide oral salmonellactlasdna oral salmonellactlasdna boosted ip speptide showed neutralizing antibody titer – serum mouse immunized im tpasdna boosted ip speptide im ctlasdna boosted ip speptide showed neutralizing antibody titer ≥ present observation may major practical value immunization civet cat since production recombinant protein e coli far le expensive production recombinant protein using eukaryotic system,2005-10-10,"Woo, Patrick C.Y.; Lau, Susanna K.P.; Tsoi, Hoi-wah; Chen, Zhi-wei; Wong, Beatrice H.L.; Zhang, Linqi; Chan, Jim K.H.; Wong, Lei-po; He, Wei; Ma, Chi; Chan, Kwok-hung; Ho, David D.; Yuen, Kwok-yung",Vaccine,,,,document_parses/pdf_json/37d90c9ba4f40fc21721415f54f821f1ee796317.json,document_parses/pmc_json/PMC7115571.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X05005451; https://api.elsevier.com/content/article/pii/S0264410X05005451,77319.0,3
92177,92177,117776,rd5bd1ae,57a851ef4ef9c13bc326a9c0e57bd24690694e06,Elsevier; PMC,"Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys",10.1016/j.vaccine.2004.11.075,PMC7115379,15837221.0,els-covid,inactivated vaccine severe acute respiratory syndrome sarsassociated coronavirus sarscov evaluated rhesus monkey monkey inoculated intramuscularly im μg vaccine pb control boosted day week challenged n strain sarscov humoral mucosal immune response clinical sign chemical index viremia monitored following immunization challenge control animal received pb developed atypical sarcov infection viral challenge according clinical virological pathological finding systematic side effect observed vaccinated animal postimmunization even high dose μg μg dosage vaccine elicited sarscov specific immune response viral infection compared partial immunity elicited μg dos result show inactivated vaccine induce effective concomitant humoral mucosal immunity sarscov infection safe monkey vaccine maybe good candidate clinical trial,2005-05-02,"Zhou, Jun; Wang, Wei; Zhong, Qiong; Hou, Wei; Yang, Zhanqiu; Xiao, Shu-Yuan; Zhu, Runqing; Tang, Zhijiao; Wang, Yong; Xian, Qiaoyang; Tang, Hongbing; Wen, Li",Vaccine,,,,document_parses/pdf_json/57a851ef4ef9c13bc326a9c0e57bd24690694e06.json,document_parses/pmc_json/PMC7115379.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X05000861; https://api.elsevier.com/content/article/pii/S0264410X05000861,44991938.0,3
92217,92217,117822,9lzuu2ps,f6e6534cb423c1823ad38d7d5c0a98c303f2efdb,Medline; PMC,Architectural Insight into Inovirus-Associated Vectors (IAVs) and Development of IAV-Based Vaccines Inducing Humoral and Cellular Responses: Implications in HIV-1 Vaccines,10.3390/v6125047,PMC4276942,25525909.0,cc-by,inovirusassociated vector iavs engineered nonlytic filamentous bacteriophage assembled primarily thousand copy major coat protein gp five copy four minor coat protein gp gp gp gp inovirus display study shown architecture inoviruses make coat protein inoviral particle accessible outside particular feature iavs allows foreign antigenic peptide displayed outer surface virion fused coat protein two decade exploited many application including antibody peptide display library drug design vaccine development infectious noninfectious disease vaccine carrier iavs shown elicit cellular humoral response various pathogen display antibody epitope coat protein despite high immunogenicity goal developing effective vaccine hiv yet materialized one possible limitation previous effort use broadly neutralizing antibody exhibited autoreactivity property past five year however new potent broadly neutralizing antibody exhibit autoreactivity property isolated hiv infected individual suggesting vaccination strategy aimed producing broadly neutralizing antibody may confer protection infection utilization new broadly neutralizing antibody combination architectural trait iavs driven current development design inovirusbased vaccine hiv article review application iavs vaccine development particular emphasis design inoviralbased vaccine hiv,2014-12-17,"Hassapis, Kyriakos A.; Stylianou, Dora C.; Kostrikis, Leondios G.",Viruses,,,,document_parses/pdf_json/f6e6534cb423c1823ad38d7d5c0a98c303f2efdb.json,document_parses/pmc_json/PMC4276942.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25525909/; https://doi.org/10.3390/v6125047,6796725.0,3
92249,92249,117860,bvvpexje,,Medline; WHO,SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment,10.3390/ijms21093377,,32397684.0,unk,current pandemic coronavirus sarscov global health emergency highly contagious nature great number patient requiring intensive care therapy high fatality rate absence specific antiviral drug passive prophylaxis vaccine treatment aim patient prevent potent virusinduced inflammatory stimulus leading acute respiratory distress syndrome ards severe prognosis mechanism action rationale employing immunological strategy range traditional chemically synthesized drug anticytokine antibody human immunoglobulin intravenous use vaccine reviewed,2020,"Prete, Marcella; Favoino, Elvira; Catacchio, Giacomo; Racanelli, Vito; Perosa, Federico","International Journal of Molecular Sciences 2020, Vol. 21, Page 3377",,#209969,,,,https://www.ncbi.nlm.nih.gov/pubmed/32397684/; https://doi.org/10.3390/ijms21093377,218619031.0,3
92280,92280,117905,huan94tf,15f99a27eec125edd5f2c431344f01883ff72129,Medline; PMC,Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus,10.1080/21645515.2017.1358325,PMC5718785,28846484.0,cc-by-nc-nd,past decade half characterized numerous emerging infectious disease new threat call rapid vaccine development pathogen middle east respiratory syndrome coronavirus merscov zika virus represent either new viral entity virus emergent new geographic locale characterized novel complication serve paradigm global spread accompany new pathogen paper review epidemiology pathogenesis merscov zika virus respect vaccine development challenge vaccine development approach clinical trial design test vaccine candidate disease entity changing epidemiology discussed,2017-08-28,"Maslow, Joel N.",Hum Vaccin Immunother,,,,document_parses/pdf_json/15f99a27eec125edd5f2c431344f01883ff72129.json,document_parses/pmc_json/PMC5718785.xml.json,https://doi.org/10.1080/21645515.2017.1358325; https://www.ncbi.nlm.nih.gov/pubmed/28846484/,22479208.0,3
92296,92296,117922,s157lwu1,56e960feeb64c50c3153251668f26b3b33d4ded2,Medline; PMC,Rotavirus diarrhea in bovines and other domestic animals,10.1007/s11259-008-9070-x,PMC7088678,18622713.0,no-cc,rotavirus diarrhea major cause death million child developing country besides causing economically significant malady neonate many domestic animal neonate infection nonviremic short incubation period manifest profuse diarrhea severe dehydration concurrent infection secondary pathogen may augment disease severity diarrhea occurs due virusmediated destruction absorption efficient enterocytes activation enteric nervous system due rotavirus enterotoxin diagnosis infection relies conventional technique like isolation cell line electron microscopy electropherotyping various serological test presently diagnosis molecular typing performed using serotype specific rtpcr sequencing genomic hybridization technique rotavirus known exhibit extreme genetic diversity outplay disinfection procedure eradication pathogen often difficult hence prevention good management practice coupled vaccination dam protecting young one practiced recently new generation prophylactic strategy including dna vaccine subunit vaccine viruslike particle vlps edible vaccine found induce sufficient level passive immunity aside infection animal zoonotic significance animal rotavirus unearthed review effort made highlight importance prevalence disease bovine pathogenesis along preventive measure salient feature rotavirus interspecies transmission ability zoonotic implication concise account infection various domestic animal poultry,2008-07-12,"Dhama, K.; Chauhan, R. S.; Mahendran, M.; Malik, S. V. S.",Vet Res Commun,,,,document_parses/pdf_json/56e960feeb64c50c3153251668f26b3b33d4ded2.json,document_parses/pmc_json/PMC7088678.xml.json,https://doi.org/10.1007/s11259-008-9070-x; https://www.ncbi.nlm.nih.gov/pubmed/18622713/,9562868.0,3
92334,92334,117974,eu80ccm6,59f0dcb0a9c96b60a795162ec2230238896a96e3,Medline; PMC,Impact of Preexisting Adenovirus Vector Immunity on Immunogenicity and Protection Conferred with an Adenovirus-Based H5N1 Influenza Vaccine,10.1371/journal.pone.0033428,PMC3303828,22432020.0,cc0,prevalence preexisting immunity adenovirus majority human population might adversely impact development adaptive immune response adenovirus vectorbased vaccine address issue primed balbc mouse either intranasally intramuscularly im varying dos wild type wt human adenovirus subtype following development immunity immunized animal via im route inoculation vector hadhanp expressing hemagglutinin ha nucleoprotein np avietnam hn influenza virus immunogenicity protection result suggest low level vector immunity virusneutralization titer induced priming mouse plaque forming unit pfu hadwt adversely impact protective efficacy vaccine furthermore high level vector immunity approximately virusneutralization titer induced priming mouse pfu hadwt overcome either increasing vaccine dose using alternate route vaccination increase priming dose pfu allowed partial protection result suggest possible strategy overcome variable level human immunity adenovirus leading better utilization vectorbased vaccine,2012-03-14,"Pandey, Aseem; Singh, Neetu; Vemula, Sai V.; Couëtil, Laurent; Katz, Jacqueline M.; Donis, Ruben; Sambhara, Suryaprakash; Mittal, Suresh K.",PLoS One,,,,document_parses/pdf_json/59f0dcb0a9c96b60a795162ec2230238896a96e3.json,document_parses/pmc_json/PMC3303828.xml.json,https://doi.org/10.1371/journal.pone.0033428; https://www.ncbi.nlm.nih.gov/pubmed/22432020/,2646944.0,3
92343,92343,117984,vng4sdn8,7bb782f2e0e2af6bdb15fc6df687f74131174348,Elsevier; Medline; PMC,"Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7–9th Sep 2015",10.1016/j.vaccine.2016.02.078,PMC7130468,26993336.0,els-covid,vaccine development greater number pathogen ever challenge exceptional level activity investment select resource promising approach significant impact public health product development vaccine advisory committee pdvac established provide strategic advice recommendation vaccine clinical development could significant impact public health low middle income country –th september pdvac convened second time committee reviewed vaccine development disease area report summarises key recommendation consultation,2016-06-03,"Giersing, Birgitte K.; Modjarrad, Kayvon; Kaslow, David C.; Moorthy, Vasee S.; Bavdekar, Ashish; Cichutek, Klaus; Cravioto, Alejandro; Fritzell, Bernard; Graham, Barney S.; Karron, Ruth; Lanata, Claudio F.; Powell, Mair; Shao, Yiming; Smith, Peter",Vaccine,,,,document_parses/pdf_json/7bb782f2e0e2af6bdb15fc6df687f74131174348.json,document_parses/pmc_json/PMC7130468.xml.json,https://doi.org/10.1016/j.vaccine.2016.02.078; https://www.ncbi.nlm.nih.gov/pubmed/26993336/; https://www.sciencedirect.com/science/article/pii/S0264410X16002917; https://api.elsevier.com/content/article/pii/S0264410X16002917,22584828.0,3
92356,92356,118002,i8l396il,cd07718ddfd1ce817710c5884795e29f40d508d6,Medline; PMC,Engineering of Live Chimeric Vaccines against Human Metapneumovirus,10.3390/pathogens9020135,PMC7168645,32093057.0,cc-by,human metapneumovirus hmpv important human pathogen along respiratory syncytial virus rsv major cause respiratory tract infection young infant development effective vaccine pneumoviruses proven particularly difficult despite year research field vaccine hmpv rsv currently available recombinant chimeric virus expressing antigen virus generated reverse genetics used simultaneous immunization one pathogen approach result development promising vaccine candidate hmpv several study indeed validated viral vector expressing hmpv antigen review summarize current effort generating recombinant chimeric vaccine hmpv discus potential optimization based correspondence rsv study,2020-02-19,"Ogonczyk Makowska, Daniela; Hamelin, Marie-Ève; Boivin, Guy",Pathogens,,,,document_parses/pdf_json/cd07718ddfd1ce817710c5884795e29f40d508d6.json,document_parses/pmc_json/PMC7168645.xml.json,https://doi.org/10.3390/pathogens9020135; https://www.ncbi.nlm.nih.gov/pubmed/32093057/,211475406.0,3
92378,92378,118031,wg7js4i9,4509a768ab8962812dbdf4c610b6d741f84c8318,Medline; PMC,Beliefs and Knowledge about Vaccination against AH1N1pdm09 Infection and Uptake Factors among Chinese Parents,10.3390/ijerph110201989,PMC3945580,24534766.0,cc-by,vaccination ahnpdm infection human swine infection hsi effective measure preventing pandemic infection especially highrisk group like child age month year study used crosssectional correlation design aimed identify predicting factor parental acceptance hsi vaccine hsiv uptake vaccination preschoolaged child hong kong total parent recruited four randomly selected kindergarten selfadministered questionnaire based health belief framework used data collection result showed number factor significantly affected tendency toward new vaccination uptake factor included parental age hsi vaccination history child family preferable price vaccine perceived severity perceived benefit perceived barrier motivating factor taking new vaccine using factor logistic regression model high nagelkerke r generated explain vaccination acceptance strong correlation parental acceptance new vaccination motivating factor vaccination uptake found indicates importance involving parent policy implementation new vaccination scheme overall order fight pandemic enhance vaccination acceptance essential government understand factor determining parental acceptance new vaccination preschoolaged child,2014-02-14,"Wu, Cynthia Sau Ting; Kwong, Enid Wai Yung; Wong, Ho Ting; Lo, Suet Hang; Wong, Anthony Siu Wo",Int J Environ Res Public Health,,,,document_parses/pdf_json/4509a768ab8962812dbdf4c610b6d741f84c8318.json,document_parses/pmc_json/PMC3945580.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/24534766/; https://doi.org/10.3390/ijerph110201989,3171687.0,3
92421,92421,118081,cy3pck75,fa2947a0f5d1eed034895da62871b9e17ac62048,Elsevier; Medline; PMC,A recombinant VSV-vectored MERS-CoV vaccine induces neutralizing antibody and T cell responses in rhesus monkeys after single dose immunization,10.1016/j.antiviral.2017.12.007,PMC7113862,29246504.0,els-covid,middle east respiratory syndrome coronavirus merscov highly threatening zoonotic pathogen since outbreak similar sarscov merscov belongs coronavirus family induce severe respiratory symptom human average case fatality rate according world health organization spike protein merscov immunogenic induce neutralizing antibody thus potential major target vaccine development constructed chimeric virus based vesicular stomatitis virus vsv g gene replaced merscov gene vsvδgmers protein efficiently incorporated viral envelope mediated cell entry binding receptor human dpp knockdown clathrin expression sirna drastically abrogated infection vsvδgmers vero cell furthermore animal study recombinant virus induced neutralizing antibody cell response rhesus monkey single intramuscular intranasal immunization dose finding indicate potential chimeric vsvδgmers rapid response vaccine candidate emerging merscov disease,2018-02-28,"Liu, Renqiang; Wang, Jinliang; Shao, Yu; Wang, Xijun; Zhang, Huilei; Shuai, Lei; Ge, Jinying; Wen, Zhiyuan; Bu, Zhigao",Antiviral Research,,,,document_parses/pdf_json/fa2947a0f5d1eed034895da62871b9e17ac62048.json,document_parses/pmc_json/PMC7113862.xml.json,https://api.elsevier.com/content/article/pii/S0166354217307301; https://doi.org/10.1016/j.antiviral.2017.12.007; https://www.sciencedirect.com/science/article/pii/S0166354217307301; https://www.ncbi.nlm.nih.gov/pubmed/29246504/,46766124.0,3
92447,92447,118113,s6ksas20,e1fadb50206234f3cc8bc1750506068f8597baa3,Elsevier; Medline; PMC,How the gut microbiome regulates host immune responses to viral vaccines,10.1016/j.coviro.2019.05.001,PMC6863389,31163292.0,els-covid,coevolution microbiota immune system forged mutually beneficial relationship relationship allows host maintain balance active immunity pathogen vaccine tolerance selfantigens food antigen child living lowincome middleincome country undernourishment repetitive gastrointestinal infection associated failure oral vaccine intestinal dysbiosis associated environmental influence well hostrelated factor compromise immune response negatively impact vaccine efficacy understand immune response viral vaccine optimally modulated mechanistic study relationship microbiome host genetics viral infection development function immune system needed discus potential role microbiome modulating vaccine response context growing understanding relationship gastrointestinal microbiota host related factor including histoblood group antigen resident immune cell population,2019-08-31,"Vlasova, Anastasia N; Takanashi, Sayaka; Miyazaki, Ayako; Rajashekara, Gireesh; Saif, Linda J",Current Opinion in Virology,,,,document_parses/pdf_json/e1fadb50206234f3cc8bc1750506068f8597baa3.json,document_parses/pmc_json/PMC6863389.xml.json,https://www.sciencedirect.com/science/article/pii/S187962571930015X; https://doi.org/10.1016/j.coviro.2019.05.001; https://api.elsevier.com/content/article/pii/S187962571930015X; https://www.ncbi.nlm.nih.gov/pubmed/31163292/,174816714.0,3
92448,92448,118115,bk8v4c5n,ebc2ff4fdabfafc1ceb338e54aa4d11240efeef9,Medline; PMC,"Protective effect of intranasal peste des petits ruminants virus and bacterin vaccinations: Clinical, hematological, serological, and serum oxidative stress changes in challenged goats",10.14202/vetworld.2019.945-950,PMC6702579,31528016.0,cc-by,background aim current vaccination peste de petits ruminant virus pprv stalled myriad challenge continuous endemicity pneumonia due fulminant bacterial complication goat present study evaluated protective effect intranasal pprv linage bacterine vaccination material method twelve west african dwarf wad goat aged month randomly grouped vaccinated within week using combination pprv lineage vaccine nig bacterin mannheimia haemolytica mh pasteurella multocida intranasally goat observed week postvaccination comingled known infected wad goat apparent clinical sign peste de petits ruminant observed clinically week postinfection pi blood sample taken hematology serum assayed antioxidant glutathione peroxidase glutathione transferase superoxide dismutase activity prooxidants malondialdehyde content reduced glutathione hydrogen peroxide generation myeloperoxidase using spectrophotometric method data subjected parametric statistic α using graphpad prism version result clinically pyrexia oculonasal discharge diarrhea anemia leukopenia increased prooxidants unvaccinated goat moderate neutrophilia leukocytosis observed pprv bacterin vaccinated goat two unvaccinated goat weak euthanized day pi goat vaccinated pprv mh showed better response clinically biochemically conclusion mucosal vaccination goat pprv vaccine bacterine protect exposure culminate development protective mucosal humoral cellmediated immune response vaccination strategy provide framework needed prevention control endemic caprine pneumonia nigeria,2019-07-03,"Jarikre, Theophilus Aghogho; Taiwo, Jeremiah Olalekan; Emikpe, Benjamin Obukowho; Akpavie, Stephen Owarioro",Vet World,,,,document_parses/pdf_json/ebc2ff4fdabfafc1ceb338e54aa4d11240efeef9.json,document_parses/pmc_json/PMC6702579.xml.json,https://doi.org/10.14202/vetworld.2019.945-950; https://www.ncbi.nlm.nih.gov/pubmed/31528016/,198381232.0,3
92478,92478,118148,8apepcdk,,Medline; PMC; WHO,News,10.1002/cind.842_3.x,PMC7162151,32313299.0,no-cc,chinese scientist released genetic information coronavirus causing outbreak sarslike illness wuhan china vaccine research institute u national institute health nih immediately began development new vaccine sars outbreak took month release viral genome get vaccine ready human trial zika virus took six month nih pushing vaccine ready testing three six month race nih team took template sars vaccine swapped enough code new virus start new vaccine researcher experience sars already knew part virus choose vaccine ’ antigen sort red flag immune system synthetic antigen prod body make antibody,2020-02-28,,Chem Ind,,#2705,,,,https://doi.org/10.1002/cind.842_3.x; https://www.ncbi.nlm.nih.gov/pubmed/32313299/,216046871.0,3
92483,92483,118153,wnrsas0k,0dc604b0982055e74bfdf5e79d15784d967b2da0; b0e50260be608b6f976de0422e4899b088ba1525,Elsevier; Medline; PMC,Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines,10.1016/j.vaccine.2014.02.004,PMC4194189,24560617.0,bronze-oa,middle east respiratory syndrome mers coronavirus merscov originally identified saudi arabia caused mers outbreak high mortality middle east europe raising serious concern pandemic potential therefore development effective vaccine crucial preventing spread future pandemic previous study shown subcutaneous sc vaccination recombinant protein containing receptorbinding domain rbd merscov fused fc human igg rbdfc induced strong systemic neutralizing antibody response vaccinated mouse compared local systemic immune response induced rbdfc via intranasal sc immunization pathway found vaccination merscov rbdfc induced systemic humoral immune response comparable induced sc vaccination including neutralizing antibody robust systemic cellular immune response significantly higher local mucosal immune response mouse lung study suggests potential developing merscov rbd protein effective safe mucosal candidate vaccine prevention respiratory tract infection caused merscov,2014-04-01,"Ma, Cuiqing; Li, Ye; Wang, Lili; Zhao, Guangyu; Tao, Xinrong; Tseng, Chien-Te K; Zhou, Yusen; Du, Lanying; Jiang, Shibo",Vaccine,,,,document_parses/pdf_json/0dc604b0982055e74bfdf5e79d15784d967b2da0.json; document_parses/pdf_json/b0e50260be608b6f976de0422e4899b088ba1525.json,document_parses/pmc_json/PMC4194189.xml.json,https://api.elsevier.com/content/article/pii/S0264410X14001765; https://doi.org/10.1016/j.vaccine.2014.02.004; https://www.ncbi.nlm.nih.gov/pubmed/24560617/; https://www.sciencedirect.com/science/article/pii/S0264410X14001765,22898237.0,3
92516,92516,118191,xkmarj73,991fb0c5b5cd686d096e2b05d8dc19ca22213df4,Medline; PMC,Induction of robust immunity response in mice by dual-expression-system-based recombinant baculovirus expressing the capsid protein of porcine circovirus type 2,10.1186/1743-422x-10-316,PMC4231451,24161107.0,cc-by,background porcine circovirus type pcv associated postweaning multisystemic wasting syndrome pmws emerging swine disease cause progressive weight loss dyspnea tachypnea anemia jaundice diarrhea piglet although baculovirus enveloped virus infects insect nature emerged vaccine vector used develop novel candidate vaccine preventive therapeutic strategy control pcv infection method immunoblotting analysis recombinant baculovirus immunofluorescent staining baculovirusinfected cell followed using antiorf monoclonal antibody balbc mouse immunized intramuscularly baculovirus titer antibody mensurated capproteinspecific enzymelinked immunosorbent assay elisa serum neutralization assay ifnγ response splenocytes harvested immunized mouse measured elisa student ttest used compare immune response different group result study successfully constructed dualexpressionsystembased recombinant baculovirus bvgdorf display pcv capsid cap protein vsvg protein viral envelope also expressing cap protein transduced mammalian cell thereby functioning subunit dna vaccine infection cap protein expressed displayed viral surface demonstrated indirect fluorescence assay immunoblotting vaccination mouse recombinant baculovirus bvgdorf successfully induced robust capproteinspecific humoral cellular immune response conclusion finding collectively demonstrate recombinant baculovirus bvgdorf potential vaccine pcv infection,2013-10-28,"Ye, Yu; Cheng, Xiaoliang; Zhang, Jie; Tong, Tiezhu; Lin, Wenyao; Liao, Ming; Fan, Huiying",Virol J,,,,document_parses/pdf_json/991fb0c5b5cd686d096e2b05d8dc19ca22213df4.json,document_parses/pmc_json/PMC4231451.xml.json,https://doi.org/10.1186/1743-422x-10-316; https://www.ncbi.nlm.nih.gov/pubmed/24161107/,7257409.0,3
92571,92571,118255,y0tbvs3t,25648bfa058251582d196e648d4ebd78ce1ff384,Elsevier; PMC,Chapter Fifteen Nasal Vaccine Delivery,10.1016/b978-0-323-39981-4.00015-4,PMC7151830,,els-covid,mucosal surface represent major site entry many pathogen major challenge vaccine development include safety stability suitable dosage form micro nanocarrierbased delivery system nasal vaccine induce humoral cellular mucosal immunity nasal route vaccination could also offer immunity several distant mucosal site oral rectal vaginal pulmonary considered simplified costeffective mode vaccination enhanced patient compliance nasal vaccine delivery system form microparticulates nanoparticulates liposome currently development prove offer immunity animal model importance potential nasal route administration vaccine unexplored chapter outline opportunity challenge potential delivery solution facilitate development improved nasal vaccine infectious disease,2017-12-31,"Ramvikas, M.; Arumugam, M.; Chakrabarti, S. R.; Jaganathan, K. S.",Micro and Nanotechnology in Vaccine Development,,,,document_parses/pdf_json/25648bfa058251582d196e648d4ebd78ce1ff384.json,document_parses/pmc_json/PMC7151830.xml.json,https://www.sciencedirect.com/science/article/pii/B9780323399814000154; https://api.elsevier.com/content/article/pii/B9780323399814000154,78113799.0,3
92588,92588,118278,jihk0j7y,f66b2dfccbb1871014417018828d2e9cafba9877,Elsevier; Medline; PMC,"Meeting report: Global vaccine and immunization research forum, 2018",10.1016/j.vaccine.2019.10.011,PMC6899432,31623915.0,els-covid,every two year global vaccine immunization research forum take stock global research vaccine immunization prior year meeting addressed vaccine discovery development decisionmaking deployment time however also featured two overarching theme “ innovating equity ” “ endtoend integration ” significant advance made last two year participant noted important goal global vaccine action plan met called urgently innovation improving access vaccine two factor highlighted crucial improving coverage focus equity sustainability throughout immunization ecosystem enabling political environment prioritizes health immunization,2019-12-10,"Dull, Peter; Friede, Martin; Hwang, Angela; Hall, B. Fenton",Vaccine,,,,document_parses/pdf_json/f66b2dfccbb1871014417018828d2e9cafba9877.json,document_parses/pmc_json/PMC6899432.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X1931374X; https://api.elsevier.com/content/article/pii/S0264410X1931374X; https://doi.org/10.1016/j.vaccine.2019.10.011; https://www.ncbi.nlm.nih.gov/pubmed/31623915/,204775694.0,3
92609,92609,118306,tlobqvvr,2d5fdcbc3c2b82ecef0748012b73fc1aa7a2ad96,Medline; PMC,A Critical HA1 Neutralizing Domain of H5N1 Influenza in an Optimal Conformation Induces Strong Cross-Protection,10.1371/journal.pone.0053568,PMC3539987,23320093.0,cc-by,highly pathogenic avian influenza hpai hn virus especially laboratorygenerated hn mutant demonstrated potential cross specie barrier infect mammal human consequently design effective safe antihn vaccine essential previously demonstrated fulllength hemagglutinin ha could induce significant neutralizing antibody response protection intended identify critical neutralizing domain cnd optimal conformation elicit strong crossneutralizing antibody protection divergent hn strain thus constructed six recombinant protein covering different region ha aanhuihn fused foldon fd fc human igg found critical fragment fused fdfc ha–fdc h numbering could elicit strongest neutralizing antibody response located nterminal region ha residue – cover receptorbinding domain rbd residue – constructed three additional recombinant fused fd plus tag ha–fdhis fc ha–fc tag ha–his respectively found ha–fdc formed oligomeric conformation induced strongest neutralizing antibody response crossprotection challenge two tested hn virus strain covering clade avietnam vn clade ashenzhenh szh ha–fc dimer ha–fdhis trimer elicited higher neutralizing antibody response protection ha–his monomer result suggest oligomeric form cnd containing rbd developed effective safe vaccine crossprotection divergent strain hn virus,2013-01-08,"Du, Lanying; Zhao, Guangyu; Sun, Shihui; Zhang, Xiujuan; Zhou, Xiaojun; Guo, Yan; Li, Ye; Zhou, Yusen; Jiang, Shibo",PLoS One,,,,document_parses/pdf_json/2d5fdcbc3c2b82ecef0748012b73fc1aa7a2ad96.json,document_parses/pmc_json/PMC3539987.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/23320093/; https://doi.org/10.1371/journal.pone.0053568,13410350.0,3
92646,92646,118347,twg849rh,a5a3e3edfad63f20fc48ba5885fb9cc863411d2e,Medline; PMC,Protective immunity by an engineered DNA vaccine for Mayaro virus,10.1371/journal.pntd.0007042,PMC6366747,30730897.0,cc-by,mayaro virus mayv genus alphavirus mosquitotransmitted emerging infectious disease cause acute febrile illness rash headache nausea may turn incapacitating persistent arthralgia victim since discovery trinidad case mayv infection largely confined northern country south america recently mayv case reported island nation caribbean sea accompanying report evidence new vector including aedes spp mosquito recently implicated global spread zika chikungunya virus competent mayv transmission true could facilitate spread mayv beyond current range despite status emerging virus licensed vaccine prevent mayv infection therapeutic treat describe development testing novel dna vaccine scmayve encodes syntheticallydesigned consensus mayv envelope sequence vivo electroporationenhanced immunization mouse vaccine induced potent humoral response including neutralizing antibody well robust tcell response multiple epitope mayv envelope importantly scmayveinduced immune response protected susceptible mouse morbidity mortality following mayv challenge,2019-02-07,"Choi, Hyeree; Kudchodkar, Sagar B.; Reuschel, Emma L.; Asija, Kanika; Borole, Piyush; Ho, Michelle; Wojtak, Krzysztof; Reed, Charles; Ramos, Stephanie; Bopp, Nathen E.; Aguilar, Patricia V.; Weaver, Scott C.; Kim, J. Joseph; Humeau, Laurent; Tebas, Pablo; Weiner, David B.; Muthumani, Kar",PLoS Negl Trop Dis,,,,document_parses/pdf_json/a5a3e3edfad63f20fc48ba5885fb9cc863411d2e.json,document_parses/pmc_json/PMC6366747.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30730897/; https://doi.org/10.1371/journal.pntd.0007042,67859121.0,3
92656,92656,118359,s27bp7ft,89d3baf8c1fd705699fccd3512d167dd47375188; 10a704781b2698846e04cb8eed622851f49e4315,Elsevier; Medline; PMC,Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates,10.1016/j.vaccine.2012.06.029,PMC3425710,22732429.0,green-oa,licensed live attenuated virus vaccine capable expressing transgene pathogen potential reduce number childhood immunization eliciting robust immunity multiple pathogen simultaneously recombinant attenuated measles virus rmv derived edmonston zagreb vaccine strain engineered express simian immunodeficiency virus siv gag protein purpose evaluating immunogenicity rmv vaccine vector rhesus macaque rmvgag immunization alone elicited robust measlesspecific humoral cellular response failed elicit transgene gagspecific immune response following aerosol intratrachealintramuscular delivery however administered priming vaccine heterologous boost recombinant adenovirus serotype expressing transgene rmvgag significantly enhanced gagspecific lymphocyte response following rad immunization gagspecific humoral response enhanced however may due either transgene vector cellular response priming rmv transgene highly effective even using suboptimal dose rad boost data demonstrate feasibility using rmv priming component heterologous primeboost vaccine regimen pathogen requiring strong cellular response,2012-09-01,"Bolton, Diane L.; Santra, Sampa; Swett, Cindy; Custers, Jerome; Song, Kaimei; Balachandran, Harikrishnan; Kozlowski, Pamela A.; Letvin, Norman; Roederer, Mario; Radošević, Katarina",Vaccine,,,,document_parses/pdf_json/89d3baf8c1fd705699fccd3512d167dd47375188.json; document_parses/pdf_json/10a704781b2698846e04cb8eed622851f49e4315.json,document_parses/pmc_json/PMC3425710.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/22732429/; https://doi.org/10.1016/j.vaccine.2012.06.029; http://europepmc.org/articles/pmc3425710?pdf=render; https://api.elsevier.com/content/article/pii/S0264410X12008821; https://www.sciencedirect.com/science/article/pii/S0264410X12008821,40912871.0,3
92763,92763,118483,3j4mqf5x,89e5e252b3311d452f628ba23f5bc2f65f275af5,Elsevier; Medline; PMC,Constrained optimal control applied to vaccination for influenza,10.1016/j.camwa.2015.12.044,PMC7125829,32288204.0,no-cc,efficient time schedule prioritization vaccine supply important mitigating impact influenza pandemic practice restriction associated limited vaccination coverage maximum daily vaccine administration extend previous work optimal control influenza reflect realistic restriction using mixed constraint state control variable optimal control problem formulated aim minimizing number infected individual considering intervention cost timedependent vaccination computed analysed using model incorporating heterogeneity population structure different setting transmissibility level vaccine coverage time delay,2016-01-21,"Kim, Jungeun; Kwon, Hee-Dae; Lee, Jeehyun",Comput Math Appl,,,,document_parses/pdf_json/89e5e252b3311d452f628ba23f5bc2f65f275af5.json,document_parses/pmc_json/PMC7125829.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32288204/; https://www.sciencedirect.com/science/article/pii/S089812211600002X; https://api.elsevier.com/content/article/pii/S089812211600002X; https://doi.org/10.1016/j.camwa.2015.12.044,2164744.0,3
92774,92774,118496,ksdnjx9u,995b8bc38c219940b11e11522fde7667b0f1aec3,Medline; PMC,Efficacy of Intranasal Administration of a Modified Live Feline Herpesvirus 1 and Feline Calicivirus Vaccine against Disease Caused by Bordetella bronchiseptica after Experimental Challenge,10.1111/j.1939-1676.2012.00982.x,PMC7166316,22860699.0,no-cc,background study suggest intranasal vaccination stimulate nonspecific immunity agent contained within vaccine effect reported cat hypothesis modified live feline herpesvirus‐ fhv‐ feline calicivirus fcv intranasal vaccine reduce clinical sign disease caused experimental infection bordetella bronchiseptica animal twenty specific pathogen‐free ‐week‐old kitten method experimental study cat randomized group cat vaccinated group administered single intranasal dose commercially available vaccine containing modified live strain fhv‐ fcv control group remained unvaccinated cat administered b bronchiseptica nasal inoculation day later observed daily clinical sign illness day result first day b bronchiseptica challenge vaccinated cat le likely clinically ill control cat median clinical score range – versus range – p nine control cat vaccinated cat recorded sneezing day – challenge p conclusion clinical importance intranasal vaccination fhv‐ fcv decreased sign illness due infectious agent contained vaccine nonspecific immunity could beneficial protection organism vaccine available protection development vaccine‐induced humoral immunity,2012-08-03,"Bradley, A.; Kinyon, J.; Frana, T.; Bolte, D.; Hyatt, D.R.; Lappin, M.R.",J Vet Intern Med,,,,document_parses/pdf_json/995b8bc38c219940b11e11522fde7667b0f1aec3.json,document_parses/pmc_json/PMC7166316.xml.json,https://doi.org/10.1111/j.1939-1676.2012.00982.x; https://www.ncbi.nlm.nih.gov/pubmed/22860699/,24743874.0,3
92813,92813,118540,dd1iyzhg,427bcae955765973787a270cb420e3f90acc4ccf,Elsevier; PMC,Immunity to transmissible gastroenteritis virus and porcine respiratory coronavirus infections in swine,10.1016/0165-2427(94)90124-4,PMC7119820,7856068.0,els-covid,despite pioneering effort identify correlate passive immunity transmissible gastroenteritis virus tgev effective vaccine control tge suckling pig remained elusive initial concept enteromammary immunologic axis monogastrics originated study lactogenic immunity tgev swine study revealed infection pregnant swine virulent tgev stimulated high titer siga antibody milk correlated protection suckling pig tge parenteral oral inoculation live attenuated killed tgev vaccine induced mainly igg antibody milk generally provided poor protection suckling pig recent appearance prcv infection swine continuing study tgev infection present unique model study mucosal immunity research using virus increased understanding various component common mucosal immune system interaction although important consideration designing effective vaccine tgev stimulation galt intestinal virus replication study addressing contribution balt immunity tgev prcv may provide insight alternative vaccine approach mechanism exposure prcv elicits variable degree immunity tgev challenge unknown virus replication gut respiratory tract major factor affecting magnitude immune response respective site may necessary recruitment specific immune cell mucosal inductive site ie galt balt balt galt migration study induction immune regulation specific response tgev prcv affect distribution pattern igm igg igaantibodysecreting cell asc lymphocyte provide valuable insight optimizing vaccine regimen elicit highest mucosal immune response optimal protection tgev challenge,1994-10-31,"Saif, L. J.; van Cott, J. L.; Brim, T. A.",Veterinary Immunology and Immunopathology,,,,document_parses/pdf_json/427bcae955765973787a270cb420e3f90acc4ccf.json,,https://www.sciencedirect.com/science/article/pii/0165242794901244; https://api.elsevier.com/content/article/pii/0165242794901244,24849681.0,3
92815,92815,118542,khbf3llr,65a49f91fda031c7e95543c2d73082b090d08ffc,Medline; PMC,Attenuation of Infectious Bronchitis Virus in Eggs Results in Different Patterns of Genomic Variation across Multiple Replicates,10.1128/jvi.00492-19,PMC6600199,31043525.0,cc-by,gammacoronavirus infectious bronchitis virus ibv cause acute highly contagious respiratory disease poultry live attenuated vaccine traditionally generated serial passage virulent strain embryonated chicken egg however molecular mechanism attenuation unknown mck virulent labadapted strain ibv egg passaged time four parallel independent replicates four final eggpassaged virus attenuated vivo exhibited similar growth phenotype adult chicken kidney cell ex vivo tracheal organ culture virus population sequenced pyrosequencing end passaging result showed overall sequence diversity ibv population increased four replicates consensuslevel single nucleotide polymorphism snp although hot spot variation identified spike nucleocapsid structural protein well ʹ untranslated region attenuated virus possessed different pattern genomic variation overall small number consensuslevel snp acquired egg passage leaving potentially short route back virulence result highlight unpredictable nature attenuation serial egg passage need develop mechanism rationally attenuate ibv next generation effective vaccine importance infectious bronchitis remains major problem global poultry industry despite existence many different vaccine ibv vaccine currently developed serial passage virulent strain embryonated hen ’ egg attenuation however little known evolution viral population process attenuation highthroughput sequencing four replicates serially eggpassaged ibv revealed different pattern genomic variation attenuated replicate consensuslevel snp raise concern small number genomic mutation required revert virulent phenotype may result vaccine breakdown field observed hot spot variation attenuated virus potential used rational attenuation virulent ibv nextgeneration vaccine design,2019-06-28,"Oade, Michael S.; Keep, Sarah; Freimanis, Graham L.; Orton, Richard J.; Britton, Paul; Hammond, John A.; Bickerton, Erica",J Virol,,,,document_parses/pdf_json/65a49f91fda031c7e95543c2d73082b090d08ffc.json,document_parses/pmc_json/PMC6600199.xml.json,https://doi.org/10.1128/jvi.00492-19; https://www.ncbi.nlm.nih.gov/pubmed/31043525/,143424793.0,3
92822,92822,118550,cp32wy70,6cdf77493d44c52ce952630eac65a794ef653ba8,Elsevier; Medline; PMC,Vector-based genetically modified vaccines: Exploiting Jenner’s legacy,10.1016/j.vaccine.2016.06.059,PMC7115478,28029542.0,els-covid,global vaccine market diverse facing plethora novel development genetic modification gm technique facilitate design ’ smarter ’ vaccine many major infectious disease human like aid malaria also human neoplastic disorder still vaccine available may speculated novel gm technology significantly contribute development promising number study conducted gm vaccine gm vaccine technology contribution gm technology newly introduced vaccine market disappointingly limited study field vectorbased gm vaccine explored data currently available actually applied newly developed vector retrieved various source synthesised analysed order provide overview use vectorbased technology field gm vaccine development still two vectorbased vaccine human vaccine market ample activity field patenting preclinical research different stage clinical research result study revealed vectorbased vaccine comprise significant part gm vaccine pipeline study highlight poxvirus adenovirus among prominent vector gm vaccine development approval first vectored human vaccine based flavivirus vector vaccine vector technology especially based poxvirus adenovirus hold great promise future vaccine development may lead cheaper method production safe vaccine disease le perfect vaccine exist today thus catering unmet medical need introduction jenner ’ vaccinia virus first vaccine two century ago eventually led recent eradication smallpox virus may basis constructing vector may help u control major scourge mankind,2016-12-07,"Ramezanpour, Bahar; Haan, Ingrid; Osterhaus, Ab; Claassen, Eric",Vaccine,,,,document_parses/pdf_json/6cdf77493d44c52ce952630eac65a794ef653ba8.json,document_parses/pmc_json/PMC7115478.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X16305102; https://api.elsevier.com/content/article/pii/S0264410X16305102; https://doi.org/10.1016/j.vaccine.2016.06.059; https://www.ncbi.nlm.nih.gov/pubmed/28029542/,205601881.0,3
92845,92845,118577,mwnnmwnw,d8890fcaa42d7688b22814ae900d8c763c5e83cc,Elsevier; Medline; PMC; WHO,An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design,10.1016/j.vaccine.2020.04.034,PMC7186210,32418793.0,no-cc,west africa ebov epidemic biggest ebov outbreak date analysis virusspecific cd tcell immunity survivor showed individual cd response least one ebov protein dominant response subject specific ebov nucleocapsid protein np suggested epitope ebov np could form important part effective tcell vaccine ebola zaire show aminoacid peptide np yqvnnleei located conserved region ebov np provides protection morbidity mortality mouse adapted ebov challenge single vaccination cbl mouse using adjuvanted microsphere peptide vaccine formulation containing np enough confer immunity mouse work suggests peptide vaccine based cd tcell immunity ebov survivor conceptually sound feasible nucleocapsid protein within sarscov contain multiple class epitope predicted hla restriction consistent broad population coverage similar approach ctl vaccine design may possible virus,2020-04-28,"Herst, C.V.; Burkholz, S.; Sidney, J.; Sette, A.; Harris, P.E.; Massey, S.; Brasel, T.; Cunha-Neto, E.; Rosa, D.S.; Chao, W.C.H.; Carback, R.; Hodge, T.; Wang, L.; Ciotlos, S.; Lloyd, P.; Rubsamen, R.",Vaccine,,#133338,,document_parses/pdf_json/d8890fcaa42d7688b22814ae900d8c763c5e83cc.json,document_parses/pmc_json/PMC7186210.xml.json,https://api.elsevier.com/content/article/pii/S0264410X20305181; https://doi.org/10.1016/j.vaccine.2020.04.034; https://www.sciencedirect.com/science/article/pii/S0264410X20305181?v=s5; https://www.ncbi.nlm.nih.gov/pubmed/32418793/,216553995.0,3
92848,92848,118582,qyflkmi9,61b8415c8659a58c24af2b8a2456bed96b61b609,Medline; PMC,Advancing a multivalent ‘Pan-anthelmintic’ vaccine against soil-transmitted nematode infections,10.1586/14760584.2014.872035,PMC3934375,24392641.0,cc-by-nc,ascaris lumbricoides sabin vaccine institute product development partnership developing pananthelmintic vaccine simultaneously target major soiltransmitted nematode infection word ascariasis trichuriasis hookworm infection approach build current bivalent human hookworm vaccine clinical development would ultimately add larval ascaris lumbricoides antigen adultstage trichuris trichiura antigen parasite stichosome selected antigen would partially reproduce protective immunity afforded uvattenuated ascaris egg trichuris stichosome extract respectively final antigen selection apply ranking system includes evaluation expression yield solubility feasibility process development absence circulating antigenspecific ige among population living helminthendemic region describe five year roadmap antigen discovery feasibility antigen selection ultimately lead scaleup expression process development manufacture good laboratory practice toxicology preclinical evaluation ultimately leading phase clinical testing,2014-01-06,"Zhan, Bin; Beaumier, Coreen M; Briggs, Neima; Jones, Kathryn M; Keegan, Brian P; Bottazzi, Maria Elena; Hotez, Peter J",Expert Rev Vaccines,,,,document_parses/pdf_json/61b8415c8659a58c24af2b8a2456bed96b61b609.json,document_parses/pmc_json/PMC3934375.xml.json,https://doi.org/10.1586/14760584.2014.872035; https://www.ncbi.nlm.nih.gov/pubmed/24392641/,15696947.0,3
92883,92883,118631,fd7d4q8k,2fe3a212a53cc099f03cadb0af66e1e9c30e4a28; 95cf6b3c44e05dc3bf6d1e5e3f912af5a7fa8a36; 2e85e487853731cc083f75a7b86e7649a7e2272c,Elsevier; Medline; PMC,An mRNA Vaccine Protects Mice against Multiple Tick-Transmitted Flavivirus Infections,10.1016/j.celrep.2018.11.082,PMC6353567,30566864.0,cc-by-nc-nd,powassan virus powv emerging ticktransmitted flavivirus circulates north america russia deer tick test positive powv certain region northern united state although powv infection cause lifethreatening encephalitis vaccine countermeasure available prevention treatment developed lipid nanoparticle lnpencapsulated modified mrna vaccine encoding powv prm e gene demonstrated immunogenicity efficacy mouse following immunization one two dos powv mrna vaccine induced high titer neutralizing antibody sterilizing immunity lethal challenge different powv strain mrna vaccine also induced crossneutralizing antibody multiple tickborne flavivirus protected mouse distantly related langat virus data demonstrate utility lnpmrna vaccine platform development vaccine protective activity multiple flavivirus,2018-12-18,"VanBlargan, Laura A.; Himansu, Sunny; Foreman, Bryant M.; Ebel, Gregory D.; Pierson, Theodore C.; Diamond, Michael S.",Cell Rep,,,,document_parses/pdf_json/2fe3a212a53cc099f03cadb0af66e1e9c30e4a28.json; document_parses/pdf_json/95cf6b3c44e05dc3bf6d1e5e3f912af5a7fa8a36.json; document_parses/pdf_json/2e85e487853731cc083f75a7b86e7649a7e2272c.json,document_parses/pmc_json/PMC6353567.xml.json,https://www.sciencedirect.com/science/article/pii/S2211124718318734; https://api.elsevier.com/content/article/pii/S2211124718318734; https://www.ncbi.nlm.nih.gov/pubmed/30566864/; https://doi.org/10.1016/j.celrep.2018.11.082,58643183.0,3
92912,92912,118677,be49k54p,70c831d8e7e72fcc93db5ec5ff3608a594a801a9,Elsevier; PMC,Identification of protective T-cell antigens for smallpox vaccines,10.1016/j.jcyt.2020.04.098,PMC7205715,,els-covid,el immediateearly protein vaccinia virus detected within hour infection potentially many immune evasion gene vaccinia exert protective effect el highly conserved among orthopoxviruses hence could provide important protective tcell epitope retained subunit attenuated vaccine therefore evaluated immunogenicity el healthy vv vaccinated donor peripheral blood mononuclear cell healthy volunteer n previously received smallpox vaccine dryvax® activated expanded using overlapping el peptide function specificity antiviral activity analyzed elspecific tcells expanded vaccinated healthy donor produced cd tcell response produced cd tcells identified epitope restricted hlab hladr elspecific tcells killed peptideloaded target cell well vacciniainfected cell cd tcells could prevent spread infectious virus virus inhibition assay epitope recognized elspecific tcells shared monkeypox although single amino acid change variola epitope homolog recognized vacciniaspecific tcells therefore might important include el deletion mutant subunit vaccine el could provide useful antigen monitor protective immunity human,2020-05-08,"Ando, Jun; Ngo, Minhtran C.; Ando, Miki; Leen, Ann; Rooney, Cliona M.",Cytotherapy,,,,document_parses/pdf_json/70c831d8e7e72fcc93db5ec5ff3608a594a801a9.json,,https://api.elsevier.com/content/article/pii/S1465324920306551; https://www.sciencedirect.com/science/article/pii/S1465324920306551?v=s5,218538740.0,3
92915,92915,118680,qu7ddcw9,6f49f5f80a68233fa4887160c779160fe27ec968,Medline; PMC,Vaccines for SARS-CoV-2: Lessons from Other Coronavirus Strains,10.1007/s40121-020-00300-x,PMC7177048,32328406.0,cc-by-nc,emergence strain coronavirus sarscov severe acute respiratory syndrome coronavirus impact global health made imperative development effective safe vaccine lethal strain sarscov add list coronavirus disease threatened global health along sars severe acute respiratory syndrome mers middle east respiratory syndrome coronaviruses emerged respectively april vaccine commercially available coronavirus strain nevertheless knowledge obtained vaccine development effort mers sars high value covid coronavirus disease review past ongoing vaccine development effort clinically relevant coronavirus strain intention information help development effective safe vaccine covid addition information naturally exposed individual animal model coronavirus strain described purpose helping development effective vaccine covid,2020-04-23,"Padron-Regalado, Eriko",Infect Dis Ther,,,,document_parses/pdf_json/6f49f5f80a68233fa4887160c779160fe27ec968.json,document_parses/pmc_json/PMC7177048.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32328406/; https://doi.org/10.1007/s40121-020-00300-x,216076468.0,3
92937,92937,118707,2hsmt0df,ece34fa085cedc92764ebd274d36932e8a4eed83; d024fa6c18cd59a5bb71fa905008bd067a3a20a6,Elsevier; Medline; PMC,Novel vaccine strategies against emerging viruses,10.1016/j.coviro.2013.02.001,PMC3644304,23477832.0,green-oa,one main public health concern emerging virus potential introduction sustained circulation among population immunologically naïve susceptible host induction protective immunity vaccination powerful tool prevent concern conferring protection population risk conventional approach develop vaccine emerging pathogen significant limitation lack experimental tool several emerging virus concern poor immunogenicity safety issue lack crossprotection antigenic variant unpredictability emergence future virus threat demand capability rapidly develop safe effective vaccine describe recent advance new vaccine strategy explored alternative classical attenuated inactivated vaccine provide example potential novel vaccine emerging virus approach might applied control many emerging pathogen,2013-04-01,"García-Sastre, Adolfo; Mena, Ignacio",Current Opinion in Virology,,,,document_parses/pdf_json/ece34fa085cedc92764ebd274d36932e8a4eed83.json; document_parses/pdf_json/d024fa6c18cd59a5bb71fa905008bd067a3a20a6.json,document_parses/pmc_json/PMC3644304.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/23477832/; http://europepmc.org/articles/pmc3644304?pdf=render; https://www.sciencedirect.com/science/article/pii/S1879625713000199; https://doi.org/10.1016/j.coviro.2013.02.001; https://api.elsevier.com/content/article/pii/S1879625713000199,44991980.0,3
93016,93016,118797,ug7ijowz,87e21bb556c860c6e57b25e6f7bbbb22c0524231,Elsevier; Medline; PMC,Vaccine platforms for the prevention of Lassa fever,10.1016/j.imlet.2019.03.008,PMC7132387,31026485.0,no-cc,lassa fever acute viral haemorrhagic illness caused lassa virus lasv endemic throughout much west africa virus primarily circulates mastomys natalensis reservoir transmitted human contact infectious rodent secretion humantohuman transmission documented well exception dengue fever lasv highest human impact haemorrhagic fever virus ongoing outbreak nigeria resulted unprecedented mortality consequently world health organization listed lasv high priority pathogen development treatment prophylactic currently licensed vaccine protect lasv infection although numerous candidate demonstrated efficacy animal model date single candidate advanced clinical trial lassa fever vaccine development effort hindered high cost biocontainment requirement absence established correlate protection uncertainty regarding extent animal model predictive vaccine efficacy human review briefly discus epidemiology biology lasv infection highlight recent progress vaccine development,2019-04-23,"Purushotham, Jyothi; Lambe, Teresa; Gilbert, Sarah C.",Immunol Lett,,,,document_parses/pdf_json/87e21bb556c860c6e57b25e6f7bbbb22c0524231.json,document_parses/pmc_json/PMC7132387.xml.json,https://api.elsevier.com/content/article/pii/S0165247819300483; https://www.ncbi.nlm.nih.gov/pubmed/31026485/; https://doi.org/10.1016/j.imlet.2019.03.008; https://www.sciencedirect.com/science/article/pii/S0165247819300483,135445726.0,3
93043,93043,118826,p8wp6yvo,dfe23d64895beefb7e0fec49126c49d982ffe8da,Medline; PMC,Making vaccines “on demand”: A potential solution for emerging pathogens and biodefense?,10.4161/hv.25611,PMC3906351,23877094.0,cc-by-nc,integrated u public health emergency medical countermeasure enterprise phemce made great stride strategic preparedness response capability numerous advance planning biothreat countermeasure development licensure manufacturing stockpiling deployment increased biodefense surveillance capability dramatically improved new tool increased awareness fostered rapid identification new potential public health pathogen unfortunately structural delay vaccine design development manufacture clinical testing licensure process remain significant obstacle effective national biodefense rapid response capability particularly true real threat “ novel pathogen ” avianorigin influenza hn hn new coronaviruses hcovemc conventional approach vaccine development production clinical testing licensure incompatible prompt deployment needed effective public health response alternative approach proposed apply computational vaccine design tool rapid production technology make possible engineer vaccine novel emerging pathogen wmd biowarfare agent countermeasure record time new tool potential significantly reduce time needed design stringofepitope vaccine previously unknown pathogen design process—from genome gene sequence ready insert dna plasmid—can accomplished le h vaccine mean “ standard ” need innovation vaccine design production process great vaccine developed starttofinish timeline would represent fold faster response current standard,2013-09-01,"De Groot, Anne S; Einck, Leo; Moise, Leonard; Chambers, Michael; Ballantyne, John; Malone, Robert W; Ardito, Matthew; Martin, William",Hum Vaccin Immunother,,,,document_parses/pdf_json/dfe23d64895beefb7e0fec49126c49d982ffe8da.json,document_parses/pmc_json/PMC3906351.xml.json,https://doi.org/10.4161/hv.25611; https://www.ncbi.nlm.nih.gov/pubmed/23877094/,17283635.0,3
93052,93052,118839,gs52k4lq,85cf0d4fd0de528e8178161a44d55112650d1058,Elsevier; Medline; PMC,Validation of the safety of MDCK cells as a substrate for the production of a cell-derived influenza vaccine,10.1016/j.biologicals.2010.04.003,PMC7129197,20537553.0,els-covid,cell culturebased production method may assist meeting increasing demand seasonal influenza vaccine developing production flexibility required addressing influenza pandemic mdckpf cell used propagation cellbased seasonal influenza vaccine optaflu® like continuous cell line grow immunocompromised mouse produce tumor therefore essential residual cell remain within vaccine cell lysates dna oncogenic cell substrate contain oncogenic virus oncogenic dna multiple redundant process ensure safety influenza vaccine produced mdckpf cell probability residual cell present dose vaccine approximately residual mdckdna ≤ng per dose ßpropiolactone used inactivate influenza virus result reduction detectable dna le base pair bp degenerate pcr specific pcr confirm exclusion oncogenic virus manufacturing process validated capacity remove inactivate virus conclude theoretical risk arising manufacturing seasonal influenza vaccine using mdckpf cell reduced level effectively zero multiple orthogonal process used production,2010-09-30,"Onions, David; Egan, William; Jarrett, Ruth; Novicki, Deborah; Gregersen, Jens-Peter",Biologicals,,,,document_parses/pdf_json/85cf0d4fd0de528e8178161a44d55112650d1058.json,document_parses/pmc_json/PMC7129197.xml.json,https://api.elsevier.com/content/article/pii/S1045105610000989; https://www.sciencedirect.com/science/article/pii/S1045105610000989; https://doi.org/10.1016/j.biologicals.2010.04.003; https://www.ncbi.nlm.nih.gov/pubmed/20537553/,12091657.0,3
93115,93115,118915,co11vspl,c8319e7c2950df8028c8b9d90581eff5e13df132,Medline; PMC,Uptake of Recommended Vaccines and Its Associated Factors Among Malaysian Pilgrims During Hajj and Umrah 2018,10.3389/fpubh.2019.00268,PMC6759542,31620419.0,cc-by,study aimed ass uptake recommended vaccine identify factor associated vaccine uptake among malaysian hajj umrah pilgrim crosssectional survey among malaysian hajj umrah pilgrim uptake recommended vaccine surveyed anonymous selfadministered questionnaire pilgrim attending predeparture hajjumrah orientation course descriptive statistic used elaborating demographic characteristic vaccine uptake respondent multiple logistic regression used predicting factor associated vaccine uptake total pilgrim participated study mean age standard deviation total participant female participant least one chronic disease uptake influenza pneumococcal vaccine respectively among pilgrim “ increased risk ” infection received influenza pneumococcal vaccine respectively gender marital status occupation common predictor associated vaccine uptake vaccination uptake among malaysian hajj umrah pilgrim low declining previous year educating pilgrim toward vaccine uptake essential exploring barrier vaccination,2019-09-18,"Goni, Mohammed Dauda; Naing, Nyi Nyi; Hasan, Habsah; Wan-Arfah, Nadiah; Deris, Zakuan Zainy; Arifin, Wan Nor; Baaba, Aisha Abubakar",Front Public Health,,,,document_parses/pdf_json/c8319e7c2950df8028c8b9d90581eff5e13df132.json,document_parses/pmc_json/PMC6759542.xml.json,https://doi.org/10.3389/fpubh.2019.00268; https://www.ncbi.nlm.nih.gov/pubmed/31620419/,202639690.0,3
93121,93121,118925,427a7i3h,fde32676b45348c92885a71347194532fe54bb49,Elsevier; PMC,Vaccines Produced by Conventional Means to Control Major Infectious Diseases of Man and Animals,10.1016/b978-0-12-039233-9.50005-6,PMC7150235,2648772.0,els-covid,publisher summary chapter review development vaccine use controlling major disease diphtheria rinderpest newcastle disease smallpox pertussis yellow fever rabies etc park–williams number pw strain used make diphtherial toxoid vaccine source toxin rendered nontoxic incubation formalin alkaline condition product retention antigenicity enabling induce antitoxin antibody make excellent pediatric vaccine vaccine rinderpest virus developed koch administering bile infected cattle animal survived permanently immune formalin chloroforminactivated vaccine developed using tissue infected animal control newcastle disease number attenuated livevirus vaccine developed widely used control disease bl strain lasota strain f strain used immunize bird age different route including addition drinking water spraying protection rabies correlate sn antibody assessed number test pasteur classical vaccine developed infected spinal cord tissue dried room temperature – day given series – inoculation beginning material dried longest progressing material dried day,1989-12-31,"BITTLE, JAMES L.; MUIR, SUSIE",Advances in Veterinary Science and Comparative Medicine,,,,document_parses/pdf_json/fde32676b45348c92885a71347194532fe54bb49.json,,https://www.sciencedirect.com/science/article/pii/B9780120392339500056; https://api.elsevier.com/content/article/pii/B9780120392339500056,10288484.0,3
93191,93191,119008,xbrkytbs,1a19bed3bfcb373626804c55b111ca79e812efd1,Medline; PMC,Construction and Immunogenicity of Novel Chimeric Virus-Like Particles Bearing Antigens of Infectious Bronchitis Virus and Newcastle Disease Virus,10.3390/v11030254,PMC6465995,30871190.0,cc-by,infectious bronchitis virus ibv newcastle disease virus ndv two poultry pathogen seriously affecting poultry industry ibv ectodomain ndv f protein separately linked transmembrane carboxyterminal domain ibv protein stmct composing r rf thus novel chimeric infectious bronchitisnewcastle disease ibnd viruslike particle vlps vaccine containing r rf ibv protein constructed transmission electron microscope tem vlps possessing similar morphology natural ibv observed evaluate immunogenicity chimeric ibnd vlps specific pathogenfree spf chicken immunized three increasing dos μg protein vlps result elisa detecting ibv ndv specific antibody il ifnγ cell cytokine indicated vaccination chimeric ibnd vlps could efficiently induce humoral cellular immune response challenge study chimeric ibnd vlps μg protein provided protection ibv ndv virulent challenge death viral rna level tissue swab greatly reduced collectively chimeric ibnd vlps highly immunogenic could provide complete protection ibv ndv virulent challenge chimeric ibnd vlps appealing vaccine candidate promising vaccine platform bearing multivalent antigen,2019-03-13,"Wu, Xuan; Zhai, Xiwen; Lai, Yan; Zuo, Lei; Zhang, Yu; Mei, Xueran; Xiang, Rong; Kang, Zhuangzhuang; Zhou, Long; Wang, Hongning",Viruses,,,,document_parses/pdf_json/1a19bed3bfcb373626804c55b111ca79e812efd1.json,document_parses/pmc_json/PMC6465995.xml.json,https://doi.org/10.3390/v11030254; https://www.ncbi.nlm.nih.gov/pubmed/30871190/,78091478.0,3
93223,93223,119046,bxqc9a7f,4485b9462ebf52c0062692d7ab7e423c2ae05d9e; 2837878533cf5c0521c9ebc530de2ffcfab12a8d,BioRxiv; MedRxiv,HCMV glycoprotein B subunit vaccine efficacy was mediated by non-neutralizing antibody effector functions,10.1101/246884,,,biorxiv,human cytomegalovirus hcmv common congenital infection worldwide frequently causing hearing loss brain damage afflicted infant vaccine prevent maternal acquisition hcmv pregnancy necessary reduce incidence infant disease glycoprotein b gb mf adjuvant subunit vaccine platform successful hcmv vaccine tested todate demonstrating approximately efficacy preventing hcmv acquisition phase ii trial however mechanism vaccine protection remains unknown plasma gbmf vaccinee peak immunogenicity tested gb epitope specificity well neutralizing nonneutralizing antihcmv effector function compared hcmvseropositive cohort gbmf vaccination elicited igg response gbbinding magnitude avidity comparable natural infection additionally igg subclass distribution similar predominant igg igg response induced gb vaccination hcmv infection however vaccineelicited antibody exhibited limited neutralization autologous virus negligible neutralization multiple heterologous strain limited binding response gb structural motif targeted neutralizing antibody including ad ad domain interestingly vaccinee highmagnitude igg response ad linear epitope demonstrating immunodominance nonneutralizing cytosolic region finally vaccineelicited igg robustly bound trimeric membraneassociated gb surface transfected hcmvinfected cell mediated virion phagocytosis though poor mediator nk cell activation altogether data suggest nonneutralizing antibody function including virion phagocytosis likely played role observed vaccinemediated protection hcmv acquisition significance cdc estimate every hour child born united state permanent neurologic disability resulting human cytomegalovirus hcmv infection – caused syndrome fetal alcohol syndrome neural tube defect combined maternal vaccine block transmission hcmv developing fetus necessary intervention prevent adverse outcome gbmf vaccine successful tested clinically todate achieving reduction hcmv acquisition manuscript establishes function epitope specificity humoral response stimulated vaccine may explain partial vaccine efficacy understanding mechanism gbmfelicited protective immune response guide rational design evaluation next generation hcmv vaccine,2018-01-11,"Nelson, Cody S.; Huffman, Tori; de la Rosa, Eduardo Cisneros; Xie, Guanhua; Vandergrift, Nathan; Pass, Robert F.; Pollara, Justin; Permar, Sallie R.",bioRxiv,,,,document_parses/pdf_json/4485b9462ebf52c0062692d7ab7e423c2ae05d9e.json; document_parses/pdf_json/2837878533cf5c0521c9ebc530de2ffcfab12a8d.json,,https://doi.org/10.1101/246884,196687576.0,3
93454,93454,119334,cob7ur35,b4e276ce333eefee623e9d425f5c538c64b567cc,Medline; PMC,The expanding role of mass spectrometry in the field of vaccine development,10.1002/mas.21571,PMC7027533,29852530.0,cc-by,biological mass spectrometry evolved core analytical technology last decade mainly unparalleled ability perform qualitative well quantitative profiling enormously complex biological sample high mass accuracy sensitivity selectivity specificity mass spectrometry‐based technique also routinely used ass glycosylation post‐translational modification disulfide bond linkage scrambling well detection host cell protein contaminant field biopharmaceuticals role mass spectrometry vaccine development limited expanding landscape global vaccine development shifting towards development recombinant vaccine review role mass spectrometry vaccine development presented ongoing effort develop vaccine disease global unmet medical need discussed regulatory challenge implementing mass spectrometry technique quality control laboratory setting highlighted,2018-05-31,"Sharma, Vaneet Kumar; Sharma, Ity; Glick, James",Mass Spectrom Rev,,,,document_parses/pdf_json/b4e276ce333eefee623e9d425f5c538c64b567cc.json,document_parses/pmc_json/PMC7027533.xml.json,https://doi.org/10.1002/mas.21571; https://www.ncbi.nlm.nih.gov/pubmed/29852530/,46919074.0,3
93535,93535,119424,1d17iafs,95f96b6514c65017589e759b23d9086f48121a80,Elsevier; Medline; PMC,Priming with a DNA vaccine and boosting with an inactivated vaccine enhance the immune response against infectious bronchitis virus,10.1016/j.jviromet.2010.03.016,PMC7112948,20307574.0,els-covid,method repeated immunization inactivated vaccine used widely increase antibody protection infectious bronchitis virus ibv however compared dna vaccine method usually induce poor cellular response present study specific pathogenfree spf chicken immunized intramuscularly dna vaccine carrying main ibv structural gene pvaxs pvaxm pvaxn respectively boosted ibv strain inactivated vaccine ass whether new strategy could enhance immune response ibv protection efficacy dna vaccine carrying different structural gene priming evaluated chicken immunized primely day boosted week later distribution dna vaccine vivo percentage cdcd cdcd subgroup peripheral blood tlymphocytes specific igg virus neutralizing antibody measured chicken challenged nasal–ocular route ibv strain week booster immunization result demonstrated priming dna vaccine encoding nucleocapsid protein pvaxn boosting inactivated ibv vaccine led dramatic augmentation humoral cellular response provided rate immune protection providing effective approach protect chicken ibv,2010-07-31,"Guo, Zicheng; Wang, Hongning; Yang, Tai; Wang, Xue; Lu, Dan; Li, Yulin; Zhang, Yi",Journal of Virological Methods,,,,document_parses/pdf_json/95f96b6514c65017589e759b23d9086f48121a80.json,document_parses/pmc_json/PMC7112948.xml.json,https://doi.org/10.1016/j.jviromet.2010.03.016; https://www.ncbi.nlm.nih.gov/pubmed/20307574/; https://www.sciencedirect.com/science/article/pii/S0166093410000960; https://api.elsevier.com/content/article/pii/S0166093410000960,24514672.0,3
93616,93616,119524,hwgjkh60,740b4f4a7e5b97edb6eb5d1c52f9f302f8dc9619,Elsevier; Medline; PMC,Expected immunizations and health protection for Hajj and Umrah 2018 —An overview,10.1016/j.tmaid.2017.10.005,PMC7110709,29037978.0,els-covid,background annual hajj umrah one largest recurring religious mass gathering across globe drawing pilgrim country living circumstance activity pilgrim may create environment occurrence spread communicable disease year health authority kingdom saudi arabia coordination international health authority update health requirement pilgrim hajj took place august september review expected obligation immunization hajj umrah result hajj umrah vaccine requirement include mandatory vaccination yellow fever quadrivalent meningococcal polysaccharide every year conjugated every year vaccine poliomyelitis vaccine influenza vaccine utilizing southern hemisphere vaccine pilgrim recommended obligatory pilgrim ciprofloxacin required individual year excluding pregnant woman chemoprophylaxis given port entry pilgrim coming meningitis belt ongoing outbreak measles europe recommended pilgrim updated immunization vaccinepreventable disease diphtheria tetanus pertussis polio measles mumps conclusion mandatory vaccine remain continued vigilance development new emerging infectious disease continuing surveillance zika virus cholera merscov ongoing,2017-10-31,"Al-Tawfiq, Jaffar A.; Gautret, Philippe; Memish, Ziad A.",Travel Medicine and Infectious Disease,,,,document_parses/pdf_json/740b4f4a7e5b97edb6eb5d1c52f9f302f8dc9619.json,document_parses/pmc_json/PMC7110709.xml.json,https://doi.org/10.1016/j.tmaid.2017.10.005; https://www.sciencedirect.com/science/article/pii/S1477893917301606; https://api.elsevier.com/content/article/pii/S1477893917301606; https://www.ncbi.nlm.nih.gov/pubmed/29037978/,13653438.0,3
93654,93654,119567,wk8lgew5,e1dd98c61bc0119c2fc9ffc6435e3eff8d3bb74f,Elsevier; Medline; PMC,Intragastric administration of attenuated Salmonella typhimurium harbouring transmissible gastroenteritis virus (TGEV) DNA vaccine induced specific antibody production,10.1016/j.vaccine.2009.06.050,PMC7126841,19573642.0,els-covid,attenuated salmonella typhimurium selected transgenic vehicle development live mucosal vaccine transmissible gastroenteritis virus tgev kb dna fragment encoding nterminal domain glycoprotein tgev amplified rtpcr cloned eukaryotic expression vector pvax recombinant plasmid pvaxs transformed electroporation attenuated typhimurium sl expression translation pvaxs delivered recombinant typhimurium sl pvaxs detected vitro vivo respectively balbc mouse inoculated orally sl pvaxs different dosage bacterium safe mouse dosage × cfu eventually eliminated spleen liver week postimmunization mouse immunized different dosage sl pvaxs elicited specific antitgev local mucosal humoral response measured indirect elisa assay moreover immunogenicity dna vaccine highly dependent dosage attenuated bacteria used oral administration cfu dosage group showed higher antibody response cfu cfu dosage group week – postimmunization result indicated attenuated typhimurium could used delivery vector oral immunization tgev dna vaccine,2009-08-13,"Yang, Heng; Cao, Sanjie; Huang, Xiaobo; Liu, Jiawen; Tang, Ying; Wen, Xintian",Vaccine,,,,document_parses/pdf_json/e1dd98c61bc0119c2fc9ffc6435e3eff8d3bb74f.json,document_parses/pmc_json/PMC7126841.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19573642/; https://www.sciencedirect.com/science/article/pii/S0264410X09009128; https://doi.org/10.1016/j.vaccine.2009.06.050; https://api.elsevier.com/content/article/pii/S0264410X09009128,26207683.0,3
93673,93673,119589,gr2de7ry,08467794d024d78c7981f7c39743a9faaa1adecb,Medline; PMC,Oral recombinant Lactobacillus vaccine targeting the intestinal microfold cells and dendritic cells for delivering the core neutralizing epitope of porcine epidemic diarrhea virus,10.1186/s12934-018-0861-7,PMC5807822,29426335.0,cc-by,background porcine epidemic diarrhea caused porcine epidemic diarrhea virus pedv led serious economic loss swine industry worldwide study oral recombinant lactobacillus casei vaccine pedv infection targeting intestinal microfold cell dendritic cell dc delivering core neutralizing epitope coe pedv spike protein developed celltargeting peptide col dendritic celltargeting peptide dcpep immunogenicity orally administered recombinant strain evaluated result immunization significantly higher level antipedv specific igg antibody pedv neutralizing activity serum mucosal siga antibody tractus genitalis intestinal mucus stool detected mouse orally administered recombinant strain ppgcoecoldcpepl expressed dcpep col targeting ligand fused pedv coe antigen compared mouse orally immunized recombinant strain ppgcoel without dcpep col targeting ligand moreover response restimulation pedv coe antigen vitro significant difference splenocyte proliferation response thassociated cytokine il level observed group mouse orally immunized ppgcoecoldcpepl p compared group mouse received ppgcoecoll ppgcoedcpepl respectively conclusion intestinal cell dcstargeting oral delivery genetically engineered lactobacillus expressing coe antigen pedv efficiently induce antipedv mucosal humoral cellular immune response via oral administration suggesting promising vaccine strategy pedv infection image see text electronic supplementary material online version article contains supplementary material available authorized user,2018-02-09,"Ma, Sunting; Wang, Li; Huang, Xuewei; Wang, Xiaona; Chen, Su; Shi, Wen; Qiao, Xinyuan; Jiang, Yanping; Tang, Lijie; Xu, Yigang; Li, Yijing",Microb Cell Fact,,,,document_parses/pdf_json/08467794d024d78c7981f7c39743a9faaa1adecb.json,document_parses/pmc_json/PMC5807822.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29426335/; https://doi.org/10.1186/s12934-018-0861-7,44200608.0,3
93709,93709,119636,ta4c7vd4,0ced6299507661eeb13e9b4ecb79619740620daf,Elsevier; Medline; PMC,Post-vaccination encephalomyelitis: Literature review and illustrative case,10.1016/j.jocn.2008.05.002,PMC7125578,18976924.0,els-covid,acute disseminated encephalomyelitis adem inflammatory demyelinating disease central nervous system usually considered monophasic disease adem form one several category primary inflammatory demyelinating disorder central nervous system including multiple sclerosis optic neuropathy acute transverse myelitis neuromyelitis optica devic ’ disease postinfectious postimmunisation encephalomyelitis make threequarters case timing febrile event associated onset neurological disease postvaccination adem associated several vaccine rabies diphtheria–tetanus–polio smallpox measles mumps rubella japanese b encephalitis pertussis influenza hepatitis b hog vaccine review adem particular emphasis vaccination precipitating factor performed literature search using medline – search term including “ adem ” “ acute disseminated encephalomyelitis ” “ encephalomyelitis ” “ vaccination ” “ immunisation ” patient presenting bilateral optic neuropathy within week “ inactivated ” influenza vaccination followed delayed onset adem month postvaccination described,2008-12-31,"Huynh, William; Cordato, Dennis J.; Kehdi, Elias; Masters, Lynette T.; Dedousis, Chris",Journal of Clinical Neuroscience,,,,document_parses/pdf_json/0ced6299507661eeb13e9b4ecb79619740620daf.json,document_parses/pmc_json/PMC7125578.xml.json,https://api.elsevier.com/content/article/pii/S0967586808001896; https://www.ncbi.nlm.nih.gov/pubmed/18976924/; https://doi.org/10.1016/j.jocn.2008.05.002; https://www.sciencedirect.com/science/article/pii/S0967586808001896,13435630.0,3
93712,93712,119639,yqciq9m5,588631c5434bdc11922450678d5d65823f62e432,Medline; PMC,A Brief Review of Computer-Assisted Approaches to Rational Design of Peptide Vaccines,10.3390/ijms17050666,PMC4881492,27153063.0,cc-by,growing incidence new viral disease increasingly frequent viral epidemic strained therapeutic preventive measure high mutability viral gene put additional strain developmental effort given high cost time requirement new drug development vaccine remain viable alternative traditional technique liveattenuated inactivated vaccine danger allergenic reaction others peptide vaccine last several year begun looked appropriate alternative economically affordable require le time development hold promise multivalent dosage development bioinformatics proteomics immunogenomics structural biology science spurred growth vaccinomics computer assisted approach serve identify suitable peptide target eventual development vaccine minireview give brief overview recent trend computer assisted vaccine development emphasis primary selection procedure probable peptide candidate vaccine development,2016-05-04,"Nandy, Ashesh; Basak, Subhash C.",Int J Mol Sci,,,,document_parses/pdf_json/588631c5434bdc11922450678d5d65823f62e432.json,document_parses/pmc_json/PMC4881492.xml.json,https://doi.org/10.3390/ijms17050666; https://www.ncbi.nlm.nih.gov/pubmed/27153063/,5172114.0,3
93722,93722,119650,rtac6hh2,189b6018d5c5a6c07a3a7f33911d9302bbc3f2c0,Elsevier; PMC,Chapter 9 Edible Vaccines,10.1016/b978-0-12-802221-4.00009-1,PMC7149355,,els-covid,vaccine considered primary tool health intervention human animal vaccine used widely especially developing country cost production reduced preserved without refrigeration developing country certain limitation like vaccine affordability need “ cold chain ” producer site use vaccine dependence injection barrier health care service plantderived vaccine face limitation research way dedicated solving limitation finding way produce oral edible vaccine transgenic plant plantderived vaccine offer increased safety envisage lowcost program mass vaccination propose wider use vaccination veterinary use,2015-12-31,"Bhatia, Saurabh; Dahiya, Randhir",Modern Applications of Plant Biotechnology in Pharmaceutical Sciences,,,,document_parses/pdf_json/189b6018d5c5a6c07a3a7f33911d9302bbc3f2c0.json,document_parses/pmc_json/PMC7149355.xml.json,https://www.sciencedirect.com/science/article/pii/B9780128022214000091; https://api.elsevier.com/content/article/pii/B9780128022214000091,82769434.0,3
93747,93747,119687,ku6n3851,6151de59e5ebb21ff2a17a4cd4ce5ea69e766758,Elsevier; Medline; PMC,"Mucosal immunity and HIV/AIDS vaccines Report of an International Workshop, 28–30 October 2007",10.1016/j.vaccine.2008.04.051,PMC7131112,18513838.0,els-covid,october joint anrsnih workshop held “ mucosal immunity hivaids vaccine ” veyrierdulac france goal meeting discus recent development understanding viral entry dissemination mucosal surface rationale designing vaccine elicit mucosal immune response various route immunization type immune response elicited lesson drawn existing vaccine viral mucosal infection recent failure merck adhiv vaccine attempt mucosal immunization siv report summarizes main concept conclusion came meeting,2008-07-29,"Girard, Marc P.; Bansal, Geetha P.; Pedroza-Martins, Livia; Dodet, Betty; Mehra, Vijay; Schito, Marco; Mathieson, Bonnie; Delfraissy, Jean-François; Bradac, James",Vaccine,,,,document_parses/pdf_json/6151de59e5ebb21ff2a17a4cd4ce5ea69e766758.json,document_parses/pmc_json/PMC7131112.xml.json,https://api.elsevier.com/content/article/pii/S0264410X08005148; https://www.sciencedirect.com/science/article/pii/S0264410X08005148; https://www.ncbi.nlm.nih.gov/pubmed/18513838/; https://doi.org/10.1016/j.vaccine.2008.04.051,205576006.0,3
93757,93757,119699,u8y47qmd,e724e9c56dedc9430663c4eb447b1b0ec08133e6; 9461c2fa9c2d30b0438e6922e1c3a31e7dd34d24,Elsevier; Medline; PMC,Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components,10.1016/j.vaccine.2019.04.056,PMC6949866,31047679.0,cc-by,variety good manufacturing practice gmp compliant process reported production nonreplicating adenovirus vector important challenge remain clinical development adenovirus vector us simian adenovirus rare human serotypes whereas reported manufacturing process mainly use serotypes adhu questionable relevance clinical vaccine development many clinically relevant vaccine transgene interfere adenovirus replication whereas reported process development us selected antigen even model transgene fluorescent protein cause little interference process typically developed single adenovirus serotype – transgene combination requiring extensive optimization new vaccine need rapid production platform small gmp batch nonreplicating adenovirus vector earlyphase vaccine trial particularly preparation response emerging pathogen outbreak platform must robust variation transgene ideally also capable producing adenovirus one serotype also highly desirable process readily implemented new facility using commercially available singleuse material avoiding need development bespoke tool cleaning validation readily scalable laterstage study report development process using singleuse stirredtank bioreactors transgenerepressing hek cell – promoter combination fully singleuse filtration ion exchange component demonstrate applicability process candidate vaccine rabies malaria rift valley fever based different adenovirus serotype compare performance range commercially available ion exchange medium including believe first published use novel medium adenovirus purification natriflo® hdq merck demonstrate need minimal process individualization vaccine product fulfils regulatory quality expectation cellspecific yield upper end previously reported literature volumetric yield range × – × purified virus particle per litre culture – l process comfortably adequate produce vaccine earlyphase trial process readily transferable gmp facility capability mammalian cell culture aseptic filling sterile product,2019-11-08,"Fedosyuk, Sofiya; Merritt, Thomas; Peralta-Alvarez, Marco Polo; Morris, Susan J; Lam, Ada; Laroudie, Nicolas; Kangokar, Anilkumar; Wright, Daniel; Warimwe, George M; Angell-Manning, Phillip; Ritchie, Adam J; Gilbert, Sarah C; Xenopoulos, Alex; Boumlic, Anissa; Douglas, Alexander D",Vaccine,,,,document_parses/pdf_json/e724e9c56dedc9430663c4eb447b1b0ec08133e6.json; document_parses/pdf_json/9461c2fa9c2d30b0438e6922e1c3a31e7dd34d24.json,document_parses/pmc_json/PMC6949866.xml.json,https://api.elsevier.com/content/article/pii/S0264410X19305328; https://www.ncbi.nlm.nih.gov/pubmed/31047679/; https://www.sciencedirect.com/science/article/pii/S0264410X19305328; https://doi.org/10.1016/j.vaccine.2019.04.056,143432792.0,3
93771,93771,119715,cmtk54ff,60cc55d9df1b0ff215bcaefe413b7b6edc5eb182,Medline; PMC,Memory immune responses and protection of chickens against a nephropathogenic infectious bronchitis virus strain by combining live heterologous and inactivated homologous vaccines,10.1292/jvms.18-0065,PMC6483904,30867350.0,cc-by-nc-nd,study evaluated antibody cellmediated immune cmi response mucosal systemic compartment protection challenge nephropathogenic brazilian bri strain infectious bronchitis virus ibv chicken submitted vaccination regime comprising priming dose heterologous live attenuated massachusetts vaccine followed booster dose experimental homologous inactivated vaccine two week later immunization protocol elicited significant increase serum lachrymal level antiibv igg antibody upregulated expression cmi response gene encoding cdβ chain granzyme homolog tracheal kidney tissue day postinfection vaccinated chicken additionally vaccinated challenged chicken showed reduced viral load microscopic lesion count tracheal kidney tissue antibody cmi response negatively correlated viral load trachea kidney conclusion combination live attenuated vaccine containing massachusetts strain booster dose inactivated vaccine containing bri ibv strain confers effective protection infection nephropathogenic homologous ibv strain induction consistent memory immune response mediated igg antibody tcd cell mucosal systemic compartment chicken submitted vaccination regime,2019-03-12,"dos SANTOS, Romeu Moreira; FERNANDO, Filipe Santos; MONTASSIER, Maria de Fátima Silva; SILVA, Ketherson Rodrigues; LOPES, Priscila Diniz; PAVANI, Caren; BORZI, Mariana Monezi; OKINO, Cintia Hiromi; MONTASSIER, Helio José",J Vet Med Sci,,,,document_parses/pdf_json/60cc55d9df1b0ff215bcaefe413b7b6edc5eb182.json,document_parses/pmc_json/PMC6483904.xml.json,https://doi.org/10.1292/jvms.18-0065; https://www.ncbi.nlm.nih.gov/pubmed/30867350/,76665035.0,3
93816,93816,119772,mzv4zik0,e13820bd50c6b964b5a65f3edf6c1d28d857dfaf,Medline; PMC,Genome sequence variation analysis of two SARS coronavirus isolates after passage in Vero cell culture,10.1007/bf03183408,PMC7089035,32214713.0,no-cc,sars coronavirus rna virus whose replication errorprone provides possibility escape host defense even lead evolution new viral strain passage transmission lot variation detected among different sarscov strain study variation helpful development efficient vaccine moreover test nucleic acid characterization genetic stability sarscov important research inactivated vaccine whole genome sequence two sars coronavirus strain passage vero cell culture determined compared early passage respectively result showed sars coronavirus strain high genetic stability although nearly generation passed four nucleotide variation observed second passage th passage sino strain identification sars inactivated vaccine moreover one nucleotide different third passage th passage sino strain sars inactivated vaccine therefore study suggested possible develop inactivated vaccine sarscov future,2004,"Jin, Weiwu; Hu, Liangxiang; Du, Zhenglin; Gao, Qiang; Gao, Hong; Ning, Ye; Feng, Jidong; Zhang, Jiansan; Yin, Weidong; Li, Ning",Chin Sci Bull,,,,document_parses/pdf_json/e13820bd50c6b964b5a65f3edf6c1d28d857dfaf.json,,https://doi.org/10.1007/bf03183408; https://www.ncbi.nlm.nih.gov/pubmed/32214713/,84570736.0,3
93858,93858,119823,xvke7sze,ed64e6c43246b10eea3b236a206e5f25d37ab564,Elsevier; Medline; PMC,Recombinant vaccines against the mononegaviruses—What we have learned from animal disease controls,10.1016/j.virusres.2011.09.038,PMC7114506,21982973.0,els-covid,mononegaviruses include number highly contagious severe diseasecausing virus animal human control viral disease development vaccine either classical method recombinant dna virus vector attempted year recently reverse genetics mononegaviruses developed used generate infectious virus possessing genome derived cloned cdna order study consequent effect viral gene manipulation phenotype technology allows u develop novel candidate vaccine particular variety different attenuation strategy produce range attenuated mononegavirus vaccine studied addition ideal nature live vaccine recombinant mononegaviruses expressing foreign protein also produced aim developing multivalent vaccine one pathogen recombinant mononegaviruses currently evaluation new viral vector vaccination reverse genetics could great potential preparation vaccine many mononegaviruses,2011-12-31,"Sato, Hiroki; Yoneda, Misako; Honda, Tomoyuki; Kai, Chieko",Virus Research,,,,document_parses/pdf_json/ed64e6c43246b10eea3b236a206e5f25d37ab564.json,document_parses/pmc_json/PMC7114506.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/21982973/; https://api.elsevier.com/content/article/pii/S0168170211003911; https://www.sciencedirect.com/science/article/pii/S0168170211003911; https://doi.org/10.1016/j.virusres.2011.09.038,205657171.0,3
93941,93941,119924,9cua2jzg,30af52ef71cc3189e5162fa07b93bd4eb1286086,Elsevier; Medline; PMC,"Biological and molecular characterization of ArkGA: A novel Arkansas serotype vaccine that is highly attenuated, efficacious, and protective against homologous challenge",10.1016/j.vaccine.2018.08.078,PMC7115623,30197283.0,els-covid,almost commercial poultry vaccinated avian coronavirus infectious bronchitis virus ibv using live attenuated vaccine mass administered spray day hatch although many different type ibv vaccine used successfully arkdpi serotype vaccine applied spray infect replicate sufficiently provide protection homologous challenge study examined different ark vaccine strain ark longer used commercially due reactivity one day old chick determine could attenuated passage embryonated egg still provide adequate protection attenuation ark vaccine achieved passage embryonated egg arkga p p p designated arkga p still reactive suitable vaccine candidate however arkga p given spray little vaccine reaction one day old broiler chick induced protection clinical sign ciliostasis following homologous challenge addition vaccinated challenged bird significantly le challenge virus important measure protection compared nonvaccinated challenged control fulllength genome virus egg passage sequenced using illumina platform data showed single nucleotide polymorphism snp accumulated region genome associated viral replication pathogenicity cell tropism arkga p accumulated snp key gene associated pathogenicity polyprotein gene ab cell tropism spike gene compared previous passage likely resulted attenuated phenotype result indicate arkga p vaccine safe spray vaccination broiler chick induces suitable protection challenge pathogenic arktype virus,2018-10-01,"Albanese, Grace A.; Lee, Dong-Hun; Cheng, I-Hsin N.; Hilt, Deborah A.; Jackwood, Mark W.; Jordan, Brian J.",Vaccine,,,,document_parses/pdf_json/30af52ef71cc3189e5162fa07b93bd4eb1286086.json,document_parses/pmc_json/PMC7115623.xml.json,https://doi.org/10.1016/j.vaccine.2018.08.078; https://www.sciencedirect.com/science/article/pii/S0264410X18312283; https://www.ncbi.nlm.nih.gov/pubmed/30197283/; https://api.elsevier.com/content/article/pii/S0264410X18312283,52176258.0,3
94007,94007,120007,fi2b29ih,469f56e7c8db4736c730dd334c9b46319833fc69,Elsevier; Medline; PMC,MERS-CoV spike protein: Targets for vaccines and therapeutics,10.1016/j.antiviral.2016.07.015,PMC7113765,27468951.0,els-covid,disease outbreak caused middle east respiratory syndrome coronavirus merscov still ongoing middle east people infected since first reported september despite great effort licensed vaccine therapeutic merscov remain unavailable merscov spike protein important viral antigen known mediate hostreceptor binding virus entry well induce robust humoral cellmediated response human infection review highlight importance protein merscov life cycle summarize recent advance development vaccine therapeutic based protein discus strategy explored develop new medical countermeasure merscov,2016-09-30,"Wang, Qihui; Wong, Gary; Lu, Guangwen; Yan, Jinghua; Gao, George F.",Antiviral Research,,,,document_parses/pdf_json/469f56e7c8db4736c730dd334c9b46319833fc69.json,document_parses/pmc_json/PMC7113765.xml.json,https://doi.org/10.1016/j.antiviral.2016.07.015; https://www.ncbi.nlm.nih.gov/pubmed/27468951/; https://api.elsevier.com/content/article/pii/S0166354216301826; https://www.sciencedirect.com/science/article/pii/S0166354216301826,20269339.0,3
94086,94086,120107,ikq9t2v7,63e48e3587d77a7186d24882b837a4009dd2fd96,Elsevier; Medline; PMC,Development of an inactivated candidate vaccine against Chandipura virus (Rhabdoviridae: Vesiculovirus),10.1016/j.vaccine.2011.04.063,PMC7115669,21549791.0,els-covid,vero cell based vaccine candidate chandipura chp virus rhabdoviridae vesiculovirus developed evaluated immunogenicity mouse virus purified ultracentrifugation glycerol cushion followed differential centrifugation – sucrose gradient inactivated βpropio lactone concentration inactivated product blended aluminium phosphate immunized weekold swiss albino mouse neutralizing antibody range detected seroconversion nd rd dose respectively immunized mouse antibody titer survived live virus challenge vaccine candidate potential efficient vaccine chp virus,2011-06-20,"Jadi, R. S.; Sudeep, A. B.; Barde, P. V.; Arankalle, V. A.; Mishra, A. C.",Vaccine,,,,document_parses/pdf_json/63e48e3587d77a7186d24882b837a4009dd2fd96.json,document_parses/pmc_json/PMC7115669.xml.json,https://doi.org/10.1016/j.vaccine.2011.04.063; https://api.elsevier.com/content/article/pii/S0264410X11006086; https://www.sciencedirect.com/science/article/pii/S0264410X11006086; https://www.ncbi.nlm.nih.gov/pubmed/21549791/,31889233.0,3
94112,94112,120136,ynulxpto,747c9c3ab814444e24806776cdb7316e1e24a5bb,Medline; PMC,Molecular Biology and Inhibitors of Hepatitis A Virus,10.1002/med.21292,PMC7168461,23722879.0,no-cc,hepatitis virus hav faeco‐orally transmitted picornavirus one main cause acute hepatitis worldwide overview molecular biology hav presented emphasis recent finding immune evasion strategy possible correlation hav atopy discussed well despite availability efficient vaccine antiviral drug targeting hav required treat severe case fulminant hepatitis contain outbreak halt potential spread vaccine‐escape variant additionally drug could used shorten period illness decrease associated economical cost several known inhibitor hav various mechanism action discussed since none molecule readily useable clinic since availability anti‐hav drug would clinical importance increased effort targeted toward discovery development antiviral,2013-05-30,"Debing, Yannick; Neyts, Johan; Thibaut, Hendrik Jan",Med Res Rev,,,,document_parses/pdf_json/747c9c3ab814444e24806776cdb7316e1e24a5bb.json,document_parses/pmc_json/PMC7168461.xml.json,https://doi.org/10.1002/med.21292; https://www.ncbi.nlm.nih.gov/pubmed/23722879/,20419081.0,3
94117,94117,120143,hkw3ksob,,Medline; WHO,Early Vaccination of Chickens Induces Suboptimal Immunity Against Infectious Bronchitis Virus,10.1637/11951-081418-reg.1,,31251518.0,unk,infectious bronchitis virus ibv highly prevalent broiler chicken despite extensive vaccination commonly conducted early hatch effect early vaccination immune response investigated chicken primed increasing age followed booster vaccination attenuated arkansas ark delmarva poultry industrytype vaccine result show vaccination day age elicits significantly lower systemic mucosal antibody response compared vaccination later time point life chicken increase ibv antibody serum secondary response booster vaccination dramatic significantly higher measured ark spike subunit protein elisa compared measuring nonark serotype wholevirus elisa underline immunogenic importance virus spike inducing antibody however level achieved following boosting differ significantly age priming thus seems booster vaccination mitigated difference detected prime immunization contrast continued rise systemic antibody booster vaccination level mucosal ibvspecific immunoglobulin decreased booster vaccination recruitment expansion cluster differentiation cd cd cdcd tcell population different immune effector site increased age remained unaltered ibv vaccination contrast peripheral blood cd cell showed significant increase ibvvaccinated chicken compared nonvaccinated agematched control primary booster immunization result current study confirm ibv vaccination day hatch induces suboptimal ibv immune response systemic mucosal compartment routine practice may contributing immunologic escape virus increased persistence vaccine virus vaccinated chicken however booster vaccination seems overcome poor initial response,2019,"Saiada, F.; Eldemery, F.; Zegpi, R. A.; Gulley, S. L.; Mishra, A.; Santen, V. L. V.; Toro, H.",Avian diseases,,#15949,,,,https://doi.org/10.1637/11951-081418-reg.1; https://www.ncbi.nlm.nih.gov/pubmed/31251518/,109349541.0,3
94140,94140,120171,ebkwv4zo,63fbcac09bf2a0133b41cb99e93dd2ce3aeeab05,Elsevier; Medline; PMC,Live-attenuated bivalent measles virus-derived vaccines targeting Middle East respiratory syndrome coronavirus induce robust and multifunctional T cell responses against both viruses in an appropriate mouse model,10.1016/j.virol.2018.05.028,PMC7118890,29902727.0,els-covid,case middle east respiratory syndrome coronavirus merscov continue occur making one who´s target accelerated vaccine development one vaccine candidate based liveattenuated measles virus mv vaccine encoding merscov spike glycoprotein merss mvvacmerssh induces robust humoral cellular immunity merss mediating protection induction nature immunity vaccination mvvacmerssh novel mvvacmersn characterized focused necessity vector replication nature induced cell since functional cd cell contribute importantly clearance merscov immunity merscov mv detected mvsusceptible mouse immunization uvinactivated virus replicationcompetent mvvacmerssh triggered robust neutralizing antibody titer also adult mouse furthermore significant fraction mers covspecific cd cell mvspecific cd cell simultaneously expressing ifnγ tnfα induced revealing mvvacmerssh induces multifunctional cellular immunity,2018-08-31,"Bodmer, Bianca S.; Fiedler, Anna H.; Hanauer, Jan R.H.; Prüfer, Steffen; Mühlebach, Michael D.",Virology,,,,document_parses/pdf_json/63fbcac09bf2a0133b41cb99e93dd2ce3aeeab05.json,document_parses/pmc_json/PMC7118890.xml.json,https://api.elsevier.com/content/article/pii/S0042682218301697; https://www.sciencedirect.com/science/article/pii/S0042682218301697; https://www.ncbi.nlm.nih.gov/pubmed/29902727/; https://doi.org/10.1016/j.virol.2018.05.028,49209754.0,3
94220,94220,120280,d03byeee,b06cfb82a09d5c325037eb5da4b8bf200ed28042,Elsevier; PMC,Enhance immune response to DNA vaccine based on a novel multicomponent supramolecular assembly,10.1016/j.biomaterials.2007.07.002,PMC7124441,17686512.0,no-cc,dna vaccination tremendous potential treating preventing numerous disease traditional vaccine ineffective technique limited low immunogenicity current synthetic dna delivery system versatile safe substantially le efficient virus novel multicomponent supramolecular system involving preparation mannosebearing chitosan oligomers microspheres entrapping complex dna vaccine polyethylenimine developed mimic many beneficial property virus delivery intramuscular immunization balbc mouse microspheres induced enhanced serum antibody response two order magnitude greater naked dna vaccine additionally contrast naked dna microspheres induced potent cytotoxic lymphocyte response low dose consequently formulation dna vaccine multicomponent vector powerful mean increasing vaccine potency,2007-08-07,"Zhou, Xianfeng; Liu, Bin; Yu, Xianghui; Zha, Xiao; Zhang, Xizhen; Wang, Xueyun; Chen, Yu; Chen, Yan; Chen, Yue; Shan, Yaming; Jin, Yinghua; Wu, Yongge; Liu, Junqiu; Kong, Wei; Shen, Jiacong",Biomaterials,,,,document_parses/pdf_json/b06cfb82a09d5c325037eb5da4b8bf200ed28042.json,document_parses/pmc_json/PMC7124441.xml.json,https://www.sciencedirect.com/science/article/pii/S0142961207005248; https://api.elsevier.com/content/article/pii/S0142961207005248,45838222.0,3
94277,94277,120349,znx5p3yp,4f79e13634fcf92a42627cba54239d6999707e26,Elsevier; Medline; PMC; WHO,SARS-CoV-2: A New Song Recalls an Old Melody,10.1016/j.chom.2020.04.019,PMC7219427,32407706.0,no-cc,virus causing sars outbreak – current covid pandemic related betacoronaviruses insight learned sars inform sarscov vaccine development focusing important lesson sars vaccine development two sars vaccine evaluated human may guide sarscov vaccine design testing implementation,2020-05-13,"Subbarao, Kanta",Cell Host Microbe,,#245360,,document_parses/pdf_json/4f79e13634fcf92a42627cba54239d6999707e26.json,document_parses/pmc_json/PMC7219427.xml.json,https://doi.org/10.1016/j.chom.2020.04.019; https://www.ncbi.nlm.nih.gov/pubmed/32407706/; https://www.sciencedirect.com/science/article/pii/S1931312820302468; https://api.elsevier.com/content/article/pii/S1931312820302468,218615173.0,3
94320,94320,120402,4xbkqk47,b834d6b3d7fea0675cca9098fe4055f25f413514,Medline; PMC,Transgene Pflanzen als orale Impfstoffe Grüne Revolution in der Medizin?: Grüne Revolution in der Medizin?,10.1007/s001120050775,PMC7082806,32214485.0,no-cc,method molecular biotechnology possible today produce therapeutical effectiv protein plant called edible vaccine used active immunization well passive immunization efficient production recombinant protein procedure developed leaf treated genetically modified bacteria instead time consuming regeneration transgenic plant orally applicated vaccine complete systematic immune response induced comparison parenteral injection time higher dosis antigen necessary immunogenity antigen produced plant confirmed several animal experiment clinical study recombinant antibody transgenic plant caries pathogen streptococcus mutans successful future study focus improved production rate search suitable plant specie phenomenon oral tolerance,2001,"Commandeur, U.; Fischer, R.",Monatsschr Kinderheilkd,,,,document_parses/pdf_json/b834d6b3d7fea0675cca9098fe4055f25f413514.json,,https://doi.org/10.1007/s001120050775; https://www.ncbi.nlm.nih.gov/pubmed/32214485/,38031916.0,3
94389,94389,120489,xipds5nt,,Medline; WHO,SARS-CoV-2 Rates in BCG-Vaccinated and Unvaccinated Young Adults.,10.1001/jama.2020.8189,,32401274.0,unk,confirmed case coronavirus disease covid casefatality rate vary among country one reason could national policy regarding childhood bcg vaccination fewer confirmed case lower death toll reported country v without universal bcg vaccine coverage comparing outbreak characteristic country influenced potential confounders different phase outbreak mean age affected population management pandemic amount test administered definition covid–related death underreporting bcg vaccine routinely administered newborn israel part national immunization program overall vaccine acceptance rate israel high greater coverage since vaccine administered immigrant country high prevalence tuberculosis change allowed comparison infection rate proportion severe covid disease similar population differing bcg status individual born year year cessation universal bcg vaccine program method current policy israeli ministry health test severe acute respiratory syndrome coronavirus sarscov every patient symptom could compatible covid cough dyspnea fever nasopharyngeal swab tested realtime reverse transcriptase–polymerase chain reaction approved laboratory march april test per patient included result stratified birth year population data specific birth year obtained national central bureau statistic χ test used compare proportion rate per population positive test result among person symptom compatible covid born aged year born aged year sided significance threshold set p lt study deemed exempt shamir medical center institutional review board data deidentified statistical analysis performed using r software version r foundation result test result reviewed patient born birth cohort period malemean age year among likely unvaccinated people born total birth cohort malemean age year statistically significant difference proportion positive test result bcgvaccinated group v unvaccinated group difference ci − p positivity rate per vaccinated group v unvaccinated groupdifference per ci − per p case severe disease mechanical ventilation intensive care unit admission group death reported table discussion cohort israeli adult aged year bcg vaccination childhood associated similar rate positive test result sarscov compared vaccination small number severe case conclusion association bcg status severity disease reached although bcg vaccine given protect tuberculosis also found exert nonspecific beneficial effect protection infectious disease enhance immunogenicity certain vaccine influenza vaccine effect thought mediated partly heterologous effect adaptive immunity cell–mediated crossreactivity also potentiation innate immune response strength study large populationbased cohort comparison similar age group thus limiting confounders minimum main limitation inclusion population ho born israel unknown vaccination status however immigrant country vaccinate bcg within age group minority older younger population group respectively overrepresented one group addition rate per represent positivity rate population person tested preselected based reported symptom conclusion study support idea bcg vaccination childhood protective effect covid adulthood,2020-05-13,"Hamiel, Uri; Kozer, Eran; Youngster, Ilan",JAMA,,#245579,,,,https://doi.org/10.1001/jama.2020.8189; https://www.ncbi.nlm.nih.gov/pubmed/32401274/,218620258.0,3
94482,94482,120603,21irqpxj,d7d18451d2d40ee20ca1587c39e02977fb286ab5,Medline; PMC,Predicting Promiscuous T Cell Epitopes for Designing a Vaccine Against Streptococcus pyogenes,10.1007/s12010-018-2804-5,PMC7091373,29948995.0,no-cc,one dangerous human pathogen high prevalence worldwide streptococcus pyogenes major impact global morbidity mortality major challenge pyogenes vaccine development detection epitope confer protection infection multiple pyogenes type aim identify conserved immunogenic antigen pyogenes potential candidate vaccine design future eight important surface protein analyzed using different prediction server strongest epitope selected ability stimulate humoral cellmediated immune system molecular docking performed measuring freebinding energy selected epitope seven epitope three surface protein selected potential candidate vaccine development conservation selected epitope among different streptococcus type checked vitro vivo test required validate suitability epitope vaccine design,2018-06-11,"Ebrahimi, Samira; Mohabatkar, Hassan; Behbahani, Mandana",Appl Biochem Biotechnol,,,,document_parses/pdf_json/d7d18451d2d40ee20ca1587c39e02977fb286ab5.json,document_parses/pmc_json/PMC7091373.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29948995/; https://doi.org/10.1007/s12010-018-2804-5,49433711.0,3
94494,94494,120621,l3d19xur,eaca4d1f48201c3ad99d6156490cd6156b1d34b3,Elsevier; Medline; PMC,Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells,10.1016/j.vaccine.2008.07.050,PMC7115550,18691624.0,els-covid,recombinant canarypox virus alvac extensively studied vaccine vector development new vaccine strategy chronic infectious disease cancer however mechanism alvac initiate immune response completely elucidated order determine type innate immunity triggered alvac characterized gene expression profile human monocyte derived dendritic cell mddcs upon alvac infection cell permissive poxvirus infection play key role initiation immune response majority gene upregulated alvac belong type interferon signaling pathway including irf stat rig mda gene involved nfκb pathway upregulated gene encoding chemokine cxcl direct target transcription factor irf among upregulated dc secretion cxcl following exposure alvac confirmed elisa many downstream type interferon activated gene antiviral activity pkr mx isg oas among others also upregulated response alvac among isg expression unconjugated form western blot analysis demonstrated view result propose alvac induces type interferon antiviral innate immunity via cytosolic patternrecognitionreceptor prr sensing doublestranded dna activation irf irf finding may aid design effective alvacvectored vaccine,2008-09-15,"Harenberg, Anke; Guillaume, Florine; Ryan, Elizabeth J.; Burdin, Nicolas; Spada, Franca",Vaccine,,,,document_parses/pdf_json/eaca4d1f48201c3ad99d6156490cd6156b1d34b3.json,document_parses/pmc_json/PMC7115550.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X08009857; https://api.elsevier.com/content/article/pii/S0264410X08009857; https://www.ncbi.nlm.nih.gov/pubmed/18691624/; https://doi.org/10.1016/j.vaccine.2008.07.050,12550701.0,3
94516,94516,120648,18fbtlfg,,Medline; WHO,3CL Hydrolase Based Multi Epitope Peptide Vaccine Against Sars-CoV-2 Using Immunoinformatics.,10.1002/jmv.25993,,32379348.0,unk,present study provides first multiepitope vaccine construct using cl hydrolase protein sarscov coronavirus cl hydrolase mpro enzyme essential proteolytic maturation virus research based immunoinformatics structural vaccinology strategy design multi epitope vaccine built using htls ctls epitope cl hydrolase protein along adjuvant enhance immune response joined short peptide linkers vaccine also carry potential bcell linear epitope region bcell discontinuous epitope interferonγ inducing epitope epitope constructed multi epitope vaccine found antigenic nonallergic nontoxic cover large human population worldwide vaccine construct modeled validated refined different program achieve highquality structure resulting highquality model applied conformational b cell epitope selection docking analysis tolllike receptor understanding capability vaccine elicit immune response insilico cloning codon adaptation also performed petb plasmid vector designed multiepitope peptide vaccine may prompt development vaccine control sarscov infection article protected copyright right reserved,2020-05-07,"Jakhar, Renu; Kaushik, Samander; Gakhar, S K",Journal of medical virology,,#197576,,,,https://www.ncbi.nlm.nih.gov/pubmed/32379348/; https://doi.org/10.1002/jmv.25993,218533676.0,3
94544,94544,120684,1qjbuofz,fbad827abaeba849f4e52dba8a07c0d60596833c; ee306e100fdffb087cfbf544c3131e7054f5e9f1; 6c1549e58428428b5ef8b321f3ad12040d8aff86,Elsevier; Medline; PMC,VIRULENCE FACTORS IN PORCINE CORONAVIRUSES AND VACCINE DESIGN,10.1016/j.virusres.2016.07.003,PMC5159199,27397100.0,bronze-oa,porcine enteric coronaviruses covs cause severe disease porcine herd worldwide leading important economic loss despite knowledge virus since ’ vaccination strategy implemented leading continuous reemergence novel virulent strain live attenuated vaccine historically efficient consider new trend development recombinant vaccine using reverse genetics system engineer attenuated virus could used effective safe modified live vaccine candidate end host cell signaling pathway influencing porcine cov virulence identified similarly identity viral protein involved modulation host cell pathway influencing cov pathogenesis analyzed information using reverse genetics system possible design virus modification viral protein acting virulence factor may lead attenuated virus therefore vaccine candidate addition novel antiviral drug may developed host cell pathway molecular mechanism affecting porcine cov replication virulence known review focused host cell response enteric porcine cov infection viral protein involved pathogenesis,2016-12-01,"Zuñiga, Sonia; Pascual-Iglesias, Alejandro; Sanchez, Carlos M.; Sola, Isabel; Enjuanes, Luis",Virus Research,,,,document_parses/pdf_json/fbad827abaeba849f4e52dba8a07c0d60596833c.json; document_parses/pdf_json/ee306e100fdffb087cfbf544c3131e7054f5e9f1.json; document_parses/pdf_json/6c1549e58428428b5ef8b321f3ad12040d8aff86.json,document_parses/pmc_json/PMC5159199.xml.json,https://api.elsevier.com/content/article/pii/S0168170216303999; https://www.sciencedirect.com/science/article/pii/S0168170216303999; https://doi.org/10.1016/j.virusres.2016.07.003; https://www.ncbi.nlm.nih.gov/pubmed/27397100/,46876769.0,3
94558,94558,120698,cm8unyy1,d3ca5f2f620d495c747bac2a00b3446b392f7535,Medline; PMC,Direct molecular detection of a broad range of bacterial and viral organisms and Streptococcus pneumoniae vaccine serotypes in children with otitis media with effusion,10.1186/s13104-016-2040-4,PMC4850712,27130295.0,cc-by,background otitis medium effusion ome cause significant morbidity child cause ome method prevention unclear look potential infectious etiology performed pilot study using multipletarget realtime polymerase chain reaction qpcr infectious agent including nine bacterial organism respiratory virus middle ear fluid mefs child ome qpcr also performed streptococcus pneumoniae serotypes contained current vaccine result fortyeight mef sample obtained qpcr detected bacterial nucleic acid na viral na alloiococcus otitidis pneumoniae detected mefs followed catarrhalis h influenzae pneumoniae rhinovirus common virus type detected found mefs serotypes included current serotype vaccine detected pneumoniae qpcrpositive mefs conclusion bacteria may play important role ome since mefs contained bacterial na research role otitidis ome helpful serotypes pneumoniae included current serotype vaccine may involved ome larger study ome pneumoniae serotypes needed help determine additional serotypes included future vaccine formulation order try prevent ome,2016-04-29,"Slinger, Robert; Duval, Melanie; Langill, Jonathan; Bromwich, Matthew; MacCormick, Johnna; Chan, Francis; Vaccani, Jean-Philippe",BMC Res Notes,,,,document_parses/pdf_json/d3ca5f2f620d495c747bac2a00b3446b392f7535.json,document_parses/pmc_json/PMC4850712.xml.json,https://doi.org/10.1186/s13104-016-2040-4; https://www.ncbi.nlm.nih.gov/pubmed/27130295/,7773199.0,3
94597,94597,120753,l6rko4xv,72f723a1b9b636d379ecb18b7ba95e4b2135f81f,Medline; PMC,Baiting studies on oral vaccination of the greater kudu (Tragelaphus strepsiceros) against rabies,10.1007/s10344-018-1220-z,PMC7088030,32214946.0,cc-by,rabies greater kudu tragelaphus strepsiceros one largest african antelope phenomenon unique namibia since mids country plagued two epizootics claimed thousand casualty among indigenous kudu population reason kudu appear exceptionally susceptible disease still remain speculative best namibian economy relies heavily trophy hunting game meat hunting ecotourism current severe spread rabies among kudu call effective measure protect antelope oral vaccination kudu may offer possibility provided efficacious oral rabies vaccine available screening study explored option attractive bait facilitate optimal vaccine uptake target specie bait distribution system maximizes bait availability target specie meanwhile minimizing bait depletion nontarget specie result show gelatinbased bait mixed local pod camel thorn tree also imported appleflavored corn meal attractants highly attractive kudu providing basis future oral rabies vaccine bait electronic supplementary material online version article sz contains supplementary material available authorized user,2018-10-09,"Hassel, Rainer; Ortmann, Steffen; Clausen, Peter; Jago, Mark; Bruwer, Floris; Lindeque, Pauline; Freuling, Conrad; Vos, Ad; Müller, Thomas",Eur,,,,document_parses/pdf_json/72f723a1b9b636d379ecb18b7ba95e4b2135f81f.json,document_parses/pmc_json/PMC7088030.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32214946/; https://doi.org/10.1007/s10344-018-1220-z,52947380.0,3
94648,94648,120814,nwuuay9y,aa41cc06412ef9f765289e650aee1190b10a8455,Elsevier; Medline; PMC,PAK1-blockers: Potential Therapeutics against COVID-19(),10.1016/j.medidd.2020.100039,PMC7166201,32313880.0,no-cc,pak raccdcactivated kinase major “ pathogenic ” kinase whose abnormal activation cause wide variety diseasesdisorders including cancer inflammation malaria pandemic viral infection including influenza hiv covid since louis pateur developed vaccine rabies general series “ specific ” vaccine used treatment viral infection mainly antibiotic general ineffective treatment viral infection however take – month till effective vaccine becomes available ventilator supplier would common tool saving life covid patient thus alternative potentially direct “ broadspectrum ” covid therapeutic several natural synthetic pakblockers propolis melatonin ciclesonide hydroxy chloroquine hq ivermection ketorolac readily available market introduced,2020-04-19,"Maruta, Hiroshi; He, Hong",Med Drug Discov,,,,document_parses/pdf_json/aa41cc06412ef9f765289e650aee1190b10a8455.json,document_parses/pmc_json/PMC7166201.xml.json,https://doi.org/10.1016/j.medidd.2020.100039; https://www.sciencedirect.com/science/article/pii/S2590098620300269; https://api.elsevier.com/content/article/pii/S2590098620300269; https://www.ncbi.nlm.nih.gov/pubmed/32313880/,215808237.0,3
94663,94663,120830,tf8j93wg,fc666c4b5e921b8ac361ba9c1140f14a25645235,Elsevier; PMC,Viral Vaccines and Antiviral Therapy,10.1016/b978-0-12-385157-4.00389-4,PMC7173488,,els-covid,article author review important viral infection affecting human prevented vaccine controlled antiviral drug different type drug vaccine listed mechanism action discussed drug include toxicity viral resistance whereas vaccine include generation autoimmune reaction contamination previously unknown pathogen reversion attenuated virulent strain reactogenicity author discus understood preventative method instituted prevent,2014-12-31,"Tselis, A.; Booss, J.",Encyclopedia of the Neurological Sciences,,,,document_parses/pdf_json/fc666c4b5e921b8ac361ba9c1140f14a25645235.json,document_parses/pmc_json/PMC7173488.xml.json,https://api.elsevier.com/content/article/pii/B9780123851574003894; https://www.sciencedirect.com/science/article/pii/B9780123851574003894,81990887.0,3
94665,94665,120832,ce8gds3o,6d801cfd44b98804dca8133aab70f876006d9130,Medline; PMC,Efficacy and immunogenicity of recombinant swinepox virus expressing the truncated S protein of a novel isolate of porcine epidemic diarrhea virus,10.1007/s00705-017-3548-1,PMC7086769,28916870.0,no-cc,porcine epidemic diarrhea virus pedv cause significant loss swine industry emergence novel pedv strain recent year decreased effectiveness pedv vaccine developed live recombinant vaccine swinepox virus vector express truncated protein rspvst recent pedv strain sq evaluated immunogenicity effectiveness swine model vaccination swine rspvst elicited robust antibody response specific homologous pedv sq serum iga titer rspvstvaccinated animal significantly higher immunized inactivated vaccine effectiveness antibody induced rspvst vaccine protection pedv tested passivetransfer model piglet challenged homologous virus sq heterologous strain cv challenged homologous virus serum rspvst vaccination provided complete protection however serum rspvst vaccination provide protection heterologous virus challenge amino acid sequence difference protein two virus identified within neutralizing epitope might contributed divergent clinical result data suggest rspvst potentially effective vaccine infection emerging pedv strain,2017-09-15,"Yuan, Xiaomin; Lin, Huixing; Li, Bin; He, Kongwang; Fan, Hongjie",Arch Virol,,,,document_parses/pdf_json/6d801cfd44b98804dca8133aab70f876006d9130.json,document_parses/pmc_json/PMC7086769.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28916870/; https://doi.org/10.1007/s00705-017-3548-1,19505711.0,3
94686,94686,120859,fskx5xue,8d45f5195da141da6fafece92e5662beb9150511,Elsevier; PMC,Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen,10.1016/j.virol.2006.07.017,PMC7126721,16919703.0,els-covid,recent study established feasibility subunitbased experimental vaccine protect animal lethal poxvirus infection individual outer membrane protein intracellular extracellular virion vaccinia virus delivered form either dna vaccine recombinant protein vaccine produced baculovirusinfected insect cell able protect mouse vaccinia virus challenge rhesus macaque monkeypox virus challenge polyvalent formulation various combination four poxvirus antigen l b achieved better protection monovalent formulation using one antigen however clear whether remaining outer membrane poxvirus protein improve efficacy current polyvalent formulation study conducted detailed analysis immunogenicity previously reported protective antigen intracellular mature virion result indicated induced strong protective antibody response effective improving efficacy previously reported polyvalent poxvirus vaccine formulation therefore excellent candidate antigen included final polyvalent subunitbased poxvirus vaccine,2006-11-25,"Sakhatskyy, Pavlo; Wang, Shixia; Chou, Te-hui W.; Lu, Shan",Virology,,,,document_parses/pdf_json/8d45f5195da141da6fafece92e5662beb9150511.json,document_parses/pmc_json/PMC7126721.xml.json,https://www.sciencedirect.com/science/article/pii/S0042682206004752; https://api.elsevier.com/content/article/pii/S0042682206004752,37009243.0,3
94690,94690,120863,28900qlr,e9473b4c6c037e520377747f6d02eeb74bf038d0,Elsevier; Medline; PMC,Vaccine-preventable disease control in the People’s Republic of China: 1949–2016,10.1016/j.vaccine.2018.10.005,PMC7115483,30497834.0,els-covid,background china immunization program one oldest largest world rate vaccinepreventable disease vpd comparable highincome country program evolution characterized ambitious target setting innovative strategy widely described method reviewed national provincial health department archive analyzed disease surveillance vaccination coverage serosurvey data conducted indepth interview senior chinese expert involved early vpd control effort result widespread immunization began smallpox diphtheria bacilluscalmette guerin vaccine pertussis tetanus polio measles japanese encephalitis je vaccine largest drop absolute vpd burden occurred establishment rural cooperative medical system cadre trained peasant health worker whose responsibility included vaccination incidence per population dropped diphtheria pertussis polio measles je averting average million vpd case year early vaccine delivered annual winter campaign using coordinated ‘ rushrelay ’ system expedite transport leveraging vaccine thermostability establishment cold chain system allowed bimonthly vaccination round timely vaccination resulting rate diphtheria pertussis measles meningitis falling polio je rate fell – progress stalled financing public health weakened broad market reform large investment public health immunization central government since led decline vpd burden increased equity – incidence per population measles pertussis je meningococcal meningitis hepatitis prevalence chronic hepatitis b infection child year fell decline china certified poliofree diphtheria last reported conclusion longterm political commitment immunization basic right ambitious target use disease incidence primary metric ass program performance nationwide scaleup successful locally developed strategy optimized use available limited resource critical china success controlling vaccinepreventable disease,2018-12-18,"Yu, Wenzhou; Lee, Lisa A.; Liu, Yanmin; Scherpbier, Robert W.; Wen, Ning; Zhang, Guomin; Zhu, Xu; Ning, Guijun; Wang, Fuzhen; Li, Yixing; Hao, Lixin; Zhang, Xuan; Wang, Huaqing",Vaccine,,,,document_parses/pdf_json/e9473b4c6c037e520377747f6d02eeb74bf038d0.json,document_parses/pmc_json/PMC7115483.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X18313574; https://api.elsevier.com/content/article/pii/S0264410X18313574; https://doi.org/10.1016/j.vaccine.2018.10.005; https://www.ncbi.nlm.nih.gov/pubmed/30497834/,54167710.0,3
94711,94711,120888,fmg7d5di,9a05fd132ae9383dfe882058bb614ef227c54760,Elsevier; PMC,The control of necrotic enteritis in sucking piglets by means of a Clostridium perfringens toxoid vaccine,10.1016/s0928-8244(99)00050-4,PMC7172454,,no-cc,necrotic enteritis sucking piglet constitutes serious problem piglet rearing unit high morbidity mortality associated disease primary causal agent clostridium perfringens type c βtoxin play decisive role pathogenesis disease toxoid vaccine use sow developed studied field trial european pharmacopoeia monograph vaccine use animal lay method efficacy testing based immunization rabbit collection pooled serum subsequent assay antitoxin antibody mouse using appropriate test toxin vaccine regarded effective induces minimum iu βantitoxin per ml rabbit serum established range – iu βantitoxin per ml rabbit serum induced sample c perfringens toxoid vaccine vaccine used field condition different rearing unit time mostly form emergency vaccination following outbreak disease outcome vaccination evaluated recording total number piglet born alive piglet loss use vaccine coupled measure resulted approximately reduction number loss,1999-06-17,"Springer, S; Selbitz, H.-J",FEMS Immunol Med Microbiol,,,,document_parses/pdf_json/9a05fd132ae9383dfe882058bb614ef227c54760.json,document_parses/pmc_json/PMC7172454.xml.json,https://api.elsevier.com/content/article/pii/S0928824499000504; https://www.sciencedirect.com/science/article/pii/S0928824499000504,216044896.0,3
94901,94901,121123,kldu8q8x,51f88d6a65a66742a19ec634400f8315fda5811e,Medline; PMC,Highly conserved regions in Ebola virus RNA dependent RNA polymerase may be act as a universal novel peptide vaccine target: a computational approach,10.1186/s40203-015-0011-4,PMC4529428,26820892.0,cc-by,purpose ebola virus ebov kind virus responsible case death worldwide average disease fatality rate although medical technology tried handle problem food drug administration fdaapproved therapeutic vaccine available prevention post exposure treatment ebola virus disease evd method present study used immunoinformatics approach design potential epitopebased vaccine rnadependent rna polymerasel ebov bioedit v sequence alignment editor jalview v clc sequence viewer v used initial sequence analysis securing conservancy sequence later immune epitope database analysis resource iedbar used identification tcell bcellepitopes associated type ii major histocompatibility complex molecule analysis finally population coverage analysis employed result core epitope “ fryeftapf ” found potential one conservancy among strain ebov also interacted type ii major histocompatibility complex molecule considered nonallergenic nature finally impressive cumulative population coverage mhci mhcii class throughout world population found proposed epitope conclusion end projected peptide gave u solid stand propose vaccine consideration might experimented potency eliciting immunity humoral cell mediated immune response vitro vivo electronic supplementary material online version article doi contains supplementary material available authorized user,2015-08-08,"Oany, Arafat Rahman; Sharmin, Tahmina; Chowdhury, Afrin Sultana; Jyoti, Tahmina Pervin; Hasan, Md. Anayet",In Silico Pharmacol,,,,document_parses/pdf_json/51f88d6a65a66742a19ec634400f8315fda5811e.json,document_parses/pmc_json/PMC4529428.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26820892/; https://doi.org/10.1186/s40203-015-0011-4,9916148.0,3
94947,94947,121180,eji6dw94,6a8534ba7e43207496048e684daadf767379d9a5; 8922dda5c6009cc69e1a90dac8d587c38f5af43f,Medline; PMC,Vaccines for the prevention against the threat of MERS-CoV,10.1586/14760584.2016.1167603,PMC5097835,26985862.0,bronze-oa,first identified middle east respiratory syndrome mers coronavirus merscov listed new category c priority pathogen high mortality merscov infection intensified potential humantohuman transmissibility mers vaccine available human use review explains immune response resulting merscov infection describes mers vaccine criterion present available small animal model evaluate efficacy mers vaccine current advance vaccine development summarized focusing specific application limitation vaccine category taken together review provides valuable guideline toward development effective safe mers vaccine article written special focus issue expert review vaccine “ vaccine biodefence ”,2016-04-06,"Du, Lanying; Tai, Wanbo; Zhou, Yusen; Jiang, Shibo",Expert Review of Vaccines,,,,document_parses/pdf_json/6a8534ba7e43207496048e684daadf767379d9a5.json; document_parses/pdf_json/8922dda5c6009cc69e1a90dac8d587c38f5af43f.json,document_parses/pmc_json/PMC5097835.xml.json,https://doi.org/10.1586/14760584.2016.1167603; https://www.ncbi.nlm.nih.gov/pubmed/26985862/; https://www.tandfonline.com/doi/pdf/10.1586/14760584.2016.1167603?needAccess=true,207196456.0,3
94975,94975,121212,6r8wvn9s,f3e48841747b33e9660801a34de2c13e93482802,Medline; PMC,Parainfluenza virus 5–vectored vaccines against human and animal infectious diseases,10.1002/rmv.1965,PMC7169218,29316047.0,no-cc,parainfluenza virus piv known canine parainfluenza virus veterinary field negative‐sense nonsegmented single‐stranded rna virus belonging paramyxoviridae family parainfluenza virus excellent viral vector used live vaccine kennel cough many year dog without safety concern grow high titer many cell type genome stable even presence foreign gene insertion far piv used develop vaccine influenza virus respiratory syncytial virus rabies virus mycobacterium tuberculosis demonstrating ability elicit robust protective immune response preclinical animal model parainfluenza virus –based vaccine administered intranasally intramuscularly orally interestingly prior exposure piv prevent piv‐vectored vaccine generating robust immunity indicating vector used encouraging result reviewed together along discussion desirable advantage piv vaccine vector aid future vaccine design accelerate progression piv‐based vaccine clinical trial,2018-01-05,"Chen, Zhenhai",Rev Med Virol,,,,document_parses/pdf_json/f3e48841747b33e9660801a34de2c13e93482802.json,document_parses/pmc_json/PMC7169218.xml.json,https://doi.org/10.1002/rmv.1965; https://www.ncbi.nlm.nih.gov/pubmed/29316047/,3707454.0,3
95098,95098,121369,r5hgfsxz,1163230242bf54779c5e9bd79ab5a1afcfc14810,Elsevier; Medline; PMC,Japanese encephalitis virus: A multi-epitope loaded peptide vaccine formulation using reverse vaccinology approach,10.1016/j.meegid.2019.104106,PMC7106040,31706079.0,no-cc,japanese encephalitis je serious leading health complication emerging expansively severely affected survival rate human being fatal disease caused je virus jev current study carried designing multiepitope loaded peptide vaccine prevent jev based reverse vaccinology silico approach octapeptide bcell hexapeptide tcell epitope belonging five protein viz e prm n n n jev determined hydrophilicity antigenicity immunogenicity aliphatic amino acid epitope estimated epitope analyzed different physicochemical parameter eg total net charge amino acid composition boman index epitope total four tcell epitope namely kradss krsrrs skrsrr kecpde one bcell epitope ie pkpcskgd found potential raising immunity human pathogen taking account outcome study pharmaceutical industry could initiate effort combine identified epitope together adjuvant carrier protein develop multiepitopeloaded peptide vaccine jev peptide vaccine cost effective could administered prophylactic measure jev infected individual combat spread virus human population however prior administration human being vaccine must pas several clinical trial,2019-11-06,"Chakraborty, Supriyo; Barman, Antara; Deb, Bornali",Infect Genet Evol,,,,document_parses/pdf_json/1163230242bf54779c5e9bd79ab5a1afcfc14810.json,document_parses/pmc_json/PMC7106040.xml.json,https://api.elsevier.com/content/article/pii/S1567134819303326; https://www.ncbi.nlm.nih.gov/pubmed/31706079/; https://www.sciencedirect.com/science/article/pii/S1567134819303326; https://doi.org/10.1016/j.meegid.2019.104106,207936976.0,3
95134,95134,121414,0k45mznj,37caa2337d7bfd9b15b44801deb7ba50743490d8,Elsevier; Medline; PMC; WHO,Efficacy of orally administered porcine epidemic diarrhea vaccine-loaded hydroxypropyl methylcellulose phthalate microspheres and RANKL-secreting L. lactis,10.1016/j.vetmic.2020.108604,PMC7117268,32122610.0,els-covid,examined efficacy combinant subunit antigenbased oral vaccine preventing porcine epidemic diarrhea virus pedv first generated soluble recombinant partial spike protein ap pedv e coli evaluated utility ap subunit vaccineloaded hydroxypropyl methylcellulose phthalate microspheres hpmcp ranklsecreting l lactis llrankl candidate oral vaccine pregnant sow pregnant sow vaccinated twice week interval dos week farrowing titer virusspecific iga antibody colostrum neutralizing antibody serum sow vaccinated hpmcp ap plus rankl increased significantly week postfirst vaccination furthermore survival rate newborn suckling piglet delivered sow vaccinated hpmcp ap plus rankl similar piglet delivered sow vaccinated commercial killed porcine epidemic diarrhea virus ped vaccine south korean government promotes ped vaccine program livekilledkilled increase titer iga igg antibody pregnant sow prevent pedv oral vaccine strategy described herein based safe efficient recombinant subunit antigen alternative ped vaccination strategy could replace traditional strategy relies attenuated live oral vaccine artificial infection virulent pedv,2020-03-31,"Choe, SeEun; Song, Sok; Piao, Dachuan; Park, Gyu-Nam; Shin, Jihye; Choi, Yun-Jaie; Kang, Sang-Kee; Cha, Ra Mi; Hyun, Bang-Hun; Park, Bong-Kyun; An, Dong-Jun",Veterinary Microbiology,,#2324,,document_parses/pdf_json/37caa2337d7bfd9b15b44801deb7ba50743490d8.json,document_parses/pmc_json/PMC7117268.xml.json,https://doi.org/10.1016/j.vetmic.2020.108604; https://www.sciencedirect.com/science/article/pii/S0378113519312581; https://api.elsevier.com/content/article/pii/S0378113519312581; https://www.ncbi.nlm.nih.gov/pubmed/32122610/,211834930.0,3
95173,95173,121461,ipgg0lnf,f33af692d3f91521c62c3da9600af432f955cc8c; 86c3e62c6f5a736ed1dd7e5097e829641b8a4580,Elsevier; Medline; PMC,Safety and Infectivity of Two Doses of Live -Attenuated Recombinant Cold-Passaged Human Parainfluenza Type 3 Virus Vaccine rHPIV3cp45 in HPIV3-Seronegative Young Children,10.1016/j.vaccine.2013.09.046,PMC3889708,24103895.0,green-oa,background human parainfluenza virus type hpiv common cause upper lower respiratory tract illness infant young child liveattenuated coldadapted hpiv vaccine evaluated infant suitable interval administration second dose vaccine defined method hpivseronegative child age month randomized blinded study receive two dos tcid tissue culture infectious dose liveattenuated recombinant coldpassaged human piv vaccine rhpivcp placebo month apart serum antibody level assessed prior approximately week dose vaccine virus infectivity defined detection vaccinehpiv nasal wash andor ≥ fold rise serum antibody titer reactogenicity assessed day following immunization result forty hpivseronegative child median age month range month enrolled received vaccine received placebo infectivity detected evaluable vaccinee following dose subject following dose among shed virus median duration viral shedding day range day dose day range day dose mean peak log viral titer pfuml sd dose compared pfuml sd dose overall reactogenicity mild difference rate fever upper respiratory infection symptom vaccine placebo group conclusion rhpivcp immunogenic welltolerated seronegative young child second dose administered month initial dose restricted previously infected vaccine virus however second dose boosted antibody response induced antibody response two previously uninfected child,2013-11-01,"Englund, Janet A.; Karron, Ruth A.; Cunningham, Coleen K; LaRussa, Philip; Melvin, Ann; Yogev, Ram; Handelsman, Ed; Siberry, George K; Thumar, Bhavanji; Schappell, Elizabeth; Bull, Catherine V.; Chu, Helen Y.; Schaap-Nutt, Anne; Buchholz, Ursula; Collins, Peter L.; Schmidt, Alexander C.",Vaccine,,,,document_parses/pdf_json/f33af692d3f91521c62c3da9600af432f955cc8c.json; document_parses/pdf_json/86c3e62c6f5a736ed1dd7e5097e829641b8a4580.json,document_parses/pmc_json/PMC3889708.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X13013005; https://api.elsevier.com/content/article/pii/S0264410X13013005; https://www.ncbi.nlm.nih.gov/pubmed/24103895/; https://doi.org/10.1016/j.vaccine.2013.09.046; http://europepmc.org/articles/pmc3889708?pdf=render,9382358.0,3
95187,95187,121480,9pfnvmlc,68d2dcc2e0271c4d7d1e0515b9a2eb0443810ea4,Elsevier; PMC,"Immunoprophylaxis against important virus diseases of horses, farm animals and birds",10.1016/j.vaccine.2008.12.063,PMC7130586,19402200.0,els-covid,since refinement tissue culture technique virus isolation propagation mid onwards veterinary virology received much academic industrial interest become major global industry largely centred vaccine development economically important virus disease food animal biotech approach widely used improved vaccine development many viral disease controlled vaccination many still lack safe efficacious vaccine additional challenge faced academia industry government likely come virus jumping specie also emergence virulent variant established virus due natural mutation also viral ecology changing respective vector adapt new habitat shown recent incursion bluetongue virus europe paper current vaccine livestock horse bird described specie specie order new promising biotech approach using reverse genetics nonreplicating viral vector alpha virus vector genetic vaccine conjunction better adjuvant better way vaccine delivery discussed well,2009-03-13,"Patel, J. R.; Heldens, J.G.M.",Vaccine,,,,document_parses/pdf_json/68d2dcc2e0271c4d7d1e0515b9a2eb0443810ea4.json,document_parses/pmc_json/PMC7130586.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X09001364; https://api.elsevier.com/content/article/pii/S0264410X09001364,19323377.0,3
95246,95246,121555,tptwr151,68986febd925e135bb10b5d3157e830a728d46d9,Elsevier; PMC,Obstetrics Risk Assessment: Evaluation of Selection Criteria for Vaccine Research Studies in Pregnant Women,10.1016/j.vaccine.2020.05.022,PMC7211583,,no-cc,vaccine designed use pregnancy vaccine trial specifically involving pregnant woman rapidly expanding one key challenge designing maternal immunization trial developing exclusion criterion requires understanding quantifying background risk adverse pregnancy outcome pregnancy studied occur independent intervention unrelated vaccine administration global alignment immunization safety assessment pregnancy gaia project developed published case definition guideline data collection analysis evaluation maternal immunization safety trial involving pregnant woman complementing work sought understand best ass obstetric risk adverse outcome differentiate assessment vaccine safety quantification obstetric risk based prior current obstetric maternal medical history developed stepwise approach evaluate quantify obstetric maternal risk factor pregnancy based review published literature guideline critically assessed factor context designing inclusion exclusion criterion maternal vaccine study anticipate risk assessment evaluation may assist clinical trialists study design decision including selection exclusion criterion vaccine trial involving pregnant woman consideration subgroup classification high low risk subject schedule consideration preferred trimester gestation intervention pregnancy additionally tool may utilized data stratification time study analysis,2020-05-11,"Eckert, Linda O.; Jones, Christine E.; Kachikis, Alisa; Bardají, Azucena; Tavares Da Silva, Fernanda; Absalon, Judith; Rouse, Caroline E.; Khalil, Asma; Cutland, Clare L.; Kochhar, Sonali; Munoz, Flor M.",Vaccine,,,,document_parses/pdf_json/68986febd925e135bb10b5d3157e830a728d46d9.json,document_parses/pmc_json/PMC7211583.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X2030640X?v=s5; https://api.elsevier.com/content/article/pii/S0264410X2030640X,218571530.0,3
95268,95268,121582,x1wemzgn,87582af39733e3ac37094edb3afec413e9f18833,Elsevier; Medline; PMC,Avian coronavirus infectious bronchitis attenuated live vaccines undergo selection of subpopulations and mutations following vaccination,10.1016/j.vaccine.2008.01.006,PMC7115600,18262691.0,els-covid,summary study interested determining high titered egg adapted modified live infectious bronchitis virus ibv vaccine contain spike gene related quasispecies undergo selection chicken following vaccination sequenced spike glycoprotein ibv vaccine different serotypes different manufacturer directly vaccine vial compared sequence reisolated virus vaccinated contactexposed bird time found difference sequence within vaccine serotype different manufacturer difference sequence different vaccine serial manufacturer intravaccine difference quasispecies comparing sequence data reisolated virus original vaccine virus able identify vivo selection viral subpopulation well mutation knowledge first report showing selection fit virus subpopulation well mutation associated replication modified live ibv vaccine virus chicken information important understanding attenuated virus vaccine including potential vaccine sarscov ensure longterm survival virus lead change pathogenesis emergence new viral pathogen information also valuable development safer modified live coronavirus vaccine,2008-03-04,"McKinley, Enid T.; Hilt, Deborah A.; Jackwood, Mark W.",Vaccine,,,,document_parses/pdf_json/87582af39733e3ac37094edb3afec413e9f18833.json,document_parses/pmc_json/PMC7115600.xml.json,https://doi.org/10.1016/j.vaccine.2008.01.006; https://www.ncbi.nlm.nih.gov/pubmed/18262691/; https://www.sciencedirect.com/science/article/pii/S0264410X0800039X; https://api.elsevier.com/content/article/pii/S0264410X0800039X,34944029.0,3
95400,95400,121739,q36ye9ff,cf98243a8c7eb0a50f3b8487f8b47149b42987ba,Elsevier; PMC,Viral Diarrhea,10.1016/b978-0-12-803678-5.00486-0,PMC7150116,,els-covid,viral gastroenteritis among common illness affecting human greatest impact extreme age spectrum disease range asymptomatic infection severe disease dehydration contrast bacterial pathogen enteric virus multiply outside host hence original inoculum common source determines infectivity prevention contamination food water control primary case whereas careful nursing handwashing prevent secondary case effective vaccine available widely used prevent rotaviral gastroenteritis vaccine cause viral gastroenteritis yet available,2017-12-31,"Kang, Gagandeep",International Encyclopedia of Public Health,,,,document_parses/pdf_json/cf98243a8c7eb0a50f3b8487f8b47149b42987ba.json,document_parses/pmc_json/PMC7150116.xml.json,https://api.elsevier.com/content/article/pii/B9780128036785004860; https://www.sciencedirect.com/science/article/pii/B9780128036785004860,4688635.0,3
95406,95406,121745,wwiopinv,5f7ff0afe6bc1aee46d74c3dcd7741a39f3d5d6d,Elsevier; PMC,Chapter 25 Preclinical Toxicology of Vaccines 1,10.1016/b978-0-12-387815-1.00025-3,PMC7161391,,els-covid,immunity targeted infectious disease may conferred enhanced vaccine manufactured recombinant form well inactivated attenuated organism vaccine meet requirement safety quality efficacy addition antigenic component various adjuvant may included vaccine evoke effective immune response ensure safety new vaccine preclinical toxicology study conducted prior initiation concurrently clinical study five different type preclinical toxicology study evaluation vaccine safety single andor repeat dose reproductive developmental mutagenicity carcinogenicity safety pharmacology adverse effect observed course study fully evaluated final safety decision made accordingly successful preclinical toxicology study depend multiple factor including using appropriate study design using right animal model evoking effective immune response additional vivo vitro assay establish identity purity safety potency vaccine play significant role assessing critical characteristic vaccine safety,2013-12-31,"Green, Martin David; Hussain Al-Humadi, Nabil",A Comprehensive Guide to Toxicology in Preclinical Drug Development,,,,document_parses/pdf_json/5f7ff0afe6bc1aee46d74c3dcd7741a39f3d5d6d.json,document_parses/pmc_json/PMC7161391.xml.json,https://api.elsevier.com/content/article/pii/B9780123878151000253; https://www.sciencedirect.com/science/article/pii/B9780123878151000253,78893049.0,3
95450,95450,121798,smlq11y9,f6c3322832e870befdabba94767a6422dfd67d2b,Medline; PMC,Nanoparticle-based vaccine development and evaluation against viral infections in pigs,10.1186/s13567-019-0712-5,PMC6833244,31694705.0,cc-by,virus infection posse persistent health challenge swine industry leading severe economic loss worldwide economic burden caused virus infection porcine reproductive respiratory syndrome virus swine influenza virus porcine epidemic diarrhea virus porcine circovirus foot mouth disease virus many others associated severe morbidity mortality loss production trade restriction investment control prevention practice pig also role zoonotic transmission viral infection human inactivated modifiedlive virus vaccine available porcine viral infection variable efficacy field condition thus improvement existing vaccine necessary increase breadth protection evolving viral strain subtypes control emerging reemerging virus eradicate virus localized different geographic area differentiate infected vaccinated animal improve disease control program nanoparticles np generated viruslike particle biodegradable biocompatible polymer liposome offer many advantage vaccine delivery platform due unique physicochemical property np help efficient antigen internalization processing antigen presenting cell activate elicit innate adaptive immunity npsbased vaccine could delivered parenteral mucosal route trigger efficient mucosal systemic immune response could used target specific immune cell mucosal microfold cell dendritic cell dc conclusion npsbased vaccine serve novel candidate vaccine several porcine viral infection potential enhance broader protective efficacy field condition review highlight recent development npsbased vaccine porcine viral pathogen npsbased vaccine delivery system induces innate adaptive immune response resulting varied level protective efficacy,2019-11-06,"Dhakal, Santosh; Renukaradhya, Gourapura J.",Vet Res,,,,document_parses/pdf_json/f6c3322832e870befdabba94767a6422dfd67d2b.json,document_parses/pmc_json/PMC6833244.xml.json,https://doi.org/10.1186/s13567-019-0712-5; https://www.ncbi.nlm.nih.gov/pubmed/31694705/,207916676.0,3
95493,95493,121851,goh0cn35,ab1216072d2b617ce819d2201747699262b5177d,Medline; PMC,Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development,10.1371/journal.pntd.0006919,PMC6336248,30653504.0,cc-by,chikungunya fever chikf emerging infectious disease caused alphavirus transmitted aedes spp mosquito mosquito control program highly efficient outbreak containment vaccine essential reduce burden disease although licensed vaccine chikf yet available many highly promising candidate undergoing preclinical study tested human trial phase review recent finding regarding need chikf vaccine provide update vaccine nearing entered clinical trial also address need tackle bottleneck vaccine development—including scientific financial barriers—and accelerate development vaccine several action taken design efficacy trial conducted course outbreak ii evaluate opportunity adopting “ animal rule ” demonstration efficacy regulatory purpose iii strengthen collective commitment nation international organization potential donor industry iv stimulate public andor private partnership invest vaccine development licensure v identify potential market effective safe chikf vaccine,2019-01-17,"Rezza, Giovanni; Weaver, Scott C.",PLoS Negl Trop Dis,,,,document_parses/pdf_json/ab1216072d2b617ce819d2201747699262b5177d.json,document_parses/pmc_json/PMC6336248.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30653504/; https://doi.org/10.1371/journal.pntd.0006919,58656663.0,3
95501,95501,121860,1c1jd9oz,b41638f869301e2af9eef7913301d55516fcf4ce,Medline; PMC,A review of vaccine development and research for industry animals in Korea,10.7774/cevr.2012.1.1.18,PMC3623508,23596575.0,cc-by-nc,vaccination proven costeffective strategy controlling wide variety infectious disease human animal last decade veterinary vaccine substantially developed demonstrated effectiveness many disease nevertheless new vaccine greatly demanded effectively control newly reemerging pathogen livestock however development veterinary vaccine challenging task part due variety pathogen host uniqueness hostsusceptibility pathogen therefore novel concept vaccine explored overcome limitation conventional vaccine greatly advanced completion genomic sequencing pathogen application comparative genomic transcriptome analysis would facilitate open opportunity investigate new generation vaccine recombinant subunit vaccine viruslike particle dna vaccine vectorvehicle vaccine currently type vaccine actively explored various livestock disease affording numerous advantage conventional vaccine including ease production immunogenicity safety multivalency single shot article author present current status development veterinary vaccine large well research activity conducted korea,2012-07-31,"Lee, Nak-Hyung; Lee, Jung-Ah; Park, Seung-Yong; Song, Chang-Seon; Choi, In-Soo; Lee, Joong-Bok",Clin Exp Vaccine Res,,,,document_parses/pdf_json/b41638f869301e2af9eef7913301d55516fcf4ce.json,document_parses/pmc_json/PMC3623508.xml.json,https://doi.org/10.7774/cevr.2012.1.1.18; https://www.ncbi.nlm.nih.gov/pubmed/23596575/,16280274.0,3
95562,95562,121932,ugmnn5fb,a704441238c2d31fa49782a37b33dc03632a7aff; eabfa97a283a231c856f7166391389568eebfdcd,Elsevier; Medline; PMC,Delivery to the lower respiratory tract is required for effective immunization with Newcastle disease virus-vectored vaccines intended for humans,10.1016/j.vaccine.2009.01.009,PMC2723768,19168110.0,green-oa,newcastle disease virus ndv avian virus evaluated development vectored human vaccine emerging pathogen previous study ndvvectored vaccine mouse model suggested potency delivery injection intranasal route compared efficacy various route delivery ndvvectored vaccine nonhuman primate model delivery ndv vectored vaccine combined intranasalintratracheal route elicited protective immune response delivery subcutaneous route intranasal route alone elicited limited protective immune response suggesting necessity vaccine delivery lower respiratory tract furthermore direct comparison vaccine based ndv mesogenic strain ndvbc similarly designed ndv vector based modified lentogenic strain carrying polybasic f cleavage site ndvvf suggested two ndv strain similar immunogenicity equally protective,2009-03-01,"DiNapoli, Joshua M.; Ward, Jerrold M.; Cheng, Lily; Yang, Lijuan; Elankumaran, Subbiah; Murphy, Brian R.; Samal, Siba K.; Collins, Peter L.; Bukreyev, Alexander",Vaccine,,,,document_parses/pdf_json/a704441238c2d31fa49782a37b33dc03632a7aff.json; document_parses/pdf_json/eabfa97a283a231c856f7166391389568eebfdcd.json,document_parses/pmc_json/PMC2723768.xml.json,https://api.elsevier.com/content/article/pii/S0264410X0900022X; http://europepmc.org/articles/pmc2723768?pdf=render; https://www.ncbi.nlm.nih.gov/pubmed/19168110/; https://www.sciencedirect.com/science/article/pii/S0264410X0900022X; https://doi.org/10.1016/j.vaccine.2009.01.009,13784527.0,3
95605,95605,121986,0jryi8fy,9fcbafc0eeffbfa061a8daf23f075ac871aaee02,Medline; PMC,Enhanced enterovirus 71 virus‐like particle yield from a new baculovirus design,10.1002/bit.25625,PMC7161748,25997678.0,no-cc,enterovirus ev responsible outbreak hand‐foot‐and‐mouth disease asia‐pacific region produce virus‐like particle vlp vaccine previously constructed recombinant baculoviruses co‐express ev p polypeptide cd protease using bac‐to‐bac® vector system recombinant baculoviruses resulted p cleavage cd subsequent vlp assembly infected insect cell caused either low vlp yield excessive vlp degradation tackle problem explored various expression cassette design flashbac gold™ vector system deficient v‐cath chia gene found recombinant baculovirus constructed using flashbac gold™ system insufficient improve ev vlp yield nonetheless bacf‐p‐ccd recombinant baculovirus constructed using flashbac goldtm system express p polh promoter cd cmv promoter dramatically improved vlp yield alleviating vlp degradation infection high fivetm cell bacf‐p‐ccd enhanced total extracellular vlp yield ≈ ≈ mgl respectively enabled release abundant vlp supernatant simplified downstream purification intramuscular immunization mouse μg purified vlp induced cross‐protective humoral response conferred protection lethal virus challenge given significantly improved extracellular vlp yield ≈ mgl potent immunogenicity conferred μg vlp one liter high fivetm culture produced ≈ dos purified vaccine thus rendering ev vlp vaccine economically viable able compete inactivated virus vaccine biotechnol bioeng – © wiley periodical inc,2015-06-30,"Lin, Shih‐Yeh; Yeh, Chia‐Tsui; Li, Wan‐Hua; Yu, Cheng‐Ping; Lin, Wen‐Chin; Yang, Jyh‐Yuan; Wu, Hsueh‐Ling; Hu, Yu‐Chen",Biotechnol Bioeng,,,,document_parses/pdf_json/9fcbafc0eeffbfa061a8daf23f075ac871aaee02.json,document_parses/pmc_json/PMC7161748.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25997678/; https://doi.org/10.1002/bit.25625,1206085.0,3
95612,95612,121997,yul4hjje,08f6ed68da2febb5fa72d43c574c3378eef6b1ad,Medline; PMC,Vaccines for the twenty-first century society,10.1038/nri3085,PMC7098427,22051890.0,no-cc,vaccine one major revolution history mankind twentieth century eliminated childhood disease used cause million death twentyfirst century vaccine also play major part safeguarding people health supported innovation derived new technology vaccine address new need twentyfirst century society characterized increased life expectancy emerging infection poverty lowincome country,2011-11-04,"Rappuoli, Rino; Mandl, Christian W.; Black, Steven; De Gregorio, Ennio",Nat Rev Immunol,,,,document_parses/pdf_json/08f6ed68da2febb5fa72d43c574c3378eef6b1ad.json,,https://www.ncbi.nlm.nih.gov/pubmed/22051890/; https://doi.org/10.1038/nri3085,10032505.0,3
95629,95629,122016,efryn8ul,,Medline; PMC,Host Factors Affecting Generation of Immunity Against Porcine Epidemic Diarrhea Virus in Pregnant and Lactating Swine and Passive Protection of Neonates,10.3390/pathogens9020130,PMC7168134,32085410.0,cc-by,porcine epidemic diarrhea virus pedv highly virulent reemerging enteric coronavirus cause acute diarrhea dehydration mortality neonatal suckling piglet despite safe effective pedv vaccine highly virulent strain unavailable making pedv prevention control challenging lactogenic immunity induced via gutmammary glandsecretory iga siga axis remains promising effective way protect suckling piglet pedv therefore successful pedv vaccine must induce protective maternal iga antibody passively transfer colostrum milk identifying variable influence lymphocyte migration iga secretion gestation lactation imperative designing maternal immunization strategy generate highest amount lactogenic immune protection pedv suckling piglet pregnancyassociated immune alteration influence viral pathogenesis adaptive immune response many different specie better understanding host immune response pedv pregnant swine may translate improved maternal immunization strategy enteric pathogen multiple specie review discus role host factor pregnancy antiviral immunity implication generating protective lactogenic immunity suckling neonate,2020-02-18,"Langel, Stephanie N.; Wang, Qiuhong; Vlasova, Anastasia N.; Saif, Linda J.",Pathogens,,,,,document_parses/pmc_json/PMC7168134.xml.json,https://doi.org/10.3390/pathogens9020130; https://www.ncbi.nlm.nih.gov/pubmed/32085410/,211245098.0,3
95636,95636,122024,ny3xrjzc,2c1c72b625f4023891f00bb34f67ae12508bb545,Elsevier; Medline; PMC,"Characterization, Pathogenicity and Protective efficacy of a Cell Culture-Derived Porcine Deltacoronavirus",10.1016/j.virusres.2020.197955,PMC7125813,32247757.0,els-covid,porcine deltacoronavirus pdcov novel swine enteropathogenic coronavirus cause acute diarrhea vomiting dehydration mortality neonatal piglet resulting significant economic loss pig industry however currently little information vaccine study commercially available vaccine pdcov hence herein pdcov strain chxjyn successfully isolated serially propagated vitro biological characteristic determined compared previously reported recently isolated pdcov strain china united state gene chxjyn strain contains novel mutation infection study revealed chxjyn pathogenic suckling piglet conventional weaned pig addition median pig diarrhea dose pdd pdcov conventional weaned pig determined logpdd ml furthermore inactivated celladapted chxjynbased vaccine candidate developed different adjuvant compared nonvaccinated pig conventional weaned pig given inactivated vaccine developed potent humoral immune response showed clinical sign viral shedding challenge indicating potent protective effect vaccine pdcov infection therefore pdcov vaccine developed study promising vaccine candidate used control pdcov infection pig,2020-04-02,"Gao, Xiang; Zhao, Donghong; Zhou, Peng; Zhang, Liping; Li, Mingxia; Li, Weiyan; Zhang, Yongguang; Wang, Yonglu; Liu, Xinsheng",Virus Res,,,,document_parses/pdf_json/2c1c72b625f4023891f00bb34f67ae12508bb545.json,document_parses/pmc_json/PMC7125813.xml.json,https://www.sciencedirect.com/science/article/pii/S0168170220300010?v=s5; https://www.ncbi.nlm.nih.gov/pubmed/32247757/; https://doi.org/10.1016/j.virusres.2020.197955; https://api.elsevier.com/content/article/pii/S0168170220300010,214755713.0,3
95686,95686,122090,dxr29anj,c2ea836920d930801cf610e286fa10b9cf1d728b,Medline; PMC,Epitope‐based peptide vaccine design and target site depiction against Ebola viruses: an immunoinformatics study,10.1111/sji.12302,PMC7169600,25857850.0,no-cc,ebola virus ebovs identified emerging threat recent year cause severe haemorrhagic fever human epitope‐based vaccine design ebovs remains top priority mere progress made regard another reason lack antiviral drug licensed vaccine although severe outbreak central africa study aimed design epitope‐based vaccine trigger significant immune response well prognosticate inhibitor bind potential drug target site using various immunoinformatics docking simulation tool capacity induce humoral cell‐mediated immunity cell b cell checked selected protein peptide region spanning amino acid sequence tlasigtaf found potential b cell epitope respectively peptide could interact hlas showed high population coverage using molecular docking epitope appraised binding hla molecule verify binding cleft interaction addition allergenicity epitope also evaluated post‐therapeutic strategy docking study predicted structure identified suitable therapeutic inhibitor targeted protein however computational epitope‐based peptide vaccine designing target site prediction ebovs open new horizon may prospective way ebola virus research result require validation vitro vivo experiment,2015-06-18,"Khan, M. A.; Hossain, M. U.; Rakib‐Uz‐Zaman, S. M.; Morshed, M. N.",Scand J Immunol,,,,document_parses/pdf_json/c2ea836920d930801cf610e286fa10b9cf1d728b.json,document_parses/pmc_json/PMC7169600.xml.json,https://doi.org/10.1111/sji.12302; https://www.ncbi.nlm.nih.gov/pubmed/25857850/,24588303.0,3
95743,95743,122161,zqz3zdoa,bb16156742a4d28f23dfd6d1810c8e36b69e04f4,Elsevier; Medline; PMC,"Molecular influenza surveillance at a tertiary university hospital during four consecutive seasons (2012–2016) in Catalonia, Spain",10.1016/j.vaccine.2019.03.046,PMC7173002,30926297.0,els-covid,background influenza virus fluv continuously evolving explain occurrence seasonal influenza epidemic need review vaccine strain composition annually aim describe genetic diversity clinical outcome fluv detected tertiary university hospital barcelona spain – season method detection fluv patient attended emergency department admitted hospital performed either immunofluorescence pcrbased assay specific realtime onestep multiplex rtpcr performed influenza fluav subtyping complete coding haemagglutinin domain ha neuraminidase na – protein sequence representative sampling molecular characterised result total fluav influenza b flubv case laboratoryconfirmed hospitalisation rate different season highest – season fluv genetically close vaccine strain except – characterised ahn virus belonged genetic group different vaccine strain – season bvictorialike virus predominant component included trivalent vaccine used mutation dg dn hadomain found ahnpdm strain icuadmitted case three ahnpdm strain carried na hy sn mutation respectively related resistance decreased susceptibility oseltamivir conclusion circulation drifted ahn strain – season related high hospitalisation rate due mismatch vaccine strain predominance flubv lineage included trivalent influenza vaccine – season highlight need use tetravalent influenza vaccine virological surveillance viral variant carrying protein change alter tropism susceptibility antiviral feature strengthened hospital setting,2019-04-24,"Andrés, Cristina; Peremiquel-Trillas, Paula; Gimferrer, Laura; Piñana, Maria; Codina, Maria Gema; Rodrigo-Pendás, José Ángel; Campins-Martí, Magda; Carmen Martín, María; Fuentes, Francisco; Rubio, Susana; Pumarola, Tomàs; Antón, Andrés",Vaccine,,,,document_parses/pdf_json/bb16156742a4d28f23dfd6d1810c8e36b69e04f4.json,document_parses/pmc_json/PMC7173002.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30926297/; https://doi.org/10.1016/j.vaccine.2019.03.046; https://api.elsevier.com/content/article/pii/S0264410X19303809; https://www.sciencedirect.com/science/article/pii/S0264410X19303809,88474178.0,3
95790,95790,122219,507necw8,11516584223d91a62cfce33470f08bec17319bf2,Elsevier; PMC,Viral and bacterial vectors of immunogenes,10.1016/0264-410x(85)90011-8,PMC7131544,4002835.0,els-covid,recent development production experimental vaccine use smallpox vaccine virus vaccinia virus carrier vector gene immunogenes code protectioninducing protein immunogen unrelated virus potential vector vaccine lie hope vaccine would cheaper safer andor effective existing vaccine pathogen vaccinia virus vector attracted attention date several immunogenes inserted genome without destroying infectivity b immunogen appear produced normally c vaccinia virus used highly successfully eradicate smallpox wide hostrange thus might find veterinary well human medical application experimental vaccine successfully tested animal prepared using immunogenes influenza virus hepatitis b virus herpes simplex virus apathogenic enteric bacteria potential vector probably enteric pathogen although potential viral vector likely realized first parasitic worm protozoa devastate million people immunogen organism identified added impetus investigate potential vector vaccine pathogen,1985-03-31,"Cavanagh, David",Vaccine,,,,document_parses/pdf_json/11516584223d91a62cfce33470f08bec17319bf2.json,,https://api.elsevier.com/content/article/pii/0264410X85900118; https://www.sciencedirect.com/science/article/pii/0264410X85900118,25990396.0,3
95874,95874,122317,47sgz7l3,89cc2ef7c7a14872165080ac0ad1b559b067948c,Elsevier; Medline; PMC,Platform technologies for modern vaccine manufacturing,10.1016/j.vaccine.2017.02.069,PMC7115529,28347504.0,els-covid,improved understanding antigenic component interaction immune system supported computational tool permit sophisticated approach modern vaccine design vaccine platform provide effective tool strategically designed peptide protein antigen modularized enhance immunogenicity modular vaccine platform overcome issue faced traditional vaccine manufacturing potential generate safe vaccine rapidly low cost review introduces two promising platform based viruslike particle liposome discus methodology challenge,2017-08-16,"Charlton Hume, Hayley K.; Lua, Linda H.L.",Vaccine,,,,document_parses/pdf_json/89cc2ef7c7a14872165080ac0ad1b559b067948c.json,document_parses/pmc_json/PMC7115529.xml.json,https://api.elsevier.com/content/article/pii/S0264410X17303651; https://www.sciencedirect.com/science/article/pii/S0264410X17303651; https://doi.org/10.1016/j.vaccine.2017.02.069; https://www.ncbi.nlm.nih.gov/pubmed/28347504/,4526672.0,3
95949,95949,122415,upsc9cf8,1694b4f8e456f966ff1fe215161bae59e59148df,Medline; PMC,A vaccine effective against Zika virus is theoretically possible but may not be delivered anytime soon,10.2147/rrtm.s108992,PMC6028058,30050335.0,cc-by-nc,following first report may unexpected emergence zika north east brazil explosive epidemic infection across latin america outbreak caused alarm among social news medium virulence transmission potential aedes mosquitoborne virus debate heightened proximity time distance forthcoming olympic game held rio de janeiro august provoking fear safety athlete spectator alike threat real perceived exacerbated movement nation separate continent person act unwittingly asymptomatic carrier pregnant female considered greatest risk microcephaly newborn infant linked yet proven caused zika infection february year world health organization declared unconfirmed association virus clinical manifestation microcephaly also guillainbarré syndrome zika epidemic “ public health emergency international concern ” antizika therapy vaccine drug currently available production former prioritized multiple funding agency history infectious disease vaccine development indicates may take several year reach market place fact zika close relative yellow fever japanese encephalitis virus already effective vaccine provides rational basis fasttracked laboratorybased preparation candidate vaccine however undertaking clinical trial pregnant female provides ethical practical hurdle overcome licensure granted public administration meanwhile public health management strategy including mosquito control program reduce breeding needed limit global spread reemerging disease,2016-07-05,"Taylor-Robinson, Andrew W",Res Rep Trop Med,,,,document_parses/pdf_json/1694b4f8e456f966ff1fe215161bae59e59148df.json,document_parses/pmc_json/PMC6028058.xml.json,https://doi.org/10.2147/rrtm.s108992; https://www.ncbi.nlm.nih.gov/pubmed/30050335/,51723527.0,3
95962,95962,122432,hduefdt3,8c1b1faa4cb3fad2424a8866062e043ac43c7f1e; 59932fb1f0b98d054deab83dbf18caa8396cb6e8,Elsevier; Medline; PMC,Human Phase 1 trial of low-dose inactivated seasonal influenza vaccine formulated with Advax™ delta inulin adjuvant,10.1016/j.vaccine.2016.05.071,PMC4949042,27342914.0,green-oa,influenza vaccine usually nonadjuvanted addition adjuvant may improve immunogenicity permit dosesparing critical vaccine supply event influenza pandemic aim firstinman study determine effect delta inulin adjuvant safety immunogenicity reduced dose seasonal influenza vaccine healthy male female adult aged – year recruited participate randomized controlled study compare safety tolerability immunogenicity reduceddose southern hemisphere trivalent inactivated influenza vaccine formulated advax™ delta inulin adjuvant ltiv adj compared fulldose standard tiv vaccine contain adjuvant ltiv adj provided equivalent immunogenicity standard tiv vaccine assessed hemagglutination inhibition hi assay vaccine strain well number heterosubtypic strain hi response sustained month postimmunisation group antibody landscape large panel hn influenza virus showed distinct age effect whereby subject year old bimodal baseline hi distribution pattern highest hi titer oldest hn isolates second hi peak influenza isolates last – year contrast subject year unimodal baseline hi distribution peak recognition hn isolates approximately year ago reduced dose tiv vaccine containing advax adjuvant well tolerated safety issue identified hence delta inulin may useful adjuvant use seasonal pandemic influenza vaccine australia new zealand clinical trial registry actrn,2016-07-01,"Gordon, David L.; Sajkov, Dimitar; Honda-Okubo, Yoshikazu; Wilks, Samuel H.; Aban, Malet; Barr, Ian G.; Petrovsky, Nikolai",Vaccine,,,,document_parses/pdf_json/8c1b1faa4cb3fad2424a8866062e043ac43c7f1e.json; document_parses/pdf_json/59932fb1f0b98d054deab83dbf18caa8396cb6e8.json,document_parses/pmc_json/PMC4949042.xml.json,http://europepmc.org/articles/pmc4949042?pdf=render; https://doi.org/10.1016/j.vaccine.2016.05.071; https://api.elsevier.com/content/article/pii/S0264410X16303978; https://www.sciencedirect.com/science/article/pii/S0264410X16303978; https://www.ncbi.nlm.nih.gov/pubmed/27342914/,29725165.0,3
95980,95980,122454,fcld1vi3,afe94c3bb91a1c03adb2ddb381ff0d754c903b50,Elsevier; Medline; PMC,Deoxynivalenol (DON) naturally contaminated feed impairs the immune response induced by porcine reproductive and respiratory syndrome virus (PRRSV) live attenuated vaccine,10.1016/j.vaccine.2015.06.069,PMC7127064,26117152.0,els-covid,cereal commodity frequently contaminated mycotoxin produced secondary metabolism fungal infection among contaminant deoxynivalenol also known vomitoxin prevalent type b trichothecene mycotoxin worldwide pig sensitive toxic effect frequently exposed naturally contaminated feed recently naturally contaminated feed shown decrease porcine reproductive respiratory syndrome virus prrsv specific antibody response following experimental infection objective study determine impact naturally contaminated feed immune response generated following vaccination prrsv live attenuated vaccine eighteen pig randomly divided three experimental group animal based content diet mg donkg fed ration one week prior vaccination duration immune response evaluation pig vaccinated intramuscularly one dose ingelvac® prrsv modified live vaccine mlv blood sample collected day − post vaccination pv tested prrsv rna rtqpcr virus specific antibody elisa result showed ingestion doncontaminated diet significantly decreased prrsv viremia pig fed control diet viremic pig viremic group receiving mg donkg respectively subsequently pig fed control diet developed prrsv specific antibody viremic pig fed contaminated diet developed prrsv specific antibody result suggest feeding pig doncontaminated diet could inhibit vaccination efficiency prrsv mlv severely impairing viral replication,2015-07-31,"Savard, Christian; Gagnon, Carl A.; Chorfi, Younes",Vaccine,,,,document_parses/pdf_json/afe94c3bb91a1c03adb2ddb381ff0d754c903b50.json,document_parses/pmc_json/PMC7127064.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X15008701; https://api.elsevier.com/content/article/pii/S0264410X15008701; https://doi.org/10.1016/j.vaccine.2015.06.069; https://www.ncbi.nlm.nih.gov/pubmed/26117152/,317462.0,3
96055,96055,122544,cotgutwd,1dc818a92b31dc871d7020ec659faaeb38e519c6; 2c54a11ecdaba1d2196f6325dcd4cfa3d9c6d428,Elsevier; Medline; PMC,"Influenza and respiratory syncytial virus (RSV) vaccines for infants: Safety, immunogenicity, and efficacy",10.1016/j.micpath.2012.11.013,PMC7127028,23247146.0,no-cc,respiratory viral infection infant young child frequently cause illness easily progress hospitalization death currently licensed vaccine prevent respiratory viral disease child younger month reflecting safety concern difficulty inducing effective immune response infant review discus vaccine developed currently developed influenza respiratory syncytial virus focus study performed demonstrate safety efficacy impact immunologic immaturity maternal antibody infant response vaccine,2012-12-13,"Beeler, Judy A.; Eichelberger, Maryna C.",Microb Pathog,,,,document_parses/pdf_json/1dc818a92b31dc871d7020ec659faaeb38e519c6.json; document_parses/pdf_json/2c54a11ecdaba1d2196f6325dcd4cfa3d9c6d428.json,document_parses/pmc_json/PMC7127028.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/23247146/; https://doi.org/10.1016/j.micpath.2012.11.013; https://api.elsevier.com/content/article/pii/S0882401012002057; https://www.sciencedirect.com/science/article/pii/S0882401012002057,1236322.0,3
96060,96060,122549,3gajz0f4,,Medline; WHO,Coronaviruses in animals and humans,10.1136/bmj.m634,,32075782.0,unk,controlling outbreak require detailed knowledge biology behaviourcoronaviruses around many year first discovered include virus contributing common cold hcove variety animal avian coronaviruses infectious bronchitis virus ibv infects poultry coronaviruses typically cause respiratory gastrointestinal illness strain ibv shown target oviduct chicken others cause severe kidney diseaseanimal avian coronaviruses high mortality rate among infected animal illustrate difficulty developing vaccine similar influenza virus despite many decade research vaccine protects strain ibv coronavirus due part continuously shifting diversity virus spike glycoprotein major immunogenic target hence good vaccine candidate animal human infectionsduring mids virus described backwater virology since none caused serious disease human however changed …,2020,"Ng, Lisa F P; Hiscox, Julian A",BMJ,,#1281,,,,https://doi.org/10.1136/bmj.m634; https://www.ncbi.nlm.nih.gov/pubmed/32075782/,211214947.0,3
96098,96098,122595,6jksnflz,f7f8c3a6f0bc371e5a2f9a32940b7eab3ca84904,Elsevier; Medline; PMC,Recombinant Newcastle disease virus (NDV) expressing Duck Tembusu virus (DTMUV) pre-membrane and envelope proteins protects ducks against DTMUV and NDV challenge,10.1016/j.vetmic.2018.03.027,PMC7117350,29685222.0,els-covid,newly emerged duck tembusu virus dtmuv responsible considerable economic loss waterfowlraising area china since meanwhile virulent newcastle disease virus ndv also caused sporadic outbreak waterfowl individual vaccine disease available however bivalent combined vaccine either disease constructed recombinant ndvvectored vaccine candidate express premembrane prm envelope e gene dtmuv designated agmprm e foreign prm e protein stably expressed agmprm e exhibited similar pathogenicity higher growth kinetics parental virus agmprm e carry fusion cleavage site accordance avirulent virus frequently isolated waterfowl induced remarkably p higher ndvspecific hemagglutination inhibition hi titer commercially available live ndv vaccine lasota strain agmprm e also elicited significantly higher p virus neutralization vn titer commercially available dtmuv inactivated vaccine hb strain agmprm e provided complete protection ndv challenge also reduced gross lesion ovarian folliculi provided protection dtmuv duck note agmprm e vaccine prevent challenged duck shedding ndv dtmuv result suggest candidate vaccine agmprm e would help decrease ndv dtmuv transmission waterfowl raising area china,2018-05-31,"Sun, Minhua; Dong, Jiawen; Li, Linlin; Lin, Qiuyan; Sun, Junying; Liu, Zhicheng; Shen, Haiyan; Zhang, Jianfeng; Ren, Tao; Zhang, Chunhong",Veterinary Microbiology,,,,document_parses/pdf_json/f7f8c3a6f0bc371e5a2f9a32940b7eab3ca84904.json,document_parses/pmc_json/PMC7117350.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29685222/; https://api.elsevier.com/content/article/pii/S0378113518301196; https://www.sciencedirect.com/science/article/pii/S0378113518301196; https://doi.org/10.1016/j.vetmic.2018.03.027,22616325.0,3
96124,96124,122627,2ljbsia2,b8b64e2414454c457d0bab4bbc925e79735beb81,Elsevier; PMC,Virus-like particles—universal molecular toolboxes,10.1016/j.copbio.2007.10.013,PMC7126091,18083549.0,els-covid,viruslike particle vlps highly organised sphere selfassemble virusderived structural antigen stable versatile subviral particle posse excellent adjuvant property capable inducing innate cognate immune response commercialised vlpbased vaccine successful protecting human hepatitis b virus hbv human papillomavirus hpv infection currently explored potential combat infectious disease cancer much insight vlpmediated immune stimulation optimised vlp design gained human immunodeficiency virus hivderived vlps presenting promising component current aid vaccine approach owing unique feature vlps virosomes vitroreconstituted vlp counterpart recently gained ground field nanobiotechnology organic template development new biomaterials,2007-12-31,"Ludwig, Christine; Wagner, Ralf",Current Opinion in Biotechnology,,,,document_parses/pdf_json/b8b64e2414454c457d0bab4bbc925e79735beb81.json,document_parses/pmc_json/PMC7126091.xml.json,https://api.elsevier.com/content/article/pii/S0958166907001462; https://www.sciencedirect.com/science/article/pii/S0958166907001462,43861203.0,3
96165,96165,122677,y4zoyqua,0e2c97d34c8c6042f26cc11e83e1a2fbac521203,Medline; PMC,A Mouse Model for Betacoronavirus Subgroup 2c Using a Bat Coronavirus Strain HKU5 Variant,10.1128/mbio.00047-14,PMC3977350,24667706.0,cc-by-nc-sa,crossspecies transmission zoonotic coronaviruses covs result pandemic disease outbreak middle east respiratory syndrome cov merscov identified caused case date mortality small animal model reported merscov pipistrellus bat coronavirus btcov strain hku betacoronavirus βcov subgroup c share identity amino acid level several region including nonstructural protein nsp nucleocapsid n protein significant drug vaccine target btcov hku described silico shown replicate culture thus hampering drug vaccine study subgroup c βcovs report synthetic reconstruction testing btcov hku containing severe acute respiratory syndrome sarscov spike glycoprotein ectodomain btcov hkuse virus replicates efficiently cell culture young aged mouse virus target airway alveolar epithelial cell unlike subgroup b sarscov vaccine elicit strong eosinophilia following challenge demonstrate btcov hku merscov nexpressing venezuelan equine encephalitis virus replicon particle vrp vaccine cause extensive eosinophilia following btcov hkuse challenge passage btcov hkuse young mouse resulted enhanced virulence causing weight loss diffuse alveolar damage hyaline membrane formation aged mouse passaged virus characterized mutation nsp nsp open reading frame orf gene finally identified inhibitor active nsp protease subgroup c βcovs syntheticgenome platform capable reconstituting emerging zoonotic viral pathogen phylogenetic relative provide new strategy identifying broadbased therapeutic evaluating vaccine outcome studying viral pathogenesis,2014-03-25,"Agnihothram, Sudhakar; Yount, Boyd L.; Donaldson, Eric F.; Huynh, Jeremy; Menachery, Vineet D.; Gralinski, Lisa E.; Graham, Rachel L.; Becker, Michelle M.; Tomar, Sakshi; Scobey, Trevor D.; Osswald, Heather L.; Whitmore, Alan; Gopal, Robin; Ghosh, Arun K.; Mesecar, Andrew; Zambon, Maria; Heise, Mark; Denison, Mark R.; Baric, Ralph S.",mBio,,,,document_parses/pdf_json/0e2c97d34c8c6042f26cc11e83e1a2fbac521203.json,document_parses/pmc_json/PMC3977350.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/24667706/; https://doi.org/10.1128/mbio.00047-14,37634964.0,3
96244,96244,122773,b8sbvy0g,5b1ff90bfb94f984a838fe6f3a806cdedc3aa182,Medline; PMC,Role of Metallic Nanoparticles in Vaccinology: Implications for Infectious Disease Vaccine Development,10.3389/fimmu.2017.00239,PMC5340775,28337198.0,cc-by,subunit vaccine safer le immunogenic liveattenuated vaccine whole cell inactivated vaccine adjuvant used enhance modulate antigen ag immunogenicity aiming induce protective longlasting immune response several molecule formulation studied adjuvanticity seven approved formulate human vaccine metallic nanoparticles menps particularly containing gold iron oxide widely used medicine diagnosis therapy used carrier drug vaccine however little known immune response elicited menps importance development new vaccine evidence particle display adjuvant characteristic promoting cell recruitment antigenpresenting cell activation cytokine production inducing humoral immune response review focus characteristic menps could facilitate induction cellular immune response particularly thelper thelper potential function adjuvant subunit vaccine,2017-03-08,"Marques Neto, Lázaro Moreira; Kipnis, André; Junqueira-Kipnis, Ana Paula",Front Immunol,,,,document_parses/pdf_json/5b1ff90bfb94f984a838fe6f3a806cdedc3aa182.json,document_parses/pmc_json/PMC5340775.xml.json,https://doi.org/10.3389/fimmu.2017.00239; https://www.ncbi.nlm.nih.gov/pubmed/28337198/,6287057.0,3
96324,96324,122872,ofuwlu1z,0428e40ab214b4133e308633148ef1e469519d3f,Elsevier; PMC,Transmissible Gastroenteritis Virus of Pigs and Porcine Epidemic Diarrhea Virus,10.1016/b978-0-12-809633-8.20928-x,PMC7157468,,no-cc,tgev pedv porcine coronaviruses typical coronavirus virion structure replication cycle virus cause diarrhea pig similar clinical symptom disease severity inversely related age animal tgev infection currently control recent emergence virulent pedv strain result significant mortality effective treatment available animal infected detection viral antigen andor genomic rna required diagnosis prevention measure include enhanced biosecurity vaccination latter effective approach commercial vaccine virus available numerous experimental vaccine development,2019-07-05,"Liu, Qiang; Gerdts, Volker",Reference Module in Life Sciences,,,,document_parses/pdf_json/0428e40ab214b4133e308633148ef1e469519d3f.json,document_parses/pmc_json/PMC7157468.xml.json,https://api.elsevier.com/content/article/pii/B978012809633820928X; https://www.sciencedirect.com/science/article/pii/B978012809633820928X,198296067.0,3
96394,96394,122956,l7dehit8,d9ec2aeafe955826d48c46a28523e4f9ebf89fc4,Elsevier; PMC,Chapter 7 Nanoparticle-based vaccines opportunities and limitations,10.1016/b978-0-12-817778-5.00007-5,PMC7153331,,els-covid,infectious disease tip iceberg economic burden developing country due resistance pathogen antibiotic lack vaccine vaccine become big challenge last decade attention focused scientific challenge new vaccine development adjuvant delivery system classical vaccine developed liveattenuated killed organism influenza smallpox bcg well subunit hepatitis b attenuated vaccine carry risk regaining pathogenicity immunosuppression condition development subunit vaccine without risk considered essential need combination adequate delivery system obtain desired cell humoral immune response infectious disease last decade use nanoparticles delivery system vaccine received special attention improve vaccine efficacy nanoparticles could composed lipid metal nonmetal inorganics several polymer viruslike particle tested research already approved human animal use characteristic nanoparticles allowed targeting desired antigenpresenting cell improve immunization strategy induce protection main characteristic nanoparticles protect antigen early proteolytic degradation control antigen release help antigen uptake processing antigenpresenting cell safe human veterinary use addition nanoparticles could modified physicochemical property target specific cell improve vaccine efficacy chapter focus nanoparticlebased vaccine formulation approach used realize efficient delivery vaccine order induce host protective immunity infectious disease,2020-12-31,"Diaz-Arévalo, Diana; Zeng, Mingtao",Nanopharmaceuticals,,,,document_parses/pdf_json/d9ec2aeafe955826d48c46a28523e4f9ebf89fc4.json,document_parses/pmc_json/PMC7153331.xml.json,https://www.sciencedirect.com/science/article/pii/B9780128177785000075; https://api.elsevier.com/content/article/pii/B9780128177785000075,213825401.0,3
96418,96418,122984,f2htekhz,27053e838296b253c42a6b343940a6aec83a7ebb,Medline; PMC,Immunogenicity of eGFP-Marked Recombinant Lactobacillus casei against Transmissible Gastroenteritis Virus and Porcine Epidemic Diarrhea Virus,10.3390/v9100274,PMC5691626,28946696.0,cc-by,porcine transmissible gastroenteritis virus tgev porcine epidemic diarrhea virus pedv causative agent highly fatal acute diarrhea pig resulting enormous loss pig industry worldwide develop effective bivalent oral vaccine tgev pedv infection antigenic site tgev spike protein major antigen site core neutralizing epitope—coe pedv protein used immunogen enhanced green fluorescent protein egfp gene used reporter construct genetically engineered lactobacillus casei rlppgftgegfpdcoe expression protein interest recombinant l casei confirmed confocal laser scanning microscopy western blot assay immunogenicity rlppgftgegfpdcoe orally immunized mouse evaluated result showed level antipedv antitgev serum immunoglobulin g igg mucosal secreted immunoglobulin siga antibody obtained mouse immunized rlppgftgegfpdcoe well proliferation level lymphocyte significantly higher mouse orally administered phosphatebuffered saline pb rlppgtg moreover serum igg antibody showed neutralizing effect pedv tgev data suggest antibiotic resistancefree genetically engineered l casei bivalent oral vaccine provides safe promising strategy vaccine development pedv tgev,2017-09-25,"Yu, Meiling; Wang, Li; Ma, Sunting; Wang, Xiaona; Wang, Yusai; Xiao, Ya; Jiang, Yanping; Qiao, Xinyuan; Tang, Lijie; Xu, Yigang; Li, Yijing",Viruses,,,,document_parses/pdf_json/27053e838296b253c42a6b343940a6aec83a7ebb.json,document_parses/pmc_json/PMC5691626.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28946696/; https://doi.org/10.3390/v9100274,9735996.0,3
96429,96429,122996,qbi5998f,82468c289eb562a3e63d084238c08f62e617eb64,BioRxiv; MedRxiv,In silico Design of novel Multi-epitope recombinant Vaccine based on Coronavirus surface glycoprotein,10.1101/2020.03.10.985499,,,medrxiv,special significance find safe effective vaccine coronavirus disease covid induce cell b cell mediated immune response currently vaccine prevent covid project novel multiepitope vaccine covid virus based surface glycoprotein designed application bioinformatics method first seventeen potent linear bcell tcell binding epitope surface glycoprotein predicted silico epitope joined together via different linkers ability selected epitope induce interferongamma evaluate using ifnepitope web server one final vaccine constructed composed amino acid attached ribosomal protein adjuvant physicochemical property well antigenicity proposed vaccine checked defining vaccine stability ability induce cellmediated immune response threedimensional structure mentioned vaccine subjected molecular docking study mhci mhcii molecule result proposed multiepitope vaccine ribosomal protein stable construct high aliphatic content high antigenicity,2020-03-10,"Behbahani, Mandana",bioRxiv,,,,document_parses/pdf_json/82468c289eb562a3e63d084238c08f62e617eb64.json,,https://doi.org/10.1101/2020.03.10.985499,214723395.0,3
96446,96446,123015,uq0fsqh3,3c57198864b72b283d2d00c1b4b28d3cc336e9e9,Elsevier; Medline; PMC,Intranasal delivery of whole cell lysate of Mycobacterium tuberculosis induces protective immune responses to a modified live porcine reproductive and respiratory syndrome virus vaccine in pigs,10.1016/j.vaccine.2011.03.005,PMC7126640,21419164.0,els-covid,porcine reproductive respiratory syndrome prrs economically important disease pork producer worldwide commercially live killed prrsv vaccine available control prrs always successful based result mucosal immunization study viral model good mucosal vaccine may effective way elicit protective immunity control prrs outbreak present study mucosal adjuvanticity mycobacterium tuberculosis whole cell lysate mtb wcl evaluated pig administered modified live prrs virus vaccine prrsmlv intranasally mtb wcl mediated increase frequency nk cell cdand cd cell γδ cell pig lung detected importantly increased early generation prrsv specific neutralizing antibody detected prrsmlv mtb wcl compared pig inoculated vaccine alone addition increased secretion th cytokine ifnγ il correlated reciprocal reduction production immunosuppressive cytokine il tgfβ well tregulatory cell pig vaccinated prrsmlv mtb wcl complete rescue arginase level lung mediated mtb wcl observed pig inoculated prrsmlv conclusion mtb wcl may potent mucosal adjuvant prrsmlv order potentiate antiprrsv specific immune response control prrs effectively,2011-05-23,"Dwivedi, Varun; Manickam, Cordelia; Patterson, Ruthi; Dodson, Katie; Weeman, Matthew; Renukaradhya, Gourapura J.",Vaccine,,,,document_parses/pdf_json/3c57198864b72b283d2d00c1b4b28d3cc336e9e9.json,document_parses/pmc_json/PMC7126640.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X11003574; https://api.elsevier.com/content/article/pii/S0264410X11003574; https://www.ncbi.nlm.nih.gov/pubmed/21419164/; https://doi.org/10.1016/j.vaccine.2011.03.005,5535967.0,3
96473,96473,123045,1fw0xiin,8a05548f8c34051d47f568ce2135978de0f9515d,Medline; PMC,A multiplex reverse transcription-nested polymerase chain reaction for detection and differentiation of wild-type and vaccine strains of canine distemper virus,10.1186/1743-422x-7-86,PMC2880969,20433759.0,cc-by,multiplex reverse transcriptionnested polymerase chain reaction rtnpcr method developed detection differentiation wildtype vaccine strain canine distemper virus cdv pair primer p p specific cdv corresponding highly conserved region cdv genome used common primer pair firstround pcr nested pcr primer p specific cdv wildtype strain used forward primer together common reverse primer p second round nested pcr primer p p specific cdv wildtype strain vaccine strain used forward primer together common reverse primer pp second round nested pcr fragment bp amplified vaccine strain genomic rna fragment bp wildtype strain genomic rna rtnpcr two fragment bp bp amplified mixed sample vaccine wildtype strain amplification achieved uninfected cell cell infected newcastle disease virus ndv canine parvovirus cpv canine coronavirus ccv rabies virus rv canine adenovirus cav rtnpcr method used detect field sample suspected canine distemper heilongjiang jilin province sample shandong province result sample found wildtypelike vaccinestrainlike rtnpcr method used effectively detect differentiate wildtype cdvinfected dog dog vaccinated cdv vaccine thus used clinical detection epidemiological surveillance,2010-05-01,"Si, Wei; Zhou, Shun; Wang, Zhao; Cui, Shang-jin",Virol J,,,,document_parses/pdf_json/8a05548f8c34051d47f568ce2135978de0f9515d.json,document_parses/pmc_json/PMC2880969.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/20433759/; https://doi.org/10.1186/1743-422x-7-86,2490914.0,3
96530,96530,123118,ksodnkic,4bcdac71c12d45032dfb8c6753e7d94643a11283,Medline; PMC,A Novel Bacterium-Like Particle-Based Vaccine Displaying the SUDV Glycoprotein Induces Potent Humoral and Cellular Immune Responses in Mice,10.3390/v11121149,PMC6950126,31835785.0,cc-by,sudan virus sudv cause severe lethal hemorrhagic fever human nonhuman primate effective economical way protect sudan ebolavirus disease prophylactic vaccination however licensed vaccine prevent sudv infection study bacteriumlike particle blpbased vaccine displaying extracellular domain sudv glycoprotein egp developed based grampositive enhancer matrixprotein anchor gempa surface display system expression recombinant gemdisplayed egp egppagem verified western blotting immunofluorescence assay sudv blps sblps mixed montanide isa vg plus poly ic combined adjuvant could induce high sudv gpspecific igg titer robust virusneutralizing antibody titer reached sblp also elicited thelper th thelper th cellmediated immunity data indicate sblp subunit vaccine potential developed promising candidate vaccine sudv infection,2019-12-11,"Xu, Shengnan; Jiao, Cuicui; Jin, Hongli; Li, Wujian; Li, Entao; Cao, Zengguo; Shi, Zhikang; Yan, Feihu; Zhang, Shengnan; He, Hongbin; Chi, Hang; Feng, Na; Zhao, Yongkun; Gao, Yuwei; Yang, Songtao; Wang, Jianzhong; Wang, Hualei; Xia, Xianzhu",Viruses,,,,document_parses/pdf_json/4bcdac71c12d45032dfb8c6753e7d94643a11283.json,document_parses/pmc_json/PMC6950126.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31835785/; https://doi.org/10.3390/v11121149,209358575.0,3
96573,96573,123168,b76rvhia,bf87996bb6c0dbed5de9512ac2bab800417a8956,Medline; PMC,Identification of highly conserved regions in L-segment of Crimean–Congo hemorrhagic fever virus and immunoinformatic prediction about potential novel vaccine,10.2147/aabc.s75250,PMC4293217,25609983.0,cc-by-nc,crimean–congo hemorrhagic fever cchf tickborne zoonotic viral disease disease fatality rate despite wide range distribution virus cchfv basically endemic africa asia eastern europe middle east acute febrile illness associated petechia disseminated intravascular coagulation multipleorgan failure main symptom disease fatal effect cchfv considered huge threat successful therapeutic approach currently available treatment disease present study used immunoinformatics approach design potential epitopebased vaccine rnadependent rna polymerasel cchfv tcell bcell epitope assessed epitope “ dcsstppdr ” found potential one conservancy among strain cchfv epitope also found interact type ii major histocompatibility complex molecule considered nonallergenic well vivo study proposed peptide advised novel universal vaccine production might effective path prevent cchf disease,2015-01-08,"Oany, Arafat Rahman; Ahmad, Shah Adil Ishtiyaq; Hossain, Mohammad Uzzal; Jyoti, Tahmina Pervin",Adv Appl Bioinform Chem,,,,document_parses/pdf_json/bf87996bb6c0dbed5de9512ac2bab800417a8956.json,document_parses/pmc_json/PMC4293217.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25609983/; https://doi.org/10.2147/aabc.s75250,17277533.0,3
96610,96610,123213,zk5gx5r5,434bd9335384207d750282844ad8ceb545e50462,Medline; PMC,Performance of LBSap Vaccine after Intradermal Challenge with L. infantum and Saliva of Lu. longipalpis: Immunogenicity and Parasitological Evaluation,10.1371/journal.pone.0049780,PMC3506642,23189161.0,cc-by,last decade search new vaccine canine visceral leishmaniasis intensified however pattern related immune protection long period experimental infection vaccine trial still fully understood herein investigated immunogenicity parasitological level intradermal challenge leishmania infantum plus salivary gland extract dog immunized vaccine composed l braziliensis antigen plus saponin adjuvant lbsap vaccine lbsap vaccine elicited higher level total antileishmania igg well igg igg furthermore dog vaccinated increased level lymphocyte particularly circulating b cell cd cd cd lymphocyte lbsap also elicited intense vitro cell proliferation associated higher level cd lymphocyte specific vaccine soluble antigen soluble lysate l infantum antigen even day experimental challenge furthermore lbsap vaccinated dog presented high ifnγ low il tgfβ expression spleen significant reduction parasite load tissue overall result validate potential lbsap vaccine protect l infantum experimental infection strongly support evaluation efficiency lbsap cvl natural infection condition,2012-11-26,"Roatt, Bruno Mendes; Aguiar-Soares, Rodrigo Dian de Oliveira; Vitoriano-Souza, Juliana; Coura-Vital, Wendel; Braga, Samuel Leôncio; Corrêa-Oliveira, Rodrigo; Martins-Filho, Olindo Assis; Teixeira-Carvalho, Andréa; de Lana, Marta; Gontijo, Nelder Figueiredo; Marques, Marcos José; Giunchetti, Rodolfo Cordeiro; Reis, Alexandre Barbosa",PLoS One,,,,document_parses/pdf_json/434bd9335384207d750282844ad8ceb545e50462.json,document_parses/pmc_json/PMC3506642.xml.json,https://doi.org/10.1371/journal.pone.0049780; https://www.ncbi.nlm.nih.gov/pubmed/23189161/,2806620.0,3
96622,96622,123226,isypu1ga,e142106dccc14c30910e705e1159d340c6a97832,Medline; PMC,Development of a Broadly Accessible Venezuelan Equine Encephalitis Virus Replicon Particle Vaccine Platform,10.1128/jvi.00027-18,PMC5952155,29540599.0,cc-by,zoonotic virus circulate swarm animal reservoir emerge human population causing epidemic adversely affect public health portable safe effective vaccine platform needed context outbreak emergence situation work report generation characterization alphavirus replicon vaccine platform based nonselect agent attenuated venezuelan equine encephalitis vee virus vaccine strain vrp using noroviruses coronaviruses model system demonstrate utility vrp platform generation recombinant protein production viruslike particle vivo efficacy vaccine emergent virus importantly packaging biosafety level bsl condition distinguishes vrp previously reported alphavirus platform make approach accessible majority laboratory around world addition improved outcome vulnerable aged model well heterologous challenge suggest improved efficacy compared previously attenuated vrp approach taking result together vrp platform represents safe highly portable system rapidly deployed bsl condition generation candidate vaccine emerging microbial pathogen importance vee virus replicon particle provide robust established platform antigen expression vaccination utility limited requirement highcontainmentlevel facility production packaging work utilize attenuated vaccine strain capable use lower biocontainment level retaining capacity wildtype replicon particle importantly new replicon platform provides equal protection aged mouse following heterologous challenge distinguishes attenuated replicon platform together new system represents highly portable safe system use context disease emergence,2018-05-14,"Agnihothram, Sudhakar; Menachery, Vineet D.; Yount, Boyd L.; Lindesmith, Lisa C.; Scobey, Trevor; Whitmore, Alan; Schäfer, Alexandra; Heise, Mark T.; Baric, Ralph S.",J Virol,,,,document_parses/pdf_json/e142106dccc14c30910e705e1159d340c6a97832.json,document_parses/pmc_json/PMC5952155.xml.json,https://doi.org/10.1128/jvi.00027-18; https://www.ncbi.nlm.nih.gov/pubmed/29540599/,3912686.0,3
96642,96642,123249,wupictvw,d1b24d21f2004ee1ed983d5fd7526ff2809443e6,Medline; PMC,Plant-made vaccines and reagents for the One Health initiative,10.1080/21645515.2017.1356497,PMC5718809,28846485.0,cc-by-nc-nd,one health initiative increasingly becoming prominent discussion topic animal human health focus prevention spread zoonotic disease animal animal human important part one health diagnostics vaccine disease may thing – used human animal one potential problem standing way wider adoption one health principle though use conventional cell fermentation system production recombinant protein could used diagnostics vaccine often expensive easily scalable solution may use plant plant cell bioreactors molecular farming production biologics plant wellestablished science many proof principle important proof efficacy especially animal vaccine review discus molecular farming could enable important advance one health using example plantmade vacccines reagent therapeutic influenza virus ebolaviruses rabies virus bunyavirus flavivirus,2017-08-28,"Rybicki, Edward Peter",Hum Vaccin Immunother,,,,document_parses/pdf_json/d1b24d21f2004ee1ed983d5fd7526ff2809443e6.json,document_parses/pmc_json/PMC5718809.xml.json,https://doi.org/10.1080/21645515.2017.1356497; https://www.ncbi.nlm.nih.gov/pubmed/28846485/,6224862.0,3
96675,96675,123293,tonv7igl,f3f20010d78db20f4af58bb56cf7ab833bccbbf0,Elsevier; Medline; PMC,Efficacy of an inactivated genotype 2b porcine epidemic diarrhea virus vaccine in neonatal piglets,10.1016/j.vetimm.2016.04.009,PMC7126956,27185262.0,els-covid,massive outbreak porcine epidemic diarrhea virus pedv recurred south korea – affected approximately swine breeding herd across country incurring tremendous financial impact producer consumer despite nationwide use commercially available attenuated inactivated vaccine south korea pedv continued plague domestic pork industry raising concern regarding protective efficacy need new vaccine development previous study isolated serially cultivated korean pedv epidemic strain korknu vero cell availability cell culturepropagated pedv strain able explore vaccination challenge study pig therefore aim present study produce inactivated pedv vaccine using knu strain evaluate effectiveness neonatal piglet pregnant sow immunized intramuscularly inactivated adjuvanted monovalent vaccine six three week prior farrowing sixdayold piglet born vaccinated unvaccinated sow challenged homogeneous knu virus administration inactivated vaccine sow greatly increased survival rate piglet challenged virulent strain approximately significantly reduced diarrhea severity including viral shedding feces addition litter unvaccinated sow continued lose body weight throughout experiment whereas litter vaccinated sow started recovering daily weight gain day challenge furthermore strong neutralizing antibody response pedv verified immunized sow offspring absent unvaccinated control altogether data demonstrated durable lactogenic immunity present dam administrated inactivated vaccine subsequently conferred critical passive immune protection litter virulent pedv infection,2016-06-30,"Baek, Pil-Soo; Choi, Hwan-Won; Lee, Sunhee; Yoon, In-Joong; Lee, Young Ju; Lee, Du Sik; Lee, Seungyoon; Lee, Changhee",Veterinary Immunology and Immunopathology,,,,document_parses/pdf_json/f3f20010d78db20f4af58bb56cf7ab833bccbbf0.json,document_parses/pmc_json/PMC7126956.xml.json,https://www.sciencedirect.com/science/article/pii/S0165242716300666; https://api.elsevier.com/content/article/pii/S0165242716300666; https://doi.org/10.1016/j.vetimm.2016.04.009; https://www.ncbi.nlm.nih.gov/pubmed/27185262/,25125679.0,3
96711,96711,123337,5ns1onkw,b53f59da972bf628bd13f1a5d376dcdddabe0bf8,Elsevier; PMC,Chapter 11 Manufacturing Vaccines for an Emerging Viral Infection–Specific Issues Associated with the Development of a Prototype SARS Vaccine,10.1016/b978-0-12-369408-9.00011-1,PMC7149597,,els-covid,world struck surprise severe acute respiratory syndrome sars epidemic started china disease never observed man sarscoronavirus causing disease unknown uncertainty future impact epidemic important international collaboration started spontaneously sharing scientific knowledge reagent resource became quickly available public private effort undertaken develop rapidly vaccine discus importance international collaboration availability funding moreover review important challenging step industrial development sars vaccine highlighting difficulty term safety working highly pathogenic unknown virus emphasize industrial perspective inactivation decontamination experiment selection promising vaccine candidate production process choice use animal model pressing difficult situation finally briefly review unique regulatory environment created period development sars vaccine,2009-12-31,"Kusters, Inca C.; Matthews, James; Saluzzo, Jean François",Vaccines for Biodefense and Emerging and Neglected Diseases,,,,document_parses/pdf_json/b53f59da972bf628bd13f1a5d376dcdddabe0bf8.json,document_parses/pmc_json/PMC7149597.xml.json,https://api.elsevier.com/content/article/pii/B9780123694089000111; https://www.sciencedirect.com/science/article/pii/B9780123694089000111,68113456.0,3
96768,96768,123400,onrkawju,7e232c192b439ef6a844be6a2f40bbbae64469fb,Medline; PMC,Targeted antigen delivery to dendritic cells elicits robust antiviral T cell-mediated immunity in the liver,10.1038/srep43985,PMC5339819,28266658.0,cc-by,hepatotropic virus hepatitis c virus cause lifethreatening chronic liver infection million people worldwide targeted vivo antigendelivery crosspresenting dendritic cell dc proven extraordinarily efficient stimulating antigenspecific cell response determine whether approach would well suitable induce local antiviral effector cell liver compared different vaccine formulation based either targeting dec tlr crosspresenting dc formulation involving vivo dc targeting readout used vivo hepatotropic adenovirus challenge histology automated multidimensional fluorescence microscopy melc show targeted vivo antigen delivery crosspresenting dc highly effective inducing antiviral ctls capable eliminating virusinfected hepatocytes control vaccine formulation involving dc targeting failed induce immunity hepatotropic virus moreover observed distinct pattern cd cell interaction virusinfected apoptotic hepatocytes two dctargeting group suggesting different vaccine formulation may stimulate distinct type effector function finding represent important step toward future development vaccine hepatotropic virus treatment patient hepatic virus infection liver transplantation avoid reinfection,2017-03-07,"Volckmar, Julia; Gereke, Marcus; Ebensen, Thomas; Riese, Peggy; Philipsen, Lars; Lienenklaus, Stefan; Wohlleber, Dirk; Klopfleisch, Robert; Stegemann-Koniszewski, Sabine; Müller, Andreas J.; Gruber, Achim D.; Knolle, Percy; Guzman, Carlos A.; Bruder, Dunja",Sci Rep,,,,document_parses/pdf_json/7e232c192b439ef6a844be6a2f40bbbae64469fb.json,document_parses/pmc_json/PMC5339819.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28266658/; https://doi.org/10.1038/srep43985,16360885.0,3
96805,96805,123442,qfe780yj,dadb8cce14cbf09b6fbaf927b0b2524899ac028d,Medline; PMC,"Evaluation of a recombination-resistant coronavirus as a broadly applicable, rapidly implementable vaccine platform",10.1038/s42003-018-0175-7,PMC6206136,30393776.0,cc-by,emerging reemerging zoonotic viral disease major threat global health economic stability national security vaccine key reducing coronaviral disease burden however utility liveattenuated vaccine limited risk reversion repair history emergence event due prevalence zoonotic pool designing liveattenuated coronavirus vaccine rapidly broadly implemented essential outbreak preparedness show coronaviruses completely rewired transcription regulatory network trns effective vaccine sarscov trnrewired virus attenuated protect lethal sarscov challenge nt rewired trn reverts via secondsite mutation upon serial passage nt rewired trn stable suggesting extensively rewired trn might essential avoiding growth selection summary rewiring trn feasible strategy limiting reversion effective liveattenuated coronavirus vaccine candidate potentially portable across nidovirales order,2018-10-29,"Graham, Rachel L.; Deming, Damon J.; Deming, Meagan E.; Yount, Boyd L.; Baric, Ralph S.",Commun Biol,,,,document_parses/pdf_json/dadb8cce14cbf09b6fbaf927b0b2524899ac028d.json,document_parses/pmc_json/PMC6206136.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30393776/; https://doi.org/10.1038/s42003-018-0175-7,53095804.0,3
96836,96836,123479,asyebua7,e7d039694b47f3d8c4fead5832f54ac59d3c8b91,Elsevier; Medline; PMC,DNA vaccination of poultry: The current status in 2015,10.1016/j.vaccine.2015.11.043,PMC7115526,26620840.0,els-covid,dna vaccination promising alternative strategy developing new human animal vaccine massive effort made past year increase immunizing potential kind vaccine still ongoing relatively small number study concerning poultry published even though need new poultry vaccine five parameter must nevertheless taken account development vaccine effective safe inexpensive suitable mass vaccination able induce immune response presence maternal antibody appropriate dna vaccination meet requirement review describes study field performed exclusively bird chicken duck turkey evaluation avian dna vaccine efficacy performed mouse preliminary test taken consideration review first describes state art dna vaccination poultry pathogen targeted plasmid used different route vaccine administration second present strategy designed improve dna vaccine efficacy influence route administration plasmid dose age bird first inoculation increasing plasmid uptake host cell addition immunomodulators optimization plasmid backbone codon usage association vaccine antigen finally heterologous primeboost regimen final part indicate additional property dna vaccine poultry fate plasmid upon inoculation immunological consideration use dna vaccine purpose preventing infectious disease,2016-01-04,"Meunier, Marine; Chemaly, Marianne; Dory, Daniel",Vaccine,,,,document_parses/pdf_json/e7d039694b47f3d8c4fead5832f54ac59d3c8b91.json,document_parses/pmc_json/PMC7115526.xml.json,https://doi.org/10.1016/j.vaccine.2015.11.043; https://api.elsevier.com/content/article/pii/S0264410X15016850; https://www.sciencedirect.com/science/article/pii/S0264410X15016850; https://www.ncbi.nlm.nih.gov/pubmed/26620840/,24260115.0,3
96856,96856,123503,h2873psw,0bc69cf4c0bb5adcc8ec0797489ca9daf3dcfc69,Elsevier; Medline; PMC,"Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology",10.1016/j.nbt.2011.03.018,PMC7185793,21473942.0,no-cc,antibody preparation long history providing protection infectious disease although antibody remain natural hostderived defense mechanism capable completely preventing infection product compete inexpensive therapeutic antibiotic small molecule inhibitor active vaccine continued discovery monoclonal antibody mab field lead broadened cross neutralization virus demonstrable synergy antibody antibiotic bacterial disease clearly show innovation remains commercial success mabs chronic disease paralleled infectious disease several reason infectious disease immunotherapeutics limited scope endemic disease necessitate active vaccine development also complexity small market draw interest niche company rather big pharmaceutical corporation lastly cost good mab therapeutic inherently high infectious agent due need antibody cocktail better mimic polyclonal immunoglobulin preparation prevent antigenic escape case vaccine convalescent population available current polyclonal hyperimmune immunoglobulin preparation pigg modern highly efficient purification technology standardized assay potency make economic sense recent innovation broaden potency mab therapy reducing cost production discussed herein basis century effective use ab treatment growing immunocompromised population question whether antibody bright future infectious agent rather format cost effective generate safe efficacious treatment satisfy regulatory approval,2011-04-05,"Berry, Jody D.; Gaudet, Ryan G.",N Biotechnol,,,,document_parses/pdf_json/0bc69cf4c0bb5adcc8ec0797489ca9daf3dcfc69.json,document_parses/pmc_json/PMC7185793.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/21473942/; https://doi.org/10.1016/j.nbt.2011.03.018; https://api.elsevier.com/content/article/pii/S187167841100080X; https://www.sciencedirect.com/science/article/pii/S187167841100080X,23588449.0,3
96864,96864,123511,uacon432,67f31e25f97a78316c0d46de56275b53749d46eb,Elsevier; Medline; PMC,Recombinant measles viruses expressing single or multiple antigens of human immunodeficiency virus (HIV-1) induce cellular and humoral immune responses,10.1016/j.vaccine.2009.01.057,PMC7115622,19200842.0,els-covid,recombinant measles virus rmv based live attenuated measles vaccine strain mvb expressing antigen hiv clade b generated reverse genetics recombinant expressing single double antigen hiv rmvhiv genetically highly stable human diploid cell production process virus essentially similar parental mv strain yielding comparative end titer immunization tgmice different regimen formulation showed potent humoral cellular immune response mv hiv antigen recombinant mvhiv expressing gag protein conferred protective immunity tgmice highdose pseudochallenge recombinant vaccinia virus addition rmvhiv boosted antihiv antibody presence preexisting antivector antibody,2009-05-26,"Liniger, Matthias; Zuniga, Armando; Morin, Teldja Neige Azzouz; Combardiere, Behazine; Marty, Rene; Wiegand, Marian; Ilter, Orhan; Knuchel, Marlyse; Naim, Hussein Y.",Vaccine,,,,document_parses/pdf_json/67f31e25f97a78316c0d46de56275b53749d46eb.json,document_parses/pmc_json/PMC7115622.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19200842/; https://www.sciencedirect.com/science/article/pii/S0264410X09000930; https://doi.org/10.1016/j.vaccine.2009.01.057; https://api.elsevier.com/content/article/pii/S0264410X09000930,6340622.0,3
96904,96904,123565,ivmpbuwf,f19e158ac5ef5fd172df2e9f10bede9f76c31e2d,Elsevier; Medline; PMC,A chimeric multi-epitope DNA vaccine elicited specific antibody response against severe acute respiratory syndrome-associated coronavirus which attenuated the virulence of SARS-CoV in vitro,10.1016/j.imlet.2008.04.005,PMC7112888,18533276.0,els-covid,epitopebased vaccine designed induce antibody response specific severe acute respiratory syndromeassociated coronavirus sarscov developed mean increasing vaccine potency study identified four b cell epitope spike membrane protein bioinformatics analysis constructed multiepitope dna vaccine intramuscular immunization mouse vaccine sufficient induce specific prime well longterm memory humoral immune response least two candidate epitope s– m– dna prime–protein boost strategy greatly enhanced antibody generation immune serum reacted lysates sarscovinfected vero cell also neutralized cytopathic effect sars dilution novel immunogenic protein peptide revealed study provides new target sars vaccine design work indicated multiepitope dna vaccine effective mean eliciting polyvalent humoral immune response sarscov,2008-08-15,"Wang, Xiaohua; Xu, Wei; Tong, Deyan; Ni, Jing; Gao, Haifeng; Wang, Ying; Chu, Yiwei; Li, Pingping; Yang, Xiaoming; Xiong, Sidong",Immunology Letters,,,,document_parses/pdf_json/f19e158ac5ef5fd172df2e9f10bede9f76c31e2d.json,document_parses/pmc_json/PMC7112888.xml.json,https://doi.org/10.1016/j.imlet.2008.04.005; https://api.elsevier.com/content/article/pii/S0165247808001193; https://www.sciencedirect.com/science/article/pii/S0165247808001193; https://www.ncbi.nlm.nih.gov/pubmed/18533276/,29138439.0,3
96905,96905,123566,9u2tl1d5,1304ff9ef1cbd2e97a0ee662cebc837da9eb25ca,Elsevier; PMC,Vaccination of mice with recombinant baculovirus expressing spike or nucleocapsid protein of SARS-like coronavirus generates humoral and cellular immune responses,10.1016/j.molimm.2007.08.010,PMC7112626,17905435.0,els-covid,continuous effort made develop prophylactic vaccine severe acute respiratory syndrome coronavirus sarscov study two recombinant baculoviruses vacn vac constructed contained mammaliancell activate promoter element human elongation factor αsubunit efα human cytomegalovirus cmv immediateearly promoter nucleocapsid n spike gene bat sarslike cov slcov control cmv promoter mouse subcutaneously intraperitoneally injected recombinant baculovirus humoral cellular immune response induced vaccinated group secretion level ifnγ much higher il vacn vac immunized group suggesting strong th bias towards cellular immune response additionally marked increase cd cell immune response high level antisarscov humoral response also detected vacn vac immunized group contrast significantly weaker cellular immune response well le antibody production control group data demonstrates recombinant baculovirus serve effective vaccine strategy addition effective sars vaccine act prevent reemergence sarscov also provide crossprotection slcov finding study may implication developing crossprotective vaccine,2008-02-29,"Bai, Bingke; Lu, Xinya; Meng, Jin; Hu, Qinxue; Mao, Panyong; Lu, Baojing; Chen, Ze; Yuan, Zhiming; Wang, Hanzhong",Molecular Immunology,,,,document_parses/pdf_json/1304ff9ef1cbd2e97a0ee662cebc837da9eb25ca.json,document_parses/pmc_json/PMC7112626.xml.json,https://www.sciencedirect.com/science/article/pii/S0161589007007092; https://api.elsevier.com/content/article/pii/S0161589007007092,28722465.0,3
96981,96981,123655,tkzwzc57,e357e76cc29e483c1072cd5a3903f7f078fc9d27; 67877e0fb9482a90d40cb2ba43f40eef404385e4; 674900254c006df00e62e92892b6a9dc2c1318cb,Elsevier; Medline; PMC,Genetic Immunization With In Vivo Dendritic Cell-targeting Liposomal DNA Vaccine Carrier Induces Long-lasting Antitumor Immune Response,10.1038/mt.2015.215,PMC4817821,26666450.0,hybrid-oa,major limiting factor retarding clinical success dendritic cell dcbased genetic immunization dna vaccination scarcity biologically safe effective carrier system targeting antigenencoded dna vaccine dc vivo setting herein report potent mannose receptor selective vivo dctargeting liposome novel cationic amphiphile mannosemimicking shikimoyl headgroup flow cytometric experiment cell isolated draining lymph node mouse sc immunized lipoplexes pgfp plasmid model dna vaccine using anticdc antibodylabeled magnetic bead revealed vivo dctargeting property presently described liposomal dna vaccine carrier importantly sc immunization mouse electrostatic complex vivo dctargeting liposome melanoma antigenencoded dna vaccine pcmvmart induced longlasting antimelanoma immune response day post melanoma tumor challenge remarkable memory response month second tumor challenge presently described direct vivo dctargeting liposomal dna vaccine carrier expected find future exploitation toward designing effective vaccine various infectious disease cancer,2016-02-01,"Garu, Arup; Moku, Gopikrishna; Gulla, Suresh Kumar; Chaudhuri, Arabinda",Molecular Therapy,,,,document_parses/pdf_json/e357e76cc29e483c1072cd5a3903f7f078fc9d27.json; document_parses/pdf_json/67877e0fb9482a90d40cb2ba43f40eef404385e4.json; document_parses/pdf_json/674900254c006df00e62e92892b6a9dc2c1318cb.json,document_parses/pmc_json/PMC4817821.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26666450/; https://doi.org/10.1038/mt.2015.215; http://www.cell.com/article/S1525001616303434/pdf; https://www.sciencedirect.com/science/article/pii/S1525001616303434; https://api.elsevier.com/content/article/pii/S1525001616303434,25783916.0,3
96988,96988,123663,v6qry3o6,c2d51fee1e73856e4c891437f8349da3eadbe363,Elsevier; Medline; PMC,Clinical study of transcutaneous vaccination using a hydrogel patch for tetanus and diphtheria,10.1016/j.vaccine.2011.12.130,PMC7126733,22230592.0,els-covid,transcutaneous immunization tci noninvasive easytouse vaccination method demonstrated efficacy safety transcutaneous vaccine formulation using hydrogel patch animal experiment present study performed clinical study apply tci formulation vaccination tetanus diphtheria human tci device hydrogel patch antigenfree applied left brachial medial skin healthy volunteer h next hydrogel patch containing mg tetanus toxoid tt mg diphtheria toxoid dt tci formulation applied healthy volunteer h volunteer vaccinated tci formulation safety assessment patch application site observed ass local adverse event systemic adverse event determined blood test antigenfree hydrogel patch tci formulation containing tt dt induce local systemic severe adverse event vaccine efficacy estimation toxoidspecific serum antibody titer determined elisa toxinneutralizing activity induced antibody evaluated passivechallenge experiment antitt igg titer antidt igg titer increased significant effect detected paired ttest antibody titer maintained higher level vaccination least year moreover toxoidspecific antibody produced second vaccination subject antibody induced application tci formulation neutralized toxin prevented toxic death mouse addition change skin condition due application tci formulation observed vivo confocal raman spectroscopy amount water patch component stratum corneum increased application tci formulation suggesting change skin condition related antigen penetration data indicate easytouse tci system induces immune response without severe adverse reaction human easytouse safe tci formulation enables mass treatment outbreak setting increased vaccination rate developing country greatly contribute worldwide countermeasure infectious disease,2012-02-27,"Hirobe, Sachiko; Matsuo, Kazuhiko; Quan, Ying-Shu; Kamiyama, Fumio; Morito, Hironori; Asada, Hideo; Takaya, Yusuke; Mukai, Yohei; Okada, Naoki; Nakagawa, Shinsaku",Vaccine,,,,document_parses/pdf_json/c2d51fee1e73856e4c891437f8349da3eadbe363.json,document_parses/pmc_json/PMC7126733.xml.json,https://api.elsevier.com/content/article/pii/S0264410X11020913; https://www.sciencedirect.com/science/article/pii/S0264410X11020913; https://www.ncbi.nlm.nih.gov/pubmed/22230592/; https://doi.org/10.1016/j.vaccine.2011.12.130,41513020.0,3
97047,97047,123740,qjowxcdl,9a1ed211481f2c4e15f48ec3f712e73901eb628a,Medline; PMC,The Key Role of Genomics in Modern Vaccine and Drug Design for Emerging Infectious Diseases,10.1371/journal.pgen.1000612,PMC2752168,19855822.0,cc-by,argued arrival “ genomics era ” significantly shifted paradigm vaccine therapeutic development microbiological sequencebased approach genome sequence provide previously unattainable route investigate mechanism underpin pathogenesis genomics transcriptomics metabolomics structural genomics proteomics immunomics exploited perfect identification target design new vaccine drug predict effect patient furthermore human genomics related study providing insight aspect host biology important infectious disease evergrowing body genomic data new genomebased approach play critical role future enable timely development vaccine therapeutic control emerging infectious disease,2009-10-26,"Seib, Kate L.; Dougan, Gordon; Rappuoli, Rino",PLoS Genet,,,,document_parses/pdf_json/9a1ed211481f2c4e15f48ec3f712e73901eb628a.json,document_parses/pmc_json/PMC2752168.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19855822/; https://doi.org/10.1371/journal.pgen.1000612,6695734.0,3
97048,97048,123741,82g5eiyg,b67151c7d7b53355ea7aeef2187d84cb96597384,Elsevier; PMC,Chapter 7 Viral Vectors,10.1016/b978-0-12-369408-9.00007-x,PMC7149693,,els-covid,traditional vaccine development platform liveattenuated virus killed virus recombinant subunitbased vaccine often effective eliciting longterm immunity number infectious human pathogen however many human pathogen vaccine platform unsuitable human use due safety concern poor efficacy simple impracticality result much work focused use recombinant virus vector mean vaccination human pathogen viral vector express foreign protein high level host cell resulting strong longlasting immune response target protein chapter describes use virus vector context vaccination human pathogen various vector platform discussed compared contrasted,2009-12-31,"Holman, David H.; Wang, Danher; Woraratanadharm, Jan; Dong, John Y.",Vaccines for Biodefense and Emerging and Neglected Diseases,,,,document_parses/pdf_json/b67151c7d7b53355ea7aeef2187d84cb96597384.json,document_parses/pmc_json/PMC7149693.xml.json,https://api.elsevier.com/content/article/pii/B978012369408900007X; https://www.sciencedirect.com/science/article/pii/B978012369408900007X,81156437.0,3
97130,97130,123838,wp6yklrx,76418514384003ef87ee3e6922525db0b8bf0bd3,Medline; PMC,Immunogenicity of Candidate MERS-CoV DNA Vaccines Based on the Spike Protein,10.1038/srep44875,PMC5362948,28332568.0,cc-by,merscoronavirus novel zoonotic pathogen spread rapidly country since apparent endemicity wide spread reservoir host dromedary camel arabian peninsula highlight ongoing public health threat virus therefore development effective prophylactic vaccine need urgently explored given approved prophylactic therapeutic human animal date different vaccine candidate investigated serious safety concern remain protein fulllength spike proteinbased vaccine investigated immunogenicity naked dna vaccine expressing different fragment merscov protein mouse found plasmid expressing fulllength p ssubunit p could induce significant level sspecific antibody ab distinct igg isotype pattern specifically p immunization elicited balanced thth response generally higher level igg isotypes compared p vaccination interestingly mouse immunized p demonstrated significant sspecific cellular immune response importantly construct induced crossneutralizing ab multiple strain human camel origin result indicate vaccine expressing ssubunit merscov protein could represent potential vaccine candidate without possible safety concern associated fulllength proteinbased vaccine,2017-03-23,"Al-amri, Sawsan S.; Abbas, Ayman T.; Siddiq, Loai A.; Alghamdi, Abrar; Sanki, Mohammad A.; Al-Muhanna, Muhanna K.; Alhabbab, Rowa Y.; Azhar, Esam I.; Li, Xuguang; Hashem, Anwar M.",Sci Rep,,,,document_parses/pdf_json/76418514384003ef87ee3e6922525db0b8bf0bd3.json,document_parses/pmc_json/PMC5362948.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28332568/; https://doi.org/10.1038/srep44875,18469445.0,3
97142,97142,123851,fm9cf5nl,9f5178ce2d794179ff80ad8f2d31af2c8a975853,Elsevier; PMC,IgE reactivity to vaccine components in dogs that developed immediate-type allergic reactions after vaccination,10.1016/j.vetimm.2004.12.003,PMC7112531,15734545.0,els-covid,allergic reaction vaccination considered important practical problem dog however immunological mechanism well understood present study designed investigate relationship ige reactivity vaccine immediatetype allergic reaction vaccination dog serum dog developed immediatetype allergic reaction circulatory collapse cyanosis dyspnea facial edema vomiting within h vaccination nonrabies monovalent combined vaccine serum dog develop allergic reaction vaccination collected serum ige reactivity injected vaccine measured fluorometric elisa using mouse monoclonal antidog ige antibody ige reactivity fetal calf serum fcs stabilizer protein gelatin casein peptone included vaccine measured serum high level ige vaccine level serum specific ige vaccine dog immediatetype allergic reaction – fluorescence unit fu mean±sd ± fu significantly higher control dog – fu ± fu p eight dog developed immediatetype allergic reaction high level serum specific ige vaccine seven specific ige directed fcs ige reactivity vaccine serum dog almost completely inhibited fcs one dog serum ige directed gelatin casein included vaccine stabilizer result obtained study suggest immediatetype allergic reaction vaccination dog induced type hypersensitivity mediated ige directed vaccine component addition fcs gelatin casein included vaccine could causative allergen induced immediatetype allergic reaction vaccination dog,2005-04-08,"Ohmori, Keitaro; Masuda, Kenichi; Maeda, Sadatoshi; Kaburagi, Yukiko; Kurata, Keigo; Ohno, Koichi; DeBoer, Douglas J.; Tsujimoto, Hajime; Sakaguchi, Masahiro",Veterinary Immunology and Immunopathology,,,,document_parses/pdf_json/9f5178ce2d794179ff80ad8f2d31af2c8a975853.json,document_parses/pmc_json/PMC7112531.xml.json,https://api.elsevier.com/content/article/pii/S0165242704003411; https://www.sciencedirect.com/science/article/pii/S0165242704003411,19082315.0,3
97256,97256,123984,zr3qmt50,cca2dfc19d915a6bdb502560e18027b70f0c4e59; 259b254062d2435598b6a4544d79634e77725c0d,Elsevier; Medline; PMC,A SARS DNA Vaccine Induces Neutralizing Antibody and Cellular Immune Responses in Healthy Adults in a Phase I Clinical Trial,10.1016/j.vaccine.2008.09.026,PMC2612543,18824060.0,green-oa,background severe acute respiratory syndrome sars virus member coronaviridae cov family first appeared guangdong province china recognized emerging infectious disease march case death occurred epidemic report safety immunogenicity sars dna vaccine phase human study method singleplasmid dna vaccine encoding spike glycoprotein evaluated healthy adult nine subject completed dose vaccination schedule evaluated vaccine safety immune response immune response assessed intracellular cytokine staining ic elispot elisa neutralization assay result vaccine welltolerated sarscovspecific antibody detected elisa subject neutralizing antibody detected subject received dos vaccine sarscovspecific cd cell response detected vaccinee cd cell response ∼ individual conclusion vrc sars dna vaccine well tolerated produced cellular immune response neutralizing antibody healthy adult,2008-11-01,"Martin, Julie E.; Louder, Mark K.; Holman, LaSonji A.; Gordon, Ingelise J.; Enama, Mary E.; Larkin, Brenda D.; Andrews, Charla A.; Vogel, Leatrice; Koup, Richard A.; Roederer, Mario; Bailer, Robert T.; Gomez, Phillip L.; Nason, Martha; Mascola, John R.; Nabel, Gary J.; Graham, Barney S.",Vaccine,,,,document_parses/pdf_json/cca2dfc19d915a6bdb502560e18027b70f0c4e59.json; document_parses/pdf_json/259b254062d2435598b6a4544d79634e77725c0d.json,document_parses/pmc_json/PMC2612543.xml.json,http://europepmc.org/articles/pmc2612543?pdf=render; https://api.elsevier.com/content/article/pii/S0264410X08012279; https://doi.org/10.1016/j.vaccine.2008.09.026; https://www.sciencedirect.com/science/article/pii/S0264410X08012279; https://www.ncbi.nlm.nih.gov/pubmed/18824060/,13767082.0,3
97323,97323,124077,7hjmb6x3,d6681b485cbddcc32ea54b74ceae13db1f30646d,Elsevier; Medline; PMC,Crosstalk between innate and adaptive immune responses to infectious bronchitis virus after vaccination and challenge of chickens varying in serum mannose-binding lectin concentrations,10.1016/j.vaccine.2011.10.016,PMC7115549,22008821.0,els-covid,mannosebinding lectin mbl ctype collectin structural similarity cq innate patternrecognition molecule sequestered site inflammation infection mbl selectively bind distinct chemical pattern including carbohydrate expressed kind pathogen present study show serum mbl level influence ability chicken clear respiratory tract virus genome infectious bronchitis virus ibv infection primary ibv infection induced change circulating tcell population specific antibody response serum mbl level also influenced ibv vaccineinduced change circulating tcell population moreover addition mannose ibv vaccine altered vaccineinduced change circulating tcell population ibv specific vaccine infectioninduced antibody response chicken high serum mbl level data demonstrate mbl involved regulation adaptive immune response ibv,2011-11-28,"Juul-Madsen, Helle R.; Norup, Liselotte R.; Jørgensen, Poul H.; Handberg, Kurt J.; Wattrang, Eva; Dalgaard, Tina S.",Vaccine,,,,document_parses/pdf_json/d6681b485cbddcc32ea54b74ceae13db1f30646d.json,document_parses/pmc_json/PMC7115549.xml.json,https://api.elsevier.com/content/article/pii/S0264410X11016100; https://www.ncbi.nlm.nih.gov/pubmed/22008821/; https://doi.org/10.1016/j.vaccine.2011.10.016; https://www.sciencedirect.com/science/article/pii/S0264410X11016100,205588121.0,3
97348,97348,124107,kdgf5xa3,4ec02c71e62b4df8efeed2f53623778f49c7438a,Elsevier; Medline; PMC,Towards the first multi-epitope recombinant vaccine against Crimean-Congo hemorrhagic fever virus: A computer-aided vaccine design approach,10.1016/j.jbi.2019.103160,PMC7106074,30928513.0,els-covid,crimeancongo hemorrhagic fever cchf considered one major public health concern case fatality rate currently effective approved vaccine cchf study used computeraided vaccine design approach develop first multiepitope recombinant vaccine cchf purpose linear bcell tcell binding epitope two structural glycoprotein cchf virus including gc gn predicted epitope studied regarding antigenicity allergenicity hydrophobicity stability toxicity population coverage total number seven epitope including five tcell two bcell epitope screened final vaccine construct final vaccine construct composed amino acid residue organized four domain including linear bcell tcell epitope cholera toxin bsubunit ctxb along heat labile enterotoxin iic b subunit ltiic adjuvant segment joined using appropriate linkers physicochemical property well presence ifnγ inducing epitope proposed vaccine also checked determining vaccine stability solubility ability induce cellmediated immune response structure proposed vaccine subjected prediction computational bcell epitope molecular docking study mhci ii molecule furthermore molecular dynamic stimulation performed study vaccinemhcs complex stability stimulation time result suggest proposed vaccine stable well soluble water potentially antigenic result also demonstrated vaccine induce humoral cellmediated immune response could serve promising anticchf vaccine candidate,2019-05-31,"Nosrati, Mokhtar; Behbahani, Mandana; Mohabatkar, Hassan",Journal of Biomedical Informatics,,,,document_parses/pdf_json/4ec02c71e62b4df8efeed2f53623778f49c7438a.json,document_parses/pmc_json/PMC7106074.xml.json,https://www.sciencedirect.com/science/article/pii/S1532046419300784; https://doi.org/10.1016/j.jbi.2019.103160; https://api.elsevier.com/content/article/pii/S1532046419300784; https://www.ncbi.nlm.nih.gov/pubmed/30928513/,89617966.0,3
97440,97440,124228,rc3ymu9d,2ad6ccc77d12ec8c8f91076fd337a01d734e578e,Medline; PMC,New Vaccine Technologies to Combat Outbreak Situations,10.3389/fimmu.2018.01963,PMC6156540,30283434.0,cc-by,ever since development first vaccine year ago vaccination greatly decreased burden infectious disease worldwide famously leading eradication small pox allowing restriction disease polio tetanus diphtheria measles multitude research effort focus improvement established discovery new vaccine hpv human papilloma virus vaccine however radical change density age distribution traveling habit population worldwide well changing climate favor emergence old new pathogen bear risk becoming pandemic threat recent year rapid spread severe infection hiv sars ebola zika highlighted dire need global preparedness pandemic necessitates extremely rapid development comprehensive distribution vaccine potentially previously unknown pathogen emergence antibiotic resistant bacteria call new approach prevent infection given change established method identification new vaccine candidate longer sufficient ensure global protection hence new vaccine technology able achieve rapid development well large scale production pivotal importance review discus viral vector nucleic acidbased vaccine dna mrna vaccine new approach might able tackle challenge global health,2018-09-19,"Rauch, Susanne; Jasny, Edith; Schmidt, Kim E.; Petsch, Benjamin",Front Immunol,,,,document_parses/pdf_json/2ad6ccc77d12ec8c8f91076fd337a01d734e578e.json,document_parses/pmc_json/PMC6156540.xml.json,https://doi.org/10.3389/fimmu.2018.01963; https://www.ncbi.nlm.nih.gov/pubmed/30283434/,52298495.0,3
97441,97441,124229,nbuvbrly,f435af9f4c369a6738a5c079f5f9b486cf9e63e2,Medline; PMC,Recombinant Infectious Bronchitis Viruses Expressing Chimeric Spike Glycoproteins Induce Partial Protective Immunity against Homologous Challenge despite Limited Replication In Vivo,10.1128/jvi.01473-18,PMC6232476,30209177.0,cc-by,vaccination regime infectious bronchitis virus ibv based single virus serotype often induce insufficient level crossprotection serotypes two antigenically diverse vaccine used attempt provide broader protection amino acid difference surface protein spike particular subunit associated poor crossprotection homologous vaccination trial recombinant ibvs ribvs based apathogenic strain beaur conducted elucidate role protection single vaccination specificpathogenfree chicken ribv expressing virulent strain qx beaurms beaurqxs gave incomplete protection homologous challenge based ciliary activity clinical sign could conformational issue spike heterologous linked suggesting homologous might essential address homologous vaccinationchallenge trial incorporating ribvs expressing full spike beaurms subunit beaurms conducted chimeric virus grew similar titer vitro induced virusspecific partial protective immunity evident cellular infiltration reduction viral rna load trachea conjunctiva higher serum antiibv titer collectively finding show vaccination ribvs primed bird challenge virus cleared rapidly mucosal tissue head chimeric virus protect effectively beaurms based ciliary activity clinical sign booster vaccination ribv improved vivo replication may improve level protection importance infectious bronchitis virus cause acute highly contagious respiratory disease responsible significant economic loss poultry industry amino acid difference surface protein spike particular subunit associated poor crossprotection available vaccine give poor crossprotection rationally designed live attenuated vaccine based apathogenic beaur could address determine role protection series homologous vaccination trial ribvs conducted single vaccination chimeric ribvs induced virusspecific partial protective immunity characterized reduction viral load serum antibody titer however beaurms vaccination improve level protection clinical sign loss tracheal ciliary activity growth characteristic show ribvs replicated vitro similar level booster vaccination ribv improved vivo replication may improve level protection,2018-11-12,"Ellis, Samantha; Keep, Sarah; Britton, Paul; de Wit, Sjaak; Bickerton, Erica; Vervelde, Lonneke",J Virol,,,,document_parses/pdf_json/f435af9f4c369a6738a5c079f5f9b486cf9e63e2.json,document_parses/pmc_json/PMC6232476.xml.json,https://doi.org/10.1128/jvi.01473-18; https://www.ncbi.nlm.nih.gov/pubmed/30209177/,206804002.0,3
97463,97463,124252,7k1cwnpj,3c4c0c0a89ec5bbbb78747b2812a8b5f4e9bc000,Elsevier; Medline; PMC,Liposomes used as a vaccine adjuvant-delivery system: From basics to clinical immunization,10.1016/j.jconrel.2019.04.025,PMC7111479,31022431.0,els-covid,liposome widely utilized carrier improve therapeutic efficacy agent thanks merit high loading capacity targeting delivery reliable protection agent good biocompatibility versatile structure modification adjustable characteristic size surface charge membrane flexibility agent loading mode particular recent year modification immunopotentiators targeting molecule combination innovative immunization device liposome rapidly developed multifunctional vaccine adjuvantdelivery system vads high capability inducing desired immunoresponses target immune cell even cellular organelle engender lysosome escape promote ag crosspresentation thus enormously enhancing vaccination efficacy moreover decade development several product developed liposome vads already authorized clinical immunization showing great advantage conventional vaccine article describes depth critical issue relevant development liposome vads including principle underlying immunization physicochemical property liposome immunityinfluencing factor functional material modification enhance immunostimulatory function stateoftheart liposome vadss well marketed vaccine based liposome vads therefore article provides comprehensive reference development novel liposome vaccine,2019-06-10,"Wang, Ning; Chen, Minnan; Wang, Ting",Journal of Controlled Release,,,,document_parses/pdf_json/3c4c0c0a89ec5bbbb78747b2812a8b5f4e9bc000.json,document_parses/pmc_json/PMC7111479.xml.json,https://doi.org/10.1016/j.jconrel.2019.04.025; https://api.elsevier.com/content/article/pii/S0168365919302251; https://www.ncbi.nlm.nih.gov/pubmed/31022431/; https://www.sciencedirect.com/science/article/pii/S0168365919302251,133609140.0,3
97471,97471,124262,1cnmpew9,86065d8cafbc24ea3c5184dd1dbbb49e1a6ec6a7,Elsevier; PMC,Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?,10.1016/j.copbio.2004.09.001,PMC7127071,15560976.0,els-covid,safetytested modified vaccinia virus ankara mva established potent vector system development candidate recombinant vaccine versatility vector system recently demonstrated rapid production experimental mva vaccine immunization severe acute respiratory syndrome associated coronavirus promising result also obtained delivery epsteinbarr virus human cytomegalovirus antigen clinical testing mva vector vaccination immunodeficiency virus papilloma virus plasmodium falciparum melanoma moreover mva considered prime candidate vaccine safer protection orthopoxvirus infection thus vector development challenge dilemma vaccinology immunization poxvirus biothreat seems possible yet right choice made beneficial use,2004-12-31,"Drexler, Ingo; Staib, Caroline; Sutter, Gerd",Current Opinion in Biotechnology,,,,document_parses/pdf_json/86065d8cafbc24ea3c5184dd1dbbb49e1a6ec6a7.json,document_parses/pmc_json/PMC7127071.xml.json,https://api.elsevier.com/content/article/pii/S0958166904001314; https://www.sciencedirect.com/science/article/pii/S0958166904001314,24355967.0,3
97482,97482,124276,7i1kukmn,cb5fe82933ecce288d9d2503bc8d0ef9518e024c,Elsevier; Medline; PMC; WHO,The end of cordon sanitaire in Wuhan: the role of non-pharmaceutical interventions,10.1016/j.puhe.2020.05.007,PMC7221399,32410747.0,els-covid,effectiveness nonpharmaceutical intervention implemented wuhan described discussed absence vaccine proven specific safe effective treatment experience result achieved wuhan could serve good reference leader policymakers around world formulating strategy policy fighting covid,2020-05-14,"Wan, Kelvin H.; Huang, Suber S.; Ko, Chung-Nga; Lam, Dennis S.C.",Public Health,,#260352,,document_parses/pdf_json/cb5fe82933ecce288d9d2503bc8d0ef9518e024c.json,,https://www.ncbi.nlm.nih.gov/pubmed/32410747/; https://api.elsevier.com/content/article/pii/S0033350620301669; https://doi.org/10.1016/j.puhe.2020.05.007; https://www.sciencedirect.com/science/article/pii/S0033350620301669?v=s5,218616496.0,3
97503,97503,124297,h3g3sgiu,8387ba520ac3172c8b428e5c95b6aad52d23d509,Medline; PMC,A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease,10.1080/21645515.2015.1078045,PMC5049717,26309231.0,cc-by-nc,crimeancongo hemorrhagic fever cchf severe tickborne disease endemic many country africa middle east eastern europe asia – reported case fatal approved vaccine available present study attenuated poxvirus vector modified vaccinia virus ankara used develop recombinant candidate vaccine expressing cchf virus nucleoprotein cellular humoral immunogenicity confirmed mouse strain including type interferon receptor knockout mouse susceptible cchf disease despite immune response generated postimmunisation vaccine failed protect animal lethal disease challenge model,2015-08-26,"Dowall, SD; Buttigieg, KR; Findlay-Wilson, SJD; Rayner, E; Pearson, G; Miloszewska, A; Graham, VA; Carroll, MW; Hewson, R",Hum Vaccin Immunother,,,,document_parses/pdf_json/8387ba520ac3172c8b428e5c95b6aad52d23d509.json,document_parses/pmc_json/PMC5049717.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26309231/; https://doi.org/10.1080/21645515.2015.1078045,18144082.0,3
97511,97511,124307,entz52bx,5f13b07d66a17f43c2ad7eec2f8601235ffdf05c,Elsevier; PMC,Antibody induction after combined application of an adjuvanted recombinant FeLV vaccine and a multivalent modified live virus vaccine with a chlamydial component,10.1016/j.vaccine.2005.10.030,PMC7115673,16343700.0,els-covid,compatibility safety interaction antibody induction combined vaccine application assessed specific pathogenfree cat vaccinated either modified live virus vaccine containing feline calici fcv herpes fhv parvovirus fpv chlamydophila felis c felis adjuvanted recombinant feline leukaemia virus felv vaccine vaccine one syringe combined application felv elisa antibody titre unaltered however antibody production based indirect immunofluorescence assay remarkably enhanced fcv selected time point also enhanced fhv c felis diminished fpv use vaccine combination safe simplify vaccination schedule veterinary practice,2006-03-10,"Brunner, Chantal; Kanellos, Theo; Meli, Marina L.; Sutton, David J.; Gisler, Ricarda; Gomes-Keller, Maria Alice; Hofmann-Lehmann, Regina; Lutz, Hans",Vaccine,,,,document_parses/pdf_json/5f13b07d66a17f43c2ad7eec2f8601235ffdf05c.json,document_parses/pmc_json/PMC7115673.xml.json,https://api.elsevier.com/content/article/pii/S0264410X05010674; https://www.sciencedirect.com/science/article/pii/S0264410X05010674,42770497.0,3
97529,97529,124330,zsr5xjma,acedaf9a6ccc0db989317df65e131261deb6098d; 3b056578ce3e33699788288335fa6457d4394a12,Elsevier; Medline; PMC,Las vacunas de la gripe basadas en las partículas virus-like obtenidas mediante sistemas de expresión génica en células de insectos,10.1016/s1576-9887(12)70039-0,PMC7140253,32288700.0,no-cc,viruslike particle vlps multimeric protein complex mimicking organization native virus lack viral genome vlps therefore constitute safe effective approach induction neutralizing antibody surface protein influenza vlps recently developed new generation nonegg based cell culturederived vaccine candidate influenza infection flubock recombinant trivalent hemagglutinin rha vaccine produced insect cell culture using baculovirus expression system provides attractive alternative classical inactivated influenza vaccine highly purified protein vaccine administered threefold higher antigen content μg well tolerated result stronger immunogenicity long lasting immune response provides crossprotection drift influenza virus,2012-11-23,"Reina, J.",Vacunas,,,,document_parses/pdf_json/acedaf9a6ccc0db989317df65e131261deb6098d.json; document_parses/pdf_json/3b056578ce3e33699788288335fa6457d4394a12.json,document_parses/pmc_json/PMC7140253.xml.json,https://www.sciencedirect.com/science/article/pii/S1576988712700390; https://doi.org/10.1016/s1576-9887(12)70039-0; https://api.elsevier.com/content/article/pii/S1576988712700390; https://www.ncbi.nlm.nih.gov/pubmed/32288700/,73054191.0,3
97550,97550,124354,bt7071o8,11e2eb5469677f11c1c96a3948305217f89f07ac,Elsevier; Medline; PMC,A transcutaneous vaccination system using a hydrogel patch for viral and bacterial infection,10.1016/j.jconrel.2008.07.025,PMC7114651,18700159.0,els-covid,one important anthropic mission preventing global spread infectious disease vaccination available preventive treatment infectious disease availability vaccine developing country adequate report simple easytouse noninvasive hydrogel patch transcutaneous vaccination system antigen agspecific igg production induced applying agimmersed patch nonpretreated mouse auricle hairless rat back skin immunofluorescence histochemical analysis revealed langerhans cell resident epidermal layer captured antigenic protein delivered hydrogel patch promoted penetration antigenic protein stratum corneum agcapturing langerhans cell migrated draining lymph node humoral immunity elicited transcutaneous vaccination system demonstrated neutralizing activity adenoviral infection passivechallenge tetanus toxin experiment use hydrogel patch transcutaneous vaccination system facilitate global distribution effective convenient vaccine,2008-10-21,"Ishii, Yumiko; Nakae, Tomoko; Sakamoto, Fumiko; Matsuo, Kazuhiko; Matsuo, Keisuke; Quan, Ying-Shu; Kamiyama, Fumio; Fujita, Takuya; Yamamoto, Akira; Nakagawa, Shinsaku; Okada, Naoki",Journal of Controlled Release,,,,document_parses/pdf_json/11e2eb5469677f11c1c96a3948305217f89f07ac.json,document_parses/pmc_json/PMC7114651.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/18700159/; https://api.elsevier.com/content/article/pii/S0168365908003908; https://www.sciencedirect.com/science/article/pii/S0168365908003908; https://doi.org/10.1016/j.jconrel.2008.07.025,24756804.0,3
97627,97627,124443,o7qbkfzm,63bfe3719fb216531ee41e021fc08f351168febc,Elsevier; Medline; PMC,Séance bi-académique de l’Académie nationale de médecine et de l’Académie des Sciences: « Confiance et défiance vis-à-vis des vaccins »,10.1016/s0001-4079(19)30502-3,PMC7095193,32226055.0,els-covid,summary explosion vaccine th century allowed control numerous infectious plague multiple challenge oppose conservation extension success hesitation modern society front vaccination requires research life human social science order reach better understanding vaccine mechanism action improve tolerance acceptability vaccine additive ageing population increase subject risk also require improve immunogenicity efficiency existing vaccine constant emergence new epidemic development antibioresistance imposes innovation development new vaccine recent difficulty faced development vaccine malaria tuberculosis aid illustrate necessity moving beyond classical recipe elaborating new vector new adjuvant better understanding heterogeneity vaccine immunity developing alternative route immunization multidisciplinary research using recent advance molecular structural cellular biology microbiology immunology genetic engineering answer worldwide challenge,2017-03-31,"Autran, Brigitte; Combadière, Béhazine; Launay, Odile; Legrand, Roger; Locht, Camille; Tangy, Frédéric; Verger, Pierre; Garçon, Nathalie",Bulletin de l'Académie Nationale de Médecine,,,,document_parses/pdf_json/63bfe3719fb216531ee41e021fc08f351168febc.json,document_parses/pmc_json/PMC7095193.xml.json,https://www.sciencedirect.com/science/article/pii/S0001407919305023; https://www.ncbi.nlm.nih.gov/pubmed/32226055/; https://doi.org/10.1016/s0001-4079(19)30502-3; https://api.elsevier.com/content/article/pii/S0001407919305023,196518966.0,3
97644,97644,124461,rnq44lj8,9493228d25065855dfc54912ffd61ee60849e164,Elsevier; PMC,Human monoclonal antibodies by immortalization of memory B cells,10.1016/j.copbio.2007.10.011,PMC7127177,18063358.0,els-covid,administration hyper immune serum prevent treat lifethreatening infection remarkable milestone medicine biotechnology achieved century ago yet therapeutic use monoclonal antibody field developed slowly last decade compare contrast current method generate human monoclonal antibody highlight advantage exploiting human antibody repertoire using novel method allows efficient immortalization cloning human memory b cell method successfully applied isolate broadly neutralizing antibody sars hn influenza virus expected accelerate development therapeutic field infectious disease providing neutralizing antibody passive serotherapy also generating relevant information vaccine design,2007-12-31,"Lanzavecchia, Antonio; Corti, Davide; Sallusto, Federica",Current Opinion in Biotechnology,,,,document_parses/pdf_json/9493228d25065855dfc54912ffd61ee60849e164.json,document_parses/pmc_json/PMC7127177.xml.json,https://api.elsevier.com/content/article/pii/S0958166907001334; https://www.sciencedirect.com/science/article/pii/S0958166907001334,43039083.0,3
97674,97674,124497,dmb0293x,c63f31f1d46c5a3cd4d4f2baeab9ce8c3a1dd3bf,Medline; PMC,Recent Advances of Vaccine Adjuvants for Infectious Diseases,10.4110/in.2015.15.2.51,PMC4411509,25922593.0,cc-by-nc,vaccine effective costefficient method preventing disease caused infectious pathogen despite great success vaccine development safe strong vaccine still required emerging new pathogen reemerging old pathogen order improve inadequate protection conferred existing vaccine one important strategy development effective new vaccine selection usage suitable adjuvant immunologic adjuvant essential enhancing vaccine potency improvement humoral andor cellmediated immune response vaccine antigen thus formulation vaccine appropriate adjuvant attractive approach towards eliciting protective longlasting immunity human however limited number adjuvant licensed human vaccine due concern safety toxicity summarize current knowledge potential benefit adjuvant characteristic adjuvant mechanism adjuvant human vaccine adjuvant diverse mode action selected use basis type immune response desired particular vaccine better understanding current adjuvant help exploring new adjuvant formulation facilitate rational design vaccine infectious disease,2015-04-23,"Lee, Sujin; Nguyen, Minh Trang",Immune Netw,,,,document_parses/pdf_json/c63f31f1d46c5a3cd4d4f2baeab9ce8c3a1dd3bf.json,document_parses/pmc_json/PMC4411509.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25922593/; https://doi.org/10.4110/in.2015.15.2.51,1056590.0,3
97692,97692,124518,hmeg2t9m,678c6fd1ee7fdf07055bbb00725a7c8526d8015e,Medline; PMC,Vaccine Development Against Middle East Respiratory Syndrome,10.1007/s40475-016-0084-0,PMC7099997,32226714.0,no-cc,various type vaccine preclinical clinical development address recent appearance middle east respiratory syndrome mers emerging infectious disease already caused death remains threat world health causative agent respiratory disease member betacoronavirus genus phylogenetically closely related sars coronavirus caused international health emergency lesson learned outbreak severe acute respiratory syndrome undeniable technological advance vaccine development mers initially fastpaced produced several dna protein vaccine candidate promising result early preclinical testing least one vaccine candidate even entered firstinhumans clinical trial number mers case declining though infectious disease attracting increased attention question remains whether similar situation sars pandemic vaccine development halted remains priority rightfully,2016-07-11,"Lee, Hai Yen; Nyon, Mun Peak; Strych, Ulrich",Curr Trop Med Rep,,,,document_parses/pdf_json/678c6fd1ee7fdf07055bbb00725a7c8526d8015e.json,document_parses/pmc_json/PMC7099997.xml.json,https://doi.org/10.1007/s40475-016-0084-0; https://www.ncbi.nlm.nih.gov/pubmed/32226714/,88784116.0,3
97743,97743,124577,qqu8izz3,4fc79293e3efdfd44b408d923b2448ac6a5ddd0d,Medline; PMC,A self-adjuvanted nanoparticle based vaccine against infectious bronchitis virus,10.1371/journal.pone.0203771,PMC6138407,30216376.0,cc-by,infectious bronchitis virus ibv affect poultry respiratory renal reproductive system currently efficacy available live attenuated killed vaccine ibv challenged designed novel ibv vaccine alternative using highly innovative platform called selfassembling protein nanoparticle sapn vaccine b cell epitope derived second heptad repeat hr region ibv spike protein repetitively presented native trimeric conformation addition flagellin codisplayed sapn achieve selfadjuvanted effect three group chicken immunized four week age vaccine prototype ibvflagellinsapn negativecontrol construct flagellinsapn buffer control immunized chicken challenged x eid ibv strain high antibody response detected chicken immunized ibvflagellinsapn ex vivo proliferation test peripheral mononuclear cell pbmcs derived ibvflagellinsapn immunized chicken significantly higher stimulation index pbmcs chicken receiving flagellinsapn chicken immunized ibvflagellinsapn significant reduction tracheal virus shedding lesser tracheal lesion score negative control chicken data demonstrated ibvflagellinsapn hold promise vaccine ibv,2018-09-14,"Li, Jianping; Helal, Zeinab H.; Karch, Christopher P.; Mishra, Neha; Girshick, Theodore; Garmendia, Antonio; Burkhard, Peter; Khan, Mazhar I.",PLoS One,,,,document_parses/pdf_json/4fc79293e3efdfd44b408d923b2448ac6a5ddd0d.json,document_parses/pmc_json/PMC6138407.xml.json,https://doi.org/10.1371/journal.pone.0203771; https://www.ncbi.nlm.nih.gov/pubmed/30216376/,52278971.0,3
97746,97746,124581,4ejtmoht,456dd1fcd4e5ce47cc6be199ce8462f6213d814e,Medline; PMC,PIKA provides an adjuvant effect to induce strong mucosal and systemic humoral immunity against SARS-CoV,10.1007/s12250-011-3183-z,PMC7091335,21468931.0,no-cc,severe acute respiratory syndrome sars deadly infectious disease caused sars coronavirus sarscov inactivated sarscov explored vaccine sarscov however safe potent adjuvant especially efficient economical needlefree vaccination always needed urgently pandemic development safe effective mucosal adjuvant vaccine prevention emergent infectious disease sars important advancement pika stabilized derivative poly ic previously reported safe potent adjuvant mouse model present study demonstrated intraperitoneal intranasal coadministration inactivated sarscov vaccine together improved poly ic derivative induced strong antisarscov mucosal systemic humoral immune response neutralizing activity pseudotyped virus although intraperitoneal immunization inactivated sarscov vaccine alone could induce certain level neutralizing activity serum well mucosal site coadministration inactivated sarscov vaccine pika adjuvant could induce much higher neutralizing activity intranasal immunization used pika obligatorily inducing neutralizing activity serum well mucosal site correlated mucosal iga mucosal igg response overall pika could good mucosal adjuvant candidate inactivated sarscov vaccine use possible future pandemic,2011-04-07,"Gai, Wei-wei; Zhang, Yan; Zhou, Di-han; Chen, Yao-qing; Yang, Jing-yi; Yan, Hui-min",Virol Sin,,,,document_parses/pdf_json/456dd1fcd4e5ce47cc6be199ce8462f6213d814e.json,,https://www.ncbi.nlm.nih.gov/pubmed/21468931/; https://doi.org/10.1007/s12250-011-3183-z,8695283.0,3
97750,97750,124587,4qgkdhhj,96f9e6b75c3611899eb5ac11c03ca4b372bd83a1,Medline; PMC,Will plant-made biopharmaceuticals play a role in the fight against COVID-19?,10.1080/14712598.2020.1752177,PMC7157952,32250170.0,no-cc,given dramatic impact covid pandemic imperative divulge available technology potential fight virus plant biotechnology offer potential solution pandemic development lowcost vaccine antibody useful therapy prophylaxis diagnosis technology produce plantmade biopharmaceuticals already established two example therapeutic enzyme entered market influenza vaccine currently clinical trial encouraging result thus far company started developing anticovid antibody vaccine particular plantmade antibody might timely produced approved human use short term development vaccine take longer time clinical evaluation could concluded end nonetheless candidate obtained valuable tool future outbreak key aspect define exploitation technology fight covid discussed,2020-04-13,"Rosales-Mendoza, Sergio",Expert Opin Biol Ther,,,,document_parses/pdf_json/96f9e6b75c3611899eb5ac11c03ca4b372bd83a1.json,document_parses/pmc_json/PMC7157952.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32250170/; https://doi.org/10.1080/14712598.2020.1752177,214810726.0,3
97753,97753,124591,wvtqbguq,759feb3e4c9eebfd612ceaff7fa70b550b8be25f; 943551a899af7fafc837abdabf924c5787982659,Elsevier; Medline; PMC,Reverse genetics approaches to combat pathogenic arenaviruses,10.1016/j.antiviral.2008.08.002,PMC2628465,18782590.0,green-oa,several arenavirus cause hemorrhagic fever hf human evidence indicates worldwidedistributed prototypic arenavirus lymphocytic choriomeningitis virus lcmv neglected human pathogen clinical significance moreover arenavirus pose biodefense threat licensed antiarenavirus vaccine available current antiarenavirus therapy limited use ribavirin partially effective associated anemia side effect therefore important develop effective vaccine better antiviral drug combat dual threat naturally occurring intentionally introduced arenavirus infection development arenavirus reverse genetic system allowing investigator conduct detailed molecular characterization viral cisacting signal transacting factor control step arenavirus life cycle including rna synthesis packaging budding knowledge derived study uncovering potential novel target therapeutic intervention well facilitating establishment assay identify characterize candidate antiviral drug capable interfering specific step virus life cycle likewise ability generate predetermined specific mutation within arenavirus genome analyze phenotypic expression would significantly contribute elucidation arenavirushost interaction including basis ability cause severe hf turn could lead development novel potent safe arenavirus vaccine,2008-12-01,"de la Torre, Juan C.",Antiviral Research,,,,document_parses/pdf_json/759feb3e4c9eebfd612ceaff7fa70b550b8be25f.json; document_parses/pdf_json/943551a899af7fafc837abdabf924c5787982659.json,document_parses/pmc_json/PMC2628465.xml.json,http://europepmc.org/articles/pmc2628465?pdf=render; https://doi.org/10.1016/j.antiviral.2008.08.002; https://www.sciencedirect.com/science/article/pii/S0166354208003665; https://api.elsevier.com/content/article/pii/S0166354208003665; https://www.ncbi.nlm.nih.gov/pubmed/18782590/,44361300.0,3
97780,97780,124625,ju6vuywm,38ecfaefe98e438f7206f46125d06cab0531534e,Elsevier; PMC,Chapter 5 Common Myths and Legends of Rabies,10.1016/b978-0-323-63979-8.00005-2,PMC7152084,,els-covid,humankind somewhat dark yet almost fascinating supernatural relationship rabies even pasteur rabies vaccine discovery globally people continue stricken today history carried along myth legend surround diabolical virus still believe rabies treatment requires shot stomach monstrously long needle however today treatment regimen typically four vaccination five immunocompromised arm plus human rabies immune globulin chapter explores misunderstood concept rabies prevalence sign symptom exposure treatment protocol,2020-12-31,"Rohde, Rodney E.",Rabies,,,,document_parses/pdf_json/38ecfaefe98e438f7206f46125d06cab0531534e.json,document_parses/pmc_json/PMC7152084.xml.json,https://api.elsevier.com/content/article/pii/B9780323639798000052; https://www.sciencedirect.com/science/article/pii/B9780323639798000052,198816036.0,3
97848,97848,124709,itxuc5lf,3602faa031e21257cfdb816ab5f1b58d2d0eef54,Elsevier; Medline; PMC,An insect cell derived respiratory syncytial virus (RSV) F nanoparticle vaccine induces antigenic site II antibodies and protects against RSV challenge in cotton rats by active and passive immunization,10.1016/j.vaccine.2014.09.030,PMC7172787,25269094.0,els-covid,postinfectious immunity respiratory syncytial virus rsv infection result limited protection evidenced high rate infant hospitalization face high titer maternally derived rsvspecific antibody contrast rsv fusion f glycoprotein antigenic site ii humanized monoclonal antibody palivizumab motavizumab shown reduce rsvrelated hospitalization infant immunogenicity efficacy study conducted cotton rat comparing recombinant rsv f nanoparticle vaccine palivizumab controlled live rsv virus intranasal immunization formalin inactivated rsv vaccine active immunization rsv f nanoparticle vaccine containing alum adjuvant induced serum level palivizumab competing antibody pca greater passive administration mgkg palivizumab human prophylactic dose cotton rat neutralized rsva rsvb virus immunization prevented detectable rsv replication lung unlike passive administration palivizumab nasal passage challenged cotton rat histology lung tissue following rsv challenge showed enhanced disease vaccinated group contrast formalin inactivated ‘ lot ’ vaccine passive intramuscular administration rsv f vaccineinduced immune serum one day prior challenge cotton rat reduced viral titer log virus per gram lung nasal tissue dos le palivizumab recombinant rsv f nanoparticle vaccine protected lower upper respiratory tract rsv b strain infection induced polyclonal palivizumab competing antibody similar potentially broadly protective rsv palivizumab,2014-11-12,"Raghunandan, Rama; Lu, Hanxin; Zhou, Bin; Xabier, Mimi Guebre; Massare, Michael J.; Flyer, David C.; Fries, Louis F.; Smith, Gale E.; Glenn, Gregory M.",Vaccine,,,,document_parses/pdf_json/3602faa031e21257cfdb816ab5f1b58d2d0eef54.json,document_parses/pmc_json/PMC7172787.xml.json,https://doi.org/10.1016/j.vaccine.2014.09.030; https://api.elsevier.com/content/article/pii/S0264410X14012894; https://www.sciencedirect.com/science/article/pii/S0264410X14012894; https://www.ncbi.nlm.nih.gov/pubmed/25269094/,24391511.0,3
97849,97849,124710,hmw6zj3m,85b87a183b82a57846e65afdeeaa52b2d8f206f6,Medline; PMC,Safety and Immunogenicity of DNA Vaccines Encoding Ebolavirus and Marburgvirus Wild-Type Glycoproteins in a Phase I Clinical Trial,10.1093/infdis/jiu511,PMC4318920,25225676.0,bronze-oa,background ebolavirus marburgvirus cause severe hemorrhagic fever high mortality potential bioterrorism agent available vaccine therapeutic agent previous clinical trial evaluated transmembranedeleted pointmutation ebolavirus glycoprotein gps candidate vaccine construct evaluated trial encode wildtype wt gp ebolavirus zaire sudan specie marburgvirus angola strain expressed dna vaccine method vrc study evaluated safety immunogenicity dna vaccine mg administered intramuscularly biojector week homologous boost week safety evaluation included solicited reactogenicity coagulation parameter primary immune assessment done mean gpspecific enzymelinked immunosorbent assay result vaccine well tolerated serious adverse event subject positive enzymelinked immunosorbent assay result ≥ week fourth dna vaccination boosted immune response conclusion investigational ebolavirus marburgvirus wt gp dna vaccine safe well tolerated immunogenic phase study result inform filovirus vaccine research toward goal inducing protective immunity using wt gp antigen candidate vaccine regimen clinical trial registration nct,2014-09-14,"Sarwar, Uzma N.; Costner, Pamela; Enama, Mary E.; Berkowitz, Nina; Hu, Zonghui; Hendel, Cynthia S.; Sitar, Sandra; Plummer, Sarah; Mulangu, Sabue; Bailer, Robert T.; Koup, Richard A.; Mascola, John R.; Nabel, Gary J.; Sullivan, Nancy J.; Graham, Barney S.; Ledgerwood, Julie E.",Journal of Infectious Diseases,,,,document_parses/pdf_json/85b87a183b82a57846e65afdeeaa52b2d8f206f6.json,document_parses/pmc_json/PMC4318920.xml.json,https://academic.oup.com/jid/article-pdf/211/4/549/9526242/jiu511.pdf; https://doi.org/10.1093/infdis/jiu511; https://www.ncbi.nlm.nih.gov/pubmed/25225676/,15513655.0,3
97856,97856,124718,fkea2rp8,1b7c700ee3a33c0a675a5f7e71a20ce62467b900,Medline; PMC,Expression of HIV-1 antigens in plants as potential subunit vaccines,10.1186/1472-6750-8-53,PMC2443125,18573204.0,cc-by,background human immunodeficiency virus type hiv infected million people worldwide mainly subsaharan africa high prevalence hiv subtype c southern africa necessitates development cheap effective vaccine one mean production use plant number different technique successfully developed hiv prgag promising hiv vaccine candidate compared expression truncated gag pp p capsid subunit nicotiana spp using transgenic plant transient expression via agrobacterium tumefaciens recombinant tobamovirus vector also investigated influence subcellular localisation recombinant protein chloroplast endoplasmic reticulum er protein yield partially purified selected vaccine candidate tested stimulation humoral cellular immune response mouse result transient transgenic expression hiv antigen successful although expression prgag low system however agrobacteriummediated transient expression p pp yielded best mg pkg fresh weight chloroplast targeted protein level highest transient transgenic expression p pp transientlyexpressed pp immunogenic mouse homologous vaccine significantly boosted humoral cell immune response primed gag dna vaccine pthgagc conclusion transient agroinfiltration best expression recombinant protein tested p pp expressed much higher level prgag result highlight usefulness plastid signal peptide enhancing production recombinant protein meant use vaccine pp protein effectively boosted cell humoral response mouse primed dna vaccine pthgagc showing plantproduced protein potential use vaccine,2008-06-23,"Meyers, Ann; Chakauya, Ereck; Shephard, Enid; Tanzer, Fiona L; Maclean, James; Lynch, Alisson; Williamson, Anna-Lise; Rybicki, Edward P",BMC Biotechnol,,,,document_parses/pdf_json/1b7c700ee3a33c0a675a5f7e71a20ce62467b900.json,document_parses/pmc_json/PMC2443125.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/18573204/; https://doi.org/10.1186/1472-6750-8-53,10576248.0,3
97860,97860,124723,f2u1di1q,c26d655ab85161130281014409a95b087c548070; fddd6083ae049444ab80313b1093834d6949d211,Medline; PMC,Comparative safety of vaccine adjuvants: a summary of current evidence and future needs,10.1007/s40264-015-0350-4,PMC4615573,26446142.0,green-oa,improved use highly pure antigen improve vaccine safety led reduced vaccine immunogenicity efficacy led need use adjuvant improve vaccine immunogenicity ideal adjuvant maximize vaccine immunogenicity without compromising tolerability safety posing undue risk unfortunately adjuvant research lagged behind vaccine area antigen discovery consequence limited number adjuvant based aluminum salt monophosphoryl lipid oil emulsion currently approved human use recent strategic initiative support adjuvant development national institute health translate greater adjuvant choice future mechanistic study valuable better understanding adjuvant action mechanism adjuvant toxicity le well understood inflammatory dangersignal model adjuvant action implies increased vaccine reactogenicity inevitable price improved immunogenicity hence adjuvant reactogenicity may avoidable possible separate inflammation adjuvant action biggest remaining challenge adjuvant field decipher potential relationship adjuvant rare vaccine adverse reaction narcolepsy macrophagic myofasciitis alzheimer ’ disease existing adjuvant based aluminum salt strong safety record ongoing need new adjuvant intensive research adjuvant effect,2015-10-08,"Petrovsky, Nikolai",Drug Safety,,,,document_parses/pdf_json/c26d655ab85161130281014409a95b087c548070.json; document_parses/pdf_json/fddd6083ae049444ab80313b1093834d6949d211.json,document_parses/pmc_json/PMC4615573.xml.json,http://europepmc.org/articles/pmc4615573?pdf=render; https://doi.org/10.1007/s40264-015-0350-4; https://www.ncbi.nlm.nih.gov/pubmed/26446142/,20877427.0,3
97919,97919,124796,6rcezxjx,d1b10c067af8e33362698db214cb59eb14e6bf5a,Elsevier; PMC,Augmentation of immune responses to SARS coronavirus by a combination of DNA and whole killed virus vaccines,10.1016/j.vaccine.2005.04.011,PMC7115501,16005746.0,els-covid,studied immunogenicity dna sarsvaccine whole killed virus whole killed dna vaccine combination dna vaccine contained plasmid encoding sars coronavirus sarscov protein control human cmv promoter intron whole killed virus vaccine comprised sarscov propagated veroe cell subsequent βpropilactone inactivation formulated aluminum hydroxide adjuvant mouse immunized twice dna vaccine whole killed virus elicited higher antibody response mouse immunized three time dna vaccine whole killed virus vaccine mouse immunized twice whole killed virus vaccine elicited higher antibody response mouse immunized three time dna vaccine whole killed virus vaccine however combination vaccine induced thelper type th immune response whole killed virus vaccine induced helper type th immune response result demonstrate combination dna vaccine whole killed virus vaccine used enhance magnitude change bias immune response sarscov,2005-08-15,"Zakhartchouk, Alexander N.; Liu, Qiang; Petric, Martin; Babiuk, Lorne A.",Vaccine,,,,document_parses/pdf_json/d1b10c067af8e33362698db214cb59eb14e6bf5a.json,document_parses/pmc_json/PMC7115501.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X05004433; https://api.elsevier.com/content/article/pii/S0264410X05004433,19903144.0,3
97955,97955,124838,swxs5pr1,2311677b6bab8221ee5d403f9f5de32fad8ec229,Elsevier; Medline; PMC,Updated insights into the mechanism of action and clinical profile of the immunoadjuvant QS-21: A review(),10.1016/j.phymed.2019.152905,PMC7127804,31182297.0,no-cc,background vaccine adjuvant compound significantly enhanceprolong immune response coadministered antigen limitation use aluminium salt unable elicite cell response intracellular pathogen causing malaria tuberculosis aid driven development new alternative adjuvant q triterpene saponin purified quillaja saponaria purpose aim review attempt clarify mechanism action q either receptor signaling pathway vitro vivo special emphasis coadministration immunostimulants new adjuvant formulation called adjuvant system furthermore relevant clinical application presented method literature search covering period – performed using electronic database sci finder science direct medlinepubmed scopus google scholar result insight mechanism action q summarized follows vivo stimulation th humoral th cellmediated immune response action antigen presenting cell apc cell leading release th cytokine participating elimination intracellular pathogen activation nlrp inflammasome mouse apc subsequent release caspase dependent cytokine ilβ il important th response synthesis nearly q analog allowing structureactivity relationship mechanistic study unique synergy mechanism monophosphoryl lipid mpl q formulated liposome early ifnγ response promoting vaccine immunogenicity second part review related phase iiii clinical trial q mostly formulated as evaluate efficacy immunogenicity safety adjuvanted prophylactic vaccine infectious disease eg malaria herpes zoster tuberculosis aid therapeutic vaccine cancer alzheimers disease conclusion advanced phase iii clinical application led development two vaccine containing q part herpes zoster vaccine hzsu shingrix™ received license fda marketing authorization eu rtssas vaccine mosquirix™ malaria approved ema implementation subsaharan country routine use,2019-03-30,"Lacaille-Dubois, Marie-Aleth",Phytomedicine,,,,document_parses/pdf_json/2311677b6bab8221ee5d403f9f5de32fad8ec229.json,document_parses/pmc_json/PMC7127804.xml.json,https://doi.org/10.1016/j.phymed.2019.152905; https://www.sciencedirect.com/science/article/pii/S0944711319300753; https://www.ncbi.nlm.nih.gov/pubmed/31182297/; https://api.elsevier.com/content/article/pii/S0944711319300753,133340782.0,3
98074,98074,124983,ikptxviu,8055b4c692a2717a904b71e948926aaf953896e5,Medline; PMC,US-like isolates of porcine epidemic diarrhea virus from Japanese outbreaks between 2013 and 2014,10.1186/s40064-015-1552-z,PMC4668244,26693114.0,cc-by,since late outbreak porcine epidemic diarrhea virus pedv reemerged japan present study observed high detection rate pedv diarrhea sample suckling weaned sow farm experiencing acute diarrhea found positive pedv reverse transcription pcr sequencing phylogenic analysis partial spike gene orf pedv demonstrated prevailing japanese pedv isolates belonged novel genotype differed previously reported strain two pedv vaccine strain currently used japan sequence phylogenetic analysis revealed prevailing pedv isolates japan greatest genetic similarity u isolates vaccinerelated unlike vaccine strain prevailing field pedv isolates japan found number amino acid difference neutralizing epitope domain coe may affect antigenicity vaccine efficacy present study indicates recent pedv isolates may introduced japan overseas highlight urgent requirement novel vaccine controlling pedv outbreak japan,2015-12-02,"Van Diep, Nguyen; Norimine, Junzo; Sueyoshi, Masuo; Lan, Nguyen Thi; Hirai, Takuya; Yamaguchi, Ryoji",Springerplus,,,,document_parses/pdf_json/8055b4c692a2717a904b71e948926aaf953896e5.json,document_parses/pmc_json/PMC4668244.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26693114/; https://doi.org/10.1186/s40064-015-1552-z,17867900.0,3
98116,98116,125034,0q0jon8j,8d67e5c1683885f28d8b023224e65998d8e73411,Medline; PMC,"Evaluation of the efficacy of a trivalent vaccine mixture against a triple challenge with Mycoplasma hyopneumoniae, PCV2, and PRRSV and the efficacy comparison of the respective monovalent vaccines against a single challenge",10.1186/s12917-019-2091-6,PMC6794872,31619295.0,cc-by,background objective study ass efficacy trivalent vaccine mixture compare respective monovalent vaccine mycoplasma hyopneumoniae porcine circovirus type pcv porcine reproductive respiratory syndrome virus prrsv result pig triple challenged hyopneumoniae pcv prrsv following vaccination trivalent vaccine mixture exhibited significantly better growth performance compared unvaccinated challenged pig statistical difference found comparing pig population vaccinated trivalent vaccine followed triple challenge pig vaccinated monovalent hyopneumoniae vaccine followed mycoplasmal single challenge following area hyopneumoniae nasal shedding number hyopneumoniaespecific interferonγ secreting cell ifnγsc mycoplasmal lung lesion score pig vaccinated trivalent vaccine mixture followed triple challenge resulted similar reduction pcv viremia increase number pcvspecific ifnγsc reduction interstitial lung lesion score compared pig vaccinated pcv vaccine challenged pcv lastly significant difference reduction prrsv viremia increase prrsvspecific ifnγsc reduction interstitial lung lesion score pig vaccinated trivalent vaccine mixture followed triple challenge pig vaccinated monovalent prrsv vaccine followed prrsv challenge conclusion trivalent vaccine mixture efficacious triple challenge hyopneumoniae pcv prrsv trivalent vaccine mixture however result equal protection compared respective monovalent vaccine largest vaccine occurring within prrsv,2019-10-16,"Oh, Taehwan; Park, Kee Hwan; Yang, Siyeon; Jeong, Jiwoon; Kang, Ikjae; Park, Changhoon; Chae, Chanhee",BMC Vet Res,,,,document_parses/pdf_json/8d67e5c1683885f28d8b023224e65998d8e73411.json,document_parses/pmc_json/PMC6794872.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31619295/; https://doi.org/10.1186/s12917-019-2091-6,204707148.0,3
98141,98141,125069,f3f31h4r,9e96c7b07f540611fcaccb80520fb7b3432d94b5,Medline; PMC,Emerging viruses and current strategies for vaccine intervention,10.1111/cei.13295,PMC6468171,30993690.0,cc-by-nc-nd,past decade several notable virus suddenly emerged obscurity anonymity become serious global health threat provoking concern regarding sustained epidemic transmission immunologically naive human population new threat come call rapid vaccine development indeed vaccine considered critical component disease prevention emerging viral infection many case medical option limited non‐existent infection result rapid clinical deterioration effectiveness therapeutic limited classic approach vaccine development still amenable emerging virus application molecular technique virology profoundly influenced understanding virus biology vaccination method based replicating attenuated non‐replicating virus vector approach become useful vaccine platform together growing understanding viral disease emergence range vaccine strategy international commitment underpin development vaccine intervention new emerging virus may become possibility,2019-04-16,"Afrough, B.; Dowall, S.; Hewson, R.",Clin Exp Immunol,,,,document_parses/pdf_json/9e96c7b07f540611fcaccb80520fb7b3432d94b5.json,document_parses/pmc_json/PMC6468171.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30993690/; https://doi.org/10.1111/cei.13295,119523606.0,3
98157,98157,125089,9zq9f9gu,bcd61a98bcf6ab96b5e65dd3f7bfe288e6f9153a,Medline; PMC,"Stimulation of Dectin-1 and Dectin-2 during Parenteral Immunization, but Not Mincle, Induces Secretory IgA in Intestinal Mucosa",10.1155/2018/3835720,PMC5872666,29725603.0,cc-by,induction robust longlived mucosal immune response vaccination critical achieve protection numerous pathogen however traditional injected vaccine generally poor inducer mucosal immunity one effective strategy improve vaccine efficacy incorporation adjuvant molecule enhance polarize adaptive immune reaction effect sykcoupled lectin receptor agonist adjuvant induce mucosal immune reaction parenteral immunization fully studied report agonist trehalosedibehenate tdb curdlan furfurman stimulate dectin dectin mincle respectively activate transcription factor nfκb nfat ap various extent murine raw macrophage even though similar pathway activated agonist also elicit differential expression maturation marker bone marrowderived dendritic cell well differential cytokine secretion cell splenic mononuclear cell vivo assay also show agonist dectin dectin mincle induce heavy iga secretion intestinal mucosa even delivered parenterally strikingly effect appears formulationindependent collectively data suggest adjuvant based dectin dectin agonist may significantly improve efficacy parenteral vaccine inducing robust local immune reaction intestinal mucosa,2018-03-14,"Dzharullaeva, Alina S.; Tukhvatulin, Amir I.; Erokhova, Alina S.; Bandelyuk, Alina S.; Polyakov, Nikita B.; Solovyev, Andrey I.; Nikitenko, Natalia A.; Shcheblyakov, Dmitry V.; Naroditsky, Boris S.; Logunov, Denis Y.; Gintsburg, Alexander L.",J Immunol Res,,,,document_parses/pdf_json/bcd61a98bcf6ab96b5e65dd3f7bfe288e6f9153a.json,document_parses/pmc_json/PMC5872666.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29725603/; https://doi.org/10.1155/2018/3835720,13748415.0,3
98166,98166,125102,xnltsap9,e381ce0dcf2297e0b2d44e03b0a3a6371a580926,Elsevier; Medline; PMC,An exploration of midwives’ role in the promotion and provision of antenatal influenza immunization: A Mixed Methods Inquiry.,10.1016/j.wombi.2020.04.009,PMC7211614,32418653.0,els-covid,problem south australian study previously investigated role midwife promotion provision antenatal influenza immunization background influenza acquired pregnancy serious sequalae mother fetus recent study demonstrated influenza vaccine pregnancy safe effective despite evidence suggests vaccine uptake pregnancy suboptimal australia worldwide aim aim study investigate role midwife promotion provision antenatal influenza vaccine provide statistical thematic description barrier enablers midwife encounter method mixed method study incorporated cross sectional online survey indepth interview conducted midwife employed urban regional south australia finding quantitative data available midwife midwife participated interview recruitment interview phase last question survey whilst midwife indicated education vaccine promotion part role immunization knowledge varied registered nursemidwives rmrn registered midwife rm p quantitative data showed midwife felt sufficiently educated provide vaccine midwife received formal immunization training likely recommend vaccine p qualitative data confirmed result identified lack immunization education barrier practise conclusion midwife identified immunization knowledge deficit midwife received immunization education likely actively promote provide vaccine pregnant woman finding indicate need immunization education midwife tertiary practice setting,2020-05-11,"Smith, Susan Elizabeth",Women Birth,,,,document_parses/pdf_json/e381ce0dcf2297e0b2d44e03b0a3a6371a580926.json,,https://doi.org/10.1016/j.wombi.2020.04.009; https://www.ncbi.nlm.nih.gov/pubmed/32418653/; https://www.sciencedirect.com/science/article/pii/S1871519220302389?v=s5; https://api.elsevier.com/content/article/pii/S1871519220302389,218571682.0,3
98287,98287,125236,nb6miso7,9189faee88e17c0cfdc158fc8aa8975850427cd1,Elsevier; PMC,Immune responses in Balb/c mice induced by a candidate SARS-CoV inactivated vaccine prepared from F69 strain,10.1016/j.vaccine.2004.11.073,PMC7115646,15837220.0,els-covid,immunogenicity candidateinactivated vaccine prepared sarscov f strain evaluated balbc mouse potent humoral immune response induced elicitation three time immunization week interval vaccine combined three type adjuvant freunds adjuvant aloh adjuvant cpg adjuvant titer specific igg antibody three test group peaked sixth week first vaccination significant difference existed kinetics specific igg antibody level strong neutralizing capacity exhibited microcytopathic effect neutralization test indicated specific antibody protective western blot assay demonstrated specificity induced serum antibody,2005-05-02,"Zhang, Chuan-hai; Lu, Jia-hai; Wang, Yi-fei; Zheng, Huan-ying; Xiong, Sheng; Zhang, Mei-ying; Liu, Xin-jian; Li, Jiu-xiang; Wan, Zhuo-yue; Yan, Xin-ge; Qi, Shu-Yuan; Cui, Zhiyong; Zhang, Biliang",Vaccine,,,,document_parses/pdf_json/9189faee88e17c0cfdc158fc8aa8975850427cd1.json,document_parses/pmc_json/PMC7115646.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X05000939; https://api.elsevier.com/content/article/pii/S0264410X05000939,25905505.0,3
98308,98308,125260,by3vijj9,c4605351a6f163494f4d470cbc57eb2194af2ca1,Elsevier; Medline; PMC,Assessment of the safety and efficacy of an attenuated live vaccine based on highly virulent genotype 2b porcine epidemic diarrhea virus in nursing piglets,10.1016/j.vetmic.2019.03.009,PMC7117296,30955799.0,els-covid,previously reported generation attenuated knus delorf virus continuous propagation highly virulent gb porcine epidemic diarrhea virus pedv vero cell present study aimed ass safety delorf evaluate effectiveness live vaccine primebooster vaccination reversion virulence experiment revealed delorf strain retains attenuated phenotype genetic stability five successive passage susceptible piglet pregnant sow primed orally delorf live vaccine boosted intramuscularly twice commercial killed vaccine week interval prior parturition sow vaccination regimen completely protected nursing piglet virulent gb challenge evidenced increase survival rate significant reduction diarrhea intensity including amount duration pedv fecal shedding addition despite – day period weight loss piglet vaccinated sow challenge daily weight gain recovered day postchallenge became similar unchallenged pig unvaccinated sow course experiment furthermore strong antibody response pedv verified serum colostrum immunized sow primeboost treatment offspring altogether data demonstrated attenuated delorf strain guarantee safety host animal reversion virulence suitable effective primary live vaccine providing durable maternal lactogenic immunity passive piglet protection,2019-04-30,"Jang, Guehwan; Won, Hokeun; Lee, Dong-Uk; Noh, Yun-Hee; Lee, Seung-Chul; Choi, Hwan-Won; Yoon, In-Joong; Lee, Yoo Jin; Sang Yoo, Han; Lee, Changhee",Veterinary Microbiology,,,,document_parses/pdf_json/c4605351a6f163494f4d470cbc57eb2194af2ca1.json,document_parses/pmc_json/PMC7117296.xml.json,https://www.sciencedirect.com/science/article/pii/S0378113519301300; https://doi.org/10.1016/j.vetmic.2019.03.009; https://www.ncbi.nlm.nih.gov/pubmed/30955799/; https://api.elsevier.com/content/article/pii/S0378113519301300,91203829.0,3
98311,98311,125263,gpb25fga,b5f25901015340a5312e3c9f6b4fc7b1a6744df9,Medline; PMC,"A Highly Immunogenic, Protective, and Safe Adenovirus-Based Vaccine Expressing Middle East Respiratory Syndrome Coronavirus S1-CD40L Fusion Protein in a Transgenic Human Dipeptidyl Peptidase 4 Mouse Model",10.1093/infdis/jiz137,PMC7107499,30911758.0,no-cc,background infection control measure played major role limiting humancameltohuman transmission middle east respiratory syndrome coronavirus merscov however development effective safe human camel vaccine warranted method extended optimized previous recombinant adenovirus rad–based vaccine platform characterized vivo amplified cdmediated specific response generate merscov subunitbased vaccine generated rad construct expressing cdtargeted fusion protein radsfcdl untargeted rad green fluorescent protein radgfp evaluated efficacy safety human dipeptidyl peptidase transgenic hdpp tg mouse result immunization hdpp tg mouse single dose radsfcdl elicited robust significant specific immunoglobulin g neutralizing antibody induced dos rad merscov challenge vaccine conferred complete protection morbidity mortality evidenced significantly undetectablereduced pulmonary viral load compared control group however rads– radsfcdl–immunized mouse exhibited marked pulmonary perivascular hemorrhage post–merscov challenge despite observed protection conclusion incorporation cdl radbased merscov vaccine targeting molecule molecular adjuvant enhances immunogenicity efficacy also prevents inadvertent pulmonary pathology viral challenge thereby offering promising strategy enhance safety potency vaccine,2019-11-15,"Hashem, Anwar M; Algaissi, Abdullah; Agrawal, Anurodh Shankar; Al-amri, Sawsan S; Alhabbab, Rowa Y; Sohrab, Sayed S; S. Almasoud, Abdulrahman; Alharbi, Naif Khalaf; Peng, Bi-Hung; Russell, Marsha; Li, Xuguang; Tseng, Chien-Te K",J Infect Dis,,,,document_parses/pdf_json/b5f25901015340a5312e3c9f6b4fc7b1a6744df9.json,document_parses/pmc_json/PMC7107499.xml.json,https://doi.org/10.1093/infdis/jiz137; https://www.ncbi.nlm.nih.gov/pubmed/30911758/,85516924.0,3
98395,98395,125364,lfn9ggg3,57570091beaa720453406818912b8a7cb2f56fa0,Elsevier; PMC,LC16m8: An attenuated smallpox vaccine,10.1016/j.vaccine.2006.03.087,PMC7115618,17052815.0,els-covid,frequency moderate severe adverse reaction associated smallpox vaccine currently stockpiled u continued threat bioterrorism prompted development effective vaccine improved safety profile lcm attenuated replicating smallpox vaccine derived lister strain vaccinia currently licensed japan safely used child shown markedly le neurotoxicity unattenuated vaccine nonclinical study lcm immunogenic single dose recent study two different animal model demonstrated protective efficacy equivalent fdalicensed smallpox vaccine article review history available scientific literature regarding lcm provides comparison smallpox vaccine,2006-11-17,"Kenner, Julie; Cameron, Fiona; Empig, Cyril; Jobes, David V.; Gurwith, Marc",Vaccine,,,,document_parses/pdf_json/57570091beaa720453406818912b8a7cb2f56fa0.json,document_parses/pmc_json/PMC7115618.xml.json,https://api.elsevier.com/content/article/pii/S0264410X06004142; https://www.sciencedirect.com/science/article/pii/S0264410X06004142,730375.0,3
98434,98434,125411,uqz07cbb,febe223f9c10bc8bf3145f190e62ca2fc9f0ebd3,Elsevier; Medline; PMC,Advances in peste des petits ruminants vaccines,10.1016/j.vetmic.2017.01.010,PMC7130925,28161212.0,els-covid,peste de petits ruminant ppr highly contagious disease small ruminant lead high morbidity mortality thereby result devastating economic consequence livestock industry ppr currently endemic across part asia africa two region highest concentration poor people world sheep goat particularly contribute significantly towards upliftment livelihood poor marginal farmer region context ppr directly affecting viability sheep goat husbandry emerged major hurdle development region control ppr region could significantly contribute poverty alleviation therefore office international de epizooties oie food agricultural organization fao targeted control eradication ppr priority order achieve goal potent safe efficacious liveattenuated ppr vaccine longlasting immunity available immunoprophylaxis however liveattenuated ppr vaccine thermolabile need maintenance effective cold chain deliver field addition infected animal differentiated vaccinated animal overcome limitation recombinant vaccine developed review comprehensively describes latest development ppr vaccine,2017-07-31,"Kumar, Naveen; Barua, Sanjay; Riyesh, Thachamvally; Tripathi, Bhupendra N.",Veterinary Microbiology,,,,document_parses/pdf_json/febe223f9c10bc8bf3145f190e62ca2fc9f0ebd3.json,document_parses/pmc_json/PMC7130925.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28161212/; https://doi.org/10.1016/j.vetmic.2017.01.010; https://www.sciencedirect.com/science/article/pii/S0378113517300548; https://api.elsevier.com/content/article/pii/S0378113517300548,4406542.0,3
98435,98435,125412,cuyboyqc,235e5cda4dc7631fda5c27fd58f99ee0d261a0a0,Elsevier; Medline; PMC,Harnessing self-assembled peptide nanoparticles in epitope vaccine design,10.1016/j.biotechadv.2017.05.002,PMC7127164,28522213.0,no-cc,vaccination one successful breakthrough medical history recent year epitopebased subunit vaccine introduced safer alternative traditional vaccine however suffer limited immunogenicity nanotechnology shown value solving issue different kind nanovaccines employed among viruslike nanoparticles vlps selfassembled peptide nanoparticles sapns seem promising recently sapns attracted special interest due unique property including molecular specificity biodegradability biocompatibility also resemble pathogen term size multivalency allows orderly repetitive display antigen surface induces stronger immune response single immunogen vaccine design sapn selfadjuvanticity regarded outstanding advantage since use toxic adjuvant longer required sapns usually composed helical βsheet secondary structure tailored natural peptide de novo structure flexibility subunit selection open door wide variety molecule different characteristic sapn engineering emerging area novel structure expected generated future particularly rapid progress related computational tool aim review provide stateoftheart overview selfassembled peptide nanoparticles use vaccine design recent study additionally principle design application computational approach vaccine design summarized,2017-05-15,"Negahdaripour, Manica; Golkar, Nasim; Hajighahramani, Nasim; Kianpour, Sedigheh; Nezafat, Navid; Ghasemi, Younes",Biotechnol Adv,,,,document_parses/pdf_json/235e5cda4dc7631fda5c27fd58f99ee0d261a0a0.json,document_parses/pmc_json/PMC7127164.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28522213/; https://www.sciencedirect.com/science/article/pii/S073497501730054X; https://doi.org/10.1016/j.biotechadv.2017.05.002; https://api.elsevier.com/content/article/pii/S073497501730054X,4580338.0,3
98475,98475,125462,biq0chyn,0beba87e3366b16efad5fc85a9fb2be33e63e019,Elsevier; PMC,Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease,10.1016/s0264-410x(00)00183-3,PMC7125741,10930670.0,els-covid,recently developed transmissible vaccine immunize rabbit myxomatosis rabbit haemorrhagic disease based recombinant myxoma virus mv expressing rabbit haemorrhagic disease virus rhdv capsid protein bárcena et al horizontal transmissible protection myxomatosis rabbit haemorragic disease using recombinant myxoma virus j virol – administration recombinant virus protects rabbit lethal rhdv mv challenge furthermore recombinant virus capable horizontal spreading promoting protection contact animal thus providing opportunity immunize wild rabbit population however potential risk must extensively evaluated considering field use study several safety issue concerning proposed vaccine evaluated laboratory condition result indicated vaccine administration safe even fold overdose undesirable effect detected upon administration immunosuppressed pregnant rabbit recombinant virus maintained attenuated phenotype passage vivo,2000-09-15,"Torres, Juan M; Ramı́rez, Miguel A; Morales, Mónica; Bárcena, Juan; Vázquez, Belén; Espuña, Enric; Pagès-Manté, Albert; Sánchez-Vizcaı́no, José M",Vaccine,,,,document_parses/pdf_json/0beba87e3366b16efad5fc85a9fb2be33e63e019.json,document_parses/pmc_json/PMC7125741.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X00001833; https://api.elsevier.com/content/article/pii/S0264410X00001833,16943519.0,3
98506,98506,125498,hag6qydb,d3ffa11f429a355f465a235232ad67b52c495342,Elsevier; Medline; PMC,Engineering Coronaviruses to Evaluate Emergence and Pathogenic Potential,10.1016/j.tim.2016.04.001,PMC7119051,27095615.0,els-covid,recent study provides platform generating infectious coronavirus genome using sequence data examining capability replicating human cell causing disease animal model evaluating therapeutic vaccine similar approach could used ass potential human emergence pathogenicity virus,2016-06-30,"Lau, Susanna K.P.; Woo, Patrick C.Y.",Trends in Microbiology,,,,document_parses/pdf_json/d3ffa11f429a355f465a235232ad67b52c495342.json,document_parses/pmc_json/PMC7119051.xml.json,https://www.sciencedirect.com/science/article/pii/S0966842X16300038; https://doi.org/10.1016/j.tim.2016.04.001; https://www.ncbi.nlm.nih.gov/pubmed/27095615/; https://api.elsevier.com/content/article/pii/S0966842X16300038,3579692.0,3
98533,98533,125533,6o2upns3,22b6982820cdeb330dc2086ea69713f6e109a671,Medline; PMC,Recombinant Chimeric Transmissible Gastroenteritis Virus (TGEV)—Porcine Epidemic Diarrhea Virus (PEDV) Virus Provides Protection against Virulent PEDV,10.3390/v11080682,PMC6723174,31349683.0,cc-by,porcine epidemic diarrhea virus pedv enteric coronavirus causing high morbidity mortality porcine herd worldwide although inactivated live attenuated vaccine extensively used emergence highly virulent strain recurrent outbreak even vaccinated farm highlight need effective vaccine engineering genetically defined live attenuated vaccine rational approach novel vaccine development line engineered attenuated virus based transmissible gastroenteritis virus tgev genome expressing chimeric spike protein virulent united state u pedv strain virus rtgevrsspedv attenuated highlysensitive fivedayold piglet infected animal lose weight none died addition virus caused minor tissue damage compared virulent virus rtgevrsspedv vaccine candidate also attenuated threeweekold animal used evaluate protection conferred virus compared protection induced infection virulent pedv u strain pedvnvsl rtgevrsspedv virus protected challenge virulent pedv strain reducing challenge virus titer jejunum leading undetectable challenge virus rna level feces rtgevrsspedv virus induced humoral immune response specific pedv including neutralizing antibody altogether data indicated rtgevrsspedv promising vaccine candidate virulent pedv infection,2019-07-25,"Pascual-Iglesias, Alejandro; Sanchez, Carlos M.; Penzes, Zoltan; Sola, Isabel; Enjuanes, Luis; Zuñiga, Sonia",Viruses,,,,document_parses/pdf_json/22b6982820cdeb330dc2086ea69713f6e109a671.json,document_parses/pmc_json/PMC6723174.xml.json,https://doi.org/10.3390/v11080682; https://www.ncbi.nlm.nih.gov/pubmed/31349683/,198933728.0,3
98539,98539,125539,0s81kuwt,3ba40deeea33744e3cb9b8d80c01af0ad63ec2f6,Medline; PMC,Advances Towards Painless Vaccination and Newer Modes of Vaccine Delivery,10.1007/s12098-017-2377-2,PMC7090876,28620730.0,no-cc,vaccine successful reducing mortality morbidity delivered intramuscular intravenous route associated pain baby bring lot anxiety parent marked increase number injection required first two year life completing vaccination schedule hence need painless vaccine delivery system numerous new route vaccination like oral nasal transdermal route tried oral polio intranasal influenza already success newer approach like edible vaccine nasal spray dry powder preparation jet injector microneedles nanopatches promising delivering painless vaccine many clinical trial vaccine delivery system painless also cost effective safe easy administer mass population may devoid need cold chain painless delivery system ensure better compliance vaccination schedule,2017-06-16,"Garg, Neha; Aggarwal, Anju",Indian J Pediatr,,,,document_parses/pdf_json/3ba40deeea33744e3cb9b8d80c01af0ad63ec2f6.json,document_parses/pmc_json/PMC7090876.xml.json,https://doi.org/10.1007/s12098-017-2377-2; https://www.ncbi.nlm.nih.gov/pubmed/28620730/,4228831.0,3
98592,98592,125610,vouu56rr,1f8d30466ceebe01d54f02c0f3fa49de023b1600,Medline; PMC,Viruses to fight other viruses: the influenza vaccine case,10.15252/emmm.202012059,PMC7207152,32320128.0,cc-by,undoubtedly vaccination one health intervention showing major impact humankind vaccine remain one effective safest way tackle infection current coronavirus pandemic exception hope ongoing international effort succeed developing vaccine soon scenario present work published edition embo molecular medicine demminger colleague demminger et al timeliness exemplify step needed develop effective vaccine,2020-04-22,"Bengoechea, Jose A",EMBO Mol Med,,,,document_parses/pdf_json/1f8d30466ceebe01d54f02c0f3fa49de023b1600.json,document_parses/pmc_json/PMC7207152.xml.json,https://doi.org/10.15252/emmm.202012059; https://www.ncbi.nlm.nih.gov/pubmed/32320128/,216074186.0,3
98614,98614,125638,bnjkmegh,2ca704516c253ae250de0ed2598315aa1beceda8,Elsevier; PMC,Induction of mucosal immune responses and protection against enteric viruses: rotavirus infection of gnotobiotic pigs as a model,10.1016/s0165-2427(02)00046-6,PMC7119626,12072229.0,no-cc,enteric virus major cause diarrhea animal human among rotavirus one important cause diarrhea young animal human infant lack understanding mechanism induce intestinal immunity correlate protective immunity neonate impaired development safe effective vaccine enteric virus study candidate vaccine using adult mouse model subclinical enteric viral infection often predict vaccine efficacy disease evaluated neonatal large animal series study conducted using neonatal gnotobiotic pig model rotavirus infection diarrhea identify correlate protective immunity evaluate traditional novel vaccine approach induction mucosal immune response protection enteric virus gnotobiotic pig recovered infection virulent wa human rotavirus hrv mimic natural infection high number intestinal iga rotavirusspecific primary antibodysecreting cell ascs memory bcells recall antigen measured elispot assay correlated complete protection rotavirus challenge shortterm iga memory bcells resident ileum major site rotavirus replication spleen bone marrow major resident site longerterm igg memory bcells candidate rotavirus vaccine evaluated pig ability induce intestinal systemic asc protection rotavirus infection diarrhea included attenuated live virus inactivated virus baculovirusexpressed doublelayered rotaviruslike particle vlps combination candidate vaccine various adjuvant delivery system immunization route tested including incomplete freund ’ adjuvant im immunization mutant escherichia coli heat labile enterotoxin rg mlt immunization shown orally administered replicating vaccine effective priming intestinal iga asc memory bcell response administered nonreplicating vlps plus mlt effective booster vaccine conclude protective immunity depends magnitude location viral proteinspecificity isotype antibody response induced vaccination therefore highly effective enteric viral vaccine induce sufficient level intestinal iga antibody ii include viral antigen induce neutralizing antibody iii require use effective mucosal adjuvant antigen delivery system nonreplicating oral vaccine,2002-09-10,"Yuan, Lijuan; Saif, Linda J",Vet Immunol Immunopathol,,,,document_parses/pdf_json/2ca704516c253ae250de0ed2598315aa1beceda8.json,document_parses/pmc_json/PMC7119626.xml.json,https://www.sciencedirect.com/science/article/pii/S0165242702000466; https://api.elsevier.com/content/article/pii/S0165242702000466,25715489.0,3
98620,98620,125647,bytd4ueh,c9f8a0a6ee96deb896a2dcb0a19c3eb76074a22d,Medline; PMC,Middle East respiratory syndrome: obstacles and prospects for vaccine development,10.1586/14760584.2015.1036033,PMC4832601,25864502.0,bronze-oa,recent emergence middle east respiratory syndrome mers highlight need engineer new method expediting vaccine development emerging disease however several obstacle prevent pursuit licensable mers vaccine first lack suitable animal model mers complicates vivo testing candidate vaccine second due low number mers case pharmaceutical company little incentive pursue mers vaccine production cost clinical trial high addition timeline bench research approved vaccine use year longer using novel method costsaving strategy genetically engineered vaccine produced quickly costeffectively along progress mers animal model development obstacle circumvented least mitigated,2015-04-11,"Papaneri, Amy B.; Johnson, Reed F.; Wada, Jiro; Bollinger, Laura; Jahrling, Peter B.; Kuhn, Jens H.",Expert Review of Vaccines,,,,document_parses/pdf_json/c9f8a0a6ee96deb896a2dcb0a19c3eb76074a22d.json,document_parses/pmc_json/PMC4832601.xml.json,https://www.tandfonline.com/doi/pdf/10.1586/14760584.2015.1036033?needAccess=true; https://www.ncbi.nlm.nih.gov/pubmed/25864502/; https://doi.org/10.1586/14760584.2015.1036033,40578570.0,3
98732,98732,125782,kjf2bq0g,f7c3160bef4169d29e2a8bdd79dd6e9056d4774c,Medline; PMC,Chikungunya: A Potentially Emerging Epidemic?,10.1371/journal.pntd.0000623,PMC2860491,20436958.0,cc-by,chikungunya virus mosquitoborne emerging pathogen major health impact human cause fever disease headache rash nausea vomiting myalgia arthralgia indigenous tropical africa recent large outbreak reported part south east asia several neighboring island – europe furthermore positive case confirmed united state traveler returning known outbreak area currently vaccine antiviral treatment threat emerging global pandemic peculiar problem associated immediate seasonal epidemic warrant development effective vaccine review summarize evidence supporting concept,2010-04-27,"Thiboutot, Michelle M.; Kannan, Senthil; Kawalekar, Omkar U.; Shedlock, Devon J.; Khan, Amir S.; Sarangan, Gopalsamy; Srikanth, Padma; Weiner, David B.; Muthumani, Karuppiah",PLoS Negl Trop Dis,,,,document_parses/pdf_json/f7c3160bef4169d29e2a8bdd79dd6e9056d4774c.json,document_parses/pmc_json/PMC2860491.xml.json,https://doi.org/10.1371/journal.pntd.0000623; https://www.ncbi.nlm.nih.gov/pubmed/20436958/,2381211.0,3
98758,98758,125819,cetmg1km,53d3510688e5395d0fcb9c04098f72d2ca4c7e58,Elsevier; PMC,DNA Vaccine,10.1016/s0065-2660(05)54011-2,PMC7119308,16096015.0,els-covid,dna vaccine proven one promising application field gene therapy due unique ability readily induce humoral well cellular immune response attracted great interest concept first confirmed early thousand article related dna vaccine published scientist began realize although dna vaccine effective small animal model effectiveness recent clinical trail rather disappointing therefore current effort shifted understanding different performance dna vaccine mouse large animal model transfer success dna vaccine small animal large animal human,2005-12-31,"Cui, Zhengrong",Advances in Genetics,,,,document_parses/pdf_json/53d3510688e5395d0fcb9c04098f72d2ca4c7e58.json,document_parses/pmc_json/PMC7119308.xml.json,https://api.elsevier.com/content/article/pii/S0065266005540112; https://www.sciencedirect.com/science/article/pii/S0065266005540112,45529147.0,3
98809,98809,125882,5cwm7b6r,b16e5ea6902ab84e40164075fa83741d8b877b53,Medline; PMC,Host responses from innate to adaptive immunity after vaccination: Molecular and cellular events,10.1007/s10059-009-0015-1,PMC6280669,19214429.0,no-cc,availability effective vaccine profound positive effect improving quality public health preventing infectious disease despite many successful vaccine still old new emerging pathogen vaccine available better understanding vaccine work providing protection help improve current vaccine well develop effective vaccine pathogen proper mean control recent study focused innate immunity first line host defense role inducing adaptive immunity study intense area research reveal immunological mechanism vaccine work protection tolllike receptor tlrs family receptor pathogenassociated molecular pattern cell innate immune system play critical role detecting responding microbial infection importantly innate immune system modulates quantity quality longterm b cell memory protective immune response pathogen limited study suggest vaccine mimic natural infection andor structure pathogen seem effective inducing longterm protective immunity better understanding similarity difference molecular cellular event host response vaccination pathogen infection would enable rationale design novel preventive measure many challenging pathogen,2009-02-05,"Kang, Sang-Moo; Compans, Richard W.",Mol Cells,,,,document_parses/pdf_json/b16e5ea6902ab84e40164075fa83741d8b877b53.json,,https://www.ncbi.nlm.nih.gov/pubmed/19214429/; https://doi.org/10.1007/s10059-009-0015-1,207047574.0,3
98865,98865,125951,epyc37sz,a26ffcce0878ea2ebab2a7ed46a9761244fda936,Medline; PMC,Effectiveness of adjuvanted seasonal influenza vaccines (Inflexal V(®) and Fluad(®)) in preventing hospitalization for influenza and pneumonia in the elderly: A matched case-control study,10.4161/hv.22231,PMC3667930,23143775.0,cc-by-nc,annual vaccination main mean preventing influenza elderly order evaluate effectiveness adjuvanted seasonal influenza vaccine available italy preventing hospitalization influenza pneumonia matched casecontrol study performed elderly subject – season genoa italy case control matched ratio according gender age socioeconomic status type influenza vaccine vaccine effectiveness calculated ive orx crude odds ratio estimated conditional logistic regression model adjusted odds ratio estimated multivariable logistic model study area influenza activity moderate – season optimal matching circulating virus vaccine strain recruited casecontrol pair case control vaccinated adjuvanted influenza vaccine fluad® considered together inflexal v® associated significant reduction risk hospitalization effectiveness ci – adjusted vaccine effectiveness ci – ci – inflexal v® fluad® respectively adjuvanted vaccine proved effective although result displayed statistical significance inflexal v® p fluad® statistical significance reached p study first provide information effectiveness inflexal v® term reducing hospitalization influenza pneumonia elderly demonstrates vaccine yield high degree protection use would generate considerable saving national health service,2013-01-01,"Gasparini, Roberto; Amicizia, Daniela; Lai, Piero Luigi; Rossi, Stefania; Panatto, Donatella",Hum Vaccin Immunother,,,,document_parses/pdf_json/a26ffcce0878ea2ebab2a7ed46a9761244fda936.json,document_parses/pmc_json/PMC3667930.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/23143775/; https://doi.org/10.4161/hv.22231,16862684.0,3
98919,98919,126013,ni0r4850,cd3e95954a7d61cfe7a2d0a37267306c77d1b493,Medline; PMC,A Web Resource for Designing Subunit Vaccine Against Major Pathogenic Species of Bacteria,10.3389/fimmu.2018.02280,PMC6190870,30356876.0,cc-by,evolution led expansion survival strategy pathogen including bacteria emergence drug resistant strain proved major global threat vaccination promising strategy protect human population reverse vaccinology robust vaccine development approach especially availability largescale sequencing data rapidly dropping cost technique acquiring data various organism present study implement immunoinformatic approach screening possible antigenic protein among various pathogenic bacteria systemically arrive epitopebased vaccine candidate pathogenic bacteria thousand four hundred fifty nine virulence factor five hundred forty six product essential gene appraised target protein predict potential epitope potential stimulate different arm immune system address selftolerance selfepitopes identified mapping human proteome removed analysis revealed protein bacterial specie found virulent well essential survival proved suitable vaccine target specie addition prediction mhcii binder b cell cell epitope well adjuvant individually protein bacterial specie stringent criterion lead u identify unique epitope predicted tcell epitope bcell epitope mhc ii binder vaccine adjuvant order provide service scientific community developed web server vactarbac designing vaccine specie bacteria platform integrates number tool includes visualization tool present antigenicityepitopes density antigenic sequence tool help user identify promiscuous vaccine candidate pathogenic antigen server vactarbac available url httpwebsiiitdeduinraghavavactarbac,2018-10-02,"Nagpal, Gandharva; Usmani, Salman Sadullah; Raghava, Gajendra P. S.",Front Immunol,,,,document_parses/pdf_json/cd3e95954a7d61cfe7a2d0a37267306c77d1b493.json,document_parses/pmc_json/PMC6190870.xml.json,https://doi.org/10.3389/fimmu.2018.02280; https://www.ncbi.nlm.nih.gov/pubmed/30356876/,52902802.0,3
98935,98935,126039,7t1bzc7f,71491672e3ebbdb760264a8a3318e5207a7456e6,Elsevier; PMC,Chapter Seven Vaccine Adjuvant Nanotechnologies,10.1016/b978-0-323-39981-4.00007-5,PMC7151801,,els-covid,increasing sophistication vaccine adjuvant design driven improved understanding importance nanoscale feature adjuvant immunological function newly available advanced nanomanufacturing technique allow precise control adjuvant particle size shape texture surface chemistry novel adjuvant concept include selfassembling particle targeted immune delivery individual concept combined create single integrated vaccine nanoparticlecombining antigen adjuvant dctargeting element process concept adjuvant broadened include immunestimulatory substance also design feature enhance immune response relevant vaccine antigen modern definition adjuvant includes classical immune stimulators also aspect particle size shape surface chemistry enhance vaccine immunogenicity even includes purely physical process texturing particle surface maximize immunogenicity looking forward adjuvant increasingly seen separate addon item wholly integrated element complete vaccine delivery package hence vaccine system increasingly approach complexity sophistication pathogen incorporating highly specific particle property content behavior designed maximize immune system recognition drive immune response specific direction affords maximal protection,2017-12-31,"Barclay, T.; Petrovsky, N.",Micro and Nanotechnology in Vaccine Development,,,,document_parses/pdf_json/71491672e3ebbdb760264a8a3318e5207a7456e6.json,document_parses/pmc_json/PMC7151801.xml.json,https://www.sciencedirect.com/science/article/pii/B9780323399814000075; https://api.elsevier.com/content/article/pii/B9780323399814000075,138340343.0,3
98954,98954,126062,kv9n2qj3,565a2da4adb3d97eb2c9e303be04343d3e32986f,Medline; PMC,A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective,10.1099/jmm.0.000565,PMC7079582,28855003.0,bronze-oa,laboratoryconfirmed case middle east respiratory syndrome coronavirus merscov country mortality rate specific therapy current therapy mainly adapted severe acute respiratory syndrome sarscov treatment including broadspectrum antibiotic corticosteroid interferon ribavirin lopinavir–ritonavir mycophenolate mofetil subject wellorganized clinical trial development specific therapy vaccine therefore urgently required examine existing potential therapy vaccine molecular perspective include viral protein targeting inhibitor host protease including tmprss cathepsin l furin protease viral mpro plpro protease convalescent plasma vaccine candidate medline database searched using combination variation term including ‘ middle east respiratory syndrome coronavirus ’ ‘ merscov ’ ‘ sars ’ ‘ therapy ’ ‘ molecular ’ ‘ vaccine ’ ‘ prophylactic ’ ‘ protein ’ ‘ dpp ’ ‘ heptad repeat ’ ‘ protease ’ ‘ inhibitor ’ ‘ antiviral ’ ‘ broadspectrum ’ ‘ interferon ’ ‘ convalescent plasma ’ ‘ lopinavir ritonavir ’ ‘ antibody ’ ‘ antiviral peptide ’ ‘ live attenuated virus ’ many option development merscovspecific therapy currently merscov considered pandemic potential however high mortality rate potential mutation could increase transmissibility give urgency search direct effective therapy welldesigned controlled clinical trial needed existing therapy prospective direct therapy,2017-09-01,"Rabaan, Ali A.; Alahmed, Shamsah H.; Bazzi, Ali M.; Alhani, Hatem M.",Journal of Medical Microbiology,,,,document_parses/pdf_json/565a2da4adb3d97eb2c9e303be04343d3e32986f.json,document_parses/pmc_json/PMC7079582.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28855003/; https://doi.org/10.1099/jmm.0.000565,36102633.0,3
99038,99038,126168,4v2tl0gi,07e425b0a2cb18dc7e27723172b276c1c1c4487a,Medline; PMC,Progress towards the prevention and treatment of norovirus infections,10.2217/fmb.13.109,PMC3904215,24199805.0,cc-by,noroviruses recognized major cause acute gastroenteritis developed world yet ability prevent control infection limited recent work highlighted typically acute infection population immunocompromised patient often experience longterm infection may last many year cohort patient regularly exposed infectious material example care worker others would benefit greatly development vaccine antiviral therapy licensed vaccine antiviral yet developed work past year area intensified trial vaccine candidate proven promising numerous antiviral target small molecule inhibitor efficacy cell culture identified however study area required order make suitable clinical use,2013-11-26,"Arias, Armando; Emmott, Edward; Vashist, Surender; Goodfellow, Ian",Future Microbiol,,,,document_parses/pdf_json/07e425b0a2cb18dc7e27723172b276c1c1c4487a.json,document_parses/pmc_json/PMC3904215.xml.json,https://doi.org/10.2217/fmb.13.109; https://www.ncbi.nlm.nih.gov/pubmed/24199805/,9889155.0,3
99045,99045,126179,628k0ii5,12928aeec557f9957cd7490eaa046d1a113e71cb,Elsevier; Medline; PMC,The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats,10.1016/s1473-3099(15)00416-8,PMC7106346,26526664.0,els-covid,summary support accelerated development ebola vaccine preclinical research clinical trial november wellcome trust center infectious disease research policy cidrap university minnesota established wellcome trustcidrap ebola vaccine team b initiative ongoing initiative includes expert global experience various phase bringing new vaccine market funding research development manufacturing determination safety efficacy regulatory approval vaccination delivery also includes expert community engagement strategy ethical issue germane vaccination policy including eight african scientist direct experience developing implementing vaccination policy africa ebola vaccine team b member worked range vaccination programme polio eradication africa globally development meningococcal disease vaccination campaign africa malaria hivaids vaccine research also provide perspective experience inform future situation urgent development vaccine needed comment role independent expert group team b support national international public health authority toward addressing public health crisis,2016-01-31,"Osterholm, Michael; Moore, Kristine; Ostrowsky, Julie; Kimball-Baker, Kathleen; Farrar, Jeremy",The Lancet Infectious Diseases,,,,document_parses/pdf_json/12928aeec557f9957cd7490eaa046d1a113e71cb.json,document_parses/pmc_json/PMC7106346.xml.json,https://api.elsevier.com/content/article/pii/S1473309915004168; https://www.ncbi.nlm.nih.gov/pubmed/26526664/; https://www.sciencedirect.com/science/article/pii/S1473309915004168; https://doi.org/10.1016/s1473-3099(15)00416-8,206154270.0,3
99060,99060,126198,b44qnmbm,ecdca42f05a92b1b2bcac04e7bdb291831c0a410; 56503c049375713bf552b646d62b2cac38dee77e,Medline; PMC,Middle East respiratory syndrome: current status and future prospects for vaccine development,10.1517/14712598.2015.1092518,PMC4636333,26414077.0,bronze-oa,outbreak middle east respiratory syndrome mers previously middle east recently south korea raised serious concern worldwide reinforcing importance developing effective safe vaccine merscoronavirus merscov number vaccine candidate developed basis viral vector recombinant protein dna nanoparticles recombinant merscov shown efficacy laboratory animal however paucity financial support made difficult transfer effective candidate preclinical stage clinical trial summarize currently available mers vaccine candidate illustrate strategy future development aim provoking government agency big pharma invest fund developing efficacious safe mers vaccine,2015-09-28,"Du, Lanying; Jiang, Shibo",Expert Opinion on Biological Therapy,,,,document_parses/pdf_json/ecdca42f05a92b1b2bcac04e7bdb291831c0a410.json; document_parses/pdf_json/56503c049375713bf552b646d62b2cac38dee77e.json,document_parses/pmc_json/PMC4636333.xml.json,https://www.tandfonline.com/doi/pdf/10.1517/14712598.2015.1092518?needAccess=true; https://doi.org/10.1517/14712598.2015.1092518; https://www.ncbi.nlm.nih.gov/pubmed/26414077/,294203.0,3
99073,99073,126216,6y3xvmds,9c5443d8bf13edb87f6b39e2e0d58b7b1bbaf67c,Elsevier; Medline; PMC,MF59 formulated with CpG ODN as a potent adjuvant of recombinant HSP65-MUC1 for inducing anti-MUC1(+) tumor immunity in mice,10.1016/j.intimp.2012.05.003,PMC7106219,22595192.0,no-cc,mf oilinwater emulsion adjuvant approved influenza vaccine human use europe due th inducing property mf seldom tested cancer vaccine study mf formulated ctype cpg oligodeoxynucleotide yw tested th adjuvant activity induce immune response hspmuc recombinant fusion protein incorporating mycobacterial heat shock protein hsp mucin cell surface associated muc derived peptide combination yw mf mfyw could confer potent th biasing property adjuvant enhanced immunogenicity hspmuc induce significantly higher level specific iggc increased ifnγ mrna expression splenocytes generation antigenspecific cytotoxic lymphocyte mouse prophylactically applied mfyw adjuvant containing hspmuc inhibited growth muc b melanoma prolonged survival tumorbearing mouse contrast adjuvant containing mf hspmuc absence yw promoted growth muc b melanoma mouse result suggest mf plus cpg oligodeoxynucleotide might developed efficient adjuvant tumor vaccine melanoma possibly tumor,2012-05-14,"Yang, Ming; Yan, Youyou; Fang, Mingli; Wan, Min; Wu, Xiuli; Zhang, Xiaoling; Zhao, Tiesuo; Wei, Hongfei; Song, Dandan; Wang, Liying; Yu, Yongli",Int Immunopharmacol,,,,document_parses/pdf_json/9c5443d8bf13edb87f6b39e2e0d58b7b1bbaf67c.json,document_parses/pmc_json/PMC7106219.xml.json,https://doi.org/10.1016/j.intimp.2012.05.003; https://www.ncbi.nlm.nih.gov/pubmed/22595192/; https://www.sciencedirect.com/science/article/pii/S1567576912001324; https://api.elsevier.com/content/article/pii/S1567576912001324,205473019.0,3
99102,99102,126249,p88ys6bk,4f630985687a83ad9134d060d5fc832daa91fe7e,Elsevier; Medline; PMC,"WHO Working Group on Technical Specifications for Manufacture and Evaluation of Yellow Fever Vaccines, Geneva, Switzerland, 13–14 May 2009",10.1016/j.vaccine.2010.10.070,PMC7131007,21055492.0,els-covid,may convened meeting working group technical specification manufacturing evaluating yellow fever yf vaccine geneva switzerland initiate revision recommendation formerly requirement yf vaccine published technical report series number working group consisting expert academia industry national regulatory authority national control laboratory reviewed latest issue safety efficacy quality yf vaccine agreed revision focus live attenuated yf vaccine virus lineage ii nonclinical clinical guideline new vaccine prepared lineage developed,2010-12-06,"Ferguson, Morag; Shin, Jinho; Knezevic, Ivana; Minor, Philip; Barrett, Alan",Vaccine,,,,document_parses/pdf_json/4f630985687a83ad9134d060d5fc832daa91fe7e.json,document_parses/pmc_json/PMC7131007.xml.json,https://api.elsevier.com/content/article/pii/S0264410X10015719; https://www.ncbi.nlm.nih.gov/pubmed/21055492/; https://doi.org/10.1016/j.vaccine.2010.10.070; https://www.sciencedirect.com/science/article/pii/S0264410X10015719,33744205.0,3
99148,99148,126309,lkyxu54h,,Medline; WHO,Administration with Vaccinia Virus Encoding Canine Parvovirus 2 vp2 Elicits Systemic Immune Responses in Mice and Dogs.,10.1089/vim.2019.0164,,32364832.0,unk,canine parvovirus type cpv highly contagious cause serious often fatal disease young dog despite widespread availability attenuated vaccine safer stable effective cpv vaccine candidate still exploration vaccinia virus vv already proved safe stable effective vaccine vector study generated vvbased cpv vaccine candidate vvcpvvp evaluated immunogenicity mouse dog exogenous vp gene cpv replaced major virulence gene hemagglutinin ha vv expressed efficiently stably vitro subsequently intramuscular immunization mouse induced robust lasting systemic immune response including neutralizing antibody cpva cpvb cpvvpspecific interferon gamma ifnγ secreting cell addition administration highdose vvcpvvp cause significant side effect mouse thus indicating marked safety vaccine candidate importantly singledose vaccination vvcpvvp elicited substantial antibody response provided comparable protection dog attenuated cpv vaccine collectively study demonstrated vvcpvvp could used promising vaccine candidate preventing cpv infection dog,2020-05-04,"Zhao, Wanbo; Wang, Xiaomei; Li, Yi; Li, Yaoming",Viral immunology,,#165137,,,,https://doi.org/10.1089/vim.2019.0164; https://www.ncbi.nlm.nih.gov/pubmed/32364832/,218504718.0,3
99195,99195,126364,hotxaou2,ce9804c67aeb7683387d4e9a5c02ee7766eab379,Medline; PMC,Virus-Induced T Cell-Mediated Heterologous Immunity and Vaccine Development,10.3389/fimmu.2020.00513,PMC7137989,32296430.0,cc-by,heterologous immunity hi consequence encounter specific antigen alter subsequent immune response different antigen happen innate immune system level—often called trained immunity innate immune memory—andor adaptive immune system level involving memory cell antibody virus may also induce cellmediated hi confer protection drive immunopathology virus subtypes related unrelated virus pathogen auto alloantigens important understand underlying mechanism development antiviral “ universal ” vaccine broader cell response rather subtypespecific antibody response case influenza furthermore knowledge determinant vaccinemediated hi may inform public health policy provide suggestion repurposing existing vaccine introduce hi provide overview evidence virus antiviral vaccineinduced cellmediated crossreactive response also discus factor influencing final clinical outcome virusmediated hi well nonspecific beneficial effect live attenuated antiviral vaccine measles vaccinia available epidemiological mechanistic data implication development new vaccine personalized vaccinology presented finally formulate future research priority opportunity,2020-03-31,"Balz, Kathrin; Trassl, Lilith; Härtel, Valerie; Nelson, Philipp P.; Skevaki, Chrysanthi",Front Immunol,,,,document_parses/pdf_json/ce9804c67aeb7683387d4e9a5c02ee7766eab379.json,document_parses/pmc_json/PMC7137989.xml.json,https://doi.org/10.3389/fimmu.2020.00513; https://www.ncbi.nlm.nih.gov/pubmed/32296430/,214718654.0,3
99208,99208,126380,strhszpd,a9754e66d1d118157221031daab60604bab2ad14; 6c7a191615cd7156e9b30cffbd9d474bcc9a69a4,Medline; PMC,Current advancements and potential strategies in the development of MERS-CoV vaccines,10.1586/14760584.2014.912134,PMC4241375,24766432.0,bronze-oa,middle east respiratory syndrome mers newly emerging infectious disease caused novel coronavirus merscoronavirus merscov new member lineage c βcoronavirus βcov increased human case high mortality rate merscov infection make essential develop safe effective vaccine review current advancement potential strategy development mers vaccine particularly subunit vaccine based merscov spike protein receptorbinding domain rbd discussed improve efficacy subunit vaccine novel adjuvant formulation route administration well currently available animal model evaluating vivo efficacy merscov vaccine also addressed overall strategy may important implication development effective safe vaccine merscov future,2014-04-26,"Zhang, Naru; Jiang, Shibo; Du, Lanying",Expert Review of Vaccines,,,,document_parses/pdf_json/a9754e66d1d118157221031daab60604bab2ad14.json; document_parses/pdf_json/6c7a191615cd7156e9b30cffbd9d474bcc9a69a4.json,document_parses/pmc_json/PMC4241375.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/24766432/; https://doi.org/10.1586/14760584.2014.912134; https://www.tandfonline.com/doi/pdf/10.1586/14760584.2014.912134?needAccess=true,5371425.0,3
99233,99233,126409,dkqxfqk6,0a23247c10fffc2f925c2ddee2451c552286d89b,Elsevier; Medline; PMC,Vaccines for the Elderly: The Quest for the Ideal Animal Model,10.1016/j.jcpa.2009.10.005,PMC7094446,19897204.0,els-covid,summary decline protective immune response following vaccination one main feature immunosenescence improved vaccine candidate elderly adult thus urgently needed scientific regulatory requirement new vaccine must first evaluated preclinical level continuing quest ideal animal model perform study main advantage limitation murine model commonly used human vaccine research large animal model reviewed discussed,2010-01-31,"Boudet, F.",Journal of Comparative Pathology,,,,document_parses/pdf_json/0a23247c10fffc2f925c2ddee2451c552286d89b.json,document_parses/pmc_json/PMC7094446.xml.json,https://api.elsevier.com/content/article/pii/S0021997509003296; https://www.sciencedirect.com/science/article/pii/S0021997509003296; https://www.ncbi.nlm.nih.gov/pubmed/19897204/; https://doi.org/10.1016/j.jcpa.2009.10.005,25088621.0,3
99235,99235,126411,ta5y54lu,3c3a1e707eaf3efae5ae22cced7d4850ffc1f587,Medline; PMC,Systems Biology-Based Platforms to Accelerate Research of Emerging Infectious Diseases,10.3349/ymj.2018.59.2.176,PMC5823818,29436184.0,cc-by-nc,emerging infectious disease eids pose major threat public health security given dynamic nature significant impact eids effective way prevent protect develop vaccine advance system biology approach provide integrative way understand complex immune response pathogen lead greater understanding eid pathogenesis facilitate evaluation newly developed vaccineinduced immunity timely manner recent year advance high throughput technology enabled researcher successfully apply system biology method analyze immune response variety pathogen vaccine despite recent advance computational biological challenge impede wider application system biology approach review highlight recent advance field system immunology vaccinology present way system biologybased platform applied accelerate deeper understanding molecular mechanism immunity eids,2018-03-01,"Oh, Soo-Jin; Choi, Young-Ki; Shin, Ok Sarah",Yonsei Med J,,,,document_parses/pdf_json/3c3a1e707eaf3efae5ae22cced7d4850ffc1f587.json,document_parses/pmc_json/PMC5823818.xml.json,https://doi.org/10.3349/ymj.2018.59.2.176; https://www.ncbi.nlm.nih.gov/pubmed/29436184/,31604128.0,3
99251,99251,126429,j6lbxlm3,,Medline; WHO,Covid-19: What do we know so far about a vaccine?,10.1136/bmj.m1679,,32340998.0,unk,world health organization announced potential covid candidate vaccine assessed april including seven approved human testing clinical trial bmj look know far seven three tested beijing vaccine company cansino biological collaboration beijing institute biotechnology vaccine phase ii trial vaccine us adenovirus vector set tested healthy adult people control group look adverse reaction within day level covid neutralising antibody antibody coronavirus spike protein day participant followed six month however move phase ii good sign result phase trial looked adverse reaction seven day injection made public sinovac another beijing based company currently testing inactivatedvirus covid vaccine picovacc randomised double blinded placebo controlled phase trial involving adult company planning test vaccine another people phase ii trial preprint concerning vaccine ’ effectiveness mouse rat nonhuman primate found conferred “ complete protection ” sarscov strain circulating worldwide third candidate beijing institute biological product wuhan institute biological product also evaluated little information …,2020,"Mahase, Elisabeth",BMJ,,#125431,,,,https://doi.org/10.1136/bmj.m1679; https://www.ncbi.nlm.nih.gov/pubmed/32340998/,216593820.0,3
99307,99307,126495,exh42azl,b86c590a17d44679d13f690c7eb082d56c195777,Elsevier; Medline; PMC,Designing self-assembled peptide nanovaccine against Streptococcus pneumoniae: An in silico strategy,10.1016/j.mcp.2019.101446,PMC7126903,31520715.0,els-covid,streptococcus pneumoniae main cause disease meningitis pneumoniae sepsis especially child old people due costly antibiotic treatment increasing resistance pneumococcus developing highefficient protective vaccine pathogen urgent need although pneumoniae polysaccharide vaccine ppv pneumonia conjugate vaccine pcv efficient pneumococcal vaccine child adult group serotype replacement pneumoniae strain cause reduction efficacy vaccine overcoming aforesaid drawback epitopebased vaccine introduced relevant alternative previous research epitope vaccine designed based immunodominant epitope pspa cbpa antigen cellular stimulant phtd piua humoral stimulant low immunogenicity main disadvantage epitope vaccine current study applied coiledcoil selfassembled structure developing vaccine recently selfassembled peptide nanoparticles sapns gained much attention field vaccine development due multivalency selfadjuvanticity biocompatibility size similarity pathogen regard final designed vaccine comprised cytotoxic lymphocyte ctl epitope pspa cbpa helper lymphocyte htl epitope phtd piua pentamer trimmer oligomeric domain form stranded stranded coiledcoils selfassembled scaffold diphtheria toxoid dtd universal thelper fused appropriate linkers four different arrangement based order abovementioned compartment constructed modeled validated find structure structural physicochemical immunoinformatics analysis final vaccine construct represented vaccine could stimulate potent immune response pneumoniae however potency approved via various vivo vitro immunological test,2019-12-31,"Dorosti, Hesam; Eslami, Mahboobeh; Nezafat, Navid; Fadaei, Fardin; Ghasemi, Younes",Molecular and Cellular Probes,,,,document_parses/pdf_json/b86c590a17d44679d13f690c7eb082d56c195777.json,document_parses/pmc_json/PMC7126903.xml.json,https://doi.org/10.1016/j.mcp.2019.101446; https://www.ncbi.nlm.nih.gov/pubmed/31520715/; https://api.elsevier.com/content/article/pii/S0890850819303007; https://www.sciencedirect.com/science/article/pii/S0890850819303007,202573391.0,3
99313,99313,126503,vyx4t42i,8a8374824a12da118a082abac386d81a2f906ada,Medline; PMC,"The route of inoculation determines the tissue tropism of modified vaccinia tiantan expressing the spike glycoprotein of SARS‐CoV in mice,",10.1002/jmv.21667,PMC7166938,20336714.0,no-cc,live replication‐competent modified vaccinia virus tiantan mvtt attractive vaccine vector yet little known tissue tropism pathology vivo recently demonstrated recombinant mvtt expressing spike glycoprotein sars‐cov namely mvtt‐s superior non‐replicating modified vaccinia ankara mva‐s inducing high level neutralizing antibody mucosal vaccination study determined tissue tropism safety mvtt‐s vaccine administrated various route including intramuscular im intranasal intravaginal ivag inoculation respectively using real‐time pcr nested pcr immunohistochemistry situ hybridization assay found mvtt‐s able produce transient infection case within hr post‐inoculation yet major site viral replication various tissue organ dependent route viral administration demonstrated im injection mvtt‐s primarily targeted draining inguinal lymph node whereas mucosal inoculation broader range tissue infection inoculation involved infection lung kidney spleen cervix lymph node ivag administration targeted uterus ovary kidney spleen critically infection cause severe pathogenic consequence infected tissue consistent attenuated phenotype mvtt‐s finding implication optimization vaccination route study correlation magnitude immune response extent tissue involvement vivo j med virol – © wiley‐liss inc,2010-03-24,"Liu, Huan; Yu, Wenbo; Tang, Xian; Wang, Haibo; Ouyang, Wenjie; Zhou, Jingying; Chen, Zhiwei",J Med Virol,,,,document_parses/pdf_json/8a8374824a12da118a082abac386d81a2f906ada.json,,https://www.ncbi.nlm.nih.gov/pubmed/20336714/; https://doi.org/10.1002/jmv.21667,32400167.0,3
99353,99353,126551,2uvibr2j,,BioRxiv; MedRxiv,Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: Immunoinformatics and in silico approaches,10.1101/2020.02.28.970343,,,biorxiv,coronavirus disease covid associated pneumonia caused severe acute respiratory coronavirus sarscov first reported wuhan china december till date vaccine completely effective drug available cure covid therefore effective vaccine sarscov needed design study conducted design effective multiepitope vaccine mev sarscov seven antigenic protein taken target epitope b cell ifnγ cell predicted highly antigenic overlapping epitope shortlisted selected cell epitope indicated significant interaction hlabinding allele coverage world ’ population finally amino acid long mev designed connecting sixteen mhc class twelve mhc class ii epitope suitable linkers adjuvant linkers adjuvant added enhance immunogenicity response vaccine allergenicity physiochemical property antigenicity structural detail mev analyzed order ensure safety immunogenicity mev construct nonallergenic antigenic molecular docking demonstrated stable strong binding affinity mev tlr tlr codon optimization silico cloning ensured increased expression escherichia coli k system however ensure safety immunogenic profile proposed vaccine need experimentally validated,2020-03-02,"Tahir ul Qamar, Muhammad; Rehman, Abdur; Ashfaq, Usman Ali; Awan, Muhammad Qasim; Fatima, Israr; Shahid, Farah; Chen, Ling-Ling",bioRxiv,,,,,,https://doi.org/10.1101/2020.02.28.970343,213812068.0,3
99360,99360,126559,1i1n3gw8,a592e1ee9470fff431f30f6c22786ed248c0977e,Elsevier; Medline; PMC,The receptor binding domain of MERS-CoV: The dawn of vaccine and treatment development,10.1016/j.jfma.2013.11.006,PMC7127315,24342026.0,els-covid,newly emerged middle east respiratory syndrome coronavirus merscov becoming another “ sarslike ” threat world extremely high death rate ∼ vaccine efficient therapeutic identification structure merscov receptor binding domain rbd complex dipeptidyl peptidase dpp raise hope alleviating currently severe situation review examined molecular basis rbdreceptor interaction outline whyhow could use merscov rbd develop vaccine antiviral drug,2014-03-31,"Zhou, Nan; Zhang, Yun; Zhang, Jin-Chun; Feng, Ling; Bao, Jin-Ku",Journal of the Formosan Medical Association,,,,document_parses/pdf_json/a592e1ee9470fff431f30f6c22786ed248c0977e.json,document_parses/pmc_json/PMC7127315.xml.json,https://www.sciencedirect.com/science/article/pii/S0929664613004026; https://doi.org/10.1016/j.jfma.2013.11.006; https://www.ncbi.nlm.nih.gov/pubmed/24342026/; https://api.elsevier.com/content/article/pii/S0929664613004026,45744266.0,3
99369,99369,126570,z6vddid9,,Medline; PMC,Vaccination in Hajj: An Overview of the Recent Findings,10.4103/2008-7802.195826,PMC5200976,28105294.0,cc-by-nc-sa,background two million people annually travel kingdom saudi arabia perform hajj pilgrim may risk exposure communicable disease mass gathering vaccination contagious disease prevent many morbidity mortality aim study review paper evaluated effectiveness compliance vaccine applied hajj method used pubmed scopus search international medical database key word follows hajj haj vaccine vaccination immunization time interval search beginning may one hundred thirty paper extracted content subsequently reviewed title screening original article included study nonenglish article excluded study result considering extracted paper almost pilgrim vaccinated meningococcal disease using influenza pneumococcal vaccine rate different among pilgrim vaccine taking according specific condition conclusion finding regarding influenza vaccine effectiveness contradictory study confirmed flu vaccine effectiveness others rejected usefulness meningococcal immunization effective preventive tool high compliance hajj pilgrim investigation recommended vaccine,2016-12-15,"Razavi, Seyed Mansour; Saeednejad, Mina; Salamati, Payman",Int J Prev Med,,,,,document_parses/pmc_json/PMC5200976.xml.json,https://doi.org/10.4103/2008-7802.195826; https://www.ncbi.nlm.nih.gov/pubmed/28105294/,9872911.0,3
99400,99400,126606,8ydh6jev,8c933d955d8adf7828db8ff08bd7106ea6fa448a,Elsevier; PMC,Heterogeneity of porcine reproductive and respiratory syndrome virus: implications for current vaccine efficacy and future vaccine development,10.1016/s0378-1135(00)00196-6,PMC7117501,10831854.0,els-covid,porcine reproductive respiratory syndrome virus prrsv continues major problem pork industry worldwide increasing data indicate prrsv strain differ virulence infected pig biologically antigenically genetically heterogeneous evident current vaccine based single prrsv strain effective protecting infection genetically diverse field strain prrsv recent outbreak atypical acute prrs vaccinated pig raised serious concern efficacy current vaccine provided impetus developing effective vaccine special attention review given published work antigenic pathogenic genetic variation prrsv potential implication vaccine efficacy development although ample data documenting heterogeneous nature prrsv strain information regarding heterogeneity generated clinical impact may scarce observed heterogeneity likely pose major obstacle effective prevention control prrs remains urgent need fundamental research virus understand basic biology mechanism heterogeneity pathogenesis prrsv,2000-06-12,"Meng, X. J",Veterinary Microbiology,,,,document_parses/pdf_json/8c933d955d8adf7828db8ff08bd7106ea6fa448a.json,document_parses/pmc_json/PMC7117501.xml.json,https://api.elsevier.com/content/article/pii/S0378113500001966; https://www.sciencedirect.com/science/article/pii/S0378113500001966,39527845.0,3
99450,99450,126673,fgdyzzty,18d51b527546f388651b7d1322d9a9538c333b61,Medline; PMC,A LAIR-1 insertion generates broadly reactive antibodies against malaria variant antigens,10.1038/nature16450,PMC4869849,26700814.0,no-cc,plasmodium falciparum antigen expressed surface infected erythrocyte important target naturally acquired immunity malaria high number variability provide pathogen powerful mean escape host antibodies– although broadly reactive antibody antigen could useful therapeutic vaccine design identification proven elusive report isolation human monoclonal antibody recognize erythrocyte infected different p falciparum isolates opsonize cell binding member rifin family antibody acquired broad reactivity novel mechanism insertion large dna fragment v dj segment insert necessary sufficient binding rifins encodes entire amino acid collagenbinding domain lair ig superfamily inhibitory receptor encoded chromosome two donor studied antibody produced single expanded b cell clone carry distinct somatic mutation lair domain abolish binding collagen increase binding infected erythrocyte finding illustrate biologically relevant example novel mechanism antibody diversification interchromosomal dna transposition demonstrate existence conserved epitope may suitable candidate development malaria vaccine,2015-12-23,"Tan, Joshua; Pieper, Kathrin; Piccoli, Luca; Abdi, Abdirahman; Perez, Mathilde Foglierini; Geiger, Roger; Tully, Claire Maria; Jarrossay, David; Maina Ndungu, Francis; Wambua, Juliana; Bejon, Philip; Fregni, Chiara Silacci; Fernandez-Rodriguez, Blanca; Barbieri, Sonia; Bianchi, Siro; Marsh, Kevin; Thathy, Vandana; Corti, Davide; Sallusto, Federica; Bull, Peter; Lanzavecchia, Antonio",Nature,,,,document_parses/pdf_json/18d51b527546f388651b7d1322d9a9538c333b61.json,document_parses/pmc_json/PMC4869849.xml.json,https://doi.org/10.1038/nature16450; https://www.ncbi.nlm.nih.gov/pubmed/26700814/,985565.0,3
99475,99475,126703,vt930bns,bc64088b806d6f43c4888ddb00a0479c8e57d33e,Medline; PMC,"Dynamic profiles, biodistribution and integration evaluation after intramuscular/intravenous delivery of a novel therapeutic DNA vaccine encoding chicken type II collagen for rheumatoid arthritis in vaccinated normal rodent",10.1186/s12951-019-0528-5,PMC6729025,31492169.0,cc-by,background persistence biodistribution risk integration host genome new therapeutic dna vaccine must established preclinical study previously developed dna vaccine pcdnaccola encoding chicken type ii collagen ccii treatment rheumatoid arthritis ra present study characterized dynamic profile biodistribution potential genomic dna integration normal vaccinated rodent result realtime quantitative pcr analysis rtqpcr animal administered single dose pcdnaccola μgkg intramuscular injection showed ccola mrna level blood peaked h postimmunization rapidly declined undetectable day – ccola transcript detected muscle injection site day – postimmunization starting day transcript detected heart liver lung kidney spleen thymus expressed lung day ccola mrna present testis ovary time point noninvasive vivo fluorescence imaging revealed ccii protein expression h day h day administration pcdnaccola via intravenous intramuscular route respectively protein disappeared day importantly ccola integrated host genome conclusion result indicate pcdnaccola vaccine rapidly cleared within short period time therefore safe merit development therapeutic vaccine ra treatment,2019-09-06,"Zhao, Xiao; Long, Juan; Liang, Fei; Liu, Nan; Sun, Yuying; Xi, Yongzhi",J Nanobiotechnology,,,,document_parses/pdf_json/bc64088b806d6f43c4888ddb00a0479c8e57d33e.json,document_parses/pmc_json/PMC6729025.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31492169/; https://doi.org/10.1186/s12951-019-0528-5,201838838.0,3
99494,99494,126726,ent4vu3z,3184616f8c024012a6d2d460222d2fb5e56fd98a,Medline; PMC,A public antibody lineage that potently inhibits malaria infection by dual binding to the circumsporozoite protein,10.1038/nm.4513,PMC5893353,29554084.0,no-cc,immunization attenuated plasmodium falciparum sporozoite pfspz shown protective feature antibody response induced treatment remain unclear investigate response high resolution isolated igm igg monoclonal antibody tanzanian volunteer immunized repeated injection irradiated pfspz found protected controlled human malaria infection chmi infectious homologous pfspz igg monoclonal isolated bound p falciparum circumsporozoite protein pfcsp recognized distinct epitope nterminus nanp repeat region cterminus strikingly effective antibody assessed humanized mouse model bound repeat region also minimal peptide pfcsp nterminal junction rtss vaccine dualspecific antibody isolated different donor used vh vh allele carrying tryptophan arginine position using structural mutational data describe element required germline recognition affinity maturation study provides potent neutralizing antibody relevant information lineagetargeted vaccine design immunization strategy,2018-03-19,"Tan, Joshua; Sack, Brandon K; Oyen, David; Zenklusen, Isabelle; Piccoli, Luca; Barbieri, Sonia; Foglierini, Mathilde; Fregni, Chiara Silacci; Marcandalli, Jessica; Jongo, Said; Abdulla, Salim; Perez, Laurent; Corradin, Giampietro; Varani, Luca; Sallusto, Federica; Sim, B Kim Lee; Hoffman, Stephen L; Kappe, Stefan H I; Daubenberger, Claudia; Wilson, Ian A; Lanzavecchia, Antonio",Nat Med,,,,document_parses/pdf_json/3184616f8c024012a6d2d460222d2fb5e56fd98a.json,document_parses/pmc_json/PMC5893353.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29554084/; https://doi.org/10.1038/nm.4513,4719150.0,3
99498,99498,126730,tozv6u89,ae90c817f26e02354fbc4944059f132f32395285,Elsevier; Medline; PMC,Nanoengineering of vaccines using natural polysaccharides,10.1016/j.biotechadv.2015.05.010,PMC7127432,26049133.0,no-cc,currently licensed vaccine prevent pathogenesis around virus bacteria nevertheless still important challenge area include development active noninvasive thermoresistant vaccine important biotechnological advance led safer subunit antigen protein peptide nucleic acid however limited immunogenicity demanded potent adjuvant strengthen immune response particulate nanocarriers hold high potential adjuvant vaccination due pathogenlike size structure enhance immune response mimicking natural infection process additionally tailored noninvasive mucosal administration needlefree vaccination control delivery associated antigen specific location prolonged time opening room singledose vaccination moreover allow coassociation immunostimulatory molecule improve overall adjuvant capacity natural ubiquitous character polysaccharide together intrinsic immunomodulating property biocompatibility biodegradability justify interest engineering nanovaccines review aim provide stateoftheart overview regarding application nanotechnology vaccine delivery focus recent advance development application polysaccharidebased antigen nanocarriers,2015-11-01,"Cordeiro, Ana Sara; Alonso, María José; de la Fuente, María",Biotechnol Adv,,,,document_parses/pdf_json/ae90c817f26e02354fbc4944059f132f32395285.json,document_parses/pmc_json/PMC7127432.xml.json,https://www.sciencedirect.com/science/article/pii/S0734975015300094; https://api.elsevier.com/content/article/pii/S0734975015300094; https://doi.org/10.1016/j.biotechadv.2015.05.010; https://www.ncbi.nlm.nih.gov/pubmed/26049133/,45980499.0,3
99506,99506,126739,kez0m3ae,651d3cd95998b7221345e6369aed91ad13eb2a22; ca8bccec7f0c81fd1f6ce1073770b1693f01df46,Elsevier; Medline; PMC,Structure-Based Design of Prefusion-Stabilized Filovirus Glycoprotein Trimers,10.1016/j.celrep.2020.03.025,PMC7118701,32234486.0,no-cc,ebola virus cause severe hemorrhagic fever often leading death human trimeric fusion glycoprotein gp sole target neutralizing antibody major focus vaccine development soluble gp ectodomains unstable mostly monomeric fused heterologous trimerization domain report structurebased design ebola marburg gp trimer based stabilizing mutation hinge loop refolding region substitution partially buried charge interface gp gp subunit combined substitution tp kf substantially increased trimer expression ebola gp protein determined crystal structure stabilized gp makona zaire ebolavirus strain without trimerization domain complexed ligand structure reveals stabilized gp adopts trimeric prefusion conformation provides insight triggering gp conformational change inform future filovirus vaccine development,2020-03-31,"Rutten, Lucy; Gilman, Morgan S.A.; Blokland, Sven; Juraszek, Jarek; McLellan, Jason S.; Langedijk, Johannes P.M.",Cell Rep,,,,document_parses/pdf_json/651d3cd95998b7221345e6369aed91ad13eb2a22.json; document_parses/pdf_json/ca8bccec7f0c81fd1f6ce1073770b1693f01df46.json,document_parses/pmc_json/PMC7118701.xml.json,https://doi.org/10.1016/j.celrep.2020.03.025; https://www.ncbi.nlm.nih.gov/pubmed/32234486/; https://www.sciencedirect.com/science/article/pii/S2211124720303399; https://api.elsevier.com/content/article/pii/S2211124720303399,214758746.0,3
99521,99521,126758,fsmoog13,1d8ed60ab07f4ba567277143966536d7ffb7e6ea,Elsevier; Medline; PMC,A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immunogenicity in dogs,10.1016/j.vaccine.2007.11.057,PMC7115610,18180079.0,els-covid,summary vaccine canine visceral leishmaniasis cvl comprising leishmania braziliensis promastigote protein sand fly gland extract sge saponin adjuvant evaluated dog model order analyse immunogenicity candidate vaccine vaccine candidate elicited strong antigenicity dog respect specific sge leishmania humoral immune response major saliva protein recognized serum immunized dog exhibited molecular weight kda related resistance pattern leishmania infection immunophenotypic analysis revealed increased circulating cd bcells cd tcells reflected higher count cd cd tcells observed interaction potential antigenpresenting cell evaluated cd monocyte lymphocyte activation status indicated relationship innate adaptive immune response higher frequency l chagasi antigenspecific cd tlymphocytes positive association intense cell proliferation addition progressively higher production serum nitric oxide level showed profile compatible anticvl vaccine potential study immunological response challenge l chagasi may provide important information lead better understanding vaccine trial efficacy,2008-01-30,"Giunchetti, Rodolfo Cordeiro; Corrêa-Oliveira, Rodrigo; Martins-Filho, Olindo Assis; Teixeira-Carvalho, Andréa; Roatt, Bruno Mendes; Aguiar-Soares, Rodrigo Dian de Oliveira; Coura-Vital, Wendel; Abreu, Raquel Tropia de; Malaquias, Luiz Cosme Cotta; Gontijo, Nelder Figueiredo; Brodskyn, Cláudia; Oliveira, Camila Indiani de; Costa, Dirceu Joaquim; de Lana, Marta; Reis, Alexandre Barbosa",Vaccine,,,,document_parses/pdf_json/1d8ed60ab07f4ba567277143966536d7ffb7e6ea.json,document_parses/pmc_json/PMC7115610.xml.json,https://api.elsevier.com/content/article/pii/S0264410X07013758; https://www.sciencedirect.com/science/article/pii/S0264410X07013758; https://www.ncbi.nlm.nih.gov/pubmed/18180079/; https://doi.org/10.1016/j.vaccine.2007.11.057,37196694.0,3
99580,99580,126833,r5va3y1n,28a1d5f0ab7ef183e07269f2f70c35d8ccd9cdea,Elsevier; PMC,Chapter 48 Mucosal Vaccine Development for Veterinary and Aquatic Diseases,10.1016/b978-0-12-811924-2.00048-1,PMC7149622,,els-covid,pathogen food antigen enter host via mucosal surface effective mucosal immunity critical maintaining homeostasis immune regulation tolerance induction effective immune response needed thus mucosaassociated lymphoid tissue represent important target vaccination indeed year research clearly demonstrated benefit mucosal vaccination versus systemic vaccination benefit include local induction secretory immunoglobulin siga well activation maturation mucosal dendritic cell homing effector cell mucosal surface expression specific host defense peptide innate effector molecule addition mucosal vaccination offer opportunity induce colostral lactogenic immunity pregnancy possibility avoiding neutralization early life vaccine maternal antibody critical protecting susceptible infectious disease moreover mucosal administration offer advantage inducing effective systemic immunity mucosal immunity enhancing vaccine efficacy providing improved protection number animal vaccine already administered via mucosal surface many come next year gratifying see veterinary vaccine development yet taken leadership role exploring innovative approach technology mucosal vaccination veterinary field consideration mucosal vaccine development use necessarily include cost often penny per dose mass delivery preferably avoids animal restraint economic trade consideration chapter provide overview existing vaccine technology discus advantage disadvantage,2020-12-31,"Wilson, Heather L.; Gerdts, Volker; Babiuk, Lorne A.",Mucosal Vaccines,,,,document_parses/pdf_json/28a1d5f0ab7ef183e07269f2f70c35d8ccd9cdea.json,document_parses/pmc_json/PMC7149622.xml.json,https://api.elsevier.com/content/article/pii/B9780128119242000481; https://www.sciencedirect.com/science/article/pii/B9780128119242000481,208428556.0,3
99583,99583,126836,ocr1ttcz,81bf72bed294b556985ff244cc7d00d7b0b2235e; f2d95ab758e878195eefa64325961667efeb4c14,Medline; PMC,A Zika virus vaccine expressing premembrane-envelope-NS1 polyprotein,10.1038/s41467-018-05276-4,PMC6076265,30076287.0,cc-by,current effort develop zika virus zikv subunit vaccine focused premembrane prm envelope e protein role n zikvspecific immune response protection poorly understood develop attenuated recombinant vesicular stomatitis virus rvsvbased vaccine expressing zikv prmens polyprotein vectored vaccine candidate attenuated mouse single immunization induces zikvspecific antibody cell immune response provide protection zikv challenge coexpression prm e n induces significantly higher level th th cytokine response prme addition n alone capable conferring partial protection zikv infection mouse even though induce neutralizing antibody result demonstrate attenuated rvsv coexpressing prm e n promising vaccine candidate protection zikv infection highlight important role n zikvspecific cellular immune response,2018-08-03,"Li, Anzhong; Yu, Jingyou; Lu, Mijia; Ma, Yuanmei; Attia, Zayed; Shan, Chao; Xue, Miaoge; Liang, Xueya; Craig, Kelsey; Makadiya, Nirajkumar; He, Jennifer J.; Jennings, Ryan; Shi, Pei-Yong; Peeples, Mark E.; Liu, Shan-Lu; Boyaka, Prosper N.; Li, Jianrong",Nat Commun,,,,document_parses/pdf_json/81bf72bed294b556985ff244cc7d00d7b0b2235e.json; document_parses/pdf_json/f2d95ab758e878195eefa64325961667efeb4c14.json,document_parses/pmc_json/PMC6076265.xml.json,https://doi.org/10.1038/s41467-018-05276-4; https://www.ncbi.nlm.nih.gov/pubmed/30076287/,51911663.0,3
99608,99608,126865,od4c6fcg,2a9c022937a3b8db471fa3cdb9dbc151e0d89a1a,Elsevier; PMC,Aerosolimpfung von Mäusen mit inaktiviertem Influenzavirus,10.1016/s0172-5599(80)80016-2,PMC7134401,6254287.0,els-covid,nmri mouse vaccinated aerosol technique using ethylethylenimine inactivated polyethylenglycol concentrated virus strain apr hon without addition bordetella pertussis extract bpe adjuvant immune response vaccinated animal controlled challenge infection via aerosol technique examination hai antibody serum washing lung single aerosol vaccination weak protection observed vaccine contained bpe second immunization vaccine containing bpe induced high degree immunity even reduced amount antigen used booster vaccination three aerosol vaccine dos twoweeks interval however unable infect immunized animal even largest amount challenge virus approximately ld addition bpe adjuvant induced significantly better protection resulted much higher titre hai antibody serum respiratory tract compared mouse vaccinated procedure without bpe,1980-06-30,"Neukirch, Manfred; Bauer, Kurt","Zentralblatt für Bakteriologie. 1. Abt. Originale A, Medizinische Mikrobiologie, Infektionskrankheiten und Parasitologie",,,,document_parses/pdf_json/2a9c022937a3b8db471fa3cdb9dbc151e0d89a1a.json,,https://api.elsevier.com/content/article/pii/S0172559980800162; https://www.sciencedirect.com/science/article/pii/S0172559980800162,57768156.0,3
99627,99627,126888,3b6r4yyf,c5019620a14eff41b9e38d681e0c8aa5cede332d,Elsevier; PMC,Exosomal vaccines containing the S protein of the SARS coronavirus induce high levels of neutralizing antibodies,10.1016/j.virol.2006.12.011,PMC7103344,17258782.0,els-covid,infection sarsassociated coronavirus sarscov induces atypical pulmonary disease high lethality rate although initial sars epidemic contained sporadic outbreak disease still occur suggesting continuous need vaccine virus therefore explored exosomebased vaccine containing spike protein sarscov scontaining exosomes obtained replacing transmembrane cytoplasmic domain protein vsvg immunogenicity efficacy scontaining exosomes tested mouse compared adenoviral vector vaccine expressing protein scontaining exosomes adenoviral vector vaccine induced neutralizing antibody titer priming sars exosomal vaccine boosting adenoviral vector neutralizing antibody titer exceeded observed convalescent serum sars patient approach effective sarssexpressing tumor challenge model thus warrant investigation,2007-05-25,"Kuate, Seraphin; Cinatl, Jindrich; Doerr, Hans Wilhelm; Überla, Klaus",Virology,,,,document_parses/pdf_json/c5019620a14eff41b9e38d681e0c8aa5cede332d.json,document_parses/pmc_json/PMC7103344.xml.json,https://api.elsevier.com/content/article/pii/S0042682206008981; https://www.sciencedirect.com/science/article/pii/S0042682206008981,34245972.0,3
99628,99628,126890,baqaqsli,5862087b0247f999dc8dfc37d1cf00d6498569b7,Elsevier; PMC,14 Animal Vaccines,10.1016/b978-012369366-2/50016-6,PMC7149985,,els-covid,publisher summary rabies terrestrial animal primarily carnivore caused classic genotype rabies virus even though widespread vaccination domestic dog one effective factor reduction human rabies number human death worldwide greater combined death polio meningococcal meningitis japanese encephalitis yellow fever severe acute respiratory syndrome avian influenze bird flutools available highly efficacious safe animal human vaccine multiple factor however prevent use effectively many area world several decade virtually rabies nerve tissue origin nto vaccine inactivated phenol using method described semple nto vaccine currently use mass vaccination campaign africa latin america caribbean primarily produced rabies virusinfected suckling mouse brain lamb brain vaccine shown effective campaign however ntokilled vaccine dog animal often past resulted postvaccinal nervous system reaction could result death vaccinated animal,2007-12-31,"DREESEN, DAVID W.",Rabies,,,,document_parses/pdf_json/5862087b0247f999dc8dfc37d1cf00d6498569b7.json,document_parses/pmc_json/PMC7149985.xml.json,https://www.sciencedirect.com/science/article/pii/B9780123693662500166; https://api.elsevier.com/content/article/pii/B9780123693662500166,86127297.0,3
99629,99629,126891,jwjr67po,1db4b821651dc127f8cfeaf504b67bc41e3ad645,Medline; PMC,New immunization strategies: adapting to global challenges,10.1007/s00103-019-03066-x,PMC7079946,31802153.0,no-cc,immunization made enormous contribution global health global vaccination coverage dramatically improved mortality rate among child due vaccinepreventable disease significantly reduced since creation expanded programme immunization formation gavi vaccine alliance development global vaccine action plan however challenge remain persisting inequity vaccine uptake contribute continued occurrence outbreak vaccinepreventable disease inequality immunization coverage geography urbanrural socioeconomic status jeopardize achievement global immunization goal call renewed immunization strategy take account emerging opportunity building better immunization system service well development new vaccine product delivery technology strategy need achieve equity vaccination coverage across within country require participation community better understanding vaccine acceptance hesitancy expansion vaccination across life course approach improve immunization middleincome country enhanced use data possible financial nonfinancial incentive vaccine also important role play comprehensive disease control including fight antimicrobial resistance lesson learned disease eradication elimination effort polio measles maternal neonatal tetanus instrumental enhancing global immunization strategy line revised goal target new immunization agenda currently developed,2019-12-04,"Mantel, Carsten; Cherian, Thomas",Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz,,,,document_parses/pdf_json/1db4b821651dc127f8cfeaf504b67bc41e3ad645.json,document_parses/pmc_json/PMC7079946.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31802153/; https://doi.org/10.1007/s00103-019-03066-x,208612974.0,3
99637,99637,126901,1lxd2457,3dd5c77b7143804f7f5c44a5d034f2518e17fff1,Medline; PMC,Evaluation of the Efficacy of a Recombinant Adenovirus Expressing the Spike Protein of Porcine Epidemic Diarrhea Virus in Pigs,10.1155/2019/8530273,PMC6800969,31687402.0,cc-by,recent year many study shown recombinant adenovirus live vectorbased vaccine promising novel vaccine candidate virus infection therefore study new type recombinant adenovirus expressing spike protein porcine epidemic diarrhea virus pedv radpedvs generated characteristic determined efficacy vaccine candidate evaluated weekold pig result showed protein could well expressed high level radpedvsinfected cell viral titer could reach pfuml animal experimental result showed radpedvs elicited significant pedvspecific humoral immune response vaccination p addition radpedvs provided partial protection pig highly virulent pedv challenge result presented study indicate adenovirus vector used vaccine delivery vector development pedv vaccine promising novel vaccine candidate future prevention control porcine epidemic diarrhea ped efficacy still need improved future,2019-10-08,"Liu, Xinsheng; Zhao, Donghong; Zhou, Peng; Zhang, Yongguang; Wang, Yonglu",Biomed Res Int,,,,document_parses/pdf_json/3dd5c77b7143804f7f5c44a5d034f2518e17fff1.json,document_parses/pmc_json/PMC6800969.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31687402/; https://doi.org/10.1155/2019/8530273,207898102.0,3
99699,99699,126971,zfuphzeu,9cbb53fbb5873a0b307a6206b0fa4c7f552e393e; 45ba3b5b8fa3bda8382468b68cff5c361b6569e1,Elsevier; Medline; PMC,Rapid development of vaccines against emerging pathogens: The replication-deficient simian adenovirus platform technology,10.1016/j.vaccine.2017.04.085,PMC5571606,28576573.0,cc-by,despite fact multiple small outbreak ebola virus disease large outbreak occurred vaccine drug available use clinical development multiple candidate vaccine initiated parallel attempt contain outbreak one vaccine eventually tested phase iii trial order better prepared future outbreak known human pathogen platform technology accelerate vaccine development employed allowing vaccine developer take advantage detailed knowledge vaccine platform facilitating rapid progress clinical trial eventually vaccine stockpile review give example one vaccine platform replicationdeficient simian adenovirus describes progress human livestock vaccine development three outbreak pathogen ebola virus rift valley fever virus middle east respiratory syndrome coronavirus,2017-08-16,"Gilbert, Sarah C.; Warimwe, George M.",Vaccine,,,,document_parses/pdf_json/9cbb53fbb5873a0b307a6206b0fa4c7f552e393e.json; document_parses/pdf_json/45ba3b5b8fa3bda8382468b68cff5c361b6569e1.json,document_parses/pmc_json/PMC5571606.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28576573/; https://www.sciencedirect.com/science/article/pii/S0264410X17306011; https://api.elsevier.com/content/article/pii/S0264410X17306011; https://doi.org/10.1016/j.vaccine.2017.04.085,4538005.0,3
99726,99726,127002,8fxlo3lr,9405b40aa26445cd02d7382bf256641ca774de46,Medline; PMC,Cholesteryl Pullulan Encapsulated TNF-α Nanoparticles Are an Effective Mucosal Vaccine Adjuvant against Influenza Virus,10.1155/2015/471468,PMC4569761,26421290.0,cc-by,encapsulated tumor necrosis factorα tnfα major proinflammatory cytokine cholesteryl pullulan chp prepare tnfchp nanoparticles report describe immuneenhancing capability nanoparticles act vaccine adjuvant tnfchp nanoparticles showed excellent storage stability enhanced host immune response external immunogen nanoparticles effective via nasal route administration inducing systemic igg well mucosal iga applied nanoparticles model experimental influenza virus infection investigate adjuvant ability tnfchp nanoparticles combined conventional split vaccine protected mouse via nasal administration lethal challenge apr hn influenza virus mechanistic study showed nanoparticles enhanced antigen uptake dendritic cell dc moderately induced expression inflammationrelated gene nasopharynx lymphoid tissue nalt leading activation b cell preliminary safety study revealed severe toxicity tnfchp nanoparticles slighttomoderate influence nasal mucosa observed repeated administration seemed reversible data show tnfchp nanoparticles effectively enhance humoral cellular immunity could potential adjuvant vaccine infectious disease especially mucosa,2015-09-01,"Nagatomo, Daiki; Taniai, Madoka; Ariyasu, Harumi; Taniguchi, Mutsuko; Aga, Miho; Ariyasu, Toshio; Ohta, Tsunetaka; Fukuda, Shigeharu",Biomed Res Int,,,,document_parses/pdf_json/9405b40aa26445cd02d7382bf256641ca774de46.json,document_parses/pmc_json/PMC4569761.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26421290/; https://doi.org/10.1155/2015/471468,15526568.0,3
99736,99736,127015,id1cxmk1,bcf1bc15c1b56c4dd0cc08b1eaa1cee1a6411e0e,Medline; PMC,Immune responses to T-cell epitopes of SARS CoV-N protein are enhanced by N immunization with a chimera of lysosome-associated membrane protein,10.1038/gt.2009.92,PMC7091638,19727132.0,no-cc,previous study gupta et al dominant tcell epitope sars covnn protein predicted software spectrum interferon ifnγ response balbc mouse immunized two different form sars covn plasmid analyzed cluster dominant tcell epitope sars covn protein found nterminus amino acid – basis study four different plasmid constructed dna encoding unmodified n pn n− pn− endogenous cytoplasmic protein ii dna encoding lysosomeassociated membrane protein lamp chimera n plampn n− plampn− immune response mouse four construct evaluated result showed marked difference response immunized mouse single priming immunization plampn construct sufficient elicit antibody response enzymelinked immunospot elispot assay indicated plampn− plampn plasmid elicited greater ifnγ response pn pn pn− construct induced low undetectable level cytokine secretion also found plampn− construct promoted longlasting tcell memory response without additional boost month three immunization finding show dna vaccine even epitopebased dna vaccine using lamp chimera elicit humoral cellular immune response,2009-09-03,"Yang, K; Sun, K; Srinivasan, K N; Salmon, J; Marques, E T; Xu, J; August, J T",Gene Ther,,,,document_parses/pdf_json/bcf1bc15c1b56c4dd0cc08b1eaa1cee1a6411e0e.json,document_parses/pmc_json/PMC7091638.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19727132/; https://doi.org/10.1038/gt.2009.92,5826051.0,3
99738,99738,127018,m0xlnm6n,20712c775ecc5b087dd6243208e5f47646e37756,Elsevier; PMC,Chapter 97 Emerging Viral Infections,10.1016/b978-0-12-382227-7.00097-5,PMC7150298,,els-covid,emerging reemerging viral disease pose continuous health threat disease burden human research effort mitigate effect infectious threat focusing improved surveillance diagnostic capability also development intervention strategy like use vaccine antiviral agent crucial describe genomic approach may aid mitigating viral threat highlighting potential role limitation genomics approach virus surveillance diagnostics development vaccine antiviral keywords antiviral diagnostics emerging infectious disease evolution diversity gene expression profiling genomewide association study genomewide functional screen host genomics prevention surveillance treatment viral genomics virus discovery vaccine,2013-12-31,"Osterhaus, Albert D.M.E.; Smits, Saskia L.",Genomic and Personalized Medicine,,,,document_parses/pdf_json/20712c775ecc5b087dd6243208e5f47646e37756.json,document_parses/pmc_json/PMC7150298.xml.json,https://www.sciencedirect.com/science/article/pii/B9780123822277000975; https://api.elsevier.com/content/article/pii/B9780123822277000975,89396032.0,3
99857,99857,127175,1evsmqw6,9816684f175677470e6a73be3f370a90dde1be82; 8f0818f3cefecc27fb87796d4f79318dd22ee8ba,Medline; PMC,Antibody-profiling technologies for studying humoral responses to infectious agents,10.1586/erv.10.50,PMC3417761,20518713.0,green-oa,analysis humoral response different infectious agent critical infectious disease diagnostics understanding pathogenic mechanism development monitoring vaccine elisa often used measure antibody response one several target new antibodyprofiling technology protein microarrays evaluate antibody response hundred even thousand recombinant antigen one time largescale study uncovered new antigenic target provided new insight vaccine research yielded overview immunoreactivity almost entire proteome certain pathogen however solidphase antigen array also drawback limit type information obtained including suboptimal detection conformational epitope high background due impure antigen narrow dynamic range detection developed solutionphase antibodyprofiling technology luciferase immunoprecipitation system lip harness lightemitting recombinant antigen fusion protein quantitatively measure patient antibody titer owing highly linear light output luciferase reporter antibody detected without serum dilution dynamic range detection often spanning seven order magnitude lip applied iteratively multiple target antigen highdefinition antibody profile obtained discus application different antibodyprofiling technology associated limitation particular emphasis protein microarrays also describe lip detail discus several clinically relevant us technology together new technology offer new tool understanding humoral response known emerging infectious agent,2010-06-01,"Burbelo, Peter D; Ching, Kathryn H; Bush, Emily R; Han, Brian L; Iadarola, Michael J",Expert Review of Vaccines,,,,document_parses/pdf_json/9816684f175677470e6a73be3f370a90dde1be82.json; document_parses/pdf_json/8f0818f3cefecc27fb87796d4f79318dd22ee8ba.json,document_parses/pmc_json/PMC3417761.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/20518713/; http://europepmc.org/articles/pmc3417761?pdf=render; https://doi.org/10.1586/erv.10.50,1992824.0,3
99867,99867,127185,pv1k5yun,ceec51711b85aaa6423f8d0279141d879494fb10,Elsevier; Medline; PMC,A recombinant DNA and vaccinia virus prime–boost regimen induces potent long-term T-cell responses to HCV in BALB/c mice,10.1016/j.vaccine.2009.02.003,PMC7115398,19356609.0,els-covid,explore best prime–boost regimen evaluate tcellular response memory hcv constructed two dna vaccine candidate pvrccee paavcee two recombinant virus rttvee raavee assessed immune response different prime–boost pattern balbc mouse rttvee boosted immune response hcv dna vaccine prime significantly inverted terminal repeat sequence harboring dna construct paavcee best prime agent study study provides new information prime–boost regimen longterm tcell response hcv vaccine development,2009-03-26,"Deng, Yao; Zhang, Ke; Tan, Wenjie; Wang, Yue; Chen, Hong; Wu, Xiaobing; Ruan, Li",Vaccine,,,,document_parses/pdf_json/ceec51711b85aaa6423f8d0279141d879494fb10.json,document_parses/pmc_json/PMC7115398.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19356609/; https://api.elsevier.com/content/article/pii/S0264410X0900214X; https://doi.org/10.1016/j.vaccine.2009.02.003; https://www.sciencedirect.com/science/article/pii/S0264410X0900214X,205578348.0,3
99870,99870,127190,om858szl,9114000b181ef9558ec7f3cbf19e00d2dcdadfab; 3bc701d90e31eb0a194c4df2315201f91628d07d,Elsevier; PMC,"A review of licensed viral vaccines, some of their safety concerns, and the advances in the development of investigational viral vaccines",10.1016/j.jinf.2004.05.018,PMC7126106,15337336.0,no-cc,viral vaccine could considered among important medical achievement th century prevented much suffering saved many life although curative antiviral drug exist desperately depend effort academic governmental industrial scientist advancement viral vaccine prevention control infectious disease next decade hope see advancement development current investigational viral vaccine childhood adult infection article review licensed viral vaccine safety concern advance development investigational viral vaccine,2004-07-20,"Huang, David B.; Wu, Jashin J.; Tyring, Stephen K.",J Infect,,,,document_parses/pdf_json/9114000b181ef9558ec7f3cbf19e00d2dcdadfab.json; document_parses/pdf_json/3bc701d90e31eb0a194c4df2315201f91628d07d.json,document_parses/pmc_json/PMC7126106.xml.json,https://www.sciencedirect.com/science/article/pii/S0163445304001161; https://api.elsevier.com/content/article/pii/S0163445304001161,24648529.0,3
99888,99888,127212,qgwmlcfr,800e040bf531655b9253c5240df8a5cbd449982c,Elsevier; PMC,Vaccine Target Discovery,10.1016/b978-0-12-809633-8.20100-3,PMC7148608,,els-covid,rise novel infectious agent disease pandemic new era vaccine discovery necessary address new field immunomics described synergistically powered integrating bioinformatics methodology technological advance biology highthroughput instrumentation incorporating biological data immunology molecular biology current genomics proteomics immunomics geared deliver insight immune function optimal stimulation immune response precise mapping rational selection immune target cover antigenic diversity effort expected contribute towards development new generation vaccine tailored genetic makeup human population pathogen vaccine technology also explored prevention control noncommunicable disease,2019-12-31,"Chong, Li C.; Khan, Asif M.",Encyclopedia of Bioinformatics and Computational Biology,,,,document_parses/pdf_json/800e040bf531655b9253c5240df8a5cbd449982c.json,document_parses/pmc_json/PMC7148608.xml.json,https://www.sciencedirect.com/science/article/pii/B9780128096338201003; https://api.elsevier.com/content/article/pii/B9780128096338201003,214757698.0,3
99920,99920,127252,z1mg2kc0,,Medline; PMC,Accelerating vaccine development and deployment: report of a Royal Society satellite meeting,10.1098/rstb.2011.0100,PMC3146780,21893549.0,cc-by,royal society convened meeting th th november review current way vaccine developed deployed make recommendation process might accelerated meeting brought together academic industry representative research sponsor regulator government advisor representative international public health agency broad geographical background discussion held chatham house rule highthroughput screening new vaccine antigen candidate seen driving force vaccine discovery multistakeholder smallscale manufacturing facility capable rapid production clinical grade vaccine currently need expanded human veterinary area need tiered regulatory standard differentially tailored experimental commercial vaccine allow accelerated vaccine efficacy testing improved crossfertilization knowledge industry academia human veterinary vaccine developer could lead rapid application promising approach technology new product development identification bestpractices development checklist product development plan implementation programme seen lowcost opportunity shorten timeline vaccine progression laboratory bench people need,2011-10-12,"Bregu, Migena; Draper, Simon J.; Hill, Adrian V. S.; Greenwood, Brian M.",Philos Trans R Soc Lond B Biol Sci,,,,,,https://doi.org/10.1098/rstb.2011.0100; https://www.ncbi.nlm.nih.gov/pubmed/21893549/,6739853.0,3
99954,99954,127291,dtabar23,4a16d8faf320e92f3717a0caa71bc1c9c0b7ce44,Elsevier; Medline; PMC,Recombinant feline coronaviruses as vaccine candidates confer protection in SPF but not in conventional cats,10.1016/j.vetmic.2013.10.015,PMC7117248,24513277.0,els-covid,feline infectious peritonitis virus fipv major pathogen felidae despite extensive effort taken past decade development “ ideal ” live attenuated fipv vaccine successful yet present study provide data immunisation experiment recombinant fcov pair differing truncation pbfipvdf completion pbfipvdfri orfabc region previous vivo study virus proved show character low virulent avirulent fcov phenotype respectively therefore hypothesised ability virus possible vaccine candidate conferring protection specific pathogen free spf domestic shorthair well conventional purebred british shorthair cat spf cat two oronasal two intramuscular vaccination two week interval vaccine candidate provided protection lethal homologous challenge highly virulent fipv df strain contrast conventional purebred british shorthair cat develop protection immunised vaccination regime group pbfipvdfri immunised animal developed antibodydependent enhancement ade prolonged survival observed animal showed fulminant disease course genetic probably immunological difference spf nonspf purebred kitten explain different outcome vaccination experiment data highlight diverse immune response spf conventional cat suggest decisive role previous infection heterologous causative agent outcome vaccination fip,2014-03-14,"Bálint, Ádám; Farsang, Attila; Szeredi, Levente; Zádori, Zoltán; Belák, Sándor",Veterinary Microbiology,,,,document_parses/pdf_json/4a16d8faf320e92f3717a0caa71bc1c9c0b7ce44.json,document_parses/pmc_json/PMC7117248.xml.json,https://www.sciencedirect.com/science/article/pii/S0378113513004884; https://api.elsevier.com/content/article/pii/S0378113513004884; https://doi.org/10.1016/j.vetmic.2013.10.015; https://www.ncbi.nlm.nih.gov/pubmed/24513277/,205623743.0,3
99960,99960,127298,kkg8ocsk,b4670d1961a9652df5363d430e76eb4b9f729b6b,Elsevier; Medline; PMC,Successful cross-protective efficacy induced by heat-adapted live attenuated nephropathogenic infectious bronchitis virus derived from a natural recombinant strain,10.1016/j.vaccine.2015.07.043,PMC7130781,26218899.0,els-covid,natural recombinant nephropathogenic k strain infectious bronchitis virus ibv heatadapted possible future use live attenuated vaccine k strain selected successive serial passage specificpathogen free spf embryonated egg suboptimal higher temperature °c unlike parental strain attenuated strain designated k hp found safe dayold spf chick showed neither mortality sign morbidity rarely induced ciliostasis histological change trachea kidney intraocular finespray administration k hp provided almost complete protection two distinct subgroup nephropathogenic strain kmlike qxlike subgroup elicited production high titer neutralizing antibody neutralization index conclude k hp vaccine virus rapidly attenuated heat adaptation exhibit desired level attenuation immunogenicity protective efficacy required live attenuated vaccine result indicate k vaccine could helpful reduction economic loss caused recently emergent nephropathogenic ibv infection many country,2015-12-16,"Lim, Tae-Hyun; Youn, Ha-Na; Yuk, Seong-Su; Kwon, Jung-Hoon; Hong, Woo-Tack; Gwon, Gyeong-Bin; Lee, Jung-Ah; Lee, Joong-Bok; Lee, Sang-Won; Song, Chang-Seon",Vaccine,,,,document_parses/pdf_json/b4670d1961a9652df5363d430e76eb4b9f729b6b.json,document_parses/pmc_json/PMC7130781.xml.json,https://api.elsevier.com/content/article/pii/S0264410X15010026; https://www.sciencedirect.com/science/article/pii/S0264410X15010026; https://www.ncbi.nlm.nih.gov/pubmed/26218899/; https://doi.org/10.1016/j.vaccine.2015.07.043,1655916.0,3
99968,99968,127308,8ces57rn,cc31e7cdeb3bc41d96c0de64506579d59b6fa443,Elsevier; Medline; PMC,"International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georgia, United States, 19–20 July 2007",10.1016/j.vaccine.2008.11.072,PMC7131739,19071179.0,els-covid,international meeting bordetella pertussis assay standardization harmonization held center disease control prevention cdc atlanta ga – july goal meeting harmonize immunoassay used pertussis diagnostics vaccine evaluation agreed upon academic government researcher regulatory authority vaccine manufacturer world health organization primary objective provide epidemiologic laboratory statistical background support global harmonization overview current status global epidemiology pathogenesis immunology pertussis develop consensus opinion existing gap understanding standardization pertussis assay used serodiagnosis vaccine evaluation search multicenter process addressing priority gap presentation discussion content expert addressed objective prioritized list action item improve standardization harmonization pertussis assay identified group discussion end meeting major item included identify group organize prepare maintain distribute proficiency panel key reagent reference control serum encourage development identification one reference laboratory serve anchor resource laboratory define performancebased assay method serve reference point evaluating laboratory difference develop guidance quality reagent eg pertussis toxin antigen method demonstrate suitability establish international working group harmonize criterion evaluate result obtained reference proficiency panel serum create inventory determine amount appropriate wellcharacterized serum available globally used bridging reagent vaccine licensure seek specific guidance regulatory authority regarding expectation requirement licensure new multicomponent pertussis vaccine,2009-02-05,"Tondella, M. L.; Carlone, G. M.; Messonnier, N.; Quinn, C. P.; Meade, B. D.; Burns, D. L.; Cherry, J. D.; Guiso, N.; Hewlett, E. L.; Edwards, K. M.; Xing, D.; Giammanco, A.; Wirsing von König, C. H.; Han, L.; Hueston, L.; Robbins, J. B.; Powell, M.; Mink, C. M.; Poolman, J. T.; Hildreth, S. W.; Lynn, F.; Morris, A.",Vaccine,,,,document_parses/pdf_json/cc31e7cdeb3bc41d96c0de64506579d59b6fa443.json,document_parses/pmc_json/PMC7131739.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19071179/; https://api.elsevier.com/content/article/pii/S0264410X08015946; https://doi.org/10.1016/j.vaccine.2008.11.072; https://www.sciencedirect.com/science/article/pii/S0264410X08015946,7550974.0,3
100003,100003,127354,1zs5zzo4,7025adb3524178a0d5d6da644084869ca26412a9,Medline; PMC,An adenoviral vector-based mucosal vaccine is effective in protection against botulism,10.1038/gt.2008.181,PMC7094725,19129860.0,no-cc,replicationincompetent adenoviral vector encoding heavy chain cfragment hc botulinum neurotoxin type c bontc evaluated mucosal vaccine botulism mouse model single intranasal inoculation adenoviral vector elicited high level hcspecific igg igg igga serum iga mucosal secretion early week vaccination antigenspecific serum antibody maintained high level least th week immune serum showed high potency neutralizing bontc indicated vitro toxin neutralization assay mouse receiving single dose × pfu plaqueforming unit adenoviral vector completely protected challenge × mld bontc protective immunity showed vaccine dose dependence × pfu adenoviral vector addition animal receiving single intranasal dose × pfu adenoviral vector could protected × mld week vaccination animal preexisting immunity adenovirus could also vaccinated intranasally protected lethal challenge bontc result suggest adenoviral vector highly effective genebased mucosal vaccine botulism,2009-01-08,"Xu, Q; Pichichero, M E; Simpson, L L; Elias, Md; Smith, L A; Zeng, M",Gene Ther,,,,document_parses/pdf_json/7025adb3524178a0d5d6da644084869ca26412a9.json,document_parses/pmc_json/PMC7094725.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19129860/; https://doi.org/10.1038/gt.2008.181,20793308.0,3
100024,100024,127380,bd2ndoug,b1ec83bddfe11fc5f176972ca4ae358b4f46c79f,Medline; PMC,Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients,10.1186/1743-422x-7-299,PMC2988023,21047436.0,cc-by,background spike protein sarscov mediates receptorbinding also induces neutralizing antibody previously identified receptorbinding domain rbd protein major target neutralizing antibody animal model thus proposed rbdbased vaccine however antigenicity immunogenicity rbd human need characterized result two panel serum sample recovered sars patient included antibody response rbd measured elisa microneutralization assay found rbd protein induced potent antibody response recovered sars patient rbdspecific antibody could persist high titer three year followup furthermore affinity purified antirbd antibody possessed robust neutralizing activity conclusion rbd sarscov highly immunogenic human mediates protective response rbdbased vaccine diagnostic approach developed,2010-11-04,"Cao, Zhiliang; Liu, Lifeng; Du, Lanying; Zhang, Chao; Jiang, Shibo; Li, Taisheng; He, Yuxian",Virol J,,,,document_parses/pdf_json/b1ec83bddfe11fc5f176972ca4ae358b4f46c79f.json,document_parses/pmc_json/PMC2988023.xml.json,https://doi.org/10.1186/1743-422x-7-299; https://www.ncbi.nlm.nih.gov/pubmed/21047436/,972764.0,3
100054,100054,127415,p1idx9lz,6b1b1794fd25ebbbe0839b59ed72f3cbe3e2188b,Medline; PMC,Recombinant infectious bronchitis virus (IBV) H120 vaccine strain expressing the hemagglutinin-neuraminidase (HN) protein of Newcastle disease virus (NDV) protects chickens against IBV and NDV challenge,10.1007/s00705-016-2764-4,PMC7087005,26873815.0,no-cc,infectious bronchitis ib newcastle disease nd common viral disease chicken caused infectious bronchitis virus ibv newcastle disease virus ndv respectively vaccination live attenuated strain ibvh ndvlasota important control ib nd however conventional live attenuated vaccine expensive result inability differentiate infected vaccinated chicken therefore urgent need develop new efficacious vaccine study using previously established reverse genetics system generated recombinant ibv virus based ibv h vaccine strain expressing haemagglutininneuraminidase hn protein ndv recombinant virus rhhna exhibited growth dynamic pathogenicity viral titer similar parental ibv h acquired hemagglutination activity ndv vaccination spf chicken rhhna virus induced humoral response level comparable lasotah commercial bivalent vaccine provided significant protection challenge virulent ibv ndv summary result study indicate ibv h strain could serve effective tool designing vaccine ib infectious disease generation ibv rhhna provides solid foundation development effective bivalent vaccine ibv ndv,2016-02-12,"Yang, Xin; Zhou, Yingshun; Li, Jianan; Fu, Li; Ji, Gaosheng; Zeng, Fanya; Zhou, Long; Gao, Wenqian; Wang, Hongning",Arch Virol,,,,document_parses/pdf_json/6b1b1794fd25ebbbe0839b59ed72f3cbe3e2188b.json,document_parses/pmc_json/PMC7087005.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26873815/; https://doi.org/10.1007/s00705-016-2764-4,15923434.0,3
100104,100104,127474,noyagzc6,b897789885d7e354ff7991528d15340bad90ff57,Elsevier; Medline; PMC,Heterologous Boosting of Recombinant Adenoviral Prime Immunization With a Novel Vesicular Stomatitis Virus–vectored Tuberculosis Vaccine,10.1038/mt.2008.59,PMC7185538,18388911.0,no-cc,pulmonary tuberculosis tb remains serious health problem worldwide effective vaccination strategy needed report development novel tb vaccine using vesicular stomatitis virus vsv viral vector system express aga vsvaga shown immunogenic given mouse either intranasal intramuscular im route although distinct tcell profile resulted route immunization intranasal delivery generated mucosal tcell response protective upon pulmonary mycobacterium tuberculosis mtb challenge protection manifested early timepoint immunization sustained potential vsvaga used mucosal booster parenteral priming adenoviral tb vaccine expressing aga adaga investigated vsvaga immunization markedly boosted antigenspecific tcell response airway lumen also augmenting immune activation systemic compartment adaga priming translated significantly better protective efficacy pulmonary challenge mtb either vaccine used alone study therefore suggests vsv vector system promising candidate used heterologous viral primeboost immunization regimen intracellular bacterial infection,2016-12-14,"Roediger, Elizabeth K; Kugathasan, Kapilan; Zhang, XiZhong; Lichty, Brian D; Xing, Zhou",Mol Ther,,,,document_parses/pdf_json/b897789885d7e354ff7991528d15340bad90ff57.json,document_parses/pmc_json/PMC7185538.xml.json,https://api.elsevier.com/content/article/pii/S1525001616317439; https://doi.org/10.1038/mt.2008.59; https://www.sciencedirect.com/science/article/pii/S1525001616317439; https://www.ncbi.nlm.nih.gov/pubmed/18388911/,25984543.0,3
100119,100119,127496,5d7np15t,074a55da5161bcf7f63991d18567e99b0dc98fb4,Elsevier; Medline; PMC,"Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials",10.1016/s0140-6736(17)33105-7,PMC6379903,29217376.0,bronze-oa,background zika virus epidemic associated congenital infection prompted rapid vaccine development assessed two new dna vaccine expressing premembrane envelope zika virus structural protein method two phase randomised openlabel trial involving healthy adult volunteer vrc trial done three centre assessed plasmid vrc zika virus japanese encephalitis virus chimera vrc done one centre assessed plasmid vrc wildtype zika virus eligible participant aged – year vrc – year vrc participant randomly assigned computergenerated randomisation schedule prepared study statistician participant received intramuscular injection mg vaccine vrc participant assigned receive vaccination via needle syringe week week week week vrc participant assigned receive vaccination week via singledose needle syringe injection one deltoid splitdose needle syringe needlefree injection stratis device pharmajet golden co usa deltoid trial followed volunteer month primary endpoint safety assessed local systemic reactogenicity day vaccination adverse event day vaccination secondary endpoint trial immunogenicity week last vaccination trial registered clinicaltrialsgov number nct nct finding vrc enrolled participant group vrc enrolled participant group one participant vrc two vrc withdrew one dose vaccine included safety analysis vaccine safe well tolerated local systemic symptom mild moderate study pain tenderness injection site frequent local symptom participant vrc vrc malaise headache frequent systemic symptom respectively vrc respectively vrc vrc participant received splitdose vaccination needlefree injection detectable positive antibody response geometric mean titre highest across group trial interpretation vrc well tolerated advanced phase efficacy testing,2018-02-01,"Gaudinski, Martin R; Houser, Katherine V; Morabito, Kaitlyn M; Hu, Zonghui; Yamshchikov, Galina; Rothwell, Ro Shauna; Berkowitz, Nina; Mendoza, Floreliz; Saunders, Jamie G; Novik, Laura; Hendel, Cynthia S; Holman, LaSonji A; Gordon, Ingelise J; Cox, Josephine H; Edupuganti, Srilatha; McArthur, Monica A; Rouphael, Nadine G; Lyke, Kirsten E; Cummings, Ginny E; Sitar, Sandra; Bailer, Robert T; Foreman, Bryant M; Burgomaster, Katherine; Pelc, Rebecca S; Gordon, David N; DeMaso, Christina R; Dowd, Kimberly A; Laurencot, Carolyn; Schwartz, Richard M; Mascola, John R; Graham, Barney S; Pierson, Theodore C; Ledgerwood, Julie E; Chen, Grace L",The Lancet,,,,document_parses/pdf_json/074a55da5161bcf7f63991d18567e99b0dc98fb4.json,document_parses/pmc_json/PMC6379903.xml.json,https://api.elsevier.com/content/article/pii/S0140673617331057; http://www.thelancet.com/article/S0140673617331057/pdf; https://doi.org/10.1016/s0140-6736(17)33105-7; https://www.sciencedirect.com/science/article/pii/S0140673617331057; https://www.ncbi.nlm.nih.gov/pubmed/29217376/,46846227.0,3
100127,100127,127505,65ip2yy6,afc1d001d3a53966f37467dcc2d61ed28c2fdd01; 1e3e6a494bf303c11a8344b479b740f032b1855f,Elsevier; Medline; PMC,Capacity of serotype 19A and 15B/C Streptococcus pneumoniae isolates for experimental otitis media: implications for the conjugate vaccine,10.1016/j.vaccine.2009.12.078,PMC2851619,20067753.0,green-oa,nonvaccine streptococcus pneumoniae serotypes increasingly associated disease evaluated isolates sequence type st different serotype bc growth vitro pathogenic potential chinchilla otitis medium model also developed qpcr assay quantitatively ass isolate circumventing need selectable marker vitro study showed faster growth serotype bc equally capable colonization middle ear infection model serotype included new conjugate vaccine formulation serotype bc noncapsular vaccine target important disease prevention effort,2010-03-01,"Laufer, Alison S.; Thomas, Jonathan C.; Figueira, Marisol; Gent, Janneane F.; Pelton, Stephen I.; Pettigrew, Melinda M.",Vaccine,,,,document_parses/pdf_json/afc1d001d3a53966f37467dcc2d61ed28c2fdd01.json; document_parses/pdf_json/1e3e6a494bf303c11a8344b479b740f032b1855f.json,document_parses/pmc_json/PMC2851619.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/20067753/; http://europepmc.org/articles/pmc2851619?pdf=render; https://doi.org/10.1016/j.vaccine.2009.12.078; https://api.elsevier.com/content/article/pii/S0264410X10000149; https://www.sciencedirect.com/science/article/pii/S0264410X10000149,25097058.0,3
100207,100207,127602,ft5kwtk7,2e83f16bbbc37d4cf2eba3dd0479e4ec7da6fc41,Medline; PMC,LBSapSal-vaccinated dogs exhibit increased circulating T-lymphocyte subsets (CD4(+) and CD8(+)) as well as a reduction of parasitism after challenge with Leishmania infantum plus salivary gland of Lutzomyia longipalpis,10.1186/1756-3305-7-61,PMC3943450,24507702.0,cc-by,background development protective vaccine canine visceral leishmaniasis cvl alternative approach interrupting domestic cycle leishmania infantum given importance sand fly salivary protein potent immunogen obligatorily codeposited transmission leishmania parasite inclusion antileishmania vaccine investigated last decade context previously immunized dog vaccine composed l braziliensis antigen plus saponin adjuvant sand fly salivary gland extract lbsapsal vaccine vaccine elicited increase antisaliva antileishmania igg isotypes higher count specific circulating cd cell high production method investigated immunogenicity protective effect lbsapsal vaccination intradermal challenge × latelogphase l infantum promastigotes presence sand fly saliva lutzomyia longipalpis dog followed day challenge result lbsapsal vaccine present extensive antigenic diversity persistent humoral cellular immune response indicating resistance cvl triggered high level total igg subtypes igg igg expansion circulating cd cd cd lymphocyte leishmaniaspecific reduction splenic parasite load conclusion result encourage study vaccine strategy addressing leishmania antigen combination protein present saliva vector,2014-02-07,"Aguiar-Soares, Rodrigo Dian de Oliveira; Roatt, Bruno Mendes; Ker, Henrique Gama; Moreira, Nádia das Dores; Mathias, Fernando Augusto Siqueira; Cardoso, Jamille Mirelle de Oliveira; Gontijo, Nelder Figueiredo; Bruna-Romero, Oscar; Teixeira-Carvalho, Andréa; Martins-Filho, Olindo Assis; Corrêa-Oliveira, Rodrigo; Giunchetti, Rodolfo Cordeiro; Reis, Alexandre Barbosa",Parasit Vectors,,,,document_parses/pdf_json/2e83f16bbbc37d4cf2eba3dd0479e4ec7da6fc41.json,document_parses/pmc_json/PMC3943450.xml.json,https://doi.org/10.1186/1756-3305-7-61; https://www.ncbi.nlm.nih.gov/pubmed/24507702/,1031353.0,3
100212,100212,127608,bz4hzmc2,6bc3441afe8aa103e7b28ceda7be4abc13471d8f,Elsevier; Medline; PMC,Reverse spillover of avian viral vaccine strains from domesticated poultry to wild birds,10.1016/j.vaccine.2017.05.033,PMC7173293,28533052.0,no-cc,transmission virus commercial poultry wild bird emerging paradigm livestock–wildlife interface report identification isolation vaccine strain avian paramyxovirus serotype apmv avian coronaviruses acov different wild bird specie across eight egyptian governorates january december surveillance avian respiratory virus freeranging wild bird n identified three specie harboured excreted apmv acovs genetic characterization phylogenetic analysis recovered virus revealed close association widely utilized vaccine strain country result highlight potential spillover vaccineviruses probably due extensive use liveattenuated vaccine commercial poultry close interaction domesticated wild bird population exploring full spectrum vaccinederived viral vaccine strain wild bird might help ass emergence future wildbirds origin virus,2017-06-16,"Rohaim, M.A.; El Naggar, R.F.; Helal, A.M.; Hussein, H.A.; Munir, Muhammad",Vaccine,,,,document_parses/pdf_json/6bc3441afe8aa103e7b28ceda7be4abc13471d8f.json,document_parses/pmc_json/PMC7173293.xml.json,https://api.elsevier.com/content/article/pii/S0264410X17306576; https://www.sciencedirect.com/science/article/pii/S0264410X17306576; https://www.ncbi.nlm.nih.gov/pubmed/28533052/; https://doi.org/10.1016/j.vaccine.2017.05.033,3786030.0,3
100235,100235,127636,jb7u9xn6,85b43c086b804389a1363732f85de88cca9cdffc,Elsevier; Medline; PMC,Vaccines for porcine epidemic diarrhea virus and other swine coronaviruses,10.1016/j.vetmic.2016.11.029,PMC7117160,27964998.0,els-covid,recent introduction porcine epidemic diarrhea virus pedv north american swine herd highlighted need effective vaccine swine coronaviruses vaccine transmissible gastroenteritis virus tgev available producer around world long time effective vaccine pedv deltacoronaviruses recently developed still development review existing vaccine technology swine coronaviruses highlight promising technology may help control important virus future,2017-07-31,"Gerdts, Volker; Zakhartchouk, Alexander",Veterinary Microbiology,,,,document_parses/pdf_json/85b43c086b804389a1363732f85de88cca9cdffc.json,document_parses/pmc_json/PMC7117160.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/27964998/; https://www.sciencedirect.com/science/article/pii/S0378113516307349; https://doi.org/10.1016/j.vetmic.2016.11.029; https://api.elsevier.com/content/article/pii/S0378113516307349,4420347.0,3
100309,100309,127730,vqu1ry66,5a0de643480abc0020d8941110964b46fd7d17b7,Elsevier; Medline; PMC,Production of soluble truncated spike protein of porcine epidemic diarrhea virus from inclusion bodies of Escherichia coli through refolding,10.1016/j.pep.2016.05.018,PMC7173294,27260969.0,no-cc,emergence highly pathogenic variant porcine epidemic diarrhea virus pedv strain north american asian country greatly threatened global swine industry therefore development effective vaccine pedv variant strain urgently needed recently reported nterminal domain ntd domain pedv spike protein responsible binding nacetylneuraminic acid neuac possible sugar coreceptor therefore ntd domain could attractive target development subunit vaccine study ntd spanning amino acid residue domain pedv variant strain expressed escherichia coli bl de form inclusion body ibs ibs solubilized mm sodium acetate ph buffer containing urea mm dithiothreitol yield solubilized ibs refolded fold flash dilution purified onestep cation exchange chromatography purity yield cd spectrum showed characteristic pattern alpha helical structure indirect elisa purified showed strong reactivity mouse antipedv serum addition immunization mouse μg purified elicited highly potent serum igg titer finally mouse antiserum showed immune reactivity native pedv protein immunofluorescence assay result suggest purified may potential used subunit vaccine pedv variant strain,2016-05-31,"Piao, Da-Chuan; Lee, Yoon-Seok; Bok, Jin-Duck; Cho, Chong-Su; Hong, Zhong-Shan; Kang, Sang-Kee; Choi, Yun-Jaie",Protein Expr Purif,,,,document_parses/pdf_json/5a0de643480abc0020d8941110964b46fd7d17b7.json,document_parses/pmc_json/PMC7173294.xml.json,https://api.elsevier.com/content/article/pii/S1046592816300973; https://www.ncbi.nlm.nih.gov/pubmed/27260969/; https://www.sciencedirect.com/science/article/pii/S1046592816300973; https://doi.org/10.1016/j.pep.2016.05.018,21925622.0,3
100314,100314,127736,3xk2w0d2,e7a8dfcde06b70cb86b30074d9008635252d6301,Medline; PMC,Computer aided selection of candidate vaccine antigens,10.1186/1745-7580-6-s2-s1,PMC2981880,21067543.0,cc-by,immunoinformatics emergent branch informatics science long ago pullulated tree knowledge bioinformatics discipline applies informatic technique problem immune system great extent immunoinformatics typified epitope prediction method found disappointingly limited use design discovery new vaccine area proper computational support generally lacking extant vaccine based around isolated epitope rather correspond chemicallytreated attenuated whole pathogen correspond individual protein extract whole pathogen correspond complex carbohydrate chapter attempt review progress asyetunderexplored area immunoinformatics computational discovery whole protein antigen effective development antigen prediction method would significantly reduce laboratory resource required identify pathogenic protein candidate subunit vaccine begin review placing antigen prediction firmly context exploring role reverse vaccinology design discovery vaccine also highlight several competing yet ultimately complementary methodological approach subcellular location prediction identifying antigen using sequence similarity use sophisticated statistical approach predicting probability antigen characteristic end exploring system immunomics approach prediction immunogenicity would prove helpful prediction antigen,2010-11-03,"Flower, Darren R; Macdonald, Isabel K; Ramakrishnan, Kamna; Davies, Matthew N; Doytchinova, Irini A",Immunome Res,,,,document_parses/pdf_json/e7a8dfcde06b70cb86b30074d9008635252d6301.json,document_parses/pmc_json/PMC2981880.xml.json,https://doi.org/10.1186/1745-7580-6-s2-s1; https://www.ncbi.nlm.nih.gov/pubmed/21067543/,7816076.0,3
100322,100322,127744,cngz535o,3734e22e57f8cfabd3ebcfc291dc3a81af82cba4,Elsevier; Medline; PMC,"Chapter Five Modified Vaccinia Virus Ankara History, Value in Basic Research, and Current Perspectives for Vaccine Development",10.1016/bs.aivir.2016.07.001,PMC7112317,28057259.0,els-covid,safety tested modified vaccinia virus ankara mva licensed thirdgeneration vaccine smallpox serf potent vector system development new candidate vaccine infectious disease cancer historically mva developed serial tissue culture passage primary chicken cell vaccinia virus strain ankara clinically used avoid undesirable side effect conventional smallpox vaccination adapted growth avian cell mva lost ability replicate mammalian host lack many gene orthopoxviruses use conquer host cell environment biologically wellcharacterized mutant virus mva facilitates fundamental research elucidate function poxvirus hostinteraction factor extremely safe viral vector mva vaccine found immunogenic protective various preclinical infection model multiple recombinant mva currently undergo clinical testing vaccination human immunodeficiency virus mycobacterium tuberculosis plasmodium falciparum versatility mva vector vaccine platform readily demonstrated swift development experimental vaccine immunization emerging infection middle east respiratory syndrome recent advance include promising result clinical testing recombinant mvaproducing antigen highly pathogenic avian influenza virus hn ebola virus review summarizes current knowledge mva unique strain vaccinia virus discus prospect exploiting virus research tool poxvirus biology safe viral vector vaccine challenge existing future bottleneck vaccinology,2017-12-31,"Volz, A.; Sutter, G.",Advances in Virus Research,,,,document_parses/pdf_json/3734e22e57f8cfabd3ebcfc291dc3a81af82cba4.json,document_parses/pmc_json/PMC7112317.xml.json,https://www.sciencedirect.com/science/article/pii/S0065352716300380; https://doi.org/10.1016/bs.aivir.2016.07.001; https://www.ncbi.nlm.nih.gov/pubmed/28057259/; https://api.elsevier.com/content/article/pii/S0065352716300380,26772762.0,3
100336,100336,127761,qlekpl0e,ac8b5e9b4a49a1062eddf4fc48a19778e66e9a78,Medline; PMC,The Interplay between Dengue Virus and the Human Innate Immune System: A Game of Hide and Seek,10.3390/vaccines7040145,PMC6963221,31658677.0,cc-by,world population risk infection dengue virus denv constitute serious threat public health antiviral therapy available potentially lethal disease efficacy approved vaccine optimal safety recently questioned order develop better vaccine based attenuated andor chimeric virus one must consider human immune system engaged denv infection activation innate immunity detection virus cellular sensor first line defence pathogen trigger cascade event establishes antiviral state cell level lead global immunological response however denv evolved interfere innate immune signalling multiple level hence dampening antiviral response favouring viral replication dissemination review elaborates interplay denv innate immune system special focus given viral countermeasure mechanism reported last decade taken consideration vaccine development,2019-10-10,"Tremblay, Nicolas; Freppel, Wesley; Sow, Aïssatou Aïcha; Chatel-Chaix, Laurent",Vaccines (Basel),,,,document_parses/pdf_json/ac8b5e9b4a49a1062eddf4fc48a19778e66e9a78.json,document_parses/pmc_json/PMC6963221.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31658677/; https://doi.org/10.3390/vaccines7040145,204953384.0,3
100428,100428,127870,wegpeews,fdcf8309d26eae0e94846942fc347babc5365514,Medline; PMC,Viral nanoparticles and virus‐like particles: platforms for contemporary vaccine design,10.1002/wnan.119,PMC7169818,20872839.0,no-cc,current vaccine provide protection infectious disease primarily relied attenuated inactivated pathogen virus‐like particle vlps comprised capsid protein initiate immune response include genetic material required replication promote immunogenicity developed approved vaccine case addition many vlps used molecular platform genetic fusion chemical attachment heterologous antigenic epitope approach shown provide protective immunity foreign epitope many case variety vlps virus‐based nanoparticles developed use vaccine epitope platform particle potential increase efficacy current vaccine well treat disease effective vaccine available wire nanomed nanobiotechnol – wnan therapeutic approach drug discovery nanomedicine infectious disease,2010-09-24,"Plummer, Emily M.; Manchester, Marianne",Wiley Interdiscip Rev Nanomed Nanobiotechnol,,,,document_parses/pdf_json/fdcf8309d26eae0e94846942fc347babc5365514.json,document_parses/pmc_json/PMC7169818.xml.json,https://doi.org/10.1002/wnan.119; https://www.ncbi.nlm.nih.gov/pubmed/20872839/,42811148.0,3
100433,100433,127876,hmrr8zy7,7871f62facbecd9f3a12f4278c7aefaaec8899d6,Medline; PMC,Comparative Pathogenesis and Systems Biology for Biodefense Virus Vaccine Development,10.1155/2010/236528,PMC2896660,20617142.0,no-cc,developing vaccine biothreat agent present number challenge discovery preclinical development licensure need high containment work live agent limit amount type research done using complete pathogen small market reduce potential return industry however number tool comparative pathogenesis viral strain molecular level novel computational approach used understand basis viral attenuation characterize protective immune response amount basic molecular knowledge grows able take advantage tool rationally attenuate virus strain candidate vaccine also ass immunogenicity safety silico review discus basic understanding pathogenesis allied system biology machine learning method impact biodefense vaccinology,2010-06-06,"Bowick, Gavin C.; Barrett, Alan D. T.",J Biomed Biotechnol,,,,document_parses/pdf_json/7871f62facbecd9f3a12f4278c7aefaaec8899d6.json,document_parses/pmc_json/PMC2896660.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/20617142/; https://doi.org/10.1155/2010/236528,11319363.0,3
100475,100475,127924,0czzjeop,37dc89ad4e28d979fdc0f238581b1a60ba80d295,Elsevier; PMC,Comparison of a fimbrial versus an autotransporter display system for viral epitopes on an attenuated Salmonella vaccine vector,10.1016/j.vaccine.2006.11.006,PMC7115504,17169467.0,els-covid,attenuated salmonella used vector deliver foreign antigen live vaccine previously developed efficient surfacedisplay system genetically engineering p fimbria present transmissible gastroenteritis virus tgev c epitope induction antitgev antibody salmonella vaccine vector system compared autotransporter protein surface display system tgev c epitope fused passenger domain misl autotransporter salmonella expression misl p subunit fasafusions tgev epitope control vivoinduced promoter expression tgev epitope salmonella typhimurium c crp cya asd pgte vaccine strain greater epitope fused misl fused p fasa subunit however balbc mouse orally immunized salmonella vector expressing tgev epitope either one fusion construct together highest level antitgev antibody obtained ptgev immunogendisplaying vector result suggested better immune response towards specific epitope could obtained using polymeric display system fimbria,2007-02-19,"Chen, Huaiqing; Schifferli, Dieter M.",Vaccine,,,,document_parses/pdf_json/37dc89ad4e28d979fdc0f238581b1a60ba80d295.json,document_parses/pmc_json/PMC7115504.xml.json,https://api.elsevier.com/content/article/pii/S0264410X06012011; https://www.sciencedirect.com/science/article/pii/S0264410X06012011,39013103.0,3
100508,100508,127968,6r9cgkgw,d7252e5db5944b4fda6436bc3b72a480c903b3f4,Medline; PMC; WHO,COVID-19 vaccines: breaking record times to first-in-human trials,10.1038/s41541-020-0188-3,PMC7193619,32377399.0,cc-by,twentyfirst century come new era vaccinology recombinant genetic technology contributed setting unprecedented fast pace vaccine development clearly demonstrated recent covid pandemic,2020-04-30,"Kim, Young Chan; Dema, Barbara; Reyes-Sandoval, Arturo",NPJ Vaccines,,#152257,,document_parses/pdf_json/d7252e5db5944b4fda6436bc3b72a480c903b3f4.json,document_parses/pmc_json/PMC7193619.xml.json,https://doi.org/10.1038/s41541-020-0188-3; https://www.ncbi.nlm.nih.gov/pubmed/32377399/,216650351.0,3
100549,100549,128018,qek9jy2c,8283f147574b1e6ea7ce216707b66a6b3e23fc94,Medline; PMC,Evaluation of glycoprotein E subunit and live attenuated varicella‐zoster virus vaccines formulated with a single‐strand RNA‐based adjuvant,10.1002/iid3.297,PMC7212201,32167678.0,cc-by,introduction varicella‐zoster virus vzv human alphaherpesvirus elicits chickenpox shingle andor postherpetic neuralgia live attenuated vaccine lav glycoprotein e ge subunit vaccine developed prevent vzv‐induced disease recently reported single‐strand rna ssrna based intergenic region internal ribosome entry site cricket paralysis virus crpv effective adjuvant protein‐based virus‐like particle‐based vaccine chinese hamster ovary expression system lav okask strain method appraised adjuvant effect crpv ssrna encoding ge gene formulated two vaccine using vzv‐primed cbl mouse guinea pig humoral immunity cell‐mediated immunity assessed enzyme‐linked immunosorbent assay elisa elispot ge subunit vaccine elisa fluorescent antibody membrane antigen lav result ge subunit vaccine‐induced ge‐specific antibody cd t‐cell response indicated interferon‐γ ifn‐γ interleukin‐ secretion ssrna‐based adjuvant containing vzv ge gene therefore ssrna adjuvant combined ge antigen trigger innate immune response induce adaptive immune response ultimately activate humoral cell‐mediated response vzv lav could also induce vzv‐specific antibody ifn‐γ stimulated lav whereas effect ssrna vaccine adjuvant could confirmed however ssrna adjuvant increased vzv‐specific neutralizing antibody response conclusion taken together result highlight ge subunit vaccine lav developed study functional vzv vaccine ssrnas appear function better adjuvant subunit vaccine lav,2020-03-13,"Lee, Su Jeen; Park, Hyo‐Jung; Ko, Hae Li; Lee, Jung Eun; Lee, Hyun Joo; Kim, Hun; Nam, Jae‐Hwan",Immun Inflamm Dis,,,,document_parses/pdf_json/8283f147574b1e6ea7ce216707b66a6b3e23fc94.json,document_parses/pmc_json/PMC7212201.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32167678/; https://doi.org/10.1002/iid3.297,212693757.0,3
100583,100583,128057,k3cme2s2,7f60c9d00f903457244719182bd27821116dcfa6,Elsevier; Medline; PMC,Bovine adenovirus-3 as a vaccine delivery vehicle,10.1016/j.vaccine.2014.11.055,PMC7115382,25498212.0,els-covid,use vaccine effective relatively inexpensive mean controlling infectious disease cause heavy economic loss livestock industry animal loss decreased productivity treatment expense decreased carcass quality however vaccine produced conventional mean imperfect many respect including virulence safety efficacy moreover vaccine animal disease although genetic engineering provided new way producing effective vaccine cost production veterinary use critical criterion selecting method production delivery vaccine cost effective production intrinsic ability enter cell made adenovirus vector highly efficient tool delivery vaccine antigen moreover adenovirus induce humoral cellular immune response expressed vaccine antigen since nonhuman adenovirus specie specific development animal specific adenovirus vaccine delivery vector evaluated review summarizes work related development bovine adenovirus vaccine delivery vehicle animal particularly cattle,2015-01-15,"Ayalew, Lisanework E.; Kumar, Pankaj; Gaba, Amit; Makadiya, Niraj; Tikoo, Suresh K.",Vaccine,,,,document_parses/pdf_json/7f60c9d00f903457244719182bd27821116dcfa6.json,document_parses/pmc_json/PMC7115382.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25498212/; https://api.elsevier.com/content/article/pii/S0264410X14016120; https://www.sciencedirect.com/science/article/pii/S0264410X14016120; https://doi.org/10.1016/j.vaccine.2014.11.055,30628262.0,3
100682,100682,128184,u361oua5,2b3e73ad2f395eba2016663de34d90751be15038,Elsevier; Medline; PMC,A novel Chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines,10.1016/j.vaccine.2008.12.051,PMC7115565,19162112.0,els-covid,use adenovirus ad vaccine vector hindered preexisting immunity human ad human population order overcome limitation uncommon alternative ad serotypes need utilized study e–e deleted recombinant ad based chimpanzee serotype chad engineered express human carcinoembryonic antigen cea protein rat neu extracellulartransmembrane domain ecdtm chad vector tested cea transgenic ceatg balbneut mouse show immunologic tolerance antigen chad capable inducing immune response comparable serotypebased vector thus breaking tolerance tumor associated antigen taas achieving antitumor effect importance chad overcome preexisting immunity work conjunction dna electroporation dnaep ad vaccine based common human serotypes,2009-02-25,"Peruzzi, Daniela; Dharmapuri, Sridhar; Cirillo, Agostino; Bruni, Bruno Ercole; Nicosia, Alfredo; Cortese, Riccardo; Colloca, Stefano; Ciliberto, Gennaro; La Monica, Nicola; Aurisicchio, Luigi",Vaccine,,,,document_parses/pdf_json/2b3e73ad2f395eba2016663de34d90751be15038.json,document_parses/pmc_json/PMC7115565.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19162112/; https://api.elsevier.com/content/article/pii/S0264410X09000127; https://doi.org/10.1016/j.vaccine.2008.12.051; https://www.sciencedirect.com/science/article/pii/S0264410X09000127,205577903.0,3
100745,100745,128262,653opx0h,544d61a716a23113ecb8bf04f412fbc6ba206942,Medline; PMC,Biodegradable Nanoparticle-Entrapped Vaccine Induces Cross-Protective Immune Response against a Virulent Heterologous Respiratory Viral Infection in Pigs,10.1371/journal.pone.0051794,PMC3519908,23240064.0,cc-by,biodegradable nanoparticlebased vaccine development research unexplored large animal human study illustrated efficacy nanoparticleentrapped uvkilled virus vaccine economically important respiratory viral disease pig called porcine reproductive respiratory syndrome virus prrsv entrapped plga poly lactidecoglycolides nanoparticles killed prrsv antigen nanokag detected phagocytosis pig alveolar macrophage single dos nanokag vaccine administered intranasally pig upregulated innate prrsv specific adaptive response virulent heterologous prrsv challenge study nanokag vaccine significantly reduced lung pathology viremia viral load lung immunologically enhanced innate adaptive immune cell population associated cytokine decreased secretion immunosuppressive mediator observed mucosal site blood summary demonstrated benefit intranasal delivery nanoparticlebased viral vaccine eliciting crossprotective immune response pig potential large animal model,2012-12-11,"Dwivedi, Varun; Manickam, Cordelia; Binjawadagi, Basavaraj; Joyappa, Dechamma; Renukaradhya, Gourapura J.",PLoS One,,,,document_parses/pdf_json/544d61a716a23113ecb8bf04f412fbc6ba206942.json,document_parses/pmc_json/PMC3519908.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/23240064/; https://doi.org/10.1371/journal.pone.0051794,9198235.0,3
100746,100746,128263,zlr7lkqx,b3df59be98a5200756fc64ee24de80525f616e1c,Elsevier; PMC,Chapter 4 Virus-Like Particle and Nanoparticle Vaccines,10.1016/b978-0-12-802302-0.00003-0,PMC7150090,,els-covid,atomiclevel structural information advance synthetic biology nanotechnology created new opportunity generating vaccine way possible using traditional method novel approach recombinant vaccine design opening door development vaccine challenging target chapter discus exceptional humoral immunogenicity viruslike particle vlps related nanoparticles application vaccine development emergence new category vaccine platform based recent insight multiple field study including immunology virology nanotechnology structural biology synthetic biology bioengineering multidisciplinary work vlp nanoparticle immunogen already yielding dividend public health also likely result safer potent broadly protective vaccine wide variety human animal pathogen well target host protein interest,2017-12-31,"Kanekiyo, M.; Buck, C. B.",Human Vaccines,,,,document_parses/pdf_json/b3df59be98a5200756fc64ee24de80525f616e1c.json,document_parses/pmc_json/PMC7150090.xml.json,https://api.elsevier.com/content/article/pii/B9780128023020000030; https://www.sciencedirect.com/science/article/pii/B9780128023020000030,90083312.0,3
100754,100754,128276,wtjlqhv4,,Medline; PMC,A Veterinary Vaccine Development Process Map to assist in the development of new vaccines,10.1016/j.vaccine.2020.05.007,PMC7200350,32418794.0,no-cc,uk government recognised importance vaccine control new emerging disease threat established uk vaccine network focus specific area need one understanding involved development new vaccine potential bottleneck rapid response face pandemic covid working group established initially produce vaccine development process map human vaccine however view importance animal wellbeing significant impact disease zoonotic potential similar map created outlining veterinary vaccine development process paper describes production map cover process generation target product profile tpp discovery feasibility product development registration,2020-05-06,"James Francis, Michael",Vaccine,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/32418794/; https://doi.org/10.1016/j.vaccine.2020.05.007,218679509.0,3
100828,100828,128363,y7jp49rj,f570f099d9ff961e399d29261ccf3b2998cba63e,Elsevier; PMC,Rotaviruses: Immunological Determinants of Protection Against Infection and Disease,10.1016/s0065-3527(08)60329-2,PMC7130874,7817873.0,els-covid,publisher summary chapter focus four important question remain unanswered importance virus serotype formulating optimal vaccine immunological effector arm likely protects rotavirus disease mean virus antigen best presented host elicit protective immune response advantage disadvantage replicating agent compared nonreplicating agent candidate rotavirus vaccine although two protein vp vp probably important inducing protection challenge clearly demonstrated inclusion epidemiologically important human p g type important protection human disease immunological effector arm clearly explains protection heterotypic challenge protection disease predicted rotavirusspecific neutralizing antibody serum oral inoculation may necessary induce protective virusspecific immune response intestinal mucosal surface parenteral inoculation experimental animal rotavirus induces immune response intestinal mucosal surface protective challenge induction rotavirusspecific protective immune response probably associated presence virusspecific b cell intestinal lymphoid tissue virusspecific siga igg intestinal mucosal surface experimental evidence support hypothesis neither rotavirus replication presentation rotavirus antigen intestinal mucosal surface necessary achieve aim,1994-12-31,"Offit, Paul A.",Advances in Virus Research,,,,document_parses/pdf_json/f570f099d9ff961e399d29261ccf3b2998cba63e.json,,https://www.sciencedirect.com/science/article/pii/S0065352708603292; https://api.elsevier.com/content/article/pii/S0065352708603292,23163706.0,3
100842,100842,128382,87g7g5au,d94ef771dd5097cb7e2c3563f73644fd8a83bbcf,Elsevier; PMC,Chapter 36 SARS,10.1016/b978-0-12-369408-9.00036-6,PMC7149452,,els-covid,five year first severe acute respiratory syndrome sars outbreak several candidate sarscoronavirus cov vaccine various stage preclinical clinical development based observation sarscov infection efficiently controlled upon passive transfer antibody directed spike protein sarscov vaccine containing protein formulated animal immunized inactivated whole virus vaccine liverecombinant vaccine expressing sarscov protein eg using rabies virus vesicular stomatitis virus bovine parainfluenza virus type adenovirus attenuated vaccinia virus mva vector well mouse immunized dna vaccine expressing protein gene developed neutralizing antibody sarscov protected sarscov challenge although much effort focused developing sars vaccine commercial viability vaccine sarscov ultimately depend whether virus reemerges near future vaccine induce highly crossreactive neutralizing antibody protect newly emerging virus related sarscov protect gastrointestinal respiratory tract absence significant side effect given fact previous outbreak mainly elderly succumbed infection special attention given vaccine able efficiently protect aged individual,2009-12-31,"Haagmans, Bart L.; Osterhaus, Albert D.M.E.",Vaccines for Biodefense and Emerging and Neglected Diseases,,,,document_parses/pdf_json/d94ef771dd5097cb7e2c3563f73644fd8a83bbcf.json,document_parses/pmc_json/PMC7149452.xml.json,https://api.elsevier.com/content/article/pii/B9780123694089000366; https://www.sciencedirect.com/science/article/pii/B9780123694089000366,82122348.0,3
100895,100895,128449,uqxzds6g,8c34e09a2de5c62460eaf9258b999db404719dcb,Medline; PMC,Dietary Probiotic Compound Improves Reproductive Performance of Porcine Epidemic Diarrhea Virus-Infected Sows Reared in a Japanese Commercial Swine Farm under Vaccine Control Condition,10.3389/fimmu.2017.01877,PMC5743915,29312349.0,cc-by,lactogenic immunity transferred piglet inoculation live vaccine pregnant sow proved limited control porcine epidemic diarrhea ped hence evaluated efficacy administration probiotic compound containing bacillus mesentericus clostridium butyricum enterococcus faecalis together commercial liveattenuated ped vaccine nisseiken ped live vaccine nisseiken tokyo japan improve health reproductive performance pedinfected sow twenty pregnant sow pedpositive farm equally divided probioticsadministered vp control vc sow group commercial liveattenuated vaccine injected per manufacturer ’ instruction probiotic compound gday orally administered vp week preparturition day postparturition ppd vp significantly higher body weight ppd vc v kg p day postparturition ppd v kgday ppd v kgday milk produced vp significantly p greater vc total immunoglobulin iga igg concentration day significantly p higher whey vp gdl respectively vc gdl respectively however total igg concentration whey vp vc ppd ppd differ antibody titer significantly higher day serum vp vc v geometric mean p likewise antibody titer whey vp vc found similar day v geometric mean p consequently vp fewer day weaning return estrus vc v day p moreover piglet vp significantly p higher litter weight birth glitter lower mortality suckling vc glitter respectively summary probioticsupplemented pedvaccinated sow healthier transferred pedspecific antibody via colostrum piglet greater litter weight birth reduced mortality suckling,2017-12-22,"Inatomi, Takio; Amatatsu, Masaaki; Romero-Pérez, Gustavo A.; Inoue, Ryo; Tsukahara, Takamitsu",Front Immunol,,,,document_parses/pdf_json/8c34e09a2de5c62460eaf9258b999db404719dcb.json,document_parses/pmc_json/PMC5743915.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29312349/; https://doi.org/10.3389/fimmu.2017.01877,1823414.0,3
100902,100902,128456,bn0ixqgc,79a82ee9007a1ecba6be491e8c675f3d00becba4,Elsevier; PMC,Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: Implications for a subunit vaccine,10.1016/j.vaccine.2006.06.084,PMC7115608,16919855.0,els-covid,studied immunogenicity antisars subunit vaccine comprised fragment sars coronavirus sarscov spike protein amino acid – s– containing receptorbinding domain protein fragment purified culture supernatant stably transformed hekt cell secreting tagged version protein vaccine given subcutaneously ssvev mouse saline alum adjuvant alum plus cpg oligodeoxynucleotides odn mouse immunized adjuvanted antigen elicited strong antibody cellular immune response furthermore adding cpg odn alum resulted increased igga antibody titer higher number infγsecreting murine splenocytes mouse vaccinated s– deglycosylated pngase f dgs– showed lower neutralizing antibody response similar number infγproducing cell spleen finding suggests carbohydrate important immunogenicity s– protein fragment provide useful information designing effective safe sars subunit vaccine,2007-01-02,"Zakhartchouk, Alexander N.; Sharon, Chetna; Satkunarajah, Malathy; Auperin, Thierry; Viswanathan, Sathiyanarayanan; Mutwiri, George; Petric, Martin; See, Raymond H.; Brunham, Robert C.; Finlay, B. Brett; Cameron, Cheryl; Kelvin, David J.; Cochrane, Alan; Rini, James M.; Babiuk, Lorne A.",Vaccine,,,,document_parses/pdf_json/79a82ee9007a1ecba6be491e8c675f3d00becba4.json,document_parses/pmc_json/PMC7115608.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X06008826; https://api.elsevier.com/content/article/pii/S0264410X06008826,22542697.0,3
100969,100969,128540,vtkdqmwv,9c620b0fd9f2134b3393f63cd52f08f22d6247e6; 9e4e243fca179d7b5585c5ad6e5c3be35df164bb,Elsevier; Medline; PMC,"Enhanced Humoral Response to Influenza Vaccine in Aged Mice with A Novel Adjuvant, rOv-ASP-1",10.1016/j.vaccine.2016.01.003,PMC4731280,26795365.0,green-oa,immunization best way prevent seasonal epidemic pandemic influenza two kind influenza vaccine available united state inactivated vaccine tiv attenuated vaccine however tiv approved immunization elderly population aged population highest rate influenza vaccination protective efficacy low evidenced elderly individual highest mortality associated influenza recently reported adjuvant derived helminth parasite onchocerca volvulus named volvulus activationassociated secreted protein ovasp significantly enhance protective efficacy inactivated vaccine tiv young adult mouse current study examined whether recombinant ovasp rovasp enhance efficacy tiv aged mouse well primary immunization tiv alone produced low level influenzaspecific antibody total igg igg iggc aged mouse antibody level significantly increased immunization tivrovasp importantly level total igg aged mouse administered tivrovasp comparable young adult mouse immunized tiv alone coadministration rovasp induced low level crossreactive antibody enhanced protective efficacy tiv aged mouse reflected significantly increased survival challenge heterologous influenza virus rovasp also superior conventional adjuvant alum inducing specific igg tiv immunization aged mouse conferring protection challenge result demonstrate rovasp may serve potential adjuvant influenza vaccine improve efficacy protection elderly,2016-02-01,"Jiang, Jiu; Fisher, Erin M.; Concannon, Mark; Lustigman, Sara; Shen, Hao; Murasko, Donna M.",Vaccine,,,,document_parses/pdf_json/9c620b0fd9f2134b3393f63cd52f08f22d6247e6.json; document_parses/pdf_json/9e4e243fca179d7b5585c5ad6e5c3be35df164bb.json,document_parses/pmc_json/PMC4731280.xml.json,https://doi.org/10.1016/j.vaccine.2016.01.003; https://api.elsevier.com/content/article/pii/S0264410X16000220; http://europepmc.org/articles/pmc4731280?pdf=render; https://www.sciencedirect.com/science/article/pii/S0264410X16000220; https://www.ncbi.nlm.nih.gov/pubmed/26795365/,22974990.0,3
100970,100970,128541,ks7s0uhf,f7185938312bfa794681998fe0bff4e2697c053d,Medline; PMC,An Overview on the Field of Micro- and Nanotechnologies for Synthetic Peptide-Based Vaccines,10.1155/2011/181646,PMC3134826,21773041.0,cc-by,development synthetic peptidebased vaccine many advantage comparison vaccine based live attenuated organism inactivated killed organism toxin peptidebased vaccine revert virulent form allow better conservation produced easily safely however generate weaker immune response vaccine inclusion adjuvant andor use vaccine delivery system almost always needed among vaccine delivery system micro nanoparticulated one attractive particulate nature increase crosspresentation peptide addition passively actively targeted antigen presenting cell furthermore particulate adjuvant able directly activate innate immune system vivo summarize micro nanoparticulated vaccine delivery system used field synthetic peptidebased vaccine well strategy increase immunogenicity,2011-06-15,"Salvador, Aiala; Igartua, Manoli; Hernández, Rosa Maria; Pedraz, José Luis",J Drug Deliv,,,,document_parses/pdf_json/f7185938312bfa794681998fe0bff4e2697c053d.json,document_parses/pmc_json/PMC3134826.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/21773041/; https://doi.org/10.1155/2011/181646,3007822.0,3
100993,100993,128568,p17oomzn,5c52c8e0a6040be3a5c99f0e239e361a400870e2,Elsevier; PMC,Chapter 30 Measles,10.1016/b978-0-12-369408-9.00030-5,PMC7149578,,els-covid,measles highly contagious disease characterized prodromal illness fever cough coryza conjunctivitis followed appearance generalized maculopapular rash measles virus nonsegmented singlestranded negativesense rna virus member morbillivirus genus family paramyxoviridae although rna virus high mutation rate measles virus antigenically monotypic virus surface protein responsible inducing protective immunity retained antigenic structure public health significance measles vaccine developed decade ago single measles virus strain remain protective worldwide prior development widespread use measles vaccine million case measles estimated occur year resulting million death several live attenuated measles vaccine available either singleantigen vaccine combination rubella mumps vaccine mr mmr vaccine currently used measles vaccine derived edmonston strain measles virus isolated enders peebles measles vaccine recommended susceptible child adult vaccine contraindicated despite progress reducing measles mortality measles remains major cause vaccinepreventable death important cause morbidity mortality child particularly subsaharan africa asia ideal measles vaccine would inexpensive safe heatstable immunogenic neonate young infant administered single dose without needle syringe number vaccine candidate characteristic undergoing preclinical study including dna vaccine various viral bacterial vectored vaccine high infectivity measles virus characteristic suitable biothreat agent however increasingly high level measles vaccination coverage throughout world part accelerated measles control effort would protect many deliberate use measles virus biothreat agent genetic engineering measles virus strain neutralized antibody induced current attenuated measles vaccine would likely reduced infectivity suggested fact wildtype measles virus mutated alter neutralizing epitope measles virus meet many biological criterion disease eradication measles virus nonhuman reservoir accurately diagnosed measles vaccination highly effective intervention measles virus differs smallpox polio virus highly infectious necessitating higher level population immunity interrupt transmission remains unclear whether threat bioterrorism precludes stopping measles vaccination eradication provision second opportunity measles vaccination likely could stopped following eradication,2009-12-31,"Moss, William J.; Griffin, Diane E.; Feinstone, W. Harry",Vaccines for Biodefense and Emerging and Neglected Diseases,,,,document_parses/pdf_json/5c52c8e0a6040be3a5c99f0e239e361a400870e2.json,document_parses/pmc_json/PMC7149578.xml.json,https://api.elsevier.com/content/article/pii/B9780123694089000305; https://www.sciencedirect.com/science/article/pii/B9780123694089000305,58585391.0,3
101018,101018,128596,ilfh0ds7,2ad9d14f7f65cb860f407759ae6307a2841d3541; ac214d6bd3b4db8cc28b85f435816dc374b61d88,Elsevier; Medline; PMC,Vaccine Technologies: From Whole Organisms to Rationally Designed Protein Assemblies,10.1016/j.bcp.2016.05.001,PMC5079805,27157411.0,green-oa,vaccine single significant advancement public health preventing morbidity mortality million people annually vaccine development traditionally focused whole organism vaccine either live attenuated inactivated vaccine successful many different infectious disease whole organism expensive produce require culture infectious agent potential cause vaccine associated disease host advancing technology desire develop safe cost effective vaccine candidate field began focus development recombinantly expressed antigen known subunit vaccine tolerable subunit vaccine tend le immunogenic attempt made increase immunogenicity addition adjuvant either immunostimulatory molecule antigen delivery system increase immune response vaccine area extreme interest application nanotechnology vaccine development allows antigen expressed particulate delivery system one exciting example nanovaccines rationally designed protein nanoparticles nanoparticles use basic tenant structural biology biophysical chemistry vaccinology develop protective safe easily manufactured vaccine rationally developed nanoparticle vaccine one promising candidate future vaccine development,2016-11-01,"Karch, Christopher P.; Burkhard, Peter",Biochemical Pharmacology,,,,document_parses/pdf_json/2ad9d14f7f65cb860f407759ae6307a2841d3541.json; document_parses/pdf_json/ac214d6bd3b4db8cc28b85f435816dc374b61d88.json,document_parses/pmc_json/PMC5079805.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/27157411/; https://api.elsevier.com/content/article/pii/S0006295216300740; https://doi.org/10.1016/j.bcp.2016.05.001; http://europepmc.org/articles/pmc5079805?pdf=render; https://www.sciencedirect.com/science/article/pii/S0006295216300740,46263328.0,3
101065,101065,128648,11dnyh3r,b36e50f60fea94dd15621dfd9552c7eefe31c3f8,Elsevier; Medline; PMC,Important mammalian veterinary viral immunodiseases and their control,10.1016/j.vaccine.2012.01.014,PMC7130670,22261411.0,els-covid,paper offer overview important veterinary viral disease mammal stemming aberrant immune response disease reviewed comprise due lentiviruses equine infectious anaemia visnamaedi caprine arthritis encephalitis feline immunodeficiency disease caused virus feline infectious peritonitis feline leukaemia canine distemper aquatic counterpart aleutian disease malignant catarrhal fever also consider prospect immunoprophylaxis disease briefly control measure realised outlook effective vaccine many disease remote paper describes current status vaccine research difficulty encountered development,2012-02-27,"Patel, J. R.; Heldens, J.G.M.; Bakonyi, T.; Rusvai, M.",Vaccine,,,,document_parses/pdf_json/b36e50f60fea94dd15621dfd9552c7eefe31c3f8.json,document_parses/pmc_json/PMC7130670.xml.json,https://doi.org/10.1016/j.vaccine.2012.01.014; https://www.ncbi.nlm.nih.gov/pubmed/22261411/; https://www.sciencedirect.com/science/article/pii/S0264410X12000291; https://api.elsevier.com/content/article/pii/S0264410X12000291,38283565.0,3
101071,101071,128654,ctikde7d,777328a5bc26d551df06e62b64682c03c25dde03,Medline; PMC,Dendritic Cell-Specific Antigen Delivery by Coronavirus Vaccine Vectors Induces Long-Lasting Protective Antiviral and Antitumor Immunity,10.1128/mbio.00171-10,PMC2939679,20844609.0,no-cc,efficient vaccination infectious agent tumor depends specific antigen targeting dendritic cell dc report biosafe coronavirusbased vaccine vector facilitate delivery multiple antigen immunostimulatory cytokine professional antigenpresenting cell vitro vivo vaccine vector based heavily attenuated murine coronavirus genome generated express epitope lymphocytic choriomeningitis virus glycoprotein human melana combination immunostimulatory cytokine granulocytemacrophage colonystimulating factor gmcsf vector selectively targeted dc vitro vivo resulting vectormediated antigen expression efficient maturation dc single application low vector dos elicited strong longlasting cytotoxic tcell response providing protective antiviral antitumor immunity furthermore human dc transduced melanarecombinant human coronavirus e efficiently activated tumorspecific cd cell taken together novel vaccine platform well suited deliver antigen immunostimulatory cytokine dc initiate maintain protective immunity,2010-09-14,"Cervantes-Barragan, Luisa; Züst, Roland; Maier, Reinhard; Sierro, Sophie; Janda, Jozef; Levy, Frederic; Speiser, Daniel; Romero, Pedro; Rohrlich, Pierre-Simon; Ludewig, Burkhard; Thiel, Volker",mBio,,,,document_parses/pdf_json/777328a5bc26d551df06e62b64682c03c25dde03.json,document_parses/pmc_json/PMC2939679.xml.json,https://doi.org/10.1128/mbio.00171-10; https://www.ncbi.nlm.nih.gov/pubmed/20844609/,14204907.0,3
101074,101074,128658,6os5iy5w,7a7bfe6bea6e18ea0e4011e4a8407d7628c32d26,Medline; PMC,Structural and genetic basis for development of broadly neutralizing influenza antibodies,10.1038/nature11371,PMC7095019,22932267.0,no-cc,influenza virus take yearly toll human life despite effort contain seasonal vaccine virus evade human immunity evolution variant resist neutralization identification antibody recognize invariant structure influenza haemagglutinin ha protein invigorated effort develop universal influenza vaccine specifically antibody highly conserved stem region ha neutralize diverse viral subtypes antibody largely derive specific antibody gene heavychain variable region ighv limited affinity maturation germline ancestor ha stimulates naive b cell mature induce protective immunity unknown address question analysed structural genetic basis engagement maturation broadly neutralizing antibody show germlineencoded precursor antibody act functional bcell antigen receptor bcrs initiate subsequent affinity maturation neither germline precursor prototypic antibody cr ref two natural human ighv antibody bound ha soluble immunoglobuling igg however three ighv precursor engaged ha antibody expressed cell surface igm ha triggered bcrassociated tyrosine kinase signalling germline transmembrane igm recognition virus neutralization dependent solely heavy chain affinity maturation cr required seven amino acid complementaritydetermining region cdr h framework region fr restore full activity finding provide insight initial event lead generation broadly neutralizing antibody influenza informing rational design vaccine elicit antibody providing model relevant infectious disease including human immunodeficiency virusaids data suggest selected immunoglobulin gene recognize specific protein structural ‘ pattern ’ provide substrate affinity maturation supplementary information online version article doinature contains supplementary material available authorized user,2012-08-29,"Lingwood, Daniel; McTamney, Patrick M.; Yassine, Hadi M.; Whittle, James R. R.; Guo, Xiaoti; Boyington, Jeffrey C.; Wei, Chih-Jen; Nabel, Gary J.",Nature,,,,document_parses/pdf_json/7a7bfe6bea6e18ea0e4011e4a8407d7628c32d26.json,document_parses/pmc_json/PMC7095019.xml.json,https://doi.org/10.1038/nature11371; https://www.ncbi.nlm.nih.gov/pubmed/22932267/,205230087.0,3
101091,101091,128675,w6wxsg4p,0f1f7b2859429c26a3e8e0ce1356b1b5184afc96,Elsevier; Medline; PMC,Newcastle disease vaccines—A solved problem or a continuous challenge?,10.1016/j.vetmic.2016.12.019,PMC7131810,28024856.0,els-covid,newcastle disease nd defined world organisation animal health infection poultry virulent strain newcastle disease virus ndv lesion affecting neurological gastrointestinal respiratory reproductive system often observed control nd must include strict biosecurity prevents virulent ndv contacting poultry also proper administration efficacious vaccine administered correctly healthy bird nd vaccine formulated ndv low virulence viralvectored vaccine express ndv fusion protein able prevent clinical disease mortality chicken upon infection virulent ndv live inactivated vaccine widely used since ’ recombinant antigenically matched vaccine adopted recently country many vaccine approach evaluated experimentally despite decade research development towards formulation optimal nd vaccine improvement still needed impediment prevent outbreak include uneven vaccine application using mass administration technique larger commercial setting difficulty associated vaccinating freeroaming multiage bird village flock difficulty maintaining cold chain preserve thermolabile antigen vaccine incomplete improper immunization often result disease death poultry infection virulent ndv another cause decreased vaccine efficacy existence antibody including maternal bird neutralize vaccine thereby reduce effectiveness nd vaccine review historical perspective summary current situation nd ndv strain review traditional experimental nd vaccine presented,2017-07-31,"Dimitrov, Kiril M.; Afonso, Claudio L.; Yu, Qingzhong; Miller, Patti J.",Veterinary Microbiology,,,,document_parses/pdf_json/0f1f7b2859429c26a3e8e0ce1356b1b5184afc96.json,document_parses/pmc_json/PMC7131810.xml.json,https://doi.org/10.1016/j.vetmic.2016.12.019; https://www.ncbi.nlm.nih.gov/pubmed/28024856/; https://api.elsevier.com/content/article/pii/S0378113516308045; https://www.sciencedirect.com/science/article/pii/S0378113516308045,205627157.0,3
101156,101156,128754,3q9x1bwm,,Medline; PMC,Porcine epidemic diarrhea virus virus-like particles produced in insect cells induce specific immune responses in mice,10.1007/s11262-017-1450-2,PMC7088547,28357676.0,no-cc,porcine epidemic diarrhea virus pedv cause – mortality neonatal piglet one devastating viral disease affecting swine worldwide date lack effective vaccine drug main problem preventing control global spread pedv study produced pedv viruslike particle vlps composed e protein baculovirus expression system tested via indirect immunofluorescence assay ifaand western blot analysis electron microscopy showed morphological structure pedv vlps similar protovirus microneutralization assay elispot analysis demonstrated pedv vlps induced highly specific antibody response thmediated humoral immunity result pedv vlps displayed excellent immunogenicity mouse therefore vlpbased vaccine potential prevent pedv infection,2017-03-29,"Wang, Cuiling; Yan, Feihu; Zheng, Xuexing; Wang, Hualei; Jin, Hongli; Wang, Chong; Zhao, Yongkun; Feng, Na; Wang, Tiecheng; Gao, Yuwei; Yang, Songtao; Xia, Xianzhu",Virus Genes,,,,,document_parses/pmc_json/PMC7088547.xml.json,https://doi.org/10.1007/s11262-017-1450-2; https://www.ncbi.nlm.nih.gov/pubmed/28357676/,13494679.0,3
101178,101178,128782,gm2g36hc,fe14106f9f3d2b3b6d8ea619cfcc4363148dc84b,Medline; PMC,Immune response development after vaccination of 1-day-old naïve pigs with a Porcine Reproductive and Respiratory Syndrome 1-based modified live virus vaccine,10.1186/s40813-018-0112-7,PMC6359793,30761215.0,cc-by,background development innate adaptive immune response porcine reproductive respiratory syndrome virus prrsv vaccination dayold pig prrsv based modified live virus mlv vaccine intramuscular im intranasal route characterised challenge heterologous prrsv isolate week postvaccination twentyfive prrsvseronegative piglet used day age pig administered single dose vaccine via im n route n control group n received saline solution vaccination pig bled day level cytokine il il ifnα measured elisa test serum tnfα ifnγ measured elisa elispot respectively stimulated peripheral blood mononuclear cell serum neutralising antibody na vaccine strain measured result induction il rare indicating il mediated immunomodulationimmune dysfunction feature vaccine challenge virus il detected two pig following vaccination majority pig challenge indicating ability produce innate immune response impaired tnfα detected vaccinated pig day challenge minority pig produced tnfα ifnα detected vaccinated pig following vaccination indicating potential development effective th adaptive immune response ifnγsecreting cell detected vaccinated pig vaccination na vaccine strain first detected day pig vaccinated route remained similar level challenge challenge boost na observed efficacy vaccine demonstrated reduction viraemia nasal shedding challenge conclusion administration prrsv based mlv vaccine dayold piglet able induce immune response characterised undetectable low level il il tnfα increase ifnα expression within first seven day gradual increase number antigenspecific ifnγsecreting cell induction detectable na challenge heterologous strain rapid boost na titre indicating priming effect vaccine,2019-02-02,"Balasch, Monica; Fort, Maria; Taylor, Lucas P.; Díaz, Ivan; Mateu, Enric; Calvert, Jay G.",Porcine Health Manag,,,,document_parses/pdf_json/fe14106f9f3d2b3b6d8ea619cfcc4363148dc84b.json,document_parses/pmc_json/PMC6359793.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30761215/; https://doi.org/10.1186/s40813-018-0112-7,61155455.0,3
101182,101182,128787,081o2zmd,d5076ff3eb3e96c862345fa109990f9a7b99b842,Medline; PMC,Evaluation on the Efficacy and Immunogenicity of Recombinant DNA Plasmids Expressing Spike Genes from Porcine Transmissible Gastroenteritis Virus and Porcine Epidemic Diarrhea Virus,10.1371/journal.pone.0057468,PMC3602451,23526943.0,cc-by,porcine transmissible gastroenteritis virus tgev porcine epidemic diarrhea virus pdev cause severe diarrhea pig development effective vaccine tgev pedv one important prevention measure spike protein surface glycoprotein tgev pedv induce specific neutralization antibody candidate antigen vaccination attempt study open reading frame tgev protein addition protein pedv inserted eukaryotic expression vector pires resulting recombinant plasmid pirestgevspedvs pirestgevspedvs subsequently – week old kunming mouse inoculated dna plasmid lymphocyte proliferation assay virus neutralization assay ifnγ assay ctl activity assay performed tgevpedv specific antibody response well kinetic change lymphocyte subgroup immunized mouse analyzed result showed recombinant dna plasmid increased proliferation lymphocyte number cd cd lymphocyte subgroup addition dna vaccine induced high level ifnγ immunized mouse specific ctl activity pirestgevspedvs group became significant day postimmunization day postimmunization recombinant dna plasmid bearing fulllength gene tgev pedv stimulated higher level specific antibody neutralizing antibody immunized mouse,2013-03-19,"Meng, Fandan; Ren, Yudong; Suo, Siqingaowa; Sun, Xuejiao; Li, Xunliang; Li, Pengchong; Yang, Wei; Li, Guangxing; Li, Lu; Schwegmann-Wessels, Christel; Herrler, Georg; Ren, Xiaofeng",PLoS One,,,,document_parses/pdf_json/d5076ff3eb3e96c862345fa109990f9a7b99b842.json,document_parses/pmc_json/PMC3602451.xml.json,https://doi.org/10.1371/journal.pone.0057468; https://www.ncbi.nlm.nih.gov/pubmed/23526943/,15903958.0,3
101220,101220,128828,drj2hucu,428a06a5762a1399d5ffb50f2dd8e566228c4932,Elsevier; Medline; PMC,Effect of vaccination strategies on the dynamic behavior of epidemic spreading and vaccine coverage,10.1016/j.chaos.2014.04.005,PMC7126457,32288360.0,els-covid,transmission infectious yet vaccinepreventable disease typical complex social phenomenon increasing level vaccine update population help inhibit epidemic spreading turn however discourages people participate vaccination campaign due “ externality effect ” raised vaccination herein study impact vaccination strategy pure continuous rather adopt vaccination definitely individual choose taking vaccine probability continuous randomly mutation vaccination dynamic spatial susceptiblevaccinatedinfectedrecovered svir epidemiological model mean extensive montecarlo simulation show crossover behavior final vaccine coverage purestrategy case continuousstrategy case remarkably final vaccination level epidemic size continuousstrategy case le purestrategy case vaccination cheap explain phenomenon analyzing organization process individual continuousstrategy case equilibrium result robust svir dynamic defined spatial network like erdős–rényi barabási–albert network,2014-06-30,"Cai, Chao-Ran; Wu, Zhi-Xi; Guan, Jian-Yue","Chaos, Solitons & Fractals",,,,document_parses/pdf_json/428a06a5762a1399d5ffb50f2dd8e566228c4932.json,document_parses/pmc_json/PMC7126457.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32288360/; https://doi.org/10.1016/j.chaos.2014.04.005; https://api.elsevier.com/content/article/pii/S0960077914000514; https://www.sciencedirect.com/science/article/pii/S0960077914000514,121373356.0,3
101229,101229,128839,yuqc6dk0,2feee102eda67b8b2839d523ecb483ad42b53bd7,Elsevier; Medline; PMC,Enhancement of the immunogenicity of an infectious bronchitis virus DNA vaccine by a bicistronic plasmid encoding nucleocapsid protein and interleukin-2,10.1016/j.jviromet.2008.01.017,PMC7119663,18329109.0,no-cc,dna vaccine infectious bronchitis virus ibv induce specific humoral cellmediated immunity however compared conventional vaccine dna vaccine usually induce poor antibody response develop potent ibv dna vaccine formulation monocistronic vector encoding nucleocapsid protein ibv bicistronic vector separately encoding nucleocapsid protein immunestimulatory interleukin constructed dna vaccine administered quadriceps muscle chicken induced humoral cellular response evaluated significant difference elisa antibody level elicited either monocistronic bicistronic dna vaccine percentage cd cdcd cdcd subgroup peripheral blood tlymphocytes chicken immunized bicistronic dna vaccine higher chicken immunized monocistronic dna vaccine chicken challenged virulent strain ibv protective efficacy could enhanced significantly immunization bicistronic dna vaccine result demonstrated bicistronic dna vaccine effective approach increase ibv dna vaccine immunogenicity,2008-03-07,"Tang, Mengjun; Wang, Hongning; Zhou, Sheng; Tian, Guobao",J Virol Methods,,,,document_parses/pdf_json/2feee102eda67b8b2839d523ecb483ad42b53bd7.json,document_parses/pmc_json/PMC7119663.xml.json,https://doi.org/10.1016/j.jviromet.2008.01.017; https://www.ncbi.nlm.nih.gov/pubmed/18329109/; https://api.elsevier.com/content/article/pii/S0166093408000268; https://www.sciencedirect.com/science/article/pii/S0166093408000268,9930148.0,3
101261,101261,128883,3jhka8wl,c58ab09c8c9068b939850a5e78e5c8613dcf4afb,Medline; PMC,Pathogenicity of porcine deltacoronavirus (PDCoV) strain NH and immunization of pregnant sows with an inactivated PDCoV vaccine protects 5‐day‐old neonatal piglets from virulent challenge,10.1111/tbed.13369,PMC7168751,31541590.0,no-cc,study pathogenicity porcine deltacoronavirus pdcov strain nh passage p evaluated found pdcov strain nh enteropathogenic ‐day‐old pig pathogenicity experiment provided challenge model studying protection efficiency passive immunity order investigate protective efficacy passive immunity newborn piglet pregnant sow vaccinated either pdcov‐inactivated vaccine houhai acupoint n dmem negative control n using primeboost strategy day delivery pdcov spike s‐specific igg neutralizing antibody na response detected immunized sow piglet born immunized sow pdcov spike s‐specific siga also detected colostrum milk immunized sow five day post‐farrowing piglet orally challenged pdcov strain nh tcidpiglet severe diarrhoea high level viral rna copy substantial intestinal villus atrophy detected piglet born unimmunized sow piglet born immunized sow challenge group displayed mild moderate diarrhoea lower viral rna copy minor intestinal villus damage compared piglet born unimmunized sow post‐challenge mock piglet exhibited typical clinical symptom challenge experiment result indicated inactivated pdcov vaccine exhibited protective efficacy piglet finding suggest inactivated pdcov vaccine potential effective vaccine providing protection virulent pdcov,2019-09-30,"Zhang, Jialin; Chen, Jianfei; Liu, Ye; Da, Shi; Shi, Hongyan; Zhang, Xin; Liu, Jianbo; Cao, Liyan; Zhu, Xiangdong; Wang, Xiaobo; Ji, Zhaoyang; Feng, Li",Transbound Emerg Dis,,,,document_parses/pdf_json/c58ab09c8c9068b939850a5e78e5c8613dcf4afb.json,document_parses/pmc_json/PMC7168751.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31541590/; https://doi.org/10.1111/tbed.13369,202710885.0,3
101274,101274,128899,zkuj22oc,d9fac21a48ccd35eae742af95eaa6a6638fe8a3e,Medline; PMC,Plant-Derived Antigens as Mucosal Vaccines,10.1007/82_2011_158,PMC7122597,21811930.0,no-cc,last two decade researcher developed robust system recombinant subunit vaccine production plant stably transiently transformed plant particular advantage enable immunization human animal via mucosal delivery initial goal immunize orally ingestion plantderived antigen proven difficult attain although many study demonstrated antibody production human animal case protection pathogen challenge substantial hurdle strategy lowantigen content crudely processed plant material limited antigen stability gut alternative intranasal delivery purified plantderived antigen expressed robust viral vector especially viruslike particle use pattern recognition receptor agonist adjuvant mucosal delivery plantderived antigen substantially enhance serum mucosal antibody response chapter briefly review method recombinant protein expression plant describe progress human animal vaccine use mucosal delivery route attempt compile comprehensive list focus study progressed clinical trial showed strong indication efficacy animal finally discus regulatory concern regarding plantbased vaccine,2011-08-03,"Mason, H. S.; Herbst-Kralovetz, M. M.",Mucosal Vaccines,,,,document_parses/pdf_json/d9fac21a48ccd35eae742af95eaa6a6638fe8a3e.json,document_parses/pmc_json/PMC7122597.xml.json,https://doi.org/10.1007/82_2011_158; https://www.ncbi.nlm.nih.gov/pubmed/21811930/,9935780.0,3
101338,101338,128976,l6wqi58t,83a9e757fc42183eef4f36f50cf84044f7b780fb; 96f74d611693ebad68d8cd10862e9a972bd3bdc5; 1b174862fbd8a1f806012fb3af55223ddf0224ec,Medline; PMC,Evaluation of candidate vaccine approaches for MERS-CoV,10.1038/ncomms8712,PMC4525294,26218507.0,cc-by,emergence middle east respiratory syndrome coronavirus merscov cause severe respiratory disease highlight need effective approach cov vaccine development effort focused solely receptorbinding domain rbd viral spike glycoprotein may optimize neutralizing antibody nab response show immunogen based fulllength dna subunit protein elicit robust serumneutralizing activity several merscov strain mouse nonhuman primate serological analysis isolation murine monoclonal antibody revealed immunization elicits nabs rbd nonrbd portion subunit multiple neutralization mechanism demonstrated solving atomic structure nabrbd complex sequencing neutralization escape virus constructing merscov variant serological assay immunization rhesus macaque confers protection merscovinduced radiographic pneumonia assessed using computerized tomography supporting strategy promising approach merscov vaccine development,2015-07-28,"Wang, Lingshu; Shi, Wei; Joyce, M. Gordon; Modjarrad, Kayvon; Zhang, Yi; Leung, Kwanyee; Lees, Christopher R.; Zhou, Tongqing; Yassine, Hadi M.; Kanekiyo, Masaru; Yang, Zhi-yong; Chen, Xuejun; Becker, Michelle M.; Freeman, Megan; Vogel, Leatrice; Johnson, Joshua C.; Olinger, Gene; Todd, John P.; Bagci, Ulas; Solomon, Jeffrey; Mollura, Daniel J.; Hensley, Lisa; Jahrling, Peter; Denison, Mark R.; Rao, Srinivas S.; Subbarao, Kanta; Kwong, Peter D.; Mascola, John R.; Kong, Wing-Pui; Graham, Barney S.",Nat Commun,,,,document_parses/pdf_json/83a9e757fc42183eef4f36f50cf84044f7b780fb.json; document_parses/pdf_json/96f74d611693ebad68d8cd10862e9a972bd3bdc5.json; document_parses/pdf_json/1b174862fbd8a1f806012fb3af55223ddf0224ec.json,document_parses/pmc_json/PMC4525294.xml.json,https://doi.org/10.1038/ncomms8712; https://www.ncbi.nlm.nih.gov/pubmed/26218507/,16262651.0,3
101472,101472,129150,8h8lwg5p,3e1874b3a7b354af8cb25bfcd127ba887afe92c2,Medline; PMC,A New Quaternary Structure Epitope on Dengue Virus Serotype 2 Is the Target of Durable Type-Specific Neutralizing Antibodies,10.1128/mbio.01461-15,PMC4620467,26463165.0,cc-by-nc-sa,dengue virus serotype denv widespread responsible severe epidemic primary denv infection stimulate serotypespecific protective response leading vaccine failed induce similar protective response using human monoclonal antibody hmabs isolated dengue case structureguided design chimeric denv describe major site denv envelope e protein targeted neutralizing antibody denvspecific neutralizing hmab bind quaternary structure epitope engineered recovered recombinant denv displayed epitope denv neutralizing antibody people exposed infection live vaccine tracked epitope denv chimera chimera remained sensitive denv antibody indicating major neutralizing epitope denv different site ability transplant complex epitope denv serotypes demonstrates hitherto underappreciated structural flexibility flavivirus could harnessed develop new vaccine diagnostics,2015-10-13,"Gallichotte, E. N.; Widman, D. G.; Yount, B. L.; Wahala, W. M.; Durbin, A.; Whitehead, S.; Sariol, C. A.; Crowe, J. E.; de Silva, A. M.; Baric, R. S.",mBio,,,,document_parses/pdf_json/3e1874b3a7b354af8cb25bfcd127ba887afe92c2.json,document_parses/pmc_json/PMC4620467.xml.json,https://doi.org/10.1128/mbio.01461-15; https://www.ncbi.nlm.nih.gov/pubmed/26463165/,17815575.0,3
101489,101489,129174,bp9ubajv,819d63a71302ab84053f5cb07e97ebd0fa3c773b,Elsevier; Medline; PMC,Structure-based antigen design: a strategy for next generation vaccines,10.1016/j.tibtech.2008.08.002,PMC7114313,18977045.0,els-covid,vaccine design progressing empiricism towards increasingly rational presentation target protective immunity nevertheless current vaccine antigen essentially native macromolecule pathogen molecule adapted evade induce immunity high resolution structure reveal electrostatic surface recognized neutralizing antibody architecture underlying surface thereby identifying substructure must left intact changed optimize biochemical immunologic performance armed detailed structural information engineer optimized antigen stable homogeneous efficiently produced making immunization practical affordable understanding structural basis immunogenicity immunodominance allow u improve vaccine efficacy broaden range vaccinepreventable disease,2008-12-31,"Dormitzer, Philip R.; Ulmer, Jeffrey B.; Rappuoli, Rino",Trends in Biotechnology,,,,document_parses/pdf_json/819d63a71302ab84053f5cb07e97ebd0fa3c773b.json,document_parses/pmc_json/PMC7114313.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/18977045/; https://api.elsevier.com/content/article/pii/S0167779908002473; https://www.sciencedirect.com/science/article/pii/S0167779908002473; https://doi.org/10.1016/j.tibtech.2008.08.002,40262389.0,3
101518,101518,129210,xee6npr3,b314ee4f0d78ecaff2a89fb000e7c4f9f4640301,Medline; PMC,The potential danger of suboptimal antibody responses in COVID-19,10.1038/s41577-020-0321-6,PMC7187142,32317716.0,no-cc,desperate need effective therapy vaccine sarscov mitigate growing economic crisis ensued societal lockdown vaccine developed unprecedented speed already clinical trial without preclinical testing safety efficacy yet safety evaluation candidate vaccine must overlooked,2020-04-21,"Iwasaki, Akiko; Yang, Yexin",Nat Rev Immunol,,,,document_parses/pdf_json/b314ee4f0d78ecaff2a89fb000e7c4f9f4640301.json,document_parses/pmc_json/PMC7187142.xml.json,https://doi.org/10.1038/s41577-020-0321-6; https://www.ncbi.nlm.nih.gov/pubmed/32317716/,216048832.0,3
101522,101522,129214,bbgal3ll,a81fbdb3bc7956412cd686e72115f4cddf1090be,Medline; PMC,The Journey of in vivo Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road,10.3389/fimmu.2018.02052,PMC6141723,30254636.0,cc-by,dendritic cell dc recognized highly potent antigenpresenting cell able stimulate cytotoxic lymphocyte ctl response antitumor activity consequently dc explored cellular vaccine cancer immunotherapy end dc modified tumor antigen enable presentation antigenderived peptide ctls review discus use viral vector situ modification dc focusing clinical application anticancer vaccine among viral vector discussed derived virus belonging family poxviridae adenoviridae retroviridae togaviridae paramyxoviridae rhabdoviridae shed light combination viral vectorbased vaccination tcell supporting strategy bring strategy next level,2018-09-11,"Goyvaerts, Cleo; Breckpot, Karine",Front Immunol,,,,document_parses/pdf_json/a81fbdb3bc7956412cd686e72115f4cddf1090be.json,document_parses/pmc_json/PMC6141723.xml.json,https://doi.org/10.3389/fimmu.2018.02052; https://www.ncbi.nlm.nih.gov/pubmed/30254636/,52185398.0,3
101562,101562,129264,2drhoz70,1e091f4356b605ca9b9922f3e374e506bf354120,Elsevier; Medline; PMC,Inactivated porcine reproductive and respiratory syndrome virus vaccine adjuvanted with Montanide™ Gel 01 ST elicits virus-specific cross-protective inter-genotypic response in piglets,10.1016/j.vetmic.2016.06.014,PMC7111292,27527768.0,els-covid,efficacy novel beiinactivated porcine reproductive respiratory syndrome virus prrsv candidate vaccine pig developed ribsp republic kazakhstan delivered adjuvant montanide™ gel st dkvadj compared commercial killed prrsv vaccine nvdcjxa ckvadj used widely swine herd republic kazakhstan clinical parameter body temperature respiratory disease score virological immunological profile elisa virus neutralizing vn antibody titer macroscopic lung lesion viral load lung quantitative realtime pcr cell culture assay assessed vaccinated genotype prrsv challenged pig result showed commercial vaccine failed protect pig adequately clinical disease viremia lung lesion caused challenged field isolates kazakh strain prrsv type type genotype contrast clinical protection absence viremia lung lesion dkvadj vaccinated pig associated generation vn antibody homologous vaccine strain lkz prrsv type heterogeneous type prrsv strain cm challenged pig thus data indicated induction crossprotective vn antibody dkvadj vaccine importantly demonstrated inactivated prrsv vaccine could also induce crossprotective response across viral genotype,2016-08-30,"Tabynov, Kairat; Sansyzbay, Abylay; Tulemissova, Zhanara; Tabynov, Kaissar; Dhakal, Santosh; Samoltyrova, Aigul; Renukaradhya, Gourapura J.; Mambetaliyev, Muratbay",Veterinary Microbiology,,,,document_parses/pdf_json/1e091f4356b605ca9b9922f3e374e506bf354120.json,document_parses/pmc_json/PMC7111292.xml.json,https://doi.org/10.1016/j.vetmic.2016.06.014; https://www.sciencedirect.com/science/article/pii/S0378113516301778; https://api.elsevier.com/content/article/pii/S0378113516301778; https://www.ncbi.nlm.nih.gov/pubmed/27527768/,2456207.0,3
101571,101571,129275,9fv9xrln,ca3b01ce0715b67fc7eb1515424514a4bcc41e27,Medline; PMC,Use of GFP to Investigate Expression of Plant-Derived Vaccines,10.1007/978-1-59745-559-6_19,PMC7120478,19378126.0,no-cc,plant lowcost bioreactors production various biopharmaceuticals including oral vaccine plantderived oral vaccine potentially useful combating viral infection involving mucosal immunity transgenic plant generated successfully produce mucosal vaccine cholera hepatitis b footandmouth disease norwalk virus first step toward generation oral vaccine severe acute respiratory syndrome coronavirus sarscov expressed recombinant protein sarscov transformed tobacco since plant transformation regeneration stable transformants require considerable time initially used green fluorescent protein gfp tag antigen transient expression gfp fused carboxyterminus expression sgfp show expression recombinant agroinfiltration tobacco leaf gfp tag enables relatively quick confirmation antigen expression plant cell fluorescent microscopy analysis using gfp precedes stable plant transformation enable rapid screening multiple construct attain optimal recombinant protein expression furthermore approach determines subcellular localization recombinant protein plant cell providing information optimal subcellular targeting production plant bioreactors,2009,"Li, Hong-Ye; Chye, Mee-Len",Viral Applications of Green Fluorescent Protein,,,,document_parses/pdf_json/ca3b01ce0715b67fc7eb1515424514a4bcc41e27.json,document_parses/pmc_json/PMC7120478.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19378126/; https://doi.org/10.1007/978-1-59745-559-6_19,206671710.0,3
101581,101581,129288,kqquxzhe,a29b3907d45b7fd0610bd65d903c40f357e6f399,Elsevier; PMC,FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review,10.1016/s0165-2427(02)00227-1,PMC7119750,12459160.0,els-covid,feline immunodeficiency virus fiv natural infection domestic cat result acquired immunodeficiency syndrome resembling human immunodeficiency virus hiv infection human worldwide prevalence fiv infection domestic cat reported range hence effective fiv vaccine important impact veterinary medicine addition used small animal aid model human since discovery fiv reported fiv vaccine research pursued molecular conventional vaccine approach toward development commercial product published fiv vaccine trial result present compiled update veterinary clinical research community immunologic experimental efficacy status vaccine brief report included outcome year collaborative work industry academia led recent usda approval first animal lentivirus vaccine dualsubtype fiv vaccine immunogenicity efficacy experimental prototype dualsubtype fiv vaccine efficacy currently approved commercial dualsubtype fiv vaccine felovax fiv discussed potential crossreactivity complication commercial fiv diagnostic test idexx snap combo test® western blot assay serum previously vaccinated cat also discussed finally recommendation made unbiased critical testing new fiv vaccine currently usda approved vaccine future vaccine development,2002-12-31,"Uhl, E. W; Heaton-Jones, T. G; Pu, R; Yamamoto, J. K",Veterinary Immunology and Immunopathology,,,,document_parses/pdf_json/a29b3907d45b7fd0610bd65d903c40f357e6f399.json,document_parses/pmc_json/PMC7119750.xml.json,https://www.sciencedirect.com/science/article/pii/S0165242702002271; https://api.elsevier.com/content/article/pii/S0165242702002271,24668215.0,3
101608,101608,129322,ejtt1zid,73b01d59d850c6989d529157fb5197dc4128d8d1,Medline; PMC,Surface-displayed porcine reproductive and respiratory syndrome virus from cell culture onto gram-positive enhancer matrix particles,10.1007/s10295-018-2061-1,PMC7088258,30046953.0,no-cc,vaccine immunization one effective way control porcine reproductive respiratory syndrome virus prrsv infection impurity one main factor affecting vaccine safety efficacy present novel innovative prrsv purification approach based surface display technology first bifunctional protein pagrft protein anchorgriffithsin crucial factor purification process successfully produced escherichia coli yielding mgl broth culture prrsv purification performed incubation pagrft prrsv grampositive enhancer matrix gem particle followed centrifugation collect virion loaded onto gem particle result showed bulk impurity removed pagrft could capture prrsv onto gem particle lactic acid bacteriabased purification method promising ease operation low cost easy scaleup may represent candidate method largescale purification virus vaccine production,2018-07-25,"Li, Lan; Qiao, Xuwen; Chen, Jin; Zhang, Yuanpeng; Zheng, Qisheng; Hou, Jibo",J Ind Microbiol Biotechnol,,,,document_parses/pdf_json/73b01d59d850c6989d529157fb5197dc4128d8d1.json,document_parses/pmc_json/PMC7088258.xml.json,https://doi.org/10.1007/s10295-018-2061-1; https://www.ncbi.nlm.nih.gov/pubmed/30046953/,51720700.0,3
101679,101679,129411,xvcalxk5,7199ccf73298f72b106f9b3b07abe28b8b56f80d,Medline; PMC,Characterization and immunogenicity of norovirus capsid-derived virus-like particles purified by anion exchange chromatography,10.1007/s00705-012-1565-7,PMC7087179,23229011.0,no-cc,recombinant baculovirus bv expression system widely applied production viral capsid protein viruslike particle vlps use immunogen vaccine candidate traditional density gradient purification vlps enable complete elimination bvderived impurity including live virus envelope glycoprotein gp baculoviral dna used additional purification system based ionic strength purify norovirus nov gii capsidderived vlps anion exchange chromatography purification led highly purified vlps free bv impurity intact morphology addition highly purified vlps induced strong novspecific antibody response balbc mouse describe method nov vlp purification several method determining purity including quantitative pcr bv dna detection,2012-12-11,"Huhti, L.; Tamminen, K.; Vesikari, T.; Blazevic, V.",Arch Virol,,,,document_parses/pdf_json/7199ccf73298f72b106f9b3b07abe28b8b56f80d.json,document_parses/pmc_json/PMC7087179.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/23229011/; https://doi.org/10.1007/s00705-012-1565-7,10655976.0,3
101934,101934,129717,srbqee6d,380c77bb8b8549ca4e8a7c73e8f490ab207fbf8f,Medline; PMC,"Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine",10.1007/s00705-011-1145-2,PMC7087187,22012269.0,no-cc,claim possible rationally design structurebased hiv vaccine based misconception regarding nature protein epitope immunological specificity attempt use reverse vaccinology generate hiv vaccine basis structure viral epitope bound monoclonal neutralizing antibody failed far possible extrapolate observed antigenic structure immunogenic structure required vaccine vaccine immunogenicity depends numerous extrinsic factor host immunoglobulin gene repertoire presence various cellular regulatory mechanism immunized host process antibody affinity maturation factor played role appearance neutralizing antibody used select epitope investigated potential vaccine immunogen expected present identical form host vaccinated possible rationally design optimize epitope fit one particular antibody molecule improve paratope binding efficacy monoclonal antibody intended passive immunotherapy possible rationally design hiv vaccine immunogen elicit protective polyclonal antibody response predetermined efficacy effective vaccine immunogen discovered investigating experimentally immunogenicity candidate molecule demonstrating ability induce protective immune response discovered determining epitope engineered antigen molecule recognized neutralizing monoclonal antibody mean empirical immunogenicity trial rather structural analysis antigen offer best hope discovering hiv vaccine,2011-10-20,"Van Regenmortel, Marc H. V.",Arch Virol,,,,document_parses/pdf_json/380c77bb8b8549ca4e8a7c73e8f490ab207fbf8f.json,document_parses/pmc_json/PMC7087187.xml.json,https://doi.org/10.1007/s00705-011-1145-2; https://www.ncbi.nlm.nih.gov/pubmed/22012269/,15735669.0,3
101944,101944,129728,hq4jb2wy,,Medline; PMC; WHO,Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses,10.3389/fmicb.2020.00298,PMC7105881,32265848.0,cc-by,seven coronaviruses covs isolated human far among three emerging pathogenic covs including severe acute respiratory syndrome coronavirus sarscov middle east respiratory syndrome coronavirus merscov newly identified cov ncov caused continue cause severe infection human posing significant threat global public health sarscov infection human case fatality rate first reported china merscov infection human case fatality rate first reported saudi arabia june ncov first reported china december currently infecting people case fatality rate sarscov merscov zoonotic virus using bat natural reservoir transmitting intermediate host leading human infection nevertheless intermediate host ncov still investigation vaccine new cov available although variety vaccine developed infection sarscov merscov none approved use human review described structure function key protein emerging human covs overviewed current vaccine type developed sarscov merscov summarized recent advance subunit vaccine two pathogenic human covs subunit vaccine introduced basis fulllength spike protein receptorbinding domain rbd nonrbd protein fragment nons structural protein potential factor affecting subunit vaccine also illustrated overall review helpful rapid design development vaccine new ncov future covs pandemic potential review written topic antiviral emerging virus vaccine therapeutic virology section frontier microbiology,2020-02-28,"Wang, Ning; Shang, Jian; Jiang, Shibo; Du, Lanying",Front Microbiol,,#2793,,,document_parses/pmc_json/PMC7105881.xml.json,https://doi.org/10.3389/fmicb.2020.00298; https://www.ncbi.nlm.nih.gov/pubmed/32265848/,211534466.0,3
101963,101963,129750,3z0ysber,72e1f47796b2283c03f3d7aa4f6044592f8c198d,Medline; PMC,An inactivated vaccine made from a U.S. field isolate of porcine epidemic disease virus is immunogenic in pigs as demonstrated by a dose-titration,10.1186/s12917-015-0357-1,PMC4404228,25881296.0,cc-by,background porcine epidemic diarrhea virus pedv highly pathogenic transmissible virus swine first detected u may caused tremendous loss swine industry due difficulty isolating growing virus cell culture vaccine study using cell culture propagated pedv performed u strain pig therefore objective study evaluate humoral immune response selected inactivated pedv vaccine candidate dosetitration manner result pedv isolated pig diarrhea complete genome sequencing found nucleotide identity u pedv inactivated adjuvanted monovalent vaccine administered intramuscularly five week old pig dose titration experimental design ranging log tissue culture infective dose tcidml evaluate immunogenicity using fluorescent focus neutralization assay ffn fluorescent microsphere immunoassay fmia enzymelinked immunosorbent assay elisa serum pig vaccinated log tcidml inactivated virus showed significantly higher ffn titer well fmia elisa value log tcidml vaccinates negative control conclusion result demonstrate immunogenicity pedv inactivated viral vaccine u strain via dosetitration future vaccinationchallenge study would illustrate efficacy inactivated vaccine help evaluate protective ffn titer elisa fmia response,2015-03-15,"Collin, Emily A; Anbalagan, Srivishnupriya; Okda, Faten; Batman, Ron; Nelson, Eric; Hause, Ben M",BMC Vet Res,,,,document_parses/pdf_json/72e1f47796b2283c03f3d7aa4f6044592f8c198d.json,document_parses/pmc_json/PMC4404228.xml.json,https://doi.org/10.1186/s12917-015-0357-1; https://www.ncbi.nlm.nih.gov/pubmed/25881296/,8998410.0,3
102086,102086,129910,3rr0j5tk,985f2253ef842c0bd15013ac3314061d880d12a4,Medline; PMC,Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines,10.1038/ncomms13473,PMC5121417,27874853.0,cc-by,viral subunit vaccine often contain immunodominant nonneutralizing epitope divert host immune response epitope eliminated vaccine design reliable method evaluating epitope capacity elicit neutralizing immune response introduce new concept ‘ neutralizing immunogenicity index nii evaluate epitope neutralizing immunogenicity determine nii mask epitope glycan probe ass epitope contribution vaccine overall neutralizing immunogenicity proofofconcept measure nii different epitope immunogen comprised receptorbinding domain mers coronavirus merscov design variant form vaccine masking epitope negative nii score engineered vaccine demonstrates significantly enhanced efficacy protecting transgenic mouse lethal merscov challenge study may guide rational design highly effective subunit vaccine combat merscov lifethreatening virus,2016-11-22,"Du, Lanying; Tai, Wanbo; Yang, Yang; Zhao, Guangyu; Zhu, Qing; Sun, Shihui; Liu, Chang; Tao, Xinrong; Tseng, Chien-Te K.; Perlman, Stanley; Jiang, Shibo; Zhou, Yusen; Li, Fang",Nat Commun,,,,document_parses/pdf_json/985f2253ef842c0bd15013ac3314061d880d12a4.json,document_parses/pmc_json/PMC5121417.xml.json,https://doi.org/10.1038/ncomms13473; https://www.ncbi.nlm.nih.gov/pubmed/27874853/,18484660.0,3
102092,102092,129918,rlf5nv5q,7c1b1d84d22611ce472b1f7593d594a2f90355ce,Elsevier; Medline; PMC,Newcastle disease virus: Current status and our understanding,10.1016/j.virusres.2014.02.016,PMC7127793,24589707.0,els-covid,newcastle disease nd one highly pathogenic viral disease avian specie nd economically significant huge mortality morbidity associated disease endemic many third world country agriculture serf primary source national income newcastle disease virus ndv belongs family paramyxoviridae well characterized member among avian paramyxovirus serotypes recent year ndv lured virologist pathogenic potential also oncolytic activity use vaccine vector human animal ndv based recombinant vaccine offer pertinent choice construction live attenuated vaccine due modular nature transcription minimum recombination frequency lack dna phase replication current understanding ndv biology expanding rapidly availability modern molecular biology tool highthroughput complete genome sequencing,2014-05-12,"Ganar, Ketan; Das, Moushumee; Sinha, Sugandha; Kumar, Sachin",Virus Research,,,,document_parses/pdf_json/7c1b1d84d22611ce472b1f7593d594a2f90355ce.json,document_parses/pmc_json/PMC7127793.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/24589707/; https://doi.org/10.1016/j.virusres.2014.02.016; https://api.elsevier.com/content/article/pii/S016817021400080X; https://www.sciencedirect.com/science/article/pii/S016817021400080X,46047982.0,3
102116,102116,129947,f0ahybvs,d77dcb77a4a620fd1de81f309bff0e04e2578272,Medline; PMC,Hotspot Hunter: a computational system for large-scale screening and selection of candidate immunological hotspots in pathogen proteomes,10.1186/1471-2105-9-s1-s19,PMC2259420,18315850.0,cc-by,background tcell epitope promiscuously bind multiple allele human leukocyte antigen hla supertype prime target development vaccine immunotherapy relevant large proportion human population presence cluster promiscuous tcell epitope immunological hotspot observed several antigen cluster may exploited facilitate development epitopebased vaccine selecting small number hotspot elicit required tcell activation function given large size pathogen proteome including variant strain computational tool necessary automated screening selection immunological hotspot result hotspot hunter webbased computational system largescale screening selection candidate immunological hotspot pathogen proteome analysis antigenic diversity allows screening selection hotspot specific four common hla supertypes namely hla class b class ii dr system us artificial neural network support vector machine method predictive engine soft computing principle employed integrate prediction result produced method robust prediction performance experimental validation prediction showed hotspot hunter successfully identify majority real hotspot user predict hotspot single protein sequence set aligned protein sequence representing pathogen proteome latter feature provides global view localization hotspot proteome set enabling analysis antigenic diversity shift hotspot across protein variant system also allows integration prediction result four supertypes identification hotspot common across multiple supertypes target selection feature system shortlist candidate peptide hotspot formulation epitopebased vaccine could effective multiple variant pathogen applicable large proportion human population conclusion hotspot hunter publicly accessible new generation computational tool aiding epitopebased vaccine design,2008-02-13,"Zhang, Guang Lan; Khan, Asif M; Srinivasan, Kellathur N; Heiny, AT; Lee, KX; Kwoh, Chee Keong; August, J Thomas; Brusic, Vladimir",BMC Bioinformatics,,,,document_parses/pdf_json/d77dcb77a4a620fd1de81f309bff0e04e2578272.json,document_parses/pmc_json/PMC2259420.xml.json,https://doi.org/10.1186/1471-2105-9-s1-s19; https://www.ncbi.nlm.nih.gov/pubmed/18315850/,1596617.0,3
102136,102136,129980,q3bc5x63,0b5bb18c32ee90f61fb1c36c888aabad80cc631c,Medline; PMC,Viral vaccines and their manufacturing cell substrates: New trends and designs in modern vaccinology,10.1002/biot.201400387,PMC7161866,26212697.0,no-cc,vaccination one effective intervention global health worldwide vaccination program significantly reduced number death caused infectious agent successful example eradication smallpox two century vaccination campaign since first variolation administration today knowledge immunology increased substantially knowledge combined introduction cell culture dna recombinant technology revolutionized vaccine design review focus vaccine human viral pathogen recent development vaccine design cell substrate used manufacture production attenuated inactivated vaccine requires use respective permissible cell substrate production recombinant antigen virus‐like particle vectored vaccine chimeric vaccine requires use – often development – specific cell line indeed development novel modern viral vaccine design combined stringent safety requirement manufacture better understanding animal cell metabolism physiology increasing awareness importance cell line development engineering area new era modern vaccinology arriving offering extensive toolbox materialize novel creative idea vaccine design manufacture,2015-07-24,"Rodrigues, Ana F.; Soares, Hugo R.; Guerreiro, Miguel R.; Alves, Paula M.; Coroadinha, Ana S.",Biotechnol J,,,,document_parses/pdf_json/0b5bb18c32ee90f61fb1c36c888aabad80cc631c.json,document_parses/pmc_json/PMC7161866.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26212697/; https://doi.org/10.1002/biot.201400387,205491271.0,3
102139,102139,129983,2bqeboy4,5c51ebd67d7cd75ad59decdf8fd6b07152d37818,Elsevier; PMC,Immune responses with DNA vaccines encoded different gene fragments of severe acute respiratory syndrome coronavirus in BALB/c mice,10.1016/j.bbrc.2004.11.147,PMC7092945,15629440.0,els-covid,analyze immune response dna vaccine encoded different gene fragment severe acute respiratory syndrome coronavirus sarscov sarscov gene fragment membrane nucleocapsid n spike sa spike b sb protein cloned pcdna invitrogen vector form plasmid pcdnam pcdnan pcdnasa pcdnasb respectively mouse immunized intramuscularly pcdnam pcdnan pcdnasa–pcdnasb plasmid blood collected serum separated humoral immune response detected enzymelinked immunosorbent assay cellular immune response sarscov dna vaccine detected lymphoproliferation assay cytotoxic lymphocyte assay result show cellular humoral immune response detected immunization pcdnam pcdnan pcdnasa–pcdnasb plasmid balbc mouse however pcdnam stimulated highest cellular immune response plasmid pcdnasa–pcdnasb stimulated highest humoral immune response week present result suggest dna immunization pcdnam pcdnan pcdnasa–pcdnasb could used potential dna vaccination approach induce antibody balbc mouse also illustrate gene immunization sars dna vaccine different immune response character,2005-02-04,"Wang, Zhijun; Yuan, Zhenghong; Matsumoto, Mitsuharu; Hengge, Ulrich R.; Chang, Yung-Fu",Biochemical and Biophysical Research Communications,,,,document_parses/pdf_json/5c51ebd67d7cd75ad59decdf8fd6b07152d37818.json,document_parses/pmc_json/PMC7092945.xml.json,https://www.sciencedirect.com/science/article/pii/S0006291X04027615; https://api.elsevier.com/content/article/pii/S0006291X04027615,20019644.0,3
102149,102149,129995,p83ondy8,9e91991355bc76a376b379387983a5ac08f179ab,Medline; PMC,Low-fidelity Venezuelan equine encephalitis virus polymerase mutants to improve live-attenuated vaccine safety and efficacy,10.1093/ve/vey004,PMC5841381,29593882.0,cc-by-nc,rna virus replication potential incorporate mutation affect virulence pathogenesis liveattenuated vaccine implication stability replication may result mutation either restore wildtype phenotype via reversion compensate attenuating mutation increasing virulence pseudoreversion recent study demonstrated altering mutation rate rna virus effective attenuation tool validate safety lowfidelity mutation increase vaccine attenuation several mutation rnadependent rnapolymerase rdrp tested liveattenuated venezuelan equine encephalitis virus vaccine strain tc next generation sequencing passage presence mutagen revealed mutant containing three mutation rdrp tc x decreased replication fidelity second mutant tc x displayed change fidelity shared many phenotypic characteristic tc x mutant exhibited increased albeit inconsistent attenuation infant mouse model well increased immunogenicity complete protection lethal challenge adult murine model compared parent tc serial passaging highly permissive model mutant increased virulence remained le virulent parent tc result suggest incorporation lowfidelity mutation rdrp liveattenuated vaccine rna virus confer increased immunogenicity whilst showing evidence increased attenuation however theory construct may result effective vaccine instability vaccine phenotype decrease likelihood effective vaccine strategy,2018-03-06,"Kautz, Tiffany F; Guerbois, Mathilde; Khanipov, Kamil; Patterson, Edward I; Langsjoen, Rose M; Yun, Ruimei; Warmbrod, Kelsey L; Fofanov, Yuriy; Weaver, Scott C; Forrester, Naomi L",Virus Evol,,,,document_parses/pdf_json/9e91991355bc76a376b379387983a5ac08f179ab.json,document_parses/pmc_json/PMC5841381.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29593882/; https://doi.org/10.1093/ve/vey004,4381372.0,3
102231,102231,130096,8r4xc8tn,c8f6c26a8275c6cbbeb30dc984f058902455ed52,Medline; PMC,Rational Design of Zika Virus Subunit Vaccine with Enhanced Efficacy,10.1128/jvi.02187-18,PMC6694833,31189716.0,cc-by,zika virus zikv infection pregnant woman lead fetal death malformation previously reported zikv envelope protein domain iii ediii subunit vaccine candidate crossneutralization activity however like many subunit vaccine efficacy limited improve efficacy subunit vaccine identified nonneutralizing epitope zikv ediii surrounding residue buried fulllength envelope protein becomes exposed recombinant ediii shielded epitope engineered glycan probe compared wildtype ediii mutant ediii induced significantly stronger neutralizing antibody three mouse strain also demonstrated significantly improved efficacy fully protecting mouse particularly pregnant mouse fetus highdose lethal zikv challenge moreover mutant ediii immune serum significantly enhanced passive protective efficacy fully protecting mouse lethal zikv challenge passive protection positively associated neutralizing antibody titer showed enhanced efficacy mutant ediii due shielding immunodominant nonneutralizing epitope surrounding residue led immune refocusing neutralizing epitope taken together result study reveal intrinsic limitation subunit vaccine artificially exposed immunodominant nonneutralizing epitope overcome glycan shielding additionally mutant zikv protein generated study promising subunit vaccine candidate high efficacy preventing zikv infection mouse importance viral subunit vaccine generally show low efficacy study revealed intrinsic limitation subunit vaccine design artificially exposed surface subunit vaccine contain epitope unfavorable vaccine efficacy specifically identified epitope zika virus zikv envelope protein domain iii ediii buried fulllength envelope protein becomes exposed recombinant ediii shielded epitope glycan resulting mutant ediii vaccine demonstrated significantly enhanced efficacy wildtype ediii vaccine protecting animal model zikv infection therefore intrinsic limitation subunit vaccine overcome shielding artificially exposed unfavorable epitope engineered ediii vaccine generated study promising vaccine candidate developed battle zikv infection,2019-08-13,"Tai, Wanbo; Chen, Jiawei; Zhao, Guangyu; Geng, Qibin; He, Lei; Chen, Yuehong; Zhou, Yusen; Li, Fang; Du, Lanying",J Virol,,,,document_parses/pdf_json/c8f6c26a8275c6cbbeb30dc984f058902455ed52.json,document_parses/pmc_json/PMC6694833.xml.json,https://doi.org/10.1128/jvi.02187-18; https://www.ncbi.nlm.nih.gov/pubmed/31189716/,189813350.0,3
102238,102238,130103,270a15s0,4ddcba8a21dabd170334389aabae8b87e0f62ab0; 6a017719e92f20761baf333ad6a87378eab4dd6a,Elsevier; Medline; PMC,Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes increase T cell responses and provide protection against SRAS-CoV infection,10.1016/j.vaccine.2008.01.025,PMC2600875,18289745.0,bronze-oa,development vaccine severe acute respiratory syndrome sars coronavirus sarscov crucial prevention sars reemergence receptorbinding domain rbd sarscov spike protein important target developing safe effective sars vaccine previous study demonstrated vaccination adenoassociated virus encoding rbd rbdraav induces high titer neutralizing antibody study assessed immune response protective effect immunization rbdraav primerbdspecific cell peptide boost compared vaccination rbdraav rbdpeptides alone result indicated rbdraav primerbdpeptide boost induced similar th neutralizing antibody response stronger th ctl response rbdraav primeboost resulting immune response protected vaccinated mouse subsequent sarscov challenge evidenced lower level viral replication mouse lung tissue however significant immune response protective effect detected mouse vaccinated rbdpeptides blank aav alone since cell epitope highly conserved boosting peptide may induce production effector memory cell result suggest vaccination protocol used may ideal providing effective universal longterm protection sarscov infection,2008-03-01,"Du, Lanying; Zhao, Guangyu; Lin, Yongping; Chan, Chris CS; He, Yuxian; Jiang, Shibo; Wu, Changyou; Jin, Dong-Yan; Yuen, Kwok-Yung; Zhou, Yusen; Zheng, Bo-Jian",Vaccine,,,,document_parses/pdf_json/4ddcba8a21dabd170334389aabae8b87e0f62ab0.json; document_parses/pdf_json/6a017719e92f20761baf333ad6a87378eab4dd6a.json,document_parses/pmc_json/PMC2600875.xml.json,https://doi.org/10.1016/j.vaccine.2008.01.025; https://www.ncbi.nlm.nih.gov/pubmed/18289745/; https://api.elsevier.com/content/article/pii/S0264410X08000716; https://www.sciencedirect.com/science/article/pii/S0264410X08000716,25088819.0,3
102276,102276,130149,scfnbyh7,61843499666ad3d4f0ea75554cd06a745e9a7f8e,Medline; PMC,Different evolutionary trajectories of vaccine-controlled and non-controlled avian infectious bronchitis viruses in commercial poultry,10.1371/journal.pone.0176709,PMC5417570,28472110.0,cc0,determine genetic epidemiological relationship infectious bronchitis virus ibv isolates commercial poultry attenuated live ibv vaccine conducted phylogenetic network analysis fulllength sequence arkansas ark massachusetts mass delmarva dmv type virus isolated clinical case different diagnostic laboratory phylogenetic network analysis ark isolates showed two predominant group linked mutation consistent subpopulation found commercial vaccine ibv type addition number satellite group surrounding two predominant population observed ark type virus likely due mutation associated nature vaccine persist flock phylogenetic network analysis masstype virus show two grouping corresponding different manufacturer vaccine sequence satellite group observed masstype virus consistent persistence vaccine type field time collection vaccine used dmv type virus phylogenetic network analysis showed dispersed network suggesting clear change genetic distribution selection pressure analysis showed dmv masstype strain evolving negative selection whereas ark type virus evolved positive selection data support hypothesis live attenuated vaccine usage play role genetic profile similar ib virus field phylogenetic network analysis used identify vaccine vaccine origin isolates important understanding role live vaccine play evolutionary trajectory virus,2017-05-04,"Jackwood, Mark W.; Lee, Dong-Hun",PLoS One,,,,document_parses/pdf_json/61843499666ad3d4f0ea75554cd06a745e9a7f8e.json,document_parses/pmc_json/PMC5417570.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28472110/; https://doi.org/10.1371/journal.pone.0176709,5836573.0,3
102308,102308,130192,zhmx8f4v,1d32215c90a79509e66eb1f6e3e05b077d08ee1b,Medline; PMC,Assembly of Replication-Incompetent African Horse Sickness Virus Particles: Rational Design of Vaccines for All Serotypes,10.1128/jvi.00548-16,PMC4984648,27279609.0,cc-by,african horse sickness virus ahsv orbivirus reoviridae family nine different serotypes cause devastating disease equid virion particle composed seven protein organized three concentric layer outer layer made vp vp middle layer made vp inner layer made vp encloses replicase complex vp vp vp genome doublestranded rna segment study sought develop highly efficacious candidate vaccine ahsv serotypes taking account immunogenic safety property also virus productivity stability parameter essential criterion vaccine candidate achieve goal first established highly efficient reverse genetics rg system ahsv serotype ahsv subsequently vpdefective ahsv strain combination trans complementation vp used generate defective particle nine serotypes required exchange two five rna segment achieve equivalent titer particle reassortantdefective virus could amplified propagated high titer cell complemented vp totally incompetent cell furthermore replicationincompetent ahsv particle demonstrated highly protective homologous virulent virus challenge type interferon receptor ifnarknockout mouse thus defective virus potential used development safe stable vaccine candidate rg system also provides powerful tool study role individual ahsv protein virus assembly morphogenesis pathogenesis importance african horse sickness virus transmitted biting midge cause african horse sickness equid mortality reaching naive horse therefore development efficient vaccine extremely important due major economic loss equine industry establishment highly efficient rg system replicationdeficient virus nine ahsv serotypes generated defective virus achieved high titer cell line complemented vp failed propagate wildtype mammalian insect cell importantly candidate vaccine strain showed strong protective efficacy ahsv infection ifnar−− mouse model,2016-07-27,"Lulla, Valeria; Lulla, Aleksei; Wernike, Kerstin; Aebischer, Andrea; Beer, Martin; Roy, Polly",J Virol,,,,document_parses/pdf_json/1d32215c90a79509e66eb1f6e3e05b077d08ee1b.json,document_parses/pmc_json/PMC4984648.xml.json,https://doi.org/10.1128/jvi.00548-16; https://www.ncbi.nlm.nih.gov/pubmed/27279609/,4783935.0,3
102315,102315,130202,85xiqz2w,7ed89e5691a56b6757c21984c3bbb733b5a2dfdc,Medline; PMC,Porcine epidemic diarrhea: a review of current epidemiology and available vaccines,10.7774/cevr.2015.4.2.166,PMC4524901,26273575.0,cc-by-nc,porcine epidemic diarrhea virus pedv alphacoronavirus family coronaviridae cause acute diarrhea vomiting dehydration high mortality rate neonatal piglet pedv also cause diarrhea agalactia abnormal reproductive cycle pregnant sow although pedv first identified europe resulted significant economic loss many asian swineraising country including korea china japan vietnam philippine however april present major outbreak pedv reported united state canada mexico moreover intercontinental transmission pedv increased mortality rate seronegative neonatal piglet resulting loss u pig population emergence reemergence pedv indicates virus able evade current vaccine strategy continuous emergence multiple mutant strain several region aggravated porcine epidemic diarrhea endemic condition highlighted need new vaccine based current circulating pedv epidemic pedv strain tend pathogenic cause increased death pig thereby causing substantial financial loss swine producer review described epidemiology pedv several country present molecular characterization current strain also discus pedv vaccine related issue,2015-07-29,"Song, Daesub; Moon, Hyoungjoon; Kang, Bokyu",Clin Exp Vaccine Res,,,,document_parses/pdf_json/7ed89e5691a56b6757c21984c3bbb733b5a2dfdc.json,document_parses/pmc_json/PMC4524901.xml.json,https://doi.org/10.7774/cevr.2015.4.2.166; https://www.ncbi.nlm.nih.gov/pubmed/26273575/,2455834.0,3
102344,102344,130235,gvy4ox06,f90214b5be3d05b41a61bd6b6e0d8268c1b5c2b8,Elsevier; Medline; PMC,A novel DNA vaccine containing multiple TB-specific epitopes casted in a natural structure (ECANS) confers protective immunity against pulmonary mycobacterial challenge,10.1016/j.vaccine.2009.06.093,PMC7115364,19615961.0,els-covid,epitopebased dna vaccine designed induce cell response specific mycobacterium tuberculosis tb developed mean addressing vaccine potency study predicted cell epitope esat agab cfp antigen constructed ecans epitope casted natural structure dna vaccine inserting epitope dna segment separately gene backbone tbderived hsp heat shock protein carrier immunogenicity protective efficacy pecan dna vaccine assessed balbc mouse intramuscular immunization dos μg ecans dna followed mycobaterial challenge week last immunization compared plasmid encoding hsp pecan dna immunization elicited remarkably higher level ifnγ production cd cd cell coupled higher frequency antigenspecific cell higher ctl activity significantly enhanced level th cytokine ifnγ il increased serum iggaigg ratio also noted indicating predominant th immune response achieved pecan dna immunization consequence better protection mycobacterium bovis bcg challenge achieved evidenced reduced bacterial load lung spleen profound attenuation lung inflammation injury result suggested multit cellepitope based ecans gene vaccine induced cell response multiple cell epitope led enhanced protection mycobacterial challenge strategy might useful platform design multit cell epitopebased vaccine tb infection,2009-08-27,"Gao, Haifeng; Yue, Yan; Hu, Linkun; Xu, Wei; Xiong, Sidong",Vaccine,,,,document_parses/pdf_json/f90214b5be3d05b41a61bd6b6e0d8268c1b5c2b8.json,document_parses/pmc_json/PMC7115364.xml.json,https://api.elsevier.com/content/article/pii/S0264410X09009797; https://doi.org/10.1016/j.vaccine.2009.06.093; https://www.ncbi.nlm.nih.gov/pubmed/19615961/; https://www.sciencedirect.com/science/article/pii/S0264410X09009797,5193411.0,3
102350,102350,130242,4pxm6iwa,887ef0dc296e27f317019b8e1cec781455c1f381,Elsevier; PMC,Viral diseases of the respiratory system,10.1093/ps/77.8.1143,PMC7107121,9706079.0,els-covid,infectious bronchitis newcastle disease infectious laryngotracheitis avian influenza pneumovirus virus frequently affect respiratory tract chicken tendency change antigenic property infectious bronchitis currently viral disease present poultry producing area world new serotypes variant strain reported several country current commercially available vaccine always provide protection new field isolates vaccination program constantly adjusted attempt improve protection disease infectious laryngotracheitis appeared broiler industry serious disease improved vaccine needed control disease broiler u control highly pathogenic form avian influenza velogenic form newcastle disease achieved eradication country effective vaccine used control newcastle avian influenza avian pneumovirus infection also emerging disease chicken turkey,1998-08-01,"Villegas, P",Poultry Science,,,,document_parses/pdf_json/887ef0dc296e27f317019b8e1cec781455c1f381.json,,https://api.elsevier.com/content/article/pii/S0032579119409358; https://www.sciencedirect.com/science/article/pii/S0032579119409358,3617643.0,3
102368,102368,130265,ege73lyf,11ef1846bb816e2884da201195b43ff8f4520cbb,Medline; PMC,Functional Nanomaterials Can Optimize the Efficacy of Vaccines,10.1002/smll.201401707,PMC7169483,25238620.0,no-cc,nanoscale material improve efficacy vaccine herein review latest development use nanomaterials vaccine highlighting relationship nanoscale physicochemical characteristic working mechanism nanomaterials paper show current status development researcher employ functional nanomaterials vector andor immunoregulators vaccine also provides u clue improving design application nanomaterials optimize efficacy vaccine,2014-09-19,"Liu, Ye; Xu, Yingying; Tian, Yue; Chen, Chunying; Wang, Chen; Jiang, Xingyu",Small,,,,document_parses/pdf_json/11ef1846bb816e2884da201195b43ff8f4520cbb.json,document_parses/pmc_json/PMC7169483.xml.json,https://doi.org/10.1002/smll.201401707; https://www.ncbi.nlm.nih.gov/pubmed/25238620/,20865878.0,3
102386,102386,130285,ae2x2wpg,c011d2d3f5da3faf42cce9f5cd3e230549119491,Elsevier; PMC,Immunodominant viral peptides as determinants of cross-reactivity in the immune system – Can we develop wide spectrum viral vaccines?,10.1016/j.mehy.2005.05.041,PMC7131089,16051445.0,els-covid,summary look back edward jenner vaccination young man help thinking lucky crazy crazy decided test human hypothesis based mainly traditional belief people acquired cowpox udder cow thereafter resistant smallpox quite devastating disease lucky even considering know time succeeded induce protection pathogen induction immune response directed different agent able protect young man took first step towards development vast new field vaccination acceptable say jenner lucky succeeded promoting protection smallpox using cowpox virus induction protection crossreactive way believed quite rare nevertheless example crossreactive immune response described beginning admit crossreactivity far common important used think review crossreactivity immune system plasticity cell recognition based existence cell receptor promiscuous recognition crossrecognition conserved viral immunodominant epitope propose two approach develop wide spectrum viral vaccine first one based identification characterization cloning immunodominant viral epitope able stimulate response different virus produced peptide could purified serve basis vaccine therapy second strategy based identification conserved pattern immunodominant viral peptide production synthetic peptide containing amino acid residue necessary mhc anchoring tcr contact although still far complete knowledge crossreactivity phenomenon immune system analysis immunodominant viral epitope identification particular “ viral pattern ” seems important step towards development wide spectrum viral vaccine,2005-12-31,"Vieira, G. F.; Chies, J.A.B.",Medical Hypotheses,,,,document_parses/pdf_json/c011d2d3f5da3faf42cce9f5cd3e230549119491.json,document_parses/pmc_json/PMC7131089.xml.json,https://www.sciencedirect.com/science/article/pii/S0306987705002999; https://api.elsevier.com/content/article/pii/S0306987705002999,25699190.0,3
102451,102451,130362,cw7734a0,d9c174a11b8d2bd0a4df65b17e576934f3cce31c,Medline; PMC,Development of a recombinant Newcastle disease virus-vectored vaccine for infectious bronchitis virus variant strains circulating in Egypt,10.1186/s13567-019-0631-5,PMC6371441,30744668.0,cc-by,infectious bronchitis virus ibv cause major disease problem poultry industry worldwide currently used liveattenuated vaccine tendency mutate andor recombine circulating field strain resulting emergence vaccinederived variant virus order circumvent issue develop vaccine relevant egypt neighboring country recombinant avirulent newcastle disease virus rndv strain lasota constructed express codonoptimized glycoprotein egyptian ibv variant strain ibvckegcu belonging gi lineage prevalent egypt middle east wild type two modified version ibv protein expressed individually rndv high level protein expression detected vitro western blot immunofluorescence analysis rndvvectored ibv vaccine candidate genetically stable slightly attenuated showed growth pattern comparable parental rlasota virus singledose vaccination dayold spf white leghorn chick rndvs expressing ibv protein provided significant protection clinical disease ibv challenge show reduction tracheal viral shedding singledose vaccination also provided complete protection virulent ndv challenge however primeboost vaccination using rndv expressing wild type ibv protein provided better protection ibv challenge clinical sign significantly reduced tracheal viral shedding result indicate ndvvectored ibv vaccine promising bivalent vaccine candidate control infectious bronchitis newcastle disease egypt electronic supplementary material online version article contains supplementary material available authorized user,2019-02-11,"Abozeid, Hassanein H.; Paldurai, Anandan; Varghese, Berin P.; Khattar, Sunil K.; Afifi, Manal A.; Zouelfakkar, Sahar; El-Deeb, Ayman H.; El-Kady, Magdy F.; Samal, Siba K.",Vet Res,,,,document_parses/pdf_json/d9c174a11b8d2bd0a4df65b17e576934f3cce31c.json,document_parses/pmc_json/PMC6371441.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30744668/; https://doi.org/10.1186/s13567-019-0631-5,67789882.0,3
102486,102486,130404,w5nhgc1e,2dc031b8f66e1770ed3699bb6ecbee2c53aa98d6,Elsevier; Medline; PMC,Whither vaccines?,10.1016/s0163-4453(17)30184-6,PMC7172359,28646957.0,els-covid,summary currently used vaccine major effect eliminating common infection largely duplicating immune response induced natural infection vaccinology face complex problem waning antibody immunosenescence evasion immunity pathogen deviation immunity microbiome induction inhibitory response complexity antigen required protection fortunately vaccine development incorporating knowledge immunology structural biology system biology synthetic chemistry meet challenge addition international organisation developing new funding licensing pathway vaccine aimed pathogen epidemic potential emerge tropical area,2017-06-30,"Rodrigues, Charlene M.C.; Pinto, Marta V.; Sadarangani, Manish; Plotkin, Stanley A.",Journal of Infection,,,,document_parses/pdf_json/2dc031b8f66e1770ed3699bb6ecbee2c53aa98d6.json,,https://www.ncbi.nlm.nih.gov/pubmed/28646957/; https://api.elsevier.com/content/article/pii/S0163445317301846; https://doi.org/10.1016/s0163-4453(17)30184-6; https://www.sciencedirect.com/science/article/pii/S0163445317301846,43501319.0,3
102488,102488,130408,0h5vgi5c,33e30f666e78cfa175db1140d1e3e5fb21275610,Elsevier; Medline; PMC,Immunogenicity of a DNA-launched replicon-based canine parvovirus DNA vaccine expressing VP2 antigen in dogs,10.1016/j.rvsc.2012.01.017,PMC7111809,22349592.0,els-covid,repliconbased dna vaccine encoding vp gene canine parvovirus cpv developed cloning cpvvp gene repliconbased dna vaccine vector palpha characteristic repliconbased dna vaccine like selfamplification transcript induction apoptosis analyzed transfected mammalian cell palphacpvvp injected intradermal dnalaunched repliconbased dna vaccine dog induced cpvspecific humoral cell mediated immune response virus neutralization antibody lymphocyte proliferative response higher conventional cpv dna vaccine commercial cpv vaccine result indicated dnalaunched repliconbased cpv dna vaccine effective inducing cpvspecific humoral cellular immune response considered effective alternative conventional cpv dna vaccine commercial cpv vaccine,2012-10-31,"Dahiya, Shyam S.; Saini, Mohini; Kumar, Pankaj; Gupta, Praveen K.",Research in Veterinary Science,,,,document_parses/pdf_json/33e30f666e78cfa175db1140d1e3e5fb21275610.json,document_parses/pmc_json/PMC7111809.xml.json,https://doi.org/10.1016/j.rvsc.2012.01.017; https://api.elsevier.com/content/article/pii/S0034528812000616; https://www.sciencedirect.com/science/article/pii/S0034528812000616; https://www.ncbi.nlm.nih.gov/pubmed/22349592/,8424649.0,3
102489,102489,130409,4kfz9r4e,d9721101e6249841a689af220434b2256c95aebe,Elsevier; Medline; PMC,Nucleoside hydrolase DNA vaccine against canine visceral leishmaniasis,10.1016/j.provac.2009.07.019,PMC7129871,32288909.0,els-covid,nucleoside hydrolase nh main marker fml complex leishmania donovani antigen licensed leishmune® vaccine prophylaxis canine visceral leishmaniasis dna vaccine mouse induces th immune response vaccinated mongrel dog vrnh vaccine prophylaxis immunotherapy high dose leishmania chagasi infection x infective amastigotes untreated control developed symptom higher parasitelymphocyte ratio smaller dth reaction lower proportion nhspecific cd cell sustained nhspecific cd cell count dog prophylaxis group immunotherapy treated group enlarged dth reaction enhanced cd sustained cd lymphocyte proportion also detected however without reduction symptom parasitelymphocyte ratio indicating vaccine sufficiently potent prevent control disease treatment determined higher survival rate antifml antibody increased vaccinated control dog antinh antibody increased vaccinee p parasite load untreated survivor control dog parasite felt outside ic vaccinated dog ic – suggesting vaccination treatment succeeded reducing leishmania infective burden accordingly untreated control dog showed lower level ifn γβ il il il β actinrelative quantification conclude vrnh vaccine induces strong prophylactic protection milder immunotherapeutic effect high dose canine experimental infection leishmania chagasi,2009-12-31,"Borja-Cabrera, GP; Santos, FB; Picillo, E; Gravino, AE; Manna, L; Palatnik-de-Sousa, CB",Procedia in Vaccinology,,,,document_parses/pdf_json/d9721101e6249841a689af220434b2256c95aebe.json,,https://www.sciencedirect.com/science/article/pii/S1877282X09000502; https://doi.org/10.1016/j.provac.2009.07.019; https://www.ncbi.nlm.nih.gov/pubmed/32288909/; https://api.elsevier.com/content/article/pii/S1877282X09000502,86477184.0,3
102495,102495,130415,b8mfn6o9,d268877551cde701225d92c4c89098d69173e8d9,Medline; PMC,Development of Vaccine Delivery Vehicles Based on Lactic Acid Bacteria,10.1007/s12033-011-9450-2,PMC7090618,21901278.0,no-cc,live recombinant bacteria represent attractive antigen delivery system able induce mucosal systemic immune response heterologous antigen first live recombinant bacterial vector developed derived attenuated pathogenic microorganism addition difficulty often encountered construction stable attenuated mutant pathogenic organism attenuated pathogen may retain residual virulence level render unsuitable vaccination partially immunocompetent individual infant elderly immunocompromised patient alternative strategy nonpathogenic foodgrade lactic acid bacteria lab maybe used live antigen carrier article review lab vaccine constructed using antigen tetanus toxin fragment c bacterial viral parasitic infective agent protection study performed antigen utilized development lab vaccine briefly described along efficiency system protection study moreover key factor affecting performance system highlighted,2011-09-07,"Tarahomjoo, Shirin",Mol Biotechnol,,,,document_parses/pdf_json/d268877551cde701225d92c4c89098d69173e8d9.json,document_parses/pmc_json/PMC7090618.xml.json,https://doi.org/10.1007/s12033-011-9450-2; https://www.ncbi.nlm.nih.gov/pubmed/21901278/,207376762.0,3
102520,102520,130441,ogb83fgc,da95b9a06e4d0db35503357ccbec0e23c973b85f,Elsevier; PMC,A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses,10.1016/j.vaccine.2005.08.055,PMC7115667,16214268.0,els-covid,doubleinactivated candidate whole virus vaccine severe acute respiratory syndrome associated coronavirus sarscov developed manufactured large scale using fermenter culture serum protein free vero cell two step inactivation procedure involving sequential formaldehyde uv inactivation utilised order ensure extremely high safety margin respect residual infectivity immunogenicity doubleinactivated vaccine characterised mouse model mouse immunised twice candidate sarscov vaccine developed high antibody titre sarscov spike protein high level neutralising antibody use adjuvant aloh minor effect immunogenicity vaccine addition cell mediated immunity measured interferonγ interleukin stimulation elicited vaccination moreover vaccine confers protective immunity demonstrated prevention sarscov replication respiratory tract mouse intranasal challenge sarscov protection mouse correlated antibody titre sarscov protein neutralising antibody titre,2006-01-30,"Spruth, Martin; Kistner, Otfried; Savidis-Dacho, Helga; Hitter, Elisabeth; Crowe, Brian; Gerencer, Marijan; Brühl, Peter; Grillberger, Leopold; Reiter, Manfred; Tauer, Christa; Mundt, Wolfgang; Barrett, P. Noel",Vaccine,,,,document_parses/pdf_json/da95b9a06e4d0db35503357ccbec0e23c973b85f.json,document_parses/pmc_json/PMC7115667.xml.json,https://api.elsevier.com/content/article/pii/S0264410X05008674; https://www.sciencedirect.com/science/article/pii/S0264410X05008674,22439297.0,3
102570,102570,130500,2mhhtpcr,87cc7c4ce4f857e235f5fe0fffc2513cf9e653d9,Medline; PMC,Emerging Highly Virulent Porcine Epidemic Diarrhea Virus: Molecular Mechanisms of Attenuation and Rational Design of Live Attenuated Vaccines,10.3390/ijms20215478,PMC6862049,31689903.0,cc-by,highly virulent porcine epidemic diarrhea virus pedv emerged china infects pig age cause severe diarrhea high mortality rate newborn pig leading devastating economic loss pork industry worldwide effective safe vaccine highly virulent pedv strain still unavailable hampering prevention control eradication disease herd vaccination pregnant sow live attenuated vaccine lav effective strategy induce lactogenic immunity sow provides passive protection suckling piglet pedv via colostrum beestings first milk milk several lav candidate developed via serially passaging highly virulent pedv isolates nonporcine vero cell however efficacy induction sufficient protection virulent pedv challenge vary vivo review summarize current knowledge virulencerelated mutation pedv potential role pedv attenuation vivo successful development reverse genetics system pedv also discus use generate promising lav candidate safe effective genetically stable article provides timely insight rational design effective safe pedv lav candidate,2019-11-04,"Hou, Yixuan; Wang, Qiuhong",Int J Mol Sci,,,,document_parses/pdf_json/87cc7c4ce4f857e235f5fe0fffc2513cf9e653d9.json,document_parses/pmc_json/PMC6862049.xml.json,https://doi.org/10.3390/ijms20215478; https://www.ncbi.nlm.nih.gov/pubmed/31689903/,207888954.0,3
102597,102597,130533,zw5pr2ug,74cc1a3efb04282e8e89616e58b7749183fc0146,Elsevier; Medline; PMC,Outer membrane vesicles harboring modified lipid A moiety augment the efficacy of an influenza vaccine exhibiting reduced endotoxicity in a mouse model,10.1016/j.vaccine.2016.12.025,PMC7115551,28024958.0,els-covid,influenza acute respiratory disease major health problem worldwide since mucosal immunity play critical role protection influenza virus infection mucosal immunization considered promising vaccination route however except liveattenuated vaccine effective killed recombinant mucosal influenza vaccine date outer membrane vesicle omvs nanosized vesicle produced gramnegative bacteria contain various bacterial component capable stimulating immune system host generated omv low endotoxicity fmomv modifying structure lipid moiety lipopolysaccharide investigated effect intranasal vaccine adjuvant influenza vaccine model model fmomv exhibited reduced tolllike receptor stimulating activity attenuated endotoxicity compared native omv intranasal injection vaccine antigen fmomv significantly increased systemic antibody cell response mucosal iga level frequency lungresident influenzaspecific cell addition number antigenbearing cd dendritic cell mediastinal lymph node significantly increased fmomv coadministration notably mouse coimmunized fmomv showed significantly higher protection rate challenge lethal dose homologous heterologous influenza virus without adverse effect result show potential fmomv effective mucosal adjuvant intranasal vaccine,2017-01-23,"Lee, Tae-Young; Kim, Chang-Ung; Bae, Eun-Hye; Seo, Sang-Hwan; Jeong, Dae Gwin; Yoon, Sun-Woo; Chang, Kyu-Tae; Kim, Young Sang; Kim, Sang-Hyun; Kim, Doo-Jin",Vaccine,,,,document_parses/pdf_json/74cc1a3efb04282e8e89616e58b7749183fc0146.json,document_parses/pmc_json/PMC7115551.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X16312324; https://doi.org/10.1016/j.vaccine.2016.12.025; https://www.ncbi.nlm.nih.gov/pubmed/28024958/; https://api.elsevier.com/content/article/pii/S0264410X16312324,33383649.0,3
102609,102609,130549,90p6wiz9,f78956e70c8bd1756ffb24ae47c35c3217bed384,Medline; PMC,Peptide Vaccine: Progress and Challenges,10.3390/vaccines2030515,PMC4494216,26344743.0,cc-by,conventional vaccine strategy highly efficacious several decade reducing mortality morbidity due infectious disease bane conventional vaccine include whole organism large protein appear inclusion unnecessary antigenic load contributes little protective immune response complicates situation inducing allergenic andor reactogenic response peptide vaccine attractive alternative strategy relies usage short peptide fragment engineer induction highly targeted immune response consequently avoiding allergenic andor reactogenic sequence conversely peptide vaccine used isolation often weakly immunogenic require particulate carrier delivery adjuvanting article discus specific advantage consideration targeted induction immune response peptide vaccine progress development vaccine various disease additionally also discus development particulate carrier strategy inherent challenge regard safety combining technology peptide vaccine,2014-07-02,"Li, Weidang; Joshi, Medha D.; Singhania, Smita; Ramsey, Kyle H.; Murthy, Ashlesh K.",Vaccines (Basel),,,,document_parses/pdf_json/f78956e70c8bd1756ffb24ae47c35c3217bed384.json,document_parses/pmc_json/PMC4494216.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26344743/; https://doi.org/10.3390/vaccines2030515,11616975.0,3
102631,102631,130575,2saf53oc,403be352ce64603bdb313a00238d5b77b7305321,Medline; PMC,"Genetic characterization of S1 gene of infectious bronchitis virus isolated from commercial poultry flocks in West Java, Indonesia",10.14202/vetworld.2019.231-235,PMC6460881,31040563.0,cc-by,background aim infectious bronchitis ib still major problem among poultry industry indonesia ib outbreak continue happen even vaccinated flock emergence new ib virus ibv variant might lead mismatching vaccine virus strain circulating virus strain may reason vaccination failure information circulating ibv region important decide ib vaccine used however information recent ibv strain circulated indonesia genetic character limited therefore aim research determine genetic characterization gene ibv isolated commercial poultry flock west java indonesia material method total viral isolate sample collected chicken clinical sign reduced egg production six ib live vaccine used control reference vaccine represent ibv strain including h h cr primer xce xce used amplify gene partially result twentysix sample showed positive result gene ibv reverse transcriptionpolymerase chain reaction three ibv isolates indonesiaka indonesiaka indonesiap selected nucleotide sequencing phylogenetic analysis nucleotide partial gene show isolates indonesiaka indonesiaka homology ibv vaccine strain isolate indonesiap homology ibv vaccine strain conclusion result indicates least two ibv strain circulating among poultry west java indonesia ibv close vaccine strain present study provides update circulating ibv commercial poultry flock west java indonesia might use guidance selecting proper ib vaccine strain improve ib vaccination efficacy certain region,2019-02-11,"Setiawaty, Rahajeng; Soejoedono, Retno Damajanti; Poetri, Okti Nadia",Vet World,,,,document_parses/pdf_json/403be352ce64603bdb313a00238d5b77b7305321.json,document_parses/pmc_json/PMC6460881.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31040563/; https://doi.org/10.14202/vetworld.2019.231-235,91816418.0,3
102683,102683,130635,9ztagh01,c947f644fe2bb88d61d3baba16922eb6440ae423,Elsevier; PMC,Biomimetic nanoparticles as universal influenza vaccine,10.1016/j.smaim.2020.03.001,PMC7152890,,els-covid,pandemic virus infection seasonal influenza severe acute respiratory syndrome coronavirus middle east respiratory syndrome coronavirus pose major public health threat globally much effort devoted suppress virus including vaccine prevention autoimmunity enhancement antivirus drug treatment among strategy development novel improved vaccine technology attracts broad attention nip virus outbreak bud avoid appearance public health emergency therefore wang et al recently offer promising mean develop universal viral vaccine biomimetic nanoparticles,2020-04-13,"Wang, Fengyuan; Chen, Guopu; Zhao, Yuanjin",,,,,document_parses/pdf_json/c947f644fe2bb88d61d3baba16922eb6440ae423.json,,https://api.elsevier.com/content/article/pii/S259018342030003X; https://www.sciencedirect.com/science/article/pii/S259018342030003X?v=s5,215741085.0,3
102697,102697,130652,dlak6b0p,5931c8a2146123a830e21a82deee51ab4dab54e3,Elsevier; Medline; PMC,HoBi-like pestivirus experimental infection in pregnant ewes: Reproductive disorders and generation of persistently infected lambs,10.1016/j.vetmic.2015.05.011,PMC7172706,26013415.0,no-cc,order evaluate sheep experimental model test efficacy hobilike pestivirus vaccine cattle sheep different stage pregnancy day experimentally infected italian prototype isolate italy irrespective stage pregnancy virus inoculation resulted reproductive failure consisting abortion stillbirth birth weak persistently infected pi lamb aborted fetus stillborn dead lamb displayed extensive histopathological change consisting hemorrhage congestion mononuclear infiltration major organ pestiviral antigen detected immunohistochemistry tissue remarkable signal lung kidney pi lamb constantly viremic shed virus nasal secretion feces case one detectable hobilike pestivirus antibody assumption colostrum single seropositive infected lamb showed lowtiter viremia viral shedding ceased several week month observation period study prof sheep susceptible reproduction failure caused hobilike pestivirus infection serve suitable model evaluation fetal protection induced homologous experimental vaccine,2015-08-05,"Decaro, Nicola; Losurdo, Michele; Larocca, Vittorio; Lucente, Maria Stella; Mari, Viviana; Varello, Katia; Patruno, Giovanni; Camero, Michele; Sciarra, Marina; Occhiogrosso, Leonardo; Tempesta, Maria; Iulini, Barbara; Buonavoglia, Canio",Vet Microbiol,,,,document_parses/pdf_json/5931c8a2146123a830e21a82deee51ab4dab54e3.json,document_parses/pmc_json/PMC7172706.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26013415/; https://api.elsevier.com/content/article/pii/S0378113515001959; https://doi.org/10.1016/j.vetmic.2015.05.011; https://www.sciencedirect.com/science/article/pii/S0378113515001959,13323895.0,3
102700,102700,130657,pp8rmkep,f26b4d2b79d661c896a22c4050ae0818effafe8f,Elsevier; Medline; PMC,Novel strategies and approaches to develop the next generation of vaccines against porcine reproductive and respiratory syndrome virus (PRRSV),10.1016/j.virusres.2010.07.020,PMC7132426,20655962.0,els-covid,porcine reproductive respiratory syndrome virus prrsv economically important swine pathogen since discovery early tremendous progress made understanding molecular biology pathogenesis prrsv although modified liveattenuated vaccine mlvs inactivated vaccine prrsv available decade disease remains difficult control efficacy vaccine especially heterologous strain remain questionable mlvs generally effective homologous strain variable success heterologous strain outcome inactivated vaccine field promising development prrsv reverse genetics system acquisition new understanding antiprrsv immunity rational design next generation prrsv vaccine explored review discussed recent advance antiprrsv immunity vaccinology recent progress prrsv vaccine development particularly reverse genetics systembased vaccine development provided perspective potential novel strategy approach may applicable development next generation prrsv vaccine,2010-12-31,"Huang, Y. W.; Meng, X. J.",Virus Research,,,,document_parses/pdf_json/f26b4d2b79d661c896a22c4050ae0818effafe8f.json,document_parses/pmc_json/PMC7132426.xml.json,https://doi.org/10.1016/j.virusres.2010.07.020; https://www.ncbi.nlm.nih.gov/pubmed/20655962/; https://api.elsevier.com/content/article/pii/S0168170210002479; https://www.sciencedirect.com/science/article/pii/S0168170210002479,22807123.0,3
102716,102716,130677,xtct6e5n,1f2fa602a76a8bbef2d8ed3790a41fc2ccced303,Medline; PMC,Human Metapneumovirus: A Largely Unrecognized Threat to Human Health,10.3390/pathogens9020109,PMC7169409,32069879.0,cc-by,human metapneumovirus hmpv infects child five year age virus cause upper lower respiratory tract disease life threatening highrisk population include young child exposed virus first time elderly currently standard treatment licensed vaccine hmpv although several attractive vaccine candidate developed preclinical study raised awareness impact hmpv public health needed drive research complete vaccine development thereby prevent significant virusassociated morbidity mortality worldwide,2020-02-13,"Russell, Charles J.; Penkert, Rhiannon R.; Kim, Sonnie; Hurwitz, Julia L.",Pathogens,,,,document_parses/pdf_json/1f2fa602a76a8bbef2d8ed3790a41fc2ccced303.json,document_parses/pmc_json/PMC7169409.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32069879/; https://doi.org/10.3390/pathogens9020109,211190530.0,3
102757,102757,130725,rfu0bkag,646825ece8ed3e5260449ed19109e1b79e3ac7cf,Elsevier; PMC,Expression of Immunogenic Glycoprotein S Polypeptides from Transmissible Gastroenteritis Coronavirus in Transgenic Plants,10.1006/viro.1998.9315,PMC7130976,9791026.0,els-covid,use transgenic plant vaccine production system described recently report immunological response elicited two recombinant version glycoprotein swinetransmissible gastroenteritis coronavirus tgev expressed transgenic plant arabidoposis plant genetically transformed cdna construct encoding either nterminal domain amino acid residue – fulllength glycoprotein tgev responsible neutralizing antibody induction virus control cauliflower mosaic virus camv promoter genomic dna mrna analysis leaf extract transformed plant demonstrated incorporation foreign cdna arabidopsis genome well transcription expression recombinant polypeptide observed transgenic plant elisa using specific antibody mouse immunized leaf extract transgenic plant developed antibody reacted specifically tgev elisa immunoprecipitated virusinduced protein neutralized virus infectivity result conclude transgenic plant expressing glycoprotein polypeptide may possibly used source recombinant antigen vaccine production,1998-09-30,"Gómez, N.; Carrillo, C.; Salinas, J.; Parra, F.; Borca, M. V.; Escribano, J. M.",Virology,,,,document_parses/pdf_json/646825ece8ed3e5260449ed19109e1b79e3ac7cf.json,,https://www.sciencedirect.com/science/article/pii/S0042682298993151; https://api.elsevier.com/content/article/pii/S0042682298993151,13379502.0,3
102878,102878,130871,mo4mvwch,bd4fc9d981f442dbc210a67500cabf238e259801,Elsevier; Medline; PMC,Role of vaccine efficacy in the vaccination behavior under myopic update rule on complex networks,10.1016/j.chaos.2019.109425,PMC7111283,32288356.0,els-covid,effectively prevent diffusion infectious disease become intriguing topic field public hygienics noted nonperiodic infectious disease many people hope obtain vaccine epidemic time inoculated rather end epidemic however vaccine may fail result invalid storage transportation usage vaccinated individual may become resusceptible infected outbreak end build new framework considers imperfect vaccination one cycle infectious disease within spatially structured heterogeneous population meanwhile propose new vaccination update rule myopic update rule based one focal player ’ perception regarding disease outbreak one susceptible individual make decision adopt vaccine comparing perceived payoff vaccination perceived one infected extensive montecarlo simulation performed demonstrate imperfect vaccination behavior myopic update rule spatially structured heterogeneous population result indicate healthy individual often willing inoculate vaccine myopic update rule stop infectious disease spread particular found vaccine efficacy influence fraction vaccinated individual much relative cost vaccination regular lattice meanwhile vaccine efficacy sensitive heterogeneous scalefree network current result helpful analyze model choice vaccination strategy disease outbreak,2020-01-31,"Huang, Jiechen; Wang, Juan; Xia, Chengyi","Chaos, Solitons & Fractals",,,,document_parses/pdf_json/bd4fc9d981f442dbc210a67500cabf238e259801.json,document_parses/pmc_json/PMC7111283.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32288356/; https://api.elsevier.com/content/article/pii/S0960077919303662; https://doi.org/10.1016/j.chaos.2019.109425; https://www.sciencedirect.com/science/article/pii/S0960077919303662,203042151.0,3
102893,102893,130888,cldrzet3,6f6c1cccdaf6a2a22ffdd30f2eeadba5f063c30f,Elsevier; PMC,"Chapter 5 Trends in Nonparenteral Delivery of Biologics, Vaccines and Cancer Therapies",10.1016/b978-0-12-416603-5.00005-5,PMC7150203,,els-covid,recent year witnessed development advancement many nonparenteral biologics vaccine human use chapter discus various nonparenteral route administration oral route administration preferred patient compliant method transdermal buccal pulmonary route also discussed developed novel technology using nanoparticles microparticles deliver vaccine oral transdermal route administration new technology enable formulation vaccine particle containing vaccine antigen without loss biological activity formulation process also multiple antigen targeting ligand adjuvant encapsulated within particle administered orally particle designed withstand acidic environment stomach targeted peyer ’ patch gutassociated mucosal immune system vaccine particulate nature readily taken phagocytic antigen presenting cell apc cell dendritic cell macrophage peyer ’ patch intestine resulting strong immune response antibody production particular interest fact particle release antigen slow sustained manner prolonged time period intracellularly apc resulting strong mucosal systemic immunity oral administration without need added adjuvant typically present current vaccine preparation needle required oral vaccine method vaccine delivery inexpensive suitable mass vaccination developing world well developed world chapter discus study conducted wide array vaccine including infectious disease vaccine cancer vaccine method vaccine delivery enables delivery wide spectrum vaccine prophylactic therapeutic use including oral transdermal vaccine cancer human papillomavirus melanoma ovarian breast prostate encouraging result respect cancer therapy comparison made conventional cancer therapy immunotherapy wide range nanocarriers available delivery biologics vaccine cancer therapy nanotechnology gained welldeserved limelight also attracted attention regulatory body although present certain challenge must considered marketing nanocarriers,2015-12-31,"D’Souza, Martin J.; Gala, Rikhav P.; Ubale, Ruhi V.; D’Souza, Bernadette; Vo, Trinh Phuong; Parenky, Ashwin C.; Mulla, Nihal S.; D’Sa, Sucheta; D’Souza, Marissa; Braz-Gomes, Kim; D’Souza, Nigel; Chiriva-Internati, Maurizio; Zughaier, Susu","Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies",,,,document_parses/pdf_json/6f6c1cccdaf6a2a22ffdd30f2eeadba5f063c30f.json,document_parses/pmc_json/PMC7150203.xml.json,https://www.sciencedirect.com/science/article/pii/B9780124166035000055; https://api.elsevier.com/content/article/pii/B9780124166035000055,73962583.0,3
102906,102906,130903,4vkag60z,15809bb71d850eff6ee3183c850e8c59ed1518c1,Elsevier; Medline; PMC,Recombinant measles AIK-C vaccine strain expressing heterologous virus antigens,10.1016/j.vaccine.2015.10.127,PMC7115616,26562316.0,els-covid,attenuated measles vaccine developed year ago used throughout world recombinant measles vaccine candidate developed express several heterologous virus protective antigen immunogenicity protective action confirmed using experimental animal transgenic mouse cotton rat primate recent development measles vaccinebased vectored vaccine candidate reviewed information recombinant measles vaccine expressing respiratory syncytial virus protein shown discussed,2016-01-04,"Nakayama, Tetsuo; Sawada, Akihito; Yamaji, Yoshiaki; Ito, Takashi",Vaccine,,,,document_parses/pdf_json/15809bb71d850eff6ee3183c850e8c59ed1518c1.json,document_parses/pmc_json/PMC7115616.xml.json,https://api.elsevier.com/content/article/pii/S0264410X15015832; https://www.ncbi.nlm.nih.gov/pubmed/26562316/; https://doi.org/10.1016/j.vaccine.2015.10.127; https://www.sciencedirect.com/science/article/pii/S0264410X15015832,20853958.0,3
102926,102926,130930,270nzddu,f7d847b4be2909d97034632505a1e647638c42fa; c5c10db0016a742df3533a2b8846a4aeba18bb74,Medline; PMC,Measles Vaccines Designed for Enhanced CD8(+) T Cell Activation,10.3390/v12020242,PMC7077255,32098134.0,cc-by,priming activation cd cell response crucial achieve antiviral antitumor immunity live attenuated measles vaccine strain used successfully immunization decade currently investigated trial oncolytic virotherapy available reverse genetics system allow insertion additional gene including heterologous antigen designed recombinant measles vaccine vector priming activation antigenspecific cd cell proofofconcept used cytotoxic lymphocyte ctl line specific melanomaassociated differentiation antigen tyrosinaserelated protein trp model antigen chicken ovalbumin ovum respectively generated recombinant measles vaccine vector trp ovum epitope cassette variant expression fulllength antigen respective immunodominant cd epitope additional variant mediating secretion proteasomal degradation epitope show recombinant measles virus vector mediate varying level mhc class mhcirestricted epitope presentation leading activation cognate ctls indicated secretion interferongamma ifnγ vitro importantly recombinant ovum vaccine also mediate priming naïve oti cd cell dendritic cell vaccine variant prime activate cognate cell ifnγ release enhanced using secreted epitope variant variant epitope string targeted proteasome principle presented study facilitate design recombinant vaccine elicit cd response pathogen tumor antigen,2020-02-21,"Busch, Elena; Kubon, Kristina D.; Mayer, Johanna K. M.; Pidelaserra-Martí, Gemma; Albert, Jessica; Hoyler, Birgit; Heidbuechel, Johannes P. W.; Stephenson, Kyle B.; Lichty, Brian D.; Osen, Wolfram; Eichmüller, Stefan B.; Jäger, Dirk; Ungerechts, Guy; Engeland, Christine E.",Viruses,,,,document_parses/pdf_json/f7d847b4be2909d97034632505a1e647638c42fa.json; document_parses/pdf_json/c5c10db0016a742df3533a2b8846a4aeba18bb74.json,document_parses/pmc_json/PMC7077255.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/32098134/; https://doi.org/10.3390/v12020242,211523668.0,3
102969,102969,130982,opi8aa5i,7d262832606b297d4d1cd2af7a45578d10823418,Medline; PMC,Chimpanzee adenoviral vectors as vaccines for outbreak pathogens,10.1080/21645515.2017.1383575,PMC5718829,29083948.0,cc-by,– ebola outbreak west africa highlighted potential large disease outbreak caused emerging pathogen generated considerable focus preparedness future epidemic discus driver strategy practical consideration developing vaccine outbreak pathogen chimpanzee adenoviral chad vector developed vaccine candidate multiple infectious disease prostate cancer chad vector safe induce antigenspecific cellular humoral immunity age group well circumventing problem preexisting immunity encountered human ad vector reason viral vector provide attractive platform stockpiling vaccine emergency deployment response threatened outbreak emerging pathogen work already underway develop vaccine number outbreak pathogen also review progress approach particularly lassa fever nipah mers,2017-10-30,"Ewer, Katie; Sebastian, Sarah; Spencer, Alexandra J.; Gilbert, Sarah; Hill, Adrian V. S.; Lambe, Teresa",Hum Vaccin Immunother,,,,document_parses/pdf_json/7d262832606b297d4d1cd2af7a45578d10823418.json,document_parses/pmc_json/PMC5718829.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29083948/; https://doi.org/10.1080/21645515.2017.1383575,21855411.0,3
103058,103058,131081,q4zuslmp,919375a1d0c4d7bb9230e44b929051aa0ca740e0,Elsevier; Medline; PMC,Vaccine-induced enhancement of viral infections,10.1016/j.vaccine.2008.10.087,PMC7131326,19022319.0,els-covid,example vaccineinduced enhancement susceptibility virus infection aberrant viral pathogenesis documented infection member different virus family several mechanism many still poorly understood basis phenomenon vaccine development lentivirus infection general hivaids particular little successful certain experimental lentiviral vaccine even proved counterproductive rendered vaccinated subject susceptible infection rather protecting vaccineinduced enhanced susceptibility infection certain virus like feline coronavirus dengue virus feline immunodeficiency virus shown antibodydependent enhancement ade play important role mechanism may either absence combination ade involved consequently vaccineinduced enhancement major stumble block development certain flavi corona paramyxo lentivirus vaccine also recent failure development vaccine hiv may least part attributed induction enhanced susceptibility infection may well delicate balance induction protective immunity one hand induction enhanced susceptibility present paper review currently known mechanism vaccineinduced enhancement susceptibility virus infection aberrant viral pathogenesis,2009-01-22,"Huisman, W.; Martina, B.E.E.; Rimmelzwaan, G. F.; Gruters, R. A.; Osterhaus, A.D.M.E.",Vaccine,,,,document_parses/pdf_json/919375a1d0c4d7bb9230e44b929051aa0ca740e0.json,document_parses/pmc_json/PMC7131326.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19022319/; https://www.sciencedirect.com/science/article/pii/S0264410X08015053; https://doi.org/10.1016/j.vaccine.2008.10.087; https://api.elsevier.com/content/article/pii/S0264410X08015053,20034429.0,3
103117,103117,131153,3utk3k6z,1a3090ed02d858bd208be9cfdb17d7a497fc35ee,Elsevier; PMC,Safety and efficacy of an infectious bronchitis virus used for chicken embryo vaccination,10.1016/j.vaccine.2006.06.040,PMC7126498,16860445.0,els-covid,commercial vaccine ovo vaccination yet developed infectious bronchitis virus ibv major coronavirus poultry industry recombinant ibvs based beaudette strain expressing beaudette spike protein beaur virulent strain beaurms assessed potential prototype vaccine application dayold embryo pathogenicity assessed observing effect hatchability andor production nasal discharge andor effect ciliary activity trachea various time point post hatch contrast commercial ibv vaccine given ovo beaur beaurms strain reduce hatchability cause nasal discharge caused minimal damage ciliated epithelium trachea presence spike protein virulent virus increase pathogenicity virus according criterion used assessment beaurms strain efficacy showed protected chick challenge virulent ib virus dose dependent manner egg passage beaurms strain beaurms ep increase pathogenicity though improve efficacy based serology protection virulent challenge beaurms ep efficacious beaurms protecting bird virulent challenge providing better serological antibody response beaurms ep induced serological response similar commercial vaccine given dayold though commercial vaccine provided slightly higher efficacy result promising development embryo safe efficacious ibv vaccine ovo application,2006-11-17,"Tarpey, I.; Orbell, S. J.; Britton, P.; Casais, R.; Hodgson, T.; Lin, F.; Hogan, E.; Cavanagh, D.",Vaccine,,,,document_parses/pdf_json/1a3090ed02d858bd208be9cfdb17d7a497fc35ee.json,document_parses/pmc_json/PMC7126498.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X06007687; https://api.elsevier.com/content/article/pii/S0264410X06007687,21080220.0,3
103175,103175,131227,5ns2t5i2,4e951550757b4a9f7b9b5167c9774a1113c787e9,Medline; PMC,Safety and immunogenicity of an MF59™-adjuvanted subunit influenza vaccine in elderly Chinese subjects,10.1186/1742-4933-5-2,PMC2291031,18289372.0,cc-by,background safety immunogenicity mf™adjuvanted subunit influenza vaccine submf™ fluad® novartis vaccine evaluated among elderly chinese subject ≥ year age preliminary phase openlabel study n ass safety – day postvaccination comparative observerblind randomised controlled clinical trial n performed ass safety immunogenicity versus nonadjuvanted subunit influenza vaccine subunit agrippal® novartis vaccine subject randomised receive submf™ subunit result vaccine well tolerated vaccinerelated serious adverse event reported phase trial observerblind study local systemic reaction generally similar vaccine – day postvaccination however injectionsite induration frequent among subunit group p mild pain injection site fever frequent among submf™ recipient p ≤ vaccine induced significant p increase geometric mean titre gmt three strain tested versus baseline gmt ahn ahn b significantly higher submf™ group p p p respectively gmt ratio ahn ahn b also significantly higher submf™ group p p p respectively similarly percentage subject achieving seroprotection seroconversion day greater submf™ recipient reaching significance ahn p conclusion mf™adjuvanted subunit influenza vaccine well tolerated elderly chinese subject induces higher level immunogenicity nonadjuvanted subunit influenza vaccine population high risk influenzarelated complication clinical trial registry nct,2008-02-20,"Li, Rongcheng; Fang, Hanhua; Li, Yanping; Liu, Youping; Pellegrini, Michele; Podda, Audino",Immun Ageing,,,,document_parses/pdf_json/4e951550757b4a9f7b9b5167c9774a1113c787e9.json,document_parses/pmc_json/PMC2291031.xml.json,https://doi.org/10.1186/1742-4933-5-2; https://www.ncbi.nlm.nih.gov/pubmed/18289372/,14894277.0,3
103227,103227,131294,gebdyeia,915266f52a5f9c7360670df5de7b51d20e0a8cfa,Medline; PMC,The US Military Commitment to Vaccine Development: A Century of Successes and Challenges,10.3389/fimmu.2018.01397,PMC6021486,29977239.0,cc-by,u military leading proponent vaccine development since founding general george washington ordered entire american army variolated smallpox recognizing serious threat posed military operation recommendation dr john morgan physicianinchief american army wrote treatise variolation although case smallpox still occurred far fewer expected believed vaccination program contributed victory war independence effective military force requires personnel healthy combat ready worldwide deployment given geography u military operation military personnel also protected disease endemic potential area conflict reason unknown many u military strongly supported vaccine research development four category communicable infectious disease threaten military personnel disease spread easily densely populated area respiratory dysenteric disease vectorborne disease disease carried mosquito insect sexually transmitted disease hepatitis hiv gonorrhea disease associated biological warfare category u military supported research provided basis many vaccine available today although preventive measure development drug provided relief burden malaria dengue hiv u military continues fund research development prophylactic vaccine contribute force health protection global health past year newly recognized infection zika severe acute respiratory syndrome middle east respiratory syndrome virus pushed u military fund research fast track clinical trial quickly effectively develop vaccine emerging disease u military personnel present every region globe one costeffective way maintain military effectiveness develop vaccine prioritized threat military member ’ health,2018-06-21,"Ratto-Kim, Silvia; Yoon, In-Kyu; Paris, Robert M.; Excler, Jean-Louis; Kim, Jerome H.; O’Connell, Robert J.",Front Immunol,,,,document_parses/pdf_json/915266f52a5f9c7360670df5de7b51d20e0a8cfa.json,document_parses/pmc_json/PMC6021486.xml.json,https://doi.org/10.3389/fimmu.2018.01397; https://www.ncbi.nlm.nih.gov/pubmed/29977239/,49318990.0,3
103255,103255,131327,kea2xw1g,6be6ca48112c227ce80a36601ea8b464edbf1367,Medline; PMC,"Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head",10.3390/vaccines3020239,PMC4494343,26343187.0,cc-by,influenza virus huge impact public health current influenza vaccine need updated annually protect poorly antigenic drift variant novel emerging subtypes vaccination influenza improved two important way either inducing broadly protective immune response decreasing time vaccine production relevant especially pandemic outbreak review outline current effort develop socalled “ universal influenza vaccine ” describing antigen may induce broadly protective immunity novel vaccine production platform facilitate timely availability vaccine,2015-03-26,"Wiersma, Lidewij C. M.; Rimmelzwaan, Guus F.; de Vries, Rory D.",Vaccines (Basel),,,,document_parses/pdf_json/6be6ca48112c227ce80a36601ea8b464edbf1367.json,document_parses/pmc_json/PMC4494343.xml.json,https://doi.org/10.3390/vaccines3020239; https://www.ncbi.nlm.nih.gov/pubmed/26343187/,5218215.0,3
103299,103299,131385,kuuyvf90,008cf2148ee4383534191b3736096878cad82c67,Elsevier; Medline; PMC,Chapter Eight Molecular Basis of Coronavirus Virulence and Vaccine Development,10.1016/bs.aivir.2016.08.003,PMC7112271,27712626.0,els-covid,virus vaccine immunogenic sufficiently stable safe suitable induce longlasting immunity meet requirement vaccine study need provide comprehensive understanding protective role antiviral b tcellmediated immune response ii complexity plasticity major viral antigen iii virus molecular biology pathogenesis many type vaccine including subunit vaccine wholeinactivated virus vectored liveattenuated virus vaccine featuring specific advantage limitation nonliving virus vaccine clear advantage safe stable may cause side effect le efficacious compared liveattenuated virus vaccine case latter induce longlasting immunity may require special safety measure prevent reversion highly virulent virus following vaccination chapter summarizes recent progress development coronavirus cov vaccine focusing two zoonotic covs severe acute respiratory syndrome cov sarscov middle east respiratory syndrome cov cause deadly disease epidemic human development attenuated virus vaccine combat infection caused highly pathogenic covs largely based identification characterization viral virulence protein example interfere innate adaptive immune response involved interaction specific cell type macrophage dendritic epithelial cell lymphocyte thereby modulating antiviral host response viral pathogenesis potentially resulting deleterious side effect following vaccination,2016-12-31,"Enjuanes, L.; Zuñiga, S.; Castaño-Rodriguez, C.; Gutierrez-Alvarez, J.; Canton, J.; Sola, I.",Advances in Virus Research,,,,document_parses/pdf_json/008cf2148ee4383534191b3736096878cad82c67.json,document_parses/pmc_json/PMC7112271.xml.json,https://www.sciencedirect.com/science/article/pii/S0065352716300422; https://api.elsevier.com/content/article/pii/S0065352716300422; https://www.ncbi.nlm.nih.gov/pubmed/27712626/; https://doi.org/10.1016/bs.aivir.2016.08.003,5320630.0,3
103306,103306,131397,os758lsd,,BioRxiv; MedRxiv,Protection of Rhesus Macaque from SARS-Coronavirus challenge by recombinant adenovirus vaccine,10.1101/2020.02.17.951939,,,biorxiv,recombinant adenovirus vaccine sars coronavirus sarscov constructed contains fragment n orf gene rhesus macaque immunized recombinant adenovirus generated antigenspecific humoral cellular response furthermore vaccine provided significant protection subsequent live sarscov challenge contrast three four monkey immunized placebo suffered severe alveolar damage pulmonary destruction,2020-02-21,"Chen, Yiyou; Wei, Qiang; Li, Ruobing; Gao, Hong; Zhu, Hua; Deng, Wei; Bao, Linlin; Tong, Wei; Cong, Zhe; Jiang, Hong; Qin, Chuan",bioRxiv,,,,,,https://doi.org/10.1101/2020.02.17.951939,214459887.0,3
103347,103347,131448,x32eqn6j,820f3633db1b3b98889e6a0d257d10d385be85c8,Medline; PMC,Prime immunization with rotavirus VLP 2/6 followed by boosting with an adenovirus expressing VP6 induces protective immunization against rotavirus in mice,10.1186/1743-422x-8-3,PMC3024956,21205330.0,cc-by,background rotavirus rv main cause severe gastroenteritis child effective vaccination regime rv substantially reduce morbidity mortality previous study demonstrated efficacy viruslike particle formed rv vp vp vlp well recombinant adenovirus expressing rv vp rad eliciting protective immunity rv however efficacy primeboost strategy incorporates vlp rad inducing protective immunity rv addressed assessed immune effect different regimen mouse including rad primevlp boost radvlp vlp primerad boost vlprad rad alone vlp alone result mouse immunized vlprad regimen elicit stronger humoral mucosal cellular immune response immunized regimen rv challenging experiment showed highest reduction viral shedding achieved vlprad group compared radvlp vlp alone rad alone treatment group reduction rv shedding mouse correlated fecal igg r p iga r p conclusion vlp primerad boost regimen effective conferring immunoprotection rv challenge mouse finding may lay groundwork alternative strategy novel rv vaccine development,2011-01-05,"Zhou, Hongli; Guo, Li; Wang, Min; Qu, Jianguo; Zhao, Zhendong; Wang, Jianwei; Hung, Tao",Virol J,,,,document_parses/pdf_json/820f3633db1b3b98889e6a0d257d10d385be85c8.json,document_parses/pmc_json/PMC3024956.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/21205330/; https://doi.org/10.1186/1743-422x-8-3,13361124.0,3
103436,103436,131560,e0m0h926,2ff451eed16e4189c7c7cc680bfbb1aabf1e6294,Elsevier; PMC,Vaccines for Viral and Parasitic Diseases Produced with Baculovirus Vectors,10.1016/s0065-3527(06)68006-8,PMC7112334,16997013.0,els-covid,baculovirus–insect cell expression system approved system production viral antigen vaccine potential human animal used production subunit vaccine parasitic disease well many candidate subunit vaccine expressed system immunization commonly led protective immunity pathogen challenge first vaccine produced insect cell animal use market chapter deal tailoring baculovirus–insect cell expression system vaccine production term expression level integrity immunogenicity recombinant protein baculovirus genome stability various expression strategy discussed including chimeric virus‐like particle baculovirus display foreign antigen budded virion occlusion body specialized baculovirus vector mammalian promoter express antigen immunized individual historical overview show wide variety viral glycoprotein successfully expressed system vaccine purpose potential expression system antiparasite vaccine illustrated combination subunit vaccine marker test based antigen expressed insect cell provides powerful tool combat disease monitor infectious agent,2006-12-31,"van Oers, Monique M.",Advances in Virus Research,,,,document_parses/pdf_json/2ff451eed16e4189c7c7cc680bfbb1aabf1e6294.json,document_parses/pmc_json/PMC7112334.xml.json,https://api.elsevier.com/content/article/pii/S0065352706680068; https://www.sciencedirect.com/science/article/pii/S0065352706680068,6365299.0,3
103444,103444,131570,52sbckm3,def69723f3ff30495aab9e155921db015a6aac41,Medline; PMC,Establishment of minimal positive-control conditions to ensure brain safety during rapid development of emergency vaccines,10.4142/jvs.2017.18.s1.371,PMC5583425,28859273.0,cc-by-nc,increase international human material exchange contagious infectious epidemic occurring one effective method epidemic inhibition rapid development supply vaccine considering safety brain vaccine development important however manual brain safety assay new vaccine uniform effective globally therefore aim study establish positivecontrol protocol effective brain safety test enhance rapid vaccine development bloodbrain barrier tight junction provide selective defense brain however possible destroy important microstructures administering lipopolysaccharides lp thereby artificially increasing permeability brain parenchyma study test condition established degree brain penetration brain destruction newly developed vaccine quantitatively identified effective condition suggested measuring timedependent expression tight junction biomarkers zonula occludens zo occludin two type mouse cbl icr following exposure two type lp salmonella escherichia future hope use developed positivecontrol protocol help speed determination brain safety novel vaccine,2017-08-22,"Baek, Hyekyung; Kim, Kwang Ho; Park, Min Young; Kim, Kyeongryun; Ko, Bokyeong; Seo, Hyung Seok; Kim, Byoung Soo; Hahn, Tae-Wook; Yi, Sun Shin",J Vet Sci,,,,document_parses/pdf_json/def69723f3ff30495aab9e155921db015a6aac41.json,document_parses/pmc_json/PMC5583425.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28859273/; https://doi.org/10.4142/jvs.2017.18.s1.371,4788847.0,3
103465,103465,131598,3wl9ebdy,04ae258dc2d337cf80a7cede2a0f2c2bff9c4710,Elsevier; PMC,Vaccination antivirale et immunité muqueuse respiratoire Un concept séduisant pour des résultats encore décevants,10.1016/s0755-4982(05)84165-x,PMC7134628,16230967.0,els-covid,point essentiels • le surface muqueuses de l ’ arbre respiratoire constituent une porte ’ entrée très importante et un site critique pour la réponse immune le principaux anticorps sécrétés localement appartiennent à l ’ isotype iga sig le cellules effectrices qui dominent au niveau de la muqueuse ne sont pa de cellules iga de type b mais le lymphocyte qui peuvent représenter jusqu ’ à de la totalité de population lymphocytaires de la muqueuse • l ’ immunoprophylaxie par voie muqueuse constitue une approche intéressante pour contrôler le infection acquises par cette voie de immunoglobulines spécifiques administrées localement peuvent prévenir de infection virales comme cela été démontré pour le virus respiratoire syncytial mais le quantités ’ anticorps nécessaires pour être active sont très importantes et difficiles à obtenir • parmi le facteurs susceptibles ’ induire une réponse immune muqueuse et une immunité à médiation cellulaire trouve la voie orale ou respiratoire et de virus réplicatifs • très peu de vaccins antiviraux muqueux ont été développés le seul exemple pour le virus respiratoires reste le vaccin grippal atténué administré par voie nasale ’ autres vaccins commercialisés par voie parentérale ont été utilisés expérimentalement par voie nasale qu ’ il ’ agisse de vaccins vivants varicelle rougeole ou inactivés grippe injectable il n ’ induisent par cette voie inhabituelle qu ’ une réponse locale modérée • la voie muqueuse ne constitue pa une voie essentielle et incontournable pour élaborer un vaccin actif contre de virus respiratoires l ’ exemple du vaccin grippe atténué administré par voie nasale est prometteur pour l ’ avenir de la vaccination par voie muqueuse key point • mucosal surface respiratory tract represent major portal entry human virus critical component mammalian immunologic repertoire major antibody isotype external secretion secretory immunoglobin siga major effector cell mucosal surface however iga b cell lymphocyte may account mucosal lymphoid cell population • mucosal immunoprophylaxis theoretically important approach control infection acquired portal passive antibody protect mucosal viral infection shown respiratory syncytial virus high quantity passive antibody needed restrict virus replication mucosal surface • factor likely induce mucosal antibody cellmediated immune response include oral respiratory route immunization active effectively replicating vaccine agent • antiviral vaccine developed protect mucosal surface respiratory tract attenuated influenza virus vaccine us nasal route vaccine approved parenteral use administered experimentally nasal route include active replicating inactive nonreplicating vaccine route induce moderate local mucosal response • neither development mucosal immunity administration vaccine via mucosal route essential control prevention respiratory viral infection disease acquired respiratory tract nonetheless example live attenuated intranasal influenza vaccine induces systemic local immune response promising future mucosal immunization respiratory viral infection,2005-10-31,"Denis, F.; Alain, S.; Hantz, S.; Lagrange, P.",La Presse Médicale,,,,document_parses/pdf_json/04ae258dc2d337cf80a7cede2a0f2c2bff9c4710.json,,https://www.sciencedirect.com/science/article/pii/S075549820584165X; https://api.elsevier.com/content/article/pii/S075549820584165X,72592658.0,3
103468,103468,131601,owcapg8h,8c2cfca9f2eee4a00231a2a3a2cfe1e60e798672,Medline; PMC,Inducing Dose Sparing with Inactivated Polio Virus Formulated in Adjuvant CAF01,10.1371/journal.pone.0100879,PMC4067388,24956110.0,cc-by,development new low cost inactivated polio virus based vaccine ipv high priority required eradicate polio addition vaccine constitutes realistic polio vaccine posteradication era one way reduce cost vaccine increase immunogenicity use adjuvant caf adjuvant previously shown safe potent adjuvant several antigen show mouse ipv formulated caf induced increased systemic protective immunity measured binding neutralization antibody titer serum caf also influenced kinetics cellular humoral response ipv produce faster well stronger response dominated igga iggb iggc isotypes well ipv specific cell secreting ifnγil finally intestinal immunity also priority polio vaccine present vaccine strategy based simultaneous priming intradermal intramuscular site generate intestinal immune response polio virus taken together ipvcaf formulation constitutes new promising vaccine polio ability generate strong humoral cellular immunity polio virus,2014-06-23,"Dietrich, Jes; Andreasen, Lars Vibe; Andersen, Peter; Agger, Else Marie",PLoS One,,,,document_parses/pdf_json/8c2cfca9f2eee4a00231a2a3a2cfe1e60e798672.json,document_parses/pmc_json/PMC4067388.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/24956110/; https://doi.org/10.1371/journal.pone.0100879,16213482.0,3
103487,103487,131627,bdoavpsb,84f8946f903a07243c54bde0a3e6d5ccecf9c5b9,Medline; PMC,Antibody response to equine coronavirus in horses inoculated with a bovine coronavirus vaccine,10.1292/jvms.17-0414,PMC5709570,28993568.0,cc-by-nc-nd,vaccine equine coronavirus ecov far unavailable bovine coronavirus bcov antigenically related ecov therefore possible bcov vaccine induce antibody ecov horse study investigated antibody response ecov horse inoculated bcov vaccine virus neutralization test showed antibody titer ecov increased six horse tested day post inoculation although antibody titer lower ecov bcov study showed bcov vaccine provides horse antibody ecov extent unclear whether antibody provided bcov vaccine effective ecov therefore ecov challenge study needed evaluate efficacy vaccine future,2017-10-06,"NEMOTO, Manabu; KANNO, Toru; BANNAI, Hiroshi; TSUJIMURA, Koji; YAMANAKA, Takashi; KOKADO, Hiroshi",J Vet Med Sci,,,,document_parses/pdf_json/84f8946f903a07243c54bde0a3e6d5ccecf9c5b9.json,document_parses/pmc_json/PMC5709570.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28993568/; https://doi.org/10.1292/jvms.17-0414,33061090.0,3
103501,103501,131643,bdse9o26,2fadf74eaae82e5005e0b31d8e07afc739b32f72,Elsevier; PMC,Development of vaccines and passive immunotherapy against SARS corona virus using SCID-PBL/hu mouse models,10.1016/j.vaccine.2007.01.032,PMC7115525,17289225.0,els-covid,investigated novel vaccine strategy severe acute respiratory syndrome sars cov using cdna construct encoding structural antigen e n protein derived sars cov pbl healthy human volunteer administered ip il receptor γchain disrupted scid mouse scidpblhu mouse constructed mouse used analyze human immune response vivo sars dna vaccine n dna vaccine induced human ctl specific sars cov antigen alternatively sars dna vaccine inducing human neutralizing antibody human monoclonal antibody sars cov developed result show vaccine induce virusspecific immune response provide useful tool development protective therapeutic vaccine,2007-04-20,"Okada, Masaji; Okuno, Yoshinobu; Hashimoto, Satomi; Kita, Yoko; Kanamaru, Noriko; Nishida, Yasuko; Tsunai, Yoshie; Inoue, Ruriko; Nakatani, Hitoshi; Fukamizu, Reiko; Namie, Yumi; Yamada, Junko; Takao, Kyoko; Asai, Ritsuko; Asaki, Ryoko; Kase, Tetsuo; Takemoto, Yuji; Yoshida, Shigeto; Peiris, J.S.M.; Chen, Pei-Jer; Yamamoto, Naoki; Nomura, Tatsuji; Ishida, Isao; Morikawa, Shigeru; Tashiro, Masato; Sakatani, Mitsunori",Vaccine,,,,document_parses/pdf_json/2fadf74eaae82e5005e0b31d8e07afc739b32f72.json,document_parses/pmc_json/PMC7115525.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X07000503; https://api.elsevier.com/content/article/pii/S0264410X07000503,22825287.0,3
103523,103523,131667,15q6qr4z,02a29bd2f39ecdbbb5e51a003c0bc7818029f384,Medline; PMC,A Recombinant Influenza A/H1N1 Carrying A Short Immunogenic Peptide of MERS-CoV as Bivalent Vaccine in BALB/c Mice,10.3390/pathogens8040281,PMC6963271,31810359.0,cc-by,middle east respiratory syndrome coronavirus merscov became global human health threat since first documentation human efficient vaccine prophylaxis human hotspot infection eg saudi arabia necessary commercial vaccine yet approved study chimeric dna construct designed encode influenza ahn na protein flanking immunogenic amino acid aa – merscov spike protein using generated chimeric construct novel recombinant vaccine strain pandemic influenza virus hnpdm merscov generated chimeric bivalent chimeric bivalent vaccine strain comprises recombinant prbased vaccine expressing pb ha chimeric na pandemic hn interestingly increase replication efficiency generated vaccine strain observed compared prbased hnpdm vaccine strain lack merscov spike peptide insert balbc mouse inactivated chimeric bivalent vaccine induced potent specific neutralizing antibody merscov hnpdm novel approach succeeded developing recombinant influenza virus potential use bivalent vaccine hnpdm merscov approach provides basis future development chimeric influenzabased vaccine merscov virus,2019-12-02,"Shehata, Mahmoud M.; Kandeil, Ahmed; Mostafa, Ahmed; Mahmoud, Sara H.; Gomaa, Mokhtar R.; El-Shesheny, Rabeh; Webby, Richard; Kayali, Ghazi; A. Ali, Mohamed",Pathogens,,,,document_parses/pdf_json/02a29bd2f39ecdbbb5e51a003c0bc7818029f384.json,document_parses/pmc_json/PMC6963271.xml.json,https://doi.org/10.3390/pathogens8040281; https://www.ncbi.nlm.nih.gov/pubmed/31810359/,208813001.0,3
103526,103526,131671,15ev0b9d,40b0d0a814b137b7925799d7dd8053e8567f36da,Elsevier; Medline; PMC,Epitope selection and their placement for increased virus neutralization in a novel vaccination strategy for porcine epidemic diarrhea virus utilizing the Hepatitis B virus core antigen,10.1016/j.vaccine.2018.06.015,PMC7172244,29914846.0,no-cc,porcine epidemic diarrhea virus pedv member alphacoronaviridae genus within coronaviridae family causative agent porcine epidemic diarrhea disease mortality rate high suckling piglet pedv cause severe economic loss existence decade panzootic starting renewed interest development universal vaccine toward pedv report detail several design change made hepatitis b virus core antigen hbcagbased recombinant vaccine strategy effect vivo initially several multiantigen vaccine candidate able elicit antibody specific three four bcell epitope inserted chimeric protein however lack virus neutralization led redesign vaccine focus newly redesigned vaccine elicit strong immune response ysnigvck amino acid motif pedv genetically modified new vaccine candidate able elicit strong antibody ab response ysnigvck epitope correlated increased ability neutralize co strain pedv additionally location inserted pedv epitope within vector protein shown affect immune recognition toward native hbcag vaccination,2018-07-16,"Gillam, Frank; Zhang, Chenming",Vaccine,,,,document_parses/pdf_json/40b0d0a814b137b7925799d7dd8053e8567f36da.json,document_parses/pmc_json/PMC7172244.xml.json,https://api.elsevier.com/content/article/pii/S0264410X18308314; https://www.sciencedirect.com/science/article/pii/S0264410X18308314; https://www.ncbi.nlm.nih.gov/pubmed/29914846/; https://doi.org/10.1016/j.vaccine.2018.06.015,49296594.0,3
103534,103534,131681,ykzsoafe,c9a1b9d5a594fa236622538ebf994551cf0e886d,Medline; PMC,Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus,10.1080/21645515.2015.1021527,PMC4514392,25874632.0,bronze-oa,middle east respiratory syndrome mers emerging infectious disease caused mers coronavirus merscov continuous increase mers case posed serious threat public health worldwide calling development safe effective mers vaccine previously shown recombinant protein containing residue – merscov receptorbinding domain rbd fused human fc sfc induced highly potent antimerscov neutralizing antibody presence mf adjuvant optimized dos sfc using mf adjuvant order elicit strong immune response minimal amount antigen result showed sfc μg able induce immunized mouse potent humoral cellular immune response particularly sfc μg elicited strong neutralizing antibody response pseudotyped live merscov similar induced μg respectively result suggest rbdbased subunit mers vaccine candidate dose low one μg sufficiently potent induce strong humoral cellular immune response including neutralizing antibody merscov infection thus providing guidance determining optimal dosage rbdbased mers vaccine future clinical trial applying dosesparing strategy subunit vaccine trial,2015-04-15,"Tang, Jian; Zhang, Naru; Tao, Xinrong; Zhao, Guangyu; Guo, Yan; Tseng, Chien-Te K; Jiang, Shibo; Du, Lanying; Zhou, Yusen",Human Vaccines & Immunotherapeutics,,,,document_parses/pdf_json/c9a1b9d5a594fa236622538ebf994551cf0e886d.json,document_parses/pmc_json/PMC4514392.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25874632/; https://doi.org/10.1080/21645515.2015.1021527; https://www.tandfonline.com/doi/pdf/10.1080/21645515.2015.1021527?needAccess=true,39185260.0,3
103551,103551,131699,05dsghbw,031fb114a068c900631395c7be12bfb7655cacfb; 484416d84e17ba89ca310ec7efb7b913fa864eec,Elsevier; Medline; PMC,"Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety",10.1016/j.vaccine.2015.09.030,PMC4639457,26407920.0,green-oa,ongoing need new adjuvant facilitate development vaccine hiv tuberculosis malaria cancer amongst many others unfortunately potent adjuvant often associated toxicity safety issue inulin plantderived polysaccharide immunological activity native soluble form crystallised stable microparticles delta inulin acquires potent adjuvant activity delta inulin shown enhance humoral cellular immune response broad range coadministered viral bacterial parasitic toxin antigen inulin normally crystallises large heterogeneous particle broad size distribution variable solubility temperature ensure reproducible delta inulin particle consistent size distribution temperature solubility current good manufacturing practice cgmp process designed produce advax™ adjuvant cgmp form advax™ adjuvant proved successful human trial vaccine seasonal pandemic influenza hepatitis b insect sting anaphylaxis enhancing antibody tcell response time safe well tolerated advax™ adjuvant thereby represents novel human adjuvant positive effect humoral cellular immunity review describes discovery development advax™ adjuvant research unique mechanism action,2015-11-01,"Petrovsky, Nikolai; Cooper, Peter D.",Vaccine,,,,document_parses/pdf_json/031fb114a068c900631395c7be12bfb7655cacfb.json; document_parses/pdf_json/484416d84e17ba89ca310ec7efb7b913fa864eec.json,document_parses/pmc_json/PMC4639457.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26407920/; https://www.sciencedirect.com/science/article/pii/S0264410X15013067; http://europepmc.org/articles/pmc4639457?pdf=render; https://doi.org/10.1016/j.vaccine.2015.09.030; https://api.elsevier.com/content/article/pii/S0264410X15013067,27482191.0,3
103560,103560,131709,6olrc9se,,Elsevier; Medline; PMC,The race for treatments,10.1016/s0262-4079(20)30237-2,PMC7131140,32287791.0,els-covid,take time develop coronavirus vaccine existing drug may help save life say michael le page,2020-02-08,"Le Page, Michael",New Scientist,,,,,,https://api.elsevier.com/content/article/pii/S0262407920302372; https://www.sciencedirect.com/science/article/pii/S0262407920302372; https://doi.org/10.1016/s0262-4079(20)30237-2; https://www.ncbi.nlm.nih.gov/pubmed/32287791/,214757948.0,3
103573,103573,131723,x0bio5bl,8e67618920b0226e661e20a2c36b4436857d9590,Medline; PMC,Why do I need it? I am not at risk! Public perceptions towards the pandemic (H1N1) 2009 vaccine,10.1186/1471-2334-10-99,PMC2864274,20403201.0,cc-by,background th september pandemic hn influenza vaccine made available adult child aged year australia acceptance novel vaccine influenced perception risk including risk infection risk death severe illness risk serious vaccine sideeffects surveyed sample resident sydney australia ascertain risk perception attitude towards pandemic willingness accept pandemic hn influenza vaccine method sampled resident using crosssectional intercept design phase member public approached shopping pedestrian mall undertake survey september october survey measured perceived risk seriousness disease recent behavioural change likely acceptance pandemic hn vaccine issue relating uptake perceived safety result respondent majority felt low low risk acquiring hn respondent believed disease would seriously extremely affect health nearly half reported response swine flu outbreak undertaken one investigated behavioural change overall selfreported likelihood accepting vaccination novel hn conclusion participant believe high risk acquiring pandemic hn half sample indicated would accept vaccine participant vaccinated seasonal influenza likely receive hn vaccine concern safety possibility side effect vaccine development process need addressed,2010-04-19,"Seale, Holly; Heywood, Anita E; McLaws, Mary-Louise; Ward, Kirsten F; Lowbridge, Chris P; Van, Debbie; MacIntyre, C Raina",BMC Infect Dis,,,,document_parses/pdf_json/8e67618920b0226e661e20a2c36b4436857d9590.json,document_parses/pmc_json/PMC2864274.xml.json,https://doi.org/10.1186/1471-2334-10-99; https://www.ncbi.nlm.nih.gov/pubmed/20403201/,16703754.0,3
103590,103590,131743,qxzc8gfb,87c19723aad115f46c01690bfdf5722dd7a6a575,Elsevier; PMC,Chapter 10 Advax Adjuvant A Potent and Safe Immunopotentiator Composed of Delta Inulin,10.1016/b978-0-12-804019-5.00010-4,PMC7150192,,els-covid,highly potent adjuvant commonly reactogenicity safety issue unlike immunologically active polysaccharide inulin immune activity native soluble form crystallized stable delta inulin isoform acquires potent immune action notably delta inulin enhances humoral cellular immune response vaccine antigen translating enhanced protection broad range viral bacterial parasitic toxinmediated disease delta inulin distinct compared typical vaccine adjuvant require adsorption antigen appear work induction inflammatory danger signal delta inulin manufactured current good manufacturing practice referred advax proved safe effective human trial influenza vaccine hepatitis b vaccine insect sting allergy vaccine advax thereby represents novel nonreactogenic immune modulator potential utility across broad range human prophylactic therapeutic vaccine,2017-12-31,"Petroski, N.",Immunopotentiators in Modern Vaccines,,,,document_parses/pdf_json/87c19723aad115f46c01690bfdf5722dd7a6a575.json,document_parses/pmc_json/PMC7150192.xml.json,https://www.sciencedirect.com/science/article/pii/B9780128040195000104; https://api.elsevier.com/content/article/pii/B9780128040195000104,89859546.0,3
103636,103636,131801,wzcas4zd,20e79fc5f7893e8decf5f86711ab3ea1802346e2,Elsevier; Medline; PMC,Mapping the neutralizing epitopes of F18 fimbrial adhesin subunit FedF of enterotoxigenic Escherichia coli (ETEC),10.1016/j.vetmic.2019.02.015,PMC7173344,30827385.0,no-cc,k f fimbrial enterotoxigenic escherichia coli etec major cause postweaning diarrhea pwd pig vaccine induces broad immunity prevent k f fimbrial etec bacterial attachment colonization pig small intestine neutralize enterotoxin enterotoxicity would effective pwd structurebased multiepitopefusionantigen mefa technology using backbone immunogen present neutralizing epitope representing virulence factor capacitates development broadly protective etec vaccine neutralizing epitope identified k fimbrial adhesin faeg enterotoxin f fimbrial adhesin study silico identified immunodominant epitope fac fimbrial subunit fedf play critical role f fimbrial adherence genetically fused epitope carrier examined immunogenicity epitope fusion determined epitopederived antibody neutralizing activity f fimbrial adherence data showed seven immunedominant epitope identified fedf subunit fused heterologous human etec adhesin subunit cfab epitope fusion induced antif antibody subcutaneously immunized mouse moreover antibody derived fusion significantly blocked adherence ffimbrial e coli bacteria pig intestinal cell line ipecj seven epitope exhibited neutralizing activity result study identified fedf epitope ipsssgtltcqagt qpdatgswyd effective antibody f fimbrial adherence suggested future application pwd vaccine development,2019-02-06,"Lu, Ti; Seo, Hyesuk; Moxley, Rodney A.; Zhang, Weiping",Vet Microbiol,,,,document_parses/pdf_json/20e79fc5f7893e8decf5f86711ab3ea1802346e2.json,document_parses/pmc_json/PMC7173344.xml.json,https://www.sciencedirect.com/science/article/pii/S0378113518312239; https://www.ncbi.nlm.nih.gov/pubmed/30827385/; https://api.elsevier.com/content/article/pii/S0378113518312239; https://doi.org/10.1016/j.vetmic.2019.02.015,73476721.0,3
103637,103637,131803,08u3x1z4,7803037cc75d3eeb6975b80af4adad0d6a675fa1,Elsevier; Medline; PMC,"Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: An observer-blind, randomized trial",10.1016/j.vaccine.2013.07.007,PMC7115432,23856331.0,els-covid,background study nct evaluated immunogenicity relative protective efficacy one dose influenza ahnpdm vaccine without αtocopherol oilinwater emulsion based adjuvant system method four thousand fortyeight healthy adult aged ≥ year randomized receive one dose either adjuvanted split virion μg hemagglutinin antigen haas nonadjuvanted μg ha vaccine hemagglutination inhibition hi antibody response evaluated vaccination day month safety study vaccine evaluated entire study duration result day study vaccine induced hi immune response meeting u regulatory criterion subject – year seroprotection rate spr – seroconversion rate scr – asadjuvanted group spr – scr – nonadjuvanted group year age spr – scr – asadjuvanted group spr – scr – nonadjuvanted group asadjuvanted vaccine induced higher hi geometric mean titer nonadjuvanted vaccine time point month subject – year age vaccine group still met u regulatory criterion spr – scr – asadjuvanted group spr – scr – nonadjuvanted group protective efficacy evaluated due low number rtqpcrconfirmed ahnpdm influenza case month serious adverse event subject asadjuvanted nonadjuvanted group potentially immune mediated disease asadjuvanted nonadjuvanted group reported conclusion single dose either adjuvanted nonadjuvanted influenza ahnpdm vaccine induced protective hi antibody level acalifornia strain persisted month – year population,2013-09-13,"Yang, William H.; Dionne, Marc; Kyle, Michael; Aggarwal, Naresh; Li, Ping; Madariaga, Miguel; Godeaux, Olivier; Vaughn, David W.",Vaccine,,,,document_parses/pdf_json/7803037cc75d3eeb6975b80af4adad0d6a675fa1.json,document_parses/pmc_json/PMC7115432.xml.json,https://doi.org/10.1016/j.vaccine.2013.07.007; https://www.sciencedirect.com/science/article/pii/S0264410X13009286; https://api.elsevier.com/content/article/pii/S0264410X13009286; https://www.ncbi.nlm.nih.gov/pubmed/23856331/,25880491.0,3
103704,103704,131879,cdctlduc,,Elsevier; WHO,The hunt for covid-19 drugs,10.1016/s0262-4079(20)30525-x,,,els-covid,many drug vaccine developed tested,2020-03-14,"MacKenzie, Debora",New Scientist,,#8446,,,,https://api.elsevier.com/content/article/pii/S026240792030525X; https://www.sciencedirect.com/science/article/pii/S026240792030525X; https://doi.org/10.1016/s0262-4079(20)30525-x,214755402.0,3
103729,103729,131911,p6w6awsu,d393b682c4a5c15fd285020e35c1a61da098f1d5,Elsevier; PMC,A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague,10.1016/j.vaccine.2004.02.036,PMC7126436,15308359.0,els-covid,urgent need develop effective vaccine pneumonic plague highly lethal contagious disease caused gramnegative bacterium yersinia pestis demonstrate novel dna vaccine expressing modified v antigen lcrv pestis human tissue plasminogen activator tpa signal sequence elicited strong vspecific antibody response balbc mouse tpav dna vaccine protected mouse intranasal challenge lethal dos pestis comparison dna vaccine expressing wild type v antigen much le effective tpav formed oligomers spontaneously elicited higher igga antiv antibody response immunized mouse suggesting increased th type cellular immune response data indicate antigen engineering effective inducing high quality protective immune response conformationally sensitive antigen result support optimized dna vaccine potential protect bacterial pathogen generally recognized,2004-09-03,"Wang, Shixia; Heilman, Destin; Liu, Fangjun; Giehl, Theodore; Joshi, Swati; Huang, Xiaoyun; Chou, Te-hui; Goguen, Jon; Lu, Shan",Vaccine,,,,document_parses/pdf_json/d393b682c4a5c15fd285020e35c1a61da098f1d5.json,document_parses/pmc_json/PMC7126436.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X04002099; https://api.elsevier.com/content/article/pii/S0264410X04002099,3256090.0,3
103762,103762,131955,mhfu0e9r,1fc272e29cf664fd24c582541095b47dcaca7f5f,Medline; PMC,Improving Cross-Protection against Influenza Virus Using Recombinant Vaccinia Vaccine Expressing NP and M2 Ectodomain Tandem Repeats,10.1007/s12250-019-00138-9,PMC6814692,31240620.0,no-cc,conventional influenza vaccine need designed manufactured yearly however occasionally provide poor protection owing antigenic mismatch hence urgent need develop universal vaccine influenza virus using nucleoprotein np extracellular domain matrix protein gene influenza virus abeijing hn constructed four recombinant vaccinia virusbased influenza vaccine carrying np fused one four copy gene different order recombinant vaccinia virus used immunize balbc mouse humoral cellular response measured immunized mouse challenged influenza virus apuerto rico pr npspecific humoral response elicited mouse immunized recombinant vaccinia virus carrying fulllength np robust mespecific humoral response elicited mouse immunized recombinant vaccinia virus carrying multiple copy recombinant virus elicited np mespecific cellular immune response mouse immunization rvjmenp induced remarkably higher level il il cytokine specific furthermore rvjmenp immunization provided highest crossprotection mouse challenged mld pr therefore crossprotection potentially correlate np mespecific humoral cellular immune response induced rvjmenp express fusion antigen fulllength np preceded four repeat result suggest rational fusion np multiple antigen critical toward inducing protective immune response menp fusion antigen may employed develop universal influenza vaccine electronic supplementary material online version article contains supplementary material available authorized user,2019-06-25,"Wang, Wenling; Huang, Baoying; Wang, Xiuping; Tan, Wenjie; Ruan, Li",Virol Sin,,,,document_parses/pdf_json/1fc272e29cf664fd24c582541095b47dcaca7f5f.json,document_parses/pmc_json/PMC6814692.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31240620/; https://doi.org/10.1007/s12250-019-00138-9,195354086.0,3
103773,103773,131971,7xy4s483,057a931d8bfabff534eddd75a96af84a1b6b3deb,Medline; PMC,A broadly neutralizing germline-like human monoclonal antibody against dengue virus envelope domain III,10.1371/journal.ppat.1007836,PMC6615639,31242272.0,cc0,dengue widespread vectorborne viral disease caused dengue virus denv safe effective drug approved clinical use using sequential antigen panning yeast antibody library derived healthy donor denv envelop protein domain iii diii combined depletion entry defective diii mutant identified crossreactive human monoclonal antibody mab bound high affinity denv diii four denv serotypes immunogenetic analysis indicated germlinelike mab somatic mutation closest vh vλ germline gene importantly demonstrated potently neutralized denv vitro mouse model denv infection without detectable antibodydependent enhancement ade effect epitope mapped highly conserved region diii may guide design effective dengue vaccine immunogen furthermore first germlinelike mab derived naïve antibody library could neutralize four denv serotypes tool exploring mechanism denv infection promising therapeutic candidate,2019-06-26,"Hu, Dan; Zhu, Zhongyu; Li, Shun; Deng, Yongqiang; Wu, Yanling; Zhang, Nana; Puri, Vinita; Wang, Chunyu; Zou, Peng; Lei, Cheng; Tian, Xiaolong; Wang, Yulu; Zhao, Qi; Li, Wei; Prabakaran, Ponraj; Feng, Yang; Cardosa, Jane; Qin, Chengfeng; Zhou, Xiaohui; Dimitrov, Dimiter S.; Ying, Tianlei",PLoS Pathog,,,,document_parses/pdf_json/057a931d8bfabff534eddd75a96af84a1b6b3deb.json,document_parses/pmc_json/PMC6615639.xml.json,https://doi.org/10.1371/journal.ppat.1007836; https://www.ncbi.nlm.nih.gov/pubmed/31242272/,195695756.0,3
103806,103806,132008,zu0ubwfq,1dbc2cf5296dfb4317275d42c1788a289cd689cb,Elsevier; PMC,The challenge of PRRS immunology,10.1016/j.tvjl.2007.05.022,PMC7110845,17644436.0,els-covid,porcine reproductive respiratory syndrome prrs one challenging subject research veterinary viral immunology immune response prrs virus prrsv still poorly understood infected pig develop strong rapid humoral response initial antibody confer protection even harmful mediating antibodydependent enhancement disease contrast development neutralising antibody na delayed generation cellmediated immune response prrsvspecific interferon ifnγ secreting cell initially erratic spite induction strong rapid na ifnγ response seem required effective vaccination prrsv strongly modulates host ’ immune response virus inhibits key cytokine ifnα may induce regulatory cytokine interleukin il development na seems impaired existence decoy epitope close main neutralisation epitope glycoprotein ability modulate host immune response probably varies among strain isolates genetic diversity virus high shown diversity serious implication development vaccine since immunity induced one strain may partial different strain even within genotype panorama development newer universally efficacious prrsv vaccine challenging present state knowledge allows optimism collaborative effort undertaken scientific community,2008-09-30,"Mateu, E.; Diaz, I.",The Veterinary Journal,,,,document_parses/pdf_json/1dbc2cf5296dfb4317275d42c1788a289cd689cb.json,document_parses/pmc_json/PMC7110845.xml.json,https://api.elsevier.com/content/article/pii/S1090023307002031; https://www.sciencedirect.com/science/article/pii/S1090023307002031,32864314.0,3
103843,103843,132054,d2j9wpqk,f89d5c37625138c6d8520506adcc5d258efb044e,Elsevier; Medline; PMC; WHO,Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2,10.1016/j.micpath.2020.104236,PMC7196559,32376359.0,no-cc,coronavirus disease covid emerging infectious disease first reported wuhan china subsequently spread worldwide absence antiviral immunomodulatory therapy disease spreading alarming rate possibility resurgence covid place lockdown already worked also developing thus controlling covid vaccine may better option drug mrnabased anticovid candidate vaccine entered phase clinical trial however efficacy potency evaluated validated since vaccine high failure rate alternative presenting new designed multipeptide subunitbased epitope vaccine covid recombinant vaccine construct comprises adjuvant cytotoxic tlymphocyte ctl helper tlymphocyte htl bcell epitope joined linkers computational data suggest vaccine nontoxic nonallergenic thermostable capability elicit humoral cellmediated immune response stabilization vaccine construct validated molecular dynamic simulation study unique vaccine made highly antigenic epitope three protein prominent role hostreceptor recognition viral entry pathogenicity advocate vaccine must synthesized tested urgently public health priority,2020-05-04,"Kalita, Parismita; Padhi, AdityaK.; Zhang, Kam Y.J.; Tripathi, Timir",Microb Pathog,,#165205,,document_parses/pdf_json/f89d5c37625138c6d8520506adcc5d258efb044e.json,document_parses/pmc_json/PMC7196559.xml.json,https://api.elsevier.com/content/article/pii/S0882401020305234; https://www.sciencedirect.com/science/article/pii/S0882401020305234?v=s5; https://www.ncbi.nlm.nih.gov/pubmed/32376359/; https://doi.org/10.1016/j.micpath.2020.104236,218482292.0,3
103845,103845,132056,r5zydz79,00c88aab2bfcca0db253c972382e5eee245d071e,Medline; PMC,Production of complex viral glycoproteins in plants as vaccine immunogens,10.1111/pbi.12963,PMC6097131,29890031.0,cc-by,plant molecular farming offer cost‐effective scalable approach expression recombinant protein proposed alternative conventional production platform developing country recent year numerous proof concept established plant produce biologically active recombinant protein immunologically relevant vaccine antigen comparable made conventional expression system driving many advance remarkable plasticity plant proteome enables extensive engineering host cell well development improved expression vector facilitating higher level protein production date plant‐derived viral glycoprotein tested human influenza haemagglutinin express mgkg however many viral glycoprotein potential vaccine immunogen accumulate low level planta critical consideration production many protein heterologous expression system complexity post‐translational modification control folding glycosylation disulphide bridging required reproduce native glycoprotein structure review address potential shortcoming plant expression system discus strategy optimally exploit technology production immunologically relevant structurally authentic glycoprotein use vaccine immunogen,2018-07-06,"Margolin, Emmanuel; Chapman, Ros; Williamson, Anna‐Lise; Rybicki, Edward P.; Meyers, Ann E.",Plant Biotechnol J,,,,document_parses/pdf_json/00c88aab2bfcca0db253c972382e5eee245d071e.json,document_parses/pmc_json/PMC6097131.xml.json,https://doi.org/10.1111/pbi.12963; https://www.ncbi.nlm.nih.gov/pubmed/29890031/,48356426.0,3
103892,103892,132119,4ynsgu6c,fd5ec0d0abf8e987b847aad629795e6311c41c77,Elsevier; Medline; PMC,Veterinary vaccine development from an industrial perspective,10.1016/j.tvjl.2007.11.009,PMC7110856,18313956.0,els-covid,veterinary vaccine currently available europe part world developed veterinary pharmaceutical industry development vaccine veterinary use economic endeavour take many year many obstacle along path successful development launch vaccine industrial development vaccine veterinary use usually start proof concept based robust academic research vaccine made available veterinary community marketing authorisation granted veterinary authority review give brief description regulatory requirement fulfilled vaccine admitted market vaccine produced quality controlled environment guarantee delivery product consistent quality well defined animal consumer safety efficacy characteristic regulatory manufacturing legislative framework development take place described well trend development production system recent development bacterial viral parasite vaccine research development also addressed development novel adjuvant use expanding knowledge immunology disease pathology described,2008-10-31,"Heldens, J.G.M.; Patel, J. R.; Chanter, N.; ten Thij, G. J.; Gravendijck, M.; Schijns, V.E.J.C.; Langen, A.; Schetters, Th.P.M.",The Veterinary Journal,,,,document_parses/pdf_json/fd5ec0d0abf8e987b847aad629795e6311c41c77.json,document_parses/pmc_json/PMC7110856.xml.json,https://doi.org/10.1016/j.tvjl.2007.11.009; https://www.ncbi.nlm.nih.gov/pubmed/18313956/; https://api.elsevier.com/content/article/pii/S1090023307003930; https://www.sciencedirect.com/science/article/pii/S1090023307003930,3094427.0,3
103904,103904,132135,c7bmrjzi,e63f49d69364214383bb4bd983e941816b11b8da,Medline; PMC,Characterization of the Immune Response of MERS-CoV Vaccine Candidates Derived from Two Different Vectors in Mice,10.3390/v12010125,PMC7019946,31968702.0,cc-by,middle east respiratory syndrome mers acute highmortalityrate severe infectious disease caused emerging mers coronavirus merscov cause severe respiratory disease continuous spread great pandemic potential merscov make necessarily important develop effective vaccine previously demonstrated application grampositive enhancer matrix gem particle bacterial vector displaying merscov receptorbinding domain rbd promising mers vaccine candidate capable producing potential neutralization antibody also used rabies virus rv viral vector design recombinant vaccine expressing merscov spike protein surface rv study compared immunological efficacy vaccine candidate balbc mouse term level humoral cellular immune response result show rabies virus vectorbased vaccine induce remarkably earlier antibody response higher level cellular immunity gem particle vector however gem particle vectorbased vaccine candidate induce remarkably higher antibody response even low dose µg result indicate vaccine constructed using different vaccine vector platform pathogen different rate trend humoral cellular immune response animal model discovery provides alternative vaccine development platform merscov vaccine development also provides theoretical basis future selection vaccine vector platform specific pathogen,2020-01-20,"Li, Entao; Yan, Feihu; Huang, Pei; Chi, Hang; Xu, Shengnan; Li, Guohua; Liu, Chuanyu; Feng, Na; Wang, Hualei; Zhao, Yongkun; Yang, Songtao; Xia, Xianzhu",Viruses,,,,document_parses/pdf_json/e63f49d69364214383bb4bd983e941816b11b8da.json,document_parses/pmc_json/PMC7019946.xml.json,https://doi.org/10.3390/v12010125; https://www.ncbi.nlm.nih.gov/pubmed/31968702/,210873849.0,3
103905,103905,132136,tlsuyede,b574bf0f935b4f092e6df566f24ce24020474b66; 319b8c97174d684a0e0f50dff4ecfdab294d2a05,Elsevier; Medline; PMC,Vaccine or field strains: the jigsaw pattern of infectious bronchitis virus molecular epidemiology in Poland,10.3382/ps/pez473,PMC6870560,31399745.0,cc-by-nc,infectious bronchitis ib caused infectious bronchitis virus ibv account severe economic loss poultry industry continuous emergence multitude ibv variant pose many challenge diagnosis control live attenuated vaccine despite routine use still play significant role driving ibv evolution complicating epidemiological scenario unfortunately impact different vaccination strategy ib control epidemiology diagnosis rarely investigated work present result largescale diagnostic survey performed poland study ibv molecular epidemiology vaccination may affect viral circulation field purpose sample collected may january tested reverse transcriptionpcr ibv sequenced vaccine field strain discriminated based genetic anamnestic information commonly detected lineage b variant sporadic detection qx mass dlike strain detected strain vaccine origin matched one applied vaccine genetically related vaccine implemented respective protocol besides practical value proper planning vaccination protocol poland result suggest fraction circulating strain field one imposing careful assessment actual ibv field menace moreover phenomenon like vaccine spreading persistence seem occur commonly stressing need study epidemiological consequence extensive use live vaccine,2019-08-09,"Legnardi, Matteo; Franzo, Giovanni; Koutoulis, Konstantinos C; Wiśniewski, Marek; Catelli, Elena; Tucciarone, Claudia Maria; Cecchinato, Mattia",Poult Sci,,,,document_parses/pdf_json/b574bf0f935b4f092e6df566f24ce24020474b66.json; document_parses/pdf_json/319b8c97174d684a0e0f50dff4ecfdab294d2a05.json,document_parses/pmc_json/PMC6870560.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31399745/; https://api.elsevier.com/content/article/pii/S0032579119579457; https://doi.org/10.3382/ps/pez473; https://www.sciencedirect.com/science/article/pii/S0032579119579457,199518184.0,3
103941,103941,132181,39kepzzm,91531177c812eedf1e965f086c510c6e603250ce,Elsevier; Medline; PMC,The National Vaccine Advisory Committee at 30: Impact and opportunity,10.1016/j.vaccine.2018.01.068,PMC7115546,29422369.0,els-covid,thirty year passage legislation created national vaccine advisory committee nvac “ achieve optimal prevention human infectious disease immunization achieve optimal prevention adverse reaction vaccine ” review reflects nvac ’ role impact u vaccine immunization enterprise external advisor department health human service reviewed history nvac context principle establishment focus report recommendation performed systematic literature review identify nvac report published widelyaccessible public health journal reviewed available archive identify report resolution approved committee published journal characterized key issue considered nvac according five goal national vaccine plan predominance nvac activity date related implementation immunization across lifespan many aspect system needed foster goal full immunization reflecting impact nvac date review identified nvac approved report published journal standalone resolution unique unpublished report development new improved vaccine continues represent significant priority nvac identified several challenge related future vaccine innovation given many factor impact policy change vaccine immunization enterprise encountered challenge associated demonstrating attribution specific policy change nvac recommendation although difficult quantify review suggests nvac played important role improvement u immunization enterprise past year nvac continue play important role supporting u immunization going forward,2018-03-07,"Thompson, Kimberly M.; Gellin, Bruce G.; Hinman, Alan R.; Orenstein, Walter A.",Vaccine,,,,document_parses/pdf_json/91531177c812eedf1e965f086c510c6e603250ce.json,document_parses/pmc_json/PMC7115546.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29422369/; https://doi.org/10.1016/j.vaccine.2018.01.068; https://api.elsevier.com/content/article/pii/S0264410X18301294; https://www.sciencedirect.com/science/article/pii/S0264410X18301294,4581193.0,3
103994,103994,132246,vk59ghjm,817a885e9613363e08ef920a9e5826a4cb9e1c1e,Medline; PMC,Newcastle disease virus vectored vaccines as bivalent or antigen delivery vaccines,10.7774/cevr.2017.6.2.72,PMC5540967,28775971.0,cc-by-nc,recent advance reverse genetics technique make possible manipulate genome rna virus newcastle disease virus ndv several ndv vaccine strain used vaccine vector poultry mammal human express antigen different pathogen safety immunogenicity protective efficacy ndvvectored vaccine evaluated preclinical clinical study vaccine safe mammal human poultry bivalent ndvvectored vaccine pathogen economic importance poultry industry developed bivalent vaccine confer solid protective immunity ndv foreign antigen case ndvvectored vaccine induce strong local systemic immune response target foreign antigen review summarizes development ndvvectored vaccine potential use base designing effective vaccine veterinary human use,2017-07-26,"Choi, Kang-Seuk",Clin Exp Vaccine Res,,,,document_parses/pdf_json/817a885e9613363e08ef920a9e5826a4cb9e1c1e.json,document_parses/pmc_json/PMC5540967.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28775971/; https://doi.org/10.7774/cevr.2017.6.2.72,19459871.0,3
104029,104029,132297,8k18vl0r,3c0aeff3b6882e1af191bdf3d6452476004230df; c9f2ba9d8fea3008779442c4ed578dfeb558fb66,Medline; PMC,The promise and challenge of high-throughput sequencing of the antibody repertoire,10.1038/nbt.2782,PMC4113560,24441474.0,green-oa,effort determine antibody repertoire encoded b cell blood lymphoid organ using highthroughput dna sequencing technology advancing extremely rapid pace transforming understanding humoral immune response information gained highthroughput dna sequencing immunoglobulin gene igseq applied detect bcell malignancy high sensitivity discover antibody specific antigen interest guide vaccine development understand autoimmunity rapid progress development experimental protocol informatics analysis tool helping reduce sequencing artifact achieve precise quantification clonal diversity extract pertinent biological information said broader application igseq especially clinical setting require development standardized experimental design framework enable sharing metaanalysis sequencing data generated different laboratory,2014-01-19,"Georgiou, George; Ippolito, Gregory C; Beausang, John; Busse, Christian E; Wardemann, Hedda; Quake, Stephen R",Nature Biotechnology,,,,document_parses/pdf_json/3c0aeff3b6882e1af191bdf3d6452476004230df.json; document_parses/pdf_json/c9f2ba9d8fea3008779442c4ed578dfeb558fb66.json,document_parses/pmc_json/PMC4113560.xml.json,https://doi.org/10.1038/nbt.2782; https://www.ncbi.nlm.nih.gov/pubmed/24441474/; http://europepmc.org/articles/pmc4113560?pdf=render,28880618.0,3
104087,104087,132361,spkg3hbv,3849786c8c14c11ae4b19b4543672421e5d169fd,Medline; PMC,Plant-based vaccines against viruses,10.1186/s12985-014-0205-0,PMC4264547,25465382.0,cc-by,plantmade “ biofarmed ” viral vaccine earliest product technology plant molecular farming remain brightest prospect success field proof principle efficacy exist many candidate viral veterinary vaccine use plantmade viral antigen monoclonal antibody therapy animal even human viral disease also well established review explores prominent recent advance biofarming viral vaccine therapy including recent use zmapp ebolavirus infection explores possible future application technology,2014-12-03,"Rybicki, Edward P",Virol J,,,,document_parses/pdf_json/3849786c8c14c11ae4b19b4543672421e5d169fd.json,document_parses/pmc_json/PMC4264547.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/25465382/; https://doi.org/10.1186/s12985-014-0205-0,15989522.0,3
104224,104224,132538,cse6bdz8,6bc66c3abc451b39ae1bba08b1f1ff3f7e7f5b95,Medline; PMC,Adjuvanted poly(lactic-co-glycolic) acid nanoparticle-entrapped inactivated porcine reproductive and respiratory syndrome virus vaccine elicits cross-protective immune response in pigs,10.2147/ijn.s56127,PMC3908835,24493925.0,cc-by-nc,porcine reproductive respiratory syndrome prrs caused prrs virus prrsv economically devastating disease causing daily loss approximately million u pork industry current vaccine failed completely prevent prrs outbreak recently shown polylacticcoglycolic acid plga nanoparticleentrapped inactivated prrsv vaccine npkag induces crossprotective immune response pig improve crossprotective efficacy npkag vaccine formulation slightly modified pig coadministered vaccine twice intranasally potent adjuvant mycobacterium tuberculosis wholecell lysate vaccinated virulent heterologous prrsvchallenged pig immune correlate blood follows enhanced prrsvspecific antibody response enhanced avidity immunoglobulin igg iga isotypes associated augmented virusneutralizing antibody titer comparable increased level virusspecific igg igg antibody subtypes production high level thelper th th cytokine indicative balanced th–th response suppressed immunosuppressive cytokine response increased frequency interferonγ lymphocyte subset expanded population antigenpresenting cell importantly complete clearance detectable replicating challenged heterologous prrsv close threefold reduction viral ribonucleic acid load detected blood conclusion intranasal delivery adjuvanted npkag vaccine formulation growing pig elicited broadly crossprotective immune response showing potential innovative vaccination strategy prevent prrs outbreak pig similar approach control respiratory disease food animal human appears feasible,2014-01-24,"Binjawadagi, Basavaraj; Dwivedi, Varun; Manickam, Cordelia; Ouyang, Kang; Wu, Yun; Lee, Ly James; Torrelles, Jordi B; Renukaradhya, Gourapura J",Int J Nanomedicine,,,,document_parses/pdf_json/6bc66c3abc451b39ae1bba08b1f1ff3f7e7f5b95.json,document_parses/pmc_json/PMC3908835.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/24493925/; https://doi.org/10.2147/ijn.s56127,9059196.0,3
104281,104281,132604,nlnugpty,81ce440540188d860e44b25dbbf288393a815e02,Medline; PMC,New Vaccine Design and Delivery Technologies,10.1093/infdis/jiy745,PMC6452296,30715361.0,no-cc,technological advance immunology protein design genetic delivery unlocked new possibility vaccine concept delivery technology previously inaccessible nextgeneration vaccine design effort particularly promising potential provide solution challenging target conventional approach proven ineffective—for example universal influenza vaccine perspective discus emerging approach vaccine design engineering based recent insight immunology structural biology computational biology immunoengineering anticipate cuttingedge interdisciplinary approach lead breakthrough vaccine concept everevolving reemerging influenza virus important ramification global public health,2019-04-15,"Kanekiyo, Masaru; Ellis, Daniel; King, Neil P",J Infect Dis,,,,document_parses/pdf_json/81ce440540188d860e44b25dbbf288393a815e02.json,document_parses/pmc_json/PMC6452296.xml.json,https://doi.org/10.1093/infdis/jiy745; https://www.ncbi.nlm.nih.gov/pubmed/30715361/,73416462.0,3
104319,104319,132647,d50bxe7c,0ae348a31cc35a76cf9e0999fa3e5369636ffc31,Elsevier; Medline; PMC,Efficacy and immunogenicity of recombinant swinepox virus expressing the A epitope of the TGEV S protein,10.1016/j.vaccine.2015.06.057,PMC7172626,26116254.0,no-cc,explore possibility developing vaccine transmissible gastroenteritis virus tgev infection recombinant swinepox virus rspvsa expressing tgev protective antigen constructed immune response protection efficacy vaccination vector assessed mouse pig model indirect elisa assay suggested mouse vaccinated rspvsa level igg tgev enhanced dramatically cytokine assay employed result indicated thtype thtype cytokine level raised vaccination rspvsa mouse model result passive immunity protection test new born piglet demonstrated recombinant livevector vaccine rspvsa could protect piglet spv infection significant clinical symptom rspvsa treatment group experiment data suggest novel recombinant swinepox virus potential vaccine tgev infection,2015-07-31,"Yuan, Xiaomin; Lin, Huixing; Fan, Hongjie",Vaccine,,,,document_parses/pdf_json/0ae348a31cc35a76cf9e0999fa3e5369636ffc31.json,document_parses/pmc_json/PMC7172626.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26116254/; https://api.elsevier.com/content/article/pii/S0264410X15008580; https://www.sciencedirect.com/science/article/pii/S0264410X15008580; https://doi.org/10.1016/j.vaccine.2015.06.057,33127786.0,3
104336,104336,132669,09hmet7r,6e8e102a4453c1bf7d9d4886d32d6aa1bebb3e53,Medline; PMC,Transfer of Anti-Rotavirus Antibodies during Pregnancy and in Milk Following Maternal Vaccination with a Herpes Simplex Virus Type-1 Amplicon Vector,10.3390/ijms18020431,PMC5343965,28212334.0,cc-by,rotavirus rv important enteric pathogen newborn human animal causing diarrhea rare case death especially young individual rotavirus vaccine presently used modified live vaccine lack complete biological safety previous work laboratory suggested vaccine based situ produced noninfectious rotaviruslike particle rvlps efficient entirely safe however using either vaccine active mucosal immunization induce protective immunity newborn due immature immune system therefore hypothesized offspring vaccinated dam passively immunized either transfer maternal antibody pregnancy taking antibody milk using codon optimized polycistronic gene expression cassette packaged herpesvirus particle simultaneous expression rv capsid gene led intracellular formation rvlps various cell line vaccinated dam developed strong rv specific igg antibody response determined serum milk mother pup moreover serum naïve pup nursed vaccinated dam also rv specific antibody suggesting lactogenic transfer antibody although full protection pup achieved mouse model observation important development improved vaccine rv human well various animal specie,2017-02-16,"Meier, Anita F.; Suter, Mark; Schraner, Elisabeth M.; Humbel, Bruno M.; Tobler, Kurt; Ackermann, Mathias; Laimbacher, Andrea S.",Int J Mol Sci,,,,document_parses/pdf_json/6e8e102a4453c1bf7d9d4886d32d6aa1bebb3e53.json,document_parses/pmc_json/PMC5343965.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28212334/; https://doi.org/10.3390/ijms18020431,14135525.0,3
104361,104361,132698,qeo5dfxg,,BioRxiv; MedRxiv,Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus in China (SARS-CoV-2),10.1101/2020.03.03.962332,,,medrxiv,new coronavirus sarscov recently discovered wuhan china caused infection case death due rapidly growing case unavailability specific therapy desperate need vaccine combat epidemic sarscov present study performed silico approach based available virus genome identify antigenic bcell epitope humanleukocyteantigen hla restricted tcell epitope total bcell epitope initially identified higher potential immunogenicity used vaccine design tcell epitope predicted showed affinity popular hla allele chinese population based epitope vaccine candidate designed inspected safety risk including potential toxicity human homologous pharmaceutical peptide bioactive peptide majority vaccine peptide contained bcell tcell epitope may interact prevalent hla allele accounting chinese population docking analysis showed stable hydrogen bond epitope corresponding hla allele conclusion putative antigenic peptide may elicit resistance response viral infection vitro vivo experiment required validate effectiveness peptide vaccine,2020-03-03,"Feng, Ye; Qiu, Min; Zou, Shengmei; Li, Yun; Luo, Kai; Chen, Rongchang; Sun, Yingqiang; Wang, Kui; Zhuang, Xinlei; Zhang, Shanshan; Chen, Shuqing; Mo, Fan",bioRxiv,,,,,,https://doi.org/10.1101/2020.03.03.962332,214232050.0,3
104401,104401,132752,6niz8q08,f8e6c1da1ba9b222863bb9369bfc92a7a908b6e0,Medline; PMC,Evolution of infectious bronchitis virus in the field after homologous vaccination introduction,10.1186/s13567-019-0713-4,PMC6842459,31706335.0,cc-by,despite fact vaccine resistance typically considered rare phenomenon episode vaccine failure reported increasing frequency intensivelyraised livestock infectious bronchitis virus ibv widespread avian coronavirus whose control relies mainly extensive vaccine administration unfortunately continuous emergence new vaccineimmunity escaping variant prompt development new vaccine present work molecular epidemiology study performed evaluate potential role homologous vaccination driving ibv evolution undertaken assessing ibv viral rna sequence orf encoding portion viral surface glycoprotein introduction new live vaccine broiler farm northernitaly result several biostatistics analysis consistently demonstrate presence higher pressure postvaccination period natural selection detected essentially site located protein surface within nearby domain involved viral attachment related function evidence strongly support action vaccineinduced immunity conditioning viral evolution potentially leading emergence new vaccineescape variant great plasticity rapidlyevolving rnaviruses response human intervention extends beyond poultry industry demonstrated claiming attention due relevance animal especially human health,2019-11-09,"Franzo, Giovanni; Legnardi, Matteo; Tucciarone, Claudia Maria; Drigo, Michele; Martini, Marco; Cecchinato, Mattia",Vet Res,,,,document_parses/pdf_json/f8e6c1da1ba9b222863bb9369bfc92a7a908b6e0.json,document_parses/pmc_json/PMC6842459.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31706335/; https://doi.org/10.1186/s13567-019-0713-4,207951720.0,3
104464,104464,132833,hfa9w2dg,f63cd990f80bf23a1c1ac68e58f8e6bcaa460cd8,Elsevier; Medline; PMC,The level of decoy epitope in PCV2 vaccine affects the neutralizing activity of sera in the immunized animals,10.1016/j.bbrc.2018.01.141,PMC7092900,29374509.0,els-covid,viral pathogen evolved wide range tactic evade host immune response thus propagate effectively one efficient tactic divert host immune response toward immunodominant decoy epitope induce nonneutralizing antibody toward epitope therefore expected amount decoy epitope subunit vaccine affect level neutralizing antibody immunized animal study tested hypothesis generating antibody specific decoy epitope capsid protein porcine circovirus type pcv using antibody found two commercial vaccine contained statistically different amount decoy epitope vaccine lower level decoy epitope induced significantly higher level neutralizing antibody immunization antibody used analytical tool monitor quality vaccine batch batch,2018-02-12,"Jin, Junyeong; Park, Changhoon; Cho, Sun-Hee; Chung, Junho",Biochemical and Biophysical Research Communications,,,,document_parses/pdf_json/f63cd990f80bf23a1c1ac68e58f8e6bcaa460cd8.json,document_parses/pmc_json/PMC7092900.xml.json,https://www.sciencedirect.com/science/article/pii/S0006291X18301621; https://www.ncbi.nlm.nih.gov/pubmed/29374509/; https://api.elsevier.com/content/article/pii/S0006291X18301621; https://doi.org/10.1016/j.bbrc.2018.01.141,35520381.0,3
104497,104497,132878,7cklwv5x,bcde15209d8d14135e73cdf3f208401dd6ded3be,Elsevier; PMC,Commensal bacteria as a novel delivery system for subunit vaccines directed against agents of bioterrorism,10.1016/j.addr.2005.01.015,PMC7125890,15935879.0,els-covid,following anthrax attack recent sars outbreak concern emerging reemerging infectious disease catalyzed renewed interest developing new vaccination strategy provide rapid flexible response option future threat probability encountering one exotic agent unknown essential new vaccine formulation employ method provide effective protection extremely good safety profile used either military civilian population one approach potentially satisfies criterion use live recombinant grampositive commensal bacteria expression vector review provides overview system advantage limitation detail example grampositive commensal bacteria developed fifth generation vaccine class biowarfare pathogen namely smallpox,2005-06-17,"Wilson, Rebecca L.; Hruby, Dennis E.",Advanced Drug Delivery Reviews,,,,document_parses/pdf_json/bcde15209d8d14135e73cdf3f208401dd6ded3be.json,document_parses/pmc_json/PMC7125890.xml.json,https://www.sciencedirect.com/science/article/pii/S0169409X05000505; https://api.elsevier.com/content/article/pii/S0169409X05000505,43683251.0,3
104533,104533,132925,cq6bk5nx,8ac60c43cffb0af459331a7cab49bd236576741b,Elsevier; Medline; PMC,Healthcare workers and H1N1 vaccination: Does having a chronic disease make a difference?,10.1016/j.vaccine.2011.12.037,PMC7127734,22178521.0,els-covid,introduction novel hn vaccine manufactured response pandemic study describes willingness vaccinated hn among healthcare worker hcws primary healthcare clinic without chronic medical condition reason refusing vaccination whether sought additional information make informed decision vaccination material method anonymous survey conducted november among medical nursing allied health operation hcws nine primary care clinic singapore participant asked chronic medical condition associated influenzarelated complication example asthma stroke heart disease cancer diabetes mellitus renal disease perception towards vaccination hn seasonal influenza within preceding year result initial response rate completed survey analysed among respondent reported least chronic disease asthma hypertension dyslipidaemia main chronic condition respondent willing vaccinated hn male ci – time likely female receive hn vaccination – year old ci – ci – time willing year old considered accepting seasonal influenza vaccine time likely ci – principal barrier “ fear side effect ” “ unsure vaccine effectiveness ” although attended hnrelated talk hcws felt sufficient information wanted information vaccine safety profile contraindication conclusion fewer hcws expressed willingness receive hn vaccination lower past rate influenza vaccine hcws primary care clinic chronic condition perceive higher risk developing hnrelated complication willing rest hcws accept hn vaccination vaccine side effect effectiveness main concern uptake hn vaccine may improve targeted health information covering vaccine safety profile,2012-02-01,"Toh, Matthias Paul Han Sim; Kannan, Predeebha; Chen, Yongchang; Chng, Florence Liong Cheu; Tang, Wern Ee",Vaccine,,,,document_parses/pdf_json/8ac60c43cffb0af459331a7cab49bd236576741b.json,document_parses/pmc_json/PMC7127734.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X11019608; https://www.ncbi.nlm.nih.gov/pubmed/22178521/; https://doi.org/10.1016/j.vaccine.2011.12.037; https://api.elsevier.com/content/article/pii/S0264410X11019608,1469795.0,3
104534,104534,132926,byqhzyzi,2b7fa2b89a714a2f919546c37dbe56a7e4203ac0,Elsevier; Medline; PMC,Enterovirus 71 vaccine: close but still far,10.1016/j.ijid.2009.12.002,PMC7110504,20400350.0,els-covid,summary background enterovirus ev member enterovirus genus picornaviridae family one causative pathogen handfootandmouth disease hfmd common etiological agent isolated hfmd patient complicated neurological disorder ev become increasingly important neurotropic enterovirus postpoliomyelitis eradication era effective antiviral agent vaccine virus currently still development reviewed publication development ev vaccine order provide overview field method fiftyfive article ev vaccine development published collected sun yatsen university library reviewed result various type vaccine developed ev result published date vaccine ev development appear elicit immune response rodent monkey according established regulatory standard may relatively easy acquire license use inactivated virus order meet immediate demand ev control regard attenuated vaccine critical increase genetic stability clinical use due risk virulent revertants viruslike particle vlp vaccine conserving conformational epitope also risk virulent revertants another promising vaccine candidate ev need development vp capsid protein backbone antigen protein developing subunit vaccine epitope vaccine remain viable potential vaccine strategy worthy study development conclusion conservation threedimensional structure important ev inactivated vaccine vlp vaccine induce strong immune response develop ev vaccine high protection efficacy strategy use adjuvant strong promoter tissuespecific promoter addition mucosal immune adjuvant considered,2010-09-30,"Zhang, Dingmei; Lu, Jiayuan; Lu, Jiahai",International Journal of Infectious Diseases,,,,document_parses/pdf_json/2b7fa2b89a714a2f919546c37dbe56a7e4203ac0.json,document_parses/pmc_json/PMC7110504.xml.json,https://api.elsevier.com/content/article/pii/S1201971210023131; https://www.sciencedirect.com/science/article/pii/S1201971210023131; https://doi.org/10.1016/j.ijid.2009.12.002; https://www.ncbi.nlm.nih.gov/pubmed/20400350/,44988247.0,3
104542,104542,132937,d3oyf7j0,7a16fe9d867203bf83dfe50ef6dd93b8e1179db7,Medline; PMC,Immunization with Live Human Rhinovirus (HRV) 16 Induces Protection in Cotton Rats against HRV14 Infection,10.3389/fmicb.2017.01646,PMC5583225,28912760.0,cc-by,human rhinovirus hrvs main cause coldlike illness currently vaccine antiviral therapy hrvs available prevent mitigate hrv infection antigenically heterogeneous hrv serotypes ∼ hrvs belonging major group specie b development small animal model susceptible infection major group hrvs would beneficial vaccine research previously showed cotton rat sigmodon hispidus semipermissive hrv major group specie hrva virus infection replicating upper lower respiratory tract measurable pathology mucus production expression inflammatory mediator herein report intranasal infection cotton rat hrv major group specie hrvb virus result isolation infectious virus nose lung similar hrv intramuscular immunization live hrv induces homologous protection correlated high level serum neutralizing antibody vaccination challenge experiment hrv hrv evaluate development crossprotective immunity demonstrate intramuscular immunization live hrv significantly protects animal hrv challenge determination immunological mechanism involved heterologous protection characterization infection major hrv serotypes cotton rat could enhance robustness model define heterotypic relationship diverse group virus thereby increase potential development multiserotype hrv vaccine,2017-08-31,"Patel, Mira C.; Pletneva, Lioubov M.; Boukhvalova, Marina S.; Vogel, Stefanie N.; Kajon, Adriana E.; Blanco, Jorge C. G.",Front Microbiol,,,,document_parses/pdf_json/7a16fe9d867203bf83dfe50ef6dd93b8e1179db7.json,document_parses/pmc_json/PMC5583225.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28912760/; https://doi.org/10.3389/fmicb.2017.01646,22601905.0,3
104573,104573,132974,6kistim2,aa1c6214d417c22959df8d0b04c21713dc94d036,Medline; PMC,"Porcine epidemic diarrhoea virus: a comprehensive review of molecular epidemiology, diagnosis, and vaccines",10.1007/s11262-012-0713-1,PMC7089188,22270324.0,no-cc,porcine epidemic diarrhoea virus pedv member coronaviridae family cause acute diarrhoea dehydration pig although first identified europe become increasingly problematic many asian country including korea china japan philippine thailand economic impact pedv substantial given result significant morbidity mortality neonatal piglet associated increased cost related vaccination disinfection recently progress made understanding molecular epidemiology pedv thereby leading development new vaccine current review first describe molecular genetic characteristic pedv discus molecular epidemiology diagnosis vaccine available pedv treated,2012-01-22,"Song, Daesub; Park, Bongkyun",Virus Genes,,,,document_parses/pdf_json/aa1c6214d417c22959df8d0b04c21713dc94d036.json,document_parses/pmc_json/PMC7089188.xml.json,https://doi.org/10.1007/s11262-012-0713-1; https://www.ncbi.nlm.nih.gov/pubmed/22270324/,79482.0,3
104582,104582,132985,l8gszu1s,6469f23b0ff4f266e861252af11ab413d9682029,Medline; PMC,Safety and immunogenicity of a potential checkpoint blockade vaccine for canine melanoma,10.1007/s00262-018-2201-5,PMC7080056,30051333.0,no-cc,human immunotherapy checkpoint blockade achieved significant breakthrough recent year study checkpoint blockade vaccine canine melanoma tested safety immunogenicity five healthy adult dog received mixture three replicationdefective chimpanzeederived adenoviral vector one expressing mouse fibroblastassociated protein mfap others expressing canine melanomaassociated antigen trp trp fused herpes simplex glycoprotein checkpoint inhibitor herpes virus entry mediator hvem pathway vaccine mixture shown well tolerated increased frequency caninetrpspecific activated cd cd cell secreting interferonifnγ tumor necrosis factor tnfα interleukin il alone combination four five five dog respectively avoid excessive bleeds response ctrp analyzed dog responded increased frequency mfapspecific activated cd cd cell result safetyimmunogenicity trial invite testing checkpoint blockade vaccine combination dog melanoma electronic supplementary material online version article contains supplementary material available authorized user,2018-07-26,"Kurupati, Raj K.; Zhou, Xiangyang; Xiang, Zhiquan; Keller, Lorraine H.; Ertl, Hildegund C. J.",Cancer Immunol Immunother,,,,document_parses/pdf_json/6469f23b0ff4f266e861252af11ab413d9682029.json,document_parses/pmc_json/PMC7080056.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30051333/; https://doi.org/10.1007/s00262-018-2201-5,51724572.0,3
104616,104616,133029,t3q81z1e,12f92e293a8840feb11154daaf317dca3f5a48b6,Elsevier; Medline; PMC,Free and perfectly safe but only partially effective vaccines can harm everyone(),10.1016/j.geb.2020.05.001,PMC7207171,32395013.0,no-cc,risk compensation undermine ability partiallyeffective vaccine curb epidemic vaccinated agent may optimally choose engage risky interaction result may increase everyones infection probability show that—in contrast prediction standard models—things worse free perfectly safe partially effective vaccine reduce everyones welfare hence fail satisfy—in strong sense—the fundamental principle “ first harm ” main departure standard economic epidemiological model allow agent strategically choose partner show creates strategic complementarity risky interaction result introduction partiallyeffective vaccine lead much denser interaction structure—whose negative welfare effect overwhelm beneficial direct welfare effect intervention,2020-05-08,"Talamàs, Eduard; Vohra, Rakesh",Games Econ Behav,,,,document_parses/pdf_json/12f92e293a8840feb11154daaf317dca3f5a48b6.json,document_parses/pmc_json/PMC7207171.xml.json,https://www.sciencedirect.com/science/article/pii/S089982562030066X?v=s5; https://doi.org/10.1016/j.geb.2020.05.001; https://api.elsevier.com/content/article/pii/S089982562030066X; https://www.ncbi.nlm.nih.gov/pubmed/32395013/,218551678.0,3
104630,104630,133045,75yqvjdk,84317229254324b8c2da97e65895ab9529311fef,Elsevier; Medline; PMC,Outbreak response as an essential component of vaccine development,10.1016/s1473-3099(19)30305-6,PMC7106413,31256955.0,els-covid,summary coalition epidemic preparedness innovation cepi created result emerging global consensus coordinated international intergovernmental effort needed develop deploy new vaccine prevent future epidemic although disease outbreak relatively brief early outbreak response activity provide important opportunity make progress vaccine development cepi identified six area prepared work organisation global community combat priority pathogen including hypothetical disease x supporting early activity area even vaccine candidate yet available,2019-11-30,"Hatchett, Richard; Lurie, Nicole",The Lancet Infectious Diseases,,,,document_parses/pdf_json/84317229254324b8c2da97e65895ab9529311fef.json,document_parses/pmc_json/PMC7106413.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31256955/; https://doi.org/10.1016/s1473-3099(19)30305-6; https://www.sciencedirect.com/science/article/pii/S1473309919303056; https://api.elsevier.com/content/article/pii/S1473309919303056,195763640.0,3
104643,104643,133060,eq4obbte,df63498139215f0a8be1adb2fb21b5bcb0caa889,Elsevier; Medline; PMC,Rabies DNA vaccine: No impact of MHC Class I and Class II targeting sequences on immune response and protection against lethal challenge,10.1016/j.vaccine.2009.01.128,PMC7115670,19356616.0,els-covid,rabies progressive fatal encephalitis estimate rabies death million pep every year worldwide variety cellculture derived vaccine available prophylaxis rabies however high cost restricts usage developing country case often encountered driving quest newer vaccine formulation dna vaccine promising amongst explored strategy antigen trafficking various cellular compartment aiming improving humoral cellular immunity strategy include use signal sequence namely tissue plasminogen activator tpa ubiquitin uq lysosomalassociated membrane protein lamp tpa lamp combination aimed enhancing cd cell antibody response contrast uq tag utilized enhancing cd response potency modified dna vaccine assessed total antibody response antibody isotypes cytokine profile neutralizing antibody titer protection conferred vivo challenge enhanced comparison native unmodified vaccine response elicited pertain type target sequence directed arm immunity interestingly dna vaccine designed generate different type immune response yielded effect similar response conclusion data indicate directing target sequence exclusive deciding factor type extent immune response elicited emphasizes antigen dependence immune enhancement strategy,2009-03-26,"Kaur, Manpreet; Rai, Anant; Bhatnagar, Rakesh",Vaccine,,,,document_parses/pdf_json/df63498139215f0a8be1adb2fb21b5bcb0caa889.json,document_parses/pmc_json/PMC7115670.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19356616/; https://doi.org/10.1016/j.vaccine.2009.01.128; https://www.sciencedirect.com/science/article/pii/S0264410X0900200X; https://api.elsevier.com/content/article/pii/S0264410X0900200X,25441203.0,3
104653,104653,133073,rg366bk2,695c98c88802f05a1fe080f1f50ba04b1d6511f3,Elsevier; Medline; PMC,Testing for viral contaminants of veterinary vaccines in Hungary,10.1016/j.biologicals.2010.01.007,PMC7129912,20338783.0,els-covid,safety veterinary vaccine paramount importance significantly jeopardised extraneous agent bacteria mycoplasma chlamydia virus several critical step vaccine manufacture involve potential risk viral contamination virus extraneous agent divided two main group group agent pestivirus chicken anaemia virus cav egg drop syndrome virus edsv wellknown manufacturer authority compendial detection method clear guideline legislation established minimise risk contamination agent contrary group group agent like torque teno virus ttv rd replicationcompetent feline γretrovirus recently recognised role contaminant need investigation randomly selected veterinary vaccine used tested nucleic acid amplification cav edsv ttv pestivirus contamination examined vaccine used vaccine used based random selection vaccine addition random test done vaccine used batch live aujeszkys disease vaccine submitted laboratory official control authority batch release ocabr also tested pestivirus,2010-05-31,"Kulcsar, Gabor; Farsang, Attila; Soos, T.",Biologicals,,,,document_parses/pdf_json/695c98c88802f05a1fe080f1f50ba04b1d6511f3.json,document_parses/pmc_json/PMC7129912.xml.json,https://api.elsevier.com/content/article/pii/S1045105610000084; https://doi.org/10.1016/j.biologicals.2010.01.007; https://www.sciencedirect.com/science/article/pii/S1045105610000084; https://www.ncbi.nlm.nih.gov/pubmed/20338783/,45304850.0,3
104765,104765,133215,jrqhilgf,494c12e69a184761d961154377519151c9fd10c8,Elsevier; Medline; PMC,Attenuated live infectious bronchitis virus QX vaccine disseminates slowly to target organs distant from the site of inoculation,10.1016/j.vaccine.2019.11.064,PMC7115521,31822427.0,els-covid,infectious bronchitis ib highly contagious respiratory disease poultry caused avian coronavirus infectious bronchitis virus ibv currently one relevant genotype circulating worldwide ibvqx gi vaccine developed passaging virulent qx strain embryonated chicken egg explored attenuated phenotype commercially available qx live vaccine ib primo qx specific pathogen free broiler hatch bird inoculated qx vaccine virulent progenitor ibvd postmortem swab tissue collected day eight day post infection ass viral replication morphological change trachea viral rna replication protein expression comparable group virus induced morphologically comparable lesion trachea albeit short delay vaccinated bird contrast kidney qx vaccine viral rna nearly absent coincided lack morphological change organ contrast high viral rna titer abundant lesion kidney ibv infection furthermore qx vaccine showed reduced ability reach replicate conjunctiva intestine including cloaca resulting significantly lower titer delayed protein expression respectively nephropathogenic ibvs might reach kidney also via ascending route cloaca based observation viral rna detected cloaca one day detection kidney kidney distal tubular segment collecting duct ureter positive viral antigen taken together attenuated phenotype qx vaccine seems rely slower dissemination lower replication target tissue site inoculation,2020-02-05,"Laconi, A.; Weerts, E.A.W.S.; Bloodgood, J.C.G.; Deniz Marrero, J. P.; Berends, A. J.; Cocciolo, G.; de Wit, J. J.; Verheije, M. H.",Vaccine,,,,document_parses/pdf_json/494c12e69a184761d961154377519151c9fd10c8.json,document_parses/pmc_json/PMC7115521.xml.json,https://www.sciencedirect.com/science/article/pii/S0264410X19316184; https://api.elsevier.com/content/article/pii/S0264410X19316184; https://doi.org/10.1016/j.vaccine.2019.11.064; https://www.ncbi.nlm.nih.gov/pubmed/31822427/,209312692.0,3
104776,104776,133229,u2abo951,63ba7a9441e902d90110b076bd1e623ce4a0e1ab,Medline; PMC,"Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future",10.3390/vaccines2040707,PMC4494249,26344888.0,cc-by,serological technique commonly used quantify influenzaspecific antibody include haemagglutination inhibition hi single radial haemolysis srh virus neutralization vn assay hi srh established reproducible technique whereas vn demanding every new influenza vaccine need fulfil strict criterion issued european medicine agency ema order licensed criterion currently apply exclusively srh hi assay refer two different target groups—healthy adult elderly vaccine recipient age group considered ie child purpose timely review highlight current scenario correlate protection concerning influenza vaccine underline need revise criterion assay currently use addition srh hi assay technical advantage provided technique vn assay pseudotypebased neutralization assay neuraminidase cellmediated immunity assay need considered regulated via ema criterion considering many significant advantage could offer development effective vaccine,2014-10-13,"Trombetta, Claudia Maria; Perini, Daniele; Mather, Stuart; Temperton, Nigel; Montomoli, Emanuele",Vaccines (Basel),,,,document_parses/pdf_json/63ba7a9441e902d90110b076bd1e623ce4a0e1ab.json,document_parses/pmc_json/PMC4494249.xml.json,https://doi.org/10.3390/vaccines2040707; https://www.ncbi.nlm.nih.gov/pubmed/26344888/,16416761.0,3
104799,104799,133260,1spgrrmw,2e18ad30b21c44e8b5e1f54fc015ce512c19e1a7,Medline; PMC,Molecular aspects of MERS-CoV,10.1007/s11684-017-0521-z,PMC7089120,28500431.0,no-cc,middle east respiratory syndrome coronavirus merscov betacoronavirus cause acute respiratory distress human associated relatively high mortality rate since first identified patient died jeddah hospital world health organization notified laboratoryconfirmed case country including death case occurred saudi arabia merscovancestors may found oldworld bat vespertilionidae family proposed bat camel switching event transmission merscov human likely result multiple zoonotic transfer dromedary camel humantohuman transmission appears require close contact infected person outbreak mainly occurring hospital environment outbreak associated inadequate infection prevention control implementation resulting recommendation basic advanced infection prevention control measure world health organization issuing government guideline based recommendation affected country including saudi arabia evolutionary change virus particularly viral spike protein mediates virushost cell contact may potentially increase transmission virus effort ongoing identify specific evidencebased therapy vaccine broadspectrum antiviral nitazoxanide shown vitro activity merscov synthetic peptide candidate vaccine based region spike protein shown promise rodent nonhuman primate model gls prophylactic dnaplasmid vaccine encoding protein first merscov vaccine tested human monoclonal antibody given promising result animal model potential use outbreak situation,2017-05-13,"Rabaan, Ali A.; Bazzi, Ali M.; Al-Ahmed, Shamsah H.; Al-Tawfiq, Jaffar A.",Front Med,,,,document_parses/pdf_json/2e18ad30b21c44e8b5e1f54fc015ce512c19e1a7.json,,https://doi.org/10.1007/s11684-017-0521-z; https://www.ncbi.nlm.nih.gov/pubmed/28500431/,207302475.0,3
104818,104818,133285,dqs21e0q,1238290e9600f11ae2728a4aa0a711e4b9511211,Elsevier; Medline; PMC; WHO,Trained immunity: a tool for reducing susceptibility and severity of SARS-CoV-2 infection,10.1016/j.cell.2020.04.042,PMC7196902,32437659.0,els-covid,sarscov infection mild majority individual progress severe pneumonia small proportion patient increased susceptibility severe disease elderly individual comorbidities argues initial defect antiviral host defense mechanism longterm boosting innate immune response also termed ‘ trained immunity ’ certain live vaccine bcg oral polio vaccine measles induces heterologous protection infection epigenetic transcriptional functional reprogramming innate immune cell propose induction trained immunity whole microorganism vaccine may represent important tool reducing susceptibility severity sarscov,2020-05-04,"Netea, Mihai G.; Giamarellos-Bourboulis, Evangelos J.; Domínguez-Andrés, Jorge; Curtis, Nigel; van Crevel, Reinout; van de Veerdonk, Frank L.; Bonten, Marc",Cell,,#125393,,document_parses/pdf_json/1238290e9600f11ae2728a4aa0a711e4b9511211.json,,https://www.ncbi.nlm.nih.gov/pubmed/32437659/; https://www.sciencedirect.com/science/article/pii/S0092867420305079?v=s5; https://api.elsevier.com/content/article/pii/S0092867420305079; https://doi.org/10.1016/j.cell.2020.04.042,218482335.0,3
104837,104837,133322,mx5k92un,8b04b876333c5f04650b8f9415d440431abd209c,Elsevier; Medline; PMC,Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice,10.1016/j.vaccine.2014.08.058,PMC7115510,25192975.0,els-covid,new type coronavirus identified causative agent underlying middle east respiratory syndrome mers mers coronavirus merscov spread middle east case originating middle east also occurred european union usa eight hundred thirtyseven case merscov infection confirmed date including death merscov infected dromedary camel population middle east high rate representing immediate source human infection merscov spike protein characteristic structural component viral envelope considered key target vaccine coronavirus infection initial attempt develop merscov vaccine ultimately target dromedary camel constructed two recombinant adenoviral vector encoding fulllength merscov protein admerss extracellular domain protein admerss balbc mouse immunized candidate vaccine intramuscularly boosted three week later intranasally vaccinated animal antibody response spike protein neutralized merscov vitro result show adenoviralbased vaccine induce merscovspecific immune response mouse hold promise development preventive vaccine target animal reservoir might effective measure eliminate transmission merscov human,2014-10-14,"Kim, Eun; Okada, Kaori; Kenniston, Tom; Raj, V. Stalin; AlHajri, Mohd M.; Farag, Elmoubasher A.B.A.; AlHajri, Farhoud; Osterhaus, Albert D.M.E.; Haagmans, Bart L.; Gambotto, Andrea",Vaccine,,,,document_parses/pdf_json/8b04b876333c5f04650b8f9415d440431abd209c.json,document_parses/pmc_json/PMC7115510.xml.json,https://api.elsevier.com/content/article/pii/S0264410X14011992; https://www.sciencedirect.com/science/article/pii/S0264410X14011992; https://www.ncbi.nlm.nih.gov/pubmed/25192975/; https://doi.org/10.1016/j.vaccine.2014.08.058,43140395.0,3
104864,104864,133358,vxaut12z,0435e76b6c0f0c7adc362a7df0667721beb14af0,Medline; PMC,Vaccines and Vaccination for Veterinary Viral Diseases: A General Overview,10.1007/978-1-4939-3008-1_1,PMC7115012,26458826.0,no-cc,high number infectious disease affecting livestock companion animal caused pathogen viral etiology ensuring maximum standard quality welfare animal production requires developing effective tool halt prevent spread infectious disease affecting animal husbandry date one best strategy implement vaccination policy whenever possible however many currently manufactured vaccine relies classical vaccine technology killed attenuated vaccine circumstance may optimal term safety adequate widespread application diseasefree country risk disease introduction one step ahead needed improve adapt vaccine manufacturing use new generation vaccine technology already tested experimental setting present context animal viral disease veterinary interest overview current vaccine technology approached virus pathogen brief insight type immunity elicited,2015-06-01,"Brun, Alejandro",Vaccine Technologies for Veterinary Viral Diseases,,,,document_parses/pdf_json/0435e76b6c0f0c7adc362a7df0667721beb14af0.json,document_parses/pmc_json/PMC7115012.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/26458826/; https://doi.org/10.1007/978-1-4939-3008-1_1,20256534.0,3
104915,104915,133419,dcui85lw,f25b4e8858297fd2716bfbf5c5c5d4dc95e9fec1,Elsevier; PMC,Chapter 59 Respiratory Virus Vaccines,10.1016/b978-0-12-415847-4.00059-8,PMC7149605,,els-covid,chapter review main viral pathogen respiratory tract immune response induce currently available vaccine vaccine development control main virus responsible acute respiratory infection people include respiratory syncytial influenza human parainfluenza human metapneumo human rhino corona adenovirus licensed vaccine available influenza virus vaccine pathogen either clinical trial preclinical stage development majority study evaluating respiratory virus vaccine measure serum antibody response although cellular humoral response contribute clearance primary infection neutralizing antibody known protect secondary infection humoral response readily detected vaccination inactivated subunit vaccine however fewer individual seroconvert vaccination live vaccine alternative immune mechanism mucosal antibody response probably responsible protection live attenuated vaccine immune correlate protection investigation,2015-12-31,"Broadbent, Andrew J.; Boonnak, Kobporn; Subbarao, Kanta",Mucosal Immunology,,,,document_parses/pdf_json/f25b4e8858297fd2716bfbf5c5c5d4dc95e9fec1.json,document_parses/pmc_json/PMC7149605.xml.json,https://www.sciencedirect.com/science/article/pii/B9780124158474000598; https://api.elsevier.com/content/article/pii/B9780124158474000598,38661831.0,3
104958,104958,133471,gkm4g6co,31047a34b6e7cfe9ebd619ed6f518b5e983fd650,Medline; PMC,Emergence and genetic analysis of variant pathogenic 4/91 (serotype 793/B) infectious bronchitis virus in Egypt during 2019,10.1007/s11262-019-01693-9,PMC7088710,31372921.0,no-cc,infectious bronchitis virus ibv affect vaccinated unvaccinated flock worldwide significant impact poultry industry aim present study characterize emerging variant pathogenic ibv originating field outbreak vaccinated egyptian layer flock sample collected diseasesuspected flock history administration live inactivated ibv vaccine type virus propagation embryonated chicken egg eces three successive passage revealed typical ibv lesion curling dwarfism reported isolate identified realtime reverse transcriptase pcr assay targeting nucleocapsid n gene characterized fulllength spike gene sequencing phylogenetic analysis revealed clustering isolated virus within genotype gi lineage deduced amino acid sequence identity revealed – – similarity currently used classic h variant vaccine strain cr egypt respectively recombination analysis gave evidence distinct pattern origin studied isolate providing another example intragenotypic recombination among ibvs first example recombination within gi lineage egyptian field studied isolate ibvckegfadllah emerged result recombination variant group egyvar genotype gi lineage major parent cr variant vaccine strain genotype gi lineage minor parent data suggest mutation recombination may contributing emergence ibv variant ascertain importance disease monitoring vaccinated flock well reappropriation current vaccine strategy electronic supplementary material online version article contains supplementary material available authorized user,2019-08-01,"Rohaim, Mohammed A.; El Naggar, Rania F.; Hamoud, Mohamed M.; Bazid, Abdel-Hamid I.; Gamal, Abdulrhman M.; Laban, Samah E.; Abdel-Sabour, Mohammed A.; Nasr, Shimaa A. E.; Zaki, Manal M.; Shabbir, Muhammad Z.; Zahran, Osama K.; Munir, Muhammad",Virus Genes,,,,document_parses/pdf_json/31047a34b6e7cfe9ebd619ed6f518b5e983fd650.json,,https://doi.org/10.1007/s11262-019-01693-9; https://www.ncbi.nlm.nih.gov/pubmed/31372921/,199380037.0,3
104965,104965,133481,63yvpuqx,96617d15b023d538e1103dd1dc77d23f7f4ec63b,Medline; PMC,Detection and activation of HIV broadly neutralizing antibody precursor B cells using anti-idiotypes,10.1084/jem.20190164,PMC6780997,31345930.0,cc-by-nc-sa,many tested vaccine fail provide protection disease despite induction antibody bind pathogen interest light much interest rationally designed subunit vaccine direct antibody response protective epitope produced panel antiidiotype antibody able specifically recognize inferred germline version human immunodeficiency virus hiv broadly neutralizing antibody b iglb determined crystal structure two antiidiotypes complex iglb used antiidiotypes identify rare naive human b cell expressing b cell receptor similarity iglb immunization multimerized version antiidiotype induced proliferation transgenic murine b cell expressing iglb heavy chain vivo despite presence deletion anergy within population together data indicate antiidiotypes valuable tool study induction potentially protective antibody,2019-10-07,"Bancroft, Tara; DeBuysscher, Blair L.; Weidle, Connor; Schwartz, Allison; Wall, Abigail; Gray, Matthew D.; Feng, Junli; Steach, Holly R.; Fitzpatrick, Kristin S.; Gewe, Mesfin M.; Skog, Patrick D.; Doyle-Cooper, Colleen; Ota, Takayuki; Strong, Roland K.; Nemazee, David; Pancera, Marie; Stamatatos, Leonidas; McGuire, Andrew T.; Taylor, Justin J.",J Exp Med,,,,document_parses/pdf_json/96617d15b023d538e1103dd1dc77d23f7f4ec63b.json,document_parses/pmc_json/PMC6780997.xml.json,https://doi.org/10.1084/jem.20190164; https://www.ncbi.nlm.nih.gov/pubmed/31345930/,198911385.0,3
104979,104979,133498,35dqn861,c5b9e163cb1a1071368da7bbb3f16382199cbc81,Elsevier; PMC,Chapter 8 Omics and Edible Vaccines,10.1016/b978-0-12-815870-8.00008-5,PMC7150077,,els-covid,molecular farming provides unprecedented approach production metabolite protein medicinal value plant used previously agricultural setting plant act protein factory synthesize variety protein free pathogen plasma protein growth factor vaccine method provides novel tempting inexpensive easy safe alternative technique protein antigen production advent transgenic plant possible produce unlimited amount subunit vaccine oral useedible parenteral use protein used pharmaceuticalmedicinal purpose recombinant protein antibody industrial enzyme plant numerous advantage production system account scalability safety economic example le cost production involved hepatitis b nucleocapsid antigen using transgenic tobacco biopharming molecular farming provides important resource cheaper drug production used treatment cancer heart disease infectious disease pharmaceutical product manufactured genetically engineered plant extracted purified also known pharmaceutical produced plant edible vaccine cheaper cost easy administer mostly oral route failsafe acceptable society especially developing country vaccine targeted provide systemic well mucosal type immunity predicted future child may get immunization munching food instead getting enduring shot production edible vaccine consists process introducing selected gene desired quality plant induce altered transgenic plant produce encoded protein natural way vaccine provide safer alternative help reduction cost production shipping also decrease potential hazard associated conventional vaccine however becoming reality readily availability edible vaccine challenged many problem technical regulatory nonscientific issue ruled rectified chapter provides insight current scenario future application new preventive modality,2018-12-31,"Munshi, Anjana; Sharma, Vandana",Omics Technologies and Bio-Engineering,,,,document_parses/pdf_json/c5b9e163cb1a1071368da7bbb3f16382199cbc81.json,document_parses/pmc_json/PMC7150077.xml.json,https://www.sciencedirect.com/science/article/pii/B9780128158708000085; https://api.elsevier.com/content/article/pii/B9780128158708000085,90985548.0,3
104992,104992,133512,1n0o6w67,36eaec58a5d37602d2932074f554858a22acdfe3,Elsevier; PMC,"Pulmonary DNA vaccination: Concepts, possibilities and perspectives",10.1016/j.jconrel.2005.05.028,PMC7114572,16054263.0,els-covid,mucosal immunity establishes first line defence pathogen entering body via mucosal surface besides eliciting local systemic immunity mucosal vaccination strategy noninvasive nature may increase patient compliance reduce need vaccine application trained personnel relatively new concept mucosal immunization using dna vaccine advantage dna vaccine opportunity combine genetic information various antigen epitope stimulatory cytokine enhanced stability ease production make class vaccine attractive suitable mucosal application contrast area intranasal vaccination recent study focused pulmonary immunization involvement pulmonary immune system eliciting protective immune response inhaled pathogen review focus dna vaccine delivery lung promising approach prevent pulmonaryassociated disease caused inhaled pathogen attractive immunological feature lung site immunization mechanism action dna vaccine pulmonary application vaccine using novel delivery system discussed also examine pulmonary disease prone prevention therapeutical intervention application dna vaccine,2005-09-20,"Bivas-Benita, Maytal; Ottenhoff, Tom H.M.; Junginger, Hans E.; Borchard, Gerrit",Journal of Controlled Release,,,,document_parses/pdf_json/36eaec58a5d37602d2932074f554858a22acdfe3.json,document_parses/pmc_json/PMC7114572.xml.json,https://api.elsevier.com/content/article/pii/S016836590500266X; https://www.sciencedirect.com/science/article/pii/S016836590500266X,6323398.0,3
105005,105005,133535,kx43u0n4,b4a0898920270c599908b3efbf4f7342a8b56c8e,Medline; PMC,Nod2 is required for antigen-specific humoral responses against antigens orally delivered using a recombinant Lactobacillus vaccine platform,10.1371/journal.pone.0196950,PMC5937747,29734365.0,cc-by,safe efficacious orallydelivered mucosal vaccine platform desperately needed combat plethora mucosally transmitted pathogen lactobacillus spp emerged attractive candidate meet need known activate host innate immune response specie strainspecific manner selected bacterial isolates mutant investigated role key innate immune pathway required induction innate subsequent adaptive immune response coculture murine macrophage l gasseri strain nck l acidophilus strain ncfm ncfmderived mutants—nck nck—elicited mblike phenotype associated th skewing immune regulatory function ncfm mb phenotype dependent expression lipoteichoic acid layer protein use macrophage genetic knockout identified tolllike receptor tlr cytosolic nucleotidebinding oligomerization domain containing nod receptor inflammasomeassociated caspase contributor macrophage activation nod cooperating caspase induce inflammasome derived interleukin ilβ pyroptosisindependent fashion finally utilizing ncfmbased mucosal vaccine platform surface expression human immunodeficiency virus type hiv gag membrane proximal external region mper demonstrated nod signaling required antigenspecific mucosal systemic humoral response show lactobacillus differentially utilize innate immune pathway highlight nod key mediator macrophage function antigenspecific humoral response lactobacillus acidophilus mucosal vaccine platform,2018-05-07,"Bumgardner, Sara A.; Zhang, Lin; LaVoy, Alora S.; Andre, Barbara; Frank, Chad B.; Kajikawa, Akinobu; Klaenhammer, Todd R.; Dean, Gregg A.",PLoS One,,,,document_parses/pdf_json/b4a0898920270c599908b3efbf4f7342a8b56c8e.json,document_parses/pmc_json/PMC5937747.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/29734365/; https://doi.org/10.1371/journal.pone.0196950,13687451.0,3
105056,105056,133597,p8qbxi57,b149eb40c3b58f04a6ebc5dd0adaab13e19fa572,Elsevier; PMC,The interference by maternally-derived antibody with active immunization of farm animals against foot-and-mouth disease,10.1016/s0007-1935(95)80127-8,PMC7130139,7552194.0,els-covid,summary footandmouth disease fmd highly contagious disease affectingruminants pig country control fmd relies predominantly vaccination young stock ingest specific antifmd virus antibody colostrum maternallyderived antibody mda provides immediate protection infection fmd virus also interferes development active immunity following vaccination however susceptibility infection precedes ability respond vaccination presence mda currently available vaccine overcome inhibitory effect mda protection young stock provided isolation fmd virus,1995-12-31,"Kitching, R. P.; Salt, J. S.",British Veterinary Journal,,,,document_parses/pdf_json/b149eb40c3b58f04a6ebc5dd0adaab13e19fa572.json,,https://www.sciencedirect.com/science/article/pii/S0007193595801278; https://api.elsevier.com/content/article/pii/S0007193595801278,44527018.0,3
105104,105104,133658,whrblh1b,4eea4c989b10f3f5a235693877b8df2aa4c72522,Elsevier; PMC,A placebo-controlled trial of two intranasal vaccines to prevent tracheobronchitis (kennel cough) in dogs entering a humane shelter,10.1016/j.prevetmed.2003.10.001,PMC7126306,15156996.0,els-covid,placebocontrolled field trial conducted compare effectiveness intranasal vaccine containing bordetella bronchiseptica canineparainfluenza virus inbpa without inbp canineadenovirus type prevention kennel cough humane shelter dog examined admission shelter without respiratory sign disease assigned daily rotating basis receive one three vaccine enrolled healthy dog dog monitored day postvaccination coughing clinical sign respiratory disease thirtythree confidence interval ci dog inbp group ci dog inbpa group ci dog inp group coughed spontaneously ≥ day within day vaccination p inbp inbpa vaccine effective respectively reducing coughing compared placebo vaccine strongest prognostic factor coughing regardless vaccine group number day spent shelter additional day increasing risk coughing ci low incidence coughing shelter study precluded observation difference vaccine effectiveness difference vaccineassociated adverse event coughing sneezing nasal ocular discharge noted first day postadministration thereafter,2004-02-26,"Edinboro, Charlotte H.; Ward, Michael P.; Glickman, Larry T.",Preventive Veterinary Medicine,,,,document_parses/pdf_json/4eea4c989b10f3f5a235693877b8df2aa4c72522.json,document_parses/pmc_json/PMC7126306.xml.json,https://www.sciencedirect.com/science/article/pii/S0167587703002769; https://api.elsevier.com/content/article/pii/S0167587703002769,36416992.0,3
105150,105150,133711,2071v9fu,5b45de2f44dbed76d9997f1088e62c4dfcd82a72,Elsevier; Medline; PMC,A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection,10.1016/j.virol.2016.10.005,PMC5167628,27750111.0,els-covid,middle east respiratory syndrome mers coronavirus merscov first identified continues threaten human health worldwide mers vaccine licensed human use reinforcing urgency develop safe efficacious vaccine prevent mers merscov spike protein form trimer receptorbinding domain rbd serf vaccine target nevertheless protective efficacy rbd native trimeric form never evaluated study trimeric protein rbdfd generated fusing rbd foldon trimerization motif bound strongly receptor merscov dipeptidyl peptidase dpp elicited robust rbdspecific neutralizing antibody mouse maintaining longterm neutralizing activity merscov infection rbdfd potently protected hdpp transgenic mouse lethal merscov challenge result suggest merscov rbd trimeric form maintains native conformation induces protective neutralizing antibody making candidate therapeutic development,2016-12-31,"Tai, Wanbo; Zhao, Guangyu; Sun, Shihun; Guo, Yan; Wang, Yufei; Tao, Xinrong; Tseng, Chien-Te K.; Li, Fang; Jiang, Shibo; Du, Lanying; Zhou, Yusen",Virology,,,,document_parses/pdf_json/5b45de2f44dbed76d9997f1088e62c4dfcd82a72.json,document_parses/pmc_json/PMC5167628.xml.json,https://www.sciencedirect.com/science/article/pii/S0042682216303002; https://doi.org/10.1016/j.virol.2016.10.005; https://api.elsevier.com/content/article/pii/S0042682216303002; https://www.ncbi.nlm.nih.gov/pubmed/27750111/,4642568.0,3
105179,105179,133748,45hi4iz2,9a9f7135f8ea0664e278c913bc12bb1413b09d4c,Medline; PMC,Establishment of a Bluetongue Virus Infection Model in Mice that Are Deficient in the Alpha/Beta Interferon Receptor,10.1371/journal.pone.0005171,PMC2663843,19357779.0,cc-by,bluetongue bt noncontagious insecttransmitted disease ruminant caused bluetongue virus btv laboratory animal model would greatly facilitate study pathogenesis immune response vaccination btv herein show adult mouse deficient type ifn receptor ifnar−− highly susceptible btv btv infection virus administered intravenously disease characterized ocular discharge apathy starting hour postinfection quickly leading animal death within hour inoculation infectious virus recovered spleen lung thymus lymph node indicating systemic infection addition lymphoid depletion spleen severe pneumonia observed infected mouse furthermore ifnar−− adult mouse immunized btv inactivated vaccine showed induction neutralizing antibody btv complete protection challenge lethal dose virus data indicate mouse model may facilitate study btv pathogenesis development new effective vaccine btv,2009-04-09,"Calvo-Pinilla, Eva; Rodríguez-Calvo, Teresa; Anguita, Juan; Sevilla, Noemí; Ortego, Javier",PLoS One,,,,document_parses/pdf_json/9a9f7135f8ea0664e278c913bc12bb1413b09d4c.json,document_parses/pmc_json/PMC2663843.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/19357779/; https://doi.org/10.1371/journal.pone.0005171,921150.0,3
105245,105245,133827,uxnbie09,8003a720b0a0e15fc535a39d7ae6d7a444a2cb4c; 1a9597a57cd6c3255a954c3a466dc211f5673382,Elsevier; PMC,Alpha-beta T cells provide protection against lethal encephalitis in the murine model of VEEV infection,10.1016/j.virol.2007.05.041,PMC2067255,17610927.0,green-oa,evaluated safety immunogenicity chimeric alphavirus vaccine candidate mouse selective immunodeficiency vaccine candidate highly attenuated mouse deficiency b cell compartment well mouse deficient gammainterferon responsiveness however level protection varied among strain tested wild type mouse protected lethal veev challenge contrast alphabeta αβ tcrdeficient mouse developed lethal encephalitis following veev challenge mouse deficient gammadelta γδ cell protected surprisingly vaccine potency diminished animal lacking interferongamma receptor alpha chain rchain minority vaccinated immunoglobulin heavy chaindeficient μmt mouse survived challenge suggests neutralizing antibody may absolutely required protection prolonged replication encephalitic veev brain preimmunized mouse lethal adoptive transfer experiment indicate cd cell required protection,2007-10-01,"Paessler, Slobodan; Yun, Nadezhda E.; Judy, Barbara M.; Dziuba, Natallia; Zacks, Michele A.; Grund, Anna H.; Frolov, Ilya; Campbell, Gerald A.; Weaver, Scott C.; Estes, D. Mark",Virology,,,,document_parses/pdf_json/8003a720b0a0e15fc535a39d7ae6d7a444a2cb4c.json; document_parses/pdf_json/1a9597a57cd6c3255a954c3a466dc211f5673382.json,document_parses/pmc_json/PMC2067255.xml.json,https://www.sciencedirect.com/science/article/pii/S0042682207004035; https://api.elsevier.com/content/article/pii/S0042682207004035; http://europepmc.org/articles/pmc2067255?pdf=render,13238238.0,3
105323,105323,133920,vioqjrko,f908bca6a7e32a9bd496fcd234f08605131e555a,Medline; PMC,Issues in vaccinology: Present challenges and future directions,10.1002/eji.201746942,PMC7163762,28861908.0,no-cc,vaccination principal highly cost‐effective mean controlling infectious disease providing direct protection pathogen conferring long‐lasting immunological memory inducing population‐level herd immunity despite rapid ongoing progress vaccinology remain many obstacle development deployment novel improved vaccine include underlying science induce sustain appropriate protective immune response well bureaucratic logistic socio‐political hurdle failure distribute administer existing vaccine at‐risk community continues account large proportion infant mortality worldwide almost million child access basic vaccine several million still die year result emerging epidemic pandemic disease pose significant threat global health prosperity many infectious disease provide continuous cyclical burden healthcare system also need addressed gap knowledge human immune system stand way developing technology overcome individual pathogenic variation challenge tackling infectious disease direction field preventive medicine may take improve current picture global health focus review,2017-09-27,"Sheerin, Dylan; Openshaw, Peter JM; Pollard, Andrew J",Eur J Immunol,,,,document_parses/pdf_json/f908bca6a7e32a9bd496fcd234f08605131e555a.json,document_parses/pmc_json/PMC7163762.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/28861908/; https://doi.org/10.1002/eji.201746942,4534013.0,3
105329,105329,133926,nxn63xbw,9b3127bf657a3117c2c1f4543e01ee068a9fb0bf,Elsevier; Medline; PMC,Virus-like particles as a highly efficient vaccine platform: Diversity of targets and production systems and advances in clinical development,10.1016/j.vaccine.2012.10.083,PMC7115575,23142589.0,els-covid,viruslike particle vlps class subunit vaccine differentiate soluble recombinant antigen stronger protective immunogenicity associated vlp structure like parental virus vlps either nonenveloped enveloped form following expression one several viral structural protein recombinant heterologous system depending complexity vlp produced either prokaryotic eukaryotic expression system using targetencoding recombinant vector case assembled cellfree condition date wide variety vlpbased candidate vaccine targeting various viral bacterial parasitic fungal pathogen well noninfectious disease produced different expression system vlps entered clinical development licensed commercialized article review vlpbased vaccine produced different system immunogenicity animal model status clinical development,2012-12-17,"Kushnir, Natasha; Streatfield, Stephen J.; Yusibov, Vidadi",Vaccine,,,,document_parses/pdf_json/9b3127bf657a3117c2c1f4543e01ee068a9fb0bf.json,document_parses/pmc_json/PMC7115575.xml.json,https://api.elsevier.com/content/article/pii/S0264410X12015563; https://doi.org/10.1016/j.vaccine.2012.10.083; https://www.sciencedirect.com/science/article/pii/S0264410X12015563; https://www.ncbi.nlm.nih.gov/pubmed/23142589/,205591561.0,3
105339,105339,133941,3a9vjpvn,b3e090d13dc03080e5316be2e1cef9bb3bc45cdf,Medline; PMC,Synthetic biology for bioengineering virus‐like particle vaccines,10.1002/bit.26890,PMC7161758,30597533.0,no-cc,vaccination effective method disease prevention control many virus bacteria caused catastrophic pandemic eg smallpox poliomyelitis measles diphtheria either eradicated effectively controlled routine vaccination program nonetheless vaccine manufacturing remains incredibly challenging virus exhibiting high antigenic diversity high mutation rate fairly contested using traditional vaccine production method complexity surrounding manufacturing process impose significant limitation virus‐like particle vlps recombinantly produced viral structure exhibit immunoprotective trait native virus noninfectious several vlps compositionally match given natural virus developed licensed vaccine expansively plethora study confirms vlps designed safely present heterologous antigen variety pathogen unrelated chosen carrier vlps owing design versatility vlps offer technological opportunity modernize vaccine supply disease response rational bioengineering opportunity greatly enhanced application synthetic biology redesign construction novel biological entity review outline synthetic biology currently applied engineer vlp function manufacturing process current developing technology identification novel target‐specific antigen usefulness rational engineering vlp function eg presentation structurally diverse antigen enhanced antigen immunogenicity improved vaccine stability described applied manufacturing process synthetic biology approach also overcome specific challenge vlp vaccine production finally address several challenge benefit associated translation vlp vaccine development industry,2018-12-31,"Charlton Hume, Hayley K.; Vidigal, João; Carrondo, Manuel J. T.; Middelberg, Anton P. J.; Roldão, António; Lua, Linda H. L.",Biotechnol Bioeng,,,,document_parses/pdf_json/b3e090d13dc03080e5316be2e1cef9bb3bc45cdf.json,document_parses/pmc_json/PMC7161758.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/30597533/; https://doi.org/10.1002/bit.26890,58667133.0,3
105426,105426,134041,1jikrn37,0e12e3191e6ce998f711be57eba12fe211dd3f72,Elsevier; Medline; PMC,Immunogenicity assay of the Leishmune(®) vaccine against canine visceral leishmaniasis in Brazil,10.1016/j.vaccine.2008.07.029,PMC7173152,18675868.0,no-cc,leishmune® industrialized version fmlsaponin vaccine shown develop – protection vaccinated dog – vaccine efficacy field canine visceral leishmaniasis cvl brazil leishmune® proven safe tolerable transmissionblocking vaccine render vaccinated dog noninfectious sand fly vector present investigation healthy seronegative dog endemic epidemic area brazil monitored leishmune®induced immunogenicity year trial another group untreated exposed dog also studied parallel group seronegative day strong immunogenicity induced leishmune® vaccine demonstrated fmlseroconversion increase absorbency dth positive reaction increase skin test size diameter average increase cd total lymphocyte population blood expected q saponincontaining vaccine sustained proportion cd cell average increased proportion cd b lymphocyte leishmune®induced protection cvl demonstrated result asymptomatic dog end first year healthy survivor end second year among vaccinated dog compared asymptomatic survivor dog p monitored untreated exposed cohort spite low vaccine coverage possible detect p reduction belo horizonte p reduction araçatuba incidence cvl among vaccinated dog compared global incidence cvl town respectively preliminary result support potential use leishmune® prevent cvl epidemic,2008-09-15,"Borja-Cabrera, G.P.; Santos, F.N.; Bauer, F.S.; Parra, L.E.; Menz, I.; Morgado, A.A.; Soares, I.S.; Batista, L.M.M.; Palatnik-de-Sousa, C.B.",Vaccine,,,,document_parses/pdf_json/0e12e3191e6ce998f711be57eba12fe211dd3f72.json,document_parses/pmc_json/PMC7173152.xml.json,https://api.elsevier.com/content/article/pii/S0264410X08009730; https://doi.org/10.1016/j.vaccine.2008.07.029; https://www.sciencedirect.com/science/article/pii/S0264410X08009730; https://www.ncbi.nlm.nih.gov/pubmed/18675868/,23262512.0,3
105434,105434,134049,ljlo42ry,4f737481c074112fffd66bb6048fb46931406baf,Elsevier; PMC,Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines,10.1016/j.virol.2006.03.049,PMC7111904,16793110.0,els-covid,development effective vaccine severe acute respiratory syndrome sars remains priority prevent possible reemergence sars coronavirus sarscov previously demonstrated receptorbinding domain rbd sarscov protein major target neutralizing antibody suggests rbd may serve ideal vaccine candidate recombinant adenoassociated virus raav proven effective system gene delivery vaccine development study novel vaccine sarscov developed based raav delivery system gene encoding rbd cloned paavireshrgfp plasmid immunogenicity induced resulting recombinant rbdraav evaluated balbc mouse result demonstrated single dose rbdraav vaccination could induce sufficient neutralizing antibody sarscov infection two repeated dos vaccination boosted neutralizing antibody time level achieved single dose immunization level antibody continued increase entire duration experiment month result suggested rbdraav promising sars candidate vaccine,2006-09-15,"Du, Lanying; He, Yuxian; Wang, Yijia; Zhang, Haojie; Ma, Selene; Wong, Charlotte K.L.; Wu, Sharon H.W.; Ng, Fai; Huang, Jian-Dong; Yuen, Kwok-Yung; Jiang, Shibo; Zhou, Yusen; Zheng, Bo-Jian",Virology,,,,document_parses/pdf_json/4f737481c074112fffd66bb6048fb46931406baf.json,document_parses/pmc_json/PMC7111904.xml.json,https://api.elsevier.com/content/article/pii/S0042682206002352; https://www.sciencedirect.com/science/article/pii/S0042682206002352,28283190.0,3
105482,105482,134113,t8vorgje,c2d64f7e6452161fdf14a03c0513594d47c79be7,Elsevier; Medline; PMC,Developing and financing neglected disease vaccines in our new era of “blue marble health” and the anthropocene epoch,10.1016/j.vaccine.2017.02.002,PMC7126365,28262333.0,els-covid,new finding widespread neglected disease among poor living wealthy group g economy concept “ blue marble health ” offer innovative mechanism financing urgently new vaccine especially vectorborne neglected tropical disease ntds approach could complement parallel recently suggested global vaccine development fund pandemic threat,2017-09-25,"Hotez, Peter J.",Vaccine,,,,document_parses/pdf_json/c2d64f7e6452161fdf14a03c0513594d47c79be7.json,document_parses/pmc_json/PMC7126365.xml.json,https://api.elsevier.com/content/article/pii/S0264410X17301652; https://doi.org/10.1016/j.vaccine.2017.02.002; https://www.ncbi.nlm.nih.gov/pubmed/28262333/; https://www.sciencedirect.com/science/article/pii/S0264410X17301652,3883018.0,3
105484,105484,134115,pux58dut,89da54123ba1ef030869fd671971dd907fc7feae,Elsevier; Medline; PMC,Engineering DNA vaccines against infectious diseases,10.1016/j.actbio.2018.08.033,PMC7105045,30172933.0,els-covid,engineering vaccinebased therapeutic infectious disease highly challenging trial formulation often found nonspecific ineffective thermally hydrolytically unstable andor toxic vaccine greatly improved therapeutic landscape treating infectious disease significantly reduced threat therapeutic preventative approach furthermore advent recombinant technology greatly facilitated growth within vaccine realm mitigating risk virulence reversion despite making production process cumbersome addition seroconversion also enhanced recombinant technology kinetic nonkinetic approach discussed herein recombinant technology greatly improved amino acidbased vaccine dnabased vaccine plateau interest reached scientific community regard dna vaccine endeavor decrease interest may likely attributed difficulty improving immunogenic property associated dna vaccine although research demonstrating improvement optimization end despite improvement extent knowledge currently regulatory bodyapproved dna vaccine human use four vaccine approved animal use article discus engineering dna vaccine infectious disease discussing advantage disadvantage emphasis application dna vaccine statement significance review paper summarizes state engineeredrecombinant dna vaccine field scope entailing “ engineering dna vaccine infectious disease ” endeavor emphasize recent advance recapitulating current state field addition discussing dna therapeutic already clinically translated review also examines current research development challenge thwarting progression review cover recombinant dnabased subunit vaccine internalization processing enhancing immune protection via adjuvant manufacturing engineering dna safety stability delivery dna vaccine plasmid controlling gene expression using plasmid engineering gene circuit overcoming immunogenic issue commercial success hope review inspire research dna vaccine development,2018-10-15,"Lee, Jihui; Arun Kumar, Shreedevi; Jhan, Yong Yu; Bishop, Corey J.",Acta Biomaterialia,,,,document_parses/pdf_json/89da54123ba1ef030869fd671971dd907fc7feae.json,document_parses/pmc_json/PMC7105045.xml.json,https://doi.org/10.1016/j.actbio.2018.08.033; https://api.elsevier.com/content/article/pii/S1742706118305002; https://www.sciencedirect.com/science/article/pii/S1742706118305002; https://www.ncbi.nlm.nih.gov/pubmed/30172933/,52145912.0,3
105486,105486,134118,v5ei8991,d690af2217392d3b4686d86b6cb0434918f71f9b,Medline; PMC,Emerging infectious disease laboratory and diagnostic preparedness to accelerate vaccine development,10.1080/21645515.2019.1634992,PMC6816404,31268394.0,cc-by-nc-nd,rapid vaccine development response outbreak new emerging infectious disease eid goal targeted public health agency worldwide goal becomes complicated standardized set viral immunological assay accepted wellcharacterized sample standard reagent approved diagnostic test eid pathogen diagnosis infection critical importance public health also vaccine development order track incident infection clinical trial differentiate natural infection response vaccinerelated called study design exclude subject prior exposure vaccine efficacy trial review emerging infectious disease biological standard development vaccine clinical assay development trial execution recent experience merscov zika virus example great need establish advance standardized reagent sample panel control assay support rapid advancement vaccine development effort response eid outbreak,2019-07-16,"Roberts, Christine C.",Hum Vaccin Immunother,,,,document_parses/pdf_json/d690af2217392d3b4686d86b6cb0434918f71f9b.json,document_parses/pmc_json/PMC6816404.xml.json,https://www.ncbi.nlm.nih.gov/pubmed/31268394/; https://doi.org/10.1080/21645515.2019.1634992,195788259.0,3
